1. TITLE PAGE

Clinical Study Report

NOAH - AFNET 6

*N*on-vitamin K antagonist *O*ral anticoagulants
in patients with *A*trial *H*igh rate episodes

Name of test drug/investigational product:

- edoxaban
- acetylsalicylic acid (ASA)

Indication studied: Atrial high rate episodes (subclinical atrial fibrillation)

An investigator-driven, prospective, parallel-group, randomised, double-blind, multi-centre trial phase IIIb, event-driven, comparing edoxaban 30/60 mg vs placebo respectively ASA 100 mg (in patients with an ASA indication).

First patient in (FPI): 21.06.2016

Last patient in (LPI): 07.09.2022

Last patient out (LPO): 31.12.2022

The study was terminated prematurely but after all patients enrolled according to sample size calculation following a unanimous recommendation by the Data and Safety Monitoring Board (DSMB) on 26.08.2022 to terminate the study and a unanimous vote by the study's Steering Committee on 02.09.2022 to follow this recommendation. A final assessment was performed after formal study termination in all patients still in follow-up according to study protocol.

Patient population: Adult patients aged ≥65 with atrial high rate episodes (duration at least 6 min and frequency at least 170 bpm), detected by implantable devices and a CHA_2DS_2VASc score of 2 or more. Patients with history of overt atrial fibrillation or atrial flutter, patients with a clear contraindication for oral anticoagulation, patients with a clear need for oral anticoagulation, and patients with indication for long-term antiplatelet therapy other than ASA or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT), were not suitable for NOAH - AFNET 6.

Legal Sponsor: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork], Mendelstraße 11, 48149 Münster, Germany

Protocol identification:

- EudraCT number: 2015-003997-33
- NCT number: NCT02618577
- ISRCTN number: ISRCTN17309850

International Chief Investigator: Prof. Paulus Kirchhof, MD, Hamburg and Münster, Germany

Author of the clinical study report: Marcus Klein, PhD, CRI – The Clinical Research Institute GmbH, Rosa-Bavarese-Str. 3, 80639 Munich

Responsible statistician: Prof. Antonia Zapf, PhD, Institute of Medical Biometry and Epidemiology - University Medical Center Hamburg-Eppendorf

The trial was conducted in accordance with the principles of the Declaration of Helsinki and with the Good Clinical Practice guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Essential study documents are being retained by each investigator for the time period as required by national legislation.

Date of the report: 21.12.2023

2. SYNOPSIS

Name of Sponsor/Company: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]		
Name of Finished Product: Lixiana 30/60 mg		
Name of Active Ingredient: edoxaban		

Title of Study:
Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH - AFNET 6)

Investigators: Dr. Wolfgang Dichtl, AT; Prof. Kurt Huber, AT; Prof. Daniel Scherr, AT; Dr. Michael Derndorfer, AT; Dr. Attilla Mihalcz, AT; Prof. Jutta Bergler-Klein, AT; Prof. Lukas Motloch, AT; Dr. Hannes Alber, AT; Dr. Franz Xaver Roithinger, AT; Dr. Frank Provenier, BE; Dr. Hielko Miljoen, BE; Dr. Yves Cruysberghs, BE; Dr. Johan Vijgen, BE; Dr. Rene Tavernier, BE; Prof. Vasil Velchev, BG; Dr. Valeri Gelev, BG; Dr. Borislav Borisov, BG; Dr. Dimitar Markov, BG; Dr. Stepan Havranek, CZ; Dr. Rostislav Polasek, CZ; Dr. Katja Holm, DK; Prof. Jens Cosedis Nielsen, DK; Dr. Ulrik Hintze, DK; Dr. Uffe Gang, DK; Dr. Andi Eie Albertsen, DK; Prof. Jean Luc Pasquie, FR; Prof. Jacques Mansourati, FR; Dr. Nelly Amara, FR; Dr. Jean-Marc Sellal, FR; Prof. Eloi Marijon, FR; Dr. Francois Jourda, FR; Dr. Jean Baptiste Berneau, FR; Prof. Nicolas Lellouche, FR; Dr. Nicolas Delarche, FR; Dr. Bruno Degand, FR; Prof. Philippe Maury, FR; Dr. Peter Nordbeck, DE; Dr. Christoph Schöbel, DE; Dr. Sören Fischer, DE; Prof. Gerhard Hindricks, DE; Dr. Abdul Parwani, DE; Prof. Jan Schrickel, DE; Dr. Tobias Tönnis, DE; Prof. Roland Tilz, DE; Dr. Daniel Zimmer, DE; Prof. Stefan Kääb, DE; Prof. Thomas Rostock, DE; Prof. Lars Eckardt, DE; Prof. Steffen Behrens, DE; Dr. Stefan Kuster, DE; Dr. Thomas Gaspar, DE; Dr. Thomas Schröder, DE; Dr. Jens Taggeselle, DE; Dr. Anselm Bäumer, DE; Dr. Martin Prohaska, DE; Dr. Dietmar Boscher, DE; Dr. Johannes Aring, DE; Prof. Philipp Sommer, DE; Dr. Ralph Bosch, DE; Dr. Felix Pröpper, DE; Dr. Kahtan Alkoppa, DE; Dr. Matthias Stratmann, DE; Dr. Christoph Axthelm, DE; Peter Falk, DE; Dr. Mathias Busch, DE; Dr. David Duncker, DE; Dr. Hans-Holger Ebert, DE; Dr. Ayham Al-Zoebi, DE; Dr. Siegfried Gerke, DE; Prof. Martin Bergmann, DE; Dr. Karl Wilhelm, DE; Dr. Gerd Ringwald, DE; Dr. Christian Ukena, DE; Johannes Härtig, DE; Dr. Boris Rudic, DE; Prof. Andreas Götte, DE; Dr. Andreas Wilke, DE; Dr. Tillman Dahme, DE; Dr. Armin Sause, DE; Dr. Burkhard Hügl, DE; Dr. Detlev Moll, DE; Dr. Angelika Tamm, DE; Dr. Reinhard Stöhring, DE; Dr. Martin Borlich, DE; Ehab Shahock, DE; Prof. Michael Jeserich, DE; Dr. Claudius Hansen, DE; Dr. Roland Prondzinsky, DE; Dr. Ralf Birkemeyer, DE; Dr. Ulrich Overhoff, DE; Dr. Patrick Koppitz, DE; Dr. Kati Fikenzer, DE; Prof. Volker Schächinger, DE; Dr. Dirk Große-Meininghaus, DE; Prof. Emmanuel Simantirakis, GR; Prof. Vassilis Vassilikos, GR; Dr. Gabor Duray, HU; Dr. Gergely G. Nagy, HU; Prof. Bela Merkely, HU; Dr. Emanuele Bertaglia, IT; Prof. Antonio Dello Russo, IT; Dr. Eduardo Celentano, IT; Prof. Ciro Indolfi, IT; Prof. Guiseppe Boriani, IT; Dr. Marco Canepa, IT; Dr. Matteo Bertini, IT; Dr. Francesco Pergolini, IT; Prof. Igor Diemberger, IT; Dr. Raymond Tukkie, NL; Dr. Joris R. De Groot, NL; Dr. Iris Westendorp, NL; Dr. Marc Brouwer, NL; Dr. Shmaila Saleem-Talib, NL; Dr. Martin E.W. Hemels, NL; Dr. Reza Alizadeh Dehnavi, NL; Dr. Pieter Nierop, NL; Dr. Ismail Aksoy, NL; Dr. Reinhart Dorman, NL; Dr. Thomas Oosterhof, NL; Dr. Cornelis Kievit, NL; Dr. Jacobus Plomp, NL; Dr. Dirk Schellings, NL; Prof. Marcin Grabowski, PL; Prof. Andrzej Lubinski, PL; Dr. Rafal Sznajder, PL; Dr. Piotr Futyma, PL; Dr. Pawel Miekus, PL; Dr. Elzbieta Dulak, PL; Prof. Jaroslaw Kasprzak, PL; Dr. Marcin Kuniewicz, PL; Dr. Monika Lica Gorzynska, PL; Prof. Wlodzimierz Musial, PL; Dr. Marcin Kostkiewicz, PL; Dr. Pawel Jesionowski, PL; Dr. Lukasz Pastwa, PL; Dr. Grzegorz Skonieczny, PL; Prof. Marek Gierlotka, PL; Dr. Krzysztof Przybycien, PL; Dr. Vitor Paulo Martins, PT; Dr. Dinis Mesquita, PT; Dr. Anca Rodica Dan, RO; Prof. Dan Dobreanu, RO; Dr. Stefan-Horia Rosianu, RO; Prof. Lluis Mont, ES; Dr. Ermengol Valles, ES; Dr. Julian Perez-Villacastin, ES;

Name of Sponsor/Company: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]		
Name of Finished Product: Lixiana 30/60 mg		
Name of Active Ingredient: edoxaban		
Dr. Luis Tercedor, ES; Dr. Nuria Basterra Sola, ES; Dr. Roger Villuendas, ES; Dr. Rafael Hidalgo, ES; Dr. Juan Jose Gomez Doblas, ES; Dr. Francisco Marin, ES; Prof. Jose Luis Merino, ES; Dr. Manuel Martinez-Selles, ES; Dr. Abel Garcia del Egido, ES; Dr. Pilar Cabanas, ES; Dr. Ignasi Anguera, ES; Dr. Javier Garcia Seara, ES; Prof. Aurelio Quesada, ES; Dr. Joaquin Osca, ES; Dr. Rafael Salguero Bodes, ES; Dr. Diego Perez, ES; Dr. Juan Cosin Sales, ES; Dr. Marta Pombo, ES; Prof. Pyotr Platonov, SE; Prof. Carina Blomström Lundqvist, SE; Dr. Anna Bjorkenheim, SE; Dr. Fredrik Utter, SE; Prof. Mykola Rishko, UA; Prof. Valerii Batushkin, UA; Prof. Yuriy Karpenko, UA; Prof. Andriy Klantsa, UA; Dr. Gavrylo Kovtun, UA; Dr. Mykola Kushnir, UA; Prof. Vira Tseluyko, UA; Dr. Sergiy Veremchuk, UA; Dr. Svitlana Zhurba, UA; Prof. Oleg Sychov, UA; Dr. Dmytro Volkov, UA; Prof. Olena Koval, UA; Prof. Anatolii Rudenko, UA; Prof. Borys Kravchuk, UA; Dr. Abdul Maher, GB; Dr. Jolanta Sobolewska, GB; Dr. Ron Simon, GB; Dr. Mark Dayer, GB; Dr. Justin Cooke, GB; Dr. Rick Veasey, GB; Prof. Ghulam Andre Ng, GB; Dr. Jacek Majewski, GB; Dr. Andrew Mitchell, GB; Dr. Philip Campbell, GB; Dr. Joseph De Bono, GB; Dr. Shouvik Haldar, GB; Dr. Matthew Bates, GB; Dr. Kim Rajappan, GB; Dr. Edward Davies, GB; Dr. Justin Lee, GB; Dr. Douglas Elder, GB; Dr. Sudipta Chattopadhyay, GB; Dr. Anita Arya, GB; Dr. Craig Barr, GB; Dr. David Wilson, GB; Dr. Afzal Sohaib, GB; Dr. Andrew J. Moriarty, GB; Dr. Fu Siong Ng, GB		
Study centres: 206 sites in 18 European countries: AT, Uniklinik Innsbruck; AT, Wilhelminenspital, Wien; AT, Uniklinik Graz; AT, KHS Elisabethinen, Linz; AT, Uniklinik Krems; AT, AKH Wien; AT, Uniklinik Salzburg; AT, KHS Klagenfurt; AT, KHS Wiener Neustadt; BE, Hospital Maria Middelares, Gent; BE, Univ.-Hospital Antwerpen, Edegem; BE, Hospital Maaseik; BE, Hospital Jessa Hasselt; BE, Hospital Brugge-Oostende; BG, Univ.-Hospital St. Anna, Sofia; BG, Hospital Tokuda, Sofia; BG, Hospital Stara Zagora; BG, Univ.-Hospital Queen Giovanna, Sofia; CZ, Univ.-Hospital Prague; CZ, Hospital Liberec; DK, Univ.-Hospital, Aalborg; DK, Univ.-Hospital, Aarhus; DK, Hospital Esbjerg; DK, Univ.-Hospital Roskilde; DK, Hospital Viborg; FR, CHU de Montpellier; FR, CHU Brest; FR, Hôpital Nantes; FR, CHU Brabois, Nancy; FR, CHU European Georges-Pompidou, Paris; FR, Hopital Auxerre; FR, Hôpital Bayonne; FR, CHU Créteil; FR, Hôpital Pau; FR, CHU Poitiers; FR, CHU Rangueil, Toulouse; DE, Uniklinik Würzburg; DE, Uniklinik Charité Campus Mitte, Berlin; DE, KHS St. Vinzenz, Köln; DE, Herzzentrum Leipzig; DE, Uniklinik Charité Virchow, Berlin; DE, Uniklinik Bonn; DE, Herzzentrum Hamburg; DE, Uniklinik Lübeck; DE, Klinik Augustinum, München; DE, Uniklinik Großhadern, München; DE, Uniklinik Mainz; DE, Uniklinik Münster; DE, KHS Humboldt Klinikum, Berlin; DE, KHS Ratzeburg; DE, Uniklinik HZ Dresden; DE, Kardiologische Praxis Altona, Hamburg; DE, Praxis Dr. Taggeselle, Markkleeberg; DE, Praxis Dr. Bäumer, Köln; DE, Praxis Dr. Prohaska, Mühldorf; DE, Praxis Dr. Boscher, Biberach; DE, Klinikum Leverkusen; DE, KHS HDZ Bad Oeynhausen; DE, Cardio Centrum Ludwigsburg-Bietigheim; DE, Polikum Friedenau, Berlin; DE, Kardiologische Praxis Nienburg; DE, Praxis Dr. Stratmann, Dortmund; DE, Cardiologicum Dresden & Pirna; DE, Herz- und Gefäßzentrum Bad Bevensen; DE, Uniklinik Greifswald; DE, Uniklinik Hannover; DE, Gemeinschaftspraxis Ebert / Stenzel, Riesa; DE, Praxis Dr. Al-Zoebi, Wermsdorf; DE, Praxisgemeinschaft Cardio-Soest; DE, Cardiologicum Hamburg; DE, Praxis MVZ Dr. Wilhelm, Dachau; DE, Kardiologie im Friedrichspalais, Bruchsal; DE, Uniklinik Homburg/Saar; DE, Herzzentrum Lahr; DE, Uniklinik Mannheim; DE, KHS Paderborn; DE, Kardiologische Praxis, Papenburg; DE, Uniklinik Ulm; DE, Uniklinik Wuppertal; DE, KHS Neuwied; DE, Praxis Remscheid; DE, Kardiologische Praxis Wittenberg; DE, Praxis Dr. Stöhring,		

Name of Sponsor/Company: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]		
Name of Finished Product: Lixiana 30/60 mg		
Name of Active Ingredient: edoxaban		

Bad Homburg; DE, KHS Bad Segeberg; DE, KHS Rüsselsheim; DE, Praxis Dres. Haggenmiller/Jeserich, Nürnberg; DE, Herz- und Gefäßzentrum Göttingen; DE, KHS Merseburg; DE, Herzklinik Ulm; DE, Herz- und Gefäßzentrum Siegen; DE, Herzzentrum Bremen; DE, Uniklinik Leipzig; DE, Klinikum Fulda; DE, KHS Cottbus; GR, Univ.-Hospital, Heraklion; GR, Hospital Thessaloniki; HU, Univ.-Hospital Defence Forces, Budapest; HU, Hospital Miskolc; HU, Univ.-Hospital Semmelweis, Budapest; IT, Univ.-Hospital, Padova; IT, Univ.-Hospital Ancona; IT, Hospital Bergamo; IT, Univ.-Hospital Catanzaro; IT, Hospital Modena; IT, Hospital San Martino, Genova; IT, Univ.-Hospital St. Anna, Cona; IT, Hospital Maggiore, Bologna; IT, Univ.-Hosp. S.Orsola-Malpighi, Bologna; NL, Hospital Haarlem; NL, AMC Amsterdam; NL, Hospital Beverwijk; NL, Univ. - Hospital Nijmegen; NL, Hospital Den Haag; NL, Hospital Arnhem; NL, Hospital Gouda; NL, Hospital Franciscus, Rotterdam; NL, Hospital Goes; NL, Hospital Roosendaal; NL, Hospital Ede; NL, Hospital Dirksland; NL, Hospital Blaricum; NL, Hospital Doetinchem; PL, Univ.-Hospital Warsaw; PL, Practice Lekarska Lodz; PL, Univ.-Hospital, Katowice; PL, Hospital Rzeszow; PL, Heartcenter Sopot; PL, Cardiostym Gdynia; PL, Hospital Provincial Specialist, Lodz; PL, Hospital Jana Pawła II, Krakow; PL, Medical Centre, Chojnice; PL, Medical Centre Bialystok; PL, Indywidualna Praktyka Lekarska, Rzeszow; PL, Medical Centre, Zielona Gora; PL, Hospital Grodzisk Mazowiecki; PL, Hospital Torun; PL, Univ.-Hospital, Opole; PL, Medical Centre Twoja Przychodnia, Szczecin; PT, Hospital Santarem; PT, Hospital Setubal; RO, Univ.-Hospital Colentina, Bucharest; RO, Cardiovascular Disease Institute, Targu Mures; RO, Heart Institute, Cluj-Napoca; ES, Univ.-Hospital Barcelona; ES, Hospital Del Mar, Barcelona; ES, Univ.-Hospital San Carlos Madrid; ES, Univ.-Hospital Granada; ES, Hospital Navarra, Pamplona; ES, Univ.-Hospital Germans Trias, Badalona; ES, Univ.-Hospital Virgen Macarena, Sevilla; ES, Univ.-Hospital Malaga; ES, Univ.-Hospital Murcia; ES, Univ.-Hospital La Paz, Madrid; ES, Univ.-Hospital Gregorio Maranón, Madrid; ES, Univ.-Hospital, Leon; ES, Hospital Vigo; ES, Univ.-Hospital Bellvitge, Barcelona; ES, Univ.-Hospital Santiago; ES, Univ.-Hospital Consorcio Valencia; ES, Univ.-Hospital La Fe, Valencia; ES, Hospital 12 de Octubre, Madrid; ES, Univ.-Hospital Oviedo; ES, Univ.-Hospital Vilanova, Valencia; ES, Hospital Costa del Sol, Marbella; SE, Univ.-Hospital Lund; SE, Univ.-Hospital Uppsala; SE, Univ.-Hospital Örebro; SE, Hospital Helsingborg; UA, Univ.-Hospital Uzhhorod; UA, City Hospital, Kiev; UA, Hospital Odessa; UA, Hospital Khmelnytskyi; UA, Hospital Heart Institute, Kiev; UA, Hospital Zhytomyr; UA, Univ.-Hospital Kharkiv; UA, Hospital Feofaniya, Kiev; UA, Hospital Cherkasy; UA, Hospital Strazhesko, Kiev; UA, Hospital Zaycev, Kharkiv; UA, Hospital Dnipro; UA, Hospital Amosov Surgical Treatment, Kiev; UA, Hospital Amosov Arrhythmias, Kiev; GB, Hospital Birmingham; GB, Hospital Oldham; GB, Univ.-Hospital North Middlesex, London; GB, Hospital Musgrove Park, Taunton; GB, Hospital Chesterfield; GB, Hospital Eastbourne; GB, Hospital Glenfield, Leicester; GB, Hospital Carlisle; GB, Hospital Jersey; GB, Hospital Royal Gwent, Newport; GB, Hospital Queen Elizabeth, Birmingham; GB, Hospital Harefield; GB, Univ.-Hospital Middlesbrough; GB, Hospital Oxford; GB, Hospital Plymouth; GB, Hospital Teaching, Sheffield; GB, Hospital Dundee; GB, Univ.-Hospital Milton Keynes; GB, Hospital Wolverhampton; GB, Hospital Dudley; GB, Hospital Worcester; GB, Univ.-Hosp. Ilford; GB, Hospital Craigavon; GB, Univ.-Hospital West Middlesex, Isleworth

Publication (reference):

Kirchhof, Paulus et al. “Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.” The New England journal of medicine vol. 389,13 (2023): 1167-1179. doi:10.1056/NEJMoa2303062

Name of Sponsor/Company: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]		
Name of Finished Product: Lixiana 30/60 mg		
Name of Active Ingredient: edoxaban		
Studied period (years): 6,5 **date of first enrolment:** 24.06.2016 **date of last completed:** 30.12.2022 The trial was terminated early on the basis of safety concerns and the results of an independent, informal assessment of futility for the efficacy of edoxaban.	**Phase of development**: IIIb	
Objectives: To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE but without overt AF and at least two stroke risk factors leading to a modified CHA2DS2VASc score of 2 or more.		
Methodology: An investigator-driven, prospective, parallel-group, randomised, double-blind, multi-centre trial phase IIIb, event-driven trial was conducted involving patients 65 years of age or older who had AHREs lasting for at least 6 minutes and who had at least one additional risk factor for stroke. Patients were randomly assigned in a 1:1 ratio to receive edoxaban or placebo. The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis. The safety outcome was a composite of death from any cause or major bleeding.		
Number of patients (planned and analysed): The number of patients initially planned was 3,400 (randomized and treated), after a planned, blinded interim analysis performed after about 1,000 patient-years of follow-up this number was adapted to 2,538. The analysis population consisted of 2,534 patients (1,270 in the edoxaban group and 1,264 in the placebo group).		
Diagnosis and main criteria for inclusion: Patients 65 years of age or older who had AHREs lasting for at least 6 minutes with a frequency of at least 170 bpm, detected by implantable devices and who had at least one additional risk factor for stroke without a history of overt atrial fibrillation (AF).		
Test product, dose and mode of administration: Edoxaban, 60 mg tablets, once daily (OD), oral; Edoxaban, 30 mg tablets, OD, oral.		
Duration of treatment: Each patient was followed until the end of the global trial and received treatment from randomisation until withdrawal, death or discontinuation of treatment due to patient's request or medical reasons (i.e. indication or contraindication for oral anticoagulation or increased risk for bleeding).		
Reference therapy, dose and mode of administration: Acetylsalicylic acid (ASA) 100 mg tablets, OD, oral; matching placebo tablets, OD, oral		

Name of Sponsor/Company: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]		
Name of Finished Product: Lixiana 30/60 mg		
Name of Active Ingredient: edoxaban		

Criteria for evaluation:

Efficacy: The primary efficacy outcome was a first occurrence of a composite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis.

Safety: The safety outcome was a composite of death from any cause or major bleeding, as defined by the International Society on Thrombosis and Haemostasis.

Statistical methods: The trial was designed as an event-driven trial. On the basis of event rates reported in previous trials, the primary efficacy outcome was tested for a difference between the groups at an overall two-sided type I error rate of 5%. The sample size was calculated on the basis of an enrolment period of 71 months, a 32% risk reduction in the occurrence of a primary efficacy outcome event with edoxaban as compared with placebo (an assumed hazard ratio of 0.68), a hazard rate of 0.02 for the competing event of non-cardiovascular death, and a hazard rate of 0.287 for the development of overt atrial fibrillation. The analyses of the primary efficacy outcome and the safety outcome were performed in the modified intention-to-treat population, which included all the patients who had undergone randomization and received at least one dose of edoxaban or placebo/ASA. For the primary efficacy analysis, data were censored at the time of development of atrial fibrillation (as documented on an ECG), loss to follow-up, withdrawal of consent, or unblinding of the trial-group assignment. All the data from the trial sites in Ukraine were censored on February 24, 2022, the start of the Russian invasion.

For the primary efficacy analysis, a cause-specific Cox proportional hazards model was used, along with the Breslow method to handle tied time points for events, with a frailty term for trial site, the trial-group assignment as a predictor variable, and the randomization strata indication for ASA as a covariate. The outcome results are reported as group-specific event rates in percentage per patient-years and as adjusted estimated cause-specific hazard ratios with a two-sided 95% confidence interval and corresponding P value. Cumulative incidence curves were generated with the use of the Aalen–Johansen estimator, which takes into account competing events; otherwise, Kaplan–Meier curves were used.

The time-to-event secondary outcomes were analysed in the same way as the primary efficacy outcome.

SUMMARY - CONCLUSIONS

EFFICACY RESULTS: A primary efficacy outcome event occurred in 83 patients (3.3% per patient-year) in the edoxaban group and in 101 patients (4.0% per patient-year) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.60 to 1.08; P = 0.15). The incidence of stroke was approximately 1% per patient-year in both groups.

SAFETY RESULTS: A safety outcome event occurred in 149 patients (5.9% per patient-year) in the edoxaban group and in 114 patients (4.5% per patient-year) in the placebo group (hazard ratio, 1.31; 95% CI, 1.02 to 1.67; P = 0.03).

CONCLUSION: The trial was terminated early, at a median follow-up of 21 months, on the basis of safety concerns and the results of an independent, informal assessment of futility for the efficacy of edoxaban; at termination, the planned enrolment had been completed.
Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not

Name of Sponsor/Company: Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]		
Name of Finished Product: Lixiana 30/60 mg		
Name of Active Ingredient: edoxaban		

significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. The results may support the conclusion from our trial that, in patients with AHREs but without ECG-documented atrial fibrillation, AHREs are better managed without anticoagulation.

Date of the report: 21.12.2023

3. TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT

1. TITLE PAGE 1
2. SYNOPSIS 3
3. TABLE OF CONTENTS FOR THE INDIVIDUAL CLINICAL STUDY REPORT 9
4. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 12
5. ETHICS 13
   - 5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB) 13
   - 5.2 Ethical Conduct of the Study 14
   - 5.3 Patient Information and Consent 14
6. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE 14
7. INTRODUCTION 16
8. STUDY OBJECTIVES 16
9. INVESTIGATIONAL PLAN 17
   - 9.1 Overall Study Design and Plan-Description 17
   - 9.2 Discussion of Study Design, including the Choice of Control Groups 18
   - 9.3 Selection of Study Population 20
   - 9.3.1 Inclusion criteria 20
   - 9.3.2 Exclusion criteria 21
   - 9.3.3 Removal of patients from therapy or assessment 22
   - 9.4 Treatments 22
   - 9.4.1 Treatments administered 22
   - 9.4.2 Identity of investigational product(s) 24
   - 9.4.3 Method of assigning patients to treatment groups 25
   - 9.4.4 Selection of doses in the study 25
   - 9.4.5 Selection and timing of dose for each patient 26
   - 9.4.6 Blinding 26
   - 9.4.7 Prior and concomitant therapy 27
   - 9.4.8 Treatment compliance 28
   - 9.5 Efficacy and Safety Variables 29
   - 9.5.1 Efficacy and safety measurements assessed and flow chart 29
   - 9.5.2 Primary efficacy variable(s) 34
   - 9.6 Data Quality Assurance 34
   - 9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size 35
   - 9.7.1 Statistical and analytical plans 35
   - 9.7.2 Determination of sample size 41
   - 9.8 Changes in the Conduct of the Study or Planned Analyses 43

10. STUDY PATIENTS 44
10.1 Disposition of Patients 44
10.2 Protocol Deviations 46
11. EFFICACY EVALUATION 47
11.1 Data Sets Analysed 47
11.2 Demographic and Other Baseline Characteristics 48
11.3 Measurements of Treatment Compliance 49
11.4 Efficacy Results and Tabulations of Individual Patient Data 49
11.4.1 Analysis of efficacy 49
11.4.2 Statistical/analytical issues 50
11.4.2.1 Adjustments for Covariates 51
11.4.2.2 Handling of Dropouts or Missing Data 52
11.4.2.3 Interim Analyses and Data Monitoring 52
11.4.2.4 Multiple Comparisons/Multiplicity 53
11.4.2.5 Use of an "Efficacy Subset" of Patients 53
11.4.2.6 Examination of Subgroups 53
11.4.3 Efficacy conclusions 53
12. SAFETY EVALUATION 53
12.1 Extent of Exposure 53
12.2 Adverse Events (AEs) 55
12.2.1 Brief summary of adverse events 55
12.2.2 Display of adverse events 55
12.2.3 Analysis of adverse events 56
12.2.4 Listing of adverse events by patient 56
12.3 Serious Adverse Events (SAE) 56
12.3.1 Brief summary of serious adverse events 56
12.3.2 Display of serious adverse events 56
12.3.3 Analysis of serious adverse events 56
12.3.4 Listing of serious adverse events 58
12.4 Deaths and serious adverse events related to the IMP 58
12.4.1 Listing of deaths 58
12.4.2 Narratives of deaths and serious adverse events related to the IMP 58
12.4.3 Analysis and discussion of deaths and serious adverse events related to the IMP 58
12.5 Safety Conclusions 58
13. DISCUSSION AND OVERALL CONCLUSIONS 58
14. TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT 60
14.1 Demographic Data 60

14.2 Efficacy Data 63
14.3 Safety Data 72
14.3.1 Displays of adverse events 72
14.3.2 Displays of serious adverse events 73
14.3.3 Listings of deaths 76
14.3.4 Narratives of deaths and serious adverse events related to the IMP 86
15. REFERENCE LIST 101
16. APPENDICES 105
16.1 Study Information 105
16.1.1 Clinical Trial Protocol 105
16.1.2 Sample case report form (unique pages only) 180
16.1.3 List of IECs or IRBs - representative written information for patient and sample consent forms 225
16.1.4 Lists of investigators and other important participants in the study 227
16.1.5 Signature of sponsor's responsible medical officer 243
16.1.6 Listing of patients receiving test drug(s)/investigational product(s) from specific batches, where more than one batch was used 244
16.1.7 Randomisation scheme and codes (patient identification and treatment assigned) 472
16.1.8 Audit certificates 491
16.1.9 Documentation of statistical methods 492
16.1.10 Publications based on the study 536
16.1.11 Important publications referenced in the report 536
16.2 Patient Data Listings 537
16.2.1 Discontinued patients 537
16.2.2 Protocol deviations 568
16.2.3 Patients excluded from the efficacy analysis 616
16.2.4 Demographic data 619
16.2.5 Compliance and/or Drug Concentration Data (if available) 718
16.2.6 Adverse event listings (each patient) 757
16.2.7 Serious adverse event listings (each patient) 899
16.3 Other 1114

4. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

ACS	Acute coronary syndrome
AE	adverse event
AF	atrial fibrillation
AFNET	Atrial Fibrillation NETwork
AHRE	atrial high rate episodes
ALT	alanine transaminase
ASA	Acetylsalicylic acid
aPCC	activated prothrombin complex concentrate
aPTT	activated Partial Thromboplastin Time
AST	aspartate transaminase
CABG	coronary artery bypass graft surgery
CrCl	creatinine clearance
CRF	Case Report Form
CRO	Contract Research Organisation
CV	Curriculum Vitae
DSMB	Data and Safety Monitoring Board
EC	Ethics Committee
DAPT	dual antiplatelet therapy
ECG	electrocardiography
eCRF	electronic case report form
EHRA	European Heart Rhythm Association
EQ-5D	Euroquol 5D questionnaire
ERC	Endpoint Review Committee
FU	follow-up
GCP	Good Clinical Practice
HF	heart failure
ICF	informed consent form
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IIT	Investigator Initiated Trial
INR	International Normalised Ratio
IRB	Institutional Review Board
ISTH	International Society on Thrombosis and Haemostasis

ITT	intention-to-treat
LVEF	left ventricular ejection fraction
MACES	Major Adverse Cardiovascular Events
MedDRA	Medical Dictionary for Regulatory Activities
MI	myocardial infarction
MoCA	Montreal cognitive assessment
mITT	modified intention-to-treat
NIHSS	National Institutes of Health Stroke Scale
NOAC	Non-vitamin K antagonist oral anticoagulants
NYHA	New York Heart Association
OD	once daily
PACT-Q	Perception of AntiCoagulant Treatment Questionnaire
PCC	Prothrombin complex concentrate
PCI	percutaneous coronary intervention
PE	physical examination
PI	principal investigator
QoL	Quality-of-life
RBSMP	Risk Based Study Monitoring Plan
SAE	serious adverse event
SC	Steering Committee
SmPC	Summary of Product Characteristics
SOP	Standard Operating Procedure
SUSAR	suspected unexpected serious adverse event
TEE	transesophageal echocardiogram
TIA	transient ischemic attack
VKA	vitamin K antagonist

5. ETHICS

5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)

Before initiating the study in each country, approval of the corresponding Independent Ethics Committee / Institutional Review Board (IEC/IRB) was obtained. During the trial, any substantial modification to the clinical trial protocol was submitted to the IEC/IRB. A list of all consulted institutions is provided in Table 19.

5.2 Ethical Conduct of the Study

The trial was conducted in accordance with the principles laid down in the Declaration of Helsinki in its version of October 2013 (Fortaleza).

5.3 Patient Information and Consent

A signed, ethics committee (EC)/institutional review board (IRB) approved informed consent form, written in accordance with country-specific applicable data privacy acts, the Declaration of Helsinki and the applicable laws for research using drugs was obtained from every patient prior to any study-related procedure. Patients provided a separate signed informed consent to obtain a study-specific extra blood sample. Patients were given sufficient time to consider participation in the study. After any modification to the protocol or the information related to the study medication that could affect the patient's participation in the study, an addendum to the informed consent form specifying the modification was compiled and the patients must agree to sign this addendum indicating that they re-consent to further participate in the study.

A sample patient consent form is provided in 16.1.3.

6. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

Principal investigators

The trial was usually conducted by a team of individuals at the trial site. The responsible investigator as leader of the team was the principal investigator (PI). The PI was qualified by education, training, and experience in order to assume responsibility for the proper conduct of the trial. All qualifications specified by the applicable regulatory requirement(s) had to be met. Evidence of qualifications was provided in form of curriculum vitaes, GCP certificates and qualification forms provided by the sponsor. The appropriate qualification of the PI of each study site was assessed by the responsible ECs. The PI was responsible to ensure the qualification of the investigators in his study site according to the respective national regulations and the conduct of the study in accordance with the approved study protocol.

A list of all sites and principal investigators participating in the trial is provided in Table 20.

Sponsor of the trial

The sponsor of the NOAH - AFNET 6 trial is the Atrial Fibrillation Network (AFNET). AFNET is a non-profit academic research organization that conducts investigator-initiated clinical research projects with support from public funders and industry partners. AFNET conducted the trial, with support from the trial committees, in collaboration with a contract research organization (see below). Daiichi Sankyo Europe, the manufacturer of edoxaban, provided the doses of edoxaban and placebo to AFNET. Daiichi Sankyo Europe and the German Center for Cardiovascular Research funded the trial but did not participate in the trial design, data collection, or data analysis. There were no agreements between the investigators and Daiichi Sankyo Europe.

Contract research organization

The management of the trial was entirely performed by the contract research organization (CRO) CRI — the Clinical Research Institute GmbH, Munich, Germany. This included planning, drafting, organization, implementation and supervision of all procedures pertaining to the trial. CRI was authorized to outsource tasks to freelancers and subcontractors if agreed by the sponsor.

Steering Committee

The Steering Committee (SC) consisted of a group of expert cardiologists, a neurologist, and an expert biostatistician. The primary responsibility of the SC was to provide overall supervision of the trial to ensure that it was conducted according to the state of the art in medicine and science following the guidelines for Good Clinical Practice (ICH-GCP) and all relevant regulations. The trial's SC monitored and reviewed the project status and was responsible for the medical and scientific policy of the Trial. It provided advice to the Sponsor and to the investigators on all aspects of the trial. Its composition is provided in Table 21.

Data Safety Monitoring Board

The Data Safety Monitoring Board (DSMB) as an independent group of experts guided the trial and advised the SC. It consisted of one statistician and two clinicians with expertise in clinical trials and in the management of patients in the scope of the study. They regularly monitored the recruitment and conduct of the trial, data quality and timeliness, the distribution of therapies within the study groups, the Serious Adverse Events (SAEs) and further Adverse Events (AEs) selected to their discretion during the course of the trial. The DSMB performed unblinded interim analyses following a plan set out in the DSMB charter, and gave recommendations to the SC to continue and finally to stop the trial. Its composition is provided in Table 21.

Endpoint Review Committee

The independent Endpoint Review Committee (ERC) consisted of four experts in cardiology and stroke neurology. The ERC reviewed data on general Serious Adverse Events (SAEs), as well as endpoint-specific data, applying complex medical definitions to provide standardised adjudicated outcomes. It was blinded to treatment when performing centralised adjudication. Also, the centralised adjudication process was designed to both preserve the independence of the ERC and prevent any undue bias that could impact its decision-making processes. The ERC's composition is provided in Table 21.

National Coordinators

National coordinators were selected experts that supported submission to the competent authorities and IRB/IEC in their individual countries. The national coordinators provided their expertise regarding regulatory affairs in their countries. The national coordinators supervised and monitored the patient recruitment, and support recruitment measures on a national level. A national coordinator could also be a member of the SC. All appointed national coordinators are provided in Table 21.

Central facilities of the trial

The Institute of Medical Biometry and Epidemiology at the University Medical Center Hamburg Eppendorf was the core statistical unit.

Additional, study-specific blood samples drawn from patients who consented were send to a central blood bank in Hamburg, Germany (Universitäres Herzzentrum Hamburg; UKE).

Device interrogations derived from the study patient's implanted devices were centrally review by an independent core analysis centre (Maastricht UMC+ Heart+Vascular Center).

7. INTRODUCTION

Oral anticoagulation using vitamin K antagonists (1) or direct-acting, non-vitamin K antagonist oral inhibitors of factor II or Xa2 (NOAC) reduces the rates of ischemic strokes in patients with atrial fibrillation. The non-vitamin K antagonists are currently preferred over vitamin K antagonists due to a lower risk of bleeding (2; 3). Oral anticoagulation is often only initiated after a stroke in patients with atrial fibrillation (4). Systematic rhythm monitoring to detect atrial fibrillation can enable earlier detection of atrial fibrillation and initiation of anticoagulation (5; 6). Implanted cardiac devices detect short episodes of atrial arrhythmias on electrograms recorded by intracardiac or subcutaneous sensors enabling continuous monitoring of cardiac rhythm. Arrhythmias detected by these types of continuous rhythm monitoring are called subclinical atrial fibrillation or atrial high-rate episodes (AHRE). Because cardiac electrical activity recorded during AHRE episodes resemble those recorded during atrial fibrillation (7), some clinicians have initiated oral anticoagulation in patients with AHRE, especially when there are several clinical stroke risk factors or when AHRE episodes last longer than 24 hours (7). Due to their rarity and episodic nature, AHRE typically remain undiagnosed in patients not undergoing long-term implantable rhythm monitoring (8). The effectiveness of oral anticoagulation has been shown in patients with ECG-documented atrial fibrillation (1; 2). In the absence of atrial fibrillation, oral anticoagulation therapy is generally not effective for stroke prevention, for example, after embolic stroke of unknown source (9; 10) or in patients with heart failure (11; 12). The Non vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes trial (NOAH - AFNET 6) compared the efficacy and safety of oral anticoagulation using the non-vitamin K antagonist, edoxaban, to no anticoagulation in patients with AHRE who had conventional stroke risk factors.

8. STUDY OBJECTIVES

The study objective was to test whether oral anticoagulation with the NOAC edoxaban is superior to no anticoagulation therapy (antiplatelet therapy or no therapy depending on cardiovascular risk) to prevent stroke, systemic embolism, or cardio-vascular death in patients with AHRE but without overt AF and at least two stroke risk factors leading to a modified CHA2DS2VASc score of 2 or more.

9. INVESTIGATIONAL PLAN

9.1 Overall Study Design and Plan-Description

NOAH - AFNET 6 is an investigator-initiated, prospective, parallel-group, double-blind, double-dummy, randomised trial, which was conducted in 18 European countries.

The trial was designed as an event-driven trial with an initially estimated number of 3,400 randomised and treated patients, which was subsequently reduced to 2,538 patients on the basis of a planned, blinded interim analysis that was performed after 1,000 patient-years of follow-up. A total of n=220 primary efficacy outcome events were anticipated. The sample size was calculated on the basis of an enrolment period of 71 months (adjusted from 54 months during the planned interim analysis). All patients were followed until the global end of the trial.

Eligible patients were 65 years of age or older with AHREs detected by implanted devices and no history of atrial fibrillation as documented on an electrocardiogram (ECG). Qualifying AHREs could be captured by pacemakers, defibrillators, resynchronization devices, or implanted loop recorders with long-term rhythm-monitoring capabilities. Patients had to have AHREs at least 2 months after implantation of the device. A qualifying AHRE had to involve an atrial rate of at least 170 beats per minute and had to last 6 minutes or longer; there was no upper limit of duration of the AHRE. Patients were also required to have one or more of the following risk factors for stroke: heart failure, hypertension, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease (previous myocardial infarction, aortic plaque, or peripheral, carotid, or cerebral arterial disease), or an age of 75 years or older.

Eligible patients were randomly assigned in a 1:1 ratio to receive edoxaban (anticoagulation) or placebo in a double-blind, double-dummy design. Randomization was performed with the use of blocks of variable size and was stratified according to the indication for ASA therapy. Anticoagulation consisted of the factor Xa inhibitor edoxaban at the dose approved for the prevention of stroke in patients with atrial fibrillation (60 mg once daily). Criteria for a dose reduction to 30 mg once daily, as approved by European regulatory authorities (a body weight of ≤60 kg, a creatinine clearance of 15 to 50 ml per minute, or the concomitant use of strong P-glycoprotein inhibitors), were assessed at the baseline visit and at each subsequent visit, and appropriate dose adjustments were made. Doses of edoxaban and placebo were dispensed in quantities that were anticipated to be adequate for 6 months. The placebo group received a double-dummy placebo tablet that contained either no active compound or ASA at a dose of 100 mg daily; the tablet that a patient received was determined on the basis of the accepted indications for the use of ASA, which included peripheral or coronary artery disease, a previous myocardial infarction, or a previous stroke. Eligibility for the receipt of ASA therapy was determined by the investigator at the baseline visit and each time the trial drug was dispensed.

In a similarly designed study, the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial (13), approx. 4,000 patients were enrolled. In ARTESiA, patients were randomized to receive apixaban or aspirin as compared to either edoxaban or aspirin/placebo in NOAH - AFNET 6. Patients in ARTESiA were ≥55 years old and had additional risk factors for stroke, approximating CHA_2DS_2-VASc ≥4 (i.e. minimum CHA_2DS_2-VASc score of 2 in those ≥75 years or with a history of stroke or transient ischaemic attack, or a score ≥3 in those younger than 75 and without a history of

cerebrovascular event). Similarly, in NOAH - AFNET 6 patients were >65 years and had at least one additional risk factor. Slightly different primary efficacy outcome events have been established for these two studies, with ARTESiA considering the composite of stroke and systemic embolism, while the primary outcome parameter in NOAH - AFNET 6 was a composite of stroke, systemic embolism, or cardiovascular death. The definitions of stroke and cardiovascular death were very similar in both trials. Systemic embolism included pulmonary embolism and myocardial infarction in NOAH-AFNET 6, but not in ARTESiA. Both trials reported major bleeding events based on the ISTH classification.




Figure 1 Study Flow Chart

9.2 Discussion of Study Design, including the Choice of Control Groups

The NOACs provide similar or slightly better stroke prevention, and appear slightly safer compared to VKAs (2; 14). Edoxaban at a dose regime of 60 mg once daily (OD) with a planned dose reduction to 30 mg OD in patients with reduced edoxaban elimination as outlined in the edoxaban Summary of Product Characteristics (SmPC) has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial (15), edoxaban prevented strokes at least as effectively as VKA therapy (hazard ratio 0.8 (0.63 – 0.99), p<0.0001 for non-inferiority (15)). Furthermore, importantly for the design of NOAH - AFNET 6, an edoxaban dose regime of 60 mg OD caused less major bleeding events than VKA therapy in the ENGAGE trial (hazard ratio 0.8 [0.71 – 0.91], p<0.0001). Thus, an edoxaban 60 mg OD therapy regimen provided an intervention that is safer than VKA (20% less major bleeding events, CI 9% – 37%), and at least as effective in preventing strokes in non valvular AF patients. This intervention was expected to prevent clinical and subclinical strokes and thereby improve quality of life, and maintain cognitive function.

This randomised trial, therefore, tested the hypothesis that oral anticoagulation with the NOAC edoxaban used in a 60 mg OD dose regime is superior to antiplatelet therapy or no therapy depending on cardiovascular risk to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE, but without AF, and with at least two stroke risk factors. If combined with another similarly sized trial (ARTESIA, NCT01938248), the data were believed to likely change clinical practice in this patient group, with benefits for a large number of patients with AHRE. The results may also inform future guidance on the management of patients with atrial arrhythmias detected by implantable ECG monitors.

All study drugs are market approved for prevention of stroke in patients with non-valvular AF. Although AHRE are presently not considered equal to AF documented by conventional ECG recordings, VKA and NOACs are currently used for patients with AHRE in clinical routine (off-label use), and the documentation of short-lasting arrhythmias that resemble atrial fibrillation is considered “non valvular AF” by many clinicians, although data supporting the use of anticoagulants in general are lacking in this population. Other clinicians will strive to document AF in the usual way in AHRE patients. Thus, there is true clinical equipoise for the use of anticoagulation in patients with AHRE. In view of the potential benefits for stroke prevention in this population, this is a clinically important issue that calls for resolution in a controlled clinical trial.

The other patient characteristics of the NOAH - AFNET 6 population and the use of edoxaban in the trial mirror the European label of edoxaban to ensure that the use of edoxaban is limited to patients in whom safety information exists from the completed phase III programme leading to the market authorisation of edoxaban in Europe (15). The sponsor of NOAH - AFNET 6 and the scientific partner, the European Society of Cardiology, have carefully considered how to define the phase of this investigator-initiated trial, also in view of the fact that edoxaban has been evaluated in a large clinical trial program in patients with very similar characteristics compared to those to be enrolled in NOAH - AFNET 6, and in view of the conduct of a similar trial (ARTESIA, NCT01938248) as phase IV. Reflecting the equipoise of anticoagulation and the uncertainty whether AHRE represent an early form of AF, NOAH - AFNET 6 was conducted as a phase IIIb study.

All concomitant study procedures were standard care procedures according to applicable medical guidelines used within the recommended indications. All participating study sites had to document sufficient experience in the management of patients with implanted pacemakers, defibrillators, cardiac resynchronisation devices or insertable cardiac monitors and of patients with AF.

The risk of therapy within NOAH - AFNET 6 seemed acceptable in view of the favourable safety profile of an edoxaban 60 mg OD regime in the ENGAGE-TIMI 48 trial compared to warfarin. In light of existing data for apixaban and warfarin, the bleeding risk on edoxaban may only slightly exceed that of ASA therapy (16; 17). Thus, the individual risk of study patients in the group randomised to treatment with NOAC will not differ from the risk of therapy in clinical routine treatment for prevention of stroke in patients with non-valvular AF. Patients randomised to treatment with NOAC have an increased risk for bleeding events compared to patients randomised to the group that undergoes usual care. Event rates for AHRE patients did not exist and were generated in NOAH - AFNET 6. Based on the observed baseline stroke rates in AHRE patients, similar effect differences were expected for NOAH - AFNET 6.




Figure 2 Major efficacy and safety event rates for AF patients randomised to an edoxaban 60 mg OD regime in the ENGAGE-TIMI 48 trial compared to event rates reported in patients randomised to ASA in the AVERROES and BAFTA trials (3, 6, 23). All events are given as annualised rates in percent. This figure is replicated in the sample size estimation section.

9.3 Selection of Study Population

9.3.1 Inclusion criteria

The intended population for this study consisted of patients who have had documented AHRE but no history of overt AF at the time of randomisation and a risk for stroke fulfilling the inclusion criteria as listed below, i.e. approximating a modified CHA2DS2VASc score of 2 or more. This population had a clinical risk profile that would make patients with ECG-documented AF eligible for oral anticoagulation.

An adequate detection of AHRE by the implanted device was essential for screening of eligible patients to be included in NOAH - AFNET 6. Device interrogations derived from the implanted device containing the index AHRE episode that led to inclusion was digitally uploaded for central review by an independent core analysis centre. The results of review did not lead to post-hoc exclusion of the patients if criteria of AHRE were not met but were detected as protocol violations relevant for stability measures of final analysis and led to training of corresponding study sites to prevent future violations, therefore assuring a standard quality of adequate AHRE detection.

The study protocol outlined adequate settings of devices for adequate identification of AHRE episodes in patients who were potentially eligible for NOAH - AFNET 6 (refer to Appendix XIII of the protocol; 16.1.1).

General Inclusion criteria

I1 Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation.

I2. AHRE detection feature activated for adequate detection of AHRE.

I3. AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device.
Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible.

I4. Age ≥ 65 years.

I5. In addition, at least one of the following cardiovascular conditions leading to a modified CHA_2DS_2VASc score of 2 or more:

- Age ≥ 75 years;
- Heart failure (clinically overt or LVEF < 45%);
- Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure > 145/90 mmHg);
- Diabetes mellitus;
- Prior stroke or transient ischemic attack (TIA);
- Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE]).

I6. Provision of signed informed consent.

9.3.2 Exclusion criteria

Exclusion criteria were defined in order to reduce individual risk as well as risk for an unfavourable outcome of the trial. Additional criteria were chosen not only to narrowly define the study population but also to ensure comparability to similar trials conducted.

General exclusion criteria

E1. Any disease that limits life expectancy to less than 1 year.

E2. Participation in another controlled clinical trial, either within the past two months or still ongoing.

E3. Previous participation in the present trial NOAH - AFNET 6.

E4. Drug abuse or clinically manifest alcohol abuse.

Exclusion criteria related to a cardiac condition

E5. Any history of overt AF or atrial flutter.

E6. Indication for oral anticoagulation (e.g. deep venous thrombosis).

E7. Contraindication for oral anticoagulation in general.

E8. Contraindication for edoxaban as stated in the current SmPC.

E9. Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present.

E10. Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation.

Exclusion criteria based on laboratory abnormalities

E11. End stage renal disease (creatinine clearance (CrCl) < 15 ml/min as calculated by the Cockcroft-Gault method, refer to 7.1.1.).

Legal exclusion criterion (applicable in countries where legally required)

E.12. All persons exempt from participation in a clinical trial by law.

9.3.3 Removal of patients from therapy or assessment

The investigator was not able to decide about the discontinuation of study participation of any patient. The investigator's only option was to discontinue study medication for compelling medical reasons, such as the development of a contraindication or indication for oral anticoagulation. In this case, however, the patient was continued to be followed-up according to study protocol.

If a patient was randomised but discontinued study participation prior to exposure to study medication, that patient did not undergo follow-up. Such patients were replaced by enrolling other, additional patients.

Once a patient had been randomised and at least one dose of study medication was taken, but he/she discontinued study drug, the patient was followed according to study protocol (intention-to-treat) until global end of study or withdrawal or death.

The patients were advised in the informed consent forms that they have the right to withdraw from study participation at any time without statement of reasons.

In case, a protocol violation was noticed, the patient remained in the intention-to-treat group and was followed according to protocol.

Patients were followed according to the study protocol irrespective of whether they experienced any out-come event.

9.4 Treatments

9.4.1 Treatments administered

In this study, investigational products were:

- edoxaban 60 mg tablets,
- edoxaban 30 mg tablets,
- ASA 100 mg tablets, and
- matching placebo tablets.

This double-blind, double-dummy, randomized trial was designed to evaluate the safety and efficacy of the **NOAC** edoxaban in comparison to **usual care** consisting of either ASA or no antithrombotic therapy depending on the indication for use of antiplatelet therapy. Patients received study medication OD for oral intake depending on the random group throughout the whole study duration.




Figure 3 Drug supply scheme: The usual care group is divided into antiplatelet and placebo therapy defined (stratified) by indication of antiplatelet therapy existing at inclusion.

Patients of the "**NOAC**" group received anticoagulation therapy with edoxaban. Patients in the "**Usual Care**" group received either ASA or no antithrombotic therapy depending on the indication for use of antiplatelet therapy (stratification at the time of randomisation). All patients received identical number and form of study medication using the "double-dummy" technique:

- In the "**NOAC**" group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg was administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminated the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.
- In the "**Usual Care**" group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg was administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator.
- A documented change of indication for use of antiplatelet therapy in follow-up lead to blinded exchange of double-dummy study drug according to actual indication. In case of a new indication for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT), blind treatment with study drugs was terminated and adequate treatment according to medical guidelines was provided by the treating physician. The patient remained in regular study follow-up until the global end of the trial.




Figure 4 Treatment scheme: Double-dummy scheme was applied. Edoxaban was either administered in doses of 30 mg or 60 mg tablets OD, as described elsewhere in this section. ASA was administered in dose of 100 mg tablet OD.

9.4.2 Identity of investigational product(s)

The following investigational medicinal products were provided by the manufacturer of edoxaban (Daiichi Sankyo Europe):

Table 1 Investigational medicinal products

Product	Dosage	Appearance, shape and size
Edoxaban	60 mg	Yellow film-coated tablets, round-shaped (10.6 mm diameter, tablet core 10.0 mm), not debossed
Edoxaban	30 mg	Yellow film-coated tablets, round-shaped (8.6 mm diameter), not debossed
Acetylsalicylic acid	100 mg	White film-coated tablets, round-shaped (10.3 mm diameter, tablet core 10.0 mm), not debossed
Matching placebos to all drugs	-	Comparable in colour, shape, size and weight

All study drugs were packaged in study-specific blisters and medication kit boxes with the following contents:

- Kit 1: Blister edoxaban 30 mg + ASA 100 mg placebo
- Kit 2: Blister edoxaban 60 mg + ASA 100 mg placebo
- Kit 3: Blister edoxaban 30 mg placebo + ASA 100 mg
- Kit 4: Blister edoxaban 60 mg placebo + ASA 100 mg
- Kit 5: Blister edoxaban 30 mg placebo + ASA 100 mg placebo
- Kit 6: Blister edoxaban 60 mg placebo + ASA 100 mg placebo

The sponsor assured that adequate labelling, storage, and distribution including import of study drugs to study sites on demand was provided by drug suppliers. All quality management requests related to manufacturing, labelling, storage, distribution and reporting defined in applicable international and national standards were followed by the drug suppliers subcontracted by the sponsor.

It was assured by the EDC system MARVIN, serving also as drug logistic tool in this trial, that no study drug with an upcoming expiry date could be assigned to a patient by excluding affected kits from the stock of available study drugs. The safety margin of exclusion was scaled according to the number of daily dosages contained in a study drug kit, including a buffer of several days of potential delayed intakes, minimizing the risk of a study drug kit expiring during its regular use.

Before any approaching expiry of a study drug lot, the supply of replacement study drug kits to the individual study site was initiated, and the complete return of all expiring study drug kits to the supplier and its destruction by the supplier, or, where required, the local destruction at the study site, was requested and monitored.

Each patient with the assigned medication kit batch number is shown in Table 22.

Due to the double-blind design, the different storage conditions for edoxaban, ASS or placebo could not be followed individually but the most restrictive had to be considered. Thus, all study drugs had to be stored continuously between 2 and 25° C. Temperature had to be controlled and documented, e.g. by means of temperature logger provided by the sponsor. Detailed instructions for handling of temperature logging were provided. When temperatures exceeded <2°C or > 25°C, the investigator had to inform the CRO and report the duration of the exceedance and the peak temperature. The CRO subsequently informed the sponsor who gave advice on actions to be taken in cooperation with the manufacturer of the study drugs.

9.4.3 Method of assigning patients to treatment groups

Study patients were randomised to one of two parallel groups in a 1:1 design, designated as “NOAC” and “Usual Care”. Randomisation was stratified by indication for use of antiplatelet therapy as assessed by the responsible investigator at the time of randomisation.

The randomization sequence was generated using STATA12 SE (StataCorp, 2011) with blocks of variable sizes of 4 to 8 entries to ensure allocation concealment could not be breached, by guessing the sequence at the end of each block. Patients were randomized in a 1:1 ratio to one of the two parallel groups NOAC or usual care arms, stratified by indication for ASA and study site. The randomisation was performed with the integrated randomisation service in the web-based EDC system MARVIN used as eCRF. According to protocol, requirements and design of the eCRF, randomisation could only be performed after informed consent had been obtained and all in- and exclusion criteria had been confirmed by study site staff. Multiple randomisations or pseudo-randomisations of subjects were prevented by the integrated randomisation service. The account ID of the person performing the randomisation in the e-trial management system and the corresponding time stamp was automatically documented in an electronic audit trail.

A table exhibiting the randomisation codes, patient identifier, and treatment assigned should is presented in Table 23.

9.4.4 Selection of doses in the study

Edoxaban

Edoxaban was applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:

- Impaired renal function (CrCl 15-50 ml/min*; Cockcroft-Gault), or
- Low body weight (≤60 kg), or
- Patients receiving the p-glycoprotein inhibitors ketoconazole, ciclosporin, erythromycin, or dronedarone.

If conditions for reduced dosage of edoxaban were not anymore fulfilled during the study, dosage of edoxaban was increased as stated in the SmPC.

The e-trial management system automatically identified those conditions if adequately documented by the study site personnel and supplied an appropriate medication box containing either 60 mg or 30 mg tablets in patients randomised to edoxaban. However, the investigator finally needed either to confirm the calculated dosage or adjust the dosage according to his medical decision and provide a reason for doing so.

Acetylsalicylic acid

ASA has been used for decades as standard therapeutic agent for antithrombotic therapy according to corresponding medical guidelines. Here, either tablets of 100 mg ASA were applied or matching placebo tablets. The e-trial management system automatically identified the indication for use of antiplatelet therapy as assessed by the responsible investigator, if adequately documented, and supplied an appropriate medication bottle. Indications for providing ASA with the study medication included previous myocardial infarction, PCI, or CABG, and secondary prevention of stroke.

Placebos

Matching placebo tablets were applied which are comparable in size, weight, shape and colour to

- edoxaban 60 mg tablets,
- edoxaban 30 mg tablets,
- ASA 100 mg tablets.

9.4.5 Selection and timing of dose for each patient

Study patients were randomised to one of two parallel groups in a 1:1 design, designated as “NOAC” and “Usual Care”. Randomisation was stratified by indication for use of antiplatelet therapy as assessed by the responsible investigator at the time of randomisation.

Randomisation was done per study site in blocks of variable size to allow minimising potential confounders related to different healthcare practice. A randomisation list was created by the responsible study statistician before study start, and imported into the randomisation server of the e-trial management system. During the trial, randomisation was performed by each site personnel within the eCRF of the e-trial management system according to the imported randomisation list. The investigator had to document several clinical items prior to randomisation to verify eligibility of the patient for randomisation and to determine the stratum. The e-trial management system displayed the medication number to be used, not the random group, and asked for confirmation by authorised study personnel. The account ID of the person performing the randomisation in the e-trial management system and the corresponding time stamp was automatically documented in an electronic audit trail.

Patient-specific dosages were already described in detail in the previous chapters of this report.

A sample of specific instructions to patients about medication intake are provided in section 16.3.

9.4.6 Blinding

To maintain blinding of study treatment, all study drugs were prepared in tablets matching edoxaban and ASA tablets in form, size and colour (see 9.4.2 for more details). Patients, investigators and staff of study sites, committee members, and the sponsor’s and CRO’s staff conducting the study, did not have access to individual patient treatment assignments. The members of the DSMB had access to such assignments on demand.

Blinding was critical to the integrity of this clinical trial. However, the patient’s treatment may have been revealed by the investigator in a medical emergency, in which knowledge of the investigational product would have been instrumental for further treatment decisions. A newly occurring indication for change of dosage of

the study drugs or for initiation or termination of antiplatelet therapy was not a valid reason for unblinding since procedures for blinded change of dosage and antiplatelet therapy were offered. Before breaking the blind of an individual patient's blinded treatment, the investigator had to determine that the information is necessary, i.e., that it will alter the patient's immediate management. In many cases, particularly when the emergency was clearly not study drug-related, the situation may have been managed by assuming that the patient is receiving active product without unblinding.

Every patient was provided with an alert card. The alert card

- indicated that the patient was participating in a double-blind clinical trial,
- provided the trial number and acronym,
- noted that the patient may have been receiving either edoxaban or ASA or placebo, and
- included the investigator's name and phone number for providing information to emergency medical personnel.

Unblinding

In a medical emergency and if knowledge of the patient's randomised treatment assignment would have had a meaningful impact on individual management, the patient's treatment assignment could be unblinded. However, whenever possible, the need to break the blind had to be discussed first with the CRO's medical advisor or project director.

Information regarding patient's treatment assignment were provided only to those who were caring for the patient and as few other people as possible. Thus, bias was minimised by assuring that the Endpoint Review Committee (ERC) remained blinded to treatment assignment, even if the investigator had been unblinded.

Unblinding of a patient's treatment was managed and tracked centrally in the e-trial management system. The investigator who was breaking the blind had to document date and reason for code break in the eCRF and in the patient's medical records. The CRO received an automated email containing all necessary information on the code break (however without information regarding treatment) at the same time of the data being documented in the eCRF. In case the eCRF system was not reachable the investigator had to contact the CRO's hotline to induce unblinding.

9.4.7 Prior and concomitant therapy

The concomitant use of antiplatelet agents was discouraged in all study patients, because the concomitant use of an oral anticoagulant and antiplatelet agents increases the risk of bleeding without known benefits. Patients who required treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy, at the start of the trial were not eligible for the trial (refer to exclusion criteria). If the indication for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy, appeared after inclusion into the trial, therapy with blinded study drugs had to be stopped permanently and other adequate, open-label therapy had to be started according to applicable medical guidelines. All other concomitant medication was allowed to be used within the trial if in line with the contraindications given in the current SmPC of edoxaban.

In the eCRF, all concomitant drugs were documented by generic name and dosage administered.

9.4.8 Treatment compliance

The study drugs were supplied to the study sites in sufficient quantity according to local needs, e. g. expected recruitment rate. The respective time of drug supply was determined by the CRO but supply itself was provided by the Drug Supplier.

The logistics of study drug distribution were managed and tracked centrally in the e-trial management system. Each study medication unit was supplied with a unique medication number together with a corresponding unique verifier printed on study specific labels. A list of all unique medication numbers together with the corresponding unique verifiers of the provided study medication were hosted in the materials tool of the e-trial management system.

Labelling followed requirements as specified in Volume 4, EU Guidelines to Good Manufacturing Practice, Annex 13, Investigational Medicinal Products. National requirements were taken into consideration. The Drug Supplier responsible for labelling and delivery of study drug to study sites received automated supply orders via e-mail from the e-trial management system as soon as a pre-defined minimal number of study drugs in stock at the study site was reached. Triggers for supply orders were individually defined for the different types of study drugs. Tracking of study drugs to be sent to study sites were performed in the e-trial management system revealing information on medication numbers and verifiers, date of shipment and recipient by study site. Receipt of study drug had to be tracked in the e-trial management system by the receiving site staff by entering the verifier printed on each label.

When a patient was randomised, the e-trial management system displayed the medication numbers to be used. Site staff had to confirm dispense of the pre-defined study drugs to the patient by entering in the e-trial management system the corresponding verifiers printed on each label of the study drugs. By doing so, the investigator documented each dispensing of study medication to a patient with the patient's ID, study site ID and the date of dispensing (automatically allocated by the e-trial management system). Comparable procedures were performed at each drug/device visit in follow-up.

Patients were asked to bring all unused or partly used medication at each visit in follow-up. The investigator assessed patients' compliance with study drug by asking the patient about medication intake and by pill count during every clinical visit and at the end of follow-up. In case the patient did not take the assigned study drugs for a period of more than 7 consecutive days the date, duration and reason for interruption had to be documented.

Compliance with study drug was defined as following (percentages refer to the period between the last documented follow-up visit and the next, ideally 6 months):

- Intake of study drugs < 80% of the number of pills calculated for the corresponding time period: non-compliance.
- Intake of study drugs 80% to < 90% of the number of pills calculated for the corresponding time period: acceptable compliance.
- Intake of study drugs 90% or more of the number of pills calculated for the corresponding time period: good compliance.

In case of non-compliance the investigator had to instruct the patient about importance of regular drug intake.

Any unused or partly used study medication had to be returned to the drug supplier periodically or latest at the end of the trial in the corresponding study site, depending on the amount of such medication in local stock. Returned study medication was tracked by the investigator in the e-trial management system in a way comparable to the procedures at study medication dispense. The shipment of returned or unused study medication to the drug supplier was managed by the CRO but performed by the investigator.

9.5 Efficacy and Safety Variables

9.5.1 Efficacy and safety measurements assessed and flow chart

Assessments and study schedule

A patient met eligibility criteria of the study if all inclusion and exclusion criteria were fulfilled as described in the sections above. Prior to any trial related procedure, a signed informed consent form had to be obtained from every patient to be included in the trial and kept on file at the local study site.

Clinical follow-up visits were performed at months 12, 24, and 36. Starting at month 6 and subsequently alternating to clinical follow-up visits, patients visited the study site for dispensing study drug and upload of device interrogations derived from the implanted device (“drug/device visit”). After month 36, no more scheduled clinical visits took place but “drug/device visits” in 6-monthly intervals until end of study, only. All patients were followed for outcome and safety until global end of the trial.

After the global end of study was announced by the CRO, all regular scheduled follow-up visits had to be cancelled, but a final in person visit was scheduled for all patients still in follow-up at the time of global end of study. In patients with premature termination of study drug before global end of study the final visit was performed as final phone call assessing for clinical events, AEs and SAEs, only.

All study assessments and their schedule are outlined in detail in Table 2.

Table 2 Study visit schedule

Assessment	Baseline Visit Day 0	Drug/ Device Visit* Month 6	Clinical Visit* Month 12	Drug/ Device Visit* Month 18	Clinical Visit* Month 24	Drug/ Device Visit* Month 30**	Clinical Visit* Month 36	Final Visit***
Signed ICF (medical informed consent)	X							
Check inclusion & exclusion criteria	X							
Physical examination (PE) / medical history	X		X		X		X	
Karnofsky score	X		X		X			
Modified Rankin scale			X [1]		X [1]		X [1]	
12-lead ECG	X	X	X	X	X	X	X	X
Number of AHREs, upload of device interrogations from implanted device	X	X	X	X	X	X	X	X
Laboratory parameters (blood sample)	X [2]		X [3]					
Cognitive function test (MoCA)	X		X		X			
Quality-of-Life questionnaire (EQ-5D)[4]	X		X		X			
Patient 's satisfaction and symptom severity questionnaire[4] (mEHRA score, PACT-Q)	X		X		X			
Supply of study drug	X	X	X	X	X	X	X	
Return of study drug		X	X	X	X	X	X	X
Adverse event (AE) /serious adverse event (SAE)		X	X	X	X	X	X	X

* Time window +/- 2 weeks

** or longer if required

*** within 3 months after confirmation that the required number of adjudicated endpoints has been reached (will be announced by CRO)

[1] Assessment of modified Rankin scale only in pts. with stroke during study participation; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed

[2] Blood sample not older than 28 days at the date of randomisation (full blood cell count, serum creatinine, AST, ALT, bilirubin, aPTT, and INR) + extra blood sample for central analyses

[3] Extra blood sample for central analyses, only

[4] All Quality-of-Life measures and satisfaction questionnaires should ideally be completed prior to the clinical consultation.

Electrocardiogram

All patients underwent 12-lead ECG at baseline and as part of the clinical follow-up visits. Operators recording ECGs had to ensure that chest leads were placed in the proper position and electrodes made good skin contact to minimize noise and artefacts. The reversal of limb leads and the switching of precordial leads are known to cause important alterations in ECGs.

All ECGs were uploaded digitally onto a central server, requiring an ECG machine capable of exporting an adequate digital format that could then be uploaded.

The ECG recording had to be digitally annotated with the date of recording, patient study ID and gender, only. No patient identifying annotations (e. g. last name, first name, date of birth) must have been be documented.

In case an ECG was only available as paper version, a copy had to be faxed or mailed to the CRO for further analyses to be performed by a central evaluation centre.

Blood samples

Routine laboratory parameters obtained within clinical routine procedures were part of the standard work-up of the patient's status before study participation in order to verify the enrolment criteria and therefore not considered to be part of study related procedures. If these parameters could be assessed from a blood sample not older than 28 days at the date of inclusion, blood sampling and analysis did not have to be repeated within the study baseline visit. Parameters included a full blood cell count, serum creatinine, AST, ALT, bilirubin, aPTT, and INR. All blood parameters were determined at the local laboratory of the study sites provided their analytical laboratories were certified. The eCRF captured laboratory values and information whether their value was normal or abnormal.

At baseline and at clinical visit month 12, a study-specific blood sample was collected (20 ml whole blood) and sent to a central laboratory for archiving for later analysis (analyses of factors and mechanisms of AF, stroke, and bleeding, including genetic markers) which will be performed either in the central laboratory of the trial or within scientific collaborations. All analyses will be supervised by the Steering Committee. Patients provided a separate signed informed consent to obtain this extra blood sample. Details regarding handling and shipment of these blood samples are described in a separate manual.

Quality of life, experience, symptoms and cognitive function

All patients were requested to complete quality-of-life, symptom and experience questionnaires and undergo cognitive function testing at baseline, 12 and 24 months. It was hypothesised that the intervention will lead to improved quality-of-life, reduce symptoms, improve patient experience and maintain cognitive function. This hypothesis is based on the observation that AF, including "asymptomatic" forms, is associated with reduced quality of life (18). Observational data suggested that small cerebral emboli are common in patients with short AF episodes (19; 20), and can contribute to reduced quality of life (21; 22). Based on the assumption that AHRE are a very early form of AF conveying a risk of stroke including silent brain lesions, it was expected that quality of life and cognitive function in AHRE patients will also be reduced.

Quality of life was assessed using the EuroQoL EQ-5D L questionnaire. Patients were asked to rate severity of their current problems according to 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). Patients were therefore being classified into 3,125 possible health states which could be converted into an EQ-5D index score. On the visual analogue scale patients were asked to rate their own health state relative to full health (score=100) or worst imaginable health state (score=0).

Patients' expectations of, and satisfaction with their anticoagulant treatment were assessed using the Perception AntiCoagulant Treatment Questionnaire (PACT-Q). This is a validated tool which takes around 10 minutes to complete (23; 24).

Patient perception of the severity of their symptoms was assessed using the modified EHRA score (25).

Clinical Assessment of Performance Status and Cognitive Function

Performance status was assessed using the Karnofsky Performance Status Scale (26; 27). The Karnofsky score runs from 100 to 0, where 100 is "perfect" health and 0 is death, and has previously been used in AF patients (28):

100% – normal, no complaints, no signs of disease90% – capable of normal activity, few symptoms or signs of disease
80% – normal activity with some difficulty, some symptoms or signs
70% – caring for self, not capable of normal activity or work
60% – requiring some help, can take care of most personal requirements
50% – requires help often, requires frequent medical care
40% – disabled, requires special care and help
30% – severely disabled, hospital admission indicated but no risk of death
20% – very ill, urgently requiring admission, requires supportive measures or treatment
10% – moribund, rapidly progressive fatal disease processes
0% – death

Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) (29); a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.

Adverse Event Reporting

Following the patient's randomisation in the study, all AEs, whether related or not related to study drug, had to be collected. However, within the context of the NOAH - AFNET 6 trial, no specific AEs and/or laboratory abnormalities were being considered as critical to safety evaluations. Thus, reporting of AEs not fulfilling any criteria of seriousness was not time critical.

A newly diagnosed concomitant disease was also considered an AE. However, onset of ECG-documented AF and subsequently confirmed diagnosis of AF after randomisation was not considered an AE and did not require documentation in an AE form in the eCRF unless any criterion for seriousness was met.

Serious Adverse Event Reporting

Following the patient's written consent to participate in the study, all SAEs, whether related or not related to study drug, had be collected.

The investigator had to specify and report in the eCRF the nature of the sign or symptom leading to the SAE, the date of onset of the sign or symptom, the date of resolution (duration) of the specific event (not of the underlying disease), the intensity, interventions performed (if any), the relationship to study treatment, and the outcome.

All SAEs, whether related or unrelated to study drug, had to be reported expeditiously to the CRO through the SAE section of the eCRF within 24 hours of becoming aware of the event. An SAE form within the eCRF had to be completed for any event where doubt existed regarding its status of seriousness. Copies of the discharge letter, of all reports regarding examinations carried out and/or diagnostic findings had to be faxed to the CRO. For laboratory results, the laboratory normal ranges had to be included. All documents had to be sent to the CRO after adequate blinding of patient identifiers, only.

Follow-up of any SAE that was fatal or life threatening had to be provided within one additional calendar week.

Any SAE reporting (initial reporting and follow-up information on e.g. changes of an ongoing SAE's intensity or relationship to the investigational product or outcome) was done through the SAE section of the eCRF and an automated email notification system within the e-trial management system, i.e. no extra SAE form (case report form) needed to be faxed but the CRO received an automated email containing all necessary information on the SAE at the same time of the data was being documented or changes of relevant SAE data were being made in the eCRF.

The investigator had to take all appropriate measures to ensure the safety of the patients, notably he / she had to follow-up the outcome of any AE or SAE (clinical signs, laboratory values or other, etc.) until the return to normal or consolidation of the patient's condition. In case of any SAE, the patient had to be followed until clinical recovery was completed and laboratory results have returned to normal, or until progression has been stabilized.

The sponsor forwarded via contracted CRO all SAEs immediately after awareness to the pharmacovigilance department of the edoxaban manufacturer for inclusion in their global safety database. The relevant SAE data was retrieved from data documented by the investigator within the eCRF and sent to the edoxaban manufacturer digitally. Changes of relevant SAE data (including deletion of SAEs if relevant criteria are not met) were also forwarded to the pharmacovigilance department of the edoxaban manufacturer. Patient identifying data consisted of patient ID number, year of birth, gender and site ID number, only.

According to legal requirements and international standards, annual safety reports were prepared by the sponsor or its responsible subcontractors and forwarded to responsible authorities of all participating countries and to all corresponding ECs / IRBs.

SAE intensities were defined as follows:

- Mild: Patient is aware of signs and symptoms but they are easily tolerated
- Moderate: Signs/symptoms cause sufficient discomfort to interfere with usual activities
- Severe: Patient is incapable to work or perform usual activities
- Very severe: Signs/symptoms are debilitating, significantly incapacitate patient despite symptomatic therapy

9.5.2 Primary efficacy variable(s)

The primary outcome parameter of NOAH - AFNET 6 is defined as the time from randomisation to the first occurrence of stroke, systemic embolism or cardiovascular death. A detailed definition of these outcome events is provided in Appendix III of the study protocol (16.1.1).

9.6 Data Quality Assurance

Initiation visit

At each study site an initiation visit was performed by a representative of the CRO before enrolment of the first patient at this site. The visit was conducted in adherence to a pre-defined checklist in order to ensure standardized training of site personnel. The following topics were trained in detail:

- Presentation, based on study protocol: study aim, administration, In- /exclusion criteria, randomisation / stratification, visit schedule., patient reported outcomes, primary and secondary outcomes, definition SAE / AE, study drug, withdrawal / modification of consent, etc.
- Presentation of investigator site file (ISF): Handling temperature logger, logistics of blood samples, important patient documents, etc.
- Presentation of eCRF: Specifics of data entry (data entry manual was provided), exercises in demo version, etc.
- Current status, administrative topics: Scheduling monitoring visits, appointments, patient screening, site status, essential documents, delegation log, laboratory certificates, etc.
- Monitoring: Definition ‘Source Data’, as well as access, documentation of first medication intake, medication storage, supply, and return, etc.

Monitoring

Quality management (e. g. on-site monitoring visits, off-site central monitoring, and other tasks of quality control) were carried out based on a Risk Based Study Monitoring Plan (RBSMP). The RBSMP identified the requirement to perform an ongoing review of any eCRF item (automated, by means of statistics and by research professionals, e. g. manual queries), the amount of source data verification and review, the frequency of on-site monitoring visits and actions to be taken based on the result of central and on-site monitoring. Thus, frequency of on-site visits and amount of source data verification was dynamic and dependent on performance and quality of each study site. Monitoring of the study sites during the trial was performed by authorised, qualified representatives of the designated CRO.

The main duty of the monitor was to help the sponsor and the investigator to maintain a high level of ethical, scientific, technical and regulatory quality in all aspects of the trial. At regular intervals during the study, the

local site was contacted through monitoring visits, letters/ emails or telephone calls by a monitor to review the progress of the study.

Independent close out visits were performed, primarily to collect study drugs. The close out visit may have been combined with the last regular monitoring visit.

Monitoring by telephone

The monitor or adequate members of the in-house project team conducted telephone monitoring contacts on average every two months per study centre. Prior to these contacts, central monitoring of the eCRF will be conducted for sites having recruited patients (e.g. check regarding data queries to be answered / to be closed, incomplete data). The focus of these phone monitoring contacts was:

- Recruitment status / recruitment forecast.
- eCRF documentation.
- Occurrence of SAEs.
- Problems if any, necessary support if required.

Investigator meetings

Investigator meetings were deemed crucial for ensuring that this trial was conducted in a standardized and compliant manner, leading to reliable and meaningful results. Therefore, investigator meetings were held in average 2-3 times per year (primarily as face-to-face meetings) and served several important purposes:

- Protocol Review including its objectives, procedures, and requirements.
- Training on how to conduct the study, including how to collect data, administer treatments, and handle adverse events.
- Regulatory Compliance by means of raising awareness and adherence to regulatory requirements.
- Data Quality by means of emphasizing the importance of data accuracy and integrity.
- Collaboration among investigators.
- Q&A in order to avoid misunderstandings and protocol deviations.
- Motivation of study staff.

Auditing procedures

On 22. + 23.02.2017 the Sponsor of the trial had commissioned an audit of its own operating department with the following scope: “To assess gaps in potential areas for improvement of general systems and procedures of the auditee, with focus on Quality Management and sponsor oversight activities.”

Although not in focus, some general aspects of the NOAH - AFNET 6 trial were part of this audit due to its broad scope. The audit certificate is provided in 16.1.8.

9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size

9.7.1 Statistical and analytical plans

In this section the analysis planned before unblinding of evaluating statisticians are described. This based on the study protocol and the statistical analysis plan (SAP).

Primary hypothesis

The main aim of the proposed study was to test the null hypothesis that the hazard rate, which is assumed to be constant during the study period, is identical in the two groups, i.e. the aim to demonstrate that oral anticoagulation with the NOAC edoxaban is superior (test for difference) to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE but without overt AF and at least two stroke risk factors leading to a modified CHA2DS2VASc score of 2 or more.

Primary outcome

The primary outcome parameter of NOAH - AFNET 6 is defined as the time from randomization to the first occurrence of a composite of ischemic stroke, systemic embolism or cardiovascular death.

Secondary outcomes

The secondary outcome parameters are defined as

a) time from randomization to components of the primary outcome (time to first event, i.e. for the non-fatal events (ischemic stroke and systemic embolism) only the respective first event is used),
b) time from randomization to all-cause death,
c) time from randomization to first occurrence of Major Adverse Cardiac Events (MACEs: cardiovascular death, myocardial infarction, acute coronary syndrome (ACS); percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)),
d) time from randomization to first occurrence of ischemic stroke or systemic arterial embolism (composite),
e) time to first occurrence of major bleeding event
f) number of major bleeding events according to the International Society on Thrombosis and Haemostasis (ISTH) definitions,
g) quality of life changes at 12 and 24 months compared to baseline (assessed by EQ-5D including its visual-analogue scale and by the Karnofsky scale (EuroQol Research Foundation, 2019), (van Hout & Janssen, 2012),
h) patient satisfaction changes at 12 and 24 months compared to baseline (assessed by modified EHRA score and PACT-Q2 (Prins, et al., 2009a), (Prins, et al., 2009b))
i) cognitive function changes (MoCA) at 12 and 24 months compared to baseline
j) changes of autonomy status only in patients with stroke during study participation, assessed at each clinical follow-up visit by modified Rankin scale; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed.

Safety outcome

Are captured with the primary outcome and in the previous section c), d), e), f).

Additionally, the combined outcome of time from randomization to death or time from randomization to first occurrence of major bleeding (composite outcome) will be analysed.

For all analyses of secondary, safety, and patient reported outcomes a test for difference will be used. Analyses of secondary, safety, and patient reported outcomes will be performed exploratory without adjustment for multiplicity.

Sample size

NOAH - AFNET 6 is an event-driven trial with a planned number of randomised and treated patients of n=2,538 and an anticipated number of primary efficacy outcome events of n=220. The protocol includes an adjustment of the sample size based on an analysis of events after 1000 observed patient-years. Details of sample size calculation can be found in the following section (9.7.2).

Statistical interim analyses and stopping guidance

The Steering Committee (SC) has assessed pooled event rates after about 1,000 patient-years of observation in the mITT (modified intention-to-treat) study population (without knowledge of study group assignment or study treatment). Alternatively, the interim analysis could have been conducted after about 24 months after enrolment of the first patient (this was not the case). Sample size or inclusion criteria (e.g. enrichment for patients at higher risk for events should low event rates be observed, or adaptation of sample size based on observed event rates, or alternatively reduction of the number of patients needed based on observed events) were adapted to reflect the observed event rates.

The pooled event rate was calculated as the ratio of the sum of all observed primary events until the time point of interim analysis and corresponding person-years, defined as the sum of all observed follow-up times (in years) for each patient between randomization and the event date (patients with primary events), or the date of development of overt AF, date of unblinding, or the last documented follow-up information (all other patients). The corresponding 95%-confidence interval was estimated using the quadratic approximation to the Poisson log likelihood for the log-rate parameter.

The event rate was 4.61% (95%-confidence interval: 3.46%, 6.16 %). This event rate was not significantly different to the assumed event rate of 4.4% per year (p=0.748). Adjustments in the sample size or in the inclusion criteria were discussed in the SC based on this result. No changes were decided. However, since the recruitment rate was lower than expected, the required accrual period changed from 54 to 71 months. The sample size, which was initially estimated to be 3,400 patients, was subsequently reduced to 2,538 patients.

Timing of final analysis

NOAH - AFNET 6 is an event-driven trial with a planned number of randomised patients of n=2,538 and a fixed number of valid events (n=220). The total duration of the trial is an estimate based on observed outcome rates in other large trials with similar populations. The total number of events in the trial is depending on the time at risk that is the follow-up time of all patients. In practice, the event-driven design may result in slight variation of the of the total number of patients enrolled if observed event rates do not exactly match the assumed rates. All patients will be followed until the global end of the trial. Remaining medication will be collected at the final visit. As given in the study protocol following estimation for the study duration is made: Screening and enrolment of patients is expected to be accomplished after 71 months. Based on the sample size estimation, it is expected that the required number of adjudicated (verified primary outcome events) will be reached 12 months after enrolment of the last patient. Due to the time required to obtain follow-up information and to adjudicate events (about 3 months to perform a final study visit in all patients still in the trial plus 4 months for receiving adjudication by ERC to confirm that the required number of adjudicated endpoints have been reached), a total

study duration of 71 + 12 + 3 + 4 = 90 months is expected. The total study duration of 90 months (about 7.5 years) was adapted based on an interim analysis. After that and data management the final analysis can be conducted.

Global end of study (EOS) is defined as the last Final Visit performed in a study patient. This date will be approved by the sponsor and announced by the CRI.

The global end of study will be announced by the CRI after all necessary primary efficacy outcome events have been reached.

This procedure can result in more than the anticipated primary events within the final analysis (depending on the amount of events that can be adjudicated).

The accrual time and hence the total study time was further adapted in 2022 due to loss of Ukrainian participants and the lower than expected event rate. The steering committee decided to censor all Ukrainian patients on the last documented contact before the 24th February 2022, the day of the outbreak of war in Ukraine, to protect the trial against unexpected changes in event rates due to the influence of war on Ukrainian patients.

Analysis of the primary outcome

The **primary outcome** was the time from randomisation to the first occurrence of stroke, systemic embolism or cardiovascular death. Patients who developed overt AF during the trial period were censored at that point in time but followed according to protocol until the global end of the trial. All other patients who did not reach the primary efficacy outcome by the global end of the study were censored at that time point. All randomised patients were included in the analysis on a modified intention-to-treat-basis.

A cause-specific Cox-proportional hazards model with frailty for centres and the fixed effects random group and ASA, i.e. an adjusted estimated (cause-specific) hazard ratio (hazard ratio of edoxaban vs usual care) with two-sided 95% confidence interval, and corresponding p-value are provided as well as cumulative incidence curves gained from the Aalen-Johansen estimates for competing risks analysis. The proportional hazards assumption was checked graphically (e.g. Schoenfeld residuals, -log-log-survival) and met.

Analysis of the secondary outcome

The following **secondary outcome** were analysed in the same way as the primary outcome: time to components of primary outcome, time to major adverse cardiac events (MACEs), time to stroke or arterial embolism, time to major bleeding events.

Time to all-cause death was analysed using an adjusted Cox-proportional hazards model (hazard ratio of edoxaban vs usual care) with the fixed effects random group and ASA and a frailty term for study side. The Kaplan-Meier estimated was used for visualization.

The following continuous secondary outcomes:

g) change in quality of life (EQ-5D and Karnofsky score),
h) patient satisfaction (PACT-Q2, EHRA),
i) cognitive function (MoCA),

at 12 and 24 months were analysed using the difference to baseline as outcome in the following model:

- baseline and randomization strata (ASA) adjusted linear mixed effects regression with a restricted maximum likelihood approach using the Newton-Raphson algorithm,
- with a time (12 and 24 months) by treatment interaction if interaction p-value <0.05; else only both main effects
- the dependency structure of the time points will be modelled by including the study side as random effect (independent identically distributed) and patient nested within study side, with an unstructured variance covariance matrix of the residuals matrix (time points).

Normal distributed residuals were checked graphically via histogram of residuals and nor deviation was seen.

Adjusted mean values and adjusted effect estimators (mean differences) with corresponding confidence intervals and p-values are given.

f) Number of major bleeding events according to ISTH: randomization strata adjusted mixed negative binomial regression with the individual observational time as offset.

The analysis for the continuous secondary outcomes was specified in the SAP and differed to the study protocol.

Safety analysis

Safety analyses was performed based on the data of the safety population following the ITT principle.

The primary **safety outcome** in this study is a composite of cardiovascular death, stroke, and systemic embolism which was going to be analysed using time-to-event methodology as described above. Similar analyses and summary statistics were to be provided for the components of this safety composite outcome.

SAEs were going to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary in its actual version at the start of the study by Lowest Level Terms (LLT). Treatment related SAEs were going to be summarized under each treatment group, by system organ class (SOC) and preferred term (PT).

Subgroup analysis

Explorative **subgroup analyses** with respect to the primary outcome that allow identifying determinants of treatment success were going to be performed by the appropriate interaction tests for each subgroup separately. Each test was going to be performed at a significance level of alpha=5% and within the mITT population. Predefined subgroups were:

- Sex
- Age groups split by median as well as ≥75 years
- Maximal duration of AHRE episodes (>24 hrs vs other)
- AHRE duration split by median
- Stratified by CHA2DS2VASc score / factors
  - congestive heart failure history
  - hypertension history
  - diabetes history
  - Stroke/TIA/thromboembolism history
  - Vascular disease history (prior MI, peripheral artery disease, or aortic plaque)

- high comorbidity burden (CHA2DS2VASc score >5 and CHA2DS2VASc score > median)
- Adherence:
  - Non-adherence: Intake of study drugs < 80% of the number of daily dosages calculated for the corresponding time period.
  - Acceptable adherence: Intake of study drugs 80% to < 90% of the number of daily dosages calculated for the corresponding time period.
  - Good adherence: Intake of study drugs 90% or more of the number of daily dosages calculated for the corresponding time period.
- Patients without any AHRE during the study duration

Additional analyses

For the explorative multiple cause-specific Cox proportional hazard models with fixed effects for random group and ASA and a frailty for study site and the inclusion of several covariates, the additional covariates were chosen by the SC and include:

- Age
- Sex
- congestive heart failure history
- hypertension history
- diabetes history
- stroke/TIA/thromboembolism history
- vascular disease history (prior MI, peripheral artery disease, or aortic plaque)
- aspirin intake at baseline
- Non-Steroidal Anti-Inflammatory Drugs

Data Monitoring

The DSMB, whose roles and responsibilities as well as composition was described in section 6, was tasked with review of the following items:

- Interim/cumulative data for evidence of safety, based on general adverse events as documented by investigators and on safety outcomes as validated by the Endpoint Review Committee. Safety outcomes are defined as components of the primary outcome parameters, all-cause death, and major bleeding events (according to the International Society on Thrombosis and Haemostasis (ISTH) definitions);
- Interim/cumulative data for evidence of efficacy based on the primary outcome parameters according to pre-established statistical guidelines, if appropriate;
- Data quality, completeness, and timeliness;
- Performance of individual centres;
- Adequacy of compliance with goals for recruitment and retention, including those related to the participation of women and minorities;
- Adherence to the protocol;
- Factors that might affect the study outcome or compromise the confidentiality of the trial data (such as protocol violations, unmasking, etc.);
- Factors external to the study such as scientific or therapeutic developments that may impact participant safety or the ethics of the study.

9.7.2 Determination of sample size

Estimation of stroke rates in the NOAH - AFNET 6 population

The table below gives the estimated annual event rates based on previously published trials. Taken together, this information formed the basis for the sample size estimation and for the risk assessment for individual patients enrolled into the trial.

Table 3 Published annual stroke and cardiovascular death event rates in patients with documented AHRE.

	Stroke	Cardiovascular death	Sum
ASSERT (30), 261 pts, 2.5 yrs. FU	1.7	2.9	4.45
MOST (31), 160 pts, 2.25 yrs. FU	5	4.2	9.2
AT500 (32), 725 pts, 1.833 yrs. FU	3.6		
Botto et al (33), 223 pts., 1 yr. FU	3.2		
AVERROES ASA arm (16), 2791 pts, 1.1 yrs. FU	3.4	3.1	6.4
AVERROES and ACTIVE ASA arms pAF (34), 1576 pts, 1.1 yrs. FU	2.1	3.1	5.2
ROCKET-AF pAF patients (35), 2514 pts, 2.4 yrs. FU	1.7	3.5	4.9
SOS (36), 4287 pts, 2.17 yrs. FU	1.2		
Estimated event rate control (weighed by patient-years FU)	*1.9*	*3.3*	*5.3*


Event rates are split by stroke and cardiovascular death. The sum of these two components determined the estimate for the primary outcome. All events are rounded to one decimal after calculation.

Estimation of the safety of edoxaban in the NOAH - AFNET 6 population

The safety assessment for the trial participants was based on the favourable bleeding profile of a edoxaban 60 mg OD regime compared to warfarin in the ENGAGE-TIMI 48 trial, combined with the observations made in BAFTA and AVERROES that acetylsalicylic acid does not cause more severe bleeding events or therapy discontinuation than warfarin (15; 16; 17). Thus, the risk for patients randomised to edoxaban seemed very small. The safety assessment was in line with the observed small bleeding rates in the ENGAGE-TIMI 48 trial (Figure 5).

Development of overt, diagnosed AF in patients with AHRE

Some patients with AHRE were expected to develop overt, diagnosed AF during the follow-up time. As diagnosis of overt AF constitutes an indication for oral anticoagulation, these patients were going to be censored at the time of developing overt AF. In addition to expected event rates and the potential for event reduction, the sample size estimate recognised that these patients were going to be censored at this moment. Most of these patients were going to be additional to the expected attrition rate in this double blind randomised trial. Based on data published in the ASSERT study and in a small portion of the MOST trial population, 13-16% of patients with AHRE will develop overt AF over a follow up time of 2.5 years (30; 31). Based on the increased use of clinical ECG monitoring, e.g. by Holter ECGs, it was expected that this rate was going to be higher in the NOAH - AFNET 6 population.



	stroke, systemic embolism, or cardiovascular death	fatal bleeding	haemorrhagic stroke plus other ICH	Major extracranial haemorrhage
ENGAGE edoxaban 60 mg OD dosing regime	3.85	0.20	0.39	2.65
AVERROES aspirin	6.40	0.20	0.50	*1.2**
BAFTA aspirin	8.10	0.10	0.50	2.00

Figure 5 Major efficacy and safety annual event rates for patients randomised to edoxaban 60 mg OD in the ENGAGE-TIMI 48 trial compared to event rates reported in patients randomised to acetylsalicylic acid in the AVERROES and BAFTA trials *(16; 15; 17)*. All events are given as annualised rates in percent.
*For the AVERROES acetylsalicylic acid group, only the AVERROES major bleeds are reported, although some of the "clinically relevant non-major bleeds" in AVERROES would have been classified as "major" in BAFTA and ENGAGE.

Estimation of the benefit of edoxaban in the NOAH - AFNET 6 population

Patients randomised to edoxaban were going to have a reduction in stroke or TIA rates by 2/3 (67%), (16; 37), and a 10% reduction in cardio-vascular death. The effect estimate for stroke prevention was based on the effect size observed for stroke prevention with VKAs vs. acetylsalicylic acid, assuming that edoxaban is at least as effective as dose-adjusted warfarin in preventing strokes in AHRE patients (38; 39). This assumption discounted the fact that NOAH - AFNET 6 was going to compare the potentially more effective agent edoxaban to a control therapy that was going to consist of acetylsalicylic acid or placebo. The effect size for reduction in cardiovascular death was the point estimate of reduction in cardiovascular deaths observed in the four NOAC trials compared to warfarin. This conservative estimate was thus based on the assumption that the mortality benefit of edoxaban vs. usual care in NOAH - AFNET 6 was not bigger than the mortality benefit of edoxaban compared to dose-adjusted warfarin observed in ENGAGE-TIMI 48 and in the other three NOAC trials (2).

These assumptions resulted in an estimated event rate of 0.64% per year for stroke and a 3% event rate for cardiovascular death.

Sample size

Based on these assumptions, computation of sample size was based on a hazard ratio of 0.68, accrual period of 71 months and minimal follow-up of 12 months. Specifically, it assumed annual hazard rates of 5.3% for the standard treatment group versus 3.64% for the NOAC group. This was equivalent to median event-free survival of 13 years for the standard treatment group versus 19 years for the NOAC group. This effect size was considered realistic, in the sense that an effect of this order of magnitude could be reasonably anticipated in this field of research.

The criterion for significance (alpha) was set at two tailed 5% and for power (1-beta) at 80%. Thus, if the true population hazard ratio of control to treated patients was 0.68 then at least 220 events were expected to be observed. Assuming that the competing event of non-cardiac death had a hazard rate of 0.02 for both groups then at least 865 patients per group were needed to have a power of 80% to detect as significant that difference at the two-sided 5% level of significance. Patients who developed overt AF during the trial period were going to be censored at that time point. The hazard of developing overt AF or of dropping out of the trial for other reasons (e.g. withdrawal of consent) was assumed to be at 0.287 throughout the trial. This 0.287 hazard was equivalent to 25% first year development of overt AF or of dropping out of the trial for other reasons, and went up to 57% by the end of the third year. Taking this into account, the number of patients per group became 1,269 (40; 41; 42). This estimate was based on the assumption that 5% patients per year were going to decide to stop the study during the follow-up. In addition, it was expected that 16% of the patients were going to develop overt AF, thus requiring oral anticoagulation outside of the trial, over a follow-up period of 2.5 years (based on ASSERT, 41/261 patients over 2.5 year follow-up) (30; 31). Thus, 2,538 patients had to be randomised and treated.

9.8 Changes in the Conduct of the Study or Planned Analyses

Throughout the trial period, several changes were made in the conduct of the study, focusing on elements that improved the study's execution and/or planned analyses.

After a blind re-calculation by the study statistician the recruitment duration was increased from 27 to 54 months. As a consequence, the total number of required patients was reduced from 3,400 to 2,686. This also led to a prospective increase of IMP exposure time in approx. 500 patients already enrolled at that time. It was clarified that the expected number of patients was described as patients who have been randomised and took at least one dose of study drug (randomised and treated; Amendment no.2, dated 27.04.2018).

Also during the course of the year 2018 two inclusion criteria were adapted:

- I1: Insertable cardiac monitors were added to the list of implanted devices for detecting AHRE as meanwhile these devices were assessed as reliable as pacemakers and defibrillators in detection and recording of AHRE.
- I3: Atrial rate of documented AHRE was set to 170 bpm (previously 180 bpm) as experience throughout the trial conduct showed that factory setting of most devices were not changed and mostly were set at 170-175 bpm.

Moreover, due to manufacturers supply difficulties the brand of the comparator ASA (formerly HEXAL) had to be changed. The tablets in circulation were continued to be used and the new brand was introduced in parallel. The active ingredients remained identical (Amendment no.3, dated 06.11.2018)

Lastly, in 2019 the number of patients (2,686 to 2,538), number of primary efficacy outcome events (222 to 220), duration of recruitment (54 to 71 months), maximum follow-up time (69 to 83 months) and total study duration (73 to 90 months) were adapted based on the interim analysis after 1,000 observation years. The results of the interim analysis in short form were included in the study protocol (Amendment no. 4, dated 01.12.2019).

10. STUDY PATIENTS

10.1 Disposition of Patients

A total of 2,608 patients with AHRE were randomly assigned to a treatment group across 206 sites in 18 European countries between 24th June 2016 and 6th September 2022. The modified intention-to-treat analysis population consisted of 2,534 patients (Figure 6). Drop-out prior to receiving treatment was similar between groups.

Of 1,270 patients who received edoxaban, 365 (29%) received 30 mg at baseline; 134 patients withdrew their consent and 234 developed AF. Of 1,264 patients treated with placebo, 683 (54%) received acetylsalicylic acid; 134 patients withdrew their consent, 230 developed AF.




Figure 6 CONSORT Flow chart

A listing of all individual patients discontinued from the study after enrolment, broken down by centre and treatment group, is displayed in Table 24.

10.2 Protocol Deviations

The following protocol deviations were specified by the SC:

- Deviation from inclusion criteria is a major protocol deviation, i.e. if the following is not fulfilled:
  - Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation (not major for ILR (implantable loop recorder))
  - AHRE detection feature activated for adequate detection of AHRE (not major if AHRE episodes were reviewed by site and adequate criteria found)
  - AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally. Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple “box change” operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible.
  - modified CHA2DS2VASc score of 2 or more
- Deviation from exclusion criteria is a major protocol deviation, i.e. if the following is observed:
  - Any disease that limits life expectancy to less than 1 year
  - Participation in another controlled clinical trial, either within the past two months or still ongoing.
  - Previous participation in the present trial NOAH - AFNET 6.
  - Drug abuse or clinically manifest alcohol abuse.
  - Any history of overt AF or atrial flutter
  - Indication for oral anticoagulation (e.g. deep venous thrombosis).
  - Contraindication for oral anticoagulation in general
  - Contraindication for edoxaban as stated in the current SmPC.
  - Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present.
  - Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation.
  - End stage renal disease (creatinine clearance < 15 ml/min as calculated by the Cockcroft-Gault method).
  - All persons exempt from participation in a clinical trial by law.
- Deviation related to study therapy defined as major:
  - Intake of study drugs < 80% of the number of pills calculated for the corresponding time period
  - Permanent stop of IMP intake without indication or contraindication for oral anticoagulation
  - Measurement of creatinine value at baseline visit older 28 days if it is not measured within 6 months of therapy initiation
- Deviation related to study procedures defined as major:
  - No complete chain of medication supply if interruption is 20% or more of the planned treatment time (aligned with definition of adherence)
  - Simultaneous intake of study medication and other oral anticoagulation
  - Simultaneous intake of study medication and any antiplatelet agent

Table 25 summarises all observed protocol deviations in the mITT population, defined as ‘major’. Individual patients with these protocol deviations are listed in Table 26, broken down by study centre.

11. EFFICACY EVALUATION

11.1 Data Sets Analysed

The population primarily used for all analyses was the modified intention-to-treat population (mITT). Additionally, the Per protocol and Safety populations were analysed.

mITT population

The mITT population consists of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug. The mITT doesn't include patients that were randomized but a) have AF onset before 1st dose of IMP, or b) die before 1st dose of IMP, c) withdrew their consent before 1st dose of IMP or d) are lost to follow up before 1st dose of the IMP.

A tabular listing of all patients excluded from the efficacy analysis is provided in Table 27.

Per protocol population

The Per Protocol population consists of mITT populations patients who have no major protocol violation. Definition of major protocol violations are provided in section 10.2. If possible, patients with major protocol deviation were censored at the time of a major protocol deviation for the per protocol population. The censoring time of the major protocol deviation was used if it occurred before a primary event or other censoring was observed.

Safety population

Safety data was collected on all enrolled patients (i.e. all patients that signed informed consent) in this study.

Furthermore, for all outcomes the following applies:

Information on the number and level of withdrawals/drop outs, number included in the analysis and the number died are presented in CONSORT diagram format with numbers and reasons for withdrawal and/or exclusion from analysis given at each visit.

- Modification of consent (MOC): Patients who wish to withdraw from the study are asked to maintain consent for minimal effort follow-up, allowing to use their clinical data achieved at the clinically indicated visits. All available data will be used until the end of study (no drop out of patient).
- Withdrawal of consent (WOC): If patients withdraw consent to any further study participation, data will be used until time of withdrawal and censored afterwards.
- Complete withdrawal: Patient request deletion of all his/her data.
- Early withdrawal: Withdrawal of patient's consent (WOC) within the first month after study inclusion. Patients with early withdrawal will be included in primary analysis. Furthermore, a sensitivity analysis will be conducted without these patients.

For time-to-event outcomes the following applies:

Event definition: No matter what, i.e. although events might occur in quick succession, the first event that was observed is used within analysis. Primary outcomes that occur within one day of unblinding will be counted as primary outcomes.

Trial specific censoring

Patients who developed overt AF during the trial period were censored at that point in time but followed according to protocol until the global end of the trial. From time point of unblinding, the subject was censored for analysis in the mITT population. Patients without an event at the end of follow-up had their efficacy measure censored at the end of follow-up. If a patient was lost to follow-up, the last time point of contact was used as censoring time point in case of no event, else the event time point was used for analysis. If a patient withdrew his/her consent but accepted that data till this time point of withdrawal could be used, the time point of last contact was used as censoring time point in case of no event, else the event time point was used for analysis.

All the data from the trial sites in Ukraine were censored on February 24, 2022, the start of the Russian invasion.

All time-to-event outcomes were also analysed for the safety population and for the per-protocol population as well as the following population used for sensitivity analysis:

- using the mITT population with censoring of patients at the time of discontinuation of IMP
- without censoring for overt AF or for unblinding
- without patients who withdrew their consent (early or late and early only, i.e. <1 month).

Missing values

For the primary outcome the worst case scenario is used for missing values, i.e. deaths of unknown cause will be classified as CVD in all analyses. No other imputation will be conducted for any analysis.

11.2 Demographic and Other Baseline Characteristics

The number of patients observed was 2,608, of which 2,534 are included in the mITT population. The patients were included from 206 centres in 18 European countries. First patient was randomized on 24. June 2016 and the last patient was randomized on 06. September 2022.

The mean age of patients was 77.5 years, median CHA2DS2-VASc score 4 (range 0 to 9, higher scores indicating greater stroke risk), and median AHRE duration 2.8 hours, most with rates >200 beats per minute (Table 8). The median number of AHRE episodes was 2.0 in each group. Demographic data and clinical characteristics were similar between groups (Table 8). The representativeness of the trial population is shown in Table 9. Ethnicity and race were not systematically recorded; the populations were primarily Caucasian/White in participating centres and countries.

All relevant individual patient demographics are presented in Table 28.

11.3 Measurements of Treatment Compliance

The measures taken to ensure and document treatment compliance are described in section 9.4.8. The individual treatment compliance, based on questioning the patient about medication intake and documentation of pill count by study centres, are demonstrated in Table 29.

11.4 Efficacy Results and Tabulations of Individual Patient Data

11.4.1 Analysis of efficacy

Primary outcomes

The trial was stopped prematurely following recommendations of the DSMB and the SC. At the time of termination of the trial, enrolment of all planned patients was complete and 184/220 planned patients had experienced a first primary outcome during a median follow-up duration of 21 months per patient in both randomized groups (placebo 21 months (IQR, 9 to 38); edoxaban 21 months (IQR, 11 to 38)).

The primary efficacy outcome occurred in 83/2,556 patient-years (3.3%/year) assigned to anticoagulation and in 101/2,494 patient-years (4.0%/year) assigned to no anticoagulation (HR 0.81; 95% confidence interval [CI], 0.60 to 1.08; p = 0.15;Table 10, Figure 8A).

Secondary outcomes

Strokes occurred in 22 patients (0.9%/year) assigned to anticoagulation and in 27 patients (1.1%/year) assigned to placebo (Table 10). A first occurrence of systemic embolism was observed in 14 patients (0.5%/year) assigned to anticoagulation and in 28 patients (1.1%/year) assigned to placebo. The pre-specified outcome of combined ischemic stroke and systemic embolism rate was 25/2566 patient-years(1%/year) in patients assigned to anticoagulation and 38/2508 patient-years (1.5%/year) in patients assigned to placebo (HR, 0.65; 95% CI, 0.39 to 1.07). Cardiovascular death occurred in 52 patients (2.0%/year) assigned to anticoagulation and in 57 patients (2.2%/year) assigned to placebo (Table 10). Major bleeding events occurred in 53 patients assigned to anticoagulation and in 25 patients assigned to placebo (HR, 2.10; 95% CI, 1.30 to 3.38). Death occurred in 111 patients assigned to anticoagulation, and in 94 assigned to placebo (HR, 1.16; 95% CI, 0.88 to 1.53; Table 13).

The average EQ-5D-VAS score worsened over time without a substantial difference between trial groups (Table 14). Other patient-reported outcomes, cognitive function, and functional status did not change appreciably over time and were similar between trial groups (Table 14).

Safety outcome

The composite safety outcome occurred in 149 patients (5.9%/year) assigned to anticoagulation and in 114 patients (4.5%/year) assigned to no anticoagulation; HR 1.31; 95% CI, 1.02 to 1.67; p =0.03; Table 10, Figure 8B).

Sensitivity and subgroup outcome

Sensitivity analyses, outcomes in subgroups, per protocol, and results in the safety population of all randomized patients were generally similar to the primary analysis (Table 11, Figure 9, Figure 10, Table 12).

11.4.2 Statistical/analytical issues

The trial had an event-driven design (43) and used a modified intention to treat analysis. Based on event rates in recently published trials, the primary outcome was tested for a difference between treatment groups with an overall two-sided type 1 error rate of 5%. Sample size was estimated at 3,400 patients and adjusted to 2,538 patients at a planned, blind interim analysis without alpha spending after 1,000 patient-years of follow-up (43). The overall event rate at that time point (4.6%) was not markedly different from the expected rate. The number of required primary outcome events was anticipated to be approximately 222 to show a difference between the treatment groups with a power of 80%. Sample size was calculated based on an enrolment period of 71 months (adjusted from 54 months during the planned interim analysis), a 32% risk reduction in the primary outcome (assumed hazard ratio of 0.68), a hazard rate for the competing event non-cardiac death of 0.02, and a hazard rate of 0.287 to develop overt AF13. The DSMB decided at the outset of the trial that there would be no formal stopping rule.

Categorical data are summarized by numbers and percentages. Continuous data are summarized by mean and standard deviation or median with 1st and 3rd quartile (interquartile range, IQR) as appropriate. The primary outcome analysis was performed in all randomized patients receiving at least one dose of study drug (modified intention-to-treat population: mITT). For the primary analysis, patients were censored when they developed ECG-documented AF, rhythm or event data were inadvertently unblinded, were lost to follow-up, or withdrew consent. All Ukrainian patients were censored from 24th February 2022, the day of the Russian invasion.

For the primary analysis, a cause-specific Cox-proportional hazards model using Breslow method to handle tied failures was conducted, with frailty for centres, the predictor randomized group and the randomization strata indication for acetylsalicylic acid as covariate and under the assumption of independent censoring. The proportional hazards assumption was confirmed using graphical methods. The outcome results are reported as group-specific event rates in percent per patient-years and as adjusted estimated cause-specific hazard ratio with a two-sided 95% confidence interval and corresponding p-value. In the case of competing events, cumulative incidence curves are shown using Aalen-Johansen estimates that take account for competing events, otherwise Kaplan-Meier curves are used. The time-to-event secondary outcomes were analysed in the same way as the primary outcome. There was no pre-specified plan for the adjustment of the widths of confidence intervals in differences between groups for secondary outcomes and no definite conclusions can be drawn from these data. The continuous secondary outcomes were analysed using the difference from the follow-up values at 12 and 24 months to baseline. Therefore, negative values reflect a decrease from baseline. Post hoc mean differences were estimated with a linear mixed-effects regression with a restricted maximum likelihood approach using the Newton-Raphson algorithm. The interaction between follow-up (12 and 24 months) and randomized group was estimated if the p-value of the interaction was <0.05, otherwise the independent effects of follow-up and randomized group were estimated, each adjusted for the respective

baseline values of the score and acetylsalicylic acid indication at randomization. The dependency structure of the time points was modelled by including the study site as a random effect and patient nested within the study site. A common unstructured (co)variance structure was used to model the within-patient errors. Denominator degrees of freedom were estimated using the containment method. All time-to-event outcomes were also analysed for the safety population (all randomized patients) and for the per-protocol population. The per-protocol analysis estimated the treatment effect in patients who exactly met all inclusion and exclusion criteria, took the study medication predominantly as scheduled, and did not take any other oral anticoagulation or antiplatelet agent, assuming that the occurrence of protocol deviations is independent from the randomized groups. In two sensitivity analyses, only patients with core-lab verified adequate AHRE at baseline were analysed and only patients who did not withdraw their consent. The impact of different causes of censoring was assessed in the mITT population (censoring for permanent treatment discontinuation, censoring at Covid-19 infection, or censoring of Ukrainian patients on 24th February 2022). For the primary outcome the worst-case scenario was used for missing values, i.e. deaths of unknown cause were classified as cardiovascular death (44). No other imputation was conducted for primary and safety outcome analysis. All analyses were conducted using StataCorp. 2021 (Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC.) and R (version 4.2.3).

The detailed documentation of statistical methods is provided in the NOAH - AFNET 6 Statistical Analysis Plan in 16.1.9.

11.4.2.1 Adjustments for Covariates

In the explorative multiple Cox regression for the primary outcome (see “Additional analyses” in section 9.7.1) it was seen that the treatment effect did not change. However, it seems that patients who had diabetes mellitus at baseline had a relevant increased rate for the primary outcome. For non-steroidal anti-inflammatory drugs at baseline this might also be the case, however the corresponding confidence interval is very wide. For the other co-variables there seems to be no relevant influence (Figure 7).




Figure 7 Adjusted effects on first primary outcome

11.4.2.2 Handling of Dropouts or Missing Data

For the primary outcome the worst case scenario will be used for missing values, i.e. deaths of unknown cause will be classified as cardiovascular death (44) in all analyses. No other imputation was conducted for any analysis, since there were too many missing values (for the continuous) outcomes.

11.4.2.3 Interim Analyses and Data Monitoring

The SC has assessed pooled event rates after about 1,000 patient-years of observation in the mITT (modified intention-to-treat; see Section 3.3.1) study population (without knowledge of study group assignment or study treatment).

The modified intention to treat population (mITT) consists of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug. The mITT doesn't include patients that were randomized but a) have AF onset before 1st dose of IMP, or b) die before 1st dose of IMP, c) withdrew their consent before 1st dose of IMP or d) are lost to follow up before 1st dose of the IMP.

Sample size or inclusion criteria (e.g. enrichment for patients at higher risk for events should low event rates be observed, or adaptation of sample size based on observed event rates, or alternatively reduction of the number of patients needed based on observed events) were adapted to reflect the observed event rates.

The pooled event rate was calculated as the ratio of the sum of all observed primary events until the time point of interim analysis and corresponding person-years, defined as the sum of all observed follow-up times (in years) for each patient between randomization and the event date (patients with primary events), or the date of development of overt AF, date of unblinding, or the last documented follow-up information (all other patients). The corresponding 95%-confidence interval was estimated using the quadratic approximation to the Poisson log likelihood for the log-rate parameter. The event rate of 4.4%, assumed for the sample size calculations, was not greater than the upper 95% limit.

The complete interim analysis performed in the year 2019 is provided in 16.1.9.

On 2 September 2022, the NOAH - AFNET 6 sponsor, the Atrial Fibrillation NETwork (AFNET), decided to terminate the NOAH - AFNET 6 study prematurely. This decision follows a unanimous recommendation by the DSMB on 26 August 2022 to terminate the study and a unanimous vote by the study's SC on 2 September 2022 to follow this recommendation.

As reasons for its recommendation to terminate NOAH - AFNET 6 the DSMB cited an observed trend towards futility of efficacy combined with safety concerns.

Furthermore, on the basis of a unanimous vote of the SC, the decision was taken by the sponsor to orderly terminate the trial, i.e., the final patient visit should have been performed for each patient still in follow-up as soon as possible, and all patients still taking IMP should have conducted a regular final visit at the study site at which the IMP intake ended.

11.4.2.4 Multiple Comparisons/Multiplicity

No adjustment for multiple testing was conducted since there was only one primary outcome with a two group comparison. All other analyses are considered explorative.

11.4.2.5 Use of an "Efficacy Subset" of Patients

Various sensitivity analyses were conducted, including the primary outcome analysis based on a population where all randomized patients were included. No change in effect was seen.

11.4.2.6 Examination of Subgroups

Outcomes in subgroups were generally similar to the primary analysis (Figure 9, Figure 10). Interaction p-values between subgroup and randomization group are reported and none was <0.05 suggesting that no subgroup has to be distinguished regarding the treatment effect

11.4.3 Efficacy conclusions

In patients with atrial high-rate episodes detected by implantable devices, edoxaban did not significantly reduce a composite primary clinical outcome of stroke, systemic embolism or cardiovascular death compared to placebo/ASA treatment, but increased a composite safety outcome of major bleeding and death. Stroke rates were low in both treatment groups.

For other secondary outcomes no clinically relevant effects were seen.

12. SAFETY EVALUATION

12.1 Extent of Exposure

Patients were randomly assigned in a 1:1 ratio to anticoagulation or placebo in a double-blind, double-dummy design. Patients were randomized in blocks of variable size at each trial site and stratified by indication for acetylsalicylic acid therapy.

Anticoagulation consisted of the factor Xa inhibitor edoxaban in the dose approved for stroke prevention in patients with atrial fibrillation (60 mg once daily). Criteria for dose reduction to 30 mg once daily approved by European regulatory authorities (body weight<60 kg, CrCl<50 ml/min or the concomitant use of strong P-glycoprotein inhibitors) were collected at the baseline visit and at each and appropriate dose adjustments were made. Trial drugs were dispensed in quantities anticipated to be adequate for 6 months. The control group received a double-dummy placebo containing no active compound or acetylsalicylic acid 100 mg daily based on accepted indications for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke. Eligibility for acetylsalicylic acid therapy was determined at the baseline visit and each time trial drug was dispensed. Duration of exposure in days are summarized by study drug in Table 4.

Table 4 Duration of exposure to study drugs

Study drug	Mean (SD)	Range	Quartiles (25% - 50% - 75%)	N patients
Edoxaban placebo[1] intake (days)	590.8 +- 490.3	1.0 - 2224.0	183.0 - 475.5 - 902.2	1264
Edoxaban 30 mg intake (days)	459.0 +- 412.6	1.0 - 1948.0	170.0 - 328.0 - 665.0	497
Edoxaban 60 mg intake (days)	518.8 +- 434.1	1.0 - 2171.0	176.0 - 385.5 - 767.0	970
ASA[2] placebo intake (days)	529.6 +- 456.9	1.0 - 2224.0	180.0 - 379.0 - 770.0	1403
ASA intake (days)	507.3 +- 433.7	1.0 - 2061.0	174.0 - 367.0 - 745.0	1449

[1] 30 + 60 mg combined

[2] ASA = Acetylsalicylic acid

12.2 Adverse Events (AEs)

12.2.1 Brief summary of adverse events

As all study treatments in this trial were marketed and in-line with clinical practice, even knowing that the administration of edoxaban in AHRE patients without overt non-valvular AF is not in-line with the approved label, adverse events were expected to occur in similar clinical manifestations and at a comparable rate as the known adverse events of the approved therapies applied in the trial. The observed and recorded AEs in this trial do not indicate otherwise.

In the Safety population (N=2,608) a total of N=1,380 patients experienced an AE (Table 5). With a total number of N=3,392 recorded AEs a mean of 2.46 AEs per patient was observed within a mean study period of 27.5 months (Table 5, Table 15). Of N=3,392 initially recorded AEs N=932 were defined as ‘serious’ (Table 15) which will subsequently be considered in the analysis of serious adverse events (SAEs). The remaining N=2,460 ‘non serious’ AEs will be discussed in this section.

12.2.2 Display of adverse events

Table 5 Summary of patients with adverse events (AEs)

	Placebo (N=1302)	Edoxaban (N=1306)	Total (N=2608)
No of AEs per patient			
N	662	718	1380
N-Miss	640	588	1228
Mean ± SD	2.38 ± 2.31	2.53 ± 2.53	2.46 ± 2.43
Median (Q1, Q3)	2.00 (1.00, 3.00)	2.00 (1.00, 3.00)	2.00 (1.00, 3.00)
Min. - Max.	1.00 - 25.00	1.00 - 25.00	1.00 - 25.00

12.2.3 Analysis of adverse events

In the edoxaban group more AEs were recorded (N=1,318) compared to the placebo group (N=1,142). In the edoxaban group more events were assessed as causally related to the blinded study drug ASA as well as edoxaban (Table 15). In total N=268 bleeding events/haematomas (10.9%; Placebo group: N=81; edoxaban group: N=187) and N=2,191 other events (89.1%; Placebo group: N=1,060; Edoxaban group: N=1,131) were recorded.

12.2.4 Listing of adverse events by patient

A line listing of all AEs is provided in Table 30.

12.3 Serious Adverse Events (SAE)

12.3.1 Brief summary of serious adverse events

Following the patient's written consent to participate in the study, all SAEs, whether related or not related to study drug, had to be collected.

In the Safety population (N=2,608) a total of N=965 patients experienced at least one SAE (Table 6) within a mean observation period of 27.5 months. With a total number of N=2,024 recorded SAEs a mean of 2.10 SAEs per patient was observed (Table 6, Table 16).

12.3.2 Display of serious adverse events

Table 6 Summary of patients with adverse events (AEs)

	Placebo (N=1302)	Edoxaban (N=1306)	Total (N=2608)
No of SAEs per patient			
N	467	498	965
N-Miss	835	808	1643
Mean ± SD	1.96 ± 1.54	2.22 ± 1.99	2.10 ± 1.79
Median (Q1, Q3)	1.00 (1.00, 2.00)	2.00 (1.00, 3.00)	1.00 (1.00, 3.00)
Min. - Max.	1.00 - 12.00	1.00 - 21.00	1.00 - 21.00

12.3.3 Analysis of serious adverse events

In the edoxaban group more SAEs were recorded (N=1,107) compared to the placebo group (N=917). Only few events were assessed as causally related to the blinded study drug ASA (placebo group: N=18; Edoxaban group: N=33) as well as edoxaban (placebo group: N=25; Edoxaban group: N=60). The majority of recorded SAEs was of moderate intensity. The cumulated observed types of SAEs, as adjudicated by ERC, were mostly similar among the groups with the exception for minor bleedings and major bleedings (according ISTH,

including haemorrhagic stroke). Most prominently, more than twice as many major bleedings were observed in the edoxaban group (N=78 vs. N=34) with an event per patient year of 0.013 vs. 0.006 (Table 7; Table 16).

Table 7 *SAE event rates*

SAE type (adjudicated by ERC)	Placebo group: N events	Placebo group: Event rate per patient year	Edoxaban group: N events	Edoxaban group: Event rate per patient year
Death as primary event, e.g. sudden death, not death as outcome of another event	55	0.009	62	0.010
Ischemic stroke (including transient events with matching lesion on cerebral imaging)	29	0.005	25	0.004
Stroke, unknown cause	2	< 0.001	-	-
TIA	5	0.001	7	0.001
Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	34	0.006	78	0.013
Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	3	0.001	12	0.002
Minor Bleeding	14	0.002	27	0.005
Stable AP (no ACS)	11	0.002	18	0.003
ACS	11	0.002	8	0.001
Peripheral (limb) embolism	4	0.001	1	< 0.001
Abdominal embolism	1	< 0.001	-	-
Myocardial Infarction	20	0.003	17	0.003
Pulmonary embolism	10	0.002	3	0.001
Worsening of heart failure	113	0.019	118	0.020
Hospitalisation due to AF	47	0.008	45	0.008
Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	28	0.005	30	0.005
Change of a pacemaker, ICD or any other cardiac device	78	0.013	65	0.011
Any type of cardiovascular surgery	7	0.001	10	0.002
Syncope	7	0.001	7	0.001
Other cardiovascular event	43	0.007	51	0.009
Non-cardiovascular event	392	0.065	521	0.087
Not assessable	-	-	1	< 0.001
No SAE	3	0.001	1	< 0.001
Total	917	0.153	1107	0.185

12.3.4 Listing of serious adverse events

A line listing of all SAEs is provided in Table 31.

12.4 Deaths and serious adverse events related to the IMP

12.4.1 Listing of deaths

In total, N=267 deaths were recorded, which are listed in Table 17.

12.4.2 Narratives of deaths and serious adverse events related to the IMP

All deaths and serious adverse events which were assessed as causally related to blinded study drug edoxaban and corresponding case narratives are listed in Table 18. Events that were unrelated to the IMP are not shown.

12.4.3 Analysis and discussion of deaths and serious adverse events related to the IMP

Of the N=267 observed deaths N=126 were of no cardiovascular cause. The other most prevalent observed deaths were due to unknown cause, due to heart failure, and sudden cardiac death (in this order). There was no notable difference between the placebo and edoxaban group (Table 17).

Overall, a total of N=95 SAEs were clinically assessed as causally related to the blinded study drug edoxaban. The events mainly comprised minor and major bleedings.

12.5 Safety Conclusions

In patients with atrial high-rate episodes detected by implantable devices stroke rates were unexpected low in both treatment groups, representing a lower risk of this type of arrhythmia compared to clinically overt atrial fibrillation documented in body surface ECGs. The NOAC edoxaban increased in this patient population significantly a composite safety outcome of major bleeding and death compared to placebo/ASA treatment.

13. DISCUSSION AND OVERALL CONCLUSIONS

This randomized, double-blind, double-dummy trial found that oral anticoagulation with edoxaban, used in doses approved for atrial fibrillation, did not significantly reduce a composite outcome of stroke, systemic embolism, or cardiovascular death in patients with atrial high-rate episodes compared to no anticoagulation. However, the NOAC edoxaban increased the rate of a composite of major bleeding and death. Event rates were generally within expected ranges with the exception of an unexpected low rate of stroke in both trial groups.

The clinical characteristics of the population studied in NOAH - AFNET 6, including age and clinical stroke risk factors, are consistent with a high stroke risk in patients with atrial fibrillation. Despite enrolling a high-risk population, the observed stroke rate in patients without oral anticoagulation was considerably lower than the stroke rate in a cohort study in Swedish patients with atrial fibrillation and a CHA2DS2-VASc score of 4 and not receiving oral anticoagulation (44), and lower than the stroke rates in patients with atrial fibrillation randomized

to acetylsalicylic acid in AVERROES (16) and in trials of vitamin K antagonists (1; 17). Furthermore, the stroke rate without oral anticoagulation in our trial was lower than the stroke rate in patients with atrial fibrillation treated with edoxaban in ENGAGE AF (15). The increased rate of major bleeding in patients assigned to edoxaban in this trial is an expected side effect of anticoagulation therapy (1; 16; 15; 45). The observed major bleeding rates on anticoagulation therapy are also consistent with major bleeding rates with edoxaban in ENGAGE AF (15), in ELDERCARE-AF (46), and in clinical practice (47).

The findings of this trial of low stroke rate without anticoagulation that was not further reduced by edoxaban may call for consideration of the efficacy and safety of anticoagulation therapy in patients with AHRE (7; 48; 49). The main difference between the population studied in NOAH - AFNET 6 and patients with ECG-documented atrial fibrillation appears to be the paucity of typical atrial arrhythmias in patients with AHRE, termed low arrhythmia burden (7). Published observations show that a low arrhythmia burden contributes to a low stroke rate in patients with atrial fibrillation, similar to the low stroke rate in patients with AHRE found in this trial: Paroxysmal atrial fibrillation is associated with a lower stroke rate than persistent or permanent atrial fibrillation (34; 50). Early rhythm control reduces cardiovascular events including stroke (51) and this effect is mediated by attaining sinus rhythm, reflecting a reduced arrhythmia burden (52). Taken together, these findings and the low stroke rate in NOAH - AFNET 6 may indicate caution when initiating anticoagulation therapy in patients with device-detected AHRE.

This trial has several limitations. Due to the premature termination after accrual of 184 of originally planned 222 primary outcome events, the trial does not have sufficient power to detect or rule out a small beneficial effect of oral anticoagulation on stroke prevention. The generalizability of these findings with edoxaban to other NOACs is not known. Ongoing trials are designed to determine the efficacy and safety of NOAC therapy after successful rhythm control therapy (53). Similar trials may be warranted to evaluate the efficacy and safety of oral anticoagulation in patients with rare atrial arrhythmias detected by consumer electronics without ECG-documented atrial fibrillation (5; 49). Our trial enrolled predominantly Caucasian patients in Europe; results may differ in other ethnic and racial groups. The low stroke rate observed in this trial and in the LOOP study (54) suggest a need for methods in addition to clinical stroke risk prediction formulas to improve stroke risk estimation in patients with infrequent atrial arrhythmias detected by long-term monitoring. Finally, we did not systematically collect information on the interval from detection of AHRE and randomization but the intention was to enrol patients soon after detection of the rhythm disturbance and any imbalances between trial groups would presumably be obviated by the randomization process.

In a trial conducted in patients with high atrial rate-episodes detected by implanted devices, ≥65 years of age but not with detectable atrial fibrillation but having other stroke risk factors, anticoagulation with edoxaban compared to placebo resulted in low but similar rates of a composite outcome of cardiovascular death, stroke, or systemic embolism but higher rates of major bleeding.

14. TABLES, FIGURES AND GRAPHS REFERRED TO BUT NOT INCLUDED IN THE TEXT

14.1 Demographic Data

Table 8 Demographics and clinical characteristics

Characteristics	Edoxaban (N=1270)	Placebo (N=1264)	Total (N=2534)
Age, mean ± SD	77.4 ± 6.5	77.5 ± 6.8	77.5 ± 6.7
Age ≥ 75 years, N	845/1270 (66.5%)	854/1264 (67.6%)	1699/2534 (67.0%)
Female Sex, N (%)	469/1270 (36.9%)	478/1264 (37.8%)	947/2534 (37.4%)
Device recording AHRE, N (%)			
Pacemaker	1017/1270 (80.1%)	1053/1264 (83.3%)	2070/2534 (81.7%)
Defibrillator	100/1270 (7.9%)	88/1266 (7.0%)	188/2534 (7.4%)
Cardiac Resynchronization device	138/1270 (10.9%)	113/1266 (8.9%)	251/2534 (0.9%)
Implanted loop recorder	15/1270 (1.2%)	10/1266 (0.8%)	25/2534 (1.0%)
AHRE[a] episode duration [hours], median (1st, 3rd quantiles)	1194.0 (94.0%) 2.8 (0.8, 9.2)	1193.0 (94.4%) 2.8 (0.7, 9.5)	2387.0 (94.2%) 2.8 (0.8, 9.4)
AHRE with atrial rates >200 beats per minute, N (%)	918/944 (97.2%)	895/924 (96.9%)	1813/1868 (97.1%)
CHA_2DS_2-VASc score, median (IQR)	4.0 (3.0, 5.0)	4.0 (3.0, 5.0)	4.0 (3.0, 5.0)
CHA_2DS_2-VA score, median (IQR)	3.0 (3.0, 4.0)	3.0 (3.0, 4.0)	3.0 (3.0, 4.0)
Heart failure[b], N (%)	361/1270 (28.4%)	335/1264 (26.5%)	696/2534 (27.5%)
Hypertension[c], N (%)	1096/1270 (86.3%)	1107/1264 (87.6%)	2203/2534 (86.9%)
Diabetes mellitus, N (%)	350/1270 (27.6%)	331/1264 (26.2%)	681/2534 (26.9%)
Prior stroke or transient ischemic attack, N (%)	122/1270 (9.6%)	131/1264 (10.4%)	253/2534 (10.0%)
Prior myocardial infarction, PCI, or CABG, N (%)	353/1270 (27.8%)	316/1264 (25.0%)	669/2534 (26.4%)
Acetylsalicylic acid indication at randomization, N (%)	684/1270 (53.9%)	683/1264 (54.0%)	1367/2534 (53.9%)
Edoxaban dose reduction (30 mg OD) indication, N (%)	365/1270 (28.7%)	382/1264 (30.2%)	747/2534 (29.5%)

Estimated creatinine clearance [ml/min], mean ± SD	66.4 ± 23.6	65.7 ± 23.2	66.0 ± 23.4
Hemoglobin [g/l], N (%)[d], mean ± SD	1205.0 (94.9%) 138.9 ± 17.5	1212.0 (95.9%) 138.6 ± 16.9	2417.0 (95.4%) 138.8 ± 17.1
Heart rate [beats per minute], N (%)[d], mean ± SD	1196.0 (94.2%) 68.9±10.9	1198.0 (94.8%) 68.4±10.8	2394.0 (94.5%) 68.7±10.8
Cardiovascular Therapies			
Beta blocker, N (%)	741/1263 (58.7%)	734/1248 (58.8%)	1475/2511 (58.7%)
Antihypertensive therapy, N (%)	1155/1263 (91.4%)	1139/1248 (91.3%)	2294/2511 (91.4%)
ACE inhibitor, ARB; or neprilysin-valsartan, N (%)	889/1263 (70.4%)	868/1248 (69.6%)	1757/2511 (70.0%)
Loop diuretics, N (%)	325/1263 (25.7%)	331/1248 (26.5%)	656/2511 (26.1%)
Mineralocorticoid receptor antagonists, N (%)	209/1263 (16.5%)	189/1248 (15.1%)	398/2511 (15.9%)
Statins, N (%)	762/1263 (60.3%)	731/1248 (58.6%)	1493/2511 (59.5%)

Table 9 Representativeness of Study Participants

Category		
Disease, problem or condition under investigation	Atrial fibrillation (AF)	atrial high rate episodes (AHRE)
Special considerations related to		
Sex and gender	AF is a common condition that affects both men and women (55). While women have a lower incidence of AF compared to men, the lifetime risk of developing AF is comparable for both sexes due to the fact that women have a longer life expectancy (56).	The incidence of overall implantation of cardiac implantable electronic devices (CIED) is twice as high in men than in women (57). The overrepresentation of men in studies regarding AHRE may be attributable to this particular factor[4].
Age	The prevalence of AF is higher among older patients and increases with age (58; 59). Similarly the risk of bleeding complications due to anticoagulants increases with age (60).	The incidence of CIED implantation increases notably in elderly individuals (57). Thus, the occurrence of AHRE detected by CIED is also particularly higher in populations over 70 years of age (61).
Race and ethnic group	The prevalence of clinically detected AF is lower in African American than in white populations, even after adjusting for AF risk factors. However, this discrepancy appears to be attributed to under-detection of AF in African American individuals compared to Caucasian and Asian Americans (62).	In the ASSERT study black Africans, Chinese, and Japanese had lower incidences of AF detected by CIED compared to Europeans. In the case of black Africans, this was despite an increased prevalence of AF risk factors (63).
Geography	There are higher incidence rates for AF in developed regions compared with developing countries[5]. This could be due to higher prevalence of AF-related risk factors and/or to better detection of AF in these regions. The prevalence of AF-related complications and bleeding associated with anticoagulation varies geographically, with non-Asian countries experiencing the highest morbidity rates, while Asian and non-European countries have the lowest rates of anticoagulant adoption (64).	There are no data on the geographical distribution of incidence rates of AHRE. Most studies have been conducted in Europe, North America and Australia.
other considerations		
Overall representativeness of the trial	In NOAH - AFNET 6, 2536 patients with AHRE episodes lasting 6 minutes or more and with an atrial rate of 170 bpm or more were randomized and analysed in 206 institutions located in 18 European countries were randomized. The proportion of women in the study population was 37.4 %. This is similar to other CIED studies. Older patients were adequately represented. The mean age of the study participants was 77.5 ± 6.7 years, which is similar to the age distribution of AF in the general population. Information on ethnicity and race was not systematically recorded due to the predominance of Caucasians in Central Europe in the age group considered.	

14.2 Efficacy Data


Table 10 Efficacy outcomes in the *NOAH - AFNET 6* trial population by random group

	Edoxaban	Placebo	Edoxaban vs. Placebo	
	Events/patient-years (incidence per patient-years %)	Events/patient-years (incidence per patient-years %)	Adjusted hazard ratio (95% CI)	p-value
Primary Outcome[a]	83/2556 (3.3)	101/2494 (4.0)	0.81 (0.60 to 1.08)	0.15
Ischemic stroke	22/2572 (0.9)	27/2518 (1.1)	0.79 (0.45 to 1.39)	
Systemic embolism	14/2578 (0.5)	28/2514(1.1)	0.51 (0.27 to 0.96)	
Myocardial Infarction	10/2589 (0.4)	16/2523 (0.6)		
Pulmonary embolism	3/2589 (0.1)	9/2532 (0.4)		
Peripheral limb embolism	1/2592 (0.0)	3/2535 (0.1)		
Abdominal embolism	0/2595 (0.0)	1/2539 (0.0)		
Cardiovascular death	52/2595 (2.0)	57/2539 (2.3)	0.90 (0.62 to 1.31)	
Death due to acute myocardial infarction	1/2595 (0.0)	4/2539 (0.2)		
Sudden cardiac death	18/2595 (0.7)	13/2539 (0.5)		
Death due to heart failure	13/2595 (0.5)	15/2539 (0.6)		
Death due to stroke	1/2595 (0.0)	3/2539 (0.1)		
Death due to cardiovascular haemorrhage	2/2595 (0.1)	1/2539 (0.0)		
Death due to other cardiovascular cause	1/2595 (0.0)	4/2539 (0.2)		
Death of unknown cause (counted as cardiovascular)	16/2595 (0.6)	17/2539 (0.7)		
MACE	92/2532 (3.6)	102/2484(4.1)	0.89 (0.67 to 1.18)	
Ischemic stroke or systemic embolism	25/2566 (1.0)	38/2508 (1.5)	0.65 (0.39 to 1.07)	

All numbers indicate patients with a first occurrence of an event.

[a] time to the first occurrence of a composite of cardiovascular death, stroke (both ischemic and haemorrhagic stroke), or systemic embolism

95 %CI, 95% confidence interval; MACE, Major Adverse Cardiac Events (MACEs: cardiovascular death, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, coronary artery bypass graft)






Figure 8 (A) Aalen–Johansen cumulative-incidence curves, in which competing events are taken into account, if any, showing time to the composite outcome of first cardiovascular death, stroke, or systemic embolism (primary efficacy outcome) and (B) Aalen-Johansen curves showing time to a first major bleeding or death (safety outcome)*.
** Kaplan-Meier curves for panel 2B will be identical to the Aalen-Johansen curve shown here as all-cause death is part of the safety outcome.*

Table 11 Results of sensitivity analyses for efficacy and safety outcomes by randomized group

	Edoxaban	Placebo	Adjusted hazard ratio (95% CI)	N
Primary Efficacy Outcome[a]				
Restricted to patients				
with adequate AHRE at baseline	83/2442 (3.4)	96/2421 (4.0)	0.86 (0.64 to 1.16)	2,444
without WOC	83/2376 (3.5)	95/2332 (4.1)	0.86 (0.64 to 1.16)	2,260
without early WOC	83/2556 (3.3)	101/2495 (4.0)	0.81 (0.60 to 1.08)	2,505
Without censoring at				
unblinding or development of ECG-documented AF	100/2904 (3.4)	117/2789 (4.2)	0.82 (0.63 to 1.07)	2,534
24 February 2022 for Ukrainian patients	84/2622 (3.2)	101/2563 (3.9)	0.82 (0.61 to 1.09)	2,534
With censoring at				
discontinuation of study drug	38/2023 (1.9)	58/2061 (2.8)	0.67 (0.44 to 1.00)	2,534
Covid- 19 infection	79/2501 (3.2)	100/2452(4.1)	0.78 (0.58 to 1.05)	2,534
Primary Safety Outcome[b]				
Restricted to patients				
with core-lab verified adequate AHRE	145/2420 (6.0)	110/2434 (4.5)	1.34 (1.05 to 1.72)	2,444
without WOC	168/2702 (6.2)	143/2632 (5.4)	1.14 (0.91 to 1.42)	2,260
without early WOC	175/2892 (6.1)	143/2807 (5.1)	1.18 (10.95 to 1.48)	2,505
Without censoring at				
unblinding or development of ECG-documented AF	175/2893 (6.1)	143/2807 (5.1)	1.18 (0.95 to 1.48)	2,534
24 February 2022 for Ukrainian patients	150/2600 (5.8)	115/2578 (4.5)	1.31 (1.02 to 1.67)	2,534
With censoring at				
discontinuation of study drug	66/2019 (3.3)	42/2053 (2.1)	1.61 (1.09 to 2.37)	2,534
Covid-19 infection	131/2479 (5.3)	99/2470 (4.0)	1.34 (1.03 to 1.74)	2,534

All numbers indicate patients with a first occurrence of an event. Numbers in brackets indicate incidence rates calculated per 100 patient-years (percent). 95 %CI, 95% confidence interval; AHRE, Atrial high-rate episode; WOC, withdrawal of consent; AF, atrial fibrillation.

[a] time to the first occurrence of a composite of cardiovascular death, stroke (both ischemic and haemorrhagic stroke), or systemic embolism

[b] time to the first occurrence of composite of all-cause death or major bleeding




Figure 9 Forest plot of the primary efficacy outcome for predefined subgroups of baseline parameters within the mITT population. There was no interaction between treatment and any of the subgroups. AHRE duration is given in (hours:minutes)




Figure 10 Forest plot of the primary safety outcome for predefined subgroups of baseline parameters within the mITT population. There was no interaction between treatment and any of the subgroups

Table 12 Results of the per protocol population, patients who exactly match the target population (i.e., meet all inclusion and exclusion criteria) and are adherent (i.e., taking the study medication predominantly as scheduled and not taking any other oral anticoagulation or antiplatelet agent), for efficacy and safety outcomes by randomized group

	Edoxaban	Placebo	Adjusted hazard ratio (95% CI)	N
Primary Efficacy Outcome[a]	46/1645(2.8)	62/1737 (3.6)	0.78 (0.53 to 1.15)	2,501
Primary Safety Outcome[b]	86/1636 (5.3)	61/1754(3.5)	1.53 (1.10 to 2.12)	2,501

[a] time to the first occurrence of a composite of cardiovascular death, stroke (both ischemic and haemorrhagic stroke), or systemic embolism
[b] time to the first occurrence of composite of all-cause death or major bleeding

Table 13 Safety outcomes in the *NOAH - AFNET 6* trial population by randomized group

	Edoxaban	Placebo	Edoxaban vs. Placebo	
	Events/patient-years (incidence per patient-years %)	Events/patient-years (incidence per patient-years %)	Adjusted hazard ratio (95% CI)	p-value
Primary Safety Outcome[a]	149/2533 (5.9)	114/2507 (4.6)	1.31 (1.02 to 1.67)	0.03
All-cause death	111/2595 (4.3)	94/2539 (3.7)	1.16 (0.88 to 1.53)	0.28
Cardiovascular death (details see Table 2)	52/2595 (2.0)	57/2539 (2.3)		
Cancer-related	22/2595 (0.8)	9/2539 (0.4)		
Covid-19 associated	15/2595 (0.6)	12/2539 (0.5)		
Due to acute infection or sepsis	12/2595 (0.5)	9/2539 (0.4)		
Frailty, old age	3/2595 (0.1)	2/2539 (0.1)		
Due to accident or polytrauma	3/2595 (0.1)	1/2539 (0)		
Due to Lung disease	2/2595 (0.1)	1/2539 (0)		
Due to acute abdomen	0/2595 (0)	2/2539 (0.1)		
Kidney-related	1/2595 (0)	0/2539 (0)		
Dementia-related	0/2595 (0)	1/2539 (0)		
Suicide	1/2595 (0)	0/2539 (0)		
Major bleeding	53/2533 (2.1)	25/2507 (1.0)	2.10 (1.30 to 3.38)	0.002
Number of major bleedings, mean ± SD	0.06 ± 0.35	0.02 ± 0.16	3.06[b] (1.74 to 5.36)	<0.001

All numbers indicate patients with a first occurrence of an event.

[a] time to the first occurrence of a composite of all-cause death or major bleeding

[b] adjusted rate ratio (95% CI)

95 %CI, 95% confidence interval

All deaths were adjudicated by the endpoint review committee as cardiovascular or non-cardiovascular. Detailed causes of non-cardiovascular deaths shown here are based on MedDRA coding.

Table 14 Change in patient-reported outcomes and functional status in the *NOAH - AFNET 6* trial population by randomized group during follow-up at 12 and 24 months[a]

Outcome	Edoxaban		Placebo		Edoxaban vs. Placebo
	n/N	adjusted mean change from baseline[a] (95% CI)	n/N	adjusted mean change from baseline[b] (95% CI)	adjusted mean difference (95% CI)
MoCA					
to FU12	715 /856	-0.03 (-0.36 to 0.29)	685/838	-0.06 (-0.49 to 0.27)	0.03 (-0.27 to 0.32)
to FU24	443/576	-0.16 (-0.51 to 0.19)	425/539	-0.18 (-0.54 to 0.17)	
Karnofsky score					
to FU12	822/856	-1.14 (-1.98 to -0.31)	804/838	-1.41 (-2.26 to -0.57)	0.27 (-0.56 to 1.09)
to FU24	549/576	-2.28 (-3.23 to -1.33)	516/539	-2.55 (-3.50 to -1.59)	
PACT-Q convenience					
to FU12	583/856	0.84 (-0.26 to 1.93)	569/838	1.15 (-0.14 to 2.05)	-0.12 (-1.12 to 0.87)
to FU24	372/576	1.35 (0.20 to 2.49)	362/539	1.47 (0.32 to 2.61)	
PACT-Q satisfaction					
to FU12	508/856	2.97 (1.36 to 4.57)	484/838	4.01 (2.39 to 5.62)	-1.04 (-2.60 to 0.52)
to FU24	319/576	3.80 (2.12 to 5.48)	311/539	4.84 (3.15 to 6.52)	
EQ-5D-5L UK Index					
to FU12	666/856	-0.01 (-0.03 to 0.00)	640/838	-0.01 (-0.02 to 0.01)	-0.01 (-0.02 to 0.01)
to FU24	423/576	-0.04 (-0.05 to -0.02)	407/539	-0.02 (-0.05 to -0.02)	
EQ-5D-5L VAS					
to FU12	660/856	-0.75 (-2.08 to 0.57)	630/838	-0.71 (-2.06 to 0.64)	-0.04 (-1.46 to 1.38)
to FU24	424/576	-1.72 (-3.18 to -0.27)	391/539	-1.68 (-3.16 to 0.20)	
Stroke Severity in patients with a stroke estimated by the Modified Rankin Scale at FU24, median (IQR)	10	2.5 (2.0, 3.0)	14	2.0 (2.0, 3.0)	NA

[a] As a sensitivity analysis for these results, we additionally used a two-step approach, first estimating the probability of dropout among persisting patients to construct inverse probability weights (IPWs) and then fitting generalised estimating equations using these IPWs. The

predictive model for dropout probability at a given time point used the following predictors: randomized group, acetylsalicylic acid indication at randomization, and prior information (at baseline and at follow-up) about the score under study. The results of these two methods differ only marginally in all scores.

[b] Average marginal effect

n, number of patients included in the analysis; 95 %CI, 95% confidence interval; FU12, 12 months follow-up; FU24, 24 months follow-up; SD, standard deviation; MoCA, Montreal Cognitive Assessment (Total possible score is 30 points; a score of 26 or above is considered normal); PACT-Q Perception of Anticoagulant Treatment Questionnaire; EQ-5D-5L, EuroQoL 5 dimensions; EQ-5D-5L VAS, EuroQoL visual analogue scale (full health (score=100) or worst imaginable health state (score=0)

14.3 Safety Data

14.3.1 Displays of adverse events

Table 15 Summary of adverse event intensities, criteria for seriousness and causal relationship to ASA, edoxaban or underlying disease

	Placebo (N=1576)	Edoxaban (N=1816)	Total (N=3392)
Intensity of AE			
N	1141	1318	2459
N-Miss	435	498	933
Mild	783 (68.6%)	884 (67.1%)	1667 (67.8%)
Moderate	316 (27.7%)	408 (31.0%)	724 (29.4%)
Severe	41 (3.6%)	23 (1.7%)	64 (2.6%)
Very severe	1 (0.1%)	3 (0.2%)	4 (0.2%)
Does this AE fulfil a criterion for seriousness?			
N	1576	1816	3392
No	1142 (72.5%)	1318 (72.6%)	2460 (72.5%)
Yes	434 (27.5%)	498 (27.4%)	932 (27.5%)
Causal relationship to blinded study drug ASA			
N	1141	1318	2459
N-Miss	435	498	933
related	63 (5.5%)	128 (9.7%)	191 (7.8%)
not related	1078 (94.5%)	1190 (90.3%)	2268 (92.2%)
Causal relationship to blinded study drug edoxaban			
N	1141	1318	2459
N-Miss	435	498	933
related	93 (8.2%)	195 (14.8%)	288 (11.7%)
not related	1048 (91.8%)	1123 (85.2%)	2171 (88.3%)
Causal relationship to concomitant therapy / underlying disease			
N	154	191	345
N-Miss	1422	1625	3047
related	31 (20.1%)	24 (12.6%)	55 (15.9%)
not related	123 (79.9%)	167 (87.4%)	290 (84.1%)

14.3.2 Displays of serious adverse events

Table 16 Summary of serious adverse event types as adjudicated, intensities, criteria for seriousness and causal relationship to ASA, edoxaban or underlying disease

	Placebo (N=917)	Edoxaban (N=1107)	Total (N=2024)
Cumulated ERC adjudication: Type of SAE			
N-Miss	0	1	1
Death as primary event, e.g. sudden death, not death as outcome of another event	55 (6.0%)	62 (5.6%)	117 (5.8%)
TIA	5 (0.5%)	7 (0.6%)	12 (0.6%)
Ischemic stroke (including transient events with matching lesion on cerebral imaging)	29 (3.2%)	25 (2.3%)	54 (2.7%)
Stroke, unknown cause	2 (0.2%)	0 (0.0%)	2 (0.1%)
Peripheral (limb) embolism	4 (0.4%)	1 (0.1%)	5 (0.2%)
Abdominal embolism	1 (0.1%)	0 (0.0%)	1 (0.0%)
Pulmonary embolism	10 (1.1%)	3 (0.3%)	13 (0.6%)
Other embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)
Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	34 (3.7%)	78 (7.1%)	112 (5.5%)
Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	3 (0.3%)	12 (1.1%)	15 (0.7%)
Minor Bleeding	14 (1.5%)	27 (2.4%)	41 (2.0%)
ACS	11 (1.2%)	8 (0.7%)	19 (0.9%)
Stable AP (no ACS)	11 (1.2%)	18 (1.6%)	29 (1.4%)
Worsening of heart failure	113 (12.3%)	118 (10.7%)	231 (11.4%)
Syncope	7 (0.8%)	7 (0.6%)	14 (0.7%)

	Placebo (N=917)	Edoxaban (N=1107)	Total (N=2024)
Change of a pacemaker, ICD or any other cardiac device	78 (8.5%)	65 (5.9%)	143 (7.1%)
Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	28 (3.1%)	30 (2.7%)	58 (2.9%)
Any type of cardiovascular surgery	7 (0.8%)	10 (0.9%)	17 (0.8%)
Hospitalisation due to AF	47 (5.1%)	45 (4.1%)	92 (4.5%)
Other cardiovascular event	43 (4.7%)	51 (4.6%)	94 (4.6%)
Myocardial Infarction	20 (2.2%)	17 (1.5%)	37 (1.8%)
Non-cardiovascular event	392 (42.7%)	521 (47.1%)	913 (45.1%)
No SAE	3 (0.3%)	1 (0.1%)	4 (0.2%)
Cumulated ERC adjudication: Aetiology (TOAST criteria)			
N-Miss	887	1082	1969
Large-artery atherosclerosis	3 (10.0%)	2 (8.0%)	5 (9.1%)
Cardioembolism	13 (43.3%)	7 (28.0%)	20 (36.4%)
Small-vessel occlusion	5 (16.7%)	9 (36.0%)	14 (25.5%)
Stroke of other determined aetiology (e.g. large vessel dissection)	0 (0.0%)	2 (8.0%)	2 (3.6%)
Stroke of undetermined aetiology	9 (30.0%)	5 (20.0%)	14 (25.5%)
Intensity of SAE			
N-Miss	65	70	135
Mild	215 (25.2%)	248 (23.9%)	463 (24.5%)
Moderate	386 (45.3%)	477 (46.0%)	863 (45.7%)
Severe	187 (21.9%)	235 (22.7%)	422 (22.3%)
Very severe	64 (7.5%)	77 (7.4%)	141 (7.5%)
Causal relationship to blinded study drug edoxaban			
related	25 (2.7%)	60 (5.4%)	85 (4.2%)

	Placebo (N=917)	Edoxaban (N=1107)	Total (N=2024)
not related	892 (97.3%)	1047 (94.6%)	1939 (95.8%)
Causal relationship to blinded study drug ASA			
related	18 (2.0%)	33 (3.0%)	51 (2.5%)
not related	899 (98.0%)	1074 (97.0%)	1973 (97.5%)
Causal relationship to concomitant therapy / underlying disease			
N-Miss	753	922	1675
related	67 (40.9%)	61 (33.0%)	128 (36.7%)
not related	97 (59.1%)	124 (67.0%)	221 (63.3%)

14.3.3 Listings of deaths

Table 17 Listing of all recorded deaths

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
288	9	Placebo	ASA	87	m	20.01.2022	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
720	9	Placebo	ASA	85	m	23.12.2019	Death of unknown cause	10011906	Death
879	9	Placebo	ASA	75	m	11.07.2022	No cardiovascular cause	10011906, 10039203, 10028224, 10028200	Death, Road traffic accident, Multiple injuries, Multiple fractures
1192	9	Placebo	ASA	74	m	07.09.2020	Death of unknown cause	10011906	Death
1974	9	Placebo	ASA	88	m	02.10.2022	Death of unknown cause	10011906	Death
1847	9	Placebo	no ASA	75	m	24.08.2022	No cardiovascular cause	10015145, 10011906, 10069339, 10060738, 10070255	Erysipelas, Death, Acute kidney injury, Intervertebral discitis, Coronavirus test positive
57	9	Edoxaban	ASA	79	m	07.05.2018	Death of unknown cause	10011906	Death
66	9	Edoxaban	ASA	88	f	27.05.2021	Death of unknown cause	10011906	Death
93	9	Edoxaban	ASA	85	m	30.07.2019	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
393	9	Edoxaban	ASA	89	m	14.03.2020	No cardiovascular cause	10011906, 10046571, 10038435	Death, Urinary tract infection, Renal failure
719	9	Edoxaban	ASA	90	f	27.02.2020	Sudden cardiac death	10049418	Sudden cardiac death
1338	9	Edoxaban	ASA	88	m	25.09.2020	No cardiovascular cause	10011906, 10017758, 10062194	Death, Gastric cancer, Metastasis
410	9	Edoxaban	no ASA	71	f	18.02.2020	Sudden cardiac death	10049418, 10007515	Sudden cardiac death, Cardiac arrest
1706	12	Edoxaban	ASA	86	m	17.08.2020	No cardiovascular cause	10011906, 10014665, 10040070	Death, Endocarditis, Septic shock
1752	12	Edoxaban	ASA	86	m	06.03.2021	Sudden cardiac death	10049418	Sudden cardiac death
1789	12	Edoxaban	no ASA	92	m	19.04.2022	No cardiovascular cause	10011906, 10003549	Death, Asthenia
1633	19	Edoxaban	ASA	75	m	16.11.2021	Death due to other cardiovascular causes	10011906, 10007649, 10002916, 10011077, 10066152, 10052989, 10051379, 10014665, 10049434	Death, Cardiovascular disorder, Aortic valve replacement, Coronary artery bypass, Transfusion, Intra-aortic balloon placement, Systemic inflammatory response syndrome, Endocarditis, Cardiac pacemaker replacement
265	23	Edoxaban	ASA	79	m	05.09.2019	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
122	23	Edoxaban	no ASA	76	m	08.10.2018	Sudden cardiac death	10049418, 10017964	Sudden cardiac death, Gastrointestinal infection
442	34	Placebo	ASA	93	f	16.06.2018	No cardiovascular cause	10062585, 10040047, 10011906	Peripheral arterial occlusive disease, Sepsis, Death
414	38	Placebo	no ASA	81	m	23.12.2018	No cardiovascular cause	10011906, 10058467	Death, Lung neoplasm malignant
1351	39	Placebo	ASA	74	m	16.12.2019	Death due to other cardiovascular causes	10011906, 10007649, 10027395	Death, Cardiovascular disorder, Mesenteric artery embolism
1755	57	Edoxaban	ASA	81	m	17.06.2021	No cardiovascular cause	10011906, 10016454, 10038695	Death, Femur fracture, Respiratory failure
24	59	Placebo	ASA	69	m	09.12.2018	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
98	59	Edoxaban	ASA	73	m	20.02.2017	Sudden cardiac death	10049418	Sudden cardiac death
416	59	Edoxaban	ASA	90	f	03.08.2019	Sudden cardiac death	10049418	Sudden cardiac death
1245	59	Edoxaban	ASA	90	m	01.02.2022	Sudden cardiac death	10049418	Sudden cardiac death
58	59	Edoxaban	no ASA	79	m	06.11.2020	No cardiovascular cause	10061902, 10014802, 10011906	Pancreatic neoplasm, Endoscopic retrograde cholangiopancreatography, Death
149	59	Edoxaban	no ASA	80	m	22.05.2021	No cardiovascular cause	10011906, 10022694	Death, Intestinal perforation
511	70	Placebo	ASA	82	m	28.02.2020	Sudden cardiac death	10049418	Sudden cardiac death
1950	70	Placebo	ASA	76	m	08.02.2022	No cardiovascular cause	10011906, 10040047, 10040070, 10027070, 10010007, 10000279	Death, Sepsis, Septic shock, Mediastinal abscess, Colonoscopy, Abscess drainage
1741	70	Edoxaban	no ASA	89	m	06.01.2022	Death of unknown cause	10011906	Death
352	86	Edoxaban	ASA	86	m	04.06.2022	No cardiovascular cause	10011906, 10035664	Death, Pneumonia
1189	86	Edoxaban	no ASA	81	f	26.12.2020	No cardiovascular cause	10011906, 10044412	Death, Transitional cell carcinoma
28	95	Placebo	ASA	73	f	09.11.2016	No cardiovascular cause	10011906, 10038695	Death, Respiratory failure
30	95	Placebo	no ASA	82	m	23.06.2019	No cardiovascular cause	10011906, 10035664	Death, Pneumonia
1368	95	Placebo	no ASA	79	f	02.01.2021	Death due to acute myocardial infarction (MI)	10049993, 10000891, 10070255, 10065608, 10051592	Cardiac death, Acute myocardial infarction, Coronavirus test positive, Percutaneous coronary intervention, Acute coronary syndrome
10	95	Edoxaban	ASA	93	m	19.06.2022	No cardiovascular cause	10011906, 10033609	Death, Pancreatic carcinoma
14	95	Edoxaban	ASA	72	m	12.07.2021	No cardiovascular cause	10011906, 10009944	Death, Colon cancer
846	100	Placebo	ASA	76	m	17.08.2022	No cardiovascular cause	10011906, 10003549	Death, Asthenia
124	100	Edoxaban	ASA	78	m	24.02.2021	No cardiovascular cause	10011906, 10062362, 10035664	Death, Viral test negative, Pneumonia
17	117	Placebo	ASA	71	f	26.04.2022	Death of unknown cause	10011906	Death
320	117	Edoxaban	ASA	85	m	24.11.2019	Death of unknown cause	10011906	Death
943	117	Edoxaban	ASA	83	m	10.03.2020	No cardiovascular cause	10011906, 10040070, 10023696, 10074984	Death, Septic shock, Laparotomy, Abdominal incarcerated hernia
103	121	Placebo	ASA	90	f	04.07.2019	No cardiovascular cause	10011906, 10048709	Death, Urosepsis
130	121	Placebo	no ASA	86	f	14.12.2021	Sudden cardiac death	10049418	Sudden cardiac death
109	121	Edoxaban	ASA	76	m	16.02.2018	Death due to stroke	10061256, 10011906	Ischaemic stroke, Death
266	132	Placebo	no ASA	78	m	27.02.2019	No cardiovascular cause	10011906, 10070976, 10069689, 10042361, 10000370, 10042364	Death, Craniocerebral injury, Spinal column injury, Subdural haematoma, Accident at home, Subdural haemorrhage
7	136	Placebo	ASA	72	m	16.08.2016	Death due to other cardiovascular causes	10011906, 10007649, 10047290, 10038695, 10040047	Death, Cardiovascular disorder, Ventricular fibrillation, Respiratory failure, Sepsis
114	140	Placebo	ASA	87	f	23.07.2022	No cardiovascular cause	10033609, 10011906, 10027457	Pancreatic carcinoma, Death, Metastases to liver
171	140	Placebo	ASA	83	m	15.07.2019	Sudden cardiac death	10049418	Sudden cardiac death

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
1926	140	Placebo	no ASA	70	f	15.04.2021	No cardiovascular cause	10011906, 10070255, 10040070	Death, Coronavirus test positive, Septic shock
254	140	Edoxaban	ASA	87	f	18.01.2022	No cardiovascular cause	10011906, 10070255	Death, Coronavirus test positive
212	140	Edoxaban	no ASA	88	m	28.01.2020	No cardiovascular cause	10011906, 10038435, 10038695	Death, Renal failure, Respiratory failure
251	140	Edoxaban	no ASA	83	m	14.10.2019	No cardiovascular cause	10011906, 10041569, 10038695	Death, Spinal fracture, Respiratory failure
319	153	Placebo	ASA	75	m	12.02.2018	Death due to heart failure (HF)	10064848, 10049993, 10007554	Chronic kidney disease, Cardiac death, Cardiac failure
35	153	Edoxaban	no ASA	84	m	23.01.2017	No cardiovascular cause	10011906, 10051379, 10069339, 10064848	Death, Systemic inflammatory response syndrome, Acute kidney injury, Chronic kidney disease
230	161	Edoxaban	ASA	84	m	27.05.2019	No cardiovascular cause	10011906, 10010144	Death, Completed suicide
459	161	Edoxaban	ASA	86	m	19.05.2021	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1319	173	Placebo	no ASA	85	m	21.07.2021	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
242	173	Edoxaban	ASA	74	m	23.08.2019	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1758	173	Edoxaban	ASA	71	m	08.07.2021	No cardiovascular cause	10011906, 10058467, 10062194	Death, Lung neoplasm malignant, Metastasis
1008	174	Placebo	ASA	73	f	31.03.2020	No cardiovascular cause	10070255, 10011906, 10035664, 10009657, 10048709	Coronavirus test positive, Death, Pneumonia, Clostridium difficile colitis, Urosepsis
306	174	Edoxaban	ASA	84	m	05.02.2018	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
398	195	Edoxaban	ASA	75	m	22.01.2022	Death of unknown cause	10011906	Death
283	195	Edoxaban	no ASA	83	m	25.04.2019	No cardiovascular cause	10011906, 10058467	Death, Lung neoplasm malignant
366	205	Placebo	ASA	98	f	10.01.2018	Death of unknown cause	10011906	Death
207	205	Placebo	no ASA	83	m	28.02.2021	Death of unknown cause	10011906	Death
80	205	Edoxaban	ASA	88	f	13.07.2018	Death of unknown cause	10011906	Death
336	205	Edoxaban	ASA	81	m	22.08.2022	Death due to other cardiovascular causes	10011906, 10007649, 10028600	Death, Cardiovascular disorder, Myocardial ischaemia
516	208	Placebo	no ASA	83	m	03.02.2021	No cardiovascular cause	10028997, 10011906	Neoplasm malignant, Death
1306	208	Edoxaban	no ASA	83	m	23.11.2020	No cardiovascular cause	10070255, 10011906	Coronavirus test positive, Death
79	209	Placebo	ASA	87	m	30.11.2022	Death of unknown cause	10011906	Death
143	211	Placebo	ASA	82	m	14.12.2020	No cardiovascular cause	10011906, 10028997	Death, Neoplasm malignant
250	211	Placebo	ASA	83	m	14.02.2019	No cardiovascular cause	10011906	Death
356	211	Edoxaban	ASA	88	m	08.06.2019	No cardiovascular cause	10007554, 10050017, 10011906	Cardiac failure, Lung cancer metastatic, Death
1670	226	Edoxaban	ASA	91	m	20.08.2021	No cardiovascular cause	10011906, 10058467, 10062362	Death, Lung neoplasm malignant, Viral test negative
1164	226	Edoxaban	no ASA	72	f	13.06.2021	No cardiovascular cause	10033609, 10011906, 10002034, 10066152, 10055798	Pancreatic carcinoma, Death, Anaemia, Transfusion, Haemorrhage
749	232	Edoxaban	no ASA	73	m	02.02.2021	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
1544	264	Placebo	no ASA	81	m	20.10.2021	No cardiovascular cause	10011906, 10028997	Death, Neoplasm malignant
1330	264	Edoxaban	ASA	67	f	21.06.2022	Death due to acute myocardial infarction (MI)	10049993, 10000891	Cardiac death, Acute myocardial infarction
1219	267	Placebo	ASA	66	m	07.02.2021	No cardiovascular cause	10011906, 10023825	Death, Laryngeal cancer
215	308	Placebo	ASA	83	m	25.11.2021	Death of unknown cause	10011906	Death
72	377	Placebo	ASA	86	m	14.07.2021	No cardiovascular cause	10018001, 10011906, 10038749	Gastrointestinal perforation, Death, Resuscitation
704	414	Placebo	ASA	86	f	10.09.2021	No cardiovascular cause	10011906, 10006417	Death, Bronchial carcinoma
1654	414	Placebo	ASA	85	m	27.01.2021	No cardiovascular cause	10011906, 10017982, 10061778	Death, Gastrointestinal necrosis, Colectomy
1783	414	Edoxaban	ASA	89	m	25.06.2021	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
246	414	Edoxaban	no ASA	102	f	21.08.2021	Death of unknown cause	10009944, 10011906	Colon cancer, Death
2183	414	Edoxaban	no ASA	73	m	27.11.2022	No cardiovascular cause	10011906, 10061536, 10035664, 10003504, 10038695	Death, Parkinson's disease, Pneumonia, Aspiration, Respiratory failure
125	416	Placebo	no ASA	80	f	01.08.2021	Death of unknown cause	10011906	Death
84	416	Edoxaban	no ASA	80	f	17.03.2017	Death of unknown cause	10011906	Death
464	419	Placebo	no ASA	71	m	21.05.2021	No cardiovascular cause	10070255, 10035664, 10011906	Coronavirus test positive, Pneumonia, Death
690	419	Placebo	no ASA	66	m	08.08.2019	Sudden cardiac death	10049418	Sudden cardiac death
1137	419	Placebo	no ASA	92	f	17.10.2022	No cardiovascular cause	10011906, 10048709	Death, Urosepsis
157	421	Placebo	ASA	83	m	04.06.2017	Sudden cardiac death	10049418	Sudden cardiac death
161	421	Placebo	ASA	82	f	07.11.2020	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1841	421	Placebo	ASA	84	m	08.02.2021	Death of unknown cause	10011906	Death
1884	421	Placebo	ASA	86	m	18.10.2021	No cardiovascular cause	10011906, 10009944	Death, Colon cancer
768	421	Placebo	no ASA	89	m	04.01.2022	Sudden cardiac death	10049418	Sudden cardiac death
1216	421	Placebo	no ASA	83	m	28.02.2022	No cardiovascular cause	10011906, 10070255, 10002034, 10066152, 10077361	Death, Coronavirus test positive, Anaemia, Transfusion, Multiple organ dysfunction syndrome
2283	421	Placebo	no ASA	88	m	11.03.2022	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
353	421	Edoxaban	ASA	79	m	23.03.2020	No cardiovascular cause	10011906, 10063914	Death, Multimorbidity
1590	421	Edoxaban	ASA	90	m	09.09.2022	No cardiovascular cause	10011906, 10016173, 10022116, 10077361	Death, Fall, Injury, Multiple organ dysfunction syndrome
1940	421	Edoxaban	ASA	88	f	10.09.2021	Death due to heart failure (HF)	10049993, 10007554, 10046571	Cardiac death, Cardiac failure, Urinary tract infection
2228	421	Edoxaban	ASA	69	m	22.08.2022	No cardiovascular cause	10011906, 10040070, 10038435, 10007554	Death, Septic shock, Renal failure, Cardiac failure
1668	421	Edoxaban	no ASA	72	m	04.08.2021	Death of unknown cause	10011906	Death

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
1796	426	Edoxaban	no ASA	81	m	24.10.2021	Death due to cardiovascular haemorrhage	10011906, 10007649, 10055798, 10017955, 10061816, 10014819, 10066152	Death, Cardiovascular disorder, Haemorrhage, Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Transfusion
785	445	Placebo	ASA	83	m	24.01.2020	Death due to cardiovascular haemorrhage	10011906, 10007649, 10055798, 10017955	Death, Cardiovascular disorder, Haemorrhage, Gastrointestinal haemorrhage
535	479	Placebo	no ASA	92	m	27.07.2019	Death due to heart failure (HF)	10049993, 10035664, 10007554	Cardiac death, Pneumonia, Cardiac failure
2	488	Placebo	ASA	85	m	04.03.2022	Death due to heart failure (HF)	10049993, 10007554, 10016173	Cardiac death, Cardiac failure, Fall
45	488	Placebo	ASA	89	m	09.02.2019	Death of unknown cause	10011906	Death
189	488	Placebo	ASA	83	f	01.06.2019	No cardiovascular cause	10011906, 10035664	Death, Pneumonia
206	488	Placebo	ASA	83	f	08.09.2020	Death of unknown cause	10011906	Death
370	488	Placebo	ASA	78	m	06.09.2020	Death of unknown cause	10011906	Death
1099	488	Placebo	ASA	88	f	22.11.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
5	488	Placebo	no ASA	72	f	09.01.2022	Death due to other cardiovascular causes	10037377, 10011906, 10007649	Pulmonary embolism, Death, Cardiovascular disorder
134	488	Placebo	no ASA	89	m	22.05.2022	No cardiovascular cause	10011906, 10003549	Death, Asthenia
357	488	Placebo	no ASA	83	m	13.08.2022	No cardiovascular cause	10011906, 10030137	Death, Oesophageal adenocarcinoma
20	488	Edoxaban	ASA	80	m	02.01.2018	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
280	488	Edoxaban	ASA	79	m	16.12.2017	Sudden cardiac death	10049418	Sudden cardiac death
318	488	Edoxaban	ASA	94	f	25.12.2021	Death of unknown cause	10011906	Death
810	488	Edoxaban	ASA	93	f	23.04.2021	Death of unknown cause	10011906	Death
42	488	Edoxaban	no ASA	66	m	20.06.2018	No cardiovascular cause	10035664, 10040070, 10011906	Pneumonia, Septic shock, Death
166	502	Edoxaban	ASA	87	m	07.08.2017	No cardiovascular cause	10011906, 10035664	Death, Pneumonia
102	502	Edoxaban	no ASA	77	m	09.07.2019	Sudden cardiac death	10049418	Sudden cardiac death
1399	529	Placebo	ASA	85	m	01.10.2020	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
703	529	Edoxaban	ASA	86	m	09.08.2022	Death of unknown cause	10011906, 10003549	Death, Asthenia
1593	529	Edoxaban	no ASA	86	f	01.07.2022	No cardiovascular cause	10011906, 10035664	Death, Pneumonia
315	530	Placebo	ASA	69	f	11.11.2020	No cardiovascular cause	10070255, 10023804, 10061778, 10010041, 10021321, 10009895, 10017955, 10066152, 10036410, 10011906	Coronavirus test positive, Large intestine perforation, Colectomy, Colostomy, Ileostomy, Colitis ischaemic, Gastrointestinal haemorrhage, Transfusion, Postoperative wound infection, Death
1513	530	Edoxaban	ASA	81	m	29.03.2020	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
311	532	Placebo	ASA	76	m	11.01.2020	No cardiovascular cause	10011906, 10040070, 10038749	Death, Septic shock, Resuscitation
538	535	Edoxaban	ASA	87	f	13.04.2022	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
756	535	Edoxaban	no ASA	81	f	12.03.2019	No cardiovascular cause	10035598, 10011906	Pleural effusion, Death

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
276	536	Edoxaban	ASA	79	m	20.03.2020	No cardiovascular cause	10011906, 10048709	Death, Urosepsis
855	541	Edoxaban	ASA	90	f	09.06.2022	No cardiovascular cause	10011906, 10008593	Death, Cholangiocarcinoma
1508	544	Placebo	ASA	73	m	09.08.2020	Death due to heart failure (HF)	10049993, 10007554, 10062362	Cardiac death, Cardiac failure, Viral test negative
137	544	Placebo	no ASA	88	f	29.05.2020	No cardiovascular cause	10011906, 10008614	Death, Cholecystitis acute
1190	544	Edoxaban	ASA	73	m	23.11.2021	No cardiovascular cause	10011906, 10038695, 10035664, 10062362	Death, Respiratory failure, Pneumonia, Viral test negative
1345	544	Edoxaban	no ASA	80	m	29.11.2020	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1517	547	Placebo	ASA	88	f	05.12.2021	Death due to stroke	10011906, 10061256, 10014498, 10043568	Death, Ischaemic stroke, Embolic stroke, Thrombolysis
918	547	Placebo	no ASA	85	m	15.11.2020	Death due to stroke	10011906, 10008190, 10061256, 10014498, 10062362, 10043530	Death, Cerebrovascular accident, Ischaemic stroke, Embolic stroke, Viral test negative, Thrombectomy
922	547	Placebo	no ASA	84	m	13.08.2022	Death due to stroke	10061256, 10062362, 10011906, 10014498	Ischaemic stroke, Viral test negative, Death, Embolic stroke
392	547	Edoxaban	ASA	83	m	31.03.2020	No cardiovascular cause	10070255, 10011906, 10035664	Coronavirus test positive, Death, Pneumonia
1369	547	Edoxaban	ASA	87	m	13.11.2021	No cardiovascular cause	10011906, 10040047	Death, Sepsis
2055	547	Edoxaban	ASA	84	m	01.07.2022	No cardiovascular cause	10011906, 10036909, 10018867, 10066152	Death, Prostate cancer metastatic, Haematuria, Transfusion
2214	547	Edoxaban	ASA	68	m	27.09.2022	No cardiovascular cause	10011906, 10040070, 10008604, 10014802, 10028997	Death, Septic shock, Cholangitis, Endoscopic retrograde cholangiopancreatography, Neoplasm malignant
714	557	Edoxaban	ASA	76	m	13.10.2019	Death due to heart failure (HF)	10007554, 10049993	Cardiac failure, Cardiac death
462	564	Placebo	ASA	90	f	02.05.2019	Sudden cardiac death	10049418	Sudden cardiac death
1110	564	Placebo	ASA	87	m	04.06.2022	No cardiovascular cause	10011906, 10028200, 10022116	Death, Multiple fractures, Injury
389	564	Placebo	no ASA	84	f	09.03.2018	Death of unknown cause	10011906	Death
601	619	Edoxaban	no ASA	89	f	19.06.2021	Death of unknown cause	10011906	Death
643	641	Placebo	ASA	89	f	10.01.2019	Sudden cardiac death	10049418	Sudden cardiac death
478	641	Placebo	no ASA	82	f	19.04.2018	Death due to other cardiovascular causes	10011906, 10007649	Death, Cardiovascular disorder
632	641	Placebo	no ASA	78	m	15.05.2019	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1015	641	Edoxaban	no ASA	78	m	25.03.2019	Death of unknown cause	10012601, 10014561, 10058467, 10011906, 10055798, 10059175	Diabetes mellitus, Emphysema, Lung neoplasm malignant, Death, Haemorrhage, Intestinal haemorrhage
549	655	Edoxaban	ASA	77	m	12.11.2020	No cardiovascular cause	10011906, 10035664, 10070255	Death, Pneumonia, Coronavirus test positive
223	663	Edoxaban	no ASA	75	m	22.03.2019	Death due to heart failure (HF)	10007554, 10049993	Cardiac failure, Cardiac death
269	673	Placebo	ASA	92	m	23.07.2020	Sudden cardiac death	10049418	Sudden cardiac death
87	673	Placebo	no ASA	82	f	29.06.2018	Sudden cardiac death	10049418	Sudden cardiac death

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
194	673	Placebo	no ASA	84	m	16.04.2020	Death due to heart failure (HF)	10049993, 10007554, 10062362	Cardiac death, Cardiac failure, Viral test negative
1150	673	Placebo	no ASA	83	m	10.10.2020	No cardiovascular cause	10011906, 10036909, 10035664, 10062362	Death, Prostate cancer metastatic, Pneumonia, Viral test negative
948	673	Edoxaban	ASA	85	m	30.08.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1713	673	Edoxaban	ASA	85	m	12.04.2022	No cardiovascular cause	10011906, 10028537	Death, Myelofibrosis
427	673	Edoxaban	no ASA	93	m	11.08.2021	Death of unknown cause	10011906	Death
707	673	Edoxaban	no ASA	91	f	28.06.2020	Death due to heart failure (HF)	10049993, 10013663, 10007554, 10013654	Cardiac death, Drug dependence, Cardiac failure, Drug abuse
307	675	Placebo	no ASA	75	m	06.01.2019	No cardiovascular cause	10011906, 10012271	Death, Dementia Alzheimer's type
507	675	Edoxaban	no ASA	84	m	09.01.2021	No cardiovascular cause	10011906, 10033609	Death, Pancreatic carcinoma
942	675	Edoxaban	no ASA	87	m	02.02.2022	Death due to other cardiovascular causes	10011906, 10007649, 10062585, 10034576	Death, Cardiovascular disorder, Peripheral arterial occlusive disease, Peripheral ischaemia
772	680	Placebo	ASA	72	m	17.11.2020	Death of unknown cause	10011906	Death
783	680	Placebo	ASA	73	m	02.07.2020	Sudden cardiac death	10049418	Sudden cardiac death
902	680	Placebo	ASA	78	f	02.11.2019	Death due to heart failure (HF)	10049993, 10007554, 10061161, 10016454	Cardiac death, Cardiac failure, Pelvic fracture, Femur fracture
1347	680	Placebo	ASA	72	m	20.01.2021	No cardiovascular cause	10061256, 10011906, 10070255	Ischaemic stroke, Death, Coronavirus test positive
1609	680	Placebo	ASA	76	m	23.07.2021	No cardiovascular cause	10011906, 10064687, 10049071	Death, Device related infection, Vascular operation
2031	680	Placebo	no ASA	76	m	19.03.2022	Death due to acute myocardial infarction (MI)	10049993, 10000891, 10062362, 10051592	Cardiac death, Acute myocardial infarction, Viral test negative, Acute coronary syndrome
698	680	Edoxaban	ASA	89	f	02.02.2020	Death due to heart failure (HF)	10049993, 10061008, 10007554	Cardiac death, Biliary tract disorder, Cardiac failure
934	680	Edoxaban	ASA	81	m	17.06.2021	No cardiovascular cause	10011906, 10005003	Death, Bladder cancer
1065	680	Edoxaban	ASA	80	f	10.10.2020	No cardiovascular cause	10011906, 10053942, 10008111, 10028533, 10066152, 10016173	Death, Cerebral haematoma, Cerebral haemorrhage, Myelodysplastic syndrome, Transfusion, Fall
1292	680	Edoxaban	ASA	73	m	20.08.2020	Sudden cardiac death	10049418, 10038749	Sudden cardiac death, Resuscitation
1530	680	Edoxaban	ASA	82	f	29.01.2022	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1887	680	Edoxaban	ASA	89	m	18.12.2021	No cardiovascular cause	10011906, 10070255, 10022611	Death, Coronavirus test positive, Interstitial lung disease
123	688	Placebo	ASA	80	m	19.08.2019	Death of unknown cause	10011906	Death
1373	688	Edoxaban	ASA	85	m	25.04.2022	Death of unknown cause	10011906	Death
231	688	Edoxaban	no ASA	86	m	13.10.2021	No cardiovascular cause	10011906, 10009033	Death, Chronic obstructive pulmonary disease
1229	692	Edoxaban	ASA	68	m	29.06.2021	No cardiovascular cause	10040070, 10007515, 10011906, 10062194	Septic shock, Cardiac arrest, Death, Metastasis
162	698	Placebo	no ASA	78	m	27.12.2021	Death of unknown cause	10011906	Death

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
219	698	Edoxaban	ASA	85	f	02.12.2017	Death of unknown cause	10011906	Death
226	698	Edoxaban	ASA	77	m	07.07.2022	No cardiovascular cause	10011906, 10057847, 10014802	Death, Biliary sepsis, Endoscopic retrograde cholangiopancreatography
2153	705	Edoxaban	no ASA	66	f	11.12.2021	Death due to cardiovascular haemorrhage	10011906, 10007649, 10055798, 10066152, 10053757, 10014819, 10017955	Death, Cardiovascular disorder, Haemorrhage, Transfusion, Therapeutic procedure, Endoscopy upper gastrointestinal tract, Gastrointestinal haemorrhage
282	706	Placebo	no ASA	97	m	16.12.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
437	707	Edoxaban	ASA	78	m	19.08.2022	No cardiovascular cause	10011906, 10050017, 10035598, 10035664	Death, Lung cancer metastatic, Pleural effusion, Pneumonia
1226	707	Edoxaban	ASA	81	m	16.03.2022	Death due to heart failure (HF)	10049993, 10007554, 10035664	Cardiac death, Cardiac failure, Pneumonia
374	708	Edoxaban	no ASA	95	f	27.08.2021	Sudden cardiac death	10049418	Sudden cardiac death
611	711	Edoxaban	no ASA	86	m	02.10.2020	Death of unknown cause	10011906, 10028980	Death, Neoplasm
1392	725	Placebo	ASA	91	m	26.11.2021	No cardiovascular cause	10011906, 10058467	Death, Lung neoplasm malignant
1947	725	Placebo	ASA	85	m	15.11.2022	Death of unknown cause	10011906	Death
2197	725	Placebo	ASA	95	m	13.06.2022	Death due to cardiovascular haemorrhage	10011906, 10007649, 10055798, 10042361	Death, Cardiovascular disorder, Haemorrhage, Subdural haematoma
2105	725	Edoxaban	ASA	69	m	15.03.2022	No cardiovascular cause	10011906, 10058467	Death, Lung neoplasm malignant
1839	725	Edoxaban	no ASA	77	m	15.12.2020	Sudden cardiac death	10049418	Sudden cardiac death
1560	730	Placebo	no ASA	90	f	22.08.2021	Death of unknown cause	10011906	Death
799	735	Placebo	ASA	74	m	29.12.2020	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
866	740	Edoxaban	no ASA	82	f	21.03.2022	No cardiovascular cause	10011906, 10003549	Death, Asthenia
1909	741	Edoxaban	no ASA	79	m	03.02.2021	Death due to stroke	10061256, 10011906	Ischaemic stroke, Death
957	748	Placebo	ASA	88	m	07.09.2020	Death due to acute myocardial infarction (MI)	10049993, 10000891	Cardiac death, Acute myocardial infarction
1056	748	Placebo	ASA	90	f	26.10.2020	Death of unknown cause	10011906	Death
1251	748	Placebo	ASA	95	m	04.09.2022	No cardiovascular cause	10069339, 10012174, 10011906, 10027457, 10038394	Acute kidney injury, Dehydration, Death, Metastases to liver, Renal cancer stage IV
1272	748	Placebo	ASA	85	f	01.07.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1285	748	Placebo	ASA	90	m	16.06.2022	Sudden cardiac death	10049418	Sudden cardiac death
1674	748	Placebo	ASA	91	f	08.08.2022	No cardiovascular cause	10035664, 10070255, 10011906	Pneumonia, Coronavirus test positive, Death
2384	748	Placebo	ASA	87	m	15.07.2022	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
281	748	Edoxaban	ASA	76	m	18.07.2022	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1249	748	Edoxaban	no ASA	77	f	07.04.2020	No cardiovascular cause	10011906, 10062194, 10014733	Death, Metastasis, Endometrial cancer
1301	748	Edoxaban	no ASA	98	f	30.10.2021	Death of unknown cause	10011906	Death
1341	768	Placebo	no ASA	89	f	22.01.2022	Death of unknown cause	10011906, 10003988	Death, Back pain

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
660	775	Placebo	ASA	74	f	10.10.2020	No cardiovascular cause	10011906, 10058467, 10062194, 10023696	Death, Lung neoplasm malignant, Metastasis, Laparotomy
1555	775	Placebo	ASA	77	m	30.12.2020	Death of unknown cause	10011906, 10007554	Death, Cardiac failure
299	776	Edoxaban	ASA	85	m	17.07.2018	No cardiovascular cause	10011906, 10035664	Death, Pneumonia
625	780	Edoxaban	no ASA	79	m	12.04.2019	No cardiovascular cause	10017955, 10061968, 10011906	Gastrointestinal haemorrhage, Gastric neoplasm, Death
1827	788	Placebo	ASA	77	m	08.11.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1421	800	Placebo	ASA	76	m	28.02.2021	No cardiovascular cause	10035664, 10070255, 10011906	Pneumonia, Coronavirus test positive, Death
1667	800	Placebo	no ASA	81	m	20.04.2021	Death due to stroke	10014498, 10061256, 10062362	Embolic stroke, Ischaemic stroke, Viral test negative
420	800	Edoxaban	ASA	90	m	02.01.2021	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1128	800	Edoxaban	ASA	77	m	24.12.2019	Sudden cardiac death	10049418	Sudden cardiac death
1603	800	Edoxaban	ASA	86	m	08.01.2021	No cardiovascular cause	10011906, 10033645	Death, Pancreatitis
620	801	Placebo	ASA	70	m	13.10.2022	No cardiovascular cause	10002034, 10061816, 10014819, 10017865, 10017955, 10066152, 10035664, 10069339, 10011906	Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Gastritis erosive, Gastrointestinal haemorrhage, Transfusion, Pneumonia, Acute kidney injury, Death
693	801	Placebo	ASA	65	m	27.10.2018	Death due to cardiovascular procedures	10065608, 10011077, 10011906, 10057461, 10000891	Percutaneous coronary intervention, Coronary artery bypass, Death, Cardiac procedure complication, Acute myocardial infarction
1184	801	Edoxaban	ASA	79	m	10.03.2020	No cardiovascular cause	10011906, 10059518	Death, Pleural mesothelioma malignant
741	801	Edoxaban	no ASA	83	m	29.05.2022	No cardiovascular cause	10011906, 10014819, 10010007, 10070255, 10035664, 10002034, 10077361, 10038695	Death, Endoscopy upper gastrointestinal tract, Colonoscopy, Coronavirus test positive, Pneumonia, Anaemia, Multiple organ dysfunction syndrome, Respiratory failure
349	802	Placebo	ASA	83	m	17.04.2018	Death due to heart failure (HF)	10023126, 10018867, 10049993, 10007554, 10014802	Jaundice, Haematuria, Cardiac death, Cardiac failure, Endoscopic retrograde cholangiopancreatography
1082	802	Edoxaban	ASA	84	m	10.07.2020	No cardiovascular cause	10011906, 10005003, 10062194, 10066152	Death, Bladder cancer, Metastasis, Transfusion
1812	815	Placebo	no ASA	88	f	02.11.2021	No cardiovascular cause	10070255, 10011906, 10035664	Coronavirus test positive, Death, Pneumonia
2200	815	Edoxaban	no ASA	84	m	23.11.2021	No cardiovascular cause	10011906, 10039203	Death, Road traffic accident
987	833	Placebo	ASA	77	m	12.06.2020	No cardiovascular cause	10011906, 10037383	Death, Pulmonary fibrosis
976	833	Edoxaban	ASA	84	m	16.02.2021	No cardiovascular cause	10011906, 10051905	Death, Coronavirus infection
795	836	Placebo	no ASA	82	m	25.11.2021	No cardiovascular cause	10011906, 10035664, 10062362	Death, Pneumonia, Viral test negative
849	836	Edoxaban	no ASA	80	f	31.05.2020	No cardiovascular cause	10008958, 10011906, 10040070	Chronic lymphocytic leukaemia, Death, Septic shock
850	870	Placebo	ASA	80	f	09.12.2018	Death of unknown cause	10011906	Death
1030	870	Placebo	ASA	68	f	01.10.2020	Death of unknown cause	10011906	Death
1684	870	Edoxaban	ASA	80	m	06.12.2021	Death of unknown cause	10011906	Death

Patient -ID	Centre -ID	Random group	Random stratum (indication)[1]	Age at event	Sex	Death date	Death type (adjudicated by ERC)	Preferred term (code)	Preferred term (name)
1973	870	Edoxaban	ASA	71	m	05.05.2021	Sudden cardiac death	10049418	Sudden cardiac death
776	872	Placebo	no ASA	83	m	06.08.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
891	872	Placebo	no ASA	80	m	02.08.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
792	874	Placebo	no ASA	94	f	19.10.2019	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
858	874	Edoxaban	ASA	73	m	07.05.2021	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
932	874	Edoxaban	ASA	89	f	10.08.2021	No cardiovascular cause	10011906, 10008958	Death, Chronic lymphocytic leukaemia
1469	874	Edoxaban	ASA	83	f	02.11.2020	Death due to heart failure (HF)	10007554, 10049993	Cardiac failure, Cardiac death
1726	874	Edoxaban	ASA	71	f	31.01.2021	Sudden cardiac death	10049418	Sudden cardiac death
646	875	Placebo	ASA	69	m	13.05.2022	No cardiovascular cause	10011906, 10038086	Death, Rectosigmoid cancer
1027	875	Edoxaban	ASA	78	m	17.02.2022	No cardiovascular cause	10070255, 10035664, 10011906	Coronavirus test positive, Pneumonia, Death
2167	875	Edoxaban	ASA	77	m	22.08.2021	Death due to acute myocardial infarction (MI)	10049993, 10000891	Cardiac death, Acute myocardial infarction
706	877	Edoxaban	ASA	85	m	05.04.2021	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
853	877	Edoxaban	ASA	69	m	04.12.2020	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure
1084	877	Edoxaban	no ASA	95	m	24.02.2022	Death of unknown cause	10011906	Death
1679	877	Edoxaban	no ASA	70	f	13.05.2022	Death of unknown cause	10011906	Death
2550	965	Placebo	no ASA	86	m	26.08.2022	No cardiovascular cause	10011906, 10001150, 10062194	Death, Adenocarcinoma gastric, Metastasis
1314	1028	Edoxaban	no ASA	82	m	31.03.2022	No cardiovascular cause	10011906, 10041823	Death, Squamous cell carcinoma
949	1029	Placebo	ASA	83	m	10.02.2020	Death due to acute myocardial infarction (MI)	10049993, 10000891	Cardiac death, Acute myocardial infarction
1467	1039	Edoxaban	ASA	81	m	14.12.2021	Sudden cardiac death	10049418	Sudden cardiac death
1842	1074	Edoxaban	ASA	68	m	05.02.2021	No cardiovascular cause	10011906, 10007554, 10070255	Death, Cardiac failure, Coronavirus test positive
1968	1074	Edoxaban	no ASA	84	f	23.07.2021	Death due to other cardiovascular causes	10011906, 10007649, 10071564, 10040943	Death, Cardiovascular disorder, Limb amputation, Skin ulcer
2561	1074	Edoxaban	no ASA	68	m	10.04.2022	Sudden cardiac death	10049418	Sudden cardiac death
2078	1080	Placebo	ASA	84	f	10.12.2021	Sudden cardiac death	10049418	Sudden cardiac death
1688	1080	Placebo	no ASA	73	m	29.01.2021	No cardiovascular cause	10011906, 10070255	Death, Coronavirus test positive
1778	1080	Edoxaban	ASA	83	m	27.01.2021	Sudden cardiac death	10049418	Sudden cardiac death
1462	1080	Edoxaban	no ASA	81	f	03.01.2021	No cardiovascular cause	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1358	1089	Placebo	no ASA	82	m	28.01.2020	Sudden cardiac death	10049418	Sudden cardiac death
1522	1089	Placebo	no ASA	85	m	22.08.2020	Sudden cardiac death	10049418, 10038749	Sudden cardiac death, Resuscitation
2377	1121	Edoxaban	no ASA	91	m	28.12.2021	Death due to heart failure (HF)	10049993, 10007554	Cardiac death, Cardiac failure

[1] ASA = Acetylsalicylic acid

14.3.4 Narratives of deaths and serious adverse events related to the IMP

Table 18 Narratives of deaths and serious adverse events with causal relationship to blinded study drug Edoxaban, as judged by the investigator

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
908	9	E	ASA	69	m	00449 -2	SAE 449-1: Five days hospital stay for planned surgical repair of a hydrocele and spermatocele. The operation was carried out without complications. SAE 449-2: On the day after the intervention the patient took the study medication by mistake without a medical indication and developed an extensive scrotal hematoma. A second surgical intervention was performed to drain the hematoma and after observation the patient was discharged in good conditions for ambulatory follow up.	13.03.2019	15.03.2019	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	None, i.e. still ongoing	Recovered/resolved		
908	9	E	ASA	71	m	01231 -1	SAE 01231-1 Three day elective hospital stay due to hemorrhoids III degree. Surgical treatment with circular mucopexy was performed. SAE 01231-2: Postoperatively, patient developed bleeding which could not be stopped by tamponade. Surgical revision was necesary (ISTH criteria for major bleeding fulfiled). Origin of bleeding could not be found but bleeding was controlled. The patient could be discharged stable.	05.05.2021	06.05.2021	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
908	9	E	ASA	71	m	01231 -2	SAE 01231-1 Three day elective hospital stay due to hemorrhoids III degree. Surgical treatment with circular mucopexy was performed. SAE 01231-2: Postoperatively, patient developed bleeding which could not be stopped by tamponade. Surgical revision was necesary (ISTH criteria for major bleeding fulfiled). Origin of bleeding could not be found but bleeding was controlled. The patient could be discharged stable.	07.05.2021	08.05.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved		
908	9	E	ASA	71	m	01242	2 days hospital stay due to hematochezia after treatment of haemorrhoids (mucopexy). Anal tamponade was put in place. Hb decreased 3 points in total (ISTH criteria for major bleeding fulfilled). Proctoscopy showed no evidence of active bleeding. Study medication was paused and ASS was started. Hb was stable. Discharged in stable condition.	19.05.2021	21.05.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
1338	9	E	ASA	88	m	00651	11 day hospitalization due to gastroesophageal junction variceal bleeding (Criteria for major bleeding: Symptomatic bleeding in a critical area or organ met). The patient was succesfully treated with metal clips. The Hb was stable at 8,0 and no transfusions were necessary. Biopsy showed high grade dysplasia of the esophagus. The patient was discharged in stable conditions. The study drug was permanently discontinued due to this event.	10.02.2020	21.02.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
1816	9	E	ASA	73	m	01161	3 days hospital stay for elective gastroscopy and colonoscopy due to positive hemoccult test and iron anemia. Patient suffered from blood in stool since two weeks and stopped when he paused study medication for planned intervention. ISTH criteria for major bleeding were NOT met. Tumor in rectum was detected. Covid-19 test was negative. Discharged in stable condition for ambulatory follow up.	26.04.2021	29.04.2021	Non-cardiovascular event	Not applicable (no intake of study drug)	Recovered/resolved		
1581	12	E	ASA	86	f	00774	Seven day hospitalization due to increasing weakness, exertional dyspnoea and vertigo. Diagnosis: normocytic anaemia (Hb 5,4 g/dl). The patient received three packed red cell transfusions, stabilizing the Hb (9,4 g/dl). Despite a positive haemoccult test and consisting haematuria the	05.06.2020	12.06.2020	Major Bleeding in non-surgical patients (according	Temporarily discontinued due	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							patient rejected furhter diagnostic examinatiosn. He was discharged in improved conditions. The study drug was temporarily discontinued due to this event.			ISTH, including haemorrhagic stroke)	to this event			
692	23	P	ASA	81	m	00541	4 days hospital stay due to surgical removal of a post surgical hematoma in a patient with previous reversed total shoulder prothesis surgery. Postoperatively the Hb was 7,7. Therefore, the patient received two packed red cell transfusions (Criteria for major bleeding in surgical patients fulfilled). Control showed Hb of 10,2. The patient was treated with antibiotics. He was discharged in improved conditions. The study drug was temporarily discontinued due to this event.	12.11.2019	15.11.2019	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved with sequelae		
861	40	E	no ASA	82	m	00253	2 day hospital stay due to melena. Emergency gastroscopy showed no hemorrhage source. Colonoscopy revealed two angiodysplasias, these were treated with argon plasma coagulation. Furthermore multiple small adenoma were seen, but not removed due to unclear anticoagulative therapy. This will be planned for a later date. Patient was discharged in improved conditions.	18.12.2018	20.12.2018	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved		
272	49	E	no ASA	72	f	00127	2 day hospital stay due to hematochezia after rectoprexy. Colonoscopy revealed a circular ulcus aprox. 10 cm from ano, but no active bleeding. Bleeding stopped after studymedication was paused. Stool regulation was recommended. Patient was discharged.	15.04.2018	17.04.2018	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
966	57	E	ASA	79	f	00592	Three day hospitalization due to haemorrhagic-erosive gastro-esophageal reflux and long segment barrett mucosa with hematemesis. The patient was treated with proton pump inhibitors. Simultaneous cephalgia was treated with analgetics, CT showed no signs of bleeding or infarction. The patient was discharged in stable conditions. The study drug was temporarily discontinued due to this event.	26.08.2019	29.08.2019	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
528	59	E	ASA	83	f	01665-2	1665-1. 13 day hospital stay for bypass surgery due to severe PAD. Study medication was paused. 1665-2. The patient developed postoperative bleeding. Revision had to be performed. Two erythrocyte concentrates and iron were substituted. Anticoagulation with rivaroxaban for PAD was started. Discharged into geriatric care.	26.02.2022	07.03.2022	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Not applicable (no intake of study drug)	Recovered/resolved		
655	59	E	ASA	88	f	01035	12 days hospital stay due to anemia. Lab confirmed microcytic, hypochromic anemia. 2 blood transfusions were performed and patient received iron IV. Gastro and colonoscopy showed erosions and multiple diverticula but no signs of bleeding (ISTH criteria for major bleeding not met) Further lab analyses showed no particular pathology. Patient suffered from dypsnea and leg pain; sonography showed no sign of thrombosis. Therapy with pain medication and diuretics. The patient was discharged to geriatric rehabilitation.	15.10.2020	26.10.2020	Minor Bleeding	None, i.e. still ongoing	Recovered/resolved		
1245	59	E	ASA	88	m	00626	Three day hospitalization due to severe pain in the right knee. Puncture of the joint showed a small amount of bloody secretion (Hb not available). Conservative therapy succesfully cleared the symptoms. The patient was discharged in good conditions. The study drug was temporarily discontinued due to this event.	05.01.2020	08.01.2020	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
1920	59	E	no ASA	86	f	01569	11 days hospitalisation due to symptomatic gonarthrosis. Before patient was hospitalised, she got physiotherapy which led to haematomas in right leg. Tendency to build haematomas was known since study participation.	12.12.2021	23.12.2021	Minor Bleeding	None, i.e. still ongoing	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							Lab showed increased infection parameters. Knee joint puncture showed no presence of empyema, but a bloody articular effusion. Elastic bandage was put on the knee. Since TSH was low, dose of L-Thyroxine was reduced. Hyponatraemia was treated with diuretics and jonosteril. Patient showed hypotension; antihypertensive medication was adapted. Discharged in stable condition.							
1148	70	P	ASA	82	m	00506	Eight day hospitalization due to spontaneous subdural hematoma (Hb not available) with headache, paresthesia and speech deficiencies. cCTs showed no signs of progression and ischaemia. EEG showed no signs of malfunctions. Doppler sonography showed no relevant stenosis. The patient was treated with Monoembolex and analgesics. The symptoms diminished during the stay. The patient was discharged in stable conditions. The study drug was temporarily discontinued due to this event.	10.09.2019	18.09.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
16	70	E	no ASA	77	m	00868	6 days hospital stay due to macrohematuria in a patient with history of prostate cancer. During hospitalisation an urethrocystoscopy showed a lesion of the prostatic urethra which was excised. The procedure underwent without complications and the patient was discharged for ambulatory follow-up.	27.05.2020	02.06.2020	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
1189	86	E	no ASA	80	f	00473	7 day hospital stay due to anaemia (Hb 4,56 g/dl) and fatigue suspectedly from bleeding of a previous diagnosed colon angiodysplasia. According to medical report from next hospitalisation (See SAE 482) the patient received three red blood cells packs. NSAID therapy was stopped immediately. Surgical evaluation was recommended. The patient was discharged in improved conditions (Hb 9,46 g/dl). The study drug was permanently discontinued due to this event.	05.08.2019	12.08.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
1066	95	P	no ASA	75	m	00652	Three day hospitalization due to recurring macrohematuria (Hb drop less than 2g/dL. Therefore, no ISTH criteria for major bleeding met) after preceding TUR-P surgery. The patient had already been hospitalized for macrohematuria one week before. Sonography of the bladder showed no blockage, tamponade or residual urine. A reduction of the clexane dosage stopped the bleeding. Study medication was restarted one week after discharge and clexane was stopped. The patient was discharged in improved conditions. The study drug had already been temporarily discontinued at the previous hospitalization.	09.06.2019	12.06.2019	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
1066	95	P	no ASA	75	m	00676	Two day hospitalization due to macrohaematuria and urinary retention. Hb was not affected (ISTH criteria for major bleeding not met). The patient was treated with a catheter, the tamponade of the bladder was manually cleared out. The procedure underwent without any complications. The patient was discharged in good conditions. The study drug was temporarily discontinued due to this event.	01.06.2019	03.06.2019	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
320	117	E	ASA	83	m	00156	6 day hospital admission due to gastrointestinal bleeding. Patient presents with thoracic pain and dyspnea for the last week and has a history of chronic kidney failure. Laboratory showed a Hb level of 7g/dl. Therefore concentrated red cells were given. A colonoscopy revealed three angiectases, which were clipped. Due to this study medication was discontinued permanently. Patient was discharged in better conditions and with stable Hb-levels of 9,1 g/dl.	29.06.2018	05.07.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
109	121	E	ASA	76	m	00040	6 day hospital stay due to anaemia with Hb 5, 3 g/dl at admission. No active bleeding found. Removal of sigmoid polyp during colonoscopy. Ther.: 2 RCC transfusions, iron supplementation. The patient was discharged in good condition. Hb at discharge 7,6 g/dl.	11.08.2017	17.08.2017	Major Bleeding in non-surgical patients (according	Permanently discontinued due	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
										ISTH, including haemorrhagic stroke)	to this event			
436	140	E	ASA	77	f	00172	1 day elective hospital stay for exchange of a transurethral DJ-catheter right, status after consecutive urinary transport disorder. Patient reported microhematuria since several months caused by an incrusting ureteral stent. Procedure underwent without any complications. Stuy medication was interrupted temporary.	06.07.2018	07.07.2018	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
622	140	E	ASA	83	f	00170	1 day elective hospital stay for removal of a transurethral DJ-catheter left, status after consecutive urinary transport disorder. No complications during the procedure. Study medication was temporary discontinued. Patient was discharged in good conditions.	03.08.2018	04.08.2018	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
207	205	P	no ASA	82	m	00808	Five days hospital stay due to anemia in a patient with chronic kidney disease. Due to the low Hb value (6.5g/dl) the patient received two blood transfusions. No signs of active bleeding. Rectal examination without melena or fresh blood (ISTH criteria for major bleeding not met). Myeloma screen negative. Patient was discharged in good clinical conditions and the erythropoietin dose was adjusted. He will be followed ambulatory.	26.06.2020	01.07.2020	Non-cardiovascular event	Permanently discontinued due to this event	Recovered/resolved		
1434	226	P	ASA	87	f	01006	Bleeding from the right superior temporal artery with residual blood stratum in th inferior foveal retina (ISTH criteria for major bleeding met; symptomatic bleeding in a critical area or organ). Patient refused any intervention. No further therapy was performed. The patient was discharged home with remaining vision disorder.	11.11.2020	11.11.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	None, i.e. still ongoing	Recovered/resolved with sequelae		
970	414	E	ASA	95	m	01505	6 days hospital stay due to anaemia. Patient presented with dyspnoea and bloody stool. Lab showed Hb of 6.9 g/dL (prior lab: 13 g/dL) (ISTH criteria of major bleeding fulfilled). Four pRBCs were transfused. Even with elevated BNP and troponin, ECG showed no relevant new pathologies. Cause of bleeding was not found during thoraco-abdominopelvic scan. Due to advanced age of patient, colonoscopy was not performed. Discharged in stable condition.	11.11.2021	17.11.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Not applicable (no intake of study drug)	Recovered/resolved		
2183	414	E	no ASA	72	m	01613	11 days hospital stay due to head trauma after a fall. Cerebral scanner showed severe atrophy and hygroma as well as bleeding in left temporal lobe. Haemorrhage was diminishing in following scanners. Study medication was stopped. Wound was stitched up. Sonography revealed torn tendons. Tilt table test was positive suggesting orthostatic hypotension; support stocking was prescribed. Patient was suffering from advanced Parkinson´s disease. Dose of pramipexole is reduced. Due to moderate malnutrition, food supplements were started. Covid-19 test was negative. Discharged in stable condition.	30.01.2022	10.02.2022	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
116	421	P	ASA	67	m	00020	Patient fell on May 3rd. Hospital admission on May 8th due to persistent headache. Dg: - traumatic fracture of os frontale - subarachnoid bleeding - subdural bleeding in region of falx cerebri - contusion bleeding	03.05.2017	18.05.2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							Ther: conservative Discharge May 16th							
503	421	E	ASA	76	m	00347	9 day hospitalization due to haematochezia. Performed gastroscopy hasn't shown any signs of bleeding, the performed colonoscopy showed bleeding diverticulosis as origin for bleeding.. Histologically there were signs of a slight chronic gastritis. The patient was treated with proton pump inhibitors. The patient was discharged in better conditions. The study drug was permanently discontinued due to this event.	25.04.2019	04.05.2019	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved		
1046	421	E	ASA	73	m	00710	Seven day hospitalization due to anaemia (Hb 6,4 g/dl). Diagnosis: upper gastrointestinal bleedingtreated with clipping. The patient received 4 packed red cell transfusions in total (ISTH criteria for major bleeding met). The patient was discharged home in improved conditions. The study drug was temporarily discontinued due to this event.	15.04.2020	22.04.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
508	427	P	ASA	86	m	00116	Colonoscopy due to large episode of sudden rectal bleeding and slight bleeding since two weeks after. Known history of rectal bleeding. Colonoscopy showed no pathology, but some diverticular disease and piles, which most likely caused the bleeding. Due to this event the studymedication was disrupted permanently.	06.04.2018	07.04.2018	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved with sequelae		
651	445	E	ASA	94	m	00318	4 day elective hospitalization due to tarry stool. Gastroscopy showed three duodenal ulcers, which were treated with proton pump inhibitors. The patient was discharged in improved conditions. The study drug was temporarily discontinued due to this event.	14.03.2019	18.03.2019	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
31	488	E	ASA	88	m	00349	3 day hospitalization due to gastrointestinal bleeding (Hb 12,7 g/dl). Gastroscopy showed reflux esophagitis and several flat ulcers in the stomach and duodenum. The colonoscopy showed a diverticulosis with constriction of the lumen and five polyps that have been endoscopically removed. The study medication was temporarily discontinued due to this event. The patient was discharged in stable conditions.	23.04.2019	26.04.2019	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
31	488	E	ASA	89	m	00736	Six day hospitalization due to anaemia (Hb 6,5 g/dl), probably due to gastrointestinal bleeding on basis of anticoagulants. Gastroscopy showed gastritis and suspicion of mucosal atrophy. The patient received two packed red cell transfusions (ISTH criteria for major bleeding fulfilled), iron substitution and diuretics with consequent Hb value increase to 8,1 g/dl. The patient was discharged in improved conditions. The study drug was permanently discontinued due to this event.	14.05.2020	20.05.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
1244	488	E	ASA	77	m	01310	4 day hospital stay due to hematemesis. During the hospital stay patient presented with multiple episodes of melaena. Gastroscopy showed no acute bleeding. Reflux esophagitis and multiple ulcers were diagnosed. Hb drop was suspected as result of one time bleeding. Hb. drop 1.9g/dl. Hence, ISTH criteria for major bleeding NOT met. Spontaneous improvement of general condition. Covid-19 negative. Discharged in improved condition.	27.06.2021	01.07.2021	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
1244	488	E	ASA	78	m	01780	9-day hospital stay due to hematemesis. Gastroscopy showed reflux esophagitis. No active bleeding, but diffuse oozing sites and redness of the stomach and duodenum mucosa. Normalized coagulation parameters after PPSB and vitamin K were substituted. Due to gastritis and duodenitis, proton pump inhibitors and sucralfate were started. Study medication was	11.05.2022	20.05.2022	Minor Bleeding	Temporarily discontinued due	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							interrupted, and statine and antihypertensives were started. Hb remained stable between admission and discharge with no need for blood transfusion. Patient discharged.				to this event			
121	488	E	no ASA	90	m	00337	5 days hospital stay due to general malaise, tarry stool and left hip pain. During hospitalization anemia requiring volume replacement and transfusion of 2 red blood cell concentrates was documented . Upper endoscopic examination as well as one colonoscopy were performed but no gastrointestinal bleeding was found (ISTH criteria for major bleeding not met). Patient was discharged in stable conditions and a outpatient-CT examination was scheduled for further investigation of the anemia cause.	25.03.2019	30.03.2019	Non-cardiovascular event	Permanently discontinued due to this event	Recovered/resolved		
102	502	E	no ASA	76	m	00273	8 day hospital stay due to intracranial bleeding. Patient became unconscious, fell and presented seizure. CCT showed a left sided subdural haematoma, intracerebral haemorrhage occipital and subarachnoidal blood left frontobasal. No given indication for surgery. Antagonisation of blood thinning medication was administered. Study medication was discontinued permanently. Patient was discharged fully recovered.	21.10.2018	29.10.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
227	502	E	no ASA	84	m	00635	Six day hospitalization due to orthostatic syncope. During hospitalisation anaemia (Hb 7,1 g/dl) was diagnosed. A gastroscopy showed peptic ulcer. No obvious signs of bleeding but iron, folic acid and and vitamine B12 deficients were confirmed (ISTH criteria for major bleeding not met). Therefore, substitution therapy was started. The patient was discharged in improved conditions.	11.01.2020	17.01.2020	Syncope	None, i.e. still ongoing	Recovered/resolved		
227	502	E	no ASA	85	m	01065	4 day hospital stay due to severe anemia with Hb of 6,2 g/dl in a patient with suspicious of monoclonal gammopathy of unclear significance. Increased Hb of 7,8 g/dl after one erythrocyte concentrate was given. Gastroscopic examination only showed a gastric angiodyplasia (ISTH criteria of major bleeding not met) Iron deficiency suspected as genesis of anemia. Daily iron substitution was recommended. The patient was discharged stable for ambulatory follow-up.	09.11.2020	13.11.2020	Non-cardiovascular event	None, i.e. still ongoing	Recovered/resolved		
2577	519	E	ASA	75	f	01985	14-day hospital stay due to worsening of general condition with weakness. Lab showed Hb of 5.3 g/dl. Suspicion of GI bleeding was formed. Study medication was stopped prior to hospitalization by the cardiologist. Gastroscopy showed no sign of bleeding. Coloscopy showed no bleeding but revealed a small polyp, which was ablated, and sigma diverticulosis. Capsule endoscopy showed bleeding in the jejunum. Four erythrocyte concentrates were given. Hb stable at 8.6 g/dl. COVID-19 negative. Discharged.	26.09.2022	10.10.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
1693	535	E	ASA	81	m	01844	6-day hospital stay due to iron deficiency anaemia and vertigo. Additionally, Hb drop from 11.9 in November to 8 g/dl on the date of hospital admission. No blood in the stool. Iron was substituted and two units of erythrocyte concentrates were transfused. COVID-19 was negative. Gastroscopy and colonoscopy were performed. Colonoscopy revealed two angiodysplasia-type vascular lesions near the ileocaecal valve, with slight bleeding on contact. Bleeding lesions were treated with local adrenaline. Stabilization of Hb up to 10.9 g/dl. In view of the clinical improvement, it was decided to discharge the patient.	15.03.2022	21.03.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	None, i.e. still ongoing	Recovered/resolved		
1345	544	E	no ASA	79	m	00823	Eight day hospitalization due to iron deficiency anaemia (Hb 9,8). Endoscopic diagnostics showed no signs of bleeding. Treatment included intravenous iron supplements and empiric antibiotics due to a self limiting fever during the hospital stay. The patient was discharged in stable conditions.	07.07.2020	15.07.2020	Non-cardiovascular event	Temporarily discontinued due	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
											to this event			
1367	544	E	no ASA	75	m	00876	6 days hospital stay due to severe anemia and rectal bleeding (Hb at admission 6.2g/dl, previous value from march 2020 9.6g/ dl). During hospitalisation the patient received two blood tranfusions (ISTH criteria for major bleeding fulfilled). The patient underwent gastroscopy and colonoscopy. An anal fisure and two colonic angiodysplastic lesions were detected and treated wtith argon plasma. The patient was discharged in improved clinical condition.	28.08.2020	04.09.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
1369	547	E	ASA	86	m	01186	Ten days hospital stay due to decompensation of heart failure in the context of anemia. During the hospitaliation anemia with Hb of 6.7g/dl was confirmed (Hb in 11.2019 12g/dl) and fecal occult blood test resulted positive. Therefore, ISTH criteria for major bleeding met. Study medication was permanently stopped and the patient received one blood transfusion (Hb post-transfusion 7.7g/dl). PCR for Covid was negative. After clinical improvement the patient was discharged for ambulatory follow-up.	05.03.2021	15.03.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
1160	547	E	no ASA	72	m	00495	Two day hospital stay due to hematochezia in a patient that took 20 NSAID pills (aspirin and ibuprofen) due to shoulder pain together with study medication. During hospitalisation a colonoscopy evidenced mucosal lesions in colon and terminal ileon as well as two polyps 10 cm proximal to anal margin. A polypectomy was performed. The patient was diagnosed with gastrointestinal bleeding secondary non-steroidal anti-inflammatory drug intake. Hemoglobin levels reported in the discharge letter during this hospitalisation were: During hospitalisation 12g/d, level at discharge 13.2 g/dl. No blood transfusions were performed. (NO major bleeding criteria). Patient was discharged in good conditions.	30.09.2019	02.10.2019	Minor Bleeding	None, i.e. still ongoing	Recovered/resolved		
1471	608	E	no ASA	86	m	01108	11 day hospital stay due to hematuria. Prostate resection due to prostate hyperplasia was performed. Suspected as reason for hematuria. HB remained stabled (ISTH criteria for major bleeding NOT met) Bladder stones in the area of the prostate was found and removed. Discharged stable.	11.07.2020	22.07.2020	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
1015	641	E	no ASA	78	m	00333	Death due to intestinal bleeding in a patient with multiple morbidity (Type 2 diabetes mellitus, pulmonary emphysema with severe obstruction, LES, second degree BAV, lung cancer.)	25.03.2019		Death as primary event, e.g. sudden death, not death as outcome of another event	Permanently discontinued due to this event	Death	3.25.2019	Death of unknown cause
379	655	E	ASA	84	m	00871	29 day hospitalization due to hematoma and vasculitis of the right leg. The patient was treated with aspirin. He was discharged in stable conditions. The study drug was permanently discontinued due to this event.	01.07.2018	30.07.2018	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved		
461	655	E	no ASA	80	f	00909	Outpatient visit due to anaemia and melena with haemoglobin drop of aprox. 3g/dl (Hb 10,5 g/dl, ISTH criteria for major bleeding met). The study medication was stopped. Patient was followed up as outpatient. A gastroscopy and colonoscopy performed in December confirmed absence of bleeding. The patient's cardiovascular system remained stable.	23.09.2020	22.12.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
91	673	E	no ASA	82	m	00008 -1	SAE 8-1: Hospital admission due to black faeces (melenae) since 48 hours, no abdominal pain, no other symptoms, no dyspnoea, no thoracic pain. Endoscopy performed. Laboratory: Hb 6,6 g/dl, HK 19,6% Dg: upper gastrointestinal tract bleeding, probably Dieulafoy's lesion (bleeding ulcus ventriculi). Endoscopically treated. SAE 8-2: Aditionally episode of cardiac decompensation SAE 8-3: respiratory infection during course 10 days hospital stay, recovered at discharge.	14.02.2017	24.02.2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
1866	673	E	no ASA	73	f	01612	5-day hospital stay due to upper gastrointestinal bleeding with melaena. Gastroscopy showed a lesion with acute bleeding in the stomach. Most likely angiodysplasia. Electrocoagulation was successfully performed. Severe anaemia with Hb of 4g/dl was diagnosed. 6 erythrocyte concentrates were substituted. Anticoagulation was restarted. No recurrent Hb drop. Dose of bisoprolol was adapted due to bradycardia. COVID-19 negative. Discharged in stable condition.	01.01.2022	10.02.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
888	674	P	no ASA	82	f	01351	3 days hospital stay due to left epistaxis in context of hypertensive derailment (180 mmHG). Tamponade was put in place. ECG showed SR with multiple supraventricular extrasystoles. Discharged in stable condition.	31.08.2021	03.09.2021	Minor Bleeding	Temporarily discontinued due to this event	Recovered/resolved		
307	675	P	no ASA	74	m	00174 -2	3 day hospital stay due to an iscemic stroke. Patient was found with sypmtoms of aphasia, right sided hemianopsia and hemiparesis. In additions the patient is not able to follow instructions. Head CT reveals a leftsided parietal subacute infarction, with hemorragic transformation and an old occipital infarction. In course of time the level of consciounsness improved, but the hemiparesis maintains. Due to this studymedication was discontinued permanently. Patient was discharged with consequential damages.	06.08.2018	09.08.2018	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved		
240	675	E	no ASA	75	m	00344	Hemoglobin drop in a patient with previous diagnosis of colon cancer. The drop in hemoglobin occured over months (Hb drop from 14.1 g/dl in March 2018 to 11.3 g/dl in October 2018,see SAE documents). The patient underwent a resection of the colon tumor (March 2019; see SAE 341). Hemoglobin values returned to normal range. There are no other medical reports available for this patient, also no report of blood transfusions that might been administrated. Since no active bleeding was documented the ISTH criteria for major bleeding are not met.	23.11.2018	22.03.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Not applicable (no intake of study drug)	Recovered/resolved		
1065	680	E	ASA	80	f	00921	Hospitalisation after fall in a patient with diagnosis of myelodysplastic syndrome. In the ER an haematoma in the lateral-posterior area of the right thigh was showed. Additionally non-contrast CT of the head showed a minor intracerebral haematoma (5mm) of the righ frontal lobe without indications for surgical treatment. Also, fecal occult blood test resulted positive. Study medication was interrupted since the start of the event. During the hospital stay 2 blood transfusions were performed. Previous Hb from 29.08.20: 8.7 g/dl; Hb at admission 04.10.20: 6.9 g/dl; after transfusion: 9.8 g/dl (Criteria for major bleeding met). The patient died on 10.10.2020 one day after being transfered to another hospital (due to administrative reasons). The death certificate states the cause of death as follows: Underlaying cause of death heart failure, secondary cause haemorrhagic anemia.	04.10.2020		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Death	10.10.2020	No cardiovascular cause

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
2281	688	P	ASA	80	f	01923	21-day hospital stay due to falling at home. CCT showed subarachnoidal bleeding and fracture of petrous bone and maxillary sinus walls. Patient was hospitalized in ICU for monitoring. The patient presented with haematootorrhea, aphasia and retrograde amnesia. CCT showed progression of subarachnoidal hematoma without signs of cerebral compression. No indication for surgical intervention. Improvement of aphasia. Due to impaired hearing after the fall, the neck, nose, and ear department was consulted. Therapy with prednisone was started. Due to the unknown reason for the fall, a pacemaker assessment was initiated. No pathological findings for the day of the fall, but several episodes of AF were detected. The study drug was permanently discontinued but initially, no open-label oral anticoagulation will be started due to the risk of falling. Discharged.	23.06.2022	14.07.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
906	689	P	ASA	79	m	00291	7 day hospital stay due to suspicion of gastrointestinal bleeding because of black feces. Performed gastroscopy and colonoscopy haven`t shown any signs of intestinal haemorrhage, but characteristics of gastroesophageal reflux grade 3 and also two small polyps in caecum. Histopathology analysis has shown a mild bulbitis. A polypectomy is scheduled in 2 months. Patient in a good condition was discharged home.	19.02.2019	26.02.2019	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
219	698	E	ASA	85	f	00072	Patient died at home after treatment for intracerebral bleeding was administered. Exact reason for death is unknown. No medical reports are available.	02.12.2017		Death as primary event, e.g. sudden death, not death as outcome of another event		Death	12.2.2017	
219	698	E	ASA	85	f	00077	8 days hospital stay. Hospitalization via emergency unit due to diarrhea and vomiting several times since the morning. CCT was performed and revealed cerebellar hemorrhage and impaired drainage of cerebral fluid. After discussion with relatives, no further treatment due to presumed will of patient. Discharged home at request of relatives.	20.11.2017	28.11.2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
226	698	E	ASA	77	m	01580	3 day hospital stay due to symptomatic severe anemia with Hb of 4.3g/dl. Patient reported of dizziness, dyspnea and loss of appetite. Gastroscopy showed antrum-corpus-gastritis. Therapy with PPIs was started. Coloscopy showed bleeding with origin in colon/rectum. Exact localization could not be found. Hb increased up to 5.8g/dl after 2 erythrocyte concentrates were substituted. Due to decreased serum iron and transferrin, iron was substituted. Discharged home in improved condition.	19.01.2022	22.01.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	None, i.e. still ongoing	Recovered/resolved		
2437	705	P	ASA	88	f	02001-1	2001-1. 18-day hospital stay due to falling on the head. The patient was diagnosed with skull fracture and subdural and subarachnoidal bleeding. Conservative therapy was initiated. 2001-2. Three days after hospital admission the patient felt thoracic pain. ECG showed wide complex tachycardia. Due to suspicion of atrial flutter pharmacological conversion with amiodarone was initiated. Successfully performed. Saturation of amiodarone was started. Pacemaker assessment confirmed episodes of atrial flutter. CCT showed regression of bleeding and a small area of subacute infarction. Acetylsalicylic to be restarted after one week. Study medication was stopped. Antihypertensive medication was adapted. COVID-19 negative. Discharged.	29.09.2022	17.10.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
1748	705	P	no ASA	76	m	01625	8 day hospital stay due to melaena and bleedy diarrhea. Hb of 8.7 g/dl (two weeks prior: 14.0 g/dl). Anemia suspected as genesis. Diagnostics showed no bleedings. Hb dropped permanently during hospital stay (down to 7.0 g/dl). Two erythrocyte concentrates and iron were given. Antihypertensive medication and trial medication was paused. Patient presented with T-negativities. Trial medication was restarted. Discharged in improved condition.	17.02.2022	25.02.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved		
2153	705	E	no ASA	66	f	01343	Patient presented with events of hematemesis, haematochezia, nasal bleeding and vaginal bleeding. Lab showed Hb of 10.0 g/dL in comparison to 15.06.2021: 13.9 g/dL. ISTH criteria for severe bleeding are fulfilled. Study medication was stopped. Patient wanted to do colonoscopy and gastroscopy in external facility.	20.07.2021	07.08.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved		
437	707	E	ASA	75	m	00647	6 days hospital stay due to elective transurethral resection of the urinary bladder due to carcinoma. Surgery underwent without complications. Patient discharged home in stable condition.	05.12.2019	11.12.2019	Non-cardiovascular event	Not applicable (no intake of study drug)	Recovered/resolved		
1226	707	E	ASA	79	m	00607	8 days hospital stay due to decompsated heart failure and angina pectoris in the context of chronic kidney disease and anemia (Hb 10.2g/dL). An ECG showed ST depression. A coronography was performed which showed the stenosis of RCx and RMS. The condition was not assessed as ACS but as decompensated hart failure. Patient was treated with nitrates. After improvement of her clinical condition patient was discharged for ambulatory follow-up.	06.01.2020	14.01.2020	Worsening of heart failure	Permanently discontinued due to this event	Recovered/resolved with sequelae		
518	711	E	no ASA	86	m	00345	Major bleeding no admission to hospital. Drop in hemoglobin level of 4.9 g/dl. Patient was treated as outpatient and the hemoglobin increased after stop of study medication	28.09.2018	30.11.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
2494	725	E	ASA	70	m	01628-1	1628-1. 1-day hospital stay due to significant anaemia during the course of rectorrhagia. Lab showed Hb of 7 g/dl. Two units of blood were transfused over the course of the entire hospitalisation. Hb stable at 10 g/dl. Colonoscopy revealed angiodysplasia treated with argon-plasma-coagulation. 1628-2. 12-day hospital stay due to detection of increased myocardial parameters. Myocardial infarction in the context of three-vessel disease was diagnosed. PCTA with recanalization was successfully performed. Discharged.	27.02.2022	28.02.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
532	748	E	ASA	82	f	00664	Five day hospitalization due to dyspnea and anaemia (Hb 8,1 g/dl). Diagnoses: lower gastrointestinal bleeding, diverticulosis and gastritis. The patient received two packed red cell transfusions (Hb 12,3 at discharged). The study drug was temporarily discontinued, the patient received ASS. The patient was discharged in good conditions.	21.02.2020	26.02.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
555	748	E	ASA	69	m	00189	6 day hospital stay due to upper gastrointestinal haemorrhage. Patient presents with hematemesis and melanea in emergency department. No abdominal pain. Endoscopy revealed a duodenal ulcer, which was treated with injection of suprarenin. Hb levels stabilised after transfusion of concentrated red blood cells. Furthermore an eradication therapy with clarithromycin, amoxicillin and pantozol was administered. Study medication was discontinued permanently. Patient was discharged home fully recoverd.	12.09.2018	18.09.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
555	748	E	ASA	69	m	00201	17 day hospital stay due to bleeding gastrointestinal ulcer and a secondary myocardial infarction. Gastrointestinal bleeding was treated in an emergency operation but caused a major drop of Hb levels down to 6,5 mg/dl. Afterwards laboratory showed elevated Troponin levels. Cardiac catheter examination revealed a significant main artery stenosis, which was stented, after stabilisation of Hb levels. Study medication was interrupted permanently. Patient was discharged in improved general conditions.	22.09.2018	09.10.2018	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Not applicable (no intake of study drug)	Recovered/resolved		
928	748	E	ASA	84	f	00403	7 day hospitalization due to normochromic normocytic anaemia (Hb 4,2 g/dl). The study drug was discontinued and the patient treated with three red cell concentrates. After an initial increase the haemoglobin decreased again and another red cell concentrate became necessary. Endoscopic diagnosis showed erosive pangastritis and two small lipomas but no active bleeding. Coloscopy and sonography showed no signs of active bleeding (ISTH criteria not met). The patient was treated with a proton pump inhibitor and ASS. The patient was discharged in stable conditions.	02.07.2019	09.07.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
928	748	E	ASA	84	f	00409	2 day elective hospitalization due to a CCT showing concrements in the right ureter. Ureterorenoscopy showed no signs of concrements. The patient was treated by implanting a JJ stent into the right ureter. The procedure underwent without any complications. On the second postoperative day the catheter and the stent were removed. Both kidneys were free of urinary retention. The patient was discharged in good conditions.	06.06.2019	08.06.2019	Non-cardiovascular event	None, i.e. still ongoing	Recovered/resolved		
2203	748	E	ASA	86	m	01450	1 overnight stay due to positive fecal immunochemical test. Lab showed no abnormalities. Colonoscopy revealed sigma diverticulosis and known haemorrhoids. Adenoma was excised and clip was put in place. Due to low blood pressure, further examinations were advised. Covid-19 test was negative. Discharged in stable condition.	27.10.2021	28.10.2021	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
458	752	E	no ASA	81	m	00383	Patient attended the emergency room on 03.06.2019 due to melena, gastric bleeding and anemia with Hb 9.9g/L (previous control Hb 13g/L). A gastroscopy was scheduled for 13.06.2019 and the patient was discharged on the same day. On 10.06.2019 the patient attended the emergency room again due to rectal bleeding but due to stable clinical condition was discharged on the same day. On 13.06.2019 a gastroscopy showed a subcardial neoplasy and a biopsy confirmed an adenocarcinom moderately diferenciated. On 01.07 a CT scan confirmed the subcardial endoluminal lesion. On 04.08.2019 the hemoglobine levels increased and surgical intervention to remove the tumor was planned. Since the patient withdrew his consent no further information is available.	03.06.2019	04.08.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved		
448	756	P	no ASA	78	m	00587	4 days hospital stay due to post-traumatic right hemothorax (Criteria for major bleedings in non surgical patients fulfilled: symptomatic bleeding in a critical area or organ, in this case in the pleural cavity) and multiple rib bones fractures. At admission a toracic drainage was placed. After	27.11.2019	01.12.2019	Major Bleeding in non-surgical patients (according ISTH, including	Temporarily discontinued due	Recovered/resolved		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							confirmation of resolution of the hemothorax and clinical improvement the patient was discharged in stable condition for ambulatory follow-up.			haemorrhagic stroke)	to this event			
1603	800	E	ASA	86	m	00920 -2	SAE 920-1: According to documentation, the patient was hospitalized due to cardiac decompensation on 24.09.2020. Intravenous diuretic therapy was initiated and the insulin therapy was optimised. The symptoms of the patients improved. SAE 920-2: However, on 02.10.2020 the patient experienced left sided muscle weakness. The CT examination of the brain showed a low-grade right-sided fronto-pariental subdural haematoma. The IMP was stopped permanently on 02.10.2020. Neurosurgical examination was performed and conservative treatment was proposed. A control CT scan showed regression of the hematoma. The patient was discharged home on 07.10.2020	02.10.2020	07.10.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
1332	800	E	no ASA	80	m	00555	9 days hospital stay after cutting lesion of the left upper arm with haematoma formation. Duplex echography ruled out deep vein thrombosis. No blood transfusion was needed. After no further abnormalities and decrease of pain and swelling the patient was discharged.	27.11.2019	06.12.2019	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved		
599	801	P	no ASA	74	m	00420	2 days hospitalisation due to blurred vision. Opthalmic exam revealed an acute macular bleeding and layer detachment. Aflibercept injection was administered and bleeding stopped. The patient was discharged with remaining vision impairments. Study medication was discontinued due to this event.	06.07.2019	09.07.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
793	801	P	no ASA	76	f	00866	9 days hospital stay for further diagnosis of dyspnoe and progressing tiredness. Chest X-rax, echocardiography showed no progression. Abdominal ultrasound was normal. The laboratory test showed major anemia. Gastroscopy and colonoscopy were perfomed, no bleeding source was identified (ISTH criteria for major bleeding not met). The symptoms of the patients improved; thus, the patient was discharged home on 2020.08.05. The NOAH medication was stopped between 27.07.2020-11.08.2020.	27.07.2020	05.08.2020	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
639	801	E	no ASA	78	m	00175	Three day hospitalisation due to haemoptysis. Sputum sample: brown-black clotted blood and jellylike. Patient mentioned that he accidentally took double dose of study medication. Study medication was discontinued due to this event. Haemoptysis could be due to underlying lung cancer (Patient had prostatic cancer and is now tumour free since 2 years). Patient refused further investigations such as thoracic CT. Patient was discharged.	13.08.2018	16.08.2018	Minor Bleeding	Permanently discontinued due to this event	Recovered/resolved		
741	801	E	no ASA	83	m	01696	According to documentation, the patient was hospitalized due to paleness, anaemia, positive Weber test, and unknown infection on the 29th March. The NOAH medication was stopped. The patient developed fever, sepsis, pneumonia and he was intubated for several days. Several iv. antibiotics were applied, the condition slightly improved then the patient had COVID infection. He was transferred to the COVID unit of the Semmelweis Univeristy, specific treatment was given to him. He underwent colonoscopy and gastroscopy and a huge polypus of the duodenum was seen, but intervention was not possible. The anticoagulation of the patient was permanently stopped, even though clinical atrial fibrillation was documented. Preventive dosage of LMWH was given to him. The patient was sub-febrile for days, TEE was performed that showed infective	29.03.2022		Non-cardiovascular event	Permanently discontinued due to this event	Death	5.29.2022	No cardiovascular cause

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							endocarditis of the aortic valve and the pacemaker lead. Urgent cardiac surgery of the aortic valve was planned and the patient was transferred on 13.05.2022 to the Cardiac Surgery Department of the Semmelweis Univ. Due to the general poor condition, open heart surgery was found not to feasible and the operation was therefore contraindicated. He was transferred back to the Internal Medicine Department of the Semmelweis Univ. On 20.05.2022 the patient suffered from an acute renal failure, then a rapid progression was seen and the patient died of an acute respiratory failure on 29.05.2022.							
1334	801	E	no ASA	81	m	00714	4 days hospital stay due to differentilal diagnosis of severe anaemia (Hb of 83 g/dl). A gastroscopy was performed without colonoscopy because the patient refused further hospitalisation. The date of hospital discharge was 28.04.2020. The cause of the anaemia was not confirmed (ISTH criteria for major bleeding not met) and the GI specialist suggested not to continue the NOAH medication.	24.04.2020	28.04.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
1772	801	E	no ASA	78	f	00945-1	SAE 945-1: According to documentation, the patient complained of paleness, unwellness and dark black faeces. The local emergency department found severe anaemia (Hb 7.2 g/dl). The NOAH medication was immediately terminated. Gastroscopy was negative; the colonoscopy showed diverticulosis sigmae that was the source of bleeding. The patient received 2 blood transfusions (ISTH criteria for major bleeding met). SAE 945-2: According to documentation, during the same hospitalization, the patient experience aniscoria, left sided hemiparesis, dysarthria, sensation deficit, facial asymmetry. The CT scan showed bilateral frontal meningeomas, chronic ischaemic lesions. CT angiography was not performed due to severe hyponatraemia and restlessness of the patient. Thrombolysis was not performed due to the anaemia. SAE 945-3: According to documentation, in parallel to the neurological symptoms, the lab test showed that the serum sodium level was 118 mmol/L. Intravenous sodium was administered and the serum level reached 126 mmol/L when the patient was discharged back from the Stroke unit to the Gastroenterology. They reported that the neurological symptoms was most probably not due to the hyponatraemia. Stroke is an independent diagnosis. At the GI re-admission, sodium level was recovered to 137 mmol/L. The patient was discharged on 02.11.2020.	26.10.2020	02.11.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Permanently discontinued due to this event	Recovered/resolved with sequelae		
629	802	P	no ASA	82	f	00632	No hospitalization. Patient was treated for recurrent macular oedema and preretinal haemorrhage after right central vein occlusion at outpatient clinic. She was treated with intravitreal lucentis injections and discharged in stable conditions. The study drug was permanently discontinued due to this event.	15.10.2019	30.07.2020	Other cardiovascular event	Permanently discontinued due to this event	Recovered/resolved with sequelae		
1904	815	P	ASA	87	m	01130	3 days hospitalization due to anemia, lower abdominal pain and dark stools. 5 units of concentrated red blood cells were transfused (ISTH criteria for major bleeding fulfilled). The colonoscopy revealed haemorrhoids with no other pathologies. In tomography, the prostate gland enlarged with 15x9 mm contraction enhancement. Further treatment at a urology clinic. The patient was discharged home in good general condition.	23.03.2021	25.03.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved		
476	826	E	ASA	81	m	00597	Two day hospitalization due to anaemia (Hb 4,8 mmol/L) and black stool, probably on basis of DOACs. Gastroscopy showed a moderately differentiated adenocarcinoma but no signs of bleeding (ISTH criteria for	08.01.2020	10.01.2020	Major Bleeding in non-surgical patients	Permanently discontin	Recovered/resolved with		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
							major bleeding not met). The patient was treated with red blood cell and iron transfusions (afterwards Hb 5,5 mmol/L). The patient was discharged in stable conditions. The study medication was permanently discontinued due to this event.			(according ISTH, including haemorrhagic stroke)	ued due to this event	sequela e		
987	833	P	ASA	77	m	00656 -2	SAE 656 -1: 44 days hospital stay due to pneumonia in a patient with known interstitial lung disease, arterial hypertension and diabetes mellitus. Due to clinical presentation (yellow sputum, fever, increased inflammatory parameters and suggesting x-rax image) the pneumonia was treated as bacterial with empiric antibiotic therapy. No suspicion of COVID-19 infection. During hospitalization the patient developed urosepsis, dehydration and worsening of renal failure that was treated with fluid substitution but triggered worsening of known cardiac failure which was treated with diuretic therapy und adjustment of fluid therapy. SAE 656 -2: Capsule endoscopy showed a post-pyloric bleeding ulcer with Hb drop from 12,6g/dL to 8g/dL. The patient received 3 blood transfusions and iron substitution (criteria for major bleeding fulfilled). Additionally, atrial fibrillation was detected on the surface EKG. Therefore, open label apixaban was started. After antibiotic and medical treatment and improvement of clinical condition the patient was discharged for rehabilitation.	14.02.2020	16.02.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Not applicable (no intake of study drug)	Recovered/resolved		
890	877	E	no ASA	79	f	00303	Bleeding from the rectum for 4 days since 14 Feb 2019. Colonoscopy revealed a colorectal polyp. Patient stopped by herself drug consumption on 17 Feb 2019.	14.02.2019	17.02.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Temporarily discontinued due to this event	Recovered/resolved		
1495	884	P	ASA	66	m	01426	10 days hospital stay due to bloody stool, diarrhoea and generalised abdominal pain. CT revealed colitis. Stool cultures showed presence of E. coli. Antibiotics and fluids were given. Patient discharged in improved and stable condition.	05.10.2021	15.10.2021	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
984	901	P	ASA	75	m	00379	3 day elective hospitalization due to transurethral resection of the urinary bladder tumor (TUR-B). Procedure underwent without complications. A postoperative macrohaematuria (Hb 13 g/dl) ceased spontaneously. Follow-up showed no complications. The patient was discharged in good conditions. The study drug was temporarily discontinued due to this event.	08.05.2019	11.05.2019	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
1057	901	E	no ASA	72	f	00369	5 day hospitalization due to fatigue and general weakness. Diagnoses: iron deficiancy anaemia (Hb 6,2 g/dl), pneumonia right, antrum gastritis. Gastroscopy and colonoscopy showed no bleeding sources (ISTH criteria for major bleeding not met). X-ray showed pneumonia of the right lung. The patient was treated with two red cell concentrates (afterwards Hb 9,9 g/dl), oral iron substitution and antibiotics. Check ups concerning the haemoglobin and iron levels as well as a continued iron substitution have been recommended. The patient was discharged in improved conditions. The study drug was temporarily discontinued due to this event.	29.05.2019	03.06.2019	Non-cardiovascular event	Temporarily discontinued due to this event	Recovered/resolved		
1561	1028	P	no ASA	74	m	01668	2 day hospital stay due to haematuria after transurethral resection of the prostate and bladder biopsy four weeks ago. Bladder washout and irrigation were performed. Study medication was interrupted for two weeks. The bladder catheter was removed. Discharged.	14.01.2022	16.01.2022	Minor Bleeding	Temporarily discontinued due	Recovered/resolved with		

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Case narrative	Onset date	Stop date	SAE type (ERC)	Action regarding study drug	Outcome	Death date	Death type (adjudicated by ERC)
											to this event	sequela e		
1502	1089	P	no ASA	75	m	00935	Four day hospitalization due to macrohaematuria of patient with known adenocarcinoma of the prostate. The patient had been treated with antibiotics with no improvement. No Hb drop documented. No Transfusion required. Therefore, ISTH criteria for major bleeding not met. COVID-19 test was negative. A three way catheter was inserted and bladder irrigation performed. Trial without catheter failed, further diagnostics were arranged. The patient was discharged in good conditions.	10.10.2020	14.10.2020	Minor Bleeding	None, i.e. still ongoing	Recover ed/resol ved		

[1] P = Placebo; E= Edoxaban

[2] ASA = Acetylsalicylic acid

15. REFERENCE LIST

1. **Hart RG, Pearce LA, Aguilar MI.** Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med.* 2007.

2. **Ruff CT, Giugliano RP, Braunwald E, et al.** Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. . *Lancet.* 2013.

3. **Hindricks G, Potpara T, Dagres N, et al.** 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the ERC. *Eur Heart J.* 2021.

4. **Grond M, Jauss M, Hamann G, et al.** Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. *Stroke.* 2013.

5. **Schnabel RB, Marinelli EA, Arbelo E, et al.** Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. *Europace.* 2022.

6. **Freedman B, Camm J, Calkins H, et al.** Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. *Circulation.* 2017.

7. **Toennis T, Bertaglia E, Brandes A, et al.** The influence of Atrial High Rate Episodes on Stroke and Cardiovascular Death - An update. *Europace.* 2023.

8. **Gladstone DJ, Spring M, Dorian P, et al.** Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med.* 2014.

9. **Hart RG, Sharma M, Mundl H, et al.** Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. *N Engl J Med.* 2018.

10. **Diener HC, Sacco RL, Easton JD, et al.** Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. *N Engl J Med.* 2019.

11. **Zannad F, Anker SD, Byra WM, et al.** Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. *N Engl J Med.* 2018.

12. **Homma S, Thompson JL, Pullicino PM, et al.** Warfarin and aspirin in patients with heart failure and sinus rhythm. *N Engl J Med.* 2012.

13. **Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, Mairesse GH, Mabo P, Camm AJ, Healey JS.** Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. *Am Heart J.* 2017.

14. **Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA.** Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. *Circulation.* 13. Jan 2015.

15. **Giugliano RP, Ruff CT, Braunwald E, et al.** Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2013.

16. **Connolly S, Eikelboom J, Joyner C, et al.** Apixaban in patients with atrial fibrillation. *N Engl J Med.* 2011.

17. **Mant J, Hobbs FD, Fletcher K, et al.** Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the AgedStudy, BAFTA): a randomised controlled trial. . *Lancet.* 2007.

18. **Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC, Investigators R.** Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. *Heart Rhythm.* 2014.

19. **Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, Barbieri M, Rizzo MR, Mauro C, Paolisso G.** Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. *J Am Coll Cardiol.* 2013.

20. **Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P, Wersching H.** Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. *Eur Heart J.* 2008.

21. **Vermeer SE, Longstreth WT, Jr., Koudstaal PJ.** Silent brain infarcts: a systematic review. *Lancet Neurol.* 2007.

22. **Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM.** Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med.* 2003.

23. **Prins MH, Marrel A, Carita P, Anderson D, Bousser MG, Crijns H, Consoli S, Arnould B.** Multinational development of a questionnaire assessing patient satisfaction with anti-coagulant treatment: thePerception of Anticoagulant Treatment Questionnaire" (PACT-Q). *Health Qual Life Outcomes.* 2009.

24. **Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR.** Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). *Health Qual Life Outcomes.* 2009.

25. **Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D.** The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. *Europace.* 2014.

26. **Schag CC, Heinrich RL, Ganz PA.** Karnofsky performance status revisited: reliability, validity, and guidelines. *J Clin Oncol.* 1984.

27. **Grieco A, Long CJ.** Investigation of the Karnofsky performance status as a measure of quality of life. *Health Psychol.* 1984.

28. **Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W et al.** Targeted pharmacological reversal of electrical remodeling after cardioversion—rationale and design of the Flecainide Short-Long (Flec-SL) trial. *Am Heart J.* 2005.

29. **Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H.** The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc.* 2005.

30. **Healey JS, Connolly SJ, Gold MR, et al.** Subclinical atrial fibrillation and the risk of stroke. *N Engl J Med.* 2012.

31. **Glotzer TV, Hellkamp AS, Zimmerman J, et al.** Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). *Circulation.* 2003.

32. **Capucci A, Santini, M., Padeletti, L. et al.** Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. *J Am Coll Cardiol.* 2005.

33. **Botto GL, Padeletti L, Santini M, et al.** Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. *J Cardiovasc Electrophysiol.* 2009.

34. **Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ.** Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J.* 2014.

35. **Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP, on behalf of the R-AFSC, Investigators.** Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. *Eur Heart J.* 2014.

36. **Boriani G, Glotzer TV, Santini M, et al.** Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). *Eur Heart J.* 2014.

37. **Aguilar MI, Hart R, Pearce LA.** Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. *Cochrane Database Syst Rev.* 2007.

38. **Camm AJ, Lip GY, De Caterina R, et al.** 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J.* 2012.

39. **Hart RG, Pearce LA, Aguilar MI.** Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. *Ann Intern Med.* 2007.

40. **Lachin JM, Foulkes MA.** Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. *Biometrics.* 1986.

41. **M, Pintilie.** Dealing with competing risks: testing covariates and calculating sample size. *Statist. Med.* 2002.

42. **Latouche RA, Porche A.** Sample size calculations in the presence of competing risks. *Statist. Med.* 2007.

43. **Kirchhof P, Blank BF, Calvert M, et al.** Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. *Am Heart J.* 2017.

44. **Hicks KA, Mahaffey KW, Mehran R, et al.** Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation.* 2018.

45. **Friberg L, Rosenqvist M, Lip GY.** Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J.* 2012.

46. **Okumura K, Akao M, Yoshida T, et al.** Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. *N Engl J Med.* 2020.

47. **Kirchhof P, Pecen L, Bakhai A, et al.** Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care. *Eur Heart J Cardiovasc Pharmacother.* 2022.

48. **Sanna T, Diener HC, Passman RS, et al.** Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med.* 2014.

49. **Force USPST, Davidson KW, Barry MJ, et al.** Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement. *JAMA.* 2022.

50. **Link MS, Giugliano RP, Ruff CT, et al.** Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolys in Myocardial Infarction 48). *Circ Arrhythm Electrophysiol.* 2017.

51. **Kirchhof P, Camm AJ, Goette A, et al.** Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *N Engl J Med.* 2020.

52. **Eckardt L, Sehner S, Suling A, et al.** Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. *Eur Heart J.* 2022.

53. **Verma A, Ha ACT, Kirchhof P, et al.** The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. *Am Heart J.* 2018.

54. **Svendsen JH, Diederichsen SZ, Hojberg S, et al.** Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. *Lancet.* Lancet 2021.

55. **Tsao CW, Aday AW, Almarzooq ZI, et al.** Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation.* 2022.

56. **Schnabel RB, Yin X, Gona P, et al.** 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. *Lancet.* 2015.

57. **Vaidya VR, Asirvatham R, Kowlgi GN, et al.** Trends in Cardiovascular Implantable Electronic Device Insertion Between 1988 and 2018 in Olmsted County. *JACC Clin Electrophysiol.* 2022.

58. **Chugh SS, Havmoeller R, Narayanan K, et al.** Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. *Circulation.* 2014.

59. **Lippi G, Sanchis-Gomar F, Cervellin G.** Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *Int J Stroke.* 2021.

60. **Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR.** Risks of oral anticoagulant therapy with increasing age. *Arch Intern Med.* 2005.

61. **Bertaglia E, Blank B, Blomstrom-Lundqvist C, et al.** Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. *Europace.* 2019.

62. **Heckbert SR, Austin TR, Jensen PN, et al.** Differences by Race/Ethnicity in the Prevalence of Clinically Detected and Monitor-Detected Atrial Fibrillation: MESA. *Circ Arrhythm Electrophysiol.* 2020.

63. **Lau CP, Gbadebo TD, Connolly SJ, et al.** Ethnic differences in atrial fibrillation identified using implanted cardiac devices. *J Cardiovasc Electrophysiol.* 2013.

64. **Fox KAA, Virdone S, Bassand JP, et al.** Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. *BMJ Open.* 2022.

65. **White, I. R., & Royston, P.** Imputing missing covariate values for the Cox. *Stat Med.* 2009.

16. APPENDICES

16.1 Study Information

16.1.1 Clinical Trial Protocol

CLINICAL TRIAL PROTOCOL

NOAH - AFNET 6

*N*on-vitamin K antagonist *O*ral anticoagulants in patients with *A*trial *H*igh rate episodes

An Investigator-driven, Prospective, Parallel-group, Randomised, Double-blind, Multi-centre Trial initiated by the European Society of Cardiology and AFNET

EudraCT number: 2015-003997-33
NCT number: NCT02618577
ISRCTN number: ISRCTN17309850

Responsible Sponsor:
Kompetenznetz Vorhofflimmern e.V. (AFNET)
[Atrial Fibrillation NETwork]
Mendelstraße 11
48149 Münster, Germany

Version control:
No. 1.0 dated 2016-05-06, (dated 2016-10-10 (valid in France, only))
No. 2.0 dated 2017-12-01
No. 3.0 dated 2018-04-27
No. 4.0 dated 2018-11-06
No. 5.0 dated 2019-12-01
No. 5.1 dated 2020-10-01

INTERNATIONAL CHIEF INVESTIGATOR

Professor Paulus Kirchhof, Hamburg and Münster, Germany
The University Medical Center Hamburg – Eppendorf
University Heart & Vascular Center, Department of Cardiology
Martinistraße 52
20251 Hamburg, Germany
Email: p.kirchhof@uke.de
Phone +49 407 410 524 38
Fax: +49 407 410 558 62

SPONSOR

Kompetenznetz Vorhofflimmern e.V. (AFNET)
[Atrial Fibrillation NETwork]
Represented by Professor Andreas Götte, member of the board of directors
Mendelstraße 11
48149 Münster, Germany
Email: info@kompetenznetz-vorhofflimmern.de
Phone: +49 251 980 1340
Fax: +49 251 980 1349
http://www.kompetenznetz-vorhofflimmern.de/english

CONTRACT RESEARCH ORGANISATION (CRO)

CRI – The Clinical Research Institute GmbH
Arnulfstr. 19
80335 München, Germany
Email: noah@cri-muc.eu
Phone: +49 89 990 1649-963
Fax: +49 89 990 1649-863

All information in this study protocol including attachments provided to you as investigator, potential investigator, sub-investigator or committee member must be treated confidentially. The right to use this information is limited to you, your staff, members of the relevant committees or entitled authorities. The objectives and the content of this study, as well as its results, must be treated confidentially and may not be made available to third parties at any time before, during and after the study without written approval of the sponsor except to the extent necessary to get informed consent from patients. This applies to investigators and all supporting staff involved in the study. Transmission, duplication or use for publication is permitted only with the written agreement of the sponsor.

This protocol has been written in accordance with current applicable guidelines (ICH-GCP and EU-Directive 2001/20/EC) as well as all other relevant additional references, medical and legal ones.

Prepared by Elisabeth Freund, MSc (CRI), Thomas Fetsch, MD (CRI), Paulus Kirchhof, and the NOAH – AFNET 6 nucleus group

Table of Contents

1. Summary 7
2. Abbreviations 10
3. Introduction 12
   - 3.1 Background Information 12
   - 3.2 Study Rationale 12
   - 3.3 Benefit-risk Assessment 13
4. Study Objectives 14
   - 4.1 Primary Outcome Parameters 15
   - 4.2 Secondary Outcome Parameters 15
5. Study Design 15
   - 5.1 Flow Chart 16
6. Selection of Patients 16
   - 6.1 Informed Consent 16
   - 6.2 Study Population 17
     - 6.2.1 Number of patients 17
     - 6.2.2 Inclusion criteria 17
     - 6.2.3 Exclusion criteria 18
     - 6.2.4 Adequate detection of AHRE 18
     - 6.2.5 Randomisation 19
7. Therapy 19
   - 7.1 Study Drugs / Investigational Medicinal Products 20
     - 7.1.1 Description of edoxaban 20
     - 7.1.2 Description of acetylsalicylic acid (ASA) 21
     - 7.1.3 Description of placebo 21
     - 7.1.4 Identification of study drugs 21
     - 7.1.5 Storage condition 21
   - 7.2 Non-investigational Products 21
   - 7.3 Compliance with Study Drugs, Dispensing and Return 22
   - 7.4 Blinding/Unblinding 23
   - 7.5 Temporary or Permanent Discontinuation of Study Drugs 23
   - 7.6 Concomitant Medication 25
   - 7.7 Post-study Treatment 25
8. Adverse Event Reporting 25
   - 8.1 Adverse Events 25

8.2 Adverse Drug Reactions 26
8.3 Serious Adverse Events 26
8.4 Recording and Reporting Serious Adverse Events 27
8.4.1 Definition of intensity 27
8.4.2 Definition of causality 28
8.5 Adverse Event Follow-up Procedures 28
8.6 Handling of Expedited Safety Reports 28
9. Study Schedule 28
9.1 Visit Schedule 28
9.2 Baseline Visit 30
9.2.1 Documentation of the qualifying AHRE 30
9.3 Follow-up 31
9.3.1 Clinical visits (Months 12, 24, and 36) 31
9.3.2 Drug/device visits (Months 6, 18, and 30 or longer if required) 31
9.3.3 Triggered visit „Discontinuation of study drug" 32
9.3.4 Final visit (at global end of study) 32
9.4 Patient withdrawal from the study 33
9.5 Electrocardiogram 33
9.6 Blood Samples 33
9.7 Quality of Life, Experience, Symptoms and Cognitive Function 34
9.7.1 Patient Reported Outcomes: quality of life, experience and symptoms 34
9.8 Clinical Assessment of Performance Status and Cognitive Function 34
9.9 Measures to be taken in case of a Pandemic 35
10. Duration of Study Participation 36
10.1 Overall Duration of the Study 36
10.2 Duration of Study Participation for Individual Patients 36
11. Stopping and Discontinuation Criteria 36
11.1 Discontinuation Criteria for the Study and Study Sites 36
11.2 Discontinuation Criteria for Patients 36
12. Statistics 37
12.1 Statistical Methods 37
12.1.1 Analysis of the primary outcome 37
12.1.2 Analysis of the secondary outcome 37
12.1.3 Continuous secondary endpoints will be analysed as change from baseline using the baseline adjusted analysis of covariance (ANCOVA). Safety analysis 38
12.1.4 Subgroup analysis 38
12.2 Sample Size and Power Calculations 38

12.3 Interim Analysis and reassessment of the Sample Size 40
12.4 Patient Selection for Analyses 40

13. Access to Source Data / Documents 41
13.1 Source Data 41
13.2 Source Documents 41
13.3 Direct Access 41

14. Quality Control and Quality Assurance 41
14.1 Quality Control 41
14.2 Initiation Visit 41
14.3 Study Monitoring 42
14.4 Close Out Visit 42
14.5 Quality Assurance 42
14.5.1 Inspections 42
14.5.2 Audits 42

15. Ethical and Legal Consideration 43
15.1 Ethical Consideration 43
15.1.1 Institutional Review Board / Independent Ethics Committee 43
15.1.2 Steering Committee 43
15.1.3 Endpoint Review Committee 43
15.1.4 Data and Safety Monitoring Board 44
15.1.5 National coordinators 44
15.2 Legal Consideration 44
15.3 Modification of Protocol 44
15.4 Financing and Insurance 44
15.5 Investigators' Information on IMP 45
15.6 Personal Data and Data Protection 45
15.7 Data Handling and Record Keeping 45
15.7.1 Completion of case report forms 45
15.7.2 Archiving 45
15.8 Confidentiality 45
15.9 Responsibilities 46

16. Final Report and Publication Policy, Property Rights 46

17. Definitions and Classification 46
17.1 Protocol Violation 46
17.2 Major Protocol Violation 46

18. References 47

19. Signatures 52
Appendix I: Members of the Steering Committee 53
Appendix II: Time Schedule 55
Appendix III: Definition of primary outcome events 58
Appendix IV: International Society on Thrombosis and Haemostasis (ISTH) Bleeding Definitions 60
Appendix V: Definition of overt AF 61
Appendix VI: Change management of anticoagulants at discontinuation of study drug 62
Appendix VII: ESC guidelines 2010 63
Appendix VIII: Suggestions for optimal programming of devices for adequate detection of AHRE 64
Appendix IX: Declaration of Helsinki (Version Fortaleza, October 2013) 65

1. Summary

TITLE	***N***on-vitamin K antagonist ***O***ral anticoagulants in patients with ***A***trial ***H***igh rate episodes (NOAH - AFNET 6)
INTERNATIONAL CHIEF INVESTIGATOR	Professor Paulus Kirchhof, Hamburg and Münster, Germany
SPONSOR	Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]
BACKGROUND AND RATIONALE	Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all available data that demonstrate a beneficial effect of oral anti-coagulation for stroke prevention have been collected in populations with AF documented by conventional ECG recordings. It is well established that a large proportion of AF episodes remain undiagnosed ("silent AF"), and many of these patients present with a stroke as the first clinical sign of AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap. Pace-makers, defibrillators, cardiac resynchronisation devices, and insertable cardiac monitors already provide automated algorithms alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE. A sizeable portion of these patients develops clinically detected AF over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF. In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHRE. The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial, edoxaban prevented strokes at least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.
STUDY OBJECTIVE(S)	To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE but without overt AF and at least two stroke risk factors leading to a modified CHA_2DS_2VASc score of 2 or more.
STUDY DESIGN	Investigator-initiated, prospective, parallel-group, randomised, double-blind, multi-centre trial. Although it can be argued that the indication tested is within the registered label of edoxaban, NOAH – AFNET 6 will be conducted as a phase IIIb study.
STUDY POPULATION Medical condition / Main selection criteria	The following main criteria must be present for eligibility into the study: ▪ Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior

	to randomisation ▪ AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device ▪ Age ≥ 65 years ▪ In addition, **at least one** of the following cardiovascular conditions leading to a modified CHA_2DS_2VASc score of 2 or more: ✓ Age ≥ 75 years, ✓ heart failure (clinically overt or LVEF < 45%), ✓ arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure > 145/90 mmHg), ✓ diabetes mellitus, ✓ prior stroke or transient ischemic attack (TIA), ✓ vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE]). Patients with history of overt AF or atrial flutter, patients with a clear contraindication for oral anticoagulation, patients with a clear need for oral anticoagulation, and patients with indication for long-term antiplatelet therapy other than acetylsalicylic acid (ASA) or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT) are not suitable for NOAH - AFNET 6.
Number of patients Expected number of sites	NOAH - AFNET 6 is an event-driven trial with a planned number of randomised and treated patients of n=2,538 and an anticipated number of primary endpoints of n=220. Patient recruitment is expected to be completed after 71 months. Approximately 200 to 250 sites in Europe with adequate experience in follow-up of implanted pacemakers, defibrillators or insertable cardiac monitors in clinical routine.
INVESTIGATIONAL INTERVENTIONS	Investigational medicinal product (IMP) being tested: edoxaban IMP used as a comparator: acetylsalicylic acid or placebo (depending on the indication for use of antiplatelet therapy) Edoxaban will be used in NOAH - AFNET 6 at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics: ✓ Impaired renal function (CrCl 15-50 ml/min), or ✓ low body weight (≤60 kg), or ✓ patients receiving the p-glycoprotein inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.
PRIMARY OUTCOME PARAMETERS	Time from randomisation to the first occurrence of stroke, systemic embolism, or cardiovascular death. A detailed definition of these outcome events is provided in Appendix III.
SECONDARY OUTCOME	▪ Components of the primary outcome ▪ Major Adverse Cardiac Events (MACEs: cardiovascular death, myocardial

PARAMETERS	infarction, acute coronary syndrome (ACS), PCI, CABG) ▪ Stroke or systemic arterial embolism ▪ All-cause death ▪ Major bleeding events according to the ISTH definitions ▪ Quality of life changes at 12 and 24 months compared to baseline ▪ Patient satisfaction at 12 and 24 months compared to baseline ▪ Cost effectiveness and health resource utilisation ▪ Patient autonomy changes at 12 and 24 months compared to baseline including chronic consequences of stroke (aphasia, hemianopia ("mild stroke")) ▪ Cognitive function at 12 and 24 months compared to baseline
ASSESSMENT SCHEDULE	1. Enrolment and randomisation 2. Scheduled clinical follow-up at months 12, 24 and 36 after randomisation 3. "Drug/device visits" for dispensing of study drug and upload of device interrogations derived from the implanted device at months 6, 18, and 30 (continued in 6 months intervals after 36-months visit, if necessary) 4. Final end of study visit after the required number of primary outcome events has been accrued and verified
STATISTICAL CONSIDERATIONS	The main aim of the proposed study is to test the null hypothesis that the hazard rate, which is assumed to be constant during the study period, is identical in the two groups (usual care and NOAC). Based on the stroke and death rates of published trials (MOST, ASSERT, Medtronic AT500 data set, SOS), an annualised rate of stroke, systemic embolism, or cardiovascular death of 5.3% in the control group is expected. The primary analysis is in the modified intention-to-treat population, consisting of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug. Patients who develop overt AF during the trial period will be censored at that point in time but followed according to protocol until the global end of the trial. All other patients who will not reach the endpoint by the end of the study will be censored at that time point. Cumulative incidence curves and corresponding p-values from competing risk analysis as well as tables with estimated (cause-specific) hazard ratios, confidence intervals, and corresponding p-values will be provided. The Cox-proportional hazards model will be used to estimate the (cause-specific) hazard ratio of edoxaban versus usual care. Safety analysis will be performed with all patients enrolled.
DURATION OF STUDY PERIOD	Duration per patient: Mean expected follow-up time of 42 months with a minimum follow-up time of 12 months and an expected maximum follow-up time of presumably 83 months. Every patient will be followed-up until global end of study. The exact duration of follow-up will be determined by the accrual of events (event-driven trial). The trial will be terminated after 220 evaluable primary outcomes have occurred. The total study duration of 90 months (around 7.5 years) was adapted based on an interim analysis.

2. Abbreviations

ACS	Acute coronary syndrome
AE	adverse event
AF	atrial fibrillation
AFNET	Atrial Fibrillation NETwork
AHRE	atrial high rate episodes
ALT	alanine transaminase
ASA	Acetylsalicylic acid
aPCC	activated prothrombin complex concentrate
aPTT	activated Partial Thromboplastin Time
AST	aspartate transaminase
CABG	coronary artery bypass graft surgery
CrCl	creatinine clearance
CRF	Case Report Form
CRO	Contract Research Organisation
CV	Curriculum Vitae
DSMB	Data and Safety Monitoring Board
EC	Ethics Committee
DAPT	dual antiplatelet therapy
ECG	electrocardiography
e-CRF	electronic case report form
EHRA	European Heart Rhythm Association
EQ-5D	Euroquol 5D questionnaire
ERC	Endpoint Review Committee
FU	follow-up
GCP	Good Clinical Practice
HF	heart failure
ICF	informed consent form
ICH	International Conference on Harmonisation
IEC	Independent Ethics Committee
IIT	Investigator Initiated Trial
INR	International Normalised Ratio
IRB	Institutional Review Board
ISTH	International Society on Thrombosis and Haemostasis
ITT	intention-to-treat
LVEF	left ventricular ejection fraction

MACES	Major Adverse Cardiovascular Events
MedDRA	Medical Dictionary for Regulatory Activities
MI	myocardial infarction
MoCA	Montreal cognitive assessment
mITT	modified intention-to-treat
NIHSS	National Institutes of Health Stroke Scale
NOAC	Non-vitamin K antagonist oral anticoagulants
NYHA	New York Heart Association
OD	once daily
PACT-Q	Perception of AntiCoagulant Treatment Questionnaire
PCC	Prothrombin complex concentrate
PCI	percutaneous coronary intervention
PE	physical examination
PI	principal investigator
QoL	Quality-of-life
RBSMP	Risk Based Study Monitoring Plan
SAE	serious adverse event
SmPC	Summary of Product Characteristics
SOP	Standard Operating Procedure
SUSAR	suspected unexpected serious adverse event
TEE	transesophageal echocardiogram
TIA	transient ischemic attack
VKA	vitamin K antagonist

The terms “trial” and “study” as well as “study drug” and “study medication” are being used interchangeably throughout this protocol.

3. Introduction

3.1 Background Information

Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. Unlike strokes of other aetiology, which can be prevented by antiplatelet therapy, strokes in patients with AF require oral anticoagulation for adequate stroke prevention (1). Recently, four new, non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced into clinical practice that provide alternatives to vitamin K antagonist (VKA) therapy (2-6). Edoxaban is one of these NOACs. The NOACs including edoxaban provide similar or slightly better stroke prevention, and appear slightly safer compared to VKAs (7), but seem easier to use than VKAs. The NOAH - AFNET 6 trial will only commence in countries where edoxaban has been approved for stroke prevention in atrial fibrillation.

So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional ECG recordings (8). Studies in other populations in the absence of AF, e.g. heart failure, had outcomes whereby slight reductions in stroke were counterbalanced by increased bleeding (9). This illustrates the need to target anticoagulant therapy to patients at high risk for stroke events related to AF.

It is well established that many AF episodes remain undiagnosed ("silent AF"; 1). Often, a potentially preventable stroke is the first clinical manifestation of AF in patients with undiagnosed silent AF. Therefore, better techniques to detect silent AF are needed. Published and ongoing studies suggest that systematic intermittent ECG screening, using patient-operated devices (10, 11), "opportunistic screening" (1, 12), or Holter ECG recordings, e.g. in survivors of a stroke (3, 14), are capable of detecting additional patients with hitherto undiagnosed, silent AF. Although these non-invasive techniques increase the diagnostic yield of patients with silent AF, they will still miss many patients (15).

Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap (15). While dedicated implanted rhythm monitoring devices are currently evaluated, most modern pacemakers, defibrillators, cardiac resynchronisation devices, and insertable cardiac monitors already provide automated algorithms alerting to the occurrence of highly organised atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE; 16, 18, 19). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE (16, 17). Indeed, a sizeable portion of these patients develops clinically detected AF over time, but often only after the first stroke (16, 42). Thus, AHRE can be assumed an early manifestation of paroxysmal AF.

On the other hand, the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF, and automated detection algorithms of AHRE by implanted devices have a good sensitivity, but not a sufficient specificity to distinguish AF from other arrhythmias or artefacts when compared to Holter ECG recordings analysed by specialists (18). In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHRE, and more studies are needed to determine whether oral anticoagulation should be recommended for these patients (1, 19).

3.2 Study Rationale

The NOACs provide similar or slightly better stroke prevention, and appear slightly safer compared to VKAs (7, 45). Edoxaban at a dose regime of 60 mg once daily (OD) with a planned dose reduction to 30 mg OD in patients with reduced edoxaban elimination as outlined in the edoxaban Summary of Product Characteristics [SmPC] has a favourable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial (6), edoxaban prevented strokes at least as effectively as VKA therapy (hazard ratio 0.8 (0.63 – 0.99), p<0.0001 for non-inferiority; (6)). Furthermore, importantly for the design of NOAH - AFNET 6, an edoxaban dose regime of 60 mg OD caused less major bleeding events than VKA therapy in the ENGAGE trial (hazard ratio 0.8 [0.71 – 0.91], p<0.0001). Thus, an edoxaban 60 mg OD therapy regimen provides an intervention that is safer than VKA (20% less major bleeding events, CI 9% – 37%), and at least as effective in preventing

strokes in non valvular AF patients. This intervention is expected to prevent clinical and subclinical strokes and thereby improve quality of life, and maintain cognitive function.

This randomised trial, therefore, tests the hypothesis that oral anticoagulation with the NOAC edoxaban used in a 60 mg OD dose regime is superior to antiplatelet therapy (or no therapy depending on cardiovascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE, but without AF, and with at least two stroke risk factors.

If combined with another similarly sized trial (ARTESIA, NCT01938248), the data are likely to change clinical practice in this patient group, with benefits for a large number of patients with AHRE. The NOAH - AFNET 6 Steering Committee plans combined analyses of the results of these two trials. The results of NOAH - AFNET 6 may also inform future guidance on the management of patients with atrial arrhythmias detected by implantable ECG monitors.

3.3 Benefit-risk Assessment

General risk assessment of the NOAH - AFNET 6 trial: All study drugs are market approved for prevention of stroke in patients with non-valvular AF. Although AHRE are presently not considered equal to AF documented by conventional ECG recordings, VKA and NOACs are currently used for patients with AHRE in clinical routine (off-label use), and the documentation of short-lasting arrhythmias that resemble atrial fibrillation is considered "non valvular AF" by many clinicians, although data supporting the use of anticoagulants in general are lacking in this population. Other clinicians will strive to document AF in the usual way in AHRE patients. Thus, there is true clinical equipoise for the use of anticoagulation in patients with AHRE. In view of the potential benefits for stroke prevention in this population, this is a clinically important issue that calls for resolution in a controlled clinical trial.

The other patient characteristics of the NOAH – AFNET 6 population and the use of edoxaban in the trial mirror the European label of edoxaban to ensure that the use of edoxaban is limited to patients in whom safety information exists from the completed phase III programme leading to the market authorisation of edoxaban in Europe (6). The sponsor of NOAH – AFNET 6 and the scientific partner, the European Society of Cardiology, have carefully considered how to define the phase of this investigator-initiated trial, also in view of the fact that edoxaban has been evaluated in a large clinical trial program in patients with very similar characteristics compared to those to be enrolled in NOAH – AFNET 6, and in view of the conduct of a similar trial (ARTESIA, NCT01938248) as phase IV. Reflecting the equipoise of anticoagulation and the uncertainty whether AHRE represent an early form of AF, NOAH – AFNET 6 will be conducted as a phase IIIb study.

All concomitant study procedures are standard care procedures according to applicable medical guidelines used within the recommended indications. All participating study sites have to document sufficient experience in the management of patients with implanted pacemakers, defibrillators, cardiac resynchronisation devices or insertable cardiac monitors and of patients with AF.

Thus, the overall risk level of the NOAH – AFNET 6 trial is expected to be low.

Assessment of the individual risk of study patients: The risk of therapy within NOAH - AFNET 6 seems acceptable in view of the favourable safety profile of an edoxaban 60 mg OD regime in the ENGAGE-TIMI 48 trial compared to warfarin. In light of existing data for apixaban and warfarin, the bleeding risk on edoxaban may only slightly exceed that of acetylsalicylic acid therapy (3, 23). Thus, the individual risk of study patients in the group randomised to treatment with NOAC will not differ from the risk of therapy in clinical routine treatment for prevention of stroke in patients with non-valvular AF. Patients randomised to treatment with NOAC have an increased risk for bleeding events compared to patients randomised to the group that undergoes usual care. Event rates for AHRE patients do not exist and will be generated in NOAH - AFNET 6. Based on the observed baseline stroke rates in AHRE patients (refer to section 12), similar effect differences are expected for NOAH - AFNET 6.




Figure 1: Major efficacy and safety event rates for AF patients randomised to an edoxaban 60 mg OD regime in the ENGAGE-TIMI 48 trial compared to event rates reported in patients randomised to acetylsalicylic acid in the AVERROES and BAFTA trials (3, 6, 23). All events are given as annualised rates in percent. This figure is replicated in the sample size estimation section.

General benefit of study patients: All patients participating in NOAH - AFNET 6 will have the added benefit of careful standardised monitoring of their anticoagulant treatment by their study physicians as well as of additional quality management by the CRO, the sponsor, the independent Data and Safety Monitoring Board and the Steering Committee.

Individual benefit of study patients: Patients randomised to edoxaban will receive a treatment that has been shown to be safer with a reduced annualized rate of major bleedings (hazard ratio 0.80) compared to VKA and slightly more effective to prevent stroke or systemic embolism than VKA with reduced annualized rates of these events (hazard ratio 0.79) in general AF populations (6). VKA therapy in general AF patients itself was demonstrated to be three times more effective in preventing stroke or systemic embolism compared to antiplatelet therapy (22). Based on the existing literature, it is likely that a similar benefit will be conveyed by edoxaban in patients with AHRE detected by pacemaker. By participating in the NOAH - AFNET 6 trial, patients will receive this safe anticoagulant earlier than in usual care, i.e. when atrial arrhythmias are documented by the implanted device rather than by the ordinary ECG, with the potential for added stroke prevention.

4. Study Objectives

To demonstrate that oral anticoagulation with the NOAC edoxaban is superior to current therapy (antiplatelet therapy or no therapy depending on cardiovascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE but without overt AF (Appendix I) and at least two stroke risk factors leading to a modified CHA2DS2VASc score of 2 or more.

4.1 Primary Outcome Parameters

The primary outcome parameter of NOAH - AFNET 6 is defined as the time from randomisation to the first occurrence of stroke, systemic embolism or cardiovascular death. A detailed definition of these outcome events is provided in Appendix III.

4.2 Secondary Outcome Parameters

The secondary outcome parameters are defined as

- components of the primary outcome,
- Major Adverse Cardiac Events (MACEs: cardiovascular death, myocardial infarction, acute coronary syndrome (ACS); PCI, CABG),
- stroke or systemic arterial embolism
- all-cause death,
- major bleeding events according to the International Society on Thrombosis and Haemostasis (ISTH) definitions (60, 61), (Appendix IV)
- quality of life changes at 12 and 24 months compared to baseline (assessed by EQ-5D including its visual-analogue scale and by the Karnofsky scale),
- patient satisfaction at 12 and 24 months compared to baseline (assessed by modified EHRA score (36) and PACT-Q (43))
- cost effectiveness and health resource utilisation estimated by quantification of relevant events, interventions, nights spent in hospital and cardiovascular therapies,
- changes of autonomy status only in patients with stroke during study participation, potentially assessed at each clinical follow-up visit by modified Rankin scale; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed,
- cognitive function (MoCA) at 12 and 24 months compared to baseline.

5. Study Design

NOAH - AFNET 6 is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multicentre trial. The trial tests whether oral anticoagulation using the NOAC edoxaban is superior to current therapy to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE. The trial will be conducted in several European countries (details of study sites are provided in a separate document).

NOAH - AFNET 6 is an event-driven trial with a planned number of randomised and treated patients of n=2,538 and an anticipated number of primary endpoints of n=220. The total duration of the trial is an estimate based on observed outcome rates in other large trials with similar populations. The total number of events in the trial is depending on the observed hazard rates and on the time at risk, which is the follow-up time of all patients. In practice, the event-driven design may result in slight variation of the expected trial duration and of the total number of patients enrolled if observed event rates do not exactly match the assumed rates. All patients will be followed until the global end of the trial.

5.1 Flow Chart




Figure 2: Study flow chart

6. Selection of Patients

6.1 Informed Consent

A signed, ethics committee (EC) /institutional review board (IRB) approved informed consent form, written in accordance with country-specific applicable data privacy acts, the Declaration of Helsinki (Appendix IX) and the applicable laws for research using medical devices and drugs, will be obtained from every patient prior to any study-related procedure. All clinical data needed to evaluate the potential eligibility of a patient before study inclusion, e. g. recent laboratory results, ECG recordings or other technical parameters, are considered to be performed during clinical routine and are therefore not considered to be part of study related procedures. Participants will be advised that their quality of life and satisfaction data are collected for research purposes and will not be used to guide clinical care.

The investigator or responsible medical staff will explain the nature, purpose and risks of the study and provide the patient with a copy of the patient information sheet. The patient will be given sufficient time to consider the study's implications before deciding whether to participate.

Should there be any modifications to the protocol, such that this would directly affect the patient's participation in the study, e.g. a change in any procedure, an addendum to the informed consent form specifying the modification must be compiled and the patients must agree to sign this addendum indicating that they re-consent to further participate in the modified study.

A signed copy of the patient's informed consent form must be maintained in the study file on site. The patient's permanent medical records should indicate the patient's study participation. A patient information sheet will be handed out to the patient unless declined by him/her.

6.2 Study Population

The intended population for this study consists of patients who have documented AHRE but no history of overt AF at the time of randomisation and a risk for stroke fulfilling the inclusion criteria as listed below, i.e. approximating a modified CHA_2DS_2VASc score of 2 or more. This population has a clinical risk profile that would make patients with ECG-documented AF eligible for oral anticoagulation. In view of the uncertainty around event rates in patients with documented AHRE, a blind assessment of event rates is planned during the trial. It will be considered to adjust the trial population should event rates be lower than anticipated (see below for details). Patients will be recruited by contracted study sites only. The aim is to activate approximately 200 to 250 sites in Europe with adequate experience in follow-up of implanted pacemakers, defibrillators or insertable cardiac monitors in clinical routine and in treatment of patients with AF. Patient recruitment is expected to be completed after 71 months.

6.2.1 Number of patients

A total of 2,538 patients will be randomised and treated throughout Europe. Patients who develop overt AF during the trial period will be censored at that time point but followed according to protocol until the global end of the trial. The hazard of developing overt AF is assumed to remain constant and it is estimated at 0.287. The sample size may be adapted once in a blinded manner as described in the statistics section (refer to section 12).

6.2.2 Inclusion criteria

I1. Pacemaker ,defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation.

I2. AHRE detection feature activated for adequate detection of AHRE (refer to Appendix XIII).

I3. AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device.
Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible.

I4. Age ≥ 65 years.

I5. In addition, at least one of the following cardiovascular conditions leading to a modified CHA_2DS_2VASc score of 2 or more:

- Age ≥ 75 years;
- Heart failure (clinically overt or LVEF < 45%);
- Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure > 145/90 mmHg);
- Diabetes mellitus;
- Prior stroke or transient ischemic attack (TIA);
- Vascular disease (previous myocardial infarction, peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE]).

I6. Provision of signed informed consent.

6.2.3 Exclusion criteria

General exclusion criteria

E1. Any disease that limits life expectancy to less than 1 year.

E2. Participation in another controlled clinical trial, either within the past two months or still ongoing.

E3. Previous participation in the present trial NOAH - AFNET 6.

E4. Drug abuse or clinically manifest alcohol abuse.

Exclusion criteria related to a cardiac condition

E5. Any history of overt AF or atrial flutter.

E6. Indication for oral anticoagulation (e.g. deep venous thrombosis).

E7. Contraindication for oral anticoagulation in general.

E8. Contraindication for edoxaban as stated in the current SmPC.

E9. Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present.

E10. Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation.

Exclusion criteria based on laboratory abnormalities

E11. End stage renal disease (creatinine clearance (CrCl) < 15 ml/min as calculated by the Cockcroft-Gault method, refer to 7.1.1.).

Legal exclusion criterion (applicable in countries where legally required)

E.12. All persons exempt from participation in a clinical trial by law.

6.2.4 Adequate detection of AHRE

An adequate detection of AHRE by the implanted device is essential for screening of eligible patients to be included in NOAH - AFNET 6. Device interrogations derived from the implanted device containing the index AHRE episode that led to inclusion will be digitally uploaded for central review by an independent core analysis centre. The results of review will not lead to post-hoc exclusion of the patients if criteria of AHRE are not met but will detect protocol violations relevant for stability measures of final analysis and will lead to training of corresponding study sites to prevent future violations and therefore assure a standard quality of adequate AHRE detection.

The following paragraph outlines adequate settings of devices for adequate identification of AHRE episodes in patients who are potentially eligible for NOAH - AFNET 6:

- The intracardiac electrogram (IEGM) storage should be activated while the atrial tachycardia detection rate should be set to 170 bpm. Episodes at lower atrial rates are not qualifying episodes for NOAH - AFNET 6. Higher rate thresholds are acceptable, but may miss some episodes that would make patients eligible for NOAH - AFNET 6. Although false atrial tachyarrhythmia detection due to repetitive non-reentrant ventriculo-atrial synchrony is rare for episodes greater than 6 minutes in duration, this phenomenon can be diagnosed by checking the stored IEGMs and can be eliminated by avoiding very long programmed AV delays and/or by increasing the post-ventricular atrial refractory period.
- For pacemakers and implantable cardioverter-defibrillators (ICDs) with programmable atrial electrogram configuration, the latter should be programmed Atip-Aring, in order to avoid noise detection and the use of short tip-to-ring spacing atrial leads (<10 mm) is strongly recommended.

- Finally the devices should be optimally programmed according to the individual patient and to the most recent practice guidelines (25, 26, 27), ensuring as far as possible optimum hemodynamic and avoiding unnecessary ventricular pacing.

Cardiac rhythm management device manufacturers use different detection algorithms and settings for the most accurate device diagnostics and EGM recordings. Detailed information will be provided in a separate instruction document "Appendix VIII: Suggestions for optimal programming of devices for adequate detection of AHRE" (see Appendix VIII).

6.2.5 Randomisation

Study patients will be randomised to one of two parallel groups in a 1:1 design, designated as "NOAC" and "Usual Care". Randomisation will be stratified by indication for use of antiplatelet therapy as assessed by the responsible investigator at the time of randomisation.

Randomisation will be done per study site in blocks of variable size to allow minimising potential confounders related to different healthcare practice. A randomisation list will be created by the responsible study statistician before study start, and imported into the randomisation server of the e-trial management system. During the trial, randomisation will be performed by each site personnel within the e-CRF of the e-trial management system according to the imported randomisation list. The investigator has to document several clinical items prior to randomisation to verify eligibility of the patient for randomisation and to determine the stratum. The e-trial management system displays the medication number to be used, not the random group, and asks for confirmation by authorised study personnel. The account ID of the person performing the randomisation in the e-trial management system and the corresponding time stamp will automatically be documented in an electronic audit trail.

7. Therapy

NOAH - AFNET 6 is a double-blind trial designed to evaluate the safety and efficacy of the NOAC edoxaban in comparison to usual care consisting of either ASA or no antithrombotic therapy depending on the indication for use of antiplatelet therapy. Patients will receive study medication OD for oral intake depending on the random group throughout the whole study duration.

Patients of the "NOAC" group will receive anticoagulation therapy with edoxaban. Patients in the "Usual Care" group will receive either acetylsalicylic acid (ASA) or no antithrombotic therapy depending on the indication for use of antiplatelet therapy (stratification at the time of randomisation). All patients will receive identical number and form of study medication using the "double-dummy" technique:

- In the "NOAC" group one edoxaban tablet plus one placebo tablet matching in colour, weight, form and size to ASA 100 mg will be administered per day irrespective of stratum according to indication for use of antiplatelet therapy. The use of edoxaban eliminates the necessity of parallel intake of ASA 100 mg in case of an indication for use of antiplatelet therapy.
- In the "Usual Care" group either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator.
- A documented change of indication for use of antiplatelet therapy in follow-up will lead to blinded exchange of double-dummy study drug according to actual indication. In case of a new indication for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT), blind treatment with study drugs has to be terminated and adequate treatment according to medical guidelines has to be provided by the treating physician. The patient will remain in regular study follow-up until the global end of the trial.

7.1 Study Drugs / Investigational Medicinal Products

An investigational medicinal product is defined as follows by the European Commission (The rules governing medicinal products in the European Union, Volume 10, Clinical Trials, 2006):

A pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical study, including products already with a marketed authorisation but used or assembled (formulated or packaged) in a way different from the authorised form, or when used for an unauthorised indication, or when used to gain further information about the authorised form.

In this protocol, investigational products are:

- edoxaban 60 mg tablets,
- edoxaban 30 mg tablets,
- ASA 100 mg tablets, and
- matching placebo tablets.




Figure 3: Drug supply schema.
The usual care group is divided into antiplatelet and placebo therapy defined (stratified) by indication of antiplatelet therapy existing at inclusion into NOAH - AFNET 6.

7.1.1 Description of edoxaban

Edoxaban has been tested in large trials and will be applied in NOAH - AFNET 6 at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:

1. Impaired renal function (CrCl 15-50 ml/min*), or
2. Low body weight (≤60 kg), or
3. Patients receiving the p-glycoprotein inhibitors ketoconazole, ciclosporin, erythromycin, or dronedarone.

If conditions for reduced dosage of edoxaban are not anymore fulfilled during the study, dosage of edoxaban should be increased as stated in the SmPC.

The e-trial management system will automatically identify those conditions if adequately documented by the study site personnel and supply an appropriate medication box containing either 60 mg or 30 mg tablets in patients randomised to edoxaban. However, the investigator finally needs either to confirm the calculated dosage or adjust the dosage according to his medical decision and provide a reason for doing so.

* calculated by the Cockcroft-Gault method:
For male: ((140 - age [years])/ Serum creatinine value [mg/dl])* (weight[Kg] / 72)
For female 0.85 * ((140 - age [years])/ Serum creatinine value [mg/dl])* (weight[Kg] / 72)

7.1.2 Description of acetylsalicylic acid (ASA)

ASA has been used for decades as standard therapeutic agent for antithrombotic therapy according to corresponding medical guidelines. Within NOAH - AFNET 6 either tablets of 100 mg ASA will be applied or matching placebo tablets. The e-trial management system will automatically identify the indication for use of antiplatelet therapy as assessed by the responsible investigator, if adequately documented, and supply an appropriate medication bottle.

7.1.3 Description of placebo

Matching placebo tablets will be applied which are comparable in size, weight, shape and colour to

- edoxaban 60 mg tablets,
- edoxaban 30 mg tablets,
- ASA 100 mg tablets.

7.1.4 Identification of study drugs

The following investigational medicinal products will be provided by the manufacturer of edoxaban:

Product	Potency
Edoxaban tablets + matching placebo	60 mg
Edoxaban tablets + matching placebo	30 mg
ASA tablets + matching placebo	100 mg

Table 1: Investigational medicinal products

All study drugs will be packed in study-specific blisters. The sponsor will assure that adequate labelling, storage, and distribution including import of study drugs to study sites on demand is provided by drug suppliers. All quality management requests related to manufacturing, labelling, storage, distribution and reporting defined in applicable international and national standards will be followed by the drug suppliers subcontracted by the sponsor.

7.1.5 Storage condition

Due to the double-blind design, the different storage conditions for edoxaban, ASS or placebo cannot be followed individually but the most restrictive has to be considered. Thus, all study drugs have to be stored continuously between 2 and 25° C. Temperature has to be controlled and documented, e.g. by means of temperature logger provided by the sponsor. Detailed instructions for handling of temperature logging will be provided. In case of exceedance (<2°C or > 25°C) the investigator has to inform the CRO and report the duration of the exceedance and the peak temperature. The CRO will subsequently inform the sponsor who will give advice on actions to be taken in cooperation with the manufacturer of the study drugs.

7.2 Non-investigational Products

Other medications used in the study as support or escape medication for preventative, diagnostic, or therapeutic reasons, as components of the standard of care for a given diagnosis, are considered non-investigational products.

7.3 Compliance with Study Drugs, Dispensing and Return

The study drugs will be supplied to the study sites in sufficient quantity according to local needs, e. g. expected recruitment rate. The respective time of drug supply will be determined by the CRO but supply itself will be provided by the Drug Supplier.

The logistics of study drug distribution will be managed and tracked centrally in the e-trial management system. Each study medication unit will be supplied with a unique medication number together with a corresponding unique verifier printed on study specific labels. A list of all unique medication numbers together with the corresponding unique verifiers of the provided study medication will be hosted in the materials tool of the e-trial management system.

Labelling follows requirements as specified in Volume 4, EU Guidelines to Good Manufacturing Practice, Annex 13, Investigational Medicinal Products. National requirements will be taken into consideration. The Drug Supplier responsible for labelling and delivery of study drug to study sites receives automated supply orders via e-mail from the e-trial management system as soon as a pre-defined minimal number of study drugs in stock at the study site is reached. Triggers for supply orders are individually defined for the different types of study drugs. Tracking of study drugs to be sent to study sites will be performed in the e-trial management system revealing information on medication numbers and verifiers, date of shipment and recipient by study site. Receipt of study drug has to be tracked in the e-trial management system by the receiving site staff by entering the verifier printed on each label.

When a patient is randomised, the e-trial management system displays the medication numbers to be used. Site staff has to confirm dispense of the pre-defined study drugs to the patient by entering in the e-trial management system the corresponding verifiers printed on each label of the study drugs. By doing so, the investigator documents each dispensing of study medication to a patient with the patient's ID, study site ID and the date of dispensing (automatically allocated by the e-trial management system). Comparable procedures will be performed at each drug/device visit in follow-up.

Patients will be asked to bring all unused or partly used medication at each visit in follow-up. The investigator will assess patients' compliance with study drug by asking the patient about medication intake and by pill count during every clinical visit and at the end of follow-up. In case the patient did not take the assigned study drugs for a period of more than 7 consecutive days the date, duration and reason for interruption has to be documented.

Compliance with study drug is defined as following (percentages refer to the period between the last documented follow-up visit and the next, ideally 6 months):

- Intake of study drugs < 80% of the number of pills calculated for the corresponding time period: non-compliance.
- Intake of study drugs 80% to < 90% of the number of pills calculated for the corresponding time period: acceptable compliance.
- Intake of study drugs 90% or more of the number of pills calculated for the corresponding time period: good compliance.

In case of non-compliance the investigator has to instruct the patient about importance of regular drug intake.

Any unused or partly used study medication has to be returned to the drug supplier periodically or latest at the end of the trial in the corresponding study site, depending on the amount of such medication in local stock. Returned study medication will be tracked by the investigator in the e-trial management system in a way comparable to the procedures at study medication dispense. The shipment of returned or unused study medication to the drug supplier will be managed by the CRO but performed by the investigator.

7.4 Blinding/Unblinding

To maintain blinding of study treatment, all study drugs will be prepared in tablets matching edoxaban and ASA tablets in form, size and colour. Patients, investigators and staff of study sites, committee members, and the sponsor's and CRO's staff conducting the study, will not have access to individual patient treatment assignments. The members of the Data and Safety Monitoring Board (DSMB) will have access to such assignments on demand.

Blinding is critical to the integrity of this clinical trial. However, the patient's treatment may be revealed by the investigator in a medical emergency, in which knowledge of the investigational product would be instrumental for further treatment decisions. A newly occurring indication for change of dosage of the study drugs or for initiation or termination of antiplatelet therapy is not a valid reason for unblinding since procedures for blinded change of dosage and antiplatelet therapy are offered. Before breaking the blind of an individual patient's blinded treatment, the investigator should have determined that the information is necessary, i.e., that it will alter the patient's immediate management. In many cases, particularly when the emergency is clearly not study drug-related, the situation may be managed by assuming that the patient is receiving active product without unblinding.

Every patient will be provided with an alert card. The alert card:

- indicates that the patient is participating in a double-blind clinical trial,
- provides the trial number and acronym,
- will note that the patient may be receiving either edoxaban or ASA or placebo, and
- includes the investigator's name and phone number for providing information to emergency medical personnel.

Unblinding: In a medical emergency and if knowledge of the patient's randomised treatment assignment would have a meaningful impact on individual management, the patient's treatment assignment can be unblinded. However, whenever possible, the need to break the blind should first be discussed with the CRO's medical advisor or project director.

Information regarding patient's treatment assignment should be provided only to those who are caring for the patient and as few other people as possible. Thus, bias will be minimised by assuring that the Endpoint Review Committee (ERC) remains blinded to treatment assignment, even if the investigator has been unblinded.

Unblinding of a patient's treatment will be managed and tracked centrally in the e-trial management system. The investigator who is breaking the blind has to document date and reason for code break in the e-CRF and in the patient's medical records. The CRO will receive an automated email containing all necessary information on the code break (however without information regarding treatment) at the same time of the data being documented in the e-CRF. In case the e-CRF system is not reachable the investigator has to contact the CRO's hotline to induce unblinding.

7.5 Temporary or Permanent Discontinuation of Study Drugs

In case of newly occurring

- clinical indication for oral anticoagulation (such as new diagnosis of overt AF), or
- contraindications as given in the current SmPC of edoxaban or of ASA, or
- clinical indication for long term treatment (> 6 months) with any antiplatelet agent in addition to study medication, especially dual antiplatelet (DAPT) therapy, or
- contraindications for oral anticoagulation in general, or
- patient's request of permanent study drug discontinuation,

therapy with blinded study medication should be stopped permanently and other adequate, open-label therapy should be started according to applicable medical guidelines.

In case of clinical indication for temporary treatment with antiplatelet agent in addition to study medication (≤ 6 months duration), study medication should not be stopped permanently but discontinued temporarily, only, for the duration of prescription of any antiplatelet agent in addition to study medication.

Date and reason of discontinuation of study drugs have to be documented (refer to section 9.3.3). Be aware of the fact that overt AF can only reliably be diagnosed by external ECG recordings according to ESC guidelines 2010, (Appendix VII).

The initiation of oral anticoagulation should follow local clinical practice in patients who develop overt AF or another indication for oral anticoagulation. The study medication should be stopped just prior to initiation of effective oral anticoagulation. Compared to usual care, where the patient is not anticoagulated prior to AF detection, this will provide the same timing and effectiveness of oral anticoagulation in patients randomised to usual care (ASA or no therapy), and a better anticoagulation (edoxaban) until initiation of oral anticoagulation in the patients randomised to edoxaban. This regime applies to all patients. For details refer to Appendix VI.

If anticoagulation must be temporarily discontinued for medical reasons, e.g. in case of bleeding or to reduce the risk of bleeding during surgical or other procedures, study medication should be stopped as soon as possible and preferably at least 24 hours before the procedure.

In case of non-life-threatening bleeding time is the most important antidote of the NOACs in view of the relatively short elimination half-lives. After cessation of treatment, restoration of haemostasis is to be expected within 12–24 h after the last taken dose, given plasma half-life of around 12 h for edoxaban. In addition, standard supportive measurements (such as mechanical compression, surgical haemostasis, fluid replacement, and other haemodynamic support) should be provided.

In case of life-threatening bleeding the administration of prothrombin complex concentrate (PCC) or activated prothrombin complex concentrate (aPCC) can be considered in a patient with life-threatening bleeding if immediate haemostatic support is required. Clinical trials and registry data with NOACs have shown that this is rarely needed. The choice between PCC and aPCC may depend on their availability and the experience of the treatment centre. However, the efficacy of PCC or aPCC in patients who are actively bleeding has not been firmly established and one has to balance the potential prothrombotic effects against the potential anticoagulant benefits.

For details on adequate therapy in case of bleeding please refer to chapter 9, page 20 ff. of the Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation attached as Appendix VI.

Date, duration and reason for interruption have to be documented in the corresponding AE or SAE form of the e-CRF. In deciding whether a procedure should be delayed until 24 hours after the last dose of study medication, the potentially increased risk of bleeding should be weighed against the urgency of the intervention. Study medication should be restarted after the surgical or other procedures as soon as adequate haemostasis has been established. If oral medicinal products cannot be taken during or after surgical intervention, consider administering a parenteral anticoagulant and then switch to oral study medication.

If the patient did not take the assigned study drugs for any other reason (intended or unintended) this has to be documented in the e-CRF as part of the compliance measure at each follow-up visit (refer to section 7.3).

Discontinuation of study drug, temporary or permanent, will not result in termination of study participation (intention-to-treat principle). In any case of discontinuation of study drug the patient will be followed according to study protocol until the global end of the trial.

7.6 Concomitant Medication

The concomitant use of antiplatelet agents is discouraged in all study patients, because the concomitant use of an oral anticoagulant and antiplatelet agents increases the risk of bleeding without known benefits. Patients who require treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy, at the start of the trial are not eligible for NOAH - AFNET 6 (refer to 6.2.3, exclusion criteria). If the indication for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy, appears after inclusion into the trial therapy with blinded study drugs should be stopped permanently and other adequate, open-label therapy should be started according to applicable medical guidelines (refer to 7.5, temporary or permanent discontinuation of study drugs). All other concomitant medication can be used within the NOAH - AFNET 6 trial if in line with the contraindications given in the current SmPC of edoxaban.

In the e-CRF, all concomitant drugs will be documented by generic name and dosage administered.

7.7 Post-study Treatment

It is at the discretion of the treating physician which kind of therapy will be prescribed to the patient once their participation in the study has ended (global study end or premature study discontinuation). It is recommended to strictly follow the applicable medical guidelines and the market authorisation of the intended drugs.

8. Adverse Event Reporting

As all study treatments in NOAH - AFNET 6 are marketed and in-line with clinical practice, even knowing that the administration of edoxaban in AHRE patients without overt non-valvular AF is not in-line with the approved label, adverse events are expected to occur in similar clinical manifestations and at a comparable rate as the known adverse events of the approved therapies applied in the trial (i.e. "low risk trial").

8.1 Adverse Events

An **adverse event (AE)** is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

A newly diagnosed concomitant disease is also considered an AE. However, onset of ECG-documented AF and subsequently confirmed diagnosis of AF after randomisation is not considered an AE and does not require documentation in an AE form in the e-CRF unless any criterion for seriousness is met. Onset of AF has to be documented in a special "AF onset form".

Following the patient's randomisation in the study, all AEs, whether related or not related to study drug, must be collected. However, within the context of the NOAH – AFNET 6 trial, no specific AEs and/or laboratory abnormalities are being considered as critical to safety evaluations. Thus, reporting of AEs not fulfilling any criteria of seriousness (refer to section 8.3) is not time critical.

All AEs will be documented by study site personnel in the relevant section of the e-CRF specifying:

- the type of AE
- the diagnosis of the underlying illness or disorder rather than its individual symptoms.
- the date of onset,
- the date of resolution,
- the outcome,
- the intensity,

- the causal relationship to study drug, and if related, the suspected study drug, and
- the action taken with regard to study drugs.

8.2 Adverse Drug Reactions

According to Directive 2001/20/EC, Adverse Drug Reactions (ADRs) are all untoward and unintended responses to an investigational medicinal product related to any dose administered, irrespective of its degree of seriousness. Events associated with placebo will usually not satisfy the criteria for a serious adverse drug reaction. For all ADRs an assessment of "expectedness" will be performed by the sponsor or its responsible subcontractors.

8.3 Serious Adverse Events

A **Serious Adverse Event (SAE)** is any untoward medical occurrence that

- results in death or,
- is life-threatening
  (defined as an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) or,
- requires inpatient hospitalisation or prolongation of existing hospitalisation
  (defined as inpatient care of more than one calendar day [= at least one overnight stay]; see also **NOTE** below) or,
- results in persistent or significant disability/ incapacity or,
- is a congenital anomaly / birth defect, or
- is a medically important event
  (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation but, based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention [e.g., medical, surgical] to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).

More than one of the above criteria can be applicable to each event.

These characteristics/consequences have to be considered at the time of the event. For example, regarding a life-threatening event, this refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.

NOTE: The following hospitalisations are not considered SAEs:

- A visit to any hospital department or emergency room which does not result in an overnight stay (unless considered an "important medical event" or an immediate life-threatening event).
- Any non-emergency medical or surgical admission planned before signing consent.
- Routine health assessment requiring admission for baseline/trending of health status (e.g. routine colonoscopy).
- Any overnight hospital stay required only for overnight diagnostic procedure (e.g. sleep laboratory).
- Admission encountered for another life circumstance that carries no bearing on health status and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, caregiver respite, family circumstances, administrative).

8.4 Recording and Reporting Serious Adverse Events

Following the patient's written consent to participate in the study, all SAEs, whether related or not related to study drug, must be collected.

The investigator should specify and report in the e-CRF the nature of the sign or symptom leading to the SAE, the date of onset of the sign or symptom, the date of resolution (duration) of the specific event (not of the underlying disease), the intensity, interventions performed (if any), the relationship to study treatment, and the outcome.

All SAEs, whether related or unrelated to study drug, must be reported expeditiously to the CRO through the SAE section of the e-CRF within 24 hours of becoming aware of the event. An SAE form within the e-CRF should be completed for any event where doubt exists regarding its status of seriousness. As a minimum, the investigator has to fill out the following items of the internet-based SAE form:

- type of event,
- description,
- date of onset,
- criteria for seriousness,
- causal relationship to study drug, and if related, the suspected study drug.

As soon as further information regarding the event is available (e.g. discharge letter), the investigator should complete the documentation in the e-CRF and sign it electronically. Copies of the discharge letter, of all reports regarding examinations carried out and/or diagnostic findings should be faxed to the CRO. For laboratory results, the laboratory normal ranges should be included. All documents should be sent to the CRO after adequate blinding of patient identifiers, only.

Follow-up of any SAE that is fatal or life threatening should be provided within one additional calendar week.

Any SAE reporting (initial reporting and follow-up information on e.g. changes of an ongoing SAE's intensity or relationship to the investigational product or outcome) is done through the SAE section of the e-CRF and an automated email notification system within the e-trial management system, i.e. no extra SAE form needs to be faxed but the CRO will receive an automated email containing all necessary information on the SAE at the same time of the data being documented or changes of relevant SAE data being made in the e-CRF.

The sponsor will via contracted CRO forward all SAEs immediately after awareness to the pharmacovigilance department of the edoxaban manufacturer for inclusion in their global safety database. The relevant SAE data will be retrieved from data documented by the investigator within the e-CRF and sent to the edoxaban manufacturer digitally. Changes of relevant SAE data (including deletion of SAEs if relevant criteria are not met) will also be forwarded to the pharmacovigilance department of the edoxaban manufacturer. Patient identifying data will consist of patient ID number, year of birth, gender and site ID number, only.

According to legal requirements and international standards, annual safety reports will be prepared by the sponsor or its responsible subcontractors and forwarded to responsible authorities of all participating countries and to all corresponding ECs / IRBs.

8.4.1 Definition of intensity

Intensity	Definition
Mild	Patient is aware of signs and symptoms but they are easily tolerated
Moderate	Signs/symptoms cause sufficient discomfort to interfere with usual activities
Severe	Patient is incapable to work or perform usual activities
Very severe	Signs/symptoms are debilitating, significantly incapacitate patient despite symptomatic therapy

8.4.2 Definition of causality

In accordance with Council of International Organisations of Medical Sciences (CIOMS), causality of an event will be assessed as:

not related: No causal relationship exists between the study treatment and the event but an obvious alternative cause exists, e.g. the patient's underlying medical condition or concomitant therapy.

or

related: There is a reasonable / plausible possibility that the event may have been caused by the study treatment (e.g. the event cannot be explained by concomitant disease(s) or other drugs/treatments).

8.5 Adverse Event Follow-up Procedures

The investigator should take all appropriate measures to ensure the safety of the patients, notably he / she should follow-up the outcome of any AE or SAE (clinical signs, laboratory values or other, etc.) until the return to normal or consolidation of the patient's condition.

In case of any SAE, the patient must be followed until clinical recovery is completed and laboratory results have returned to normal, or until progression has been stabilized. This may imply that follow-up will continue after termination of the trial, and that additional investigation may be requested by the CRO team.

8.6 Handling of Expedited Safety Reports

This applies to any SAE that is considered related to study drug and the nature or severity is not consistent with the applicable product information (suspected unexpected serious adverse event; SUSAR). The expectedness of an adverse reaction will be determined by the sponsor or its responsible subcontractors according to the Reference Safety Information (RSI) document of each study drug. The RSI will be clearly identified before global start of the trial and is the same in all participating countries.

The sponsor will act in strict compliance with all applicable laws and regulations and will ensure that any delegate strictly abides by the same. The sponsor or its responsible subcontractors will notify the competent authorities, corresponding ECs / IRBs and all principal investigators concerned of any SUSAR in-line with applicable regulatory requirements. In addition, the sponsor or its responsible subcontractors will inform the marketing authorisation holder of the study drug of the previous notification to the competent authorities.

Before notification of a SUSAR to the competent authorities and corresponding ECs / IRBs, unblinding for this patient must be performed by the sponsor or its responsible subcontractors, however blinding should be maintained for the investigator and for the biostatisticians responsible for data analysis and interpretation. Unblinding of a patient's treatment will be managed and tracked centrally in the e-trial management system. The person performing code break has to document date and reason in the e-CRF.

9. Study Schedule

All data and assessments described in the following sections have to be documented as defined in the e-CRF, even if not described in detail in the study protocol.

9.1 Visit Schedule

The expected timing and assessment of the study are outlined in the following table:

Assessment	**Baseline Visit** Day 0	**Drug/Device Visit*** Month 6	**Clinical Visit*** Month 12	**Drug/Device Visit*** Month 18	**Clinical Visit*** Month 24	**Drug/Device Visit*** Month 30**	**Clinical Visit*** Month 36	**Final Visit*****
Signed ICF (medical informed consent)	X							
Check inclusion & exclusion criteria	X							
Physical examination (PE) / medical history	X		X		X		X	
Karnofsky score	X		X		X			
Modified Rankin scale			X[1]		X[1]		X[1]	
12-lead ECG	X	X	X	X	X	X	X	X
Number of AHRE, upload of device interrogations from implanted device	X	X	X	X	X	X	X	X
Laboratory parameters (blood sample)	X[2]		X[3]					
Cognitive function test (MoCA)	X		X		X			
Quality-of-Life questionnaire (EQ-5D)[4]	X		X		X			
Patient 's satisfaction and symptom severity questionnaire[4] (mEHRA score, PACT-Q)	X		X		X			
Supply of study drug	X	X	X	X	X	X	X	
Return of study drug		X	X	X	X	X	X	X
Adverse event (AE) /serious adverse event (SAE)		X	X	X	X	X	X	X

Table 2: Study visit schedules

* Time window +/- 2 weeks
** or longer if required
*** within 3 months after confirmation that the required number of adjudicated endpoints has been reached (will be announced by CRO)
[1] Assessment of modified Rankin scale only in pts. with stroke during study participation; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed
[2] Blood sample not older than 28 days at the date of randomisation (full blood cell count, serum creatinine, AST, ALT, bilirubin, aPTT, and INR) + extra blood sample for central analyses
[3] Extra blood sample for central analyses, only
[4] All Quality-of-Life measures and satisfaction questionnaires should ideally be completed prior to the clinical consultation.

9.2 Baseline Visit

A patient meets eligibility criteria of the study if all inclusion and exclusion criteria are fulfilled as described in the sections above. Prior to any trial related procedure a signed informed consent form has to be obtained from every patient to be included in NOAH – AFNET 6 and kept on file locally.

At the baseline visit, the investigator or designee will:

- Obtain patients' informed consent;
- Document all inclusion and exclusion criteria (refer to section 9.2.1 for qualifying AHRE);
- Assess patients' medical history;
- Assess quality-of-life (EQ-5D questionnaire) prior to the main clinical consultation (refer to section 9.7);
- Assess patient' s satisfaction and symptom severity (PACT-Q questionnaire and modified EHRA score) prior to the main clinical consultation (refer to section 9.7);
- Obtain a 12-lead ECG and digitally upload the ECG to a provided system (refer to section 9.5);
- Perform a physical examination including actual weight;
- Assess function of implanted device and AHRE detection settings, number of AHRE;
- Upload interrogations derived from the implanted device according to upload instructions (will be given as a separate instruction document);
- Obtain blood samples for laboratory assessments (refer to section 9.6);
- Collect a blood sample for storage in the central laboratory (separate informed consent required; refer to section 9.6);
- Assess cognitive function (MoCA test; refer to section 9.8);
- Assess performance status (Karnofsky score; refer to section 9.8);
- Initiate study therapy.

9.2.1 Documentation of the qualifying AHRE

Presence of AHRE is an essential inclusion criterion for NOAH - AFNET 6. Documentation of the qualifying AHRE is essential to monitor inclusion criteria. To allow meaningful assessment of the qualifying AHRE, a digital upload onto a provided system is mandatory to perform a central review. Description of events without documentation of the episode is not sufficient for documentation of the qualifying AHRE. The results of review will not lead to post-hoc exclusion of the patients if criteria of AHRE are not met but will detect protocol violations relevant for stability measures of final analysis and will lead to training of corresponding study sites to prevent future violations and therefore assure a standard quality of adequate AHRE detection.

If AHRE has not been confirmed (i.e. index condition for NOAH - AFNET 6 is not fulfilled),

- and no study medication has been administered, the patient will not remain in the study (refer to section 11.2);
- and at least one dose of study medication has been administered, the patient will remain in the study (principle of intention-to-treat) and has to be followed according to protocol until the end of the trial.

9.3 Follow-up

NOAH - AFNET 6 is an event-driven trial. All patients will be followed until the global end of the trial. Sample size has been estimated based on a minimal follow-up time of 12 months after the end of enrolment and assuming an enrolment time of 71 months.

Clinical follow-up visits will be performed at months 12, 24, and 36. Starting at month 6 and subsequently alternating to clinical follow-up visits, patients will come to the study site for dispensing study drug and up-load of device interrogations derived from the implanted device ("drug/device visit"). After month 36, no more scheduled clinical visits will take place but "drug/device visits" in 6-monthly intervals until end of study, only.

All patients will be followed for outcome and safety until global end of the trial. After the required number of primary outcome events has been accrued and verified, all patients will be seen for a final end of study visit.

For all scheduled follow-up visits, a time window of +/- 2 weeks is allowed.

9.3.1 Clinical visits (Months 12, 24, and 36)

At each visit, the investigator or designee will

- Assess the AHRE detection settings in the implanted device;
- Assess overall heart rhythm, number of AHRE, and history of AF since preceding visit;
- Upload device interrogations derived from the implanted device according to upload instructions (will be given as a separate instruction document);
- Perform a physical examination including actual weight;
- Obtain a 12-lead ECG and digitally upload the ECG to a provided system (refer to section 9.5);
- Assess for clinical events, AEs, SAEs, and contraindications for edoxaban or oral anticoagulation that occurred since the preceding visit / contact;
- Assess modified Rankin scale in patients with stroke during study participation; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed
- Assess and document adherence to study therapy by asking the patient and by pill count;
- Dispense new study medication as far as required and collect remaining study medication.

At month 12 and 24 the investigator or designee will in addition:

- Assess quality-of-life (EQ-5D questionnaire) prior to the clinical consultation (refer to section 9.7);
- Assess performance status (Karnofsky score; refer to section 9.8);
- Assess patient' s satisfaction and symptom severity (PACT-Q questionnaire and modified EHRA score) prior to the main clinical consultation (refer to section 9.7);
- Assess cognitive function (MoCA test; refer to section 9.8).

At month 12 the investigator or designee will in addition:

- Obtain blood sample for central analyses (refer to section 9.6).

9.3.2 Drug/device visits (Months 6, 18, and 30 or longer if required)

At each drug/device visit, the investigator or designee will

- Record patients weight, dispense new study medication as far as required and collect used/empty study medication;
- Assess and document adherence to study therapy by asking the patient and by pill count;

- Obtain a 12-lead ECG and digitally upload the ECG to a provided system (refer to section 9.5);
- Upload device interrogations derived from the implanted device according to upload instructions (will be given as a separate instruction document);
- Assess for clinical events, AEs and SAEs that occurred since the preceding visit / contact.

9.3.3 Triggered visit „Discontinuation of study drug"

If the study drug needs to be discontinued for medical reasons (e.g. in case of clinical indication for anticoagulation or antithrombotic therapy such as new diagnosis of AF or in case of contraindications given in the current SmPC of edoxaban or for oral anticoagulation in general) or the patient's request of study drug discontinuation (refer to section 7.5) this has to be documented in the e-CRF and the investigator or his designee will

- Assess the AHRE detection settings in the implanted device;
- Assess overall heart rhythm, number of AHRE, and history of AF since preceding visit;
- Upload device interrogations derived from the implanted device according to upload instructions (will be given as a separate instruction document);
- In case of new diagnosis of AF as reason for discontinuation of study drug, upload first ECG available with documentation of AF;
- Assess for clinical events, AEs and SAEs that occurred since the preceding visit / contact;
- Document date and reason for discontinuation of study drug;
- Assess and document previous adherence to study drug by asking the patient and by pill count;
- Collect all study medication.

Although having discontinued study drug, these patients will be followed according to study protocol until global end of study (intention-to-treat).

9.3.4 Final visit (at global end of study)

The global end of study will be announced by the CRO after all necessary primary endpoints have been reached. All regular scheduled follow-up visits have to be cancelled after this point in time, but a final in person visit has to be scheduled for all patients still in follow-up at the time of global end of study. It is expected that this visit will be scheduled, performed and documented within 3 months after announcement by the CRO. At that visit, the investigator or his designee will

- Assess overall heart rhythm, number of AHRE, and history of AF since preceding visit;
- Upload device interrogations derived from the implanted device according to upload instructions (will be given as a separate instruction document);
- Obtain a 12-lead ECG and digitally upload the ECG to a provided system (refer to section 9.5);
- Assess for clinical events, AEs and SAEs that occurred since the preceding visit / contact;
- Assess and document previous adherence to study drug by asking the patient and by pill count;
- Terminate study medication intake and collect all remaining study medication;
- Document and start change management to therapy after end of study in each patient.

In patients with premature termination of study drug before global end of study the final visit might be performed as final phone call assessing for clinical events, AEs and SAEs, only.

After termination of study treatment it is at the discretion of the treating physician which kind of therapy will be prescribed to the patient. It is recommended to strictly follow the applicable medical guidelines and the market authorisation of the intended drugs.

9.4 Patient withdrawal from the study

Termination of treatment with study medication for any reason does not necessarily mean premature study withdrawal or termination of study procedures. Individual study participation is only terminated in case of death or patient's explicit wish. It is expected that a large proportion of patients wishing to withdraw consent for further study participation wish to avoid the time and effort of study-specific visits at the study site rather than completely withdrawing from study participation. All study patients wear an implanted device with the need of personal visits for periodic device checks in clinical routine. Patients expressing the wish to withdraw from the study will therefore be asked to maintain consent for minimal effort follow-up, allowing to use their clinical data achieved at the clinically indicated visits within the NOAH - AFNET 6 trial (modification of consent). All study patients wearing an implanted device with home monitoring capacity should be asked to consent for a follow-up allowing using their device data achieved by remote monitoring.

If a patient completely withdraws consent to any further study participation, the investigator should contact the patient and

- Assess overall heart rhythm, number of AHRE, and history of AF since preceding visit;
- Upload device interrogations derived from the implanted device according to upload instructions;
- Assess for clinical events, AEs and SAEs that occurred since the preceding visit / contact;
- Assess and document adherence to study therapy by asking the patient and by pill count;
- Collect all study medication

These data will be documented in the e-CRF in a withdrawal visit.

9.5 Electrocardiogram

All patients will undergo 12-lead ECG at baseline and as part of the clinical follow-up visits. Operators recording ECGs should ensure that chest leads are placed in the proper position and electrodes make good skin contact to minimize noise and artefacts. The reversal of limb leads and the switching of precordial leads are known to cause important alterations in ECGs.

All ECGs will be uploaded digitally onto a central server. This requires an ECG machine capable of exporting an adequate digital format that can then be uploaded. Details regarding upload of ECGs are described in a separate ECG upload manual.

The ECG recording should be digitally annotated with the date of recording, patient study ID and gender, only. No patient identifying annotations (e. g. last name, first name, date of birth) must be documented.

In case an ECG is only available as paper version, a copy has to be faxed or mailed to the CRO for further analyses to be performed by a central evaluation centre.

9.6 Blood Samples

Routine laboratory parameters obtained within clinical routine procedures are part of the standard work-up of the patient's status before study participation in order to verify the enrolment criteria and therefore not considered to be part of study related procedures. If these parameters can be assessed from a blood sample not older than 28 days at the date of inclusion, blood sampling and analysis do not have to be repeated within the study baseline visit. Parameters include a full blood cell count, serum creatinine, AST, ALT, bilirubin, aPTT, and INR. All blood parameters will be determined at the local laboratory of the study sites provided

their analytical laboratories are certified. The e-CRF will collect laboratory values and information whether the value is normal or abnormal.

At baseline and at clinical visit month 12, a study-specific blood sample will be collected (20 ml whole blood) and sent to a central laboratory for archiving for later analysis (analyses of factors and mechanisms of AF, stroke, and bleeding, including genetic markers) which will be performed either in the central laboratory of the trial or within scientific collaborations. All analyses will be supervised by the Steering Committee. Patients will provide a separate signed informed consent to obtain this extra blood sample. Details regarding handling and shipment of these blood samples are described in a separate manual.

9.7 Quality of Life, Experience, Symptoms and Cognitive Function

All patients will be requested to complete quality-of-life, symptom and experience questionnaires and undergo cognitive function testing at baseline, 12 and 24 months. It is hypothesised that the intervention will lead to improved quality-of-life, reduce symptoms, improve patient experience and maintain cognitive function. This hypothesis is based on the observation that AF, including "asymptomatic" forms, is associated with reduced quality of life (44). Observational data suggest that small cerebral emboli are common in patients with short AF episodes (51, 55) and can contribute to reduced quality of life (56, 57). Based on the assumption that AHRE are a very early form of AF conveying a risk of stroke including silent brain lesions, it is expected that quality of life and cognitive function in AHRE patients will also be reduced. Furthermore, the collection of EQ-5D information will provide a valid basis to compare the intervention tested in NOAH - AFNET 6 to other interventions in terms of utility and cost effectiveness. This will inform payers and providers of health care services and allow to put the findings of NOAH - AFNET 6 into a broader health care perspective (58, 59). Significant benefits should be observed within 12 months of treatment and be maintained thereafter. All assessments will be conducted in accordance with the QOL Site Training Manual (will be given as a separate instruction manual) prior to the main clinical consultation.

9.7.1 Patient Reported Outcomes: quality of life, experience and symptoms

Quality of life will be assessed using the EuroQoL EQ-5D L questionnaire. The EQ-5D is a self-administered, validated, generic preference-based measure of health status that comprises a 5-question multi-attribute questionnaire and a visual analogue self-rating scale (46, 47, 48). Patients are asked to rate severity of their current problems according to 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). Patients can therefore be classified into 3,125 possible health states which can be converted into an EQ-5D index score. On the visual analogue scale patients are asked to rate their own health state relative to full health (score=100) or worst imaginable health state (score=0).

Patients' expectations of, and satisfaction with their anticoagulant treatment will be assessed using the Perception AntiCoagulant Treatment Questionnaire (PACT-Q). This is a validated tool which takes around 10 minutes to complete (49, 50).

Patient perception of the severity of their symptoms will be assessed using the modified EHRA score (36).

9.8 Clinical Assessment of Performance Status and Cognitive Function

Performance status will be assessed using the Karnofsky Performance Status Scale (52, 53). The Karnofsky score runs from 100 to 0, where 100 is "perfect" health and 0 is death, and has previously been used in AF patients (54):

100% – normal, no complaints, no signs of disease
90% – capable of normal activity, few symptoms or signs of disease
80% – normal activity with some difficulty, some symptoms or signs
70% – caring for self, not capable of normal activity or work
60% – requiring some help, can take care of most personal requirements
50% – requires help often, requires frequent medical care

40% – disabled, requires special care and help
30% – severely disabled, hospital admission indicated but no risk of death
20% – very ill, urgently requiring admission, requires supportive measures or treatment
10% – moribund, rapidly progressive fatal disease processes
0% – death

Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA; 62); a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.

9.9 Measures to be taken in case of a Pandemic

In case of a pandemic, actions should be taken by the study sites in order to support the safe continuation of the NOAH - AFNET 6 study and to protect the study population from harm. The goal is to keep as many patients as possible in the study without endangering their safety or health in order to allow a meaningful continuation of the study and not to jeopardize the quality of the study data. Measures will be taken by the sponsor to warrant the continued supply of study medication and medical care during study participation. Based on local requirements, the study team shall perform a risk assessment to determine whether the actions described below and potentially additional actions will be implemented at its site to assure the patients' safety.

- In case an increased risk due to progressive pandemic is foreseeable, patients should be invited to the study site early, regardless of the calculated visit date, to assure medication supply for the next 6 months.
- Study patients should be contacted by phone before a FU-visit, in order to clarify whether their state of health allows them to visit the study site without an increased risk to themselves or others.

If a personal FU-visit at the study site is possible:

- Examinations which are not relevant for the safety of the patient may be omitted to shorten the duration of the patient's stay at the site.
- To reduce the number of examinations, study medication may be dispensed based on patient records, consultation with the general practitioner or an interview with the patient.
- The study team shall adhere to local requirements and polices related to infection control for the pandemic.

In case of a lockdown or (self-)quarantine of study patients:

- FU-visits should be performed by phone with the focus on evaluation of any new adverse events as well as information necessary to determine safety aspects with regard to supply of the study drug.
- Study medication may be sent by taxi or courier after a FU-visit by phone. Date and time of dispatch as well as delivery to the patient has to be documented.
- Study patients with an implanted device with home monitoring capacity should be monitored remotely.
- Remote enrolment of study patients may be performed based on patient records and an interview with the patient. To reduce the number of assessments, examinations may be limited to those that are relevant for the patient's safety and the assignment of study medication.

Each action, especially deviations from the study protocol, needs to be documented for every patient affected.

10. Duration of Study Participation

10.1 Overall Duration of the Study

Screening and enrolment of patients is expected to be accomplished after 71 months. Based on the sample size estimation, it is expected that the required number of adjudicated / verified primary outcome events will be reached 12 months after enrolment of the last patient. Due to the time required to obtain follow-up information and to adjudicate events (about 3 months to perform a final study visit in all patients still in the trial plus 4 months for receiving SAE documents and adjudication by ERC to confirm that the required number of adjudicated endpoints have been reached), a total study duration of 71 + 12 + 3 + 4 = 90 months is expected. The total study duration of 90 months (about 7.5 years) was adapted based on an interim analysis.

Global end of study (EOS) is defined in Appendix II as the last Final Visit performed in a study patient. This date will be approved by the sponsor and announced by the CRO.

10.2 Duration of Study Participation for Individual Patients

Based on the sample size estimation, the expected mean follow-up time will be about 42 months per patient with a minimum follow-up time of 12 months and a maximum follow-up time of presumably 83 months until end of final visit after required number of endpoints has been reached. Every patient will be followed-up until global end of study. The exact duration of follow-up will be determined by the accrual of events (event-driven study).

11. Stopping and Discontinuation Criteria

When the study is terminated, the nature of termination will be documented (scheduled end/discontinuation with justification). Discontinuation of the study will be communicated in writing according to the legal requirement. The decision to stop the study will be reached jointly by the sponsor and the SC.

11.1 Discontinuation Criteria for the Study and Study Sites

Following a recommendation of the Data and Safety Monitoring Board (DSMB), the SC may decide discontinuation of the study due to efficacy criteria or adverse reactions in either study group. Discontinuation of the study can also be decided if patients cannot be recruited in sufficient numbers within a certain time period. Detailed criteria for a premature stopping of the entire trial based on safety concerns will be defined in the DSMB and SC charters.

Furthermore, the sponsor in collaboration with the international chief investigator has the right to close local study sites for enrolment of further patients if a major protocol violation occurs, if the site does not comply with the study protocol or decisions of the committees or the international chief investigator or if the site remains inactive for several months. Such decisions will always be taken on a case-by-case basis, but may be taken e.g. if the study procedures and study therapy is not delivered according to protocol and after reminders to adhere to the protocol from the study team.

11.2 Discontinuation Criteria for Patients

The investigator is not able to decide about the discontinuation of study participation of any patient. The investigator has only the option to discontinue study medication for compelling medical reasons. In this case, however, the patient will continue to be followed-up according to study protocol.

If a patient has been randomised but discontinued study participation prior to exposure to study medication, that patient will not be followed. Such patients will be replaced by enrolling other, additional patients.

Once a patient has been randomised and at least one dose of study medication was taken, but he/she discontinued study drug, the patient has to be followed according to study protocol (intention-to-treat) until global end of study.

The patients will be advised in the informed consent forms that they have the right to withdraw from study participation at any time without statement of reasons. However, the investigator should try to find out the reason for patient's withdrawal of consent and document these in the e-CRF.

In case, a protocol violation is noticed, the patient will remain in the intention-to-treat group and will be followed according to protocol.

Patients will be followed according to the study protocol irrespective of whether they experience any outcome event.

Reasonable effort should be made to contact any patient lost to follow-up during the course of the study in order to complete assessments and retrieve any outstanding data. The responsible investigator will take all acceptable measures to retrieve information on vital status of all patients enrolled in the trial.

12. Statistics

The main aim of the proposed study is to test the null hypothesis that the hazard rate, which is assumed to be constant during the study period, is identical in the two groups (usual care and NOAC).

Based on the stroke and death rates of published trials (MOST, ASSERT, Medtronic AT500 data set, SOS), an annualised rate of stroke, systemic embolism, or cardiovascular death of 5.3% in the control group is expected (details given in section 12.2).

12.1 Statistical Methods

The null hypothesis will be tested in a two-arm randomised trial in which patients are entered and then followed if either (a) a primary endpoint is observed or (b) the patient develops overt AF or (c) the observation period ends. Based on the sample size estimate, it is expected that patients will be accrued in a period of 71 months and followed up for the whole duration of study patient recruitment plus at least 12 months until the end of regular follow-up. The exact study duration will depend on the number of adjudicated primary outcome events.

12.1.1 Analysis of the primary outcome

The primary endpoint is the time from randomisation to the first occurrence of stroke, systemic embolism or cardiovascular death. Patients who develop overt AF during the trial period will be censored at that point in time but followed according to protocol until the global end of the trial. All other patients who will not reach the primary endpoint by the global end of the study will be censored at that time point. All randomised patients will be included in the analysis on a modified intention-to-treat-basis.

Cumulative incidence curves and corresponding p-values from competing risk analysis as well as tables with estimated (cause-specific) hazard ratios, confidence intervals, and corresponding p-values will be provided. The Cox-proportional hazards model will be used to estimate the (cause-specific) hazard ratio of edoxaban versus usual care.

12.1.2 Analysis of the secondary outcome

The following secondary endpoints will be analysed in the same way as the primary endpoint: time to components of primary outcome, time to major adverse cardiac events (MACEs), time to stroke or arterial embolism, time to major bleeding events.

Time to all-cause death will be analysed using Kaplan-Meier curves and corresponding p-values from the log-rank test as well as tables with estimated hazard ratios, confidence intervals, and corresponding p-values from a Cox-proportional hazards model.

12.1.3 Continuous secondary endpoints will be analysed as change from baseline using the baseline adjusted analysis of covariance (ANCOVA). Safety analysis

Safety data include adverse events as defined in section 8.1, primary safety endpoints, and data for other safety evaluations. Safety data will be collected on all enrolled patients (i.e. all patients that signed informed consent) in this study.

The primary safety outcome in this study is a composite of cardiovascular death, stroke, and systemic embolism which will be analysed using time-to-event methodology as described in section 12.1.1. Similar analyses and summary statistics will be provided for the components of this safety composite endpoint.

SAEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary in its actual version at the start of the study by Lowest Level Terms (LLT). Treatment related SAEs will be summarized under each treatment group, by system organ class (SOC) and preferred term (PT). Comparisons between treatment groups will be made using Fisher's exact tests for the proportion of subjects with an AE (grouped under one preferred term). SAEs will be summarized by severity and relation to study treatment received.

12.1.4 Subgroup analysis

A list of subgroup criteria will be pre-specified in the statistical analysis plan.

12.2 Sample Size and Power Calculations

Estimation of stroke rates in the NOAH - AFNET 6 population. The table below gives the estimated annual event rates based on recently published trials. Taken together, this information forms the basis for the sample size estimation and for the risk assessment for individual patients enrolled into NOAH - AFNET 6.

	Stroke	Cardiovascular death	Sum
ASSERT (16), 261 pts, 2.5 yrs. FU	1.7	2.9	4.45
MOST (17), 160 pts, 2.25 yrs. FU	5	4.2	9.2
AT500 (28), 725 pts, 1.833 yrs. FU	3.6		
Botto et al (31), 223 pts., 1 yr. FU	3.2		
AVERROES ASA arm (3), 2791 pts, 1.1 yrs. FU	3.4	3.1	6.4
AVERROES and ACTIVE ASA arms pAF (37), 1576 pts, 1.1 yrs. FU	2.1	3.1	5.2
ROCKET-AF pAF patients (38), 2514 pts, 2.4 yrs. FU	1.7	3.5	4.9
SOS (32), 4287 pts, 2.17 yrs. FU	1.2		
Estimated event rate control (weighed by patient-years FU)	*1.9*	*3.3*	5.3

Table 3: Published annual stroke and cardiovascular death event rates in patients with documented AHRE. Event rates are split by stroke and cardiovascular death. The sum of these two components determines the estimate for the primary outcome. All events are rounded to one decimal after calculation.

Estimation of the safety of edoxaban in the NOAH - AFNET 6 population. The safety assessment for the NOAH - AFNET 6 trial participants is based on the favourable bleeding profile of a edoxaban 60 mg OD re-

gime compared to warfarin in the ENGAGE-TIMI 48 trial, combined with the observations made in BAFTA and AVERROES that acetylsalicylic acid does not cause more severe bleeding events or therapy discontinuation than warfarin (3, 6, 23). Thus, the risk for patients randomised to edoxaban seems very small. The safety assessment is in line with the observed small bleeding rates in the ENGAGE-TIMI 48 trial (Table 4).

Development of overt, diagnosed AF in patients with AHRE. Some patients with AHRE will develop overt, diagnosed AF during the follow-up time. As diagnosis of overt AF constitutes an indication for oral anticoagulation, these patients will be censored at the time of developing overt AF. In addition to expected event rates and the potential for event reduction, the sample size estimate recognises that these patients will be censored at this moment. Most of these patients will be additional to the expected attrition rate in this double blind randomised trial. Based on data published in the ASSERT study and in a small portion of the MOST trial population, 13-16% of patients with AHRE will develop overt AF over a follow up time of 2.5 years (16, 17). Based on the increased use of clinical ECG monitoring, e.g. by Holter ECGs, it is expected that this rate will be higher in the NOAH - AFNET 6 population.




Figure 4

	stroke, systemic embolism, or cardiovascular death	fatal bleeding	hemorrhagic stroke plus other ICH	Major extracranial hemorrhage
ENGAGE edoxaban 60 mg OD dosing regime	3.85	0.20	0.39	2.65
AVERROES aspirin	6.40	0.20	0.50	*1.2**
BAFTA aspirin	8.10	0.10	0.50	2.00

Table 4

Figure 4 and corresponding Table 4
Major efficacy and safety annual event rates for patients randomised to edoxaban 60 mg OD in the ENGAGE-TIMI 48 trial compared to event rates reported in patients randomised to acetylsalicylic acid in the AVERROES and BAFTA trials (3, 6, 23). All events are given as annualised rates in percent.
*For the AVERROES acetylsalicylic acid group, only the AVERROES major bleeds are reported, although some of the "clinically relevant non-major bleeds" in AVERROES would have been classified as "major" in BAFTA and ENGAGE.

Estimation of the benefit of edoxaban in the NOAH - AFNET 6 population. Patients randomised to edoxaban will have a reduction in stroke or TIA rates by 2/3 (67%), (3, 39), and a 10% reduction in cardiovascular death. The effect estimate for stroke prevention is based on the effect size observed for stroke prevention with VKAs vs. acetylsalicylic acid, assuming that edoxaban is at least as effective as dose-adjusted warfarin in preventing strokes in AHRE patients (1, 33). This assumption discounts the fact that NOAH - AFNET 6 will compare the potentially more effective agent edoxaban to a control therapy that will consist of acetylsalicylic acid or placebo. The effect size for reduction in cardiovascular death is the point estimate of reduction in cardiovascular deaths observed in the four NOAC trials compared to warfarin. This conservative estimate is thus based on the assumption that the mortality benefit of edoxaban vs. usual care in NOAH - AFNET 6 is not bigger than the mortality benefit of edoxaban compared to dose-adjusted warfarin observed in ENGAGE-TIMI 48 and in the other three NOAC trials (34). These assumptions result in an estimated event rate of 0.64% per year for stroke and a 3% event rate for cardiovascular death. The event rate in the edoxaban group in NOAH - AFNET 6 (3.64% per year) is very similar to the observed event rate in patients enrolled in ENGAGE and randomised to edoxaban that match the NOAH - AFNET 6 inclusion criteria (3.45% per year, unpublished data provided by Daiichi Sankyo based on analysis of the ENGAGE data base).

Sample size. Based on these assumptions, computation of sample size is based on a hazard ratio of 0.68, accrual period of 71 months and minimal follow-up of 12 months. Specifically, it assumes annual hazard rates of 5.3% for the standard treatment group versus 3.64% for the NOAC group. This is equivalent to median event-free survival of 13 years for the standard treatment group versus 19 years for the NOAC group. This effect size is considered realistic, in the sense that an effect of this order of magnitude can be reasonably anticipated in this field of research.

The criterion for significance (alpha) is set at two tailed 5% and for power (1-beta) at 80%. Thus, if the true population hazard ratio of control to treated patients is 0.68 then at least 220 events are expected to be observed. Assuming that the competing event of non-cardiac death has a hazard rate of 0.02 for both groups then at least 865 patients per group are needed to have a power of 80% to detect as significant that difference at the two-sided 5% level of significance. Patients who develop overt AF during the trial period will be censored at that time point. The hazard of developing overt AF or of dropping out of the trial for other reasons (e.g. withdrawal of consent) is assumed to be at 0.287 throughout the trial. This 0.287 hazard is equivalent to 25% first year development of overt AF or of dropping out of the trial for other reasons, and goes up to 57% by the end of the third year. Taking this into account, the number of patients per group becomes 1,269 (63, 64, 65). This estimate is based on the assumption that 5% patients per year will decide to stop the study during the follow-up. In addition, it is expected that 16% of the patients will develop overt AF, and thus require oral anticoagulation outside of the trial, over a follow-up period of 2.5 years (based on ASSERT, 41/261 patients over 2.5 year follow-up) (16, 17). Thus, 2,538 patients have to be randomised and treated.

12.3 Interim Analysis and reassessment of the Sample Size

The Steering Committee assessed pooled event rates after about 1,000 patient-years of observation in the entire study population (without knowledge of study group assignment or study treatment). The event rate was 4.61% (95%-confidence interval: 3.46%, 6.16 %). This event rate is not significantly different to the assumed event rate of 4.4% per year (p=0.748). In this respect, the number of required events does not change. However, since the recruitment rate was lower than expected, the required accrual period changes from 54 to 71 months.

12.4 Patient Selection for Analyses

Under the mITT principle, all randomised patients with a qualifying AHRE (refer to section 6.2.4) and intake of at least one dose of study drug will be included in the primary analysis and censoring mechanism will be applied to those patients without event at the end of the study follow-up. Patients without an event at the end of follow-up will have their efficacy measure censored at the end of follow-up. Patients without an event and who are lost to follow-up will be censored on the day of last contact with the patient. In addition, a sensitivity

(robustness) analysis will be conducted using per-protocol population (i.e., among those without major protocol violations).

Patients who develop overt AF during the trial period will be censored at that time point. The hazard of developing overt AF is assumed to remain constant and it is estimated at 0.287.

Safety analysis will be performed on all enrolled patients (i.e. all patients that signed informed consent) in this study.

13. Access to Source Data / Documents

13.1 Source Data

Source data are defined as all information in original records and certified copies of original records of clinical findings, observations or other activities in a clinical study necessary for the reconstruction and evaluation of the study. Source data are contained in source documents.

13.2 Source Documents

Source documents are defined as original documents, data and records (e.g. hospital records, clinical and office charts, electronic patient records, laboratory notes, memoranda, patient diaries or evaluation check lists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions, microfiches, photographic negatives, microfilm or magnetic media, x-rays, patient files, records kept at pharmacy, at the laboratories and at medico technical departments) involved in this clinical study.

In case of data that are result of patient reporting and will not be documented in clinical routine, the e-CRF is the source document, if the patients answer is documented there without prior documentation on paper.

13.3 Direct Access

Direct access is defined as the permission to examine, analyse, verify and reproduce any records and reports that are important to evaluation of a clinical study. Any party with direct access should take all reasonable precautions within the constraints of the applicable regulatory requirements to maintain the confidentiality of patient identities and sponsor proprietary information.

The investigator agrees that representatives or the designees of the sponsor such as monitors and auditors, and appropriate Regulatory Agencies will be given direct access to the regular clinical files of the patient.

14. Quality Control and Quality Assurance

14.1 Quality Control

Quality Control is defined as the operational techniques and activities, such as monitoring, undertaken within the quality assurance system to verify that the requirements for quality of the study related activities have been fulfilled.

Quality Control should be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly.

14.2 Initiation Visit

At each site an initiation visit will be performed by a representative of the CRO before enrolment of the first patient at this site.

14.3 Study Monitoring

A Risk Based Study Monitoring Plan (RBSMP) will establish the guidelines for conducting quality management (e. g. on-site monitoring visits, off-site central monitoring, and other tasks of quality control). The RBSMP will identify the requirement to perform an ongoing review of any e-CRF item (automated, by means of statistics and by research professionals, e. g. manual queries), the amount of source data verification and review, the frequency of on-site monitoring visits and actions to be taken based on the result of central and on-site monitoring. Thus, frequency of on-site visits and amount of source data verification is dynamic and dependent on performance and quality of each study site. Authorised, qualified representatives of the designated CRO will accomplish the monitoring of the study sites during the trial.

It is important that the investigator and relevant personnel are available during the monitoring visits and that an appropriate location and sufficient amount of time is devoted to the process. During the monitoring visit a PC with internet connection should be available to the monitor for direct connection to the internet database of the study and to all the data of the patients if stored in the data system of the hospital or catheter lab.

The main duty of the monitor is to help the sponsor and the investigator to maintain a high level of ethical, scientific, technical and regulatory quality in all aspects of the trial. At regular intervals during the study, the local site will be contacted through monitoring visits, letters/ emails or telephone calls by a monitor to review the progress of the study.

14.4 Close Out Visit

Independent close out visits will be performed, primarily to collect study drugs. The close out visit may be combined with the last monitoring visit.

14.5 Quality Assurance

Quality Assurance is defined as the planned and systematic actions that are established to ensure that the study is performed and the data are generated, documented (recorded) and reported in compliance with Good Clinical Practice (GCP) and the applicable regulatory requirements.

The investigator should permit auditing by or on behalf of the sponsor and inspection by applicable regulatory authorities. The investigator shall take appropriate measures required by the sponsor to take corrective actions for all problems found during the audit or inspections.

14.5.1 Inspections

An Inspection is defined as the act by a regulatory authority of conducting an official review of documents, facilities, records and any other resources that are deemed by the authorities to be related to the clinical study and that may be located at the site of the study, or at the Sponsors and/or clinical research organisation facilities or at any other establishments deemed appropriate by the regulatory authorities.

14.5.2 Audits

An audit is a systematic and independent review of study related activities and documents to determine whether the validated study related activities were conducted and the data were recorded, analysed and accurately reported according to the protocol, designated Standard Operating Procedure (SOP), Good Clinical Practice (GCP) and the applicable regulatory requirements. An independent audit at the study site may take place at any time during or after the study.

15. Ethical and Legal Consideration

This is an investigator initiated (IIT), phase IIIb trial which meets all relevant ethical and regulatory standards (ICH-GCP). The trial will be conducted in accordance with the principles laid down in the Declaration of Helsinki in its version of October 2013 (Fortaleza) (Appendix IX).

Before initiating the study in each country, approval of the corresponding regulatory authority and Institutional Review Board/ Independent Ethics Committee (IRB / IEC) will be obtained.

15.1 Ethical Consideration

15.1.1 Institutional Review Board / Independent Ethics Committee

Provided this is not contradictory to national law, the local investigator is responsible for submitting an application to the appropriate IRB / IEC. Furthermore the local investigator is required to forward to the sponsor a copy of the written and dated approval or favourable opinion of the local IRB/ IEC signed by the chairman and including information on the composition of the IRB / IEC. The trial (study number, clinical trial protocol title and version number), the documents reviewed (clinical trial protocol, informed consent form, investigator's CV, etc.) and the date of the review should be clearly stated on the written IRB/ IEC approval/ favourable opinion. The corresponding national coordinator together with the CRO will provide substantial support for any IRB / IEC submission. The sponsor is responsible to assure that approval of the local IRB / IEC in each country is obtained prior to study start in the respective study site or country in accordance with local requirements.

During the trial, any substantial modification to the clinical trial protocol will be submitted to the IRB / IEC. It will also be informed of any event likely to affect the safety of patients or the continued conduct of the trial, in particular of any change in safety.

If requested, a progress report is sent to the IRB / IEC annually and a summary of the trial's outcome at the end of the study.

15.1.2 Steering Committee

The trial Steering Committee (SC) will consist of a small group of expert cardiologists, a neurologist, and an expert biostatistician (refer to Appendix I). The functions of the SC are the following:

- Overall responsibility for the execution and scientific reporting of the trial.
- Advice on the scientific and clinical aspects of the study protocol and related documents.
- Responsibility for the conduct of the study according to the guidelines of good clinical practice (GCP) including the monitoring of patient recruitment.
- Reassessment of the sample size based on the blind review of the biostatistician.
- Reassessment of benefit/ risk ratio following the recommendations of the DSMB.
- Decisions on continuation or termination of the study based on the recommendations of the DSMB.

A SC charter providing operating procedures and responsibilities will be discussed and enacted at the latest during the second meeting. Meeting frequency will be defined by the committee and may vary depending on tasks. Meetings may be conference calls or face-to-face meetings. Minutes of each meeting will be provided.

15.1.3 Endpoint Review Committee

The Endpoint Review Committee (ERC) will consist of four experts in cardiology and stroke neurology. The committee will centrally adjudicate all primary outcome events as well as any hospitalisation for other reason and any other SAE. Adjudication will primarily be performed as a continuous online-process within the e-trial management system, depending on the number of documented and cleaned SAEs. If needed, additional

meetings may be performed, either face-to-face or conference calls. Minutes of each meeting will be provided.

An ERC charter providing operating procedures and responsibilities will be discussed and enacted latest at the kick-off meeting prior to start of adjudication.

15.1.4 Data and Safety Monitoring Board

The Data and Safety Monitoring Board (DSMB) is an independent group of experts that advises the SC and study investigators. It will consist of one statistician and two clinicians with expertise in clinical trials and in the management of patients in the scope of the study. The members of the DSMB serve in an individual capacity and provide their expertise and recommendations. They regularly monitor the recruitment and conduct of trial, data quality and timeliness, the distribution of therapies within the study groups, the SAEs and further AEs selected to their discretion during the course of the trial. DSMB will perform unblinded interim analyses following a plan set out in the DSMB charter, and give recommendations to the SC to continue or stop the trial. The Haybittle-Peto boundary (40, 41) will be implemented as stopping rule guidance for the DSMB.

A DSMB charter providing operating procedures and responsibilities will be kept as a separate document and discussed and enacted latest at the second meeting. Meeting frequency will be defined by the committee and may vary depending on tasks. Meetings may be conference calls or face-to-face meetings and may have an open part with guests and a closed part. Minutes of each meeting will be provided. After each meeting, recommendations will be given to the SC in a written form.

15.1.5 National coordinators

National coordinators are selected experts that support submission to the competent authorities and IRB/IEC in their individual countries. The national coordinators provide their expertise regarding regulatory affairs in their countries. The national coordinators supervise and monitor the patient recruitment, and support recruitment measures on a national level. A national coordinator can also be a member of the SC.

15.2 Legal Consideration

The study will be notified to the competent authority of each participating country and approval obtained prior to study start in the respective country. Submission to relevant regulatory authorities in all participating countries lies within the sponsor's responsibility (if not required otherwise according to country specific requirements). The corresponding national coordinator will provide substantial support for any submission process. The study will be performed in accordance with the respective national legislation in each country.

15.3 Modification of Protocol

Any substantial modification to the clinical trial protocol requires written approval/favourable opinion by the IRB / IEC prior to its implementation, unless there are overriding safety reasons that require immediate action. In some instances, a modification may require a change to the informed consent form. In this case, the investigator must receive an IRB /IEC approval/favourable opinion concerning the revised informed consent form prior to implementation of the change.

Substantial modifications will be notified to the competent authorities too.

15.4 Financing and Insurance

The costs necessary to perform the study will be agreed upon with each investigator and will be documented in a separate financial agreement which will be signed by the investigator and the CRO on behalf of the sponsor, prior to the study commencing.

A patient insurance has been effected by the sponsor of the trial. Country specific requirements will be taken into account.

The insurance certificate as well as the insurance conditions will be handed out to all investigators. On demand, the insurance conditions have to be provided to the patients.

15.5 Investigators' Information on IMP

Edoxaban as well as acetylsalicylic acid are authority approved and marketed in all European countries. The respective summary of product characteristics is publicly available in the internet.

15.6 Personal Data and Data Protection

All data obtained in the context of the clinical trial are subject to data protection. This applies to patients' data as well as to investigators' personal data which may be included in any database of the sponsor or the CRO.

The investigating physicians shall take care that patient documents (e.g. copies of reports on special findings) transmitted to the CRO or the sponsor contain no names, but only the year of birth and a relevant patient number. The storage of data for statistical analysis shall likewise be performed only under the patient's random/study number.

15.7 Data Handling and Record Keeping

15.7.1 Completion of case report forms

All medical data in this trial are to be recorded directly in the e-CRFs. Documentation on paper will be restricted to exceptional circumstances only.

The investigator must ensure the accuracy, completeness and timeliness (and legibility in case of documentation on paper) of data.

15.7.2 Archiving

The investigator must maintain confidential all study documentation, and take measures to prevent accidental or premature destruction of these documents. The investigator has to retain the study documents (i.e. investigator site file) after the completion or discontinuation of the study for the time period as required by national legislation. This especially applies to patients' signed informed consent forms and the patient identification list.

The investigator must notify the sponsor prior to destroying any essential study documents within the specified period following completion or discontinuation of the trial.

15.8 Confidentiality

All information disclosed or provided by the sponsor (or any company / institution acting on his behalf), or produced during the trial, including, but not limited to, the clinical trial protocol, the e-CRFs and the results obtained during the course of the trial, is confidential. The investigator or any person under his/her authority agrees to undertake to keep confidential and not to disclose the information to any third party without the prior written approval of the sponsor. The sub-investigators shall be bound by the same obligation as the investigator. The investigator shall inform the sub-investigators of the confidential nature of the trial. Both, the investigator and the sub-investigators shall use the information solely for the purposes of the trial, to the exclusion of any use for their own or for a third party's account.

15.9 Responsibilities

The sponsor of this trial is responsible to health authorities for taking all reasonable steps to ensure the proper conduct of the trial with regard to ethical aspects, clinical trial protocol compliance, integrity and validity of the data recording.

16. Final Report and Publication Policy, Property Rights

The sponsor will be responsible for preparing the final study report that is to be signed by the SC. The sponsor will communicate the results of the trial to the investigators, authorities and IRBs/ECs.

The SC will be primarily responsible for the creation, review and submission of publications and presentations relating to the major aspects of the study within a timely fashion after completion of the study. All analyses will be the responsibility of the SC. Manuscripts for publication will be drafted by members of the SC or other interested investigators. All manuscripts will be subject to coordinated submission and review prior to submission. Coordination will be done by SC.

NOAH - AFNET 6 is an investigator-driven trial. Interested investigators and academic initiatives will be encouraged and supported as appropriate if they propose additional issues that may be studied within the main trial. These materials must be submitted to the SC for review and comment prior to publication or public dissemination. All relevant measures for transparency of clinical trials, and especially the recommendations of the editors of the major medical journals, will be met.

The publication rules are regulated separately and described in detail in a publication policy that is confirmed by the SC.

All information and documents provided by the sponsor or its representatives are and remain the sole property of the sponsor. The investigator shall not mention any information for any other intellectual property rights.

All results, data, documents and inventions, which arise directly or indirectly from the trial in any form, shall be the immediate and exclusive property of the sponsor.

17. Definitions and Classification

17.1 Protocol Violation

Protocol violations are any unapproved changes, deviations or departures from the study design or procedures of a research project that are under the investigator's control and that have not been reviewed and approved by the SC.

17.2 Major Protocol Violation

Major protocol violations are any unapproved changes in the research study design and/or procedures that are within the investigator's control and not in accordance with the IRB- or EC-approved protocol that may affect the participant's rights, safety or well-being, or the completeness, accuracy and reliability of the study data. Patients with major protocol violations will be excluded from the per protocol analysis. Some major protocol violations may be reported to regulatory authorities within defined time periods as mandated. Study specific definitions of major protocol violations will be given by the SC.

18. References

1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21): 2719-47.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
3. Connolly S, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-17.
4. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
5. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
6. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2013.
8. European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31(19): 2369-429.
9. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. N Engl J Med 2012.
10. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013; 127(8): 930-7.
11. Samol A, Masin M, Gellner R, et al. Prevalence of unknown atrial fibrillation in patients with risk factors. Europace 2012.
12. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007; 335(7616): 383.
13. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35(7): 1647-51.
14. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72 hours Holter ECG in patients with ischemic stroke. . Stroke 2013; in press.
15. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009; 30(24): 2969-77c.
16. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366(2): 120-9.
17. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107(12): 1614-9.

18. Hindricks G, Pokushalov E, Urban L, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation - results of the XPECT trial. Circ Arrhythm Electrophysiol 2010; 3(2): 141-7.
19. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost 2011; 106(6): 1012-9.
20. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet 2012; 380(9838): 238-46.
21. Kirchhof P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST). Am H J 2013; published on line 4 August 2013: http://dx.doi.org/10.1016/j.ahj.2013.05.015.
22. Gage BF, Waterman AD, Shannon W, et al. Validation of Clinical Classification Schemes for Predicting StrokeResults From the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
23. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503
24. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-67.
25. Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29):2281-329.
26. Gillis AM, Russo AM, Ellenbogen KA, et al. HRS/ACCF expert consensus statement on pacemaker device and mode selection. J Am Coll Cardiol. 2012;60(7):682-703.
27. Epstein AE, Dimarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm. 2008;5(6):934-55.
28. Capucci A, Santini, M., Padeletti, L. et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol. 46:1913-1920 (2005)
29. Ziegler PD, Glotzer TV, Daoud EG et al.Incidence of Newly Detected Atrial Arrhythmias Via Implantable Devices in Patients With a History of Thromboembolic Events. Stroke. 41:256-260 (2010)
30. Glotzer TV, Daoud EG, Wyse DG, et al. The Relationship between Daily Atrial Tachyarrhythmia Burden from Implantable Device Diagnostics and Stroke Risk: The TRENDS Study. Circ Arrhythm Electrophysiol. 2:474-480 (2009)
31. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol. 20:241-248 (2009)
32. Boriani G, Glotzer TV, Santini M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J. 35:508-516 (2014)
33. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147(8):590-2.

34. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.

35. Anderson HV, Weintraub WS, Radford MJ, Kremers MS, Roe MT, Shaw RE, Pinchotti DM, Tcheng JE. Standardized cardiovascular data for clinical research, registries, and patient care: a report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure project. J Am Coll Cardiol. 2013;61(18):1835-46.

36. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965-72.

37. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2014.

38. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, Piccini JP, on behalf of the R-AFSC, Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J. 2014.

39. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007(3):CD006186.

40. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34(6):585-612.

41. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44(526):793-7.

42. Israel CW, Ehrlich JR, Grönefeld G, Klesius A, Lawo T, Lemke B, Hohnloser SH. Prevalence, characteristics and clinical implications of regular atrial tachyarrhythmias in patients with atrial fibrillation: insights from a study using a new implantable device. J Am Coll Cardiol. 2001 Aug;38(2):355-63.

43. MH Prins, I Guillemin, H Gilet, S Gabriel, B Essers, G Raskob, and SR Kahn. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009; 7: 30.

44. Rienstra M, Vermond RA, Crijns HJ, Tijssen JG, Van Gelder IC, Investigators R. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. Heart Rhythm. 2014;11(6):939-45.

45. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015 Jan 13;131(2):157-64.

46. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdf

47. M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research.

48. Janssen MF, Pickard AS, Golicki D, Gudex C, Niewada M, Scalone L, Swinburn P, Busschbach J. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study

49. Prins MH, Marrel A, Carita P, Anderson D, Bousser MG, Crijns H, Consoli S, Arnould B. Multinational development of a questionnaire assessing patient satisfaction with anti-coagulant treatment: the Perception of Anticoagulant Treatment Questionnaire" (PACT-Q). Health Qual Life Outcomes. 2009 Feb 6; 7:9

50. Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 7;7(1):30

51. Marfella R, Sasso FC, Siniscalchi M, Cirillo M, Paolisso P, Sardu C, Barbieri M, Rizzo MR, Mauro C, Paolisso G. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J Am Coll Cardiol. 2013;62(6):525-30.

52. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2 :187 – 93.

53. Grieco A, Long CJ. Investigation of the Karnofsky performance status as a measure of quality of life. Health Psychol 1984; 3:129 – 42.

54. Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W et al.. Targeted pharmacological reversal of electrical remodeling after cardioversion—rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005;150 :899

55. Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, Kirchhof P, Wersching H. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29(17):2125-32

56. Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6(7):611-9.

57. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-22.

58. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448 e1-19.

59. von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, Ladwig KH. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis-data from the German Competence Network on Atrial Fibrillation. Europace. 2015.

60. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Apr 2005. J Thromb Haemost 3 (4): 692-4.

61. Schulmann S, Angeras U, Bergqvist D, Eriksson B, Lassen M R, Fisher W and on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. Jan 2010. J Thromb Haemost 8 (1): 202-4.

62. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-9.

63. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986 Sep;42(3):507-19.

64. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Statist. Med. 2002; 21:3317–3324

65. A. Latouche A.Porche R. Sample size calculations in the presence of competing risks. Statist. Med. 2007; 26:5370–5380

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
_____	Prof Melanie Calvert Digitally signed by Prof Melanie Calvert Date: 2020.11.18 07:42:00 Z _____ Melanie Calvert
_____	_____ John Camm
_____	_____ Gregory Chlouverakis (study statistician)
_____	_____ Christoph Diener
_____	_____ Andreas Götte (sponsor representative)
_____	_____ Paulus Kirchhof (international chief investigator)
_____	_____ Gregory Lip
_____	_____ Emmanuel Simantirakis
_____	_____ Panos Vardas
_____	_____ Antonia Zapf (study statistician)
_____	_____ Signature principle investigator
	_____ (Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
	Melanie Calvert
18/11/2020	John Camm
	Gregory Chlouverakis (study statistician)
	Christoph Diener
	Andreas Götte (sponsor representative)
	Paulus Kirchhof (international chief investigator)
	Gregory Lip
	Emmanuel Simantirakis
	Panos Vardas
	Antonia Zapf (study statistician)
	Signature principle investigator
	(Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
	Melanie Calvert
	John Camm
18/11/2020	 Digitally signed by Grigorios Chlouverakis Date: 2020.11.18 12:51:12 +02'00' Gregory Chlouverakis (study statistician)
	Christoph Diener
	Andreas Götte (sponsor representative)
	Paulus Kirchhof (international chief investigator)
	Gregory Lip
	Emmanuel Simantirakis
	Panos Vardas
	Antonia Zapf (study statistician)
	Signature principle investigator
	(Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
	Melanie Calvert
	John Camm
	Gregory Chlouverakis (study statistician)
15 - NOV - 2020	Christoph Diener
	Andreas Götte (sponsor representative)
	Paulus Kirchhof (international chief investigator)
	Gregory Lip
	Emmanuel Simantirakis
	Panos Vardas
	Antonia Zapf (study statistician)
	Signature principle investigator
	(Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
	Melanie Calvert
	John Camm
	Gregory Chlouverakis (study statistician)
	Christoph Diener
20/11/2023	Andreas Götte (sponsor representative)
	Paulus Kirchhof (international chief investigator)
	Gregory Lip
	Emmanuel Simantirakis
	Panos Vardas
	Antonia Zapf (study statistician)
	Signature principle investigator
	(Name principle investigator; printed)


19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
	Melanie Calvert
	John Camm
	Gregory Chlouverakis (study statistician)
	Christoph Diener
	Andreas Götte (sponsor representative)
18 Nov 2020	Paulus Kirchhof (international chief investigator)
	Gregory Lip
	Emmanuel Simantirakis
	Panos Vardas
	Antonia Zapf (study statistician)
	Signature principle investigator
	(Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
_____	_____ Melanie Calvert
_____	_____ John Camm
_____	_____ Gregory Chlouverakis (study statistician)
_____	_____ Christoph Diener
_____	_____ Andreas Götte (sponsor representative)
_____	_____ Paulus Kirchhof (international chief investigator)
18 Nov 2020	 Gregory Lip
_____	_____ Emmanuel Simantirakis
_____	_____ Panos Vardas
_____	_____ Antonia Zapf (study statistician)
_____	_____ Signature principle investigator
	_____ (Name principle investigator; printed)


19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
	Melanie Calvert
	John Camm
	Gregory Chlouverakis (study statistician)
	Christoph Diener
	Andreas Götte (sponsor representative)
	Paulus Kirchhof (international chief investigator)
	Gregory Lip
19/11/2020	Emmanuel Simantirakis
	Panos Vardas
	Antonia Zapf (study statistician)
	Signature principle investigator
	(Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
_____	_____ Melanie Calvert
_____	_____ John Camm
_____	_____ Gregory Chlouverakis (study statistician)
_____	_____ Christoph Diener
_____	_____ Andreas Götte (sponsor representative)
_____	_____ Paulus Kirchhof (international chief investigator)
_____	_____ Gregory Lip
_____	_____ Emmanuel Simantirakis
18/11/2020	 Panos Vardas
_____	_____ Antonia Zapf (study statistician)
_____	_____ Signature principle investigator
	_____ (Name principle investigator; printed)

19. Signatures

The undersigned have read this protocol and agreed to conduct this study in accordance with all stipulations of the protocol, with the current EU regulation, with the principles of good clinical practice, and in accordance with the Declaration of Helsinki.

Date	Signature
_____	_____ Melanie Calvert
_____	_____ John Camm
_____	_____ Gregory Chlouverakis (study statistician)
_____	_____ Christoph Diener
_____	_____ Andreas Götte (sponsor representative)
_____	_____ Paulus Kirchhof (international chief investigator)
_____	_____ Gregory Lip
_____	_____ Emmanuel Simantirakis
_____	_____ Panos Vardas
19.11.2020	 Antonia Zapf (study statistician)
_____	_____ Signature principle investigator
	_____ (Name principle investigator; printed)

Appendix I: Members of the Steering Committee

(in alphabetical order)

Melanie Calvert
PROM and patient experience expert
Primary Care Clinical Sciences
School of Health and Population Sciences
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham B15 2TT, United Kingdom
Email: m.calvert@bham.ac.uk

John Camm
St. George's Hospital Medical School, Cranmer Terrace
SW 17 ORE London, United Kingdom
Email: jcamm@sgul.ac.uk

Hans-Christoph Diener
University Duisburg-Essen, Department of Neurology
Hufelandstr 55
45122 Essen, Germany
Email: hans.diener@uk-essen.de

Andreas Goette (sponsor representative)
St. Vincenz Krankenhaus, Am Busdorf 2
33098 Paderborn, Germany
Email: andreas.goette@vincenz.de

Paulus Kirchhof (chair)
The University Medical Center Hamburg – Eppendorf
University Heart & Vascular Center, Department of Cardiology
Martinistraße 52, 20251 Hamburg, Germany
Email: p.kirchhof@uke.de

Gregory Lip
Liverpool Centre for Cardiovascular Science
University of Liverpool
Liverpool, United Kingdom
Email: Gregory.Lip@liverpool.ac.uk

Emmanuel Simantirakis
Heraklion University, Department of Cardiology
PO Box 1352 Stavrakia
711 10 Heraklion, Greece
Email: esimant@hotmail.com

Panos Vardas
Hygeia Hospitals Group, Heart Sector
15123 Athens, Greece
Email: pvardas@hygeia.gr

Study Statisticians:
Gregory Chlouverakis
School of Medicine
University of Crete
Gallos Campus
Rethymno, 74100, Greece
Email: gchlouve@med.uoc.gr

and

Antonia Zapf
Universitätsklinikum Hamburg-Eppendorf
Institut für Medizinische Biometrie und Epidemiologie
Martinistraße 52
20246 Hamburg
Email: a.zapf@uke.de

Representative of Daiichi Sankyo (non-voting)
Daiichi Sankyo Europe GmbH
Zielstattstr. 48
81379 München, Germany

Appendix II: Time Schedule

FPI depends on release of study drugs; FPI estimated late in 1st quarter 2016.

	Tasks	Date
Draft study planning	Draft Protocol, review and finalisation by Steering Committee	December 2014
Availability of study drug	Market authorisation of edoxaban within the EU	25.06.2015
Final study planning	Final protocol	January 2015
Study preparation	Definition of study drug types and supply procedures	December 2015
	Set up of the e-trial management system, preparation of e-CRF; preparation of all other study relevant documentation	October 2015 - January 2016
	Site selection, site contacts, site evaluation	November 2015 - November 2020
	Initial EC and CA submission in each participating country	January 2016- July 2020
Study initiation	Site contracting	January 2016 - December 2020
	Supply of the sites with study materials, initiation visits	May 2016 - December 2020
	Recruitment period (FPI to LPI)	June 2016 - April 2022
Study duration*	Treatment and follow-up until all necessary primary endpoints have been reached	May 2022 – April 2023
	Treatment and follow-up until last patient last visit (global end of study)	May 2023 – July 2023
	Mean follow-up period of all patients, assuming a linear patient recruitment	42 months (minimum 12 months, maximum presumably 83 months)
Interim analysis	Assessment of pooled event rates after 1,000 patient-years of observation in the entire study population, alternatively 24 months after enrolment of the first patient	Q4 2019
Results	Primary EP Analysis acc. to SAP	Q4 2023
	Submission of primary result paper for publication	Q4 2023

*NOAH – AFNET 6 is an event driven trial. The total study duration may therefore be longer or shorter than the estimates given here.

Definition of terms

- **Patient's Start Of Participation (PSOP)**
  - Date informed consent signed
- **Patient's Start Of Study (PSOS)**
  - Date and time of randomisation.
- **Patient's Start Of Treatment (PSOT)**
  - Date and time of intake of first dose of study medication.
- **Primary Endpoint Database Lock (PEDBL), global end of regular follow-up**
  - First date when the number of needed valid primary first endpoints has been verified. This date will be approved by sponsor. An endpoint is verified as valid primary endpoint after ERC assessment, only. The verification of a valid primary endpoint as first primary endpoint in a patient is performed by means of statistics.
- **Last Visit, termination of study medication in each patient before global end of study**
  - Final Visit of each study patient after end of regular follow-up to be performed in all patients still in follow-up at the time of PEDBL.
- **Extended Reporting Period (ERP)**
  - Period after each individual Final Visit until global EOS for reporting of AEs after termination of study medication.
- **Last Patient Last Visit (LPLV), global End Of Study (EOS)**
  - LPLV is the last Final Visit performed in a study patient, equivalent to global End Of Study (EOS). This date will be approved by sponsor.
- **Final Database Lock (FDBL)**
  - After EOS, final data cleaning and last ERC assessment. This date will be approved by sponsor.
- **Notification of EOS to regulatory bodies**
  - Within 90 days after EOS this event has to be notified to all involved regulatory bodies. This date will be approved by sponsor.
- **Study Closure**
  - Date of all contracts closed and all administrative procedures finished.
- **Final Report**
  - Within one year after EOS a final report according to applicable international standards has to be provided to all involved regulatory bodies.

Appendix III: Definition of primary outcome events

Stroke comprises ischemic strokes as defined by the FDA (any stroke associated with a 4 point or greater increase in the NIHSS score at the time of the stroke compared to baseline) and includes ischemic infarction with (transient) clinical symptoms that resolve completely within 24 hours, but have a matching lesion on brain imaging as well as ischemic infarction interrupted by death within 24 hours. In contrast to the FDA definition, subarachnoid haemorrhage and haemorrhagic stroke are not counted as stroke in this trial but as major bleeding event.

Systemic embolism will be defined as an acute vascular occlusion of an extremity or organ not occurring in the central nervous system, documented by means of imaging, surgery, or autopsy.

Cardiovascular death will be defined according to the Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials developed by the Standardized Data Collection for Cardiovascular Trials Initiative (35):

Cardiovascular death includes death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to cardiovascular procedures, death due to cardiovascular haemorrhage, and death due to other cardiovascular causes.

- Death due to acute MI refers to a death by any cardiovascular mechanism (e.g., arrhythmia, sudden death, HF, stroke, pulmonary embolus, peripheral arterial disease) ≤ 30 days after a MI related to the immediate consequences of the MI, such as progressive HF or recalcitrant arrhythmia. There may be assessable mechanisms of cardiovascular death during this time period, but for simplicity, if the cardiovascular death occurs ≤ 30 days of the MI, it will be considered a death due to MI.
- Acute MI should be verified to the extent possible by the diagnostic criteria outlined for acute MI (24) or by autopsy findings showing recent MI or recent coronary thrombosis.
- Death resulting from a procedure to treat a MI (percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG)), or to treat a complication resulting from MI, should also be considered death due to acute MI.
- Death resulting from an elective coronary procedure to treat myocardial ischemia (i.e., chronic stable angina) or death due to a MI that occurs as a direct consequence of a cardiovascular investigation/ procedure/ operation should be considered as a death due to a cardiovascular procedure.
- Sudden cardiac death refers to a death that occurs unexpectedly, not following an acute MI, and includes the following deaths:
  - Death witnessed and occurring without new or worsening symptoms
  - Death witnessed within 60 minutes of the onset of new or worsening cardiac symptoms, unless the symptoms suggest acute MI
  - Death witnessed and attributed to an identified arrhythmia (e.g., captured on an electrocardiographic (ECG) recording, witnessed on a monitor, or unwitnessed but found on review of recordings obtained by an implanted device (e.g. a defibrillator, pacemaker, or ECG recorder)
  - Death after unsuccessful resuscitation from cardiac arrest
  - Death after successful resuscitation from cardiac arrest and without identification of a specific cardiac or non-cardiac aetiology
  - Unwitnessed death in a subject seen alive and clinically stable ≤ 24 hours prior to being found dead without any evidence supporting a specific non-cardiovascular cause of death (information regarding the patient's clinical status preceding death should be provided, if available).
  - General considerations regarding sudden cardiac death
    Unless additional information suggests an alternate specific cause of death (e.g., death due to

other cardiovascular causes), if a patient is seen alive ≤ 24 hours of being found dead, sudden cardiac death should be recorded. For patients who were not observed alive within 24 hours of death, undetermined cause of death should be recorded (e.g., a subject found dead in bed, but who had not been seen by family for several days).

- Death due to HF refers to a death in association with clinically worsening symptoms and/or signs of HF regardless of HF aetiology. Deaths due to HF can have various aetiologies, including single or recurrent MIs, ischemic or non-ischemic cardiomyopathy, hypertension, or valvular disease.
- Death due to stroke refers to death after a stroke that is either a direct consequence of the stroke or a complication of the stroke. Acute stroke should be verified to the extent possible by the diagnostic criteria outlined for stroke.
- Death due to cardiovascular procedures refers to death caused by the immediate complications of a cardiac procedure.
- Death due to cardiovascular haemorrhage refers to death related to haemorrhage such as a non-stroke intracranial haemorrhage, non-procedural or non-traumatic vascular rupture (e.g., aortic aneurysm), or haemorrhage causing cardiac tamponade.
- Death due to other cardiovascular causes refers to a CV death not included in the above categories but with a specific, known cause (e.g., pulmonary embolism or peripheral arterial disease).

Appendix IV: International Society on Thrombosis and Haemostasis (ISTH) Bleeding Definitions

Major Bleeding in Non-Surgical Patients (60)

1. Fatal bleeding.

and/or

2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome.

and/or

3. Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells.

Major Bleeding in Surgical Patients (61)

1. Fatal bleeding.

and/or

2. Bleeding that is symptomatic and occurs in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, pericardial, in a non-operated joint, or intramuscular with compartment syndrome, assessed in consultation with the surgeon.

and/or

3. Extrasurgical site bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells, with temporal association within 24–48 h to the bleeding.

and/or

4. Surgical site bleeding that requires a second intervention (open, arthroscopic, endovascular) or a hemarthrosis of sufficient size as to interfere with rehabilitation by delaying mobilization or delayed wound healing, resulting in prolonged hospitalisation or a deep wound infection.

and/or

5. Surgical site bleeding that is unexpected and prolonged and/ or sufficiently large to cause hemodynamic instability, as assessed by the surgeon. There should be an associate fall in hemoglobin level of at least 2 g/dL (1.24 mmol/L), or transfusion, indicated by the bleeding, of at least two units of whole blood or red cells, with temporal association within 24 h to the bleeding.
6. The period for collection of these data is from start of surgery until five half-lives after the last dose of the drug with the longest half-life and with the longest treatment period (in case of unequal active treatment durations).
7. The population is those who have received at least one dose of the study drug.

Appendix V: Definition of overt AF

According to the definition as per ESC guidelines, AF is defined as a cardiac arrhythmia with the following characteristics:

1. The surface ECG shows 'absolutely' irregular RR intervals (AF is therefore sometimes known as arrhythmia absoluta), i.e. RR intervals that do not follow a repetitive pattern.
2. There are no distinct P waves on the surface ECG. Some apparently regular atrial electrical activity may be seen in some ECG leads, most often in lead V1.
3. The atrial cycle length (when visible), i.e. the interval between two atrial activations, is usually variable and <200 ms (>300 bpm).

An irregular pulse should always raise the suspicion of AF, but a surface ECG recording is necessary to diagnose AF. Any arrhythmia that has the ECG characteristics of AF and lasts sufficiently long for a 12-lead ECG to be recorded, or at least 30 s on a rhythm strip, should be considered as AF.

Within the context of NOAH - AFNET 6, an intracardiac ECG recording is not considered sufficient to prove occurrence of overt AF.

Appendix VI: Change management of anticoagulants at discontinuation of study drug

Hein Heidbuchel, Peter Verhamme, Marco Alings, Matthias Antz, Hans-Christoph Diener, Werner Hacke, Jonas Oldgren, Peter Sinnaeve, A. John Camm, and Paulus Kirchhof
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace doi:10.1093/europace/euv309

(separate document)

Appendix VII: ESC guidelines 2010

(A. John Camm (Chairperson) (UK), Paulus Kirchhof (Germany), Gregory Y.H. Lip (UK), Ulrich Schotten (The Netherlands), Irene Savelieva (UK), Sabine Ernst (UK), Isabelle C. Van Gelder (The Netherlands), Nawwar Al-Attar (France), Gerhard Hindricks (Germany), Bernard Prendergast (UK), Hein Heidbuchel (Belgium), Ottavio Alfieri (Italy), Annalisa Angelini (Italy), Dan Atar (Norway), Paolo Colonna (Italy), Raffaele De Caterina (Italy), Johan De Sutter (Belgium), Andreas Goette (Germany), Bulent Gorenek (Turkey), Magnus Heldal (Norway), Stefan H. Hohloser (Germany), Philippe Kolh (Belgium), Jean-Yves Le Heuzey (France), Piotr Ponikowski (Poland), Frans H. Rutten (The Netherlands). Guidelines for the management of atrial fibrillation. European Heart Journal (2010)

(separate document)

Appendix VIII: Suggestions for optimal programming of devices for adequate detection of AHRE

The following section outlines adequate settings of devices for correct identification of AHRE episodes in patients who are potentially eligible for NOAH - AFNET 6:

- The intracardiac electrogram (IEGM) storage should be activated while the atrial tachycardia detection rate must be set to 170 bpm. Episodes at lower atrial rates are not qualifying episodes for NOAH - AFNET 6. Higher rate thresholds are acceptable, but may miss some episodes that would make patients eligible for NOAH - AFNET 6. Although false atrial tachyarrhythmia detection due to repetitive non-re-entrant ventriculo-atrial synchrony is rare for episodes greater than 6 minutes in duration, this phenomenon can be diagnosed by checking the stored IEGMs and can be eliminated by avoiding very long programmed AV delays and/or by increasing the postventricular atrial refractory period.
- For pacemakers and implantable cardioverter-defibrillators (ICDs) with programmable atrial electrogram configuration, the later should be programmed Atip-Aring, in order to avoid noise detection and the use of short tip-to-ring spacing atrial leads (<10 mm) is strongly recommended.
- Finally the devices should be optimally programmed according to the individual patient and to the most recent practice guidelines (25, 26, 27), ensuring as far as possible optimum hemodynamic and avoiding unnecessary ventricular pacing.

Cardiac rhythm management (CRM) device manufacturers use different detection algorithms and settings for the most accurate device diagnostics and EGM recordings. In general two different technologies have been employed: 1. Mode switch based and 2. Rate and pattern based.

1. **Mode switch (MS) based AHRE detection** is very common in many pacemakers and defibrillators manufactured by different companies.
   a) **Medtronic** employs this technology for all CRM devices: In detail the nominal setting for mode switch is set at 185 bpm and IEGM recording is set nominally "on" for atrial high rate and ventricular high rate episodes. In the case the device is programmed with mode switch "off", the device can still detect and record AHRE by programming
   Data Collection Setup => AHRE => Detection Rate (Nominal 200 bpm) and Detection Duration (Nominal 5 sec) which can be programmed up to 60 sec.
   b) **Vitatron CRM** devices implanted after 2010 follow the same programming nominal values and recommendations as Medtronic (see above).
   c) **St Jude Medical** CRM devices also use mode switch triggered detection (nominally set at 180 bpm) and in the case that mode switch is turned "off" the device can use the high atrial rate setting for a consecutive number of cycles that the rate is exceeded. As they are both nominally "off", they should be activated. The IEGM recording is nominally "off" and must be programmed "on" (AT/AF detection trigger). St Jude Medical defibrillators follow the same AHRE detection method, however, they must have mode switch "on".
   d) **Boston Scientific** pacemakers and defibrillators use the same method (mode switch based) for detecting AHRE. Mode switch is nominally "on" and nominal values for trigger rate is nominally set at 170 bpm, mode switch duration at 8 cardiac cycles and entry and exit count at 8 cardiac cycles as well. IEGM recording is nominally "on".
   e) **Biotronik** uses both mode switch and rate based detection triggers of AHRE nominally set "on" with cut-off rates at 160 and 200 bpm, respectively. IEGM recording is nominally "on".
   f) **Sorin Group** CRM devices also use both mode switch and atrial burst-based detection triggers for AHRE detection and recording. IEGMs are always set to "on".
2. **Rate and pattern based detection** is mainly employed by Medtronic ICD devices and latest technology CRM devices: Both types of devices monitor the sequence of events in the atrial and ventricular channel and combine with exceeding a programmed threshold of atrial rate. This monitoring is nominally "on", the threshold is nominally set at 171 bpm and IEGM recording is always "on".

Appendix IX: Declaration of Helsinki (Version Fortaleza, October 2013)

http://www.wma.net/en/30publications/10policies/b3/

16.1.2 Sample case report form (unique pages only)

Sample of eCRF

English version (June 1st, 2016)

NOTE: This sample CRF cannot reflect the dynamics that will work in the electronic CRF, only. The sole purpose of this document is to provide an overview of all data items within MARVIN.
NOT to be used for documentation!
The currently valid version of the CRF is always the electronic version (i.e. MARVIN)!

Content

Inclusion visit **4**
- Base data 4
- Inclusion criteria 4
- Exclusion criteria 5
- AHRE upload 6
- Indication for ASA 6
- Assessment of edoxaban dosage 6
- Confirmation of ASA indication and edoxaban dosage 7
- Randomisation 7
- Dispensing of medication 7
- Start of study drug 7
- Medical history 8
- Concomitant diseases 10
- Physical examination 10
- Patient questionnaires 11
- 12-lead body surface ECG 12
- Blood sample for central analysis 12
- Laboratory parameters 13
- Concomittant medication 14

Clinical visit 14
- Clinical visit base data 14
- Follow-up history 14
- Compliance with study drug 15
- Drug count 15
- Contraindications 16

Assessment of edoxaban dosage 16
Confirmation of ASA indication and edoxaban dosage 17
Dispensing of medication 17
AHRE upload 17
Physical examination 18
Patient questionnaires 19
12-lead body surface ECG 19
Blood sample for central analysis 20
Concomittant medication 21
Adverse event 21
Drug/Device visit 22
Base data drug/device visit 22
Follow-up history 22
Compliance with study drug 23
Drug count 23
Contraindications 24
Assessment of edoxaban dosage 24
Confirmation of ASA indication and edoxaban dosage 24
Dispensing of medication 25
AHRE upload 25
12-lead body surface ECG 26
Concomittant medication 26
Adverse event 27
AF onset 28
SAE 29
Base data of SAE 29
Data on stroke or TIA 30
Interventions 30
Hospital discharge / death 31
Data on death as outcome 31
SAE documents 31
Concomittant medication 31
Discontinuation of study drug visit 32
Follow-up history 32
Compliance with study drug 33
Drug count 33
AHRE upload 34
12-lead body surface ECG 34
Concomittant medication 35
Adverse event 35

Withdrawal/modification of consent **36**
Withdrawal / modification of consent base data 36
Follow-up history 36
AHRE upload 37
Concomittant medication 37
Adverse event 37
Minimal effort FU **38**
Base data 38
Follow-up history 38
AHRE upload 38
Concomittant medication 39
Adverse event 39
Final visit **40**
Base data final visit 40
Follow-up history 40
Compliance with study drug 41
Drug count 41
AHRE upload 42
12-lead body surface ECG 42
Concomittant medication 43
Adverse event 43

Inclusion visit*

Base data*

Base data*

Date of patient's inclusion*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Was the patient included in the NOAH - AFNET 6 study during an out-patient visit or during an inpatient-hospitalisation (i.e. at least one overnight stay?)*	∇ Inpatient hospitalisation ∇ Out-patient visit (no overnight stay) ∇ Inpatient hospitalisation but discharged on day of randomisation
Date of discharge*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Sex*	O Male O Female
Year of birth*	_ _ _ _
Has the patient's birthday already passed this year?*	O Yes O No
Calculated age (at day of inclusion)*	_ _ _

Calculated visit dates for follow-up (time window +/- 1 months)*

Drug/device visit 6 months	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Follow-up 12 months	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Drug/Device visit 18 months	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Follow-up 24 months	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Drug/device visit 30 months	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Follow-up 36 months	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Inclusion criteria*

Inclusion criteria*

Pacemaker or defibrillator implanted for any reason with feature of detection of AHRE*	∇ Yes ∇ No
Device implanted at least 2 months prior to randomisation*	∇ Yes ∇ No
AHRE detection feature activated adequately according to "Suggestions for optimal programming of devices for adequate detection of AHRE" (refer to Appendix VIII of the study protocol)*	∇ Yes ∇ No

* = mandatory item

Inclusion visit*

Inclusion criteria*

AHRE (≥ 180 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally* Any AHRE episode recorded after adequate setting of AHRE detection algorithms is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible.	∇ Yes ∇ No
Provision of signed informed consent*	∇ Yes ∇ No
Date of patient's signature*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Age ≥ 65 years (calculated)*	∇ Yes ∇ No

In addition, at least one of the following cardiovascular conditions leading to a CHA2DS2VASc score of 2 or more:*

Age ≥ 75 years (calculated)*	∇ Yes ∇ No
Heart failure (clinically overt or LVEF < 45%)*	∇ Yes ∇ No
Arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure > 145/90 mmHg)*	∇ Yes ∇ No
Diabetes mellitus*	∇ Yes ∇ No
Prior stroke or transient ischemic attack (TIA)*	∇ Yes ∇ No
Vascular disease (peripheral, carotid/cerebral, or aortic plaques on transesophageal echocardiogram [TEE])*	∇ Yes ∇ No

Exclusion criteria*

Exclusion criteria*

Any disease that limits life expectancy to less than 1 year*	∇ Yes ∇ No
Participation in another clinical trial, either within the past 2 months or still ongoing*	∇ Yes ∇ No
Previous participation in the present trial NOAH - AFNET 6*	∇ Yes ∇ No
Drug abuse or clinically manifest alcohol abuse*	∇ Yes ∇ No
Any history of overt AF or atrial flutter*	∇ Yes ∇ No
Indication for oral anticoagulation (e.g. deep vein thrombosis)*	∇ Yes ∇ No
Contraindication for oral anticoagulation in general*	∇ Yes ∇ No
Contraindication for edoxaban as stated in the current SmPC*	∇ Yes ∇ No

Inclusion visit*

Exclusion criteria*	
Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present.*	∇ Yes ∇ No
Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation*	∇ Yes ∇ No
End stage renal disease creatinine clearance * Creatinine clearance < 15 ml/min as calculated by the Cockcroft-Gault Method	∇ Yes ∇ No

Randomisation*

AHRE upload*	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of first AHRE in this download*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Indication for ASA*	
Patient currently has an **indication** for ASA* Please document "Yes" if an indication exists even if a contraindication prohibits the intake	∇ Yes ∇ No
Unstable angina pectoris*	∇ Yes ∇ No
Acute myocardial infarction*	∇ Yes ∇ No
Prevention of re-infarction*	∇ Yes ∇ No
After arterial vascular or general surgical interventions (e.g. after CABG or after PTCA)*	∇ Yes ∇ No
For prevention of transitory ischaemic attacks (TIA) and strokes	∇ Yes ∇ No
Patient currently has a **contraindication** for ASA*	∇ Yes ∇ No
Indication for ASA (calculated) In case patient is randomised to edoxaban group, this will not change study medication. In case of usual care group patient, this will add blinded ASA treatment	∇ Yes ∇ No

Assessment of edoxaban dosage*	
Weight*	_ _ _ , _ kg
Serum creatinine*	_ _ _ , _ _ [ ]mg/dl [ ]µmol/l
Creatinine clearance (calculated)*	_ _ _ , _ _ ml/min
Impaired renal function (calculated)* defined as creatinine clearance ≤ 50 ml/min	∇ Yes ∇ No

Inclusion visit*

Assessment of edoxaban dosage*	
Current intake of glycoprotein p inhibitors: ketoconazole, ciclosporin, erythromycin or dronedarone*	∇ Yes ∇ No
Recommended dosage of edoxaban for this patient according to SmPC/IB (calculated)*	∇ 30 mg once daily ∇ 60 mg once daily
Confirmation of ASA indication and edoxaban dosage*	
Can you confirm the suggested status of indication for ASA?*	∇ Yes, ASA administration is indicated for this patient ∇ No, ASA administration is not indicated, contrary to the recommendation
Please provide medical justification* **English language only!**	_ _ _ _ _ _ _ _ _
Can you confirm the suggested status of indication for ASA?*	∇ Yes, ASA administration is not indicated for this patient ∇ No, ASA administration is indicated, contrary to the recommendation
Please provide medical justification* **English language only!**	_ _ _ _ _ _ _ _ _
Can you confirm the suggested dosage of edoxaban?*	∇ Yes, 30 mg is the adequate dosage for this patient ∇ No, 60 mg is the adequate dosage for this patient, contrary to the recommendation
Please provide medical justification* **English language only!**	_ _ _ _ _ _ _ _ _
Can you confirm the suggested dosage of edoxaban?*	∇ Yes, 60 mg is the adequate dosage for this patient ∇ No, 30 mg is the adequate dosage for this patient, contrary to the recommendation
Please provide medical justification* **English language only!**	_ _ _ _ _ _ _ _ _
Randomisation*	
Randomise and dispense material now?*	∇ Yes
Date of randomisation (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Dispensing of medication*	
Medication number to be dispensed (displayed)* *If the displayed medication should be not available for dispense, please immediately contact the NOAH-AFNET6 hotline (+49 89 990 1649 963)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Please enter verifier (4 digits)*	_ _ _ _
Earliest possible date for next regular visit with regard to amount of study drugs*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Calculated date of next regular visit with regard to randomisation date*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Latest possible date for next regular visit with regard to amount of study drugs*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Start of study drug*	
Date 1st dose of study drug administered, i.e. day patient took first dose*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Inclusion visit*

Medical history*

Medical history of device implantation*

Type of implanted device*	∇ PM ∇ PM-CRT ∇ ICD ∇ ICD-CRT
Indication for device implantation*	∇ Tachy-brady syndrome ∇ Higher degree AV block ∇ Bundle branch block with syncope ∇ Unexplained syncope ∇ Other symptomatic bradycardia
Indication for device implantation*	∇ Left bundle branch block and heart failure with reduced ejection fraction ∇ Other QRS widening and heart failure with reduced ejection fraction
Indication for device implantation*	∇ survived sudden death or VT (secondary prevention) ∇ Primary prevention with LVEF < 30% ∇ Primary prevention in inherited cardiomyopathies ∇ Other primary prevention indication
Indication for device implantation*	∇ survived sudden death or VT (secondary prevention) ∇ Primary prevention with LVEF < 30% ∇ Primary prevention in inherited cardiomyopathies ∇ Other primary prevention indication ∇ Left bundle branch block and heart failure with reduced ejection fraction ∇ Other QRS widening and heart failure with reduced ejection fraction
Manufacturer of implanted device*	∇ Medtronic ∇ Vitatron ∇ St. Jude Medical ∇ Boston Scientific Group ∇ Biotronic ∇ Sorin Group ∇ Other
Please specify "other"*	_ _ _ _ _ _ _ _ _ _
English language only!	
Model of implanted device*	_ _
Date of implantation of current device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
If exact date is unknown please document the 1st day of the corresponding month	
Type of implanted leads*	∇ Only atrial ∇ Only ventricular ∇ Atrial + ventricular ∇ 3 leads of CRT ∇ Leadless device
Date of most recent implantation of leads*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
If exact date is unknown please document the 1st day of the corresponding month	
Current pacing mode*	∇ VVI ∇ AAI ∇ DDD ∇ CRT ∇ Other

Inclusion visit*

Medical history of AHRE*

First known occurrence of AHRE (date)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Were AHRE associated with symptoms?*	∇ No ∇ Yes ∇ Unknown
Please specify symptoms*	_ _ _ _ _ _ _ _ _ _
English language only!	
Atrial fibrillation symptom score (EHRA)*	∇ EHRA I ∇ EHRA IIa ∇ EHRA IIb ∇ EHRA III ∇ EHRA IV ∇ unknown
The EHRA classification relates specifically to the time when the patient feels to be in the arrhythmia. The EHRA score hereby refers to the symptom qualities palpitations, fatigue, dizziness, dyspnoea, anxiety, and chest pain. One or more of these qualities may be present AND related to AF.	
EHRA I = no symptoms *EHRA IIa = mild symptoms, normal daily activity not affected, symptoms not troublesome for patient* *EHRA IIb = moderate symptoms, normal daily activity not affected, but patient troubled by symptoms* *EHRA III = severe symptoms, normal daily activity affected* *EHRA IV = disabling symptoms, normal daily activity discontinued*	

Medical history*

History of stroke*	∇ Yes ∇ No
Date of last stroke*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
If exact date is unknown please document the 1st day of the corresponding month	
History of TIA*	∇ Yes ∇ No
History of PCI*	∇ Yes ∇ No
Date of last PCI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
If exact date is unknown please document the 1st day of the corresponding month	
History of CABG*	∇ Yes ∇ No
Date of last CABG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
If exact date is unknown please document the 1st day of the corresponding month	
History of heart failure*	∇ Yes ∇ No
History of myocardial infarction*	∇ Yes ∇ No
History of valve replacement*	∇ Yes, tricuspid valve ∇ Yes, mitral valve ∇ Yes, aortic valve ∇ Yes, pulmonal valve ∇ Yes, multiple valves ∇ No
History of atrial fibrillation*	∇ Yes ∇ No
History of ventricular arrhythmias*	∇ Yes ∇ No
History of arterial embolism*	∇ Yes ∇ No
History of venous thrombosis*	∇ Yes ∇ No
History of other cardiovascular diseases*	∇ Yes ∇ No

Other relevant medical history *

Disease*	_ _ _ _ _ _ _ _ _ _
English language only!	

Inclusion visit*

Concomitant diseases*

Cardiomyopathy*	∇ No ∇ Hypertrophic cardiomyopathy ∇ Dilatative cardiomyopathy ∇ Arrhythmogenic right ventricular cardiomyopathy ∇ Other cardiomyopathy
Valvular heart disease* *Only document clinically severe valvular diseases at least requiring specific therapy*	∇ Yes ∇ No
Confirmed coronary artery disease*	∇ Yes ∇ No
Confirmed carotid stenosis (>50% lumen reduction)*	∇ No ∇ Yes, left side ∇ Yes, right side ∇ Yes, both sides
Arterial hypertension*	∇ Yes ∇ No
Diabetes mellitus*	∇ No ∇ Yes, oral antidiabetics ∇ Yes, insulin therapy ∇ Yes, oral antidiabetics AND insulin therapy
Year of diagnosis*	_ _ _ _
Hypercholesterinaemia*	∇ Yes ∇ No
Peripheral arterial vascular disease*	∇ Yes ∇ No
Other relevant concomitant diseases*	∇ Yes ∇ No

Other relevant concomitant diseases*

Disease*	_ _ _ _ _ _ _ _ _

Physical examination*

Height*	_ _ _ cm
Body Mass Index (calculated)*	_ _ . _
Heart failure (NYHA classification)* *I = Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs etc* *II = Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity* *III = Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20–100 m) Comfortable only at rest.* *IV = Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients*	∇ No heart failure ∇ I ∇ II ∇ III ∇ IV
Other important findings of physical examination **English language only!**	_ _ _ _ _ _ _ _ _
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"* **English language only!**	_ _ _ _ _ _ _ _ _

Inclusion visit*

Karnofsky score*	∇ 100% - normal, no complaints, no signs of disease ∇ 90% - capable of normal activity, few symptoms or signs of disease ∇ 80% - normal activity with some difficulty, some symptoms or signs ∇ 70% - caring for self, not capable of normal activity or work ∇ 60% - requiring some help, can take care of most personal requirements ∇ 50% - requires help often, requires frequent medical care ∇ 40% - disabled, requires special care and help ∇ 30% - severely disabled, hospital admission indicated but no risk of death ∇ 20% - very ill, urgently requiring admission, requires supportive measures or treatment ∇ 10% - moribund, rapidly progressive fatal disease processes ∇ 0% - dead ∇ not done

Patient questionnaires*

MoCA (to be performed in a patient interview: please use the forms filed in the site file section 4 for documentation and transcribe the results AFTER the interview into the eCRF)*

Was MoCA test performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Visuospatial / executive (max. 5 points)*	_
Naming (max. 3 points)*	_
Attention (max. 6 points)*	_
Language (max. 3 points)*	_
Abstraction (max. 2 points)*	_
Delayed Recall (max. 5 points)*	_
Orientation (max. 6 points)*	_
≤ 12 years formal education*	∇ Yes ∇ No
MoCA total score (calculated)	_ _

EQ-5D: Please hand out the questionnaire together with a return envelope (site file section 4) to the patient. Data entry of the EQ-5D will be performed at CRI!*

Was the questionnaire handed out to the patient?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	

PACT-Q: Please hand out the questionnaire together with a return envelope (site file section 4) to the patient. Data entry of the PACT-Q will be performed at CRI!*

Was the questionnaire handed out to the patient?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	

Inclusion visit*

12-lead body surface ECG*

Current ECG available?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of ECG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Heart rhythm*	∇ Sinus rhythm ∇ Atrial fibrillation ∇ Continuous pacing ∇ Pacing and AF ∇ Other
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Heart rate*	_ _ _ beats/minute
QRS interval*	_ _ _ ms
PR interval*	_ _ _ ms
QT duration*	_ _ _ _ ms
QTc (calculated)*	_ _ _ ms
Other relevant ECG findings*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Is digital ECG report (e.g. DICOM, HL7 format) available?*	∇ digital ECG report available for upload ∇ only print out available (please fax to CRI) ∇ no ECG report available
Please upload digital ECG*	[Upload file]
Date of ECG upload (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
To be completed by CRI	∇ ECG checked
Date ECG report was faxed to CRI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
ECG print-out (will be up-loaded by CRI)	[Upload file]

Laboratory parameters*

Blood sample for central analysis (20 ml whole blood) => please complete in order to display barcode number!*

Has the patient provided written consent to blood sampling?*	O Yes O No
Blood sample taken for storage in central lab?*	∇ Yes ∇ No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of blood-drawing*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date blood sample shipped*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Inclusion visit*

Please attach barcode labels with the same number as specified below to tubes*

Barcode label to be used (automatically displayed)*	_ _ _ _ _ _ _ _ _ _
In case the specified barcode is not available, please press the button next to the barcode number. Another barcode number will then be assigned.	
Please enter verifier (4 digits)*	_ _ _ _

Laboratory parameters*

Was blood sample taken for local analysis?*	∇ Yes ∇ No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of blood-drawing*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Haemoglobin*	_ _ _ , _ _ [ ]mmol/l [ ]g/dl
Haemoglobin assessment*	O clinically normal O clinically abnormal
Hematocrit*	_ _ , _ _ %
Hematocrit assessment*	O clinically normal O clinically abnormal
Red blood cells*	_ _ , _ [ ]x 10^12/l [ ]x 10^6/µl [ ]/pl
Red blood cell assessment*	O clinically normal O clinically abnormal
MCH (calculated)*	_ _ , _ _ pg
MCHC (calculated)*	_ _ _ , _ g/l
Leucocytes*	_ _ , _ [ ]x 10^9/l [ ]x 1000/µl [ ]/nl
Leucocytes assessment*	O clinically normal O clinically abnormal
Thrombocytes*	_ _ _ [ ]x 10^9/l [ ]x 1000/µl [ ]/nl
Thrombocytes assessment*	O clinically normal O clinically abnormal
INR*	_ _ , _
INR assessment*	O clinically normal O clinically abnormal
aPTT*	_ _ _ , _ sec
aPTT assessment*	O clinically normal O clinically abnormal
ALT (GTP)*	_ _ _ , _ _ [ ]U/l [ ]µkat/l
ALT (GTP) assessment*	O clinically normal O clinically abnormal
AST (GOT)*	_ _ _ , _ _ [ ]U/l [ ]µkat/l
AST (GOT) assessment*	O clinically normal O clinically abnormal
Total bilirubin*	_ _ _ , _ _ [ ]mg/dl [ ]µmol/l
Total bilirubin assessment*	O clinically normal O clinically abnormal
Cholesterol*	_ _ _ , _ _ [ ]mg/dl [ ]mmol/l
Cholesterol assessment*	O clinically normal O clinically abnormal

Concomittant medication*

Generic name*	External Codelist: mc_medication_list
Route of administration*	∇ Oral ∇ Intramuscular ∇ Topical ∇ Sublingual ∇ Inhalation ∇ Intravenous ∇ Intranasal ∇ Parenteral ∇ Subcutaneous ∇ Other
Administered since*	∇ This visit ∇ Up to 1 month ∇ 1 - 3 months ∇ 3 - 6 months ∇ 6 - 12 months ∇ More than 12 months ∇ Unknown
Dosage*	_ _ _ _ _ . _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml

Clinical visit*

Clinical visit base data*

Visit date*

Date of visit*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Please select type of visit*

Visit type*	∇ Clinical visit 12 months ∇ Clinical visit 24 months ∇ Clinical visit 36 months ∇ Clinical visit unscheduled
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	

Follow-up history*

Has the patient reported any adverse event since last visit*	∇ Yes ∇ No
Was AF newly diagnosed since last visit?*	∇ Yes ∇ No
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"*	_ _ _ _ _ _ _ _ _ _
English language only!	
Has patient withdrawn or modified his/her consent?*	∇ Yes ∇ No

Clinical visit*

Study drug*

Compliance with study drug*

Did the patient confirm that she/he has taken study drug regularly?*	∇ No ∇ Yes ∇ Not assessable
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Was intake of study drug temporarily discontinued since last visit?*	∇ Yes, once ∇ Yes, multiple times ∇ No ∇ Not assessable
Only interruptions of at least 8 days have to be documented	
Was intake of study drug permanently stopped since last visit?*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	

Temporary discontinuation of study drugs*

Reason*	∇ AE/SAE ∇ Other reason
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Drug count: only document blisters returned by the patient belonging to the box that was dispensed last visit (single blister(s) belonging to another box must be documented in the respective visit)*

Are box/blisters available for drug count?*	∇ Yes ∇ No
Only blisters of the box that was dispensed at the last "Drug/Device visit" or "Clinical visit" before this visit may be documented here. If the patient returned additional boxes or blisters, that were dispensed earlier in the trial, document its drug count in the visit, directly following its dispense.	
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Medication number of box (7-digit alphanumeric)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Number of days since dispense of this box*	_ _ _ _
Total number of used daily dosages (calculated)*	_ _ _
Total number of unused daily dosages returned by patient (calculated)*	_ _ _
Compliance with study drug (calculated based on number of returned tablets)*	_ _ _ %

Clinical visit*

Drug count for box *	
Blister*	_ _
Status*	O Available, empty O Available, full O Available, partial O Not available
Number of white tablets*	_ _
Number of yellow tablets*	_ _
Reason*	O Lost O Patient forgot at home O Unknown
Contraindications*	
Has the patient developed a new **indication** for edoxaban?*	∇ Yes ∇ No
Has the patient developed a **contraindication** for edoxaban?*	∇ Yes ∇ No
Has the patient developed a contraindication for oral anticoagulation in general?*	∇ Yes ∇ No
Has the patient developed an indication for dual antiplatelet therapy?*	∇ Yes ∇ No
Patient currently has an **indication** for ASA*	∇ Yes ∇ No
Please document "Yes" if an indication exists even if a contraindication prohibits the intake	
Unstable angina pectoris*	∇ Yes ∇ No
Acute myocardial infarction*	∇ Yes ∇ No
Prevention of re-infarction*	∇ Yes ∇ No
After arterial vascular or general surgical interventions (e.g. after CABG or after PTCA)*	∇ Yes ∇ No
For prevention of transitory ischaemic attacks (TIA) and strokes*	∇ Yes ∇ No
Patient currently has a **contraindication** for ASA*	∇ Yes ∇ No
Indication for ASA (calculated)*	∇ Yes ∇ No
In case patient is randomised to edoxaban group, this will not change study medication. In case of usual care group patient, this will add blinded ASA treatment	
Assessment of edoxaban dosage*	
Weight*	_ _ _ , _ kg
Serum creatinine*	_ _ _ , _ _ [ ]mg/dl [ ]µmol/l
Creatinine clearance (calculated)*	_ _ _ , _ _ ml/min
Impaired renal function (calculated)*	∇ Yes ∇ No
defined as creatinine clearance ≤ 50 ml/min	
Current intake of glycoprotein p inhibitors: ketoconazole, ciclosporin, erythromycin or dronedarone*	∇ Yes ∇ No
Recommended dosage of edoxaban for this patient according to SmPC/IB (calculated)*	∇ 30 mg once daily ∇ 60 mg once daily

Clinical visit*

Confirmation of ASA indication and edoxaban dosage*

Can you confirm the suggested status of indication for ASA?*	∇ Yes, ASA administration is indicated for this patient ∇ No, ASA administration is not indicated, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	
Can you confirm the suggested status of indication for ASA?*	∇ Yes, ASA administration is not indicated for this patient ∇ No, ASA administration is indicated, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	
Can you confirm the suggested dosage of edoxaban?*	∇ Yes, 30 mg is the adequate dosage for this patient ∇ No, 60 mg is the adequate dosage for this patient, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	
Can you confirm the suggested dosage of edoxaban?*	∇ Yes, 60 mg is the adequate dosage for this patient ∇ No, 30 mg is the adequate dosage for this patient, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	

Dispensing of medication*

Dispense medication now?*	∇ Yes
Date medication was dispensed to patient	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Medication number to be dispensed (displayed)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
If the displayed medication should be not available for dispense, please immediately contact the NOAH-AFNET6 hotline (+49 89 990 1649 963)	
Please enter verifier (4 digits)*	_ _ _ _
Earliest possible date for next regular visit with regard to amount of study drugs*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Calculated date of next regular visit with regard to randomisation date*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Latest possible date for next regular visit with regard to amount of study drugs*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

AHRE detection*

AHRE upload*

Was AHRE download performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of previous device interrogation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Clinical visit*

Physical examination*

Body Mass Index (calculated)*	_ _ , _
Heart failure (NYHA classification)* *I = Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs etc* *II = Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity* *III = Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20–100 m) Comfortable only at rest.* *IV = Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients*	∇ No heart failure ∇ I ∇ II ∇ III ∇ IV
Other important findings of physical examination **English language only!**	_ _ _ _ _ _ _ _ _
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"* **English language only!**	_ _ _ _ _ _ _ _ _
Karnofsky score*	∇ 100% - normal, no complaints, no signs of disease ∇ 90% - capable of normal activity, few symptoms or signs of disease ∇ 80% - normal activity with some difficulty, some symptoms or signs ∇ 70% - caring for self, not capable of normal activity or work ∇ 60% - requiring some help, can take care of most personal requirements ∇ 50% - requires help often, requires frequent medical care ∇ 40% - disabled, requires special care and help ∇ 30% - severely disabled, hospital admission indicated but no risk of death ∇ 20% - very ill, urgently requiring admission, requires supportive measures or treatment ∇ 10% - moribund, rapidly progressive fatal disease processes ∇ 0% - dead ∇ not done
Modified Rankin Scale* *Grade 0: No symptoms* *Grade I: No significant disability (able to carry out all usual duties, despite some symptoms)* *Grade II: Slight disability (unable to carry out some of previous activities but able to look after own affairs without assistance)* *Grade III: Moderate disability (requiring some help but able to walk without assistance)* *Grade IV: Moderate severe disability (unable to walk without assistance and unable to attend to own bodily needs without assistance)* *Grade V: Severe disability (bedridden, incontinent and requiring constant nursing care and attention)* *Grade VI: Dead*	∇ Grade 0 No Symptoms ∇ Grade I No significant disability ∇ Grade II Slight disability ∇ Grade III Moderate disability ∇ Grade IV Moderate severe disability ∇ Grade V Severe disability ∇ Grade VI Dead ∇ Not done

Clinical visit*

Patient questionnaires*

MoCA (to be performed in a patient interview: please use the forms filed in the site file section 4 for documentation and transcribe the results AFTER the interview into the eCRF)*

Was MoCA test performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Visuospatial / executive (max. 5 points)*	_
Naming (max. 3 points)*	_
Attention (max. 6 points)*	_
Language (max. 3 points)*	_
Abstraction (max. 2 points)*	_
Delayed Recall (max. 5 points)*	_
Orientation (max. 6 points)*	_
≤ 12 years formal education*	∇ Yes ∇ No
MoCA total score (calculated)	_ _

EQ-5D: Please hand out the questionnaire together with a return envelope (site file section 4) to the patient. Data entry of the EQ-5D will be performed at CRI!*

Was the questionnaire handed out to the patient?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	

PACT-Q: Please hand out the questionnaire together with a return envelope (site file section 4) to the patient. Data entry of the PACT-Q will be performed at CRI!*

Was the questionnaire handed out to the patient?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	

12-lead body surface ECG*

12-lead body surface ECG*

Current ECG available?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of ECG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Heart rhythm*	∇ Sinus rhythm ∇ Atrial fibrillation ∇ Continuous pacing ∇ Pacing and AF ∇ Other
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Heart rate*	_ _ _ beats/minute
QRS interval*	_ _ _ ms
PR interval*	_ _ _ ms
QT duration*	_ _ _ _ ms
QTc (calculated)*	_ _ _ ms

Clinical visit*

12-lead body surface ECG*

Other relevant ECG findings*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Is digital ECG report (e.g. DICOM, HL7 format) available?*	∇ digital ECG report available for upload ∇ only print out available (please fax to CRI) ∇ no ECG report available
Please upload digital ECG*	[Upload file]
Date of ECG upload (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
To be completed by CRI	∇ ECG checked
Date ECG report was faxed to CRI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
ECG print-out (will be up-loaded by CRI)	[Upload file]

Laboratory parameters*

Blood sample for central analysis (20 ml whole blood) => please complete in order to display barcode number!*

Has the patient provided written consent to blood sampling?*	O Yes O No
Blood sample taken for storage in central lab?*	∇ Yes ∇ No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of blood-drawing*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date blood sample shipped*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Please attach barcode labels with the same number as specified below to tubes*

Barcode label to be used (automatically displayed)* In case the specified barcode is not available, please press the button next to the barcode number. Another barcode number will then be assigned.	_ _ _ _ _ _ _ _ _ _
Please enter verifier (4 digits)*	_ _ _ _

Clinical visit*

Concomitant medication*

Generic name*	External Codelist: xc_medication_list
Previous dosage*	_ _ _ _ _ _ . _ _ , _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g
Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ . _ _ , _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm
If exact date is unknown please document the 1st day of the corresponding month	

Adverse event*

Adverse event*

Does this AE fulfill a criterion for seriousness?*	O Yes O No
Be aware that the seriousness of an AE is independent of AE intensity *Criteria for seriousness: Event* *- results in death or,* *- is life-threatening or,* *- requires inpatient hospitalisation or prolongation of existing hospitalisation or,* *- results in persistent or significant disability/ incapacity or,* *- is a congenital anomaly / birth defect, or* *- is a medically important event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation, but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).*	
Start date of AE*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Description of AE (diagnosis rather than symptoms)* **English language only!**	_ _ _ _ _ _ _ _ _ _
Intensity of AE*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related
Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify* **English language only!**	_ _ _ _ _ _ _ _ _ _
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)

Adverse event*

Outcome of event* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown
Stopping date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
SAE sequencer (calculated)*	_ _ _ _ _ _ _ _ _ _

Temporary discontinuation of study drugs*

Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Drug/Device visit*

Base data drug/device visit*

Visit date*

Date of visit*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Please select type of visit*

Visit type*	∇ Drug/Device visit 6 months ∇ Drug/Device visit 18 months ∇ Drug/Device visit 30 months ∇ Drug/Device visit 42 months ∇ Drug/Device visit unscheduled

Follow-up history*

Has the patient reported any adverse event since last visit*	∇ Yes ∇ No
Was AF newly diagnosed since last visit?*	∇ Yes ∇ No
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"* **English language only!**	_ _ _ _ _ _ _ _ _ _
Has patient withdrawn or modified his/her consent?*	∇ Yes ∇ No

Drug/Device visit*

Study drug*

Compliance with study drug*

Did the patient confirm that she/he has taken study drug regularly?*	∇ No ∇ Yes ∇ Not assessable
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Was intake of study drug temporarily discontinued since last visit?*	∇ Yes, once ∇ Yes, multiple times ∇ No ∇ Not assessable
Only interruptions of at least 8 days have to be documented	
Was intake of study drug permanently stopped since last visit?*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	

Temporary discontinuation of study drugs*

Reason*	∇ AE/SAE ∇ Other reason
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Drug count: only document blisters returned by the patient belonging to the box that was dispensed last visit (single blister(s) belonging to another box must be documented in the respective visit)*

Are box/blisters available for drug count?*	∇ Yes ∇ No
Only blisters of the box that was dispensed at the last "Drug/Device visit" or "Clinical visit" before this visit may be documented here. If the patient returned additional boxes or blisters, that were dispensed earlier in the trial, document its drug count in the visit, directly following its dispense.	
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Medication number of box (7-digit alphanumeric)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Number of days since dispense of this box*	_ _ _ _
Total number of used daily dosages (calculated)*	_ _ _
Total number of unused daily dosages returned by patient (calculated)*	_ _ _
Compliance with study drug (calculated based on number of returned tablets)*	_ _ _ %

Drug count for box*

Blister*	_ _
Status*	O Available, empty O Available, full O Available, partial O Not available
Number of white tablets*	_ _
Number of yellow tablets*	_ _
Reason*	O Lost O Patient forgot at home O Unknown

Drug/Device visit*

Contraindications*	
Has the patient developed a new **indication** for edoxaban?*	∇ Yes ∇ No
Has the patient developed a **contraindication** for edoxaban?*	∇ Yes ∇ No
Has the patient developed a contraindication for oral anticoagulation in general?*	∇ Yes ∇ No
Has the patient developed an indication for dual antiplatelet therapy?*	∇ Yes ∇ No
Patient currently has an **indication** for ASA*	∇ Yes ∇ No
Please document "Yes" if an indication exists even if a contraindication prohibits the intake	
Unstable angina pectoris*	∇ Yes ∇ No
Acute myocardial infarction*	∇ Yes ∇ No
Prevention of re-infarction*	∇ Yes ∇ No
After arterial vascular or general surgical interventions (e.g. after CABG or after PTCA)*	∇ Yes ∇ No
For prevention of transitory ischaemic attacks (TIA) and strokes*	∇ Yes ∇ No
Patient currently has a **contraindication** for ASA*	∇ Yes ∇ No
Indication for ASA (calculated)*	∇ Yes ∇ No
In case patient is randomised to edoxaban group, this will not change study medication. In case of usual care group patient, this will add blinded ASA treatment	
Assessment of edoxaban dosage*	
Weight*	_ _ _ , _ kg
Serum creatinine*	_ _ _ , _ _ [ ]mg/dl [ ]µmol/l
Creatinine clearance (calculated)*	_ _ _ , _ _ ml/min
Impaired renal function (calculated)*	∇ Yes ∇ No
defined as creatinine clearance ≤ 50 ml/min	
Current intake of glycoprotein p inhibitors: ketoconazole, ciclosporin, erythromycin or dronedarone*	∇ Yes ∇ No
Recommended dosage of edoxaban for this patient according to SmPC/IB (calculated)*	∇ 30 mg once daily ∇ 60 mg once daily
Confirmation of ASA indication and edoxaban dosage*	
Can you confirm the suggested status of indication for ASA?*	∇ Yes, ASA administration is indicated for this patient ∇ No, ASA administration is not indicated, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	
Can you confirm the suggested status of indication for ASA?*	∇ Yes, ASA administration is not indicated for this patient ∇ No, ASA administration is indicated, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	

Drug/Device visit*

Confirmation of ASA indication and edoxaban dosage*

Can you confirm the suggested dosage of edoxaban?*	∇ Yes, 30 mg is the adequate dosage for this patient ∇ No, 60 mg is the adequate dosage for this patient, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	
Can you confirm the suggested dosage of edoxaban?*	∇ Yes, 60 mg is the adequate dosage for this patient ∇ No, 30 mg is the adequate dosage for this patient, contrary to the recommendation
Please provide medical justification*	_ _ _ _ _ _ _ _ _
English language only!	

Dispensing of medication*

Dispense medication now?*	∇ Yes
Date medication was dispensed to patient	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Medication number to be dispensed (displayed)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
If the displayed medication should be not available for dispense, please immediately contact the NOAH-AFNET6 hotline (+49 89 990 1649 963)	
Please enter verifier (4 digits)*	_ _ _ _
Earliest possible date for next regular visit with regard to amount of study drugs*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Calculated date of next regular visit with regard to randomisation date*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Latest possible date for next regular visit with regard to amount of study drugs*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

AHRE detection*

AHRE upload*

Was AHRE download performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of previous device interrogation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Drug/Device visit*

12-lead body surface ECG*

Current ECG available?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of ECG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Heart rhythm*	∇ Sinus rhythm ∇ Atrial fibrillation ∇ Continuous pacing ∇ Pacing and AF ∇ Other
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Heart rate*	_ _ _ beats/minute
QRS interval*	_ _ _ ms
PR interval*	_ _ _ ms
QT duration*	_ _ _ _ ms
QTc (calculated)*	_ _ _ ms
Other relevant ECG findings*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Is digital ECG report (e.g. DICOM, HL7 format) available?*	∇ digital ECG report available for upload ∇ only print out available (please fax to CRI) ∇ no ECG report available
Please upload digital ECG*	[Upload file]
Date of ECG upload (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
To be completed by CRI	∇ ECG checked
Date ECG report was faxed to CRI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
ECG print-out (will be up-loaded by CRI)	[Upload file]

Concomitant medication*

Generic name*	External Codelist: xc_medication_list
Previous dosage*	_ _ _ _ _ _ . _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g
Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ . _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm

Drug/Device visit*

Adverse event*

Adverse event*

Does this AE fulfill a criterion for seriousness?* *Be aware that the seriousness of an AE is independent of AE intensity* *Criteria for seriousness: Event* *- results in death or,* *- is life-threatening or,* *- requires inpatient hospitalisation or prolongation of existing hospitalisation or,* *- results in persistent or significant disability/ incapacity or,* *- is a congenital anomaly / birth defect, or* *- is a medically important event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation, but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).*	O Yes O No
Start date of AE*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Description of AE (diagnosis rather than symptoms)* **English language only!**	_ _ _ _ _ _ _ _ _
Intensity of AE*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related
Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)
Outcome of event* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown
Stopping date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
SAE sequencer (calculated)*	_ _ _ _ _ _ _ _ _

Temporary discontinuation of study drugs*

Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

AF onset*

AF onset form*

In case of AF therapy with blinded study medication should be stopped permanently and other adequate, open-label therapy should be started according to applicable medical guidelines.
Date and reason of discontinuation of study drugs have to be documented in a "Discontinuation of study medication" visit.
Be aware of the fact that overt AF can only reliably be diagnosed by external ECG recordings according to medical guidelines.

AF onset*

Date of first body surface ECG with documentation of AF*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Is digital ECG report (e.g. DICOM, HL7 format) available?*	∇ digital ECG report available for upload ∇ only print out available (please fax to CRI) ∇ no ECG report available
Please upload digital ECG*	[Upload file]
Date of ECG upload (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date ECG report was faxed to CRI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
ECG print-out (will be up-loaded by CRI)	[Upload file]
Mean heart rate during first AF*	_ _ _
To be completed by CRI	∇ ECG checked
Atrial fibrillation symptom score (EHRA)* *The EHRA classification relates specifically to the time when the patient feels to be in the arrhythmia. The EHRA score hereby refers to the symptom qualities palpitations, fatigue, dizziness, dyspnoea, anxiety, and chest pain. One or more of these qualities may be present AND related to AF.* *EHRA I = no symptoms* *EHRA IIa = mild symptoms, normal daily activity not affected, symptoms not troublesome for patient* *EHRA IIb = moderate symptoms, normal daily activity not affected, but patient troubled by symptoms* *EHRA III = severe symptoms, normal daily activity affected* *EHRA IV = disabling symptoms, normal daily activity discontinued*	∇ EHRA I ∇ EHRA IIa ∇ EHRA IIb ∇ EHRA III ∇ EHRA IV ∇ unknown
AF symptom frequency*	∇ Occasional (less than once per month) ∇ Intermediate (once per month - almost daily) ∇ Frequent (at least daily) ∇ unknown

SAE*

SAE*

Base data of SAE*

Criteria for seriousness (choose the most appropriate)* *Definition "other medically important event":* *Report when the event does not fit the other outcomes, but the event may jeopardize the patient and may require medical or surgical intervention (treatment) to prevent one of the other outcomes. Examples include allergic bronchospasm (a serious problem with breathing) requiring treatment in an emergency room, serious blood dyscrasias (blood disorders) or seizures/convulsions that do not result in hospitalization. The development of drug dependence or drug abuse would also be examples of important medical events.*	∇ Death ∇ Life threatening event ∇ Unplanned hospitalisation ∇ Prolongation of existing hospitalisation ∇ Persistent / significant disability or incapacity ∇ Congenital anomaly / birth defect ∇ Other medically important event
Onset of event* In case of death as primary event: date of death	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of notification (i.e. date study staff became aware of SAE)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Type of SAE*	∇ Death as primary event, not death as outcome of another event ∇ Stroke / TIA ∇ Major bleeding (according to ISTH) ∇ Systemic embolism ∇ Other event
Description of SAE (diagnosis rather than symptoms)* **English language only!**	_ _ _ _ _ _ _ _ _
Relation to a hospital stay*	∇ Main reason for hospital admission ∇ Reason for prolongation of existing hospital stay ∇ No hospital stay ∇ No prolongation of existing hospital stay
Date of hospital admission*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Estimated number of additional overnight stays caused by this event*	_ _ _
Intensity of SAE* *Mild - Patient is aware of signs and symptoms but they are easily tolerated Very severe - Signs/symptoms are debilitating, significantly incapacitate patient despite symptomatic therapy Moderate - Signs/symptoms cause sufficient discomfort to interfere with usual activities* *Severe - Patient is incapable to work or perform usual activities Very severe - Signs/symptoms are debilitating, significantly incapacitate patient despite symptomatic therapy*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related
Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify* **English language only!**	_ _ _ _ _ _ _ _ _

SAE*

Base data of SAE*

Outcome of SAE* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown
Stop date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Temporary discontinuation of study drugs*

Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Data on stroke or TIA*

Type of stroke*	∇ TIA ∇ Ischemic stroke (i.e. including events with transient clinical symptoms but with matching lesion on brain imaging) ∇ Haemorrhagic stroke ∇ Subarachnoid haemorrhage ∇ Stroke, other cause ∇ Stroke, unknown cause (i.e. no brain imaging available)
Diagnostic procedures*	O Brain CT O Brain MRI O Other
Please specify* **English language only!**	_ _ _ _ _ _ _ _ _

Interventions*

Interventions related to SAE*

Percutaneous coronary intervention (PCI)*	∇ Yes ∇ No
Date PCI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Coronary bypass surgery (CABG)*	∇ Yes ∇ No
Date CABG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Heart valve surgery or percutaneous valve replacement or repair*	∇ Yes ∇ No
Date heart valve intervention*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Exchange/upgrade of pacemaker, ICD, CRT or any other cardiac device*	∇ Yes ∇ No
Date exchange /upgrade*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Percutaneous cerebrovascular or peripheral intervention*	∇ Yes ∇ No
Date Percutaneous cerebrovascular or peripheral intervention*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Electrical cardioversion for AF or atrial flutter*	∇ Yes ∇ No
Date electrical cardioversion*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Catheter ablation for arrhythmias*	∇ Yes ∇ No
Date ablation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Cerebrovascular surgery or interventions for stroke or bleeding events*	∇ Yes ∇ No
Date surgery / intervention*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Vascular surgery*	∇ Yes ∇ No
Date of vascular surgery*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

SAE*

Interventions related to SAE*

Other interventions*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	

Hospital discharge / death*

Hospital discharge*

Has patient already been discharged?*	∇ Yes ∇ No
Date of hospital discharge*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Data on death as outcome*

Short death narrative*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of death*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of death (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of notification of death (i.e. date study staff became aware of death)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

SAE documents*

Please send copies of following documents to CRI (fax +49 89 / 990 1649-863)*

Discharge letter / final report*	∇ Available and sent to CRI ∇ Available, not sent to CRI yet ∇ Report not yet available ∇ Not performed ∇ Unknown, if performed
Brain CT / MRI*	∇ Available and sent to CRI ∇ Available, not sent to CRI yet ∇ Report not yet available ∇ Not performed ∇ Unknown, if performed
Autopsy report*	∇ Available and sent to CRI ∇ Available, not sent to CRI yet ∇ Report not yet available ∇ Not performed ∇ Unknown, if performed
Other documents*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	

Concomittant medication*

Generic name*	External Codelist: xc_medication_list
Previous dosage*	_ _ _ _ _ _ _ _ _ _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g

Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ _ _ , _ _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm

Discontinuation of study drug visit*

Discontinuation of study drugs*

Discontinuation of study drugs*

Please specify reason for discontinuation of study drug*	∇ Clinical indication for oral anticoagulation (e.g. new diagnosis of over AF) ∇ Contraindication for edoxaban or ASA (as given in the current investigator's brochure) ∇ Contraindication for oral anticoagulation in general ∇ Patient's request (however, patient is still being followed-up in the study) ∇ Patient completely withdraws consent to any further study participation ∇ Death ∇ Other reason
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of discontinuation of study drugs, i.e. patient took last dose of study drug*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Subsequent oral anticoagulation therapy*	∇ Yes, NOAC ∇ Yes, vitamin K antagonist ∇ No oral anticoagulation
Subsequent NOAC*	∇ Apixaban ∇ Dabigatran ∇ Edoxaban ∇ Rivaroxaban

Follow-up history*

Has the patient reported any adverse event since last visit*	∇ Yes ∇ No
Was AF newly diagnosed since last visit?*	∇ Yes ∇ No
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"*	_ _ _ _ _ _ _ _ _ _
English language only!	
Has patient withdrawn or modified his/her consent?*	∇ Yes ∇ No

Discontinuation of study drug visit*

Study drug*

Compliance with study drug*

Did the patient confirm that she/he has taken study drug regularly?*	∇ No ∇ Yes ∇ Not assessable
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Was intake of study drug temporarily discontinued since last visit?*	∇ Yes, once ∇ Yes, multiple times ∇ No ∇ Not assessable
Only interruptions of at least 8 days have to be documented	

Temporary discontinuation of study drugs*

Reason*	∇ AE/SAE ∇ Other reason
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Drug count: only document blisters returned by the patient belonging to the box that was dispensed last visit (single blister(s) belonging to another box must be documented in the respective visit)*

Are box/blisters available for drug count?*	∇ Yes ∇ No
Only blisters of the box that was dispensed at the last "Drug/Device visit" or "Clinical visit" before this visit may be documented here. If the patient returned additional boxes or blisters, that were dispensed earlier in the trial, document its drug count in the visit, directly following its dispense.	
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Medication number of box (7-digit alphanumeric)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Number of days since dispense of this box*	_ _ _ _
Total number of used daily dosages (calculated)*	_ _ _
Total number of unused daily dosages returned by patient (calculated)*	_ _ _
Compliance with study drug (calculated based on number of returned tablets)*	_ _ _ %

Drug count for box*

Blister*	_ _
Status*	O Available, empty O Available, full O Available, partial O Not available
Number of white tablets*	_ _
Number of yellow tablets*	_ _
Reason*	O Lost O Patient forgot at home O Unknown

Discontinuation of study drug visit*

AHRE detection*

AHRE upload*

Was AHRE download performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of previous device interrogation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

12-lead body surface ECG*

12-lead body surface ECG*

Current ECG available?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of ECG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Heart rhythm*	∇ Sinus rhythm ∇ Atrial fibrillation ∇ Continuous pacing ∇ Pacing and AF ∇ Other
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Heart rate*	_ _ _ beats/minute
QRS interval*	_ _ _ ms
PR interval*	_ _ _ ms
QT duration*	_ _ _ _ ms
QTc (calculated)*	_ _ _ ms
Other relevant ECG findings*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Is digital ECG report (e.g. DICOM, HL7 format) available?*	∇ digital ECG report available for upload ∇ only print out available (please fax to CRI) ∇ no ECG report available
Please upload digital ECG*	[Upload file]
Date of ECG upload (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
To be completed by CRI	∇ ECG checked
Date ECG report was faxed to CRI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
ECG print-out (will be up-loaded by CRI)	[Upload file]

Discontinuation of study drug visit*

Concomitant medication*

Generic name*	External Codelist: xc_medication_list
Previous dosage*	_ _ _ _ _ _ . _ _ , _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g
Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ . _ _ , _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm
If exact date is unknown please document the 1st day of the corresponding month	

Adverse event*

Adverse event*

Does this AE fulfill a criterion for seriousness?*	O Yes O No
Be aware that the seriousness of an AE is independent of AE intensity *Criteria for seriousness: Event* *- results in death or,* *- is life-threatening or,* *- requires inpatient hospitalisation or prolongation of existing hospitalisation or,* *- results in persistent or significant disability/ incapacity or,* *- is a congenital anomaly / birth defect, or* *- is a medically important event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation, but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).*	
Start date of AE*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Description of AE (diagnosis rather than symptoms)* **English language only!**	_ _ _ _ _ _ _ _ _ _
Intensity of AE*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related
Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)
Outcome of event* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown

Adverse event*	
Stopping date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Temporary discontinuation of study drugs*	
Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Withdrawal/modification of consent*

Withdrawal / modification of consent base data*

Details regarding withdrawal / modification of consent*	
Kind of change to patient consent* Modification of Patient informed consent =**Patient still consents to use of his/her clinical data obtained in clinical routine and device data, minimal effort FU)** **Complete withdrawal =premature termination of the study**	∇ Patient still consents to use of his/her clinical and device data obtained in clinical routine (=minimal effort FU) ∇ Complete withdrawal of patient informed consent (=premature termination of the study)
When did the patient withdraw / modify his/her consent?*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
How did you learn about the patient's wish to withdraw from the study?*	∇ At a personal visit ∇ During a phone call with the patient ∇ Contact with patient's relative ∇ Letter written by patient ∇ Other
Please specify* **English language only!**	_ _ _ _ _ _ _ _ _
Date of patient's signature on modification of informed consent form*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Reason for premature study termination* **English language only!**	_ _ _ _ _ _ _ _ _
Comment **English language only!**	_ _ _ _ _ _ _ _ _
Follow-up history*	
Has the patient reported any adverse event since last visit*	∇ Yes ∇ No
Was AF newly diagnosed since last visit?*	∇ Yes ∇ No
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"* **English language only!**	_ _ _ _ _ _ _ _ _

Withdrawal/modification of consent*

AHRE detection*

AHRE upload*

Was AHRE download performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of previous device interrogation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Concomittant medication*

Concomitant medication*

Generic name*	External Codelist: `nc_medication_list`
Previous dosage*	_ _ _ _ _ _ _ _ , _ _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g
Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ _ _ , _ _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm

Adverse event*

Adverse event*

Does this AE fulfill a criterion for seriousness?*	O Yes O No
Be aware that the seriousness of an AE is independent of AE intensity *Criteria for seriousness: Event* *- results in death or,* *- is life-threatening or,* *- requires inpatient hospitalisation or prolongation of existing hospitalisation or,* *- results in persistent or significant disability/ incapacity or,* *- is a congenital anomaly / birth defect, or* *- is a medically important event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation, but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).*	
Start date of AE*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Description of AE (diagnosis rather than symptoms)*	_ _ _ _ _ _ _ _ _ _
English language only!	
Intensity of AE*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related

Adverse event*

Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify*	_ _ _ _ _ _ _ _ _
English language only!	
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)
Outcome of event* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown
Stopping date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Temporary discontinuation of study drugs*

Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Minimal effort FU*

Base data*

Visit date*

Date of visit*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Follow-up history*

Has the patient reported any adverse event since last visit*	∇ Yes ∇ No
Was AF newly diagnosed since last visit?*	∇ Yes ∇ No
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"*	_ _ _ _ _ _ _ _ _
English language only!	
Has patient withdrawn or modified his/her consent?*	∇ Yes ∇ No

AHRE detection*

AHRE upload*

Was AHRE download performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _
English language only!	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of previous device interrogation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Minimal effort FU*

Concomittant medication*

Generic name*	External Codelist: xc_medication_list
Previous dosage*	_ _ _ _ _ _ . _ _ , _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g
Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ . _ _ , _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm
If exact date is unknown please document the 1st day of the particular month.	

Adverse event*

Adverse event*

Does this AE fulfill a criterion for seriousness?*	O Yes O No
Be aware that the seriousness of an AE is independent of AE intensity *Criteria for seriousness: Event* *- results in death or,* *- is life-threatening or,* *- requires inpatient hospitalisation or prolongation of existing hospitalisation or,* *- results in persistent or significant disability/ incapacity or,* *- is a congenital anomaly / birth defect, or* *- is a medically important event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation, but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).*	
Start date of AE*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Description of AE (diagnosis rather than symptoms)*	_ _ _ _ _ _ _ _ _ _
English language only!	
Intensity of AE*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related
Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)

Adverse event*

Outcome of event* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown
Stopping date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Temporary discontinuation of study drugs*

Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Final visit*

Base data final visit*

Visit date*

Date of visit*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Visit type final visit*

Type of final contact*	∇ In person visit ∇ Phone visit
Reason* **English language only!**	_ _ _ _ _ _ _ _ _ _

Follow-up history*

Has the patient reported any adverse event since last visit*	∇ Yes ∇ No
Was AF newly diagnosed since last visit?*	∇ Yes ∇ No
Overall heart rhythm*	∇ Sinus rhythm prevails ∇ Atrial fibrillation prevails ∇ Pacing prevails ∇ Pacing and AF ∇ Other
Please specify "other"* **English language only!**	_ _ _ _ _ _ _ _ _ _
Has patient withdrawn or modified his/her consent?*	∇ Yes ∇ No

Final visit*

Study drug*

Compliance with study drug*

Did the patient confirm that she/he has taken study drug regularly?*	∇ No ∇ Yes ∇ Not assessable
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Was intake of study drug temporarily discontinued since last visit?* Only interruptions of at least 8 days have to be documented	∇ Yes, once ∇ Yes, multiple times ∇ No ∇ Not assessable
Was intake of study drug permanently stopped since last visit?*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	

Temporary discontinuation of study drugs*

Reason*	∇ AE/SAE ∇ Other reason
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Drug count: only document blisters returned by the patient belonging to the box that was dispensed last visit (single blister(s) belonging to another box must be documented in the respective visit)*

Are box/blisters available for drug count?* *Only blisters of the box that was dispensed at the last "Drug/Device visit" or "Clinical visit" before this visit may be documented here. If the patient returned additional boxes or blisters, that were dispensed earlier in the trial, document its drug count in the visit, directly following its dispense.*	∇ Yes ∇ No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Medication number of box (7-digit alphanumeric)*	_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Number of days since dispense of this box*	_ _ _ _
Total number of used daily dosages (calculated)*	_ _ _
Total number of unused daily dosages returned by patient (calculated)*	_ _ _
Compliance with study drug (calculated based on number of returned tablets)*	_ _ _ %

Final visit*

Drug count for box*	
Blister*	_ _
Status*	O Available, empty O Available, full O Available, partial O Not available
Number of white tablets*	_ _
Number of yellow tablets*	_ _
Reason*	O Lost O Patient forgot at home O Unknown

AHRE detection*

AHRE upload*	
Was AHRE download performed?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of AHRE download from device*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of previous device interrogation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Please upload digital AHRE records*	[Upload file]
Date of AHRE record upload (calculated)	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

12-lead body surface ECG*

12-lead body surface ECG*	
Current ECG available?*	O Yes O No
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
Date of ECG*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Heart rhythm*	∇ Sinus rhythm ∇ Atrial fibrillation ∇ Continuous pacing ∇ Pacing and AF ∇ Other
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Heart rate*	_ _ _ beats/minute
QRS interval*	_ _ _ ms
PR interval*	_ _ _ ms
QT duration*	_ _ _ _ ms
QTc (calculated)*	_ _ _ ms
Other relevant ECG findings*	∇ Yes ∇ No
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	

Final visit*

12-lead body surface ECG*

Is digital ECG report (e.g. DICOM, HL7 format) available?*	∇ digital ECG report available for upload ∇ only print out available (please fax to CRI) ∇ no ECG report available
Please upload digital ECG*	[Upload file]
Date of ECG upload (calculated)*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Reason*	_ _ _ _ _ _ _ _ _ _
English language only!	
To be completed by CRI	∇ ECG checked
Date ECG report was faxed to CRI*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
ECG print-out (will be up-loaded by CRI)	[Upload file]

Concomittant medication*

Generic name*	External Codelist: `xc_medication_list`
Previous dosage*	_ _ _ _ _ _ _ _ _ _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g
Current status of intake*	∇ Continue ∇ New administration (this visit) ∇ New administration (+date) ∇ Stopped (+date) ∇ Change of dosage ∇ Unknown
Dosage*	_ _ _ _ _ _ _ _ _ _ _ _ [ ]mg [ ]IU [ ]if necessary [ ]µg [ ]g [ ]ml
Date*	_ _ /_ _ /_ _ _ _ _ _ : _ _ mm/dd/yyyy hh:mm
If exact date is unknown please document the 1st day of the particular month.	

Adverse event*

Adverse event*

Does this AE fulfill a criterion for seriousness?*	O Yes O No
Be aware that the seriousness of an AE is independent of AE intensity *Criteria for seriousness: Event* *- results in death or,* *- is life-threatening or,* *- requires inpatient hospitalisation or prolongation of existing hospitalisation or,* *- results in persistent or significant disability/ incapacity or,* *- is a congenital anomaly / birth defect, or* *- is a medically important event (defined as a medical event(s) that may not be immediately life-threatening or result in death or hospitalisation, but based upon appropriate medical and scientific judgment, may jeopardize the patient or may require intervention to prevent one of the other serious outcomes listed in the definition above. Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalisation).*	
Start date of AE*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

Final visit*

Adverse event*	
Description of AE (diagnosis rather than symptoms)*	_ _ _ _ _ _ _ _ _ _
English language only!	
Intensity of AE*	∇ Mild ∇ Moderate ∇ Severe ∇ Very severe
Causal relationship to blinded study drug edoxaban*	∇ related ∇ not related
Causal relationship to blinded study drug ASA*	∇ related ∇ not related
Causal relationship to concomitant therapy / underlying disease*	∇ related ∇ not related
Please specify*	_ _ _ _ _ _ _ _ _ _
English language only!	
Action taken with regard to study drug*	∇ None, i.e. still ongoing ∇ Permanently discontinued due to this event ∇ Temporarily discontinued due to this event ∇ Not applicable (no intake of study drug)
Outcome of event* *Please specify the outcome at the time of documentation and update when new information is available.*	∇ Recovered/resolved ∇ Event ongoing ∇ Recovered/resolved with sequelae ∇ Death ∇ Unknown
Stopping date of event*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Temporary discontinuation of study drugs*	
Date of discontinuation*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy
Date of restart*	_ _ /_ _ /_ _ _ _ mm/dd/yyyy

16.1.3 List of IECs or IRBs - representative written information for patient and sample consent forms

Table 19 List of all IECs and IRBs consulted

Country	IEC/IRB name
Austria	Ethikkommission der Medizinischen Universität Graz
Austria	Ethikkommission der Medizinischen Universität Wien
Austria	EthikKommission der Stadt Wien
Austria	Ethikkommission des Landes Kärnten
Austria	Ethikkommission des Landes Niederösterreich
Austria	Ethikkommission des Landes Niederösterreich
Austria	Ethikkommission für das Bundesland Salzburg
Austria	Johannes Kepler Universität Linz Ethikkommission der MED
Austria	Ethikkommission der Medizinischen Universität Innsbruck
Belgium	Algemeen Ziekenhuis St. Lucas Gent - AZ Maria Middelares
Belgium	AZ Sint-Jan Brugge-Oostende AV
Belgium	Ethische Toetsingscommissie Ziekenhuis Hasselt Committee University Hasselt
Belgium	ZMK, Ziekenhuis maas en Kempen, Ethics Comittee
Belgium	Ethisch Komité Universitair Ziekenhuis Antwerpen
Bulgaria	UMHAT St. Anna AD, Local Ethics Committee
Czech Republic	Ethics Committee of District Hospital Liberec
Czech Republic	Ethic Committee of the General University Hospital in Prague
Denmark	Den Videnskabsetiske Komité for Region Syddanmark, Regionshuset
France	CPP Ile de France VI, Groupe Hospitalier Pitié-Salpêtrière
Germany	Ethikkommission an der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn
Germany	Ethik-Kommission an der Medizinischen Fakultät der Universität Leipzig
Germany	Ethikkommission an der Technischen Universität Dresden
Germany	Ethikkommission an der Universitätsmedizin Greifswald
Germany	Ethikkommission bei der Ärztekammer des Saarlandes
Germany	Ethikkommission bei der Ärztekammer Schleswig-Holstein
Germany	Ethik-Kommission bei der Landesärztekammer Baden-Württemberg
Germany	Ethik-Kommission bei der medizinischen Fakultät der Universität Würzburg
Germany	Ethik-Kommission der Ärztekammer Hamburg
Germany	Ethikkommission der Ärztekammer Niedersachsen
Germany	Ethikkommission der Ärztekammer Nordrhein
Germany	Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Medizinischen Fakultät der Westfälischen Wilhelms-Universität Münster
Germany	Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Medizinischen Fakultät der Westfälischen Wilhelms-Universität Münster
Germany	Ethik-Kommission der Bayerischen Landesärztekammer
Germany	Ethikkommission der Landesärztekammer Brandenburg
Germany	Ethik-Kommission der Landesärztekammer in Hessen

Country	IEC/IRB name
Germany	Ethik-Kommission der Landesärztekammer Rheinland-Pfalz
Germany	Ethikkommission der Med. Fakultät der LMU München
Germany	Ethik-Kommission der Medizinischen Fakultät der Ruhr-Universität Bochum Sitz Ostwestfalen
Germany	Ethik-Kommission der MHH (Medizinische Hochschule Hannover)
Germany	Ethikkommission der sächsischen Landesärztekammer
Germany	Ethikkommission der Universität Ulm
Germany	Ethik-Kommission des Landes Berlin
Germany	Ethikkommission des Landes Sachsen-Anhalt
Germany	Ethikkommission Universität zu Lübeck Medizinische Fakultät des Universitätsklinikums Schleswig-Holstein (UKSH) Lübeck Campus Lübeck
Germany	Medizinische Ethikkommission II der Medizinischen Fakultät Mannheim
Germany	Ethikkommission an der Technischen Universität Dresden
Greece	Ethnikos Organimos Pharmakon (EOF)
Hungary	Medical Research Council
Italy	Comitato Etico per la Sperimentazione Clinica (CESC) della Provincia di Padova
Italy	Comitato Etico Regionale Calabria Sezione Area Centro
Italy	Comitato Etico Regionale della Liguria (Sezione N. 2)
Italy	Comitato Etico Regionale Marche
Italy	Comitato Etico Unico della Provincia di Ferrara
Italy	Comitato Etico indipendente Istituto Clinico Humanitas
Italy	Comitato Etico per la Sperimentazione Clinica (CESC) della Provincia di Padova
Netherlands	Academisch Medisch Centrum Amsterdam
Poland	Okregowa Izba Lekarska w Lodzi
Portugal	National Ethics Committee for Clinical Research
Romania	Bioethics Committee of Medicines and Medical Devices - Medicines for Human Use
Spain	CEIC Hospital Clínic de Barcelona
Sweden	Regionala etikprövningsnämnden i Uppsala
Ukraine	The Ministry of Health of Ukraine
United Kingdom	Health and Social Services Department - Jersey Ethics Committee
United Kingdom	East Midlands - Leicester South Research Ethics Committee

16.1.4 Lists of investigators and other important participants in the study

Table 20 Sites and Investigators

Country	Study centre name	Investigator name
Austria	AT, Uniklinik Innsbruck	Dr. Wolfgang Dichtl
Austria	AT, Wilhelminenspital, Wien	Prof. Kurt Huber
Austria	AT, Uniklinik Graz	Prof. Daniel Scherr
Austria	AT, KHS Elisabethinen, Linz	Dr. Michael Derndorfer
Austria	AT, Uniklinik Krems	Dr. Attilla Mihalcz
Austria	AT, AKH Wien	Prof. Jutta Bergler-Klein
Austria	AT, Uniklinik Salzburg	Prof. Lukas Motloch
Austria	AT, KHS Klagenfurt	Dr. Hannes Alber
Austria	AT, KHS Wiener Neustadt	Dr. Franz Xaver Roithinger
Belgium	BE, Hospital Maria Middelares, Gent	Dr. Frank Provenier
Belgium	BE, Univ.-Hospital Antwerpen, Edegem	Dr. Hielko Miljoen
Belgium	BE, Hospital Maaseik	Dr. Yves Cruysberghs
Belgium	BE, Hospital Jessa Hasselt	Dr. Johan Vijgen
Belgium	BE, Hospital Brugge-Oostende	Dr. Rene Tavernier
Bulgaria	BG, Univ.-Hospital St. Anna, Sofia	Prof. Vasil Velchev
Bulgaria	BG, Hospital Tokuda, Sofia	Dr. Valeri Gelev
Bulgaria	BG, Hospital Stara Zagora	Dr. Borislav Borisov
Bulgaria	BG, Univ.-Hospital Queen Giovanna, Sofia	Dr. Dimitar Markov
Czech Republic	CZ, Univ.-Hospital Prague	Dr. Stepan Havranek
Czech Republic	CZ, Hospital Liberec	Dr. Rostislav Polasek
Denmark	DK, Univ.-Hospital, Aalborg	Dr. Katja Holm
Denmark	DK, Univ.-Hospital, Aarhus	Prof. Jens Cosedis Nielsen
Denmark	DK, Hospital Esbjerg	Dr. Ulrik Hintze
Denmark	DK, Univ.-Hospital Roskilde	Dr. Uffe Gang
Denmark	DK, Hospital Viborg	Dr. Andi Eie Albertsen
France	FR, CHU de Montpellier	Prof. Jean Luc Pasquie
France	FR, CHU Brest	Prof. Jacques Mansourati
France	FR, Hôpital Nantes	Dr. Nelly Amara
France	FR, CHU Brabois, Nancy	Dr. Jean-Marc Sellal
France	FR, CHU European Georges-Pompidou, Paris	Prof. Eloi Marijon
France	FR, Hopital Auxerre	Dr. Francois Jourda
France	FR, Hôpital Bayonne	Dr. Jean Baptiste Berneau
France	FR, CHU Créteil	Prof. Nicolas Lellouche
France	FR, Hôpital Pau	Dr. Nicolas Delarche
France	FR, CHU Poitiers	Dr. Bruno Degand
France	FR, CHU Rangueil, Toulouse	Prof. Philippe Maury
Germany	DE, Uniklinik Würzburg	Dr. Peter Nordbeck
Germany	DE, Uniklinik Charité Campus Mitte, Berlin	Dr. Christoph Schöbel
Germany	DE, KHS St. Vinzenz, Köln	Dr. Sören Fischer
Germany	DE, Herzzentrum Leipzig	Prof. Gerhard Hindricks
Germany	DE, Uniklinik Charité Virchow, Berlin	Dr. Abdul Parwani
Germany	DE, Uniklinik Bonn	Prof. Jan Schrickel
Germany	DE, Herzzentrum Hamburg	Dr. Tobias Tönnis

Country	Study centre name	Investigator name
Germany	DE, Uniklinik Lübeck	Prof. Roland Tilz
Germany	DE, Klinik Augustinum, München	Dr. Daniel Zimmer
Germany	DE, Uniklinik Großhadern, München	Prof. Stefan Kääb
Germany	DE, Uniklinik Mainz	Prof. Thomas Rostock
Germany	DE, Uniklinik Münster	Prof. Lars Eckardt
Germany	DE, KHS Humboldt Klinikum, Berlin	Prof. Steffen Behrens
Germany	DE, KHS Ratzeburg	Dr. Stefan Kuster
Germany	DE, Uniklinik HZ Dresden	Dr. Thomas Gaspar
Germany	DE, Kardiologische Praxis Altona, Hamburg	Dr. Thomas Schröder
Germany	DE, Praxis Dr. Taggeselle, Markkleeberg	Dr. Jens Taggeselle
Germany	DE, Praxis Dr. Bäumer, Köln	Dr. Anselm Bäumer
Germany	DE, Praxis Dr. Prohaska, Mühldorf	Dr. Martin Prohaska
Germany	DE, Praxis Dr. Boscher, Biberach	Dr. Dietmar Boscher
Germany	DE, Klinikum Leverkusen	Dr. Johannes Aring
Germany	DE, KHS HDZ Bad Oeynhausen	Prof. Philipp Sommer
Germany	DE, Cardio Centrum Ludwigsburg-Bietigheim	Dr. Ralph Bosch
Germany	DE, Polikum Friedenau, Berlin	Dr. Felix Pröpper
Germany	DE, Kardiologische Praxis Nienburg	Dr. Kahtan Alkoppa
Germany	DE, Praxis Dr. Stratmann, Dortmund	Dr. Matthias Stratmann
Germany	DE, Cardiologicum Dresden & Pirna	Dr. Christoph Axthelm
Germany	DE, Herz- und Gefäßzentrum Bad Bevensen	Peter Falk
Germany	DE, Uniklinik Greifswald	Dr. Mathias Busch
Germany	DE, Uniklinik Hannover	Dr. David Duncker
Germany	DE, Gemeinschaftspraxis Ebert / Stenzel, Riesa	Dr. Hans-Holger Ebert
Germany	DE, Praxis Dr. Al-Zoebi, Wermsdorf	Dr. Ayham Al-Zoebi
Germany	DE, Praxisgemeinschaft Cardio-Soest	Dr. Siegfried Gerke
Germany	DE, Cardiologicum Hamburg	Prof. Martin Bergmann
Germany	DE, Praxis MVZ Dr. Wilhelm, Dachau	Dr. Karl Wilhelm
Germany	DE, Kardiologie im Friedrichspalais, Bruchsal	Dr. Gerd Ringwald
Germany	DE, Uniklinik Homburg/Saar	Dr. Christian Ukena
Germany	DE, Herzzentrum Lahr	Johannes Härtig
Germany	DE, Uniklinik Mannheim	Dr. Boris Rudic
Germany	DE, KHS Paderborn	Prof. Andreas Götte
Germany	DE, Kardiologische Praxis, Papenburg	Dr. Andreas Wilke
Germany	DE, Uniklinik Ulm	Dr. Tillman Dahme
Germany	DE, Uniklinik Wuppertal	Dr. Armin Sause
Germany	DE, KHS Neuwied	Dr. Burkhard Hügl
Germany	DE, Praxis Remscheid	Dr. Detlev Moll
Germany	DE, Kardiologische Praxis Wittenberg	Dr. Angelika Tamm
Germany	DE, Praxis Dr. Stöhring, Bad Homburg	Dr. Reinhard Stöhring
Germany	DE, KHS Bad Segeberg	Dr. Martin Borlich
Germany	DE, KHS Rüsselsheim	Ehab Shahock
Germany	DE, Praxis Dres. Haggenmiller/Jeserich, Nürnberg	Prof. Michael Jeserich
Germany	DE, Herz- und Gefäßzentrum Göttingen	Dr. Claudius Hansen
Germany	DE, KHS Merseburg	Dr. Roland Prondzinsky

Country	Study centre name	Investigator name
Germany	DE, Herzklinik Ulm	Dr. Ralf Birkemeyer
Germany	DE, Herz- und Gefäßzentrum Siegen	Dr. Ulrich Overhoff
Germany	DE, Herzzentrum Bremen	Dr. Patrick Koppitz
Germany	DE, Uniklinik Leipzig	Dr. Kati Fikenzer
Germany	DE, Klinikum Fulda	Prof. Volker Schächinger
Germany	DE, KHS Cottbus	Dr. Dirk Große-Meininghaus
Greece	GR, Univ.-Hospital, Heraklion	Prof. Emmanuel Simantirakis
Greece	GR, Hospital Thessaloniki	Prof. Vassilis Vassilikos
Hungary	HU, Univ.-Hospital Defence Forces, Budapest	Dr. Gabor Duray
Hungary	HU, Hospital Miskolc	Dr. Gergely G. Nagy
Hungary	HU, Univ.-Hospital Semmelweis, Budapest	Prof. Bela Merkely
Italy	IT, Univ.-Hospital, Padova	Dr. Emanuele Bertaglia
Italy	IT, Univ.-Hospital Ancona	Prof. Antonio Dello Russo
Italy	IT, Hospital Bergamo	Dr. Eduardo Celentano
Italy	IT, Univ.-Hospital Catanzaro	Prof. Ciro Indolfi
Italy	IT, Hospital Modena	Prof. Guiseppe Boriani
Italy	IT, Hospital San Martino, Genova	Dr. Marco Canepa
Italy	IT, Univ.-Hospital St. Anna, Cona	Dr. Matteo Bertini
Italy	IT, Hospital Maggiore, Bologna	Dr. Francesco Pergolini
Italy	IT, Univ.-Hosp. S.Orsola-Malpighi, Bologna	Prof. Igor Diemberger
Netherlands	NL, Hospital Haarlem	Dr. Raymond Tukkie
Netherlands	NL, AMC Amsterdam	Dr. Joris R. De Groot
Netherlands	NL, Hospital Beverwijk	Dr. Iris Westendorp
Netherlands	NL, Univ. - Hospital Nijmegen	Dr. Marc Brouwer
Netherlands	NL, Hospital Den Haag	Dr. Shmaila Saleem-Talib
Netherlands	NL, Hospital Arnhem	Dr. Martin E.W. Hemels
Netherlands	NL, Hospital Gouda	Dr. Reza Alizadeh Dehnavi
Netherlands	NL, Hospital Franciscus, Rotterdam	Dr. Pieter Nierop
Netherlands	NL, Hospital Goes	Dr. Ismail Aksoy
Netherlands	NL, Hospital Roosendaal	Dr. Reinhart Dorman
Netherlands	NL, Hospital Ede	Dr. Thomas Oosterhof
Netherlands	NL, Hospital Dirksland	Dr. Cornelis Kievit
Netherlands	NL, Hospital Blaricum	Dr. Jacobus Plomp
Netherlands	NL, Hospital Doetinchem	Dr. Dirk Schellings
Poland	PL, Univ.-Hospital Warsaw	Prof. Marcin Grabowski
Poland	PL, Practice Lekarska Lodz	Prof. Andrzej Lubinski
Poland	PL, Univ.-Hospital, Katowice	Dr. Rafal Sznajder
Poland	PL, Hospital Rzeszow	Dr. Piotr Futyma
Poland	PL, Heartcenter Sopot	Dr. Pawel Miekus
Poland	PL, Cardiostym Gdynia	Dr. Elzbieta Dulak
Poland	PL, Hospital Provincial Specialist, Lodz	Prof. Jaroslaw Kasprzak
Poland	PL, Hospital Jana Pawła II, Krakow	Dr. Marcin Kuniewicz
Poland	PL, Medical Centre, Chojnice	Dr. Monika Lica Gorzynska
Poland	PL, Medical Centre Bialystok	Prof. Wlodzimierz Musial
Poland	PL, Indywidualna Praktyka Lekarska, Rzeszow	Dr. Marcin Kostkiewicz

Country	Study centre name	Investigator name
Poland	PL, Medical Centre, Zielona Gora	Dr. Pawel Jesionowski
Poland	PL, Hospital Grodzisk Mazowiecki	Dr. Lukasz Pastwa
Poland	PL, Hospital Torun	Dr. Grzegorz Skonieczny
Poland	PL, Univ.-Hospital, Opole	Prof. Marek Gierlotka
Poland	PL, Medical Centre Twoja Przychodnia, Szczecin	Dr. Krzysztof Przybycien
Portugal	PT, Hospital Santarem	Dr. Vitor Paulo Martins
Portugal	PT, Hospital Setubal	Dr. Dinis Mesquita
Romania	RO, Univ.-Hospital Colentina, Bucharest	Dr. Anca Rodica Dan
Romania	RO, Cardiovascular Disease Institute, Targu Mures	Prof. Dan Dobreanu
Romania	RO, Heart Institute, Cluj-Napoca	Dr. Stefan-Horia Rosianu
Spain	ES, Univ.-Hospital Barcelona	Prof. Lluis Mont
Spain	ES, Hospital Del Mar, Barcelona	Dr. Ermengol Valles
Spain	ES, Univ.-Hospital San Carlos Madrid	Dr. Julian Perez-Villacastin
Spain	ES, Univ.-Hospital Granada	Dr. Luis Tercedor
Spain	ES, Hospital Navarra, Pamplona	Dr. Nuria Basterra Sola
Spain	ES, Univ.-Hospital Germans Trias, Badalona	Dr. Roger Villuendas
Spain	ES, Univ.-Hospital Virgen Macarena, Sevilla	Dr. Rafael Hidalgo
Spain	ES, Univ.-Hospital Malaga	Dr. Juan Jose Gomez Doblas
Spain	ES, Univ.-Hospital Murcia	Dr. Francisco Marin
Spain	ES, Univ.-Hospital La Paz, Madrid	Prof. Jose Luis Merino
Spain	ES, Univ.-Hospital Gregorio Maranón, Madrid	Dr. Manuel Martinez-Selles
Spain	ES, Univ.-Hospital, Leon	Dr. Abel Garcia del Egido
Spain	ES, Hospital Vigo	Dr. Pilar Cabanas
Spain	ES, Univ.-Hospital Bellvitge, Barcelona	Dr. Ignasi Anguera
Spain	ES, Univ.-Hospital Santiago	Dr. Javier Garcia Seara
Spain	ES, Univ.-Hospital Consorcio Valencia	Prof. Aurelio Quesada
Spain	ES, Univ.-Hospital La Fe, Valencia	Dr. Joaquin Osca
Spain	ES, Hospital 12 de Octubre, Madrid	Dr. Rafael Salguero Bodes
Spain	ES, Univ.-Hospital Oviedo	Dr. Diego Perez
Spain	ES, Univ.-Hospital Vilanova, Valencia	Dr. Juan Cosin Sales
Spain	ES, Hospital Costa del Sol, Marbella	Dr. Marta Pombo
Sweden	SE, Univ.-Hospital Lund	Prof. Pyotr Platonov
Sweden	SE, Univ.-Hospital Uppsala	Prof. Carina Blomström Lundqvist
Sweden	SE, Univ.-Hospital Örebro	Dr. Anna Bjorkenheim
Sweden	SE, Hospital Helsingborg	Dr. Fredrik Utter
Ukraine	UA, Univ.-Hospital Uzhhorod	Prof. Mykola Rishko
Ukraine	UA, City Hospital, Kiev	Prof. Valerii Batushkin
Ukraine	UA, Hospital Odessa	Prof. Yuriy Karpenko
Ukraine	UA, Hospital Khmelnytskyi	Prof. Andriy Klantsa
Ukraine	UA, Hospital Heart Institute, Kiev	Dr. Gavrylo Kovtun
Ukraine	UA, Hospital Zhytomyr	Dr. Mykola Kushnir
Ukraine	UA, Univ.-Hospital Kharkiv	Prof. Vira Tseluyko
Ukraine	UA, Hospital Feofaniya, Kiev	Dr. Sergiy Veremchuk
Ukraine	UA, Hospital Cherkasy	Dr. Svitlana Zhurba
Ukraine	UA, Hospital Strazhesko, Kiev	Prof. Oleg Sychov

Country	Study centre name	Investigator name
Ukraine	UA, Hospital Zaycev, Kharkiv	Dr. Dmytro Volkov
Ukraine	UA, Hospital Dnipro	Prof. Olena Koval
Ukraine	UA, Hospital Amosov Surgical Treatment, Kiev	Prof. Anatolii Rudenko
Ukraine	UA, Hospital Amosov Arrhythmias, Kiev	Prof. Borys Kravchuk
United Kingdom	GB, Hospital Birmingham	Dr. Abdul Maher
United Kingdom	GB, Hospital Oldham	Dr. Jolanta Sobolewska
United Kingdom	GB, Univ.-Hospital North Middlesex, London	Dr. Ron Simon
United Kingdom	GB, Hospital Musgrove Park, Taunton	Dr. Mark Dayer
United Kingdom	GB, Hospital Chesterfield	Dr. Justin Cooke
United Kingdom	GB, Hospital Eastbourne	Dr. Rick Veasey
United Kingdom	GB, Hospital Glenfield, Leicester	Prof. Ghulam Andre Ng
United Kingdom	GB, Hospital Carlisle	Dr. Jacek Majewski
United Kingdom	GB, Hospital Jersey	Dr. Andrew Mitchell
United Kingdom	GB, Hospital Royal Gwent, Newport	Dr. Philip Campbell
United Kingdom	GB, Hospital Queen Elizabeth, Birmingham	Dr. Joseph De Bono
United Kingdom	GB, Hospital Harefield	Dr. Shouvik Haldar
United Kingdom	GB, Univ.-Hospital Middlesbrough	Dr. Matthew Bates
United Kingdom	GB, Hospital Oxford	Dr. Kim Rajappan
United Kingdom	GB, Hospital Plymouth	Dr. Edward Davies
United Kingdom	GB, Hospital Teaching, Sheffield	Dr. Justin Lee
United Kingdom	GB, Hospital Dundee	Dr. Douglas Elder
United Kingdom	GB, Univ.-Hospital Milton Keynes	Dr. Sudipta Chattopadhyay
United Kingdom	GB, Hospital Wolverhampton	Dr. Anita Arya
United Kingdom	GB, Hospital Dudley	Dr. Craig Barr
United Kingdom	GB, Hospital Worcester	Dr. David Wilson
United Kingdom	GB, Univ.-Hosp. Ilford	Dr. Afzal Sohaib
United Kingdom	GB, Hospital Craigavon	Dr. Andrew J. Moriarty
United Kingdom	GB, Univ.-Hospital West Middlesex, Isleworth	Dr. Fu Siong Ng

Table 21 NOAH - AFNET 6 committee members

N°	Name	Institution	Country
National Coordinators			
1	Wolfgang Dichtl	University Innsbruck, Innsbruck	Austria
2	Andrea Sarkozy	University Ziekenhuis, Antwerpen	Belgium
3	Vasil Velchev	University Hospital St. Anna, Sofia	Bulgaria
4	Dan Wichterle	Institute for Clinical and Medicine (IKEM), Prague	Czech Republic
5	Axel Brandes	University of Southern Denmark, Odense	Denmark
6	Eloi Marijon	European Hospital Pompidou, Paris	France
7	Tobias Tönnis	University Hospital of Hamburg-Eppendorf, Hamburg	Germany
8	Kim Rajappan	Oxford University Hospital, Oxford	Great Britain

9	Emmanuel Simantirakis	University General Hospital PAGNH, Heraklion	Greece
10	Belá Merkely	Semmelweis University Heart and Vascular Center, Budapest	Hungary
11	Emanuele Bertaglia	Azienda Hospital Padova, Padova	Italy
12	Joris de Groot	Academic Medical Center, Amsterdam	The Netherlands
13	Andrzej Lubinski	Clinic Lekarska, Lodz	Poland
14	Nuno Cabanelas	Amadora-Sintra Hospital, Santarem	Portugal
15	Andrei Dan	Hospital Colentina, Bucharest	Romania
16	Carina Blomström Lundqvist	Academic Hospital Uppsala, Uppsala	Sweden
17	Lluis Mont	Hospital Clinic Barcelona	Spain
Steering Committee			
1	Hans Diener	University Duisburg-Essen, Essen	Germany
2	Andreas Götte	St. Vinzenz Hospital, Paderborn	Germany
3	Paulus Kirchhof (Chair)	University Hospital Hamburg-Eppendorf, Hamburg	Germany
4	Matthias Lamparter (non voting)	Daiichi Sankyo Europe GmbH	Germany
5	Antonia Zapf	University Hospital Hamburg-Eppendorf, Hamburg	Germany
6	Melanie Calvert	University of Birmingham, Birmingham	Great Britain
7	Gregory Lip	University of Liverpool, Liverpool	Great Britain
8	A. John Camm	St. George´s Medical School of London, London	Great Britain
9	Panos Vardas	Department of Cardiology, Heraklion University Hospital, Crete	Greece
10	Emmanuel Simantirakis	Department of Cardiology, Heraklion University Hospital, Crete	Greece
11	Gregory Chlouverakis	University of Crete	Greece
Endpoint Review Committee			
1	Timolaos Rizos	University of Heidelberg, Heidelberg	Germany
2	Jan Steffel	Hospital of Hirslanden, Hirslanden	Germany
3	Raffaele De Caterina	University of Pisa, Pisa	Italy
4	Helmut Klein	University of Rochester, New York State	United State of America
Data Safety and Monitoring Board			
1	Jonas Oldgren	University of Uppsala, Uppsala	Finland
2	Marie-Germaine Bousser	Diderot University, Paris	France
3	Jan Tijssen	University of Amsterdam, Amsterdam	Netherlands

Patient's name / date of birth: _____

Patient ID (acc. to MARVIN eCRF): |__|__|__|__|

Study Centre: .....
(Address and phone number)

Investigator: .....
(Name)

Patient Information Sheet

Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
(NOAH– AFNET 6; EudraCT No. 2015-003997-33)

Dear Patient,

We would like to invite you to take part in a clinical trial described below.

Clinical trials are needed to improve existing treatments and find out if new medicines are effective and acceptable for the patients.

In accordance with the legal requirements, the clinical trial presented here called NOAH – AFNET 6 study, has been approved by the competent Ethics Committee and authorised by the relevant competent authority. The NOAH – AFNET 6 study will be conducted in approximately 17 European countries, and it is planned to recruit approximately 2,550 patients. The study is initiated by the Atrial Fibrillation NETwork (Kompetenznetz Vorhofflimmern e.V., AFNET, www.kompetenznetz-vorhofflimmern.de), an academic research association in which scientists and physicians collaborate throughout Europe. AFNET provides the funding and is responsible for this study (sponsor).

Your participation in this clinical trial is voluntary. You will only be included in this trial if you provide your consent in writing. If you decide to not participate in the NOAH – AFNET 6 study, or decide to discontinue your participation at a later point, it will not affect your usual medical care.

You have already been contacted about the planned study. The information provided below explains the aim and course of the study. A study physician will conduct an informed consent discussion with you. Please do not hesitate to ask questions about anything that is not clear to you. You will be given sufficient time to consider whether you would like to take part in this trial.

1. Why is this trial conducted?

Atrial fibrillation (AF), a common type of heart rhythm disorder, presents very often as short episodes (less than an hour to several hours) of an irregular heart rhythm, terminating and recurring spontaneously. AF is often not noticed by patients ("asymptomatic AF"). Symptomatic and asymptomatic AF carries the general risk of increased clotting of blood particles which can subsequently occlude blood vessels in different areas of the body. Thus, AF represents an important underlying disease for stroke, especially so called ischemic stroke (i.e. when a blood vessel carrying blood to the brain is blocked by a blood clot). Patients with additional heart and vessel-related risk factors (e.g. high blood pressure, diabetes, heart muscle weakness [heart failure], age over 75 years) are even more likely to suffer a stroke. It is well known that long-term treatment with so called oral anticoagulant drugs has a beneficial effect for stroke prevention in patients with AF.

AF that is not noticed ("asymptomatic AF") is often not picked up ("silent AF"). Thus, large proportions of AF episodes often go completely unnoticed and thus remain undiagnosed, and many of these patients present with a stroke as the first clinical sign of AF. Earlier detection of AF episodes followed by early initiation of concise oral anticoagulation could prevent such events. However, oral anticoagulation is also associated with a moderately increased risk of bleeding, and that treatment should therefore only be taken if an indication for

preventive anti-clotting therapy, e. g. AF, is given.

Most recent research results gained evidence that even very early stages of AF, so called "atrial high rate episodes" (AHRE), are associated with an increased risk of stroke in follow-up. A sizeable portion of these patients develops overt AF over time. AHREs can only be detected by continuous ECG monitoring of heart rhythm, i.e. by implanted electrical devices recording and reporting heart rhythm continuously.

You are eligible to take part in this trial because you have an implanted pacemaker or defibrillator enabling continuous monitoring of atrial rhythm and your physician detected AHREs in the routine recordings of your device. In addition, you have one or more established risk factors for development of stroke. Research in populations with overt AF demonstrated the beneficial effect of oral anticoagulation for stroke prevention but no data exist to show such benefits in populations presenting with AHRE, the very early stage of AF.

Vitamin K antagonists (VKAs) are routinely used in clinical practice for stroke prevention in patients with AF. However, these bear the risk of important bleeding events and need to be dose-adjusted for each individual depending on blood values taken repetitively. Non-vitamin K antagonist oral anticoagulants (NOACs) have been introduced into clinical practice in recent years as an alternative, appearing safer than VKAs and being administered in a fixed dose, without the necessity of repetitive blood samples and individual adjustment. One of these NOACs, edoxaban, has been approved by health authorities for stroke prevention in patients with AF.

The aim of the NOAH- AFNET 6 study is to demonstrate that long-term oral anticoagulation with edoxaban is superior to the current strategy of no oral anticoagulation in AHRE patients who present with two additional risk factors for stroke.

2. Will I definitely receive the investigational product?

You will be allocated to either “NOAC” group (treatment with edoxaban) or to “Usual Care” group (treatment with no anticoagulation therapy or just with acetylsalicylic acid (ASA), depending on the indication for antiplatelet therapy). This allocation is made in equal proportion for both study groups. To which treatment group you will be allocated will be randomly selected by a computer programme. In order to objectively collect study data, neither you, nor your doctor will know which treatment group you are in (this is called "double-blind"). If for safety reasons it is necessary to find out which treatment group you are in (un-blinding), this can be done immediately.

Because edoxaban and ASA tablets have different appearance, it is necessary to take two tablets one of which is a placebo, respectively (this method is called “double dummy”). A placebo is an identical looking tablet, which, however, contains no active ingredient. The double dummy technique also ensures that no selection or treatment bias will be possible by study physician or study patient.

If you are randomly allocated to “**NOAC” group**, you will be taking two tablets once a day: one tablet containing edoxaban (60 mg) and one tablet of placebo. The edoxaban dose will be reduced to 30 mg if you meet one of the following criteria at the start or during the study: impaired renal function, body weight ≤ 60 kg or necessity of intake of a p-glycoprotein inhibitor (medication avoiding clotting of blood particles).

In case you are randomly allocated to the **“Usual care” group**, you will also be taking two tablets once a day. In case of indication for antiplatelet therapy, one tablet containing ASA and one tablet of placebo. In case of no indication for antiplatelet therapy, you will be taking two tablets of placebo.

If, prior to the study, you have been prescribed ASA for daily intake you will be supplied with corresponding agents in any case and should stop the intake of your previously prescribed brand of ASA.

It is important that you take the study medication as instructed for the entire duration of your participation. Please report any missed doses to your study doctor.

Under certain medical circumstances, your study physician may decide to discontinue study medication. If this happens, your study doctor will discuss your treatment options with you. One example of such situation is diagnosis of overt AF whilst you are participating in this study.

3. What will happen to me in the trial?

Once your written informed consent is taken, your medical history will be recorded, and you will undergo a comprehensive medical examination, according to the usual local clinical practice. This examination will include blood pressure measurement, ECG at rest, and blood sampling (approx. 15 ml) for routine analyses. Additionally your study physician will be conducting a test to assess your attention, concentration and memory using a MoCA test ("Montreal Cognitive Assessment"). You will be asked to assess your current state of health on a scale from 0 ("very poor") to 100 ("excellent") and to complete two questionnaires to ascertain the effects of your heart condition and the effect of study treatment on your quality of life. It is very important for us to understand the effect of your disease and treatment on your quality of life; so that we can provide future patients with information on what they can expect to experience. Because only you truly know how you feel, we would like you to complete the questionnaires without input from family, loved ones or your clinical team.

Answering these questions should take less than 10 minutes.

After this baseline examination three clinical follow-up visits will take place at annual intervals (months 12, 24, and 36) in the hospital/ medical practice of your study physician. At 12 and 24 months visit the examinations will include blood pressure measurement and ECG at rest. In addition, you will again be asked to complete the MoCA test and assess your current state of health on a scale from 0 ("very poor") to 100 ("excellent") as well as to complete the two quality of life questionnaires. During the 36 months visit only physical examination and ECG at rest will be performed. In addition recorded data from your implanted device will be downloaded during all visits in order to assess the number of AHRE that occurred.

In between these clinical follow-up visits, you will attend the hospital/medical practice of your study physician, likewise at annual intervals (months 6, 18, and 30; continued in 6 months intervals after 36-months visit, if necessary) for dispensing of study medication, control of your implanted device and performing an ECG. The number of these "drug/device visits" will depend on the total duration of this clinical trial: in any case you will regularly be followed-up until the end of the entire study. The estimated length of time you will be in the NOAH – AFNET 6 study is somewhere between 12 months and approximately 42 months. At the global end of the study one final visit will be performed to collect unused study drugs and to perform a final assessment of events which might have happened since the previous study visit.

You will be asked to separately consent for two additional blood samples of 20 ml each (to be taken at the initial examination and after 12 months). They will be analysed to gain further insights into the development and classification of atrial fibrillation so as to develop improved treatment options for the future. The blood samples will be stored in a central laboratory (located at Universitäres Herzzentrum Hamburg, Martinistr. 52, 20246 Hamburg, Germany) for analysis at the end of the study. Your blood sample will be analysed in "pseudonymised" form, i.e. without disclosure of your identity. For further scientific analyses your blood samples might also be transferred to other laboratories, which can be located outside of Europe. In these countries rules of data protection can be different from those in Europe.

Except for the "MoCA test", the questionnaires, and the additional blood samples, all examinations stated above would be performed in usual clinical care if you did not participate in this clinical trial.

IMPORTANT: Any other medicines (also those available without prescription) may only be taken after consultation with your study physician. **If you receive treatment from other physicians, you need to inform them about your participation in the NOAH – AFNET 6 study. Inform your study physician as soon as possible of any hospital stay and any medical treatment you receive during your participation in this study.** You will be given a patient card, which you should always carry with you. This patient card contains your patient ID and the phone number of your study physician. Please show this patient card to all other physicians or healthcare professionals treating you.

4. What personal benefit do I get when taking part in the study?

The intake of NOACs reduces the risk for stroke in patients with atrial fibrillation. A similar effect is also expected for patients with AHRE. Therefore, if you are randomly assigned to the "NOAC" group and receive treatment with edoxaban the potential risk of suffering a stroke or a vessel blockage by blood clots might be

reduced. Since the effect of NOACs in the prevention of strokes and vessel blockages in patients with AHRE is not yet proven, it is however possible that you will not benefit from participating in this trial.

If you receive "Usual care" treatment your prospects of treatment will probably not be changed by the participation in this trial in comparison with not taking part.

5. What risks are associated with participating in the study?

There are no additional risks in this study other than those which may occur with therapy in clinical routine treatment for prevention of stroke. Even simple procedures, e.g. blood sampling, may involve undesirable side effects. These may include bruising at the puncture site or infections. However, the overall risks in the study do not exceed the risks of adverse events in routine clinical care.

We have listed the possible side effects of treatment with either edoxaban or ASA in the tables below.

Treatment with edoxaban or ASA may increase the risk of visible or occult bleeding. However, the intensity and extent of bleeding may vary.

Treatment with edoxaban may involve the following side effects as given in the market authorisation documents:

Common	Uncommon	Rare
▪ Abdominal pain ▪ Abnormal liver blood tests ▪ Bleeding from the skin or under the skin ▪ Anaemia ▪ Bleeding from the nose ▪ Bleeding from the vagina ▪ Rash ▪ Bleeding in the bowel ▪ Bleeding from the moth and/or throat ▪ Blood found in your urine ▪ Bleeding following an injury (puncture) ▪ Bleeding in the stomach ▪ Dizziness ▪ Feeling sick ▪ Headache ▪ Itching	▪ Other types of bleeding ▪ Bleeding in the eyes ▪ Bleeding from a surgical wound following an operation ▪ Blood in the spit when coughing ▪ Bleeding in the brain ▪ Reduced number of platelets in your blood (which can affect clotting) ▪ Allergic reaction ▪ Hives	▪ Bleeding in the muscles ▪ Bleeding in joints ▪ Bleeding in the abdomen ▪ Bleeding in the heart ▪ Bleeding into the skull ▪ Bleeding following a surgical procedure

Treatment with ASA may involve the following side effects as given in the market authorisation documents:

Common	Uncommon	Rare	Very rare	Not known
▪ Abdominal pain ▪ Nausea ▪ Vomiting ▪ Diarrhoea ▪ Minor blood loss from the gastrointestinal tract (micro-bleeding)	▪ Skin reaction ▪ Gastrointestinal ulcers ▪ Gastrointestinal inflammations ▪ Iron deficiency anaemia (at prolonged application)	▪ Serious bleeding (e.g. cerebral bleeding) ▪ Hypersensitivity reactions of the skin, respiratory tract (asthma), the gastrointestinal tract, cardiovascular system ▪ Reye´s syndrome	▪ Increase liver values ▪ Renal dysfunction ▪ Acute renal failure ▪ Hypoglycaemia	▪ Narrowing of intestinal space in patients with previous damaged intestinal mucosa

Please immediately notify your study physician or his/her staff of any symptoms, diseases or injuries that occur in the course of the clinical trial. This particularly applies to symptoms perceived to be serious.

6. What other treatment options are available outside the study?

If you do not wish to participate in this clinical trial, your study physician will decide your further treatment taking into consideration the applicable medical guidelines and the market authorisation of the intended drugs. Your refusal to take part in the study will not affect your routine clinical care.

7. Who cannot participate in this clinical trial?

Your physician will discuss with you all possible criteria, which permit the study participation.

In particular you cannot participate in this clinical trial if you are already taking part in other clinical trials or have participated in clinical trials during the last two months.

8. Will I incur any costs as a result of participating in the clinical trial?

By participating in this study, you will not incur any costs beyond those of the regular treatment. Any additional expense allowance will not be provided.

9. Will I be insured during the clinical trial?

To cover for the event of study-related health impairment, you will have insurance coverage within the scope of the insurance terms. The sum insured in the event of a claim is up to EUR xxxxx. This insurance will be taken out based on a statutory obligation for all clinical trials, not because impairment is expected to occur. The insurance coverage will not extend to impairments that are not directly associated with the participation in the clinical trial, such as accidents on the way to and from the study centre.

In order not to jeopardise the insurance coverage, you need to observe the following rules:

a) Except in case of emergency, you may only undergo another medical treatment during this trial after prior consultation with your study physician. You must immediately inform the study physician of any emergency treatment you may receive.
b) If you suspect that your health has been impaired or existing symptoms have worsened as a result of your participation in the clinical trial, you must immediately notify the insurer directly:

Name and address of insurer:	xxxx
	xxxx
Phone:	xxxx
Insurance number:	xxxx

A copy of the insurance terms will be handed out to you.

10. Will I be informed about any new information emerging during the clinical trial?

If any new information emerges that may affect your willingness or ability to continue participation in this trial, you will be immediately informed. You will be given opportunity to discuss the new findings and decide if you wish to continue in the study.

11. Who will decide whether I drop out of the clinical trial?

You may terminate your participation at any time without giving any reasons and without this entailing any disadvantage regarding your medical treatment. If you no longer wish to take part in the NOAH – AFNET 6 study, you will be asked to confirm your decision in writing.

Sometimes clinical trials are stopped early. If this happens, the study physician will discuss your further treatment with you.

If you decide to withdraw from this trial, or your participation has to be stopped for another reason, it is

important that an early final study visit, including the assessments described in section 3, is performed.

Following your withdrawal from the study you will receive routine clinical care.

12. What will happen to my data?

All information about what happens to you during the clinical trial and any relevant information about your medical history will be recorded in secure electronic database

In order to ensure that all data is transferred correctly from your patient file to the trial database, the entries in these documentation sheets will be compared with the original data by authorised staff members of the sponsor and / or the competent regulatory authority or governmental health authorities (*add local health regulatory institution;* European Medicines Agency, as well as other regulatory authorities) and by specially trained employees on behalf of the sponsor obliged to maintain confidentiality, referred to as "monitors" or "auditors". Furthermore, an authorised representative of a domestic and/or foreign regulatory authority or a monitor is permitted to produce copies of the pseudonymised documents. Pseudonymisation means that no personal data, such as your name, but only a numeric code and your year of birth will be used.

All information will be treated as strictly confidential. Your name or other identifying information will not appear in these reported data and/or in any scientific publications that may result from this clinical trial.

The data relevant to the clinical trial will be stored centrally in pseudonymised form and if necessary, forwarded to the above-mentioned authorities for the purpose of revision. CRI, The Clinical Research Institute GmbH, Arnulfstr. 19, 80335 Munich, Germany, on behalf of the sponsor will be responsible for data processing and data quality assurance within the scope of this clinical trial. The person responsible for data processing is Dr. Michael Wolf (phone: +49 89 990 1649-905, email: datenverarbeitung@cri-muc.eu). The statistical evaluation of the data will be carried out in pseudomysed form (i.e. only numeric code without reference to you) at the Department of Biostatistics and Bioinformatics of University of Crete, Gallos Campus, Rethymno, 74100, Greece and the Institute of Medical Biometry and Epidemiology of the University Medical Center Hamburg- Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

The data will be protected against unauthorised access at all times. While handling your data, the data privacy regulations will be observed.

The responsible data protection officers are:

a) for the study centre: .....

.....

.....

b) for the sponsor: Jochen Lutz
Radix GmbH, Datenschutzbeauftragter
Lerchenauer Str. 277, 80995 München, Germany
Telefon: +49 1701894772
E-Mail: datenschutz.afnet@lspost.de

c) for CRI (processor): Jochen Lutz
Radix GmbH, Datenschutzbeauftragter
Lerchenauer Str. 277, 80995 München, Germany
Phone: +49 89 990 1649 771
E-Mail: dataprotection@cri-muc.eu

According to the General Data Protection Regulation you have a right of appeal to a data protection supervisory authority. The bodies responsible for this study are:

a) for the study centre: .....

.....

.....

b) for the sponsor: Landesbeauftragte für Datenschutz und Informationsfreiheit Nordrhein-Westfalen
Kavalleriestraße 2-4, 40213 Düsseldorf, Germany
Postfach 20 04 44, 40102 Düsseldorf, Germany
Phone: +49 211 38 424-0
Email: poststelle@ldi.nrw.de

c) for CRI (processor):

Bayerisches Landesamt für Datenschutzaufsicht (BayLDA)
Promenade 18
91522 Ansbach
Phone: +49 981 180093-0
Homepage: www.lda.bayern.de

For further details, in particular concerning your right to withdraw your consent, please see the declaration of consent attached to this patient information sheet.

13. Who can I contact if I have any further questions?

Consultation at the study centre
You have the opportunity to consult with the study physician or his deputy at any time. The phone number is also printed on your patient card.

Patient ID (acc. to MARVIN-eCRF): |__|__|__|__|



Patient Informed Consent Form

_N_on-vitamin K antagonist _O_ral anticoagulants
in patients with _A_trial _H_igh rate episodes
(NOAH – AFNET 6; EudraCT No. 2015-003997-33)

I have been fully informed about the purpose, procedures, risks and aims of this clinical trial by _____ *(name of physician obtaining consent)* in a personal consultation. I had the opportunity to ask questions, which were answered adequately. I had sufficient time to decide whether to take part in this clinical trial. Furthermore, I have read and understood the written patient information sheet as well as the data privacy policy provided below. I have received a copy of the patient information sheet.

I am aware that my participation is voluntary and that I may withdraw my consent at any time without giving any reasons. This withdrawal will not affect my further treatment.

Data Privacy Policy

I am aware that personal data, in particular my medical findings, will be collected, stored and evaluated in a pseudonymised form as part of this clinical trial. The data will be used in accordance with the statutory provisions and is subject to the following voluntary declaration of consent before participating in the clinical trial; this means that I am not allowed to take part in the clinical trial without providing my consent below.

1. I agree to my personal data, in particular data relating to my state of health, being recorded on paper and on electronic data carriers at the study centre named on page 1 as part of this clinical trial. The data collected may be forwarded in pseudonymised (coded) form to:
   a) CRI – The Clinical Research Institute GmbH for the purpose of data processing
   b) the sponsor of the study, Atrial Fibrillation NETwork (Kompetenznetz Vorhofflimmern e.V., AFNET
   c) the Department of Biostatistics and Bioinformatics of the University Crete and the Institute of Medical Biometry and Epidemiology of the University Medical Center Hamburg- Eppendorf for the purpose of scientific evaluation
   d) in case of undesirable events: to the respective competent Ethics Committee and the competent higher federal authority as well as the European Clinical Trials Database of the European Medicines Agency (EudraCT database)
   e) any by the sponsor delegated institution for data processing or data analysis
   f) independent trial supervision committees for quality assurance.
2. Furthermore, I agree to authorised representatives of the sponsor, who are obliged to maintain confidentiality, as well as the competent regulatory authorities inspecting my personal data stored by the Investigator, in particular data relating to my state of health, if necessary to ensure the proper implementation of the study. I hereby release the study physician from the medical confidentiality for this activity.
3. I have been informed that I can contact the data protection officers mentioned in section 12 in case of any questions and that I have the right to lodge a complaint with a supervisory authority mentioned in section 12.
4. I have been informed that I have the right to receive information (including transfer of a copy free of charge) of my personal data and to request if necessary its correction or deletion.

5. I agree to my data being stored for a period of at least ten years following completion or premature termination of the trial. After this period, my personal data will be deleted, unless this conflicts with legal, regulatory or contractual retention periods.
   In the event that I prematurely terminate my participation in the clinical trial, my data collected by that point in time will, for legal reasons, not be deleted immediately but only on the dates stated above.
6. I understand that I will be asked to complete quality of life questionnaires as part of the study and that these will not be used to directly inform my clinical care.
7. I agree to my general practitioner / attending physician

   .....

   Name

   being informed about my participation in the clinical trial *(please cross out if you do not agree)*.

I hereby agree to participate in the above named clinical trial.

*To be completed by the **patient** personally*

_____	_____	_____
First name, last name (block letters)	Date	Signature

I have conducted the informed consent discussion and obtained the Patient's consent.

*To be completed by the **physician obtaining consent** personally*

_____	_____	_____
First name, last name (block letters)	Date	Signature

Patient ID (acc. to MARVIN-eCRF): |__|__|__|__|



Declaration of Consent to Human Blood Analysis

Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
(NOAH – AFNET 6; EudraCT No. 2015-003997-33)

I have been informed by _____ *(name of physician obtaining consent)* that the above clinical trial will involve the taking of blood samples of 20 ml each as part of the initial and 12 months examination for the purpose of scientific analyses. I had the opportunity to ask questions, which were answered adequately.

I have been informed that the blood samples taken as part of the initial examination and as part of the clinical visit after 12 months will be sent to a central laboratory (located at Universitäres Herzzentrum Hamburg, Martinistr. 52, 20246 Hamburg, Germany) for later analyses and will be stored there for a period of no more than 10 years after completion of the entire study. For further scientific analyses your blood samples might also be transferred to other laboratories, which can be located outside of Europe. In these countries rules of data protection can be different from those in Europe. After the period of 10 years, all samples will be destroyed. These analyses are aimed at gaining further insights into the development of atrial fibrillation so as to develop improved treatment options for the future. I am aware that these analyses will be carried out on pseudonymised samples. I have understood that genetic examinations may also be performed as part of this procedure. These examinations will be performed exclusively with regard to my medical condition.

I have been assured that the sample taken will be used for research, only, not for commercial purposes.

Medical confidentiality will strictly be maintained according to applicable data privacy regulations. I have been informed that some analyses of blood samples might be performed in a non-European country.

I have been informed that I can withdraw my consent at any time without giving reasons.

I agree to the taking, analysis and pseudonymised (i.e. not under my name, only under a study number) storage of the blood sample taken as part of this clinical trial.

*To be completed by the **patient** personally*

_____	_____	_____
First name, last name (block letters)	Date	Signature

*To be completed by the **physician obtaining consent** personally*

_____	_____	_____
First name, last name (block letters)	Date	Signature

16.1.5 Signature of sponsor's responsible medical officer

Signature of Sponsor's Responsible Medical Officer

STUDY TITLE: *N*on-vitamin K antagonist *O*ral anticoagulants in patients with *A*trial *H*igh rate episodes

STUDY NUMBER: NOAH - AFNET 6

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study

SPONSOR'S RESPONSIBLE MEDICAL OFFICER: _____ SIGNATURE _____

AFFILIATION: St. Vincent Hospital

DATE: 30/12/2023

16.1.6 Listing of patients receiving test drug(s)/investigational product(s) from specific batches, where more than one batch was used

Table 22 Assigned medication kit batch numbers per patient

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
48	9	Placebo	ASA indication	RAU156A	15.11.17 10:32	2018-09-01	Edoxaban 60mg / ASA indication
48	9	Placebo	ASA indication	CXZ445E	23.5.18 9:44	2020-01-01	Edoxaban 60mg / ASA indication
48	9	Placebo	ASA indication	MLG627L	15.11.16 10:28	2018-09-01	Edoxaban 60mg / ASA indication
48	9	Placebo	ASA indication	XXX562X	3.5.17 9:05	2018-09-01	Edoxaban 60mg / no ASA indication
75	9	Placebo	ASA indication	YGW554L	17.1.17 10:11	2018-09-01	Edoxaban 30mg / ASA indication
118	9	Placebo	ASA indication	RAE971V	22.3.17 9:21	2018-09-01	Edoxaban 30mg / ASA indication
170	9	Placebo	ASA indication	FAX967X	23.5.17 9:54	2018-09-01	Edoxaban 30mg / ASA indication
192	9	Placebo	ASA indication	BPS534Z	13.6.17 12:08	2018-09-01	Edoxaban 60mg / ASA indication
288	9	Placebo	ASA indication	BKR482X	29.9.17 14:19	2018-09-01	Edoxaban 60mg / ASA indication
434	9	Placebo	ASA indication	ZSR381K	7.2.18 14:03	2018-09-01	Edoxaban 30mg / ASA indication
468	9	Placebo	ASA indication	VWS318M	29.8.19 8:32	2021-12-31	Edoxaban 60mg / ASA indication
468	9	Placebo	ASA indication	KBH415Y	27.2.20 9:05	2021-12-31	Edoxaban 60mg / ASA indication
468	9	Placebo	ASA indication	YTK339E	27.8.20 10:28	2021-12-31	Edoxaban 60mg / ASA indication
468	9	Placebo	ASA indication	UUW823V	28.2.19 9:08	2020-01-01	Edoxaban 60mg / ASA indication
468	9	Placebo	ASA indication	NPK195D	26.8.21 9:01	2022-08-31	Edoxaban 30mg / ASA indication
468	9	Placebo	ASA indication	RFY994W	28.2.18 15:07	2020-01-01	Edoxaban 60mg / ASA indication
468	9	Placebo	ASA indication	HMN653U	23.8.18 8:41	2020-01-01	Edoxaban 60mg / ASA indication
468	9	Placebo	ASA indication	VTS397B	18.2.21 9:40	2022-08-31	Edoxaban 30mg / ASA indication
468	9	Placebo	ASA indication	YCC283F	30.3.22 8:00	2024-11-30	Edoxaban 30mg / ASA indication
561	9	Placebo	ASA indication	LZS596A	19.5.20 9:46	2021-12-31	Edoxaban 60mg / ASA indication
561	9	Placebo	ASA indication	XEV226D	18.6.20 10:10	2022-08-31	Edoxaban 30mg / ASA indication
561	9	Placebo	ASA indication	CUF819A	18.5.18 14:01	2020-01-01	Edoxaban 30mg / ASA indication
561	9	Placebo	ASA indication	MNX392W	23.5.19 9:05	2020-01-01	Edoxaban 30mg / ASA indication
561	9	Placebo	ASA indication	VUE832R	20.11.19 10:51	2022-08-31	Edoxaban 30mg / ASA indication
561	9	Placebo	ASA indication	PAZ825D	20.11.18 10:08	2020-01-01	Edoxaban 30mg / ASA indication
681	9	Placebo	ASA indication	EWU536B	21.8.18 13:04	2020-01-01	Edoxaban 30mg / ASA indication
681	9	Placebo	ASA indication	DDV842C	27.8.20 8:14	2022-08-31	Edoxaban 30mg / ASA indication
681	9	Placebo	ASA indication	YZS239Z	21.2.19 10:36	2020-01-01	Edoxaban 30mg / ASA indication
681	9	Placebo	ASA indication	UYN337N	19.2.20 10:28	2022-08-31	Edoxaban 30mg / ASA indication
681	9	Placebo	ASA indication	RVL694L	22.8.19 9:37	2022-08-31	Edoxaban 30mg / ASA indication
694	9	Placebo	ASA indication	TCE984X	3.9.18 13:32	2020-01-01	Edoxaban 60mg / ASA indication
720	9	Placebo	ASA indication	MBF759S	21.9.18 13:31	2020-01-01	Edoxaban 60mg / ASA indication
758	9	Placebo	ASA indication	ACM389N	22.10.20 9:15	2022-08-31	Edoxaban 30mg / ASA indication
758	9	Placebo	ASA indication	MFX941R	17.3.20 8:11	2022-08-31	Edoxaban 30mg / ASA indication
758	9	Placebo	ASA indication	UEW192A	18.4.19 9:34	2020-01-01	Edoxaban 30mg / ASA indication
758	9	Placebo	ASA indication	GME922H	24.10.19 8:43	2022-08-31	Edoxaban 30mg / ASA indication
758	9	Placebo	ASA indication	ZTM948X	18.10.18 12:55	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
879	9	Placebo	ASA indication	HHX424N	10.12.18 15:14	2020-01-01	Edoxaban 60mg / ASA indication
1192	9	Placebo	ASA indication	BCX886T	16.6.20 10:30	2022-08-31	Edoxaban 30mg / ASA indication
1192	9	Placebo	ASA indication	MDV217F	19.6.19 11:19	2022-08-31	Edoxaban 30mg / ASA indication
1192	9	Placebo	ASA indication	CZH871S	12.12.19 9:55	2022-08-31	Edoxaban 30mg / ASA indication
1204	9	Placebo	ASA indication	FVU514G	19.12.19 11:05	2022-08-31	Edoxaban 30mg / ASA indication
1204	9	Placebo	ASA indication	RWY674V	26.6.19 10:13	2022-08-31	Edoxaban 30mg / ASA indication
1213	9	Placebo	ASA indication	BZG234U	11.7.19 11:24	2022-08-31	Edoxaban 30mg / ASA indication
1259	9	Placebo	ASA indication	RRX869S	25.2.21 8:50	2021-12-31	Edoxaban 60mg / ASA indication
1259	9	Placebo	ASA indication	XMH518T	25.8.20 10:46	2021-12-31	Edoxaban 60mg / ASA indication
1259	9	Placebo	ASA indication	SKB177C	18.8.22 10:02	2024-04-30	Edoxaban 60mg / ASA indication
1259	9	Placebo	ASA indication	WCX769G	27.2.20 10:17	2021-12-31	Edoxaban 60mg / ASA indication
1259	9	Placebo	ASA indication	ACD989P	19.8.21 8:52	2024-04-30	Edoxaban 60mg / ASA indication
1259	9	Placebo	ASA indication	EAP552E	27.8.19 8:23	2021-12-31	Edoxaban 60mg / ASA indication
1259	9	Placebo	ASA indication	GYW933Z	15.2.22 11:22	2024-04-30	Edoxaban 60mg / ASA indication
1600	9	Placebo	ASA indication	HPX614W	28.5.20 9:02	2021-12-31	Edoxaban 60mg / ASA indication
1600	9	Placebo	ASA indication	KLN966N	24.5.22 9:29	2024-04-30	Edoxaban 60mg / ASA indication
1600	9	Placebo	ASA indication	RBZ492Z	26.5.21 9:58	2021-12-31	Edoxaban 60mg / ASA indication
1600	9	Placebo	ASA indication	WGR477S	25.11.21 10:08	2024-04-30	Edoxaban 60mg / ASA indication
1600	9	Placebo	ASA indication	CTK291E	26.11.20 10:36	2021-12-31	Edoxaban 60mg / ASA indication
1641	9	Placebo	ASA indication	CPB231F	6.7.21 7:49	2022-08-31	Edoxaban 30mg / ASA indication
1641	9	Placebo	ASA indication	UEY215Z	5.7.22 8:15	2024-11-30	Edoxaban 30mg / ASA indication
1641	9	Placebo	ASA indication	WGH987M	11.1.22 9:18	2024-04-30	Edoxaban 60mg / ASA indication
1641	9	Placebo	ASA indication	RRR171Y	17.12.20 9:39	2021-12-31	Edoxaban 60mg / ASA indication
1641	9	Placebo	ASA indication	SDR591F	17.6.20 9:16	2022-08-31	Edoxaban 30mg / ASA indication
1817	9	Placebo	ASA indication	KBX916X	8.4.21 9:30	2022-08-31	Edoxaban 30mg / ASA indication
1817	9	Placebo	ASA indication	RAP173K	6.10.20 11:42	2021-12-31	Edoxaban 60mg / ASA indication
1871	9	Placebo	ASA indication	SUC737P	24.5.22 11:04	2024-11-30	Edoxaban 30mg / ASA indication
1871	9	Placebo	ASA indication	KCS352Y	18.11.20 9:26	2022-08-31	Edoxaban 30mg / ASA indication
1871	9	Placebo	ASA indication	URP993V	20.5.21 8:35	2022-08-31	Edoxaban 30mg / ASA indication
1871	9	Placebo	ASA indication	KKS877R	25.11.21 10:10	2022-08-31	Edoxaban 30mg / ASA indication
1974	9	Placebo	ASA indication	AEH767Y	23.2.21 9:56	2022-08-31	Edoxaban 30mg / ASA indication
1974	9	Placebo	ASA indication	AAN234D	26.8.21 8:06	2024-04-30	Edoxaban 60mg / ASA indication
1974	9	Placebo	ASA indication	CRH636B	1.2.22 9:22	2022-08-31	Edoxaban 30mg / ASA indication
1974	9	Placebo	ASA indication	PPC139V	3.8.22 8:28	2024-11-30	Edoxaban 30mg / ASA indication
2221	9	Placebo	ASA indication	AAG442V	12.8.21 7:22	2024-04-30	Edoxaban 60mg / ASA indication
2221	9	Placebo	ASA indication	AAZ896N	15.2.22 9:34	2024-04-30	Edoxaban 60mg / ASA indication
2221	9	Placebo	ASA indication	DHG438H	23.8.22 8:43	2024-04-30	Edoxaban 60mg / ASA indication
2311	9	Placebo	ASA indication	UKB684M	19.10.21 11:05	2022-08-31	Edoxaban 30mg / ASA indication
2311	9	Placebo	ASA indication	YFM222X	12.4.22 9:10	2024-11-30	Edoxaban 30mg / ASA indication
2406	9	Placebo	ASA indication	WHE469C	22.12.21 8:26	2024-04-30	Edoxaban 60mg / ASA indication
2406	9	Placebo	ASA indication	SRZ259D	21.6.22 8:52	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2599	9	Placebo	ASA indication	SSX955Z	28.4.22 8:57	2024-04-30	Edoxaban 60mg / ASA indication
2624	9	Placebo	ASA indication	ZYE669V	24.5.22 8:10	2024-04-30	Edoxaban 60mg / ASA indication
2741	9	Placebo	ASA indication	WLA729U	24.8.22 9:00	2024-04-30	Edoxaban 60mg / ASA indication
92	9	Placebo	no ASA indication	VCN551F	13.2.20 9:11	2021-12-31	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	MGW386D	9.8.18 9:27	2020-01-01	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	ULB176N	8.2.17 13:01	2018-09-01	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	GDP673M	10.8.17 9:08	2018-09-01	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	KUP437S	20.8.20 7:59	2021-12-31	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	CRE646R	14.2.19 10:42	2020-01-01	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	NEL791R	4.3.21 8:35	2021-12-31	Edoxaban 60mg / no ASA indication
92	9	Placebo	no ASA indication	XBS847M	8.8.19 8:25	2021-12-31	Edoxaban 60mg / ASA indication
92	9	Placebo	no ASA indication	XAS914E	31.1.18 10:20	2018-09-01	Edoxaban 60mg / no ASA indication
96	9	Placebo	no ASA indication	PVL654G	31.1.18 10:02	2018-09-01	Edoxaban 60mg / no ASA indication
96	9	Placebo	no ASA indication	ALP682W	9.8.18 9:15	2020-01-01	Edoxaban 60mg / no ASA indication
96	9	Placebo	no ASA indication	FUD797L	8.8.19 8:34	2022-08-31	Edoxaban 30mg / no ASA indication
96	9	Placebo	no ASA indication	LMG232V	10.8.17 10:10	2018-09-01	Edoxaban 60mg / no ASA indication
96	9	Placebo	no ASA indication	UUF219T	10.2.17 10:21	2018-09-01	Edoxaban 60mg / no ASA indication
96	9	Placebo	no ASA indication	YVL345P	14.2.19 11:08	2020-01-01	Edoxaban 30mg / no ASA indication
697	9	Placebo	no ASA indication	WZS932U	5.9.18 14:31	2020-01-01	Edoxaban 30mg / no ASA indication
830	9	Placebo	no ASA indication	VYV944N	19.11.18 14:22	2020-01-01	Edoxaban 30mg / no ASA indication
830	9	Placebo	no ASA indication	WMN449T	14.11.19 10:07	2022-08-31	Edoxaban 30mg / no ASA indication
830	9	Placebo	no ASA indication	WSB751B	16.5.19 10:14	2020-01-01	Edoxaban 30mg / no ASA indication
878	9	Placebo	no ASA indication	TZC477F	10.12.18 14:49	2020-01-01	Edoxaban 60mg / no ASA indication
1570	9	Placebo	no ASA indication	NCB993P	13.10.20 8:15	2021-12-31	Edoxaban 60mg / no ASA indication
1570	9	Placebo	no ASA indication	KPK963M	15.4.21 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
1570	9	Placebo	no ASA indication	FLK942W	14.4.20 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
1570	9	Placebo	no ASA indication	AAW368L	20.10.21 8:55	2024-04-30	Edoxaban 60mg / no ASA indication
1847	9	Placebo	no ASA indication	HEG251R	6.5.21 8:07	2022-08-31	Edoxaban 30mg / no ASA indication
1847	9	Placebo	no ASA indication	XLL976U	18.5.22 8:53	2024-11-30	Edoxaban 30mg / no ASA indication
1847	9	Placebo	no ASA indication	TUA933D	3.11.20 11:45	2022-08-31	Edoxaban 30mg / no ASA indication
1847	9	Placebo	no ASA indication	MBN771V	16.11.21 8:07	2022-08-31	Edoxaban 30mg / no ASA indication
2226	9	Placebo	no ASA indication	LZM447F	15.2.22 9:29	2022-08-31	Edoxaban 30mg / no ASA indication
2226	9	Placebo	no ASA indication	XLW729V	16.8.22 9:02	2024-11-30	Edoxaban 30mg / no ASA indication
2226	9	Placebo	no ASA indication	ZAR455W	17.8.21 7:48	2022-08-31	Edoxaban 30mg / no ASA indication
2403	9	Placebo	no ASA indication	HGP444G	7.6.22 9:13	2024-04-30	Edoxaban 60mg / no ASA indication
2403	9	Placebo	no ASA indication	ABL573Z	21.12.21 9:05	2024-04-30	Edoxaban 60mg / no ASA indication
2408	9	Placebo	no ASA indication	ABK775D	22.12.21 10:29	2024-04-30	Edoxaban 60mg / no ASA indication
2563	9	Placebo	no ASA indication	AAX432K	30.3.22 7:44	2024-04-30	Edoxaban 60mg / no ASA indication
57	9	Edoxaban	ASA indication	FMM471W	6.12.16 12:12	2018-09-01	Edoxaban 30mg / ASA indication
66	9	Edoxaban	ASA indication	CST174H	20.6.17 10:00	2018-09-01	Edoxaban 30mg / ASA indication
66	9	Edoxaban	ASA indication	DWH538C	21.12.16 14:42	2018-09-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
93	9	Edoxaban	ASA indication	FLM186K	31.1.18 9:42	2018-09-01	Edoxaban 60mg / ASA indication
93	9	Edoxaban	ASA indication	NHL621R	8.2.17 14:12	2018-09-01	Edoxaban 60mg / ASA indication
93	9	Edoxaban	ASA indication	PZM667D	10.8.17 8:18	2018-09-01	Edoxaban 60mg / ASA indication
93	9	Edoxaban	ASA indication	NLK576X	9.8.18 9:07	2020-01-01	Edoxaban 30mg / ASA indication
129	9	Edoxaban	ASA indication	AGX155S	29.9.17 9:04	2018-09-01	Edoxaban 60mg / ASA indication
129	9	Edoxaban	ASA indication	XPY336W	31.3.17 8:57	2018-09-01	Edoxaban 60mg / ASA indication
153	9	Edoxaban	ASA indication	MCW885Y	7.11.19 9:44	2022-08-31	Edoxaban 30mg / ASA indication
153	9	Edoxaban	ASA indication	TFW761M	4.5.17 8:34	2018-09-01	Edoxaban 60mg / ASA indication
153	9	Edoxaban	ASA indication	ANK537G	2.5.19 9:14	2020-01-01	Edoxaban 30mg / ASA indication
153	9	Edoxaban	ASA indication	LTK711R	14.5.20 8:28	2021-12-31	Edoxaban 60mg / ASA indication
153	9	Edoxaban	ASA indication	GRU968U	3.5.18 9:27	2020-01-01	Edoxaban 30mg / ASA indication
153	9	Edoxaban	ASA indication	MGT668W	5.11.20 10:08	2022-08-31	Edoxaban 30mg / ASA indication
153	9	Edoxaban	ASA indication	ZDL331F	2.11.17 9:38	2018-09-01	Edoxaban 60mg / ASA indication
153	9	Edoxaban	ASA indication	PGD965T	2.11.18 9:15	2020-01-01	Edoxaban 30mg / ASA indication
237	9	Edoxaban	ASA indication	WZM611L	28.7.17 8:38	2018-09-01	Edoxaban 30mg / ASA indication
393	9	Edoxaban	ASA indication	CAZ699B	12.7.18 9:08	2020-01-01	Edoxaban 30mg / ASA indication
393	9	Edoxaban	ASA indication	DDD492M	9.1.18 11:01	2018-09-01	Edoxaban 30mg / ASA indication
485	9	Edoxaban	ASA indication	WMU352U	13.9.18 9:34	2020-01-01	Edoxaban 30mg / ASA indication
485	9	Edoxaban	ASA indication	NSN675L	15.3.18 13:36	2020-01-01	Edoxaban 30mg / ASA indication
666	9	Edoxaban	ASA indication	KDC657X	17.2.21 10:05	2022-08-31	Edoxaban 30mg / ASA indication
666	9	Edoxaban	ASA indication	RYA472W	20.8.20 8:48	2022-08-31	Edoxaban 30mg / no ASA indication
666	9	Edoxaban	ASA indication	WLA492D	13.2.20 11:16	2022-08-31	Edoxaban 30mg / no ASA indication
666	9	Edoxaban	ASA indication	AEN529W	8.8.19 10:20	2022-08-31	Edoxaban 30mg / no ASA indication
666	9	Edoxaban	ASA indication	SPM725T	15.2.22 9:51	2022-08-31	Edoxaban 30mg / ASA indication
666	9	Edoxaban	ASA indication	PNS819W	16.8.22 9:11	2024-11-30	Edoxaban 30mg / ASA indication
666	9	Edoxaban	ASA indication	HSV191G	14.2.19 11:44	2020-01-01	Edoxaban 30mg / ASA indication
666	9	Edoxaban	ASA indication	CWD165M	13.8.18 13:00	2020-01-01	Edoxaban 30mg / ASA indication
666	9	Edoxaban	ASA indication	NYG748T	26.8.21 8:39	2022-08-31	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	SKW622Y	25.2.21 9:43	2022-08-31	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	YBT829B	24.2.22 9:45	2024-11-30	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	SNL666G	23.8.22 9:17	2024-11-30	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	ANC236G	21.8.18 12:49	2020-01-01	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	DUX233R	22.8.19 8:09	2022-08-31	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	MTC336B	20.2.20 9:44	2022-08-31	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	PMC687P	21.2.19 9:21	2020-01-01	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	NSE112K	25.8.21 8:26	2022-08-31	Edoxaban 30mg / ASA indication
682	9	Edoxaban	ASA indication	PUE695Z	27.8.20 9:06	2022-08-31	Edoxaban 30mg / ASA indication
719	9	Edoxaban	ASA indication	GEH296M	21.3.19 10:57	2020-01-01	Edoxaban 30mg / ASA indication
719	9	Edoxaban	ASA indication	WWF542U	21.9.18 12:15	2020-01-01	Edoxaban 30mg / ASA indication
731	9	Edoxaban	ASA indication	YLW429U	10.10.19 9:32	2021-12-31	Edoxaban 60mg / ASA indication
731	9	Edoxaban	ASA indication	GVK322K	17.3.20 9:04	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
731	9	Edoxaban	ASA indication	PHF334L	6.4.21 10:12	2021-12-31	Edoxaban 60mg / ASA indication
731	9	Edoxaban	ASA indication	ADC466R	19.10.21 8:57	2024-04-30	Edoxaban 60mg / ASA indication
731	9	Edoxaban	ASA indication	ZZF983E	11.4.19 9:35	2020-01-01	Edoxaban 60mg / ASA indication
731	9	Edoxaban	ASA indication	NTN198S	12.4.22 9:28	2024-04-30	Edoxaban 60mg / ASA indication
731	9	Edoxaban	ASA indication	BFZ582X	8.10.20 8:36	2021-12-31	Edoxaban 60mg / ASA indication
731	9	Edoxaban	ASA indication	SVH794S	3.10.18 13:09	2020-01-01	Edoxaban 60mg / ASA indication
843	9	Edoxaban	ASA indication	ZUP552W	23.11.18 11:01	2020-01-01	Edoxaban 60mg / ASA indication
908	9	Edoxaban	ASA indication	UUC388T	28.5.19 12:00	2020-01-01	Edoxaban 60mg / ASA indication
908	9	Edoxaban	ASA indication	SFV965C	26.11.20 10:28	2021-12-31	Edoxaban 60mg / ASA indication
908	9	Edoxaban	ASA indication	HBM862E	21.12.18 8:32	2020-01-01	Edoxaban 60mg / ASA indication
908	9	Edoxaban	ASA indication	NPC993T	28.11.19 10:11	2021-12-31	Edoxaban 60mg / ASA indication
908	9	Edoxaban	ASA indication	VKW576A	26.5.20 8:38	2021-12-31	Edoxaban 60mg / ASA indication
1126	9	Edoxaban	ASA indication	TRD396G	14.11.19 11:56	2022-08-31	Edoxaban 30mg / ASA indication
1126	9	Edoxaban	ASA indication	RYN572M	14.5.19 13:40	2020-01-01	Edoxaban 30mg / ASA indication
1126	9	Edoxaban	ASA indication	HSS647X	14.5.20 11:14	2022-08-31	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	KEW381W	17.11.20 10:06	2022-08-31	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	VVM899H	13.5.20 8:02	2022-08-31	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	TCH716L	6.11.19 10:00	2022-08-31	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	RMH793K	19.5.22 8:12	2024-11-30	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	ANH813Y	19.5.21 8:52	2022-08-31	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	UWR811R	15.5.19 8:04	2020-01-01	Edoxaban 30mg / ASA indication
1127	9	Edoxaban	ASA indication	HNM933Y	17.11.21 10:19	2022-08-31	Edoxaban 30mg / ASA indication
1178	9	Edoxaban	ASA indication	APG446B	17.6.21 11:04	2022-08-31	Edoxaban 30mg / ASA indication
1178	9	Edoxaban	ASA indication	LWC851B	16.6.20 9:27	2022-08-31	Edoxaban 30mg / ASA indication
1178	9	Edoxaban	ASA indication	SLP644V	22.12.20 12:44	2022-08-31	Edoxaban 30mg / ASA indication
1178	9	Edoxaban	ASA indication	MMY724R	12.6.19 8:56	2020-01-01	Edoxaban 30mg / ASA indication
1178	9	Edoxaban	ASA indication	ZWD297Y	12.12.19 12:22	2022-08-31	Edoxaban 30mg / ASA indication
1278	9	Edoxaban	ASA indication	VKD514H	11.9.19 9:04	2022-08-31	Edoxaban 30mg / ASA indication
1338	9	Edoxaban	ASA indication	BWB847T	17.10.19 12:36	2022-08-31	Edoxaban 30mg / ASA indication
1346	9	Edoxaban	ASA indication	XRD247N	23.10.19 8:45	2022-08-31	Edoxaban 30mg / ASA indication
1816	9	Edoxaban	ASA indication	PPP393N	15.4.21 9:22	2021-12-31	Edoxaban 60mg / ASA indication
1816	9	Edoxaban	ASA indication	TTT353W	6.10.20 9:15	2021-12-31	Edoxaban 60mg / ASA indication
1961	9	Edoxaban	ASA indication	EEK482R	16.2.21 9:56	2021-12-31	Edoxaban 60mg / ASA indication
1961	9	Edoxaban	ASA indication	CGK439S	8.2.22 9:57	2022-08-31	Edoxaban 30mg / ASA indication
1961	9	Edoxaban	ASA indication	ACC299P	12.8.21 9:57	2024-04-30	Edoxaban 60mg / ASA indication
1961	9	Edoxaban	ASA indication	NSL178L	9.8.22 10:22	2024-04-30	Edoxaban 60mg / ASA indication
2044	9	Edoxaban	ASA indication	DSA428D	14.4.21 8:15	2021-12-31	Edoxaban 60mg / ASA indication
2044	9	Edoxaban	ASA indication	SRH664C	21.10.21 9:29	2022-08-31	Edoxaban 30mg / ASA indication
2044	9	Edoxaban	ASA indication	YAF712N	26.4.22 9:59	2024-11-30	Edoxaban 30mg / ASA indication
2210	9	Edoxaban	ASA indication	BSK957B	10.5.22 9:51	2024-04-30	Edoxaban 60mg / ASA indication
2210	9	Edoxaban	ASA indication	ADG924U	23.11.21 9:34	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2333	9	Edoxaban	ASA indication	ABY338U	9.11.21 9:41	2024-04-30	Edoxaban 60mg / ASA indication
2333	9	Edoxaban	ASA indication	EKW136C	10.5.22 10:25	2024-04-30	Edoxaban 60mg / ASA indication
2421	9	Edoxaban	ASA indication	ZCX256V	4.8.22 9:02	2024-04-30	Edoxaban 60mg / ASA indication
2421	9	Edoxaban	ASA indication	BUG737L	11.1.22 8:40	2024-04-30	Edoxaban 60mg / ASA indication
2479	9	Edoxaban	ASA indication	GHG667P	15.2.22 11:15	2024-04-30	Edoxaban 60mg / ASA indication
2479	9	Edoxaban	ASA indication	WFL885S	23.8.22 10:13	2024-04-30	Edoxaban 60mg / ASA indication
46	9	Edoxaban	no ASA indication	HGZ427W	3.5.17 8:59	2018-09-01	Edoxaban 30mg / ASA indication
46	9	Edoxaban	no ASA indication	XEC127Z	6.6.19 9:38	2020-01-01	Edoxaban 30mg / ASA indication
46	9	Edoxaban	no ASA indication	TXV653B	23.5.18 9:31	2020-01-01	Edoxaban 30mg / no ASA indication
46	9	Edoxaban	no ASA indication	UVH363Z	13.5.20 11:02	2022-08-31	Edoxaban 30mg / ASA indication
46	9	Edoxaban	no ASA indication	ZER959G	21.11.19 9:30	2022-08-31	Edoxaban 30mg / ASA indication
46	9	Edoxaban	no ASA indication	XXZ897W	10.11.16 10:28	2018-09-01	Edoxaban 30mg / no ASA indication
46	9	Edoxaban	no ASA indication	PUM339R	15.11.17 10:02	2018-09-01	Edoxaban 30mg / no ASA indication
46	9	Edoxaban	no ASA indication	LEU214U	29.11.18 9:20	2020-01-01	Edoxaban 30mg / ASA indication
54	9	Edoxaban	no ASA indication	WLC579M	22.11.18 11:38	2020-01-01	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	HCE253D	25.5.18 13:05	2020-01-01	Edoxaban 60mg / no ASA indication
54	9	Edoxaban	no ASA indication	BZN882X	26.11.20 11:05	2021-12-31	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	NNF189Z	23.5.19 10:39	2020-01-01	Edoxaban 60mg / no ASA indication
54	9	Edoxaban	no ASA indication	ZBC449L	9.6.22 7:47	2024-04-30	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	EXL813Y	4.6.20 8:33	2021-12-31	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	RGE472P	2.6.21 9:16	2021-12-31	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	NAF825Z	21.11.19 10:50	2021-12-31	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	HKE661Y	13.12.17 10:18	2018-09-01	Edoxaban 60mg / no ASA indication
54	9	Edoxaban	no ASA indication	ZPP834N	24.11.16 14:31	2018-09-01	Edoxaban 60mg / no ASA indication
54	9	Edoxaban	no ASA indication	WZM613K	22.12.21 10:04	2024-04-30	Edoxaban 60mg / ASA indication
54	9	Edoxaban	no ASA indication	LLE138A	30.5.17 9:59	2018-09-01	Edoxaban 60mg / no ASA indication
100	9	Edoxaban	no ASA indication	PVP556V	16.8.17 9:30	2018-09-01	Edoxaban 60mg / no ASA indication
100	9	Edoxaban	no ASA indication	AYN147B	17.2.17 11:27	2018-09-01	Edoxaban 60mg / no ASA indication
410	9	Edoxaban	no ASA indication	DFW345K	18.1.18 14:08	2018-09-01	Edoxaban 60mg / no ASA indication
536	9	Edoxaban	no ASA indication	TXX925R	25.10.18 9:14	2020-01-01	Edoxaban 30mg / ASA indication
536	9	Edoxaban	no ASA indication	RGU637U	25.4.18 13:47	2020-01-01	Edoxaban 30mg / no ASA indication
536	9	Edoxaban	no ASA indication	MVH161Z	25.4.19 8:01	2020-01-01	Edoxaban 30mg / ASA indication
1692	9	Edoxaban	no ASA indication	LLU224F	21.1.21 10:42	2021-12-31	Edoxaban 60mg / no ASA indication
1692	9	Edoxaban	no ASA indication	MMM784S	16.7.20 9:10	2021-12-31	Edoxaban 60mg / no ASA indication
1879	9	Edoxaban	no ASA indication	PLR893M	8.6.21 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
1879	9	Edoxaban	no ASA indication	SYL982K	24.11.20 11:58	2021-12-31	Edoxaban 60mg / no ASA indication
1879	9	Edoxaban	no ASA indication	AGA462D	7.12.21 11:34	2024-04-30	Edoxaban 60mg / no ASA indication
1879	9	Edoxaban	no ASA indication	HPP975T	14.6.22 7:23	2024-04-30	Edoxaban 60mg / no ASA indication
1897	9	Edoxaban	no ASA indication	PRF529X	8.6.21 8:25	2021-12-31	Edoxaban 60mg / no ASA indication
1897	9	Edoxaban	no ASA indication	AGD286W	15.12.21 7:10	2024-04-30	Edoxaban 60mg / no ASA indication
1897	9	Edoxaban	no ASA indication	TPA582W	9.12.20 10:12	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1897	9	Edoxaban	no ASA indication	BXF879W	14.6.22 8:37	2024-04-30	Edoxaban 60mg / no ASA indication
2297	9	Edoxaban	no ASA indication	ABN539V	5.10.21 9:28	2024-04-30	Edoxaban 60mg / no ASA indication
2615	9	Edoxaban	no ASA indication	ABX813V	17.5.22 8:24	2024-04-30	Edoxaban 60mg / no ASA indication
2700	9	Edoxaban	no ASA indication	HNS813L	7.7.22 7:17	2024-04-30	Edoxaban 60mg / no ASA indication
1582	12	Placebo	ASA indication	DNS995P	11.5.20 9:35	2022-08-31	Edoxaban 30mg / ASA indication
1701	12	Placebo	ASA indication	RGG717T	22.7.20 11:29	2021-12-31	Edoxaban 60mg / ASA indication
1701	12	Placebo	ASA indication	TNC655Y	29.1.21 10:49	2021-12-31	Edoxaban 60mg / ASA indication
1787	12	Placebo	ASA indication	HMV312S	17.9.20 9:41	2021-12-31	Edoxaban 60mg / ASA indication
2622	12	Placebo	ASA indication	BWK748A	20.5.22 11:54	2024-04-30	Edoxaban 60mg / ASA indication
2684	12	Placebo	ASA indication	BVR367T	1.7.22 10:05	2024-04-30	Edoxaban 60mg / ASA indication
2708	12	Placebo	ASA indication	BUU951R	11.7.22 12:07	2024-04-30	Edoxaban 60mg / ASA indication
1687	12	Placebo	no ASA indication	WKT116X	14.7.20 9:07	2022-08-31	Edoxaban 30mg / no ASA indication
1698	12	Placebo	no ASA indication	CYW722D	21.7.20 7:45	2021-12-31	Edoxaban 60mg / no ASA indication
1760	12	Placebo	no ASA indication	GAV196Z	9.3.21 11:27	2022-08-31	Edoxaban 30mg / no ASA indication
1760	12	Placebo	no ASA indication	FYG217F	14.9.21 11:45	2022-08-31	Edoxaban 30mg / no ASA indication
1760	12	Placebo	no ASA indication	EKE157D	8.9.20 10:16	2022-08-31	Edoxaban 30mg / no ASA indication
1775	12	Placebo	no ASA indication	MRF248S	14.9.20 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
1581	12	Edoxaban	ASA indication	BVC658X	8.5.20 10:04	2022-08-31	Edoxaban 30mg / ASA indication
1706	12	Edoxaban	ASA indication	LHX776W	24.7.20 7:49	2022-08-31	Edoxaban 30mg / ASA indication
1752	12	Edoxaban	ASA indication	UFY366P	2.9.20 10:57	2021-12-31	Edoxaban 60mg / ASA indication
1752	12	Edoxaban	ASA indication	LEG146T	2.3.21 9:48	2022-08-31	Edoxaban 30mg / no ASA indication
1761	12	Edoxaban	ASA indication	KNL985N	9.3.21 12:57	2022-08-31	Edoxaban 30mg / ASA indication
1761	12	Edoxaban	ASA indication	YFB997K	8.3.22 11:39	2024-11-30	Edoxaban 30mg / ASA indication
1761	12	Edoxaban	ASA indication	BTD664A	8.9.20 11:19	2022-08-31	Edoxaban 30mg / ASA indication
1761	12	Edoxaban	ASA indication	KGA733D	14.9.21 10:45	2022-08-31	Edoxaban 30mg / ASA indication
1651	12	Edoxaban	no ASA indication	CZE672G	17.12.20 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
1651	12	Edoxaban	no ASA indication	PNN298V	19.6.20 10:03	2021-12-31	Edoxaban 60mg / no ASA indication
1658	12	Edoxaban	no ASA indication	BPV563F	21.6.21 10:51	2024-04-30	Edoxaban 60mg / no ASA indication
1658	12	Edoxaban	no ASA indication	MUS813K	24.6.20 10:03	2021-12-31	Edoxaban 60mg / no ASA indication
1658	12	Edoxaban	no ASA indication	YZW742F	14.6.22 11:14	2024-04-30	Edoxaban 60mg / no ASA indication
1658	12	Edoxaban	no ASA indication	BZS497S	22.12.20 7:57	2021-12-31	Edoxaban 60mg / no ASA indication
1658	12	Edoxaban	no ASA indication	BPN126L	15.12.21 11:15	2024-04-30	Edoxaban 60mg / no ASA indication
1789	12	Edoxaban	no ASA indication	BML719G	17.9.20 10:11	2022-08-31	Edoxaban 30mg / no ASA indication
2608	12	Edoxaban	no ASA indication	XDG131A	6.5.22 10:47	2024-04-30	Edoxaban 60mg / no ASA indication
2649	12	Edoxaban	no ASA indication	BPP222H	9.6.22 11:12	2024-04-30	Edoxaban 60mg / no ASA indication
1269	16	Placebo	ASA indication	ZVT752K	11.8.20 10:17	2022-08-31	Edoxaban 30mg / ASA indication
1269	16	Placebo	ASA indication	UWN991T	18.2.20 11:11	2022-08-31	Edoxaban 30mg / ASA indication
1269	16	Placebo	ASA indication	HMM814P	29.8.19 14:14	2022-08-31	Edoxaban 30mg / ASA indication
148	16	Placebo	no ASA indication	STR272S	3.5.17 12:17	2018-09-01	Edoxaban 30mg / no ASA indication
1165	16	Edoxaban	ASA indication	AUX484Y	9.6.20 6:54	2021-12-31	Edoxaban 60mg / ASA indication
1165	16	Edoxaban	ASA indication	PNG886F	14.12.21 11:01	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1165	16	Edoxaban	ASA indication	YBS637W	11.6.19 11:17	2020-01-01	Edoxaban 60mg / ASA indication
1165	16	Edoxaban	ASA indication	PNH523S	7.6.22 7:25	2024-04-30	Edoxaban 60mg / ASA indication
1165	16	Edoxaban	ASA indication	CXZ473X	8.6.21 7:58	2021-12-31	Edoxaban 60mg / ASA indication
1165	16	Edoxaban	ASA indication	VAT316D	3.12.19 7:49	2021-12-31	Edoxaban 60mg / ASA indication
1165	16	Edoxaban	ASA indication	YUY891X	8.12.20 9:15	2022-08-31	Edoxaban 30mg / ASA indication
1179	16	Edoxaban	ASA indication	KUC232Y	9.6.20 7:56	2021-12-31	Edoxaban 60mg / ASA indication
1179	16	Edoxaban	ASA indication	NZB329X	9.6.20 9:14	2022-08-31	Edoxaban 30mg / ASA indication
1179	16	Edoxaban	ASA indication	HFU311Y	8.12.20 9:51	2021-12-31	Edoxaban 60mg / ASA indication
1179	16	Edoxaban	ASA indication	ATW666P	21.12.21 11:15	2022-08-31	Edoxaban 30mg / ASA indication
1179	16	Edoxaban	ASA indication	YHD574D	7.6.22 8:29	2024-11-30	Edoxaban 30mg / ASA indication
1179	16	Edoxaban	ASA indication	NRH548G	13.6.19 7:45	2020-01-01	Edoxaban 30mg / ASA indication
1179	16	Edoxaban	ASA indication	ATB465K	10.12.19 10:26	2022-08-31	Edoxaban 30mg / ASA indication
1179	16	Edoxaban	ASA indication	WMH158R	8.6.21 9:37	2021-12-31	Edoxaban 60mg / ASA indication
385	16	Edoxaban	no ASA indication	XNV868Y	8.1.18 8:54	2018-09-01	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	GMC452V	15.12.20 9:42	2022-08-31	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	VTL465C	16.12.21 16:18	2022-08-31	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	FVK863K	10.7.18 6:40	2020-01-01	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	WSL572R	22.1.19 10:51	2020-01-01	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	VXC473N	23.7.19 10:07	2022-08-31	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	VZK329W	7.1.20 8:36	2022-08-31	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	NZG611S	7.7.20 7:26	2022-08-31	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	VTR211R	15.6.21 9:39	2022-08-31	Edoxaban 30mg / no ASA indication
385	16	Edoxaban	no ASA indication	YLE385F	14.6.22 7:22	2024-11-30	Edoxaban 30mg / no ASA indication
440	16	Edoxaban	no ASA indication	WZV395H	10.7.18 9:16	2020-01-01	Edoxaban 60mg / no ASA indication
440	16	Edoxaban	no ASA indication	ZRT633R	6.9.18 12:45	2020-01-01	Edoxaban 60mg / no ASA indication
440	16	Edoxaban	no ASA indication	PNG853U	13.2.18 10:16	2018-09-01	Edoxaban 60mg / no ASA indication
1033	16	Edoxaban	no ASA indication	EXR432B	25.3.19 7:45	2020-01-01	Edoxaban 60mg / no ASA indication
446	17	Placebo	ASA indication	EAN699C	25.2.20 13:43	2021-12-31	Edoxaban 60mg / no ASA indication
446	17	Placebo	ASA indication	BAU348H	26.8.19 8:45	2021-12-31	Edoxaban 60mg / ASA indication
446	17	Placebo	ASA indication	PSL781D	2.9.21 12:55	2024-04-30	Edoxaban 60mg / no ASA indication
446	17	Placebo	ASA indication	CHE245H	4.9.18 6:53	2020-01-01	Edoxaban 60mg / ASA indication
446	17	Placebo	ASA indication	REP382D	19.2.19 15:07	2020-01-01	Edoxaban 60mg / ASA indication
446	17	Placebo	ASA indication	KME979Y	15.2.18 11:02	2018-09-01	Edoxaban 60mg / ASA indication
446	17	Placebo	ASA indication	HRA228R	13.8.20 12:47	2021-12-31	Edoxaban 60mg / no ASA indication
446	17	Placebo	ASA indication	RSU845V	23.2.21 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
1598	17	Placebo	no ASA indication	MAU979Z	31.5.21 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
1598	17	Placebo	no ASA indication	PSL137A	17.5.22 10:33	2024-04-30	Edoxaban 60mg / no ASA indication
1598	17	Placebo	no ASA indication	HFX648L	27.5.20 12:36	2021-12-31	Edoxaban 60mg / no ASA indication
1598	17	Placebo	no ASA indication	PSL945P	30.11.21 9:39	2024-04-30	Edoxaban 60mg / no ASA indication
1598	17	Placebo	no ASA indication	RZT441M	16.11.20 8:23	2021-12-31	Edoxaban 60mg / no ASA indication
364	17	Edoxaban	ASA indication	GXE439W	6.12.17 14:03	2018-09-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
409	17	Edoxaban	no ASA indication	FFV111Y	18.1.21 13:50	2021-12-31	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	NXN915F	7.1.19 16:10	2020-01-01	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	FGW152G	20.1.20 14:23	2021-12-31	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	MXW439N	18.1.18 11:28	2018-09-01	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	EAA611S	8.7.19 12:50	2021-12-31	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	PNF689N	12.7.21 8:39	2024-04-30	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	BZU728T	30.7.20 6:50	2021-12-31	Edoxaban 60mg / no ASA indication
409	17	Edoxaban	no ASA indication	NFM631L	25.6.18 13:49	2020-01-01	Edoxaban 60mg / no ASA indication
263	19	Placebo	ASA indication	HFE389N	24.8.17 8:27	2018-09-01	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	XHF445D	27.5.20 11:39	2021-12-31	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	PMB525N	1.6.22 12:33	2024-04-30	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	HSG223E	20.6.18 14:53	2020-01-01	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	YRH488B	9.6.21 14:30	2021-12-31	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	NND717Y	20.11.19 13:29	2021-12-31	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	RGZ824R	29.5.19 14:24	2020-01-01	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	HBT189B	19.12.18 13:23	2020-01-01	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	PMT453B	8.12.21 12:26	2024-04-30	Edoxaban 60mg / ASA indication
600	19	Placebo	ASA indication	FAM256U	25.11.20 13:06	2021-12-31	Edoxaban 60mg / ASA indication
120	19	Placebo	no ASA indication	EYD791G	19.9.18 12:49	2020-01-01	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	PFA274H	16.9.20 11:36	2022-08-31	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	GME169T	23.9.19 11:37	2022-08-31	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	EVL672H	21.3.18 14:14	2020-01-01	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	ZBF918B	7.9.22 13:59	2024-11-30	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	FGS616P	17.3.21 13:00	2022-08-31	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	SXN114T	22.3.17 15:15	2018-09-01	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	YMP316X	9.3.22 11:13	2024-11-30	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	RPK273K	22.9.21 11:34	2022-08-31	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	KHT871V	13.9.17 12:54	2018-09-01	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	HVG229K	27.3.19 13:51	2020-01-01	Edoxaban 30mg / no ASA indication
120	19	Placebo	no ASA indication	ZYF391V	18.3.20 10:39	2022-08-31	Edoxaban 30mg / no ASA indication
203	19	Edoxaban	ASA indication	TBK742M	20.12.17 10:51	2018-09-01	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	WWR547F	6.6.18 9:32	2020-01-01	Edoxaban 60mg / no ASA indication
203	19	Edoxaban	ASA indication	KYT391C	16.12.19 8:59	2021-12-31	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	WGC262C	8.6.20 7:25	2021-12-31	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	FGD664P	13.6.22 8:11	2024-04-30	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	CDC391S	17.6.19 9:55	2020-01-01	Edoxaban 30mg / ASA indication
203	19	Edoxaban	ASA indication	KSV172L	27.6.17 11:27	2018-09-01	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	PPS327E	13.12.21 8:37	2024-04-30	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	FAU238P	17.12.18 9:43	2020-01-01	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	WGK911F	7.6.21 7:32	2021-12-31	Edoxaban 60mg / ASA indication
203	19	Edoxaban	ASA indication	AMM475W	14.12.20 8:38	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
329	19	Edoxaban	ASA indication	SYP623V	24.10.18 13:52	2020-01-01	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	CGD434A	28.10.20 12:49	2021-12-31	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	VPT517M	7.5.18 9:23	2020-01-01	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	PSU594A	24.11.21 14:01	2024-04-30	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	WFY886R	6.5.21 10:33	2021-12-31	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	PCN358V	23.10.19 11:39	2022-08-31	Edoxaban 30mg / ASA indication
329	19	Edoxaban	ASA indication	PSB378P	18.5.22 13:16	2024-04-30	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	ERT555T	7.11.17 10:58	2018-09-01	Edoxaban 60mg / ASA indication
329	19	Edoxaban	ASA indication	PPH278D	24.4.19 13:14	2020-01-01	Edoxaban 30mg / ASA indication
329	19	Edoxaban	ASA indication	ZBW222X	22.4.20 7:34	2022-08-31	Edoxaban 30mg / ASA indication
1633	19	Edoxaban	ASA indication	CTM151U	16.6.20 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1633	19	Edoxaban	ASA indication	LGC471D	15.6.21 7:58	2021-12-31	Edoxaban 60mg / ASA indication
1633	19	Edoxaban	ASA indication	AYV891Z	15.12.20 7:59	2021-12-31	Edoxaban 60mg / ASA indication
340	19	Edoxaban	no ASA indication	HVU128K	3.5.18 9:30	2020-01-01	Edoxaban 30mg / no ASA indication
340	19	Edoxaban	no ASA indication	MUG188U	7.5.20 7:02	2022-08-31	Edoxaban 30mg / no ASA indication
340	19	Edoxaban	no ASA indication	LRH226D	5.11.18 9:49	2020-01-01	Edoxaban 30mg / no ASA indication
340	19	Edoxaban	no ASA indication	NWH762X	16.11.17 10:18	2018-09-01	Edoxaban 30mg / no ASA indication
340	19	Edoxaban	no ASA indication	YHU286N	2.5.19 8:30	2020-01-01	Edoxaban 30mg / no ASA indication
340	19	Edoxaban	no ASA indication	ZFY224M	7.11.19 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
805	19	Edoxaban	no ASA indication	MGY838S	8.11.18 10:55	2020-01-01	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	GWV888K	2.5.19 8:01	2020-01-01	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	VAN785B	12.11.20 10:00	2021-12-31	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	AXK462D	6.5.21 8:58	2021-12-31	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	EVU291U	7.11.19 10:11	2021-12-31	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	KNE287N	7.5.20 8:08	2021-12-31	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	PNH614K	5.5.22 8:41	2024-04-30	Edoxaban 60mg / no ASA indication
805	19	Edoxaban	no ASA indication	PNG128V	18.11.21 9:49	2024-04-30	Edoxaban 60mg / no ASA indication
624	22	Edoxaban	ASA indication	FAL459H	10.1.19 8:45	2020-01-01	Edoxaban 60mg / ASA indication
624	22	Edoxaban	ASA indication	GGZ454S	11.7.18 9:31	2020-01-01	Edoxaban 60mg / ASA indication
504	23	Placebo	ASA indication	KDC321Y	9.10.19 14:30	2022-08-31	Edoxaban 30mg / ASA indication
504	23	Placebo	ASA indication	WGN784P	17.4.19 8:19	2020-01-01	Edoxaban 30mg / ASA indication
504	23	Placebo	ASA indication	ZMA513N	2.10.20 13:51	2022-08-31	Edoxaban 30mg / ASA indication
504	23	Placebo	ASA indication	XTX648H	4.10.18 8:35	2020-01-01	Edoxaban 30mg / ASA indication
504	23	Placebo	ASA indication	DYL553R	3.10.18 8:52	2020-01-01	Edoxaban 60mg / ASA indication
504	23	Placebo	ASA indication	PUD989C	28.3.18 12:24	2020-01-01	Edoxaban 30mg / ASA indication
504	23	Placebo	ASA indication	FAX195C	20.3.20 9:35	2022-08-31	Edoxaban 30mg / ASA indication
692	23	Placebo	ASA indication	TEA749D	6.3.19 8:58	2020-01-01	Edoxaban 30mg / ASA indication
692	23	Placebo	ASA indication	GYE421R	11.3.20 9:45	2022-08-31	Edoxaban 30mg / ASA indication
692	23	Placebo	ASA indication	CGA248H	31.8.18 10:03	2020-01-01	Edoxaban 30mg / ASA indication
692	23	Placebo	ASA indication	SHM445M	11.9.19 15:19	2022-08-31	Edoxaban 30mg / ASA indication
692	23	Placebo	ASA indication	NFK411Y	18.8.21 7:34	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
692	23	Placebo	ASA indication	KTK967K	25.8.20 9:57	2022-08-31	Edoxaban 30mg / ASA indication
692	23	Placebo	ASA indication	NVT141W	25.2.21 15:09	2022-08-31	Edoxaban 30mg / ASA indication
234	23	Edoxaban	ASA indication	CNS167M	27.7.18 7:44	2020-01-01	Edoxaban 30mg / ASA indication
234	23	Edoxaban	ASA indication	LDW588V	24.1.18 8:42	2018-09-01	Edoxaban 30mg / ASA indication
234	23	Edoxaban	ASA indication	AFU363R	26.7.17 6:34	2018-09-01	Edoxaban 30mg / ASA indication
265	23	Edoxaban	ASA indication	WHM296V	31.8.17 12:19	2018-09-01	Edoxaban 60mg / ASA indication
265	23	Edoxaban	ASA indication	PSY597P	30.8.18 8:51	2020-01-01	Edoxaban 60mg / ASA indication
265	23	Edoxaban	ASA indication	WSU617E	14.2.18 13:56	2018-09-01	Edoxaban 60mg / no ASA indication
122	23	Edoxaban	no ASA indication	TSP727U	24.3.17 7:35	2018-09-01	Edoxaban 60mg / no ASA indication
150	33	Placebo	ASA indication	NED494D	8.11.17 13:44	2018-09-01	Edoxaban 30mg / ASA indication
150	33	Placebo	ASA indication	FKX871D	9.5.18 13:00	2020-01-01	Edoxaban 30mg / ASA indication
150	33	Placebo	ASA indication	ZGN691D	6.5.20 10:23	2022-08-31	Edoxaban 30mg / ASA indication
150	33	Placebo	ASA indication	GNH739E	3.5.17 13:34	2018-09-01	Edoxaban 60mg / ASA indication
150	33	Placebo	ASA indication	HXY536R	13.11.18 10:10	2020-01-01	Edoxaban 30mg / ASA indication
150	33	Placebo	ASA indication	BHS963U	4.11.20 10:34	2021-12-31	Edoxaban 60mg / ASA indication
150	33	Placebo	ASA indication	VZG942R	14.5.19 11:09	2020-01-01	Edoxaban 30mg / ASA indication
150	33	Placebo	ASA indication	VUE282U	12.11.19 9:23	2022-08-31	Edoxaban 30mg / ASA indication
216	33	Placebo	ASA indication	YCY831A	10.1.18 8:06	2018-09-01	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	YWZ983M	8.1.20 8:22	2021-12-31	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	BXN464C	12.1.22 8:51	2024-04-30	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	AVD335B	4.7.18 9:08	2020-01-01	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	XAT965L	9.1.19 10:48	2020-01-01	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	ZHX256K	10.7.17 7:35	2018-09-01	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	DZL459A	3.7.19 7:21	2021-12-31	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	BWR493S	15.6.22 8:25	2024-04-30	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	BWP578A	7.7.21 8:42	2024-04-30	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	CXY532R	7.7.20 7:48	2021-12-31	Edoxaban 60mg / ASA indication
216	33	Placebo	ASA indication	UPD847A	13.1.21 8:15	2021-12-31	Edoxaban 60mg / ASA indication
1413	33	Placebo	ASA indication	RED413B	27.5.20 9:50	2022-08-31	Edoxaban 30mg / ASA indication
1413	33	Placebo	ASA indication	ZYS789W	25.5.22 9:23	2024-11-30	Edoxaban 30mg / ASA indication
1413	33	Placebo	ASA indication	ETD524G	24.11.21 9:46	2022-08-31	Edoxaban 30mg / ASA indication
1413	33	Placebo	ASA indication	KZL946S	26.5.21 9:17	2022-08-31	Edoxaban 30mg / ASA indication
1413	33	Placebo	ASA indication	BTH194N	18.11.20 10:51	2022-08-31	Edoxaban 30mg / ASA indication
1413	33	Placebo	ASA indication	KVW749Y	27.11.19 13:05	2022-08-31	Edoxaban 30mg / ASA indication
221	33	Placebo	no ASA indication	KVW589M	23.1.18 10:56	2018-09-01	Edoxaban 60mg / no ASA indication
221	33	Placebo	no ASA indication	USK741T	15.1.19 10:54	2020-01-01	Edoxaban 60mg / no ASA indication
221	33	Placebo	no ASA indication	ENP976N	11.7.17 10:37	2018-09-01	Edoxaban 30mg / no ASA indication
221	33	Placebo	no ASA indication	RPH474N	14.1.20 10:21	2022-08-31	Edoxaban 30mg / no ASA indication
221	33	Placebo	no ASA indication	LBN636H	19.1.21 8:36	2022-08-31	Edoxaban 30mg / no ASA indication
221	33	Placebo	no ASA indication	MLC255Z	11.1.22 9:45	2022-08-31	Edoxaban 30mg / no ASA indication
221	33	Placebo	no ASA indication	GME954F	16.7.19 10:05	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
221	33	Placebo	no ASA indication	APA857H	14.7.20 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
221	33	Placebo	no ASA indication	KNX755S	17.7.18 8:11	2020-01-01	Edoxaban 30mg / no ASA indication
221	33	Placebo	no ASA indication	BMM872X	15.7.21 12:19	2024-04-30	Edoxaban 60mg / no ASA indication
221	33	Placebo	no ASA indication	ZTH893P	7.7.22 10:19	2024-11-30	Edoxaban 30mg / no ASA indication
235	33	Edoxaban	ASA indication	GSN535A	26.7.17 14:07	2018-09-01	Edoxaban 60mg / ASA indication
235	33	Edoxaban	ASA indication	DGH652Z	24.7.19 11:12	2021-12-31	Edoxaban 60mg / ASA indication
235	33	Edoxaban	ASA indication	LMY288S	30.1.19 13:49	2020-01-01	Edoxaban 60mg / ASA indication
235	33	Edoxaban	ASA indication	CDH696U	1.8.18 12:54	2020-01-01	Edoxaban 60mg / ASA indication
235	33	Edoxaban	ASA indication	XLB774V	31.1.18 13:00	2018-09-01	Edoxaban 60mg / no ASA indication
1206	33	Edoxaban	ASA indication	DAC673S	17.12.19 10:04	2022-08-31	Edoxaban 30mg / ASA indication
1206	33	Edoxaban	ASA indication	LRT814K	27.6.19 10:27	2022-08-31	Edoxaban 30mg / ASA indication
1378	33	Edoxaban	ASA indication	ATF677X	20.11.19 11:54	2021-12-31	Edoxaban 60mg / ASA indication
442	34	Placebo	ASA indication	BZH658K	13.2.18 13:52	2018-09-01	Edoxaban 30mg / ASA indication
59	35	Placebo	ASA indication	DEF533F	8.12.16 10:39	2018-09-01	Edoxaban 30mg / ASA indication
453	35	Placebo	ASA indication	CGN929K	21.2.18 8:45	2020-01-01	Edoxaban 30mg / ASA indication
260	35	Edoxaban	no ASA indication	ZDH781D	22.8.17 9:23	2018-09-01	Edoxaban 30mg / no ASA indication
260	35	Edoxaban	no ASA indication	ZZM475C	7.3.18 8:44	2020-01-01	Edoxaban 60mg / no ASA indication
566	38	Placebo	ASA indication	LTN662V	23.5.18 13:30	2020-01-01	Edoxaban 60mg / ASA indication
414	38	Placebo	no ASA indication	GSS222P	24.1.18 14:27	2018-09-01	Edoxaban 60mg / no ASA indication
305	38	Edoxaban	no ASA indication	BBP655N	17.10.17 10:01	2018-09-01	Edoxaban 30mg / no ASA indication
1351	39	Placebo	ASA indication	GKC976G	25.10.19 13:57	2021-12-31	Edoxaban 60mg / ASA indication
1391	39	Placebo	ASA indication	HMP349G	25.11.19 15:00	2022-08-31	Edoxaban 30mg / ASA indication
2005	39	Placebo	no ASA indication	KSB256X	11.3.21 15:19	2021-12-31	Edoxaban 60mg / no ASA indication
2005	39	Placebo	no ASA indication	BPF651V	13.9.21 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
1186	39	Edoxaban	ASA indication	LAV137V	18.12.19 15:16	2022-08-31	Edoxaban 30mg / no ASA indication
1186	39	Edoxaban	ASA indication	CMX955H	18.6.19 13:05	2020-01-01	Edoxaban 30mg / ASA indication
300	40	Placebo	ASA indication	LED383G	5.10.18 7:36	2020-01-01	Edoxaban 60mg / ASA indication
300	40	Placebo	ASA indication	YYZ382U	10.4.18 7:32	2020-01-01	Edoxaban 60mg / ASA indication
300	40	Placebo	ASA indication	RZV234C	16.10.17 8:54	2018-09-01	Edoxaban 60mg / ASA indication
300	40	Placebo	ASA indication	EVY184S	27.3.19 9:25	2020-01-01	Edoxaban 60mg / ASA indication
861	40	Edoxaban	no ASA indication	CPK318S	3.12.18 14:23	2020-01-01	Edoxaban 30mg / no ASA indication
2013	42	Placebo	ASA indication	CLV977R	10.9.21 7:18	2024-04-30	Edoxaban 60mg / ASA indication
2013	42	Placebo	ASA indication	RTE243H	15.3.22 9:45	2024-04-30	Edoxaban 60mg / ASA indication
2013	42	Placebo	ASA indication	SKZ613M	16.3.21 11:38	2021-12-31	Edoxaban 60mg / ASA indication
2122	42	Placebo	ASA indication	XXW927X	19.5.22 10:40	2024-04-30	Edoxaban 60mg / ASA indication
2122	42	Placebo	ASA indication	RSU367Y	26.5.21 9:29	2021-12-31	Edoxaban 60mg / ASA indication
2122	42	Placebo	ASA indication	YRZ996C	17.11.21 11:40	2024-04-30	Edoxaban 60mg / ASA indication
2219	42	Placebo	ASA indication	NHR599F	10.2.22 13:35	2024-04-30	Edoxaban 60mg / ASA indication
2219	42	Placebo	ASA indication	NWH963T	9.8.22 10:41	2024-04-30	Edoxaban 60mg / ASA indication
2219	42	Placebo	ASA indication	FFA346X	10.8.21 9:50	2022-08-31	Edoxaban 30mg / ASA indication
2296	42	Placebo	ASA indication	RTM285H	1.4.22 8:34	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2296	42	Placebo	ASA indication	CMK294T	1.10.21 10:17	2024-04-30	Edoxaban 60mg / ASA indication
2439	42	Placebo	ASA indication	YSG515G	20.1.22 12:57	2024-04-30	Edoxaban 60mg / ASA indication
2439	42	Placebo	ASA indication	XXD889R	27.6.22 11:35	2024-04-30	Edoxaban 60mg / ASA indication
2443	42	Placebo	ASA indication	CLY211B	24.1.22 11:43	2024-04-30	Edoxaban 60mg / ASA indication
2443	42	Placebo	ASA indication	NHF921Z	22.7.22 8:41	2024-04-30	Edoxaban 60mg / ASA indication
2250	42	Placebo	no ASA indication	BWM759K	30.8.21 10:46	2024-04-30	Edoxaban 60mg / no ASA indication
2250	42	Placebo	no ASA indication	DPS383F	3.3.22 13:21	2024-11-30	Edoxaban 30mg / no ASA indication
2376	42	Placebo	no ASA indication	DNN325H	7.6.22 8:00	2024-11-30	Edoxaban 30mg / no ASA indication
2376	42	Placebo	no ASA indication	NPW572X	2.12.21 12:36	2022-08-31	Edoxaban 30mg / no ASA indication
567	42	Edoxaban	ASA indication	SKP333D	7.12.18 7:59	2020-01-01	Edoxaban 60mg / ASA indication
567	42	Edoxaban	ASA indication	BTF176K	24.5.18 8:20	2020-01-01	Edoxaban 60mg / ASA indication
2103	42	Edoxaban	ASA indication	CEG171B	23.11.21 11:07	2024-04-30	Edoxaban 60mg / ASA indication
2103	42	Edoxaban	ASA indication	CDP832T	23.5.22 9:53	2024-04-30	Edoxaban 60mg / ASA indication
2103	42	Edoxaban	ASA indication	SVL883X	17.5.21 11:39	2021-12-31	Edoxaban 60mg / ASA indication
2683	42	Edoxaban	ASA indication	CDA368G	1.7.22 9:37	2024-04-30	Edoxaban 60mg / ASA indication
2692	42	Edoxaban	ASA indication	LDG492H	5.7.22 10:56	2024-04-30	Edoxaban 60mg / ASA indication
2698	42	Edoxaban	ASA indication	HCP974B	6.7.22 11:51	2024-04-30	Edoxaban 60mg / ASA indication
2733	42	Edoxaban	ASA indication	DTV715X	10.8.22 7:59	2024-11-30	Edoxaban 30mg / ASA indication
1953	42	Edoxaban	no ASA indication	PKT593P	16.8.21 10:36	2022-08-31	Edoxaban 30mg / no ASA indication
1953	42	Edoxaban	no ASA indication	YZZ573K	10.2.21 11:02	2022-08-31	Edoxaban 30mg / no ASA indication
1953	42	Edoxaban	no ASA indication	BXU447R	4.2.22 9:43	2022-08-31	Edoxaban 30mg / no ASA indication
2564	42	Edoxaban	no ASA indication	DPU792T	30.3.22 9:22	2024-11-30	Edoxaban 30mg / no ASA indication
397	43	Placebo	ASA indication	MGC432A	28.1.19 11:40	2020-01-01	Edoxaban 60mg / ASA indication
397	43	Placebo	ASA indication	MMG855X	19.7.18 9:08	2020-01-01	Edoxaban 60mg / ASA indication
397	43	Placebo	ASA indication	SAB519M	15.1.18 11:29	2018-09-01	Edoxaban 60mg / ASA indication
845	43	Placebo	ASA indication	LPF683A	26.11.18 13:06	2020-01-01	Edoxaban 30mg / ASA indication
258	43	Edoxaban	ASA indication	DFC745C	21.8.17 10:00	2018-09-01	Edoxaban 60mg / ASA indication
258	43	Edoxaban	ASA indication	WNV119F	21.2.18 13:16	2020-01-01	Edoxaban 30mg / ASA indication
258	43	Edoxaban	ASA indication	ADP232G	22.8.18 12:39	2020-01-01	Edoxaban 30mg / ASA indication
472	44	Placebo	ASA indication	XLR349W	19.9.18 12:09	2020-01-01	Edoxaban 30mg / ASA indication
472	44	Placebo	ASA indication	CTY524W	7.3.18 13:42	2020-01-01	Edoxaban 30mg / ASA indication
1426	44	Placebo	ASA indication	HAZ272B	17.6.20 13:09	2021-12-31	Edoxaban 60mg / no ASA indication
1426	44	Placebo	ASA indication	HBX952T	4.12.19 10:30	2021-12-31	Edoxaban 60mg / ASA indication
1274	44	Edoxaban	ASA indication	RTC753X	5.9.19 9:59	2021-12-31	Edoxaban 60mg / ASA indication
2019	44	Edoxaban	ASA indication	LEW722X	18.3.21 12:50	2022-08-31	Edoxaban 30mg / ASA indication
2019	44	Edoxaban	ASA indication	WDD112D	29.9.21 9:23	2022-08-31	Edoxaban 30mg / ASA indication
2019	44	Edoxaban	ASA indication	DRB327X	28.3.22 14:11	2024-11-30	Edoxaban 30mg / ASA indication
95	46	Placebo	ASA indication	TFS914M	10.8.17 12:46	2018-09-01	Edoxaban 60mg / ASA indication
95	46	Placebo	ASA indication	GPN131Z	3.8.18 12:17	2020-01-01	Edoxaban 60mg / ASA indication
95	46	Placebo	ASA indication	CLD736H	10.2.17 10:26	2018-09-01	Edoxaban 60mg / ASA indication
95	46	Placebo	ASA indication	LST926N	20.2.18 13:45	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
145	46	Placebo	ASA indication	VET784W	3.5.18 12:57	2020-01-01	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	FNX243V	9.11.18 10:32	2020-01-01	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	LEX123Y	26.4.17 9:38	2018-09-01	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	EMH271H	7.5.20 8:11	2021-12-31	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	XET139Y	29.10.20 11:01	2021-12-31	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	AZW435U	7.11.19 10:13	2021-12-31	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	GBU855U	26.10.17 11:15	2018-09-01	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	CNS265H	26.4.22 10:30	2024-04-30	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	NGR733A	2.5.19 11:51	2020-01-01	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	CNN265U	28.10.21 10:32	2024-04-30	Edoxaban 60mg / ASA indication
145	46	Placebo	ASA indication	FSC633A	28.4.21 6:34	2021-12-31	Edoxaban 60mg / ASA indication
147	46	Placebo	ASA indication	KGH121L	27.4.17 13:22	2018-09-01	Edoxaban 60mg / ASA indication
147	46	Placebo	ASA indication	KRP264V	26.10.17 11:23	2018-09-01	Edoxaban 60mg / ASA indication
43	46	Edoxaban	ASA indication	GCA317M	3.11.16 9:40	2018-09-01	Edoxaban 60mg / ASA indication
43	46	Edoxaban	ASA indication	KCP216A	8.5.18 10:23	2020-01-01	Edoxaban 60mg / ASA indication
43	46	Edoxaban	ASA indication	FPS575Y	7.11.17 11:59	2018-09-01	Edoxaban 60mg / ASA indication
43	46	Edoxaban	ASA indication	CZX598S	2.5.17 8:54	2018-09-01	Edoxaban 60mg / ASA indication
43	46	Edoxaban	ASA indication	VBG692P	6.11.18 12:05	2020-01-01	Edoxaban 60mg / ASA indication
69	46	Edoxaban	ASA indication	NWL787S	6.7.17 10:19	2018-09-01	Edoxaban 30mg / ASA indication
69	46	Edoxaban	ASA indication	PVY971F	11.1.17 9:47	2018-09-01	Edoxaban 60mg / ASA indication
63	46	Edoxaban	no ASA indication	XAA649U	15.12.16 13:27	2018-09-01	Edoxaban 60mg / no ASA indication
287	49	Placebo	ASA indication	RWZ984H	28.9.17 9:56	2018-09-01	Edoxaban 60mg / ASA indication
363	49	Placebo	no ASA indication	GWA754K	6.12.17 12:54	2018-09-01	Edoxaban 60mg / no ASA indication
243	49	Edoxaban	no ASA indication	ZLW146W	25.7.18 13:38	2020-01-01	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	UTY929F	29.7.19 12:23	2022-08-31	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	VCA844B	1.2.22 11:22	2022-08-31	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	CLU628N	3.8.20 10:38	2022-08-31	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	FFD638S	4.2.19 10:10	2020-01-01	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	KCE956R	16.8.21 7:13	2022-08-31	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	FYR364K	3.8.17 12:17	2018-09-01	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	XUY149U	3.8.22 11:29	2024-11-30	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	LHD731V	22.2.18 10:51	2020-01-01	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	YVN627C	3.2.21 11:36	2022-08-31	Edoxaban 30mg / no ASA indication
243	49	Edoxaban	no ASA indication	XSW989A	3.2.20 15:21	2022-08-31	Edoxaban 30mg / no ASA indication
272	49	Edoxaban	no ASA indication	XUW211Z	6.9.19 11:58	2021-12-31	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	TCK343U	6.9.18 9:23	2020-01-01	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	CFY416T	6.9.21 10:08	2024-04-30	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	ZZZ453G	11.9.20 10:52	2021-12-31	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	SBM859M	9.3.21 10:47	2021-12-31	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	DSE456B	6.3.18 11:07	2020-01-01	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	WTS714W	6.9.17 10:37	2018-09-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
272	49	Edoxaban	no ASA indication	TDE768T	6.3.20 13:39	2021-12-31	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	GMM113S	20.3.19 13:47	2020-01-01	Edoxaban 60mg / no ASA indication
272	49	Edoxaban	no ASA indication	CFZ858F	8.3.22 10:30	2024-04-30	Edoxaban 60mg / no ASA indication
321	53	Edoxaban	no ASA indication	BVZ935W	8.5.18 10:03	2020-01-01	Edoxaban 60mg / no ASA indication
321	53	Edoxaban	no ASA indication	YWC757U	27.10.17 10:49	2018-09-01	Edoxaban 60mg / no ASA indication
587	57	Placebo	ASA indication	ZDA137T	3.12.19 8:24	2021-12-31	Edoxaban 60mg / ASA indication
587	57	Placebo	ASA indication	HHK398N	12.6.18 10:46	2020-01-01	Edoxaban 60mg / ASA indication
587	57	Placebo	ASA indication	SVV183T	19.11.20 8:18	2021-12-31	Edoxaban 60mg / ASA indication
587	57	Placebo	ASA indication	YEP631V	4.6.20 6:53	2021-12-31	Edoxaban 60mg / ASA indication
587	57	Placebo	ASA indication	SRZ924Z	4.12.18 7:16	2020-01-01	Edoxaban 60mg / ASA indication
587	57	Placebo	ASA indication	HHK288C	13.6.19 5:45	2020-01-01	Edoxaban 60mg / ASA indication
723	57	Placebo	ASA indication	URB125Z	26.9.19 9:38	2021-12-31	Edoxaban 60mg / ASA indication
723	57	Placebo	ASA indication	DPR786G	12.3.21 9:48	2022-08-31	Edoxaban 30mg / ASA indication
723	57	Placebo	ASA indication	GPT197C	28.8.20 7:08	2021-12-31	Edoxaban 60mg / ASA indication
723	57	Placebo	ASA indication	LNV792G	28.3.19 10:09	2020-01-01	Edoxaban 30mg / ASA indication
723	57	Placebo	ASA indication	ZGA583M	17.3.20 10:12	2021-12-31	Edoxaban 60mg / ASA indication
723	57	Placebo	ASA indication	LDR544P	27.9.18 9:29	2020-01-01	Edoxaban 60mg / ASA indication
1300	57	Placebo	ASA indication	FPZ346N	2.10.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
1300	57	Placebo	ASA indication	WWG589U	26.3.20 9:19	2021-12-31	Edoxaban 60mg / ASA indication
1300	57	Placebo	ASA indication	DHV679Y	26.9.19 10:08	2021-12-31	Edoxaban 60mg / ASA indication
1568	57	Placebo	ASA indication	RUV676V	31.3.20 12:42	2022-08-31	Edoxaban 30mg / ASA indication
1928	57	Placebo	ASA indication	DZV554V	14.1.21 13:12	2021-12-31	Edoxaban 60mg / ASA indication
2245	57	Placebo	ASA indication	DAP877C	25.8.21 9:41	2024-04-30	Edoxaban 60mg / ASA indication
2245	57	Placebo	ASA indication	CYS796E	25.2.22 8:56	2024-11-30	Edoxaban 30mg / ASA indication
2245	57	Placebo	ASA indication	DAB897C	12.8.22 8:31	2024-04-30	Edoxaban 60mg / ASA indication
2551	57	Placebo	ASA indication	CYW343C	22.3.22 10:09	2024-04-30	Edoxaban 60mg / ASA indication
2542	57	Placebo	no ASA indication	CZZ932S	18.3.22 11:48	2024-11-30	Edoxaban 30mg / no ASA indication
451	57	Edoxaban	ASA indication	NDN351H	21.2.18 12:53	2020-01-01	Edoxaban 60mg / ASA indication
593	57	Edoxaban	ASA indication	RKT788N	27.6.19 9:07	2021-12-31	Edoxaban 60mg / ASA indication
593	57	Edoxaban	ASA indication	DVE341E	7.1.20 15:28	2021-12-31	Edoxaban 60mg / ASA indication
593	57	Edoxaban	ASA indication	BAB799D	20.12.18 13:05	2020-01-01	Edoxaban 60mg / ASA indication
593	57	Edoxaban	ASA indication	VLY684P	14.6.18 14:25	2020-01-01	Edoxaban 60mg / ASA indication
593	57	Edoxaban	ASA indication	GVM189A	11.6.20 8:37	2021-12-31	Edoxaban 60mg / ASA indication
966	57	Edoxaban	ASA indication	EHG573L	1.2.22 15:07	2022-08-31	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	XMX657X	31.1.19 15:03	2020-01-01	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	EGV421R	4.7.19 7:49	2022-08-31	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	KFS585A	25.1.21 12:48	2022-08-31	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	DNT472U	26.7.22 14:19	2024-11-30	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	TDK148N	3.8.21 8:39	2022-08-31	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	USZ934H	2.1.20 10:32	2022-08-31	Edoxaban 30mg / ASA indication
966	57	Edoxaban	ASA indication	MLF415X	22.7.20 6:56	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1324	57	Edoxaban	ASA indication	BLG158L	18.2.20 9:16	2022-08-31	Edoxaban 30mg / ASA indication
1324	57	Edoxaban	ASA indication	KSH422T	10.10.19 12:57	2022-08-31	Edoxaban 30mg / ASA indication
1324	57	Edoxaban	ASA indication	DAX468Y	27.8.20 7:50	2021-12-31	Edoxaban 60mg / ASA indication
1324	57	Edoxaban	ASA indication	AAM391C	7.4.22 6:49	2024-04-30	Edoxaban 60mg / ASA indication
1324	57	Edoxaban	ASA indication	NBE446S	13.4.21 8:52	2021-12-31	Edoxaban 60mg / ASA indication
1324	57	Edoxaban	ASA indication	CTF639Z	5.10.21 7:58	2024-04-30	Edoxaban 60mg / ASA indication
1324	57	Edoxaban	ASA indication	TLE832G	8.10.20 9:11	2022-08-31	Edoxaban 30mg / ASA indication
1629	57	Edoxaban	ASA indication	DPT287R	16.6.22 8:50	2024-11-30	Edoxaban 30mg / ASA indication
1629	57	Edoxaban	ASA indication	DDC682Y	3.12.20 9:00	2021-12-31	Edoxaban 60mg / ASA indication
1629	57	Edoxaban	ASA indication	DXB967T	12.6.20 9:28	2021-12-31	Edoxaban 60mg / ASA indication
1629	57	Edoxaban	ASA indication	CTC286K	9.12.21 8:35	2024-04-30	Edoxaban 60mg / ASA indication
1629	57	Edoxaban	ASA indication	SPM843P	10.6.21 7:50	2021-12-31	Edoxaban 60mg / ASA indication
1755	57	Edoxaban	ASA indication	PZK924Y	9.3.21 9:19	2021-12-31	Edoxaban 60mg / ASA indication
1755	57	Edoxaban	ASA indication	DCL159S	3.9.20 9:30	2021-12-31	Edoxaban 60mg / ASA indication
1837	57	Edoxaban	ASA indication	ELW416W	22.4.21 8:53	2021-12-31	Edoxaban 60mg / ASA indication
1837	57	Edoxaban	ASA indication	VRY739P	21.4.22 9:34	2024-04-30	Edoxaban 60mg / ASA indication
1837	57	Edoxaban	ASA indication	PZG317S	22.10.20 10:13	2021-12-31	Edoxaban 60mg / ASA indication
1837	57	Edoxaban	ASA indication	CUN325P	21.10.21 9:21	2024-04-30	Edoxaban 60mg / ASA indication
19	59	Placebo	ASA indication	VUG154A	29.8.17 10:37	2018-09-01	Edoxaban 60mg / ASA indication
19	59	Placebo	ASA indication	USK283Z	24.9.20 7:15	2021-12-31	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	XXA373D	22.2.17 11:26	2018-09-01	Edoxaban 60mg / ASA indication
19	59	Placebo	ASA indication	AGS598E	23.9.21 10:09	2024-04-30	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	TNM757D	28.2.18 11:16	2020-01-01	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	YRK873A	10.3.22 11:17	2024-04-30	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	AHU535D	6.9.16 12:56	2018-09-01	Edoxaban 60mg / ASA indication
19	59	Placebo	ASA indication	RVU356F	7.3.19 11:19	2020-01-01	Edoxaban 60mg / ASA indication
19	59	Placebo	ASA indication	WZK224P	12.9.19 9:56	2021-12-31	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	KVM658Z	13.9.18 9:59	2020-01-01	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	SUV439S	11.3.21 11:11	2021-12-31	Edoxaban 60mg / no ASA indication
19	59	Placebo	ASA indication	PEZ271S	17.3.20 11:19	2021-12-31	Edoxaban 60mg / no ASA indication
24	59	Placebo	ASA indication	TTX946P	16.9.16 11:07	2018-09-01	Edoxaban 60mg / ASA indication
67	59	Placebo	ASA indication	BHN971K	3.7.17 10:05	2018-09-01	Edoxaban 60mg / ASA indication
67	59	Placebo	ASA indication	CBD677N	17.1.18 9:27	2018-09-01	Edoxaban 60mg / ASA indication
67	59	Placebo	ASA indication	HVZ754T	4.1.17 9:38	2018-09-01	Edoxaban 60mg / ASA indication
119	59	Placebo	ASA indication	LUR921K	22.3.17 11:36	2018-09-01	Edoxaban 60mg / ASA indication
466	59	Placebo	ASA indication	GTN299S	28.2.18 11:48	2020-01-01	Edoxaban 60mg / ASA indication
466	59	Placebo	ASA indication	LUV265C	26.2.19 11:32	2020-01-01	Edoxaban 60mg / ASA indication
466	59	Placebo	ASA indication	MXF543Z	22.8.18 10:29	2020-01-01	Edoxaban 60mg / ASA indication
679	59	Placebo	ASA indication	DKH179A	20.8.18 10:15	2020-01-01	Edoxaban 30mg / ASA indication
1063	59	Placebo	ASA indication	SBX752T	1.4.20 10:03	2021-12-31	Edoxaban 60mg / ASA indication
1063	59	Placebo	ASA indication	SUH915D	7.4.21 9:57	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1063	59	Placebo	ASA indication	WKU525A	29.3.22 9:40	2024-04-30	Edoxaban 60mg / ASA indication
1063	59	Placebo	ASA indication	YLM775K	30.9.20 10:15	2021-12-31	Edoxaban 60mg / ASA indication
1063	59	Placebo	ASA indication	RWZ278A	8.4.19 13:07	2020-01-01	Edoxaban 60mg / ASA indication
1063	59	Placebo	ASA indication	YTN826P	18.10.21 9:59	2024-04-30	Edoxaban 60mg / ASA indication
1063	59	Placebo	ASA indication	PZE829Y	25.9.19 10:02	2021-12-31	Edoxaban 60mg / ASA indication
1161	59	Placebo	ASA indication	PZB964Y	10.12.20 12:39	2021-12-31	Edoxaban 60mg / ASA indication
1161	59	Placebo	ASA indication	KKM956H	3.6.21 10:19	2021-12-31	Edoxaban 60mg / ASA indication
1161	59	Placebo	ASA indication	LHX693S	25.11.19 11:26	2021-12-31	Edoxaban 60mg / ASA indication
1161	59	Placebo	ASA indication	YSU185Z	9.12.21 11:12	2024-04-30	Edoxaban 60mg / ASA indication
1161	59	Placebo	ASA indication	FUX267V	4.6.20 10:31	2021-12-31	Edoxaban 60mg / ASA indication
1161	59	Placebo	ASA indication	EMN586R	5.6.19 9:58	2020-01-01	Edoxaban 60mg / ASA indication
1247	59	Placebo	ASA indication	UVX446Y	10.8.22 10:44	2024-04-30	Edoxaban 60mg / no ASA indication
1247	59	Placebo	ASA indication	AGV655V	17.2.22 11:11	2024-04-30	Edoxaban 60mg / ASA indication
1247	59	Placebo	ASA indication	BSX482L	12.2.20 11:29	2021-12-31	Edoxaban 60mg / ASA indication
1247	59	Placebo	ASA indication	PVS226T	16.2.21 11:07	2021-12-31	Edoxaban 60mg / ASA indication
1247	59	Placebo	ASA indication	YYF998G	8.8.19 8:15	2021-12-31	Edoxaban 60mg / ASA indication
1247	59	Placebo	ASA indication	RMU762M	19.8.20 10:48	2021-12-31	Edoxaban 60mg / ASA indication
1247	59	Placebo	ASA indication	AFV164N	17.8.21 9:53	2024-04-30	Edoxaban 60mg / ASA indication
1451	59	Placebo	ASA indication	FKM219F	16.12.19 11:32	2022-08-31	Edoxaban 30mg / ASA indication
1456	59	Placebo	ASA indication	GBF116K	8.6.22 10:03	2024-04-30	Edoxaban 60mg / ASA indication
1456	59	Placebo	ASA indication	STE662Z	1.6.21 8:37	2021-12-31	Edoxaban 60mg / no ASA indication
1456	59	Placebo	ASA indication	YTV745M	7.12.21 10:54	2024-04-30	Edoxaban 60mg / ASA indication
1456	59	Placebo	ASA indication	PSZ577B	7.12.20 10:09	2021-12-31	Edoxaban 60mg / ASA indication
1456	59	Placebo	ASA indication	BYM486Y	19.12.19 9:33	2021-12-31	Edoxaban 60mg / ASA indication
1456	59	Placebo	ASA indication	KEF519U	24.6.20 10:15	2021-12-31	Edoxaban 60mg / ASA indication
1583	59	Placebo	ASA indication	UWH565U	11.5.20 12:14	2022-08-31	Edoxaban 30mg / ASA indication
1779	59	Placebo	ASA indication	SPS959U	18.3.21 10:15	2021-12-31	Edoxaban 60mg / ASA indication
1779	59	Placebo	ASA indication	GDE139C	22.3.22 11:14	2024-04-30	Edoxaban 60mg / ASA indication
1779	59	Placebo	ASA indication	AGC814H	22.9.21 10:19	2024-04-30	Edoxaban 60mg / ASA indication
1779	59	Placebo	ASA indication	PPM555H	16.9.20 8:38	2021-12-31	Edoxaban 60mg / ASA indication
2211	59	Placebo	ASA indication	UGP834M	8.2.22 8:26	2022-08-31	Edoxaban 30mg / ASA indication
2211	59	Placebo	ASA indication	YWB152H	3.8.21 10:42	2022-08-31	Edoxaban 30mg / ASA indication
2467	59	Placebo	ASA indication	AGW751Y	3.2.22 11:31	2024-04-30	Edoxaban 60mg / ASA indication
2467	59	Placebo	ASA indication	DWS768B	9.8.22 10:25	2024-11-30	Edoxaban 30mg / ASA indication
9	59	Placebo	no ASA indication	HKA318P	20.8.19 10:45	2021-12-31	Edoxaban 60mg / no ASA indication
9	59	Placebo	no ASA indication	PAR557X	25.8.20 11:07	2022-08-31	Edoxaban 30mg / no ASA indication
9	59	Placebo	no ASA indication	TFT361R	12.2.19 11:18	2020-01-01	Edoxaban 30mg / no ASA indication
9	59	Placebo	no ASA indication	KHC679L	18.8.21 10:19	2022-08-31	Edoxaban 30mg / no ASA indication
9	59	Placebo	no ASA indication	CGY658F	6.2.18 11:26	2018-09-01	Edoxaban 60mg / no ASA indication
9	59	Placebo	no ASA indication	UNY257B	2.8.22 10:25	2024-04-30	Edoxaban 60mg / no ASA indication
9	59	Placebo	no ASA indication	LTV169K	8.8.16 12:52	2018-09-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
9	59	Placebo	no ASA indication	MLY862L	9.2.17 11:23	2018-09-01	Edoxaban 60mg / no ASA indication
9	59	Placebo	no ASA indication	LDS196C	9.2.22 11:19	2022-08-31	Edoxaban 30mg / no ASA indication
9	59	Placebo	no ASA indication	VTD911Y	7.8.18 10:37	2020-01-01	Edoxaban 60mg / no ASA indication
9	59	Placebo	no ASA indication	GVD361B	8.8.17 10:09	2018-09-01	Edoxaban 60mg / no ASA indication
9	59	Placebo	no ASA indication	GMS933W	19.2.21 11:26	2022-08-31	Edoxaban 30mg / no ASA indication
9	59	Placebo	no ASA indication	CXT368S	25.2.20 11:07	2022-08-31	Edoxaban 30mg / no ASA indication
463	59	Placebo	no ASA indication	CZF228P	20.8.18 10:45	2020-01-01	Edoxaban 60mg / no ASA indication
463	59	Placebo	no ASA indication	WDZ369A	26.2.18 11:55	2020-01-01	Edoxaban 60mg / no ASA indication
467	59	Placebo	no ASA indication	PKV786M	20.2.20 11:01	2022-08-31	Edoxaban 30mg / no ASA indication
467	59	Placebo	no ASA indication	UKY934D	15.8.19 9:59	2022-08-31	Edoxaban 30mg / no ASA indication
467	59	Placebo	no ASA indication	PZU527B	28.2.18 12:20	2020-01-01	Edoxaban 30mg / no ASA indication
467	59	Placebo	no ASA indication	HVG322N	16.8.18 10:27	2020-01-01	Edoxaban 30mg / no ASA indication
467	59	Placebo	no ASA indication	AFB788S	7.2.19 11:33	2020-01-01	Edoxaban 30mg / no ASA indication
615	59	Placebo	no ASA indication	DHM169N	5.7.18 10:25	2020-01-01	Edoxaban 60mg / no ASA indication
826	59	Placebo	no ASA indication	XPZ292E	16.11.18 13:41	2020-01-01	Edoxaban 60mg / no ASA indication
826	59	Placebo	no ASA indication	NEY188D	20.11.19 11:29	2021-12-31	Edoxaban 60mg / no ASA indication
826	59	Placebo	no ASA indication	KPR234N	21.5.19 12:27	2020-01-01	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	ULX655T	10.12.19 11:43	2021-12-31	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	GRF151L	7.12.20 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	RWS568F	19.6.19 10:17	2021-12-31	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	NUL716B	17.6.20 10:21	2021-12-31	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	AER893B	30.6.22 8:50	2024-04-30	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	KTU115M	17.6.21 10:22	2021-12-31	Edoxaban 60mg / no ASA indication
1191	59	Placebo	no ASA indication	AEY318Y	21.12.21 11:04	2024-04-30	Edoxaban 60mg / no ASA indication
1230	59	Placebo	no ASA indication	PXS931E	24.7.19 10:18	2021-12-31	Edoxaban 60mg / no ASA indication
1422	59	Placebo	no ASA indication	CZZ735U	9.6.20 11:54	2021-12-31	Edoxaban 60mg / no ASA indication
1422	59	Placebo	no ASA indication	VAA877L	7.6.21 10:13	2021-12-31	Edoxaban 60mg / no ASA indication
1422	59	Placebo	no ASA indication	XUM589P	2.12.19 11:31	2021-12-31	Edoxaban 60mg / no ASA indication
1422	59	Placebo	no ASA indication	LUL382V	10.12.20 10:34	2021-12-31	Edoxaban 60mg / no ASA indication
2612	59	Placebo	no ASA indication	YNX443N	11.5.22 7:52	2024-04-30	Edoxaban 60mg / no ASA indication
2669	59	Placebo	no ASA indication	AGD336V	23.6.22 9:38	2024-04-30	Edoxaban 60mg / no ASA indication
98	59	Edoxaban	ASA indication	CHB612B	14.2.17 13:32	2018-09-01	Edoxaban 60mg / ASA indication
186	59	Edoxaban	ASA indication	RGB371S	7.12.17 10:13	2018-09-01	Edoxaban 60mg / ASA indication
186	59	Edoxaban	ASA indication	KCE228B	9.6.17 9:24	2018-09-01	Edoxaban 60mg / ASA indication
380	59	Edoxaban	ASA indication	UCC584T	21.12.17 11:34	2018-09-01	Edoxaban 60mg / ASA indication
380	59	Edoxaban	ASA indication	PKE732M	18.12.19 11:08	2021-12-31	Edoxaban 60mg / ASA indication
380	59	Edoxaban	ASA indication	HNX757E	18.12.18 11:16	2020-01-01	Edoxaban 60mg / ASA indication
380	59	Edoxaban	ASA indication	VPL359M	25.6.19 10:50	2021-12-31	Edoxaban 60mg / ASA indication
380	59	Edoxaban	ASA indication	BHW946S	25.6.18 10:29	2020-01-01	Edoxaban 60mg / ASA indication
416	59	Edoxaban	ASA indication	PDB526V	6.2.19 9:04	2020-01-01	Edoxaban 30mg / ASA indication
416	59	Edoxaban	ASA indication	PHT283P	10.8.18 9:45	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
416	59	Edoxaban	ASA indication	KAS138D	26.1.18 11:06	2018-09-01	Edoxaban 30mg / ASA indication
493	59	Edoxaban	ASA indication	DPD454V	24.10.19 10:55	2021-12-31	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	CFR219X	20.3.18 10:08	2020-01-01	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	NVU141C	14.9.18 10:12	2020-01-01	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	STW889V	1.4.21 10:33	2021-12-31	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	AGY112G	27.9.21 10:20	2024-04-30	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	ANF744L	4.5.20 9:58	2021-12-31	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	YYA857T	21.3.22 11:13	2024-04-30	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	TUZ185B	11.11.20 10:14	2021-12-31	Edoxaban 60mg / ASA indication
493	59	Edoxaban	ASA indication	ZKC832C	25.3.19 10:37	2020-01-01	Edoxaban 60mg / ASA indication
528	59	Edoxaban	ASA indication	SAE763L	12.9.19 10:31	2022-08-31	Edoxaban 30mg / ASA indication
528	59	Edoxaban	ASA indication	SZP321F	21.9.20 10:16	2021-12-31	Edoxaban 60mg / ASA indication
528	59	Edoxaban	ASA indication	MUF219H	2.9.21 9:48	2022-08-31	Edoxaban 30mg / ASA indication
528	59	Edoxaban	ASA indication	KVX378R	16.4.18 12:08	2020-01-01	Edoxaban 60mg / ASA indication
528	59	Edoxaban	ASA indication	DGS961U	30.3.21 10:16	2022-08-31	Edoxaban 30mg / ASA indication
528	59	Edoxaban	ASA indication	RPZ379U	17.3.20 11:42	2022-08-31	Edoxaban 30mg / ASA indication
528	59	Edoxaban	ASA indication	ZZB419Y	23.8.18 10:21	2020-01-01	Edoxaban 60mg / ASA indication
528	59	Edoxaban	ASA indication	GLA689V	5.3.19 11:36	2020-01-01	Edoxaban 60mg / ASA indication
655	59	Edoxaban	ASA indication	LRY245N	19.8.19 10:18	2021-12-31	Edoxaban 60mg / ASA indication
655	59	Edoxaban	ASA indication	ETH358G	6.8.18 9:03	2020-01-01	Edoxaban 60mg / ASA indication
655	59	Edoxaban	ASA indication	RWR716P	11.2.19 11:20	2020-01-01	Edoxaban 60mg / ASA indication
655	59	Edoxaban	ASA indication	KAY995F	24.2.20 11:21	2021-12-31	Edoxaban 60mg / ASA indication
655	59	Edoxaban	ASA indication	EBL316X	24.8.20 9:45	2021-12-31	Edoxaban 60mg / ASA indication
1105	59	Edoxaban	ASA indication	AMW648K	3.5.19 10:37	2020-01-01	Edoxaban 60mg / ASA indication
1105	59	Edoxaban	ASA indication	HMZ312F	29.10.19 11:56	2021-12-31	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	VGY262L	12.12.19 11:25	2021-12-31	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	HXD911E	15.6.20 10:19	2021-12-31	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	AGA544Z	21.6.21 10:27	2024-04-30	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	YWD218S	20.12.21 11:12	2024-04-30	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	AGP865S	20.6.22 10:27	2024-04-30	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	NRG497H	21.12.20 11:18	2021-12-31	Edoxaban 60mg / ASA indication
1195	59	Edoxaban	ASA indication	LZH298Z	21.6.19 8:20	2021-12-31	Edoxaban 60mg / ASA indication
1245	59	Edoxaban	ASA indication	AMF997N	10.2.20 11:42	2022-08-31	Edoxaban 30mg / ASA indication
1245	59	Edoxaban	ASA indication	XMA582R	22.2.21 11:24	2022-08-31	Edoxaban 30mg / ASA indication
1245	59	Edoxaban	ASA indication	GKN357E	16.8.21 10:40	2022-08-31	Edoxaban 30mg / ASA indication
1245	59	Edoxaban	ASA indication	RHB851P	10.8.20 10:22	2022-08-31	Edoxaban 30mg / ASA indication
1245	59	Edoxaban	ASA indication	NTS552E	7.8.19 10:36	2022-08-31	Edoxaban 30mg / ASA indication
1490	59	Edoxaban	ASA indication	BVY888L	23.1.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication
1579	59	Edoxaban	ASA indication	GZU127M	11.5.21 10:12	2021-12-31	Edoxaban 60mg / no ASA indication
1579	59	Edoxaban	ASA indication	ZEL118B	10.11.20 11:02	2021-12-31	Edoxaban 60mg / no ASA indication
1579	59	Edoxaban	ASA indication	MEN773C	7.5.20 10:18	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2470	59	Edoxaban	ASA indication	WEP552F	7.2.22 13:30	2022-08-31	Edoxaban 30mg / ASA indication
58	59	Edoxaban	no ASA indication	FMF948X	10.12.18 11:44	2020-01-01	Edoxaban 60mg / no ASA indication
58	59	Edoxaban	no ASA indication	UPZ551H	11.6.19 10:42	2020-01-01	Edoxaban 60mg / no ASA indication
58	59	Edoxaban	no ASA indication	KMZ168L	11.6.20 8:11	2022-08-31	Edoxaban 30mg / no ASA indication
58	59	Edoxaban	no ASA indication	TRA122U	7.12.16 9:52	2018-09-01	Edoxaban 60mg / no ASA indication
58	59	Edoxaban	no ASA indication	DZU484R	5.12.17 9:00	2018-09-01	Edoxaban 30mg / no ASA indication
58	59	Edoxaban	no ASA indication	YTX458B	15.6.18 8:12	2020-01-01	Edoxaban 30mg / no ASA indication
58	59	Edoxaban	no ASA indication	ENE492H	13.6.17 8:04	2018-09-01	Edoxaban 30mg / no ASA indication
58	59	Edoxaban	no ASA indication	HPM893S	17.12.19 11:12	2022-08-31	Edoxaban 30mg / no ASA indication
149	59	Edoxaban	no ASA indication	LWL799R	16.10.18 10:45	2020-01-01	Edoxaban 60mg / no ASA indication
149	59	Edoxaban	no ASA indication	RZP227P	16.4.19 9:28	2020-01-01	Edoxaban 60mg / no ASA indication
149	59	Edoxaban	no ASA indication	RMV799R	5.10.17 10:34	2018-09-01	Edoxaban 60mg / no ASA indication
149	59	Edoxaban	no ASA indication	TXH134E	3.4.18 9:38	2020-01-01	Edoxaban 60mg / no ASA indication
149	59	Edoxaban	no ASA indication	DYV397L	2.5.17 12:24	2018-09-01	Edoxaban 60mg / no ASA indication
541	59	Edoxaban	no ASA indication	NRD554S	23.10.18 10:27	2020-01-01	Edoxaban 60mg / no ASA indication
541	59	Edoxaban	no ASA indication	MGG446M	9.12.20 11:03	2021-12-31	Edoxaban 60mg / ASA indication
541	59	Edoxaban	no ASA indication	HCT895M	3.6.20 10:16	2021-12-31	Edoxaban 60mg / ASA indication
541	59	Edoxaban	no ASA indication	AMT277U	3.5.22 10:35	2024-04-30	Edoxaban 60mg / no ASA indication
541	59	Edoxaban	no ASA indication	LZZ696X	19.12.19 11:07	2021-12-31	Edoxaban 60mg / no ASA indication
541	59	Edoxaban	no ASA indication	KNL538S	18.5.21 10:24	2021-12-31	Edoxaban 60mg / ASA indication
541	59	Edoxaban	no ASA indication	ALV344L	8.11.21 10:55	2024-04-30	Edoxaban 60mg / no ASA indication
541	59	Edoxaban	no ASA indication	KST939Y	30.4.18 9:24	2020-01-01	Edoxaban 60mg / no ASA indication
541	59	Edoxaban	no ASA indication	GKG643C	30.4.19 9:59	2020-01-01	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	XGX627Z	5.11.19 12:11	2021-12-31	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	AMW194N	17.11.21 11:21	2024-04-30	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	VPG466R	8.5.19 9:51	2020-01-01	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	TZL197V	16.11.20 11:02	2021-12-31	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	YCY485N	11.5.22 10:07	2024-04-30	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	SBC917K	11.5.20 10:22	2021-12-31	Edoxaban 60mg / no ASA indication
1115	59	Edoxaban	no ASA indication	NSL669B	10.5.21 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
1140	59	Edoxaban	no ASA indication	AZS174S	5.11.19 11:51	2021-12-31	Edoxaban 60mg / ASA indication
1140	59	Edoxaban	no ASA indication	ESE643E	23.5.19 9:40	2020-01-01	Edoxaban 30mg / no ASA indication
1293	59	Edoxaban	no ASA indication	DAK632B	23.3.20 11:03	2021-12-31	Edoxaban 60mg / no ASA indication
1293	59	Edoxaban	no ASA indication	XAB714T	2.10.20 10:32	2022-08-31	Edoxaban 30mg / no ASA indication
1293	59	Edoxaban	no ASA indication	TYN531G	18.9.19 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
1293	59	Edoxaban	no ASA indication	HMT293Y	23.9.21 10:35	2022-08-31	Edoxaban 30mg / no ASA indication
1293	59	Edoxaban	no ASA indication	FVN815U	18.3.21 11:08	2022-08-31	Edoxaban 30mg / no ASA indication
1293	59	Edoxaban	no ASA indication	ECY539X	16.3.22 11:16	2024-11-30	Edoxaban 30mg / no ASA indication
1634	59	Edoxaban	no ASA indication	PPE227N	10.12.20 9:00	2021-12-31	Edoxaban 60mg / no ASA indication
1634	59	Edoxaban	no ASA indication	YBN458H	16.6.20 9:27	2021-12-31	Edoxaban 60mg / no ASA indication
1801	59	Edoxaban	no ASA indication	DRN731K	25.9.20 8:16	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1801	59	Edoxaban	no ASA indication	AGR383S	29.9.21 10:09	2024-04-30	Edoxaban 60mg / ASA indication
1801	59	Edoxaban	no ASA indication	YXR682S	31.3.22 9:59	2024-04-30	Edoxaban 60mg / ASA indication
1801	59	Edoxaban	no ASA indication	KER117C	24.3.21 11:04	2021-12-31	Edoxaban 60mg / ASA indication
1920	59	Edoxaban	no ASA indication	ERP925E	6.1.21 11:24	2022-08-31	Edoxaban 30mg / no ASA indication
1920	59	Edoxaban	no ASA indication	PSL675S	15.7.21 10:13	2022-08-31	Edoxaban 30mg / no ASA indication
2442	59	Edoxaban	no ASA indication	FWF876L	3.8.22 9:25	2024-04-30	Edoxaban 60mg / no ASA indication
2442	59	Edoxaban	no ASA indication	ALL157T	24.1.22 9:35	2024-04-30	Edoxaban 60mg / no ASA indication
325	70	Placebo	ASA indication	FKR384D	10.5.19 7:06	2020-01-01	Edoxaban 60mg / ASA indication
325	70	Placebo	ASA indication	YPE542V	3.5.18 10:12	2020-01-01	Edoxaban 60mg / ASA indication
325	70	Placebo	ASA indication	PLT858P	1.11.18 13:26	2020-01-01	Edoxaban 60mg / ASA indication
325	70	Placebo	ASA indication	PKH413B	1.11.17 8:24	2018-09-01	Edoxaban 60mg / ASA indication
511	70	Placebo	ASA indication	NWY338Z	5.4.18 12:38	2020-01-01	Edoxaban 60mg / ASA indication
511	70	Placebo	ASA indication	GNA534A	23.10.19 12:22	2022-08-31	Edoxaban 30mg / ASA indication
511	70	Placebo	ASA indication	PUE691U	24.10.18 6:24	2020-01-01	Edoxaban 60mg / ASA indication
511	70	Placebo	ASA indication	BBB166S	2.5.19 7:35	2020-01-01	Edoxaban 60mg / ASA indication
644	70	Placebo	ASA indication	WZP222N	10.8.18 6:28	2020-01-01	Edoxaban 30mg / ASA indication
644	70	Placebo	ASA indication	FEW499D	3.4.20 15:50	2021-12-31	Edoxaban 60mg / ASA indication
644	70	Placebo	ASA indication	TDP494S	20.8.20 12:42	2022-08-31	Edoxaban 30mg / ASA indication
644	70	Placebo	ASA indication	XLT587S	21.8.19 12:05	2021-12-31	Edoxaban 60mg / ASA indication
644	70	Placebo	ASA indication	VHT644P	8.3.21 7:30	2021-12-31	Edoxaban 60mg / ASA indication
644	70	Placebo	ASA indication	MUL335U	13.2.19 7:33	2020-01-01	Edoxaban 30mg / ASA indication
765	70	Placebo	ASA indication	GCH757H	2.5.19 7:05	2020-01-01	Edoxaban 30mg / ASA indication
765	70	Placebo	ASA indication	WDN449K	23.10.18 13:56	2020-01-01	Edoxaban 30mg / ASA indication
995	70	Placebo	ASA indication	HHT339R	20.2.19 8:32	2020-01-01	Edoxaban 60mg / ASA indication
1045	70	Placebo	ASA indication	XHM718A	28.3.19 14:12	2020-01-01	Edoxaban 60mg / ASA indication
1148	70	Placebo	ASA indication	HVP653W	28.5.19 9:54	2020-01-01	Edoxaban 60mg / ASA indication
1485	70	Placebo	ASA indication	VBN113G	21.1.20 14:08	2022-08-31	Edoxaban 30mg / ASA indication
1485	70	Placebo	ASA indication	MUR251Z	29.1.21 12:12	2022-08-31	Edoxaban 30mg / ASA indication
1485	70	Placebo	ASA indication	DYW658T	1.3.22 9:00	2024-11-30	Edoxaban 30mg / ASA indication
1485	70	Placebo	ASA indication	BVS288T	21.7.20 11:48	2022-08-31	Edoxaban 30mg / ASA indication
1485	70	Placebo	ASA indication	GVH618B	27.7.21 6:19	2022-08-31	Edoxaban 30mg / ASA indication
1727	70	Placebo	ASA indication	AHT936T	24.2.22 13:23	2024-04-30	Edoxaban 60mg / ASA indication
1727	70	Placebo	ASA indication	XLD935C	11.8.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication
1727	70	Placebo	ASA indication	RMW151U	18.2.21 11:08	2021-12-31	Edoxaban 60mg / ASA indication
1727	70	Placebo	ASA indication	AKF193H	6.8.21 12:09	2024-04-30	Edoxaban 60mg / ASA indication
1727	70	Placebo	ASA indication	SNW731N	31.8.22 12:36	2024-04-30	Edoxaban 60mg / ASA indication
1751	70	Placebo	ASA indication	WDC871T	31.8.20 12:33	2022-08-31	Edoxaban 30mg / ASA indication
1950	70	Placebo	ASA indication	LWE651N	5.2.21 13:48	2021-12-31	Edoxaban 60mg / ASA indication
1950	70	Placebo	ASA indication	ALL393G	17.8.21 8:00	2024-04-30	Edoxaban 60mg / ASA indication
2028	70	Placebo	ASA indication	ZCR571W	25.3.21 15:53	2022-08-31	Edoxaban 30mg / ASA indication
2425	70	Placebo	ASA indication	GZM434M	12.1.22 8:38	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2438	70	Placebo	ASA indication	XDK569N	20.1.22 13:51	2024-04-30	Edoxaban 60mg / ASA indication
2438	70	Placebo	ASA indication	ZEY558N	27.7.22 11:51	2024-04-30	Edoxaban 60mg / ASA indication
2475	70	Placebo	ASA indication	GHW379G	11.2.22 12:45	2022-08-31	Edoxaban 30mg / ASA indication
2475	70	Placebo	ASA indication	VRM798E	18.8.22 14:21	2024-04-30	Edoxaban 60mg / ASA indication
2554	70	Placebo	ASA indication	ALG543Z	23.3.22 9:10	2024-04-30	Edoxaban 60mg / ASA indication
2686	70	Placebo	ASA indication	SBL228A	1.7.22 11:36	2024-04-30	Edoxaban 60mg / ASA indication
151	70	Placebo	no ASA indication	PNG891F	10.11.17 9:58	2018-09-01	Edoxaban 30mg / no ASA indication
151	70	Placebo	no ASA indication	CTB887G	3.5.17 15:01	2018-09-01	Edoxaban 30mg / no ASA indication
401	70	Placebo	no ASA indication	PKA523N	12.1.18 14:50	2018-09-01	Edoxaban 60mg / no ASA indication
401	70	Placebo	no ASA indication	YMY455M	17.7.18 7:54	2020-01-01	Edoxaban 60mg / no ASA indication
401	70	Placebo	no ASA indication	TVZ164E	18.12.19 11:46	2021-12-31	Edoxaban 60mg / no ASA indication
401	70	Placebo	no ASA indication	BGD852N	15.1.19 12:56	2020-01-01	Edoxaban 60mg / no ASA indication
401	70	Placebo	no ASA indication	MKE298B	2.7.19 12:21	2021-12-31	Edoxaban 60mg / no ASA indication
418	70	Placebo	no ASA indication	VSR591Y	8.8.19 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
418	70	Placebo	no ASA indication	ZUH386P	19.2.19 10:15	2020-01-01	Edoxaban 30mg / no ASA indication
418	70	Placebo	no ASA indication	TZY225U	9.8.18 9:01	2020-01-01	Edoxaban 30mg / no ASA indication
418	70	Placebo	no ASA indication	XAE373V	29.1.18 13:13	2018-09-01	Edoxaban 60mg / no ASA indication
479	70	Placebo	no ASA indication	EWY617N	12.3.18 11:49	2020-01-01	Edoxaban 30mg / no ASA indication
1114	70	Placebo	no ASA indication	XZP611H	8.10.19 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
1114	70	Placebo	no ASA indication	MEU717H	8.5.19 9:45	2020-01-01	Edoxaban 60mg / no ASA indication
1304	70	Placebo	no ASA indication	FMK933N	25.9.20 13:59	2021-12-31	Edoxaban 60mg / no ASA indication
1304	70	Placebo	no ASA indication	CZB288U	13.4.21 12:43	2021-12-31	Edoxaban 60mg / no ASA indication
1304	70	Placebo	no ASA indication	GFE433L	30.9.19 9:29	2021-12-31	Edoxaban 60mg / no ASA indication
1304	70	Placebo	no ASA indication	HNW798T	3.4.20 15:04	2021-12-31	Edoxaban 60mg / no ASA indication
1304	70	Placebo	no ASA indication	AKM265W	10.5.22 8:49	2024-04-30	Edoxaban 60mg / no ASA indication
1304	70	Placebo	no ASA indication	VKY726W	27.10.21 7:34	2024-04-30	Edoxaban 60mg / no ASA indication
1714	70	Placebo	no ASA indication	WAP372B	16.2.21 7:29	2021-12-31	Edoxaban 60mg / ASA indication
1714	70	Placebo	no ASA indication	BSX337G	31.7.20 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
1730	70	Placebo	no ASA indication	LWX854V	13.8.20 8:18	2021-12-31	Edoxaban 60mg / no ASA indication
1910	70	Placebo	no ASA indication	YSC642L	17.12.20 8:18	2022-08-31	Edoxaban 30mg / no ASA indication
2517	70	Placebo	no ASA indication	AHE211A	7.3.22 14:12	2024-04-30	Edoxaban 60mg / no ASA indication
105	70	Edoxaban	ASA indication	PTG673F	1.3.17 13:10	2018-09-01	Edoxaban 60mg / ASA indication
105	70	Edoxaban	ASA indication	BEE517M	6.9.17 12:41	2018-09-01	Edoxaban 60mg / ASA indication
105	70	Edoxaban	ASA indication	AAW944V	9.10.19 13:10	2021-12-31	Edoxaban 60mg / ASA indication
105	70	Edoxaban	ASA indication	HKZ347T	5.9.18 12:06	2020-01-01	Edoxaban 60mg / no ASA indication
105	70	Edoxaban	ASA indication	VFM769F	27.3.19 14:51	2020-01-01	Edoxaban 60mg / ASA indication
105	70	Edoxaban	ASA indication	SKM473N	9.3.18 12:16	2020-01-01	Edoxaban 60mg / no ASA indication
662	70	Edoxaban	ASA indication	ESA317Z	10.8.18 7:31	2020-01-01	Edoxaban 30mg / ASA indication
674	70	Edoxaban	ASA indication	KPX612Z	17.8.18 12:57	2020-01-01	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	LUS617F	10.5.19 12:23	2020-01-01	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	BYL464E	6.11.19 12:02	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
774	70	Edoxaban	ASA indication	EWE223B	26.10.18 8:57	2020-01-01	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	ASN375W	21.4.21 13:39	2022-08-31	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	PGU841P	27.4.20 10:39	2022-08-31	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	TWG921B	22.10.20 11:17	2022-08-31	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	ETX221B	27.4.22 11:38	2024-11-30	Edoxaban 30mg / ASA indication
774	70	Edoxaban	ASA indication	RAM764X	21.10.21 11:40	2022-08-31	Edoxaban 30mg / ASA indication
881	70	Edoxaban	ASA indication	CNT221T	11.12.18 9:16	2020-01-01	Edoxaban 30mg / ASA indication
1134	70	Edoxaban	ASA indication	UAW686K	25.11.20 10:28	2021-12-31	Edoxaban 60mg / ASA indication
1134	70	Edoxaban	ASA indication	FBY369Z	21.5.19 9:52	2020-01-01	Edoxaban 60mg / ASA indication
1134	70	Edoxaban	ASA indication	DEC372Y	25.11.19 12:29	2021-12-31	Edoxaban 60mg / ASA indication
1134	70	Edoxaban	ASA indication	XPN471C	24.5.22 12:18	2024-04-30	Edoxaban 60mg / ASA indication
1134	70	Edoxaban	ASA indication	SUF454N	27.5.20 12:46	2021-12-31	Edoxaban 60mg / ASA indication
1134	70	Edoxaban	ASA indication	MHA596S	25.5.21 9:33	2021-12-31	Edoxaban 60mg / ASA indication
1134	70	Edoxaban	ASA indication	AKG237G	23.11.21 12:06	2024-04-30	Edoxaban 60mg / ASA indication
1599	70	Edoxaban	ASA indication	TWW965T	26.11.20 12:35	2021-12-31	Edoxaban 60mg / ASA indication
1599	70	Edoxaban	ASA indication	XHE252X	17.12.21 10:59	2024-04-30	Edoxaban 60mg / ASA indication
1599	70	Edoxaban	ASA indication	STL986G	22.6.22 10:52	2024-04-30	Edoxaban 60mg / ASA indication
1599	70	Edoxaban	ASA indication	GEV584L	27.5.20 12:32	2021-12-31	Edoxaban 60mg / ASA indication
1599	70	Edoxaban	ASA indication	ECB522W	31.5.21 12:37	2021-12-31	Edoxaban 60mg / ASA indication
1725	70	Edoxaban	ASA indication	ANM792K	17.8.21 6:02	2024-04-30	Edoxaban 60mg / ASA indication
1725	70	Edoxaban	ASA indication	DYP136W	23.2.22 7:58	2024-04-30	Edoxaban 60mg / ASA indication
1725	70	Edoxaban	ASA indication	NPB829A	31.8.22 11:55	2024-04-30	Edoxaban 60mg / ASA indication
1725	70	Edoxaban	ASA indication	TZG683Y	12.2.21 11:03	2021-12-31	Edoxaban 60mg / ASA indication
1725	70	Edoxaban	ASA indication	YTR712E	6.8.20 12:15	2021-12-31	Edoxaban 60mg / ASA indication
1805	70	Edoxaban	ASA indication	VSX519E	31.3.21 9:34	2021-12-31	Edoxaban 60mg / ASA indication
1805	70	Edoxaban	ASA indication	XEZ878E	14.10.21 8:44	2024-04-30	Edoxaban 60mg / ASA indication
1805	70	Edoxaban	ASA indication	PTB126V	1.10.20 12:03	2021-12-31	Edoxaban 60mg / ASA indication
1805	70	Edoxaban	ASA indication	NPV528W	14.4.22 10:49	2024-04-30	Edoxaban 60mg / ASA indication
1808	70	Edoxaban	ASA indication	LWY688U	1.10.20 10:26	2021-12-31	Edoxaban 60mg / ASA indication
1808	70	Edoxaban	ASA indication	RUF528K	30.3.21 6:54	2021-12-31	Edoxaban 60mg / ASA indication
1964	70	Edoxaban	ASA indication	RGG796W	17.2.21 13:48	2021-12-31	Edoxaban 60mg / ASA indication
1964	70	Edoxaban	ASA indication	AKP499C	20.8.21 7:03	2024-04-30	Edoxaban 60mg / ASA indication
1964	70	Edoxaban	ASA indication	DSG148V	11.2.22 10:59	2024-04-30	Edoxaban 60mg / ASA indication
1964	70	Edoxaban	ASA indication	PZS986B	31.8.22 13:37	2024-11-30	Edoxaban 30mg / ASA indication
2014	70	Edoxaban	ASA indication	NYF652N	8.4.22 14:29	2024-11-30	Edoxaban 30mg / ASA indication
2014	70	Edoxaban	ASA indication	WPP385N	18.3.21 7:10	2022-08-31	Edoxaban 30mg / ASA indication
2014	70	Edoxaban	ASA indication	TVN666L	24.9.21 7:51	2022-08-31	Edoxaban 30mg / ASA indication
2068	70	Edoxaban	ASA indication	LVN583V	28.4.21 8:27	2021-12-31	Edoxaban 60mg / ASA indication
2182	70	Edoxaban	ASA indication	APM257E	9.7.21 7:56	2024-04-30	Edoxaban 60mg / ASA indication
2529	70	Edoxaban	ASA indication	ETM511P	11.3.22 11:06	2024-11-30	Edoxaban 30mg / ASA indication
16	70	Edoxaban	no ASA indication	SHR627V	10.2.20 11:14	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
16	70	Edoxaban	no ASA indication	KTU115A	31.8.16 10:12	2018-09-01	Edoxaban 60mg / no ASA indication
16	70	Edoxaban	no ASA indication	YBB793R	27.2.19 13:42	2020-01-01	Edoxaban 60mg / no ASA indication
16	70	Edoxaban	no ASA indication	PSS825W	12.8.19 8:16	2021-12-31	Edoxaban 60mg / no ASA indication
16	70	Edoxaban	no ASA indication	TCD125F	6.9.17 5:52	2018-09-01	Edoxaban 60mg / no ASA indication
16	70	Edoxaban	no ASA indication	HLE453P	8.3.18 13:26	2020-01-01	Edoxaban 60mg / no ASA indication
16	70	Edoxaban	no ASA indication	GUU483K	24.2.17 11:56	2018-09-01	Edoxaban 60mg / no ASA indication
16	70	Edoxaban	no ASA indication	DXW435Z	6.9.18 12:28	2020-01-01	Edoxaban 60mg / no ASA indication
253	70	Edoxaban	no ASA indication	YXA227L	16.8.17 8:41	2018-09-01	Edoxaban 60mg / no ASA indication
253	70	Edoxaban	no ASA indication	BYC732X	16.8.18 13:25	2020-01-01	Edoxaban 60mg / no ASA indication
253	70	Edoxaban	no ASA indication	AKV699G	19.2.18 16:18	2020-01-01	Edoxaban 60mg / no ASA indication
253	70	Edoxaban	no ASA indication	LZR755E	18.2.19 13:05	2020-01-01	Edoxaban 60mg / no ASA indication
402	70	Edoxaban	no ASA indication	SNY987U	12.7.18 12:39	2020-01-01	Edoxaban 30mg / no ASA indication
402	70	Edoxaban	no ASA indication	HPA565V	12.1.18 13:53	2018-09-01	Edoxaban 30mg / no ASA indication
514	70	Edoxaban	no ASA indication	FWH458S	11.4.18 7:47	2020-01-01	Edoxaban 60mg / no ASA indication
514	70	Edoxaban	no ASA indication	TXN395U	5.10.18 11:36	2020-01-01	Edoxaban 60mg / no ASA indication
1320	70	Edoxaban	no ASA indication	PWC913F	8.10.19 11:38	2022-08-31	Edoxaban 30mg / no ASA indication
1569	70	Edoxaban	no ASA indication	DTF285C	3.4.20 15:27	2021-12-31	Edoxaban 60mg / no ASA indication
1569	70	Edoxaban	no ASA indication	WGA576V	18.9.20 10:54	2021-12-31	Edoxaban 60mg / ASA indication
1741	70	Edoxaban	no ASA indication	EFX834U	6.9.21 7:30	2022-08-31	Edoxaban 30mg / no ASA indication
1741	70	Edoxaban	no ASA indication	HKX228G	21.8.20 11:39	2022-08-31	Edoxaban 30mg / no ASA indication
1741	70	Edoxaban	no ASA indication	LFK822D	26.2.21 14:25	2022-08-31	Edoxaban 30mg / no ASA indication
1829	70	Edoxaban	no ASA indication	SSP365U	19.4.21 8:03	2022-08-31	Edoxaban 30mg / no ASA indication
1829	70	Edoxaban	no ASA indication	EHA433N	1.7.22 6:53	2024-11-30	Edoxaban 30mg / no ASA indication
1829	70	Edoxaban	no ASA indication	XAX338Z	21.10.21 12:55	2022-08-31	Edoxaban 30mg / no ASA indication
1829	70	Edoxaban	no ASA indication	WXE226Z	19.10.20 13:38	2022-08-31	Edoxaban 30mg / no ASA indication
2171	70	Edoxaban	no ASA indication	MDL437B	28.6.21 12:31	2022-08-31	Edoxaban 30mg / no ASA indication
2171	70	Edoxaban	no ASA indication	XFV828D	3.1.22 9:34	2022-08-31	Edoxaban 30mg / no ASA indication
2171	70	Edoxaban	no ASA indication	PHK311N	7.7.22 6:41	2024-11-30	Edoxaban 30mg / no ASA indication
373	86	Placebo	ASA indication	LAS591M	12.12.17 14:47	2018-09-01	Edoxaban 60mg / ASA indication
404	86	Placebo	ASA indication	XFW258W	10.1.19 8:51	2020-01-01	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	UYY285N	15.1.18 16:38	2018-09-01	Edoxaban 60mg / ASA indication
404	86	Placebo	ASA indication	SSX744Y	5.8.20 12:28	2022-08-31	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	DZC831K	5.1.21 15:21	2022-08-31	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	MBD788G	25.7.19 12:45	2022-08-31	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	CEX556R	30.1.20 14:09	2022-08-31	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	EUW566S	2.7.18 14:51	2020-01-01	Edoxaban 30mg / no ASA indication
404	86	Placebo	ASA indication	NRH765L	2.8.21 16:12	2022-08-31	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	NPR656U	6.1.22 11:50	2022-08-31	Edoxaban 30mg / ASA indication
404	86	Placebo	ASA indication	CRA663Z	7.7.22 9:52	2024-11-30	Edoxaban 30mg / ASA indication
1016	86	Placebo	ASA indication	DDN571T	20.2.20 14:01	2021-12-31	Edoxaban 60mg / ASA indication
1016	86	Placebo	ASA indication	YWM447S	29.8.19 13:37	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1016	86	Placebo	ASA indication	WHG546R	22.2.22 15:01	2024-04-30	Edoxaban 60mg / ASA indication
1016	86	Placebo	ASA indication	DAX586L	23.8.21 14:43	2024-04-30	Edoxaban 60mg / ASA indication
1016	86	Placebo	ASA indication	MWS586L	5.3.19 15:43	2020-01-01	Edoxaban 60mg / ASA indication
1016	86	Placebo	ASA indication	CMA533L	24.2.21 12:05	2021-12-31	Edoxaban 60mg / ASA indication
1016	86	Placebo	ASA indication	YLY332T	26.8.20 12:17	2021-12-31	Edoxaban 60mg / ASA indication
1016	86	Placebo	ASA indication	DCP791M	24.8.22 11:38	2024-04-30	Edoxaban 60mg / ASA indication
1262	86	Placebo	ASA indication	SUB511F	26.2.20 11:45	2021-12-31	Edoxaban 60mg / ASA indication
1262	86	Placebo	ASA indication	SVH565M	25.2.21 15:22	2021-12-31	Edoxaban 60mg / ASA indication
1262	86	Placebo	ASA indication	MWP291E	27.8.19 13:49	2021-12-31	Edoxaban 60mg / ASA indication
1262	86	Placebo	ASA indication	WTH288N	3.9.20 12:33	2021-12-31	Edoxaban 60mg / ASA indication
1262	86	Placebo	ASA indication	ZST433C	2.9.22 11:13	2024-04-30	Edoxaban 60mg / no ASA indication
1262	86	Placebo	ASA indication	DBP353B	25.8.21 10:57	2024-04-30	Edoxaban 60mg / ASA indication
1262	86	Placebo	ASA indication	WKB552K	3.3.22 14:20	2024-04-30	Edoxaban 60mg / ASA indication
554	86	Placebo	no ASA indication	KSB622Z	15.5.18 14:14	2020-01-01	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	LYM831B	9.12.20 13:31	2021-12-31	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	CLE573Z	7.7.21 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	CKV895X	9.12.21 13:10	2024-04-30	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	BPD838F	5.6.20 9:21	2021-12-31	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	WMC655E	14.4.22 11:06	2024-04-30	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	LCX367N	3.3.20 14:46	2021-12-31	Edoxaban 60mg / no ASA indication
1542	86	Placebo	no ASA indication	WTE994F	15.3.21 11:35	2021-12-31	Edoxaban 60mg / no ASA indication
338	86	Edoxaban	ASA indication	TGF452L	14.11.17 15:29	2018-09-01	Edoxaban 60mg / ASA indication
338	86	Edoxaban	ASA indication	NKG963D	28.5.18 6:50	2020-01-01	Edoxaban 60mg / no ASA indication
352	86	Edoxaban	ASA indication	TGR558A	28.11.17 15:23	2018-09-01	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	BDS212H	28.3.19 15:07	2020-01-01	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	CMG796L	24.3.20 9:11	2021-12-31	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	FFS226L	23.3.21 15:12	2021-12-31	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	XCK822C	12.9.19 13:24	2021-12-31	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	BBV269B	24.9.20 13:27	2021-12-31	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	RCP555N	25.9.18 14:52	2020-01-01	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	WZM743H	29.9.21 11:04	2024-04-30	Edoxaban 60mg / ASA indication
722	86	Edoxaban	ASA indication	ALD719Y	29.3.22 8:50	2024-04-30	Edoxaban 60mg / ASA indication
1263	86	Edoxaban	ASA indication	ZKH847W	13.2.20 14:49	2021-12-31	Edoxaban 60mg / ASA indication
1263	86	Edoxaban	ASA indication	CXW259X	19.8.21 13:13	2024-04-30	Edoxaban 60mg / ASA indication
1263	86	Edoxaban	ASA indication	ALW271X	21.2.22 14:05	2024-04-30	Edoxaban 60mg / ASA indication
1263	86	Edoxaban	ASA indication	ZSV483W	18.8.20 14:02	2021-12-31	Edoxaban 60mg / ASA indication
1263	86	Edoxaban	ASA indication	XWH158V	16.8.22 13:35	2024-04-30	Edoxaban 60mg / ASA indication
1263	86	Edoxaban	ASA indication	MCY253F	17.2.21 12:02	2021-12-31	Edoxaban 60mg / no ASA indication
1263	86	Edoxaban	ASA indication	YMS598V	27.8.19 15:20	2021-12-31	Edoxaban 60mg / ASA indication
1374	86	Edoxaban	ASA indication	CVS257B	1.11.21 10:48	2024-04-30	Edoxaban 60mg / ASA indication
1374	86	Edoxaban	ASA indication	PGU122Y	2.5.22 9:18	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1374	86	Edoxaban	ASA indication	MDU256B	26.10.20 9:38	2021-12-31	Edoxaban 60mg / ASA indication
1374	86	Edoxaban	ASA indication	RHX691T	11.11.19 9:07	2021-12-31	Edoxaban 60mg / ASA indication
1374	86	Edoxaban	ASA indication	BHY996A	29.4.20 15:08	2021-12-31	Edoxaban 60mg / ASA indication
1374	86	Edoxaban	ASA indication	FLY427U	26.4.21 8:11	2021-12-31	Edoxaban 60mg / ASA indication
1428	86	Edoxaban	ASA indication	TBT739B	6.5.21 14:25	2021-12-31	Edoxaban 60mg / ASA indication
1428	86	Edoxaban	ASA indication	TDZ486Z	3.12.19 14:44	2021-12-31	Edoxaban 60mg / ASA indication
1428	86	Edoxaban	ASA indication	MYA186D	19.5.20 9:12	2021-12-31	Edoxaban 60mg / ASA indication
1428	86	Edoxaban	ASA indication	MFC248L	12.11.20 14:46	2021-12-31	Edoxaban 60mg / ASA indication
1428	86	Edoxaban	ASA indication	CWD629Z	18.11.21 16:20	2024-04-30	Edoxaban 60mg / ASA indication
672	86	Edoxaban	no ASA indication	MWV361E	14.8.18 14:49	2020-01-01	Edoxaban 60mg / no ASA indication
1189	86	Edoxaban	no ASA indication	PFD194D	18.6.19 13:46	2020-01-01	Edoxaban 30mg / no ASA indication
1379	86	Edoxaban	no ASA indication	LDH621R	30.11.20 14:36	2021-12-31	Edoxaban 60mg / no ASA indication
1379	86	Edoxaban	no ASA indication	DTF218P	12.11.19 15:39	2021-12-31	Edoxaban 60mg / no ASA indication
1379	86	Edoxaban	no ASA indication	WNS484N	9.6.20 14:39	2021-12-31	Edoxaban 60mg / no ASA indication
1379	86	Edoxaban	no ASA indication	CSV774S	12.5.22 12:58	2024-04-30	Edoxaban 60mg / no ASA indication
1379	86	Edoxaban	no ASA indication	KUC135H	3.5.21 13:12	2021-12-31	Edoxaban 60mg / no ASA indication
1379	86	Edoxaban	no ASA indication	CRG865A	2.11.21 10:33	2024-04-30	Edoxaban 60mg / no ASA indication
18	95	Placebo	ASA indication	VPK477A	6.9.16 8:01	2018-09-01	Edoxaban 60mg / ASA indication
28	95	Placebo	ASA indication	UUT774B	21.9.16 5:47	2018-09-01	Edoxaban 60mg / ASA indication
38	95	Placebo	ASA indication	XFE522C	4.4.17 11:56	2018-09-01	Edoxaban 60mg / no ASA indication
38	95	Placebo	ASA indication	KDL326D	2.5.18 9:21	2020-01-01	Edoxaban 60mg / no ASA indication
38	95	Placebo	ASA indication	KWM286T	19.10.16 7:49	2018-09-01	Edoxaban 60mg / ASA indication
38	95	Placebo	ASA indication	XYS485Y	19.10.17 9:02	2018-09-01	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	MYS475B	2.11.17 10:15	2018-09-01	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	WHK472S	8.11.16 10:32	2018-09-01	Edoxaban 60mg / ASA indication
44	95	Placebo	ASA indication	BHW292M	16.4.19 10:51	2020-01-01	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	MNH719U	29.10.19 10:19	2021-12-31	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	RUN547W	13.11.18 10:47	2020-01-01	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	KDZ741N	6.10.20 9:40	2021-12-31	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	KSM387U	4.5.17 8:21	2018-09-01	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	FZM636B	17.5.18 9:52	2020-01-01	Edoxaban 60mg / no ASA indication
44	95	Placebo	ASA indication	AYU228M	21.4.20 9:38	2021-12-31	Edoxaban 60mg / no ASA indication
22	95	Placebo	no ASA indication	RXK175F	21.3.17 11:26	2018-09-01	Edoxaban 60mg / ASA indication
22	95	Placebo	no ASA indication	ACK127W	29.3.18 11:05	2020-01-01	Edoxaban 60mg / ASA indication
22	95	Placebo	no ASA indication	KSY437B	13.9.16 12:34	2018-09-01	Edoxaban 60mg / no ASA indication
22	95	Placebo	no ASA indication	DVU315Z	28.9.17 10:11	2018-09-01	Edoxaban 60mg / ASA indication
26	95	Placebo	no ASA indication	HNN954A	21.3.17 15:15	2018-09-01	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	ELY347E	22.3.19 7:24	2020-01-01	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	UXH398D	11.9.18 8:10	2020-01-01	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	ZAL662D	2.2.21 9:38	2022-08-31	Edoxaban 30mg / no ASA indication
26	95	Placebo	no ASA indication	YLE612Z	21.9.17 12:43	2018-09-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
26	95	Placebo	no ASA indication	WPW747S	10.3.22 10:14	2024-04-30	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	CZC951D	21.3.18 9:22	2020-01-01	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	XGU573E	25.2.20 11:12	2021-12-31	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	CDR815W	19.9.16 10:33	2018-09-01	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	PBA692X	18.8.20 9:57	2021-12-31	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	AXN395E	20.8.19 11:45	2021-12-31	Edoxaban 60mg / no ASA indication
26	95	Placebo	no ASA indication	CPM598S	24.8.21 11:20	2024-04-30	Edoxaban 60mg / no ASA indication
30	95	Placebo	no ASA indication	ATU679M	11.9.18 11:17	2020-01-01	Edoxaban 60mg / no ASA indication
30	95	Placebo	no ASA indication	DBN987B	19.9.17 8:34	2018-09-01	Edoxaban 60mg / ASA indication
30	95	Placebo	no ASA indication	SYM831A	21.3.18 12:02	2020-01-01	Edoxaban 60mg / no ASA indication
30	95	Placebo	no ASA indication	WCH245T	21.3.17 9:33	2018-09-01	Edoxaban 60mg / ASA indication
30	95	Placebo	no ASA indication	YBG451L	21.9.16 9:23	2018-09-01	Edoxaban 60mg / no ASA indication
71	95	Placebo	no ASA indication	SDL141F	13.1.17 8:36	2018-09-01	Edoxaban 60mg / no ASA indication
71	95	Placebo	no ASA indication	NVV762D	13.12.18 8:37	2020-01-01	Edoxaban 60mg / no ASA indication
71	95	Placebo	no ASA indication	YRG622N	7.12.17 13:03	2018-09-01	Edoxaban 60mg / no ASA indication
71	95	Placebo	no ASA indication	ZSB421C	19.6.18 6:19	2020-01-01	Edoxaban 60mg / no ASA indication
71	95	Placebo	no ASA indication	ABW412T	29.6.17 7:33	2018-09-01	Edoxaban 60mg / no ASA indication
534	95	Placebo	no ASA indication	WBB257H	25.4.18 9:11	2020-01-01	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	WSX893K	1.10.19 12:11	2021-12-31	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	FCV153P	6.10.20 8:29	2021-12-31	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	XZV891S	20.4.21 8:15	2021-12-31	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	CPE173R	7.10.21 7:54	2024-04-30	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	ECN869S	7.4.20 9:08	2021-12-31	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	CGK988P	9.4.19 9:15	2020-01-01	Edoxaban 60mg / no ASA indication
1066	95	Placebo	no ASA indication	PDN797E	7.4.22 7:58	2024-11-30	Edoxaban 30mg / no ASA indication
1368	95	Placebo	no ASA indication	GKN317B	6.10.20 11:32	2022-08-31	Edoxaban 30mg / no ASA indication
1368	95	Placebo	no ASA indication	ZNV144U	6.11.19 10:23	2022-08-31	Edoxaban 30mg / no ASA indication
1368	95	Placebo	no ASA indication	ZAV821D	21.4.20 10:52	2022-08-31	Edoxaban 30mg / no ASA indication
2287	95	Placebo	no ASA indication	CNF241H	28.9.21 9:52	2024-04-30	Edoxaban 60mg / no ASA indication
2287	95	Placebo	no ASA indication	WMF854V	16.3.22 10:20	2024-04-30	Edoxaban 60mg / no ASA indication
2287	95	Placebo	no ASA indication	WNT849X	6.9.22 9:19	2024-04-30	Edoxaban 60mg / no ASA indication
10	95	Edoxaban	ASA indication	AMD195U	9.8.16 12:23	2018-09-01	Edoxaban 60mg / ASA indication
14	95	Edoxaban	ASA indication	DXH897L	3.4.17 8:46	2018-09-01	Edoxaban 60mg / no ASA indication
14	95	Edoxaban	ASA indication	HSR179A	8.2.18 10:16	2018-09-01	Edoxaban 60mg / ASA indication
14	95	Edoxaban	ASA indication	YXD167N	22.3.19 7:21	2020-01-01	Edoxaban 60mg / no ASA indication
14	95	Edoxaban	ASA indication	MVB663S	25.2.21 9:39	2022-08-31	Edoxaban 30mg / no ASA indication
14	95	Edoxaban	ASA indication	VAY299K	25.2.20 11:37	2021-12-31	Edoxaban 60mg / ASA indication
14	95	Edoxaban	ASA indication	DPG889X	16.8.18 9:49	2020-01-01	Edoxaban 60mg / no ASA indication
14	95	Edoxaban	ASA indication	SAY343T	25.2.21 8:34	2022-08-31	Edoxaban 30mg / ASA indication
14	95	Edoxaban	ASA indication	ZPK997E	31.8.16 6:34	2018-09-01	Edoxaban 60mg / ASA indication
14	95	Edoxaban	ASA indication	YWE113C	13.9.19 7:49	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
14	95	Edoxaban	ASA indication	BUD868P	4.9.17 7:01	2018-09-01	Edoxaban 60mg / no ASA indication
14	95	Edoxaban	ASA indication	SAX924N	3.9.20 10:50	2021-12-31	Edoxaban 60mg / no ASA indication
53	95	Edoxaban	ASA indication	PZM269D	17.5.18 10:24	2020-01-01	Edoxaban 30mg / no ASA indication
53	95	Edoxaban	ASA indication	RPN128R	23.11.16 11:18	2018-09-01	Edoxaban 60mg / ASA indication
53	95	Edoxaban	ASA indication	BDW685M	16.5.17 11:48	2018-09-01	Edoxaban 30mg / no ASA indication
53	95	Edoxaban	ASA indication	SSM382Y	16.5.17 9:53	2018-09-01	Edoxaban 60mg / no ASA indication
53	95	Edoxaban	ASA indication	EZT332Z	3.11.17 10:02	2018-09-01	Edoxaban 30mg / no ASA indication
1175	95	Edoxaban	ASA indication	CTS271V	29.3.22 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
1175	95	Edoxaban	ASA indication	UXN828E	12.3.20 10:19	2021-12-31	Edoxaban 60mg / no ASA indication
1175	95	Edoxaban	ASA indication	SFV883F	2.3.21 11:11	2021-12-31	Edoxaban 60mg / no ASA indication
1175	95	Edoxaban	ASA indication	MWD199P	11.6.19 11:48	2020-01-01	Edoxaban 60mg / ASA indication
1175	95	Edoxaban	ASA indication	EGC651R	15.9.20 8:50	2021-12-31	Edoxaban 60mg / no ASA indication
1175	95	Edoxaban	ASA indication	WNN796L	14.9.21 8:45	2024-04-30	Edoxaban 60mg / no ASA indication
1175	95	Edoxaban	ASA indication	FFN992T	17.12.19 12:28	2021-12-31	Edoxaban 60mg / no ASA indication
13	95	Edoxaban	no ASA indication	CAR957C	30.8.16 11:00	2018-09-01	Edoxaban 30mg / no ASA indication
29	95	Edoxaban	no ASA indication	EWY328P	7.3.17 12:45	2018-09-01	Edoxaban 60mg / ASA indication
29	95	Edoxaban	no ASA indication	HRD426D	17.8.17 10:16	2018-09-01	Edoxaban 60mg / no ASA indication
29	95	Edoxaban	no ASA indication	VVP438G	21.9.16 7:30	2018-09-01	Edoxaban 60mg / no ASA indication
117	95	Edoxaban	no ASA indication	NKN994B	21.3.18 11:02	2020-01-01	Edoxaban 60mg / no ASA indication
117	95	Edoxaban	no ASA indication	EPW964B	11.9.18 9:31	2020-01-01	Edoxaban 60mg / no ASA indication
117	95	Edoxaban	no ASA indication	CWT491M	10.9.19 9:15	2021-12-31	Edoxaban 60mg / no ASA indication
117	95	Edoxaban	no ASA indication	LEM138U	19.9.17 9:23	2018-09-01	Edoxaban 60mg / no ASA indication
117	95	Edoxaban	no ASA indication	XBH727N	21.3.17 13:12	2018-09-01	Edoxaban 60mg / no ASA indication
117	95	Edoxaban	no ASA indication	YMT974R	5.3.19 10:53	2020-01-01	Edoxaban 60mg / no ASA indication
180	95	Edoxaban	no ASA indication	NUY976Y	2.11.17 13:10	2018-09-01	Edoxaban 30mg / no ASA indication
180	95	Edoxaban	no ASA indication	TWS776D	17.5.18 11:38	2020-01-01	Edoxaban 60mg / no ASA indication
180	95	Edoxaban	no ASA indication	BRD986T	23.11.21 10:04	2022-08-31	Edoxaban 30mg / no ASA indication
180	95	Edoxaban	no ASA indication	LMK424R	28.4.20 10:51	2022-08-31	Edoxaban 30mg / no ASA indication
180	95	Edoxaban	no ASA indication	PST386D	5.11.19 12:14	2021-12-31	Edoxaban 60mg / no ASA indication
180	95	Edoxaban	no ASA indication	PFF685V	13.10.20 10:39	2022-08-31	Edoxaban 30mg / no ASA indication
180	95	Edoxaban	no ASA indication	PFF356F	13.11.18 12:49	2020-01-01	Edoxaban 60mg / no ASA indication
180	95	Edoxaban	no ASA indication	CZN522F	7.6.17 7:18	2018-09-01	Edoxaban 60mg / no ASA indication
180	95	Edoxaban	no ASA indication	ELM133B	7.6.22 8:40	2024-11-30	Edoxaban 30mg / no ASA indication
180	95	Edoxaban	no ASA indication	BRU463E	12.5.21 8:26	2022-08-31	Edoxaban 30mg / no ASA indication
180	95	Edoxaban	no ASA indication	TEZ655M	16.4.19 11:38	2020-01-01	Edoxaban 60mg / no ASA indication
202	95	Edoxaban	no ASA indication	KNF929E	27.6.17 7:34	2018-09-01	Edoxaban 60mg / no ASA indication
533	95	Edoxaban	no ASA indication	DGU395C	25.4.18 7:45	2020-01-01	Edoxaban 60mg / no ASA indication
533	95	Edoxaban	no ASA indication	ELA663N	22.3.19 7:27	2020-01-01	Edoxaban 60mg / no ASA indication
533	95	Edoxaban	no ASA indication	LZM754X	24.9.19 9:56	2021-12-31	Edoxaban 60mg / no ASA indication
533	95	Edoxaban	no ASA indication	KBL799N	27.9.18 10:56	2020-01-01	Edoxaban 60mg / no ASA indication
820	95	Edoxaban	no ASA indication	EZY935N	4.12.18 6:52	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
4	100	Placebo	ASA indication	NBT419B	9.1.17 12:58	2018-09-01	Edoxaban 30mg / ASA indication
4	100	Placebo	ASA indication	TFM737A	7.7.16 10:40	2018-09-01	Edoxaban 60mg / ASA indication
846	100	Placebo	ASA indication	PCP946W	13.5.19 7:32	2020-01-01	Edoxaban 60mg / ASA indication
846	100	Placebo	ASA indication	PYK133F	26.11.18 12:08	2020-01-01	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	WWP523P	21.5.19 7:41	2020-01-01	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	VZT298A	17.6.21 10:22	2021-12-31	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	SCA682V	25.5.20 8:23	2021-12-31	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	WNG471S	27.11.18 9:47	2020-01-01	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	DEX611U	9.12.21 11:09	2024-04-30	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	DGU255U	9.6.22 9:20	2024-04-30	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	AGH963V	3.12.20 11:50	2021-12-31	Edoxaban 60mg / ASA indication
848	100	Placebo	ASA indication	HTM271H	27.11.19 9:53	2021-12-31	Edoxaban 60mg / ASA indication
1969	100	Placebo	ASA indication	ZHK768Y	18.2.21 14:28	2022-08-31	Edoxaban 30mg / ASA indication
1969	100	Placebo	ASA indication	ULW844D	10.8.21 10:03	2022-08-31	Edoxaban 30mg / ASA indication
1969	100	Placebo	ASA indication	EUX546B	21.2.22 16:25	2024-11-30	Edoxaban 30mg / no ASA indication
1969	100	Placebo	ASA indication	SYU441R	11.8.22 12:55	2024-11-30	Edoxaban 30mg / no ASA indication
1604	100	Placebo	no ASA indication	EMD324K	28.5.20 13:51	2021-12-31	Edoxaban 60mg / no ASA indication
2653	100	Placebo	no ASA indication	EUA125T	14.6.22 14:39	2024-11-30	Edoxaban 30mg / no ASA indication
124	100	Edoxaban	ASA indication	MUC414W	17.9.18 8:10	2020-01-01	Edoxaban 60mg / ASA indication
124	100	Edoxaban	ASA indication	XKT273T	29.3.17 8:10	2018-09-01	Edoxaban 30mg / ASA indication
124	100	Edoxaban	ASA indication	KRB229D	21.9.17 8:52	2018-09-01	Edoxaban 60mg / ASA indication
124	100	Edoxaban	ASA indication	TNK845Z	19.9.19 7:58	2022-08-31	Edoxaban 30mg / ASA indication
124	100	Edoxaban	ASA indication	RLW487R	26.3.18 9:55	2020-01-01	Edoxaban 30mg / no ASA indication
124	100	Edoxaban	ASA indication	ZAM961R	27.3.19 9:11	2020-01-01	Edoxaban 60mg / ASA indication
527	100	Edoxaban	ASA indication	WWH239K	11.10.18 8:19	2020-01-01	Edoxaban 30mg / ASA indication
527	100	Edoxaban	ASA indication	DWS469S	16.4.18 10:03	2020-01-01	Edoxaban 30mg / ASA indication
527	100	Edoxaban	ASA indication	RWM996Y	6.10.20 9:23	2022-08-31	Edoxaban 30mg / no ASA indication
527	100	Edoxaban	ASA indication	CGM138G	13.4.21 7:49	2022-08-31	Edoxaban 30mg / ASA indication
527	100	Edoxaban	ASA indication	NRC571A	10.10.19 7:27	2022-08-31	Edoxaban 30mg / no ASA indication
527	100	Edoxaban	ASA indication	PLE898X	2.4.20 8:20	2022-08-31	Edoxaban 30mg / no ASA indication
527	100	Edoxaban	ASA indication	BWY291V	26.10.21 7:27	2022-08-31	Edoxaban 30mg / no ASA indication
527	100	Edoxaban	ASA indication	EZM881F	26.4.22 7:37	2024-11-30	Edoxaban 30mg / ASA indication
527	100	Edoxaban	ASA indication	FFX846S	4.4.19 8:23	2020-01-01	Edoxaban 30mg / ASA indication
537	100	Edoxaban	ASA indication	ESE272H	29.10.18 12:18	2020-01-01	Edoxaban 60mg / ASA indication
537	100	Edoxaban	ASA indication	DAY165B	26.4.18 11:30	2020-01-01	Edoxaban 60mg / ASA indication
537	100	Edoxaban	ASA indication	GBF872Y	17.4.19 7:57	2020-01-01	Edoxaban 30mg / ASA indication
933	100	Edoxaban	ASA indication	BHF484C	4.7.19 9:31	2022-08-31	Edoxaban 30mg / ASA indication
933	100	Edoxaban	ASA indication	BVT872E	2.3.21 11:37	2022-08-31	Edoxaban 30mg / no ASA indication
933	100	Edoxaban	ASA indication	KDK844P	14.9.21 13:46	2022-08-31	Edoxaban 30mg / ASA indication
933	100	Edoxaban	ASA indication	VLF189L	9.1.20 10:48	2022-08-31	Edoxaban 30mg / ASA indication
933	100	Edoxaban	ASA indication	EMT378N	15.3.22 15:08	2024-11-30	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
933	100	Edoxaban	ASA indication	ZCW561E	6.7.20 9:59	2022-08-31	Edoxaban 30mg / ASA indication
933	100	Edoxaban	ASA indication	NYS829L	15.1.19 11:04	2020-01-01	Edoxaban 30mg / ASA indication
1327	100	Edoxaban	ASA indication	GCW627V	14.11.19 12:23	2022-08-31	Edoxaban 30mg / ASA indication
1327	100	Edoxaban	ASA indication	WRX396Z	7.5.20 9:59	2022-08-31	Edoxaban 30mg / ASA indication
1327	100	Edoxaban	ASA indication	KKK851D	11.11.21 10:58	2022-08-31	Edoxaban 30mg / ASA indication
1327	100	Edoxaban	ASA indication	DVM963D	10.5.21 10:01	2022-08-31	Edoxaban 30mg / ASA indication
1327	100	Edoxaban	ASA indication	CFE759G	5.11.20 11:19	2022-08-31	Edoxaban 30mg / ASA indication
201	109	Placebo	ASA indication	TLF124P	27.6.17 6:50	2018-09-01	Edoxaban 30mg / ASA indication
39	113	Placebo	ASA indication	GBZ869P	25.4.17 8:51	2018-09-01	Edoxaban 30mg / ASA indication
39	113	Placebo	ASA indication	SZX227F	26.10.17 12:24	2018-09-01	Edoxaban 30mg / ASA indication
39	113	Placebo	ASA indication	NUR834P	24.10.16 8:12	2018-09-01	Edoxaban 30mg / ASA indication
60	113	Placebo	ASA indication	MSV872Y	13.6.17 8:52	2018-09-01	Edoxaban 60mg / ASA indication
60	113	Placebo	ASA indication	XEN623G	13.12.16 10:45	2018-09-01	Edoxaban 60mg / ASA indication
37	113	Placebo	no ASA indication	MXE448R	19.10.17 13:57	2018-09-01	Edoxaban 60mg / no ASA indication
37	113	Placebo	no ASA indication	YHN956G	10.4.17 15:39	2018-09-01	Edoxaban 60mg / no ASA indication
37	113	Placebo	no ASA indication	HRC476V	9.10.18 9:49	2020-01-01	Edoxaban 60mg / no ASA indication
37	113	Placebo	no ASA indication	WEV542C	13.10.16 7:24	2018-09-01	Edoxaban 60mg / no ASA indication
37	113	Placebo	no ASA indication	FHY595T	3.4.18 13:43	2020-01-01	Edoxaban 60mg / no ASA indication
62	113	Placebo	no ASA indication	YBC842Y	22.6.17 8:09	2018-09-01	Edoxaban 60mg / no ASA indication
62	113	Placebo	no ASA indication	ZTM235U	10.12.18 10:41	2020-01-01	Edoxaban 60mg / no ASA indication
62	113	Placebo	no ASA indication	UZX227T	12.12.17 9:28	2018-09-01	Edoxaban 60mg / no ASA indication
62	113	Placebo	no ASA indication	GRV833B	15.12.16 8:44	2018-09-01	Edoxaban 60mg / no ASA indication
62	113	Placebo	no ASA indication	PRP628Y	26.6.18 13:01	2020-01-01	Edoxaban 60mg / no ASA indication
62	113	Placebo	no ASA indication	BUS714A	28.5.19 9:09	2020-01-01	Edoxaban 60mg / no ASA indication
154	113	Placebo	no ASA indication	HDR377R	27.10.17 10:29	2018-09-01	Edoxaban 60mg / no ASA indication
154	113	Placebo	no ASA indication	PYM766M	4.5.17 9:04	2018-09-01	Edoxaban 60mg / no ASA indication
154	113	Placebo	no ASA indication	XPD888V	29.4.19 13:22	2020-01-01	Edoxaban 60mg / no ASA indication
154	113	Placebo	no ASA indication	KXL119Y	24.10.18 8:03	2020-01-01	Edoxaban 60mg / no ASA indication
154	113	Placebo	no ASA indication	RWC798G	29.4.19 9:17	2020-01-01	Edoxaban 60mg / ASA indication
154	113	Placebo	no ASA indication	BUM515K	25.4.18 7:58	2020-01-01	Edoxaban 60mg / no ASA indication
369	113	Edoxaban	ASA indication	PLT795F	4.6.19 8:03	2020-01-01	Edoxaban 30mg / ASA indication
369	113	Edoxaban	ASA indication	NNN692V	11.6.18 10:26	2020-01-01	Edoxaban 30mg / ASA indication
369	113	Edoxaban	ASA indication	TER156U	17.12.18 9:03	2020-01-01	Edoxaban 30mg / ASA indication
369	113	Edoxaban	ASA indication	BKG168D	11.12.17 11:29	2018-09-01	Edoxaban 30mg / ASA indication
36	113	Edoxaban	no ASA indication	BSH773B	11.10.16 7:03	2018-09-01	Edoxaban 60mg / no ASA indication
40	113	Edoxaban	no ASA indication	CSD656S	24.10.16 9:12	2018-09-01	Edoxaban 60mg / no ASA indication
65	113	Edoxaban	no ASA indication	DYP463B	20.12.16 10:16	2018-09-01	Edoxaban 60mg / no ASA indication
65	113	Edoxaban	no ASA indication	ZGH355E	20.6.18 6:10	2020-01-01	Edoxaban 60mg / no ASA indication
65	113	Edoxaban	no ASA indication	ZKY886C	16.6.17 12:31	2018-09-01	Edoxaban 60mg / no ASA indication
65	113	Edoxaban	no ASA indication	ZDN685F	19.6.18 10:47	2020-01-01	Edoxaban 60mg / ASA indication
65	113	Edoxaban	no ASA indication	HBB537F	7.12.17 8:43	2018-09-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
411	113	Edoxaban	no ASA indication	VCA987Y	23.1.18 9:52	2018-09-01	Edoxaban 60mg / no ASA indication
17	117	Placebo	ASA indication	AXB858E	2.9.16 10:20	2018-09-01	Edoxaban 60mg / ASA indication
23	117	Placebo	ASA indication	AXR259W	15.9.17 9:10	2018-09-01	Edoxaban 60mg / ASA indication
23	117	Placebo	ASA indication	LWV175Y	20.9.18 9:10	2020-01-01	Edoxaban 60mg / ASA indication
23	117	Placebo	ASA indication	HTV262G	21.3.19 11:47	2020-01-01	Edoxaban 30mg / ASA indication
23	117	Placebo	ASA indication	PDG313Z	27.3.17 9:39	2018-09-01	Edoxaban 60mg / no ASA indication
23	117	Placebo	ASA indication	WPN494V	1.10.19 10:36	2021-12-31	Edoxaban 60mg / ASA indication
23	117	Placebo	ASA indication	CTH576N	16.9.16 10:11	2018-09-01	Edoxaban 60mg / ASA indication
23	117	Placebo	ASA indication	PKB282Y	14.3.18 10:32	2020-01-01	Edoxaban 30mg / ASA indication
1155	117	Placebo	no ASA indication	MVU623Z	2.12.19 14:10	2021-12-31	Edoxaban 60mg / no ASA indication
1155	117	Placebo	no ASA indication	GWU543B	31.5.19 13:30	2020-01-01	Edoxaban 60mg / no ASA indication
1155	117	Placebo	no ASA indication	HNW824F	5.6.20 13:08	2021-12-31	Edoxaban 60mg / no ASA indication
1739	117	Placebo	no ASA indication	YBM976K	20.8.20 15:41	2022-08-31	Edoxaban 30mg / no ASA indication
1739	117	Placebo	no ASA indication	MDG581S	26.2.21 14:13	2022-08-31	Edoxaban 30mg / no ASA indication
264	117	Edoxaban	ASA indication	MDK321L	21.2.18 12:28	2020-01-01	Edoxaban 60mg / ASA indication
264	117	Edoxaban	ASA indication	NVM757H	24.8.17 9:25	2018-09-01	Edoxaban 60mg / ASA indication
264	117	Edoxaban	ASA indication	CLM426R	22.8.18 11:52	2020-01-01	Edoxaban 60mg / ASA indication
320	117	Edoxaban	ASA indication	ZAN949Z	26.4.18 15:00	2020-01-01	Edoxaban 30mg / ASA indication
320	117	Edoxaban	ASA indication	ARW299S	26.10.17 13:03	2018-09-01	Edoxaban 30mg / ASA indication
320	117	Edoxaban	ASA indication	ZVH114E	26.4.18 12:42	2020-01-01	Edoxaban 30mg / no ASA indication
663	117	Edoxaban	ASA indication	PDF854T	10.8.18 9:26	2020-01-01	Edoxaban 60mg / ASA indication
663	117	Edoxaban	ASA indication	CUH784M	6.8.19 13:37	2021-12-31	Edoxaban 60mg / ASA indication
663	117	Edoxaban	ASA indication	USW144C	19.2.19 11:11	2020-01-01	Edoxaban 60mg / ASA indication
943	117	Edoxaban	ASA indication	CEH551X	19.7.19 13:26	2022-08-31	Edoxaban 30mg / ASA indication
943	117	Edoxaban	ASA indication	MZN633F	16.1.20 13:19	2022-08-31	Edoxaban 30mg / ASA indication
943	117	Edoxaban	ASA indication	YEE626N	18.1.19 11:04	2020-01-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	VTG182Z	6.12.16 10:58	2018-09-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	DLW515T	12.6.17 6:52	2018-09-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	CVF777V	5.12.18 10:19	2020-01-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	NMZ182N	20.5.19 6:23	2020-01-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	FSW151G	7.12.17 9:09	2018-09-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	BPX574V	7.6.18 7:46	2020-01-01	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	XUK143E	7.5.20 8:37	2022-08-31	Edoxaban 30mg / ASA indication
56	121	Placebo	ASA indication	ATC165C	15.11.19 9:25	2022-08-31	Edoxaban 30mg / ASA indication
103	121	Placebo	ASA indication	TAL919L	1.9.17 9:04	2018-09-01	Edoxaban 60mg / no ASA indication
103	121	Placebo	ASA indication	AYD417D	1.3.17 11:25	2018-09-01	Edoxaban 60mg / ASA indication
355	121	Placebo	ASA indication	RLN771E	30.11.17 10:21	2018-09-01	Edoxaban 60mg / ASA indication
355	121	Placebo	ASA indication	GDR443F	14.5.19 13:18	2020-01-01	Edoxaban 30mg / ASA indication
355	121	Placebo	ASA indication	SXR738E	22.11.18 10:46	2020-01-01	Edoxaban 60mg / ASA indication
355	121	Placebo	ASA indication	CBD375V	21.11.19 9:10	2022-08-31	Edoxaban 30mg / ASA indication
355	121	Placebo	ASA indication	NRP245M	29.5.18 8:54	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
130	121	Placebo	no ASA indication	VUY712L	18.10.17 11:05	2018-09-01	Edoxaban 30mg / no ASA indication
130	121	Placebo	no ASA indication	XKR168T	31.3.17 10:24	2018-09-01	Edoxaban 30mg / no ASA indication
41	121	Edoxaban	ASA indication	LVF339P	25.10.16 12:38	2018-09-01	Edoxaban 30mg / ASA indication
109	121	Edoxaban	ASA indication	TMM747D	13.3.17 11:30	2018-09-01	Edoxaban 30mg / ASA indication
359	121	Edoxaban	ASA indication	AGM298Z	4.12.17 12:38	2018-09-01	Edoxaban 60mg / ASA indication
111	121	Edoxaban	no ASA indication	WEL388H	12.9.17 10:05	2018-09-01	Edoxaban 60mg / no ASA indication
111	121	Edoxaban	no ASA indication	SAD257L	14.3.17 12:38	2018-09-01	Edoxaban 60mg / no ASA indication
101	132	Placebo	ASA indication	FAU332V	4.3.19 10:00	2020-01-01	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	TEG659N	11.9.17 7:35	2018-09-01	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	LEB395X	5.10.20 8:40	2021-12-31	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	TCH997H	2.9.19 7:51	2021-12-31	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	VCF683A	5.10.20 7:10	2021-12-31	Edoxaban 60mg / no ASA indication
101	132	Placebo	ASA indication	ZZN381R	22.8.22 7:22	2024-04-30	Edoxaban 60mg / no ASA indication
101	132	Placebo	ASA indication	TWK786K	21.2.17 8:39	2018-09-01	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	NGN485X	5.3.18 9:53	2020-01-01	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	DRP318E	16.8.21 10:08	2024-04-30	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	RMR631Y	13.8.18 8:39	2020-01-01	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	MLH415D	1.3.21 10:18	2021-12-31	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	CWB642Z	23.3.20 8:22	2021-12-31	Edoxaban 60mg / ASA indication
101	132	Placebo	ASA indication	WKB571F	21.2.22 8:31	2024-04-30	Edoxaban 60mg / ASA indication
229	132	Placebo	ASA indication	VTX451D	31.7.20 7:20	2021-12-31	Edoxaban 60mg / ASA indication
229	132	Placebo	ASA indication	MAE117G	21.1.19 8:56	2020-01-01	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	UNU975K	28.1.22 8:56	2022-08-31	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	WFC896Z	25.7.22 10:37	2024-11-30	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	FMF828D	22.1.21 9:58	2022-08-31	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	FFF894M	19.7.19 9:45	2022-08-31	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	SEL223Y	19.7.17 15:52	2018-09-01	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	MHV682H	24.1.18 17:52	2018-09-01	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	EKK751R	13.8.18 11:20	2020-01-01	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	YLC934U	23.7.21 7:49	2022-08-31	Edoxaban 30mg / ASA indication
229	132	Placebo	ASA indication	WSA576V	31.1.20 8:39	2022-08-31	Edoxaban 30mg / ASA indication
1612	132	Placebo	ASA indication	NFT118X	7.6.21 8:28	2021-12-31	Edoxaban 60mg / ASA indication
1612	132	Placebo	ASA indication	FGA868F	5.6.20 8:13	2021-12-31	Edoxaban 60mg / ASA indication
1612	132	Placebo	ASA indication	MDC592Z	7.12.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1958	132	Placebo	ASA indication	YSF615D	20.8.21 9:10	2022-08-31	Edoxaban 30mg / ASA indication
1958	132	Placebo	ASA indication	HDS353M	12.2.21 13:09	2022-08-31	Edoxaban 30mg / ASA indication
8	132	Placebo	no ASA indication	EXT699V	18.7.16 9:43	2018-09-01	Edoxaban 30mg / no ASA indication
8	132	Placebo	no ASA indication	XLH456L	16.1.17 9:10	2018-09-01	Edoxaban 30mg / no ASA indication
73	132	Placebo	no ASA indication	TBD182H	7.2.18 17:40	2018-09-01	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	SZT464D	20.1.20 7:31	2021-12-31	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	ELA633E	22.7.19 6:40	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
73	132	Placebo	no ASA indication	CXB984N	17.1.22 9:53	2024-04-30	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	SVZ523V	25.7.18 6:44	2020-01-01	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	ZZT312B	18.7.22 9:15	2024-04-30	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	WDD866K	16.1.17 10:52	2018-09-01	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	KUC523P	1.2.21 8:02	2021-12-31	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	ZGF626C	17.7.17 10:05	2018-09-01	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	WWU583B	20.7.20 7:41	2021-12-31	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	MEX766E	14.1.19 7:35	2020-01-01	Edoxaban 60mg / no ASA indication
73	132	Placebo	no ASA indication	HHN618S	19.7.21 6:55	2024-04-30	Edoxaban 60mg / no ASA indication
266	132	Placebo	no ASA indication	UGA814C	31.8.17 14:46	2018-09-01	Edoxaban 60mg / no ASA indication
1383	132	Placebo	no ASA indication	FDC657H	13.5.20 14:31	2021-12-31	Edoxaban 60mg / no ASA indication
1383	132	Placebo	no ASA indication	WRU182B	23.5.22 7:08	2024-04-30	Edoxaban 60mg / no ASA indication
1383	132	Placebo	no ASA indication	GPR297P	18.11.20 13:44	2021-12-31	Edoxaban 60mg / no ASA indication
1383	132	Placebo	no ASA indication	TNR325C	13.11.19 15:46	2021-12-31	Edoxaban 60mg / no ASA indication
1383	132	Placebo	no ASA indication	MUV355U	9.6.21 13:11	2021-12-31	Edoxaban 60mg / no ASA indication
1383	132	Placebo	no ASA indication	CXA315C	19.11.21 7:34	2024-04-30	Edoxaban 60mg / no ASA indication
1436	132	Placebo	no ASA indication	KZV371X	15.6.20 10:46	2022-08-31	Edoxaban 30mg / no ASA indication
1436	132	Placebo	no ASA indication	GLS564H	6.12.19 10:17	2022-08-31	Edoxaban 30mg / no ASA indication
1436	132	Placebo	no ASA indication	FCS462X	3.6.22 10:00	2024-11-30	Edoxaban 30mg / no ASA indication
1436	132	Placebo	no ASA indication	LLD721G	14.12.20 10:49	2022-08-31	Edoxaban 30mg / no ASA indication
1436	132	Placebo	no ASA indication	CXK315T	25.6.21 8:19	2022-08-31	Edoxaban 30mg / no ASA indication
1436	132	Placebo	no ASA indication	ZAG127H	29.11.21 11:34	2022-08-31	Edoxaban 30mg / no ASA indication
2629	132	Placebo	no ASA indication	KSS327N	30.5.22 9:42	2024-04-30	Edoxaban 60mg / no ASA indication
295	132	Edoxaban	ASA indication	VXP518A	8.4.19 8:33	2020-01-01	Edoxaban 30mg / ASA indication
295	132	Edoxaban	ASA indication	LRM981B	9.4.18 8:27	2020-01-01	Edoxaban 30mg / ASA indication
295	132	Edoxaban	ASA indication	DNF948K	15.10.18 7:39	2020-01-01	Edoxaban 30mg / ASA indication
295	132	Edoxaban	ASA indication	YTU648H	9.10.17 7:39	2018-09-01	Edoxaban 30mg / ASA indication
295	132	Edoxaban	ASA indication	VUX284R	7.10.19 8:13	2022-08-31	Edoxaban 30mg / ASA indication
388	132	Edoxaban	ASA indication	CBZ541R	9.7.18 6:34	2020-01-01	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	SMX469H	13.1.20 8:02	2021-12-31	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	AVK848E	13.7.20 6:48	2021-12-31	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	NCL118R	11.1.21 10:04	2021-12-31	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	DAU615Z	12.7.21 7:30	2024-04-30	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	LTD992R	11.7.22 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	PEL754G	8.1.18 12:16	2018-09-01	Edoxaban 60mg / ASA indication
388	132	Edoxaban	ASA indication	HFL786G	10.1.22 10:11	2024-04-30	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	UNM731V	21.1.19 7:50	2020-01-01	Edoxaban 60mg / no ASA indication
388	132	Edoxaban	ASA indication	WLM324E	15.7.19 11:57	2021-12-31	Edoxaban 60mg / no ASA indication
1902	132	Edoxaban	ASA indication	XUZ857M	11.6.21 9:48	2021-12-31	Edoxaban 60mg / ASA indication
1902	132	Edoxaban	ASA indication	SXB943S	15.12.21 16:23	2022-08-31	Edoxaban 30mg / ASA indication
1902	132	Edoxaban	ASA indication	XYT381Y	11.12.20 10:47	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1902	132	Edoxaban	ASA indication	DGA272W	15.12.21 17:19	2024-04-30	Edoxaban 60mg / ASA indication
1983	132	Edoxaban	ASA indication	PSY492V	23.8.21 10:05	2022-08-31	Edoxaban 30mg / ASA indication
1983	132	Edoxaban	ASA indication	UUE825X	22.8.22 9:35	2024-11-30	Edoxaban 30mg / ASA indication
1983	132	Edoxaban	ASA indication	DGN724A	26.2.21 8:27	2022-08-31	Edoxaban 30mg / ASA indication
1983	132	Edoxaban	ASA indication	FKB955R	23.2.22 14:46	2024-11-30	Edoxaban 30mg / ASA indication
6	132	Edoxaban	no ASA indication	KFF335G	8.7.16 13:27	2018-09-01	Edoxaban 60mg / no ASA indication
51	132	Edoxaban	no ASA indication	ELL175L	21.11.16 10:11	2018-09-01	Edoxaban 30mg / no ASA indication
51	132	Edoxaban	no ASA indication	YST759P	4.12.17 11:46	2018-09-01	Edoxaban 60mg / no ASA indication
51	132	Edoxaban	no ASA indication	VDU427L	29.5.17 7:54	2018-09-01	Edoxaban 60mg / no ASA indication
70	132	Edoxaban	no ASA indication	HEN213S	19.1.18 11:06	2018-09-01	Edoxaban 30mg / no ASA indication
70	132	Edoxaban	no ASA indication	GUD711F	13.1.17 8:34	2018-09-01	Edoxaban 60mg / no ASA indication
70	132	Edoxaban	no ASA indication	RHD953L	7.8.17 6:40	2018-09-01	Edoxaban 60mg / no ASA indication
739	132	Edoxaban	no ASA indication	URS646K	20.4.20 9:06	2022-08-31	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	ETN271B	4.4.22 7:40	2024-11-30	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	UHS636F	28.10.20 16:37	2022-08-31	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	PTN441Y	8.4.19 10:50	2020-01-01	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	RKF629T	18.10.21 9:27	2022-08-31	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	CSB528M	12.4.21 8:39	2022-08-31	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	CHN393E	8.10.18 10:39	2020-01-01	Edoxaban 60mg / no ASA indication
739	132	Edoxaban	no ASA indication	ZNG169B	26.11.18 9:46	2020-01-01	Edoxaban 30mg / no ASA indication
739	132	Edoxaban	no ASA indication	XMY237P	14.10.19 10:52	2022-08-31	Edoxaban 30mg / no ASA indication
2392	132	Edoxaban	no ASA indication	CZZ958U	15.12.21 14:50	2024-04-30	Edoxaban 60mg / no ASA indication
2392	132	Edoxaban	no ASA indication	WNV953N	13.6.22 8:00	2024-04-30	Edoxaban 60mg / no ASA indication
400	133	Placebo	ASA indication	CFS852T	12.1.18 14:02	2018-09-01	Edoxaban 60mg / ASA indication
618	133	Placebo	ASA indication	YKG697A	9.7.19 9:50	2021-12-31	Edoxaban 60mg / ASA indication
618	133	Placebo	ASA indication	UUE248B	6.7.18 13:18	2020-01-01	Edoxaban 60mg / ASA indication
618	133	Placebo	ASA indication	ZPT845D	3.1.19 14:20	2020-01-01	Edoxaban 60mg / ASA indication
618	133	Placebo	ASA indication	MPF437Y	21.1.20 8:43	2021-12-31	Edoxaban 60mg / ASA indication
477	133	Placebo	no ASA indication	AHK741V	9.3.18 13:40	2020-01-01	Edoxaban 60mg / no ASA indication
82	133	Edoxaban	ASA indication	BNM419L	27.7.17 14:46	2018-09-01	Edoxaban 30mg / ASA indication
82	133	Edoxaban	ASA indication	AZC143R	7.2.19 15:10	2020-01-01	Edoxaban 30mg / no ASA indication
82	133	Edoxaban	ASA indication	EEM361A	13.8.19 8:49	2022-08-31	Edoxaban 30mg / no ASA indication
82	133	Edoxaban	ASA indication	LMT561R	7.2.18 13:50	2018-09-01	Edoxaban 30mg / ASA indication
82	133	Edoxaban	ASA indication	ZCE985Y	28.1.20 9:16	2022-08-31	Edoxaban 30mg / ASA indication
82	133	Edoxaban	ASA indication	LYE192V	9.8.18 12:45	2020-01-01	Edoxaban 30mg / ASA indication
82	133	Edoxaban	ASA indication	ZMF496F	27.1.17 13:31	2018-09-01	Edoxaban 30mg / ASA indication
188	133	Edoxaban	ASA indication	HYK332F	13.6.18 13:28	2020-01-01	Edoxaban 30mg / no ASA indication
188	133	Edoxaban	ASA indication	TKV981Z	8.12.17 11:52	2018-09-01	Edoxaban 60mg / ASA indication
188	133	Edoxaban	ASA indication	CDD254T	24.7.20 9:47	2021-12-31	Edoxaban 60mg / ASA indication
188	133	Edoxaban	ASA indication	CAA437A	23.6.21 11:56	2024-04-30	Edoxaban 60mg / ASA indication
188	133	Edoxaban	ASA indication	ARD861T	9.6.17 13:20	2018-09-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
188	133	Edoxaban	ASA indication	YPF627M	9.12.20 8:33	2021-12-31	Edoxaban 60mg / ASA indication
188	133	Edoxaban	ASA indication	LVW181N	7.1.20 9:01	2022-08-31	Edoxaban 30mg / no ASA indication
188	133	Edoxaban	ASA indication	MAC678W	13.12.18 16:53	2020-01-01	Edoxaban 60mg / ASA indication
188	133	Edoxaban	ASA indication	SXS782U	26.6.19 9:58	2022-08-31	Edoxaban 30mg / ASA indication
634	133	Edoxaban	ASA indication	GDR839L	20.7.18 12:42	2020-01-01	Edoxaban 30mg / ASA indication
97	135	Placebo	no ASA indication	MMZ963Y	13.2.17 12:09	2018-09-01	Edoxaban 60mg / no ASA indication
376	135	Placebo	no ASA indication	BRD126H	20.12.17 7:41	2018-09-01	Edoxaban 30mg / no ASA indication
328	135	Edoxaban	ASA indication	RNW974G	7.11.17 10:13	2018-09-01	Edoxaban 30mg / ASA indication
328	135	Edoxaban	ASA indication	VMC769P	8.5.18 7:08	2020-01-01	Edoxaban 30mg / no ASA indication
328	135	Edoxaban	ASA indication	XZH344K	13.11.18 8:34	2020-01-01	Edoxaban 30mg / no ASA indication
339	135	Edoxaban	ASA indication	XRD475P	15.11.17 9:12	2018-09-01	Edoxaban 60mg / ASA indication
7	136	Placebo	ASA indication	AAM723P	15.7.16 8:37	2018-09-01	Edoxaban 60mg / ASA indication
33	136	Placebo	ASA indication	WKU263N	30.9.16 11:32	2018-09-01	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	ZFD949R	9.12.19 14:28	2021-12-31	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	PVU759S	28.5.20 11:21	2021-12-31	Edoxaban 60mg / no ASA indication
34	136	Edoxaban	ASA indication	VTN291Z	29.4.19 10:19	2020-01-01	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	ZXV939G	17.3.17 11:56	2018-09-01	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	SYK964S	13.4.18 9:45	2020-01-01	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	BXR254Y	30.9.16 11:55	2018-09-01	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	FSA886X	29.9.17 10:54	2018-09-01	Edoxaban 60mg / ASA indication
34	136	Edoxaban	ASA indication	MSG615G	22.10.18 9:14	2020-01-01	Edoxaban 60mg / ASA indication
132	136	Edoxaban	ASA indication	HNF833V	10.4.18 12:44	2020-01-01	Edoxaban 60mg / ASA indication
132	136	Edoxaban	ASA indication	EVB196C	5.4.17 9:16	2018-09-01	Edoxaban 60mg / ASA indication
132	136	Edoxaban	ASA indication	FLS338N	17.10.17 12:04	2018-09-01	Edoxaban 60mg / ASA indication
52	140	Placebo	ASA indication	LNU448F	20.5.19 9:09	2020-01-01	Edoxaban 60mg / no ASA indication
52	140	Placebo	ASA indication	PNK927N	26.5.20 9:05	2021-12-31	Edoxaban 60mg / no ASA indication
52	140	Placebo	ASA indication	RTY398L	11.5.21 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
52	140	Placebo	ASA indication	WHF681R	16.11.21 10:19	2024-04-30	Edoxaban 60mg / no ASA indication
52	140	Placebo	ASA indication	ALD499R	17.5.22 7:41	2024-11-30	Edoxaban 30mg / no ASA indication
52	140	Placebo	ASA indication	HSP289F	11.6.18 16:01	2020-01-01	Edoxaban 60mg / ASA indication
52	140	Placebo	ASA indication	KMT464L	22.11.16 7:41	2018-09-01	Edoxaban 60mg / ASA indication
52	140	Placebo	ASA indication	PZC336S	22.5.17 10:52	2018-09-01	Edoxaban 60mg / ASA indication
52	140	Placebo	ASA indication	WKD158X	27.11.17 8:23	2018-09-01	Edoxaban 60mg / ASA indication
52	140	Placebo	ASA indication	LAV917H	30.11.20 10:20	2021-12-31	Edoxaban 60mg / no ASA indication
52	140	Placebo	ASA indication	CZZ727Z	26.11.18 8:53	2020-01-01	Edoxaban 60mg / no ASA indication
52	140	Placebo	ASA indication	DNU118W	25.11.19 11:09	2021-12-31	Edoxaban 60mg / no ASA indication
114	140	Placebo	ASA indication	MWV448B	22.3.18 17:02	2020-01-01	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	VYR122Z	20.3.17 14:05	2018-09-01	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	FCC173U	19.9.19 16:04	2021-12-31	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	LMK521Z	19.3.20 16:44	2021-12-31	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	UDY953K	20.9.18 15:34	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
114	140	Placebo	ASA indication	TSU827R	18.3.21 16:33	2021-12-31	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	VML797E	16.9.21 15:16	2024-04-30	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	SYX955M	14.9.17 15:27	2018-09-01	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	MEA644L	24.3.22 15:53	2024-04-30	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	MMR959G	17.9.20 15:06	2021-12-31	Edoxaban 60mg / ASA indication
114	140	Placebo	ASA indication	EKZ184P	21.3.19 17:17	2020-01-01	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	TDE843M	5.5.20 9:45	2021-12-31	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	FWU457P	6.11.20 8:09	2021-12-31	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	YPY698M	14.5.19 9:10	2020-01-01	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	MEV989Z	17.5.22 7:03	2024-04-30	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	VLT348L	15.5.18 9:44	2020-01-01	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	SVW955U	18.5.21 12:13	2021-12-31	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	ZMH224W	15.5.17 8:21	2018-09-01	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	VWA749F	20.11.17 10:35	2018-09-01	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	ZGV327V	12.11.18 10:12	2020-01-01	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	GUS352U	11.11.19 10:34	2021-12-31	Edoxaban 60mg / ASA indication
160	140	Placebo	ASA indication	XNC283N	16.11.21 8:31	2024-04-30	Edoxaban 60mg / ASA indication
171	140	Placebo	ASA indication	HZY659N	30.5.18 12:08	2020-01-01	Edoxaban 30mg / ASA indication
171	140	Placebo	ASA indication	YEY157B	29.5.17 9:45	2018-09-01	Edoxaban 30mg / ASA indication
171	140	Placebo	ASA indication	RXS419W	6.12.17 13:18	2018-09-01	Edoxaban 30mg / ASA indication
225	140	Placebo	ASA indication	ZTZ671W	4.7.18 12:55	2020-01-01	Edoxaban 60mg / ASA indication
225	140	Placebo	ASA indication	DMB587X	24.6.20 6:57	2021-12-31	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	PRZ963R	3.7.19 12:07	2021-12-31	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	ZXP454X	12.7.22 11:31	2024-04-30	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	VYN679A	9.1.19 12:42	2020-01-01	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	EFX828C	23.6.21 8:13	2024-04-30	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	EFY255Z	4.1.22 9:08	2024-04-30	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	KUD964T	10.1.18 13:23	2018-09-01	Edoxaban 60mg / ASA indication
225	140	Placebo	ASA indication	BKZ364F	12.7.17 10:49	2018-09-01	Edoxaban 60mg / ASA indication
225	140	Placebo	ASA indication	SLX491L	9.1.20 14:42	2021-12-31	Edoxaban 60mg / no ASA indication
225	140	Placebo	ASA indication	KGL547S	9.12.20 12:09	2021-12-31	Edoxaban 60mg / no ASA indication
257	140	Placebo	ASA indication	MMW222S	17.8.17 12:24	2018-09-01	Edoxaban 30mg / ASA indication
399	140	Placebo	ASA indication	UUR866N	26.7.18 12:44	2020-01-01	Edoxaban 60mg / ASA indication
399	140	Placebo	ASA indication	TFN562B	11.1.18 14:48	2018-09-01	Edoxaban 60mg / ASA indication
482	140	Placebo	ASA indication	BHW195S	14.3.18 12:36	2020-01-01	Edoxaban 60mg / ASA indication
551	140	Placebo	ASA indication	BDL991A	11.11.19 9:44	2022-08-31	Edoxaban 30mg / ASA indication
551	140	Placebo	ASA indication	KUW449D	12.11.18 9:10	2020-01-01	Edoxaban 30mg / ASA indication
551	140	Placebo	ASA indication	TKY575A	5.5.20 8:26	2022-08-31	Edoxaban 30mg / ASA indication
551	140	Placebo	ASA indication	VLP288G	14.5.19 8:02	2020-01-01	Edoxaban 30mg / ASA indication
551	140	Placebo	ASA indication	XHK981L	18.5.21 9:30	2022-08-31	Edoxaban 30mg / ASA indication
551	140	Placebo	ASA indication	MWV251Z	6.11.20 10:18	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
551	140	Placebo	ASA indication	CPY221T	15.5.18 7:42	2020-01-01	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	YDN215W	2.12.20 12:52	2022-08-31	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	NSV464S	30.11.21 13:11	2022-08-31	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	PPT283T	20.5.20 13:05	2022-08-31	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	HCZ434R	22.11.18 13:26	2020-01-01	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	VBS244D	29.5.19 10:20	2020-01-01	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	MKH238S	23.5.18 12:02	2020-01-01	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	UGE968U	27.11.19 11:00	2022-08-31	Edoxaban 30mg / ASA indication
565	140	Placebo	ASA indication	TCX269H	19.5.21 11:44	2022-08-31	Edoxaban 30mg / ASA indication
803	140	Placebo	ASA indication	XAS485G	7.11.18 12:57	2020-01-01	Edoxaban 60mg / ASA indication
803	140	Placebo	ASA indication	HGN943N	6.5.20 11:22	2021-12-31	Edoxaban 60mg / ASA indication
803	140	Placebo	ASA indication	MWD782G	11.11.20 12:27	2021-12-31	Edoxaban 60mg / ASA indication
803	140	Placebo	ASA indication	HWC136N	8.5.19 11:42	2020-01-01	Edoxaban 60mg / ASA indication
803	140	Placebo	ASA indication	BHT437P	13.11.19 13:05	2021-12-31	Edoxaban 60mg / ASA indication
803	140	Placebo	ASA indication	UTC889N	11.11.21 10:47	2024-04-30	Edoxaban 60mg / ASA indication
803	140	Placebo	ASA indication	YSL155C	12.5.21 11:44	2021-12-31	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	LYT215R	17.1.19 11:29	2020-01-01	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	RSS239G	20.1.21 12:50	2021-12-31	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	FTU375F	22.7.20 10:51	2021-12-31	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	KTB377Y	18.1.22 12:33	2024-04-30	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	ASX997B	12.7.22 10:54	2024-04-30	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	FZH225G	29.1.20 9:52	2021-12-31	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	LXU398H	18.7.19 12:30	2021-12-31	Edoxaban 60mg / ASA indication
941	140	Placebo	ASA indication	UTG663C	21.7.21 11:47	2024-04-30	Edoxaban 60mg / ASA indication
1094	140	Placebo	ASA indication	UHA651A	24.4.19 9:55	2020-01-01	Edoxaban 60mg / ASA indication
1438	140	Placebo	ASA indication	MAK883K	9.12.19 8:50	2021-12-31	Edoxaban 60mg / ASA indication
1438	140	Placebo	ASA indication	EXP522L	22.6.21 12:27	2024-04-30	Edoxaban 60mg / ASA indication
1438	140	Placebo	ASA indication	VNP957W	30.11.21 9:55	2024-04-30	Edoxaban 60mg / ASA indication
1438	140	Placebo	ASA indication	BNC193X	14.12.20 10:36	2021-12-31	Edoxaban 60mg / ASA indication
1438	140	Placebo	ASA indication	UED498M	8.6.20 8:31	2021-12-31	Edoxaban 60mg / ASA indication
1438	140	Placebo	ASA indication	XUN397C	31.5.22 8:55	2024-04-30	Edoxaban 60mg / ASA indication
1439	140	Placebo	ASA indication	FUH628X	4.12.20 7:43	2021-12-31	Edoxaban 60mg / ASA indication
1439	140	Placebo	ASA indication	KTU622S	5.6.20 6:41	2021-12-31	Edoxaban 60mg / ASA indication
1439	140	Placebo	ASA indication	BMF149A	14.12.21 9:01	2024-04-30	Edoxaban 60mg / ASA indication
1439	140	Placebo	ASA indication	SPR212F	9.12.19 10:08	2021-12-31	Edoxaban 60mg / ASA indication
1439	140	Placebo	ASA indication	APU648P	20.6.22 6:51	2024-04-30	Edoxaban 60mg / ASA indication
1439	140	Placebo	ASA indication	SXX585W	8.6.21 8:07	2021-12-31	Edoxaban 60mg / ASA indication
1466	140	Placebo	ASA indication	APA848Z	8.7.20 9:24	2021-12-31	Edoxaban 60mg / ASA indication
1466	140	Placebo	ASA indication	EXE564F	30.6.21 9:03	2024-04-30	Edoxaban 60mg / ASA indication
1466	140	Placebo	ASA indication	WVW651S	2.1.20 13:46	2021-12-31	Edoxaban 60mg / ASA indication
1466	140	Placebo	ASA indication	TRL255C	13.1.21 12:57	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1466	140	Placebo	ASA indication	CGH825F	4.1.22 9:37	2024-04-30	Edoxaban 60mg / ASA indication
1466	140	Placebo	ASA indication	RZB896X	12.7.22 12:00	2024-04-30	Edoxaban 60mg / ASA indication
1655	140	Placebo	ASA indication	HEE834P	14.12.20 11:07	2021-12-31	Edoxaban 60mg / ASA indication
1655	140	Placebo	ASA indication	ASR691T	23.6.20 8:08	2021-12-31	Edoxaban 60mg / ASA indication
1666	140	Placebo	ASA indication	TAM492T	5.1.21 14:47	2021-12-31	Edoxaban 60mg / ASA indication
1666	140	Placebo	ASA indication	ATK894A	22.6.22 8:13	2024-04-30	Edoxaban 60mg / ASA indication
1666	140	Placebo	ASA indication	AAB547K	29.6.20 10:06	2021-12-31	Edoxaban 60mg / ASA indication
1666	140	Placebo	ASA indication	CHL562Z	20.12.21 9:31	2024-04-30	Edoxaban 60mg / ASA indication
1666	140	Placebo	ASA indication	EXL137U	29.6.21 8:13	2024-04-30	Edoxaban 60mg / ASA indication
1930	140	Placebo	ASA indication	SUB196N	18.1.21 9:56	2022-08-31	Edoxaban 30mg / ASA indication
1930	140	Placebo	ASA indication	VVE591F	22.7.21 7:25	2022-08-31	Edoxaban 30mg / ASA indication
2349	140	Placebo	ASA indication	UZC386P	16.11.21 10:46	2024-04-30	Edoxaban 60mg / ASA indication
2349	140	Placebo	ASA indication	GTP153T	17.5.22 9:18	2024-04-30	Edoxaban 60mg / ASA indication
2631	140	Placebo	ASA indication	GWP672K	31.5.22 12:21	2024-04-30	Edoxaban 60mg / ASA indication
2661	140	Placebo	ASA indication	ANH261S	21.6.22 8:41	2024-04-30	Edoxaban 60mg / ASA indication
68	140	Placebo	no ASA indication	AEA845C	9.1.17 10:49	2018-09-01	Edoxaban 60mg / no ASA indication
68	140	Placebo	no ASA indication	ZPF237K	10.7.17 8:53	2018-09-01	Edoxaban 60mg / no ASA indication
99	140	Placebo	no ASA indication	EAL293K	16.2.17 9:48	2018-09-01	Edoxaban 60mg / no ASA indication
113	140	Placebo	no ASA indication	XCE536F	22.9.17 6:50	2018-09-01	Edoxaban 60mg / no ASA indication
113	140	Placebo	no ASA indication	BUK256G	20.3.17 10:24	2018-09-01	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	PNA632K	22.8.18 6:47	2020-01-01	Edoxaban 30mg / no ASA indication
432	140	Placebo	no ASA indication	VAZ498X	27.1.21 12:04	2021-12-31	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	ZXE982V	1.8.18 12:00	2020-01-01	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	HWR664P	9.8.22 9:20	2024-04-30	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	CVV895C	8.2.22 12:39	2024-04-30	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	BPE375D	7.2.18 8:48	2018-09-01	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	XLG422H	15.8.19 12:32	2021-12-31	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	EYR185A	5.2.20 10:49	2021-12-31	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	PPH111K	6.2.19 13:28	2020-01-01	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	VLG883P	4.8.21 11:37	2024-04-30	Edoxaban 60mg / no ASA indication
432	140	Placebo	no ASA indication	YNN885Z	29.7.20 9:43	2021-12-31	Edoxaban 60mg / no ASA indication
539	140	Placebo	no ASA indication	ZMH747P	17.4.19 12:20	2020-01-01	Edoxaban 30mg / no ASA indication
539	140	Placebo	no ASA indication	DYA262M	27.3.20 8:37	2022-08-31	Edoxaban 30mg / no ASA indication
539	140	Placebo	no ASA indication	TRW888Y	25.10.18 14:15	2020-01-01	Edoxaban 30mg / no ASA indication
539	140	Placebo	no ASA indication	KTF271W	31.3.21 12:03	2022-08-31	Edoxaban 30mg / no ASA indication
539	140	Placebo	no ASA indication	XRF968K	9.10.19 12:39	2022-08-31	Edoxaban 30mg / no ASA indication
539	140	Placebo	no ASA indication	UCY677H	26.4.18 14:21	2020-01-01	Edoxaban 30mg / no ASA indication
539	140	Placebo	no ASA indication	YKS686H	17.9.20 15:29	2022-08-31	Edoxaban 30mg / no ASA indication
669	140	Placebo	no ASA indication	RPS469B	11.2.19 10:44	2020-01-01	Edoxaban 60mg / no ASA indication
669	140	Placebo	no ASA indication	TXF436N	23.8.19 9:04	2021-12-31	Edoxaban 60mg / no ASA indication
669	140	Placebo	no ASA indication	HDK226K	14.8.18 8:12	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
713	140	Placebo	no ASA indication	WCY337C	2.10.19 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
713	140	Placebo	no ASA indication	PAX689R	15.9.21 12:45	2022-08-31	Edoxaban 30mg / no ASA indication
713	140	Placebo	no ASA indication	WRY583C	20.3.19 12:48	2020-01-01	Edoxaban 60mg / no ASA indication
713	140	Placebo	no ASA indication	RWD639K	6.9.22 12:03	2024-11-30	Edoxaban 30mg / no ASA indication
713	140	Placebo	no ASA indication	BYG872E	26.3.20 14:54	2021-12-31	Edoxaban 60mg / no ASA indication
713	140	Placebo	no ASA indication	CAS934X	24.9.20 14:10	2021-12-31	Edoxaban 60mg / no ASA indication
713	140	Placebo	no ASA indication	PRT519B	19.9.18 12:21	2020-01-01	Edoxaban 60mg / no ASA indication
713	140	Placebo	no ASA indication	ZTS886D	17.3.21 13:31	2021-12-31	Edoxaban 60mg / no ASA indication
713	140	Placebo	no ASA indication	AKS873E	1.3.22 13:07	2024-11-30	Edoxaban 30mg / no ASA indication
1101	140	Placebo	no ASA indication	WRP541E	2.5.19 13:01	2020-01-01	Edoxaban 60mg / no ASA indication
1101	140	Placebo	no ASA indication	HFX432W	13.11.19 13:41	2022-08-31	Edoxaban 30mg / no ASA indication
1101	140	Placebo	no ASA indication	HUP347C	20.5.20 11:53	2022-08-31	Edoxaban 30mg / no ASA indication
1101	140	Placebo	no ASA indication	BVA316S	11.11.20 13:04	2022-08-31	Edoxaban 30mg / no ASA indication
1389	140	Placebo	no ASA indication	KYG984E	12.5.21 12:47	2021-12-31	Edoxaban 60mg / no ASA indication
1389	140	Placebo	no ASA indication	YUV792N	2.11.21 11:12	2024-04-30	Edoxaban 60mg / no ASA indication
1389	140	Placebo	no ASA indication	BSB267M	10.5.22 11:12	2024-04-30	Edoxaban 60mg / no ASA indication
1389	140	Placebo	no ASA indication	ACB243B	2.12.20 14:18	2021-12-31	Edoxaban 60mg / no ASA indication
1389	140	Placebo	no ASA indication	VZU277W	14.11.19 15:54	2021-12-31	Edoxaban 60mg / no ASA indication
1389	140	Placebo	no ASA indication	MVS781S	20.5.20 12:19	2021-12-31	Edoxaban 60mg / no ASA indication
1496	140	Placebo	no ASA indication	SBM294R	20.1.21 13:27	2021-12-31	Edoxaban 60mg / no ASA indication
1496	140	Placebo	no ASA indication	MUN922S	29.7.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1496	140	Placebo	no ASA indication	KVL214A	18.1.22 13:08	2024-04-30	Edoxaban 60mg / ASA indication
1496	140	Placebo	no ASA indication	TVE993Z	2.8.22 9:12	2024-04-30	Edoxaban 60mg / ASA indication
1496	140	Placebo	no ASA indication	UXC586P	21.7.21 12:29	2024-04-30	Edoxaban 60mg / ASA indication
1496	140	Placebo	no ASA indication	MDW227D	29.1.20 13:27	2021-12-31	Edoxaban 60mg / no ASA indication
1826	140	Placebo	no ASA indication	EBZ888F	14.4.21 11:42	2021-12-31	Edoxaban 60mg / no ASA indication
1826	140	Placebo	no ASA indication	LGW867L	14.10.20 11:44	2021-12-31	Edoxaban 60mg / no ASA indication
1826	140	Placebo	no ASA indication	VLV763W	5.10.21 12:13	2024-04-30	Edoxaban 60mg / no ASA indication
1826	140	Placebo	no ASA indication	SDW753L	14.4.22 10:43	2024-04-30	Edoxaban 60mg / no ASA indication
1926	140	Placebo	no ASA indication	RTC228F	13.1.21 12:02	2022-08-31	Edoxaban 30mg / no ASA indication
2202	140	Placebo	no ASA indication	VEY375N	21.7.21 13:14	2024-04-30	Edoxaban 60mg / no ASA indication
2202	140	Placebo	no ASA indication	WHM526D	18.1.22 13:40	2024-04-30	Edoxaban 60mg / no ASA indication
2202	140	Placebo	no ASA indication	ZXW458W	5.7.22 9:35	2024-04-30	Edoxaban 60mg / no ASA indication
2238	140	Placebo	no ASA indication	LWS295N	1.3.22 12:01	2024-04-30	Edoxaban 60mg / no ASA indication
2238	140	Placebo	no ASA indication	SCX517E	6.9.22 11:15	2024-04-30	Edoxaban 60mg / no ASA indication
2238	140	Placebo	no ASA indication	EHD449M	24.8.21 9:12	2024-04-30	Edoxaban 60mg / no ASA indication
2618	140	Placebo	no ASA indication	NXA967L	17.5.22 11:27	2024-11-30	Edoxaban 30mg / no ASA indication
85	140	Edoxaban	ASA indication	PDV136W	23.7.19 8:09	2021-12-31	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	SXD535M	19.1.21 8:48	2021-12-31	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	VND166B	23.7.21 8:57	2024-04-30	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	YWA481C	31.1.20 9:11	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
85	140	Edoxaban	ASA indication	SFR956K	30.7.18 8:48	2020-01-01	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	KYB859P	4.8.20 7:16	2021-12-31	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	APM437U	31.1.17 10:05	2018-09-01	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	KBR525A	1.8.17 8:46	2018-09-01	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	BGL289Y	25.7.22 9:35	2024-04-30	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	GBB397T	22.1.18 10:45	2018-09-01	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	UCW492G	22.1.19 9:03	2020-01-01	Edoxaban 60mg / ASA indication
85	140	Edoxaban	ASA indication	FKG454X	18.1.22 9:46	2024-04-30	Edoxaban 60mg / ASA indication
136	140	Edoxaban	ASA indication	PHC919D	11.4.17 9:51	2018-09-01	Edoxaban 60mg / ASA indication
136	140	Edoxaban	ASA indication	KWL473R	19.4.18 14:10	2020-01-01	Edoxaban 60mg / ASA indication
136	140	Edoxaban	ASA indication	VTE924W	25.10.18 13:58	2020-01-01	Edoxaban 60mg / ASA indication
136	140	Edoxaban	ASA indication	PZG691D	19.10.17 13:38	2018-09-01	Edoxaban 60mg / ASA indication
136	140	Edoxaban	ASA indication	UEH747T	17.4.19 12:50	2020-01-01	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	DFF926N	11.6.18 16:02	2020-01-01	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	GHB718M	12.6.17 7:51	2018-09-01	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	WTN748T	14.12.21 10:03	2024-04-30	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	YVU939X	7.6.22 8:04	2024-04-30	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	BVF925B	7.12.18 8:04	2020-01-01	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	KMM876P	7.6.19 7:10	2020-01-01	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	KCL392X	11.12.20 9:24	2021-12-31	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	EGH536C	20.12.17 14:09	2018-09-01	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	VZS414A	11.6.20 10:21	2021-12-31	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	LTC291L	6.12.19 9:11	2021-12-31	Edoxaban 60mg / ASA indication
190	140	Edoxaban	ASA indication	VCK692R	8.6.21 9:14	2021-12-31	Edoxaban 60mg / ASA indication
209	140	Edoxaban	ASA indication	GZM572P	29.6.17 7:35	2018-09-01	Edoxaban 30mg / ASA indication
252	140	Edoxaban	ASA indication	PAD296Z	14.8.17 11:58	2018-09-01	Edoxaban 60mg / ASA indication
254	140	Edoxaban	ASA indication	ZBH455A	28.2.18 12:37	2020-01-01	Edoxaban 30mg / ASA indication
254	140	Edoxaban	ASA indication	UUV788X	16.8.17 11:41	2018-09-01	Edoxaban 30mg / ASA indication
407	140	Edoxaban	ASA indication	YEM126G	26.7.18 14:15	2020-01-01	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	NTE526V	24.1.19 14:35	2020-01-01	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	PMX143P	8.7.20 9:29	2021-12-31	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	SSN584K	20.1.21 12:17	2021-12-31	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	TDH695V	8.1.20 12:54	2021-12-31	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	GSV423B	17.1.18 12:56	2018-09-01	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	UEU484W	5.7.22 12:01	2024-04-30	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	CPR761N	11.7.19 13:17	2021-12-31	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	DGS418P	11.1.22 13:15	2024-04-30	Edoxaban 60mg / ASA indication
407	140	Edoxaban	ASA indication	EMD969V	14.7.21 12:59	2024-04-30	Edoxaban 60mg / ASA indication
436	140	Edoxaban	ASA indication	PTW858V	15.8.18 12:28	2020-01-01	Edoxaban 60mg / ASA indication
436	140	Edoxaban	ASA indication	WYH322B	22.8.19 13:47	2021-12-31	Edoxaban 60mg / ASA indication
436	140	Edoxaban	ASA indication	XHA268L	8.2.18 10:57	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
436	140	Edoxaban	ASA indication	YAZ151U	13.2.19 12:48	2020-01-01	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	AKH259B	4.4.19 13:24	2020-01-01	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	SLK172M	27.3.20 10:13	2021-12-31	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	AZR894B	3.4.18 12:06	2020-01-01	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	XSM198S	1.4.21 13:43	2021-12-31	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	PKR426C	10.10.19 14:10	2021-12-31	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	KHP488P	29.3.22 11:05	2024-04-30	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	EGD725D	8.10.20 15:05	2021-12-31	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	EFU762H	27.9.18 13:21	2020-01-01	Edoxaban 60mg / ASA indication
506	140	Edoxaban	ASA indication	VYC329R	16.9.21 14:29	2024-04-30	Edoxaban 60mg / ASA indication
622	140	Edoxaban	ASA indication	YHA558H	10.7.18 8:54	2020-01-01	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	AET128C	9.1.19 13:11	2020-01-01	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	ADV649B	12.7.22 11:09	2024-11-30	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	XUN799K	29.7.20 9:07	2022-08-31	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	RBU553V	10.7.19 12:11	2022-08-31	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	WAV191F	29.1.20 12:31	2022-08-31	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	WYC474K	4.1.22 9:53	2022-08-31	Edoxaban 30mg / ASA indication
622	140	Edoxaban	ASA indication	SRL986U	20.1.21 13:08	2021-12-31	Edoxaban 60mg / ASA indication
622	140	Edoxaban	ASA indication	ELS643A	14.7.21 12:09	2024-04-30	Edoxaban 60mg / ASA indication
717	140	Edoxaban	ASA indication	KSE144T	19.9.19 13:00	2022-08-31	Edoxaban 30mg / ASA indication
717	140	Edoxaban	ASA indication	DHA957V	20.9.18 14:36	2020-01-01	Edoxaban 30mg / ASA indication
717	140	Edoxaban	ASA indication	YKP216A	13.3.19 13:04	2020-01-01	Edoxaban 30mg / ASA indication
717	140	Edoxaban	ASA indication	RUV336E	19.3.20 14:56	2022-08-31	Edoxaban 30mg / ASA indication
717	140	Edoxaban	ASA indication	YMZ669B	17.9.20 14:08	2022-08-31	Edoxaban 30mg / ASA indication
717	140	Edoxaban	ASA indication	XDU933A	17.3.21 12:59	2022-08-31	Edoxaban 30mg / ASA indication
717	140	Edoxaban	ASA indication	ENH159V	15.9.21 12:11	2022-08-31	Edoxaban 30mg / ASA indication
841	140	Edoxaban	ASA indication	HSL468P	29.5.19 12:05	2020-01-01	Edoxaban 60mg / ASA indication
841	140	Edoxaban	ASA indication	WMP971E	22.11.18 15:42	2020-01-01	Edoxaban 60mg / ASA indication
1266	140	Edoxaban	ASA indication	RSE191D	6.5.20 11:50	2021-12-31	Edoxaban 60mg / ASA indication
1266	140	Edoxaban	ASA indication	SNR834D	28.8.19 11:29	2021-12-31	Edoxaban 60mg / ASA indication
1394	140	Edoxaban	ASA indication	EGP247V	20.11.20 7:34	2021-12-31	Edoxaban 60mg / ASA indication
1394	140	Edoxaban	ASA indication	EFL729P	15.6.20 9:28	2021-12-31	Edoxaban 60mg / ASA indication
1394	140	Edoxaban	ASA indication	PXC978E	18.11.19 11:01	2021-12-31	Edoxaban 60mg / ASA indication
1406	140	Edoxaban	ASA indication	HWA713V	2.12.20 13:29	2021-12-31	Edoxaban 60mg / ASA indication
1406	140	Edoxaban	ASA indication	TEX314L	21.11.19 9:33	2021-12-31	Edoxaban 60mg / ASA indication
1406	140	Edoxaban	ASA indication	FXK987B	20.5.20 12:39	2021-12-31	Edoxaban 60mg / ASA indication
1577	140	Edoxaban	ASA indication	VXW385A	16.9.21 15:35	2024-04-30	Edoxaban 60mg / ASA indication
1577	140	Edoxaban	ASA indication	VRP842M	30.4.20 13:19	2021-12-31	Edoxaban 60mg / ASA indication
1577	140	Edoxaban	ASA indication	KDG649S	22.3.22 9:47	2024-04-30	Edoxaban 60mg / ASA indication
1577	140	Edoxaban	ASA indication	XWH559C	29.3.21 8:30	2021-12-31	Edoxaban 60mg / ASA indication
1577	140	Edoxaban	ASA indication	GZH392G	14.10.20 12:04	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1578	140	Edoxaban	ASA indication	SSF175Y	10.5.21 8:32	2021-12-31	Edoxaban 60mg / ASA indication
1578	140	Edoxaban	ASA indication	YEW729N	8.11.21 10:20	2024-04-30	Edoxaban 60mg / ASA indication
1578	140	Edoxaban	ASA indication	AEK868P	5.5.20 7:47	2021-12-31	Edoxaban 60mg / ASA indication
1578	140	Edoxaban	ASA indication	GVF624F	6.11.20 9:17	2021-12-31	Edoxaban 60mg / ASA indication
1578	140	Edoxaban	ASA indication	BHG376C	10.5.22 8:10	2024-04-30	Edoxaban 60mg / ASA indication
1781	140	Edoxaban	ASA indication	XSV189F	17.3.21 12:23	2021-12-31	Edoxaban 60mg / ASA indication
1781	140	Edoxaban	ASA indication	EHH722N	16.9.20 12:07	2021-12-31	Edoxaban 60mg / ASA indication
1781	140	Edoxaban	ASA indication	LEH219V	15.9.21 12:20	2022-08-31	Edoxaban 30mg / ASA indication
1889	140	Edoxaban	ASA indication	EEV639C	2.12.20 11:44	2021-12-31	Edoxaban 60mg / ASA indication
2046	140	Edoxaban	ASA indication	AAM912F	10.4.22 14:46	2024-11-30	Edoxaban 30mg / ASA indication
2046	140	Edoxaban	ASA indication	LYR853R	14.4.21 12:31	2022-08-31	Edoxaban 30mg / ASA indication
2046	140	Edoxaban	ASA indication	FVD546L	12.10.21 12:45	2022-08-31	Edoxaban 30mg / ASA indication
2096	140	Edoxaban	ASA indication	UFK459U	17.5.22 12:00	2024-04-30	Edoxaban 60mg / ASA indication
2096	140	Edoxaban	ASA indication	KRB425C	12.5.21 11:11	2021-12-31	Edoxaban 60mg / ASA indication
2096	140	Edoxaban	ASA indication	YFP992P	9.11.21 12:49	2024-04-30	Edoxaban 60mg / ASA indication
2357	140	Edoxaban	ASA indication	ERA813W	19.11.21 8:07	2024-04-30	Edoxaban 60mg / ASA indication
74	140	Edoxaban	no ASA indication	KPR257N	17.1.17 8:41	2018-09-01	Edoxaban 60mg / no ASA indication
74	140	Edoxaban	no ASA indication	NLR275N	16.1.18 10:05	2018-09-01	Edoxaban 60mg / no ASA indication
74	140	Edoxaban	no ASA indication	DLB577Z	22.1.19 9:46	2020-01-01	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	PZW971V	29.7.19 9:11	2022-08-31	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	BXA514B	13.1.20 10:08	2022-08-31	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	ATL319S	4.1.21 10:31	2022-08-31	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	MMH585V	11.7.17 8:13	2018-09-01	Edoxaban 60mg / no ASA indication
74	140	Edoxaban	no ASA indication	PKT812K	3.1.22 10:18	2022-08-31	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	PBY482L	24.7.18 9:05	2020-01-01	Edoxaban 60mg / no ASA indication
74	140	Edoxaban	no ASA indication	AXA578Z	5.7.21 6:58	2022-08-31	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	XZB865T	6.7.20 9:02	2022-08-31	Edoxaban 30mg / no ASA indication
74	140	Edoxaban	no ASA indication	AAK759L	7.7.22 9:19	2024-11-30	Edoxaban 30mg / no ASA indication
200	140	Edoxaban	no ASA indication	USG445X	5.1.18 10:58	2018-09-01	Edoxaban 60mg / no ASA indication
200	140	Edoxaban	no ASA indication	CDG936U	25.6.18 9:47	2020-01-01	Edoxaban 60mg / no ASA indication
200	140	Edoxaban	no ASA indication	YSW936A	26.6.17 12:09	2018-09-01	Edoxaban 60mg / no ASA indication
212	140	Edoxaban	no ASA indication	KZF467U	17.1.18 11:29	2018-09-01	Edoxaban 30mg / no ASA indication
212	140	Edoxaban	no ASA indication	NVY167Y	6.7.17 15:49	2018-09-01	Edoxaban 30mg / no ASA indication
212	140	Edoxaban	no ASA indication	SCB532P	26.7.18 13:39	2020-01-01	Edoxaban 30mg / no ASA indication
212	140	Edoxaban	no ASA indication	BBN357R	10.1.19 14:13	2020-01-01	Edoxaban 30mg / no ASA indication
212	140	Edoxaban	no ASA indication	YRP583X	4.7.19 12:33	2022-08-31	Edoxaban 30mg / no ASA indication
251	140	Edoxaban	no ASA indication	CDK551W	14.8.17 11:14	2018-09-01	Edoxaban 60mg / no ASA indication
331	140	Edoxaban	no ASA indication	YWS611Y	8.11.17 12:46	2018-09-01	Edoxaban 60mg / no ASA indication
568	140	Edoxaban	no ASA indication	HVW597U	24.5.18 9:07	2020-01-01	Edoxaban 30mg / no ASA indication
592	140	Edoxaban	no ASA indication	RRR757A	14.6.18 10:21	2020-01-01	Edoxaban 30mg / no ASA indication
592	140	Edoxaban	no ASA indication	EZG165S	9.1.20 13:21	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
592	140	Edoxaban	no ASA indication	BLF545W	4.7.19 14:21	2022-08-31	Edoxaban 30mg / no ASA indication
592	140	Edoxaban	no ASA indication	KCG171W	24.6.20 6:46	2022-08-31	Edoxaban 30mg / no ASA indication
592	140	Edoxaban	no ASA indication	KYR119F	20.12.18 16:03	2020-01-01	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	LBW556M	14.11.18 8:45	2020-01-01	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	AKE984V	2.8.22 9:18	2024-11-30	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	BLE748U	15.5.19 7:36	2020-01-01	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	VZW952W	5.5.21 12:00	2022-08-31	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	AYC513P	6.5.20 12:10	2022-08-31	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	GWN119L	4.11.20 13:02	2022-08-31	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	UDC288Y	13.11.19 10:37	2022-08-31	Edoxaban 30mg / no ASA indication
818	140	Edoxaban	no ASA indication	PEG292D	9.11.21 12:25	2022-08-31	Edoxaban 30mg / no ASA indication
919	140	Edoxaban	no ASA indication	GAG253C	3.7.19 11:45	2021-12-31	Edoxaban 60mg / no ASA indication
919	140	Edoxaban	no ASA indication	WUY953H	9.1.20 16:04	2021-12-31	Edoxaban 60mg / no ASA indication
919	140	Edoxaban	no ASA indication	RUB194K	9.1.19 10:09	2020-01-01	Edoxaban 60mg / no ASA indication
919	140	Edoxaban	no ASA indication	DBK589A	13.1.21 13:36	2021-12-31	Edoxaban 60mg / no ASA indication
919	140	Edoxaban	no ASA indication	PWK469B	8.7.20 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
1576	140	Edoxaban	no ASA indication	EMR321R	26.4.22 11:26	2024-04-30	Edoxaban 60mg / no ASA indication
1576	140	Edoxaban	no ASA indication	NKB371V	4.11.20 12:40	2021-12-31	Edoxaban 60mg / no ASA indication
1576	140	Edoxaban	no ASA indication	CUD493S	30.4.20 11:26	2021-12-31	Edoxaban 60mg / no ASA indication
1576	140	Edoxaban	no ASA indication	BHM719T	5.5.21 11:13	2021-12-31	Edoxaban 60mg / no ASA indication
1576	140	Edoxaban	no ASA indication	EMC935S	18.10.21 9:34	2024-04-30	Edoxaban 60mg / no ASA indication
1929	140	Edoxaban	no ASA indication	UWR388H	14.1.21 14:52	2022-08-31	Edoxaban 30mg / no ASA indication
2187	140	Edoxaban	no ASA indication	WKN749M	11.1.22 12:50	2024-04-30	Edoxaban 60mg / no ASA indication
2187	140	Edoxaban	no ASA indication	EPM221L	14.7.21 11:39	2024-04-30	Edoxaban 60mg / no ASA indication
2187	140	Edoxaban	no ASA indication	SKZ491N	5.7.22 11:39	2024-04-30	Edoxaban 60mg / no ASA indication
2204	140	Edoxaban	no ASA indication	VFY938S	25.1.22 9:04	2024-04-30	Edoxaban 60mg / no ASA indication
2204	140	Edoxaban	no ASA indication	ZDS538N	25.7.22 8:59	2024-04-30	Edoxaban 60mg / no ASA indication
2204	140	Edoxaban	no ASA indication	UZB372K	27.7.21 7:06	2024-04-30	Edoxaban 60mg / no ASA indication
2617	140	Edoxaban	no ASA indication	BCF496N	17.5.22 10:38	2024-04-30	Edoxaban 60mg / no ASA indication
2691	140	Edoxaban	no ASA indication	MYH925X	5.7.22 10:06	2024-04-30	Edoxaban 60mg / no ASA indication
671	145	Placebo	ASA indication	YLA587T	15.2.19 12:39	2020-01-01	Edoxaban 30mg / no ASA indication
671	145	Placebo	ASA indication	PLN654L	14.8.18 14:36	2020-01-01	Edoxaban 30mg / ASA indication
2585	151	Placebo	ASA indication	NGF852S	19.4.22 12:58	2024-04-30	Edoxaban 60mg / ASA indication
2537	151	Placebo	no ASA indication	MCR831W	16.3.22 11:09	2024-04-30	Edoxaban 60mg / no ASA indication
2533	151	Edoxaban	ASA indication	KUY297N	14.3.22 10:42	2024-04-30	Edoxaban 60mg / ASA indication
2572	151	Edoxaban	no ASA indication	EXV611F	5.4.22 9:10	2024-11-30	Edoxaban 30mg / no ASA indication
319	153	Placebo	ASA indication	NFC372F	26.10.17 11:59	2018-09-01	Edoxaban 30mg / ASA indication
1935	153	Placebo	ASA indication	RBM226L	21.1.21 9:22	2021-12-31	Edoxaban 60mg / ASA indication
1098	153	Placebo	no ASA indication	YSP831T	28.10.19 12:16	2021-12-31	Edoxaban 60mg / no ASA indication
1098	153	Placebo	no ASA indication	EZB348E	3.11.20 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1098	153	Placebo	no ASA indication	NZK829S	29.4.19 12:30	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1098	153	Placebo	no ASA indication	TKW677Y	11.5.20 9:23	2021-12-31	Edoxaban 60mg / no ASA indication
1098	153	Placebo	no ASA indication	DEX177W	26.10.21 10:02	2024-04-30	Edoxaban 60mg / no ASA indication
1098	153	Placebo	no ASA indication	VAG614A	27.4.21 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1098	153	Placebo	no ASA indication	DEL743A	19.4.22 9:47	2024-04-30	Edoxaban 60mg / no ASA indication
1545	153	Placebo	no ASA indication	UYH253E	8.9.20 9:18	2021-12-31	Edoxaban 60mg / no ASA indication
1545	153	Placebo	no ASA indication	NKV975W	8.9.20 8:39	2022-08-31	Edoxaban 30mg / no ASA indication
1545	153	Placebo	no ASA indication	NRD713K	5.3.20 11:02	2021-12-31	Edoxaban 60mg / no ASA indication
2142	153	Placebo	no ASA indication	UXC985Z	8.6.21 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
2142	153	Placebo	no ASA indication	DEH942G	7.12.21 10:24	2024-04-30	Edoxaban 60mg / no ASA indication
2142	153	Placebo	no ASA indication	FGB794T	7.6.22 8:38	2024-04-30	Edoxaban 60mg / no ASA indication
106	153	Edoxaban	ASA indication	WZE472Y	2.3.17 10:39	2018-09-01	Edoxaban 60mg / ASA indication
2730	153	Edoxaban	ASA indication	DGW924K	8.8.22 8:29	2024-04-30	Edoxaban 60mg / ASA indication
35	153	Edoxaban	no ASA indication	VRA323H	6.10.16 10:02	2018-09-01	Edoxaban 60mg / no ASA indication
110	154	Placebo	ASA indication	GCD133H	12.9.17 7:02	2018-09-01	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	TNX421D	12.9.19 7:00	2022-08-31	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	KZK521P	8.3.18 9:08	2020-01-01	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	NLP342M	12.3.20 7:51	2022-08-31	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	NZZ488E	10.9.20 7:40	2022-08-31	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	DAM928C	14.3.17 10:49	2018-09-01	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	TET332Z	7.3.19 8:13	2020-01-01	Edoxaban 30mg / ASA indication
110	154	Placebo	ASA indication	DGB129L	6.9.18 7:10	2020-01-01	Edoxaban 30mg / ASA indication
297	154	Placebo	ASA indication	RRH813M	27.3.18 9:16	2020-01-01	Edoxaban 30mg / ASA indication
297	154	Placebo	ASA indication	FLP998V	10.10.17 10:53	2018-09-01	Edoxaban 30mg / ASA indication
181	154	Edoxaban	ASA indication	CUD755A	8.6.17 10:28	2018-09-01	Edoxaban 30mg / ASA indication
688	154	Edoxaban	ASA indication	REC737D	28.8.18 8:19	2020-01-01	Edoxaban 30mg / ASA indication
294	161	Placebo	ASA indication	PWG338H	9.10.18 8:01	2020-01-01	Edoxaban 60mg / no ASA indication
294	161	Placebo	ASA indication	DFR977V	13.10.20 8:16	2021-12-31	Edoxaban 60mg / no ASA indication
294	161	Placebo	ASA indication	LBM845M	15.4.19 8:43	2020-01-01	Edoxaban 60mg / no ASA indication
294	161	Placebo	ASA indication	YZY562U	21.4.20 8:00	2021-12-31	Edoxaban 60mg / no ASA indication
294	161	Placebo	ASA indication	UNK168P	13.4.21 12:04	2021-12-31	Edoxaban 60mg / ASA indication
294	161	Placebo	ASA indication	HPA922D	8.10.19 13:46	2021-12-31	Edoxaban 60mg / no ASA indication
294	161	Placebo	ASA indication	XPT892B	10.4.18 7:28	2020-01-01	Edoxaban 60mg / ASA indication
294	161	Placebo	ASA indication	MXD821E	9.10.17 7:00	2018-09-01	Edoxaban 60mg / ASA indication
361	161	Placebo	ASA indication	VBE221P	5.12.17 9:03	2018-09-01	Edoxaban 30mg / ASA indication
395	161	Placebo	ASA indication	PVL956V	11.1.18 7:52	2018-09-01	Edoxaban 60mg / ASA indication
395	161	Placebo	ASA indication	FGN975F	7.1.19 8:05	2020-01-01	Edoxaban 60mg / ASA indication
395	161	Placebo	ASA indication	SMZ665R	10.7.18 7:31	2020-01-01	Edoxaban 60mg / ASA indication
978	161	Placebo	ASA indication	AUK443R	7.2.19 8:12	2020-01-01	Edoxaban 60mg / ASA indication
1543	161	Placebo	ASA indication	RPK715G	3.9.20 8:30	2021-12-31	Edoxaban 60mg / ASA indication
1543	161	Placebo	ASA indication	DTZ575C	19.8.21 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
1543	161	Placebo	ASA indication	WNT449R	5.3.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1543	161	Placebo	ASA indication	SVR312Y	1.3.21 10:40	2021-12-31	Edoxaban 60mg / no ASA indication
1543	161	Placebo	ASA indication	FZP442C	1.3.22 14:14	2024-11-30	Edoxaban 30mg / ASA indication
1543	161	Placebo	ASA indication	FXK325Z	6.9.22 9:34	2024-11-30	Edoxaban 30mg / ASA indication
2485	161	Placebo	ASA indication	EFA295U	18.2.22 8:14	2024-04-30	Edoxaban 60mg / ASA indication
230	161	Edoxaban	ASA indication	TDK327X	20.7.17 7:00	2018-09-01	Edoxaban 30mg / ASA indication
230	161	Edoxaban	ASA indication	ANB164X	30.1.18 9:14	2018-09-01	Edoxaban 30mg / ASA indication
230	161	Edoxaban	ASA indication	XMN895F	2.8.18 7:09	2020-01-01	Edoxaban 30mg / ASA indication
302	161	Edoxaban	ASA indication	UVH478L	16.4.18 6:53	2020-01-01	Edoxaban 60mg / ASA indication
302	161	Edoxaban	ASA indication	PEZ718S	22.10.18 8:13	2020-01-01	Edoxaban 60mg / ASA indication
302	161	Edoxaban	ASA indication	HNV182N	29.10.19 9:42	2021-12-31	Edoxaban 60mg / ASA indication
302	161	Edoxaban	ASA indication	LVC841U	16.10.17 7:11	2018-09-01	Edoxaban 60mg / ASA indication
302	161	Edoxaban	ASA indication	WVU839Z	25.4.19 8:07	2020-01-01	Edoxaban 60mg / ASA indication
459	161	Edoxaban	ASA indication	TDH658N	1.9.20 9:15	2021-12-31	Edoxaban 60mg / no ASA indication
459	161	Edoxaban	ASA indication	DFC742R	28.2.19 10:06	2020-01-01	Edoxaban 60mg / no ASA indication
459	161	Edoxaban	ASA indication	LZF699L	26.2.18 8:39	2020-01-01	Edoxaban 60mg / ASA indication
459	161	Edoxaban	ASA indication	UHV695V	16.2.21 10:38	2021-12-31	Edoxaban 60mg / no ASA indication
459	161	Edoxaban	ASA indication	WPS489S	20.8.19 9:15	2021-12-31	Edoxaban 60mg / no ASA indication
459	161	Edoxaban	ASA indication	VEL756S	30.8.18 7:41	2020-01-01	Edoxaban 60mg / no ASA indication
459	161	Edoxaban	ASA indication	SEV845H	2.3.20 9:57	2021-12-31	Edoxaban 60mg / no ASA indication
2417	166	Placebo	ASA indication	XKK946W	1.7.22 11:26	2024-04-30	Edoxaban 60mg / no ASA indication
2417	166	Placebo	ASA indication	XGM589G	7.1.22 11:02	2024-04-30	Edoxaban 60mg / ASA indication
2671	166	Placebo	ASA indication	GBA448X	27.6.22 12:38	2024-11-30	Edoxaban 30mg / ASA indication
2510	166	Edoxaban	no ASA indication	WYZ163D	3.3.22 12:11	2024-04-30	Edoxaban 60mg / no ASA indication
2510	166	Edoxaban	no ASA indication	TLU279K	5.9.22 11:34	2024-04-30	Edoxaban 60mg / no ASA indication
2626	166	Edoxaban	no ASA indication	WZH588B	25.5.22 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
2640	167	Placebo	ASA indication	GDE821N	3.6.22 7:25	2024-11-30	Edoxaban 30mg / ASA indication
2621	167	Placebo	no ASA indication	GHL663E	19.5.22 9:12	2024-11-30	Edoxaban 30mg / no ASA indication
2594	167	Edoxaban	no ASA indication	BBZ784G	22.4.22 11:05	2024-04-30	Edoxaban 60mg / no ASA indication
2623	167	Edoxaban	no ASA indication	AZT664W	23.5.22 8:29	2024-04-30	Edoxaban 60mg / no ASA indication
2606	171	Placebo	ASA indication	TXT168M	6.5.22 8:28	2024-04-30	Edoxaban 60mg / ASA indication
2518	171	Placebo	no ASA indication	GKA213U	8.3.22 9:36	2024-11-30	Edoxaban 30mg / no ASA indication
2717	171	Placebo	no ASA indication	UNF447R	19.7.22 11:29	2024-04-30	Edoxaban 60mg / no ASA indication
2149	171	Edoxaban	ASA indication	UZR245M	9.12.21 9:36	2024-04-30	Edoxaban 60mg / ASA indication
2149	171	Edoxaban	ASA indication	VAW461A	10.6.22 8:53	2024-04-30	Edoxaban 60mg / ASA indication
2149	171	Edoxaban	ASA indication	ADC451S	10.6.21 11:53	2021-12-31	Edoxaban 60mg / ASA indication
2304	171	Edoxaban	ASA indication	ABV319H	12.10.21 11:34	2022-08-31	Edoxaban 30mg / ASA indication
2255	171	Edoxaban	no ASA indication	UFC167D	7.3.22 9:38	2024-04-30	Edoxaban 60mg / no ASA indication
2255	171	Edoxaban	no ASA indication	UGV693F	6.9.21 9:43	2024-04-30	Edoxaban 60mg / no ASA indication
2709	171	Edoxaban	no ASA indication	UEB959D	11.7.22 12:27	2024-04-30	Edoxaban 60mg / no ASA indication
585	173	Placebo	ASA indication	YZG158N	13.6.19 10:35	2020-01-01	Edoxaban 60mg / ASA indication
585	173	Placebo	ASA indication	SPS737X	12.12.18 13:35	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
585	173	Placebo	ASA indication	ZHS593Z	11.6.18 11:04	2020-01-01	Edoxaban 60mg / ASA indication
1062	173	Placebo	ASA indication	KPR827X	9.10.19 10:19	2022-08-31	Edoxaban 30mg / ASA indication
1062	173	Placebo	ASA indication	ZHA223F	25.11.21 12:02	2022-08-31	Edoxaban 30mg / ASA indication
1062	173	Placebo	ASA indication	WBU531L	21.4.20 15:24	2022-08-31	Edoxaban 30mg / ASA indication
1062	173	Placebo	ASA indication	WWH214G	13.5.21 8:46	2022-08-31	Edoxaban 30mg / ASA indication
1062	173	Placebo	ASA indication	VKA124A	8.4.19 11:11	2020-01-01	Edoxaban 30mg / ASA indication
1062	173	Placebo	ASA indication	AGL526W	5.5.22 10:05	2024-11-30	Edoxaban 30mg / ASA indication
1062	173	Placebo	ASA indication	ESS771D	16.10.20 15:43	2022-08-31	Edoxaban 30mg / ASA indication
1540	173	Placebo	ASA indication	TZV476N	16.9.21 9:36	2024-04-30	Edoxaban 60mg / ASA indication
1540	173	Placebo	ASA indication	CKR993X	3.3.20 11:40	2021-12-31	Edoxaban 60mg / ASA indication
1540	173	Placebo	ASA indication	NKL731A	15.9.20 11:16	2021-12-31	Edoxaban 60mg / ASA indication
1540	173	Placebo	ASA indication	GAC773M	4.3.21 12:07	2021-12-31	Edoxaban 60mg / ASA indication
1540	173	Placebo	ASA indication	UBK657C	3.3.22 11:01	2024-04-30	Edoxaban 60mg / ASA indication
2042	173	Placebo	ASA indication	AKN773N	22.4.22 9:43	2024-11-30	Edoxaban 30mg / ASA indication
2042	173	Placebo	ASA indication	VRL995A	28.10.21 11:24	2022-08-31	Edoxaban 30mg / ASA indication
2042	173	Placebo	ASA indication	CYY136U	12.4.21 12:46	2022-08-31	Edoxaban 30mg / ASA indication
2124	173	Placebo	ASA indication	ZPN214F	30.11.21 13:53	2024-04-30	Edoxaban 60mg / ASA indication
2124	173	Placebo	ASA indication	ZRS144F	21.6.22 13:58	2024-04-30	Edoxaban 60mg / ASA indication
2124	173	Placebo	ASA indication	HKV372V	27.5.21 9:45	2021-12-31	Edoxaban 60mg / ASA indication
2342	173	Placebo	ASA indication	TZS157X	11.11.21 12:04	2024-04-30	Edoxaban 60mg / ASA indication
167	173	Placebo	no ASA indication	UGY628Y	22.5.18 8:50	2020-01-01	Edoxaban 60mg / no ASA indication
167	173	Placebo	no ASA indication	LSA693G	22.5.17 9:57	2018-09-01	Edoxaban 60mg / no ASA indication
167	173	Placebo	no ASA indication	BWS219M	22.11.17 10:31	2018-09-01	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	BMW281B	30.11.17 12:11	2018-09-01	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	ZLZ628N	30.11.18 11:47	2020-01-01	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	MEA269V	31.5.17 10:59	2018-09-01	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	CUW521E	29.11.19 12:53	2021-12-31	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	USX545W	16.12.21 11:30	2024-04-30	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	SGZ879L	30.5.19 11:00	2020-01-01	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	ASE894W	10.6.21 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	UTT456X	7.6.22 15:48	2024-04-30	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	PYM712Y	1.6.18 10:42	2020-01-01	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	VLF292P	19.1.21 11:57	2021-12-31	Edoxaban 60mg / no ASA indication
176	173	Placebo	no ASA indication	XGP111E	26.5.20 10:44	2021-12-31	Edoxaban 60mg / no ASA indication
553	173	Placebo	no ASA indication	MRM464L	15.5.18 11:13	2020-01-01	Edoxaban 60mg / no ASA indication
1014	173	Placebo	no ASA indication	SGH643Y	5.3.19 10:54	2020-01-01	Edoxaban 30mg / no ASA indication
1067	173	Placebo	no ASA indication	VYE414M	14.10.19 9:32	2021-12-31	Edoxaban 60mg / no ASA indication
1067	173	Placebo	no ASA indication	CLA336M	28.4.20 11:47	2021-12-31	Edoxaban 60mg / no ASA indication
1067	173	Placebo	no ASA indication	HMT287B	9.4.19 9:49	2020-01-01	Edoxaban 60mg / no ASA indication
1319	173	Placebo	no ASA indication	DWS933V	29.4.21 8:51	2022-08-31	Edoxaban 30mg / no ASA indication
1319	173	Placebo	no ASA indication	HFW665H	21.4.20 15:08	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1319	173	Placebo	no ASA indication	FZU197Z	19.10.20 8:04	2022-08-31	Edoxaban 30mg / no ASA indication
1319	173	Placebo	no ASA indication	SBL664M	8.10.19 11:15	2022-08-31	Edoxaban 30mg / no ASA indication
1488	173	Placebo	no ASA indication	SPY432Y	8.2.21 13:15	2022-08-31	Edoxaban 30mg / no ASA indication
1488	173	Placebo	no ASA indication	MFE756V	22.1.20 13:51	2022-08-31	Edoxaban 30mg / no ASA indication
1488	173	Placebo	no ASA indication	EXG918U	27.7.20 10:54	2022-08-31	Edoxaban 30mg / no ASA indication
1488	173	Placebo	no ASA indication	FNH235P	12.8.21 11:12	2022-08-31	Edoxaban 30mg / no ASA indication
1488	173	Placebo	no ASA indication	UZS635Y	1.2.22 13:53	2022-08-31	Edoxaban 30mg / no ASA indication
1488	173	Placebo	no ASA indication	ALG316N	26.7.22 15:02	2024-11-30	Edoxaban 30mg / no ASA indication
2506	173	Placebo	no ASA indication	UPY334C	1.3.22 14:18	2024-04-30	Edoxaban 60mg / no ASA indication
2506	173	Placebo	no ASA indication	VBG695V	25.8.22 10:59	2024-11-30	Edoxaban 30mg / no ASA indication
2675	173	Placebo	no ASA indication	AME795N	28.6.22 13:46	2024-11-30	Edoxaban 30mg / no ASA indication
242	173	Edoxaban	ASA indication	GPK878G	2.8.18 10:30	2020-01-01	Edoxaban 30mg / ASA indication
242	173	Edoxaban	ASA indication	APM898M	5.2.18 10:51	2018-09-01	Edoxaban 30mg / ASA indication
242	173	Edoxaban	ASA indication	YYC449N	3.8.17 10:42	2018-09-01	Edoxaban 30mg / ASA indication
1712	173	Edoxaban	ASA indication	UKR426U	29.1.21 10:14	2021-12-31	Edoxaban 60mg / ASA indication
1712	173	Edoxaban	ASA indication	VDA531V	15.7.21 10:54	2024-04-30	Edoxaban 60mg / ASA indication
1712	173	Edoxaban	ASA indication	YDL782A	30.7.20 9:05	2021-12-31	Edoxaban 60mg / ASA indication
1758	173	Edoxaban	ASA indication	BTP968A	4.9.20 10:02	2021-12-31	Edoxaban 60mg / ASA indication
1758	173	Edoxaban	ASA indication	KPL626W	4.3.21 11:02	2021-12-31	Edoxaban 60mg / ASA indication
2453	173	Edoxaban	ASA indication	VBU238D	27.1.22 11:13	2024-04-30	Edoxaban 60mg / ASA indication
2568	173	Edoxaban	ASA indication	AKL588M	31.3.22 10:47	2024-11-30	Edoxaban 30mg / ASA indication
314	173	Edoxaban	no ASA indication	DGS884W	24.10.17 10:13	2018-09-01	Edoxaban 60mg / no ASA indication
314	173	Edoxaban	no ASA indication	VHN965U	17.10.18 10:36	2020-01-01	Edoxaban 60mg / no ASA indication
314	173	Edoxaban	no ASA indication	VTK916Y	9.10.19 11:42	2021-12-31	Edoxaban 60mg / no ASA indication
314	173	Edoxaban	no ASA indication	FBM128R	16.4.18 10:22	2020-01-01	Edoxaban 60mg / no ASA indication
314	173	Edoxaban	no ASA indication	FVA135D	17.4.19 10:54	2020-01-01	Edoxaban 60mg / no ASA indication
322	173	Edoxaban	no ASA indication	KCE543S	31.10.17 10:47	2018-09-01	Edoxaban 60mg / no ASA indication
894	173	Edoxaban	no ASA indication	XGX231P	17.6.20 9:57	2021-12-31	Edoxaban 60mg / no ASA indication
894	173	Edoxaban	no ASA indication	DGP281U	16.12.21 9:50	2022-08-31	Edoxaban 30mg / no ASA indication
894	173	Edoxaban	no ASA indication	RKR696Y	14.6.22 14:39	2024-11-30	Edoxaban 30mg / no ASA indication
894	173	Edoxaban	no ASA indication	CMR944H	17.6.19 9:33	2020-01-01	Edoxaban 30mg / no ASA indication
894	173	Edoxaban	no ASA indication	YBL214C	17.12.19 11:10	2021-12-31	Edoxaban 60mg / no ASA indication
894	173	Edoxaban	no ASA indication	HXL385W	21.12.20 14:52	2021-12-31	Edoxaban 60mg / no ASA indication
894	173	Edoxaban	no ASA indication	UHL614N	17.6.21 10:10	2024-04-30	Edoxaban 60mg / no ASA indication
894	173	Edoxaban	no ASA indication	SUH115B	17.12.18 10:54	2020-01-01	Edoxaban 30mg / no ASA indication
975	173	Edoxaban	no ASA indication	GMV122A	4.2.19 11:49	2020-01-01	Edoxaban 30mg / no ASA indication
975	173	Edoxaban	no ASA indication	YUN996M	23.7.20 9:59	2022-08-31	Edoxaban 30mg / no ASA indication
975	173	Edoxaban	no ASA indication	PVY815P	5.8.19 10:48	2022-08-31	Edoxaban 30mg / no ASA indication
975	173	Edoxaban	no ASA indication	ABW419W	22.2.21 12:55	2022-08-31	Edoxaban 30mg / no ASA indication
975	173	Edoxaban	no ASA indication	ECC534H	7.2.20 11:51	2022-08-31	Edoxaban 30mg / no ASA indication
1080	173	Edoxaban	no ASA indication	GAU119E	22.10.20 9:47	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1080	173	Edoxaban	no ASA indication	HXK845K	15.4.19 10:04	2020-01-01	Edoxaban 60mg / no ASA indication
1080	173	Edoxaban	no ASA indication	XVP394T	8.10.19 9:15	2021-12-31	Edoxaban 60mg / no ASA indication
1080	173	Edoxaban	no ASA indication	VBB191M	26.4.22 12:56	2024-04-30	Edoxaban 60mg / no ASA indication
1080	173	Edoxaban	no ASA indication	PBL636G	21.4.20 15:16	2021-12-31	Edoxaban 60mg / no ASA indication
1080	173	Edoxaban	no ASA indication	HZC114K	15.4.21 9:38	2021-12-31	Edoxaban 60mg / no ASA indication
1080	173	Edoxaban	no ASA indication	VCU998T	14.10.21 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
1716	173	Edoxaban	no ASA indication	YPS216C	20.1.22 10:17	2024-04-30	Edoxaban 60mg / no ASA indication
1716	173	Edoxaban	no ASA indication	FYH366B	31.7.20 11:14	2021-12-31	Edoxaban 60mg / no ASA indication
1716	173	Edoxaban	no ASA indication	XKX649D	29.1.21 12:02	2021-12-31	Edoxaban 60mg / no ASA indication
1716	173	Edoxaban	no ASA indication	ULA155K	15.7.21 9:13	2024-04-30	Edoxaban 60mg / no ASA indication
2062	173	Edoxaban	no ASA indication	ULE511Y	28.10.21 9:11	2024-04-30	Edoxaban 60mg / no ASA indication
2062	173	Edoxaban	no ASA indication	AKZ586S	28.4.22 10:11	2024-11-30	Edoxaban 30mg / no ASA indication
2062	173	Edoxaban	no ASA indication	XPP555H	22.4.21 9:14	2021-12-31	Edoxaban 60mg / no ASA indication
2375	173	Edoxaban	no ASA indication	BCU869T	2.6.22 9:57	2024-11-30	Edoxaban 30mg / no ASA indication
2375	173	Edoxaban	no ASA indication	DNT696D	2.12.21 11:27	2022-08-31	Edoxaban 30mg / no ASA indication
2607	173	Edoxaban	no ASA indication	YPS844T	6.5.22 9:56	2024-04-30	Edoxaban 60mg / no ASA indication
1008	174	Placebo	ASA indication	LPD924Y	12.9.19 8:25	2022-08-31	Edoxaban 30mg / ASA indication
1008	174	Placebo	ASA indication	MAZ815D	27.2.19 12:18	2020-01-01	Edoxaban 30mg / ASA indication
1008	174	Placebo	ASA indication	WHG434F	26.2.20 12:59	2022-08-31	Edoxaban 30mg / ASA indication
1925	174	Placebo	ASA indication	BPH913K	13.1.21 12:49	2021-12-31	Edoxaban 60mg / ASA indication
1925	174	Placebo	ASA indication	EWK577U	14.7.21 9:20	2024-04-30	Edoxaban 60mg / ASA indication
1925	174	Placebo	ASA indication	YGX477D	13.7.22 9:42	2024-04-30	Edoxaban 60mg / no ASA indication
1925	174	Placebo	ASA indication	ACD893T	19.1.22 11:22	2024-04-30	Edoxaban 60mg / no ASA indication
2176	174	Placebo	ASA indication	FXZ952X	30.6.21 11:19	2022-08-31	Edoxaban 30mg / ASA indication
2176	174	Placebo	ASA indication	HLV999K	22.12.21 10:54	2022-08-31	Edoxaban 30mg / ASA indication
2176	174	Placebo	ASA indication	GLE893V	13.7.22 9:08	2024-11-30	Edoxaban 30mg / no ASA indication
498	174	Placebo	no ASA indication	MLV842B	28.9.18 9:43	2020-01-01	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	XLS352X	25.9.19 9:45	2021-12-31	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	EWM678S	23.9.20 10:10	2021-12-31	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	VVW619D	20.3.19 11:56	2020-01-01	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	EDT126V	22.9.21 11:08	2024-04-30	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	HVP717P	23.3.22 11:29	2024-04-30	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	YWL843K	23.3.18 11:05	2020-01-01	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	AEG985K	24.3.21 11:55	2021-12-31	Edoxaban 60mg / no ASA indication
498	174	Placebo	no ASA indication	HWU196K	2.4.20 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
1414	174	Placebo	no ASA indication	DPZ533Z	25.11.20 12:08	2021-12-31	Edoxaban 60mg / no ASA indication
1414	174	Placebo	no ASA indication	PKT553M	19.5.21 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
1414	174	Placebo	no ASA indication	RDL284B	27.5.20 10:38	2021-12-31	Edoxaban 60mg / no ASA indication
1414	174	Placebo	no ASA indication	ECM156N	24.11.21 10:47	2024-04-30	Edoxaban 60mg / no ASA indication
1414	174	Placebo	no ASA indication	DTG729A	27.11.19 13:22	2021-12-31	Edoxaban 60mg / no ASA indication
1414	174	Placebo	no ASA indication	YXH245L	1.6.22 9:56	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2069	174	Placebo	no ASA indication	PCW688M	28.4.21 10:58	2021-12-31	Edoxaban 60mg / no ASA indication
2069	174	Placebo	no ASA indication	EDL515S	27.10.21 10:48	2024-04-30	Edoxaban 60mg / no ASA indication
2069	174	Placebo	no ASA indication	ADV369D	27.4.22 10:05	2024-04-30	Edoxaban 60mg / no ASA indication
2586	174	Placebo	no ASA indication	VGR829W	20.4.22 11:06	2024-04-30	Edoxaban 60mg / no ASA indication
306	174	Edoxaban	ASA indication	ETL595U	18.10.17 13:01	2018-09-01	Edoxaban 60mg / ASA indication
613	174	Edoxaban	ASA indication	UGY312K	5.7.18 10:51	2020-01-01	Edoxaban 60mg / ASA indication
2588	174	Edoxaban	ASA indication	EKZ286F	20.4.22 12:38	2024-04-30	Edoxaban 60mg / ASA indication
172	174	Edoxaban	no ASA indication	CBG153H	29.11.17 12:13	2018-09-01	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	TCB189V	29.5.19 10:40	2020-01-01	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	FRN556V	20.11.19 12:07	2021-12-31	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	UHH995Z	30.5.18 10:02	2020-01-01	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	VKU885C	25.11.20 10:55	2021-12-31	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	ENG221T	26.5.21 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	VCX323M	24.11.21 11:33	2024-04-30	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	LEF357V	29.5.17 12:17	2018-09-01	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	UZX536E	27.5.20 9:43	2021-12-31	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	GEB458W	28.11.18 12:47	2020-01-01	Edoxaban 60mg / no ASA indication
172	174	Edoxaban	no ASA indication	YRU976U	25.5.22 9:57	2024-04-30	Edoxaban 60mg / no ASA indication
1487	174	Edoxaban	no ASA indication	EMK554S	20.1.21 11:18	2021-12-31	Edoxaban 60mg / no ASA indication
1487	174	Edoxaban	no ASA indication	URX153T	22.1.20 12:40	2021-12-31	Edoxaban 60mg / no ASA indication
1487	174	Edoxaban	no ASA indication	VCW596P	19.1.22 11:35	2024-04-30	Edoxaban 60mg / no ASA indication
1487	174	Edoxaban	no ASA indication	LCF929S	20.7.22 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
1487	174	Edoxaban	no ASA indication	EGZ763P	14.7.21 10:05	2024-04-30	Edoxaban 60mg / no ASA indication
1487	174	Edoxaban	no ASA indication	RFV849R	8.7.20 11:01	2021-12-31	Edoxaban 60mg / no ASA indication
1672	174	Edoxaban	no ASA indication	EKS376K	30.6.21 10:23	2024-04-30	Edoxaban 60mg / no ASA indication
1672	174	Edoxaban	no ASA indication	EKH537S	29.12.21 12:17	2024-04-30	Edoxaban 60mg / no ASA indication
1672	174	Edoxaban	no ASA indication	KBH949C	1.7.20 11:36	2021-12-31	Edoxaban 60mg / no ASA indication
1672	174	Edoxaban	no ASA indication	WMT459V	30.12.20 11:52	2022-08-31	Edoxaban 30mg / no ASA indication
1672	174	Edoxaban	no ASA indication	HZG925L	29.9.21 9:59	2022-08-31	Edoxaban 30mg / no ASA indication
2566	174	Edoxaban	no ASA indication	LDF951A	30.3.22 10:53	2024-04-30	Edoxaban 60mg / no ASA indication
2456	175	Placebo	ASA indication	FEB111B	31.1.22 10:23	2024-04-30	Edoxaban 60mg / ASA indication
2460	175	Placebo	ASA indication	FDS257H	1.2.22 10:55	2024-04-30	Edoxaban 60mg / ASA indication
2460	175	Placebo	ASA indication	ELA662P	26.7.22 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
515	175	Placebo	no ASA indication	NRF787E	6.4.18 11:57	2020-01-01	Edoxaban 30mg / no ASA indication
2536	175	Placebo	no ASA indication	ELC523L	16.3.22 9:55	2024-04-30	Edoxaban 60mg / no ASA indication
2523	175	Edoxaban	ASA indication	GLR259T	9.3.22 10:45	2024-11-30	Edoxaban 30mg / ASA indication
2745	175	Edoxaban	ASA indication	EWZ659U	5.9.22 8:38	2024-04-30	Edoxaban 60mg / ASA indication
487	175	Edoxaban	no ASA indication	WRB991S	21.9.18 11:39	2020-01-01	Edoxaban 60mg / no ASA indication
487	175	Edoxaban	no ASA indication	TVF813Z	20.9.19 8:34	2021-12-31	Edoxaban 60mg / no ASA indication
487	175	Edoxaban	no ASA indication	XVR545L	22.3.18 8:37	2020-01-01	Edoxaban 60mg / no ASA indication
487	175	Edoxaban	no ASA indication	FKW371D	15.3.19 10:36	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1035	175	Edoxaban	no ASA indication	SES112W	2.10.19 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
1035	175	Edoxaban	no ASA indication	CML823V	7.4.20 16:54	2021-12-31	Edoxaban 60mg / no ASA indication
1035	175	Edoxaban	no ASA indication	FYE627L	22.3.19 12:26	2020-01-01	Edoxaban 60mg / no ASA indication
2530	175	Edoxaban	no ASA indication	EUP537A	11.3.22 11:07	2024-04-30	Edoxaban 60mg / no ASA indication
128	179	Placebo	ASA indication	DMN162W	30.3.17 11:11	2018-09-01	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	FUM179C	29.4.19 10:07	2020-01-01	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	GRR366H	13.4.20 8:22	2021-12-31	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	TTL165Z	4.4.18 11:49	2020-01-01	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	VSE349U	12.4.21 11:46	2021-12-31	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	GNC922B	7.10.19 8:47	2021-12-31	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	FRU145G	21.3.22 8:37	2024-04-30	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	HSP994R	14.10.20 9:11	2021-12-31	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	ETV145U	15.10.18 10:48	2020-01-01	Edoxaban 60mg / ASA indication
510	179	Placebo	ASA indication	FRM447V	4.10.21 7:51	2024-04-30	Edoxaban 60mg / ASA indication
308	179	Placebo	no ASA indication	DGM136W	18.4.18 9:46	2020-01-01	Edoxaban 60mg / no ASA indication
308	179	Placebo	no ASA indication	KFP686M	23.4.19 10:33	2020-01-01	Edoxaban 60mg / no ASA indication
308	179	Placebo	no ASA indication	GSW237D	19.4.22 10:07	2024-11-30	Edoxaban 30mg / no ASA indication
308	179	Placebo	no ASA indication	GHC817Y	20.4.21 9:44	2022-08-31	Edoxaban 30mg / no ASA indication
308	179	Placebo	no ASA indication	BFC878F	24.10.18 10:22	2020-01-01	Edoxaban 60mg / no ASA indication
308	179	Placebo	no ASA indication	ADK666L	19.10.17 11:47	2018-09-01	Edoxaban 60mg / no ASA indication
308	179	Placebo	no ASA indication	EUS582D	18.10.21 11:04	2024-04-30	Edoxaban 60mg / no ASA indication
308	179	Placebo	no ASA indication	PLP147B	21.4.20 8:22	2021-12-31	Edoxaban 60mg / no ASA indication
308	179	Placebo	no ASA indication	GXP469Z	27.10.20 8:52	2022-08-31	Edoxaban 30mg / no ASA indication
308	179	Placebo	no ASA indication	URW213M	15.10.19 9:36	2021-12-31	Edoxaban 60mg / no ASA indication
1182	179	Placebo	no ASA indication	KHP929A	17.6.19 13:16	2020-01-01	Edoxaban 60mg / no ASA indication
1868	179	Placebo	no ASA indication	EXG175P	17.11.20 12:05	2021-12-31	Edoxaban 60mg / no ASA indication
2101	179	Placebo	no ASA indication	EXK256M	9.11.21 11:06	2024-04-30	Edoxaban 60mg / no ASA indication
2101	179	Placebo	no ASA indication	WMN543D	14.5.21 9:25	2021-12-31	Edoxaban 60mg / no ASA indication
2101	179	Placebo	no ASA indication	EWU555W	10.5.22 9:16	2024-04-30	Edoxaban 60mg / no ASA indication
1112	179	Edoxaban	ASA indication	TGC537Y	27.4.20 8:20	2021-12-31	Edoxaban 60mg / ASA indication
1112	179	Edoxaban	ASA indication	FDY341P	10.5.22 10:14	2024-04-30	Edoxaban 60mg / ASA indication
1112	179	Edoxaban	ASA indication	WNM675K	6.11.20 9:47	2021-12-31	Edoxaban 60mg / ASA indication
1112	179	Edoxaban	ASA indication	FYL771W	6.5.19 12:56	2020-01-01	Edoxaban 60mg / ASA indication
1112	179	Edoxaban	ASA indication	EBS513B	5.11.19 12:50	2021-12-31	Edoxaban 60mg / ASA indication
1112	179	Edoxaban	ASA indication	XFN996K	11.5.21 12:43	2021-12-31	Edoxaban 60mg / ASA indication
1112	179	Edoxaban	ASA indication	FHE212P	9.11.21 11:59	2024-04-30	Edoxaban 60mg / ASA indication
1147	179	Edoxaban	ASA indication	YXC325F	11.12.19 10:17	2021-12-31	Edoxaban 60mg / ASA indication
1147	179	Edoxaban	ASA indication	RTH293H	16.6.20 11:02	2021-12-31	Edoxaban 60mg / ASA indication
1147	179	Edoxaban	ASA indication	NXR879G	13.12.21 12:26	2022-08-31	Edoxaban 30mg / ASA indication
1147	179	Edoxaban	ASA indication	GSA474H	6.6.22 11:15	2024-11-30	Edoxaban 30mg / ASA indication
1147	179	Edoxaban	ASA indication	LBY876S	17.12.20 13:48	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1147	179	Edoxaban	ASA indication	WHY816B	11.6.19 11:44	2020-01-01	Edoxaban 60mg / ASA indication
1147	179	Edoxaban	ASA indication	KZW459X	2.6.21 11:44	2021-12-31	Edoxaban 60mg / ASA indication
2193	179	Edoxaban	ASA indication	FGH885F	19.7.21 16:00	2024-04-30	Edoxaban 60mg / ASA indication
296	179	Edoxaban	no ASA indication	LRS142H	9.10.17 13:04	2018-09-01	Edoxaban 60mg / no ASA indication
1132	179	Edoxaban	no ASA indication	UKR719D	20.5.19 8:18	2020-01-01	Edoxaban 60mg / no ASA indication
1270	179	Edoxaban	no ASA indication	AAC462Y	2.9.19 10:42	2022-08-31	Edoxaban 30mg / no ASA indication
1270	179	Edoxaban	no ASA indication	GEL376U	7.9.22 8:30	2024-11-30	Edoxaban 30mg / no ASA indication
1270	179	Edoxaban	no ASA indication	ACF983D	23.2.21 9:40	2021-12-31	Edoxaban 60mg / no ASA indication
1270	179	Edoxaban	no ASA indication	FDC762M	6.9.21 10:13	2024-04-30	Edoxaban 60mg / no ASA indication
1270	179	Edoxaban	no ASA indication	HRN661S	7.9.20 7:47	2021-12-31	Edoxaban 60mg / no ASA indication
1270	179	Edoxaban	no ASA indication	CEV176B	3.3.20 11:04	2021-12-31	Edoxaban 60mg / no ASA indication
1270	179	Edoxaban	no ASA indication	FDF762C	7.3.22 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
2100	179	Edoxaban	no ASA indication	FAG282L	9.11.21 11:19	2024-04-30	Edoxaban 60mg / no ASA indication
2100	179	Edoxaban	no ASA indication	BEU894F	10.5.22 8:55	2024-04-30	Edoxaban 60mg / no ASA indication
2100	179	Edoxaban	no ASA indication	HZT163P	14.5.21 9:11	2021-12-31	Edoxaban 60mg / no ASA indication
424	189	Edoxaban	ASA indication	UPH625E	1.2.18 10:35	2018-09-01	Edoxaban 30mg / ASA indication
1331	189	Edoxaban	ASA indication	AYF475Z	15.10.19 9:27	2022-08-31	Edoxaban 30mg / ASA indication
412	195	Placebo	ASA indication	NWN191Z	25.6.19 9:20	2021-12-31	Edoxaban 60mg / ASA indication
412	195	Placebo	ASA indication	SVL679Y	25.1.18 9:04	2018-09-01	Edoxaban 60mg / ASA indication
412	195	Placebo	ASA indication	UEX194N	7.1.20 12:20	2021-12-31	Edoxaban 60mg / ASA indication
412	195	Placebo	ASA indication	RZX886N	22.1.19 10:03	2020-01-01	Edoxaban 60mg / ASA indication
412	195	Placebo	ASA indication	PXU838S	15.12.20 11:59	2021-12-31	Edoxaban 60mg / no ASA indication
412	195	Placebo	ASA indication	MPD647N	22.6.21 10:50	2024-04-30	Edoxaban 60mg / no ASA indication
412	195	Placebo	ASA indication	CKS229G	24.7.18 8:22	2020-01-01	Edoxaban 60mg / ASA indication
412	195	Placebo	ASA indication	BLD762K	7.7.20 10:40	2021-12-31	Edoxaban 60mg / no ASA indication
633	195	Placebo	ASA indication	SCM992K	29.1.19 10:03	2020-01-01	Edoxaban 30mg / ASA indication
633	195	Placebo	ASA indication	XYX831K	19.7.18 12:48	2020-01-01	Edoxaban 30mg / ASA indication
1004	195	Placebo	ASA indication	FCS875T	10.9.19 9:56	2021-12-31	Edoxaban 60mg / ASA indication
1004	195	Placebo	ASA indication	NAN447T	29.7.21 14:59	2024-04-30	Edoxaban 60mg / ASA indication
1004	195	Placebo	ASA indication	HYU453Z	25.8.20 8:07	2021-12-31	Edoxaban 60mg / ASA indication
1004	195	Placebo	ASA indication	NMW221C	17.3.20 10:43	2021-12-31	Edoxaban 60mg / ASA indication
1004	195	Placebo	ASA indication	ZZN912X	26.2.19 10:13	2020-01-01	Edoxaban 60mg / ASA indication
1004	195	Placebo	ASA indication	XHA824T	16.2.21 13:14	2021-12-31	Edoxaban 60mg / ASA indication
396	195	Placebo	no ASA indication	UMT784Y	11.1.18 13:42	2018-09-01	Edoxaban 60mg / no ASA indication
1233	195	Placebo	no ASA indication	DYS395D	25.7.19 12:28	2021-12-31	Edoxaban 60mg / no ASA indication
398	195	Edoxaban	ASA indication	CBF278P	11.1.18 14:14	2018-09-01	Edoxaban 30mg / ASA indication
519	195	Edoxaban	ASA indication	XKX874D	23.10.18 7:47	2020-01-01	Edoxaban 30mg / ASA indication
519	195	Edoxaban	ASA indication	VUE755Z	10.9.19 9:47	2022-08-31	Edoxaban 30mg / ASA indication
519	195	Edoxaban	ASA indication	XCK656U	10.4.18 9:15	2020-01-01	Edoxaban 30mg / ASA indication
519	195	Edoxaban	ASA indication	TNH886L	15.9.20 11:26	2022-08-31	Edoxaban 30mg / ASA indication
519	195	Edoxaban	ASA indication	BLU816F	16.3.20 13:08	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
519	195	Edoxaban	ASA indication	TGW913T	2.4.19 10:45	2020-01-01	Edoxaban 30mg / ASA indication
617	195	Edoxaban	ASA indication	ENM495B	27.11.18 11:42	2020-01-01	Edoxaban 60mg / ASA indication
617	195	Edoxaban	ASA indication	WAW391M	5.7.18 13:07	2020-01-01	Edoxaban 60mg / ASA indication
1411	195	Edoxaban	ASA indication	RFX612W	19.5.20 10:02	2021-12-31	Edoxaban 60mg / ASA indication
1411	195	Edoxaban	ASA indication	MSC516X	26.11.19 11:25	2021-12-31	Edoxaban 60mg / ASA indication
1411	195	Edoxaban	ASA indication	UTR635T	3.11.20 12:08	2021-12-31	Edoxaban 60mg / ASA indication
169	195	Edoxaban	no ASA indication	SNC358G	24.5.17 13:21	2018-09-01	Edoxaban 60mg / no ASA indication
283	195	Edoxaban	no ASA indication	EHA886P	26.9.17 9:18	2018-09-01	Edoxaban 60mg / no ASA indication
1857	198	Placebo	ASA indication	VLN255R	17.5.21 8:59	2021-12-31	Edoxaban 60mg / ASA indication
1857	198	Placebo	ASA indication	DWE117S	10.11.20 9:46	2021-12-31	Edoxaban 60mg / ASA indication
2148	198	Placebo	ASA indication	WGL441F	10.6.21 9:33	2022-08-31	Edoxaban 30mg / ASA indication
2148	198	Placebo	ASA indication	ZMV181X	16.12.21 9:28	2022-08-31	Edoxaban 30mg / ASA indication
2148	198	Placebo	ASA indication	HMK688E	9.6.22 9:18	2024-11-30	Edoxaban 30mg / ASA indication
144	198	Placebo	no ASA indication	BWZ656K	26.4.18 13:44	2020-01-01	Edoxaban 30mg / no ASA indication
144	198	Placebo	no ASA indication	ZYY435Y	25.10.18 13:35	2020-01-01	Edoxaban 30mg / no ASA indication
144	198	Placebo	no ASA indication	UHA218U	17.10.17 9:46	2018-09-01	Edoxaban 30mg / no ASA indication
144	198	Placebo	no ASA indication	HZC952R	25.4.17 9:07	2018-09-01	Edoxaban 30mg / no ASA indication
1188	202	Placebo	ASA indication	CKC981F	10.12.19 15:14	2021-12-31	Edoxaban 60mg / ASA indication
1188	202	Placebo	ASA indication	MYF913L	31.5.22 13:33	2024-04-30	Edoxaban 60mg / no ASA indication
1188	202	Placebo	ASA indication	CXT314R	18.6.19 13:32	2020-01-01	Edoxaban 60mg / ASA indication
1188	202	Placebo	ASA indication	ESD251L	16.6.20 14:23	2021-12-31	Edoxaban 60mg / ASA indication
1188	202	Placebo	ASA indication	AGA222U	15.12.20 14:19	2021-12-31	Edoxaban 60mg / ASA indication
1188	202	Placebo	ASA indication	GNB292M	15.6.21 13:30	2021-12-31	Edoxaban 60mg / ASA indication
1188	202	Placebo	ASA indication	NGH161M	14.12.21 14:42	2024-04-30	Edoxaban 60mg / ASA indication
1125	202	Placebo	no ASA indication	YAR572Z	14.5.19 9:55	2020-01-01	Edoxaban 60mg / no ASA indication
556	202	Edoxaban	ASA indication	YRM134P	17.5.18 9:12	2020-01-01	Edoxaban 60mg / ASA indication
1146	202	Edoxaban	ASA indication	SGT443P	28.5.19 9:33	2020-01-01	Edoxaban 60mg / ASA indication
348	202	Edoxaban	no ASA indication	XCK684B	23.11.17 16:00	2018-09-01	Edoxaban 60mg / no ASA indication
419	202	Edoxaban	no ASA indication	SEY746E	6.8.19 12:58	2021-12-31	Edoxaban 60mg / no ASA indication
419	202	Edoxaban	no ASA indication	SFU161G	31.1.19 11:13	2020-01-01	Edoxaban 60mg / no ASA indication
419	202	Edoxaban	no ASA indication	KLZ828F	7.7.20 13:19	2021-12-31	Edoxaban 60mg / no ASA indication
419	202	Edoxaban	no ASA indication	EWG187G	19.7.18 14:26	2020-01-01	Edoxaban 60mg / no ASA indication
419	202	Edoxaban	no ASA indication	TUG416W	30.1.18 10:07	2018-09-01	Edoxaban 60mg / no ASA indication
419	202	Edoxaban	no ASA indication	ADN231W	21.1.20 14:45	2022-08-31	Edoxaban 30mg / no ASA indication
419	202	Edoxaban	no ASA indication	AVV298H	22.1.20 11:10	2021-12-31	Edoxaban 60mg / no ASA indication
184	205	Placebo	ASA indication	UMM821V	8.6.17 11:25	2018-09-01	Edoxaban 30mg / ASA indication
285	205	Placebo	ASA indication	TPE623F	27.9.17 12:30	2018-09-01	Edoxaban 60mg / ASA indication
285	205	Placebo	ASA indication	MGL333N	10.4.19 11:01	2020-01-01	Edoxaban 60mg / ASA indication
285	205	Placebo	ASA indication	SUP616P	9.4.18 10:25	2020-01-01	Edoxaban 60mg / ASA indication
285	205	Placebo	ASA indication	GRA917G	1.10.18 10:47	2020-01-01	Edoxaban 60mg / ASA indication
366	205	Placebo	ASA indication	LGW433S	8.12.17 11:34	2018-09-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
748	205	Placebo	ASA indication	CSG965B	18.4.19 10:36	2020-01-01	Edoxaban 60mg / ASA indication
748	205	Placebo	ASA indication	XNZ465L	3.11.20 15:04	2021-12-31	Edoxaban 60mg / no ASA indication
748	205	Placebo	ASA indication	BGA823X	11.10.18 14:09	2020-01-01	Edoxaban 60mg / ASA indication
748	205	Placebo	ASA indication	XWZ321Z	29.4.20 12:20	2021-12-31	Edoxaban 60mg / no ASA indication
748	205	Placebo	ASA indication	GBM576D	30.10.19 11:30	2021-12-31	Edoxaban 60mg / ASA indication
931	205	Placebo	ASA indication	ZCY762P	24.1.19 15:14	2020-01-01	Edoxaban 60mg / ASA indication
207	205	Placebo	no ASA indication	SZK374W	20.12.17 9:23	2018-09-01	Edoxaban 30mg / no ASA indication
207	205	Placebo	no ASA indication	FCA619R	20.6.19 10:16	2022-08-31	Edoxaban 30mg / no ASA indication
207	205	Placebo	no ASA indication	FAM956U	28.6.17 12:41	2018-09-01	Edoxaban 30mg / no ASA indication
207	205	Placebo	no ASA indication	NTU946C	18.12.19 11:40	2022-08-31	Edoxaban 30mg / no ASA indication
207	205	Placebo	no ASA indication	CGE557E	25.6.20 8:24	2022-08-31	Edoxaban 30mg / no ASA indication
207	205	Placebo	no ASA indication	VBE371M	20.6.18 12:22	2020-01-01	Edoxaban 30mg / no ASA indication
207	205	Placebo	no ASA indication	PKC935E	20.12.18 12:31	2020-01-01	Edoxaban 30mg / no ASA indication
80	205	Edoxaban	ASA indication	GPU816P	1.8.17 12:03	2018-09-01	Edoxaban 60mg / no ASA indication
80	205	Edoxaban	ASA indication	LCZ722B	27.1.17 13:51	2018-09-01	Edoxaban 60mg / ASA indication
80	205	Edoxaban	ASA indication	UCF473P	1.2.17 11:41	2018-09-01	Edoxaban 60mg / no ASA indication
336	205	Edoxaban	ASA indication	MYX925N	11.5.18 13:01	2020-01-01	Edoxaban 60mg / ASA indication
336	205	Edoxaban	ASA indication	CGV823A	10.11.17 12:56	2018-09-01	Edoxaban 60mg / ASA indication
382	205	Edoxaban	ASA indication	BLN564Y	28.12.17 11:14	2018-09-01	Edoxaban 60mg / ASA indication
946	205	Edoxaban	ASA indication	XHH472V	21.1.19 14:35	2020-01-01	Edoxaban 60mg / ASA indication
182	205	Edoxaban	no ASA indication	HXL987Z	8.6.17 9:11	2018-09-01	Edoxaban 60mg / no ASA indication
516	208	Placebo	no ASA indication	GSF597S	12.10.18 14:55	2020-01-01	Edoxaban 60mg / no ASA indication
516	208	Placebo	no ASA indication	NAK162N	27.9.19 12:43	2021-12-31	Edoxaban 60mg / no ASA indication
516	208	Placebo	no ASA indication	FGM246A	12.10.18 14:09	2020-01-01	Edoxaban 60mg / ASA indication
516	208	Placebo	no ASA indication	YZB319X	6.4.18 13:04	2020-01-01	Edoxaban 60mg / no ASA indication
516	208	Placebo	no ASA indication	YTF543R	2.10.20 12:14	2022-08-31	Edoxaban 30mg / no ASA indication
516	208	Placebo	no ASA indication	PZH779K	22.3.19 15:12	2020-01-01	Edoxaban 30mg / no ASA indication
516	208	Placebo	no ASA indication	DLB334S	3.4.20 12:47	2021-12-31	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	ZMD591E	12.4.19 14:07	2020-01-01	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	VFA167W	12.10.18 13:59	2020-01-01	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	ETH984G	15.4.21 11:13	2021-12-31	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	XTG373T	1.10.20 12:42	2021-12-31	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	KYK186S	13.4.18 13:12	2020-01-01	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	HEC113E	17.4.20 12:53	2021-12-31	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	YGM352S	18.10.19 12:22	2021-12-31	Edoxaban 60mg / no ASA indication
524	208	Placebo	no ASA indication	BKH116F	15.10.21 13:53	2024-04-30	Edoxaban 60mg / no ASA indication
1036	208	Edoxaban	ASA indication	FXA969D	22.3.19 14:28	2020-01-01	Edoxaban 60mg / ASA indication
1362	208	Edoxaban	ASA indication	UDF642S	6.5.22 13:11	2024-04-30	Edoxaban 60mg / ASA indication
1362	208	Edoxaban	ASA indication	CSC762C	13.11.20 14:09	2021-12-31	Edoxaban 60mg / ASA indication
1362	208	Edoxaban	ASA indication	PLV623A	15.5.20 12:30	2021-12-31	Edoxaban 60mg / no ASA indication
1362	208	Edoxaban	ASA indication	LWY726W	14.5.21 13:22	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1362	208	Edoxaban	ASA indication	SZX879W	8.11.19 13:49	2021-12-31	Edoxaban 60mg / ASA indication
1362	208	Edoxaban	ASA indication	BRX816P	12.11.21 14:18	2024-04-30	Edoxaban 60mg / ASA indication
1306	208	Edoxaban	no ASA indication	REL516F	4.10.19 12:18	2021-12-31	Edoxaban 60mg / no ASA indication
1306	208	Edoxaban	no ASA indication	YWN886T	2.10.20 13:06	2022-08-31	Edoxaban 30mg / no ASA indication
1306	208	Edoxaban	no ASA indication	CAA961G	20.3.20 11:43	2021-12-31	Edoxaban 60mg / no ASA indication
1449	208	Edoxaban	no ASA indication	GKK826L	13.12.19 13:18	2021-12-31	Edoxaban 60mg / no ASA indication
79	209	Placebo	ASA indication	HDS411S	11.1.18 14:15	2018-09-01	Edoxaban 30mg / ASA indication
79	209	Placebo	ASA indication	TEG714D	2.1.20 13:22	2022-08-31	Edoxaban 30mg / no ASA indication
79	209	Placebo	ASA indication	BPN756Y	20.12.18 14:13	2020-01-01	Edoxaban 30mg / ASA indication
79	209	Placebo	ASA indication	DTH395A	12.1.21 14:50	2022-08-31	Edoxaban 30mg / ASA indication
79	209	Placebo	ASA indication	GHX311L	19.7.18 11:04	2020-01-01	Edoxaban 30mg / no ASA indication
79	209	Placebo	ASA indication	ZML471A	17.7.17 15:11	2018-09-01	Edoxaban 60mg / ASA indication
79	209	Placebo	ASA indication	XLE669X	26.1.17 11:11	2018-09-01	Edoxaban 60mg / ASA indication
79	209	Placebo	ASA indication	KFL349K	1.7.20 15:20	2022-08-31	Edoxaban 30mg / ASA indication
79	209	Placebo	ASA indication	BCM515B	1.7.19 14:19	2022-08-31	Edoxaban 30mg / no ASA indication
79	209	Placebo	ASA indication	TYP834P	8.1.21 13:02	2021-12-31	Edoxaban 60mg / ASA indication
141	209	Placebo	no ASA indication	THR658L	22.11.18 13:29	2020-01-01	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	KPD299A	1.7.19 9:59	2021-12-31	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	BYU235B	22.10.21 15:51	2024-04-30	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	PZD823L	13.5.22 9:04	2024-04-30	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	CTM432F	29.11.20 21:07	2021-12-31	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	RRL192W	28.5.21 13:07	2021-12-31	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	GWP819A	20.4.17 13:59	2018-09-01	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	FCL873X	16.10.17 12:24	2018-09-01	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	AZA431Z	26.4.18 12:44	2020-01-01	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	WCV276T	2.1.20 13:50	2021-12-31	Edoxaban 60mg / no ASA indication
141	209	Placebo	no ASA indication	DVG941D	7.7.20 16:12	2021-12-31	Edoxaban 60mg / no ASA indication
1501	209	Placebo	no ASA indication	BTY468G	4.2.22 14:39	2024-04-30	Edoxaban 60mg / no ASA indication
1501	209	Placebo	no ASA indication	CCH126E	18.8.21 1:34	2024-04-30	Edoxaban 60mg / no ASA indication
1501	209	Placebo	no ASA indication	YDB888N	30.7.20 22:08	2021-12-31	Edoxaban 60mg / no ASA indication
1501	209	Placebo	no ASA indication	CTK333U	8.2.21 12:54	2021-12-31	Edoxaban 60mg / no ASA indication
1501	209	Placebo	no ASA indication	PXD992R	5.8.22 13:32	2024-04-30	Edoxaban 60mg / no ASA indication
1501	209	Placebo	no ASA indication	MYK587A	3.2.20 13:27	2021-12-31	Edoxaban 60mg / no ASA indication
143	211	Placebo	ASA indication	GUW763B	2.4.19 11:15	2020-01-01	Edoxaban 60mg / ASA indication
143	211	Placebo	ASA indication	SCM452S	9.10.18 13:13	2020-01-01	Edoxaban 30mg / ASA indication
143	211	Placebo	ASA indication	VNX468K	20.4.17 13:33	2018-09-01	Edoxaban 60mg / ASA indication
143	211	Placebo	ASA indication	TMT214V	1.10.19 11:36	2022-08-31	Edoxaban 30mg / ASA indication
143	211	Placebo	ASA indication	EKG449W	19.4.18 14:05	2020-01-01	Edoxaban 60mg / ASA indication
143	211	Placebo	ASA indication	VTS741R	12.10.17 14:25	2018-09-01	Edoxaban 60mg / no ASA indication
250	211	Placebo	ASA indication	SYU483L	14.8.17 11:41	2018-09-01	Edoxaban 30mg / ASA indication
513	211	Placebo	no ASA indication	DNU178A	3.10.18 9:52	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
513	211	Placebo	no ASA indication	LEP533R	6.10.20 12:58	2021-12-31	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	XHP756D	2.10.19 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	FWF266V	8.4.21 13:06	2021-12-31	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	CNF468W	13.10.21 13:03	2024-04-30	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	CFB966V	23.3.22 8:28	2024-04-30	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	SKA549Y	6.4.18 10:08	2020-01-01	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	SYD635L	10.4.19 9:55	2020-01-01	Edoxaban 60mg / no ASA indication
513	211	Placebo	no ASA indication	NLP163S	26.3.20 15:18	2022-08-31	Edoxaban 30mg / no ASA indication
204	211	Edoxaban	ASA indication	MHY561Y	27.6.17 15:24	2018-09-01	Edoxaban 60mg / ASA indication
356	211	Edoxaban	ASA indication	YBT195B	8.6.18 10:59	2020-01-01	Edoxaban 30mg / ASA indication
356	211	Edoxaban	ASA indication	XGK959M	1.12.17 10:44	2018-09-01	Edoxaban 30mg / ASA indication
49	217	Placebo	no ASA indication	YTA396L	15.6.18 8:44	2020-01-01	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	BPC395C	19.12.18 13:48	2020-01-01	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	ZFK155D	18.5.17 14:10	2018-09-01	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	ZDN897L	27.11.17 9:23	2018-09-01	Edoxaban 60mg / no ASA indication
49	217	Placebo	no ASA indication	CUS321A	9.6.22 10:02	2024-11-30	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	ZNX442B	20.3.20 15:11	2022-08-31	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	PFZ319K	17.11.16 13:31	2018-09-01	Edoxaban 60mg / no ASA indication
49	217	Placebo	no ASA indication	TXR496R	26.6.19 11:54	2022-08-31	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	NCP411P	10.12.19 16:14	2022-08-31	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	YDN812G	6.12.21 10:19	2022-08-31	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	CAD263W	1.12.20 15:53	2022-08-31	Edoxaban 30mg / no ASA indication
49	217	Placebo	no ASA indication	MVR431W	24.5.21 9:29	2022-08-31	Edoxaban 30mg / no ASA indication
293	226	Placebo	ASA indication	LCF884K	5.4.18 14:14	2020-01-01	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	LKW935E	13.10.20 14:33	2021-12-31	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	UMG446Z	5.10.17 15:54	2018-09-01	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	TVR327S	18.4.19 15:19	2020-01-01	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	LMM298K	11.10.18 15:49	2020-01-01	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	LHM351N	23.4.20 10:40	2021-12-31	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	WYW459V	9.4.21 14:31	2021-12-31	Edoxaban 60mg / ASA indication
293	226	Placebo	ASA indication	HLZ313Z	15.10.19 13:39	2021-12-31	Edoxaban 60mg / ASA indication
648	226	Placebo	ASA indication	LVX897K	31.7.18 12:56	2020-01-01	Edoxaban 60mg / ASA indication
1400	226	Placebo	ASA indication	HVS692D	19.11.19 16:03	2021-12-31	Edoxaban 60mg / ASA indication
1400	226	Placebo	ASA indication	HGH577D	7.5.21 13:43	2021-12-31	Edoxaban 60mg / ASA indication
1400	226	Placebo	ASA indication	FSM931C	9.11.21 14:15	2024-04-30	Edoxaban 60mg / no ASA indication
1400	226	Placebo	ASA indication	LNS329R	19.5.20 13:36	2021-12-31	Edoxaban 60mg / ASA indication
1400	226	Placebo	ASA indication	DPW146W	10.11.20 15:25	2021-12-31	Edoxaban 60mg / ASA indication
1434	226	Placebo	ASA indication	XYD689F	10.6.20 13:17	2021-12-31	Edoxaban 60mg / ASA indication
1434	226	Placebo	ASA indication	DMU926U	11.12.20 14:00	2021-12-31	Edoxaban 60mg / ASA indication
1434	226	Placebo	ASA indication	GKK279Y	29.11.21 16:21	2024-04-30	Edoxaban 60mg / ASA indication
1434	226	Placebo	ASA indication	VWE425W	5.12.19 10:36	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1434	226	Placebo	ASA indication	WXT356R	16.6.21 12:58	2021-12-31	Edoxaban 60mg / ASA indication
1630	226	Placebo	ASA indication	GLE275A	29.11.21 15:33	2024-04-30	Edoxaban 60mg / ASA indication
1630	226	Placebo	ASA indication	KEY754A	11.12.20 15:41	2021-12-31	Edoxaban 60mg / ASA indication
1630	226	Placebo	ASA indication	GES274R	12.6.20 13:53	2021-12-31	Edoxaban 60mg / ASA indication
1630	226	Placebo	ASA indication	TWY222T	16.6.21 14:39	2021-12-31	Edoxaban 60mg / ASA indication
1638	226	Placebo	no ASA indication	UHH238S	17.6.20 13:09	2022-08-31	Edoxaban 30mg / no ASA indication
1638	226	Placebo	no ASA indication	BBS971F	10.6.21 13:13	2022-08-31	Edoxaban 30mg / no ASA indication
1638	226	Placebo	no ASA indication	STS479R	15.6.22 14:49	2024-11-30	Edoxaban 30mg / no ASA indication
1638	226	Placebo	no ASA indication	ULV427T	20.1.22 15:06	2022-08-31	Edoxaban 30mg / no ASA indication
1638	226	Placebo	no ASA indication	XUW641W	21.12.20 13:00	2022-08-31	Edoxaban 30mg / no ASA indication
1710	226	Placebo	no ASA indication	NWZ535P	5.2.21 14:27	2021-12-31	Edoxaban 60mg / no ASA indication
1710	226	Placebo	no ASA indication	XLE625H	27.7.20 13:48	2021-12-31	Edoxaban 60mg / no ASA indication
2259	226	Placebo	no ASA indication	HGX339F	17.3.22 16:09	2024-11-30	Edoxaban 30mg / no ASA indication
2259	226	Placebo	no ASA indication	FSM773C	8.9.21 13:01	2024-04-30	Edoxaban 60mg / no ASA indication
239	226	Edoxaban	ASA indication	MYR413L	25.7.18 16:00	2020-01-01	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	ZRB811W	22.1.19 16:19	2020-01-01	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	SUL648Y	28.7.17 14:56	2018-09-01	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	HGE967Z	28.7.22 13:42	2024-11-30	Edoxaban 30mg / ASA indication
239	226	Edoxaban	ASA indication	GUH791L	17.7.20 12:08	2021-12-31	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	ASD623G	29.7.19 7:01	2021-12-31	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	DKA454V	23.1.18 14:16	2018-09-01	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	HCE281Y	29.1.21 13:24	2021-12-31	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	FXC592C	29.7.21 10:52	2024-04-30	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	BZL222A	4.2.20 13:47	2021-12-31	Edoxaban 60mg / ASA indication
239	226	Edoxaban	ASA indication	WKG415G	3.2.22 15:33	2024-04-30	Edoxaban 60mg / ASA indication
413	226	Edoxaban	ASA indication	AYL564K	26.7.18 15:40	2020-01-01	Edoxaban 60mg / ASA indication
413	226	Edoxaban	ASA indication	WML825L	26.1.19 9:04	2020-01-01	Edoxaban 60mg / ASA indication
413	226	Edoxaban	ASA indication	PUW386K	23.1.18 15:39	2018-09-01	Edoxaban 60mg / ASA indication
1404	226	Edoxaban	ASA indication	LTM161M	19.5.20 15:10	2022-08-31	Edoxaban 30mg / ASA indication
1404	226	Edoxaban	ASA indication	FLB799L	10.11.20 14:08	2022-08-31	Edoxaban 30mg / ASA indication
1404	226	Edoxaban	ASA indication	GCM312V	20.11.19 15:10	2022-08-31	Edoxaban 30mg / ASA indication
1404	226	Edoxaban	ASA indication	FTB944F	20.5.21 13:12	2022-08-31	Edoxaban 30mg / ASA indication
1404	226	Edoxaban	ASA indication	PUV116V	17.11.21 15:05	2022-08-31	Edoxaban 30mg / ASA indication
1404	226	Edoxaban	ASA indication	HHB252X	15.6.22 15:34	2024-11-30	Edoxaban 30mg / ASA indication
1511	226	Edoxaban	ASA indication	FYC287H	28.7.21 13:24	2024-04-30	Edoxaban 60mg / ASA indication
1511	226	Edoxaban	ASA indication	MTU157Z	5.2.21 13:39	2021-12-31	Edoxaban 60mg / ASA indication
1511	226	Edoxaban	ASA indication	VST915C	4.8.22 12:03	2024-11-30	Edoxaban 30mg / ASA indication
1511	226	Edoxaban	ASA indication	CSU983H	30.7.20 13:44	2021-12-31	Edoxaban 60mg / ASA indication
1511	226	Edoxaban	ASA indication	GNL787N	10.2.20 14:44	2021-12-31	Edoxaban 60mg / ASA indication
1511	226	Edoxaban	ASA indication	ZPA655Z	3.2.22 16:36	2022-08-31	Edoxaban 30mg / ASA indication
1670	226	Edoxaban	ASA indication	VBW537U	30.6.20 13:28	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2120	226	Edoxaban	ASA indication	MHS352P	25.5.21 11:37	2021-12-31	Edoxaban 60mg / ASA indication
2639	226	Edoxaban	ASA indication	WKB774V	1.6.22 15:31	2024-04-30	Edoxaban 60mg / ASA indication
1164	226	Edoxaban	no ASA indication	PGS642Y	6.6.19 9:29	2020-01-01	Edoxaban 30mg / no ASA indication
1164	226	Edoxaban	no ASA indication	RZP759C	6.12.19 16:17	2022-08-31	Edoxaban 30mg / no ASA indication
2089	226	Edoxaban	no ASA indication	HMZ978S	7.5.21 15:08	2022-08-31	Edoxaban 30mg / no ASA indication
2089	226	Edoxaban	no ASA indication	XUT744Z	29.10.21 13:26	2022-08-31	Edoxaban 30mg / no ASA indication
2089	226	Edoxaban	no ASA indication	HMS178C	19.5.22 14:54	2024-11-30	Edoxaban 30mg / no ASA indication
2243	226	Edoxaban	no ASA indication	FWP193U	25.8.21 8:35	2024-04-30	Edoxaban 60mg / no ASA indication
2243	226	Edoxaban	no ASA indication	FTS739S	3.3.22 15:23	2024-04-30	Edoxaban 60mg / no ASA indication
2243	226	Edoxaban	no ASA indication	FSU675Y	1.9.22 13:36	2024-04-30	Edoxaban 60mg / no ASA indication
1019	232	Edoxaban	ASA indication	BPG622P	11.3.19 15:15	2020-01-01	Edoxaban 60mg / ASA indication
1019	232	Edoxaban	ASA indication	CEW276T	25.3.21 15:26	2021-12-31	Edoxaban 60mg / ASA indication
1019	232	Edoxaban	ASA indication	HZZ233S	28.9.20 13:29	2021-12-31	Edoxaban 60mg / ASA indication
1019	232	Edoxaban	ASA indication	BZG387X	31.3.20 12:46	2021-12-31	Edoxaban 60mg / ASA indication
1019	232	Edoxaban	ASA indication	SBC199S	17.9.19 13:46	2021-12-31	Edoxaban 60mg / ASA indication
1152	232	Edoxaban	ASA indication	BVS361P	16.12.20 15:16	2021-12-31	Edoxaban 60mg / ASA indication
1152	232	Edoxaban	ASA indication	DBR637Z	3.6.22 11:51	2024-11-30	Edoxaban 30mg / ASA indication
1152	232	Edoxaban	ASA indication	FYW923P	29.11.21 13:52	2024-04-30	Edoxaban 60mg / ASA indication
1152	232	Edoxaban	ASA indication	KFH939H	5.12.19 15:07	2021-12-31	Edoxaban 60mg / ASA indication
1152	232	Edoxaban	ASA indication	HVK242S	3.6.20 13:58	2021-12-31	Edoxaban 60mg / ASA indication
1152	232	Edoxaban	ASA indication	ANZ258B	29.5.19 14:15	2020-01-01	Edoxaban 60mg / ASA indication
1152	232	Edoxaban	ASA indication	XAA778S	27.5.21 13:09	2021-12-31	Edoxaban 60mg / ASA indication
228	232	Edoxaban	no ASA indication	KLR554R	5.2.18 11:28	2018-09-01	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	LAX511W	25.7.19 13:58	2022-08-31	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	WSM476A	29.1.20 15:06	2021-12-31	Edoxaban 60mg / no ASA indication
228	232	Edoxaban	no ASA indication	YMZ647L	5.9.18 13:45	2020-01-01	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	TVT539A	11.2.21 14:31	2022-08-31	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	VVW727Y	15.7.21 12:15	2022-08-31	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	GGV537P	19.7.17 9:09	2018-09-01	Edoxaban 60mg / no ASA indication
228	232	Edoxaban	no ASA indication	VSP389F	25.1.22 7:55	2022-08-31	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	BND429V	31.7.20 12:55	2022-08-31	Edoxaban 30mg / no ASA indication
228	232	Edoxaban	no ASA indication	FTA722M	20.2.19 14:57	2020-01-01	Edoxaban 60mg / no ASA indication
228	232	Edoxaban	no ASA indication	CRV973N	20.7.22 13:53	2024-11-30	Edoxaban 30mg / no ASA indication
749	232	Edoxaban	no ASA indication	NCX759V	22.10.19 14:08	2021-12-31	Edoxaban 60mg / no ASA indication
749	232	Edoxaban	no ASA indication	UHN184F	11.10.18 14:38	2020-01-01	Edoxaban 60mg / no ASA indication
749	232	Edoxaban	no ASA indication	ADH235U	11.4.19 13:59	2020-01-01	Edoxaban 60mg / no ASA indication
747	264	Placebo	ASA indication	LSZ845S	1.10.20 8:13	2021-12-31	Edoxaban 60mg / ASA indication
747	264	Placebo	ASA indication	SKV468L	10.10.19 7:11	2021-12-31	Edoxaban 60mg / ASA indication
747	264	Placebo	ASA indication	HBK553F	8.4.21 10:00	2021-12-31	Edoxaban 60mg / no ASA indication
747	264	Placebo	ASA indication	YSS629T	8.4.21 9:50	2022-08-31	Edoxaban 30mg / ASA indication
747	264	Placebo	ASA indication	UTU588E	4.4.19 8:10	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
747	264	Placebo	ASA indication	ZCD397X	11.10.18 6:48	2020-01-01	Edoxaban 60mg / ASA indication
747	264	Placebo	ASA indication	SXC176G	30.3.20 9:25	2021-12-31	Edoxaban 60mg / ASA indication
905	264	Placebo	ASA indication	WEU558F	27.6.19 7:31	2021-12-31	Edoxaban 60mg / ASA indication
905	264	Placebo	ASA indication	KWT974Z	1.7.21 7:45	2024-04-30	Edoxaban 60mg / ASA indication
905	264	Placebo	ASA indication	HWW112G	17.12.20 9:01	2021-12-31	Edoxaban 60mg / ASA indication
905	264	Placebo	ASA indication	XBV589F	20.12.18 10:34	2020-01-01	Edoxaban 60mg / ASA indication
905	264	Placebo	ASA indication	GUP768P	25.6.20 9:10	2021-12-31	Edoxaban 60mg / ASA indication
905	264	Placebo	ASA indication	XKY627P	12.12.19 10:49	2021-12-31	Edoxaban 60mg / ASA indication
1844	264	Placebo	ASA indication	HYC966F	2.11.20 12:10	2021-12-31	Edoxaban 60mg / ASA indication
1844	264	Placebo	ASA indication	XSC448Y	18.11.21 10:48	2024-04-30	Edoxaban 60mg / ASA indication
1844	264	Placebo	ASA indication	KWY212G	23.5.22 12:47	2024-04-30	Edoxaban 60mg / ASA indication
1844	264	Placebo	ASA indication	DCD585E	10.5.21 12:03	2021-12-31	Edoxaban 60mg / ASA indication
2454	264	Placebo	ASA indication	PPZ146K	19.7.22 12:01	2024-04-30	Edoxaban 60mg / ASA indication
2454	264	Placebo	ASA indication	UPM837E	28.1.22 10:05	2024-04-30	Edoxaban 60mg / ASA indication
408	264	Placebo	no ASA indication	SXR539Z	17.7.18 8:38	2020-01-01	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	BHN953P	9.7.20 8:40	2021-12-31	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	KAZ674R	16.1.20 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	VCR414F	8.8.22 11:33	2024-04-30	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	KKX189K	8.7.21 9:25	2024-04-30	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	XSD787G	18.1.22 13:06	2024-04-30	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	UBV275E	11.7.19 9:10	2021-12-31	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	GSF188Z	18.1.18 9:44	2018-09-01	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	YFS339F	22.1.19 13:55	2020-01-01	Edoxaban 60mg / no ASA indication
408	264	Placebo	no ASA indication	SHU747D	12.1.21 10:23	2021-12-31	Edoxaban 60mg / no ASA indication
1544	264	Placebo	no ASA indication	VED663G	14.9.21 11:43	2024-04-30	Edoxaban 60mg / no ASA indication
1544	264	Placebo	no ASA indication	AXX971R	5.3.20 10:22	2021-12-31	Edoxaban 60mg / no ASA indication
1544	264	Placebo	no ASA indication	HFA179S	31.8.20 7:37	2021-12-31	Edoxaban 60mg / no ASA indication
1544	264	Placebo	no ASA indication	EFD176M	4.3.21 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
2681	264	Placebo	no ASA indication	XSF824H	30.6.22 12:54	2024-04-30	Edoxaban 60mg / no ASA indication
583	264	Edoxaban	ASA indication	FUA853T	20.12.18 8:52	2020-01-01	Edoxaban 60mg / ASA indication
583	264	Edoxaban	ASA indication	EPS294P	7.6.18 7:22	2020-01-01	Edoxaban 60mg / ASA indication
1330	264	Edoxaban	ASA indication	KCP125Y	19.10.21 12:50	2024-04-30	Edoxaban 60mg / ASA indication
1330	264	Edoxaban	ASA indication	MWZ445V	19.10.20 9:16	2021-12-31	Edoxaban 60mg / ASA indication
1330	264	Edoxaban	ASA indication	KFA625C	5.4.22 12:22	2024-04-30	Edoxaban 60mg / ASA indication
1330	264	Edoxaban	ASA indication	KRE621L	6.4.20 12:53	2021-12-31	Edoxaban 60mg / ASA indication
1330	264	Edoxaban	ASA indication	LPW981W	14.10.19 14:04	2021-12-31	Edoxaban 60mg / ASA indication
1330	264	Edoxaban	ASA indication	YVW876C	13.4.21 11:58	2021-12-31	Edoxaban 60mg / ASA indication
381	264	Edoxaban	no ASA indication	FFE463X	17.6.19 7:25	2020-01-01	Edoxaban 60mg / no ASA indication
381	264	Edoxaban	no ASA indication	CXF139U	25.11.19 13:48	2021-12-31	Edoxaban 60mg / no ASA indication
381	264	Edoxaban	no ASA indication	RSM784D	11.6.18 7:58	2020-01-01	Edoxaban 60mg / no ASA indication
381	264	Edoxaban	no ASA indication	TYE532N	3.12.18 9:15	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
381	264	Edoxaban	no ASA indication	AUH723B	22.12.17 12:57	2018-09-01	Edoxaban 60mg / no ASA indication
1753	264	Edoxaban	no ASA indication	FTR866H	1.3.21 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
1753	264	Edoxaban	no ASA indication	CWE861K	3.9.20 7:45	2021-12-31	Edoxaban 60mg / no ASA indication
1753	264	Edoxaban	no ASA indication	KGA657S	5.9.22 8:14	2024-04-30	Edoxaban 60mg / no ASA indication
1753	264	Edoxaban	no ASA indication	UVB497G	2.9.21 8:36	2024-04-30	Edoxaban 60mg / no ASA indication
1753	264	Edoxaban	no ASA indication	XDX727V	23.3.22 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
829	267	Placebo	ASA indication	GUS174F	5.8.22 6:58	2024-04-30	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	WSF345W	12.1.21 8:24	2021-12-31	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	GSP589C	21.7.21 6:13	2024-04-30	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	NTU224Y	18.12.19 7:22	2021-12-31	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	GSB615Z	26.1.22 8:02	2024-04-30	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	RTH291N	20.11.18 11:05	2020-01-01	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	DTC719Z	5.6.19 7:18	2020-01-01	Edoxaban 60mg / ASA indication
829	267	Placebo	ASA indication	PFS736U	30.6.20 6:40	2021-12-31	Edoxaban 60mg / ASA indication
1219	267	Placebo	ASA indication	CFR655Y	8.7.19 12:28	2021-12-31	Edoxaban 60mg / ASA indication
1219	267	Placebo	ASA indication	NNR811Y	20.1.20 11:30	2021-12-31	Edoxaban 60mg / ASA indication
1219	267	Placebo	ASA indication	VZH844R	15.12.20 5:33	2021-12-31	Edoxaban 60mg / ASA indication
832	267	Edoxaban	ASA indication	AEZ475X	4.12.19 9:35	2022-08-31	Edoxaban 30mg / ASA indication
832	267	Edoxaban	ASA indication	GTC396Z	21.11.18 6:57	2020-01-01	Edoxaban 30mg / ASA indication
832	267	Edoxaban	ASA indication	TMW213W	22.5.19 7:29	2020-01-01	Edoxaban 30mg / ASA indication
832	267	Edoxaban	ASA indication	UGL855A	16.6.20 6:23	2022-08-31	Edoxaban 30mg / ASA indication
920	267	Edoxaban	ASA indication	TRP927C	11.7.19 5:58	2021-12-31	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	GAK148F	24.1.22 9:35	2024-04-30	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	SKK953A	3.1.19 11:11	2020-01-01	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	UNL843W	20.1.21 8:51	2021-12-31	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	WNR728Z	14.7.20 8:07	2021-12-31	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	XZA482H	20.1.20 10:40	2021-12-31	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	FZV866N	21.7.22 8:54	2024-04-30	Edoxaban 60mg / ASA indication
920	267	Edoxaban	ASA indication	FZX248M	20.7.21 8:14	2024-04-30	Edoxaban 60mg / ASA indication
937	267	Edoxaban	ASA indication	BCZ562W	16.1.19 12:02	2020-01-01	Edoxaban 30mg / ASA indication
937	267	Edoxaban	ASA indication	WMX692G	10.9.19 8:23	2022-08-31	Edoxaban 30mg / ASA indication
215	308	Placebo	ASA indication	MVX781N	10.7.17 6:39	2018-09-01	Edoxaban 60mg / ASA indication
21	308	Placebo	no ASA indication	EHA774X	9.9.16 7:58	2018-09-01	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	KRW834A	9.3.20 17:07	2022-08-31	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	PSR787R	4.9.18 9:54	2020-01-01	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	HGT527U	27.9.21 8:17	2022-08-31	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	CEW433U	21.3.22 7:38	2024-11-30	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	CZS865S	7.9.20 10:33	2022-08-31	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	LFL817Y	6.3.18 8:44	2020-01-01	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	GUD616M	15.3.19 12:56	2020-01-01	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	CPL525Y	6.3.17 12:32	2018-09-01	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
21	308	Placebo	no ASA indication	NXH924F	5.9.17 15:36	2018-09-01	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	NLT137B	16.3.21 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
21	308	Placebo	no ASA indication	HMC187Z	18.9.19 10:02	2022-08-31	Edoxaban 30mg / no ASA indication
267	308	Placebo	no ASA indication	ZEN463F	6.3.18 8:53	2020-01-01	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	NTH415Y	15.3.19 13:00	2020-01-01	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	WWS848U	9.3.20 17:00	2021-12-31	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	NBP616B	4.9.18 7:33	2020-01-01	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	CYX752K	15.3.21 13:37	2021-12-31	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	DPH656D	27.9.21 7:49	2024-04-30	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	DPE758X	7.3.22 7:54	2024-04-30	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	AWT469V	7.9.20 9:29	2021-12-31	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	HWH893C	5.9.17 6:37	2018-09-01	Edoxaban 60mg / no ASA indication
267	308	Placebo	no ASA indication	SWT496H	16.9.19 8:20	2021-12-31	Edoxaban 60mg / no ASA indication
217	308	Edoxaban	no ASA indication	WLU499H	10.7.17 8:43	2018-09-01	Edoxaban 60mg / no ASA indication
217	308	Edoxaban	no ASA indication	UMY748W	15.1.18 11:54	2018-09-01	Edoxaban 60mg / no ASA indication
501	326	Edoxaban	ASA indication	SRU392Z	24.9.18 9:46	2020-01-01	Edoxaban 30mg / ASA indication
501	326	Edoxaban	ASA indication	UBC766G	25.3.19 15:22	2020-01-01	Edoxaban 60mg / ASA indication
501	326	Edoxaban	ASA indication	LRE152G	28.3.18 9:40	2020-01-01	Edoxaban 60mg / ASA indication
72	377	Placebo	ASA indication	UTU531F	12.7.18 9:07	2020-01-01	Edoxaban 30mg / ASA indication
72	377	Placebo	ASA indication	VTM155Z	24.1.19 11:57	2020-01-01	Edoxaban 30mg / ASA indication
72	377	Placebo	ASA indication	AYF279U	10.7.17 9:52	2018-09-01	Edoxaban 30mg / ASA indication
72	377	Placebo	ASA indication	WZT848B	8.1.18 10:37	2018-09-01	Edoxaban 30mg / ASA indication
72	377	Placebo	ASA indication	YAU549G	16.1.17 9:44	2018-09-01	Edoxaban 30mg / ASA indication
175	377	Placebo	ASA indication	XEY719D	31.5.17 10:26	2018-09-01	Edoxaban 60mg / ASA indication
175	377	Placebo	ASA indication	NEA986A	24.5.18 9:58	2020-01-01	Edoxaban 60mg / no ASA indication
175	377	Placebo	ASA indication	HEU393Z	7.12.18 11:29	2020-01-01	Edoxaban 60mg / ASA indication
175	377	Placebo	ASA indication	LBY734L	25.5.18 11:22	2020-01-01	Edoxaban 60mg / ASA indication
175	377	Placebo	ASA indication	TNG759W	29.11.17 9:49	2018-09-01	Edoxaban 60mg / ASA indication
83	377	Placebo	no ASA indication	BGY792V	30.1.17 11:09	2018-09-01	Edoxaban 60mg / no ASA indication
163	406	Placebo	ASA indication	GXK379G	15.11.17 9:26	2018-09-01	Edoxaban 60mg / ASA indication
163	406	Placebo	ASA indication	VPS236A	17.5.18 7:49	2020-01-01	Edoxaban 60mg / ASA indication
163	406	Placebo	ASA indication	RAE536F	17.5.17 10:04	2018-09-01	Edoxaban 60mg / ASA indication
1003	406	Placebo	ASA indication	VYZ296B	25.2.19 12:15	2020-01-01	Edoxaban 30mg / ASA indication
220	414	Placebo	ASA indication	WEU956K	11.1.18 10:00	2018-09-01	Edoxaban 30mg / ASA indication
220	414	Placebo	ASA indication	XKF295Z	11.7.17 8:37	2018-09-01	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	BPT588P	14.3.18 14:10	2020-01-01	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	RUW718K	17.9.19 13:09	2021-12-31	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	YZA211X	6.3.20 9:04	2021-12-31	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	ZGV446U	15.3.19 9:39	2020-01-01	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	TPF366E	25.9.20 9:38	2021-12-31	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	NUV187P	17.9.21 8:06	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
433	414	Placebo	ASA indication	CMF548G	12.9.18 7:40	2020-01-01	Edoxaban 60mg / ASA indication
433	414	Placebo	ASA indication	FLX923F	31.3.21 12:00	2021-12-31	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	NGM624V	27.6.19 8:12	2021-12-31	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	DCP483P	9.1.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	GTF147T	3.12.20 12:00	2021-12-31	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	SBS828P	17.6.21 11:43	2021-12-31	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	AMF682R	8.12.21 13:41	2024-11-30	Edoxaban 30mg / ASA indication
584	414	Placebo	ASA indication	YUT234N	7.6.18 15:08	2020-01-01	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	UVK874R	13.12.18 9:49	2020-01-01	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	FCK621L	11.6.20 8:35	2021-12-31	Edoxaban 60mg / ASA indication
584	414	Placebo	ASA indication	SPS981Y	31.5.22 12:50	2024-11-30	Edoxaban 30mg / ASA indication
704	414	Placebo	ASA indication	FCU788L	12.9.18 9:39	2020-01-01	Edoxaban 30mg / ASA indication
704	414	Placebo	ASA indication	DGD343L	21.3.19 9:20	2020-01-01	Edoxaban 30mg / ASA indication
704	414	Placebo	ASA indication	WND289N	3.10.19 11:49	2022-08-31	Edoxaban 30mg / ASA indication
1541	414	Placebo	ASA indication	UES699B	3.3.20 12:55	2021-12-31	Edoxaban 60mg / ASA indication
1654	414	Placebo	ASA indication	VNX977X	23.6.20 8:17	2021-12-31	Edoxaban 60mg / ASA indication
1654	414	Placebo	ASA indication	GSR455H	1.12.20 11:13	2021-12-31	Edoxaban 60mg / ASA indication
1792	414	Placebo	ASA indication	CHP134P	18.3.21 14:06	2022-08-31	Edoxaban 30mg / no ASA indication
1792	414	Placebo	ASA indication	TRY215K	5.9.22 13:25	2024-11-30	Edoxaban 30mg / ASA indication
1792	414	Placebo	ASA indication	AME856X	10.3.22 11:42	2024-11-30	Edoxaban 30mg / ASA indication
1792	414	Placebo	ASA indication	WDP454T	20.9.21 10:34	2022-08-31	Edoxaban 30mg / ASA indication
1792	414	Placebo	ASA indication	FCR932H	18.9.20 10:32	2022-08-31	Edoxaban 30mg / ASA indication
1845	414	Placebo	ASA indication	FNG695E	27.11.20 14:33	2022-08-31	Edoxaban 30mg / ASA indication
1845	414	Placebo	ASA indication	WEE971Y	30.11.21 14:17	2022-08-31	Edoxaban 30mg / ASA indication
1845	414	Placebo	ASA indication	RNT922M	24.5.22 14:03	2024-11-30	Edoxaban 30mg / ASA indication
1845	414	Placebo	ASA indication	SRZ957B	31.5.21 8:08	2022-08-31	Edoxaban 30mg / ASA indication
1892	414	Placebo	ASA indication	YWU481B	10.3.22 15:30	2024-04-30	Edoxaban 60mg / ASA indication
1892	414	Placebo	ASA indication	NSS443N	23.9.21 9:39	2024-04-30	Edoxaban 60mg / ASA indication
2323	414	Placebo	ASA indication	XRF979A	8.11.21 13:06	2024-04-30	Edoxaban 60mg / ASA indication
2323	414	Placebo	ASA indication	VDN815X	12.5.22 12:38	2024-04-30	Edoxaban 60mg / ASA indication
2571	414	Placebo	ASA indication	NSA743E	11.4.22 9:47	2024-04-30	Edoxaban 60mg / ASA indication
988	414	Placebo	no ASA indication	TNK619M	5.2.20 10:28	2022-08-31	Edoxaban 30mg / no ASA indication
988	414	Placebo	no ASA indication	KLF758E	13.2.19 8:44	2020-01-01	Edoxaban 30mg / no ASA indication
988	414	Placebo	no ASA indication	KXU684T	1.8.19 7:55	2022-08-31	Edoxaban 30mg / no ASA indication
988	414	Placebo	no ASA indication	UDL482R	10.3.21 10:03	2022-08-31	Edoxaban 30mg / no ASA indication
988	414	Placebo	no ASA indication	AHU178L	18.8.20 9:34	2022-08-31	Edoxaban 30mg / no ASA indication
1626	414	Placebo	no ASA indication	CKX559V	11.6.20 13:51	2022-08-31	Edoxaban 30mg / no ASA indication
1626	414	Placebo	no ASA indication	SYU968N	4.6.21 13:23	2022-08-31	Edoxaban 30mg / no ASA indication
1626	414	Placebo	no ASA indication	EYR841B	14.12.20 8:48	2022-08-31	Edoxaban 30mg / no ASA indication
1686	414	Placebo	no ASA indication	NKN591P	15.7.21 11:15	2024-04-30	Edoxaban 60mg / no ASA indication
1686	414	Placebo	no ASA indication	VKF535N	6.1.22 13:54	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1686	414	Placebo	no ASA indication	LFE186X	7.1.21 10:51	2021-12-31	Edoxaban 60mg / no ASA indication
1686	414	Placebo	no ASA indication	MXN521B	16.7.20 12:37	2021-12-31	Edoxaban 60mg / no ASA indication
1686	414	Placebo	no ASA indication	NFN958F	21.7.22 12:37	2024-04-30	Edoxaban 60mg / no ASA indication
1941	414	Placebo	no ASA indication	CFZ679B	4.2.21 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
2035	414	Placebo	no ASA indication	LZT641S	6.4.21 13:28	2022-08-31	Edoxaban 30mg / no ASA indication
2424	414	Placebo	no ASA indication	LXS478E	12.1.22 9:28	2022-08-31	Edoxaban 30mg / no ASA indication
268	414	Edoxaban	ASA indication	EZG996E	6.3.18 15:26	2020-01-01	Edoxaban 60mg / ASA indication
268	414	Edoxaban	ASA indication	LAM952B	14.9.17 12:51	2018-09-01	Edoxaban 60mg / ASA indication
346	414	Edoxaban	ASA indication	KFP778E	22.11.17 11:02	2018-09-01	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	ESF449R	12.9.19 9:07	2022-08-31	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	NMT692C	14.8.18 9:30	2020-01-01	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	FRF355G	28.2.19 12:59	2020-01-01	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	GAM763K	2.2.21 10:05	2022-08-31	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	AME253D	9.2.22 13:14	2024-11-30	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	NMY885C	9.8.22 8:58	2024-11-30	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	CDS235V	18.8.20 8:54	2022-08-31	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	FEH869S	3.3.20 11:39	2022-08-31	Edoxaban 30mg / ASA indication
670	414	Edoxaban	ASA indication	RDC243K	2.8.21 9:40	2022-08-31	Edoxaban 30mg / ASA indication
970	414	Edoxaban	ASA indication	TFN574Y	1.8.19 7:24	2022-08-31	Edoxaban 30mg / no ASA indication
970	414	Edoxaban	ASA indication	FWH994V	9.1.20 9:46	2022-08-31	Edoxaban 30mg / ASA indication
970	414	Edoxaban	ASA indication	WLW432U	23.7.20 8:05	2022-08-31	Edoxaban 30mg / ASA indication
970	414	Edoxaban	ASA indication	BUR755T	1.2.19 14:27	2020-01-01	Edoxaban 30mg / ASA indication
970	414	Edoxaban	ASA indication	BKY626X	15.7.21 13:19	2022-08-31	Edoxaban 30mg / ASA indication
970	414	Edoxaban	ASA indication	DMT237W	17.2.21 12:26	2022-08-31	Edoxaban 30mg / ASA indication
1610	414	Edoxaban	ASA indication	WZU165S	10.1.22 15:58	2022-08-31	Edoxaban 30mg / ASA indication
1610	414	Edoxaban	ASA indication	WRU456U	4.6.20 9:49	2022-08-31	Edoxaban 30mg / ASA indication
1610	414	Edoxaban	ASA indication	SBG547A	22.7.22 7:58	2024-11-30	Edoxaban 30mg / ASA indication
1610	414	Edoxaban	ASA indication	BSC149P	17.6.21 13:59	2022-08-31	Edoxaban 30mg / ASA indication
1610	414	Edoxaban	ASA indication	PGU537G	10.12.20 14:46	2022-08-31	Edoxaban 30mg / ASA indication
1777	414	Edoxaban	ASA indication	GES721M	28.9.20 7:12	2022-08-31	Edoxaban 30mg / ASA indication
1777	414	Edoxaban	ASA indication	VVD121A	11.10.21 8:07	2024-04-30	Edoxaban 60mg / ASA indication
1777	414	Edoxaban	ASA indication	ZCM598Y	7.3.22 8:38	2024-04-30	Edoxaban 60mg / ASA indication
1777	414	Edoxaban	ASA indication	HKB242S	4.11.20 8:17	2021-12-31	Edoxaban 60mg / ASA indication
1777	414	Edoxaban	ASA indication	HKF414K	19.4.21 7:43	2021-12-31	Edoxaban 60mg / ASA indication
1783	414	Edoxaban	ASA indication	XSA718R	17.9.20 9:47	2021-12-31	Edoxaban 60mg / ASA indication
1783	414	Edoxaban	ASA indication	YVH615C	6.4.21 14:22	2021-12-31	Edoxaban 60mg / ASA indication
1943	414	Edoxaban	ASA indication	EAU438X	22.2.21 14:50	2022-08-31	Edoxaban 30mg / ASA indication
1971	414	Edoxaban	ASA indication	ALV114F	20.4.22 12:22	2024-11-30	Edoxaban 30mg / ASA indication
1971	414	Edoxaban	ASA indication	RTN523C	12.10.21 12:42	2022-08-31	Edoxaban 30mg / ASA indication
2174	414	Edoxaban	ASA indication	NTK683C	1.7.21 9:33	2024-04-30	Edoxaban 60mg / ASA indication
2469	414	Edoxaban	ASA indication	NRV497X	18.3.22 14:06	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
246	414	Edoxaban	no ASA indication	VHE171U	20.2.18 9:35	2020-01-01	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	PVS135G	26.2.19 10:35	2020-01-01	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	WXG794S	25.2.20 10:54	2022-08-31	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	XED696A	11.8.20 9:57	2022-08-31	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	NFE616P	9.2.21 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	SWL895T	8.8.17 11:22	2018-09-01	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	DZP841W	11.9.18 9:41	2020-01-01	Edoxaban 30mg / no ASA indication
246	414	Edoxaban	no ASA indication	LRC886K	3.9.19 9:42	2022-08-31	Edoxaban 30mg / no ASA indication
1510	414	Edoxaban	no ASA indication	LXG446E	11.2.21 11:46	2021-12-31	Edoxaban 60mg / no ASA indication
1510	414	Edoxaban	no ASA indication	UFN835L	20.8.20 9:50	2021-12-31	Edoxaban 60mg / no ASA indication
1510	414	Edoxaban	no ASA indication	WHM278L	11.2.20 13:47	2021-12-31	Edoxaban 60mg / no ASA indication
1704	414	Edoxaban	no ASA indication	SNK188T	7.1.21 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
1704	414	Edoxaban	no ASA indication	NGA561V	15.7.21 12:15	2024-04-30	Edoxaban 60mg / no ASA indication
1704	414	Edoxaban	no ASA indication	XDA498P	20.1.22 13:24	2024-04-30	Edoxaban 60mg / no ASA indication
1704	414	Edoxaban	no ASA indication	URG361C	23.7.20 14:29	2021-12-31	Edoxaban 60mg / no ASA indication
1704	414	Edoxaban	no ASA indication	TVX229P	21.7.22 8:50	2024-04-30	Edoxaban 60mg / no ASA indication
1767	414	Edoxaban	no ASA indication	FDF262R	10.9.20 8:40	2021-12-31	Edoxaban 60mg / no ASA indication
1767	414	Edoxaban	no ASA indication	NHR129T	8.3.22 9:11	2024-04-30	Edoxaban 60mg / no ASA indication
1767	414	Edoxaban	no ASA indication	SPP166D	9.3.21 10:08	2021-12-31	Edoxaban 60mg / no ASA indication
1767	414	Edoxaban	no ASA indication	VWX281D	14.9.21 9:53	2024-04-30	Edoxaban 60mg / no ASA indication
2183	414	Edoxaban	no ASA indication	TVR324X	22.7.22 8:26	2024-04-30	Edoxaban 60mg / no ASA indication
2183	414	Edoxaban	no ASA indication	NLW616V	20.7.21 10:24	2024-04-30	Edoxaban 60mg / no ASA indication
2507	414	Edoxaban	no ASA indication	VEE773L	7.3.22 10:34	2024-04-30	Edoxaban 60mg / no ASA indication
2570	414	Edoxaban	no ASA indication	BEA989K	21.7.22 11:50	2024-11-30	Edoxaban 30mg / no ASA indication
86	416	Placebo	no ASA indication	KWM188B	2.2.17 12:08	2018-09-01	Edoxaban 30mg / no ASA indication
125	416	Placebo	no ASA indication	FVL764B	2.4.18 6:59	2020-01-01	Edoxaban 30mg / no ASA indication
125	416	Placebo	no ASA indication	BZS281G	29.3.17 10:27	2018-09-01	Edoxaban 30mg / no ASA indication
125	416	Placebo	no ASA indication	LDC754Z	5.10.17 9:35	2018-09-01	Edoxaban 30mg / no ASA indication
445	416	Placebo	no ASA indication	CCC491R	15.2.18 11:10	2018-09-01	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	VCN282G	18.4.19 8:24	2020-01-01	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	DUM873T	11.5.20 11:07	2022-08-31	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	PNE595V	9.5.18 10:28	2020-01-01	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	GHG591Z	20.5.21 7:59	2022-08-31	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	YPM636C	19.11.20 8:46	2022-08-31	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	ZNM651D	31.10.19 7:24	2022-08-31	Edoxaban 30mg / no ASA indication
547	416	Placebo	no ASA indication	PNY769N	24.10.18 7:01	2020-01-01	Edoxaban 30mg / no ASA indication
84	416	Edoxaban	no ASA indication	EFS385U	30.1.17 11:56	2018-09-01	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	MCD847Z	22.2.21 7:32	2022-08-31	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	KPY649M	19.2.18 12:04	2020-01-01	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	GTW544P	9.8.18 7:35	2020-01-01	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	SFE817F	17.2.20 9:27	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
449	416	Edoxaban	no ASA indication	EXX582A	16.8.21 7:34	2022-08-31	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	CHF754A	20.8.19 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	PNV121Z	9.8.22 8:07	2024-11-30	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	YHW462U	15.2.19 8:04	2020-01-01	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	KBM587S	21.2.22 9:50	2024-11-30	Edoxaban 30mg / no ASA indication
449	416	Edoxaban	no ASA indication	HAR494F	10.8.20 8:26	2022-08-31	Edoxaban 30mg / no ASA indication
469	416	Edoxaban	no ASA indication	RCD572L	1.3.18 11:28	2020-01-01	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	FYL842C	21.3.20 8:16	2022-08-31	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	LPE574W	12.3.21 7:26	2022-08-31	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	YNC563T	25.2.19 10:48	2020-01-01	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	KDU929K	14.3.22 8:49	2024-11-30	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	TPW928D	28.9.20 7:07	2022-08-31	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	KDG165Z	16.9.19 8:21	2022-08-31	Edoxaban 30mg / no ASA indication
1001	416	Edoxaban	no ASA indication	ELR658Z	27.9.21 7:03	2022-08-31	Edoxaban 30mg / no ASA indication
494	419	Placebo	ASA indication	EAV648M	21.9.21 9:43	2022-08-31	Edoxaban 30mg / ASA indication
494	419	Placebo	ASA indication	SYV545F	26.2.20 14:01	2022-08-31	Edoxaban 30mg / ASA indication
494	419	Placebo	ASA indication	CUV279S	8.9.20 10:37	2022-08-31	Edoxaban 30mg / no ASA indication
494	419	Placebo	ASA indication	ZMM573H	12.9.18 10:15	2020-01-01	Edoxaban 30mg / ASA indication
494	419	Placebo	ASA indication	TCX278N	8.3.19 10:17	2020-01-01	Edoxaban 30mg / ASA indication
494	419	Placebo	ASA indication	NBR566W	21.3.18 12:08	2020-01-01	Edoxaban 30mg / ASA indication
494	419	Placebo	ASA indication	YYU579B	24.3.21 10:49	2022-08-31	Edoxaban 30mg / ASA indication
494	419	Placebo	ASA indication	UBX459U	3.9.19 10:50	2021-12-31	Edoxaban 60mg / ASA indication
1858	419	Placebo	ASA indication	AWT235H	10.11.20 12:10	2021-12-31	Edoxaban 60mg / ASA indication
244	419	Placebo	no ASA indication	UDW788U	6.2.18 11:17	2018-09-01	Edoxaban 60mg / no ASA indication
244	419	Placebo	no ASA indication	GVN625D	23.7.19 10:33	2021-12-31	Edoxaban 60mg / no ASA indication
244	419	Placebo	no ASA indication	KUA181K	22.1.19 11:53	2020-01-01	Edoxaban 60mg / no ASA indication
244	419	Placebo	no ASA indication	FBC273C	17.8.18 13:29	2020-01-01	Edoxaban 60mg / no ASA indication
244	419	Placebo	no ASA indication	HYE593N	7.8.17 9:49	2018-09-01	Edoxaban 60mg / no ASA indication
464	419	Placebo	no ASA indication	BWU247B	7.3.19 13:15	2020-01-01	Edoxaban 60mg / no ASA indication
464	419	Placebo	no ASA indication	CCF127F	19.9.19 11:03	2021-12-31	Edoxaban 60mg / no ASA indication
464	419	Placebo	no ASA indication	AHZ614F	1.9.20 14:46	2021-12-31	Edoxaban 60mg / no ASA indication
464	419	Placebo	no ASA indication	KXM573M	27.2.18 8:06	2020-01-01	Edoxaban 60mg / no ASA indication
464	419	Placebo	no ASA indication	EDL299X	21.8.18 12:21	2020-01-01	Edoxaban 60mg / no ASA indication
464	419	Placebo	no ASA indication	MBP593E	27.2.20 13:38	2021-12-31	Edoxaban 60mg / no ASA indication
690	419	Placebo	no ASA indication	CRT573P	31.8.18 7:03	2020-01-01	Edoxaban 60mg / no ASA indication
690	419	Placebo	no ASA indication	ADH324Y	8.3.19 11:40	2020-01-01	Edoxaban 60mg / no ASA indication
1137	419	Placebo	no ASA indication	MPN966N	22.5.19 11:07	2020-01-01	Edoxaban 30mg / no ASA indication
247	419	Edoxaban	ASA indication	WSN997M	22.7.19 10:24	2021-12-31	Edoxaban 60mg / ASA indication
247	419	Edoxaban	ASA indication	UCS357B	9.2.18 10:29	2018-09-01	Edoxaban 60mg / ASA indication
247	419	Edoxaban	ASA indication	FPG962Y	10.2.20 11:16	2022-08-31	Edoxaban 30mg / ASA indication
247	419	Edoxaban	ASA indication	CXY326R	7.8.18 12:41	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
247	419	Edoxaban	ASA indication	URK218M	10.8.17 10:04	2018-09-01	Edoxaban 60mg / ASA indication
247	419	Edoxaban	ASA indication	HTH167E	29.1.19 11:55	2020-01-01	Edoxaban 30mg / ASA indication
1260	419	Edoxaban	ASA indication	AGG774P	27.8.19 9:08	2021-12-31	Edoxaban 60mg / ASA indication
2083	419	Edoxaban	ASA indication	WCT229R	9.11.21 10:08	2024-04-30	Edoxaban 60mg / ASA indication
2083	419	Edoxaban	ASA indication	WXC321C	4.5.21 9:17	2021-12-31	Edoxaban 60mg / ASA indication
2172	419	Edoxaban	ASA indication	GUH288G	7.1.22 10:56	2024-04-30	Edoxaban 60mg / ASA indication
2172	419	Edoxaban	ASA indication	GVB437G	29.7.22 8:36	2024-04-30	Edoxaban 60mg / ASA indication
2172	419	Edoxaban	ASA indication	GRP767S	28.6.21 13:17	2024-04-30	Edoxaban 60mg / ASA indication
2207	419	Edoxaban	ASA indication	TSL437M	28.7.21 9:08	2022-08-31	Edoxaban 30mg / ASA indication
211	419	Edoxaban	no ASA indication	KWT466X	5.7.17 8:40	2018-09-01	Edoxaban 60mg / no ASA indication
211	419	Edoxaban	no ASA indication	RUU822F	12.1.18 11:45	2018-09-01	Edoxaban 60mg / no ASA indication
323	419	Edoxaban	no ASA indication	GPE415R	30.10.18 11:51	2020-01-01	Edoxaban 60mg / no ASA indication
323	419	Edoxaban	no ASA indication	MZX418C	24.6.20 9:37	2021-12-31	Edoxaban 60mg / ASA indication
323	419	Edoxaban	no ASA indication	PDZ171A	10.7.19 15:19	2022-08-31	Edoxaban 30mg / ASA indication
323	419	Edoxaban	no ASA indication	XTD784T	26.4.18 8:51	2020-01-01	Edoxaban 60mg / no ASA indication
323	419	Edoxaban	no ASA indication	UHL767E	31.10.17 11:24	2018-09-01	Edoxaban 60mg / no ASA indication
323	419	Edoxaban	no ASA indication	DKF965Y	8.5.19 10:47	2020-01-01	Edoxaban 60mg / no ASA indication
323	419	Edoxaban	no ASA indication	VPC132S	5.11.19 12:01	2022-08-31	Edoxaban 30mg / ASA indication
637	419	Edoxaban	no ASA indication	DFR749B	3.2.21 11:07	2022-08-31	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	BDF474D	21.1.20 11:38	2022-08-31	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	NZE635H	21.7.20 9:25	2022-08-31	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	XLB263Z	27.7.21 8:39	2022-08-31	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	LPN684F	8.1.19 11:57	2020-01-01	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	YTL153M	25.1.22 9:34	2022-08-31	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	WCD816R	19.7.19 10:51	2022-08-31	Edoxaban 30mg / no ASA indication
637	419	Edoxaban	no ASA indication	ADU642R	24.7.18 9:50	2020-01-01	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	YFW864T	14.1.20 9:04	2022-08-31	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	SUT668X	21.1.19 14:01	2020-01-01	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	MFZ885H	24.7.19 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	XMH681L	3.8.21 10:03	2022-08-31	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	CAW554R	17.8.22 8:44	2024-11-30	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	YHK333X	31.1.22 11:38	2022-08-31	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	DFC768P	19.1.21 9:01	2022-08-31	Edoxaban 30mg / no ASA indication
945	419	Edoxaban	no ASA indication	SEF437L	31.7.20 7:36	2022-08-31	Edoxaban 30mg / no ASA indication
2303	419	Edoxaban	no ASA indication	GMV882P	4.4.22 10:14	2024-04-30	Edoxaban 60mg / no ASA indication
2303	419	Edoxaban	no ASA indication	GRW311P	12.10.21 10:50	2024-04-30	Edoxaban 60mg / no ASA indication
116	421	Placebo	ASA indication	NXF538G	21.3.17 11:38	2018-09-01	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	NXW736L	30.9.20 9:40	2021-12-31	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	EBF684M	4.4.19 8:13	2020-01-01	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	NNA861T	1.10.19 10:14	2021-12-31	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	NVS439P	24.3.22 10:49	2024-11-30	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
126	421	Placebo	ASA indication	UZE814C	11.4.18 7:37	2020-01-01	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	MWW336X	1.4.21 9:09	2021-12-31	Edoxaban 60mg / no ASA indication
126	421	Placebo	ASA indication	KHG467A	30.3.17 7:47	2018-09-01	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	EBC821E	2.10.17 7:44	2018-09-01	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	ZNX525P	16.3.20 9:01	2021-12-31	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	WCM612W	4.10.18 9:07	2020-01-01	Edoxaban 60mg / ASA indication
126	421	Placebo	ASA indication	UYA373H	8.10.21 8:36	2022-08-31	Edoxaban 30mg / ASA indication
157	421	Placebo	ASA indication	TAC213B	9.5.17 9:53	2018-09-01	Edoxaban 30mg / ASA indication
161	421	Placebo	ASA indication	CEK459N	16.5.17 9:48	2018-09-01	Edoxaban 30mg / ASA indication
790	421	Placebo	ASA indication	MXR782B	9.5.19 8:48	2020-01-01	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	YNP645M	29.4.21 8:26	2021-12-31	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	XGH994P	20.10.20 8:38	2021-12-31	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	TNX178N	10.5.22 10:02	2024-04-30	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	AUN352X	4.5.20 11:20	2021-12-31	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	XZP599Z	2.11.21 8:14	2024-04-30	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	PMK639Y	12.11.18 6:53	2020-01-01	Edoxaban 60mg / ASA indication
790	421	Placebo	ASA indication	ZGL214L	12.11.19 7:52	2021-12-31	Edoxaban 60mg / ASA indication
828	421	Placebo	ASA indication	CEG782L	19.11.18 11:00	2020-01-01	Edoxaban 60mg / ASA indication
1000	421	Placebo	ASA indication	ERF935V	22.2.19 11:29	2020-01-01	Edoxaban 60mg / ASA indication
1299	421	Placebo	ASA indication	EGX327X	26.9.19 7:38	2022-08-31	Edoxaban 30mg / ASA indication
1299	421	Placebo	ASA indication	TEK732T	16.3.20 8:58	2022-08-31	Edoxaban 30mg / ASA indication
1418	421	Placebo	ASA indication	BRR984R	26.5.20 12:30	2022-08-31	Edoxaban 30mg / ASA indication
1418	421	Placebo	ASA indication	XHH259B	19.11.20 13:17	2022-08-31	Edoxaban 30mg / ASA indication
1418	421	Placebo	ASA indication	PYM278A	26.5.20 0:39	2021-12-31	Edoxaban 60mg / ASA indication
1418	421	Placebo	ASA indication	ZRN855T	29.11.21 13:32	2022-08-31	Edoxaban 30mg / ASA indication
1418	421	Placebo	ASA indication	NFD559A	2.6.22 10:56	2024-11-30	Edoxaban 30mg / no ASA indication
1418	421	Placebo	ASA indication	CLZ763L	28.11.19 12:06	2022-08-31	Edoxaban 30mg / ASA indication
1418	421	Placebo	ASA indication	URX253Y	19.5.21 11:46	2022-08-31	Edoxaban 30mg / ASA indication
1729	421	Placebo	ASA indication	DAM999N	10.2.22 11:14	2024-04-30	Edoxaban 60mg / ASA indication
1729	421	Placebo	ASA indication	KKG934Z	12.8.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication
1729	421	Placebo	ASA indication	ADF724S	11.2.21 10:40	2021-12-31	Edoxaban 60mg / ASA indication
1729	421	Placebo	ASA indication	ADB193D	12.8.21 9:04	2024-04-30	Edoxaban 60mg / ASA indication
1729	421	Placebo	ASA indication	DVW593E	10.8.22 9:11	2024-04-30	Edoxaban 60mg / ASA indication
1759	421	Placebo	ASA indication	AFC276K	8.9.21 8:54	2024-04-30	Edoxaban 60mg / ASA indication
1759	421	Placebo	ASA indication	RGC498S	8.9.20 12:39	2021-12-31	Edoxaban 60mg / ASA indication
1759	421	Placebo	ASA indication	AWU416T	4.3.22 13:02	2024-04-30	Edoxaban 60mg / ASA indication
1759	421	Placebo	ASA indication	AHM557H	9.3.21 10:56	2021-12-31	Edoxaban 60mg / ASA indication
1841	421	Placebo	ASA indication	MFR413P	29.10.20 12:19	2022-08-31	Edoxaban 30mg / ASA indication
1882	421	Placebo	ASA indication	SHL564S	26.5.21 11:45	2021-12-31	Edoxaban 60mg / ASA indication
1882	421	Placebo	ASA indication	SYD425Y	23.5.22 8:58	2024-11-30	Edoxaban 30mg / ASA indication
1882	421	Placebo	ASA indication	BTV254P	25.11.20 13:59	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1882	421	Placebo	ASA indication	AWS363E	26.11.21 11:28	2024-04-30	Edoxaban 60mg / ASA indication
1884	421	Placebo	ASA indication	PBX929U	26.11.20 14:42	2021-12-31	Edoxaban 60mg / ASA indication
1949	421	Placebo	ASA indication	PKB479B	4.2.21 12:23	2021-12-31	Edoxaban 60mg / ASA indication
1949	421	Placebo	ASA indication	DRM577F	2.8.22 9:06	2024-04-30	Edoxaban 60mg / ASA indication
1949	421	Placebo	ASA indication	ADZ375P	2.8.21 8:59	2024-04-30	Edoxaban 60mg / no ASA indication
1949	421	Placebo	ASA indication	XUT164R	3.2.22 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
1979	421	Placebo	ASA indication	URS938M	24.2.21 11:55	2022-08-31	Edoxaban 30mg / ASA indication
1979	421	Placebo	ASA indication	DBV729F	23.2.22 9:53	2024-04-30	Edoxaban 60mg / ASA indication
1979	421	Placebo	ASA indication	EFT968T	24.8.21 9:24	2022-08-31	Edoxaban 30mg / ASA indication
1979	421	Placebo	ASA indication	WWS244W	30.8.22 9:04	2024-11-30	Edoxaban 30mg / ASA indication
2023	421	Placebo	ASA indication	ADE735Y	25.6.21 9:15	2024-04-30	Edoxaban 60mg / ASA indication
2023	421	Placebo	ASA indication	WNP329E	23.9.21 8:45	2024-04-30	Edoxaban 60mg / ASA indication
2023	421	Placebo	ASA indication	VLX626S	23.3.21 12:08	2022-08-31	Edoxaban 30mg / ASA indication
2023	421	Placebo	ASA indication	GFW437B	23.3.22 9:27	2024-04-30	Edoxaban 60mg / ASA indication
2111	421	Placebo	ASA indication	SSY143L	19.5.21 13:06	2021-12-31	Edoxaban 60mg / ASA indication
2111	421	Placebo	ASA indication	WLF789C	18.11.21 12:01	2024-04-30	Edoxaban 60mg / ASA indication
2111	421	Placebo	ASA indication	UKY247E	19.5.22 8:07	2024-04-30	Edoxaban 60mg / ASA indication
2227	421	Placebo	ASA indication	GMH723S	17.8.21 9:10	2022-08-31	Edoxaban 30mg / ASA indication
2325	421	Placebo	ASA indication	XYU888F	4.11.21 9:16	2024-04-30	Edoxaban 60mg / ASA indication
2347	421	Placebo	ASA indication	ZLL845A	18.5.22 8:29	2024-04-30	Edoxaban 60mg / ASA indication
2347	421	Placebo	ASA indication	ADH992C	16.11.21 9:51	2024-04-30	Edoxaban 60mg / ASA indication
2414	421	Placebo	ASA indication	NHP389B	5.1.22 11:48	2022-08-31	Edoxaban 30mg / ASA indication
2449	421	Placebo	ASA indication	ATX657X	27.1.22 10:41	2024-11-30	Edoxaban 30mg / ASA indication
2449	421	Placebo	ASA indication	WMP677M	4.8.22 7:53	2024-11-30	Edoxaban 30mg / ASA indication
2489	421	Placebo	ASA indication	ASE259U	21.2.22 11:17	2024-11-30	Edoxaban 30mg / ASA indication
2489	421	Placebo	ASA indication	RKD543X	25.8.22 7:37	2024-11-30	Edoxaban 30mg / ASA indication
2604	421	Placebo	ASA indication	NWZ156T	4.5.22 7:49	2024-11-30	Edoxaban 30mg / ASA indication
2673	421	Placebo	ASA indication	UGV365M	28.6.22 12:27	2024-11-30	Edoxaban 30mg / ASA indication
2702	421	Placebo	ASA indication	WZT942X	7.7.22 9:24	2024-04-30	Edoxaban 60mg / ASA indication
55	421	Placebo	no ASA indication	UFA149Z	17.5.18 9:11	2020-01-01	Edoxaban 60mg / no ASA indication
55	421	Placebo	no ASA indication	YGH895G	1.6.17 11:01	2018-09-01	Edoxaban 60mg / no ASA indication
55	421	Placebo	no ASA indication	ESU673D	1.12.16 10:15	2018-09-01	Edoxaban 60mg / no ASA indication
55	421	Placebo	no ASA indication	YVE296A	15.11.18 10:05	2020-01-01	Edoxaban 60mg / no ASA indication
55	421	Placebo	no ASA indication	WNC699G	24.11.17 12:30	2018-09-01	Edoxaban 60mg / no ASA indication
78	421	Placebo	no ASA indication	LFL859C	24.1.17 9:59	2018-09-01	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	EEK159C	27.6.18 8:39	2020-01-01	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	NGF154B	13.3.19 12:06	2020-01-01	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	AEL683L	9.2.22 10:40	2024-04-30	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	ZDG859H	5.12.18 8:49	2020-01-01	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	BDL984A	4.8.20 8:20	2021-12-31	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	ADA341W	9.8.21 8:33	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
430	421	Placebo	no ASA indication	PEC298Z	5.2.18 8:54	2018-09-01	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	UGA959G	25.2.20 10:37	2021-12-31	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	NMT484T	9.8.22 8:32	2024-04-30	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	PFT127S	6.8.19 7:49	2021-12-31	Edoxaban 60mg / no ASA indication
430	421	Placebo	no ASA indication	PDA143V	16.2.21 9:50	2021-12-31	Edoxaban 60mg / no ASA indication
544	421	Placebo	no ASA indication	XDS548F	3.5.18 8:10	2020-01-01	Edoxaban 60mg / no ASA indication
685	421	Placebo	no ASA indication	GWH474A	22.2.19 9:45	2020-01-01	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	EWM692A	19.2.21 10:16	2022-08-31	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	UZH156B	25.8.22 9:39	2024-11-30	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	FVL196D	23.8.18 8:35	2020-01-01	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	PUS497B	19.8.21 8:29	2022-08-31	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	AYC164C	22.2.22 9:32	2024-11-30	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	BVY795E	23.8.19 8:01	2022-08-31	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	VSH687G	20.2.20 12:51	2022-08-31	Edoxaban 30mg / no ASA indication
685	421	Placebo	no ASA indication	HSX638S	20.8.20 10:52	2022-08-31	Edoxaban 30mg / no ASA indication
768	421	Placebo	no ASA indication	VHK944B	24.10.18 13:33	2020-01-01	Edoxaban 60mg / no ASA indication
1116	421	Placebo	no ASA indication	HCV422T	7.5.20 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
1116	421	Placebo	no ASA indication	LUC261U	8.5.19 10:19	2020-01-01	Edoxaban 60mg / no ASA indication
1116	421	Placebo	no ASA indication	YAK683V	11.11.21 9:29	2024-04-30	Edoxaban 60mg / no ASA indication
1116	421	Placebo	no ASA indication	AXR764G	5.5.22 9:43	2024-11-30	Edoxaban 30mg / no ASA indication
1116	421	Placebo	no ASA indication	EUU667Y	6.5.21 7:47	2021-12-31	Edoxaban 60mg / no ASA indication
1116	421	Placebo	no ASA indication	MTT431V	13.11.19 11:40	2021-12-31	Edoxaban 60mg / no ASA indication
1116	421	Placebo	no ASA indication	UGR241P	5.11.20 10:24	2021-12-31	Edoxaban 60mg / no ASA indication
1216	421	Placebo	no ASA indication	XWU473Y	10.1.20 13:00	2022-08-31	Edoxaban 30mg / no ASA indication
1216	421	Placebo	no ASA indication	GEY874Y	12.1.21 14:18	2022-08-31	Edoxaban 30mg / no ASA indication
1216	421	Placebo	no ASA indication	RDG315T	5.7.19 9:01	2022-08-31	Edoxaban 30mg / no ASA indication
1216	421	Placebo	no ASA indication	VBM187T	12.1.22 10:44	2022-08-31	Edoxaban 30mg / no ASA indication
1216	421	Placebo	no ASA indication	XKP293N	8.7.20 10:56	2022-08-31	Edoxaban 30mg / no ASA indication
1216	421	Placebo	no ASA indication	UVF316L	1.7.21 10:16	2022-08-31	Edoxaban 30mg / no ASA indication
1357	421	Placebo	no ASA indication	SUL882S	28.10.19 15:33	2021-12-31	Edoxaban 60mg / no ASA indication
1505	421	Placebo	no ASA indication	LYD155L	5.2.20 8:50	2021-12-31	Edoxaban 60mg / no ASA indication
1804	421	Placebo	no ASA indication	GXW596P	29.3.21 9:03	2022-08-31	Edoxaban 30mg / no ASA indication
1804	421	Placebo	no ASA indication	LXC238D	30.9.20 7:42	2021-12-31	Edoxaban 60mg / no ASA indication
1804	421	Placebo	no ASA indication	CME637K	30.3.22 8:11	2024-04-30	Edoxaban 60mg / no ASA indication
1804	421	Placebo	no ASA indication	WTA497M	28.9.21 11:05	2024-04-30	Edoxaban 60mg / no ASA indication
1806	421	Placebo	no ASA indication	ABW937E	13.4.21 10:40	2021-12-31	Edoxaban 60mg / no ASA indication
1806	421	Placebo	no ASA indication	WYV116Z	30.9.20 12:08	2021-12-31	Edoxaban 60mg / no ASA indication
1806	421	Placebo	no ASA indication	WTX779Z	29.9.21 8:18	2024-04-30	Edoxaban 60mg / no ASA indication
2109	421	Placebo	no ASA indication	FEZ434H	19.5.21 12:51	2021-12-31	Edoxaban 60mg / no ASA indication
2109	421	Placebo	no ASA indication	ZUY669Z	19.5.22 8:39	2024-04-30	Edoxaban 60mg / no ASA indication
2109	421	Placebo	no ASA indication	XZC582F	9.11.21 12:27	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2232	421	Placebo	no ASA indication	ACL558E	17.8.21 12:00	2024-04-30	Edoxaban 60mg / no ASA indication
2264	421	Placebo	no ASA indication	WVH751D	13.9.21 8:23	2024-04-30	Edoxaban 60mg / no ASA indication
2283	421	Placebo	no ASA indication	XMR553C	27.9.21 7:14	2022-08-31	Edoxaban 30mg / no ASA indication
2430	421	Placebo	no ASA indication	THR569G	13.7.22 8:00	2024-11-30	Edoxaban 30mg / no ASA indication
2430	421	Placebo	no ASA indication	FZF559B	14.1.22 10:45	2022-08-31	Edoxaban 30mg / no ASA indication
2616	421	Placebo	no ASA indication	NZR951W	17.5.22 11:28	2024-11-30	Edoxaban 30mg / no ASA indication
77	421	Edoxaban	ASA indication	XAH816A	16.7.19 7:47	2021-12-31	Edoxaban 60mg / ASA indication
77	421	Edoxaban	ASA indication	FSU796K	13.7.17 10:06	2018-09-01	Edoxaban 60mg / ASA indication
77	421	Edoxaban	ASA indication	BFZ516M	8.1.19 8:40	2020-01-01	Edoxaban 60mg / ASA indication
77	421	Edoxaban	ASA indication	MFZ156T	17.1.18 10:19	2018-09-01	Edoxaban 60mg / ASA indication
77	421	Edoxaban	ASA indication	YVK152L	23.1.17 9:54	2018-09-01	Edoxaban 60mg / ASA indication
77	421	Edoxaban	ASA indication	BWY384U	12.7.18 10:30	2020-01-01	Edoxaban 60mg / ASA indication
236	421	Edoxaban	ASA indication	LVF783K	30.1.18 11:55	2018-09-01	Edoxaban 60mg / ASA indication
236	421	Edoxaban	ASA indication	ZCW542Z	3.8.18 9:34	2020-01-01	Edoxaban 30mg / ASA indication
236	421	Edoxaban	ASA indication	UDY331X	27.7.17 12:22	2018-09-01	Edoxaban 60mg / ASA indication
279	421	Edoxaban	ASA indication	ACP549W	19.9.17 10:44	2018-09-01	Edoxaban 60mg / ASA indication
353	421	Edoxaban	ASA indication	BBD691K	30.5.18 7:56	2020-01-01	Edoxaban 30mg / ASA indication
353	421	Edoxaban	ASA indication	KXD363V	11.6.19 10:53	2020-01-01	Edoxaban 30mg / ASA indication
353	421	Edoxaban	ASA indication	AGT525K	28.11.18 8:24	2020-01-01	Edoxaban 60mg / ASA indication
353	421	Edoxaban	ASA indication	XFW392N	29.11.17 9:32	2018-09-01	Edoxaban 60mg / ASA indication
503	421	Edoxaban	ASA indication	ZWK194T	28.3.19 9:27	2020-01-01	Edoxaban 60mg / ASA indication
503	421	Edoxaban	ASA indication	NMD681V	5.10.18 8:37	2020-01-01	Edoxaban 60mg / ASA indication
503	421	Edoxaban	ASA indication	ENH394P	28.3.18 10:10	2020-01-01	Edoxaban 60mg / ASA indication
985	421	Edoxaban	ASA indication	CGL711S	18.2.20 10:12	2021-12-31	Edoxaban 60mg / ASA indication
985	421	Edoxaban	ASA indication	VRK572A	22.8.19 8:38	2021-12-31	Edoxaban 60mg / ASA indication
985	421	Edoxaban	ASA indication	SYX981R	18.2.21 9:57	2021-12-31	Edoxaban 60mg / ASA indication
985	421	Edoxaban	ASA indication	KGK482N	11.2.19 14:17	2020-01-01	Edoxaban 60mg / ASA indication
985	421	Edoxaban	ASA indication	DTV725G	18.8.20 11:44	2022-08-31	Edoxaban 30mg / ASA indication
1046	421	Edoxaban	ASA indication	HAD564G	16.3.20 9:21	2021-12-31	Edoxaban 60mg / ASA indication
1046	421	Edoxaban	ASA indication	RXG445P	9.4.19 15:49	2020-01-01	Edoxaban 60mg / ASA indication
1046	421	Edoxaban	ASA indication	LGL914G	25.9.19 8:22	2021-12-31	Edoxaban 60mg / ASA indication
1225	421	Edoxaban	ASA indication	PDW151G	18.7.19 8:06	2022-08-31	Edoxaban 30mg / ASA indication
1225	421	Edoxaban	ASA indication	NBD876G	15.7.20 9:25	2022-08-31	Edoxaban 30mg / ASA indication
1225	421	Edoxaban	ASA indication	SCB714N	16.1.20 11:03	2022-08-31	Edoxaban 30mg / ASA indication
1307	421	Edoxaban	ASA indication	NEH579Z	16.3.20 9:24	2021-12-31	Edoxaban 60mg / ASA indication
1307	421	Edoxaban	ASA indication	WZP578H	1.10.21 10:53	2024-04-30	Edoxaban 60mg / ASA indication
1307	421	Edoxaban	ASA indication	FEW716T	1.10.19 8:02	2021-12-31	Edoxaban 60mg / ASA indication
1307	421	Edoxaban	ASA indication	KKA298B	1.10.20 8:16	2021-12-31	Edoxaban 60mg / ASA indication
1307	421	Edoxaban	ASA indication	NZA413G	6.4.21 8:39	2021-12-31	Edoxaban 60mg / ASA indication
1590	421	Edoxaban	ASA indication	YFG851T	24.11.20 10:43	2021-12-31	Edoxaban 60mg / ASA indication
1590	421	Edoxaban	ASA indication	YFZ684N	16.11.21 9:58	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1590	421	Edoxaban	ASA indication	TKL369S	18.5.21 9:12	2021-12-31	Edoxaban 60mg / ASA indication
1590	421	Edoxaban	ASA indication	RKH334N	18.5.20 10:33	2021-12-31	Edoxaban 60mg / ASA indication
1590	421	Edoxaban	ASA indication	YEC639G	18.5.22 10:43	2024-04-30	Edoxaban 60mg / ASA indication
1602	421	Edoxaban	ASA indication	SYZ177U	28.5.20 10:01	2021-12-31	Edoxaban 60mg / ASA indication
1883	421	Edoxaban	ASA indication	FGT649X	26.5.21 11:52	2022-08-31	Edoxaban 30mg / ASA indication
1883	421	Edoxaban	ASA indication	CCP372U	25.11.20 15:27	2021-12-31	Edoxaban 60mg / ASA indication
1899	421	Edoxaban	ASA indication	WZV979Z	9.12.21 10:06	2024-04-30	Edoxaban 60mg / ASA indication
1899	421	Edoxaban	ASA indication	WFC646W	9.12.20 15:07	2022-08-31	Edoxaban 30mg / ASA indication
1899	421	Edoxaban	ASA indication	MUP565E	10.6.21 10:19	2021-12-31	Edoxaban 60mg / ASA indication
1899	421	Edoxaban	ASA indication	RDV172B	8.6.22 8:30	2024-11-30	Edoxaban 30mg / no ASA indication
1934	421	Edoxaban	ASA indication	ATS532G	20.1.21 15:15	2021-12-31	Edoxaban 60mg / ASA indication
1934	421	Edoxaban	ASA indication	ADL438K	29.7.21 11:50	2024-04-30	Edoxaban 60mg / ASA indication
1934	421	Edoxaban	ASA indication	ARD429R	26.1.22 9:22	2024-04-30	Edoxaban 60mg / ASA indication
1934	421	Edoxaban	ASA indication	MLC887P	27.7.22 8:56	2024-04-30	Edoxaban 60mg / ASA indication
1940	421	Edoxaban	ASA indication	XXH617G	27.1.21 13:37	2022-08-31	Edoxaban 30mg / ASA indication
1956	421	Edoxaban	ASA indication	AUB882V	11.2.21 12:05	2021-12-31	Edoxaban 60mg / ASA indication
2033	421	Edoxaban	ASA indication	PHD761B	30.3.21 13:26	2021-12-31	Edoxaban 60mg / ASA indication
2034	421	Edoxaban	ASA indication	FDA425H	1.4.21 9:05	2022-08-31	Edoxaban 30mg / ASA indication
2228	421	Edoxaban	ASA indication	BBD739P	17.2.22 13:56	2024-11-30	Edoxaban 30mg / ASA indication
2228	421	Edoxaban	ASA indication	AEB324S	17.8.21 10:13	2024-04-30	Edoxaban 60mg / ASA indication
2265	421	Edoxaban	ASA indication	AFT961F	13.9.21 9:13	2024-04-30	Edoxaban 60mg / ASA indication
2265	421	Edoxaban	ASA indication	DFD595E	21.3.22 11:21	2024-04-30	Edoxaban 60mg / ASA indication
2386	421	Edoxaban	ASA indication	AFG194M	9.12.21 9:37	2024-04-30	Edoxaban 60mg / ASA indication
2386	421	Edoxaban	ASA indication	MGN125C	8.6.22 10:01	2024-11-30	Edoxaban 30mg / ASA indication
2452	421	Edoxaban	ASA indication	GXD256A	27.1.22 11:42	2022-08-31	Edoxaban 30mg / ASA indication
2452	421	Edoxaban	ASA indication	NCT138X	25.7.22 8:34	2024-11-30	Edoxaban 30mg / ASA indication
2457	421	Edoxaban	ASA indication	EFS238E	1.8.22 9:25	2024-04-30	Edoxaban 60mg / ASA indication
2457	421	Edoxaban	ASA indication	FBB365A	31.1.22 13:43	2024-04-30	Edoxaban 60mg / ASA indication
2544	421	Edoxaban	ASA indication	NBX944L	21.3.22 11:08	2024-04-30	Edoxaban 60mg / ASA indication
2596	421	Edoxaban	ASA indication	UBS483Y	27.4.22 10:34	2024-04-30	Edoxaban 60mg / ASA indication
2633	421	Edoxaban	ASA indication	TZV268C	1.6.22 7:45	2024-04-30	Edoxaban 60mg / ASA indication
2654	421	Edoxaban	ASA indication	MKG914V	15.6.22 7:02	2024-11-30	Edoxaban 30mg / ASA indication
2712	421	Edoxaban	ASA indication	EYZ148Z	14.7.22 8:43	2024-04-30	Edoxaban 60mg / ASA indication
146	421	Edoxaban	no ASA indication	UKB827R	25.10.17 9:44	2018-09-01	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	XGR647V	30.10.19 10:08	2022-08-31	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	VWM879D	8.5.19 9:09	2020-01-01	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	KDG651P	27.10.21 9:22	2022-08-31	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	SWB331P	25.4.18 9:32	2020-01-01	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	SNV952C	28.4.21 9:00	2022-08-31	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	SRG279C	26.4.17 11:27	2018-09-01	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	NDE872B	21.10.20 8:55	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
146	421	Edoxaban	no ASA indication	PZD289H	24.10.18 9:07	2020-01-01	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	XDE726R	12.5.20 11:04	2022-08-31	Edoxaban 30mg / no ASA indication
146	421	Edoxaban	no ASA indication	BZK496Y	28.4.22 10:52	2024-11-30	Edoxaban 30mg / no ASA indication
155	421	Edoxaban	no ASA indication	NUF286U	7.11.17 11:49	2018-09-01	Edoxaban 60mg / no ASA indication
155	421	Edoxaban	no ASA indication	AEE819C	8.5.17 8:55	2018-09-01	Edoxaban 60mg / no ASA indication
290	421	Edoxaban	no ASA indication	FLM591M	4.10.17 8:36	2018-09-01	Edoxaban 60mg / no ASA indication
500	421	Edoxaban	no ASA indication	KTZ346F	27.3.18 11:33	2020-01-01	Edoxaban 60mg / no ASA indication
699	421	Edoxaban	no ASA indication	RER421N	7.9.18 9:22	2020-01-01	Edoxaban 60mg / no ASA indication
854	421	Edoxaban	no ASA indication	ZPC114F	3.12.18 10:38	2020-01-01	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	VXK737M	24.6.19 13:39	2021-12-31	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	ZSP694K	28.5.20 11:18	2021-12-31	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	KRB571P	10.6.21 8:34	2021-12-31	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	KFM921B	10.12.18 10:36	2020-01-01	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	PBE462L	13.6.22 11:50	2024-11-30	Edoxaban 30mg / no ASA indication
875	421	Edoxaban	no ASA indication	TML535P	26.11.20 9:50	2021-12-31	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	DVZ728Z	4.12.19 12:02	2021-12-31	Edoxaban 60mg / no ASA indication
875	421	Edoxaban	no ASA indication	XHE538R	7.12.21 11:18	2024-04-30	Edoxaban 60mg / no ASA indication
907	421	Edoxaban	no ASA indication	CLX428Z	21.1.19 9:56	2020-01-01	Edoxaban 60mg / no ASA indication
1380	421	Edoxaban	no ASA indication	ZLL396Y	8.5.20 7:47	2021-12-31	Edoxaban 60mg / no ASA indication
1380	421	Edoxaban	no ASA indication	AKY176A	18.11.21 11:30	2024-04-30	Edoxaban 60mg / no ASA indication
1380	421	Edoxaban	no ASA indication	SZZ499G	5.5.22 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
1380	421	Edoxaban	no ASA indication	EBS965N	12.11.20 8:53	2021-12-31	Edoxaban 60mg / no ASA indication
1380	421	Edoxaban	no ASA indication	FGN172B	13.11.19 8:56	2021-12-31	Edoxaban 60mg / no ASA indication
1380	421	Edoxaban	no ASA indication	YGP541M	11.5.21 9:09	2021-12-31	Edoxaban 60mg / no ASA indication
1584	421	Edoxaban	no ASA indication	ZYY588Z	12.5.20 11:35	2021-12-31	Edoxaban 60mg / no ASA indication
1584	421	Edoxaban	no ASA indication	NKB268G	12.5.22 8:36	2024-11-30	Edoxaban 30mg / no ASA indication
1584	421	Edoxaban	no ASA indication	YYS464E	12.5.21 8:30	2022-08-31	Edoxaban 30mg / no ASA indication
1584	421	Edoxaban	no ASA indication	LGW616X	12.11.21 12:15	2022-08-31	Edoxaban 30mg / no ASA indication
1584	421	Edoxaban	no ASA indication	BPN314S	25.11.20 11:04	2022-08-31	Edoxaban 30mg / no ASA indication
1668	421	Edoxaban	no ASA indication	HRW118C	11.1.21 12:34	2021-12-31	Edoxaban 60mg / no ASA indication
1668	421	Edoxaban	no ASA indication	SUS353L	30.6.20 12:33	2021-12-31	Edoxaban 60mg / no ASA indication
1933	421	Edoxaban	no ASA indication	WPU328H	20.1.21 14:24	2022-08-31	Edoxaban 30mg / no ASA indication
1933	421	Edoxaban	no ASA indication	TCA856X	27.7.21 11:20	2022-08-31	Edoxaban 30mg / no ASA indication
1933	421	Edoxaban	no ASA indication	TBV949U	18.7.22 10:47	2024-11-30	Edoxaban 30mg / no ASA indication
1933	421	Edoxaban	no ASA indication	NTX691V	24.1.22 12:05	2022-08-31	Edoxaban 30mg / no ASA indication
1991	421	Edoxaban	no ASA indication	AKV322T	1.9.21 11:31	2024-04-30	Edoxaban 60mg / no ASA indication
1991	421	Edoxaban	no ASA indication	BWW443Z	2.3.22 9:03	2024-11-30	Edoxaban 30mg / no ASA indication
1991	421	Edoxaban	no ASA indication	RUW638G	2.3.21 10:14	2022-08-31	Edoxaban 30mg / no ASA indication
2152	421	Edoxaban	no ASA indication	NVZ152A	16.12.21 9:21	2022-08-31	Edoxaban 30mg / no ASA indication
2152	421	Edoxaban	no ASA indication	MNZ125Y	14.6.21 12:02	2022-08-31	Edoxaban 30mg / no ASA indication
2240	421	Edoxaban	no ASA indication	NYU866V	27.8.21 8:16	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2240	421	Edoxaban	no ASA indication	ATE828N	22.2.22 12:33	2024-11-30	Edoxaban 30mg / ASA indication
2240	421	Edoxaban	no ASA indication	UWU432M	16.8.22 9:30	2024-11-30	Edoxaban 30mg / ASA indication
2240	421	Edoxaban	no ASA indication	EHS434S	24.8.21 12:49	2022-08-31	Edoxaban 30mg / no ASA indication
2241	421	Edoxaban	no ASA indication	AKR958C	23.2.22 12:22	2024-04-30	Edoxaban 60mg / no ASA indication
2241	421	Edoxaban	no ASA indication	DDR672L	24.8.22 8:29	2024-04-30	Edoxaban 60mg / no ASA indication
2241	421	Edoxaban	no ASA indication	TCK534A	24.8.21 13:16	2022-08-31	Edoxaban 30mg / no ASA indication
2508	421	Edoxaban	no ASA indication	AGR849K	2.3.22 12:11	2024-04-30	Edoxaban 60mg / no ASA indication
2508	421	Edoxaban	no ASA indication	SZW922A	1.9.22 8:04	2024-04-30	Edoxaban 60mg / no ASA indication
778	426	Placebo	ASA indication	TNV741T	26.10.18 12:56	2020-01-01	Edoxaban 60mg / ASA indication
1642	426	Placebo	ASA indication	TXT818W	14.12.20 15:43	2022-08-31	Edoxaban 30mg / ASA indication
1642	426	Placebo	ASA indication	FPG232U	21.1.22 14:23	2022-08-31	Edoxaban 30mg / ASA indication
1642	426	Placebo	ASA indication	MTB157U	2.7.21 9:24	2022-08-31	Edoxaban 30mg / ASA indication
1642	426	Placebo	ASA indication	DNA378C	17.6.20 11:45	2022-08-31	Edoxaban 30mg / ASA indication
569	426	Placebo	no ASA indication	GHF495V	8.6.21 13:36	2022-08-31	Edoxaban 30mg / no ASA indication
569	426	Placebo	no ASA indication	PNB986A	10.12.21 14:44	2022-08-31	Edoxaban 30mg / no ASA indication
569	426	Placebo	no ASA indication	APB741P	15.11.18 12:29	2020-01-01	Edoxaban 60mg / no ASA indication
569	426	Placebo	no ASA indication	MPG714H	28.5.19 11:49	2020-01-01	Edoxaban 60mg / no ASA indication
569	426	Placebo	no ASA indication	FED624D	2.12.19 11:00	2021-12-31	Edoxaban 60mg / no ASA indication
569	426	Placebo	no ASA indication	RPY242P	25.5.18 7:05	2020-01-01	Edoxaban 60mg / no ASA indication
569	426	Placebo	no ASA indication	DPN848F	9.12.20 13:59	2022-08-31	Edoxaban 30mg / no ASA indication
569	426	Placebo	no ASA indication	TRT481M	10.6.20 12:14	2021-12-31	Edoxaban 60mg / no ASA indication
569	426	Placebo	no ASA indication	CCA688A	18.7.22 14:38	2024-11-30	Edoxaban 30mg / no ASA indication
1235	426	Placebo	no ASA indication	ELV559U	4.2.20 11:25	2022-08-31	Edoxaban 30mg / no ASA indication
1235	426	Placebo	no ASA indication	BNH396F	30.7.19 10:17	2022-08-31	Edoxaban 30mg / no ASA indication
718	426	Edoxaban	ASA indication	XXK546P	21.9.18 10:37	2020-01-01	Edoxaban 60mg / ASA indication
1468	426	Edoxaban	ASA indication	STU798E	22.7.20 8:24	2021-12-31	Edoxaban 60mg / ASA indication
1468	426	Edoxaban	ASA indication	VKK897C	29.1.21 11:13	2021-12-31	Edoxaban 60mg / ASA indication
1468	426	Edoxaban	ASA indication	GCW591Y	7.1.20 11:04	2021-12-31	Edoxaban 60mg / ASA indication
930	426	Edoxaban	no ASA indication	ZGA336M	29.1.21 13:25	2021-12-31	Edoxaban 60mg / no ASA indication
930	426	Edoxaban	no ASA indication	MFL911Z	22.7.20 12:46	2021-12-31	Edoxaban 60mg / no ASA indication
930	426	Edoxaban	no ASA indication	KGA381C	2.9.21 12:48	2024-04-30	Edoxaban 60mg / no ASA indication
930	426	Edoxaban	no ASA indication	HHE185W	15.4.22 13:34	2024-04-30	Edoxaban 60mg / no ASA indication
930	426	Edoxaban	no ASA indication	FBE122M	11.1.19 11:35	2020-01-01	Edoxaban 60mg / no ASA indication
930	426	Edoxaban	no ASA indication	FWA895W	22.7.19 11:07	2021-12-31	Edoxaban 60mg / no ASA indication
930	426	Edoxaban	no ASA indication	ZDT895Z	23.1.20 10:26	2021-12-31	Edoxaban 60mg / no ASA indication
1796	426	Edoxaban	no ASA indication	WHB995U	31.3.21 13:51	2021-12-31	Edoxaban 60mg / no ASA indication
1796	426	Edoxaban	no ASA indication	NZE983Y	21.9.20 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
508	427	Placebo	ASA indication	YRP345H	3.4.18 11:53	2020-01-01	Edoxaban 60mg / ASA indication
847	427	Placebo	ASA indication	KNM886Y	6.7.20 8:38	2021-12-31	Edoxaban 60mg / ASA indication
847	427	Placebo	ASA indication	DEP184U	31.5.22 7:15	2024-04-30	Edoxaban 60mg / ASA indication
847	427	Placebo	ASA indication	WVF398Y	6.1.20 15:21	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
847	427	Placebo	ASA indication	DFT888A	7.7.21 13:34	2024-04-30	Edoxaban 60mg / no ASA indication
847	427	Placebo	ASA indication	EAN739E	26.11.18 16:02	2020-01-01	Edoxaban 60mg / ASA indication
847	427	Placebo	ASA indication	BDP424D	11.2.21 13:09	2021-12-31	Edoxaban 60mg / ASA indication
847	427	Placebo	ASA indication	GNW719D	19.6.19 9:10	2021-12-31	Edoxaban 60mg / ASA indication
847	427	Placebo	ASA indication	DEW259E	30.11.21 15:33	2024-04-30	Edoxaban 60mg / ASA indication
423	427	Placebo	no ASA indication	TTM452U	23.7.18 10:19	2020-01-01	Edoxaban 60mg / no ASA indication
423	427	Placebo	no ASA indication	RKY915F	31.1.18 15:47	2018-09-01	Edoxaban 60mg / no ASA indication
438	427	Edoxaban	ASA indication	FMP252V	8.2.18 11:53	2018-09-01	Edoxaban 60mg / ASA indication
1089	427	Edoxaban	ASA indication	DVY331S	31.10.19 16:21	2021-12-31	Edoxaban 60mg / no ASA indication
1089	427	Edoxaban	ASA indication	ZZV469C	17.4.19 11:21	2020-01-01	Edoxaban 60mg / ASA indication
1089	427	Edoxaban	ASA indication	UDW841A	17.4.20 13:51	2021-12-31	Edoxaban 60mg / no ASA indication
1089	427	Edoxaban	ASA indication	KDF693T	6.11.20 12:20	2021-12-31	Edoxaban 60mg / no ASA indication
2534	428	Placebo	no ASA indication	HMY186M	15.3.22 11:50	2024-04-30	Edoxaban 60mg / no ASA indication
721	428	Edoxaban	ASA indication	PFE533U	25.9.18 10:31	2020-01-01	Edoxaban 60mg / ASA indication
2350	428	Edoxaban	ASA indication	HTU639U	17.11.21 11:50	2024-04-30	Edoxaban 60mg / ASA indication
326	428	Edoxaban	no ASA indication	VMZ578X	1.11.17 13:53	2018-09-01	Edoxaban 60mg / no ASA indication
326	428	Edoxaban	no ASA indication	TBE466E	7.5.18 13:24	2020-01-01	Edoxaban 60mg / no ASA indication
652	445	Placebo	ASA indication	STK745H	6.2.19 10:43	2020-01-01	Edoxaban 30mg / ASA indication
652	445	Placebo	ASA indication	VVT558Y	1.8.18 12:31	2020-01-01	Edoxaban 30mg / ASA indication
785	445	Placebo	ASA indication	ZGH418E	31.10.18 12:53	2020-01-01	Edoxaban 60mg / ASA indication
786	445	Placebo	ASA indication	BSB278H	30.10.19 11:17	2021-12-31	Edoxaban 60mg / ASA indication
786	445	Placebo	ASA indication	WUW627B	31.10.18 13:43	2020-01-01	Edoxaban 60mg / ASA indication
786	445	Placebo	ASA indication	DKG248L	24.4.19 10:21	2020-01-01	Edoxaban 60mg / ASA indication
2324	445	Placebo	ASA indication	MNV673S	4.11.21 9:39	2022-08-31	Edoxaban 30mg / ASA indication
2324	445	Placebo	ASA indication	KSB993S	26.4.22 10:26	2024-11-30	Edoxaban 30mg / ASA indication
2674	445	Placebo	ASA indication	SXF843A	28.6.22 13:23	2024-11-30	Edoxaban 30mg / ASA indication
650	445	Edoxaban	ASA indication	WXX543S	1.8.18 10:47	2020-01-01	Edoxaban 30mg / ASA indication
651	445	Edoxaban	ASA indication	ZND153F	6.2.19 11:15	2020-01-01	Edoxaban 30mg / ASA indication
651	445	Edoxaban	ASA indication	KUP355P	10.2.21 9:44	2022-08-31	Edoxaban 30mg / ASA indication
651	445	Edoxaban	ASA indication	EGX392S	29.7.20 9:08	2022-08-31	Edoxaban 30mg / ASA indication
651	445	Edoxaban	ASA indication	VSD249Z	1.8.18 12:15	2020-01-01	Edoxaban 30mg / ASA indication
651	445	Edoxaban	ASA indication	DRM789F	5.2.20 11:21	2022-08-31	Edoxaban 30mg / ASA indication
651	445	Edoxaban	ASA indication	XMW598N	6.9.19 14:14	2022-08-31	Edoxaban 30mg / ASA indication
1506	445	Edoxaban	ASA indication	AYX255Z	29.7.20 10:39	2021-12-31	Edoxaban 60mg / ASA indication
1506	445	Edoxaban	ASA indication	EBW155S	30.7.21 9:58	2024-04-30	Edoxaban 60mg / ASA indication
1506	445	Edoxaban	ASA indication	SBH915M	10.2.21 10:37	2021-12-31	Edoxaban 60mg / ASA indication
1506	445	Edoxaban	ASA indication	MYU664X	5.2.20 8:58	2021-12-31	Edoxaban 60mg / ASA indication
1507	445	Edoxaban	ASA indication	FME999A	25.8.20 5:21	2022-08-31	Edoxaban 30mg / ASA indication
1507	445	Edoxaban	ASA indication	MFK528W	30.7.21 11:14	2022-08-31	Edoxaban 30mg / ASA indication
1507	445	Edoxaban	ASA indication	MMP783N	11.2.20 12:48	2022-08-31	Edoxaban 30mg / ASA indication
1507	445	Edoxaban	ASA indication	KVD899G	10.2.21 11:32	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1507	445	Edoxaban	ASA indication	XMG578E	25.1.22 15:18	2022-08-31	Edoxaban 30mg / ASA indication
1507	445	Edoxaban	ASA indication	HTH138V	2.9.22 10:05	2024-11-30	Edoxaban 30mg / ASA indication
1574	445	Edoxaban	ASA indication	NRG416B	4.5.21 7:07	2022-08-31	Edoxaban 30mg / ASA indication
1574	445	Edoxaban	ASA indication	WKH486B	26.4.22 10:19	2024-04-30	Edoxaban 60mg / ASA indication
1574	445	Edoxaban	ASA indication	GKN515Z	29.4.20 10:09	2021-12-31	Edoxaban 60mg / ASA indication
1574	445	Edoxaban	ASA indication	SBR544M	21.10.20 8:38	2021-12-31	Edoxaban 60mg / ASA indication
1574	445	Edoxaban	ASA indication	SGB977Z	19.10.21 10:04	2022-08-31	Edoxaban 30mg / ASA indication
784	445	Edoxaban	no ASA indication	WTT965U	30.10.19 9:41	2022-08-31	Edoxaban 30mg / no ASA indication
784	445	Edoxaban	no ASA indication	PLK926L	24.4.19 10:06	2020-01-01	Edoxaban 30mg / no ASA indication
784	445	Edoxaban	no ASA indication	UCS165Z	29.4.20 5:22	2022-08-31	Edoxaban 30mg / no ASA indication
784	445	Edoxaban	no ASA indication	MKF116R	31.10.18 14:24	2020-01-01	Edoxaban 30mg / no ASA indication
2209	445	Edoxaban	no ASA indication	EAF836T	21.1.22 8:44	2024-04-30	Edoxaban 60mg / no ASA indication
2209	445	Edoxaban	no ASA indication	KWZ111S	30.7.21 10:12	2022-08-31	Edoxaban 30mg / no ASA indication
159	459	Placebo	ASA indication	GFX848W	25.11.19 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
159	459	Placebo	ASA indication	DKS833M	14.5.20 13:34	2021-12-31	Edoxaban 60mg / no ASA indication
159	459	Placebo	ASA indication	YPP346B	15.11.18 9:53	2020-01-01	Edoxaban 60mg / ASA indication
159	459	Placebo	ASA indication	UVS754N	27.8.21 8:12	2022-08-31	Edoxaban 30mg / no ASA indication
159	459	Placebo	ASA indication	BSH422W	7.3.22 9:01	2024-11-30	Edoxaban 30mg / no ASA indication
159	459	Placebo	ASA indication	CZB121P	29.10.20 13:47	2022-08-31	Edoxaban 30mg / no ASA indication
159	459	Placebo	ASA indication	HRT199X	12.5.17 14:29	2018-09-01	Edoxaban 60mg / ASA indication
159	459	Placebo	ASA indication	UDE867R	17.11.17 15:22	2018-09-01	Edoxaban 60mg / ASA indication
159	459	Placebo	ASA indication	PHE595R	17.5.18 13:35	2020-01-01	Edoxaban 30mg / ASA indication
159	459	Placebo	ASA indication	BPH143E	29.8.22 6:46	2024-11-30	Edoxaban 30mg / no ASA indication
159	459	Placebo	ASA indication	NDB149G	16.5.19 12:16	2020-01-01	Edoxaban 60mg / ASA indication
159	459	Placebo	ASA indication	SAS234G	29.4.21 11:25	2022-08-31	Edoxaban 30mg / no ASA indication
196	470	Edoxaban	ASA indication	CHZ123V	27.6.18 9:27	2020-01-01	Edoxaban 60mg / ASA indication
196	470	Edoxaban	ASA indication	KKG146E	13.12.17 9:53	2018-09-01	Edoxaban 60mg / ASA indication
196	470	Edoxaban	ASA indication	ULL113H	24.6.20 11:10	2022-08-31	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	HFT469G	11.12.19 9:47	2022-08-31	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	HZU526L	17.5.22 9:25	2024-11-30	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	BYN356G	4.7.19 9:10	2022-08-31	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	EUM783X	9.1.19 9:36	2020-01-01	Edoxaban 60mg / ASA indication
196	470	Edoxaban	ASA indication	HWD114Z	19.6.17 12:50	2018-09-01	Edoxaban 60mg / ASA indication
196	470	Edoxaban	ASA indication	HRN313N	8.12.21 10:24	2022-08-31	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	GBF128H	16.12.20 11:05	2022-08-31	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	MEE364L	23.6.21 10:33	2022-08-31	Edoxaban 30mg / ASA indication
196	470	Edoxaban	ASA indication	HVT135F	15.6.22 9:40	2024-11-30	Edoxaban 30mg / ASA indication
222	470	Edoxaban	ASA indication	PSF632B	10.1.18 10:45	2018-09-01	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	NNR774G	16.1.19 11:00	2020-01-01	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	DYT561L	15.1.20 11:36	2021-12-31	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	PCF622D	11.7.18 10:24	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
222	470	Edoxaban	ASA indication	YVV495U	13.1.21 10:24	2021-12-31	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	TET158K	14.7.21 10:11	2024-04-30	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	ZEC252L	12.1.22 11:07	2024-04-30	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	XEY394A	11.7.17 10:37	2018-09-01	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	RDC134D	8.7.20 10:02	2021-12-31	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	AVP735T	17.7.19 10:51	2021-12-31	Edoxaban 60mg / ASA indication
222	470	Edoxaban	ASA indication	ZDZ216X	13.7.22 8:51	2024-04-30	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	CHH631T	26.10.18 9:05	2020-01-01	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	UAU969K	16.4.19 8:33	2020-01-01	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	VDC659M	17.4.18 8:37	2020-01-01	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	VEW479S	21.10.20 8:46	2021-12-31	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	FZL333R	30.10.19 12:17	2021-12-31	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	LXR414A	15.4.20 10:59	2021-12-31	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	TFR793X	11.10.21 10:08	2024-04-30	Edoxaban 60mg / ASA indication
529	470	Edoxaban	ASA indication	FDE691U	21.4.21 8:27	2021-12-31	Edoxaban 60mg / ASA indication
304	470	Edoxaban	no ASA indication	ZUY489R	19.4.18 7:52	2020-01-01	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	RZN674A	19.10.18 8:28	2020-01-01	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	HYD154L	14.4.21 7:35	2021-12-31	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	BNE354K	12.4.19 12:56	2020-01-01	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	CSU977B	17.10.17 8:52	2018-09-01	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	MXD245X	15.4.20 9:06	2021-12-31	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	YVM365M	23.10.19 11:57	2021-12-31	Edoxaban 60mg / no ASA indication
304	470	Edoxaban	no ASA indication	SKV918L	14.10.20 9:19	2021-12-31	Edoxaban 60mg / no ASA indication
76	479	Placebo	ASA indication	XHU727R	17.1.17 16:00	2018-09-01	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	VFN214Z	16.1.18 8:24	2018-09-01	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	UBC325H	17.1.19 10:08	2020-01-01	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	FPC964P	17.7.19 8:57	2022-08-31	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	AXB612Y	23.1.20 10:29	2022-08-31	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	LUW855R	17.7.18 9:28	2020-01-01	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	YMD981U	3.7.17 13:35	2018-09-01	Edoxaban 30mg / ASA indication
76	479	Placebo	ASA indication	DPA182K	20.7.20 11:03	2022-08-31	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	NPP825C	6.9.17 13:20	2018-09-01	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	XXE537L	4.9.19 7:50	2022-08-31	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	LAG571A	6.9.18 12:26	2020-01-01	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	KNT352K	7.9.21 13:26	2022-08-31	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	HZW794R	9.3.20 15:15	2022-08-31	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	CBF637Z	7.9.20 12:04	2022-08-31	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	PXC951H	6.3.17 15:59	2018-09-01	Edoxaban 60mg / no ASA indication
107	479	Placebo	no ASA indication	KWX154V	8.3.22 14:42	2024-11-30	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	BCX217E	6.3.18 15:24	2020-01-01	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	RLG691P	6.3.19 13:54	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
107	479	Placebo	no ASA indication	SPL192A	6.9.22 12:25	2024-11-30	Edoxaban 30mg / ASA indication
107	479	Placebo	no ASA indication	KKY574W	9.3.21 13:03	2022-08-31	Edoxaban 30mg / ASA indication
535	479	Placebo	no ASA indication	ZMW398G	25.4.18 11:07	2020-01-01	Edoxaban 30mg / no ASA indication
2352	479	Edoxaban	ASA indication	SXN355A	10.5.22 7:59	2024-04-30	Edoxaban 60mg / ASA indication
2352	479	Edoxaban	ASA indication	SWK584C	18.11.21 10:19	2024-04-30	Edoxaban 60mg / ASA indication
2580	479	Edoxaban	ASA indication	STD814L	8.4.22 9:21	2024-04-30	Edoxaban 60mg / ASA indication
1246	487	Placebo	ASA indication	GPL456K	25.8.20 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
1246	487	Placebo	ASA indication	GGS272F	26.8.20 12:32	2021-12-31	Edoxaban 60mg / ASA indication
1246	487	Placebo	ASA indication	WXX428X	8.8.19 10:47	2021-12-31	Edoxaban 60mg / ASA indication
1246	487	Placebo	ASA indication	KNW992K	4.2.20 9:57	2021-12-31	Edoxaban 60mg / ASA indication
1246	487	Placebo	ASA indication	NLB642D	1.2.21 13:07	2021-12-31	Edoxaban 60mg / ASA indication
1652	487	Placebo	no ASA indication	SNZ888F	16.12.21 12:19	2024-04-30	Edoxaban 60mg / no ASA indication
1652	487	Placebo	no ASA indication	UPC324F	16.12.20 13:38	2021-12-31	Edoxaban 60mg / no ASA indication
1652	487	Placebo	no ASA indication	SPS123L	23.6.21 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
1652	487	Placebo	no ASA indication	UWR135E	22.6.20 11:59	2021-12-31	Edoxaban 60mg / no ASA indication
2059	487	Placebo	no ASA indication	SNG359W	13.10.21 13:18	2024-04-30	Edoxaban 60mg / no ASA indication
2059	487	Placebo	no ASA indication	GCC316S	11.4.22 7:38	2024-04-30	Edoxaban 60mg / no ASA indication
2059	487	Placebo	no ASA indication	LXZ648H	21.4.21 13:04	2021-12-31	Edoxaban 60mg / no ASA indication
405	487	Edoxaban	no ASA indication	AVN326T	16.1.18 13:19	2018-09-01	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	SUB611M	19.7.22 11:39	2024-04-30	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	HNA783E	18.1.21 17:01	2021-12-31	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	SUA338N	20.1.22 12:36	2024-04-30	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	WVW368C	7.1.20 12:08	2021-12-31	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	UHM679X	8.7.20 11:29	2021-12-31	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	STZ593G	15.7.21 12:37	2024-04-30	Edoxaban 60mg / no ASA indication
1215	487	Edoxaban	no ASA indication	TVG638V	15.7.19 7:20	2021-12-31	Edoxaban 60mg / no ASA indication
2491	487	Edoxaban	no ASA indication	BWB266W	23.2.22 11:11	2024-11-30	Edoxaban 30mg / no ASA indication
2491	487	Edoxaban	no ASA indication	BZZ746W	16.8.22 10:22	2024-11-30	Edoxaban 30mg / no ASA indication
2	488	Placebo	ASA indication	XNZ147N	27.10.17 9:42	2018-09-01	Edoxaban 30mg / ASA indication
2	488	Placebo	ASA indication	ZSV979B	23.5.17 7:48	2018-09-01	Edoxaban 30mg / ASA indication
2	488	Placebo	ASA indication	AVC274S	20.12.16 11:50	2018-09-01	Edoxaban 30mg / ASA indication
2	488	Placebo	ASA indication	LDG482V	24.6.16 15:15	2018-09-01	Edoxaban 30mg / ASA indication
45	488	Placebo	ASA indication	KXN696A	10.11.16 10:42	2018-09-01	Edoxaban 30mg / ASA indication
47	488	Placebo	ASA indication	HCF835P	18.5.17 13:29	2018-09-01	Edoxaban 30mg / ASA indication
47	488	Placebo	ASA indication	BBP646B	16.5.19 9:11	2020-01-01	Edoxaban 30mg / ASA indication
47	488	Placebo	ASA indication	KTP777U	15.11.17 9:16	2018-09-01	Edoxaban 30mg / ASA indication
47	488	Placebo	ASA indication	FUA414R	18.5.18 8:55	2020-01-01	Edoxaban 30mg / ASA indication
47	488	Placebo	ASA indication	KGX165Z	15.11.16 10:03	2018-09-01	Edoxaban 30mg / ASA indication
47	488	Placebo	ASA indication	TCK354L	19.11.18 11:52	2020-01-01	Edoxaban 30mg / ASA indication
64	488	Placebo	ASA indication	KUB724K	19.12.16 8:57	2018-09-01	Edoxaban 60mg / ASA indication
189	488	Placebo	ASA indication	DKF812H	10.12.18 15:19	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
189	488	Placebo	ASA indication	FLR424W	14.6.17 6:44	2018-09-01	Edoxaban 30mg / ASA indication
189	488	Placebo	ASA indication	RKM357P	12.12.17 14:35	2018-09-01	Edoxaban 30mg / ASA indication
189	488	Placebo	ASA indication	GXW285W	11.6.18 15:07	2020-01-01	Edoxaban 30mg / ASA indication
206	488	Placebo	ASA indication	NHB454G	14.12.18 10:14	2020-01-01	Edoxaban 60mg / ASA indication
206	488	Placebo	ASA indication	WSV583Y	7.6.18 12:59	2020-01-01	Edoxaban 60mg / ASA indication
206	488	Placebo	ASA indication	BCZ375P	3.6.19 9:15	2020-01-01	Edoxaban 30mg / ASA indication
206	488	Placebo	ASA indication	SFK646Z	3.12.19 10:55	2021-12-31	Edoxaban 60mg / ASA indication
206	488	Placebo	ASA indication	WUW749G	15.6.20 9:17	2021-12-31	Edoxaban 60mg / ASA indication
206	488	Placebo	ASA indication	UYG983M	12.12.17 16:14	2018-09-01	Edoxaban 60mg / ASA indication
206	488	Placebo	ASA indication	RUY842G	28.6.17 9:34	2018-09-01	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	VXH389H	10.7.17 12:15	2018-09-01	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	WED145R	10.7.18 9:34	2020-01-01	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	ZLX372U	12.7.19 9:28	2021-12-31	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	HNB715Z	16.1.18 13:36	2018-09-01	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	MUT381W	13.7.20 7:13	2021-12-31	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	ANR857D	12.7.21 9:13	2024-04-30	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	LBB119Y	13.1.20 7:26	2021-12-31	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	NVM638W	11.1.21 10:01	2021-12-31	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	EHR174C	11.1.19 9:58	2020-01-01	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	ZMF713D	14.1.22 9:49	2024-04-30	Edoxaban 60mg / ASA indication
218	488	Placebo	ASA indication	ZPB478T	18.7.22 7:58	2024-04-30	Edoxaban 60mg / ASA indication
249	488	Placebo	ASA indication	FVL233D	14.8.17 9:53	2018-09-01	Edoxaban 30mg / ASA indication
327	488	Placebo	ASA indication	BTC523S	2.11.17 10:22	2018-09-01	Edoxaban 60mg / ASA indication
370	488	Placebo	ASA indication	HYL788T	5.6.19 6:57	2020-01-01	Edoxaban 60mg / ASA indication
370	488	Placebo	ASA indication	HFL224D	12.12.18 10:46	2020-01-01	Edoxaban 60mg / ASA indication
370	488	Placebo	ASA indication	SYK416F	18.6.18 8:13	2020-01-01	Edoxaban 30mg / ASA indication
370	488	Placebo	ASA indication	RWZ794S	26.11.19 7:57	2021-12-31	Edoxaban 60mg / ASA indication
370	488	Placebo	ASA indication	DPG639P	26.5.20 7:46	2021-12-31	Edoxaban 60mg / ASA indication
370	488	Placebo	ASA indication	YPS859S	11.12.17 11:22	2018-09-01	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	HFC282X	8.3.18 11:02	2020-01-01	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	ZHS762T	5.3.19 11:15	2020-01-01	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	DXH353B	10.3.20 9:57	2021-12-31	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	CWK628C	10.3.21 10:06	2021-12-31	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	HCP951H	10.9.19 9:41	2021-12-31	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	CUT113Z	10.9.20 9:21	2021-12-31	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	VGH237B	5.9.18 10:11	2020-01-01	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	VUP968C	13.9.21 8:39	2024-04-30	Edoxaban 60mg / ASA indication
474	488	Placebo	ASA indication	VUN539B	15.3.22 10:26	2024-04-30	Edoxaban 60mg / ASA indication
1099	488	Placebo	ASA indication	PUT457P	15.10.19 9:06	2022-08-31	Edoxaban 30mg / ASA indication
1099	488	Placebo	ASA indication	MFS672F	27.4.20 7:20	2022-08-31	Edoxaban 30mg / ASA indication
1099	488	Placebo	ASA indication	MXL593W	29.4.19 14:47	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1532	488	Placebo	ASA indication	HXU639G	27.2.20 11:11	2022-08-31	Edoxaban 30mg / ASA indication
1532	488	Placebo	ASA indication	TVW234C	7.9.20 9:20	2022-08-31	Edoxaban 30mg / ASA indication
2318	488	Placebo	ASA indication	AMT934T	22.10.21 10:46	2024-04-30	Edoxaban 60mg / ASA indication
2318	488	Placebo	ASA indication	APZ227M	5.5.22 13:58	2024-04-30	Edoxaban 60mg / ASA indication
5	488	Placebo	no ASA indication	BDU251M	6.1.17 11:34	2018-09-01	Edoxaban 60mg / no ASA indication
5	488	Placebo	no ASA indication	FVY733U	10.1.18 9:36	2018-09-01	Edoxaban 60mg / no ASA indication
5	488	Placebo	no ASA indication	XLW447M	6.7.17 9:53	2018-09-01	Edoxaban 60mg / no ASA indication
5	488	Placebo	no ASA indication	KFY129B	7.7.16 8:01	2018-09-01	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	BAF513G	7.8.17 13:10	2018-09-01	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	BAH222U	6.8.19 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	ANP724G	3.8.21 8:14	2024-04-30	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	ERC139R	6.2.20 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
90	488	Placebo	no ASA indication	YBF266D	3.8.18 9:23	2020-01-01	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	FFM272Z	4.2.21 9:42	2021-12-31	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	RBN454W	5.8.20 9:24	2021-12-31	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	FEY471Y	6.2.17 11:50	2018-09-01	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	ZVW875L	5.2.18 13:40	2018-09-01	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	AMC728W	3.2.22 9:12	2024-04-30	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	APL751T	29.7.22 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
90	488	Placebo	no ASA indication	ZKY396R	5.2.19 11:06	2020-01-01	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	ARB887W	5.4.18 14:51	2020-01-01	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	KYG252W	17.3.20 15:20	2021-12-31	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	UHW912R	2.3.21 15:50	2021-12-31	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	LTG754T	12.10.17 14:41	2018-09-01	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	VWK412M	1.3.22 15:59	2024-04-30	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	HWT592K	10.4.17 9:45	2018-09-01	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	LLW941A	27.9.18 15:09	2020-01-01	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	PTT757E	28.3.19 16:11	2020-01-01	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	AXN442X	26.9.19 15:09	2021-12-31	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	TPX999T	8.9.20 14:46	2021-12-31	Edoxaban 60mg / no ASA indication
134	488	Placebo	no ASA indication	AKY694K	9.9.21 14:49	2024-04-30	Edoxaban 60mg / no ASA indication
357	488	Placebo	no ASA indication	RWL373D	9.12.19 15:08	2022-08-31	Edoxaban 30mg / no ASA indication
357	488	Placebo	no ASA indication	XXU997M	7.6.18 13:33	2020-01-01	Edoxaban 30mg / no ASA indication
357	488	Placebo	no ASA indication	MHF195A	9.6.20 14:11	2022-08-31	Edoxaban 30mg / no ASA indication
357	488	Placebo	no ASA indication	LLW799L	6.6.19 9:50	2020-01-01	Edoxaban 30mg / no ASA indication
357	488	Placebo	no ASA indication	WTD962X	4.12.17 10:44	2018-09-01	Edoxaban 30mg / no ASA indication
357	488	Placebo	no ASA indication	XPF515Y	6.12.18 11:00	2020-01-01	Edoxaban 30mg / no ASA indication
1133	488	Placebo	no ASA indication	KZK428U	17.5.22 9:02	2024-11-30	Edoxaban 30mg / no ASA indication
1133	488	Placebo	no ASA indication	GCK518A	21.5.19 9:15	2020-01-01	Edoxaban 30mg / no ASA indication
1133	488	Placebo	no ASA indication	TNT873C	18.11.19 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
1133	488	Placebo	no ASA indication	BBD865M	18.11.21 10:33	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1133	488	Placebo	no ASA indication	CYB656X	18.5.21 8:56	2022-08-31	Edoxaban 30mg / no ASA indication
1133	488	Placebo	no ASA indication	CTG381T	11.5.20 9:19	2022-08-31	Edoxaban 30mg / no ASA indication
1133	488	Placebo	no ASA indication	UWF689E	9.11.20 10:17	2022-08-31	Edoxaban 30mg / no ASA indication
1250	488	Placebo	no ASA indication	XLF279R	6.8.20 9:04	2021-12-31	Edoxaban 60mg / ASA indication
1250	488	Placebo	no ASA indication	AMH999W	29.7.21 9:24	2024-04-30	Edoxaban 60mg / ASA indication
1250	488	Placebo	no ASA indication	XNT999D	8.8.19 13:36	2021-12-31	Edoxaban 60mg / no ASA indication
1250	488	Placebo	no ASA indication	ZPR334S	3.8.22 7:19	2024-04-30	Edoxaban 60mg / ASA indication
1250	488	Placebo	no ASA indication	NRN148W	3.2.21 9:37	2021-12-31	Edoxaban 60mg / ASA indication
1250	488	Placebo	no ASA indication	ZKZ444X	2.2.22 9:25	2024-04-30	Edoxaban 60mg / ASA indication
1250	488	Placebo	no ASA indication	TPW513V	6.2.20 9:05	2021-12-31	Edoxaban 60mg / ASA indication
1361	488	Placebo	no ASA indication	TWF562B	4.11.19 15:30	2021-12-31	Edoxaban 60mg / no ASA indication
2413	488	Placebo	no ASA indication	TRF761M	6.1.22 10:09	2022-08-31	Edoxaban 30mg / no ASA indication
2413	488	Placebo	no ASA indication	NEV472Z	15.7.22 7:53	2024-11-30	Edoxaban 30mg / no ASA indication
20	488	Edoxaban	ASA indication	GHV698P	12.9.16 15:11	2018-09-01	Edoxaban 30mg / ASA indication
20	488	Edoxaban	ASA indication	NKR235Y	12.9.17 8:38	2018-09-01	Edoxaban 30mg / ASA indication
20	488	Edoxaban	ASA indication	CAN642C	20.3.17 8:09	2018-09-01	Edoxaban 30mg / ASA indication
20	488	Edoxaban	ASA indication	LNP874R	7.9.16 10:48	2018-09-01	Edoxaban 60mg / ASA indication
27	488	Edoxaban	ASA indication	XLZ141F	22.9.17 10:13	2018-09-01	Edoxaban 60mg / ASA indication
27	488	Edoxaban	ASA indication	ANF471E	22.9.16 10:09	2018-09-01	Edoxaban 60mg / ASA indication
27	488	Edoxaban	ASA indication	GAM448E	17.3.17 11:34	2018-09-01	Edoxaban 60mg / ASA indication
27	488	Edoxaban	ASA indication	ETD282Y	19.3.18 11:26	2020-01-01	Edoxaban 60mg / ASA indication
31	488	Edoxaban	ASA indication	VUW183T	25.9.17 8:14	2018-09-01	Edoxaban 30mg / ASA indication
31	488	Edoxaban	ASA indication	CWZ145B	18.9.18 8:50	2020-01-01	Edoxaban 30mg / ASA indication
31	488	Edoxaban	ASA indication	TPU123M	28.3.17 9:25	2018-09-01	Edoxaban 60mg / ASA indication
31	488	Edoxaban	ASA indication	ZGE792N	17.9.19 9:54	2021-12-31	Edoxaban 60mg / ASA indication
31	488	Edoxaban	ASA indication	EYR263C	17.3.20 14:52	2022-08-31	Edoxaban 30mg / ASA indication
31	488	Edoxaban	ASA indication	VDA324H	19.3.18 10:59	2020-01-01	Edoxaban 30mg / ASA indication
31	488	Edoxaban	ASA indication	DMP136Y	29.9.16 11:54	2018-09-01	Edoxaban 60mg / ASA indication
31	488	Edoxaban	ASA indication	WYE553L	18.3.19 10:44	2020-01-01	Edoxaban 60mg / ASA indication
50	488	Edoxaban	ASA indication	SDL834M	21.11.16 13:29	2018-09-01	Edoxaban 60mg / ASA indication
50	488	Edoxaban	ASA indication	PDH989Y	23.11.17 9:17	2018-09-01	Edoxaban 60mg / ASA indication
50	488	Edoxaban	ASA indication	WZU835D	1.6.17 13:36	2018-09-01	Edoxaban 60mg / ASA indication
135	488	Edoxaban	ASA indication	TEW819K	10.10.17 9:22	2018-09-01	Edoxaban 60mg / ASA indication
135	488	Edoxaban	ASA indication	LYB571M	10.4.17 9:36	2018-09-01	Edoxaban 30mg / ASA indication
213	488	Edoxaban	ASA indication	UVP175S	9.1.18 11:06	2018-09-01	Edoxaban 30mg / ASA indication
213	488	Edoxaban	ASA indication	NPN286M	7.7.17 8:15	2018-09-01	Edoxaban 30mg / ASA indication
213	488	Edoxaban	ASA indication	SBN119H	9.7.18 10:23	2020-01-01	Edoxaban 60mg / ASA indication
261	488	Edoxaban	ASA indication	WCV417X	22.8.17 10:34	2018-09-01	Edoxaban 60mg / ASA indication
261	488	Edoxaban	ASA indication	YLA353T	21.2.18 10:00	2020-01-01	Edoxaban 60mg / ASA indication
261	488	Edoxaban	ASA indication	BSR922D	30.8.18 6:58	2020-01-01	Edoxaban 60mg / ASA indication
261	488	Edoxaban	ASA indication	TXD374R	28.2.19 10:36	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
261	488	Edoxaban	ASA indication	EDB947M	26.8.19 8:27	2021-12-31	Edoxaban 60mg / no ASA indication
280	488	Edoxaban	ASA indication	XWP883K	19.9.17 10:59	2018-09-01	Edoxaban 60mg / ASA indication
318	488	Edoxaban	ASA indication	NLM733U	21.10.19 9:32	2022-08-31	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	LNY915A	20.4.20 9:27	2022-08-31	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	PUH423V	1.11.21 10:36	2022-08-31	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	ACP131P	26.4.21 9:36	2022-08-31	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	TEV979S	23.4.18 14:20	2020-01-01	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	YBV828K	26.10.17 13:22	2018-09-01	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	FVB224L	23.4.18 13:23	2020-01-01	Edoxaban 30mg / no ASA indication
318	488	Edoxaban	ASA indication	WLE118W	22.10.18 10:15	2020-01-01	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	HDW142K	29.4.19 9:23	2020-01-01	Edoxaban 30mg / ASA indication
318	488	Edoxaban	ASA indication	KVC943M	26.10.20 10:19	2022-08-31	Edoxaban 30mg / ASA indication
343	488	Edoxaban	ASA indication	LFT641P	8.5.19 9:14	2020-01-01	Edoxaban 60mg / ASA indication
343	488	Edoxaban	ASA indication	XNA365G	4.11.20 10:15	2021-12-31	Edoxaban 60mg / ASA indication
343	488	Edoxaban	ASA indication	LXA723V	7.11.18 11:37	2020-01-01	Edoxaban 60mg / ASA indication
343	488	Edoxaban	ASA indication	TYN438F	12.5.20 9:14	2021-12-31	Edoxaban 60mg / ASA indication
343	488	Edoxaban	ASA indication	NEX531H	20.11.17 16:10	2018-09-01	Edoxaban 60mg / ASA indication
343	488	Edoxaban	ASA indication	HGW731C	12.11.19 10:58	2021-12-31	Edoxaban 60mg / ASA indication
343	488	Edoxaban	ASA indication	NKU468Y	7.5.18 14:19	2020-01-01	Edoxaban 60mg / ASA indication
390	488	Edoxaban	ASA indication	CFR969D	9.1.18 8:52	2018-09-01	Edoxaban 60mg / ASA indication
810	488	Edoxaban	ASA indication	CVM222P	12.11.18 8:25	2020-01-01	Edoxaban 60mg / ASA indication
810	488	Edoxaban	ASA indication	EGP688Y	6.11.20 9:34	2021-12-31	Edoxaban 60mg / ASA indication
810	488	Edoxaban	ASA indication	YVP338D	20.5.19 8:11	2020-01-01	Edoxaban 60mg / ASA indication
810	488	Edoxaban	ASA indication	KZV669X	19.5.20 9:19	2021-12-31	Edoxaban 60mg / ASA indication
810	488	Edoxaban	ASA indication	CVL882W	19.11.19 10:08	2021-12-31	Edoxaban 60mg / ASA indication
1244	488	Edoxaban	ASA indication	VGW487T	4.2.20 10:01	2021-12-31	Edoxaban 60mg / ASA indication
1244	488	Edoxaban	ASA indication	VXF872M	24.1.22 10:28	2024-04-30	Edoxaban 60mg / no ASA indication
1244	488	Edoxaban	ASA indication	WXA633L	6.8.19 15:27	2021-12-31	Edoxaban 60mg / ASA indication
1244	488	Edoxaban	ASA indication	ARZ213K	26.7.21 9:14	2024-04-30	Edoxaban 60mg / no ASA indication
1244	488	Edoxaban	ASA indication	LSG299N	28.1.21 9:22	2021-12-31	Edoxaban 60mg / ASA indication
1244	488	Edoxaban	ASA indication	WTM243R	4.8.20 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1824	488	Edoxaban	ASA indication	UFS958T	22.4.21 9:12	2022-08-31	Edoxaban 30mg / ASA indication
1824	488	Edoxaban	ASA indication	KFM395H	22.4.22 8:25	2024-11-30	Edoxaban 30mg / ASA indication
1824	488	Edoxaban	ASA indication	GMB352W	13.10.20 13:25	2021-12-31	Edoxaban 60mg / ASA indication
1824	488	Edoxaban	ASA indication	ZUP295Y	21.10.21 9:28	2022-08-31	Edoxaban 30mg / ASA indication
25	488	Edoxaban	no ASA indication	URG171K	19.9.16 7:45	2018-09-01	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	ETN623K	19.9.17 7:40	2018-09-01	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	URG548C	9.9.20 9:25	2021-12-31	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	ATB783E	10.9.21 9:29	2024-04-30	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	HWP439Z	19.3.18 9:27	2020-01-01	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	DBH133K	10.9.18 8:15	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
25	488	Edoxaban	no ASA indication	WZR958U	15.3.17 11:23	2018-09-01	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	FXX618G	9.9.19 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	MND966F	9.3.20 10:28	2021-12-31	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	TXW587A	14.3.19 10:40	2020-01-01	Edoxaban 60mg / no ASA indication
25	488	Edoxaban	no ASA indication	KDP218U	9.3.21 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
42	488	Edoxaban	no ASA indication	SLG581C	15.5.17 7:16	2018-09-01	Edoxaban 60mg / no ASA indication
42	488	Edoxaban	no ASA indication	DLS182K	1.11.16 14:49	2018-09-01	Edoxaban 60mg / no ASA indication
42	488	Edoxaban	no ASA indication	XBA865Y	9.11.17 8:15	2018-09-01	Edoxaban 60mg / no ASA indication
42	488	Edoxaban	no ASA indication	PZN454Z	8.5.18 6:48	2020-01-01	Edoxaban 30mg / no ASA indication
121	488	Edoxaban	no ASA indication	PGN764P	23.3.17 10:57	2018-09-01	Edoxaban 30mg / no ASA indication
121	488	Edoxaban	no ASA indication	DAM672M	25.9.18 15:03	2020-01-01	Edoxaban 30mg / no ASA indication
121	488	Edoxaban	no ASA indication	BEF389U	4.10.17 13:58	2018-09-01	Edoxaban 30mg / no ASA indication
121	488	Edoxaban	no ASA indication	ABK837Y	22.3.18 10:21	2020-01-01	Edoxaban 30mg / no ASA indication
139	488	Edoxaban	no ASA indication	TCX291K	25.4.17 9:15	2018-09-01	Edoxaban 30mg / no ASA indication
766	488	Edoxaban	no ASA indication	DTG291B	23.10.18 15:23	2020-01-01	Edoxaban 60mg / no ASA indication
898	488	Edoxaban	no ASA indication	GDT714X	10.12.19 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
898	488	Edoxaban	no ASA indication	LWF628Y	11.6.19 8:42	2020-01-01	Edoxaban 30mg / no ASA indication
898	488	Edoxaban	no ASA indication	XWX596N	18.12.18 11:02	2020-01-01	Edoxaban 30mg / no ASA indication
898	488	Edoxaban	no ASA indication	SVB655B	9.6.20 8:13	2022-08-31	Edoxaban 30mg / no ASA indication
1586	488	Edoxaban	no ASA indication	AHD161Z	11.5.21 14:44	2022-08-31	Edoxaban 30mg / no ASA indication
1586	488	Edoxaban	no ASA indication	PFL595F	12.11.20 15:51	2022-08-31	Edoxaban 30mg / no ASA indication
1586	488	Edoxaban	no ASA indication	CNY316L	16.11.21 15:57	2022-08-31	Edoxaban 30mg / no ASA indication
1586	488	Edoxaban	no ASA indication	RZE731B	14.5.20 15:22	2022-08-31	Edoxaban 30mg / no ASA indication
1586	488	Edoxaban	no ASA indication	PAM744S	10.5.22 9:07	2024-11-30	Edoxaban 30mg / no ASA indication
1942	488	Edoxaban	no ASA indication	NBX166E	1.2.22 15:44	2024-11-30	Edoxaban 30mg / no ASA indication
1942	488	Edoxaban	no ASA indication	YNS779N	2.8.22 8:36	2024-04-30	Edoxaban 60mg / no ASA indication
1942	488	Edoxaban	no ASA indication	XEL252K	28.7.21 8:04	2022-08-31	Edoxaban 30mg / no ASA indication
1942	488	Edoxaban	no ASA indication	ZDM738H	1.2.21 9:09	2022-08-31	Edoxaban 30mg / no ASA indication
2372	488	Edoxaban	no ASA indication	ARZ773Y	2.12.21 16:39	2024-04-30	Edoxaban 60mg / no ASA indication
334	502	Placebo	ASA indication	RDE393B	10.11.17 11:15	2018-09-01	Edoxaban 60mg / ASA indication
835	502	Placebo	ASA indication	EAP596V	21.5.19 9:59	2020-01-01	Edoxaban 30mg / no ASA indication
835	502	Placebo	ASA indication	LWH471M	21.11.18 11:13	2020-01-01	Edoxaban 60mg / ASA indication
1282	502	Placebo	ASA indication	ADM991Z	12.3.20 13:36	2021-12-31	Edoxaban 60mg / ASA indication
1282	502	Placebo	ASA indication	MEU261R	12.9.19 11:40	2021-12-31	Edoxaban 60mg / ASA indication
1282	502	Placebo	ASA indication	LRZ165V	15.3.21 13:10	2021-12-31	Edoxaban 60mg / ASA indication
1282	502	Placebo	ASA indication	XEH227X	14.9.20 11:51	2021-12-31	Edoxaban 60mg / no ASA indication
1283	502	Placebo	ASA indication	WLS343K	12.9.19 12:06	2021-12-31	Edoxaban 60mg / ASA indication
1283	502	Placebo	ASA indication	EWL289M	12.3.20 14:09	2021-12-31	Edoxaban 60mg / ASA indication
1535	502	Placebo	ASA indication	ZZP917S	2.3.20 10:18	2021-12-31	Edoxaban 60mg / ASA indication
1585	502	Placebo	ASA indication	KSE932H	12.5.20 11:38	2021-12-31	Edoxaban 60mg / ASA indication
198	502	Placebo	no ASA indication	RNF643C	21.6.17 13:17	2018-09-01	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
270	502	Placebo	no ASA indication	XAA835M	5.9.17 11:33	2018-09-01	Edoxaban 30mg / no ASA indication
309	502	Placebo	no ASA indication	XYW841P	12.4.18 12:26	2020-01-01	Edoxaban 60mg / no ASA indication
309	502	Placebo	no ASA indication	ZPE872T	20.10.17 11:45	2018-09-01	Edoxaban 60mg / no ASA indication
602	502	Placebo	no ASA indication	GZL188R	21.6.18 11:18	2020-01-01	Edoxaban 60mg / no ASA indication
166	502	Edoxaban	ASA indication	VPY684H	19.5.17 11:53	2018-09-01	Edoxaban 30mg / ASA indication
195	502	Edoxaban	ASA indication	YHX535P	16.6.17 10:30	2018-09-01	Edoxaban 60mg / ASA indication
1200	502	Edoxaban	ASA indication	BUF696T	17.12.20 10:02	2021-12-31	Edoxaban 60mg / ASA indication
1200	502	Edoxaban	ASA indication	SSS551G	20.6.22 8:16	2024-04-30	Edoxaban 60mg / ASA indication
1200	502	Edoxaban	ASA indication	TAK688K	14.12.21 13:50	2024-04-30	Edoxaban 60mg / ASA indication
1200	502	Edoxaban	ASA indication	LFB656H	24.6.19 13:27	2021-12-31	Edoxaban 60mg / ASA indication
1200	502	Edoxaban	ASA indication	CKW748G	14.1.20 8:33	2021-12-31	Edoxaban 60mg / no ASA indication
1200	502	Edoxaban	ASA indication	CSC377W	14.6.21 12:07	2021-12-31	Edoxaban 60mg / ASA indication
1200	502	Edoxaban	ASA indication	NNA563C	3.7.20 8:49	2021-12-31	Edoxaban 60mg / ASA indication
1440	502	Edoxaban	ASA indication	BEH195H	9.6.20 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
1440	502	Edoxaban	ASA indication	HCT353L	8.12.20 13:24	2021-12-31	Edoxaban 60mg / no ASA indication
1440	502	Edoxaban	ASA indication	SUR839W	9.12.21 13:35	2024-04-30	Edoxaban 60mg / no ASA indication
1440	502	Edoxaban	ASA indication	LZZ531L	13.6.22 9:42	2024-04-30	Edoxaban 60mg / no ASA indication
1440	502	Edoxaban	ASA indication	VGM589T	9.6.21 10:34	2021-12-31	Edoxaban 60mg / no ASA indication
1440	502	Edoxaban	ASA indication	GTG898Z	9.12.19 14:39	2021-12-31	Edoxaban 60mg / ASA indication
1556	502	Edoxaban	ASA indication	RTG977N	3.3.21 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1556	502	Edoxaban	ASA indication	HHF472K	10.3.22 9:30	2024-04-30	Edoxaban 60mg / ASA indication
1556	502	Edoxaban	ASA indication	VDS991A	12.3.20 11:38	2021-12-31	Edoxaban 60mg / ASA indication
1556	502	Edoxaban	ASA indication	SZS677P	10.9.21 6:51	2024-04-30	Edoxaban 60mg / ASA indication
1556	502	Edoxaban	ASA indication	BUG692M	9.9.20 11:04	2021-12-31	Edoxaban 60mg / ASA indication
2081	502	Edoxaban	ASA indication	RPM128E	3.5.21 10:25	2021-12-31	Edoxaban 60mg / ASA indication
2496	502	Edoxaban	ASA indication	HKW127C	23.2.22 13:31	2024-04-30	Edoxaban 60mg / ASA indication
102	502	Edoxaban	no ASA indication	EBH782W	5.9.17 12:45	2018-09-01	Edoxaban 60mg / no ASA indication
102	502	Edoxaban	no ASA indication	DYT892C	28.2.17 14:22	2018-09-01	Edoxaban 60mg / no ASA indication
102	502	Edoxaban	no ASA indication	RGL828X	6.9.18 12:01	2020-01-01	Edoxaban 60mg / no ASA indication
102	502	Edoxaban	no ASA indication	MWX259C	6.3.18 13:12	2020-01-01	Edoxaban 60mg / no ASA indication
133	502	Edoxaban	no ASA indication	MZY666Y	5.10.17 9:37	2018-09-01	Edoxaban 60mg / no ASA indication
133	502	Edoxaban	no ASA indication	VMR346B	5.4.17 9:56	2018-09-01	Edoxaban 60mg / no ASA indication
227	502	Edoxaban	no ASA indication	UKV888X	18.7.18 12:42	2020-01-01	Edoxaban 30mg / no ASA indication
227	502	Edoxaban	no ASA indication	VNC186N	17.1.18 13:05	2018-09-01	Edoxaban 30mg / no ASA indication
227	502	Edoxaban	no ASA indication	LXS637W	30.7.20 10:18	2022-08-31	Edoxaban 30mg / no ASA indication
227	502	Edoxaban	no ASA indication	SHP432F	31.1.19 12:37	2020-01-01	Edoxaban 30mg / no ASA indication
227	502	Edoxaban	no ASA indication	BEY831P	18.7.17 14:51	2018-09-01	Edoxaban 60mg / no ASA indication
227	502	Edoxaban	no ASA indication	LUH783A	22.7.21 10:42	2022-08-31	Edoxaban 30mg / ASA indication
227	502	Edoxaban	no ASA indication	ZXH878A	31.7.19 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
227	502	Edoxaban	no ASA indication	PDA256E	30.1.20 10:45	2022-08-31	Edoxaban 30mg / no ASA indication
425	502	Edoxaban	no ASA indication	DLV517H	1.2.18 10:52	2018-09-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1782	502	Edoxaban	no ASA indication	SYM311B	16.9.20 14:25	2022-08-31	Edoxaban 30mg / no ASA indication
164	514	Placebo	no ASA indication	GAM383C	5.6.19 8:47	2020-01-01	Edoxaban 60mg / no ASA indication
164	514	Placebo	no ASA indication	FWN253N	3.12.18 8:07	2020-01-01	Edoxaban 60mg / no ASA indication
164	514	Placebo	no ASA indication	PKH665E	18.5.21 11:35	2022-08-31	Edoxaban 30mg / no ASA indication
164	514	Placebo	no ASA indication	XHA296E	20.11.17 10:00	2018-09-01	Edoxaban 30mg / no ASA indication
164	514	Placebo	no ASA indication	XHF639M	30.5.22 10:20	2024-11-30	Edoxaban 30mg / no ASA indication
164	514	Placebo	no ASA indication	WTA353M	4.6.18 6:30	2020-01-01	Edoxaban 60mg / no ASA indication
164	514	Placebo	no ASA indication	FLS733L	18.5.17 11:10	2018-09-01	Edoxaban 30mg / no ASA indication
164	514	Placebo	no ASA indication	SVR874B	16.11.21 8:23	2024-04-30	Edoxaban 60mg / no ASA indication
164	514	Placebo	no ASA indication	VCE447F	26.11.20 8:23	2021-12-31	Edoxaban 60mg / no ASA indication
164	514	Placebo	no ASA indication	DWS355V	11.12.19 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
164	514	Placebo	no ASA indication	CDZ164U	16.6.20 7:05	2021-12-31	Edoxaban 60mg / no ASA indication
456	514	Edoxaban	ASA indication	WDR982V	22.2.18 13:16	2020-01-01	Edoxaban 60mg / ASA indication
456	514	Edoxaban	ASA indication	VGA365M	23.8.18 12:51	2020-01-01	Edoxaban 60mg / no ASA indication
456	514	Edoxaban	ASA indication	HFH515B	28.2.19 13:20	2020-01-01	Edoxaban 60mg / no ASA indication
2370	519	Edoxaban	ASA indication	XXT933Y	29.11.21 11:49	2024-04-30	Edoxaban 60mg / ASA indication
2370	519	Edoxaban	ASA indication	XAR588Z	1.6.22 12:06	2024-04-30	Edoxaban 60mg / no ASA indication
2577	519	Edoxaban	ASA indication	YCS144H	7.4.22 7:55	2024-04-30	Edoxaban 60mg / ASA indication
2400	519	Edoxaban	no ASA indication	XAR572W	20.12.21 10:18	2024-04-30	Edoxaban 60mg / no ASA indication
2400	519	Edoxaban	no ASA indication	KRW327H	22.6.22 13:04	2024-04-30	Edoxaban 60mg / no ASA indication
255	529	Placebo	ASA indication	LLY312E	7.8.18 9:39	2020-01-01	Edoxaban 60mg / no ASA indication
255	529	Placebo	ASA indication	DWH335U	17.8.17 7:34	2018-09-01	Edoxaban 60mg / ASA indication
255	529	Placebo	ASA indication	HVK546Z	2.2.18 9:53	2018-09-01	Edoxaban 60mg / no ASA indication
489	529	Placebo	ASA indication	APC946M	18.9.18 8:46	2020-01-01	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	LWZ865R	28.10.21 6:47	2022-08-31	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	DHW686G	6.4.20 10:13	2022-08-31	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	WAM843R	25.3.19 10:59	2020-01-01	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	VGY991T	19.3.18 10:45	2020-01-01	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	SBN823S	5.4.22 8:59	2024-11-30	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	DSB596V	13.10.20 10:35	2022-08-31	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	KFC489E	1.10.19 9:30	2022-08-31	Edoxaban 30mg / ASA indication
489	529	Placebo	ASA indication	SCE887U	15.4.21 9:43	2022-08-31	Edoxaban 30mg / ASA indication
1072	529	Placebo	ASA indication	CPV342P	23.10.20 9:05	2021-12-31	Edoxaban 60mg / ASA indication
1072	529	Placebo	ASA indication	WYW159F	10.4.19 9:50	2020-01-01	Edoxaban 60mg / ASA indication
1072	529	Placebo	ASA indication	RNM659R	16.10.19 11:59	2021-12-31	Edoxaban 60mg / ASA indication
1072	529	Placebo	ASA indication	SFB251H	13.4.22 11:11	2024-11-30	Edoxaban 30mg / ASA indication
1072	529	Placebo	ASA indication	SDK592B	16.4.20 9:31	2021-12-31	Edoxaban 60mg / ASA indication
1072	529	Placebo	ASA indication	RAK763K	30.4.21 10:46	2021-12-31	Edoxaban 60mg / ASA indication
1072	529	Placebo	ASA indication	WFD732X	22.10.21 12:15	2024-04-30	Edoxaban 60mg / ASA indication
1254	529	Placebo	ASA indication	TLV563G	19.8.19 10:58	2022-08-31	Edoxaban 30mg / ASA indication
1399	529	Placebo	ASA indication	RSP843N	19.11.19 10:37	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1399	529	Placebo	ASA indication	FGH888B	21.5.20 12:30	2022-08-31	Edoxaban 30mg / ASA indication
1515	529	Placebo	ASA indication	RKV966D	10.2.21 11:51	2022-08-31	Edoxaban 30mg / no ASA indication
1515	529	Placebo	ASA indication	FMY758A	19.8.21 10:08	2024-04-30	Edoxaban 60mg / ASA indication
1515	529	Placebo	ASA indication	KLM176N	6.8.20 7:52	2022-08-31	Edoxaban 30mg / ASA indication
1515	529	Placebo	ASA indication	WZE332E	11.2.20 11:23	2022-08-31	Edoxaban 30mg / ASA indication
1515	529	Placebo	ASA indication	FBR782B	23.8.22 8:48	2024-04-30	Edoxaban 60mg / no ASA indication
1515	529	Placebo	ASA indication	LTA151M	24.2.22 8:37	2024-04-30	Edoxaban 60mg / no ASA indication
1550	529	Placebo	ASA indication	ALZ224E	10.2.21 12:38	2021-12-31	Edoxaban 60mg / ASA indication
1550	529	Placebo	ASA indication	UAL742Z	6.9.22 8:20	2024-04-30	Edoxaban 60mg / ASA indication
1550	529	Placebo	ASA indication	ZPK318K	24.2.22 10:08	2024-04-30	Edoxaban 60mg / ASA indication
1550	529	Placebo	ASA indication	CLY427A	10.3.20 11:13	2021-12-31	Edoxaban 60mg / ASA indication
1550	529	Placebo	ASA indication	FNC517U	25.8.21 9:42	2024-04-30	Edoxaban 60mg / ASA indication
1550	529	Placebo	ASA indication	MRE375S	6.8.20 9:21	2021-12-31	Edoxaban 60mg / ASA indication
1594	529	Placebo	ASA indication	SKC637L	25.5.22 8:05	2024-11-30	Edoxaban 30mg / ASA indication
1594	529	Placebo	ASA indication	TLB385E	26.11.20 10:41	2022-08-31	Edoxaban 30mg / ASA indication
1594	529	Placebo	ASA indication	RYD466E	20.5.20 9:55	2022-08-31	Edoxaban 30mg / ASA indication
1594	529	Placebo	ASA indication	ZTZ468X	24.11.21 11:37	2022-08-31	Edoxaban 30mg / ASA indication
1594	529	Placebo	ASA indication	KMK566L	13.5.21 10:03	2022-08-31	Edoxaban 30mg / ASA indication
1852	529	Placebo	ASA indication	GNN531N	5.11.20 11:09	2022-08-31	Edoxaban 30mg / ASA indication
1852	529	Placebo	ASA indication	ZDY957K	8.11.21 8:45	2022-08-31	Edoxaban 30mg / ASA indication
1852	529	Placebo	ASA indication	NRA377H	28.3.22 8:39	2024-11-30	Edoxaban 30mg / ASA indication
1852	529	Placebo	ASA indication	WNA436D	28.4.21 7:19	2022-08-31	Edoxaban 30mg / ASA indication
1924	529	Placebo	ASA indication	TSA972A	12.1.21 11:11	2021-12-31	Edoxaban 60mg / ASA indication
2113	529	Placebo	ASA indication	VKZ472B	1.12.21 11:54	2024-04-30	Edoxaban 60mg / ASA indication
2113	529	Placebo	ASA indication	FNV471L	25.5.22 8:58	2024-04-30	Edoxaban 60mg / ASA indication
2113	529	Placebo	ASA indication	DNT612U	20.5.21 10:13	2021-12-31	Edoxaban 60mg / ASA indication
2220	529	Placebo	ASA indication	LUA719E	11.8.21 10:15	2022-08-31	Edoxaban 30mg / ASA indication
2220	529	Placebo	ASA indication	AUH695S	24.2.22 11:53	2024-11-30	Edoxaban 30mg / ASA indication
2220	529	Placebo	ASA indication	TZV324V	23.8.22 11:36	2024-11-30	Edoxaban 30mg / ASA indication
2334	529	Placebo	ASA indication	WGB822B	9.11.21 11:10	2024-04-30	Edoxaban 60mg / ASA indication
2545	529	Placebo	ASA indication	AUW533B	21.3.22 10:38	2024-11-30	Edoxaban 30mg / ASA indication
2555	529	Placebo	ASA indication	RAR214E	23.3.22 10:34	2024-11-30	Edoxaban 30mg / ASA indication
2644	529	Placebo	ASA indication	SKW397A	8.6.22 9:18	2024-11-30	Edoxaban 30mg / ASA indication
659	529	Placebo	no ASA indication	FEU381P	18.2.19 10:35	2020-01-01	Edoxaban 60mg / no ASA indication
659	529	Placebo	no ASA indication	XKL837N	9.8.18 9:27	2020-01-01	Edoxaban 60mg / no ASA indication
712	529	Placebo	no ASA indication	YES697H	19.9.18 10:08	2020-01-01	Edoxaban 30mg / no ASA indication
1068	529	Placebo	no ASA indication	RCN645D	14.4.20 9:56	2021-12-31	Edoxaban 60mg / no ASA indication
1068	529	Placebo	no ASA indication	VPP556L	31.5.22 6:47	2024-04-30	Edoxaban 60mg / no ASA indication
1068	529	Placebo	no ASA indication	TBP651X	19.10.20 7:55	2021-12-31	Edoxaban 60mg / no ASA indication
1068	529	Placebo	no ASA indication	YBX273W	1.12.21 8:20	2024-04-30	Edoxaban 60mg / no ASA indication
1068	529	Placebo	no ASA indication	WXM718L	9.4.19 10:14	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1068	529	Placebo	no ASA indication	EYX796G	15.10.19 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1068	529	Placebo	no ASA indication	XHX985C	27.5.21 11:23	2021-12-31	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	FRV715K	21.11.19 11:18	2021-12-31	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	XTP267H	3.6.20 9:35	2021-12-31	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	EUP325H	15.12.21 12:37	2024-04-30	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	FGL259B	4.7.22 9:18	2024-04-30	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	EUB722Z	15.6.21 12:26	2024-04-30	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	HEZ418T	14.12.20 10:33	2021-12-31	Edoxaban 60mg / no ASA indication
1121	529	Placebo	no ASA indication	XFX671B	13.5.19 10:10	2020-01-01	Edoxaban 60mg / no ASA indication
1199	529	Placebo	no ASA indication	SBN844R	24.6.19 11:57	2021-12-31	Edoxaban 60mg / no ASA indication
1199	529	Placebo	no ASA indication	ETP595E	16.6.21 10:05	2024-04-30	Edoxaban 60mg / no ASA indication
1199	529	Placebo	no ASA indication	TFH826E	2.7.20 8:33	2021-12-31	Edoxaban 60mg / no ASA indication
1199	529	Placebo	no ASA indication	KSS468X	14.12.20 11:20	2021-12-31	Edoxaban 60mg / no ASA indication
1199	529	Placebo	no ASA indication	PAM897B	19.12.19 11:11	2021-12-31	Edoxaban 60mg / no ASA indication
1199	529	Placebo	no ASA indication	DXW335V	14.1.22 8:22	2024-04-30	Edoxaban 60mg / no ASA indication
1354	529	Placebo	no ASA indication	KRA781G	23.4.20 8:44	2021-12-31	Edoxaban 60mg / no ASA indication
1354	529	Placebo	no ASA indication	WRS752W	25.5.22 7:43	2024-04-30	Edoxaban 60mg / no ASA indication
1354	529	Placebo	no ASA indication	CKZ658F	6.11.20 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
1354	529	Placebo	no ASA indication	YCC499C	18.11.21 10:27	2024-04-30	Edoxaban 60mg / no ASA indication
1354	529	Placebo	no ASA indication	VRH524B	28.10.19 10:26	2021-12-31	Edoxaban 60mg / no ASA indication
1354	529	Placebo	no ASA indication	SZZ369K	13.5.21 7:15	2021-12-31	Edoxaban 60mg / no ASA indication
1632	529	Placebo	no ASA indication	HNL984V	15.12.21 11:45	2022-08-31	Edoxaban 30mg / no ASA indication
1632	529	Placebo	no ASA indication	PXX113L	28.6.22 7:13	2024-11-30	Edoxaban 30mg / no ASA indication
1632	529	Placebo	no ASA indication	KBT136V	14.12.20 11:41	2022-08-31	Edoxaban 30mg / no ASA indication
1632	529	Placebo	no ASA indication	DSL896B	15.6.20 9:44	2022-08-31	Edoxaban 30mg / no ASA indication
1632	529	Placebo	no ASA indication	RHD441A	21.6.21 9:44	2022-08-31	Edoxaban 30mg / no ASA indication
1635	529	Placebo	no ASA indication	TTB923N	16.6.20 10:03	2022-08-31	Edoxaban 30mg / no ASA indication
1635	529	Placebo	no ASA indication	AYP196G	14.12.20 12:48	2022-08-31	Edoxaban 30mg / no ASA indication
1745	529	Placebo	no ASA indication	UTS968B	24.2.21 11:59	2022-08-31	Edoxaban 30mg / no ASA indication
1745	529	Placebo	no ASA indication	AZK225E	28.2.22 9:38	2024-11-30	Edoxaban 30mg / no ASA indication
1745	529	Placebo	no ASA indication	UCX276B	29.8.22 10:08	2024-11-30	Edoxaban 30mg / no ASA indication
1745	529	Placebo	no ASA indication	VES555K	26.8.21 11:02	2024-04-30	Edoxaban 60mg / no ASA indication
1745	529	Placebo	no ASA indication	AWS429K	25.8.20 10:28	2022-08-31	Edoxaban 30mg / no ASA indication
1780	529	Placebo	no ASA indication	KKP581H	25.3.21 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
1780	529	Placebo	no ASA indication	DBL644M	16.9.20 10:03	2021-12-31	Edoxaban 60mg / no ASA indication
1780	529	Placebo	no ASA indication	XAW552F	1.10.21 9:29	2024-04-30	Edoxaban 60mg / no ASA indication
1780	529	Placebo	no ASA indication	RSG448W	23.3.22 9:28	2024-04-30	Edoxaban 60mg / no ASA indication
1813	529	Placebo	no ASA indication	KKC331S	22.4.21 10:53	2021-12-31	Edoxaban 60mg / no ASA indication
1813	529	Placebo	no ASA indication	ANL652S	5.10.20 10:09	2021-12-31	Edoxaban 60mg / no ASA indication
1848	529	Placebo	no ASA indication	CEE415G	4.11.20 10:59	2021-12-31	Edoxaban 60mg / no ASA indication
1848	529	Placebo	no ASA indication	KDL839C	13.5.21 11:23	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1848	529	Placebo	no ASA indication	KDL167C	18.11.21 12:22	2022-08-31	Edoxaban 30mg / no ASA indication
1965	529	Placebo	no ASA indication	XSM128E	18.2.21 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
1965	529	Placebo	no ASA indication	WLX842X	6.9.21 9:04	2024-04-30	Edoxaban 60mg / no ASA indication
1965	529	Placebo	no ASA indication	NWE679Z	30.3.22 9:26	2024-11-30	Edoxaban 30mg / no ASA indication
1965	529	Placebo	no ASA indication	AUG951G	23.8.22 9:39	2024-04-30	Edoxaban 60mg / no ASA indication
2011	529	Placebo	no ASA indication	XCR867E	21.9.21 11:03	2024-04-30	Edoxaban 60mg / no ASA indication
2011	529	Placebo	no ASA indication	LVB693Y	5.4.22 10:38	2024-04-30	Edoxaban 60mg / no ASA indication
2011	529	Placebo	no ASA indication	XSR736X	16.3.21 10:59	2021-12-31	Edoxaban 60mg / no ASA indication
2104	529	Placebo	no ASA indication	BCK366M	10.6.22 8:04	2024-04-30	Edoxaban 60mg / no ASA indication
2104	529	Placebo	no ASA indication	TDX987B	17.5.21 11:27	2021-12-31	Edoxaban 60mg / no ASA indication
2104	529	Placebo	no ASA indication	XCT551P	19.11.21 10:48	2024-04-30	Edoxaban 60mg / no ASA indication
2118	529	Placebo	no ASA indication	XGM535N	25.5.21 9:52	2021-12-31	Edoxaban 60mg / no ASA indication
2118	529	Placebo	no ASA indication	DYK882C	1.12.21 10:38	2024-04-30	Edoxaban 60mg / no ASA indication
2118	529	Placebo	no ASA indication	WSS596V	31.5.22 8:16	2024-04-30	Edoxaban 60mg / no ASA indication
2229	529	Placebo	no ASA indication	VEL346D	17.8.21 9:53	2024-04-30	Edoxaban 60mg / no ASA indication
2229	529	Placebo	no ASA indication	EMF615L	24.2.22 12:51	2024-04-30	Edoxaban 60mg / no ASA indication
2229	529	Placebo	no ASA indication	PWA339Y	30.8.22 9:56	2024-11-30	Edoxaban 30mg / no ASA indication
2256	529	Placebo	no ASA indication	ERR865Z	6.9.21 10:10	2024-04-30	Edoxaban 60mg / no ASA indication
2256	529	Placebo	no ASA indication	RXZ573C	30.3.22 9:56	2024-04-30	Edoxaban 60mg / no ASA indication
2258	529	Placebo	no ASA indication	NZT361L	7.9.21 10:26	2022-08-31	Edoxaban 30mg / no ASA indication
2258	529	Placebo	no ASA indication	BAB223L	22.3.22 10:09	2024-11-30	Edoxaban 30mg / no ASA indication
2647	529	Placebo	no ASA indication	AXB891P	9.6.22 14:31	2024-04-30	Edoxaban 60mg / no ASA indication
2662	529	Placebo	no ASA indication	PXZ481C	21.6.22 10:05	2024-11-30	Edoxaban 30mg / no ASA indication
658	529	Edoxaban	ASA indication	FWR565G	8.8.18 10:00	2020-01-01	Edoxaban 60mg / ASA indication
703	529	Edoxaban	ASA indication	HVD227K	2.4.20 20:44	2022-08-31	Edoxaban 30mg / ASA indication
703	529	Edoxaban	ASA indication	KLA356H	29.9.21 7:33	2022-08-31	Edoxaban 30mg / ASA indication
703	529	Edoxaban	ASA indication	GME576U	30.3.21 9:41	2022-08-31	Edoxaban 30mg / ASA indication
703	529	Edoxaban	ASA indication	SGZ611E	12.9.18 9:23	2020-01-01	Edoxaban 60mg / ASA indication
703	529	Edoxaban	ASA indication	SNB952B	18.3.19 9:06	2020-01-01	Edoxaban 30mg / ASA indication
703	529	Edoxaban	ASA indication	VGR656M	16.10.20 9:25	2022-08-31	Edoxaban 30mg / ASA indication
703	529	Edoxaban	ASA indication	YXB323T	26.9.19 13:02	2022-08-31	Edoxaban 30mg / ASA indication
1006	529	Edoxaban	ASA indication	KUM159K	27.2.19 10:46	2020-01-01	Edoxaban 30mg / ASA indication
1083	529	Edoxaban	ASA indication	DNN216Y	23.10.19 9:09	2021-12-31	Edoxaban 60mg / ASA indication
1083	529	Edoxaban	ASA indication	UKH718B	23.4.20 7:58	2021-12-31	Edoxaban 60mg / ASA indication
1083	529	Edoxaban	ASA indication	SXB731D	16.4.19 9:44	2020-01-01	Edoxaban 60mg / ASA indication
1083	529	Edoxaban	ASA indication	HKK948E	23.10.20 8:44	2021-12-31	Edoxaban 60mg / ASA indication
1201	529	Edoxaban	ASA indication	BMK571B	25.6.19 9:59	2021-12-31	Edoxaban 60mg / ASA indication
1234	529	Edoxaban	ASA indication	TZK679D	17.2.20 12:34	2021-12-31	Edoxaban 60mg / ASA indication
1234	529	Edoxaban	ASA indication	FPD529W	19.8.20 9:37	2021-12-31	Edoxaban 60mg / ASA indication
1234	529	Edoxaban	ASA indication	LTL938N	29.7.19 10:09	2021-12-31	Edoxaban 60mg / ASA indication
1595	529	Edoxaban	ASA indication	BFB524V	23.5.22 9:37	2024-11-30	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1595	529	Edoxaban	ASA indication	NTK694N	26.11.20 13:08	2021-12-31	Edoxaban 60mg / ASA indication
1595	529	Edoxaban	ASA indication	DPX135Y	21.5.20 10:05	2021-12-31	Edoxaban 60mg / ASA indication
1595	529	Edoxaban	ASA indication	GGM989S	13.5.21 11:02	2021-12-31	Edoxaban 60mg / ASA indication
1595	529	Edoxaban	ASA indication	FCW314S	18.11.21 11:47	2024-04-30	Edoxaban 60mg / ASA indication
1689	529	Edoxaban	ASA indication	VXG818R	28.7.21 9:58	2024-04-30	Edoxaban 60mg / ASA indication
1689	529	Edoxaban	ASA indication	GPX311B	15.7.20 8:20	2022-08-31	Edoxaban 30mg / ASA indication
1689	529	Edoxaban	ASA indication	NTW113X	27.1.21 10:24	2022-08-31	Edoxaban 30mg / ASA indication
1689	529	Edoxaban	ASA indication	WCV817M	9.2.22 10:24	2024-04-30	Edoxaban 60mg / ASA indication
1689	529	Edoxaban	ASA indication	MWV344A	20.7.22 9:19	2024-04-30	Edoxaban 60mg / ASA indication
1709	529	Edoxaban	ASA indication	VWS664V	27.7.20 7:58	2021-12-31	Edoxaban 60mg / ASA indication
1709	529	Edoxaban	ASA indication	FBP951V	28.7.21 10:40	2024-04-30	Edoxaban 60mg / ASA indication
1709	529	Edoxaban	ASA indication	MMU431A	28.7.22 10:26	2024-04-30	Edoxaban 60mg / ASA indication
1709	529	Edoxaban	ASA indication	VLW918K	27.1.21 11:06	2021-12-31	Edoxaban 60mg / ASA indication
1709	529	Edoxaban	ASA indication	EFL122Z	9.2.22 11:31	2024-04-30	Edoxaban 60mg / ASA indication
1763	529	Edoxaban	ASA indication	VWV514P	9.9.20 10:04	2021-12-31	Edoxaban 60mg / ASA indication
1987	529	Edoxaban	ASA indication	PEL745G	1.3.21 11:09	2021-12-31	Edoxaban 60mg / ASA indication
2451	529	Edoxaban	ASA indication	WDP659T	27.1.22 10:17	2024-04-30	Edoxaban 60mg / ASA indication
2451	529	Edoxaban	ASA indication	UGF186G	20.7.22 11:58	2024-11-30	Edoxaban 30mg / ASA indication
2459	529	Edoxaban	ASA indication	FCM434C	1.2.22 10:02	2024-04-30	Edoxaban 60mg / ASA indication
2643	529	Edoxaban	ASA indication	MSM235M	7.6.22 8:54	2024-04-30	Edoxaban 60mg / ASA indication
2659	529	Edoxaban	ASA indication	BEM398U	20.6.22 10:11	2024-11-30	Edoxaban 30mg / ASA indication
317	529	Edoxaban	no ASA indication	SLG388M	26.4.18 9:21	2020-01-01	Edoxaban 60mg / no ASA indication
317	529	Edoxaban	no ASA indication	MLG469K	30.4.19 9:42	2020-01-01	Edoxaban 60mg / no ASA indication
317	529	Edoxaban	no ASA indication	LNZ919Y	18.11.19 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
317	529	Edoxaban	no ASA indication	XUL466F	19.5.20 12:25	2021-12-31	Edoxaban 60mg / no ASA indication
317	529	Edoxaban	no ASA indication	PUL745T	26.10.18 9:30	2020-01-01	Edoxaban 60mg / no ASA indication
317	529	Edoxaban	no ASA indication	PDS775M	26.10.17 9:12	2018-09-01	Edoxaban 60mg / no ASA indication
317	529	Edoxaban	no ASA indication	FDR559V	16.11.20 10:10	2021-12-31	Edoxaban 60mg / no ASA indication
447	529	Edoxaban	no ASA indication	NVM996T	16.2.18 10:26	2018-09-01	Edoxaban 60mg / no ASA indication
926	529	Edoxaban	no ASA indication	KNV551A	9.1.19 11:10	2020-01-01	Edoxaban 60mg / no ASA indication
1050	529	Edoxaban	no ASA indication	BMW739W	2.4.19 11:07	2020-01-01	Edoxaban 60mg / no ASA indication
1198	529	Edoxaban	no ASA indication	WUU414X	19.12.19 10:21	2021-12-31	Edoxaban 60mg / no ASA indication
1198	529	Edoxaban	no ASA indication	XUD886P	24.6.19 9:32	2021-12-31	Edoxaban 60mg / no ASA indication
1343	529	Edoxaban	no ASA indication	XCV315K	22.10.19 11:28	2022-08-31	Edoxaban 30mg / no ASA indication
1343	529	Edoxaban	no ASA indication	YPK918A	19.5.21 8:57	2022-08-31	Edoxaban 30mg / no ASA indication
1343	529	Edoxaban	no ASA indication	HVM325U	10.12.21 7:10	2022-08-31	Edoxaban 30mg / no ASA indication
1343	529	Edoxaban	no ASA indication	NWM999S	25.5.22 7:25	2024-11-30	Edoxaban 30mg / no ASA indication
1343	529	Edoxaban	no ASA indication	GWB738C	3.5.20 20:53	2022-08-31	Edoxaban 30mg / no ASA indication
1343	529	Edoxaban	no ASA indication	KZP433R	6.11.20 10:32	2022-08-31	Edoxaban 30mg / no ASA indication
1503	529	Edoxaban	no ASA indication	YGU426P	20.8.21 9:42	2022-08-31	Edoxaban 30mg / no ASA indication
1503	529	Edoxaban	no ASA indication	DUK157W	4.2.20 11:04	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1503	529	Edoxaban	no ASA indication	GTS385D	6.8.20 9:47	2021-12-31	Edoxaban 60mg / no ASA indication
1503	529	Edoxaban	no ASA indication	PWE898F	23.8.22 8:00	2024-11-30	Edoxaban 30mg / no ASA indication
1503	529	Edoxaban	no ASA indication	WLP968D	10.2.21 11:00	2021-12-31	Edoxaban 60mg / no ASA indication
1503	529	Edoxaban	no ASA indication	MYX186K	28.2.22 10:52	2024-11-30	Edoxaban 30mg / no ASA indication
1593	529	Edoxaban	no ASA indication	TMM594A	25.11.20 7:55	2022-08-31	Edoxaban 30mg / no ASA indication
1593	529	Edoxaban	no ASA indication	XNF744C	19.5.20 10:04	2022-08-31	Edoxaban 30mg / no ASA indication
1593	529	Edoxaban	no ASA indication	XLB912N	1.12.21 11:28	2022-08-31	Edoxaban 30mg / no ASA indication
1593	529	Edoxaban	no ASA indication	UXB565Y	18.6.21 7:39	2022-08-31	Edoxaban 30mg / no ASA indication
1768	529	Edoxaban	no ASA indication	FHW965C	30.3.22 10:35	2024-04-30	Edoxaban 60mg / no ASA indication
1768	529	Edoxaban	no ASA indication	TMP485C	10.9.20 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1768	529	Edoxaban	no ASA indication	YLF756V	16.3.21 10:10	2021-12-31	Edoxaban 60mg / no ASA indication
1768	529	Edoxaban	no ASA indication	WCW282L	21.9.21 9:42	2024-04-30	Edoxaban 60mg / no ASA indication
1823	529	Edoxaban	no ASA indication	CKF443G	13.10.20 9:52	2021-12-31	Edoxaban 60mg / no ASA indication
1846	529	Edoxaban	no ASA indication	NTX913M	3.11.20 10:50	2021-12-31	Edoxaban 60mg / no ASA indication
1898	529	Edoxaban	no ASA indication	EMV121S	9.12.20 10:58	2021-12-31	Edoxaban 60mg / no ASA indication
1898	529	Edoxaban	no ASA indication	FFV778A	15.12.21 10:50	2024-04-30	Edoxaban 60mg / no ASA indication
1898	529	Edoxaban	no ASA indication	AKT344C	4.7.22 8:26	2024-04-30	Edoxaban 60mg / no ASA indication
1898	529	Edoxaban	no ASA indication	EZD715H	25.6.21 10:04	2024-04-30	Edoxaban 60mg / no ASA indication
1927	529	Edoxaban	no ASA indication	PEZ853H	14.1.21 10:00	2022-08-31	Edoxaban 30mg / no ASA indication
1927	529	Edoxaban	no ASA indication	TGF424R	14.7.21 10:42	2022-08-31	Edoxaban 30mg / no ASA indication
1927	529	Edoxaban	no ASA indication	CDP424X	19.1.22 10:29	2024-11-30	Edoxaban 30mg / no ASA indication
1951	529	Edoxaban	no ASA indication	WBK329S	26.8.21 9:23	2024-04-30	Edoxaban 60mg / no ASA indication
1951	529	Edoxaban	no ASA indication	SKA634C	9.3.22 11:13	2024-04-30	Edoxaban 60mg / no ASA indication
1951	529	Edoxaban	no ASA indication	WHG689F	8.2.21 10:35	2021-12-31	Edoxaban 60mg / no ASA indication
1951	529	Edoxaban	no ASA indication	VLP151P	23.8.22 9:08	2024-04-30	Edoxaban 60mg / no ASA indication
2117	529	Edoxaban	no ASA indication	XFN945T	31.5.22 7:45	2024-04-30	Edoxaban 60mg / no ASA indication
2117	529	Edoxaban	no ASA indication	BBV851L	24.5.21 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
2117	529	Edoxaban	no ASA indication	WYD468P	1.12.21 10:18	2024-04-30	Edoxaban 60mg / no ASA indication
2119	529	Edoxaban	no ASA indication	YGA671T	25.5.21 11:18	2021-12-31	Edoxaban 60mg / no ASA indication
2119	529	Edoxaban	no ASA indication	EYU376Y	1.12.21 13:30	2024-04-30	Edoxaban 60mg / no ASA indication
2119	529	Edoxaban	no ASA indication	VKB665S	31.5.22 8:59	2024-04-30	Edoxaban 60mg / no ASA indication
2216	529	Edoxaban	no ASA indication	VFV639H	9.8.21 9:50	2024-04-30	Edoxaban 60mg / no ASA indication
2216	529	Edoxaban	no ASA indication	MTP635R	24.2.22 11:27	2024-04-30	Edoxaban 60mg / no ASA indication
2223	529	Edoxaban	no ASA indication	EYY584T	16.8.21 10:28	2024-04-30	Edoxaban 60mg / no ASA indication
2223	529	Edoxaban	no ASA indication	CFG982F	24.2.22 12:25	2024-11-30	Edoxaban 30mg / no ASA indication
2223	529	Edoxaban	no ASA indication	NMU171M	30.8.22 9:02	2024-11-30	Edoxaban 30mg / no ASA indication
2328	529	Edoxaban	no ASA indication	XRB158T	8.11.21 11:07	2024-04-30	Edoxaban 60mg / no ASA indication
315	530	Placebo	ASA indication	AWD324T	25.10.17 6:45	2018-09-01	Edoxaban 60mg / ASA indication
315	530	Placebo	ASA indication	WFS675M	11.4.18 6:43	2020-01-01	Edoxaban 60mg / ASA indication
315	530	Placebo	ASA indication	RAX159F	17.10.18 6:34	2020-01-01	Edoxaban 60mg / ASA indication
1010	530	Placebo	ASA indication	KCN547C	9.3.22 8:32	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1010	530	Placebo	ASA indication	SCZ784F	1.3.19 8:13	2020-01-01	Edoxaban 60mg / ASA indication
1010	530	Placebo	ASA indication	ZWK932A	4.9.19 6:32	2021-12-31	Edoxaban 60mg / ASA indication
1010	530	Placebo	ASA indication	UVC846N	8.9.21 6:41	2024-04-30	Edoxaban 60mg / ASA indication
1010	530	Placebo	ASA indication	URU926S	3.3.20 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1010	530	Placebo	ASA indication	ZPK575D	8.9.20 7:24	2021-12-31	Edoxaban 60mg / ASA indication
1010	530	Placebo	ASA indication	GNM337P	2.3.21 8:34	2021-12-31	Edoxaban 60mg / ASA indication
2106	530	Placebo	ASA indication	YVG513D	23.11.21 8:18	2024-04-30	Edoxaban 60mg / ASA indication
2106	530	Placebo	ASA indication	PHZ646C	18.5.21 7:21	2021-12-31	Edoxaban 60mg / ASA indication
2106	530	Placebo	ASA indication	KDR339T	17.5.22 7:04	2024-04-30	Edoxaban 60mg / ASA indication
2163	530	Placebo	ASA indication	FZE879T	21.12.21 8:10	2024-04-30	Edoxaban 60mg / ASA indication
2163	530	Placebo	ASA indication	KHR158S	14.6.22 7:47	2024-04-30	Edoxaban 60mg / ASA indication
2163	530	Placebo	ASA indication	FWN714S	22.6.21 7:34	2024-04-30	Edoxaban 60mg / ASA indication
2164	530	Placebo	ASA indication	UTW592H	21.12.21 8:53	2024-04-30	Edoxaban 60mg / ASA indication
2164	530	Placebo	ASA indication	XLG212R	14.6.22 8:31	2024-04-30	Edoxaban 60mg / ASA indication
2164	530	Placebo	ASA indication	FYU555S	22.6.21 8:57	2024-04-30	Edoxaban 60mg / ASA indication
429	530	Placebo	no ASA indication	PYU338L	2.2.18 8:09	2018-09-01	Edoxaban 60mg / no ASA indication
1552	530	Placebo	no ASA indication	RFZ623G	9.3.21 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
1552	530	Placebo	no ASA indication	HDN156U	10.3.20 11:30	2021-12-31	Edoxaban 60mg / no ASA indication
1552	530	Placebo	no ASA indication	FSF955X	8.9.20 10:25	2021-12-31	Edoxaban 60mg / no ASA indication
1552	530	Placebo	no ASA indication	YRL868V	8.3.22 8:28	2024-04-30	Edoxaban 60mg / no ASA indication
1552	530	Placebo	no ASA indication	FAV814M	15.9.21 10:19	2024-04-30	Edoxaban 60mg / no ASA indication
2279	530	Placebo	no ASA indication	FAX515N	23.3.22 8:30	2024-04-30	Edoxaban 60mg / no ASA indication
2279	530	Placebo	no ASA indication	FBR979U	22.9.21 6:54	2024-04-30	Edoxaban 60mg / no ASA indication
271	530	Edoxaban	ASA indication	LYX581C	7.3.18 7:23	2020-01-01	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	NXN351T	13.3.19 7:43	2020-01-01	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	WCA124E	18.9.19 6:33	2021-12-31	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	KUM164F	11.3.20 8:02	2021-12-31	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	YPK664D	19.9.18 8:36	2020-01-01	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	NDD197G	9.3.21 8:28	2021-12-31	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	KLP144Z	16.3.22 8:38	2024-11-30	Edoxaban 30mg / ASA indication
271	530	Edoxaban	ASA indication	MUM135E	22.9.20 7:14	2021-12-31	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	RKZ144B	6.9.17 7:54	2018-09-01	Edoxaban 60mg / ASA indication
271	530	Edoxaban	ASA indication	DLA447Z	20.9.21 8:23	2022-08-31	Edoxaban 30mg / ASA indication
1059	530	Edoxaban	ASA indication	SEG852U	2.10.19 6:35	2022-08-31	Edoxaban 30mg / ASA indication
1059	530	Edoxaban	ASA indication	DGE869M	8.4.20 7:34	2022-08-31	Edoxaban 30mg / ASA indication
1059	530	Edoxaban	ASA indication	PNU979M	5.10.21 7:02	2022-08-31	Edoxaban 30mg / ASA indication
1059	530	Edoxaban	ASA indication	FTV125A	20.4.21 7:42	2022-08-31	Edoxaban 30mg / ASA indication
1059	530	Edoxaban	ASA indication	KGB819D	5.4.19 6:46	2020-01-01	Edoxaban 30mg / ASA indication
1059	530	Edoxaban	ASA indication	HNC533W	7.10.20 6:42	2022-08-31	Edoxaban 30mg / ASA indication
1237	530	Edoxaban	ASA indication	NEG628P	2.2.21 8:30	2021-12-31	Edoxaban 60mg / ASA indication
1237	530	Edoxaban	ASA indication	MGR655C	31.7.19 6:32	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1237	530	Edoxaban	ASA indication	YVM599B	29.1.20 7:28	2021-12-31	Edoxaban 60mg / ASA indication
1237	530	Edoxaban	ASA indication	FKG479Y	14.7.22 6:23	2024-04-30	Edoxaban 60mg / ASA indication
1237	530	Edoxaban	ASA indication	HRC324B	5.8.20 6:28	2021-12-31	Edoxaban 60mg / ASA indication
1237	530	Edoxaban	ASA indication	FKG852B	4.8.21 6:19	2024-04-30	Edoxaban 60mg / ASA indication
1237	530	Edoxaban	ASA indication	FKD929G	2.2.22 8:42	2024-04-30	Edoxaban 60mg / ASA indication
1513	530	Edoxaban	ASA indication	LBE243Y	11.2.20 9:28	2021-12-31	Edoxaban 60mg / ASA indication
1521	530	Edoxaban	no ASA indication	GMZ714L	18.2.20 8:48	2021-12-31	Edoxaban 60mg / no ASA indication
2548	530	Edoxaban	no ASA indication	FHG727X	22.3.22 8:35	2024-04-30	Edoxaban 60mg / no ASA indication
2652	530	Edoxaban	no ASA indication	FKE316A	14.6.22 6:55	2024-04-30	Edoxaban 60mg / no ASA indication
241	531	Placebo	no ASA indication	EGZ996Z	5.2.19 8:16	2020-01-01	Edoxaban 60mg / no ASA indication
241	531	Placebo	no ASA indication	GFT239F	30.7.18 7:15	2020-01-01	Edoxaban 60mg / no ASA indication
241	531	Placebo	no ASA indication	TXY345F	1.2.18 8:43	2018-09-01	Edoxaban 60mg / no ASA indication
241	531	Placebo	no ASA indication	PXX466M	1.8.17 8:12	2018-09-01	Edoxaban 60mg / no ASA indication
311	532	Placebo	ASA indication	SAA556W	15.11.19 9:17	2021-12-31	Edoxaban 60mg / ASA indication
311	532	Placebo	ASA indication	RTR646P	4.5.18 8:57	2020-01-01	Edoxaban 60mg / ASA indication
311	532	Placebo	ASA indication	GSR824H	23.10.17 12:44	2018-09-01	Edoxaban 30mg / ASA indication
311	532	Placebo	ASA indication	SYN682C	16.11.18 10:47	2020-01-01	Edoxaban 60mg / ASA indication
311	532	Placebo	ASA indication	RPP828H	23.4.19 8:15	2020-01-01	Edoxaban 60mg / ASA indication
563	535	Placebo	no ASA indication	UZC114S	21.11.19 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
563	535	Placebo	no ASA indication	ECT652H	22.11.18 10:44	2020-01-01	Edoxaban 30mg / no ASA indication
563	535	Placebo	no ASA indication	TWG571R	23.5.19 9:09	2020-01-01	Edoxaban 30mg / no ASA indication
563	535	Placebo	no ASA indication	KDY853Y	19.5.20 9:20	2021-12-31	Edoxaban 60mg / no ASA indication
563	535	Placebo	no ASA indication	HPM177P	22.5.18 10:23	2020-01-01	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	EMF439L	20.6.19 8:49	2021-12-31	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	ZVC438M	22.6.18 10:23	2020-01-01	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	FXM151F	1.7.22 8:31	2024-04-30	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	CNU384M	20.12.18 10:25	2020-01-01	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	MNL281D	19.12.19 10:13	2021-12-31	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	XEX689U	17.12.21 9:52	2024-04-30	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	GMU721R	18.6.20 8:27	2021-12-31	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	WMS953M	19.1.21 8:32	2021-12-31	Edoxaban 60mg / no ASA indication
605	535	Placebo	no ASA indication	FYV798N	21.7.21 8:27	2024-04-30	Edoxaban 60mg / no ASA indication
1268	535	Placebo	no ASA indication	ZRG637P	10.9.20 9:13	2021-12-31	Edoxaban 60mg / no ASA indication
1268	535	Placebo	no ASA indication	SAL182C	9.3.20 10:47	2021-12-31	Edoxaban 60mg / no ASA indication
1268	535	Placebo	no ASA indication	FYC912S	6.9.21 9:11	2024-04-30	Edoxaban 60mg / no ASA indication
1268	535	Placebo	no ASA indication	XDT538S	21.2.22 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
1268	535	Placebo	no ASA indication	WKM734F	25.2.21 12:17	2021-12-31	Edoxaban 60mg / no ASA indication
1268	535	Placebo	no ASA indication	RAV825Z	29.8.19 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1393	535	Placebo	no ASA indication	SNU395V	4.12.20 7:34	2021-12-31	Edoxaban 60mg / no ASA indication
1393	535	Placebo	no ASA indication	ZTN637S	17.5.21 8:59	2022-08-31	Edoxaban 30mg / no ASA indication
1393	535	Placebo	no ASA indication	AKY665D	18.11.19 11:08	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1393	535	Placebo	no ASA indication	LLD276E	20.5.22 10:13	2024-11-30	Edoxaban 30mg / no ASA indication
1393	535	Placebo	no ASA indication	TRF426D	21.5.20 6:17	2021-12-31	Edoxaban 60mg / no ASA indication
1393	535	Placebo	no ASA indication	DFM851D	18.11.21 11:48	2022-08-31	Edoxaban 30mg / no ASA indication
538	535	Edoxaban	ASA indication	RPL445A	26.4.18 12:46	2020-01-01	Edoxaban 30mg / ASA indication
546	535	Edoxaban	ASA indication	DYP935Z	12.11.19 10:36	2022-08-31	Edoxaban 30mg / no ASA indication
546	535	Edoxaban	ASA indication	XCN237K	8.5.18 10:16	2020-01-01	Edoxaban 30mg / ASA indication
546	535	Edoxaban	ASA indication	GLN882T	10.11.20 11:29	2022-08-31	Edoxaban 30mg / no ASA indication
546	535	Edoxaban	ASA indication	TYK138H	9.5.19 8:46	2020-01-01	Edoxaban 30mg / no ASA indication
546	535	Edoxaban	ASA indication	KBK637N	11.5.21 9:52	2022-08-31	Edoxaban 30mg / no ASA indication
546	535	Edoxaban	ASA indication	CPL626Y	26.5.20 8:48	2022-08-31	Edoxaban 30mg / no ASA indication
546	535	Edoxaban	ASA indication	LTM313P	9.5.22 8:15	2024-11-30	Edoxaban 30mg / no ASA indication
546	535	Edoxaban	ASA indication	GYT558V	9.11.18 10:59	2020-01-01	Edoxaban 30mg / ASA indication
546	535	Edoxaban	ASA indication	UAT926V	4.11.21 11:12	2022-08-31	Edoxaban 30mg / ASA indication
1693	535	Edoxaban	ASA indication	GBV332U	23.7.21 8:08	2024-04-30	Edoxaban 60mg / ASA indication
1693	535	Edoxaban	ASA indication	GCH612S	20.1.22 9:49	2024-04-30	Edoxaban 60mg / ASA indication
1693	535	Edoxaban	ASA indication	GXW841P	21.1.21 8:39	2021-12-31	Edoxaban 60mg / no ASA indication
1693	535	Edoxaban	ASA indication	EEE783U	16.7.20 9:16	2021-12-31	Edoxaban 60mg / ASA indication
1693	535	Edoxaban	ASA indication	ZSE964V	14.7.22 10:31	2024-04-30	Edoxaban 60mg / ASA indication
335	535	Edoxaban	no ASA indication	GMZ121E	2.5.19 9:08	2020-01-01	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	TZG932L	13.11.17 7:14	2018-09-01	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	XKY818M	19.4.18 10:43	2020-01-01	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	PGT749S	16.5.22 8:51	2024-04-30	Edoxaban 60mg / ASA indication
335	535	Edoxaban	no ASA indication	ALY972T	23.10.18 9:06	2020-01-01	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	AZW712X	7.11.19 10:42	2021-12-31	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	XNW358P	12.11.21 11:58	2024-04-30	Edoxaban 60mg / ASA indication
335	535	Edoxaban	no ASA indication	UAU223P	8.5.20 6:08	2021-12-31	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	BRV452T	6.11.20 10:05	2021-12-31	Edoxaban 60mg / no ASA indication
335	535	Edoxaban	no ASA indication	SHG196K	7.5.21 8:00	2021-12-31	Edoxaban 60mg / no ASA indication
631	535	Edoxaban	no ASA indication	EEU576S	17.1.20 10:51	2022-08-31	Edoxaban 30mg / no ASA indication
631	535	Edoxaban	no ASA indication	BCT958V	18.7.19 9:12	2022-08-31	Edoxaban 30mg / no ASA indication
631	535	Edoxaban	no ASA indication	SGH832D	22.1.19 10:14	2020-01-01	Edoxaban 30mg / no ASA indication
631	535	Edoxaban	no ASA indication	URW483P	18.7.18 11:21	2020-01-01	Edoxaban 30mg / no ASA indication
756	535	Edoxaban	no ASA indication	FUP457D	18.10.18 8:57	2020-01-01	Edoxaban 60mg / no ASA indication
1589	535	Edoxaban	no ASA indication	TFU873V	18.5.21 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
1589	535	Edoxaban	no ASA indication	SHA728N	23.11.20 8:57	2021-12-31	Edoxaban 60mg / no ASA indication
1589	535	Edoxaban	no ASA indication	GAZ596S	19.11.21 10:25	2024-04-30	Edoxaban 60mg / no ASA indication
1589	535	Edoxaban	no ASA indication	ZRM967W	20.5.22 9:33	2024-04-30	Edoxaban 60mg / ASA indication
1589	535	Edoxaban	no ASA indication	GBC252Z	28.3.22 8:16	2024-04-30	Edoxaban 60mg / ASA indication
1589	535	Edoxaban	no ASA indication	SCC888V	18.5.20 9:28	2021-12-31	Edoxaban 60mg / no ASA indication
1769	535	Edoxaban	no ASA indication	UVV224Y	10.9.20 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1776	535	Edoxaban	no ASA indication	KZH119D	14.9.20 9:57	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1776	535	Edoxaban	no ASA indication	GBP511L	10.3.22 10:15	2024-04-30	Edoxaban 60mg / no ASA indication
1776	535	Edoxaban	no ASA indication	GAU332W	16.9.21 8:18	2024-04-30	Edoxaban 60mg / no ASA indication
1776	535	Edoxaban	no ASA indication	GSM349P	12.3.21 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
386	536	Placebo	ASA indication	DEC635N	29.6.18 13:05	2020-01-01	Edoxaban 30mg / ASA indication
386	536	Placebo	ASA indication	DZT593N	19.12.18 11:40	2020-01-01	Edoxaban 30mg / ASA indication
386	536	Placebo	ASA indication	KPE333V	13.12.19 13:06	2022-08-31	Edoxaban 30mg / ASA indication
386	536	Placebo	ASA indication	EAL414C	12.6.19 11:56	2020-01-01	Edoxaban 30mg / ASA indication
386	536	Placebo	ASA indication	YXG258Y	5.1.18 11:38	2018-09-01	Edoxaban 30mg / ASA indication
1328	536	Placebo	ASA indication	ACW428T	14.10.19 9:48	2021-12-31	Edoxaban 60mg / ASA indication
991	536	Placebo	no ASA indication	BVN645K	13.3.20 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
991	536	Placebo	no ASA indication	WRB763M	28.5.21 10:47	2022-08-31	Edoxaban 30mg / no ASA indication
991	536	Placebo	no ASA indication	XWA874K	9.9.19 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
991	536	Placebo	no ASA indication	YES498S	11.11.20 13:19	2022-08-31	Edoxaban 30mg / no ASA indication
991	536	Placebo	no ASA indication	TAA667W	15.2.19 12:42	2020-01-01	Edoxaban 60mg / no ASA indication
276	536	Edoxaban	ASA indication	CGU882K	13.9.17 9:03	2018-09-01	Edoxaban 60mg / ASA indication
1818	536	Edoxaban	ASA indication	VVU461S	27.4.21 10:39	2021-12-31	Edoxaban 60mg / ASA indication
1818	536	Edoxaban	ASA indication	GDG968G	29.10.21 9:17	2024-04-30	Edoxaban 60mg / ASA indication
1818	536	Edoxaban	ASA indication	GBU124S	7.10.20 11:05	2021-12-31	Edoxaban 60mg / ASA indication
1818	536	Edoxaban	ASA indication	GCW884S	4.4.22 10:58	2024-04-30	Edoxaban 60mg / ASA indication
2326	536	Edoxaban	no ASA indication	BLV374Y	17.5.22 10:53	2024-11-30	Edoxaban 30mg / no ASA indication
2326	536	Edoxaban	no ASA indication	UHW181L	5.11.21 10:00	2022-08-31	Edoxaban 30mg / no ASA indication
417	541	Placebo	no ASA indication	RRS858X	26.1.18 12:29	2018-09-01	Edoxaban 60mg / no ASA indication
855	541	Edoxaban	ASA indication	EBM889S	20.5.20 8:21	2022-08-31	Edoxaban 30mg / no ASA indication
855	541	Edoxaban	ASA indication	TAY841M	29.5.19 7:45	2020-01-01	Edoxaban 30mg / no ASA indication
855	541	Edoxaban	ASA indication	ASG585S	10.5.22 10:09	2024-11-30	Edoxaban 30mg / no ASA indication
855	541	Edoxaban	ASA indication	FCG384G	13.11.20 11:07	2022-08-31	Edoxaban 30mg / no ASA indication
855	541	Edoxaban	ASA indication	HSL234W	4.5.21 10:31	2022-08-31	Edoxaban 30mg / no ASA indication
855	541	Edoxaban	ASA indication	LWY437T	30.11.18 11:41	2020-01-01	Edoxaban 30mg / ASA indication
855	541	Edoxaban	ASA indication	SVB916N	20.11.19 12:17	2022-08-31	Edoxaban 30mg / no ASA indication
855	541	Edoxaban	ASA indication	AZL185N	20.11.19 11:53	2021-12-31	Edoxaban 60mg / no ASA indication
855	541	Edoxaban	ASA indication	MNN824E	3.11.21 9:57	2022-08-31	Edoxaban 30mg / no ASA indication
470	541	Edoxaban	no ASA indication	NST977C	8.3.19 9:53	2020-01-01	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	UFR138R	15.4.21 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	FME231K	8.9.20 11:05	2021-12-31	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	GGP251U	6.9.22 8:50	2024-04-30	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	GHC951B	20.10.21 9:46	2024-04-30	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	GLV314G	1.3.22 10:19	2024-04-30	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	FVC494D	1.3.18 10:39	2020-01-01	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	GXV644P	4.9.18 9:30	2020-01-01	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	YMK525Y	12.9.19 10:05	2021-12-31	Edoxaban 60mg / no ASA indication
470	541	Edoxaban	no ASA indication	PAS346B	11.3.20 10:49	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
523	542	Placebo	no ASA indication	LVX832Z	14.10.19 9:29	2021-12-31	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	KPE285K	18.10.21 8:51	2024-04-30	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	HMC627G	19.10.20 9:35	2021-12-31	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	NUL382G	9.10.18 9:11	2020-01-01	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	KPD898C	25.4.22 10:32	2024-04-30	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	HVC787N	13.4.18 8:42	2020-01-01	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	LFU977A	16.4.19 9:03	2020-01-01	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	PGW981K	17.4.20 6:07	2021-12-31	Edoxaban 60mg / no ASA indication
523	542	Placebo	no ASA indication	NMH632G	19.4.21 9:10	2021-12-31	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	AGV225E	21.5.18 8:50	2020-01-01	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	KMK719V	20.5.19 8:51	2020-01-01	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	TGW282E	2.12.19 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	XHY719M	25.5.20 6:23	2021-12-31	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	TLA949L	24.5.21 9:27	2021-12-31	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	BBH565P	23.11.17 11:02	2018-09-01	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	YPY336L	30.5.22 9:23	2024-04-30	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	ANL855T	19.11.18 9:47	2020-01-01	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	KNW987Z	29.11.21 9:52	2024-04-30	Edoxaban 60mg / no ASA indication
347	542	Edoxaban	no ASA indication	PCA138T	30.11.20 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
177	544	Placebo	ASA indication	PZY953U	13.6.18 8:22	2020-01-01	Edoxaban 60mg / no ASA indication
177	544	Placebo	ASA indication	RFM432V	18.12.18 9:31	2020-01-01	Edoxaban 60mg / no ASA indication
177	544	Placebo	ASA indication	XUF996B	6.6.17 7:47	2018-09-01	Edoxaban 60mg / ASA indication
177	544	Placebo	ASA indication	NVF726Z	4.12.17 9:26	2018-09-01	Edoxaban 60mg / no ASA indication
179	544	Placebo	ASA indication	FVY235R	6.6.17 10:07	2018-09-01	Edoxaban 60mg / ASA indication
179	544	Placebo	ASA indication	GRA359H	28.11.19 10:27	2021-12-31	Edoxaban 60mg / no ASA indication
179	544	Placebo	ASA indication	XHK624V	4.6.21 8:19	2021-12-31	Edoxaban 60mg / ASA indication
179	544	Placebo	ASA indication	LDH185Z	3.12.21 9:36	2024-04-30	Edoxaban 60mg / ASA indication
179	544	Placebo	ASA indication	LDH356K	2.6.22 10:04	2024-04-30	Edoxaban 60mg / ASA indication
179	544	Placebo	ASA indication	DAF848Z	19.12.18 9:51	2020-01-01	Edoxaban 60mg / ASA indication
179	544	Placebo	ASA indication	SET655N	19.11.20 9:53	2021-12-31	Edoxaban 60mg / no ASA indication
179	544	Placebo	ASA indication	FYA919D	4.12.17 11:45	2018-09-01	Edoxaban 60mg / no ASA indication
179	544	Placebo	ASA indication	KRD465W	13.6.18 7:14	2020-01-01	Edoxaban 60mg / no ASA indication
179	544	Placebo	ASA indication	HUS436E	26.6.19 9:00	2021-12-31	Edoxaban 60mg / no ASA indication
179	544	Placebo	ASA indication	WMZ144B	28.5.20 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
940	544	Placebo	ASA indication	HWY593K	17.1.19 8:46	2020-01-01	Edoxaban 60mg / ASA indication
1336	544	Placebo	ASA indication	RXD179N	22.4.20 7:07	2021-12-31	Edoxaban 60mg / ASA indication
1336	544	Placebo	ASA indication	UTZ712G	17.10.19 7:36	2021-12-31	Edoxaban 60mg / ASA indication
1336	544	Placebo	ASA indication	YWR698N	23.4.20 6:24	2021-12-31	Edoxaban 60mg / ASA indication
1476	544	Placebo	ASA indication	HVF358Y	16.1.20 8:57	2021-12-31	Edoxaban 60mg / ASA indication
1482	544	Placebo	ASA indication	FDY994Z	20.7.21 7:42	2022-08-31	Edoxaban 30mg / ASA indication
1482	544	Placebo	ASA indication	YGY619L	21.1.20 8:29	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1482	544	Placebo	ASA indication	AET196C	25.8.22 10:06	2024-11-30	Edoxaban 30mg / ASA indication
1482	544	Placebo	ASA indication	ZTN935X	22.1.21 9:38	2021-12-31	Edoxaban 60mg / ASA indication
1482	544	Placebo	ASA indication	LET836V	21.1.22 9:28	2024-04-30	Edoxaban 60mg / ASA indication
1482	544	Placebo	ASA indication	HEK927E	24.7.20 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1508	544	Placebo	ASA indication	FNN916T	6.2.20 10:17	2022-08-31	Edoxaban 30mg / ASA indication
137	544	Placebo	no ASA indication	GXE175R	19.4.17 7:10	2018-09-01	Edoxaban 60mg / no ASA indication
156	544	Placebo	no ASA indication	NMP841K	21.5.18 9:20	2020-01-01	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	PDG411T	21.11.19 9:59	2022-08-31	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	TVS793T	13.5.20 6:54	2022-08-31	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	YMR829P	11.11.21 9:37	2022-08-31	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	AFP621B	19.4.22 8:58	2024-11-30	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	NVE834G	13.5.21 8:59	2022-08-31	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	VUC843M	9.5.17 7:49	2018-09-01	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	ABA236C	28.5.19 8:10	2020-01-01	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	ARH596K	10.11.17 10:01	2018-09-01	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	NGR922U	19.11.18 10:16	2020-01-01	Edoxaban 30mg / no ASA indication
156	544	Placebo	no ASA indication	HPH946C	24.11.20 9:54	2022-08-31	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	VRM754W	11.6.18 8:14	2020-01-01	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	CXF889M	18.12.19 11:37	2022-08-31	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	UZB329G	29.5.20 8:08	2022-08-31	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	HUK513H	13.12.18 9:08	2020-01-01	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	BSW433R	11.6.21 8:16	2022-08-31	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	SHY734K	10.12.21 9:52	2022-08-31	Edoxaban 30mg / ASA indication
367	544	Placebo	no ASA indication	MPR145G	11.12.17 9:47	2018-09-01	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	NRD659X	10.12.20 9:23	2022-08-31	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	YRY131L	19.6.19 8:37	2022-08-31	Edoxaban 30mg / no ASA indication
367	544	Placebo	no ASA indication	AFS884G	16.6.22 9:08	2024-11-30	Edoxaban 30mg / ASA indication
491	544	Placebo	no ASA indication	BLA736C	14.4.20 6:44	2021-12-31	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	DAX155W	10.10.19 8:40	2021-12-31	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	AGD623Y	18.3.22 11:41	2024-04-30	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	EWB444P	2.4.19 8:50	2020-01-01	Edoxaban 60mg / ASA indication
491	544	Placebo	no ASA indication	ZAB694L	10.9.20 7:30	2021-12-31	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	PPF452H	24.9.18 8:54	2020-01-01	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	TVE467B	19.3.18 10:58	2020-01-01	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	GCB718U	18.3.21 9:19	2021-12-31	Edoxaban 60mg / no ASA indication
491	544	Placebo	no ASA indication	KSY835V	23.9.21 8:28	2024-04-30	Edoxaban 60mg / no ASA indication
575	544	Placebo	no ASA indication	XFE329Y	4.12.18 9:44	2020-01-01	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	RTH415R	21.5.20 6:14	2022-08-31	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	RLM541S	20.11.20 11:30	2022-08-31	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	MYC828K	11.6.19 8:50	2020-01-01	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	YTS651N	25.11.21 9:05	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
575	544	Placebo	no ASA indication	NEC587V	24.5.22 10:12	2024-11-30	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	XVM759V	30.5.18 10:19	2020-01-01	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	NVU141K	21.5.21 8:08	2022-08-31	Edoxaban 30mg / no ASA indication
575	544	Placebo	no ASA indication	NFM254W	10.12.19 9:46	2022-08-31	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	UBL962V	5.6.20 9:28	2022-08-31	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	KZL192H	20.12.19 9:23	2022-08-31	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	AGY595X	17.6.22 8:12	2024-11-30	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	YCP481G	9.12.21 10:17	2022-08-31	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	PNS733H	20.6.19 8:35	2022-08-31	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	BYP737K	18.6.21 10:00	2022-08-31	Edoxaban 30mg / no ASA indication
1193	544	Placebo	no ASA indication	KUX662C	11.12.20 10:36	2022-08-31	Edoxaban 30mg / no ASA indication
1606	544	Placebo	no ASA indication	MET618M	20.5.22 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
1606	544	Placebo	no ASA indication	VGC422P	29.5.20 10:38	2021-12-31	Edoxaban 60mg / no ASA indication
1606	544	Placebo	no ASA indication	KSW234Z	26.11.21 10:43	2024-04-30	Edoxaban 60mg / no ASA indication
1606	544	Placebo	no ASA indication	PHA721U	19.11.20 10:34	2021-12-31	Edoxaban 60mg / no ASA indication
1606	544	Placebo	no ASA indication	FXC882M	27.5.21 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
1831	544	Placebo	no ASA indication	KSM334K	21.10.21 9:20	2024-04-30	Edoxaban 60mg / no ASA indication
1831	544	Placebo	no ASA indication	MTE329A	20.10.20 8:26	2021-12-31	Edoxaban 60mg / no ASA indication
1831	544	Placebo	no ASA indication	NPW326Z	22.4.21 9:04	2021-12-31	Edoxaban 60mg / no ASA indication
1831	544	Placebo	no ASA indication	ARS533U	7.4.22 9:06	2024-04-30	Edoxaban 60mg / no ASA indication
1854	544	Placebo	no ASA indication	SBG899E	6.11.20 10:44	2022-08-31	Edoxaban 30mg / no ASA indication
178	544	Edoxaban	ASA indication	LBU834K	4.12.17 10:21	2018-09-01	Edoxaban 30mg / no ASA indication
178	544	Edoxaban	ASA indication	NKE817K	12.6.18 8:23	2020-01-01	Edoxaban 30mg / no ASA indication
178	544	Edoxaban	ASA indication	FXT835U	6.6.17 8:48	2018-09-01	Edoxaban 30mg / ASA indication
486	544	Edoxaban	ASA indication	HCY827E	8.10.19 8:04	2022-08-31	Edoxaban 30mg / ASA indication
486	544	Edoxaban	ASA indication	SFP364C	16.3.18 8:49	2020-01-01	Edoxaban 60mg / ASA indication
486	544	Edoxaban	ASA indication	XND884P	1.4.19 9:05	2020-01-01	Edoxaban 60mg / ASA indication
486	544	Edoxaban	ASA indication	WKU642X	20.9.18 9:08	2020-01-01	Edoxaban 60mg / ASA indication
958	544	Edoxaban	ASA indication	AMA441R	4.2.20 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
958	544	Edoxaban	ASA indication	YLE115Z	29.1.19 10:33	2020-01-01	Edoxaban 60mg / ASA indication
958	544	Edoxaban	ASA indication	ZGW269B	29.7.19 8:00	2021-12-31	Edoxaban 60mg / ASA indication
958	544	Edoxaban	ASA indication	GNA586W	23.7.20 8:28	2021-12-31	Edoxaban 60mg / no ASA indication
1005	544	Edoxaban	ASA indication	ZPY178G	26.8.20 8:53	2022-08-31	Edoxaban 30mg / no ASA indication
1005	544	Edoxaban	ASA indication	CAV358E	12.3.20 9:11	2022-08-31	Edoxaban 30mg / no ASA indication
1005	544	Edoxaban	ASA indication	SEF753G	23.8.22 9:42	2024-11-30	Edoxaban 30mg / ASA indication
1005	544	Edoxaban	ASA indication	MKC357S	27.8.19 8:38	2022-08-31	Edoxaban 30mg / no ASA indication
1005	544	Edoxaban	ASA indication	FZN574U	18.2.21 9:09	2022-08-31	Edoxaban 30mg / ASA indication
1005	544	Edoxaban	ASA indication	EXE691V	26.2.19 10:34	2020-01-01	Edoxaban 30mg / ASA indication
1005	544	Edoxaban	ASA indication	AYB354E	25.8.21 8:19	2022-08-31	Edoxaban 30mg / ASA indication
1005	544	Edoxaban	ASA indication	AMN419B	1.3.22 9:28	2024-11-30	Edoxaban 30mg / ASA indication
1190	544	Edoxaban	ASA indication	BZY485R	10.12.20 8:26	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1190	544	Edoxaban	ASA indication	KSB959T	18.6.21 8:40	2024-04-30	Edoxaban 60mg / no ASA indication
1190	544	Edoxaban	ASA indication	VMK797C	19.12.19 9:09	2021-12-31	Edoxaban 60mg / ASA indication
1190	544	Edoxaban	ASA indication	YMC816U	4.6.20 8:30	2021-12-31	Edoxaban 60mg / no ASA indication
1190	544	Edoxaban	ASA indication	YSA524N	19.6.19 9:45	2021-12-31	Edoxaban 60mg / ASA indication
1370	544	Edoxaban	ASA indication	NHH125S	5.11.20 9:49	2021-12-31	Edoxaban 60mg / ASA indication
1370	544	Edoxaban	ASA indication	YEV181B	6.11.19 11:07	2021-12-31	Edoxaban 60mg / ASA indication
1370	544	Edoxaban	ASA indication	MWV717W	14.5.20 7:08	2021-12-31	Edoxaban 60mg / ASA indication
1370	544	Edoxaban	ASA indication	KUS713R	4.11.21 9:03	2024-04-30	Edoxaban 60mg / ASA indication
1370	544	Edoxaban	ASA indication	EHB914C	29.4.21 9:17	2021-12-31	Edoxaban 60mg / ASA indication
1370	544	Edoxaban	ASA indication	KSX797H	28.4.22 9:26	2024-04-30	Edoxaban 60mg / ASA indication
1683	544	Edoxaban	ASA indication	UGF465M	8.1.21 9:22	2022-08-31	Edoxaban 30mg / ASA indication
1683	544	Edoxaban	ASA indication	VLE211R	10.7.20 8:57	2022-08-31	Edoxaban 30mg / ASA indication
1683	544	Edoxaban	ASA indication	MFC972X	9.7.21 8:37	2022-08-31	Edoxaban 30mg / ASA indication
224	544	Edoxaban	no ASA indication	PDR784L	16.7.18 9:03	2020-01-01	Edoxaban 60mg / no ASA indication
224	544	Edoxaban	no ASA indication	ZCY729K	12.7.17 10:32	2018-09-01	Edoxaban 60mg / no ASA indication
224	544	Edoxaban	no ASA indication	ESC746V	10.1.18 11:39	2018-09-01	Edoxaban 60mg / no ASA indication
224	544	Edoxaban	no ASA indication	BUY646W	2.7.20 9:25	2022-08-31	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	FAN642W	14.1.21 9:48	2022-08-31	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	XXD534M	23.7.19 7:25	2022-08-31	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	FSX325X	8.1.20 9:03	2022-08-31	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	RXT532Z	8.7.22 9:28	2024-11-30	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	NPD367N	8.7.21 7:49	2022-08-31	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	TED222V	20.1.22 9:24	2022-08-31	Edoxaban 30mg / no ASA indication
224	544	Edoxaban	no ASA indication	GHU113F	16.1.19 8:56	2020-01-01	Edoxaban 60mg / no ASA indication
310	544	Edoxaban	no ASA indication	LWE116X	4.5.18 7:29	2020-01-01	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	VDF363M	5.11.18 9:46	2020-01-01	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	LGL787W	4.5.20 7:20	2021-12-31	Edoxaban 60mg / no ASA indication
310	544	Edoxaban	no ASA indication	AEM637T	21.4.22 7:39	2024-11-30	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	GEX541L	29.10.20 9:39	2021-12-31	Edoxaban 60mg / no ASA indication
310	544	Edoxaban	no ASA indication	GCX438F	20.11.19 9:29	2022-08-31	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	KTU285S	23.10.17 7:57	2018-09-01	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	BCP672B	14.5.19 7:29	2020-01-01	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	NNV336E	21.10.21 8:32	2022-08-31	Edoxaban 30mg / no ASA indication
310	544	Edoxaban	no ASA indication	UUD149B	15.4.21 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
488	544	Edoxaban	no ASA indication	MGM846U	19.3.18 10:02	2020-01-01	Edoxaban 60mg / no ASA indication
773	544	Edoxaban	no ASA indication	GEU711Y	23.4.19 8:04	2020-01-01	Edoxaban 60mg / no ASA indication
773	544	Edoxaban	no ASA indication	XAY863M	26.10.18 7:38	2020-01-01	Edoxaban 60mg / no ASA indication
839	544	Edoxaban	no ASA indication	ENA238R	22.11.18 9:51	2020-01-01	Edoxaban 60mg / no ASA indication
1345	544	Edoxaban	no ASA indication	LEB597K	23.4.20 6:31	2021-12-31	Edoxaban 60mg / no ASA indication
1345	544	Edoxaban	no ASA indication	NMW997C	23.10.19 8:22	2021-12-31	Edoxaban 60mg / no ASA indication
1345	544	Edoxaban	no ASA indication	ZKH516V	22.4.20 7:22	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1345	544	Edoxaban	no ASA indication	YFY294R	23.10.20 8:32	2021-12-31	Edoxaban 60mg / no ASA indication
1367	544	Edoxaban	no ASA indication	HPL156S	18.5.20 7:06	2021-12-31	Edoxaban 60mg / no ASA indication
1367	544	Edoxaban	no ASA indication	TTE387R	6.11.19 9:53	2021-12-31	Edoxaban 60mg / no ASA indication
275	547	Placebo	ASA indication	SBC285U	19.9.18 8:41	2020-01-01	Edoxaban 60mg / no ASA indication
275	547	Placebo	ASA indication	SFE576K	13.3.19 9:11	2020-01-01	Edoxaban 60mg / no ASA indication
275	547	Placebo	ASA indication	VVH897N	12.9.17 7:20	2018-09-01	Edoxaban 60mg / ASA indication
275	547	Placebo	ASA indication	VXL644H	20.9.21 8:32	2024-04-30	Edoxaban 60mg / ASA indication
275	547	Placebo	ASA indication	ECD358W	16.9.20 7:55	2021-12-31	Edoxaban 60mg / ASA indication
275	547	Placebo	ASA indication	UCF868U	18.9.19 7:54	2021-12-31	Edoxaban 60mg / ASA indication
275	547	Placebo	ASA indication	PNW585X	16.3.22 9:22	2024-11-30	Edoxaban 30mg / ASA indication
275	547	Placebo	ASA indication	XAM216P	14.3.18 8:51	2020-01-01	Edoxaban 60mg / ASA indication
275	547	Placebo	ASA indication	XEC147V	24.3.21 8:43	2021-12-31	Edoxaban 60mg / ASA indication
275	547	Placebo	ASA indication	VUZ924K	30.3.20 8:27	2021-12-31	Edoxaban 60mg / ASA indication
391	547	Placebo	ASA indication	CFZ318A	15.1.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication
391	547	Placebo	ASA indication	UMK331F	29.6.20 15:34	2022-08-31	Edoxaban 30mg / ASA indication
391	547	Placebo	ASA indication	ZUZ935X	19.1.22 9:19	2022-08-31	Edoxaban 30mg / ASA indication
391	547	Placebo	ASA indication	SXM144H	6.7.22 7:49	2024-11-30	Edoxaban 30mg / ASA indication
391	547	Placebo	ASA indication	XCH366P	16.1.19 9:04	2020-01-01	Edoxaban 30mg / ASA indication
391	547	Placebo	ASA indication	CGD273N	24.7.19 8:37	2021-12-31	Edoxaban 60mg / ASA indication
391	547	Placebo	ASA indication	MKC247Z	9.1.18 8:48	2018-09-01	Edoxaban 60mg / ASA indication
391	547	Placebo	ASA indication	RGR791B	11.1.21 8:55	2022-08-31	Edoxaban 30mg / ASA indication
391	547	Placebo	ASA indication	ZBV793U	11.7.18 8:10	2020-01-01	Edoxaban 60mg / ASA indication
391	547	Placebo	ASA indication	XZV376U	7.7.21 7:37	2022-08-31	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	AVM171N	21.10.20 10:45	2022-08-31	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	FTR593D	16.10.19 7:54	2022-08-31	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	KDK629S	15.4.20 7:46	2022-08-31	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	RYW342F	8.11.21 8:42	2022-08-31	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	SAX176P	27.4.22 10:29	2024-11-30	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	XAW515R	26.4.21 8:15	2022-08-31	Edoxaban 30mg / ASA indication
1088	547	Placebo	ASA indication	WLC854X	17.4.19 8:51	2020-01-01	Edoxaban 30mg / ASA indication
1517	547	Placebo	ASA indication	UCY625N	12.2.20 9:52	2021-12-31	Edoxaban 60mg / ASA indication
1906	547	Placebo	ASA indication	ZCX111X	22.12.21 9:00	2024-04-30	Edoxaban 60mg / ASA indication
1906	547	Placebo	ASA indication	LFA663M	22.6.21 9:28	2024-04-30	Edoxaban 60mg / ASA indication
1906	547	Placebo	ASA indication	PHW782D	22.6.22 8:31	2024-04-30	Edoxaban 60mg / ASA indication
1906	547	Placebo	ASA indication	PAP464Z	15.12.20 8:43	2021-12-31	Edoxaban 60mg / ASA indication
1922	547	Placebo	ASA indication	LGD161Y	7.7.21 10:05	2024-04-30	Edoxaban 60mg / ASA indication
1922	547	Placebo	ASA indication	DGF141T	11.1.21 9:42	2022-08-31	Edoxaban 30mg / ASA indication
1922	547	Placebo	ASA indication	AWU261C	19.1.22 13:35	2024-11-30	Edoxaban 30mg / ASA indication
1939	547	Placebo	ASA indication	WXZ262M	27.1.21 10:01	2022-08-31	Edoxaban 30mg / ASA indication
1939	547	Placebo	ASA indication	NLX116S	4.8.21 8:45	2022-08-31	Edoxaban 30mg / ASA indication
1939	547	Placebo	ASA indication	AYD449W	16.2.22 9:25	2024-11-30	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1939	547	Placebo	ASA indication	WAG546G	27.7.22 9:37	2024-11-30	Edoxaban 30mg / ASA indication
2218	547	Placebo	ASA indication	VWX153B	20.8.21 12:19	2024-04-30	Edoxaban 60mg / ASA indication
2218	547	Placebo	ASA indication	PKE934D	10.8.22 8:33	2024-04-30	Edoxaban 60mg / ASA indication
2218	547	Placebo	ASA indication	KHT869C	9.2.22 10:11	2024-04-30	Edoxaban 60mg / ASA indication
2412	547	Placebo	ASA indication	VWL837G	27.12.21 9:46	2024-04-30	Edoxaban 60mg / ASA indication
2412	547	Placebo	ASA indication	RSR562D	29.6.22 9:47	2024-04-30	Edoxaban 60mg / ASA indication
2447	547	Placebo	ASA indication	XLU169V	26.1.22 10:21	2024-04-30	Edoxaban 60mg / ASA indication
2447	547	Placebo	ASA indication	UMW337G	27.7.22 8:28	2024-11-30	Edoxaban 30mg / ASA indication
2735	547	Placebo	ASA indication	NZM672D	10.8.22 9:59	2024-04-30	Edoxaban 60mg / ASA indication
273	547	Placebo	no ASA indication	HSD352Z	5.9.18 8:30	2020-01-01	Edoxaban 60mg / no ASA indication
273	547	Placebo	no ASA indication	HDZ684K	6.9.17 10:31	2018-09-01	Edoxaban 60mg / no ASA indication
273	547	Placebo	no ASA indication	YVF223E	6.3.18 8:49	2020-01-01	Edoxaban 60mg / no ASA indication
273	547	Placebo	no ASA indication	MPH449A	6.3.19 9:07	2020-01-01	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	TSZ418U	7.8.19 7:27	2021-12-31	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	FKD757U	27.2.19 9:22	2020-01-01	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	VXP358C	30.8.21 7:19	2024-04-30	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	EEU378N	3.3.21 7:44	2021-12-31	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	RUZ321F	19.9.18 9:11	2020-01-01	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	BSM949L	21.2.18 9:26	2020-01-01	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	TWW556T	4.9.20 6:29	2021-12-31	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	ZAA477B	4.3.20 9:10	2021-12-31	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	VZB996Z	31.8.22 7:42	2024-04-30	Edoxaban 60mg / no ASA indication
454	547	Placebo	no ASA indication	HBH831Z	2.3.22 9:45	2024-04-30	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	ZEK159X	18.9.19 7:20	2021-12-31	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	UTT638P	30.3.20 9:35	2021-12-31	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	DUW633N	24.3.21 8:12	2021-12-31	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	VSV725T	20.9.21 7:24	2024-04-30	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	TYW595H	23.3.22 8:43	2024-04-30	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	UCV281F	12.9.18 8:51	2020-01-01	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	FTN557F	13.3.19 8:47	2020-01-01	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	TXP874Y	9.9.20 7:35	2021-12-31	Edoxaban 60mg / no ASA indication
702	547	Placebo	no ASA indication	PYN561W	7.9.22 9:35	2024-04-30	Edoxaban 60mg / no ASA indication
715	547	Placebo	no ASA indication	AFF963T	20.9.18 10:46	2020-01-01	Edoxaban 30mg / no ASA indication
715	547	Placebo	no ASA indication	VNB832X	25.9.19 9:18	2022-08-31	Edoxaban 30mg / no ASA indication
715	547	Placebo	no ASA indication	NNH962A	26.3.19 12:11	2020-01-01	Edoxaban 30mg / no ASA indication
918	547	Placebo	no ASA indication	KPD536B	26.6.19 8:37	2021-12-31	Edoxaban 60mg / no ASA indication
918	547	Placebo	no ASA indication	RWW887H	2.1.19 10:35	2020-01-01	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	DHH477K	6.7.22 8:41	2024-04-30	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	XRN426U	22.6.20 9:10	2021-12-31	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	KUD163X	7.7.21 8:59	2024-04-30	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	ZCA847E	8.1.20 9:35	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
922	547	Placebo	no ASA indication	AED866S	5.7.19 12:26	2021-12-31	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	WBM878G	15.1.21 12:31	2021-12-31	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	HDK799S	8.1.19 9:33	2020-01-01	Edoxaban 60mg / no ASA indication
922	547	Placebo	no ASA indication	ELE583C	17.1.22 13:33	2024-04-30	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	RCU596K	27.7.22 9:18	2024-04-30	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	ZKE673P	1.8.19 7:48	2021-12-31	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	KTP118U	4.8.21 8:09	2024-04-30	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	RBF332Y	12.2.20 8:58	2021-12-31	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	MSZ589T	12.8.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	WCP916C	1.2.21 9:34	2021-12-31	Edoxaban 60mg / no ASA indication
1238	547	Placebo	no ASA indication	GXT599R	2.2.22 9:16	2024-04-30	Edoxaban 60mg / no ASA indication
1554	547	Placebo	no ASA indication	VVG536U	15.9.21 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
1554	547	Placebo	no ASA indication	HZN394V	3.3.21 10:49	2021-12-31	Edoxaban 60mg / no ASA indication
1554	547	Placebo	no ASA indication	PRB345Z	20.8.20 7:56	2021-12-31	Edoxaban 60mg / no ASA indication
1554	547	Placebo	no ASA indication	FZC666L	12.3.20 10:26	2021-12-31	Edoxaban 60mg / no ASA indication
1554	547	Placebo	no ASA indication	TSD763T	16.3.22 8:50	2024-04-30	Edoxaban 60mg / no ASA indication
1653	547	Placebo	no ASA indication	BAG277V	20.12.21 9:02	2024-11-30	Edoxaban 30mg / no ASA indication
1653	547	Placebo	no ASA indication	RLP221C	22.6.21 7:35	2022-08-31	Edoxaban 30mg / no ASA indication
1653	547	Placebo	no ASA indication	DZT519B	14.12.20 8:56	2022-08-31	Edoxaban 30mg / no ASA indication
1653	547	Placebo	no ASA indication	CVB952P	22.6.20 10:05	2022-08-31	Edoxaban 30mg / no ASA indication
1903	547	Placebo	no ASA indication	CTF948G	14.12.20 9:32	2022-08-31	Edoxaban 30mg / no ASA indication
1903	547	Placebo	no ASA indication	WBS251C	15.12.21 9:25	2022-08-31	Edoxaban 30mg / no ASA indication
1903	547	Placebo	no ASA indication	SNW142P	15.6.22 7:47	2024-11-30	Edoxaban 30mg / no ASA indication
1903	547	Placebo	no ASA indication	TGL184F	22.6.21 8:32	2022-08-31	Edoxaban 30mg / no ASA indication
2051	547	Placebo	no ASA indication	DGC161T	19.4.21 7:28	2021-12-31	Edoxaban 60mg / no ASA indication
2051	547	Placebo	no ASA indication	WKE924X	20.4.22 8:23	2024-04-30	Edoxaban 60mg / no ASA indication
2051	547	Placebo	no ASA indication	XRE895R	20.10.21 7:30	2024-04-30	Edoxaban 60mg / no ASA indication
2053	547	Placebo	no ASA indication	RRC122C	19.4.21 9:06	2022-08-31	Edoxaban 30mg / no ASA indication
2127	547	Placebo	no ASA indication	ZMD865L	4.5.22 7:35	2024-04-30	Edoxaban 60mg / no ASA indication
2127	547	Placebo	no ASA indication	RDF856Y	31.5.21 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
2127	547	Placebo	no ASA indication	ZCE859Y	1.12.21 8:38	2024-04-30	Edoxaban 60mg / no ASA indication
2379	547	Placebo	no ASA indication	ZBW253S	3.12.21 9:09	2024-04-30	Edoxaban 60mg / no ASA indication
2379	547	Placebo	no ASA indication	GBS635A	15.6.22 9:19	2024-04-30	Edoxaban 60mg / no ASA indication
2407	547	Placebo	no ASA indication	XPU428G	22.12.21 10:48	2024-04-30	Edoxaban 60mg / no ASA indication
2407	547	Placebo	no ASA indication	TZE649H	29.6.22 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
2409	547	Placebo	no ASA indication	KTR618V	22.12.21 11:24	2024-04-30	Edoxaban 60mg / no ASA indication
2409	547	Placebo	no ASA indication	UZX734K	1.4.22 10:30	2024-04-30	Edoxaban 60mg / no ASA indication
2520	547	Placebo	no ASA indication	NGV744N	9.3.22 8:58	2024-04-30	Edoxaban 60mg / no ASA indication
2520	547	Placebo	no ASA indication	DGE785Y	7.9.22 8:02	2024-04-30	Edoxaban 60mg / no ASA indication
2521	547	Placebo	no ASA indication	MLH649E	9.3.22 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
2521	547	Placebo	no ASA indication	DDL596R	7.9.22 8:19	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2565	547	Placebo	no ASA indication	BHF293F	30.3.22 10:31	2024-11-30	Edoxaban 30mg / no ASA indication
2628	547	Placebo	no ASA indication	WFP289N	25.5.22 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
2632	547	Placebo	no ASA indication	SLM411K	8.6.22 14:01	2024-11-30	Edoxaban 30mg / no ASA indication
2695	547	Placebo	no ASA indication	GNE224G	6.7.22 9:33	2024-04-30	Edoxaban 60mg / no ASA indication
378	547	Edoxaban	ASA indication	YEM932L	20.12.17 9:03	2018-09-01	Edoxaban 60mg / ASA indication
392	547	Edoxaban	ASA indication	EPR853H	31.7.19 7:12	2022-08-31	Edoxaban 30mg / ASA indication
392	547	Edoxaban	ASA indication	ELF624G	11.7.18 8:44	2020-01-01	Edoxaban 30mg / ASA indication
392	547	Edoxaban	ASA indication	KLB387X	25.1.19 9:28	2020-01-01	Edoxaban 30mg / ASA indication
392	547	Edoxaban	ASA indication	BKM877R	9.1.18 9:27	2018-09-01	Edoxaban 30mg / ASA indication
392	547	Edoxaban	ASA indication	TYP123W	15.1.20 10:11	2022-08-31	Edoxaban 30mg / ASA indication
1369	547	Edoxaban	ASA indication	KTB267D	28.10.20 12:27	2022-08-31	Edoxaban 30mg / ASA indication
1369	547	Edoxaban	ASA indication	DAV477S	6.11.19 10:28	2022-08-31	Edoxaban 30mg / ASA indication
1369	547	Edoxaban	ASA indication	FFB896Y	16.9.20 8:56	2022-08-31	Edoxaban 30mg / ASA indication
1663	547	Edoxaban	ASA indication	SFL421Y	15.6.21 9:49	2021-12-31	Edoxaban 60mg / ASA indication
1663	547	Edoxaban	ASA indication	KZF381C	15.12.21 10:40	2024-04-30	Edoxaban 60mg / ASA indication
1663	547	Edoxaban	ASA indication	TFM951M	26.6.20 7:52	2021-12-31	Edoxaban 60mg / ASA indication
1663	547	Edoxaban	ASA indication	XWY475C	17.12.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1663	547	Edoxaban	ASA indication	UKR916K	22.6.22 9:49	2024-04-30	Edoxaban 60mg / ASA indication
2055	547	Edoxaban	ASA indication	VHE744P	19.4.21 11:10	2021-12-31	Edoxaban 60mg / ASA indication
2063	547	Edoxaban	ASA indication	BFV865T	20.4.22 9:07	2024-11-30	Edoxaban 30mg / ASA indication
2063	547	Edoxaban	ASA indication	ZNG462W	27.10.21 8:42	2024-04-30	Edoxaban 60mg / ASA indication
2063	547	Edoxaban	ASA indication	XPF819H	26.4.21 9:10	2021-12-31	Edoxaban 60mg / ASA indication
2214	547	Edoxaban	ASA indication	KXU628U	5.8.21 9:13	2024-04-30	Edoxaban 60mg / ASA indication
2299	547	Edoxaban	ASA indication	KXK946D	6.10.21 8:15	2024-04-30	Edoxaban 60mg / ASA indication
2299	547	Edoxaban	ASA indication	GBR361T	1.4.22 7:35	2024-04-30	Edoxaban 60mg / ASA indication
2411	547	Edoxaban	ASA indication	HRH592P	27.12.21 8:59	2022-08-31	Edoxaban 30mg / ASA indication
2522	547	Edoxaban	ASA indication	WKM295W	9.3.22 10:42	2024-04-30	Edoxaban 60mg / ASA indication
2522	547	Edoxaban	ASA indication	HRB576U	7.9.22 9:08	2024-04-30	Edoxaban 60mg / ASA indication
2605	547	Edoxaban	ASA indication	SDR269W	4.5.22 8:29	2024-04-30	Edoxaban 60mg / ASA indication
2719	547	Edoxaban	ASA indication	ARG862H	20.7.22 11:03	2024-04-30	Edoxaban 60mg / ASA indication
499	547	Edoxaban	no ASA indication	DPN226D	30.9.20 7:54	2021-12-31	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	VZG116M	29.9.21 8:19	2024-04-30	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	TWP641Y	16.3.22 8:25	2024-04-30	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	DLC934U	24.3.21 9:50	2021-12-31	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	DDD527U	26.3.19 12:35	2020-01-01	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	CXB259Z	26.3.18 9:53	2020-01-01	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	GBR852S	2.10.19 8:12	2021-12-31	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	YMF749M	20.9.18 11:37	2020-01-01	Edoxaban 60mg / no ASA indication
499	547	Edoxaban	no ASA indication	SRD565W	30.3.20 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
573	547	Edoxaban	no ASA indication	KRE695T	30.5.18 7:57	2020-01-01	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	KFU538T	5.5.20 7:36	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
864	547	Edoxaban	no ASA indication	PRM354W	27.11.19 9:29	2021-12-31	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	YRU995B	25.5.22 8:25	2024-04-30	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	DND556W	18.11.20 8:28	2021-12-31	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	MSN194D	5.6.19 8:29	2020-01-01	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	ZKC334M	5.12.18 8:28	2020-01-01	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	MFV239F	1.6.21 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
864	547	Edoxaban	no ASA indication	YLW218D	1.12.21 9:38	2024-04-30	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	VDD846X	18.12.19 9:51	2021-12-31	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	AGC974U	21.12.18 11:22	2020-01-01	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	HHX756A	22.6.22 7:59	2024-04-30	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	USV651K	26.6.19 7:50	2021-12-31	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	WBS526W	22.6.20 8:35	2021-12-31	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	RKY635M	16.12.20 9:56	2021-12-31	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	KTK234S	22.6.21 8:03	2024-04-30	Edoxaban 60mg / no ASA indication
909	547	Edoxaban	no ASA indication	GYC439W	22.12.21 8:34	2024-04-30	Edoxaban 60mg / no ASA indication
936	547	Edoxaban	no ASA indication	ZKW281P	24.7.19 8:07	2022-08-31	Edoxaban 30mg / no ASA indication
936	547	Edoxaban	no ASA indication	FMF719K	12.8.20 9:11	2022-08-31	Edoxaban 30mg / no ASA indication
936	547	Edoxaban	no ASA indication	AMG287C	16.1.19 9:59	2020-01-01	Edoxaban 30mg / no ASA indication
936	547	Edoxaban	no ASA indication	LAD331E	29.1.20 8:58	2022-08-31	Edoxaban 30mg / no ASA indication
996	547	Edoxaban	no ASA indication	GHV578K	20.2.19 8:48	2020-01-01	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	CTY799L	15.6.22 7:11	2024-04-30	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	WEM781M	19.6.19 7:58	2021-12-31	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	GAE548M	18.12.19 9:00	2021-12-31	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	DBT594L	22.6.20 10:54	2021-12-31	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	EYR466P	15.12.21 8:42	2024-04-30	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	DNS126M	2.12.20 8:19	2021-12-31	Edoxaban 60mg / no ASA indication
1160	547	Edoxaban	no ASA indication	KSL474V	16.6.21 13:12	2024-04-30	Edoxaban 60mg / no ASA indication
1622	547	Edoxaban	no ASA indication	KYD447C	16.6.21 13:23	2024-04-30	Edoxaban 60mg / no ASA indication
1622	547	Edoxaban	no ASA indication	FAR556M	15.12.21 10:09	2024-04-30	Edoxaban 60mg / no ASA indication
1622	547	Edoxaban	no ASA indication	HMR549V	22.6.22 9:20	2024-04-30	Edoxaban 60mg / no ASA indication
1622	547	Edoxaban	no ASA indication	GZN548B	10.6.20 9:38	2021-12-31	Edoxaban 60mg / no ASA indication
1622	547	Edoxaban	no ASA indication	RNH611X	16.12.20 10:16	2021-12-31	Edoxaban 60mg / no ASA indication
1932	547	Edoxaban	no ASA indication	XAW977G	20.1.21 8:56	2021-12-31	Edoxaban 60mg / no ASA indication
1932	547	Edoxaban	no ASA indication	NTL711G	20.7.22 7:41	2024-04-30	Edoxaban 60mg / no ASA indication
1932	547	Edoxaban	no ASA indication	GVD366C	19.1.22 8:51	2024-04-30	Edoxaban 60mg / no ASA indication
1932	547	Edoxaban	no ASA indication	UVT744A	4.8.21 9:15	2024-04-30	Edoxaban 60mg / no ASA indication
1938	547	Edoxaban	no ASA indication	XEA929P	27.1.21 8:56	2021-12-31	Edoxaban 60mg / no ASA indication
1938	547	Edoxaban	no ASA indication	LUP276L	27.7.22 9:02	2024-04-30	Edoxaban 60mg / no ASA indication
1938	547	Edoxaban	no ASA indication	NRD519E	2.2.22 8:47	2024-04-30	Edoxaban 60mg / no ASA indication
1938	547	Edoxaban	no ASA indication	UVG411Z	4.8.21 7:33	2024-04-30	Edoxaban 60mg / no ASA indication
2052	547	Edoxaban	no ASA indication	VUX216A	20.10.21 8:09	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2052	547	Edoxaban	no ASA indication	UYA162Z	27.4.22 9:29	2024-04-30	Edoxaban 60mg / no ASA indication
2052	547	Edoxaban	no ASA indication	UUE659T	19.4.21 8:23	2021-12-31	Edoxaban 60mg / no ASA indication
2054	547	Edoxaban	no ASA indication	LAY456K	19.4.21 10:20	2022-08-31	Edoxaban 30mg / no ASA indication
2054	547	Edoxaban	no ASA indication	MLX987B	27.10.21 8:15	2022-08-31	Edoxaban 30mg / ASA indication
2054	547	Edoxaban	no ASA indication	MKR576H	19.4.21 10:58	2022-08-31	Edoxaban 30mg / ASA indication
2054	547	Edoxaban	no ASA indication	BKE212M	27.4.22 9:05	2024-11-30	Edoxaban 30mg / ASA indication
2128	547	Edoxaban	no ASA indication	UYK685Y	31.5.21 9:17	2021-12-31	Edoxaban 60mg / no ASA indication
2128	547	Edoxaban	no ASA indication	PNY463D	25.5.22 8:45	2024-04-30	Edoxaban 60mg / no ASA indication
2128	547	Edoxaban	no ASA indication	YHS418V	1.12.21 9:13	2024-04-30	Edoxaban 60mg / no ASA indication
2129	547	Edoxaban	no ASA indication	VZK661H	1.12.21 10:06	2024-04-30	Edoxaban 60mg / no ASA indication
2129	547	Edoxaban	no ASA indication	MLE968U	31.5.21 10:22	2021-12-31	Edoxaban 60mg / no ASA indication
2129	547	Edoxaban	no ASA indication	EZR514U	25.5.22 9:14	2024-04-30	Edoxaban 60mg / no ASA indication
2213	547	Edoxaban	no ASA indication	KTK179W	9.2.22 8:10	2024-04-30	Edoxaban 60mg / no ASA indication
2213	547	Edoxaban	no ASA indication	VVT185W	10.8.21 11:53	2024-04-30	Edoxaban 60mg / no ASA indication
2213	547	Edoxaban	no ASA indication	UDK727H	10.8.22 8:01	2024-04-30	Edoxaban 60mg / no ASA indication
2380	547	Edoxaban	no ASA indication	APF275X	6.7.22 7:11	2024-04-30	Edoxaban 60mg / no ASA indication
2380	547	Edoxaban	no ASA indication	VVL627Z	3.12.21 10:21	2024-04-30	Edoxaban 60mg / no ASA indication
2493	547	Edoxaban	no ASA indication	CKF243Z	23.2.22 9:05	2024-11-30	Edoxaban 30mg / no ASA indication
2493	547	Edoxaban	no ASA indication	SMS198Z	31.8.22 7:18	2024-11-30	Edoxaban 30mg / no ASA indication
2495	547	Edoxaban	no ASA indication	PRV234Y	23.2.22 9:38	2024-04-30	Edoxaban 60mg / no ASA indication
2495	547	Edoxaban	no ASA indication	UFX421A	31.8.22 8:39	2024-04-30	Edoxaban 60mg / no ASA indication
2635	547	Edoxaban	no ASA indication	GWS457M	1.6.22 8:41	2024-04-30	Edoxaban 60mg / no ASA indication
2636	547	Edoxaban	no ASA indication	AHE886G	8.6.22 14:02	2024-04-30	Edoxaban 60mg / no ASA indication
2658	547	Edoxaban	no ASA indication	CHX392Z	20.6.22 8:37	2024-11-30	Edoxaban 30mg / no ASA indication
2718	547	Edoxaban	no ASA indication	CTT732L	20.7.22 9:47	2024-04-30	Edoxaban 60mg / no ASA indication
667	557	Placebo	ASA indication	HMT725M	13.8.18 14:01	2020-01-01	Edoxaban 30mg / ASA indication
733	557	Placebo	ASA indication	TET254G	4.4.19 10:06	2020-01-01	Edoxaban 60mg / no ASA indication
733	557	Placebo	ASA indication	AZF386B	4.10.18 9:44	2020-01-01	Edoxaban 60mg / ASA indication
460	557	Placebo	no ASA indication	TCB522H	2.9.19 9:58	2021-12-31	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	ELR723M	3.3.22 10:02	2024-04-30	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	BMM142Z	31.8.18 12:16	2020-01-01	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	AYW277F	26.2.19 10:35	2020-01-01	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	URD282P	3.3.21 10:24	2021-12-31	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	EMN625T	26.2.18 10:58	2020-01-01	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	BGR715X	2.9.20 9:09	2021-12-31	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	UKE226S	2.3.20 10:43	2021-12-31	Edoxaban 60mg / no ASA indication
460	557	Placebo	no ASA indication	EGG783D	2.9.21 10:40	2024-04-30	Edoxaban 60mg / no ASA indication
530	557	Placebo	no ASA indication	BRE959C	15.9.20 13:32	2021-12-31	Edoxaban 60mg / no ASA indication
530	557	Placebo	no ASA indication	ZGZ641D	11.4.19 8:58	2020-01-01	Edoxaban 60mg / no ASA indication
530	557	Placebo	no ASA indication	USB829N	17.3.21 14:21	2021-12-31	Edoxaban 60mg / no ASA indication
530	557	Placebo	no ASA indication	MVD192G	18.10.18 10:05	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
530	557	Placebo	no ASA indication	HVW239W	18.4.18 9:30	2020-01-01	Edoxaban 60mg / no ASA indication
530	557	Placebo	no ASA indication	AXX396Y	23.10.19 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1117	557	Placebo	no ASA indication	DZF628R	8.5.19 11:05	2020-01-01	Edoxaban 30mg / no ASA indication
1117	557	Placebo	no ASA indication	VTB998G	30.10.19 10:43	2022-08-31	Edoxaban 30mg / no ASA indication
1117	557	Placebo	no ASA indication	HGN995W	22.9.20 10:18	2022-08-31	Edoxaban 30mg / no ASA indication
502	557	Edoxaban	ASA indication	HGV129P	25.3.19 10:58	2020-01-01	Edoxaban 60mg / ASA indication
502	557	Edoxaban	ASA indication	ZHE588C	28.3.18 10:00	2020-01-01	Edoxaban 60mg / ASA indication
502	557	Edoxaban	ASA indication	PKM685Y	24.9.18 10:11	2020-01-01	Edoxaban 60mg / ASA indication
502	557	Edoxaban	ASA indication	XZR282R	23.9.19 9:53	2021-12-31	Edoxaban 60mg / ASA indication
502	557	Edoxaban	ASA indication	ESW685X	22.9.20 14:32	2021-12-31	Edoxaban 60mg / ASA indication
502	557	Edoxaban	ASA indication	HUA461V	24.3.21 12:50	2021-12-31	Edoxaban 60mg / ASA indication
714	557	Edoxaban	ASA indication	WSR971H	20.9.18 9:54	2020-01-01	Edoxaban 60mg / ASA indication
394	557	Edoxaban	no ASA indication	NXT824V	17.7.18 9:38	2020-01-01	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	TZC535P	29.9.20 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	HRS438W	14.1.20 10:49	2021-12-31	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	CKD532G	30.6.22 9:32	2024-04-30	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	XMN456L	8.1.19 11:11	2020-01-01	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	CMS228V	14.1.22 13:38	2024-04-30	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	SEW816F	9.1.18 11:49	2018-09-01	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	CNP457W	1.10.21 12:49	2024-04-30	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	ATX121A	4.7.19 9:28	2021-12-31	Edoxaban 60mg / no ASA indication
394	557	Edoxaban	no ASA indication	PRH477A	31.3.21 9:40	2021-12-31	Edoxaban 60mg / no ASA indication
598	557	Edoxaban	no ASA indication	PZR242Z	19.6.18 13:08	2020-01-01	Edoxaban 60mg / no ASA indication
1232	557	Edoxaban	no ASA indication	ZUT217G	25.7.19 9:44	2022-08-31	Edoxaban 30mg / no ASA indication
462	564	Placebo	ASA indication	CDA157K	26.2.18 11:19	2020-01-01	Edoxaban 30mg / ASA indication
1110	564	Placebo	ASA indication	YKN786C	8.11.19 14:26	2021-12-31	Edoxaban 60mg / ASA indication
1110	564	Placebo	ASA indication	PLF585C	6.5.19 10:29	2020-01-01	Edoxaban 60mg / ASA indication
389	564	Placebo	no ASA indication	ACP782A	8.1.18 12:53	2018-09-01	Edoxaban 30mg / no ASA indication
490	564	Edoxaban	ASA indication	HEG288A	27.9.18 9:03	2020-01-01	Edoxaban 60mg / ASA indication
490	564	Edoxaban	ASA indication	BLC329Y	19.3.18 11:04	2020-01-01	Edoxaban 60mg / ASA indication
548	564	Edoxaban	ASA indication	XDY181S	17.5.19 14:19	2020-01-01	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	MBR453U	15.11.21 15:04	2022-08-31	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	TGE216X	9.11.18 15:09	2020-01-01	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	KSF657P	9.5.18 14:20	2020-01-01	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	NGH648Z	27.5.20 13:07	2022-08-31	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	BAU467N	29.11.19 15:24	2022-08-31	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	EGL962U	17.5.21 14:43	2022-08-31	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	ADA415G	29.4.22 15:11	2024-11-30	Edoxaban 30mg / ASA indication
548	564	Edoxaban	ASA indication	EEK568C	20.11.20 14:23	2022-08-31	Edoxaban 30mg / ASA indication
974	564	Edoxaban	ASA indication	CAV747E	5.8.19 8:40	2021-12-31	Edoxaban 60mg / ASA indication
974	564	Edoxaban	ASA indication	ZRL813H	4.2.19 11:13	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
974	564	Edoxaban	ASA indication	EHP335F	23.7.20 13:07	2022-08-31	Edoxaban 30mg / ASA indication
974	564	Edoxaban	ASA indication	HMC553X	27.1.20 14:25	2022-08-31	Edoxaban 30mg / ASA indication
779	564	Edoxaban	no ASA indication	YMZ194A	26.10.18 13:32	2020-01-01	Edoxaban 30mg / no ASA indication
165	566	Edoxaban	ASA indication	CPB115L	22.5.18 9:00	2020-01-01	Edoxaban 60mg / ASA indication
165	566	Edoxaban	ASA indication	FVZ262A	19.5.17 7:17	2018-09-01	Edoxaban 60mg / ASA indication
165	566	Edoxaban	ASA indication	XBL198G	20.11.17 10:26	2018-09-01	Edoxaban 60mg / ASA indication
344	577	Placebo	no ASA indication	EXC122E	21.11.17 9:22	2018-09-01	Edoxaban 60mg / no ASA indication
377	605	Placebo	ASA indication	FHC977M	17.12.20 10:14	2021-12-31	Edoxaban 60mg / ASA indication
377	605	Placebo	ASA indication	UEX413T	20.12.17 9:48	2018-09-01	Edoxaban 30mg / ASA indication
377	605	Placebo	ASA indication	KDV737T	18.6.18 10:22	2020-01-01	Edoxaban 30mg / ASA indication
377	605	Placebo	ASA indication	VLM331F	9.1.20 9:24	2021-12-31	Edoxaban 60mg / ASA indication
377	605	Placebo	ASA indication	HWW213X	17.12.18 8:38	2020-01-01	Edoxaban 30mg / ASA indication
377	605	Placebo	ASA indication	FVU631B	15.6.20 7:51	2021-12-31	Edoxaban 60mg / ASA indication
377	605	Placebo	ASA indication	FLS499G	4.7.19 7:26	2021-12-31	Edoxaban 60mg / ASA indication
377	605	Placebo	ASA indication	ABS228A	17.6.19 7:24	2020-01-01	Edoxaban 30mg / ASA indication
298	605	Edoxaban	ASA indication	SBS442G	12.10.17 6:22	2018-09-01	Edoxaban 60mg / ASA indication
298	605	Edoxaban	ASA indication	ZMH133R	10.4.19 13:21	2020-01-01	Edoxaban 60mg / no ASA indication
298	605	Edoxaban	ASA indication	ELR613R	9.10.19 13:58	2021-12-31	Edoxaban 60mg / no ASA indication
298	605	Edoxaban	ASA indication	PLD948C	10.4.18 8:31	2020-01-01	Edoxaban 60mg / ASA indication
298	605	Edoxaban	ASA indication	XBA672E	10.10.18 13:23	2020-01-01	Edoxaban 60mg / no ASA indication
298	605	Edoxaban	ASA indication	DLG246Z	8.4.20 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
572	608	Placebo	ASA indication	ZUP371E	29.5.18 10:43	2020-01-01	Edoxaban 30mg / ASA indication
816	608	Placebo	ASA indication	MES512U	20.3.19 14:35	2020-01-01	Edoxaban 60mg / ASA indication
816	608	Placebo	ASA indication	EXA972Y	13.11.18 10:02	2020-01-01	Edoxaban 60mg / ASA indication
816	608	Placebo	ASA indication	WUN334S	31.3.20 7:25	2021-12-31	Edoxaban 60mg / ASA indication
816	608	Placebo	ASA indication	KAV416K	14.10.20 12:52	2021-12-31	Edoxaban 60mg / ASA indication
816	608	Placebo	ASA indication	ESH241N	17.9.19 7:27	2021-12-31	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	WDV489V	29.5.19 10:07	2020-01-01	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	EBA278A	10.6.20 9:00	2021-12-31	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	EDA198L	5.12.18 11:43	2020-01-01	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	BDW282N	11.12.19 10:48	2021-12-31	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	EMB546R	1.12.21 11:02	2024-04-30	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	BEH248C	9.12.20 9:22	2021-12-31	Edoxaban 60mg / ASA indication
868	608	Placebo	ASA indication	BED555A	9.6.21 10:11	2021-12-31	Edoxaban 60mg / ASA indication
1484	608	Placebo	ASA indication	SKD341V	22.7.20 12:32	2022-08-31	Edoxaban 30mg / ASA indication
1484	608	Placebo	ASA indication	YAB421A	21.7.21 9:50	2022-08-31	Edoxaban 30mg / ASA indication
1484	608	Placebo	ASA indication	LWU174Y	8.7.22 9:34	2024-11-30	Edoxaban 30mg / ASA indication
1484	608	Placebo	ASA indication	LXW719K	3.2.21 13:39	2022-08-31	Edoxaban 30mg / ASA indication
1484	608	Placebo	ASA indication	RHG447W	28.1.22 13:58	2022-08-31	Edoxaban 30mg / ASA indication
1484	608	Placebo	ASA indication	AYU997T	21.1.20 13:16	2022-08-31	Edoxaban 30mg / ASA indication
1774	608	Placebo	ASA indication	MEM335W	17.3.21 14:31	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1774	608	Placebo	ASA indication	AAX449R	11.9.20 13:14	2022-08-31	Edoxaban 30mg / ASA indication
1774	608	Placebo	ASA indication	EKG241C	25.3.22 15:41	2024-04-30	Edoxaban 60mg / ASA indication
1774	608	Placebo	ASA indication	FWV794F	19.8.22 14:49	2024-04-30	Edoxaban 60mg / ASA indication
1774	608	Placebo	ASA indication	EHD262Z	6.10.21 15:43	2024-04-30	Edoxaban 60mg / ASA indication
903	608	Placebo	no ASA indication	TMY545M	18.12.19 10:25	2021-12-31	Edoxaban 60mg / no ASA indication
903	608	Placebo	no ASA indication	RYU518T	12.6.19 9:29	2020-01-01	Edoxaban 30mg / no ASA indication
903	608	Placebo	no ASA indication	NDY685L	19.12.18 11:19	2020-01-01	Edoxaban 60mg / no ASA indication
1091	608	Placebo	no ASA indication	MZK285N	30.4.20 10:10	2022-08-31	Edoxaban 30mg / no ASA indication
1091	608	Placebo	no ASA indication	DNK171Y	18.10.19 15:36	2022-08-31	Edoxaban 30mg / no ASA indication
1091	608	Placebo	no ASA indication	UXV367U	18.4.19 12:38	2020-01-01	Edoxaban 30mg / no ASA indication
1450	608	Placebo	no ASA indication	GXA538E	17.6.22 15:41	2024-04-30	Edoxaban 60mg / no ASA indication
1450	608	Placebo	no ASA indication	BVX417H	10.6.20 12:39	2021-12-31	Edoxaban 60mg / no ASA indication
1450	608	Placebo	no ASA indication	WAZ948M	11.6.21 13:14	2021-12-31	Edoxaban 60mg / no ASA indication
1450	608	Placebo	no ASA indication	SMA715G	13.12.19 13:44	2021-12-31	Edoxaban 60mg / no ASA indication
1450	608	Placebo	no ASA indication	DVE364S	15.12.21 15:08	2024-04-30	Edoxaban 60mg / no ASA indication
1450	608	Placebo	no ASA indication	MWY863Z	16.12.20 14:47	2021-12-31	Edoxaban 60mg / no ASA indication
2402	608	Placebo	no ASA indication	DVZ141P	20.12.21 15:12	2024-04-30	Edoxaban 60mg / no ASA indication
2402	608	Placebo	no ASA indication	GVA134D	17.6.22 13:05	2024-04-30	Edoxaban 60mg / no ASA indication
2645	608	Placebo	no ASA indication	DVG243Y	8.6.22 10:41	2024-04-30	Edoxaban 60mg / no ASA indication
817	608	Edoxaban	ASA indication	VNN551D	13.11.18 15:54	2020-01-01	Edoxaban 60mg / ASA indication
869	608	Edoxaban	ASA indication	YGY695V	29.5.19 15:21	2020-01-01	Edoxaban 60mg / ASA indication
869	608	Edoxaban	ASA indication	ABV544R	18.12.20 13:24	2021-12-31	Edoxaban 60mg / ASA indication
869	608	Edoxaban	ASA indication	KMH369Z	11.6.21 15:04	2021-12-31	Edoxaban 60mg / ASA indication
869	608	Edoxaban	ASA indication	XRG646H	20.11.19 15:55	2021-12-31	Edoxaban 60mg / ASA indication
869	608	Edoxaban	ASA indication	LMH852S	5.12.18 15:55	2020-01-01	Edoxaban 60mg / ASA indication
869	608	Edoxaban	ASA indication	TBG396S	9.6.20 7:33	2021-12-31	Edoxaban 60mg / ASA indication
973	608	Edoxaban	ASA indication	WYZ449V	23.1.20 13:57	2021-12-31	Edoxaban 60mg / ASA indication
973	608	Edoxaban	ASA indication	DYX725W	31.7.19 12:43	2021-12-31	Edoxaban 60mg / ASA indication
973	608	Edoxaban	ASA indication	RXE767T	3.2.21 10:28	2021-12-31	Edoxaban 60mg / ASA indication
973	608	Edoxaban	ASA indication	SYF939L	22.7.20 15:02	2021-12-31	Edoxaban 60mg / ASA indication
973	608	Edoxaban	ASA indication	UZT562W	4.2.19 9:42	2020-01-01	Edoxaban 60mg / ASA indication
1791	608	Edoxaban	ASA indication	AES565C	17.9.20 14:34	2021-12-31	Edoxaban 60mg / ASA indication
1791	608	Edoxaban	ASA indication	EAT381X	8.9.21 13:14	2024-04-30	Edoxaban 60mg / ASA indication
1791	608	Edoxaban	ASA indication	VML827W	2.4.21 9:35	2021-12-31	Edoxaban 60mg / ASA indication
1791	608	Edoxaban	ASA indication	EBL534A	16.3.22 11:13	2024-04-30	Edoxaban 60mg / ASA indication
2036	608	Edoxaban	ASA indication	UMZ851T	7.4.21 13:13	2022-08-31	Edoxaban 30mg / ASA indication
954	608	Edoxaban	no ASA indication	ENG182D	28.1.19 10:01	2020-01-01	Edoxaban 60mg / no ASA indication
954	608	Edoxaban	no ASA indication	LWX749T	31.7.19 14:38	2021-12-31	Edoxaban 60mg / no ASA indication
1471	608	Edoxaban	no ASA indication	GLT896G	14.1.20 10:19	2021-12-31	Edoxaban 60mg / no ASA indication
1766	608	Edoxaban	no ASA indication	ADZ518L	5.3.21 13:59	2022-08-31	Edoxaban 30mg / no ASA indication
1766	608	Edoxaban	no ASA indication	KCH488H	8.9.21 13:36	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1766	608	Edoxaban	no ASA indication	XMX776G	9.9.20 12:59	2022-08-31	Edoxaban 30mg / no ASA indication
1766	608	Edoxaban	no ASA indication	LYE762T	16.3.22 13:37	2024-11-30	Edoxaban 30mg / no ASA indication
1766	608	Edoxaban	no ASA indication	TDY138V	19.8.22 14:31	2024-11-30	Edoxaban 30mg / no ASA indication
1993	608	Edoxaban	no ASA indication	DXD896W	4.3.22 13:58	2024-04-30	Edoxaban 60mg / no ASA indication
1993	608	Edoxaban	no ASA indication	GEB171R	3.3.21 9:26	2021-12-31	Edoxaban 60mg / no ASA indication
1993	608	Edoxaban	no ASA indication	DUH454Z	8.9.21 14:24	2024-04-30	Edoxaban 60mg / no ASA indication
601	619	Edoxaban	no ASA indication	UDD467E	5.12.19 10:22	2022-08-31	Edoxaban 30mg / no ASA indication
601	619	Edoxaban	no ASA indication	LWT959K	12.6.19 14:22	2020-01-01	Edoxaban 30mg / no ASA indication
601	619	Edoxaban	no ASA indication	USF699X	13.12.18 15:26	2020-01-01	Edoxaban 30mg / no ASA indication
601	619	Edoxaban	no ASA indication	CAV283P	5.6.20 9:32	2022-08-31	Edoxaban 30mg / no ASA indication
601	619	Edoxaban	no ASA indication	CVU857F	11.12.20 9:41	2022-08-31	Edoxaban 30mg / no ASA indication
601	619	Edoxaban	no ASA indication	DCX545P	21.6.18 8:54	2020-01-01	Edoxaban 30mg / no ASA indication
286	641	Placebo	ASA indication	YVL922T	27.9.17 15:54	2018-09-01	Edoxaban 60mg / ASA indication
552	641	Placebo	ASA indication	FDT224P	14.11.18 15:27	2020-01-01	Edoxaban 30mg / no ASA indication
552	641	Placebo	ASA indication	DUT596U	15.5.18 10:21	2020-01-01	Edoxaban 30mg / ASA indication
552	641	Placebo	ASA indication	KCT545E	1.6.21 11:58	2021-12-31	Edoxaban 60mg / ASA indication
552	641	Placebo	ASA indication	HZC559V	11.11.20 15:53	2021-12-31	Edoxaban 60mg / ASA indication
552	641	Placebo	ASA indication	VFG791C	18.12.19 15:31	2021-12-31	Edoxaban 60mg / ASA indication
552	641	Placebo	ASA indication	CVC649G	1.7.20 13:45	2021-12-31	Edoxaban 60mg / no ASA indication
552	641	Placebo	ASA indication	PPF665R	13.7.22 14:55	2024-11-30	Edoxaban 30mg / ASA indication
552	641	Placebo	ASA indication	VUS657L	29.5.19 14:02	2020-01-01	Edoxaban 60mg / ASA indication
552	641	Placebo	ASA indication	WRL583B	26.1.22 12:49	2024-04-30	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	UWM176C	10.8.21 13:03	2024-04-30	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	BVP453S	17.1.20 11:46	2021-12-31	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	KSZ327F	15.7.20 15:58	2021-12-31	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	ARF461P	6.6.18 13:45	2020-01-01	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	MGP293V	22.2.22 16:27	2024-11-30	Edoxaban 30mg / ASA indication
581	641	Placebo	ASA indication	NYR231Y	3.7.19 13:53	2021-12-31	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	EXT443P	7.9.22 14:06	2024-04-30	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	KCY344S	27.1.21 12:59	2021-12-31	Edoxaban 60mg / ASA indication
581	641	Placebo	ASA indication	AEP196Z	19.12.18 14:43	2020-01-01	Edoxaban 60mg / ASA indication
643	641	Placebo	ASA indication	ZVB893U	30.7.18 9:38	2020-01-01	Edoxaban 30mg / ASA indication
1719	641	Placebo	ASA indication	UVV789S	31.8.21 10:28	2024-04-30	Edoxaban 60mg / ASA indication
1719	641	Placebo	ASA indication	PXV931M	3.8.20 12:55	2021-12-31	Edoxaban 60mg / ASA indication
1719	641	Placebo	ASA indication	LTG296D	16.2.21 10:09	2021-12-31	Edoxaban 60mg / ASA indication
1719	641	Placebo	ASA indication	MGY811W	23.2.22 15:10	2024-11-30	Edoxaban 30mg / no ASA indication
1719	641	Placebo	ASA indication	KRB139U	7.9.22 12:59	2024-04-30	Edoxaban 60mg / ASA indication
1807	641	Placebo	ASA indication	CAB391Y	15.12.21 16:41	2022-08-31	Edoxaban 30mg / ASA indication
1807	641	Placebo	ASA indication	ULM437D	28.5.21 12:26	2022-08-31	Edoxaban 30mg / ASA indication
1807	641	Placebo	ASA indication	RPD418R	13.6.22 9:10	2024-04-30	Edoxaban 60mg / ASA indication
1807	641	Placebo	ASA indication	BLL369B	30.9.20 14:52	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2016	641	Placebo	ASA indication	VGF344D	27.10.21 15:36	2024-04-30	Edoxaban 60mg / no ASA indication
2016	641	Placebo	ASA indication	KXS525T	18.5.22 14:09	2024-04-30	Edoxaban 60mg / no ASA indication
2016	641	Placebo	ASA indication	LRE936P	17.3.21 15:23	2021-12-31	Edoxaban 60mg / ASA indication
2166	641	Placebo	ASA indication	HMU378A	23.6.21 13:47	2024-04-30	Edoxaban 60mg / ASA indication
2166	641	Placebo	ASA indication	BUT147D	2.2.22 14:58	2024-04-30	Edoxaban 60mg / ASA indication
2166	641	Placebo	ASA indication	RRM321X	27.7.22 14:07	2024-04-30	Edoxaban 60mg / ASA indication
2584	641	Placebo	ASA indication	LAS153L	13.4.22 14:36	2024-04-30	Edoxaban 60mg / ASA indication
138	641	Placebo	no ASA indication	UXE919B	18.4.18 12:30	2020-01-01	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	RMR189R	2.5.19 14:02	2020-01-01	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	GPW619R	10.11.21 14:00	2024-04-30	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	UDX412D	20.5.20 9:38	2021-12-31	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	VFY467H	18.11.20 14:50	2021-12-31	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	KAS878S	21.4.21 14:18	2021-12-31	Edoxaban 60mg / ASA indication
138	641	Placebo	no ASA indication	BVC361U	18.4.17 15:10	2018-09-01	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	AFN648L	23.10.17 8:24	2018-09-01	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	CSW886R	25.5.22 13:38	2024-04-30	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	LGX261D	24.10.18 13:54	2020-01-01	Edoxaban 60mg / no ASA indication
138	641	Placebo	no ASA indication	KMW238Z	13.11.19 15:28	2021-12-31	Edoxaban 60mg / no ASA indication
422	641	Placebo	no ASA indication	DPA729E	29.1.19 15:38	2020-01-01	Edoxaban 60mg / no ASA indication
422	641	Placebo	no ASA indication	ACY835U	10.2.21 14:38	2021-12-31	Edoxaban 60mg / no ASA indication
422	641	Placebo	no ASA indication	UBE588T	12.8.20 10:51	2022-08-31	Edoxaban 30mg / no ASA indication
422	641	Placebo	no ASA indication	WWC835L	31.1.18 14:01	2018-09-01	Edoxaban 60mg / no ASA indication
422	641	Placebo	no ASA indication	LLM482A	31.7.19 13:28	2022-08-31	Edoxaban 30mg / no ASA indication
422	641	Placebo	no ASA indication	MFZ852T	1.3.22 14:37	2024-11-30	Edoxaban 30mg / no ASA indication
422	641	Placebo	no ASA indication	DKC294L	31.1.20 11:28	2022-08-31	Edoxaban 30mg / no ASA indication
422	641	Placebo	no ASA indication	BVD114M	19.7.18 14:01	2020-01-01	Edoxaban 60mg / no ASA indication
422	641	Placebo	no ASA indication	UFF827B	23.8.21 11:42	2022-08-31	Edoxaban 30mg / no ASA indication
473	641	Placebo	no ASA indication	KUR271T	7.5.21 11:52	2021-12-31	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	ZBU611W	23.10.19 14:40	2021-12-31	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	CRS853D	29.10.20 15:11	2021-12-31	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	XKB276G	17.10.18 14:05	2020-01-01	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	GPR429P	24.11.21 15:10	2024-04-30	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	DLP518A	20.4.20 8:04	2021-12-31	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	HVN942T	10.4.19 14:56	2020-01-01	Edoxaban 60mg / no ASA indication
473	641	Placebo	no ASA indication	KCV292N	7.3.18 14:24	2020-01-01	Edoxaban 60mg / no ASA indication
478	641	Placebo	no ASA indication	ZAZ831T	12.3.18 11:15	2020-01-01	Edoxaban 30mg / no ASA indication
478	641	Placebo	no ASA indication	VPS686W	12.3.18 15:01	2020-01-01	Edoxaban 30mg / ASA indication
632	641	Placebo	no ASA indication	GNN914K	29.1.19 16:50	2020-01-01	Edoxaban 30mg / no ASA indication
632	641	Placebo	no ASA indication	FEN361F	18.7.18 13:37	2020-01-01	Edoxaban 30mg / no ASA indication
1211	641	Placebo	no ASA indication	HNF937V	3.7.19 15:01	2022-08-31	Edoxaban 30mg / no ASA indication
1430	641	Placebo	no ASA indication	YUX826B	4.12.19 15:58	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1498	641	Placebo	no ASA indication	MCX543P	29.1.20 15:03	2021-12-31	Edoxaban 60mg / no ASA indication
1834	641	Placebo	no ASA indication	BUS136Z	20.10.20 11:10	2021-12-31	Edoxaban 60mg / no ASA indication
1905	641	Placebo	no ASA indication	HNL416Y	23.6.21 12:04	2024-04-30	Edoxaban 60mg / ASA indication
1905	641	Placebo	no ASA indication	DXD751C	20.7.22 15:37	2024-04-30	Edoxaban 60mg / no ASA indication
1905	641	Placebo	no ASA indication	NLC138E	14.12.20 11:24	2022-08-31	Edoxaban 30mg / no ASA indication
1905	641	Placebo	no ASA indication	WPD153P	31.12.21 10:21	2024-04-30	Edoxaban 60mg / ASA indication
1981	641	Placebo	no ASA indication	SHW183E	24.2.21 12:52	2022-08-31	Edoxaban 30mg / no ASA indication
1981	641	Placebo	no ASA indication	NKN165E	15.6.22 16:03	2024-11-30	Edoxaban 30mg / no ASA indication
1981	641	Placebo	no ASA indication	VHG142D	20.10.21 11:18	2024-04-30	Edoxaban 60mg / no ASA indication
2168	641	Placebo	no ASA indication	GRL799K	23.6.21 14:53	2024-04-30	Edoxaban 60mg / no ASA indication
2168	641	Placebo	no ASA indication	VFZ799F	19.1.22 13:35	2024-04-30	Edoxaban 60mg / no ASA indication
2168	641	Placebo	no ASA indication	NAE268N	20.7.22 13:22	2024-04-30	Edoxaban 60mg / no ASA indication
2343	641	Placebo	no ASA indication	LFC225Y	15.11.21 10:40	2022-08-31	Edoxaban 30mg / no ASA indication
2637	641	Placebo	no ASA indication	CUL543F	1.6.22 12:56	2024-04-30	Edoxaban 60mg / no ASA indication
2667	641	Placebo	no ASA indication	CRL854Y	22.6.22 13:57	2024-04-30	Edoxaban 60mg / no ASA indication
115	641	Edoxaban	ASA indication	NBX272L	12.9.17 10:35	2018-09-01	Edoxaban 30mg / no ASA indication
115	641	Edoxaban	ASA indication	VPV977D	25.9.18 11:47	2020-01-01	Edoxaban 60mg / ASA indication
115	641	Edoxaban	ASA indication	SEL666G	21.3.17 11:46	2018-09-01	Edoxaban 60mg / ASA indication
115	641	Edoxaban	ASA indication	GBG663X	14.3.18 14:43	2020-01-01	Edoxaban 30mg / ASA indication
238	641	Edoxaban	ASA indication	FHS633M	28.7.17 9:53	2018-09-01	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	DWP679T	19.12.18 9:28	2020-01-01	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	EKS836X	18.12.19 14:56	2022-08-31	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	EUH336L	24.6.20 13:28	2022-08-31	Edoxaban 30mg / no ASA indication
589	641	Edoxaban	ASA indication	REM416F	16.12.20 14:32	2022-08-31	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	BWK796D	12.1.22 14:30	2024-04-30	Edoxaban 60mg / ASA indication
589	641	Edoxaban	ASA indication	MNY543L	13.6.18 12:44	2020-01-01	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	BAW864E	1.7.19 13:22	2022-08-31	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	KZM714N	20.7.22 16:10	2024-11-30	Edoxaban 30mg / ASA indication
589	641	Edoxaban	ASA indication	VUY876M	30.6.21 13:56	2022-08-31	Edoxaban 30mg / no ASA indication
1167	641	Edoxaban	ASA indication	KMY828W	10.6.19 10:57	2020-01-01	Edoxaban 30mg / ASA indication
1405	641	Edoxaban	ASA indication	GVS812N	28.6.21 12:00	2024-04-30	Edoxaban 60mg / ASA indication
1405	641	Edoxaban	ASA indication	NPG794P	1.6.20 9:47	2021-12-31	Edoxaban 60mg / no ASA indication
1405	641	Edoxaban	ASA indication	MRV769B	14.12.20 12:32	2022-08-31	Edoxaban 30mg / ASA indication
1405	641	Edoxaban	ASA indication	MWK622E	20.7.22 14:41	2024-04-30	Edoxaban 60mg / ASA indication
1405	641	Edoxaban	ASA indication	VZT799S	20.11.19 14:56	2021-12-31	Edoxaban 60mg / ASA indication
1405	641	Edoxaban	ASA indication	GVZ139D	10.1.22 13:23	2024-04-30	Edoxaban 60mg / ASA indication
1691	641	Edoxaban	ASA indication	WRG739N	11.2.22 10:33	2022-08-31	Edoxaban 30mg / ASA indication
1691	641	Edoxaban	ASA indication	USD164G	15.7.20 16:35	2022-08-31	Edoxaban 30mg / ASA indication
1691	641	Edoxaban	ASA indication	PVM976W	3.2.21 16:22	2022-08-31	Edoxaban 30mg / no ASA indication
1691	641	Edoxaban	ASA indication	DKE297B	3.8.21 12:40	2022-08-31	Edoxaban 30mg / ASA indication
1691	641	Edoxaban	ASA indication	MTR658V	10.8.22 10:34	2024-11-30	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1990	641	Edoxaban	ASA indication	HXX819W	1.3.21 14:05	2021-12-31	Edoxaban 60mg / ASA indication
1990	641	Edoxaban	ASA indication	VTH223B	6.9.21 9:41	2024-04-30	Edoxaban 60mg / ASA indication
1990	641	Edoxaban	ASA indication	MTK888V	17.6.22 9:16	2024-04-30	Edoxaban 60mg / ASA indication
2393	641	Edoxaban	ASA indication	HFS912Y	15.6.22 15:33	2024-04-30	Edoxaban 60mg / ASA indication
2393	641	Edoxaban	ASA indication	GXM997U	15.12.21 15:10	2024-04-30	Edoxaban 60mg / ASA indication
2463	641	Edoxaban	ASA indication	HEW966D	2.2.22 14:22	2024-04-30	Edoxaban 60mg / ASA indication
2463	641	Edoxaban	ASA indication	UDP132Y	3.8.22 10:33	2024-11-30	Edoxaban 30mg / no ASA indication
262	641	Edoxaban	no ASA indication	HKD547V	6.3.18 11:28	2020-01-01	Edoxaban 30mg / no ASA indication
262	641	Edoxaban	no ASA indication	TVU664A	22.4.20 10:35	2022-08-31	Edoxaban 30mg / no ASA indication
262	641	Edoxaban	no ASA indication	SVG685N	2.11.20 12:05	2022-08-31	Edoxaban 30mg / ASA indication
262	641	Edoxaban	no ASA indication	SSA987M	27.3.19 14:50	2020-01-01	Edoxaban 30mg / no ASA indication
262	641	Edoxaban	no ASA indication	WBX734G	23.8.17 15:28	2018-09-01	Edoxaban 30mg / no ASA indication
262	641	Edoxaban	no ASA indication	MLC386C	14.9.18 9:58	2020-01-01	Edoxaban 30mg / no ASA indication
262	641	Edoxaban	no ASA indication	KZF661B	9.10.19 13:51	2021-12-31	Edoxaban 60mg / no ASA indication
274	641	Edoxaban	no ASA indication	ZGZ255C	8.9.17 11:29	2018-09-01	Edoxaban 60mg / no ASA indication
274	641	Edoxaban	no ASA indication	BXD591R	1.10.18 11:30	2020-01-01	Edoxaban 60mg / no ASA indication
274	641	Edoxaban	no ASA indication	TZW694P	19.4.19 10:24	2020-01-01	Edoxaban 60mg / no ASA indication
274	641	Edoxaban	no ASA indication	CUN987T	19.3.18 10:45	2020-01-01	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	SEM651L	24.10.18 12:59	2020-01-01	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	ZDM899R	27.11.19 14:29	2021-12-31	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	RHM488X	4.10.17 15:10	2018-09-01	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	STZ971L	11.11.20 14:16	2021-12-31	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	APL337C	14.4.21 14:21	2021-12-31	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	ENE555W	10.6.20 8:56	2021-12-31	Edoxaban 60mg / no ASA indication
292	641	Edoxaban	no ASA indication	UUM872G	11.4.18 13:40	2020-01-01	Edoxaban 30mg / no ASA indication
292	641	Edoxaban	no ASA indication	ZNK888K	9.5.19 13:50	2020-01-01	Edoxaban 60mg / no ASA indication
588	641	Edoxaban	no ASA indication	KET446G	10.4.19 13:53	2020-01-01	Edoxaban 60mg / no ASA indication
588	641	Edoxaban	no ASA indication	AFW345F	1.6.21 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
588	641	Edoxaban	no ASA indication	SPX781B	20.6.22 10:49	2024-11-30	Edoxaban 30mg / no ASA indication
588	641	Edoxaban	no ASA indication	FAM588P	7.5.20 11:11	2022-08-31	Edoxaban 30mg / no ASA indication
588	641	Edoxaban	no ASA indication	VHX444S	1.12.21 14:47	2022-08-31	Edoxaban 30mg / no ASA indication
588	641	Edoxaban	no ASA indication	MLE114S	24.10.19 11:07	2022-08-31	Edoxaban 30mg / no ASA indication
588	641	Edoxaban	no ASA indication	LNE548G	12.6.18 13:09	2020-01-01	Edoxaban 60mg / no ASA indication
588	641	Edoxaban	no ASA indication	AFZ484X	16.11.20 10:19	2022-08-31	Edoxaban 30mg / no ASA indication
746	641	Edoxaban	no ASA indication	ERZ448N	21.5.19 8:11	2020-01-01	Edoxaban 60mg / no ASA indication
746	641	Edoxaban	no ASA indication	TDL356L	20.11.19 15:56	2021-12-31	Edoxaban 60mg / no ASA indication
746	641	Edoxaban	no ASA indication	BAH272V	10.10.18 14:11	2020-01-01	Edoxaban 60mg / no ASA indication
746	641	Edoxaban	no ASA indication	HWW136W	12.5.21 14:28	2021-12-31	Edoxaban 60mg / no ASA indication
746	641	Edoxaban	no ASA indication	EZT726M	10.6.20 9:20	2022-08-31	Edoxaban 30mg / no ASA indication
746	641	Edoxaban	no ASA indication	ATS126L	5.1.21 14:00	2021-12-31	Edoxaban 60mg / no ASA indication
746	641	Edoxaban	no ASA indication	LCW862D	29.6.22 14:34	2024-11-30	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
746	641	Edoxaban	no ASA indication	GTT661U	1.12.21 15:13	2024-04-30	Edoxaban 60mg / no ASA indication
1015	641	Edoxaban	no ASA indication	UCX536F	5.3.19 11:12	2020-01-01	Edoxaban 60mg / no ASA indication
1280	641	Edoxaban	no ASA indication	FBW175V	15.10.20 10:49	2022-08-31	Edoxaban 30mg / no ASA indication
1280	641	Edoxaban	no ASA indication	XVC499D	26.5.21 14:31	2022-08-31	Edoxaban 30mg / no ASA indication
1280	641	Edoxaban	no ASA indication	TPW956A	11.9.19 15:27	2022-08-31	Edoxaban 30mg / no ASA indication
1280	641	Edoxaban	no ASA indication	SXT811F	25.3.20 11:33	2022-08-31	Edoxaban 30mg / no ASA indication
1280	641	Edoxaban	no ASA indication	PUE425E	9.12.21 10:40	2022-08-31	Edoxaban 30mg / no ASA indication
1280	641	Edoxaban	no ASA indication	MCT145S	18.7.22 6:39	2024-11-30	Edoxaban 30mg / no ASA indication
1828	641	Edoxaban	no ASA indication	NZD275N	16.10.20 10:01	2021-12-31	Edoxaban 60mg / no ASA indication
1828	641	Edoxaban	no ASA indication	VYH775D	16.6.21 14:28	2021-12-31	Edoxaban 60mg / no ASA indication
1855	641	Edoxaban	no ASA indication	UZC868K	20.1.22 14:05	2024-04-30	Edoxaban 60mg / no ASA indication
1855	641	Edoxaban	no ASA indication	SWY969E	9.11.20 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1855	641	Edoxaban	no ASA indication	HGK338V	9.6.21 14:15	2021-12-31	Edoxaban 60mg / no ASA indication
1944	641	Edoxaban	no ASA indication	XNH675Y	19.8.21 9:52	2022-08-31	Edoxaban 30mg / no ASA indication
1944	641	Edoxaban	no ASA indication	NRL568M	9.3.22 14:14	2024-11-30	Edoxaban 30mg / no ASA indication
1944	641	Edoxaban	no ASA indication	CBW666A	2.2.21 15:06	2022-08-31	Edoxaban 30mg / no ASA indication
2112	641	Edoxaban	no ASA indication	HXU553N	19.5.21 14:15	2021-12-31	Edoxaban 60mg / no ASA indication
2112	641	Edoxaban	no ASA indication	GTB476A	20.12.21 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
2112	641	Edoxaban	no ASA indication	LYF136E	23.6.22 9:13	2024-04-30	Edoxaban 60mg / no ASA indication
2196	641	Edoxaban	no ASA indication	GTH388T	20.7.21 11:26	2024-04-30	Edoxaban 60mg / no ASA indication
2341	641	Edoxaban	no ASA indication	WPE471H	25.5.22 14:55	2024-04-30	Edoxaban 60mg / no ASA indication
2341	641	Edoxaban	no ASA indication	UZF268G	10.11.21 15:18	2024-04-30	Edoxaban 60mg / no ASA indication
2332	653	Placebo	ASA indication	TYS332D	8.11.21 15:14	2022-08-31	Edoxaban 30mg / ASA indication
2332	653	Placebo	ASA indication	BBL525Z	12.5.22 14:02	2024-11-30	Edoxaban 30mg / ASA indication
2655	653	Placebo	ASA indication	WDM836W	15.6.22 9:08	2024-04-30	Edoxaban 60mg / ASA indication
2448	653	Edoxaban	ASA indication	SLB587P	26.1.22 9:29	2022-08-31	Edoxaban 30mg / ASA indication
2487	653	Edoxaban	ASA indication	WSX296T	18.2.22 10:41	2024-04-30	Edoxaban 60mg / ASA indication
2487	653	Edoxaban	ASA indication	WSN169D	31.8.22 14:34	2024-04-30	Edoxaban 60mg / ASA indication
2486	653	Edoxaban	no ASA indication	BCC515C	18.2.22 9:39	2024-11-30	Edoxaban 30mg / no ASA indication
2486	653	Edoxaban	no ASA indication	BBB654C	31.8.22 15:29	2024-11-30	Edoxaban 30mg / no ASA indication
2498	653	Edoxaban	no ASA indication	WGY256P	24.2.22 10:12	2024-04-30	Edoxaban 60mg / no ASA indication
152	655	Placebo	ASA indication	DMX146Z	8.5.18 9:14	2020-01-01	Edoxaban 60mg / ASA indication
152	655	Placebo	ASA indication	HLA659Z	10.5.17 8:58	2018-09-01	Edoxaban 60mg / ASA indication
152	655	Placebo	ASA indication	YYB126B	14.11.19 8:43	2021-12-31	Edoxaban 60mg / ASA indication
152	655	Placebo	ASA indication	WXU757R	20.5.20 13:01	2021-12-31	Edoxaban 60mg / ASA indication
152	655	Placebo	ASA indication	NUN582R	14.11.18 11:09	2020-01-01	Edoxaban 60mg / ASA indication
152	655	Placebo	ASA indication	AZL851F	8.5.19 11:00	2020-01-01	Edoxaban 60mg / ASA indication
152	655	Placebo	ASA indication	FUK145N	15.11.17 10:51	2018-09-01	Edoxaban 60mg / ASA indication
465	655	Placebo	ASA indication	WPP519D	28.2.19 15:32	2020-01-01	Edoxaban 30mg / ASA indication
465	655	Placebo	ASA indication	TXX421F	23.8.18 11:10	2020-01-01	Edoxaban 30mg / ASA indication
465	655	Placebo	ASA indication	NSC193L	5.9.19 12:55	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
465	655	Placebo	ASA indication	ZTY264C	28.2.18 10:59	2020-01-01	Edoxaban 30mg / ASA indication
580	655	Placebo	ASA indication	UZZ738W	10.6.20 10:45	2021-12-31	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	MKV926P	26.5.22 12:05	2024-04-30	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	FBF227A	2.12.20 12:10	2021-12-31	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	KLG847C	29.5.19 11:27	2020-01-01	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	HTE348H	18.11.21 12:36	2024-04-30	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	WNF835Z	10.6.21 12:34	2021-12-31	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	KXS745U	6.6.18 10:35	2020-01-01	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	ZEZ376K	29.11.18 10:59	2020-01-01	Edoxaban 60mg / ASA indication
580	655	Placebo	ASA indication	VCR373Y	3.12.19 11:59	2021-12-31	Edoxaban 60mg / ASA indication
1457	655	Placebo	ASA indication	FAT998Y	9.12.20 12:17	2021-12-31	Edoxaban 60mg / ASA indication
1457	655	Placebo	ASA indication	USA758C	19.12.19 12:32	2021-12-31	Edoxaban 60mg / ASA indication
1457	655	Placebo	ASA indication	EVT469M	22.6.22 12:31	2024-04-30	Edoxaban 60mg / ASA indication
1457	655	Placebo	ASA indication	GGG243Y	18.6.20 12:01	2021-12-31	Edoxaban 60mg / ASA indication
1457	655	Placebo	ASA indication	VYR229C	17.6.21 10:28	2021-12-31	Edoxaban 60mg / ASA indication
1457	655	Placebo	ASA indication	FAW571L	19.1.22 12:41	2024-04-30	Edoxaban 60mg / ASA indication
560	655	Placebo	no ASA indication	LTL451A	14.11.18 15:16	2020-01-01	Edoxaban 60mg / no ASA indication
560	655	Placebo	no ASA indication	GMU265R	8.5.19 13:16	2020-01-01	Edoxaban 60mg / no ASA indication
560	655	Placebo	no ASA indication	PER339M	17.11.20 11:52	2021-12-31	Edoxaban 60mg / no ASA indication
560	655	Placebo	no ASA indication	GRA964V	13.5.20 12:32	2021-12-31	Edoxaban 60mg / no ASA indication
560	655	Placebo	no ASA indication	XFP266T	18.5.18 12:41	2020-01-01	Edoxaban 60mg / no ASA indication
560	655	Placebo	no ASA indication	PTH845C	13.11.19 14:03	2021-12-31	Edoxaban 60mg / no ASA indication
597	655	Placebo	no ASA indication	SZM692D	16.7.19 9:49	2022-08-31	Edoxaban 30mg / no ASA indication
597	655	Placebo	no ASA indication	MTD651M	19.12.18 13:47	2020-01-01	Edoxaban 60mg / no ASA indication
597	655	Placebo	no ASA indication	AKA195H	19.6.18 12:04	2020-01-01	Edoxaban 60mg / no ASA indication
1491	655	Placebo	no ASA indication	NNX697T	20.1.21 14:01	2021-12-31	Edoxaban 60mg / no ASA indication
1491	655	Placebo	no ASA indication	FFT886D	20.1.21 14:36	2021-12-31	Edoxaban 60mg / ASA indication
1491	655	Placebo	no ASA indication	HRZ195X	21.7.21 11:17	2024-04-30	Edoxaban 60mg / ASA indication
1491	655	Placebo	no ASA indication	GFW815T	4.8.20 12:45	2021-12-31	Edoxaban 60mg / no ASA indication
1491	655	Placebo	no ASA indication	MKN476U	19.7.22 7:49	2024-04-30	Edoxaban 60mg / ASA indication
1491	655	Placebo	no ASA indication	GYA444P	23.1.20 11:30	2021-12-31	Edoxaban 60mg / no ASA indication
1491	655	Placebo	no ASA indication	HRR218P	19.1.22 12:04	2024-04-30	Edoxaban 60mg / ASA indication
2582	655	Placebo	no ASA indication	GRP211G	13.4.22 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
379	655	Edoxaban	ASA indication	PLD639K	30.5.18 10:33	2020-01-01	Edoxaban 30mg / ASA indication
379	655	Edoxaban	ASA indication	AXB269H	20.12.17 14:58	2018-09-01	Edoxaban 30mg / ASA indication
549	655	Edoxaban	ASA indication	EFF444R	29.5.19 9:14	2020-01-01	Edoxaban 30mg / ASA indication
549	655	Edoxaban	ASA indication	RTL931B	10.5.18 12:52	2020-01-01	Edoxaban 60mg / ASA indication
549	655	Edoxaban	ASA indication	XRK847F	14.11.18 9:47	2020-01-01	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	SES273V	17.11.20 10:45	2022-08-31	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	MRL538T	19.5.21 10:20	2022-08-31	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	VFV619X	13.5.20 10:34	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
559	655	Edoxaban	ASA indication	EZS999N	14.11.18 14:24	2020-01-01	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	SXH387P	25.11.21 12:38	2022-08-31	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	YFB778U	18.5.18 11:52	2020-01-01	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	ZFW646T	8.5.19 12:44	2020-01-01	Edoxaban 30mg / ASA indication
559	655	Edoxaban	ASA indication	PKC474X	13.11.19 13:24	2022-08-31	Edoxaban 30mg / ASA indication
2656	655	Edoxaban	ASA indication	LES995V	15.6.22 11:38	2024-11-30	Edoxaban 30mg / ASA indication
461	655	Edoxaban	no ASA indication	ERX472G	5.9.19 11:55	2022-08-31	Edoxaban 30mg / no ASA indication
461	655	Edoxaban	no ASA indication	UUB167C	4.3.19 12:29	2020-01-01	Edoxaban 60mg / no ASA indication
461	655	Edoxaban	no ASA indication	NAR219A	23.8.18 10:36	2020-01-01	Edoxaban 60mg / no ASA indication
461	655	Edoxaban	no ASA indication	DKP337B	26.8.20 13:01	2021-12-31	Edoxaban 60mg / no ASA indication
461	655	Edoxaban	no ASA indication	ZNF428H	27.2.20 14:08	2022-08-31	Edoxaban 30mg / no ASA indication
461	655	Edoxaban	no ASA indication	PRA871X	26.2.18 11:04	2020-01-01	Edoxaban 60mg / no ASA indication
834	655	Edoxaban	no ASA indication	TBF675Y	20.11.18 13:18	2020-01-01	Edoxaban 60mg / no ASA indication
834	655	Edoxaban	no ASA indication	MDA527L	26.5.22 13:38	2024-11-30	Edoxaban 30mg / no ASA indication
834	655	Edoxaban	no ASA indication	CHK871A	2.12.20 10:49	2022-08-31	Edoxaban 30mg / no ASA indication
834	655	Edoxaban	no ASA indication	UYA185F	10.6.21 11:55	2022-08-31	Edoxaban 30mg / no ASA indication
834	655	Edoxaban	no ASA indication	GBR427R	29.5.19 9:53	2020-01-01	Edoxaban 60mg / no ASA indication
834	655	Edoxaban	no ASA indication	ULB435P	6.12.19 12:15	2021-12-31	Edoxaban 60mg / no ASA indication
834	655	Edoxaban	no ASA indication	ABU346U	18.6.20 12:40	2022-08-31	Edoxaban 30mg / no ASA indication
834	655	Edoxaban	no ASA indication	ARH975K	18.11.21 13:31	2022-08-31	Edoxaban 30mg / no ASA indication
2501	655	Edoxaban	no ASA indication	GUP751Y	25.2.22 9:58	2024-04-30	Edoxaban 60mg / no ASA indication
579	663	Placebo	no ASA indication	AYG337B	18.12.18 9:06	2020-01-01	Edoxaban 60mg / no ASA indication
579	663	Placebo	no ASA indication	XNA277Z	5.6.18 10:52	2020-01-01	Edoxaban 60mg / no ASA indication
579	663	Placebo	no ASA indication	VBU575L	12.6.19 7:46	2020-01-01	Edoxaban 60mg / no ASA indication
223	663	Edoxaban	no ASA indication	ELN485W	21.1.19 15:46	2020-01-01	Edoxaban 60mg / no ASA indication
223	663	Edoxaban	no ASA indication	TPC213X	12.7.17 10:26	2018-09-01	Edoxaban 60mg / no ASA indication
223	663	Edoxaban	no ASA indication	XYD366Z	11.1.18 9:06	2018-09-01	Edoxaban 60mg / no ASA indication
223	663	Edoxaban	no ASA indication	UTT741Z	6.7.18 8:53	2020-01-01	Edoxaban 60mg / no ASA indication
259	669	Placebo	ASA indication	SCT156M	9.1.20 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
259	669	Placebo	ASA indication	SSZ983V	15.8.18 10:13	2020-01-01	Edoxaban 60mg / ASA indication
259	669	Placebo	ASA indication	ETL265D	21.8.17 10:45	2018-09-01	Edoxaban 60mg / ASA indication
259	669	Placebo	ASA indication	BPN177B	17.1.19 8:55	2020-01-01	Edoxaban 60mg / no ASA indication
259	669	Placebo	ASA indication	MXT394K	17.7.19 9:17	2021-12-31	Edoxaban 60mg / no ASA indication
259	669	Placebo	ASA indication	VXX889X	6.2.18 9:25	2018-09-01	Edoxaban 60mg / ASA indication
1220	669	Placebo	no ASA indication	XZY442T	9.7.19 8:12	2021-12-31	Edoxaban 60mg / no ASA indication
450	669	Edoxaban	ASA indication	VXP634L	20.2.18 9:42	2020-01-01	Edoxaban 60mg / ASA indication
450	669	Edoxaban	ASA indication	HFP775U	12.2.19 10:04	2020-01-01	Edoxaban 60mg / no ASA indication
450	669	Edoxaban	ASA indication	EKN546K	4.2.20 10:05	2021-12-31	Edoxaban 60mg / no ASA indication
450	669	Edoxaban	ASA indication	PRC299K	16.8.18 9:49	2020-01-01	Edoxaban 60mg / ASA indication
450	669	Edoxaban	ASA indication	CEC852N	1.8.19 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
450	669	Edoxaban	ASA indication	TWK823N	18.8.20 8:55	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
450	669	Edoxaban	ASA indication	GDM528X	3.2.21 11:04	2021-12-31	Edoxaban 60mg / no ASA indication
1075	669	Edoxaban	no ASA indication	HNK671A	11.4.19 10:24	2020-01-01	Edoxaban 30mg / no ASA indication
1075	669	Edoxaban	no ASA indication	DNA999C	23.10.19 9:20	2022-08-31	Edoxaban 30mg / ASA indication
1075	669	Edoxaban	no ASA indication	GMX992M	22.4.20 9:48	2022-08-31	Edoxaban 30mg / no ASA indication
1075	669	Edoxaban	no ASA indication	BLA215E	15.10.20 8:10	2022-08-31	Edoxaban 30mg / no ASA indication
1075	669	Edoxaban	no ASA indication	FDF318M	13.4.21 8:24	2022-08-31	Edoxaban 30mg / no ASA indication
1723	669	Edoxaban	no ASA indication	TYZ739B	5.8.20 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
269	673	Placebo	ASA indication	UUM841R	5.9.18 7:38	2020-01-01	Edoxaban 30mg / no ASA indication
269	673	Placebo	ASA indication	KTE859A	5.9.17 11:11	2018-09-01	Edoxaban 30mg / ASA indication
269	673	Placebo	ASA indication	NER367C	14.3.19 11:42	2020-01-01	Edoxaban 30mg / no ASA indication
269	673	Placebo	ASA indication	NEL924L	5.3.18 10:14	2020-01-01	Edoxaban 30mg / no ASA indication
1097	673	Placebo	ASA indication	LRF522S	15.5.20 8:22	2021-12-31	Edoxaban 60mg / no ASA indication
1097	673	Placebo	ASA indication	ZFA967L	26.4.19 10:35	2020-01-01	Edoxaban 60mg / ASA indication
1097	673	Placebo	ASA indication	XLU355K	26.10.21 8:26	2024-04-30	Edoxaban 60mg / no ASA indication
1097	673	Placebo	ASA indication	VCB532A	29.4.22 11:24	2024-04-30	Edoxaban 60mg / no ASA indication
1097	673	Placebo	ASA indication	CGE221Y	15.10.20 13:07	2021-12-31	Edoxaban 60mg / no ASA indication
1097	673	Placebo	ASA indication	HSW122G	27.4.21 9:32	2021-12-31	Edoxaban 60mg / no ASA indication
1097	673	Placebo	ASA indication	KUN293Y	29.10.19 13:16	2021-12-31	Edoxaban 60mg / no ASA indication
1916	673	Placebo	ASA indication	ZGK534H	20.12.21 12:09	2024-04-30	Edoxaban 60mg / no ASA indication
1916	673	Placebo	ASA indication	BDK937Y	30.6.22 8:27	2024-11-30	Edoxaban 30mg / ASA indication
1916	673	Placebo	ASA indication	LVN393V	31.12.20 11:37	2022-08-31	Edoxaban 30mg / ASA indication
1916	673	Placebo	ASA indication	KGY392H	30.6.21 11:00	2022-08-31	Edoxaban 30mg / no ASA indication
2234	673	Placebo	ASA indication	RXV667S	19.8.21 11:51	2022-08-31	Edoxaban 30mg / ASA indication
2234	673	Placebo	ASA indication	BRB925H	2.3.22 10:43	2024-11-30	Edoxaban 30mg / no ASA indication
2337	673	Placebo	ASA indication	BAK347N	13.5.22 7:11	2024-04-30	Edoxaban 60mg / ASA indication
2337	673	Placebo	ASA indication	BCK259V	10.11.21 9:30	2024-04-30	Edoxaban 60mg / ASA indication
2339	673	Placebo	ASA indication	BAN811R	10.11.21 11:37	2024-04-30	Edoxaban 60mg / ASA indication
2339	673	Placebo	ASA indication	WTL775V	13.5.22 10:09	2024-04-30	Edoxaban 60mg / ASA indication
87	673	Placebo	no ASA indication	BVN356Y	2.2.17 12:21	2018-09-01	Edoxaban 60mg / no ASA indication
87	673	Placebo	no ASA indication	XFE648F	2.8.17 12:03	2018-09-01	Edoxaban 30mg / no ASA indication
87	673	Placebo	no ASA indication	FLK699P	5.2.18 12:26	2018-09-01	Edoxaban 60mg / no ASA indication
194	673	Placebo	no ASA indication	UMV519F	15.6.17 10:28	2018-09-01	Edoxaban 60mg / no ASA indication
194	673	Placebo	no ASA indication	XPC886R	13.6.19 10:40	2020-01-01	Edoxaban 60mg / no ASA indication
194	673	Placebo	no ASA indication	YBP136F	13.12.17 9:29	2018-09-01	Edoxaban 60mg / no ASA indication
194	673	Placebo	no ASA indication	SDM813W	14.6.18 7:46	2020-01-01	Edoxaban 60mg / no ASA indication
194	673	Placebo	no ASA indication	PKX548R	23.12.19 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
194	673	Placebo	no ASA indication	LWZ476A	17.12.18 12:06	2020-01-01	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	XHH186N	29.4.19 9:58	2020-01-01	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	DDZ383S	31.10.17 13:29	2018-09-01	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	MGG636Z	25.4.18 11:52	2020-01-01	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	MSU526P	3.5.22 8:24	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
324	673	Placebo	no ASA indication	BPK819R	31.10.18 12:32	2020-01-01	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	NDH431G	30.10.19 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	ECF445S	28.4.21 8:43	2021-12-31	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	URR114F	5.5.20 9:21	2021-12-31	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	KPH651E	29.10.20 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
324	673	Placebo	no ASA indication	YLC644Y	28.10.21 9:07	2024-04-30	Edoxaban 60mg / no ASA indication
821	673	Placebo	no ASA indication	MBZ629H	13.11.19 9:53	2021-12-31	Edoxaban 60mg / no ASA indication
821	673	Placebo	no ASA indication	LYU656A	15.5.19 8:38	2020-01-01	Edoxaban 60mg / no ASA indication
821	673	Placebo	no ASA indication	KFC128A	15.11.18 9:01	2020-01-01	Edoxaban 60mg / no ASA indication
833	673	Placebo	no ASA indication	BMN481C	19.11.20 11:16	2022-08-31	Edoxaban 30mg / no ASA indication
833	673	Placebo	no ASA indication	VFW193V	19.11.21 9:34	2022-08-31	Edoxaban 30mg / no ASA indication
833	673	Placebo	no ASA indication	NWC992R	26.5.21 8:41	2022-08-31	Edoxaban 30mg / no ASA indication
833	673	Placebo	no ASA indication	NGV561M	20.11.19 11:05	2021-12-31	Edoxaban 60mg / no ASA indication
833	673	Placebo	no ASA indication	PVU769A	20.5.22 8:10	2024-11-30	Edoxaban 30mg / no ASA indication
833	673	Placebo	no ASA indication	LZU717A	20.11.18 12:50	2020-01-01	Edoxaban 30mg / no ASA indication
833	673	Placebo	no ASA indication	BRT154H	21.5.19 8:34	2020-01-01	Edoxaban 30mg / no ASA indication
833	673	Placebo	no ASA indication	WPV974A	27.5.20 9:45	2021-12-31	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	WKK641K	1.10.19 8:15	2021-12-31	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	MTG868A	1.4.19 12:08	2020-01-01	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	XLH623P	30.9.21 9:43	2024-04-30	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	ZUP834Y	5.10.20 9:11	2021-12-31	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	PMW754W	7.4.21 9:06	2021-12-31	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	VLT217Y	27.3.20 9:23	2021-12-31	Edoxaban 60mg / no ASA indication
1048	673	Placebo	no ASA indication	XRE978L	31.3.22 7:59	2024-04-30	Edoxaban 60mg / no ASA indication
1150	673	Placebo	no ASA indication	DHY128A	28.11.19 9:43	2022-08-31	Edoxaban 30mg / no ASA indication
1150	673	Placebo	no ASA indication	DAK683V	2.6.20 8:43	2022-08-31	Edoxaban 30mg / no ASA indication
1150	673	Placebo	no ASA indication	FUW432R	29.5.19 11:49	2020-01-01	Edoxaban 30mg / no ASA indication
1287	673	Placebo	no ASA indication	AWN949D	16.9.21 8:43	2024-04-30	Edoxaban 60mg / no ASA indication
1287	673	Placebo	no ASA indication	RCA665Z	2.4.20 12:06	2021-12-31	Edoxaban 60mg / no ASA indication
1287	673	Placebo	no ASA indication	SGU456W	16.9.20 10:11	2021-12-31	Edoxaban 60mg / no ASA indication
1287	673	Placebo	no ASA indication	WNH242X	16.9.19 12:22	2021-12-31	Edoxaban 60mg / no ASA indication
1287	673	Placebo	no ASA indication	ECP892G	17.3.21 10:06	2021-12-31	Edoxaban 60mg / no ASA indication
1302	673	Placebo	no ASA indication	YNX877A	26.9.19 11:35	2021-12-31	Edoxaban 60mg / no ASA indication
1533	673	Placebo	no ASA indication	AXZ853E	7.9.21 9:22	2024-04-30	Edoxaban 60mg / no ASA indication
1533	673	Placebo	no ASA indication	MRD475K	28.2.20 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
1533	673	Placebo	no ASA indication	XSB175D	4.3.22 9:23	2024-04-30	Edoxaban 60mg / no ASA indication
1533	673	Placebo	no ASA indication	DRM175N	2.9.20 9:29	2021-12-31	Edoxaban 60mg / no ASA indication
1533	673	Placebo	no ASA indication	HNM842C	25.2.21 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
1567	673	Placebo	no ASA indication	URD473U	26.3.20 10:04	2021-12-31	Edoxaban 60mg / no ASA indication
1849	673	Placebo	no ASA indication	NYK679Y	4.5.21 8:30	2021-12-31	Edoxaban 60mg / no ASA indication
1849	673	Placebo	no ASA indication	XRA759U	4.11.20 11:27	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1849	673	Placebo	no ASA indication	ZHR318A	4.11.21 8:48	2024-04-30	Edoxaban 60mg / no ASA indication
1849	673	Placebo	no ASA indication	CUR442D	4.5.22 7:32	2024-04-30	Edoxaban 60mg / no ASA indication
1864	673	Placebo	no ASA indication	TYV679X	15.11.21 8:54	2022-08-31	Edoxaban 30mg / no ASA indication
1864	673	Placebo	no ASA indication	GEU684T	10.5.21 8:53	2022-08-31	Edoxaban 30mg / no ASA indication
1864	673	Placebo	no ASA indication	RLX183N	20.5.22 7:01	2024-11-30	Edoxaban 30mg / no ASA indication
1864	673	Placebo	no ASA indication	VPW759A	11.11.20 14:04	2022-08-31	Edoxaban 30mg / no ASA indication
1875	673	Placebo	no ASA indication	XSD877B	19.11.20 12:12	2021-12-31	Edoxaban 60mg / no ASA indication
1875	673	Placebo	no ASA indication	UVZ568B	27.5.21 8:50	2021-12-31	Edoxaban 60mg / no ASA indication
2086	673	Placebo	no ASA indication	LGD338R	5.5.21 9:35	2022-08-31	Edoxaban 30mg / no ASA indication
2268	673	Placebo	no ASA indication	BCV955R	14.3.22 9:01	2024-04-30	Edoxaban 60mg / ASA indication
2268	673	Placebo	no ASA indication	AYU216N	14.9.21 8:14	2024-04-30	Edoxaban 60mg / no ASA indication
2275	673	Placebo	no ASA indication	AXR275N	16.3.22 8:31	2024-04-30	Edoxaban 60mg / no ASA indication
2275	673	Placebo	no ASA indication	VMG579P	16.9.21 10:22	2024-04-30	Edoxaban 60mg / no ASA indication
2541	673	Placebo	no ASA indication	BNS855F	18.3.22 11:10	2024-11-30	Edoxaban 30mg / no ASA indication
2575	673	Placebo	no ASA indication	PVY251N	6.4.22 10:59	2024-11-30	Edoxaban 30mg / no ASA indication
948	673	Edoxaban	ASA indication	MGZ492L	5.7.19 8:35	2022-08-31	Edoxaban 30mg / no ASA indication
948	673	Edoxaban	ASA indication	TXB519T	22.1.19 14:39	2020-01-01	Edoxaban 60mg / ASA indication
1372	673	Edoxaban	ASA indication	AYU392K	6.5.20 7:11	2021-12-31	Edoxaban 60mg / no ASA indication
1372	673	Edoxaban	ASA indication	DGY442Z	7.11.19 12:00	2022-08-31	Edoxaban 30mg / ASA indication
1372	673	Edoxaban	ASA indication	TNE259V	6.5.20 9:33	2021-12-31	Edoxaban 60mg / ASA indication
1372	673	Edoxaban	ASA indication	DSA955E	5.11.20 9:19	2022-08-31	Edoxaban 30mg / no ASA indication
1372	673	Edoxaban	ASA indication	PZX255L	6.5.21 8:09	2022-08-31	Edoxaban 30mg / no ASA indication
1713	673	Edoxaban	ASA indication	BBP129U	21.7.21 7:53	2024-04-30	Edoxaban 60mg / no ASA indication
1713	673	Edoxaban	ASA indication	CFP935F	31.1.22 10:54	2024-04-30	Edoxaban 60mg / no ASA indication
1713	673	Edoxaban	ASA indication	LGA637P	30.7.20 9:19	2022-08-31	Edoxaban 30mg / ASA indication
1713	673	Edoxaban	ASA indication	WNN151M	28.1.21 9:02	2021-12-31	Edoxaban 60mg / no ASA indication
1913	673	Edoxaban	ASA indication	GFZ233H	23.6.21 9:54	2022-08-31	Edoxaban 30mg / no ASA indication
1913	673	Edoxaban	ASA indication	AZT865U	16.12.21 11:58	2024-04-30	Edoxaban 60mg / no ASA indication
1913	673	Edoxaban	ASA indication	EPH616H	21.12.20 11:51	2022-08-31	Edoxaban 30mg / ASA indication
1913	673	Edoxaban	ASA indication	RBC717W	20.6.22 7:44	2024-11-30	Edoxaban 30mg / no ASA indication
91	673	Edoxaban	no ASA indication	ZPA977W	8.2.17 12:37	2018-09-01	Edoxaban 30mg / no ASA indication
337	673	Edoxaban	no ASA indication	CKK186A	9.4.18 12:46	2020-01-01	Edoxaban 60mg / no ASA indication
337	673	Edoxaban	no ASA indication	CFG374R	5.11.18 10:42	2020-01-01	Edoxaban 60mg / no ASA indication
337	673	Edoxaban	no ASA indication	NFX217L	6.5.20 6:03	2021-12-31	Edoxaban 60mg / no ASA indication
337	673	Edoxaban	no ASA indication	UEB633C	11.11.19 10:35	2021-12-31	Edoxaban 60mg / no ASA indication
337	673	Edoxaban	no ASA indication	YKN526G	10.11.17 13:38	2018-09-01	Edoxaban 60mg / no ASA indication
337	673	Edoxaban	no ASA indication	CDN812K	7.5.19 10:29	2020-01-01	Edoxaban 60mg / no ASA indication
427	673	Edoxaban	no ASA indication	HTM227A	1.2.18 11:43	2018-09-01	Edoxaban 30mg / no ASA indication
707	673	Edoxaban	no ASA indication	ZNR972X	25.3.19 12:13	2020-01-01	Edoxaban 30mg / no ASA indication
707	673	Edoxaban	no ASA indication	RVG611B	14.9.18 12:08	2020-01-01	Edoxaban 30mg / no ASA indication
837	673	Edoxaban	no ASA indication	BAT689H	21.11.19 10:08	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
837	673	Edoxaban	no ASA indication	MZU437E	21.11.18 13:03	2020-01-01	Edoxaban 60mg / no ASA indication
837	673	Edoxaban	no ASA indication	BEY151E	25.11.20 10:18	2021-12-31	Edoxaban 60mg / no ASA indication
837	673	Edoxaban	no ASA indication	WGD457D	21.5.19 10:21	2020-01-01	Edoxaban 60mg / no ASA indication
837	673	Edoxaban	no ASA indication	NNZ562X	27.5.20 10:27	2021-12-31	Edoxaban 60mg / no ASA indication
837	673	Edoxaban	no ASA indication	SES284P	20.5.21 7:45	2021-12-31	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	KZM335K	3.10.19 9:47	2021-12-31	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	PDH522D	12.4.21 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	BAG313V	5.10.21 8:42	2024-04-30	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	SBG863V	27.3.20 10:12	2021-12-31	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	NRM828Y	5.4.22 7:16	2024-04-30	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	RRP283T	2.4.19 13:14	2020-01-01	Edoxaban 60mg / no ASA indication
1052	673	Edoxaban	no ASA indication	KRL858H	30.9.20 8:47	2021-12-31	Edoxaban 60mg / no ASA indication
1136	673	Edoxaban	no ASA indication	FSK321C	25.11.19 9:28	2022-08-31	Edoxaban 30mg / no ASA indication
1136	673	Edoxaban	no ASA indication	WRZ117K	22.5.19 10:46	2020-01-01	Edoxaban 30mg / no ASA indication
1168	673	Edoxaban	no ASA indication	AWV866W	14.12.21 9:57	2024-04-30	Edoxaban 60mg / no ASA indication
1168	673	Edoxaban	no ASA indication	DTW869V	9.6.20 9:08	2021-12-31	Edoxaban 60mg / no ASA indication
1168	673	Edoxaban	no ASA indication	HSC387B	10.6.19 12:14	2020-01-01	Edoxaban 60mg / no ASA indication
1168	673	Edoxaban	no ASA indication	YUK794R	9.6.22 7:08	2024-04-30	Edoxaban 60mg / no ASA indication
1168	673	Edoxaban	no ASA indication	UPW847C	10.12.20 12:28	2021-12-31	Edoxaban 60mg / no ASA indication
1168	673	Edoxaban	no ASA indication	RVM273Z	10.6.21 11:07	2021-12-31	Edoxaban 60mg / no ASA indication
1168	673	Edoxaban	no ASA indication	CDP655U	15.1.20 12:39	2021-12-31	Edoxaban 60mg / no ASA indication
1382	673	Edoxaban	no ASA indication	DXU484E	12.11.20 8:45	2021-12-31	Edoxaban 60mg / no ASA indication
1382	673	Edoxaban	no ASA indication	XSW983A	13.5.20 8:38	2021-12-31	Edoxaban 60mg / no ASA indication
1382	673	Edoxaban	no ASA indication	XCC582A	13.11.19 12:00	2021-12-31	Edoxaban 60mg / no ASA indication
1382	673	Edoxaban	no ASA indication	YCW669W	11.11.21 8:20	2024-04-30	Edoxaban 60mg / no ASA indication
1382	673	Edoxaban	no ASA indication	PCN658H	5.5.21 7:59	2021-12-31	Edoxaban 60mg / no ASA indication
1662	673	Edoxaban	no ASA indication	UNG139H	25.6.20 12:45	2022-08-31	Edoxaban 30mg / no ASA indication
1662	673	Edoxaban	no ASA indication	PVX951K	22.12.20 10:39	2022-08-31	Edoxaban 30mg / no ASA indication
1797	673	Edoxaban	no ASA indication	WRE556K	24.3.21 8:44	2021-12-31	Edoxaban 60mg / no ASA indication
1797	673	Edoxaban	no ASA indication	CYL418V	23.9.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1797	673	Edoxaban	no ASA indication	VLG558X	23.9.21 9:16	2024-04-30	Edoxaban 60mg / no ASA indication
1797	673	Edoxaban	no ASA indication	NUH415R	25.3.22 8:56	2024-04-30	Edoxaban 60mg / no ASA indication
1862	673	Edoxaban	no ASA indication	REZ897R	11.11.20 12:41	2022-08-31	Edoxaban 30mg / no ASA indication
1866	673	Edoxaban	no ASA indication	LGL191Z	12.11.20 11:39	2022-08-31	Edoxaban 30mg / no ASA indication
1866	673	Edoxaban	no ASA indication	YCT963U	12.11.21 9:01	2024-04-30	Edoxaban 60mg / no ASA indication
1866	673	Edoxaban	no ASA indication	SSL475R	12.5.21 8:44	2022-08-31	Edoxaban 30mg / no ASA indication
2077	673	Edoxaban	no ASA indication	VBE681G	10.11.21 10:00	2022-08-31	Edoxaban 30mg / no ASA indication
2077	673	Edoxaban	no ASA indication	CPE395F	28.4.22 8:05	2024-11-30	Edoxaban 30mg / no ASA indication
2077	673	Edoxaban	no ASA indication	WDF893H	29.4.21 12:16	2022-08-31	Edoxaban 30mg / no ASA indication
2139	673	Edoxaban	no ASA indication	EYW447K	17.12.21 8:52	2022-08-31	Edoxaban 30mg / no ASA indication
2139	673	Edoxaban	no ASA indication	PEE877V	7.6.21 7:07	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2139	673	Edoxaban	no ASA indication	CTG412V	8.6.22 8:10	2024-11-30	Edoxaban 30mg / no ASA indication
2146	673	Edoxaban	no ASA indication	VLG496T	15.12.21 10:09	2024-04-30	Edoxaban 60mg / no ASA indication
2146	673	Edoxaban	no ASA indication	YUV765T	14.6.22 9:50	2024-04-30	Edoxaban 60mg / no ASA indication
2146	673	Edoxaban	no ASA indication	SEF119C	10.6.21 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
2263	673	Edoxaban	no ASA indication	NZV254E	10.9.21 9:25	2022-08-31	Edoxaban 30mg / no ASA indication
2263	673	Edoxaban	no ASA indication	BLL924A	9.3.22 9:29	2024-11-30	Edoxaban 30mg / ASA indication
2433	673	Edoxaban	no ASA indication	HKZ716A	17.1.22 8:49	2024-04-30	Edoxaban 60mg / no ASA indication
1448	674	Placebo	ASA indication	AWF162G	13.12.19 12:39	2021-12-31	Edoxaban 60mg / ASA indication
1448	674	Placebo	ASA indication	MAE311Y	8.6.20 12:32	2022-08-31	Edoxaban 30mg / ASA indication
886	674	Placebo	no ASA indication	EPV213Y	12.12.18 10:09	2020-01-01	Edoxaban 60mg / no ASA indication
886	674	Placebo	no ASA indication	RDH224N	8.6.20 10:47	2021-12-31	Edoxaban 60mg / no ASA indication
886	674	Placebo	no ASA indication	RYE836P	16.12.20 10:41	2021-12-31	Edoxaban 60mg / no ASA indication
886	674	Placebo	no ASA indication	PNM865V	3.6.19 10:00	2020-01-01	Edoxaban 60mg / no ASA indication
886	674	Placebo	no ASA indication	HTE721C	4.12.19 12:04	2021-12-31	Edoxaban 60mg / no ASA indication
888	674	Placebo	no ASA indication	SXW496H	4.12.19 10:25	2022-08-31	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	ARR864B	10.6.22 11:15	2024-11-30	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	ZHY611B	13.6.19 8:21	2020-01-01	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	YCF591X	5.1.22 10:50	2022-08-31	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	BTS728S	16.6.21 12:24	2022-08-31	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	FMF533E	13.12.18 11:11	2020-01-01	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	BVV635B	16.12.20 10:56	2022-08-31	Edoxaban 30mg / no ASA indication
888	674	Placebo	no ASA indication	WCW377W	8.6.20 10:14	2022-08-31	Edoxaban 30mg / no ASA indication
307	675	Placebo	no ASA indication	EFF815W	19.10.17 8:30	2018-09-01	Edoxaban 60mg / no ASA indication
307	675	Placebo	no ASA indication	GYM937B	19.4.18 12:08	2020-01-01	Edoxaban 60mg / no ASA indication
345	675	Placebo	no ASA indication	XDA557D	22.11.17 8:47	2018-09-01	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	RHY644Y	14.12.18 11:19	2020-01-01	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	SEH242S	7.12.17 10:35	2018-09-01	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	CNC348Y	27.5.20 10:20	2022-08-31	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	WAG796D	25.11.20 11:46	2022-08-31	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	XNC213N	31.5.19 7:16	2020-01-01	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	DNX916L	31.5.21 11:43	2022-08-31	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	WBK512E	28.11.19 10:04	2022-08-31	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	VUP686L	14.6.18 12:06	2020-01-01	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	DFF844Z	27.5.22 10:08	2024-11-30	Edoxaban 30mg / no ASA indication
365	675	Placebo	no ASA indication	WUC451A	26.11.21 12:27	2022-08-31	Edoxaban 30mg / no ASA indication
591	675	Placebo	no ASA indication	XMB968L	4.12.19 9:42	2021-12-31	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	HXY764A	9.12.20 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	LAN145H	16.12.21 11:43	2024-04-30	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	TXT615V	14.6.18 10:30	2020-01-01	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	CDP938T	21.6.19 7:53	2021-12-31	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	KZP996E	23.6.22 10:25	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
591	675	Placebo	no ASA indication	LNM621C	14.12.18 10:45	2020-01-01	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	HKZ772Z	17.6.21 10:17	2021-12-31	Edoxaban 60mg / no ASA indication
591	675	Placebo	no ASA indication	VTH356M	3.6.20 9:02	2021-12-31	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	UKM733S	22.7.20 7:49	2021-12-31	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	HSS565H	11.1.19 10:51	2020-01-01	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	BWH411F	21.7.21 10:00	2022-08-31	Edoxaban 30mg / no ASA indication
233	675	Edoxaban	no ASA indication	GME996W	13.1.20 10:43	2021-12-31	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	ULR854N	3.2.21 11:15	2021-12-31	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	KBC324S	25.1.18 11:53	2018-09-01	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	CST825W	4.7.19 8:11	2022-08-31	Edoxaban 30mg / no ASA indication
233	675	Edoxaban	no ASA indication	LLD936V	26.1.22 11:11	2024-04-30	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	NBA744S	25.7.17 10:24	2018-09-01	Edoxaban 60mg / no ASA indication
233	675	Edoxaban	no ASA indication	GKD449M	17.7.18 8:40	2020-01-01	Edoxaban 60mg / no ASA indication
240	675	Edoxaban	no ASA indication	CSV579S	26.7.18 7:31	2020-01-01	Edoxaban 60mg / no ASA indication
240	675	Edoxaban	no ASA indication	VDP699B	31.7.17 8:27	2018-09-01	Edoxaban 60mg / no ASA indication
240	675	Edoxaban	no ASA indication	NGL298G	31.1.18 11:28	2018-09-01	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	UAN745N	11.7.18 9:56	2020-01-01	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	WZB658Y	19.7.19 9:58	2021-12-31	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	CXF491Z	7.7.20 10:13	2021-12-31	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	NNA139K	4.1.18 9:28	2018-09-01	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	LLA983E	23.6.21 9:41	2024-04-30	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	LNE314K	22.12.21 11:46	2024-04-30	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	KUM316Z	29.6.22 10:48	2024-04-30	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	KKS954X	24.1.19 10:30	2020-01-01	Edoxaban 30mg / no ASA indication
384	675	Edoxaban	no ASA indication	EGF196E	17.1.20 11:58	2021-12-31	Edoxaban 60mg / no ASA indication
384	675	Edoxaban	no ASA indication	ZSH463Z	21.12.20 12:07	2022-08-31	Edoxaban 30mg / no ASA indication
507	675	Edoxaban	no ASA indication	KAE592H	3.4.18 11:06	2020-01-01	Edoxaban 60mg / no ASA indication
942	675	Edoxaban	no ASA indication	ALV748C	18.1.19 10:30	2020-01-01	Edoxaban 60mg / no ASA indication
505	679	Placebo	no ASA indication	SVL451S	11.4.18 9:56	2020-01-01	Edoxaban 30mg / no ASA indication
1078	679	Edoxaban	no ASA indication	ZEW977G	30.4.20 6:28	2021-12-31	Edoxaban 60mg / no ASA indication
1078	679	Edoxaban	no ASA indication	THV314K	28.10.19 7:41	2021-12-31	Edoxaban 60mg / no ASA indication
1078	679	Edoxaban	no ASA indication	DBD411G	15.4.19 10:08	2020-01-01	Edoxaban 60mg / no ASA indication
711	680	Placebo	ASA indication	XVU622K	18.3.21 9:41	2022-08-31	Edoxaban 30mg / ASA indication
711	680	Placebo	ASA indication	VZV196N	18.9.18 8:59	2020-01-01	Edoxaban 30mg / ASA indication
711	680	Placebo	ASA indication	ZHT517R	20.3.19 9:08	2020-01-01	Edoxaban 30mg / ASA indication
711	680	Placebo	ASA indication	LHN565P	18.9.19 7:30	2022-08-31	Edoxaban 30mg / ASA indication
711	680	Placebo	ASA indication	GEL562B	3.4.20 6:06	2022-08-31	Edoxaban 30mg / ASA indication
711	680	Placebo	ASA indication	NZA475T	17.9.20 6:56	2022-08-31	Edoxaban 30mg / ASA indication
772	680	Placebo	ASA indication	KVH253M	25.10.18 10:13	2020-01-01	Edoxaban 60mg / ASA indication
783	680	Placebo	ASA indication	NWD489R	24.4.19 7:19	2020-01-01	Edoxaban 60mg / ASA indication
783	680	Placebo	ASA indication	YBU211L	24.4.20 10:06	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
783	680	Placebo	ASA indication	ZCC665H	31.10.18 10:03	2020-01-01	Edoxaban 60mg / ASA indication
783	680	Placebo	ASA indication	WXF227T	22.10.19 9:19	2021-12-31	Edoxaban 60mg / ASA indication
789	680	Placebo	ASA indication	UDC337T	13.11.18 12:16	2020-01-01	Edoxaban 60mg / ASA indication
836	680	Placebo	ASA indication	HAK474X	21.11.18 11:15	2020-01-01	Edoxaban 60mg / ASA indication
902	680	Placebo	ASA indication	DHB296K	19.12.18 9:32	2020-01-01	Edoxaban 30mg / ASA indication
902	680	Placebo	ASA indication	CCA276M	11.6.19 8:32	2020-01-01	Edoxaban 60mg / ASA indication
904	680	Placebo	ASA indication	SAE483W	20.12.18 10:29	2020-01-01	Edoxaban 60mg / ASA indication
904	680	Placebo	ASA indication	VCD366C	7.6.19 7:02	2020-01-01	Edoxaban 30mg / ASA indication
904	680	Placebo	ASA indication	RDZ261F	17.12.20 8:15	2022-08-31	Edoxaban 30mg / ASA indication
904	680	Placebo	ASA indication	WRG292K	17.6.20 8:48	2022-08-31	Edoxaban 30mg / ASA indication
904	680	Placebo	ASA indication	UKE456Y	24.6.22 7:08	2024-11-30	Edoxaban 30mg / ASA indication
904	680	Placebo	ASA indication	HST374S	25.6.21 9:55	2022-08-31	Edoxaban 30mg / ASA indication
904	680	Placebo	ASA indication	EFT465U	19.12.19 9:28	2022-08-31	Edoxaban 30mg / ASA indication
904	680	Placebo	ASA indication	NCT553Z	21.12.21 8:30	2022-08-31	Edoxaban 30mg / ASA indication
935	680	Placebo	ASA indication	CYE192W	13.7.20 7:21	2021-12-31	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	DSM853H	14.7.22 8:31	2024-04-30	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	SXR677A	16.1.19 11:17	2020-01-01	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	EGT938C	13.1.22 9:35	2024-04-30	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	FWT194V	18.7.19 9:42	2021-12-31	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	HEC819U	18.1.21 8:30	2021-12-31	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	BKM818Y	15.7.21 8:55	2024-04-30	Edoxaban 60mg / ASA indication
935	680	Placebo	ASA indication	NZR834R	15.1.20 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
979	680	Placebo	ASA indication	MNL429C	21.7.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	UFS858A	5.2.20 11:23	2021-12-31	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	PFY886W	18.8.22 9:08	2024-04-30	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	NWN545V	1.8.19 8:34	2021-12-31	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	UBG889L	3.2.21 11:46	2021-12-31	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	CNT553U	7.2.19 10:04	2020-01-01	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	VEN143M	18.8.21 6:40	2024-04-30	Edoxaban 60mg / ASA indication
979	680	Placebo	ASA indication	PHS184R	9.2.22 11:24	2024-04-30	Edoxaban 60mg / ASA indication
981	680	Placebo	ASA indication	YPM211U	2.2.22 10:56	2022-08-31	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	MAK568A	7.2.19 10:10	2020-01-01	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	GWV673R	30.7.19 9:09	2022-08-31	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	RAP129R	2.2.21 13:16	2022-08-31	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	KLT371Y	30.1.20 10:52	2022-08-31	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	SUP565H	17.8.22 9:22	2024-11-30	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	WGS756Z	27.1.21 9:32	2022-08-31	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	CHL515L	21.7.20 8:09	2022-08-31	Edoxaban 30mg / ASA indication
981	680	Placebo	ASA indication	PMF222M	29.7.21 10:24	2022-08-31	Edoxaban 30mg / ASA indication
1024	680	Placebo	ASA indication	PSX382M	12.3.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
1024	680	Placebo	ASA indication	YVK274M	12.9.19 7:44	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1024	680	Placebo	ASA indication	UZB522H	15.3.22 9:26	2024-04-30	Edoxaban 60mg / ASA indication
1024	680	Placebo	ASA indication	VBM635E	14.3.19 9:35	2020-01-01	Edoxaban 60mg / ASA indication
1024	680	Placebo	ASA indication	AZP222H	10.3.21 10:31	2021-12-31	Edoxaban 60mg / ASA indication
1024	680	Placebo	ASA indication	KMU459Z	10.9.20 8:32	2021-12-31	Edoxaban 60mg / ASA indication
1024	680	Placebo	ASA indication	WUT397Z	21.9.21 9:03	2024-04-30	Edoxaban 60mg / ASA indication
1037	680	Placebo	ASA indication	AYT926K	26.3.19 9:20	2020-01-01	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	DLW257U	31.3.20 9:59	2021-12-31	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	LRA677K	28.3.19 9:58	2020-01-01	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	BKC472F	30.9.21 7:12	2024-04-30	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	KRS385T	23.9.20 9:55	2021-12-31	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	RSD813N	22.3.21 10:32	2021-12-31	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	UWL643U	2.10.19 8:48	2021-12-31	Edoxaban 60mg / ASA indication
1044	680	Placebo	ASA indication	XGM298W	31.3.22 10:32	2024-04-30	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	UPL761T	1.10.19 7:22	2021-12-31	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	MCU333P	27.3.20 9:30	2021-12-31	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	BMC146L	5.10.21 7:36	2024-04-30	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	WKS879S	30.9.20 8:29	2021-12-31	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	MKW139Z	9.4.19 8:51	2020-01-01	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	XKG738V	5.4.22 7:43	2024-04-30	Edoxaban 60mg / ASA indication
1064	680	Placebo	ASA indication	TZX733X	14.4.21 7:34	2021-12-31	Edoxaban 60mg / ASA indication
1079	680	Placebo	ASA indication	DTU256G	15.4.19 9:13	2020-01-01	Edoxaban 60mg / ASA indication
1079	680	Placebo	ASA indication	MUP715Y	15.10.20 9:18	2022-08-31	Edoxaban 30mg / ASA indication
1079	680	Placebo	ASA indication	FBZ142T	13.4.21 10:19	2022-08-31	Edoxaban 30mg / ASA indication
1079	680	Placebo	ASA indication	XKH442R	13.10.21 10:48	2022-08-31	Edoxaban 30mg / ASA indication
1079	680	Placebo	ASA indication	LNY159U	16.10.19 9:27	2022-08-31	Edoxaban 30mg / ASA indication
1079	680	Placebo	ASA indication	NXB249X	23.4.20 9:38	2022-08-31	Edoxaban 30mg / ASA indication
1122	680	Placebo	ASA indication	EUZ433H	19.5.22 7:49	2024-04-30	Edoxaban 60mg / no ASA indication
1122	680	Placebo	ASA indication	MVV472H	20.5.21 7:55	2021-12-31	Edoxaban 60mg / ASA indication
1122	680	Placebo	ASA indication	BBX271Z	20.11.19 9:45	2021-12-31	Edoxaban 60mg / ASA indication
1122	680	Placebo	ASA indication	BKT921N	20.5.20 7:59	2021-12-31	Edoxaban 60mg / ASA indication
1122	680	Placebo	ASA indication	ZGT955L	14.5.19 9:00	2020-01-01	Edoxaban 60mg / ASA indication
1122	680	Placebo	ASA indication	YKW528L	18.11.21 9:09	2024-04-30	Edoxaban 60mg / ASA indication
1122	680	Placebo	ASA indication	KLK159M	19.11.20 8:42	2021-12-31	Edoxaban 60mg / ASA indication
1129	680	Placebo	ASA indication	WED438X	15.5.19 10:28	2020-01-01	Edoxaban 60mg / ASA indication
1210	680	Placebo	ASA indication	RNM711Y	3.7.19 8:54	2022-08-31	Edoxaban 30mg / ASA indication
1210	680	Placebo	ASA indication	XEY679E	8.1.20 7:59	2021-12-31	Edoxaban 60mg / no ASA indication
1231	680	Placebo	ASA indication	DUA422N	25.1.22 8:24	2024-04-30	Edoxaban 60mg / ASA indication
1231	680	Placebo	ASA indication	HSX912C	23.7.20 8:43	2021-12-31	Edoxaban 60mg / ASA indication
1231	680	Placebo	ASA indication	LMF631L	25.7.19 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1231	680	Placebo	ASA indication	EBA329M	26.7.22 10:43	2024-04-30	Edoxaban 60mg / ASA indication
1231	680	Placebo	ASA indication	UFL882D	21.1.21 8:48	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1231	680	Placebo	ASA indication	BLP211R	29.1.20 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1231	680	Placebo	ASA indication	VCH896M	27.7.21 7:37	2024-04-30	Edoxaban 60mg / ASA indication
1318	680	Placebo	ASA indication	EYL962V	8.10.19 10:53	2021-12-31	Edoxaban 60mg / ASA indication
1339	680	Placebo	ASA indication	MWM561E	22.10.19 9:46	2022-08-31	Edoxaban 30mg / ASA indication
1347	680	Placebo	ASA indication	RKU322W	23.10.19 9:13	2021-12-31	Edoxaban 60mg / ASA indication
1417	680	Placebo	ASA indication	UNY435G	28.11.19 10:39	2022-08-31	Edoxaban 30mg / ASA indication
1455	680	Placebo	ASA indication	LGL717F	25.6.20 9:19	2021-12-31	Edoxaban 60mg / ASA indication
1455	680	Placebo	ASA indication	PEE916T	19.12.19 8:36	2021-12-31	Edoxaban 60mg / ASA indication
1455	680	Placebo	ASA indication	HHR729G	18.12.20 10:11	2021-12-31	Edoxaban 60mg / ASA indication
1531	680	Placebo	ASA indication	XUP796B	25.2.21 9:31	2022-08-31	Edoxaban 30mg / ASA indication
1531	680	Placebo	ASA indication	YTM958N	27.2.20 10:00	2022-08-31	Edoxaban 30mg / ASA indication
1531	680	Placebo	ASA indication	PML945V	30.8.22 7:49	2024-04-30	Edoxaban 60mg / ASA indication
1531	680	Placebo	ASA indication	DFV989G	27.8.20 7:45	2022-08-31	Edoxaban 30mg / ASA indication
1531	680	Placebo	ASA indication	PGZ153N	22.2.22 8:43	2024-04-30	Edoxaban 60mg / ASA indication
1531	680	Placebo	ASA indication	EVN115S	31.8.21 7:29	2022-08-31	Edoxaban 30mg / ASA indication
1609	680	Placebo	ASA indication	WLV557E	3.12.20 10:10	2021-12-31	Edoxaban 60mg / ASA indication
1609	680	Placebo	ASA indication	CLA863P	4.6.20 9:35	2021-12-31	Edoxaban 60mg / ASA indication
1640	680	Placebo	ASA indication	BXK248S	15.12.21 11:28	2024-04-30	Edoxaban 60mg / ASA indication
1640	680	Placebo	ASA indication	BUX399Z	28.6.22 10:23	2024-04-30	Edoxaban 60mg / ASA indication
1640	680	Placebo	ASA indication	HXH423E	17.6.20 9:06	2021-12-31	Edoxaban 60mg / ASA indication
1640	680	Placebo	ASA indication	BMA535N	23.6.21 10:05	2024-04-30	Edoxaban 60mg / ASA indication
1640	680	Placebo	ASA indication	PUL858T	23.12.20 8:09	2022-08-31	Edoxaban 30mg / ASA indication
1799	680	Placebo	ASA indication	UYG451X	17.9.21 9:54	2022-08-31	Edoxaban 30mg / ASA indication
1799	680	Placebo	ASA indication	KTP554L	24.9.20 10:44	2022-08-31	Edoxaban 30mg / ASA indication
1799	680	Placebo	ASA indication	YKG232C	24.3.21 8:19	2022-08-31	Edoxaban 30mg / ASA indication
1815	680	Placebo	ASA indication	DPT727B	8.4.21 9:31	2022-08-31	Edoxaban 30mg / ASA indication
1815	680	Placebo	ASA indication	BGN179R	11.4.22 10:49	2024-11-30	Edoxaban 30mg / ASA indication
1815	680	Placebo	ASA indication	MRH559F	6.10.20 9:34	2022-08-31	Edoxaban 30mg / ASA indication
1815	680	Placebo	ASA indication	VTE711S	6.10.21 9:16	2022-08-31	Edoxaban 30mg / ASA indication
1821	680	Placebo	ASA indication	MRT452H	8.10.20 10:09	2022-08-31	Edoxaban 30mg / ASA indication
2045	680	Placebo	ASA indication	YVK915T	4.11.21 9:16	2024-04-30	Edoxaban 60mg / ASA indication
2045	680	Placebo	ASA indication	NZV726F	19.5.22 8:41	2024-11-30	Edoxaban 30mg / no ASA indication
2045	680	Placebo	ASA indication	UHV765G	14.4.21 10:55	2021-12-31	Edoxaban 60mg / ASA indication
2092	680	Placebo	ASA indication	WUE519G	22.11.21 10:37	2024-04-30	Edoxaban 60mg / ASA indication
2092	680	Placebo	ASA indication	YWS723Y	8.6.22 9:44	2024-04-30	Edoxaban 60mg / ASA indication
2092	680	Placebo	ASA indication	SDS356F	11.5.21 8:45	2021-12-31	Edoxaban 60mg / ASA indication
2233	680	Placebo	ASA indication	BXT869H	3.3.22 10:02	2024-11-30	Edoxaban 30mg / ASA indication
2233	680	Placebo	ASA indication	KKS793H	19.8.21 9:38	2022-08-31	Edoxaban 30mg / ASA indication
2266	680	Placebo	ASA indication	VLM758K	17.3.22 8:00	2024-04-30	Edoxaban 60mg / ASA indication
2266	680	Placebo	ASA indication	WYE161P	14.9.21 8:53	2024-04-30	Edoxaban 60mg / ASA indication
2306	680	Placebo	ASA indication	XGT455X	12.4.22 7:11	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2306	680	Placebo	ASA indication	YKU464C	14.10.21 8:26	2024-04-30	Edoxaban 60mg / ASA indication
2317	680	Placebo	ASA indication	YZD692G	27.4.22 7:34	2024-04-30	Edoxaban 60mg / ASA indication
2317	680	Placebo	ASA indication	YLE638B	22.10.21 9:04	2024-04-30	Edoxaban 60mg / ASA indication
2356	680	Placebo	ASA indication	ZDE413W	19.11.21 9:53	2024-04-30	Edoxaban 60mg / ASA indication
2356	680	Placebo	ASA indication	ZYH622L	19.5.22 6:35	2024-04-30	Edoxaban 60mg / ASA indication
2516	680	Placebo	ASA indication	PBW434A	7.3.22 9:08	2024-04-30	Edoxaban 60mg / ASA indication
2543	680	Placebo	ASA indication	UYB852Z	21.3.22 10:41	2024-04-30	Edoxaban 60mg / ASA indication
2614	680	Placebo	ASA indication	RMG326D	13.5.22 10:24	2024-11-30	Edoxaban 30mg / ASA indication
2641	680	Placebo	ASA indication	YAB981W	6.6.22 7:52	2024-04-30	Edoxaban 60mg / ASA indication
2747	680	Placebo	ASA indication	TMG934V	6.9.22 10:23	2024-11-30	Edoxaban 30mg / ASA indication
771	680	Placebo	no ASA indication	RXB478P	25.10.18 9:41	2020-01-01	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	CTC211B	12.10.21 6:47	2022-08-31	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	WEA949Y	15.4.20 8:49	2022-08-31	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	GAW738Z	13.10.20 9:31	2022-08-31	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	BTZ574L	25.4.22 10:15	2024-11-30	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	FZR287B	25.4.19 7:54	2020-01-01	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	RVS898Y	15.10.19 8:28	2022-08-31	Edoxaban 30mg / no ASA indication
771	680	Placebo	no ASA indication	KZP226K	15.4.21 9:56	2022-08-31	Edoxaban 30mg / no ASA indication
838	680	Placebo	no ASA indication	BBM561A	23.11.21 8:16	2024-04-30	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	GHS823A	29.5.20 8:18	2021-12-31	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	SRE733T	22.11.18 10:22	2020-01-01	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	FZR959W	22.5.19 7:10	2020-01-01	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	TKC673G	24.5.22 9:10	2024-04-30	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	EZU696T	2.12.20 8:18	2021-12-31	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	YCE772V	28.11.19 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
838	680	Placebo	no ASA indication	RTE777Y	20.5.21 7:17	2021-12-31	Edoxaban 60mg / no ASA indication
851	680	Placebo	no ASA indication	NYR599N	29.5.19 8:28	2020-01-01	Edoxaban 30mg / no ASA indication
851	680	Placebo	no ASA indication	ZCS632A	29.11.18 10:20	2020-01-01	Edoxaban 30mg / no ASA indication
851	680	Placebo	no ASA indication	MBB617N	10.6.20 10:28	2022-08-31	Edoxaban 30mg / no ASA indication
851	680	Placebo	no ASA indication	RPR811N	5.12.19 10:58	2022-08-31	Edoxaban 30mg / no ASA indication
1135	680	Placebo	no ASA indication	LVB892G	19.5.22 9:07	2024-04-30	Edoxaban 60mg / no ASA indication
1135	680	Placebo	no ASA indication	VCT877P	22.5.19 7:55	2020-01-01	Edoxaban 60mg / no ASA indication
1135	680	Placebo	no ASA indication	GPA598G	20.11.19 9:05	2021-12-31	Edoxaban 60mg / no ASA indication
1135	680	Placebo	no ASA indication	BBG793F	18.11.21 10:33	2024-04-30	Edoxaban 60mg / no ASA indication
1135	680	Placebo	no ASA indication	XGF548G	20.5.21 8:22	2021-12-31	Edoxaban 60mg / no ASA indication
1135	680	Placebo	no ASA indication	VFA587P	25.11.20 9:12	2021-12-31	Edoxaban 60mg / no ASA indication
1135	680	Placebo	no ASA indication	UCD579L	29.5.20 10:18	2021-12-31	Edoxaban 60mg / no ASA indication
1156	680	Placebo	no ASA indication	VYD832R	17.12.19 9:12	2022-08-31	Edoxaban 30mg / no ASA indication
1156	680	Placebo	no ASA indication	EEB418N	4.6.19 8:38	2020-01-01	Edoxaban 30mg / no ASA indication
1474	680	Placebo	no ASA indication	FPE819L	15.1.20 9:57	2021-12-31	Edoxaban 60mg / no ASA indication
1891	680	Placebo	no ASA indication	YBW927E	2.12.21 9:20	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1891	680	Placebo	no ASA indication	TFW618A	9.6.22 8:42	2024-04-30	Edoxaban 60mg / no ASA indication
1891	680	Placebo	no ASA indication	PVA874Z	10.6.21 8:51	2021-12-31	Edoxaban 60mg / no ASA indication
1891	680	Placebo	no ASA indication	ECS516M	7.12.20 11:28	2021-12-31	Edoxaban 60mg / no ASA indication
1955	680	Placebo	no ASA indication	BAT246H	28.7.21 10:03	2024-04-30	Edoxaban 60mg / no ASA indication
1955	680	Placebo	no ASA indication	YBY851K	11.2.21 10:34	2021-12-31	Edoxaban 60mg / no ASA indication
1960	680	Placebo	no ASA indication	KUC116Z	16.2.21 8:14	2022-08-31	Edoxaban 30mg / no ASA indication
2031	680	Placebo	no ASA indication	WWK244S	30.9.21 10:15	2024-04-30	Edoxaban 60mg / no ASA indication
2031	680	Placebo	no ASA indication	YFL468P	30.3.21 9:20	2021-12-31	Edoxaban 60mg / no ASA indication
2394	680	Placebo	no ASA indication	DMG328A	16.12.21 10:07	2024-04-30	Edoxaban 60mg / no ASA indication
2499	680	Placebo	no ASA indication	EWL292G	24.2.22 11:14	2024-04-30	Edoxaban 60mg / no ASA indication
2499	680	Placebo	no ASA indication	DAC732M	23.8.22 10:40	2024-04-30	Edoxaban 60mg / no ASA indication
2509	680	Placebo	no ASA indication	CBY431V	3.3.22 10:13	2024-11-30	Edoxaban 30mg / no ASA indication
2620	680	Placebo	no ASA indication	PAL561G	19.5.22 9:33	2024-11-30	Edoxaban 30mg / no ASA indication
2721	680	Placebo	no ASA indication	NKF441D	21.7.22 8:36	2024-04-30	Edoxaban 60mg / no ASA indication
623	680	Edoxaban	ASA indication	GYP618T	11.7.18 9:23	2020-01-01	Edoxaban 60mg / ASA indication
698	680	Edoxaban	ASA indication	EEG364B	6.9.18 10:03	2020-01-01	Edoxaban 30mg / ASA indication
698	680	Edoxaban	ASA indication	KVE416S	5.9.19 12:40	2022-08-31	Edoxaban 30mg / ASA indication
698	680	Edoxaban	ASA indication	FBZ168S	28.2.19 10:25	2020-01-01	Edoxaban 30mg / ASA indication
763	680	Edoxaban	ASA indication	SKX817X	29.4.21 9:13	2021-12-31	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	PNT264S	23.10.19 8:18	2021-12-31	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	TKT734H	23.10.18 9:59	2020-01-01	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	ZBP277Z	22.10.21 8:30	2024-04-30	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	UNY898K	30.4.20 7:31	2021-12-31	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	WMR851K	26.4.22 7:09	2024-04-30	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	FZS112X	29.10.20 9:03	2021-12-31	Edoxaban 60mg / ASA indication
763	680	Edoxaban	ASA indication	BGC881Y	23.4.19 8:56	2020-01-01	Edoxaban 60mg / ASA indication
813	680	Edoxaban	ASA indication	AKB795Y	12.11.19 9:53	2022-08-31	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	DVL658U	12.5.20 8:26	2022-08-31	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	VKE977X	18.5.21 10:50	2022-08-31	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	LKD132N	26.11.21 12:08	2022-08-31	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	NRH467S	12.5.22 7:42	2024-11-30	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	FPN979A	12.11.18 12:12	2020-01-01	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	YUD591K	7.5.19 8:08	2020-01-01	Edoxaban 30mg / ASA indication
813	680	Edoxaban	ASA indication	NZB131D	20.11.20 9:03	2022-08-31	Edoxaban 30mg / no ASA indication
815	680	Edoxaban	ASA indication	LRZ746N	12.5.20 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
815	680	Edoxaban	ASA indication	BYL469P	12.5.22 10:56	2024-04-30	Edoxaban 60mg / no ASA indication
815	680	Edoxaban	ASA indication	BVE547U	6.11.19 9:48	2021-12-31	Edoxaban 60mg / ASA indication
815	680	Edoxaban	ASA indication	NNX349T	13.5.21 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
815	680	Edoxaban	ASA indication	XGC985L	13.11.18 10:36	2020-01-01	Edoxaban 60mg / ASA indication
815	680	Edoxaban	ASA indication	KGC489K	12.11.20 8:35	2021-12-31	Edoxaban 60mg / no ASA indication
815	680	Edoxaban	ASA indication	EXC516G	9.5.19 8:13	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
815	680	Edoxaban	ASA indication	YMB867U	25.11.21 10:57	2024-04-30	Edoxaban 60mg / no ASA indication
887	680	Edoxaban	ASA indication	VPW868A	13.12.18 10:32	2020-01-01	Edoxaban 60mg / ASA indication
934	680	Edoxaban	ASA indication	GFV196A	16.1.19 10:24	2020-01-01	Edoxaban 30mg / ASA indication
934	680	Edoxaban	ASA indication	LPE132G	10.7.19 7:09	2022-08-31	Edoxaban 30mg / ASA indication
934	680	Edoxaban	ASA indication	TBT725W	16.1.20 10:58	2022-08-31	Edoxaban 30mg / ASA indication
934	680	Edoxaban	ASA indication	GKU425Z	14.7.20 9:46	2022-08-31	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	AEN396G	29.1.19 8:25	2020-01-01	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	AYE434K	28.1.20 7:42	2022-08-31	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	NCY247Z	28.7.22 7:18	2024-11-30	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	SXV441Y	30.7.19 8:39	2022-08-31	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	BPS916Z	27.1.22 8:39	2024-11-30	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	ZWA917C	28.7.20 10:02	2022-08-31	Edoxaban 30mg / no ASA indication
955	680	Edoxaban	ASA indication	VEM588Z	12.1.21 10:16	2022-08-31	Edoxaban 30mg / ASA indication
955	680	Edoxaban	ASA indication	MYT451U	29.7.21 8:04	2022-08-31	Edoxaban 30mg / ASA indication
993	680	Edoxaban	ASA indication	WER957T	3.9.20 10:00	2021-12-31	Edoxaban 60mg / ASA indication
993	680	Edoxaban	ASA indication	KLZ692K	20.2.20 13:15	2021-12-31	Edoxaban 60mg / ASA indication
993	680	Edoxaban	ASA indication	AHY261G	19.2.19 9:36	2020-01-01	Edoxaban 60mg / ASA indication
993	680	Edoxaban	ASA indication	KXZ743N	19.8.19 9:43	2021-12-31	Edoxaban 60mg / ASA indication
998	680	Edoxaban	ASA indication	HXF728T	21.2.19 10:22	2020-01-01	Edoxaban 30mg / ASA indication
1034	680	Edoxaban	ASA indication	SKG577C	24.3.21 9:23	2021-12-31	Edoxaban 60mg / ASA indication
1034	680	Edoxaban	ASA indication	FVP273Y	27.3.20 8:08	2021-12-31	Edoxaban 60mg / ASA indication
1034	680	Edoxaban	ASA indication	CDG233B	14.4.22 11:27	2024-04-30	Edoxaban 60mg / ASA indication
1034	680	Edoxaban	ASA indication	XWZ622A	7.10.21 9:55	2024-04-30	Edoxaban 60mg / ASA indication
1034	680	Edoxaban	ASA indication	FWE313F	22.3.19 11:28	2020-01-01	Edoxaban 60mg / ASA indication
1034	680	Edoxaban	ASA indication	YFU349Y	30.9.19 7:52	2021-12-31	Edoxaban 60mg / ASA indication
1034	680	Edoxaban	ASA indication	NCA123S	28.9.20 7:38	2021-12-31	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	FHY858S	24.9.19 10:28	2021-12-31	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	AVF925S	25.3.20 8:59	2021-12-31	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	BBC213H	7.10.21 7:47	2024-04-30	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	LUM711K	24.3.22 9:31	2024-04-30	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	SLM439P	24.3.21 10:34	2021-12-31	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	UHX814S	27.3.19 9:40	2020-01-01	Edoxaban 60mg / ASA indication
1041	680	Edoxaban	ASA indication	DDC118N	24.9.20 8:27	2021-12-31	Edoxaban 60mg / ASA indication
1054	680	Edoxaban	ASA indication	SWW459A	29.9.20 9:19	2021-12-31	Edoxaban 60mg / ASA indication
1054	680	Edoxaban	ASA indication	URW964C	25.3.20 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1054	680	Edoxaban	ASA indication	TMB217X	12.4.21 10:07	2021-12-31	Edoxaban 60mg / ASA indication
1054	680	Edoxaban	ASA indication	ZNB587S	3.10.19 8:47	2021-12-31	Edoxaban 60mg / ASA indication
1054	680	Edoxaban	ASA indication	KTC992S	3.4.19 9:49	2020-01-01	Edoxaban 60mg / ASA indication
1054	680	Edoxaban	ASA indication	XXD385S	5.10.21 6:47	2024-04-30	Edoxaban 60mg / ASA indication
1065	680	Edoxaban	ASA indication	LGM783E	30.9.20 8:07	2022-08-31	Edoxaban 30mg / ASA indication
1065	680	Edoxaban	ASA indication	FNH265B	9.4.19 8:57	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1065	680	Edoxaban	ASA indication	ZLN177G	27.3.20 8:46	2022-08-31	Edoxaban 30mg / ASA indication
1065	680	Edoxaban	ASA indication	XDZ732U	1.10.19 8:22	2022-08-31	Edoxaban 30mg / ASA indication
1087	680	Edoxaban	ASA indication	GHH724V	25.3.20 9:21	2021-12-31	Edoxaban 60mg / ASA indication
1087	680	Edoxaban	ASA indication	KER655Z	8.10.19 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1087	680	Edoxaban	ASA indication	WXB527P	17.4.19 8:43	2020-01-01	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	ZAS576L	21.10.21 7:00	2024-04-30	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	CLY735C	22.4.22 7:23	2024-04-30	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	LCL253M	22.4.21 8:54	2021-12-31	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	KSL883P	17.10.19 7:25	2021-12-31	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	ZZX482P	16.4.20 9:13	2021-12-31	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	RFV919Z	18.4.19 9:31	2020-01-01	Edoxaban 60mg / ASA indication
1090	680	Edoxaban	ASA indication	TMB963Z	22.10.20 7:29	2021-12-31	Edoxaban 60mg / ASA indication
1153	680	Edoxaban	ASA indication	BSL332K	30.5.19 8:12	2020-01-01	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	CEY665R	13.1.22 12:23	2024-04-30	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	CPZ889U	4.7.19 9:24	2021-12-31	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	MLC827Y	8.1.20 10:03	2021-12-31	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	VKZ379Y	9.7.20 8:09	2021-12-31	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	SHN666D	7.1.21 11:17	2021-12-31	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	BBD464N	7.7.21 7:47	2024-04-30	Edoxaban 60mg / ASA indication
1212	680	Edoxaban	ASA indication	WSW848T	14.7.22 9:50	2024-04-30	Edoxaban 60mg / ASA indication
1257	680	Edoxaban	ASA indication	FNF122M	19.8.20 10:29	2022-08-31	Edoxaban 30mg / ASA indication
1257	680	Edoxaban	ASA indication	SNW525B	24.8.22 9:18	2024-11-30	Edoxaban 30mg / ASA indication
1257	680	Edoxaban	ASA indication	NGB666D	25.8.21 10:04	2022-08-31	Edoxaban 30mg / ASA indication
1257	680	Edoxaban	ASA indication	ZAT839T	21.8.19 9:57	2022-08-31	Edoxaban 30mg / ASA indication
1257	680	Edoxaban	ASA indication	HVE562Z	18.2.21 10:20	2022-08-31	Edoxaban 30mg / ASA indication
1257	680	Edoxaban	ASA indication	VTR639H	12.2.20 9:37	2022-08-31	Edoxaban 30mg / ASA indication
1257	680	Edoxaban	ASA indication	BPH337M	2.3.22 11:15	2024-11-30	Edoxaban 30mg / ASA indication
1292	680	Edoxaban	ASA indication	ACN847P	20.3.20 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1292	680	Edoxaban	ASA indication	FKU545G	18.9.19 9:25	2021-12-31	Edoxaban 60mg / ASA indication
1316	680	Edoxaban	ASA indication	NEY761L	27.3.20 10:17	2021-12-31	Edoxaban 60mg / ASA indication
1316	680	Edoxaban	ASA indication	UPL563L	13.4.22 9:29	2024-04-30	Edoxaban 60mg / ASA indication
1316	680	Edoxaban	ASA indication	TWT262D	5.11.20 11:57	2021-12-31	Edoxaban 60mg / ASA indication
1316	680	Edoxaban	ASA indication	TNG121N	8.10.19 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1316	680	Edoxaban	ASA indication	TRV454Y	19.4.21 9:38	2021-12-31	Edoxaban 60mg / ASA indication
1316	680	Edoxaban	ASA indication	XWZ655N	12.10.21 10:42	2024-04-30	Edoxaban 60mg / ASA indication
1340	680	Edoxaban	ASA indication	WFR139U	15.5.20 8:37	2022-08-31	Edoxaban 30mg / no ASA indication
1340	680	Edoxaban	ASA indication	AUX931S	22.10.19 9:50	2022-08-31	Edoxaban 30mg / ASA indication
1340	680	Edoxaban	ASA indication	GMX858U	22.10.20 9:07	2022-08-31	Edoxaban 30mg / no ASA indication
1340	680	Edoxaban	ASA indication	NZE822Y	29.4.21 8:34	2022-08-31	Edoxaban 30mg / no ASA indication
1340	680	Edoxaban	ASA indication	EGB466T	28.10.21 8:36	2022-08-31	Edoxaban 30mg / no ASA indication
1340	680	Edoxaban	ASA indication	DCU384R	14.4.22 11:30	2024-11-30	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1363	680	Edoxaban	ASA indication	PLM281C	14.5.20 8:36	2022-08-31	Edoxaban 30mg / ASA indication
1363	680	Edoxaban	ASA indication	XXZ833Z	5.11.19 11:11	2022-08-31	Edoxaban 30mg / ASA indication
1530	680	Edoxaban	ASA indication	URA292N	4.2.21 9:43	2022-08-31	Edoxaban 30mg / ASA indication
1530	680	Edoxaban	ASA indication	HHC347E	26.8.20 9:23	2022-08-31	Edoxaban 30mg / ASA indication
1530	680	Edoxaban	ASA indication	NYV488V	27.2.20 9:58	2022-08-31	Edoxaban 30mg / ASA indication
1530	680	Edoxaban	ASA indication	ERG141W	18.8.21 10:02	2022-08-31	Edoxaban 30mg / ASA indication
1645	680	Edoxaban	ASA indication	HTY994B	17.12.20 8:40	2022-08-31	Edoxaban 30mg / ASA indication
1645	680	Edoxaban	ASA indication	RSY765B	21.6.22 8:33	2024-11-30	Edoxaban 30mg / ASA indication
1645	680	Edoxaban	ASA indication	XBK628Y	18.6.20 9:19	2022-08-31	Edoxaban 30mg / ASA indication
1645	680	Edoxaban	ASA indication	ETU975V	17.6.21 7:49	2022-08-31	Edoxaban 30mg / ASA indication
1645	680	Edoxaban	ASA indication	YXG646S	15.12.21 8:30	2022-08-31	Edoxaban 30mg / ASA indication
1657	680	Edoxaban	ASA indication	YST418G	24.6.20 9:38	2021-12-31	Edoxaban 60mg / ASA indication
1664	680	Edoxaban	ASA indication	GEG866R	26.6.20 9:42	2021-12-31	Edoxaban 60mg / ASA indication
1750	680	Edoxaban	ASA indication	LUW344V	10.3.21 11:35	2022-08-31	Edoxaban 30mg / ASA indication
1750	680	Edoxaban	ASA indication	VSG617P	1.9.21 10:58	2024-04-30	Edoxaban 60mg / ASA indication
1750	680	Edoxaban	ASA indication	NGE832V	9.3.22 9:56	2024-11-30	Edoxaban 30mg / ASA indication
1750	680	Edoxaban	ASA indication	NMC377T	7.9.22 12:52	2024-11-30	Edoxaban 30mg / ASA indication
1750	680	Edoxaban	ASA indication	UPD857N	31.8.20 9:38	2022-08-31	Edoxaban 30mg / ASA indication
1887	680	Edoxaban	ASA indication	TBC692E	29.10.21 10:27	2022-08-31	Edoxaban 30mg / ASA indication
1887	680	Edoxaban	ASA indication	VZH947H	1.6.21 8:06	2021-12-31	Edoxaban 60mg / ASA indication
1887	680	Edoxaban	ASA indication	FMH869N	1.12.20 9:43	2021-12-31	Edoxaban 60mg / ASA indication
1907	680	Edoxaban	ASA indication	TRZ676M	15.12.20 10:10	2021-12-31	Edoxaban 60mg / ASA indication
1907	680	Edoxaban	ASA indication	BZD811K	16.12.21 12:02	2024-04-30	Edoxaban 60mg / ASA indication
1907	680	Edoxaban	ASA indication	ZEL161A	24.6.22 11:40	2024-04-30	Edoxaban 60mg / ASA indication
1907	680	Edoxaban	ASA indication	BBR811A	28.6.21 9:46	2024-04-30	Edoxaban 60mg / ASA indication
1998	680	Edoxaban	ASA indication	VSN867S	9.9.21 7:50	2024-04-30	Edoxaban 60mg / ASA indication
1998	680	Edoxaban	ASA indication	LXX412A	9.3.22 11:02	2024-04-30	Edoxaban 60mg / ASA indication
1998	680	Edoxaban	ASA indication	FNX839Z	9.3.21 10:12	2021-12-31	Edoxaban 60mg / ASA indication
2060	680	Edoxaban	ASA indication	PDY422H	22.4.21 9:31	2021-12-31	Edoxaban 60mg / ASA indication
2060	680	Edoxaban	ASA indication	YZV932H	21.10.21 9:37	2024-04-30	Edoxaban 60mg / ASA indication
2060	680	Edoxaban	ASA indication	CBY465F	21.4.22 8:35	2024-04-30	Edoxaban 60mg / ASA indication
2065	680	Edoxaban	ASA indication	EMH746X	27.4.21 8:52	2021-12-31	Edoxaban 60mg / ASA indication
2065	680	Edoxaban	ASA indication	ZNK261K	27.10.21 10:14	2024-04-30	Edoxaban 60mg / ASA indication
2088	680	Edoxaban	ASA indication	TEG854K	7.5.21 8:48	2021-12-31	Edoxaban 60mg / ASA indication
2088	680	Edoxaban	ASA indication	WTB226B	10.5.22 7:28	2024-04-30	Edoxaban 60mg / ASA indication
2088	680	Edoxaban	ASA indication	BDA949C	4.11.21 9:00	2024-04-30	Edoxaban 60mg / ASA indication
2254	680	Edoxaban	ASA indication	VNY239B	2.9.21 11:20	2024-04-30	Edoxaban 60mg / ASA indication
2346	680	Edoxaban	ASA indication	TLH483A	16.11.21 9:29	2022-08-31	Edoxaban 30mg / ASA indication
2346	680	Edoxaban	ASA indication	XAL841K	17.5.22 8:41	2024-04-30	Edoxaban 60mg / ASA indication
2410	680	Edoxaban	ASA indication	YXL397X	23.12.21 8:03	2022-08-31	Edoxaban 30mg / ASA indication
2539	680	Edoxaban	ASA indication	SNB639N	18.3.22 10:17	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2705	680	Edoxaban	ASA indication	ZRD288F	8.7.22 9:13	2024-04-30	Edoxaban 60mg / ASA indication
2715	680	Edoxaban	ASA indication	UDR522G	19.7.22 9:39	2024-04-30	Edoxaban 60mg / ASA indication
2724	680	Edoxaban	ASA indication	UHG371M	26.7.22 8:34	2024-11-30	Edoxaban 30mg / ASA indication
668	680	Edoxaban	no ASA indication	SHK618M	6.2.20 9:40	2021-12-31	Edoxaban 60mg / no ASA indication
668	680	Edoxaban	no ASA indication	TUK164L	1.8.19 9:32	2021-12-31	Edoxaban 60mg / no ASA indication
668	680	Edoxaban	no ASA indication	TNL965H	17.2.21 10:37	2022-08-31	Edoxaban 30mg / no ASA indication
668	680	Edoxaban	no ASA indication	PSF996R	27.8.21 11:18	2022-08-31	Edoxaban 30mg / no ASA indication
668	680	Edoxaban	no ASA indication	DLT342M	5.2.19 9:57	2020-01-01	Edoxaban 60mg / no ASA indication
668	680	Edoxaban	no ASA indication	BXT777N	10.2.22 11:44	2022-08-31	Edoxaban 30mg / no ASA indication
668	680	Edoxaban	no ASA indication	DDX735H	14.8.18 8:49	2020-01-01	Edoxaban 60mg / no ASA indication
668	680	Edoxaban	no ASA indication	BYD432S	19.8.20 10:03	2022-08-31	Edoxaban 30mg / no ASA indication
729	680	Edoxaban	no ASA indication	NPC134P	30.9.20 7:28	2021-12-31	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	WRX695R	30.9.21 8:27	2024-04-30	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	VCT593G	1.4.22 7:11	2024-04-30	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	BBR425H	3.4.19 7:34	2020-01-01	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	GYS283W	2.10.19 7:58	2021-12-31	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	RTW198M	1.10.18 10:24	2020-01-01	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	YLU711L	1.4.21 7:24	2021-12-31	Edoxaban 60mg / no ASA indication
729	680	Edoxaban	no ASA indication	VES316P	26.3.20 8:56	2021-12-31	Edoxaban 60mg / no ASA indication
1071	680	Edoxaban	no ASA indication	VYX969S	16.10.19 11:00	2021-12-31	Edoxaban 60mg / no ASA indication
1071	680	Edoxaban	no ASA indication	XRK539W	10.4.19 8:49	2020-01-01	Edoxaban 60mg / no ASA indication
1248	680	Edoxaban	no ASA indication	DVP413U	11.2.20 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
1248	680	Edoxaban	no ASA indication	FPM829V	10.2.22 9:30	2024-04-30	Edoxaban 60mg / no ASA indication
1248	680	Edoxaban	no ASA indication	DVW798D	5.8.21 8:50	2022-08-31	Edoxaban 30mg / no ASA indication
1248	680	Edoxaban	no ASA indication	RGA186F	11.2.21 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
1248	680	Edoxaban	no ASA indication	BNZ672N	13.8.20 7:28	2021-12-31	Edoxaban 60mg / no ASA indication
1248	680	Edoxaban	no ASA indication	FHU565P	8.8.19 8:47	2021-12-31	Edoxaban 60mg / no ASA indication
1248	680	Edoxaban	no ASA indication	ZHH915Y	4.8.22 8:41	2024-04-30	Edoxaban 60mg / no ASA indication
1349	680	Edoxaban	no ASA indication	KFF968P	20.4.20 7:32	2021-12-31	Edoxaban 60mg / no ASA indication
1349	680	Edoxaban	no ASA indication	DSK822L	27.10.20 7:45	2022-08-31	Edoxaban 30mg / no ASA indication
1349	680	Edoxaban	no ASA indication	FXC697L	23.10.19 10:19	2021-12-31	Edoxaban 60mg / no ASA indication
1512	680	Edoxaban	no ASA indication	SYF519D	11.2.20 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
1512	680	Edoxaban	no ASA indication	LUN381W	13.8.20 7:47	2022-08-31	Edoxaban 30mg / no ASA indication
1512	680	Edoxaban	no ASA indication	CYZ565F	4.2.21 9:35	2021-12-31	Edoxaban 60mg / no ASA indication
1681	680	Edoxaban	no ASA indication	HFU385Y	9.7.20 9:02	2021-12-31	Edoxaban 60mg / no ASA indication
1681	680	Edoxaban	no ASA indication	BHG423G	13.7.21 9:49	2024-04-30	Edoxaban 60mg / no ASA indication
1681	680	Edoxaban	no ASA indication	BXV964W	7.1.21 9:57	2021-12-31	Edoxaban 60mg / no ASA indication
1832	680	Edoxaban	no ASA indication	XPP164D	20.10.21 9:03	2024-04-30	Edoxaban 60mg / no ASA indication
1832	680	Edoxaban	no ASA indication	YAP691G	20.10.20 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
1832	680	Edoxaban	no ASA indication	KMN976Z	20.4.21 8:27	2021-12-31	Edoxaban 60mg / no ASA indication
1832	680	Edoxaban	no ASA indication	XEP867N	21.4.22 7:51	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2048	680	Edoxaban	no ASA indication	XPK377L	14.10.21 7:58	2024-04-30	Edoxaban 60mg / no ASA indication
2048	680	Edoxaban	no ASA indication	WZV255L	15.4.22 10:17	2024-04-30	Edoxaban 60mg / no ASA indication
2048	680	Edoxaban	no ASA indication	YNA959C	15.4.21 10:42	2021-12-31	Edoxaban 60mg / no ASA indication
2091	680	Edoxaban	no ASA indication	LTE545L	11.5.21 8:43	2021-12-31	Edoxaban 60mg / no ASA indication
2091	680	Edoxaban	no ASA indication	YLX482E	10.11.21 12:23	2024-04-30	Edoxaban 60mg / no ASA indication
2091	680	Edoxaban	no ASA indication	YFS884V	11.5.22 10:43	2024-04-30	Edoxaban 60mg / no ASA indication
2094	680	Edoxaban	no ASA indication	BFV888L	2.12.21 7:53	2024-04-30	Edoxaban 60mg / no ASA indication
2094	680	Edoxaban	no ASA indication	FNT591H	5.5.22 10:57	2024-04-30	Edoxaban 60mg / no ASA indication
2094	680	Edoxaban	no ASA indication	NDD483H	12.5.21 8:58	2021-12-31	Edoxaban 60mg / no ASA indication
2267	680	Edoxaban	no ASA indication	BGY334K	14.9.21 9:33	2024-04-30	Edoxaban 60mg / no ASA indication
2267	680	Edoxaban	no ASA indication	THR144X	15.3.22 9:44	2024-04-30	Edoxaban 60mg / no ASA indication
2362	680	Edoxaban	no ASA indication	CXC348B	12.7.22 11:01	2024-11-30	Edoxaban 30mg / no ASA indication
2362	680	Edoxaban	no ASA indication	BRC677W	29.11.21 13:50	2022-08-31	Edoxaban 30mg / no ASA indication
2547	680	Edoxaban	no ASA indication	TCG265P	22.3.22 10:26	2024-04-30	Edoxaban 60mg / no ASA indication
1419	685	Placebo	no ASA indication	VBH724C	26.3.20 10:13	2021-12-31	Edoxaban 60mg / no ASA indication
1419	685	Placebo	no ASA indication	RAC758E	13.4.21 9:47	2022-08-31	Edoxaban 30mg / ASA indication
1419	685	Placebo	no ASA indication	XHC826A	27.5.21 9:22	2022-08-31	Edoxaban 30mg / ASA indication
1419	685	Placebo	no ASA indication	DRC669U	1.10.20 10:06	2021-12-31	Edoxaban 60mg / ASA indication
1419	685	Placebo	no ASA indication	PEU573X	5.12.19 11:28	2021-12-31	Edoxaban 60mg / no ASA indication
2027	685	Placebo	no ASA indication	WYE869H	30.9.21 12:59	2022-08-31	Edoxaban 30mg / no ASA indication
2027	685	Placebo	no ASA indication	DMS235N	25.3.21 13:26	2022-08-31	Edoxaban 30mg / no ASA indication
2027	685	Placebo	no ASA indication	DWP671L	25.3.22 10:39	2024-11-30	Edoxaban 30mg / no ASA indication
2177	685	Placebo	no ASA indication	RZA952Y	10.1.22 11:07	2024-04-30	Edoxaban 60mg / no ASA indication
2177	685	Placebo	no ASA indication	YSK755N	23.6.22 11:30	2024-04-30	Edoxaban 60mg / no ASA indication
2177	685	Placebo	no ASA indication	RZT274C	1.7.21 11:32	2024-04-30	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	YXB752U	9.6.17 9:14	2018-09-01	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	XHM439T	6.12.18 14:19	2020-01-01	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	AUK582X	13.4.21 13:07	2021-12-31	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	WYN156G	24.5.18 8:33	2020-01-01	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	RZX713M	25.5.22 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	SAU371P	2.12.21 9:23	2024-04-30	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	PRX489P	16.5.19 9:21	2020-01-01	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	DRC986V	30.11.17 9:54	2018-09-01	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	LHL311W	2.4.20 11:39	2021-12-31	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	ZEX735S	8.10.20 7:37	2021-12-31	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	URE746M	7.11.19 12:42	2021-12-31	Edoxaban 60mg / no ASA indication
185	685	Edoxaban	no ASA indication	YFA887A	27.5.21 8:27	2021-12-31	Edoxaban 60mg / no ASA indication
403	685	Edoxaban	no ASA indication	GLM928A	15.1.18 16:42	2018-09-01	Edoxaban 30mg / no ASA indication
1625	685	Edoxaban	no ASA indication	XXX152S	4.6.21 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
1625	685	Edoxaban	no ASA indication	GXZ487X	11.6.20 8:31	2021-12-31	Edoxaban 60mg / no ASA indication
1625	685	Edoxaban	no ASA indication	AVK526F	22.12.20 12:55	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1625	685	Edoxaban	no ASA indication	RZE686U	13.12.21 13:28	2024-04-30	Edoxaban 60mg / no ASA indication
1625	685	Edoxaban	no ASA indication	GKC177M	22.6.22 13:00	2024-04-30	Edoxaban 60mg / no ASA indication
358	687	Placebo	ASA indication	LCS177M	4.12.17 11:06	2018-09-01	Edoxaban 60mg / ASA indication
1157	687	Placebo	no ASA indication	WEA954T	4.6.19 9:02	2020-01-01	Edoxaban 60mg / no ASA indication
1611	687	Placebo	no ASA indication	TYY436E	10.6.21 7:26	2021-12-31	Edoxaban 60mg / no ASA indication
1611	687	Placebo	no ASA indication	PGB491D	5.6.20 7:18	2021-12-31	Edoxaban 60mg / no ASA indication
1611	687	Placebo	no ASA indication	ZVR733M	17.6.22 7:07	2024-04-30	Edoxaban 60mg / no ASA indication
1611	687	Placebo	no ASA indication	TYU959W	1.12.20 8:49	2021-12-31	Edoxaban 60mg / no ASA indication
1611	687	Placebo	no ASA indication	RKC771P	8.12.21 7:35	2024-04-30	Edoxaban 60mg / no ASA indication
2061	687	Placebo	no ASA indication	BAS398B	22.4.21 8:11	2021-12-31	Edoxaban 60mg / no ASA indication
2061	687	Placebo	no ASA indication	RHW525P	27.10.21 8:39	2024-04-30	Edoxaban 60mg / no ASA indication
2061	687	Placebo	no ASA indication	EBC514N	5.5.22 6:39	2024-04-30	Edoxaban 60mg / no ASA indication
2355	687	Placebo	no ASA indication	ZVR482K	2.6.22 8:35	2024-04-30	Edoxaban 60mg / no ASA indication
2355	687	Placebo	no ASA indication	RHU975S	19.11.21 7:33	2024-04-30	Edoxaban 60mg / no ASA indication
691	687	Edoxaban	no ASA indication	LHP349T	24.8.20 6:42	2021-12-31	Edoxaban 60mg / no ASA indication
691	687	Edoxaban	no ASA indication	FRG798N	2.9.22 6:37	2024-11-30	Edoxaban 30mg / no ASA indication
691	687	Edoxaban	no ASA indication	PKK986Z	24.2.21 7:56	2021-12-31	Edoxaban 60mg / no ASA indication
691	687	Edoxaban	no ASA indication	NGM187R	28.2.19 8:59	2020-01-01	Edoxaban 60mg / no ASA indication
691	687	Edoxaban	no ASA indication	FUL957X	22.2.22 8:01	2024-11-30	Edoxaban 30mg / no ASA indication
691	687	Edoxaban	no ASA indication	RVN946K	30.8.19 8:34	2021-12-31	Edoxaban 60mg / no ASA indication
691	687	Edoxaban	no ASA indication	NDV216A	31.8.18 8:41	2020-01-01	Edoxaban 60mg / no ASA indication
691	687	Edoxaban	no ASA indication	WDW654L	23.8.21 8:33	2022-08-31	Edoxaban 30mg / no ASA indication
691	687	Edoxaban	no ASA indication	SUR551N	5.3.20 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
1614	687	Edoxaban	no ASA indication	PHM949U	7.6.21 7:37	2021-12-31	Edoxaban 60mg / no ASA indication
1614	687	Edoxaban	no ASA indication	TES254L	8.6.20 8:52	2021-12-31	Edoxaban 60mg / no ASA indication
1614	687	Edoxaban	no ASA indication	PXF448T	13.12.21 8:42	2024-04-30	Edoxaban 60mg / no ASA indication
1614	687	Edoxaban	no ASA indication	MZS591S	2.12.20 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
123	688	Placebo	ASA indication	BZB816Y	30.3.17 9:39	2018-09-01	Edoxaban 30mg / ASA indication
728	688	Placebo	ASA indication	ENR259Y	11.4.19 9:53	2020-01-01	Edoxaban 60mg / ASA indication
728	688	Placebo	ASA indication	PCG447W	15.10.19 9:44	2021-12-31	Edoxaban 60mg / ASA indication
728	688	Placebo	ASA indication	HUZ958W	28.9.18 9:15	2020-01-01	Edoxaban 60mg / ASA indication
1209	688	Placebo	ASA indication	BEV747T	8.1.20 11:58	2021-12-31	Edoxaban 60mg / ASA indication
1209	688	Placebo	ASA indication	DBW482V	1.7.19 10:25	2021-12-31	Edoxaban 60mg / ASA indication
1312	688	Placebo	ASA indication	TPD394D	5.4.22 10:27	2024-04-30	Edoxaban 60mg / ASA indication
1312	688	Placebo	ASA indication	KDN564H	23.3.21 11:26	2021-12-31	Edoxaban 60mg / ASA indication
1312	688	Placebo	ASA indication	XUC774E	28.9.21 9:36	2024-04-30	Edoxaban 60mg / ASA indication
1312	688	Placebo	ASA indication	KVT511U	17.3.20 8:51	2021-12-31	Edoxaban 60mg / ASA indication
1312	688	Placebo	ASA indication	MZZ928U	22.9.20 8:29	2021-12-31	Edoxaban 60mg / ASA indication
1312	688	Placebo	ASA indication	DBP423R	4.10.19 8:07	2021-12-31	Edoxaban 60mg / ASA indication
1447	688	Placebo	ASA indication	MHS626E	13.12.19 8:48	2022-08-31	Edoxaban 30mg / ASA indication
1447	688	Placebo	ASA indication	DFE157U	22.6.20 7:12	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1447	688	Placebo	ASA indication	XZN954T	29.6.21 9:21	2022-08-31	Edoxaban 30mg / ASA indication
1447	688	Placebo	ASA indication	BTS847K	15.12.20 9:01	2022-08-31	Edoxaban 30mg / ASA indication
1601	688	Placebo	ASA indication	LPA644Z	28.10.20 8:27	2021-12-31	Edoxaban 60mg / ASA indication
1601	688	Placebo	ASA indication	RSG582Y	28.5.20 11:17	2021-12-31	Edoxaban 60mg / ASA indication
2165	688	Placebo	ASA indication	RYG582L	23.6.21 8:30	2024-04-30	Edoxaban 60mg / ASA indication
2165	688	Placebo	ASA indication	RZA665F	30.11.21 9:47	2024-04-30	Edoxaban 60mg / ASA indication
2252	688	Placebo	ASA indication	VGG579C	1.3.22 9:50	2024-04-30	Edoxaban 60mg / ASA indication
2252	688	Placebo	ASA indication	RZD686R	1.9.21 8:29	2024-04-30	Edoxaban 60mg / ASA indication
2281	688	Placebo	ASA indication	DSE682A	24.9.21 8:26	2022-08-31	Edoxaban 30mg / ASA indication
2281	688	Placebo	ASA indication	EWW754F	8.3.22 10:12	2024-11-30	Edoxaban 30mg / ASA indication
127	688	Placebo	no ASA indication	TZH795A	30.3.17 11:04	2018-09-01	Edoxaban 30mg / no ASA indication
628	688	Placebo	no ASA indication	UVE749H	23.1.19 9:42	2020-01-01	Edoxaban 60mg / no ASA indication
628	688	Placebo	no ASA indication	BGH995V	18.7.18 8:51	2020-01-01	Edoxaban 60mg / no ASA indication
640	688	Placebo	no ASA indication	ZMD154D	21.1.20 11:29	2021-12-31	Edoxaban 60mg / no ASA indication
640	688	Placebo	no ASA indication	NVF769W	14.7.20 9:26	2021-12-31	Edoxaban 60mg / no ASA indication
640	688	Placebo	no ASA indication	RHF598E	15.1.19 11:53	2020-01-01	Edoxaban 60mg / no ASA indication
640	688	Placebo	no ASA indication	YSL789G	27.7.18 10:17	2020-01-01	Edoxaban 60mg / no ASA indication
640	688	Placebo	no ASA indication	YYF691L	17.7.19 8:48	2021-12-31	Edoxaban 60mg / no ASA indication
640	688	Placebo	no ASA indication	NEW739B	20.1.21 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
842	688	Placebo	no ASA indication	SDT787K	23.11.18 9:27	2020-01-01	Edoxaban 60mg / no ASA indication
112	688	Edoxaban	ASA indication	AVD683A	12.9.18 8:12	2020-01-01	Edoxaban 60mg / no ASA indication
112	688	Edoxaban	ASA indication	YXT877V	16.3.17 9:15	2018-09-01	Edoxaban 60mg / ASA indication
112	688	Edoxaban	ASA indication	SPB877H	21.3.18 10:12	2020-01-01	Edoxaban 60mg / ASA indication
210	688	Edoxaban	ASA indication	MUM353C	21.12.17 9:23	2018-09-01	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	CFF771P	7.1.21 9:27	2022-08-31	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	XGK731M	12.1.22 9:04	2022-08-31	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	FVC426A	12.7.22 8:33	2024-11-30	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	XSM149H	22.6.18 7:29	2020-01-01	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	ZNA967U	19.12.18 10:01	2020-01-01	Edoxaban 30mg / ASA indication
210	688	Edoxaban	ASA indication	CFN511K	29.6.17 9:09	2018-09-01	Edoxaban 30mg / ASA indication
210	688	Edoxaban	ASA indication	ETE767W	7.1.20 8:43	2022-08-31	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	VLY965G	7.7.20 6:13	2022-08-31	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	ENP361X	25.6.19 8:51	2022-08-31	Edoxaban 30mg / no ASA indication
210	688	Edoxaban	ASA indication	XDE927U	13.7.21 6:11	2022-08-31	Edoxaban 30mg / no ASA indication
865	688	Edoxaban	ASA indication	GSW963L	5.12.18 9:52	2020-01-01	Edoxaban 60mg / ASA indication
865	688	Edoxaban	ASA indication	UTL161U	19.11.19 12:05	2021-12-31	Edoxaban 60mg / ASA indication
865	688	Edoxaban	ASA indication	TPW691W	17.11.20 10:45	2021-12-31	Edoxaban 60mg / ASA indication
865	688	Edoxaban	ASA indication	BLB975B	28.5.19 10:22	2020-01-01	Edoxaban 60mg / ASA indication
865	688	Edoxaban	ASA indication	PYA786B	19.5.20 10:42	2021-12-31	Edoxaban 60mg / ASA indication
983	688	Edoxaban	ASA indication	UYV284E	11.2.19 8:22	2020-01-01	Edoxaban 60mg / ASA indication
1373	688	Edoxaban	ASA indication	YVK637G	8.11.19 8:06	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1373	688	Edoxaban	ASA indication	HUT313L	11.5.20 9:07	2022-08-31	Edoxaban 30mg / ASA indication
1833	688	Edoxaban	ASA indication	SPS474V	7.9.21 10:16	2024-04-30	Edoxaban 60mg / ASA indication
1833	688	Edoxaban	ASA indication	NUV455T	3.3.21 11:51	2021-12-31	Edoxaban 60mg / ASA indication
1833	688	Edoxaban	ASA indication	AGN948S	20.10.20 10:15	2021-12-31	Edoxaban 60mg / ASA indication
1975	688	Edoxaban	ASA indication	GBW722F	24.2.21 11:19	2021-12-31	Edoxaban 60mg / ASA indication
1975	688	Edoxaban	ASA indication	VSY693W	2.9.21 9:04	2024-04-30	Edoxaban 60mg / ASA indication
1975	688	Edoxaban	ASA indication	YFZ354E	22.2.22 8:56	2024-04-30	Edoxaban 60mg / ASA indication
2179	688	Edoxaban	ASA indication	YFX878G	17.12.21 9:33	2024-04-30	Edoxaban 60mg / ASA indication
2179	688	Edoxaban	ASA indication	PRU653W	30.6.22 9:30	2024-04-30	Edoxaban 60mg / ASA indication
2179	688	Edoxaban	ASA indication	SPG954N	7.7.21 9:11	2024-04-30	Edoxaban 60mg / ASA indication
2677	688	Edoxaban	ASA indication	PST543D	1.7.22 6:59	2024-04-30	Edoxaban 60mg / ASA indication
183	688	Edoxaban	no ASA indication	TUM649Z	11.1.19 9:02	2020-01-01	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	KXE241D	8.6.17 10:34	2018-09-01	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	SGR153K	14.12.21 11:27	2024-04-30	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	KMF472S	6.6.18 11:18	2020-01-01	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	SPG967E	7.6.22 9:29	2024-04-30	Edoxaban 60mg / ASA indication
183	688	Edoxaban	no ASA indication	CKZ324L	20.1.21 8:31	2022-08-31	Edoxaban 30mg / no ASA indication
183	688	Edoxaban	no ASA indication	KXY453Y	3.7.19 8:32	2021-12-31	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	CFZ161A	4.12.17 9:44	2018-09-01	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	BNL433Z	8.7.20 10:08	2022-08-31	Edoxaban 30mg / no ASA indication
183	688	Edoxaban	no ASA indication	UED814P	7.1.20 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	ZLL527L	7.6.22 8:31	2024-04-30	Edoxaban 60mg / no ASA indication
183	688	Edoxaban	no ASA indication	WXL637G	23.6.21 10:38	2022-08-31	Edoxaban 30mg / no ASA indication
231	688	Edoxaban	no ASA indication	HWF741B	20.7.17 9:07	2018-09-01	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	XUU864M	15.5.18 7:15	2020-01-01	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	WRK511G	15.11.19 10:32	2021-12-31	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	VZR894L	27.5.20 10:45	2021-12-31	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	UXL366Z	30.10.18 11:16	2020-01-01	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	SNU794R	23.11.21 9:29	2024-04-30	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	EPC954A	3.5.22 10:22	2024-04-30	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	EZS993C	18.5.21 10:37	2021-12-31	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	USE987C	17.5.19 6:22	2020-01-01	Edoxaban 60mg / no ASA indication
550	688	Edoxaban	no ASA indication	APR873G	23.11.20 11:27	2021-12-31	Edoxaban 60mg / no ASA indication
1877	688	Edoxaban	no ASA indication	SCK167G	23.11.20 11:56	2021-12-31	Edoxaban 60mg / no ASA indication
2363	688	Edoxaban	no ASA indication	SGK977F	25.11.21 7:50	2024-04-30	Edoxaban 60mg / no ASA indication
2363	688	Edoxaban	no ASA indication	EPZ152V	17.5.22 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	BUT533T	4.6.20 12:34	2021-12-31	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	REC974A	5.12.19 13:43	2021-12-31	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	YVC251T	16.6.22 12:13	2024-04-30	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	DBZ474B	6.6.19 12:21	2020-01-01	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	UDB593V	20.12.18 13:21	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
906	689	Placebo	ASA indication	YUY857A	16.12.21 13:21	2024-04-30	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	YRP362G	10.12.20 13:12	2021-12-31	Edoxaban 60mg / no ASA indication
906	689	Placebo	ASA indication	XND991F	17.6.21 12:39	2021-12-31	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	BMP519N	27.9.18 11:50	2020-01-01	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	RVN844R	7.10.21 12:37	2024-04-30	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	GFD687M	14.4.20 12:41	2021-12-31	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	XNF689B	8.4.21 12:22	2021-12-31	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	MYN838T	1.10.20 12:17	2021-12-31	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	MFY376B	28.3.19 13:27	2020-01-01	Edoxaban 60mg / no ASA indication
726	689	Placebo	no ASA indication	SRM366T	1.10.19 9:39	2021-12-31	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	ABZ415W	8.8.19 12:05	2021-12-31	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	ARK223H	13.2.20 13:20	2021-12-31	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	RZM585B	29.8.22 12:00	2024-04-30	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	HKF856M	14.2.19 13:34	2020-01-01	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	RVS887F	26.8.21 12:17	2024-04-30	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	RUT222N	24.2.22 13:37	2024-04-30	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	YST693P	25.2.21 13:30	2021-12-31	Edoxaban 60mg / no ASA indication
990	689	Placebo	no ASA indication	HGW427S	17.9.20 12:24	2021-12-31	Edoxaban 60mg / no ASA indication
578	689	Edoxaban	ASA indication	FPH192D	5.6.18 8:28	2020-01-01	Edoxaban 60mg / ASA indication
578	689	Edoxaban	ASA indication	PAM284L	6.12.18 13:58	2020-01-01	Edoxaban 60mg / no ASA indication
578	689	Edoxaban	ASA indication	RPU285A	6.6.19 13:15	2020-01-01	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	GCH963T	8.7.19 10:16	2021-12-31	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	HVW126M	12.7.21 9:46	2024-04-30	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	UHX599S	13.1.20 11:50	2021-12-31	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	NGY285W	16.7.18 9:23	2020-01-01	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	WGG217R	11.1.21 10:52	2021-12-31	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	XVR266B	6.7.20 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	LRF571E	20.7.17 12:40	2018-09-01	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	KSV282U	15.1.18 10:29	2018-09-01	Edoxaban 60mg / no ASA indication
232	690	Placebo	no ASA indication	BZL275A	14.1.19 9:46	2020-01-01	Edoxaban 60mg / no ASA indication
2419	690	Placebo	no ASA indication	HVB538E	10.1.22 10:42	2024-04-30	Edoxaban 60mg / no ASA indication
2419	690	Placebo	no ASA indication	HXE219P	24.6.22 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
1989	690	Edoxaban	no ASA indication	ARU671B	1.3.21 14:56	2021-12-31	Edoxaban 60mg / no ASA indication
2190	690	Edoxaban	no ASA indication	HTD666G	15.7.22 10:18	2024-04-30	Edoxaban 60mg / no ASA indication
2190	690	Edoxaban	no ASA indication	HVX754K	15.7.21 10:08	2024-04-30	Edoxaban 60mg / no ASA indication
2190	690	Edoxaban	no ASA indication	HTM828U	17.1.22 13:17	2024-04-30	Edoxaban 60mg / no ASA indication
2428	690	Edoxaban	no ASA indication	WNH991K	13.1.22 11:02	2022-08-31	Edoxaban 30mg / no ASA indication
2428	690	Edoxaban	no ASA indication	GTT452S	22.6.22 13:19	2024-11-30	Edoxaban 30mg / no ASA indication
1229	692	Edoxaban	ASA indication	LPX227L	23.7.19 8:25	2021-12-31	Edoxaban 60mg / ASA indication
2282	693	Placebo	ASA indication	VPE354W	24.9.21 11:38	2024-04-30	Edoxaban 60mg / ASA indication
2282	693	Placebo	ASA indication	FPC929V	5.5.22 18:05	2024-11-30	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1454	693	Placebo	no ASA indication	EYN885R	7.7.21 10:58	2024-04-30	Edoxaban 60mg / no ASA indication
1454	693	Placebo	no ASA indication	THC848X	11.1.21 16:41	2021-12-31	Edoxaban 60mg / no ASA indication
1454	693	Placebo	no ASA indication	VMY214Z	19.8.22 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
1454	693	Placebo	no ASA indication	VNX189M	28.1.22 11:28	2024-04-30	Edoxaban 60mg / no ASA indication
1454	693	Placebo	no ASA indication	LGA517M	17.12.19 16:45	2021-12-31	Edoxaban 60mg / no ASA indication
1454	693	Placebo	no ASA indication	WDC168D	26.6.20 8:44	2021-12-31	Edoxaban 60mg / no ASA indication
1461	693	Placebo	no ASA indication	XGH734W	3.9.20 21:29	2021-12-31	Edoxaban 60mg / no ASA indication
1461	693	Placebo	no ASA indication	TTW752D	21.12.19 15:59	2021-12-31	Edoxaban 60mg / no ASA indication
1519	693	Placebo	no ASA indication	DVB825T	19.8.20 17:26	2021-12-31	Edoxaban 60mg / no ASA indication
1519	693	Placebo	no ASA indication	VPA962K	24.9.21 12:13	2024-04-30	Edoxaban 60mg / no ASA indication
1519	693	Placebo	no ASA indication	YTL797B	2.3.22 13:51	2024-04-30	Edoxaban 60mg / no ASA indication
1519	693	Placebo	no ASA indication	LYG749P	17.2.20 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
1519	693	Placebo	no ASA indication	TPG194M	1.3.21 12:49	2021-12-31	Edoxaban 60mg / no ASA indication
1453	693	Edoxaban	no ASA indication	NDE187S	16.12.19 14:34	2021-12-31	Edoxaban 60mg / no ASA indication
1453	693	Edoxaban	no ASA indication	HCP899W	2.8.22 7:36	2024-11-30	Edoxaban 30mg / no ASA indication
1453	693	Edoxaban	no ASA indication	FES399C	7.7.21 11:27	2024-04-30	Edoxaban 60mg / no ASA indication
1453	693	Edoxaban	no ASA indication	NZB793P	12.7.20 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1453	693	Edoxaban	no ASA indication	VSG459W	30.12.21 13:53	2024-04-30	Edoxaban 60mg / no ASA indication
1453	693	Edoxaban	no ASA indication	HTM767X	11.1.21 17:04	2021-12-31	Edoxaban 60mg / no ASA indication
1518	693	Edoxaban	no ASA indication	PCS651U	10.3.21 14:17	2021-12-31	Edoxaban 60mg / no ASA indication
1518	693	Edoxaban	no ASA indication	VAK423R	12.2.20 11:32	2022-08-31	Edoxaban 30mg / no ASA indication
1518	693	Edoxaban	no ASA indication	GMD991X	17.2.22 14:19	2024-11-30	Edoxaban 30mg / ASA indication
1518	693	Edoxaban	no ASA indication	REM751A	11.10.21 15:46	2022-08-31	Edoxaban 30mg / ASA indication
1518	693	Edoxaban	no ASA indication	TBN298N	3.9.20 15:40	2021-12-31	Edoxaban 60mg / no ASA indication
1559	693	Edoxaban	no ASA indication	ZVW129D	16.3.21 11:28	2022-08-31	Edoxaban 30mg / no ASA indication
1559	693	Edoxaban	no ASA indication	VMF571K	6.5.22 18:13	2024-04-30	Edoxaban 60mg / no ASA indication
1559	693	Edoxaban	no ASA indication	WYH586B	4.9.20 10:43	2022-08-31	Edoxaban 30mg / no ASA indication
1559	693	Edoxaban	no ASA indication	UBS384G	12.3.20 17:45	2022-08-31	Edoxaban 30mg / no ASA indication
1559	693	Edoxaban	no ASA indication	WWE374B	5.11.21 9:36	2022-08-31	Edoxaban 30mg / ASA indication
428	697	Edoxaban	ASA indication	CLS797K	1.2.18 14:05	2018-09-01	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	FLZ464P	4.2.20 14:32	2021-12-31	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	HZR797U	8.8.22 10:39	2024-04-30	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	WHP739G	1.2.21 10:27	2021-12-31	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	HZL492T	21.7.21 11:53	2024-04-30	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	CNC672A	12.2.19 13:13	2020-01-01	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	SYP488P	7.8.19 11:51	2021-12-31	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	PKA244Y	31.7.18 14:27	2020-01-01	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	HZA823P	21.1.22 9:17	2024-04-30	Edoxaban 60mg / ASA indication
428	697	Edoxaban	ASA indication	BRW579D	4.8.20 12:01	2021-12-31	Edoxaban 60mg / ASA indication
475	698	Placebo	ASA indication	PXP635U	27.2.19 11:51	2020-01-01	Edoxaban 60mg / ASA indication
475	698	Placebo	ASA indication	TRB839B	8.3.18 13:19	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
475	698	Placebo	ASA indication	SAE732V	10.9.19 7:38	2021-12-31	Edoxaban 60mg / ASA indication
475	698	Placebo	ASA indication	GPE272C	29.8.18 8:53	2020-01-01	Edoxaban 60mg / ASA indication
621	698	Placebo	ASA indication	SDG666C	25.6.21 8:02	2022-08-31	Edoxaban 30mg / ASA indication
621	698	Placebo	ASA indication	MTA169U	15.7.20 8:25	2022-08-31	Edoxaban 30mg / ASA indication
621	698	Placebo	ASA indication	FFK651G	9.7.18 11:47	2020-01-01	Edoxaban 60mg / ASA indication
621	698	Placebo	ASA indication	DUG684C	15.1.19 8:30	2020-01-01	Edoxaban 60mg / ASA indication
621	698	Placebo	ASA indication	YKY575T	1.7.19 11:15	2022-08-31	Edoxaban 30mg / ASA indication
621	698	Placebo	ASA indication	KAA218U	30.6.22 7:54	2024-11-30	Edoxaban 30mg / ASA indication
621	698	Placebo	ASA indication	RKN523H	15.1.21 9:01	2022-08-31	Edoxaban 30mg / ASA indication
621	698	Placebo	ASA indication	BVY857S	7.1.20 11:49	2022-08-31	Edoxaban 30mg / ASA indication
621	698	Placebo	ASA indication	PLZ779W	27.12.21 8:52	2022-08-31	Edoxaban 30mg / ASA indication
1123	698	Placebo	ASA indication	YRD262W	3.11.20 9:14	2021-12-31	Edoxaban 60mg / ASA indication
1123	698	Placebo	ASA indication	ZZH431Y	14.5.19 8:50	2020-01-01	Edoxaban 60mg / ASA indication
1123	698	Placebo	ASA indication	SZM271U	15.5.20 8:16	2021-12-31	Edoxaban 60mg / ASA indication
1123	698	Placebo	ASA indication	MGN714C	12.11.19 12:12	2021-12-31	Edoxaban 60mg / ASA indication
162	698	Placebo	no ASA indication	NKA724R	15.4.19 11:10	2020-01-01	Edoxaban 60mg / no ASA indication
162	698	Placebo	no ASA indication	YNR948Z	25.4.18 11:55	2020-01-01	Edoxaban 60mg / no ASA indication
162	698	Placebo	no ASA indication	XGH731S	16.5.17 13:51	2018-09-01	Edoxaban 60mg / no ASA indication
162	698	Placebo	no ASA indication	FGR377R	24.10.18 10:15	2020-01-01	Edoxaban 60mg / no ASA indication
162	698	Placebo	no ASA indication	WXL541G	8.11.17 15:14	2018-09-01	Edoxaban 60mg / no ASA indication
1176	698	Placebo	no ASA indication	FXE467H	17.12.19 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1176	698	Placebo	no ASA indication	HFD212U	22.6.20 7:38	2021-12-31	Edoxaban 60mg / no ASA indication
1176	698	Placebo	no ASA indication	TBS595P	7.12.21 11:45	2024-04-30	Edoxaban 60mg / no ASA indication
1176	698	Placebo	no ASA indication	GGM659B	8.12.20 8:34	2021-12-31	Edoxaban 60mg / no ASA indication
1176	698	Placebo	no ASA indication	NER984R	11.6.19 14:23	2020-01-01	Edoxaban 60mg / no ASA indication
1176	698	Placebo	no ASA indication	FTE225W	7.6.21 7:44	2021-12-31	Edoxaban 60mg / no ASA indication
219	698	Edoxaban	ASA indication	ZSP794U	10.7.17 15:44	2018-09-01	Edoxaban 60mg / ASA indication
226	698	Edoxaban	ASA indication	KMV636S	15.1.19 9:07	2020-01-01	Edoxaban 30mg / ASA indication
226	698	Edoxaban	ASA indication	XWK534B	13.1.20 11:39	2022-08-31	Edoxaban 30mg / ASA indication
226	698	Edoxaban	ASA indication	NNS713D	12.1.21 8:43	2021-12-31	Edoxaban 60mg / ASA indication
226	698	Edoxaban	ASA indication	TLC831L	21.7.21 7:52	2024-04-30	Edoxaban 60mg / ASA indication
226	698	Edoxaban	ASA indication	XVZ457S	12.1.18 8:58	2018-09-01	Edoxaban 60mg / ASA indication
226	698	Edoxaban	ASA indication	ULT764H	12.7.17 13:24	2018-09-01	Edoxaban 60mg / ASA indication
226	698	Edoxaban	ASA indication	AGN848M	14.7.17 13:04	2018-09-01	Edoxaban 30mg / ASA indication
226	698	Edoxaban	ASA indication	LEG369M	24.7.18 9:24	2020-01-01	Edoxaban 30mg / ASA indication
226	698	Edoxaban	ASA indication	HMD591L	26.7.19 8:04	2021-12-31	Edoxaban 60mg / ASA indication
226	698	Edoxaban	ASA indication	VCE216X	21.7.20 7:50	2021-12-31	Edoxaban 60mg / ASA indication
303	698	Edoxaban	ASA indication	PEY344W	11.4.18 7:39	2020-01-01	Edoxaban 60mg / ASA indication
303	698	Edoxaban	ASA indication	GTV744H	16.10.17 11:45	2018-09-01	Edoxaban 30mg / ASA indication
1494	698	Edoxaban	ASA indication	EUU676S	6.5.20 10:15	2022-08-31	Edoxaban 30mg / ASA indication
1494	698	Edoxaban	ASA indication	EKL768V	25.1.21 8:58	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1494	698	Edoxaban	ASA indication	PZN948E	31.1.22 9:15	2022-08-31	Edoxaban 30mg / ASA indication
1494	698	Edoxaban	ASA indication	AFK968R	15.7.20 7:39	2022-08-31	Edoxaban 30mg / ASA indication
1494	698	Edoxaban	ASA indication	HUF585B	28.7.22 11:15	2024-11-30	Edoxaban 30mg / ASA indication
1494	698	Edoxaban	ASA indication	EXH283L	28.1.20 12:23	2021-12-31	Edoxaban 60mg / ASA indication
1494	698	Edoxaban	ASA indication	PFE579B	30.7.21 7:54	2022-08-31	Edoxaban 30mg / ASA indication
193	698	Edoxaban	no ASA indication	VUH832M	20.12.17 10:32	2018-09-01	Edoxaban 60mg / no ASA indication
193	698	Edoxaban	no ASA indication	BNT574D	5.12.18 11:17	2020-01-01	Edoxaban 60mg / no ASA indication
193	698	Edoxaban	no ASA indication	XMA195V	13.6.17 11:44	2018-09-01	Edoxaban 60mg / no ASA indication
193	698	Edoxaban	no ASA indication	MUU951Y	13.6.18 11:14	2020-01-01	Edoxaban 60mg / no ASA indication
193	698	Edoxaban	no ASA indication	HLV157F	27.5.19 11:09	2020-01-01	Edoxaban 60mg / no ASA indication
1310	700	Placebo	ASA indication	NLE283U	14.9.20 12:57	2021-12-31	Edoxaban 60mg / ASA indication
1310	700	Placebo	ASA indication	AEH396N	31.3.20 8:52	2021-12-31	Edoxaban 60mg / ASA indication
1310	700	Placebo	ASA indication	XBS199S	24.3.21 10:39	2021-12-31	Edoxaban 60mg / ASA indication
1310	700	Placebo	ASA indication	SCD677Z	29.3.22 12:06	2024-04-30	Edoxaban 60mg / no ASA indication
1310	700	Placebo	ASA indication	RUL667S	28.9.21 11:46	2024-04-30	Edoxaban 60mg / ASA indication
1310	700	Placebo	ASA indication	MWR756Y	3.10.19 8:46	2021-12-31	Edoxaban 60mg / ASA indication
2483	700	Placebo	ASA indication	RUK382T	17.2.22 11:30	2024-04-30	Edoxaban 60mg / ASA indication
1018	700	Edoxaban	no ASA indication	ULF399B	26.8.19 12:36	2021-12-31	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	WZM844K	10.9.20 11:19	2021-12-31	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	SDS132D	7.9.21 11:32	2024-04-30	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	CSE413U	11.3.20 10:55	2021-12-31	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	SEH358R	7.9.22 12:31	2024-04-30	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	VSZ837E	7.3.19 14:55	2020-01-01	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	SCM838P	14.3.22 8:20	2024-04-30	Edoxaban 60mg / no ASA indication
1018	700	Edoxaban	no ASA indication	DUU536U	16.3.21 10:12	2021-12-31	Edoxaban 60mg / no ASA indication
950	702	Placebo	ASA indication	NCK287P	23.1.19 10:18	2020-01-01	Edoxaban 60mg / ASA indication
1296	702	Placebo	ASA indication	EPF416H	25.9.19 9:19	2021-12-31	Edoxaban 60mg / ASA indication
289	702	Placebo	no ASA indication	RHS598B	11.4.18 9:56	2020-01-01	Edoxaban 60mg / ASA indication
289	702	Placebo	no ASA indication	WTP986B	10.4.19 9:13	2020-01-01	Edoxaban 60mg / no ASA indication
289	702	Placebo	no ASA indication	HLR887E	9.10.19 12:22	2021-12-31	Edoxaban 60mg / ASA indication
289	702	Placebo	no ASA indication	MAV743K	10.10.18 8:21	2020-01-01	Edoxaban 60mg / ASA indication
289	702	Placebo	no ASA indication	CCB366T	18.10.17 8:23	2018-09-01	Edoxaban 60mg / no ASA indication
289	702	Placebo	no ASA indication	CLU276E	8.4.20 8:37	2021-12-31	Edoxaban 60mg / ASA indication
1031	702	Placebo	no ASA indication	PRK965W	20.3.19 11:01	2020-01-01	Edoxaban 60mg / no ASA indication
444	702	Edoxaban	ASA indication	FES364V	6.2.19 7:56	2020-01-01	Edoxaban 60mg / ASA indication
444	702	Edoxaban	ASA indication	EPU213Y	4.3.20 10:27	2021-12-31	Edoxaban 60mg / ASA indication
444	702	Edoxaban	ASA indication	GUB171S	21.2.18 10:53	2020-01-01	Edoxaban 60mg / ASA indication
444	702	Edoxaban	ASA indication	LZE327S	15.8.18 7:01	2020-01-01	Edoxaban 60mg / no ASA indication
444	702	Edoxaban	ASA indication	YHS175V	28.8.19 10:28	2021-12-31	Edoxaban 60mg / ASA indication
1381	702	Edoxaban	ASA indication	CCD539L	13.11.19 10:14	2021-12-31	Edoxaban 60mg / ASA indication
158	702	Edoxaban	no ASA indication	CMP579K	8.11.17 9:56	2018-09-01	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
158	702	Edoxaban	no ASA indication	HPB833U	10.5.17 8:04	2018-09-01	Edoxaban 30mg / no ASA indication
174	702	Edoxaban	no ASA indication	NWN527W	31.5.17 9:51	2018-09-01	Edoxaban 60mg / no ASA indication
174	702	Edoxaban	no ASA indication	GZB997C	12.12.18 9:49	2020-01-01	Edoxaban 60mg / no ASA indication
174	702	Edoxaban	no ASA indication	AMA898Z	29.11.17 10:24	2018-09-01	Edoxaban 60mg / no ASA indication
174	702	Edoxaban	no ASA indication	SNA573U	13.6.18 9:12	2020-01-01	Edoxaban 60mg / no ASA indication
635	704	Placebo	ASA indication	VWB974M	14.10.19 13:51	2021-12-31	Edoxaban 60mg / ASA indication
635	704	Placebo	ASA indication	TLM389L	6.4.20 6:49	2021-12-31	Edoxaban 60mg / ASA indication
635	704	Placebo	ASA indication	RMC594R	11.2.19 11:28	2020-01-01	Edoxaban 60mg / ASA indication
635	704	Placebo	ASA indication	MVZ887V	14.5.21 11:35	2021-12-31	Edoxaban 60mg / no ASA indication
635	704	Placebo	ASA indication	KYE651K	21.1.22 13:04	2024-04-30	Edoxaban 60mg / ASA indication
635	704	Placebo	ASA indication	CRY144H	24.7.18 7:18	2020-01-01	Edoxaban 60mg / ASA indication
635	704	Placebo	ASA indication	GKE784H	26.10.20 8:29	2021-12-31	Edoxaban 60mg / ASA indication
761	704	Placebo	ASA indication	ABX176Y	22.10.18 9:42	2020-01-01	Edoxaban 60mg / ASA indication
1528	704	Placebo	no ASA indication	HEH691D	29.5.20 9:28	2021-12-31	Edoxaban 60mg / no ASA indication
1528	704	Placebo	no ASA indication	VUX594X	17.12.20 10:57	2021-12-31	Edoxaban 60mg / no ASA indication
1528	704	Placebo	no ASA indication	XLC866B	21.2.20 10:41	2021-12-31	Edoxaban 60mg / no ASA indication
1528	704	Placebo	no ASA indication	KNN873E	16.7.21 13:49	2024-04-30	Edoxaban 60mg / no ASA indication
1528	704	Placebo	no ASA indication	KNB426P	2.2.22 10:01	2024-04-30	Edoxaban 60mg / no ASA indication
612	704	Edoxaban	ASA indication	ZCC233Z	12.7.18 7:56	2020-01-01	Edoxaban 60mg / ASA indication
649	704	Edoxaban	ASA indication	WNU973V	31.7.18 13:06	2020-01-01	Edoxaban 60mg / ASA indication
649	704	Edoxaban	ASA indication	BZD555R	11.2.19 11:15	2020-01-01	Edoxaban 60mg / ASA indication
649	704	Edoxaban	ASA indication	GCB896R	26.8.19 14:02	2021-12-31	Edoxaban 60mg / ASA indication
1412	705	Placebo	ASA indication	HAC137D	3.6.20 12:52	2022-08-31	Edoxaban 30mg / ASA indication
1412	705	Placebo	ASA indication	URU992Y	28.11.19 9:55	2022-08-31	Edoxaban 30mg / ASA indication
1682	705	Placebo	ASA indication	ZZH651H	10.7.20 7:25	2021-12-31	Edoxaban 60mg / ASA indication
1773	705	Placebo	ASA indication	NWC795Y	22.3.21 11:19	2021-12-31	Edoxaban 60mg / ASA indication
1773	705	Placebo	ASA indication	FXP177U	17.3.22 10:27	2024-04-30	Edoxaban 60mg / ASA indication
1773	705	Placebo	ASA indication	PFY151C	29.9.21 10:21	2024-04-30	Edoxaban 60mg / ASA indication
1773	705	Placebo	ASA indication	VBB777C	11.9.20 11:23	2021-12-31	Edoxaban 60mg / ASA indication
1860	705	Placebo	ASA indication	MWN416Z	11.11.20 10:50	2022-08-31	Edoxaban 30mg / ASA indication
1881	705	Placebo	ASA indication	VKF988H	26.5.21 9:12	2022-08-31	Edoxaban 30mg / ASA indication
1881	705	Placebo	ASA indication	YHB639G	23.11.21 9:26	2024-04-30	Edoxaban 60mg / ASA indication
1881	705	Placebo	ASA indication	RAS117W	1.6.22 7:26	2024-11-30	Edoxaban 30mg / ASA indication
1881	705	Placebo	ASA indication	VKA623H	30.11.21 7:48	2022-08-31	Edoxaban 30mg / ASA indication
1881	705	Placebo	ASA indication	AAK158V	25.11.20 11:14	2022-08-31	Edoxaban 30mg / ASA indication
2134	705	Placebo	ASA indication	PVV548Z	2.6.21 12:55	2021-12-31	Edoxaban 60mg / ASA indication
2157	705	Placebo	ASA indication	KMW758U	16.6.21 9:11	2021-12-31	Edoxaban 60mg / ASA indication
2157	705	Placebo	ASA indication	FSY727K	15.6.22 8:32	2024-04-30	Edoxaban 60mg / ASA indication
2157	705	Placebo	ASA indication	PGB162M	7.12.21 9:31	2024-04-30	Edoxaban 60mg / ASA indication
2390	705	Placebo	ASA indication	YGH144L	14.12.21 10:22	2024-04-30	Edoxaban 60mg / ASA indication
2390	705	Placebo	ASA indication	HNG827W	3.6.22 8:01	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2396	705	Placebo	ASA indication	XPE773W	7.6.22 8:28	2024-04-30	Edoxaban 60mg / ASA indication
2396	705	Placebo	ASA indication	FYE338U	16.12.21 11:32	2024-04-30	Edoxaban 60mg / ASA indication
2432	705	Placebo	ASA indication	NVX488A	14.1.22 12:10	2022-08-31	Edoxaban 30mg / ASA indication
2437	705	Placebo	ASA indication	USP553T	21.7.22 6:34	2024-11-30	Edoxaban 30mg / ASA indication
2437	705	Placebo	ASA indication	KHY711W	19.1.22 12:50	2024-11-30	Edoxaban 30mg / ASA indication
2556	705	Placebo	ASA indication	HRN699N	23.3.22 11:19	2024-04-30	Edoxaban 60mg / ASA indication
2579	705	Placebo	ASA indication	XMC914F	8.4.22 8:54	2024-04-30	Edoxaban 60mg / ASA indication
2742	705	Placebo	ASA indication	GWX428Z	24.8.22 10:16	2024-04-30	Edoxaban 60mg / ASA indication
1647	705	Placebo	no ASA indication	DYA831X	7.1.21 9:40	2021-12-31	Edoxaban 60mg / no ASA indication
1647	705	Placebo	no ASA indication	PGB237C	14.6.22 7:44	2024-04-30	Edoxaban 60mg / no ASA indication
1647	705	Placebo	no ASA indication	GSU558F	18.6.20 10:11	2021-12-31	Edoxaban 60mg / no ASA indication
1647	705	Placebo	no ASA indication	PGP121L	23.6.21 7:46	2024-04-30	Edoxaban 60mg / no ASA indication
1647	705	Placebo	no ASA indication	VKW699K	16.12.21 8:02	2024-04-30	Edoxaban 60mg / no ASA indication
1748	705	Placebo	no ASA indication	BMB554X	26.8.20 10:09	2021-12-31	Edoxaban 60mg / no ASA indication
1748	705	Placebo	no ASA indication	KHS115Z	25.2.22 9:25	2024-11-30	Edoxaban 30mg / ASA indication
1748	705	Placebo	no ASA indication	FMK258X	4.3.21 12:09	2021-12-31	Edoxaban 60mg / ASA indication
1748	705	Placebo	no ASA indication	PGS494F	13.9.21 10:54	2024-04-30	Edoxaban 60mg / ASA indication
2291	705	Placebo	no ASA indication	CLR747A	29.9.21 11:44	2022-08-31	Edoxaban 30mg / no ASA indication
2731	705	Placebo	no ASA indication	HVV284T	31.8.22 10:04	2024-11-30	Edoxaban 30mg / no ASA indication
1416	705	Edoxaban	ASA indication	CHF882B	3.6.20 12:35	2021-12-31	Edoxaban 60mg / ASA indication
1416	705	Edoxaban	ASA indication	TDU481G	28.11.19 12:48	2021-12-31	Edoxaban 60mg / ASA indication
1479	705	Edoxaban	ASA indication	EHN332H	17.1.20 10:38	2021-12-31	Edoxaban 60mg / ASA indication
1479	705	Edoxaban	ASA indication	ZXK463G	28.1.21 10:52	2021-12-31	Edoxaban 60mg / ASA indication
1479	705	Edoxaban	ASA indication	PFB644N	28.7.21 12:47	2024-04-30	Edoxaban 60mg / ASA indication
1479	705	Edoxaban	ASA indication	HHP385M	20.7.20 13:07	2021-12-31	Edoxaban 60mg / ASA indication
1479	705	Edoxaban	ASA indication	KAF111A	2.3.22 9:56	2024-04-30	Edoxaban 60mg / ASA indication
1479	705	Edoxaban	ASA indication	BTP711X	14.7.22 12:31	2024-04-30	Edoxaban 60mg / ASA indication
1509	705	Edoxaban	ASA indication	GKS158S	23.2.21 11:12	2022-08-31	Edoxaban 30mg / ASA indication
1509	705	Edoxaban	ASA indication	VAA796X	10.2.20 11:20	2021-12-31	Edoxaban 60mg / ASA indication
1509	705	Edoxaban	ASA indication	USG593C	11.8.20 8:25	2021-12-31	Edoxaban 60mg / ASA indication
1509	705	Edoxaban	ASA indication	PEV698X	23.8.21 10:05	2024-04-30	Edoxaban 60mg / ASA indication
1908	705	Edoxaban	ASA indication	VGU642L	16.12.20 11:05	2022-08-31	Edoxaban 30mg / ASA indication
1908	705	Edoxaban	ASA indication	EXM222M	20.12.21 9:09	2024-04-30	Edoxaban 60mg / ASA indication
1908	705	Edoxaban	ASA indication	BZK925E	25.6.21 7:28	2022-08-31	Edoxaban 30mg / ASA indication
2137	705	Edoxaban	ASA indication	PFG723B	7.12.21 10:22	2024-04-30	Edoxaban 60mg / ASA indication
2137	705	Edoxaban	ASA indication	LYT544V	4.6.21 8:05	2021-12-31	Edoxaban 60mg / ASA indication
2158	705	Edoxaban	ASA indication	PUA566U	14.12.21 10:48	2022-08-31	Edoxaban 30mg / ASA indication
2158	705	Edoxaban	ASA indication	KKZ838B	8.6.22 11:37	2024-11-30	Edoxaban 30mg / ASA indication
2158	705	Edoxaban	ASA indication	CBK427Z	16.6.21 9:58	2022-08-31	Edoxaban 30mg / ASA indication
2272	705	Edoxaban	ASA indication	XAH388Y	15.9.21 10:33	2024-04-30	Edoxaban 60mg / ASA indication
2272	705	Edoxaban	ASA indication	EVU526Y	15.3.22 8:40	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2367	705	Edoxaban	ASA indication	XAY497S	25.11.21 9:24	2024-04-30	Edoxaban 60mg / ASA indication
2367	705	Edoxaban	ASA indication	HXA991W	14.6.22 9:02	2024-04-30	Edoxaban 60mg / ASA indication
2383	705	Edoxaban	ASA indication	TCE137B	3.6.22 11:39	2024-04-30	Edoxaban 60mg / ASA indication
2383	705	Edoxaban	ASA indication	YPW843A	7.12.21 10:52	2024-04-30	Edoxaban 60mg / ASA indication
2395	705	Edoxaban	ASA indication	PSB488R	16.12.21 10:35	2022-08-31	Edoxaban 30mg / ASA indication
2395	705	Edoxaban	ASA indication	MZG941C	10.6.22 7:16	2024-11-30	Edoxaban 30mg / ASA indication
2431	705	Edoxaban	ASA indication	EUA587Z	14.1.22 11:14	2024-04-30	Edoxaban 60mg / ASA indication
2431	705	Edoxaban	ASA indication	BWP124D	14.7.22 12:32	2024-04-30	Edoxaban 60mg / ASA indication
2740	705	Edoxaban	ASA indication	LYU695D	23.8.22 11:16	2024-04-30	Edoxaban 60mg / ASA indication
1621	705	Edoxaban	no ASA indication	WEZ312K	10.6.20 10:23	2021-12-31	Edoxaban 60mg / no ASA indication
2133	705	Edoxaban	no ASA indication	PGC671B	1.12.21 8:48	2024-04-30	Edoxaban 60mg / no ASA indication
2133	705	Edoxaban	no ASA indication	TDE438B	2.6.21 11:33	2021-12-31	Edoxaban 60mg / no ASA indication
2133	705	Edoxaban	no ASA indication	TNS783C	2.6.22 9:14	2024-04-30	Edoxaban 60mg / ASA indication
2153	705	Edoxaban	no ASA indication	AXP335N	15.6.21 9:09	2022-08-31	Edoxaban 30mg / no ASA indication
654	706	Placebo	ASA indication	LHA843D	16.2.21 17:00	2021-12-31	Edoxaban 60mg / ASA indication
654	706	Placebo	ASA indication	EBT595M	19.8.22 13:32	2024-04-30	Edoxaban 60mg / ASA indication
654	706	Placebo	ASA indication	ANN464B	24.8.20 13:32	2021-12-31	Edoxaban 60mg / ASA indication
654	706	Placebo	ASA indication	AXP423P	9.8.19 13:33	2022-08-31	Edoxaban 30mg / ASA indication
654	706	Placebo	ASA indication	PRN228K	2.8.18 10:13	2020-01-01	Edoxaban 60mg / ASA indication
654	706	Placebo	ASA indication	TZM912W	19.2.20 12:56	2022-08-31	Edoxaban 30mg / ASA indication
654	706	Placebo	ASA indication	VUA193R	6.2.19 14:32	2020-01-01	Edoxaban 30mg / ASA indication
654	706	Placebo	ASA indication	DWL838M	11.8.21 7:50	2024-04-30	Edoxaban 60mg / ASA indication
654	706	Placebo	ASA indication	KHL787Z	14.2.22 11:57	2022-08-31	Edoxaban 30mg / ASA indication
282	706	Placebo	no ASA indication	NNY781K	21.9.17 13:23	2018-09-01	Edoxaban 30mg / no ASA indication
278	706	Edoxaban	ASA indication	YZC631B	10.9.18 15:39	2020-01-01	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	NZR414R	14.9.17 16:03	2018-09-01	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	BAD944L	20.3.20 10:02	2022-08-31	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	GKT822B	22.9.20 11:54	2022-08-31	Edoxaban 30mg / no ASA indication
278	706	Edoxaban	ASA indication	NKN547F	3.3.22 12:54	2024-11-30	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	LFK795R	13.9.19 13:41	2022-08-31	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	ULS336X	15.3.21 16:38	2022-08-31	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	TYB224Z	22.3.18 15:23	2020-01-01	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	WBP621R	13.3.19 14:10	2020-01-01	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	ALH717X	22.9.21 11:23	2022-08-31	Edoxaban 30mg / ASA indication
278	706	Edoxaban	ASA indication	PCV318W	23.9.20 12:20	2022-08-31	Edoxaban 30mg / ASA indication
557	706	Edoxaban	ASA indication	CGK783R	25.11.19 14:27	2021-12-31	Edoxaban 60mg / ASA indication
557	706	Edoxaban	ASA indication	GRA244E	11.6.20 14:17	2021-12-31	Edoxaban 60mg / no ASA indication
557	706	Edoxaban	ASA indication	XFW932C	22.11.18 13:14	2020-01-01	Edoxaban 60mg / ASA indication
557	706	Edoxaban	ASA indication	DWP549R	10.11.21 15:03	2024-04-30	Edoxaban 60mg / ASA indication
557	706	Edoxaban	ASA indication	SPC532A	2.12.20 15:30	2021-12-31	Edoxaban 60mg / ASA indication
557	706	Edoxaban	ASA indication	VWS679G	22.5.19 12:01	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
557	706	Edoxaban	ASA indication	BPR429S	17.5.18 11:12	2020-01-01	Edoxaban 60mg / ASA indication
557	706	Edoxaban	ASA indication	LGM886F	10.5.21 15:14	2021-12-31	Edoxaban 60mg / ASA indication
557	706	Edoxaban	ASA indication	DXB974L	6.5.22 13:35	2024-04-30	Edoxaban 60mg / ASA indication
689	706	Edoxaban	ASA indication	NKK758Z	4.3.20 14:00	2021-12-31	Edoxaban 60mg / ASA indication
689	706	Edoxaban	ASA indication	TMT437W	30.8.18 10:42	2020-01-01	Edoxaban 60mg / ASA indication
689	706	Edoxaban	ASA indication	HSF389M	6.3.19 12:58	2020-01-01	Edoxaban 60mg / ASA indication
689	706	Edoxaban	ASA indication	DXE745Y	13.9.19 13:50	2021-12-31	Edoxaban 60mg / ASA indication
208	706	Edoxaban	no ASA indication	KWV973G	9.1.19 13:46	2020-01-01	Edoxaban 60mg / no ASA indication
208	706	Edoxaban	no ASA indication	RMU532W	30.6.17 9:58	2018-09-01	Edoxaban 60mg / no ASA indication
208	706	Edoxaban	no ASA indication	UFN622F	5.7.18 14:34	2020-01-01	Edoxaban 30mg / no ASA indication
208	706	Edoxaban	no ASA indication	ZCG669D	17.7.19 12:40	2022-08-31	Edoxaban 30mg / no ASA indication
208	706	Edoxaban	no ASA indication	ZXW368R	4.1.18 11:49	2018-09-01	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	AVG199W	28.8.18 8:11	2020-01-01	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	DPM111A	18.8.20 15:13	2021-12-31	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	XXB221K	10.8.17 13:16	2018-09-01	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	EZF714X	17.2.20 15:43	2021-12-31	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	GZZ443D	27.2.19 13:48	2020-01-01	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	DPV479H	19.8.19 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
248	706	Edoxaban	no ASA indication	HBA468L	15.2.18 14:37	2018-09-01	Edoxaban 60mg / no ASA indication
480	707	Placebo	ASA indication	LCX667Z	3.10.19 7:19	2021-12-31	Edoxaban 60mg / no ASA indication
480	707	Placebo	ASA indication	XLG255F	12.3.19 9:19	2020-01-01	Edoxaban 60mg / no ASA indication
480	707	Placebo	ASA indication	ZTT938N	20.9.18 8:02	2020-01-01	Edoxaban 60mg / no ASA indication
480	707	Placebo	ASA indication	GLP913K	13.3.18 11:40	2020-01-01	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	PRM413A	9.1.20 11:09	2021-12-31	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	RNL518F	6.1.22 9:25	2024-04-30	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	RNW332K	28.6.22 8:52	2024-04-30	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	UYX444A	25.6.20 8:32	2021-12-31	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	FWD691V	7.1.21 8:53	2021-12-31	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	STW944E	4.7.19 9:08	2021-12-31	Edoxaban 60mg / ASA indication
1214	707	Placebo	ASA indication	RSC813Z	29.6.21 8:25	2024-04-30	Edoxaban 60mg / ASA indication
1820	707	Placebo	no ASA indication	HVW271C	8.4.21 10:05	2021-12-31	Edoxaban 60mg / no ASA indication
1820	707	Placebo	no ASA indication	TZU628Y	8.10.20 7:26	2021-12-31	Edoxaban 60mg / no ASA indication
1820	707	Placebo	no ASA indication	RWR739G	14.10.21 13:01	2024-04-30	Edoxaban 60mg / no ASA indication
1820	707	Placebo	no ASA indication	RWU941F	19.4.22 8:10	2024-04-30	Edoxaban 60mg / no ASA indication
437	707	Edoxaban	ASA indication	ZMP244S	8.2.18 13:14	2018-09-01	Edoxaban 60mg / ASA indication
437	707	Edoxaban	ASA indication	WDM669S	14.8.18 6:52	2020-01-01	Edoxaban 60mg / ASA indication
437	707	Edoxaban	ASA indication	DFC543C	15.8.19 6:53	2021-12-31	Edoxaban 60mg / ASA indication
437	707	Edoxaban	ASA indication	WVY488E	5.2.19 9:12	2020-01-01	Edoxaban 60mg / ASA indication
1226	707	Edoxaban	ASA indication	KNK489B	18.7.19 7:56	2022-08-31	Edoxaban 30mg / ASA indication
496	707	Edoxaban	no ASA indication	XRA824X	3.9.19 9:04	2021-12-31	Edoxaban 60mg / no ASA indication
496	707	Edoxaban	no ASA indication	EZN438Y	20.9.18 6:20	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
496	707	Edoxaban	no ASA indication	TYV244A	15.9.20 8:04	2021-12-31	Edoxaban 60mg / no ASA indication
496	707	Edoxaban	no ASA indication	FMZ178W	17.3.20 11:28	2021-12-31	Edoxaban 60mg / no ASA indication
496	707	Edoxaban	no ASA indication	XUV474X	22.3.18 8:55	2020-01-01	Edoxaban 60mg / no ASA indication
496	707	Edoxaban	no ASA indication	ESC774U	2.4.19 7:28	2020-01-01	Edoxaban 60mg / no ASA indication
522	707	Edoxaban	no ASA indication	TMP999K	12.4.18 8:11	2020-01-01	Edoxaban 30mg / no ASA indication
522	707	Edoxaban	no ASA indication	UYT261V	16.10.18 6:40	2020-01-01	Edoxaban 30mg / no ASA indication
522	707	Edoxaban	no ASA indication	HDU525L	17.4.19 9:41	2020-01-01	Edoxaban 30mg / no ASA indication
1873	707	Edoxaban	no ASA indication	UNX857X	18.5.21 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1873	707	Edoxaban	no ASA indication	KCS842P	19.11.20 9:12	2021-12-31	Edoxaban 60mg / no ASA indication
512	708	Placebo	ASA indication	FVT553D	6.4.18 6:49	2020-01-01	Edoxaban 60mg / ASA indication
525	708	Edoxaban	ASA indication	VTM824A	13.11.18 8:14	2020-01-01	Edoxaban 30mg / ASA indication
525	708	Edoxaban	ASA indication	AEN164R	16.4.18 6:22	2020-01-01	Edoxaban 30mg / ASA indication
374	708	Edoxaban	no ASA indication	VNZ753M	6.3.19 9:03	2020-01-01	Edoxaban 30mg / no ASA indication
374	708	Edoxaban	no ASA indication	HHB467T	13.12.17 10:37	2018-09-01	Edoxaban 60mg / no ASA indication
374	708	Edoxaban	no ASA indication	TFZ298H	23.7.18 5:41	2020-01-01	Edoxaban 30mg / ASA indication
374	708	Edoxaban	no ASA indication	YTA854V	12.9.19 5:23	2022-08-31	Edoxaban 30mg / no ASA indication
492	708	Edoxaban	no ASA indication	VVW776T	20.3.18 9:15	2020-01-01	Edoxaban 30mg / no ASA indication
492	708	Edoxaban	no ASA indication	VHW139C	13.11.18 8:08	2020-01-01	Edoxaban 30mg / no ASA indication
360	711	Placebo	ASA indication	DYH753Y	29.11.18 7:54	2020-01-01	Edoxaban 30mg / ASA indication
360	711	Placebo	ASA indication	UTM141R	1.6.18 13:45	2020-01-01	Edoxaban 30mg / ASA indication
360	711	Placebo	ASA indication	NKF533H	4.12.17 11:34	2018-09-01	Edoxaban 30mg / ASA indication
443	711	Placebo	ASA indication	HCA742B	14.2.19 7:45	2020-01-01	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	EBX152A	8.8.19 8:19	2021-12-31	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	UVN783D	6.2.20 15:20	2021-12-31	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	PFK791N	15.2.21 8:21	2021-12-31	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	LHX223P	19.8.21 8:24	2024-04-30	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	XUD774R	14.2.18 6:47	2018-09-01	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	PNN375B	16.8.18 6:55	2020-01-01	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	LKG668E	10.2.22 9:39	2024-04-30	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	XCM544G	13.8.20 6:42	2021-12-31	Edoxaban 60mg / ASA indication
443	711	Placebo	ASA indication	LLF639X	18.8.22 8:00	2024-04-30	Edoxaban 60mg / ASA indication
873	711	Placebo	ASA indication	YMX262P	13.6.19 10:45	2020-01-01	Edoxaban 60mg / no ASA indication
873	711	Placebo	ASA indication	UBH293Z	12.12.19 7:39	2021-12-31	Edoxaban 60mg / no ASA indication
873	711	Placebo	ASA indication	AUM846L	8.12.18 10:57	2020-01-01	Edoxaban 60mg / ASA indication
1253	711	Placebo	no ASA indication	LFB836R	20.2.20 9:52	2021-12-31	Edoxaban 60mg / no ASA indication
1253	711	Placebo	no ASA indication	RSW657F	11.2.21 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
1253	711	Placebo	no ASA indication	KUU738T	10.2.22 9:03	2024-04-30	Edoxaban 60mg / no ASA indication
1253	711	Placebo	no ASA indication	KSM911W	13.8.20 8:35	2021-12-31	Edoxaban 60mg / no ASA indication
1253	711	Placebo	no ASA indication	RZX183P	16.8.19 11:09	2021-12-31	Edoxaban 60mg / no ASA indication
1253	711	Placebo	no ASA indication	KUL111G	19.8.21 7:45	2024-04-30	Edoxaban 60mg / no ASA indication
383	711	Edoxaban	ASA indication	UAE492X	5.7.18 7:29	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
383	711	Edoxaban	ASA indication	SXV946Z	2.7.20 7:49	2021-12-31	Edoxaban 60mg / ASA indication
383	711	Edoxaban	ASA indication	KZS321G	24.6.21 7:32	2024-04-30	Edoxaban 60mg / ASA indication
383	711	Edoxaban	ASA indication	BVD956S	27.12.18 7:50	2020-01-01	Edoxaban 60mg / ASA indication
383	711	Edoxaban	ASA indication	YVP872F	27.6.19 8:55	2021-12-31	Edoxaban 60mg / ASA indication
383	711	Edoxaban	ASA indication	BNP911E	2.1.20 6:33	2021-12-31	Edoxaban 60mg / ASA indication
383	711	Edoxaban	ASA indication	MSW586K	29.12.17 14:25	2018-09-01	Edoxaban 60mg / ASA indication
383	711	Edoxaban	ASA indication	LNC978L	7.1.21 7:19	2021-12-31	Edoxaban 60mg / ASA indication
1252	711	Edoxaban	ASA indication	WUM587B	16.8.19 10:24	2021-12-31	Edoxaban 60mg / ASA indication
1458	711	Edoxaban	ASA indication	VNR975V	1.7.22 11:39	2024-04-30	Edoxaban 60mg / ASA indication
1458	711	Edoxaban	ASA indication	HDZ729Z	20.12.19 6:52	2021-12-31	Edoxaban 60mg / ASA indication
1458	711	Edoxaban	ASA indication	FHT136R	2.7.20 7:18	2021-12-31	Edoxaban 60mg / ASA indication
1458	711	Edoxaban	ASA indication	VNG922T	16.12.21 9:23	2024-04-30	Edoxaban 60mg / ASA indication
1458	711	Edoxaban	ASA indication	TTW336P	17.12.20 13:29	2021-12-31	Edoxaban 60mg / ASA indication
1458	711	Edoxaban	ASA indication	LBD131N	2.7.21 10:00	2024-04-30	Edoxaban 60mg / ASA indication
439	711	Edoxaban	no ASA indication	ZRD843B	9.2.18 6:33	2018-09-01	Edoxaban 60mg / no ASA indication
518	711	Edoxaban	no ASA indication	PFF541N	9.4.18 7:16	2020-01-01	Edoxaban 60mg / no ASA indication
518	711	Edoxaban	no ASA indication	CNY613G	20.9.18 9:36	2020-01-01	Edoxaban 60mg / no ASA indication
611	711	Edoxaban	no ASA indication	ZYY677E	27.6.19 10:05	2022-08-31	Edoxaban 30mg / no ASA indication
611	711	Edoxaban	no ASA indication	KAH951D	20.12.18 7:38	2020-01-01	Edoxaban 30mg / no ASA indication
611	711	Edoxaban	no ASA indication	BFG412Z	28.6.18 13:44	2020-01-01	Edoxaban 30mg / no ASA indication
611	711	Edoxaban	no ASA indication	EMC837P	2.7.20 9:50	2022-08-31	Edoxaban 30mg / no ASA indication
611	711	Edoxaban	no ASA indication	KZZ835S	19.12.19 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
2373	713	Placebo	ASA indication	KUY385S	31.5.22 7:29	2024-11-30	Edoxaban 30mg / ASA indication
2373	713	Placebo	ASA indication	TBP655Y	1.12.21 12:13	2022-08-31	Edoxaban 30mg / ASA indication
1013	718	Edoxaban	no ASA indication	CXB349R	26.8.20 11:50	2021-12-31	Edoxaban 60mg / no ASA indication
1013	718	Edoxaban	no ASA indication	HNG867S	5.3.19 11:43	2020-01-01	Edoxaban 60mg / no ASA indication
1013	718	Edoxaban	no ASA indication	DGP839M	26.2.20 14:13	2021-12-31	Edoxaban 60mg / no ASA indication
1013	718	Edoxaban	no ASA indication	HKX296K	11.9.19 13:14	2021-12-31	Edoxaban 60mg / no ASA indication
2630	720	Placebo	ASA indication	PUZ464N	30.5.22 10:32	2024-11-30	Edoxaban 30mg / ASA indication
2726	720	Placebo	ASA indication	TUW979V	26.7.22 10:04	2024-04-30	Edoxaban 60mg / ASA indication
2682	720	Edoxaban	no ASA indication	SHP488M	11.7.22 12:33	2024-04-30	Edoxaban 60mg / no ASA indication
1039	724	Placebo	ASA indication	HDU369F	8.10.19 6:33	2022-08-31	Edoxaban 30mg / ASA indication
1039	724	Placebo	ASA indication	VUL266G	16.4.20 9:49	2022-08-31	Edoxaban 30mg / ASA indication
1039	724	Placebo	ASA indication	DGD698C	26.3.19 9:47	2020-01-01	Edoxaban 60mg / ASA indication
1061	724	Placebo	ASA indication	ATZ231E	7.10.19 9:58	2021-12-31	Edoxaban 60mg / ASA indication
1061	724	Placebo	ASA indication	MPU667L	5.4.19 12:23	2020-01-01	Edoxaban 60mg / ASA indication
1061	724	Placebo	ASA indication	KRL992K	16.4.20 9:43	2021-12-31	Edoxaban 60mg / ASA indication
1452	724	Placebo	ASA indication	XVN482D	16.12.19 13:09	2021-12-31	Edoxaban 60mg / ASA indication
1452	724	Placebo	ASA indication	ACW578E	8.1.21 9:57	2021-12-31	Edoxaban 60mg / ASA indication
1452	724	Placebo	ASA indication	HFH339S	23.6.20 6:33	2021-12-31	Edoxaban 60mg / ASA indication
1040	724	Edoxaban	ASA indication	MRV755Z	26.3.19 11:07	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1040	724	Edoxaban	ASA indication	FSD751N	7.10.19 8:50	2021-12-31	Edoxaban 60mg / ASA indication
1040	724	Edoxaban	ASA indication	DVP898E	23.10.20 9:33	2022-08-31	Edoxaban 30mg / ASA indication
1040	724	Edoxaban	ASA indication	ZZX555Y	4.5.21 11:32	2022-08-31	Edoxaban 30mg / ASA indication
1040	724	Edoxaban	ASA indication	RHY727G	16.4.20 9:47	2022-08-31	Edoxaban 30mg / ASA indication
1040	724	Edoxaban	ASA indication	LTY428H	15.11.21 11:48	2022-08-31	Edoxaban 30mg / ASA indication
1040	724	Edoxaban	ASA indication	LXB162Y	2.5.22 8:41	2024-11-30	Edoxaban 30mg / ASA indication
1076	724	Edoxaban	ASA indication	GKU647C	21.10.19 7:15	2021-12-31	Edoxaban 60mg / ASA indication
1076	724	Edoxaban	ASA indication	HDR317C	12.4.19 9:55	2020-01-01	Edoxaban 30mg / ASA indication
1286	724	Edoxaban	no ASA indication	LBX587C	17.3.20 8:26	2021-12-31	Edoxaban 60mg / no ASA indication
1286	724	Edoxaban	no ASA indication	DNV114E	12.10.20 6:45	2021-12-31	Edoxaban 60mg / ASA indication
1286	724	Edoxaban	no ASA indication	LKV245P	13.9.21 6:58	2024-04-30	Edoxaban 60mg / no ASA indication
1286	724	Edoxaban	no ASA indication	ZLW692R	22.4.21 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1286	724	Edoxaban	no ASA indication	TXW691G	13.9.19 8:44	2021-12-31	Edoxaban 60mg / no ASA indication
796	725	Placebo	ASA indication	LYP868T	13.11.19 9:23	2021-12-31	Edoxaban 60mg / no ASA indication
796	725	Placebo	ASA indication	AUN128T	13.5.20 8:00	2021-12-31	Edoxaban 60mg / ASA indication
796	725	Placebo	ASA indication	VGB958G	27.4.21 9:38	2021-12-31	Edoxaban 60mg / ASA indication
796	725	Placebo	ASA indication	YXG885V	9.11.21 12:35	2022-08-31	Edoxaban 30mg / ASA indication
796	725	Placebo	ASA indication	SSE236B	11.5.22 11:33	2024-11-30	Edoxaban 30mg / ASA indication
796	725	Placebo	ASA indication	WAW486T	6.11.18 11:42	2020-01-01	Edoxaban 60mg / ASA indication
796	725	Placebo	ASA indication	RPM126E	15.5.19 11:06	2020-01-01	Edoxaban 60mg / no ASA indication
796	725	Placebo	ASA indication	EDX688A	19.11.20 10:10	2021-12-31	Edoxaban 60mg / ASA indication
1042	725	Placebo	ASA indication	LLP756W	27.3.19 11:22	2020-01-01	Edoxaban 60mg / ASA indication
1203	725	Placebo	ASA indication	AZE666B	30.6.20 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
1203	725	Placebo	ASA indication	VDH552F	17.12.20 10:28	2021-12-31	Edoxaban 60mg / no ASA indication
1203	725	Placebo	ASA indication	NEG933L	20.12.19 7:56	2021-12-31	Edoxaban 60mg / no ASA indication
1203	725	Placebo	ASA indication	VDM381B	15.6.21 8:45	2021-12-31	Edoxaban 60mg / no ASA indication
1203	725	Placebo	ASA indication	XVU125X	24.6.22 12:48	2024-04-30	Edoxaban 60mg / no ASA indication
1203	725	Placebo	ASA indication	LBN889P	26.6.19 7:18	2021-12-31	Edoxaban 60mg / ASA indication
1203	725	Placebo	ASA indication	HBS458K	17.12.21 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
1239	725	Placebo	ASA indication	BAN932E	23.7.20 8:03	2021-12-31	Edoxaban 60mg / ASA indication
1239	725	Placebo	ASA indication	VNE443N	4.2.21 11:33	2021-12-31	Edoxaban 60mg / ASA indication
1239	725	Placebo	ASA indication	HDH422E	27.1.22 14:20	2024-04-30	Edoxaban 60mg / ASA indication
1239	725	Placebo	ASA indication	NPT728Z	4.8.22 9:16	2024-04-30	Edoxaban 60mg / ASA indication
1239	725	Placebo	ASA indication	ZHT949Z	5.8.19 7:19	2021-12-31	Edoxaban 60mg / ASA indication
1239	725	Placebo	ASA indication	HYH942L	22.7.21 9:11	2024-04-30	Edoxaban 60mg / ASA indication
1239	725	Placebo	ASA indication	MYV573A	27.1.20 10:29	2021-12-31	Edoxaban 60mg / ASA indication
1392	725	Placebo	ASA indication	XSX871K	18.11.19 10:10	2021-12-31	Edoxaban 60mg / ASA indication
1631	725	Placebo	ASA indication	DCK523A	8.6.22 10:36	2024-04-30	Edoxaban 60mg / ASA indication
1631	725	Placebo	ASA indication	PAY432V	16.12.20 10:08	2021-12-31	Edoxaban 60mg / ASA indication
1631	725	Placebo	ASA indication	DPY686A	15.12.21 9:01	2024-04-30	Edoxaban 60mg / ASA indication
1631	725	Placebo	ASA indication	YPN374Z	15.6.20 7:06	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1631	725	Placebo	ASA indication	RTR989D	1.6.21 9:23	2021-12-31	Edoxaban 60mg / ASA indication
1639	725	Placebo	ASA indication	AFW399Y	18.6.20 6:20	2022-08-31	Edoxaban 30mg / ASA indication
1639	725	Placebo	ASA indication	PGB167D	17.12.20 10:08	2021-12-31	Edoxaban 60mg / ASA indication
1639	725	Placebo	ASA indication	PFX274R	24.6.22 11:54	2024-11-30	Edoxaban 30mg / ASA indication
1639	725	Placebo	ASA indication	CSP268F	16.12.21 10:28	2022-08-31	Edoxaban 30mg / ASA indication
1639	725	Placebo	ASA indication	HCZ455F	21.6.21 8:07	2022-08-31	Edoxaban 30mg / ASA indication
1869	725	Placebo	ASA indication	GZB741S	25.5.22 11:59	2024-04-30	Edoxaban 60mg / ASA indication
1869	725	Placebo	ASA indication	EGK896T	18.11.20 8:34	2021-12-31	Edoxaban 60mg / ASA indication
1869	725	Placebo	ASA indication	HHC141P	18.5.21 8:06	2021-12-31	Edoxaban 60mg / ASA indication
1869	725	Placebo	ASA indication	VNX712C	19.11.21 12:35	2024-04-30	Edoxaban 60mg / ASA indication
1894	725	Placebo	ASA indication	HXG885R	16.6.21 9:20	2024-04-30	Edoxaban 60mg / ASA indication
1894	725	Placebo	ASA indication	PFK445T	9.12.20 8:29	2021-12-31	Edoxaban 60mg / ASA indication
1894	725	Placebo	ASA indication	DCP925N	16.12.21 9:54	2024-04-30	Edoxaban 60mg / ASA indication
1894	725	Placebo	ASA indication	BYN751C	8.6.22 11:38	2024-04-30	Edoxaban 60mg / ASA indication
1947	725	Placebo	ASA indication	PZK337G	28.7.21 11:21	2022-08-31	Edoxaban 30mg / ASA indication
1947	725	Placebo	ASA indication	PPT184H	4.2.21 11:32	2022-08-31	Edoxaban 30mg / ASA indication
2038	725	Placebo	ASA indication	RPD715E	27.10.21 11:43	2022-08-31	Edoxaban 30mg / ASA indication
2038	725	Placebo	ASA indication	CAL683G	12.4.22 10:20	2024-11-30	Edoxaban 30mg / ASA indication
2038	725	Placebo	ASA indication	YAC526L	13.4.21 9:13	2022-08-31	Edoxaban 30mg / ASA indication
2041	725	Placebo	ASA indication	ATT623N	13.4.21 9:30	2022-08-31	Edoxaban 30mg / ASA indication
2197	725	Placebo	ASA indication	CBB497P	2.2.22 10:27	2024-11-30	Edoxaban 30mg / ASA indication
2197	725	Placebo	ASA indication	HCS822S	21.7.21 7:27	2022-08-31	Edoxaban 30mg / ASA indication
2371	725	Placebo	ASA indication	HXY777A	1.12.21 9:25	2024-04-30	Edoxaban 60mg / ASA indication
2371	725	Placebo	ASA indication	RZT929R	25.5.22 9:55	2024-04-30	Edoxaban 60mg / ASA indication
2474	725	Placebo	ASA indication	GZZ989D	10.2.22 10:54	2024-04-30	Edoxaban 60mg / ASA indication
2610	725	Placebo	ASA indication	SBG614T	10.5.22 8:48	2024-04-30	Edoxaban 60mg / ASA indication
2642	725	Placebo	ASA indication	UDF835C	6.6.22 11:01	2024-11-30	Edoxaban 30mg / ASA indication
2668	725	Placebo	ASA indication	BSR992T	24.6.22 12:06	2024-04-30	Edoxaban 60mg / ASA indication
2703	725	Placebo	ASA indication	NLV448Y	8.7.22 9:01	2024-04-30	Edoxaban 60mg / ASA indication
1154	725	Placebo	no ASA indication	RSS794D	11.12.19 11:40	2021-12-31	Edoxaban 60mg / no ASA indication
1154	725	Placebo	no ASA indication	NAZ796C	31.5.19 9:49	2020-01-01	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	RBG447U	16.12.20 10:56	2021-12-31	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	UAL485S	30.6.20 7:04	2021-12-31	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	HAN128Z	17.12.21 10:23	2024-04-30	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	PAR773A	24.6.22 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	LWV448W	20.12.19 10:10	2021-12-31	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	MKK247L	20.6.19 14:05	2021-12-31	Edoxaban 60mg / no ASA indication
1194	725	Placebo	no ASA indication	GZA693W	15.6.21 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
1442	725	Placebo	no ASA indication	ATP526L	10.12.20 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
1442	725	Placebo	no ASA indication	HUH821B	1.6.21 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1442	725	Placebo	no ASA indication	XWC889B	7.6.22 8:52	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1442	725	Placebo	no ASA indication	ZCM612R	16.6.20 7:40	2021-12-31	Edoxaban 60mg / no ASA indication
1442	725	Placebo	no ASA indication	URD275Y	11.12.19 11:32	2021-12-31	Edoxaban 60mg / no ASA indication
1442	725	Placebo	no ASA indication	PAB967K	29.3.22 7:57	2024-04-30	Edoxaban 60mg / no ASA indication
1525	725	Placebo	no ASA indication	VMR994D	11.2.21 9:58	2021-12-31	Edoxaban 60mg / no ASA indication
1525	725	Placebo	no ASA indication	PMW899H	25.8.20 9:09	2021-12-31	Edoxaban 60mg / no ASA indication
1525	725	Placebo	no ASA indication	DKB164A	12.8.22 10:02	2024-04-30	Edoxaban 60mg / no ASA indication
1525	725	Placebo	no ASA indication	FHB947X	19.2.20 11:13	2021-12-31	Edoxaban 60mg / no ASA indication
1525	725	Placebo	no ASA indication	DGF661E	10.2.22 9:42	2024-04-30	Edoxaban 60mg / no ASA indication
1525	725	Placebo	no ASA indication	GZW395Y	17.8.21 9:18	2024-04-30	Edoxaban 60mg / no ASA indication
2102	725	Placebo	no ASA indication	ARU567C	17.5.21 10:35	2022-08-31	Edoxaban 30mg / no ASA indication
2102	725	Placebo	no ASA indication	ZGK377D	9.11.21 14:54	2024-04-30	Edoxaban 60mg / no ASA indication
2102	725	Placebo	no ASA indication	VNW249W	9.11.21 9:26	2024-04-30	Edoxaban 60mg / ASA indication
2277	725	Placebo	no ASA indication	WAV815S	21.9.21 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
2277	725	Placebo	no ASA indication	PBD472F	23.3.22 9:43	2024-04-30	Edoxaban 60mg / no ASA indication
782	725	Edoxaban	ASA indication	WMU629E	10.5.19 10:20	2020-01-01	Edoxaban 30mg / no ASA indication
782	725	Edoxaban	ASA indication	BWT419N	29.10.18 15:22	2020-01-01	Edoxaban 30mg / ASA indication
782	725	Edoxaban	ASA indication	DTM186B	29.10.20 10:19	2022-08-31	Edoxaban 30mg / ASA indication
782	725	Edoxaban	ASA indication	PCR697F	18.11.19 11:14	2021-12-31	Edoxaban 60mg / ASA indication
782	725	Edoxaban	ASA indication	BZS747G	22.4.22 12:28	2024-11-30	Edoxaban 30mg / ASA indication
782	725	Edoxaban	ASA indication	YBE284E	9.11.21 13:58	2022-08-31	Edoxaban 30mg / ASA indication
782	725	Edoxaban	ASA indication	LSK652Z	28.4.21 8:23	2021-12-31	Edoxaban 60mg / ASA indication
782	725	Edoxaban	ASA indication	VWF876N	22.4.20 6:55	2022-08-31	Edoxaban 30mg / no ASA indication
822	725	Edoxaban	ASA indication	TVE472E	15.11.18 10:54	2020-01-01	Edoxaban 60mg / ASA indication
1009	725	Edoxaban	ASA indication	DRT147X	28.2.19 10:50	2020-01-01	Edoxaban 60mg / ASA indication
1329	725	Edoxaban	ASA indication	HBV774S	27.10.20 9:06	2021-12-31	Edoxaban 60mg / ASA indication
1329	725	Edoxaban	ASA indication	WEX163W	22.4.22 12:02	2024-04-30	Edoxaban 60mg / ASA indication
1329	725	Edoxaban	ASA indication	MAB341B	27.4.21 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1329	725	Edoxaban	ASA indication	KMV157T	22.4.20 7:58	2021-12-31	Edoxaban 60mg / ASA indication
1329	725	Edoxaban	ASA indication	CLS489W	14.10.19 10:10	2021-12-31	Edoxaban 60mg / ASA indication
1329	725	Edoxaban	ASA indication	WPL494F	27.10.21 9:33	2024-04-30	Edoxaban 60mg / ASA indication
1470	725	Edoxaban	ASA indication	YCM189E	13.1.20 15:54	2022-08-31	Edoxaban 30mg / ASA indication
1524	725	Edoxaban	ASA indication	MEH532W	19.2.20 8:15	2021-12-31	Edoxaban 60mg / ASA indication
1619	725	Edoxaban	ASA indication	CAV916F	10.12.20 10:30	2021-12-31	Edoxaban 60mg / ASA indication
1619	725	Edoxaban	ASA indication	ZTU271S	1.12.21 10:22	2024-04-30	Edoxaban 60mg / ASA indication
1619	725	Edoxaban	ASA indication	DGP166K	8.6.22 10:06	2024-04-30	Edoxaban 60mg / ASA indication
1619	725	Edoxaban	ASA indication	TYK318Y	1.6.21 8:33	2021-12-31	Edoxaban 60mg / ASA indication
1619	725	Edoxaban	ASA indication	RGW518T	11.6.20 7:12	2021-12-31	Edoxaban 60mg / ASA indication
1742	725	Edoxaban	ASA indication	UBP993D	25.8.20 7:09	2022-08-31	Edoxaban 30mg / ASA indication
1742	725	Edoxaban	ASA indication	NCG752G	11.2.21 13:53	2022-08-31	Edoxaban 30mg / ASA indication
1742	725	Edoxaban	ASA indication	HCL498Z	20.8.21 11:28	2022-08-31	Edoxaban 30mg / ASA indication
1946	725	Edoxaban	ASA indication	DMC821U	4.2.21 11:28	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1946	725	Edoxaban	ASA indication	WED971S	3.8.22 9:49	2024-04-30	Edoxaban 60mg / ASA indication
1946	725	Edoxaban	ASA indication	HFF852X	18.8.21 8:13	2024-04-30	Edoxaban 60mg / ASA indication
1946	725	Edoxaban	ASA indication	ZTS216T	27.1.22 13:03	2024-04-30	Edoxaban 60mg / ASA indication
1954	725	Edoxaban	ASA indication	FZT671D	10.2.21 11:03	2021-12-31	Edoxaban 60mg / ASA indication
1954	725	Edoxaban	ASA indication	GCG923S	10.2.22 11:02	2024-04-30	Edoxaban 60mg / ASA indication
1954	725	Edoxaban	ASA indication	HHY647S	19.8.21 9:05	2024-04-30	Edoxaban 60mg / ASA indication
2030	725	Edoxaban	ASA indication	MBZ676Y	30.3.21 8:30	2021-12-31	Edoxaban 60mg / ASA indication
2030	725	Edoxaban	ASA indication	NNN594N	23.3.22 10:41	2024-04-30	Edoxaban 60mg / ASA indication
2030	725	Edoxaban	ASA indication	WPP217G	21.9.21 9:36	2024-04-30	Edoxaban 60mg / ASA indication
2040	725	Edoxaban	ASA indication	MWR771N	13.4.21 9:39	2022-08-31	Edoxaban 30mg / ASA indication
2040	725	Edoxaban	ASA indication	NNF882N	12.4.22 10:05	2024-04-30	Edoxaban 60mg / ASA indication
2040	725	Edoxaban	ASA indication	GMN286N	27.10.21 9:05	2022-08-31	Edoxaban 30mg / ASA indication
2040	725	Edoxaban	ASA indication	GZF546E	12.4.22 9:49	2024-04-30	Edoxaban 60mg / no ASA indication
2105	725	Edoxaban	ASA indication	UZA224E	18.5.21 8:48	2021-12-31	Edoxaban 60mg / ASA indication
2353	725	Edoxaban	ASA indication	RCL978N	25.5.22 14:27	2024-11-30	Edoxaban 30mg / ASA indication
2353	725	Edoxaban	ASA indication	ZKN669N	29.11.21 8:21	2022-08-31	Edoxaban 30mg / ASA indication
2462	725	Edoxaban	ASA indication	HEK169H	3.2.22 11:30	2024-04-30	Edoxaban 60mg / ASA indication
2492	725	Edoxaban	ASA indication	CGV713Z	23.2.22 9:39	2024-11-30	Edoxaban 30mg / ASA indication
2492	725	Edoxaban	ASA indication	RCN187L	12.8.22 12:07	2024-11-30	Edoxaban 30mg / ASA indication
2494	725	Edoxaban	ASA indication	NMV362D	23.2.22 9:09	2024-04-30	Edoxaban 60mg / ASA indication
2602	725	Edoxaban	ASA indication	PKX541X	29.4.22 9:39	2024-11-30	Edoxaban 30mg / ASA indication
2704	725	Edoxaban	ASA indication	SMC582Y	11.7.22 9:00	2024-11-30	Edoxaban 30mg / ASA indication
1223	725	Edoxaban	no ASA indication	GDD249G	15.7.19 10:41	2021-12-31	Edoxaban 60mg / no ASA indication
1326	725	Edoxaban	no ASA indication	SNW224D	14.10.19 8:11	2022-08-31	Edoxaban 30mg / no ASA indication
1620	725	Edoxaban	no ASA indication	PPP986V	11.6.20 7:37	2021-12-31	Edoxaban 60mg / no ASA indication
1644	725	Edoxaban	no ASA indication	ERL113B	18.6.20 6:28	2021-12-31	Edoxaban 60mg / no ASA indication
1644	725	Edoxaban	no ASA indication	HBR754L	17.12.21 10:03	2024-04-30	Edoxaban 60mg / no ASA indication
1644	725	Edoxaban	no ASA indication	BNC882W	17.12.20 9:36	2021-12-31	Edoxaban 60mg / no ASA indication
1644	725	Edoxaban	no ASA indication	BTR123C	14.6.21 9:20	2021-12-31	Edoxaban 60mg / no ASA indication
1644	725	Edoxaban	no ASA indication	PTN245H	24.6.22 12:32	2024-04-30	Edoxaban 60mg / no ASA indication
1839	725	Edoxaban	no ASA indication	BXU968R	27.10.20 8:10	2021-12-31	Edoxaban 60mg / no ASA indication
2549	725	Edoxaban	no ASA indication	HBZ845G	22.3.22 9:39	2024-04-30	Edoxaban 60mg / no ASA indication
2600	725	Edoxaban	no ASA indication	DDN517L	29.4.22 7:08	2024-11-30	Edoxaban 30mg / no ASA indication
2710	725	Edoxaban	no ASA indication	DFD413H	12.7.22 8:29	2024-11-30	Edoxaban 30mg / no ASA indication
1166	728	Placebo	ASA indication	AAM782N	7.6.19 10:43	2020-01-01	Edoxaban 30mg / ASA indication
1166	728	Placebo	ASA indication	RTP812U	16.12.20 14:22	2022-08-31	Edoxaban 30mg / ASA indication
1166	728	Placebo	ASA indication	CWV782B	13.7.21 13:03	2022-08-31	Edoxaban 30mg / ASA indication
1166	728	Placebo	ASA indication	SBZ778N	16.6.20 13:16	2022-08-31	Edoxaban 30mg / ASA indication
1166	728	Placebo	ASA indication	RCV251U	18.12.19 15:26	2022-08-31	Edoxaban 30mg / ASA indication
1166	728	Placebo	ASA indication	SLC674T	13.7.22 9:58	2024-11-30	Edoxaban 30mg / ASA indication
1166	728	Placebo	ASA indication	DRT842K	27.1.22 11:52	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1124	728	Placebo	no ASA indication	TLA898W	14.5.19 10:17	2020-01-01	Edoxaban 60mg / no ASA indication
1124	728	Placebo	no ASA indication	USD613N	16.12.20 14:13	2021-12-31	Edoxaban 60mg / no ASA indication
1124	728	Placebo	no ASA indication	LRH182U	18.5.21 11:03	2021-12-31	Edoxaban 60mg / no ASA indication
1124	728	Placebo	no ASA indication	YYR229G	20.11.19 14:44	2021-12-31	Edoxaban 60mg / no ASA indication
1124	728	Placebo	no ASA indication	VKF461E	21.5.20 11:42	2021-12-31	Edoxaban 60mg / no ASA indication
1124	728	Placebo	no ASA indication	FRE861D	8.12.21 10:54	2024-04-30	Edoxaban 60mg / no ASA indication
577	728	Edoxaban	ASA indication	KLE383B	26.7.21 10:44	2022-08-31	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	WKL572B	9.6.20 13:19	2022-08-31	Edoxaban 30mg / no ASA indication
577	728	Edoxaban	ASA indication	ZVK765T	16.12.20 14:15	2022-08-31	Edoxaban 30mg / no ASA indication
577	728	Edoxaban	ASA indication	GME746M	26.6.19 10:36	2022-08-31	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	LVF984K	10.3.21 12:32	2022-08-31	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	DXN297K	19.1.22 11:46	2022-08-31	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	NZA675D	31.5.18 10:53	2020-01-01	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	PDW792Y	5.7.22 9:26	2024-11-30	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	XNX286R	13.12.18 12:34	2020-01-01	Edoxaban 30mg / ASA indication
577	728	Edoxaban	ASA indication	VLK758T	12.12.19 13:35	2022-08-31	Edoxaban 30mg / no ASA indication
387	728	Edoxaban	no ASA indication	CXB976F	5.1.18 12:28	2018-09-01	Edoxaban 60mg / no ASA indication
387	728	Edoxaban	no ASA indication	SUE757X	4.7.19 11:27	2021-12-31	Edoxaban 60mg / no ASA indication
387	728	Edoxaban	no ASA indication	RSK889T	18.7.18 10:22	2020-01-01	Edoxaban 60mg / no ASA indication
387	728	Edoxaban	no ASA indication	WCS533B	20.12.18 14:18	2020-01-01	Edoxaban 60mg / no ASA indication
452	728	Edoxaban	no ASA indication	HRZ439K	20.2.18 12:01	2020-01-01	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	ADL866R	13.6.19 10:16	2020-01-01	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	EFM914E	20.12.21 12:01	2024-04-30	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	TGA849A	2.6.20 13:36	2021-12-31	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	DXX642A	20.12.19 13:56	2021-12-31	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	EBD456X	28.6.21 11:30	2024-04-30	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	MGZ854C	11.12.18 10:25	2020-01-01	Edoxaban 60mg / no ASA indication
883	728	Edoxaban	no ASA indication	UGG131S	16.12.20 14:17	2021-12-31	Edoxaban 60mg / no ASA indication
1560	730	Placebo	no ASA indication	GPE122X	9.3.21 10:35	2022-08-31	Edoxaban 30mg / no ASA indication
1560	730	Placebo	no ASA indication	EMW136V	1.10.20 14:24	2022-08-31	Edoxaban 30mg / no ASA indication
1560	730	Placebo	no ASA indication	GBM758H	13.3.20 14:35	2022-08-31	Edoxaban 30mg / no ASA indication
2399	730	Placebo	no ASA indication	HFE387N	8.7.22 11:45	2024-04-30	Edoxaban 60mg / ASA indication
2399	730	Placebo	no ASA indication	GAZ744X	7.1.22 11:06	2024-04-30	Edoxaban 60mg / no ASA indication
799	735	Placebo	ASA indication	XDP215Z	3.5.19 15:12	2020-01-01	Edoxaban 60mg / ASA indication
799	735	Placebo	ASA indication	DRL845X	6.11.18 18:03	2020-01-01	Edoxaban 60mg / ASA indication
925	740	Placebo	ASA indication	KAD811H	7.1.20 11:44	2022-08-31	Edoxaban 30mg / ASA indication
925	740	Placebo	ASA indication	MMK929R	9.7.19 12:43	2022-08-31	Edoxaban 30mg / ASA indication
925	740	Placebo	ASA indication	MMZ286C	29.6.20 9:25	2022-08-31	Edoxaban 30mg / ASA indication
925	740	Placebo	ASA indication	AEC397S	8.1.19 15:50	2020-01-01	Edoxaban 30mg / ASA indication
925	740	Placebo	ASA indication	DSS385P	4.1.21 10:37	2022-08-31	Edoxaban 30mg / ASA indication
1886	740	Placebo	ASA indication	VCG641K	1.12.20 10:33	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1886	740	Placebo	ASA indication	ZGY114V	18.5.21 8:48	2022-08-31	Edoxaban 30mg / no ASA indication
1222	740	Placebo	no ASA indication	HGM614C	14.1.20 10:54	2021-12-31	Edoxaban 60mg / no ASA indication
1222	740	Placebo	no ASA indication	XSN969N	9.7.20 9:26	2021-12-31	Edoxaban 60mg / no ASA indication
1222	740	Placebo	no ASA indication	GCN544S	5.1.22 13:36	2024-04-30	Edoxaban 60mg / no ASA indication
1222	740	Placebo	no ASA indication	KCL618K	10.7.19 12:23	2021-12-31	Edoxaban 60mg / no ASA indication
1222	740	Placebo	no ASA indication	GMB664B	8.7.21 7:57	2024-04-30	Edoxaban 60mg / no ASA indication
1222	740	Placebo	no ASA indication	XXP534K	20.1.21 12:12	2021-12-31	Edoxaban 60mg / no ASA indication
1222	740	Placebo	no ASA indication	RSK536B	15.7.22 12:57	2024-04-30	Edoxaban 60mg / no ASA indication
431	740	Edoxaban	ASA indication	WFB839G	7.8.18 9:52	2020-01-01	Edoxaban 30mg / ASA indication
431	740	Edoxaban	ASA indication	UBA364R	6.2.18 13:20	2018-09-01	Edoxaban 30mg / ASA indication
431	740	Edoxaban	ASA indication	RHL426X	15.2.19 12:25	2020-01-01	Edoxaban 30mg / ASA indication
1058	740	Edoxaban	ASA indication	KYD451Z	24.9.19 13:48	2022-08-31	Edoxaban 30mg / ASA indication
1058	740	Edoxaban	ASA indication	UAK323E	4.4.19 12:02	2020-01-01	Edoxaban 60mg / ASA indication
2436	740	Edoxaban	ASA indication	GWU826L	18.1.22 14:58	2024-04-30	Edoxaban 60mg / ASA indication
2436	740	Edoxaban	ASA indication	HDS965X	15.7.22 12:47	2024-04-30	Edoxaban 60mg / ASA indication
753	740	Edoxaban	no ASA indication	MXM867D	22.10.19 11:04	2021-12-31	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	KRS452A	20.3.20 15:35	2021-12-31	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	EMD388Z	16.10.18 11:06	2020-01-01	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	MUV536D	9.4.19 10:02	2020-01-01	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	FCY388Z	4.10.21 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	SWZ856T	5.10.20 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	DBC885M	19.3.21 14:17	2021-12-31	Edoxaban 60mg / no ASA indication
753	740	Edoxaban	no ASA indication	FHR581L	5.4.22 14:47	2024-04-30	Edoxaban 60mg / no ASA indication
866	740	Edoxaban	no ASA indication	MKV495G	5.12.18 12:02	2020-01-01	Edoxaban 60mg / no ASA indication
866	740	Edoxaban	no ASA indication	FYW859B	4.6.19 15:05	2020-01-01	Edoxaban 60mg / no ASA indication
921	741	Placebo	ASA indication	FRE321P	6.1.20 12:12	2021-12-31	Edoxaban 60mg / ASA indication
921	741	Placebo	ASA indication	NZN784F	2.7.19 9:53	2021-12-31	Edoxaban 60mg / ASA indication
921	741	Placebo	ASA indication	KAZ834U	5.1.22 22:57	2024-04-30	Edoxaban 60mg / ASA indication
921	741	Placebo	ASA indication	HWU414M	9.7.21 9:00	2024-04-30	Edoxaban 60mg / ASA indication
921	741	Placebo	ASA indication	KSG541N	3.1.19 12:22	2020-01-01	Edoxaban 60mg / ASA indication
921	741	Placebo	ASA indication	DRP529F	4.1.21 16:06	2021-12-31	Edoxaban 60mg / ASA indication
921	741	Placebo	ASA indication	ALW562F	15.7.22 15:34	2024-04-30	Edoxaban 60mg / no ASA indication
921	741	Placebo	ASA indication	NGA645G	23.7.20 9:02	2021-12-31	Edoxaban 60mg / no ASA indication
1737	741	Placebo	ASA indication	MMM814E	4.3.21 11:13	2021-12-31	Edoxaban 60mg / ASA indication
1737	741	Placebo	ASA indication	ENY634R	1.9.22 9:40	2024-04-30	Edoxaban 60mg / no ASA indication
1737	741	Placebo	ASA indication	RER852W	20.8.20 7:05	2021-12-31	Edoxaban 60mg / ASA indication
1737	741	Placebo	ASA indication	SZK189D	19.2.22 13:26	2024-04-30	Edoxaban 60mg / ASA indication
1737	741	Placebo	ASA indication	SSS828V	20.8.21 12:21	2024-04-30	Edoxaban 60mg / ASA indication
2064	741	Placebo	ASA indication	VWN877R	27.10.21 10:12	2024-04-30	Edoxaban 60mg / ASA indication
2064	741	Placebo	ASA indication	NYH551B	27.4.22 14:55	2024-04-30	Edoxaban 60mg / no ASA indication
2064	741	Placebo	ASA indication	TUR284T	26.4.21 21:17	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2660	741	Placebo	ASA indication	UYD348K	20.6.22 13:34	2024-04-30	Edoxaban 60mg / ASA indication
2685	741	Placebo	ASA indication	KLL297H	1.7.22 12:03	2024-04-30	Edoxaban 60mg / ASA indication
421	741	Placebo	no ASA indication	VEX382M	24.1.19 12:07	2020-01-01	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	GTG275U	1.2.18 12:22	2018-09-01	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	CBW381S	6.8.20 10:50	2021-12-31	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	VBE259H	21.1.21 13:57	2021-12-31	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	KMZ339L	25.7.19 11:00	2021-12-31	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	NXN799X	6.2.20 13:35	2021-12-31	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	MYE727N	1.8.18 7:13	2020-01-01	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	GNA454P	5.8.21 11:37	2024-04-30	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	RRX256Y	11.2.22 9:45	2024-04-30	Edoxaban 60mg / no ASA indication
421	741	Placebo	no ASA indication	ENC328Z	3.8.22 14:36	2024-04-30	Edoxaban 60mg / no ASA indication
483	741	Placebo	no ASA indication	EES323U	12.9.19 12:04	2021-12-31	Edoxaban 60mg / no ASA indication
483	741	Placebo	no ASA indication	LUD415F	6.3.19 11:16	2020-01-01	Edoxaban 60mg / no ASA indication
483	741	Placebo	no ASA indication	YSP587V	13.9.18 10:55	2020-01-01	Edoxaban 60mg / no ASA indication
483	741	Placebo	no ASA indication	HKH416V	15.3.18 12:22	2020-01-01	Edoxaban 60mg / no ASA indication
484	741	Placebo	no ASA indication	FWK919E	15.3.18 15:13	2020-01-01	Edoxaban 60mg / ASA indication
484	741	Placebo	no ASA indication	ZWA483Z	15.3.18 12:23	2020-01-01	Edoxaban 60mg / no ASA indication
484	741	Placebo	no ASA indication	NYW171C	13.3.20 11:23	2021-12-31	Edoxaban 60mg / ASA indication
484	741	Placebo	no ASA indication	YLM986W	8.9.20 14:52	2021-12-31	Edoxaban 60mg / ASA indication
484	741	Placebo	no ASA indication	REX587P	20.3.19 14:34	2020-01-01	Edoxaban 60mg / ASA indication
484	741	Placebo	no ASA indication	VVF476G	16.9.19 11:01	2021-12-31	Edoxaban 60mg / ASA indication
484	741	Placebo	no ASA indication	CWP857D	13.9.18 11:55	2020-01-01	Edoxaban 60mg / ASA indication
1051	741	Placebo	no ASA indication	TUA699L	12.4.21 12:35	2021-12-31	Edoxaban 60mg / ASA indication
1051	741	Placebo	no ASA indication	BGE965A	30.9.20 10:29	2021-12-31	Edoxaban 60mg / ASA indication
1051	741	Placebo	no ASA indication	FNM712G	2.10.19 11:31	2021-12-31	Edoxaban 60mg / no ASA indication
1051	741	Placebo	no ASA indication	AXL498T	23.7.20 9:02	2021-12-31	Edoxaban 60mg / no ASA indication
1051	741	Placebo	no ASA indication	VYL294L	24.3.22 14:32	2024-04-30	Edoxaban 60mg / ASA indication
1051	741	Placebo	no ASA indication	XYE793U	2.4.19 13:12	2020-01-01	Edoxaban 60mg / no ASA indication
1051	741	Placebo	no ASA indication	TBB649H	6.10.21 14:17	2024-04-30	Edoxaban 60mg / ASA indication
1790	741	Placebo	no ASA indication	GYK569S	17.9.20 10:38	2022-08-31	Edoxaban 30mg / no ASA indication
1790	741	Placebo	no ASA indication	XDN296M	4.3.21 14:00	2022-08-31	Edoxaban 30mg / no ASA indication
1790	741	Placebo	no ASA indication	PBF437X	2.9.21 7:28	2022-08-31	Edoxaban 30mg / no ASA indication
1790	741	Placebo	no ASA indication	EPE264M	15.3.22 15:34	2024-11-30	Edoxaban 30mg / no ASA indication
1825	741	Placebo	no ASA indication	MSC969G	14.10.20 12:51	2021-12-31	Edoxaban 60mg / no ASA indication
1825	741	Placebo	no ASA indication	SVW338V	23.4.21 11:32	2021-12-31	Edoxaban 60mg / no ASA indication
1836	741	Placebo	no ASA indication	HUW746Z	21.10.20 12:24	2021-12-31	Edoxaban 60mg / no ASA indication
1850	741	Placebo	no ASA indication	SSX938K	18.5.21 8:07	2021-12-31	Edoxaban 60mg / no ASA indication
1850	741	Placebo	no ASA indication	GMN636X	13.5.22 10:15	2024-04-30	Edoxaban 60mg / no ASA indication
1850	741	Placebo	no ASA indication	HDM452T	4.11.20 16:15	2021-12-31	Edoxaban 60mg / no ASA indication
1850	741	Placebo	no ASA indication	PNR574U	17.11.21 17:13	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2015	741	Placebo	no ASA indication	NUB523N	18.3.21 12:29	2022-08-31	Edoxaban 30mg / no ASA indication
2015	741	Placebo	no ASA indication	ELU177R	17.3.22 15:57	2024-11-30	Edoxaban 30mg / no ASA indication
2015	741	Placebo	no ASA indication	XAN955H	22.9.21 13:14	2022-08-31	Edoxaban 30mg / no ASA indication
2313	741	Placebo	no ASA indication	GYH947R	21.10.21 11:56	2024-04-30	Edoxaban 60mg / no ASA indication
2313	741	Placebo	no ASA indication	NTA128X	28.4.22 11:36	2024-04-30	Edoxaban 60mg / no ASA indication
2315	741	Placebo	no ASA indication	XWX427X	21.10.21 13:05	2022-08-31	Edoxaban 30mg / no ASA indication
2650	741	Placebo	no ASA indication	NKA139X	10.6.22 9:09	2024-11-30	Edoxaban 30mg / no ASA indication
725	741	Edoxaban	ASA indication	DLB624V	27.3.19 11:33	2020-01-01	Edoxaban 60mg / ASA indication
725	741	Edoxaban	ASA indication	XZF139V	17.3.20 12:20	2021-12-31	Edoxaban 60mg / ASA indication
725	741	Edoxaban	ASA indication	VVZ938H	30.3.21 10:55	2021-12-31	Edoxaban 60mg / ASA indication
725	741	Edoxaban	ASA indication	TKH996E	23.9.19 11:21	2021-12-31	Edoxaban 60mg / ASA indication
725	741	Edoxaban	ASA indication	FPM591G	14.4.22 12:40	2024-04-30	Edoxaban 60mg / no ASA indication
725	741	Edoxaban	ASA indication	KYY727M	27.9.18 11:03	2020-01-01	Edoxaban 60mg / ASA indication
725	741	Edoxaban	ASA indication	KMC873L	30.9.21 11:06	2024-04-30	Edoxaban 60mg / ASA indication
725	741	Edoxaban	ASA indication	KAB656S	15.9.20 10:36	2021-12-31	Edoxaban 60mg / ASA indication
840	741	Edoxaban	ASA indication	SYL271V	22.10.19 11:43	2021-12-31	Edoxaban 60mg / ASA indication
840	741	Edoxaban	ASA indication	ENR971M	26.4.19 10:00	2020-01-01	Edoxaban 60mg / ASA indication
840	741	Edoxaban	ASA indication	RNG149P	22.11.18 11:55	2020-01-01	Edoxaban 60mg / ASA indication
840	741	Edoxaban	ASA indication	NTD865C	23.7.20 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1865	741	Edoxaban	ASA indication	PKU279F	12.11.20 15:10	2021-12-31	Edoxaban 60mg / ASA indication
1865	741	Edoxaban	ASA indication	TPA137Y	10.11.21 15:50	2024-04-30	Edoxaban 60mg / ASA indication
1865	741	Edoxaban	ASA indication	UUD256A	12.5.22 10:16	2024-04-30	Edoxaban 60mg / ASA indication
1865	741	Edoxaban	ASA indication	GHF666M	4.5.21 8:21	2021-12-31	Edoxaban 60mg / ASA indication
2368	741	Edoxaban	ASA indication	SAB317R	30.5.22 11:43	2024-04-30	Edoxaban 60mg / ASA indication
2368	741	Edoxaban	ASA indication	HXV611A	26.11.21 9:39	2024-04-30	Edoxaban 60mg / ASA indication
2405	741	Edoxaban	ASA indication	HNV949B	21.12.21 15:09	2024-04-30	Edoxaban 60mg / ASA indication
2405	741	Edoxaban	ASA indication	FWN236M	23.6.22 20:37	2024-04-30	Edoxaban 60mg / no ASA indication
368	741	Edoxaban	no ASA indication	KPL328W	20.6.19 13:12	2022-08-31	Edoxaban 30mg / no ASA indication
368	741	Edoxaban	no ASA indication	NMG591N	11.12.17 10:07	2018-09-01	Edoxaban 60mg / no ASA indication
368	741	Edoxaban	no ASA indication	GEH263G	13.12.18 11:51	2020-01-01	Edoxaban 60mg / no ASA indication
368	741	Edoxaban	no ASA indication	GGB364T	13.6.18 12:32	2020-01-01	Edoxaban 30mg / no ASA indication
415	741	Edoxaban	no ASA indication	BPB264E	25.1.18 11:52	2018-09-01	Edoxaban 30mg / no ASA indication
415	741	Edoxaban	no ASA indication	FVG857X	25.7.18 9:45	2020-01-01	Edoxaban 30mg / no ASA indication
415	741	Edoxaban	no ASA indication	MKT445Y	30.1.20 11:23	2022-08-31	Edoxaban 30mg / no ASA indication
415	741	Edoxaban	no ASA indication	CDV853W	30.7.19 9:01	2022-08-31	Edoxaban 30mg / no ASA indication
415	741	Edoxaban	no ASA indication	UWK546G	23.7.20 9:00	2022-08-31	Edoxaban 30mg / no ASA indication
415	741	Edoxaban	no ASA indication	WFM775F	17.1.19 11:52	2020-01-01	Edoxaban 30mg / no ASA indication
435	741	Edoxaban	no ASA indication	TRU715X	8.2.18 11:59	2018-09-01	Edoxaban 60mg / no ASA indication
1095	741	Edoxaban	no ASA indication	KUP949Y	23.7.20 9:03	2022-08-31	Edoxaban 30mg / no ASA indication
1095	741	Edoxaban	no ASA indication	FSP762U	19.5.22 8:11	2024-11-30	Edoxaban 30mg / no ASA indication
1095	741	Edoxaban	no ASA indication	GCU843F	25.4.19 11:19	2020-01-01	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1095	741	Edoxaban	no ASA indication	CRN348B	16.10.20 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
1095	741	Edoxaban	no ASA indication	VGR931R	25.10.19 9:46	2022-08-31	Edoxaban 30mg / no ASA indication
1095	741	Edoxaban	no ASA indication	TUL853H	27.10.21 9:19	2022-08-31	Edoxaban 30mg / no ASA indication
1095	741	Edoxaban	no ASA indication	TXA767G	12.4.21 15:10	2022-08-31	Edoxaban 30mg / no ASA indication
1118	741	Edoxaban	no ASA indication	UET568T	4.11.21 17:01	2022-08-31	Edoxaban 30mg / no ASA indication
1118	741	Edoxaban	no ASA indication	NKF561H	16.11.20 8:12	2022-08-31	Edoxaban 30mg / no ASA indication
1118	741	Edoxaban	no ASA indication	BMM122Z	9.5.19 11:17	2020-01-01	Edoxaban 60mg / no ASA indication
1118	741	Edoxaban	no ASA indication	EEX459A	13.11.19 11:34	2022-08-31	Edoxaban 30mg / no ASA indication
1118	741	Edoxaban	no ASA indication	CTG786M	6.8.20 11:27	2022-08-31	Edoxaban 30mg / no ASA indication
1118	741	Edoxaban	no ASA indication	FGN511C	17.5.21 14:49	2021-12-31	Edoxaban 60mg / no ASA indication
1118	741	Edoxaban	no ASA indication	PVA827E	23.5.22 13:12	2024-11-30	Edoxaban 30mg / no ASA indication
1356	741	Edoxaban	no ASA indication	SNX524M	17.3.20 14:17	2021-12-31	Edoxaban 60mg / no ASA indication
1356	741	Edoxaban	no ASA indication	HGB572X	28.9.20 11:34	2022-08-31	Edoxaban 30mg / no ASA indication
1356	741	Edoxaban	no ASA indication	HCV627L	28.10.19 12:40	2022-08-31	Edoxaban 30mg / no ASA indication
1408	741	Edoxaban	no ASA indication	PVX553S	27.5.22 9:50	2024-11-30	Edoxaban 30mg / no ASA indication
1408	741	Edoxaban	no ASA indication	LHY519U	25.11.19 11:50	2021-12-31	Edoxaban 60mg / no ASA indication
1408	741	Edoxaban	no ASA indication	MVU678M	16.11.21 19:05	2022-08-31	Edoxaban 30mg / no ASA indication
1408	741	Edoxaban	no ASA indication	FGB528L	18.5.21 8:06	2021-12-31	Edoxaban 60mg / no ASA indication
1408	741	Edoxaban	no ASA indication	UYZ213M	16.11.20 8:13	2021-12-31	Edoxaban 60mg / no ASA indication
1408	741	Edoxaban	no ASA indication	MYL752R	23.7.20 9:07	2021-12-31	Edoxaban 60mg / no ASA indication
1909	741	Edoxaban	no ASA indication	AYT829W	16.12.20 14:25	2021-12-31	Edoxaban 60mg / no ASA indication
2253	741	Edoxaban	no ASA indication	LUB245H	2.9.21 7:29	2024-04-30	Edoxaban 60mg / no ASA indication
2294	741	Edoxaban	no ASA indication	NKB449E	15.3.22 15:35	2024-04-30	Edoxaban 60mg / no ASA indication
2294	741	Edoxaban	no ASA indication	FUL123W	29.9.21 16:58	2024-04-30	Edoxaban 60mg / no ASA indication
2319	741	Edoxaban	no ASA indication	TWC745U	27.10.21 15:57	2022-08-31	Edoxaban 30mg / no ASA indication
2319	741	Edoxaban	no ASA indication	EZP729K	12.5.22 7:00	2024-11-30	Edoxaban 30mg / no ASA indication
2532	741	Edoxaban	no ASA indication	PEC869P	11.3.22 13:58	2024-04-30	Edoxaban 60mg / no ASA indication
173	748	Placebo	ASA indication	XTW184D	25.5.18 11:22	2020-01-01	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	USP651H	17.11.20 10:14	2021-12-31	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	YZX279U	26.11.21 8:50	2024-04-30	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	CRR283S	28.5.20 9:34	2021-12-31	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	GMX633R	19.11.19 11:40	2021-12-31	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	NAZ433E	6.6.19 11:11	2020-01-01	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	KED853H	30.5.17 12:11	2018-09-01	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	ZUP225K	16.5.22 9:37	2024-04-30	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	ALU423Z	23.11.18 11:46	2020-01-01	Edoxaban 60mg / ASA indication
173	748	Placebo	ASA indication	PWG878H	1.12.17 10:54	2018-09-01	Edoxaban 60mg / no ASA indication
173	748	Placebo	ASA indication	TCG152N	18.5.21 9:55	2021-12-31	Edoxaban 60mg / ASA indication
332	748	Placebo	ASA indication	XXG159U	26.10.20 11:51	2021-12-31	Edoxaban 60mg / no ASA indication
332	748	Placebo	ASA indication	BYD168E	6.5.19 9:54	2020-01-01	Edoxaban 60mg / ASA indication
332	748	Placebo	ASA indication	RWC312A	28.10.19 12:02	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
332	748	Placebo	ASA indication	MYV767E	9.11.17 8:29	2018-09-01	Edoxaban 60mg / ASA indication
332	748	Placebo	ASA indication	MGN912E	26.4.21 10:15	2021-12-31	Edoxaban 60mg / ASA indication
332	748	Placebo	ASA indication	SGP524E	30.10.18 12:00	2020-01-01	Edoxaban 60mg / ASA indication
332	748	Placebo	ASA indication	KUA992C	28.4.20 10:07	2021-12-31	Edoxaban 60mg / no ASA indication
332	748	Placebo	ASA indication	TBW148Z	7.5.18 10:31	2020-01-01	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	PMU969L	8.11.18 11:05	2020-01-01	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	UWR187K	9.5.19 10:09	2020-01-01	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	NXK511V	9.11.20 9:07	2021-12-31	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	URV682R	4.5.21 8:53	2021-12-31	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	UAW727B	5.11.19 11:14	2021-12-31	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	FBK837S	3.5.22 8:25	2024-04-30	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	DNV915N	18.5.18 10:51	2020-01-01	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	ZAR326V	5.11.21 9:47	2024-04-30	Edoxaban 60mg / ASA indication
558	748	Placebo	ASA indication	XEL298E	14.5.20 8:09	2021-12-31	Edoxaban 60mg / ASA indication
576	748	Placebo	ASA indication	AXH861M	31.5.18 8:47	2020-01-01	Edoxaban 30mg / ASA indication
604	748	Placebo	ASA indication	VGM188E	17.12.18 11:26	2020-01-01	Edoxaban 60mg / ASA indication
604	748	Placebo	ASA indication	UPX695U	21.6.18 14:31	2020-01-01	Edoxaban 60mg / ASA indication
684	748	Placebo	ASA indication	EKK418W	15.8.19 8:30	2022-08-31	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	ESL434B	15.2.21 11:39	2022-08-31	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	GTW299S	10.8.21 11:11	2022-08-31	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	VDW188G	12.8.22 10:05	2024-11-30	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	NCX667D	11.2.22 11:05	2024-11-30	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	ZBZ144R	23.8.18 8:10	2020-01-01	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	TBD468Z	11.2.19 11:22	2020-01-01	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	ZXD896L	13.2.20 9:29	2022-08-31	Edoxaban 30mg / ASA indication
684	748	Placebo	ASA indication	ATZ226T	20.8.20 8:15	2022-08-31	Edoxaban 30mg / ASA indication
957	748	Placebo	ASA indication	BKL824W	11.8.20 10:27	2021-12-31	Edoxaban 60mg / no ASA indication
957	748	Placebo	ASA indication	BRC299T	29.1.19 11:55	2020-01-01	Edoxaban 30mg / ASA indication
957	748	Placebo	ASA indication	FLR894G	29.7.19 10:32	2022-08-31	Edoxaban 30mg / ASA indication
957	748	Placebo	ASA indication	WWV433H	14.1.20 12:31	2021-12-31	Edoxaban 60mg / ASA indication
1026	748	Placebo	ASA indication	UNX973B	14.3.19 11:41	2020-01-01	Edoxaban 60mg / ASA indication
1026	748	Placebo	ASA indication	UWP699W	5.3.20 12:29	2021-12-31	Edoxaban 60mg / no ASA indication
1026	748	Placebo	ASA indication	UMZ766L	4.3.21 9:39	2021-12-31	Edoxaban 60mg / ASA indication
1026	748	Placebo	ASA indication	RXW928W	4.3.22 11:16	2024-04-30	Edoxaban 60mg / ASA indication
1026	748	Placebo	ASA indication	BMK539Z	31.8.20 10:44	2021-12-31	Edoxaban 60mg / ASA indication
1026	748	Placebo	ASA indication	BHW651N	2.9.19 10:16	2021-12-31	Edoxaban 60mg / ASA indication
1026	748	Placebo	ASA indication	VTW699V	3.9.21 7:55	2024-04-30	Edoxaban 60mg / ASA indication
1056	748	Placebo	ASA indication	PLR991C	23.9.19 10:24	2022-08-31	Edoxaban 30mg / ASA indication
1056	748	Placebo	ASA indication	ASZ983Z	26.3.20 12:02	2022-08-31	Edoxaban 30mg / ASA indication
1056	748	Placebo	ASA indication	TRK133V	4.4.19 9:43	2020-01-01	Edoxaban 30mg / ASA indication
1139	748	Placebo	ASA indication	PGA532K	23.5.19 8:31	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1251	748	Placebo	ASA indication	NHZ326Y	6.2.20 8:43	2022-08-31	Edoxaban 30mg / ASA indication
1251	748	Placebo	ASA indication	GBW459K	13.8.20 9:16	2022-08-31	Edoxaban 30mg / ASA indication
1251	748	Placebo	ASA indication	DAX267P	15.8.19 9:26	2022-08-31	Edoxaban 30mg / ASA indication
1251	748	Placebo	ASA indication	NLM556W	10.2.22 9:15	2024-11-30	Edoxaban 30mg / ASA indication
1251	748	Placebo	ASA indication	KWS977A	9.2.21 7:58	2022-08-31	Edoxaban 30mg / ASA indication
1251	748	Placebo	ASA indication	RXB798X	12.8.21 8:58	2022-08-31	Edoxaban 30mg / ASA indication
1272	748	Placebo	ASA indication	WSX387K	4.9.19 9:08	2022-08-31	Edoxaban 30mg / ASA indication
1272	748	Placebo	ASA indication	EEA727U	25.2.20 13:12	2022-08-31	Edoxaban 30mg / ASA indication
1285	748	Placebo	ASA indication	YYG361F	2.3.21 13:01	2022-08-31	Edoxaban 30mg / ASA indication
1285	748	Placebo	ASA indication	PFE613T	1.3.22 13:42	2024-11-30	Edoxaban 30mg / ASA indication
1285	748	Placebo	ASA indication	WNC284C	12.9.19 13:22	2022-08-31	Edoxaban 30mg / ASA indication
1285	748	Placebo	ASA indication	YLC739Y	3.3.20 14:53	2022-08-31	Edoxaban 30mg / ASA indication
1285	748	Placebo	ASA indication	SXW573T	2.9.21 13:10	2022-08-31	Edoxaban 30mg / ASA indication
1285	748	Placebo	ASA indication	EKM323R	10.9.20 14:16	2022-08-31	Edoxaban 30mg / ASA indication
1597	748	Placebo	ASA indication	LRB377Y	25.5.20 9:06	2022-08-31	Edoxaban 30mg / ASA indication
1659	748	Placebo	ASA indication	TAE137Y	17.6.21 8:48	2021-12-31	Edoxaban 60mg / ASA indication
1659	748	Placebo	ASA indication	ZTG618U	14.6.22 9:38	2024-04-30	Edoxaban 60mg / ASA indication
1659	748	Placebo	ASA indication	AUG582X	20.12.21 8:50	2024-04-30	Edoxaban 60mg / ASA indication
1659	748	Placebo	ASA indication	EGT721F	14.12.20 9:01	2021-12-31	Edoxaban 60mg / ASA indication
1659	748	Placebo	ASA indication	RDS315D	25.6.20 7:56	2021-12-31	Edoxaban 60mg / ASA indication
1674	748	Placebo	ASA indication	VCW956Z	2.7.20 10:48	2022-08-31	Edoxaban 30mg / ASA indication
1731	748	Placebo	ASA indication	AFS375F	13.8.20 9:28	2021-12-31	Edoxaban 60mg / ASA indication
1731	748	Placebo	ASA indication	YGN167Y	12.2.21 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1757	748	Placebo	ASA indication	MHN461W	3.9.20 12:41	2021-12-31	Edoxaban 60mg / ASA indication
1757	748	Placebo	ASA indication	ELE227C	19.2.21 11:56	2021-12-31	Edoxaban 60mg / ASA indication
2071	748	Placebo	ASA indication	VNK473R	29.4.21 9:40	2021-12-31	Edoxaban 60mg / ASA indication
2071	748	Placebo	ASA indication	HWL857F	21.4.22 9:00	2024-04-30	Edoxaban 60mg / ASA indication
2071	748	Placebo	ASA indication	VPZ336P	15.10.21 7:55	2024-04-30	Edoxaban 60mg / ASA indication
2181	748	Placebo	ASA indication	CGD346H	4.1.22 8:33	2024-11-30	Edoxaban 30mg / ASA indication
2181	748	Placebo	ASA indication	ZBY185D	8.7.21 9:39	2022-08-31	Edoxaban 30mg / ASA indication
2181	748	Placebo	ASA indication	PEA177H	28.6.22 8:35	2024-11-30	Edoxaban 30mg / ASA indication
2186	748	Placebo	ASA indication	HTN452S	14.1.22 8:38	2024-04-30	Edoxaban 60mg / ASA indication
2186	748	Placebo	ASA indication	XVC967Y	4.7.22 9:14	2024-04-30	Edoxaban 60mg / ASA indication
2186	748	Placebo	ASA indication	AXL811U	13.7.21 8:44	2024-04-30	Edoxaban 60mg / ASA indication
2191	748	Placebo	ASA indication	AYR827P	16.7.21 8:31	2024-04-30	Edoxaban 60mg / ASA indication
2191	748	Placebo	ASA indication	PPG279M	7.7.22 8:15	2024-04-30	Edoxaban 60mg / ASA indication
2191	748	Placebo	ASA indication	VTC842U	11.1.22 9:35	2024-04-30	Edoxaban 60mg / ASA indication
2195	748	Placebo	ASA indication	AWT372X	20.7.21 10:13	2024-04-30	Edoxaban 60mg / ASA indication
2199	748	Placebo	ASA indication	LLC899D	21.7.21 9:14	2022-08-31	Edoxaban 30mg / ASA indication
2199	748	Placebo	ASA indication	CBC518R	10.1.22 10:27	2024-11-30	Edoxaban 30mg / ASA indication
2327	748	Placebo	ASA indication	YHN981M	5.11.21 10:42	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2327	748	Placebo	ASA indication	RFU578R	26.4.22 13:10	2024-11-30	Edoxaban 30mg / ASA indication
2354	748	Placebo	ASA indication	TDF516X	18.11.21 10:18	2022-08-31	Edoxaban 30mg / ASA indication
2354	748	Placebo	ASA indication	SKS487C	6.5.22 9:44	2024-11-30	Edoxaban 30mg / ASA indication
2384	748	Placebo	ASA indication	VSG566P	7.12.21 10:49	2024-04-30	Edoxaban 60mg / ASA indication
2384	748	Placebo	ASA indication	HTF876E	4.7.22 10:50	2024-04-30	Edoxaban 60mg / ASA indication
2466	748	Placebo	ASA indication	RET433A	28.7.22 9:19	2024-04-30	Edoxaban 60mg / ASA indication
2466	748	Placebo	ASA indication	NET312F	3.2.22 10:12	2024-11-30	Edoxaban 30mg / ASA indication
2680	748	Placebo	ASA indication	LWL428E	30.6.22 10:21	2024-04-30	Edoxaban 60mg / ASA indication
2693	748	Placebo	ASA indication	PMZ291X	6.7.22 7:54	2024-04-30	Edoxaban 60mg / ASA indication
564	748	Placebo	no ASA indication	XEW798M	16.5.19 9:28	2020-01-01	Edoxaban 60mg / no ASA indication
564	748	Placebo	no ASA indication	DUL459U	11.11.19 11:07	2021-12-31	Edoxaban 60mg / no ASA indication
564	748	Placebo	no ASA indication	NRT449K	24.5.18 8:22	2020-01-01	Edoxaban 60mg / no ASA indication
564	748	Placebo	no ASA indication	TYL127N	12.11.18 11:34	2020-01-01	Edoxaban 60mg / no ASA indication
564	748	Placebo	no ASA indication	VVA925F	14.5.20 10:53	2021-12-31	Edoxaban 60mg / no ASA indication
564	748	Placebo	no ASA indication	WSL575N	12.11.20 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
824	748	Placebo	no ASA indication	MFB339K	5.5.20 13:38	2022-08-31	Edoxaban 30mg / no ASA indication
824	748	Placebo	no ASA indication	CHY135R	3.5.22 13:45	2024-11-30	Edoxaban 30mg / no ASA indication
824	748	Placebo	no ASA indication	PNU776K	3.11.20 15:00	2022-08-31	Edoxaban 30mg / no ASA indication
824	748	Placebo	no ASA indication	ZTW148Z	15.11.18 13:10	2020-01-01	Edoxaban 60mg / no ASA indication
824	748	Placebo	no ASA indication	VNU466H	2.11.21 13:41	2022-08-31	Edoxaban 30mg / no ASA indication
824	748	Placebo	no ASA indication	KBM566Y	7.5.19 12:17	2020-01-01	Edoxaban 30mg / no ASA indication
824	748	Placebo	no ASA indication	VNS545T	14.11.19 14:12	2022-08-31	Edoxaban 30mg / no ASA indication
824	748	Placebo	no ASA indication	VNT667E	4.5.21 13:45	2022-08-31	Edoxaban 30mg / no ASA indication
852	748	Placebo	no ASA indication	UAV424C	21.5.19 10:17	2020-01-01	Edoxaban 60mg / no ASA indication
852	748	Placebo	no ASA indication	HPT345T	28.11.19 12:32	2022-08-31	Edoxaban 30mg / no ASA indication
852	748	Placebo	no ASA indication	TKR519G	26.5.20 13:02	2022-08-31	Edoxaban 30mg / no ASA indication
852	748	Placebo	no ASA indication	CXF481D	29.11.18 10:25	2020-01-01	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	HHK456T	21.2.19 11:52	2020-01-01	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	TTV292V	28.1.20 11:44	2021-12-31	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	YYN921G	8.2.21 11:39	2021-12-31	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	AUN867P	10.8.21 8:24	2024-04-30	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	VPF162F	7.2.22 12:24	2024-04-30	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	WHU577R	17.8.20 10:06	2021-12-31	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	LBA863F	12.8.19 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
999	748	Placebo	no ASA indication	PCY728F	8.8.22 10:22	2024-04-30	Edoxaban 60mg / no ASA indication
1901	748	Placebo	no ASA indication	NWZ473K	10.12.20 10:45	2021-12-31	Edoxaban 60mg / no ASA indication
1918	748	Placebo	no ASA indication	ATX328H	22.6.21 9:57	2024-04-30	Edoxaban 60mg / no ASA indication
1918	748	Placebo	no ASA indication	WAP152A	3.1.22 12:18	2024-04-30	Edoxaban 60mg / no ASA indication
1918	748	Placebo	no ASA indication	LCA679T	5.1.21 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
1918	748	Placebo	no ASA indication	AVT455E	21.6.22 8:49	2024-04-30	Edoxaban 60mg / no ASA indication
1921	748	Placebo	no ASA indication	BRG416H	7.1.21 9:12	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1921	748	Placebo	no ASA indication	VCN591R	4.1.22 8:50	2022-08-31	Edoxaban 30mg / no ASA indication
1921	748	Placebo	no ASA indication	CKG628K	24.6.22 8:46	2024-11-30	Edoxaban 30mg / no ASA indication
1921	748	Placebo	no ASA indication	LRE414A	25.6.21 8:10	2022-08-31	Edoxaban 30mg / no ASA indication
2079	748	Placebo	no ASA indication	YTM339G	30.4.21 10:33	2021-12-31	Edoxaban 60mg / no ASA indication
2676	748	Placebo	no ASA indication	NZY497H	29.6.22 8:40	2024-04-30	Edoxaban 60mg / no ASA indication
2725	748	Placebo	no ASA indication	LFR379X	26.7.22 9:21	2024-04-30	Edoxaban 60mg / no ASA indication
199	748	Edoxaban	ASA indication	AWM779F	11.6.18 10:52	2020-01-01	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	NGS466T	10.12.18 11:34	2020-01-01	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	SRY244L	10.12.19 11:05	2021-12-31	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	BBB255P	18.6.20 10:14	2021-12-31	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	ECT268U	11.12.20 11:03	2021-12-31	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	GRK557W	23.6.17 11:52	2018-09-01	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	SDU316M	20.6.19 10:11	2021-12-31	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	LVW759V	11.12.17 10:33	2018-09-01	Edoxaban 60mg / ASA indication
199	748	Edoxaban	ASA indication	VBN557W	21.5.21 10:05	2021-12-31	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	UNF722L	10.9.18 10:58	2020-01-01	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	RTN549T	10.9.20 10:23	2021-12-31	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	HHW793N	21.9.17 8:59	2018-09-01	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	NPE922P	28.2.20 11:02	2021-12-31	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	RUN481N	11.3.22 8:48	2024-04-30	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	PMZ458B	12.9.19 9:11	2021-12-31	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	LHF247A	11.3.21 8:51	2021-12-31	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	WYU273W	9.9.21 8:05	2024-04-30	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	AZF635V	9.3.18 11:23	2020-01-01	Edoxaban 60mg / ASA indication
281	748	Edoxaban	ASA indication	CMP486G	12.3.19 9:56	2020-01-01	Edoxaban 60mg / ASA indication
532	748	Edoxaban	ASA indication	GXW279B	25.4.19 13:13	2020-01-01	Edoxaban 30mg / ASA indication
532	748	Edoxaban	ASA indication	GFL393G	19.4.18 12:55	2020-01-01	Edoxaban 60mg / ASA indication
532	748	Edoxaban	ASA indication	GPP965H	23.10.18 14:07	2020-01-01	Edoxaban 30mg / ASA indication
532	748	Edoxaban	ASA indication	AHW231C	24.10.19 12:19	2022-08-31	Edoxaban 30mg / ASA indication
555	748	Edoxaban	ASA indication	TYW456G	24.5.18 12:26	2020-01-01	Edoxaban 60mg / ASA indication
610	748	Edoxaban	ASA indication	YEG895T	18.12.18 13:28	2020-01-01	Edoxaban 60mg / ASA indication
610	748	Edoxaban	ASA indication	GSH256M	28.6.18 9:24	2020-01-01	Edoxaban 60mg / ASA indication
610	748	Edoxaban	ASA indication	WSM661M	20.6.19 15:08	2021-12-31	Edoxaban 60mg / ASA indication
675	748	Edoxaban	ASA indication	HKV763N	16.8.18 12:36	2020-01-01	Edoxaban 30mg / ASA indication
687	748	Edoxaban	ASA indication	YNR463S	23.8.18 12:21	2020-01-01	Edoxaban 60mg / ASA indication
928	748	Edoxaban	ASA indication	DUY577T	10.1.19 11:32	2020-01-01	Edoxaban 60mg / ASA indication
992	748	Edoxaban	ASA indication	KLY385V	19.8.19 9:58	2021-12-31	Edoxaban 60mg / ASA indication
992	748	Edoxaban	ASA indication	DRD888P	6.2.20 9:23	2021-12-31	Edoxaban 60mg / ASA indication
992	748	Edoxaban	ASA indication	YMS273A	18.2.19 11:53	2020-01-01	Edoxaban 60mg / ASA indication
992	748	Edoxaban	ASA indication	ARU941Y	3.8.21 12:56	2024-04-30	Edoxaban 60mg / ASA indication
992	748	Edoxaban	ASA indication	XNF719H	23.7.20 8:10	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
992	748	Edoxaban	ASA indication	UHX339R	4.2.21 9:05	2021-12-31	Edoxaban 60mg / ASA indication
992	748	Edoxaban	ASA indication	GGK476C	4.2.22 10:44	2024-04-30	Edoxaban 60mg / ASA indication
1074	748	Edoxaban	ASA indication	TPW578S	4.10.19 7:46	2021-12-31	Edoxaban 60mg / ASA indication
1074	748	Edoxaban	ASA indication	VMU646A	15.4.21 8:55	2022-08-31	Edoxaban 30mg / ASA indication
1074	748	Edoxaban	ASA indication	RNR713D	1.10.21 9:16	2022-08-31	Edoxaban 30mg / ASA indication
1074	748	Edoxaban	ASA indication	WFU769A	9.4.20 8:26	2021-12-31	Edoxaban 60mg / ASA indication
1074	748	Edoxaban	ASA indication	CHV836W	29.3.22 9:09	2024-11-30	Edoxaban 30mg / ASA indication
1074	748	Edoxaban	ASA indication	MAD158T	21.10.20 6:54	2021-12-31	Edoxaban 60mg / ASA indication
1074	748	Edoxaban	ASA indication	SEL916V	11.4.19 9:22	2020-01-01	Edoxaban 60mg / ASA indication
1096	748	Edoxaban	ASA indication	SGT618D	25.4.19 10:51	2020-01-01	Edoxaban 30mg / ASA indication
1130	748	Edoxaban	ASA indication	ZYA267E	15.11.19 11:54	2021-12-31	Edoxaban 60mg / ASA indication
1130	748	Edoxaban	ASA indication	RTM198Z	6.5.22 8:47	2024-04-30	Edoxaban 60mg / ASA indication
1130	748	Edoxaban	ASA indication	WXT492W	17.5.19 10:02	2020-01-01	Edoxaban 60mg / ASA indication
1130	748	Edoxaban	ASA indication	VMH537U	3.5.21 8:08	2021-12-31	Edoxaban 60mg / ASA indication
1130	748	Edoxaban	ASA indication	ZGL168N	8.11.21 8:44	2024-04-30	Edoxaban 60mg / ASA indication
1130	748	Edoxaban	ASA indication	DVD227E	5.11.20 8:37	2021-12-31	Edoxaban 60mg / ASA indication
1130	748	Edoxaban	ASA indication	AWC229M	7.5.20 8:35	2021-12-31	Edoxaban 60mg / ASA indication
1415	748	Edoxaban	ASA indication	DKL312V	28.11.19 9:45	2021-12-31	Edoxaban 60mg / ASA indication
1415	748	Edoxaban	ASA indication	RWH344C	19.11.20 10:34	2021-12-31	Edoxaban 60mg / ASA indication
1415	748	Edoxaban	ASA indication	ZGG341G	26.11.21 10:59	2024-04-30	Edoxaban 60mg / ASA indication
1415	748	Edoxaban	ASA indication	YTX858R	17.5.22 8:18	2024-04-30	Edoxaban 60mg / ASA indication
1415	748	Edoxaban	ASA indication	VBY593A	18.5.21 8:18	2021-12-31	Edoxaban 60mg / ASA indication
1415	748	Edoxaban	ASA indication	CBU771V	18.5.20 10:35	2021-12-31	Edoxaban 60mg / ASA indication
1591	748	Edoxaban	ASA indication	NSK667Y	7.5.21 7:00	2021-12-31	Edoxaban 60mg / ASA indication
1591	748	Edoxaban	ASA indication	EBZ533Z	18.5.20 10:44	2021-12-31	Edoxaban 60mg / ASA indication
1591	748	Edoxaban	ASA indication	ZGE685Y	16.11.21 9:54	2024-04-30	Edoxaban 60mg / ASA indication
1591	748	Edoxaban	ASA indication	DMW338X	20.11.20 11:26	2021-12-31	Edoxaban 60mg / ASA indication
1646	748	Edoxaban	ASA indication	XKG741M	7.12.20 8:40	2022-08-31	Edoxaban 30mg / ASA indication
1646	748	Edoxaban	ASA indication	PFP266C	18.6.20 8:01	2022-08-31	Edoxaban 30mg / ASA indication
1885	748	Edoxaban	ASA indication	SWE387P	26.11.20 16:33	2022-08-31	Edoxaban 30mg / ASA indication
1885	748	Edoxaban	ASA indication	VVP826W	18.5.21 10:24	2022-08-31	Edoxaban 30mg / ASA indication
1966	748	Edoxaban	ASA indication	LYN615G	18.2.21 10:31	2021-12-31	Edoxaban 60mg / ASA indication
1966	748	Edoxaban	ASA indication	WEM822B	10.8.21 9:37	2024-04-30	Edoxaban 60mg / ASA indication
1966	748	Edoxaban	ASA indication	UKY419K	9.8.22 7:56	2024-11-30	Edoxaban 30mg / ASA indication
1966	748	Edoxaban	ASA indication	CLB531S	10.2.22 10:42	2024-11-30	Edoxaban 30mg / ASA indication
2039	748	Edoxaban	ASA indication	MDE844N	31.3.22 8:34	2024-11-30	Edoxaban 30mg / ASA indication
2039	748	Edoxaban	ASA indication	XKF672P	12.4.21 9:45	2021-12-31	Edoxaban 60mg / ASA indication
2039	748	Edoxaban	ASA indication	WYB346K	28.9.21 10:18	2024-04-30	Edoxaban 60mg / ASA indication
2049	748	Edoxaban	ASA indication	WXU328L	15.10.21 8:59	2024-04-30	Edoxaban 60mg / ASA indication
2049	748	Edoxaban	ASA indication	USD136H	15.4.21 9:25	2021-12-31	Edoxaban 60mg / ASA indication
2049	748	Edoxaban	ASA indication	EHD323U	22.4.22 8:08	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2136	748	Edoxaban	ASA indication	NPC683V	3.6.21 8:45	2021-12-31	Edoxaban 60mg / ASA indication
2136	748	Edoxaban	ASA indication	ASD994B	29.11.21 8:55	2024-04-30	Edoxaban 60mg / ASA indication
2189	748	Edoxaban	ASA indication	XCF796N	17.1.22 10:40	2022-08-31	Edoxaban 30mg / ASA indication
2189	748	Edoxaban	ASA indication	PGA831P	1.7.22 9:25	2024-11-30	Edoxaban 30mg / ASA indication
2189	748	Edoxaban	ASA indication	AWW895A	15.7.21 9:22	2022-08-31	Edoxaban 30mg / ASA indication
2203	748	Edoxaban	ASA indication	AUM585K	26.7.21 9:17	2024-04-30	Edoxaban 60mg / ASA indication
2203	748	Edoxaban	ASA indication	EHB981B	25.1.22 9:53	2024-04-30	Edoxaban 60mg / ASA indication
2203	748	Edoxaban	ASA indication	NHA155E	2.8.22 8:32	2024-04-30	Edoxaban 60mg / ASA indication
2236	748	Edoxaban	ASA indication	WEV212G	23.8.21 9:31	2024-04-30	Edoxaban 60mg / ASA indication
2248	748	Edoxaban	ASA indication	WPG813R	26.8.21 10:31	2024-04-30	Edoxaban 60mg / ASA indication
2248	748	Edoxaban	ASA indication	HLL314Z	14.2.22 11:26	2024-04-30	Edoxaban 60mg / ASA indication
2248	748	Edoxaban	ASA indication	KEH817B	15.8.22 8:52	2024-04-30	Edoxaban 60mg / ASA indication
2249	748	Edoxaban	ASA indication	NEC787V	22.2.22 9:03	2024-04-30	Edoxaban 60mg / ASA indication
2249	748	Edoxaban	ASA indication	VMN147D	22.8.22 8:45	2024-04-30	Edoxaban 60mg / ASA indication
2249	748	Edoxaban	ASA indication	WNY864A	27.8.21 8:55	2024-04-30	Edoxaban 60mg / ASA indication
2422	748	Edoxaban	ASA indication	ASB692X	11.1.22 10:19	2024-04-30	Edoxaban 60mg / ASA indication
2422	748	Edoxaban	ASA indication	YTB151W	1.7.22 7:52	2024-04-30	Edoxaban 60mg / ASA indication
2455	748	Edoxaban	ASA indication	HXR657E	28.1.22 9:47	2022-08-31	Edoxaban 30mg / ASA indication
2455	748	Edoxaban	ASA indication	UPC163R	22.7.22 8:57	2024-11-30	Edoxaban 30mg / ASA indication
2613	748	Edoxaban	ASA indication	GDG854P	12.5.22 8:26	2024-04-30	Edoxaban 60mg / ASA indication
2670	748	Edoxaban	ASA indication	PHS699K	23.6.22 10:40	2024-11-30	Edoxaban 30mg / ASA indication
2716	748	Edoxaban	ASA indication	UGA782A	19.7.22 8:17	2024-04-30	Edoxaban 60mg / ASA indication
2734	748	Edoxaban	ASA indication	RVN372M	10.8.22 10:06	2024-04-30	Edoxaban 60mg / ASA indication
2746	748	Edoxaban	ASA indication	WYD923R	6.9.22 10:05	2024-11-30	Edoxaban 30mg / ASA indication
596	748	Edoxaban	no ASA indication	GWE459D	7.12.18 11:22	2020-01-01	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	ZAL994D	14.6.22 9:15	2024-04-30	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	TCH394S	18.6.18 11:58	2020-01-01	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	PZY774S	13.6.19 11:22	2020-01-01	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	DZL921C	7.12.20 10:35	2021-12-31	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	SCB423G	6.12.19 11:01	2021-12-31	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	VGX863A	4.6.20 11:01	2021-12-31	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	KLN922M	8.6.21 9:22	2021-12-31	Edoxaban 60mg / no ASA indication
596	748	Edoxaban	no ASA indication	WBF775N	10.12.21 9:40	2024-04-30	Edoxaban 60mg / no ASA indication
641	748	Edoxaban	no ASA indication	KSE626C	1.8.19 11:19	2022-08-31	Edoxaban 30mg / no ASA indication
641	748	Edoxaban	no ASA indication	NDS327W	1.2.22 13:45	2022-08-31	Edoxaban 30mg / no ASA indication
641	748	Edoxaban	no ASA indication	FXF459E	21.1.19 11:37	2020-01-01	Edoxaban 30mg / no ASA indication
641	748	Edoxaban	no ASA indication	RBC278X	15.1.21 11:40	2022-08-31	Edoxaban 30mg / no ASA indication
641	748	Edoxaban	no ASA indication	RXH772D	27.7.18 12:06	2020-01-01	Edoxaban 60mg / no ASA indication
641	748	Edoxaban	no ASA indication	FBC229Y	13.7.20 10:56	2022-08-31	Edoxaban 30mg / no ASA indication
641	748	Edoxaban	no ASA indication	NRB682G	17.1.20 11:51	2022-08-31	Edoxaban 30mg / no ASA indication
641	748	Edoxaban	no ASA indication	NZD638F	2.8.22 14:03	2024-11-30	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
641	748	Edoxaban	no ASA indication	ESW762A	26.7.21 10:58	2022-08-31	Edoxaban 30mg / no ASA indication
1249	748	Edoxaban	no ASA indication	KUP742A	6.2.20 10:25	2022-08-31	Edoxaban 30mg / no ASA indication
1249	748	Edoxaban	no ASA indication	VPC354M	8.8.19 10:07	2022-08-31	Edoxaban 30mg / no ASA indication
1301	748	Edoxaban	no ASA indication	NHH182Z	26.9.19 10:57	2022-08-31	Edoxaban 30mg / no ASA indication
1546	748	Edoxaban	no ASA indication	DGC543M	28.2.22 10:28	2024-11-30	Edoxaban 30mg / no ASA indication
1546	748	Edoxaban	no ASA indication	LHR588A	24.8.21 9:50	2022-08-31	Edoxaban 30mg / no ASA indication
1546	748	Edoxaban	no ASA indication	ZFN285U	25.2.21 11:42	2022-08-31	Edoxaban 30mg / no ASA indication
1546	748	Edoxaban	no ASA indication	UTL857K	17.9.20 10:20	2022-08-31	Edoxaban 30mg / no ASA indication
1546	748	Edoxaban	no ASA indication	TRS999G	23.8.22 9:40	2024-11-30	Edoxaban 30mg / no ASA indication
1546	748	Edoxaban	no ASA indication	FAB828P	5.3.20 10:28	2022-08-31	Edoxaban 30mg / no ASA indication
1575	748	Edoxaban	no ASA indication	UDS226K	19.10.20 10:49	2021-12-31	Edoxaban 60mg / no ASA indication
1575	748	Edoxaban	no ASA indication	ATV173C	19.4.22 9:28	2024-04-30	Edoxaban 60mg / no ASA indication
1575	748	Edoxaban	no ASA indication	VLF264G	22.4.21 8:32	2021-12-31	Edoxaban 60mg / no ASA indication
1575	748	Edoxaban	no ASA indication	AVE837D	18.10.21 8:06	2024-04-30	Edoxaban 60mg / no ASA indication
1575	748	Edoxaban	no ASA indication	DTV678Z	30.4.20 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
1982	748	Edoxaban	no ASA indication	BYT177R	25.2.21 10:30	2021-12-31	Edoxaban 60mg / no ASA indication
2222	748	Edoxaban	no ASA indication	AWG819W	12.8.21 9:32	2024-04-30	Edoxaban 60mg / no ASA indication
2358	748	Edoxaban	no ASA indication	UHM632M	19.11.21 10:45	2022-08-31	Edoxaban 30mg / no ASA indication
2358	748	Edoxaban	no ASA indication	DGA548R	12.5.22 7:56	2024-11-30	Edoxaban 30mg / no ASA indication
371	752	Placebo	ASA indication	SHV186F	30.11.18 13:40	2020-01-01	Edoxaban 30mg / ASA indication
371	752	Placebo	ASA indication	RBT763P	11.6.18 11:00	2020-01-01	Edoxaban 30mg / ASA indication
371	752	Placebo	ASA indication	FGG947P	12.12.17 10:29	2018-09-01	Edoxaban 30mg / ASA indication
457	752	Placebo	ASA indication	GWW676K	22.2.18 14:48	2020-01-01	Edoxaban 60mg / ASA indication
457	752	Placebo	ASA indication	GFW112L	22.8.19 9:21	2022-08-31	Edoxaban 30mg / ASA indication
457	752	Placebo	ASA indication	TSS219S	27.2.20 14:03	2022-08-31	Edoxaban 30mg / ASA indication
457	752	Placebo	ASA indication	FXM426G	25.2.21 13:42	2022-08-31	Edoxaban 30mg / ASA indication
457	752	Placebo	ASA indication	ZUW739R	28.2.19 9:11	2020-01-01	Edoxaban 30mg / ASA indication
457	752	Placebo	ASA indication	PLM866B	5.9.18 13:31	2020-01-01	Edoxaban 60mg / ASA indication
457	752	Placebo	ASA indication	GHH675X	12.8.20 7:26	2022-08-31	Edoxaban 30mg / ASA indication
1111	752	Placebo	ASA indication	TTM377W	14.11.19 14:02	2022-08-31	Edoxaban 30mg / ASA indication
1111	752	Placebo	ASA indication	PMB747F	6.5.19 10:35	2020-01-01	Edoxaban 30mg / ASA indication
1111	752	Placebo	ASA indication	WZM588Z	15.11.21 13:32	2022-08-31	Edoxaban 30mg / no ASA indication
1111	752	Placebo	ASA indication	GMH621Z	12.11.20 14:14	2022-08-31	Edoxaban 30mg / ASA indication
1111	752	Placebo	ASA indication	FUG457P	13.5.21 12:46	2022-08-31	Edoxaban 30mg / ASA indication
1111	752	Placebo	ASA indication	YPA941L	14.5.20 12:06	2022-08-31	Edoxaban 30mg / ASA indication
1111	752	Placebo	ASA indication	LCB756P	12.5.22 11:13	2024-11-30	Edoxaban 30mg / no ASA indication
316	752	Placebo	no ASA indication	TCF275S	18.10.19 12:29	2021-12-31	Edoxaban 60mg / ASA indication
316	752	Placebo	no ASA indication	RDM172P	15.6.18 11:06	2020-01-01	Edoxaban 60mg / ASA indication
316	752	Placebo	no ASA indication	ZHP917Z	24.5.19 13:39	2020-01-01	Edoxaban 60mg / ASA indication
316	752	Placebo	no ASA indication	DTG561K	20.4.18 12:47	2020-01-01	Edoxaban 60mg / no ASA indication
316	752	Placebo	no ASA indication	AKR978B	26.10.17 9:53	2018-09-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
316	752	Placebo	no ASA indication	GGY725T	30.10.18 14:42	2020-01-01	Edoxaban 60mg / no ASA indication
372	752	Placebo	no ASA indication	UAD575A	12.12.17 13:49	2018-09-01	Edoxaban 60mg / no ASA indication
657	752	Placebo	no ASA indication	FTS954R	7.8.18 12:49	2020-01-01	Edoxaban 30mg / no ASA indication
657	752	Placebo	no ASA indication	VWZ276P	12.2.19 15:36	2020-01-01	Edoxaban 30mg / no ASA indication
1025	752	Placebo	no ASA indication	LHU596L	14.3.19 10:38	2020-01-01	Edoxaban 60mg / no ASA indication
570	752	Edoxaban	ASA indication	CUC553R	25.5.18 13:18	2020-01-01	Edoxaban 30mg / ASA indication
862	752	Edoxaban	ASA indication	AKZ246P	22.11.19 13:16	2022-08-31	Edoxaban 30mg / ASA indication
862	752	Edoxaban	ASA indication	GYS636S	5.6.19 10:51	2020-01-01	Edoxaban 30mg / ASA indication
862	752	Edoxaban	ASA indication	HTW646L	4.12.18 12:47	2020-01-01	Edoxaban 30mg / ASA indication
862	752	Edoxaban	ASA indication	ABC117M	14.5.20 12:41	2022-08-31	Edoxaban 30mg / ASA indication
1081	752	Edoxaban	ASA indication	MFN797S	12.4.22 11:49	2024-11-30	Edoxaban 30mg / ASA indication
1081	752	Edoxaban	ASA indication	TGL251M	15.4.19 10:41	2020-01-01	Edoxaban 30mg / ASA indication
1081	752	Edoxaban	ASA indication	NXF539G	26.4.21 12:44	2022-08-31	Edoxaban 30mg / no ASA indication
1081	752	Edoxaban	ASA indication	LAX452X	10.10.19 11:13	2022-08-31	Edoxaban 30mg / ASA indication
1081	752	Edoxaban	ASA indication	PTE196P	21.10.21 12:41	2022-08-31	Edoxaban 30mg / no ASA indication
1081	752	Edoxaban	ASA indication	VWB486G	14.10.20 13:26	2022-08-31	Edoxaban 30mg / ASA indication
1081	752	Edoxaban	ASA indication	WSM479L	9.4.20 11:56	2022-08-31	Edoxaban 30mg / ASA indication
406	752	Edoxaban	no ASA indication	CBF147U	6.7.18 12:05	2020-01-01	Edoxaban 30mg / no ASA indication
406	752	Edoxaban	no ASA indication	PSV738A	28.12.18 12:35	2020-01-01	Edoxaban 30mg / no ASA indication
406	752	Edoxaban	no ASA indication	UVH771W	17.1.18 11:28	2018-09-01	Edoxaban 30mg / no ASA indication
458	752	Edoxaban	no ASA indication	YMA642V	27.2.18 13:49	2020-01-01	Edoxaban 60mg / no ASA indication
458	752	Edoxaban	no ASA indication	RMH339U	22.2.18 16:26	2020-01-01	Edoxaban 60mg / no ASA indication
458	752	Edoxaban	no ASA indication	MCX365V	5.9.18 12:11	2020-01-01	Edoxaban 60mg / no ASA indication
458	752	Edoxaban	no ASA indication	ECH715E	28.2.19 11:06	2020-01-01	Edoxaban 60mg / no ASA indication
517	752	Edoxaban	no ASA indication	UPF957C	10.10.19 12:41	2021-12-31	Edoxaban 60mg / no ASA indication
517	752	Edoxaban	no ASA indication	GWV925M	6.4.18 12:44	2020-01-01	Edoxaban 60mg / no ASA indication
517	752	Edoxaban	no ASA indication	NYX697S	8.10.18 13:33	2020-01-01	Edoxaban 60mg / no ASA indication
517	752	Edoxaban	no ASA indication	YMY276H	9.4.19 13:16	2020-01-01	Edoxaban 30mg / no ASA indication
517	752	Edoxaban	no ASA indication	ERB915M	9.4.20 11:40	2021-12-31	Edoxaban 60mg / no ASA indication
607	752	Edoxaban	no ASA indication	GKW179R	26.6.19 10:28	2021-12-31	Edoxaban 60mg / no ASA indication
607	752	Edoxaban	no ASA indication	TZK741Z	14.12.18 12:41	2020-01-01	Edoxaban 60mg / no ASA indication
607	752	Edoxaban	no ASA indication	ZHH343S	26.6.18 13:38	2020-01-01	Edoxaban 60mg / no ASA indication
863	752	Edoxaban	no ASA indication	WBP216U	11.12.19 13:40	2021-12-31	Edoxaban 60mg / no ASA indication
863	752	Edoxaban	no ASA indication	RKT758K	5.6.19 11:37	2020-01-01	Edoxaban 60mg / no ASA indication
863	752	Edoxaban	no ASA indication	ZVW393T	4.12.18 14:18	2020-01-01	Edoxaban 60mg / no ASA indication
540	756	Placebo	ASA indication	DTT444Y	27.4.18 11:40	2020-01-01	Edoxaban 60mg / ASA indication
540	756	Placebo	ASA indication	SAU766C	4.5.21 6:37	2022-08-31	Edoxaban 30mg / ASA indication
540	756	Placebo	ASA indication	LKU955G	5.5.22 7:29	2024-11-30	Edoxaban 30mg / ASA indication
540	756	Placebo	ASA indication	NPK169V	26.10.18 8:58	2020-01-01	Edoxaban 30mg / ASA indication
540	756	Placebo	ASA indication	GAV278R	23.10.19 8:19	2022-08-31	Edoxaban 30mg / ASA indication
540	756	Placebo	ASA indication	XHG112K	23.4.20 10:25	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
540	756	Placebo	ASA indication	NZU882G	23.4.19 6:29	2020-01-01	Edoxaban 60mg / ASA indication
540	756	Placebo	ASA indication	LRY543T	27.10.21 10:47	2022-08-31	Edoxaban 30mg / ASA indication
540	756	Placebo	ASA indication	PRY339K	3.11.20 7:10	2022-08-31	Edoxaban 30mg / ASA indication
1069	756	Placebo	ASA indication	TCX472Y	22.10.19 7:45	2021-12-31	Edoxaban 60mg / ASA indication
1069	756	Placebo	ASA indication	DDT211G	9.4.19 10:05	2020-01-01	Edoxaban 60mg / ASA indication
1102	756	Placebo	ASA indication	PER411B	14.5.20 11:25	2022-08-31	Edoxaban 30mg / ASA indication
1102	756	Placebo	ASA indication	CWD623H	19.11.21 9:47	2022-08-31	Edoxaban 30mg / no ASA indication
1102	756	Placebo	ASA indication	KNR681L	4.11.19 9:20	2022-08-31	Edoxaban 30mg / ASA indication
1102	756	Placebo	ASA indication	FKR716S	3.5.19 8:04	2020-01-01	Edoxaban 30mg / ASA indication
1102	756	Placebo	ASA indication	LRN477E	21.5.21 8:45	2022-08-31	Edoxaban 30mg / ASA indication
1102	756	Placebo	ASA indication	RLC715F	17.11.20 9:16	2022-08-31	Edoxaban 30mg / ASA indication
448	756	Placebo	no ASA indication	ZCG765P	19.2.19 8:44	2020-01-01	Edoxaban 60mg / no ASA indication
448	756	Placebo	no ASA indication	GBA873U	9.2.21 10:52	2021-12-31	Edoxaban 60mg / ASA indication
448	756	Placebo	no ASA indication	ZKR919X	20.8.20 7:42	2022-08-31	Edoxaban 30mg / ASA indication
448	756	Placebo	no ASA indication	VEW155S	14.8.18 8:01	2020-01-01	Edoxaban 60mg / no ASA indication
448	756	Placebo	no ASA indication	GEZ225Z	14.8.19 7:40	2021-12-31	Edoxaban 60mg / ASA indication
448	756	Placebo	no ASA indication	LKM458R	23.2.22 10:31	2024-11-30	Edoxaban 30mg / ASA indication
448	756	Placebo	no ASA indication	ZMY935K	18.2.20 10:51	2021-12-31	Edoxaban 60mg / ASA indication
448	756	Placebo	no ASA indication	EYM998A	16.2.18 10:29	2020-01-01	Edoxaban 60mg / no ASA indication
448	756	Placebo	no ASA indication	MLH663U	10.8.21 8:51	2024-04-30	Edoxaban 60mg / ASA indication
509	756	Placebo	no ASA indication	BAN133T	16.10.18 7:23	2020-01-01	Edoxaban 60mg / no ASA indication
509	756	Placebo	no ASA indication	RNY642Y	4.4.18 8:37	2020-01-01	Edoxaban 60mg / no ASA indication
495	756	Edoxaban	ASA indication	KKV273G	22.3.18 8:07	2020-01-01	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	CGF811F	25.3.19 9:08	2020-01-01	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	MBP539X	16.3.22 10:45	2024-04-30	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	BCY443A	27.11.18 12:53	2020-01-01	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	KAZ752R	26.9.19 7:12	2021-12-31	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	APY691Z	17.3.20 7:39	2021-12-31	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	CWU411A	17.9.20 7:54	2021-12-31	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	ABC833Y	15.3.21 9:21	2021-12-31	Edoxaban 60mg / ASA indication
495	756	Edoxaban	ASA indication	MFS169N	13.9.21 9:23	2024-04-30	Edoxaban 60mg / ASA indication
1255	756	Edoxaban	ASA indication	SNB184C	20.8.19 11:38	2021-12-31	Edoxaban 60mg / ASA indication
426	756	Edoxaban	no ASA indication	PGN818K	6.8.18 7:42	2020-01-01	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	LCV625H	9.2.21 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	UGM317N	18.8.20 8:28	2021-12-31	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	YAX961B	18.2.20 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	MWD132Z	21.8.19 8:06	2021-12-31	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	LYX413W	10.2.22 11:04	2024-04-30	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	MAS532S	10.8.21 9:15	2024-04-30	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	KFE959P	5.2.19 9:15	2020-01-01	Edoxaban 60mg / no ASA indication
426	756	Edoxaban	no ASA indication	CXM515S	1.2.18 11:07	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
481	758	Placebo	ASA indication	FAX281D	24.9.18 8:32	2020-01-01	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	REH816U	30.9.19 8:00	2021-12-31	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	XDS395W	14.9.20 8:28	2021-12-31	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	ELR721W	23.3.21 11:26	2022-08-31	Edoxaban 30mg / ASA indication
481	758	Placebo	ASA indication	MNX517G	20.9.21 8:04	2024-04-30	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	GHE698U	14.3.18 9:25	2020-01-01	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	MCB553E	25.3.20 7:28	2021-12-31	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	SMN458P	1.4.19 9:08	2020-01-01	Edoxaban 60mg / ASA indication
481	758	Placebo	ASA indication	MLT698F	14.3.22 9:30	2024-04-30	Edoxaban 60mg / ASA indication
1086	758	Placebo	no ASA indication	KTU474F	26.4.21 8:40	2021-12-31	Edoxaban 60mg / no ASA indication
1086	758	Placebo	no ASA indication	LEC151H	28.10.19 9:22	2021-12-31	Edoxaban 60mg / no ASA indication
1086	758	Placebo	no ASA indication	LWE619V	29.4.22 7:53	2024-04-30	Edoxaban 60mg / no ASA indication
1086	758	Placebo	no ASA indication	LWP723K	12.11.21 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
1086	758	Placebo	no ASA indication	MML711E	29.4.22 12:03	2024-04-30	Edoxaban 60mg / ASA indication
1086	758	Placebo	no ASA indication	NRA933B	17.4.19 7:07	2020-01-01	Edoxaban 60mg / no ASA indication
1086	758	Placebo	no ASA indication	HVF926M	30.4.20 9:35	2021-12-31	Edoxaban 60mg / no ASA indication
1086	758	Placebo	no ASA indication	PTY715S	26.10.20 9:12	2021-12-31	Edoxaban 60mg / no ASA indication
811	758	Edoxaban	ASA indication	KAT455F	13.5.19 8:03	2020-01-01	Edoxaban 60mg / ASA indication
811	758	Edoxaban	ASA indication	MLE775U	9.5.22 8:16	2024-04-30	Edoxaban 60mg / ASA indication
811	758	Edoxaban	ASA indication	HNY832B	24.5.21 8:22	2021-12-31	Edoxaban 60mg / no ASA indication
811	758	Edoxaban	ASA indication	UED448C	12.11.18 9:27	2020-01-01	Edoxaban 60mg / ASA indication
811	758	Edoxaban	ASA indication	MED821N	30.11.21 12:58	2024-04-30	Edoxaban 60mg / no ASA indication
811	758	Edoxaban	ASA indication	ZCW718K	28.5.20 7:51	2021-12-31	Edoxaban 60mg / ASA indication
811	758	Edoxaban	ASA indication	XNC772K	23.11.20 8:28	2021-12-31	Edoxaban 60mg / no ASA indication
811	758	Edoxaban	ASA indication	CWL378W	18.11.19 9:27	2021-12-31	Edoxaban 60mg / ASA indication
760	758	Edoxaban	no ASA indication	GVY893V	16.4.19 8:04	2020-01-01	Edoxaban 30mg / ASA indication
760	758	Edoxaban	no ASA indication	NKR592W	22.10.18 7:14	2020-01-01	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	NRU334F	10.1.20 10:08	2022-08-31	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	SRW271N	30.6.21 8:32	2022-08-31	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	ALX248D	20.12.21 10:41	2022-08-31	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	MDF421G	28.6.22 9:32	2024-11-30	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	DYF923N	22.12.20 9:16	2022-08-31	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	PHN885V	26.6.19 10:39	2022-08-31	Edoxaban 30mg / no ASA indication
1205	768	Placebo	no ASA indication	PUF149Z	23.7.20 8:37	2022-08-31	Edoxaban 30mg / no ASA indication
1341	768	Placebo	no ASA indication	KYZ792C	26.5.20 7:42	2022-08-31	Edoxaban 30mg / no ASA indication
1341	768	Placebo	no ASA indication	ASY236E	3.12.21 8:27	2022-08-31	Edoxaban 30mg / no ASA indication
1341	768	Placebo	no ASA indication	XEF611Y	22.10.19 9:46	2021-12-31	Edoxaban 60mg / no ASA indication
1341	768	Placebo	no ASA indication	SRP639A	28.4.21 6:30	2022-08-31	Edoxaban 30mg / no ASA indication
1341	768	Placebo	no ASA indication	DXA935W	4.12.20 9:20	2022-08-31	Edoxaban 30mg / no ASA indication
562	768	Edoxaban	no ASA indication	MDK359H	20.5.19 6:58	2020-01-01	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	NAG191A	27.5.21 8:27	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
562	768	Edoxaban	no ASA indication	ZAT419G	24.11.20 10:21	2021-12-31	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	CGK485F	31.5.22 9:55	2024-04-30	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	UBZ258H	25.11.19 10:49	2021-12-31	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	VRW899H	21.5.18 10:15	2020-01-01	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	PDK841Y	19.11.18 9:16	2020-01-01	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	RHY845M	30.11.21 10:21	2024-04-30	Edoxaban 60mg / no ASA indication
562	768	Edoxaban	no ASA indication	ENX373R	22.5.20 8:30	2021-12-31	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	RFE272A	29.9.21 9:45	2024-04-30	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	SDZ446U	28.4.20 12:06	2021-12-31	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	LYW418V	9.5.19 10:23	2020-01-01	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	YSL934R	9.4.21 8:53	2021-12-31	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	RHD663K	23.3.22 10:49	2024-04-30	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	BCF365D	21.10.20 10:13	2021-12-31	Edoxaban 60mg / no ASA indication
740	768	Edoxaban	no ASA indication	WDS833T	14.10.19 10:22	2022-08-31	Edoxaban 30mg / no ASA indication
740	768	Edoxaban	no ASA indication	PWF464F	8.10.18 11:28	2020-01-01	Edoxaban 60mg / no ASA indication
619	774	Placebo	ASA indication	WMY987B	8.7.19 14:45	2021-12-31	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	LGL354Y	12.8.21 12:24	2024-04-30	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	RWG678M	22.7.20 8:52	2021-12-31	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	LPH292H	9.7.18 12:50	2020-01-01	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	MFY348D	9.1.19 12:20	2020-01-01	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	HKB737S	7.7.22 11:11	2024-04-30	Edoxaban 60mg / no ASA indication
619	774	Placebo	ASA indication	GKD814A	27.1.21 9:46	2021-12-31	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	PAG419E	15.1.20 15:08	2021-12-31	Edoxaban 60mg / ASA indication
619	774	Placebo	ASA indication	KNG972Y	27.1.22 11:38	2024-04-30	Edoxaban 60mg / ASA indication
2505	774	Placebo	ASA indication	KAK179R	2.3.22 9:00	2024-11-30	Edoxaban 30mg / ASA indication
2559	774	Placebo	ASA indication	LEW429P	24.3.22 15:55	2024-04-30	Edoxaban 60mg / ASA indication
2559	774	Placebo	ASA indication	KNP674F	22.6.22 11:13	2024-11-30	Edoxaban 30mg / ASA indication
312	774	Placebo	no ASA indication	SKR137N	11.4.18 11:40	2020-01-01	Edoxaban 60mg / no ASA indication
312	774	Placebo	no ASA indication	RKG815K	24.10.17 11:58	2018-09-01	Edoxaban 60mg / no ASA indication
2581	774	Placebo	no ASA indication	HEY221E	12.4.22 15:42	2024-04-30	Edoxaban 60mg / no ASA indication
497	774	Edoxaban	ASA indication	MLP579P	19.9.18 11:00	2020-01-01	Edoxaban 60mg / ASA indication
497	774	Edoxaban	ASA indication	ZKA434C	7.10.20 13:35	2021-12-31	Edoxaban 60mg / ASA indication
497	774	Edoxaban	ASA indication	TLR743X	15.4.20 10:48	2021-12-31	Edoxaban 60mg / ASA indication
497	774	Edoxaban	ASA indication	EYD518G	22.3.18 17:07	2020-01-01	Edoxaban 60mg / ASA indication
497	774	Edoxaban	ASA indication	LRT845R	1.10.19 11:00	2021-12-31	Edoxaban 60mg / ASA indication
497	774	Edoxaban	ASA indication	HFS494P	28.3.19 14:08	2020-01-01	Edoxaban 60mg / ASA indication
497	774	Edoxaban	ASA indication	VLV312U	29.3.21 8:44	2021-12-31	Edoxaban 60mg / ASA indication
1218	774	Edoxaban	ASA indication	BEZ762X	15.1.20 11:45	2022-08-31	Edoxaban 30mg / ASA indication
1218	774	Edoxaban	ASA indication	ZNL747C	27.1.21 10:03	2022-08-31	Edoxaban 30mg / ASA indication
1218	774	Edoxaban	ASA indication	MMB588M	8.7.19 13:20	2022-08-31	Edoxaban 30mg / ASA indication
1218	774	Edoxaban	ASA indication	HUH944B	27.1.22 10:23	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1218	774	Edoxaban	ASA indication	BKM275V	22.7.20 8:26	2022-08-31	Edoxaban 30mg / ASA indication
1218	774	Edoxaban	ASA indication	LMT573S	20.7.21 12:42	2022-08-31	Edoxaban 30mg / ASA indication
1218	774	Edoxaban	ASA indication	EKZ117U	7.7.22 10:48	2024-11-30	Edoxaban 30mg / ASA indication
362	775	Placebo	ASA indication	KWP995B	5.12.18 11:08	2020-01-01	Edoxaban 30mg / ASA indication
362	775	Placebo	ASA indication	TRT598U	6.12.17 14:48	2018-09-01	Edoxaban 30mg / ASA indication
362	775	Placebo	ASA indication	DBC115V	23.5.18 8:41	2020-01-01	Edoxaban 30mg / ASA indication
660	775	Placebo	ASA indication	BSH844U	13.2.19 13:13	2020-01-01	Edoxaban 60mg / no ASA indication
660	775	Placebo	ASA indication	USX923P	9.8.18 11:08	2020-01-01	Edoxaban 60mg / ASA indication
1366	775	Placebo	ASA indication	HSZ598K	6.11.19 10:05	2021-12-31	Edoxaban 60mg / ASA indication
1555	775	Placebo	ASA indication	DAH176R	16.9.20 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1555	775	Placebo	ASA indication	HWB528B	13.3.20 7:03	2021-12-31	Edoxaban 60mg / ASA indication
1959	775	Placebo	ASA indication	EEF941B	15.2.21 10:09	2021-12-31	Edoxaban 60mg / ASA indication
1959	775	Placebo	ASA indication	XVK426X	23.2.22 9:52	2024-04-30	Edoxaban 60mg / ASA indication
1959	775	Placebo	ASA indication	SSH815V	30.8.21 8:41	2024-04-30	Edoxaban 60mg / ASA indication
2270	775	Placebo	ASA indication	SSW187V	15.9.21 8:46	2024-04-30	Edoxaban 60mg / ASA indication
1563	775	Placebo	no ASA indication	EGY294L	24.2.21 8:13	2021-12-31	Edoxaban 60mg / no ASA indication
1563	775	Placebo	no ASA indication	FSL268K	19.3.20 10:37	2021-12-31	Edoxaban 60mg / no ASA indication
1563	775	Placebo	no ASA indication	DHN312R	16.9.20 7:52	2021-12-31	Edoxaban 60mg / ASA indication
603	775	Edoxaban	ASA indication	GNB541H	8.2.19 10:12	2020-01-01	Edoxaban 60mg / no ASA indication
603	775	Edoxaban	ASA indication	KFT128S	27.2.20 12:26	2021-12-31	Edoxaban 60mg / ASA indication
603	775	Edoxaban	ASA indication	LKP972L	24.7.18 12:56	2020-01-01	Edoxaban 30mg / ASA indication
603	775	Edoxaban	ASA indication	XXN865M	14.8.19 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
603	775	Edoxaban	ASA indication	EHE786N	25.8.20 8:46	2021-12-31	Edoxaban 60mg / ASA indication
1060	775	Edoxaban	ASA indication	ANF443S	14.9.20 8:44	2021-12-31	Edoxaban 60mg / ASA indication
1060	775	Edoxaban	ASA indication	MTV335N	5.4.19 10:00	2020-01-01	Edoxaban 60mg / ASA indication
1060	775	Edoxaban	ASA indication	DZX446K	4.3.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
1060	775	Edoxaban	ASA indication	AYT142G	1.10.19 9:28	2021-12-31	Edoxaban 60mg / ASA indication
1562	775	Edoxaban	ASA indication	PXU456S	16.9.20 12:54	2021-12-31	Edoxaban 60mg / ASA indication
1562	775	Edoxaban	ASA indication	SVA975B	3.3.21 10:57	2021-12-31	Edoxaban 60mg / ASA indication
1562	775	Edoxaban	ASA indication	YEH115B	18.3.20 12:45	2022-08-31	Edoxaban 30mg / ASA indication
1851	775	Edoxaban	ASA indication	HMB874N	7.4.21 8:48	2021-12-31	Edoxaban 60mg / ASA indication
1851	775	Edoxaban	ASA indication	TNS946C	27.10.21 8:46	2024-04-30	Edoxaban 60mg / ASA indication
1851	775	Edoxaban	ASA indication	PYG767C	5.11.20 9:36	2021-12-31	Edoxaban 60mg / ASA indication
2121	775	Edoxaban	ASA indication	TPD925Z	1.12.21 14:17	2024-04-30	Edoxaban 60mg / ASA indication
2121	775	Edoxaban	ASA indication	ZUF251Z	18.5.22 7:38	2024-04-30	Edoxaban 60mg / ASA indication
2121	775	Edoxaban	ASA indication	ERV925R	26.5.21 8:53	2021-12-31	Edoxaban 60mg / ASA indication
2524	775	Edoxaban	ASA indication	ZUX596K	9.3.22 11:14	2024-04-30	Edoxaban 60mg / ASA indication
2524	775	Edoxaban	ASA indication	SGP626F	1.9.22 8:53	2024-04-30	Edoxaban 60mg / ASA indication
1350	775	Edoxaban	no ASA indication	MSX616K	22.4.20 8:59	2021-12-31	Edoxaban 60mg / ASA indication
1350	775	Edoxaban	no ASA indication	SUS716P	21.10.20 8:32	2021-12-31	Edoxaban 60mg / ASA indication
1350	775	Edoxaban	no ASA indication	TCH617U	4.4.22 12:14	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1350	775	Edoxaban	no ASA indication	TNX835N	13.10.21 8:27	2024-04-30	Edoxaban 60mg / ASA indication
1350	775	Edoxaban	no ASA indication	MCP894U	23.10.19 12:09	2021-12-31	Edoxaban 60mg / no ASA indication
1350	775	Edoxaban	no ASA indication	HPM737D	10.3.21 9:06	2021-12-31	Edoxaban 60mg / ASA indication
2145	776	Placebo	ASA indication	APD346B	10.6.21 8:32	2021-12-31	Edoxaban 60mg / ASA indication
2173	776	Placebo	ASA indication	STZ237U	14.7.22 12:35	2024-04-30	Edoxaban 60mg / ASA indication
2173	776	Placebo	ASA indication	SWL785M	29.6.21 6:39	2024-04-30	Edoxaban 60mg / ASA indication
2173	776	Placebo	ASA indication	TKK985M	3.5.22 8:11	2024-04-30	Edoxaban 60mg / no ASA indication
299	776	Edoxaban	ASA indication	ZNH321G	12.10.17 9:21	2018-09-01	Edoxaban 30mg / ASA indication
1432	776	Edoxaban	ASA indication	TDC293F	7.6.22 7:30	2024-04-30	Edoxaban 60mg / no ASA indication
1432	776	Edoxaban	ASA indication	FDC314A	5.12.19 10:27	2021-12-31	Edoxaban 60mg / ASA indication
1432	776	Edoxaban	ASA indication	MWP499V	27.5.21 12:00	2021-12-31	Edoxaban 60mg / ASA indication
1432	776	Edoxaban	ASA indication	RBB897K	4.6.20 13:12	2021-12-31	Edoxaban 60mg / ASA indication
1432	776	Edoxaban	ASA indication	FST629L	3.12.20 9:42	2021-12-31	Edoxaban 60mg / ASA indication
1432	776	Edoxaban	ASA indication	TEA961W	25.11.21 13:59	2024-04-30	Edoxaban 60mg / no ASA indication
614	776	Edoxaban	no ASA indication	EXH442V	5.7.18 8:34	2020-01-01	Edoxaban 60mg / no ASA indication
614	776	Edoxaban	no ASA indication	ZAL649X	5.7.18 14:52	2020-01-01	Edoxaban 60mg / ASA indication
2727	776	Edoxaban	no ASA indication	TEC455R	28.7.22 7:31	2024-04-30	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	RMX588E	29.3.18 9:52	2020-01-01	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	HYP349P	4.10.18 10:05	2020-01-01	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	KDA345A	26.3.20 7:58	2021-12-31	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	WVM742R	28.9.20 8:23	2021-12-31	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	LBZ634K	25.3.21 8:26	2021-12-31	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	GYF334K	21.10.19 9:23	2021-12-31	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	HTW944M	26.9.17 10:47	2018-09-01	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	TLU373B	31.3.22 9:13	2024-04-30	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	BPC863H	17.4.19 8:39	2020-01-01	Edoxaban 60mg / no ASA indication
284	780	Placebo	no ASA indication	TPE793X	30.9.21 7:42	2024-04-30	Edoxaban 60mg / no ASA indication
313	780	Edoxaban	ASA indication	EKM349S	26.4.18 7:27	2020-01-01	Edoxaban 60mg / ASA indication
313	780	Edoxaban	ASA indication	MNZ417K	23.10.19 7:57	2021-12-31	Edoxaban 60mg / ASA indication
313	780	Edoxaban	ASA indication	XLT485G	23.3.20 8:10	2021-12-31	Edoxaban 60mg / ASA indication
313	780	Edoxaban	ASA indication	SEB866N	30.10.18 7:47	2020-01-01	Edoxaban 60mg / ASA indication
313	780	Edoxaban	ASA indication	UPS231V	17.10.18 6:48	2020-01-01	Edoxaban 60mg / no ASA indication
313	780	Edoxaban	ASA indication	WMW938P	24.10.17 9:31	2018-09-01	Edoxaban 60mg / ASA indication
313	780	Edoxaban	ASA indication	HVY994K	18.4.19 7:28	2020-01-01	Edoxaban 60mg / ASA indication
781	780	Edoxaban	ASA indication	SHB896S	5.4.19 10:22	2020-01-01	Edoxaban 60mg / ASA indication
781	780	Edoxaban	ASA indication	TGN565V	24.3.20 12:33	2021-12-31	Edoxaban 60mg / ASA indication
781	780	Edoxaban	ASA indication	HUF183D	24.3.21 9:04	2021-12-31	Edoxaban 60mg / ASA indication
781	780	Edoxaban	ASA indication	GRF456S	4.10.19 7:55	2021-12-31	Edoxaban 60mg / ASA indication
781	780	Edoxaban	ASA indication	TFK422E	4.10.21 8:08	2024-04-30	Edoxaban 60mg / no ASA indication
781	780	Edoxaban	ASA indication	ZYD937C	16.9.20 9:22	2021-12-31	Edoxaban 60mg / ASA indication
781	780	Edoxaban	ASA indication	UXK692D	29.10.18 10:14	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
354	780	Edoxaban	no ASA indication	YCH598Z	29.11.17 12:28	2018-09-01	Edoxaban 60mg / no ASA indication
625	780	Edoxaban	no ASA indication	CNR495Z	12.7.18 6:42	2020-01-01	Edoxaban 60mg / no ASA indication
673	780	Edoxaban	no ASA indication	LUP268G	12.8.19 8:16	2021-12-31	Edoxaban 60mg / no ASA indication
673	780	Edoxaban	no ASA indication	PUB834B	25.2.19 11:01	2020-01-01	Edoxaban 60mg / ASA indication
673	780	Edoxaban	no ASA indication	VVB432U	25.2.19 15:38	2020-01-01	Edoxaban 60mg / no ASA indication
673	780	Edoxaban	no ASA indication	UAM479Z	16.8.18 6:11	2020-01-01	Edoxaban 60mg / no ASA indication
673	780	Edoxaban	no ASA indication	VUW698L	17.2.20 8:17	2021-12-31	Edoxaban 60mg / no ASA indication
2663	783	Placebo	ASA indication	YAN418R	21.6.22 12:10	2024-04-30	Edoxaban 60mg / ASA indication
2743	783	Placebo	no ASA indication	NYS822U	1.9.22 15:08	2024-11-30	Edoxaban 30mg / no ASA indication
1375	784	Placebo	ASA indication	UNV177A	24.11.20 10:30	2021-12-31	Edoxaban 60mg / ASA indication
1375	784	Placebo	ASA indication	YUM959V	27.5.20 9:17	2021-12-31	Edoxaban 60mg / ASA indication
1375	784	Placebo	ASA indication	RBM327M	31.5.22 6:33	2024-04-30	Edoxaban 60mg / ASA indication
1375	784	Placebo	ASA indication	SUX683K	5.5.21 9:06	2021-12-31	Edoxaban 60mg / ASA indication
1375	784	Placebo	ASA indication	HZZ539C	11.11.19 10:45	2021-12-31	Edoxaban 60mg / ASA indication
1375	784	Placebo	ASA indication	PYF996A	17.11.21 13:08	2024-04-30	Edoxaban 60mg / ASA indication
1376	784	Edoxaban	ASA indication	ENY356V	27.5.20 9:32	2021-12-31	Edoxaban 60mg / ASA indication
1376	784	Edoxaban	ASA indication	SDA476L	11.11.19 11:07	2021-12-31	Edoxaban 60mg / ASA indication
1281	785	Edoxaban	no ASA indication	RDD393A	28.3.22 8:53	2024-04-30	Edoxaban 60mg / no ASA indication
1281	785	Edoxaban	no ASA indication	CWS363R	17.3.21 9:12	2021-12-31	Edoxaban 60mg / no ASA indication
1281	785	Edoxaban	no ASA indication	BHD333X	12.9.19 9:58	2021-12-31	Edoxaban 60mg / no ASA indication
1281	785	Edoxaban	no ASA indication	FLB387R	13.3.20 8:50	2021-12-31	Edoxaban 60mg / no ASA indication
1281	785	Edoxaban	no ASA indication	PZZ917N	20.9.21 8:01	2024-04-30	Edoxaban 60mg / no ASA indication
1281	785	Edoxaban	no ASA indication	WVR798D	4.9.20 11:06	2021-12-31	Edoxaban 60mg / no ASA indication
1718	788	Placebo	ASA indication	FAF522C	4.2.22 9:44	2024-04-30	Edoxaban 60mg / no ASA indication
1718	788	Placebo	ASA indication	HHZ939D	3.8.20 9:35	2021-12-31	Edoxaban 60mg / ASA indication
1718	788	Placebo	ASA indication	RGX996Y	9.2.21 15:17	2021-12-31	Edoxaban 60mg / ASA indication
1718	788	Placebo	ASA indication	RSE123A	16.8.21 10:05	2024-04-30	Edoxaban 60mg / ASA indication
1827	788	Placebo	ASA indication	BET563S	16.10.20 8:29	2021-12-31	Edoxaban 60mg / ASA indication
1605	788	Placebo	no ASA indication	TCH577K	9.12.20 9:52	2021-12-31	Edoxaban 60mg / no ASA indication
1605	788	Placebo	no ASA indication	NAF388T	4.6.21 10:12	2021-12-31	Edoxaban 60mg / no ASA indication
1605	788	Placebo	no ASA indication	LXV883E	29.5.20 8:40	2021-12-31	Edoxaban 60mg / no ASA indication
1605	788	Placebo	no ASA indication	NGU931D	14.6.22 9:29	2024-04-30	Edoxaban 60mg / no ASA indication
1605	788	Placebo	no ASA indication	RYR683F	7.12.21 8:58	2024-04-30	Edoxaban 60mg / no ASA indication
1738	788	Placebo	no ASA indication	GRE393X	20.8.20 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1872	788	Placebo	no ASA indication	RXW758K	2.12.21 10:02	2024-04-30	Edoxaban 60mg / no ASA indication
1872	788	Placebo	no ASA indication	BSL955P	18.11.20 10:31	2021-12-31	Edoxaban 60mg / no ASA indication
1872	788	Placebo	no ASA indication	TGC966H	28.5.21 7:39	2021-12-31	Edoxaban 60mg / no ASA indication
1872	788	Placebo	no ASA indication	NBB533R	2.6.22 8:40	2024-04-30	Edoxaban 60mg / no ASA indication
2212	788	Placebo	no ASA indication	RYC551U	4.8.21 10:51	2024-04-30	Edoxaban 60mg / no ASA indication
1624	788	Edoxaban	ASA indication	PRG116F	17.12.20 11:12	2021-12-31	Edoxaban 60mg / ASA indication
1624	788	Edoxaban	ASA indication	HVX388C	10.6.20 11:12	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2295	788	Edoxaban	ASA indication	RZX113Z	30.9.21 10:56	2024-04-30	Edoxaban 60mg / ASA indication
2295	788	Edoxaban	ASA indication	RYN251P	14.4.22 9:12	2024-04-30	Edoxaban 60mg / no ASA indication
1623	788	Edoxaban	no ASA indication	RWM132K	27.12.21 10:04	2024-04-30	Edoxaban 60mg / no ASA indication
1623	788	Edoxaban	no ASA indication	MUL736N	10.6.20 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
1623	788	Edoxaban	no ASA indication	NWE112R	18.12.20 9:19	2021-12-31	Edoxaban 60mg / no ASA indication
1623	788	Edoxaban	no ASA indication	MSM875Y	11.6.21 7:40	2021-12-31	Edoxaban 60mg / no ASA indication
1733	788	Edoxaban	no ASA indication	ULK698M	17.8.20 6:38	2022-08-31	Edoxaban 30mg / no ASA indication
2007	788	Edoxaban	no ASA indication	RWW522E	20.9.21 8:23	2024-04-30	Edoxaban 60mg / no ASA indication
2007	788	Edoxaban	no ASA indication	MRF971Y	12.3.21 10:37	2021-12-31	Edoxaban 60mg / no ASA indication
2007	788	Edoxaban	no ASA indication	UBR338X	4.4.22 9:55	2024-11-30	Edoxaban 30mg / no ASA indication
884	799	Placebo	no ASA indication	MKW589P	11.12.18 11:31	2020-01-01	Edoxaban 60mg / no ASA indication
884	799	Placebo	no ASA indication	FVW415N	6.12.19 10:20	2021-12-31	Edoxaban 60mg / no ASA indication
884	799	Placebo	no ASA indication	GKX623H	3.6.19 8:38	2020-01-01	Edoxaban 60mg / no ASA indication
1163	799	Placebo	no ASA indication	FTE196L	6.6.19 8:13	2020-01-01	Edoxaban 60mg / no ASA indication
1163	799	Placebo	no ASA indication	WEC234M	22.8.19 13:38	2021-12-31	Edoxaban 60mg / no ASA indication
1291	799	Edoxaban	no ASA indication	GNT884Y	14.5.21 12:00	2021-12-31	Edoxaban 60mg / no ASA indication
1291	799	Edoxaban	no ASA indication	FMS573K	13.9.21 8:50	2024-04-30	Edoxaban 60mg / no ASA indication
1291	799	Edoxaban	no ASA indication	FEE559R	18.9.19 7:34	2021-12-31	Edoxaban 60mg / no ASA indication
1291	799	Edoxaban	no ASA indication	SPZ782S	17.7.20 7:12	2021-12-31	Edoxaban 60mg / no ASA indication
1291	799	Edoxaban	no ASA indication	UEF669F	17.9.20 7:26	2021-12-31	Edoxaban 60mg / no ASA indication
1291	799	Edoxaban	no ASA indication	FNE673G	1.4.22 11:00	2024-04-30	Edoxaban 60mg / no ASA indication
647	800	Placebo	ASA indication	AWM655V	3.2.21 9:33	2022-08-31	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	DZF152N	17.8.21 7:47	2022-08-31	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	KWB246H	5.2.20 9:15	2022-08-31	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	EEK181E	31.7.18 10:56	2020-01-01	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	GWF684F	31.1.19 9:43	2020-01-01	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	DFY651Z	3.2.22 8:29	2022-08-31	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	VDT254U	29.7.20 8:42	2022-08-31	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	FDA324X	31.7.19 9:09	2022-08-31	Edoxaban 30mg / ASA indication
647	800	Placebo	ASA indication	WBW529X	2.8.22 9:36	2024-11-30	Edoxaban 30mg / ASA indication
1221	800	Placebo	ASA indication	RRE537B	9.1.20 10:30	2021-12-31	Edoxaban 60mg / ASA indication
1221	800	Placebo	ASA indication	MDA871M	6.1.21 8:26	2021-12-31	Edoxaban 60mg / ASA indication
1221	800	Placebo	ASA indication	GHV755K	19.1.22 8:18	2024-04-30	Edoxaban 60mg / ASA indication
1221	800	Placebo	ASA indication	ZRC654N	23.7.20 9:15	2021-12-31	Edoxaban 60mg / ASA indication
1221	800	Placebo	ASA indication	TFR873K	7.7.22 7:41	2024-11-30	Edoxaban 30mg / ASA indication
1221	800	Placebo	ASA indication	VXZ624W	9.7.19 12:49	2022-08-31	Edoxaban 30mg / ASA indication
1221	800	Placebo	ASA indication	GHX831A	8.7.21 10:00	2024-04-30	Edoxaban 60mg / ASA indication
1401	800	Placebo	ASA indication	YGZ234A	20.5.21 8:50	2021-12-31	Edoxaban 60mg / ASA indication
1401	800	Placebo	ASA indication	MCW775X	25.5.20 9:04	2021-12-31	Edoxaban 60mg / ASA indication
1401	800	Placebo	ASA indication	SHB866U	20.11.20 8:57	2021-12-31	Edoxaban 60mg / ASA indication
1401	800	Placebo	ASA indication	WZC375F	18.11.21 10:17	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1401	800	Placebo	ASA indication	YNU174W	20.11.19 11:21	2021-12-31	Edoxaban 60mg / ASA indication
1401	800	Placebo	ASA indication	TEK265K	24.5.22 8:32	2024-11-30	Edoxaban 30mg / ASA indication
1421	800	Placebo	ASA indication	AZA292T	29.11.19 9:10	2021-12-31	Edoxaban 60mg / ASA indication
1527	800	Placebo	ASA indication	AHF832H	20.2.20 14:48	2022-08-31	Edoxaban 30mg / ASA indication
2634	800	Placebo	ASA indication	ZSB198S	1.6.22 7:49	2024-04-30	Edoxaban 60mg / ASA indication
571	800	Placebo	no ASA indication	DDX635W	28.5.20 8:29	2021-12-31	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	VAD213A	29.5.19 10:39	2020-01-01	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	ZXA377F	9.6.22 7:48	2024-04-30	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	BXX348P	20.11.18 9:29	2020-01-01	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	PPE138Y	29.5.18 10:50	2020-01-01	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	VSH551V	25.11.20 8:48	2021-12-31	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	NMD491T	28.11.19 10:44	2021-12-31	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	FSF257R	25.11.21 8:41	2024-04-30	Edoxaban 60mg / no ASA indication
571	800	Placebo	no ASA indication	PBV769R	27.5.21 7:41	2021-12-31	Edoxaban 60mg / no ASA indication
1667	800	Placebo	no ASA indication	UGD135Z	30.6.20 10:30	2022-08-31	Edoxaban 30mg / no ASA indication
420	800	Edoxaban	ASA indication	ZMN544C	1.8.19 9:16	2021-12-31	Edoxaban 60mg / ASA indication
420	800	Edoxaban	ASA indication	MLC583B	23.7.18 11:22	2020-01-01	Edoxaban 60mg / ASA indication
420	800	Edoxaban	ASA indication	LAB348G	4.2.19 12:54	2020-01-01	Edoxaban 60mg / ASA indication
420	800	Edoxaban	ASA indication	NUY773E	30.1.18 14:51	2020-01-01	Edoxaban 60mg / ASA indication
642	800	Edoxaban	ASA indication	HSN335X	2.8.18 13:08	2020-01-01	Edoxaban 60mg / ASA indication
653	800	Edoxaban	ASA indication	VWK487R	4.2.19 9:43	2020-01-01	Edoxaban 60mg / ASA indication
653	800	Edoxaban	ASA indication	YNN917Z	2.8.18 9:35	2020-01-01	Edoxaban 60mg / ASA indication
653	800	Edoxaban	ASA indication	SHS214G	2.8.19 7:41	2021-12-31	Edoxaban 60mg / ASA indication
1128	800	Edoxaban	ASA indication	WHL178T	15.5.19 10:00	2020-01-01	Edoxaban 60mg / ASA indication
1128	800	Edoxaban	ASA indication	XAE595D	14.11.19 10:07	2021-12-31	Edoxaban 60mg / ASA indication
1603	800	Edoxaban	ASA indication	PXW293Z	21.7.20 10:25	2022-08-31	Edoxaban 30mg / ASA indication
1603	800	Edoxaban	ASA indication	ANB444K	28.5.20 9:47	2021-12-31	Edoxaban 60mg / ASA indication
1264	800	Edoxaban	no ASA indication	YXL243C	5.9.22 9:34	2024-04-30	Edoxaban 60mg / no ASA indication
1264	800	Edoxaban	no ASA indication	YPS799S	28.8.19 11:14	2021-12-31	Edoxaban 60mg / no ASA indication
1264	800	Edoxaban	no ASA indication	CFS836Y	28.2.20 9:20	2021-12-31	Edoxaban 60mg / no ASA indication
1264	800	Edoxaban	no ASA indication	DMK628L	25.8.20 8:07	2021-12-31	Edoxaban 60mg / no ASA indication
1264	800	Edoxaban	no ASA indication	ZXL978T	24.2.21 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
1264	800	Edoxaban	no ASA indication	FRA429C	27.8.21 9:19	2024-04-30	Edoxaban 60mg / no ASA indication
1264	800	Edoxaban	no ASA indication	FSH895B	9.3.22 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
1332	800	Edoxaban	no ASA indication	AZH977B	15.10.19 9:50	2021-12-31	Edoxaban 60mg / no ASA indication
1984	800	Edoxaban	no ASA indication	YGP172L	26.2.21 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
1984	800	Edoxaban	no ASA indication	FPX147X	26.8.21 9:37	2024-04-30	Edoxaban 60mg / no ASA indication
1984	800	Edoxaban	no ASA indication	WSR772V	16.2.22 10:16	2024-04-30	Edoxaban 60mg / no ASA indication
2360	800	Edoxaban	no ASA indication	YYR263K	30.5.22 8:00	2024-04-30	Edoxaban 60mg / no ASA indication
2360	800	Edoxaban	no ASA indication	WRZ428T	23.11.21 7:54	2024-04-30	Edoxaban 60mg / no ASA indication
531	801	Placebo	ASA indication	GMX773T	10.4.19 7:49	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
531	801	Placebo	ASA indication	FMP778T	15.10.18 11:43	2020-01-01	Edoxaban 60mg / ASA indication
531	801	Placebo	ASA indication	NPD565W	18.4.18 11:04	2020-01-01	Edoxaban 60mg / ASA indication
531	801	Placebo	ASA indication	BMB139X	8.10.19 7:23	2022-08-31	Edoxaban 30mg / no ASA indication
545	801	Placebo	ASA indication	MAS259Z	3.5.18 13:52	2020-01-01	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	BDP437S	20.10.21 16:02	2024-04-30	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	HPG177S	7.11.19 9:21	2021-12-31	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	RBW689Z	5.11.18 14:00	2020-01-01	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	PNP619X	14.5.19 7:37	2020-01-01	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	RNT639D	12.5.21 14:02	2021-12-31	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	NCT779W	6.5.20 9:04	2021-12-31	Edoxaban 60mg / ASA indication
545	801	Placebo	ASA indication	SUK618D	11.11.20 8:47	2021-12-31	Edoxaban 60mg / ASA indication
620	801	Placebo	ASA indication	NDS217P	9.7.18 11:18	2020-01-01	Edoxaban 60mg / ASA indication
620	801	Placebo	ASA indication	XVN129F	16.7.19 8:34	2021-12-31	Edoxaban 60mg / ASA indication
620	801	Placebo	ASA indication	FBP368H	8.10.19 7:49	2021-12-31	Edoxaban 60mg / no ASA indication
620	801	Placebo	ASA indication	TDB973K	15.1.19 15:09	2020-01-01	Edoxaban 60mg / ASA indication
693	801	Placebo	ASA indication	XTG443Y	3.9.18 11:03	2020-01-01	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	HZU238C	15.10.19 9:55	2021-12-31	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	XCD643V	7.10.21 7:13	2024-04-30	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	AMC254C	9.4.20 7:53	2021-12-31	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	FSA226G	10.4.19 8:12	2020-01-01	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	ZKW512Z	21.4.22 7:07	2024-04-30	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	RHP842H	16.4.21 6:50	2021-12-31	Edoxaban 60mg / ASA indication
1070	801	Placebo	ASA indication	ZPV159Y	9.10.20 6:54	2021-12-31	Edoxaban 60mg / ASA indication
1183	801	Placebo	ASA indication	KTV731C	18.12.20 10:21	2021-12-31	Edoxaban 60mg / ASA indication
1183	801	Placebo	ASA indication	CMD213H	18.6.20 10:47	2021-12-31	Edoxaban 60mg / ASA indication
1183	801	Placebo	ASA indication	FEN885C	18.6.19 11:25	2021-12-31	Edoxaban 60mg / ASA indication
1183	801	Placebo	ASA indication	XXH689A	30.12.19 10:22	2021-12-31	Edoxaban 60mg / ASA indication
1187	801	Placebo	ASA indication	AES436F	18.6.19 12:33	2020-01-01	Edoxaban 30mg / ASA indication
1187	801	Placebo	ASA indication	UAD282K	30.12.19 10:28	2022-08-31	Edoxaban 30mg / ASA indication
1288	801	Placebo	ASA indication	HCD789E	18.9.20 8:33	2021-12-31	Edoxaban 60mg / ASA indication
1288	801	Placebo	ASA indication	YWR291B	17.9.19 8:52	2021-12-31	Edoxaban 60mg / ASA indication
1288	801	Placebo	ASA indication	DBS736P	27.3.20 10:03	2021-12-31	Edoxaban 60mg / ASA indication
1309	801	Placebo	ASA indication	ZBM422R	1.10.19 9:32	2021-12-31	Edoxaban 60mg / ASA indication
2387	801	Placebo	ASA indication	BEF785Y	23.6.22 7:44	2024-04-30	Edoxaban 60mg / ASA indication
2387	801	Placebo	ASA indication	VDU362V	10.12.21 9:25	2022-08-31	Edoxaban 30mg / ASA indication
2514	801	Placebo	ASA indication	SXV384W	4.3.22 10:37	2024-11-30	Edoxaban 30mg / ASA indication
2514	801	Placebo	ASA indication	RTF465P	2.9.22 7:30	2024-11-30	Edoxaban 30mg / ASA indication
2527	801	Placebo	ASA indication	SSA678N	10.3.22 9:50	2024-11-30	Edoxaban 30mg / ASA indication
595	801	Placebo	no ASA indication	TCX239K	18.6.19 10:39	2020-01-01	Edoxaban 60mg / ASA indication
595	801	Placebo	no ASA indication	ZGE144F	16.12.21 8:58	2024-04-30	Edoxaban 60mg / ASA indication
595	801	Placebo	no ASA indication	KTU527P	18.6.20 8:43	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
595	801	Placebo	no ASA indication	XBW835M	10.12.18 11:10	2020-01-01	Edoxaban 60mg / ASA indication
595	801	Placebo	no ASA indication	BEW873B	18.6.21 7:58	2024-04-30	Edoxaban 60mg / ASA indication
595	801	Placebo	no ASA indication	BDF227V	23.6.22 11:05	2024-04-30	Edoxaban 60mg / ASA indication
595	801	Placebo	no ASA indication	ZHS593G	18.12.20 8:10	2021-12-31	Edoxaban 60mg / ASA indication
595	801	Placebo	no ASA indication	DWK981F	18.6.18 10:43	2020-01-01	Edoxaban 60mg / no ASA indication
595	801	Placebo	no ASA indication	PFR844A	13.12.19 9:22	2021-12-31	Edoxaban 60mg / no ASA indication
599	801	Placebo	no ASA indication	SVD981V	17.12.18 11:48	2020-01-01	Edoxaban 30mg / ASA indication
599	801	Placebo	no ASA indication	ECG663C	20.6.18 15:29	2020-01-01	Edoxaban 30mg / no ASA indication
599	801	Placebo	no ASA indication	AMT854F	18.6.19 10:26	2020-01-01	Edoxaban 60mg / ASA indication
738	801	Placebo	no ASA indication	MWV451W	10.4.19 11:03	2020-01-01	Edoxaban 60mg / no ASA indication
738	801	Placebo	no ASA indication	LNF281D	8.10.18 9:45	2020-01-01	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	CDU139R	14.5.19 7:23	2020-01-01	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	UEN112M	5.11.18 11:57	2020-01-01	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	KDD396W	12.5.21 14:06	2022-08-31	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	VLP614R	20.10.21 16:06	2022-08-31	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	YLF819C	6.5.20 9:30	2022-08-31	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	LTE444R	13.11.20 8:24	2022-08-31	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	GTA455B	7.11.19 9:45	2022-08-31	Edoxaban 30mg / no ASA indication
793	801	Placebo	no ASA indication	PLN183Y	28.4.22 7:37	2024-11-30	Edoxaban 30mg / no ASA indication
969	801	Placebo	no ASA indication	MSG524H	1.2.19 11:23	2020-01-01	Edoxaban 30mg / no ASA indication
1289	801	Placebo	no ASA indication	CRS657R	17.9.19 10:09	2021-12-31	Edoxaban 60mg / no ASA indication
1289	801	Placebo	no ASA indication	AMG865F	18.9.20 8:38	2021-12-31	Edoxaban 60mg / no ASA indication
1289	801	Placebo	no ASA indication	AFP585Z	27.3.20 9:38	2021-12-31	Edoxaban 60mg / no ASA indication
1397	801	Placebo	no ASA indication	HZT712G	19.11.19 9:25	2022-08-31	Edoxaban 30mg / no ASA indication
1397	801	Placebo	no ASA indication	URK155V	28.5.20 7:53	2022-08-31	Edoxaban 30mg / no ASA indication
1397	801	Placebo	no ASA indication	FAY523N	9.12.21 11:12	2022-08-31	Edoxaban 30mg / no ASA indication
1397	801	Placebo	no ASA indication	RLN117G	16.6.22 7:59	2024-11-30	Edoxaban 30mg / no ASA indication
1397	801	Placebo	no ASA indication	LVX416P	26.11.20 10:35	2022-08-31	Edoxaban 30mg / no ASA indication
1397	801	Placebo	no ASA indication	NXB732Y	4.6.21 8:50	2022-08-31	Edoxaban 30mg / no ASA indication
1398	801	Placebo	no ASA indication	HED224W	4.6.21 9:39	2021-12-31	Edoxaban 60mg / no ASA indication
1398	801	Placebo	no ASA indication	SSC124B	28.5.20 8:30	2021-12-31	Edoxaban 60mg / no ASA indication
1398	801	Placebo	no ASA indication	KCD263Y	27.11.20 9:45	2021-12-31	Edoxaban 60mg / no ASA indication
1398	801	Placebo	no ASA indication	YCD723F	19.11.19 10:07	2021-12-31	Edoxaban 60mg / no ASA indication
1398	801	Placebo	no ASA indication	HNK315A	27.5.22 7:09	2024-04-30	Edoxaban 60mg / no ASA indication
1398	801	Placebo	no ASA indication	ZCM737Y	9.12.21 10:39	2024-04-30	Edoxaban 60mg / no ASA indication
1770	801	Placebo	no ASA indication	DDU197Y	15.3.21 15:49	2021-12-31	Edoxaban 60mg / no ASA indication
1770	801	Placebo	no ASA indication	ERS964Z	11.9.20 7:53	2021-12-31	Edoxaban 60mg / no ASA indication
1770	801	Placebo	no ASA indication	AZW717Z	17.9.21 7:20	2024-04-30	Edoxaban 60mg / no ASA indication
1770	801	Placebo	no ASA indication	AZG681R	11.3.22 8:17	2024-04-30	Edoxaban 60mg / no ASA indication
1809	801	Placebo	no ASA indication	VGT884E	7.10.21 8:17	2022-08-31	Edoxaban 30mg / no ASA indication
1809	801	Placebo	no ASA indication	NPY133X	2.10.20 8:40	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1809	801	Placebo	no ASA indication	NZG347N	29.3.21 6:45	2022-08-31	Edoxaban 30mg / no ASA indication
1810	801	Placebo	no ASA indication	BAN458A	7.10.21 6:37	2024-04-30	Edoxaban 60mg / no ASA indication
1810	801	Placebo	no ASA indication	WVA695A	2.10.20 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
1810	801	Placebo	no ASA indication	CZK932S	29.3.21 6:48	2021-12-31	Edoxaban 60mg / no ASA indication
1810	801	Placebo	no ASA indication	YBF562K	14.4.22 8:26	2024-04-30	Edoxaban 60mg / no ASA indication
2513	801	Placebo	no ASA indication	SEL897E	4.3.22 8:50	2024-11-30	Edoxaban 30mg / no ASA indication
2593	801	Placebo	no ASA indication	SFS191E	22.4.22 8:54	2024-11-30	Edoxaban 30mg / no ASA indication
2744	801	Placebo	no ASA indication	ZCY832N	5.9.22 9:06	2024-04-30	Edoxaban 60mg / no ASA indication
520	801	Edoxaban	ASA indication	BVK575P	15.10.18 9:32	2020-01-01	Edoxaban 30mg / ASA indication
520	801	Edoxaban	ASA indication	LVZ519P	10.4.19 10:21	2020-01-01	Edoxaban 30mg / ASA indication
520	801	Edoxaban	ASA indication	WPM372F	11.4.18 14:12	2020-01-01	Edoxaban 30mg / ASA indication
543	801	Edoxaban	ASA indication	MPH793V	19.11.19 10:35	2021-12-31	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	TGL169U	6.5.20 12:20	2021-12-31	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	VHD842K	2.5.18 13:53	2020-01-01	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	UHT326N	4.3.21 12:44	2021-12-31	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	YRD477V	20.10.21 15:59	2024-04-30	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	FNR588D	29.10.18 13:52	2020-01-01	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	APN315Z	14.5.19 10:00	2020-01-01	Edoxaban 60mg / ASA indication
543	801	Edoxaban	ASA indication	RZU354D	27.10.20 9:25	2021-12-31	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	VGD124Y	11.6.19 6:34	2020-01-01	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	ZNW353L	23.12.21 9:28	2024-04-30	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	FAY635V	17.12.18 10:32	2020-01-01	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	BWX512W	13.12.19 8:38	2021-12-31	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	PPN939C	18.6.20 7:50	2021-12-31	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	SXZ354L	23.6.22 9:22	2024-04-30	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	UGW584R	18.12.20 8:44	2021-12-31	Edoxaban 60mg / ASA indication
895	801	Edoxaban	ASA indication	AYX589Y	18.6.21 8:42	2024-04-30	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	TWE714D	4.2.21 9:27	2021-12-31	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	WZS375V	11.8.22 7:31	2024-04-30	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	BAP549N	12.8.21 7:49	2024-04-30	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	BAN238V	10.2.22 8:47	2024-04-30	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	ASF176Z	21.2.20 10:21	2021-12-31	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	LTB316C	31.7.20 8:42	2021-12-31	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	CRV126F	1.2.19 8:51	2020-01-01	Edoxaban 60mg / ASA indication
968	801	Edoxaban	ASA indication	WSR953Y	13.8.19 10:16	2021-12-31	Edoxaban 60mg / ASA indication
1021	801	Edoxaban	ASA indication	EME173K	13.3.19 10:00	2020-01-01	Edoxaban 60mg / ASA indication
1021	801	Edoxaban	ASA indication	SXF514P	20.3.20 9:27	2021-12-31	Edoxaban 60mg / ASA indication
1021	801	Edoxaban	ASA indication	TZU987F	15.3.21 15:47	2021-12-31	Edoxaban 60mg / ASA indication
1021	801	Edoxaban	ASA indication	XCF797S	17.9.21 7:59	2024-04-30	Edoxaban 60mg / ASA indication
1021	801	Edoxaban	ASA indication	ABN338F	10.9.19 8:50	2021-12-31	Edoxaban 60mg / ASA indication
1021	801	Edoxaban	ASA indication	HEV794B	11.9.20 9:12	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1170	801	Edoxaban	ASA indication	FDV362G	20.12.19 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1170	801	Edoxaban	ASA indication	CWK356K	11.6.21 8:59	2021-12-31	Edoxaban 60mg / ASA indication
1170	801	Edoxaban	ASA indication	ZPS775S	16.12.21 9:48	2024-04-30	Edoxaban 60mg / ASA indication
1170	801	Edoxaban	ASA indication	HKG128R	11.6.20 8:14	2021-12-31	Edoxaban 60mg / ASA indication
1170	801	Edoxaban	ASA indication	AGP192K	18.6.19 6:52	2021-12-31	Edoxaban 60mg / ASA indication
1170	801	Edoxaban	ASA indication	GPU755V	11.12.20 8:52	2021-12-31	Edoxaban 60mg / ASA indication
1170	801	Edoxaban	ASA indication	WVU546P	23.6.22 8:51	2024-04-30	Edoxaban 60mg / ASA indication
1184	801	Edoxaban	ASA indication	PZD879X	18.6.19 11:54	2020-01-01	Edoxaban 30mg / ASA indication
1308	801	Edoxaban	ASA indication	WLM571Y	2.10.20 7:08	2022-08-31	Edoxaban 30mg / ASA indication
1308	801	Edoxaban	ASA indication	LLX658L	29.3.21 6:42	2022-08-31	Edoxaban 30mg / ASA indication
1308	801	Edoxaban	ASA indication	LHW169A	7.10.21 9:28	2022-08-31	Edoxaban 30mg / ASA indication
1308	801	Edoxaban	ASA indication	ZGS386N	27.3.20 10:18	2021-12-31	Edoxaban 60mg / ASA indication
1308	801	Edoxaban	ASA indication	NSP425C	1.10.19 8:08	2021-12-31	Edoxaban 60mg / ASA indication
1308	801	Edoxaban	ASA indication	TXZ688V	14.4.22 7:43	2024-11-30	Edoxaban 30mg / ASA indication
1794	801	Edoxaban	ASA indication	GSD434G	24.3.22 9:24	2024-04-30	Edoxaban 60mg / ASA indication
1794	801	Edoxaban	ASA indication	GPR957P	18.9.20 8:24	2021-12-31	Edoxaban 60mg / ASA indication
1794	801	Edoxaban	ASA indication	XBV294H	30.9.21 8:11	2024-04-30	Edoxaban 60mg / ASA indication
1794	801	Edoxaban	ASA indication	RFR417S	15.3.21 15:51	2021-12-31	Edoxaban 60mg / ASA indication
1800	801	Edoxaban	ASA indication	BAT483X	24.3.22 8:54	2024-04-30	Edoxaban 60mg / ASA indication
1800	801	Edoxaban	ASA indication	CYF843U	15.3.21 15:53	2021-12-31	Edoxaban 60mg / ASA indication
1800	801	Edoxaban	ASA indication	XDR668V	30.9.21 7:39	2024-04-30	Edoxaban 60mg / ASA indication
1800	801	Edoxaban	ASA indication	SAN127C	25.9.20 7:32	2021-12-31	Edoxaban 60mg / ASA indication
2273	801	Edoxaban	ASA indication	EVY277T	16.9.21 7:33	2022-08-31	Edoxaban 30mg / ASA indication
2378	801	Edoxaban	ASA indication	TZD682E	23.6.22 6:55	2024-11-30	Edoxaban 30mg / ASA indication
2378	801	Edoxaban	ASA indication	XVP457Z	3.12.21 8:49	2022-08-31	Edoxaban 30mg / ASA indication
582	801	Edoxaban	no ASA indication	MGF359R	3.12.19 11:58	2022-08-31	Edoxaban 30mg / ASA indication
582	801	Edoxaban	no ASA indication	ZBH965X	6.6.18 14:41	2020-01-01	Edoxaban 30mg / no ASA indication
582	801	Edoxaban	no ASA indication	BLG987U	10.12.18 9:29	2020-01-01	Edoxaban 60mg / no ASA indication
582	801	Edoxaban	no ASA indication	LCM718R	11.12.20 8:22	2022-08-31	Edoxaban 30mg / ASA indication
582	801	Edoxaban	no ASA indication	TTX813Z	11.6.19 8:34	2020-01-01	Edoxaban 60mg / ASA indication
582	801	Edoxaban	no ASA indication	ZEG431V	4.6.20 8:25	2022-08-31	Edoxaban 30mg / ASA indication
582	801	Edoxaban	no ASA indication	URL949W	16.6.22 8:40	2024-11-30	Edoxaban 30mg / no ASA indication
582	801	Edoxaban	no ASA indication	DVU531M	10.6.21 9:37	2022-08-31	Edoxaban 30mg / ASA indication
582	801	Edoxaban	no ASA indication	VCF141U	16.12.21 10:21	2022-08-31	Edoxaban 30mg / ASA indication
594	801	Edoxaban	no ASA indication	PCX219U	3.12.18 9:51	2020-01-01	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	SZU482B	11.12.20 10:13	2021-12-31	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	KRV798S	19.12.19 7:41	2021-12-31	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	UFD579U	16.6.22 6:36	2024-04-30	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	KGU872F	11.6.19 9:49	2020-01-01	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	KKS984S	15.6.18 10:44	2020-01-01	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	VFR375N	10.6.21 8:21	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
594	801	Edoxaban	no ASA indication	APW229V	11.6.20 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
594	801	Edoxaban	no ASA indication	YMR688S	9.12.21 9:14	2024-04-30	Edoxaban 60mg / no ASA indication
639	801	Edoxaban	no ASA indication	XAY381G	25.7.18 13:09	2020-01-01	Edoxaban 60mg / no ASA indication
710	801	Edoxaban	no ASA indication	FYR117R	11.9.20 7:42	2021-12-31	Edoxaban 60mg / no ASA indication
710	801	Edoxaban	no ASA indication	PLZ386Y	15.3.21 15:44	2021-12-31	Edoxaban 60mg / no ASA indication
710	801	Edoxaban	no ASA indication	WTA592K	29.9.21 9:47	2024-04-30	Edoxaban 60mg / no ASA indication
710	801	Edoxaban	no ASA indication	WET755W	10.9.19 7:42	2022-08-31	Edoxaban 30mg / ASA indication
710	801	Edoxaban	no ASA indication	XNY158B	11.3.22 10:38	2024-04-30	Edoxaban 60mg / no ASA indication
710	801	Edoxaban	no ASA indication	YUL431R	17.9.18 11:22	2020-01-01	Edoxaban 30mg / no ASA indication
710	801	Edoxaban	no ASA indication	ZMB165K	13.3.19 7:30	2020-01-01	Edoxaban 60mg / ASA indication
741	801	Edoxaban	no ASA indication	PMZ835A	8.10.18 11:09	2020-01-01	Edoxaban 60mg / no ASA indication
741	801	Edoxaban	no ASA indication	TCU379C	9.10.20 8:38	2021-12-31	Edoxaban 60mg / no ASA indication
741	801	Edoxaban	no ASA indication	VFF697K	16.4.21 6:46	2021-12-31	Edoxaban 60mg / no ASA indication
741	801	Edoxaban	no ASA indication	LXZ765U	15.10.19 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
741	801	Edoxaban	no ASA indication	XXF331K	9.4.20 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
741	801	Edoxaban	no ASA indication	BCF295X	7.10.21 8:53	2024-04-30	Edoxaban 60mg / no ASA indication
741	801	Edoxaban	no ASA indication	DCA593Z	10.4.19 9:07	2020-01-01	Edoxaban 60mg / no ASA indication
1007	801	Edoxaban	no ASA indication	VFA364G	17.9.19 7:26	2021-12-31	Edoxaban 60mg / no ASA indication
1007	801	Edoxaban	no ASA indication	RZB157B	27.2.19 13:24	2020-01-01	Edoxaban 60mg / no ASA indication
1007	801	Edoxaban	no ASA indication	NZL362M	1.9.20 7:22	2021-12-31	Edoxaban 60mg / no ASA indication
1169	801	Edoxaban	no ASA indication	ULD228A	20.12.19 8:51	2021-12-31	Edoxaban 60mg / ASA indication
1169	801	Edoxaban	no ASA indication	GNU372K	11.12.20 9:27	2021-12-31	Edoxaban 60mg / ASA indication
1169	801	Edoxaban	no ASA indication	ABY719C	11.6.19 9:44	2020-01-01	Edoxaban 60mg / no ASA indication
1169	801	Edoxaban	no ASA indication	SFF845M	11.6.20 7:37	2021-12-31	Edoxaban 60mg / ASA indication
1169	801	Edoxaban	no ASA indication	GVN445B	16.6.22 7:12	2024-04-30	Edoxaban 60mg / ASA indication
1169	801	Edoxaban	no ASA indication	GDS565H	11.6.21 9:05	2021-12-31	Edoxaban 60mg / ASA indication
1169	801	Edoxaban	no ASA indication	ZPV145K	9.12.21 10:05	2024-04-30	Edoxaban 60mg / ASA indication
1334	801	Edoxaban	no ASA indication	UYH195V	15.10.19 9:44	2021-12-31	Edoxaban 60mg / no ASA indication
1334	801	Edoxaban	no ASA indication	RRT892L	23.4.20 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1460	801	Edoxaban	no ASA indication	NTT849Y	20.12.19 10:40	2021-12-31	Edoxaban 60mg / no ASA indication
1460	801	Edoxaban	no ASA indication	SUW535U	17.12.20 9:18	2021-12-31	Edoxaban 60mg / no ASA indication
1460	801	Edoxaban	no ASA indication	EAZ521Z	17.12.21 7:43	2022-08-31	Edoxaban 30mg / no ASA indication
1460	801	Edoxaban	no ASA indication	UTY848R	26.6.20 10:38	2021-12-31	Edoxaban 60mg / no ASA indication
1460	801	Edoxaban	no ASA indication	BER428R	18.6.21 8:20	2024-04-30	Edoxaban 60mg / no ASA indication
1460	801	Edoxaban	no ASA indication	TDT367S	23.6.22 8:18	2024-11-30	Edoxaban 30mg / no ASA indication
1772	801	Edoxaban	no ASA indication	FZD628F	11.9.20 9:55	2021-12-31	Edoxaban 60mg / no ASA indication
2247	801	Edoxaban	no ASA indication	URK713V	4.3.22 9:20	2024-11-30	Edoxaban 30mg / no ASA indication
2247	801	Edoxaban	no ASA indication	SAK176F	26.8.21 8:28	2022-08-31	Edoxaban 30mg / no ASA indication
2274	801	Edoxaban	no ASA indication	BFE331A	16.9.21 9:07	2024-04-30	Edoxaban 60mg / no ASA indication
2274	801	Edoxaban	no ASA indication	XPB987W	24.3.22 10:18	2024-04-30	Edoxaban 60mg / no ASA indication
2592	801	Edoxaban	no ASA indication	LAP525V	22.4.22 7:46	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
349	802	Placebo	ASA indication	ZDT568H	27.11.17 10:03	2018-09-01	Edoxaban 30mg / ASA indication
2567	802	Placebo	ASA indication	LNE443W	30.3.22 13:51	2024-04-30	Edoxaban 60mg / ASA indication
629	802	Placebo	no ASA indication	WTL546X	18.7.18 10:34	2020-01-01	Edoxaban 60mg / no ASA indication
629	802	Placebo	no ASA indication	GLD352R	22.1.19 11:31	2020-01-01	Edoxaban 60mg / no ASA indication
629	802	Placebo	no ASA indication	VVF781R	9.7.19 13:29	2021-12-31	Edoxaban 60mg / no ASA indication
2679	802	Placebo	no ASA indication	KED311B	29.6.22 12:33	2024-04-30	Edoxaban 60mg / no ASA indication
1082	802	Edoxaban	ASA indication	GNE926R	15.4.19 11:39	2020-01-01	Edoxaban 60mg / ASA indication
2351	802	Edoxaban	ASA indication	MEG821H	17.11.21 14:21	2024-04-30	Edoxaban 60mg / ASA indication
2351	802	Edoxaban	ASA indication	LVK153W	18.5.22 12:29	2024-04-30	Edoxaban 60mg / ASA indication
705	802	Edoxaban	no ASA indication	BVC684L	18.3.19 12:37	2020-01-01	Edoxaban 60mg / no ASA indication
705	802	Edoxaban	no ASA indication	SEY844S	11.9.19 11:11	2021-12-31	Edoxaban 60mg / no ASA indication
705	802	Edoxaban	no ASA indication	HLN299L	9.3.20 10:45	2021-12-31	Edoxaban 60mg / no ASA indication
705	802	Edoxaban	no ASA indication	CNG894M	12.9.18 11:52	2020-01-01	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	HSV259P	16.9.20 14:30	2021-12-31	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	GGF713X	31.3.22 12:16	2024-04-30	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	XVY422L	19.3.21 14:39	2021-12-31	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	PKP378F	20.3.20 11:05	2021-12-31	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	UEU168D	1.4.19 9:51	2020-01-01	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	GMY592T	22.9.21 13:39	2024-04-30	Edoxaban 60mg / no ASA indication
1047	802	Edoxaban	no ASA indication	ECF336S	30.9.19 10:09	2021-12-31	Edoxaban 60mg / no ASA indication
2070	813	Placebo	ASA indication	MES331L	21.10.21 11:45	2024-04-30	Edoxaban 60mg / ASA indication
2070	813	Placebo	ASA indication	BVY366E	29.4.21 8:57	2021-12-31	Edoxaban 60mg / ASA indication
2074	813	Placebo	ASA indication	LTH634S	21.10.21 12:05	2024-04-30	Edoxaban 60mg / no ASA indication
2074	813	Placebo	ASA indication	LSL788V	28.4.22 11:54	2024-04-30	Edoxaban 60mg / no ASA indication
2074	813	Placebo	ASA indication	AVY468M	29.4.21 10:30	2021-12-31	Edoxaban 60mg / ASA indication
2161	813	Edoxaban	ASA indication	LYE442L	16.12.21 13:39	2024-04-30	Edoxaban 60mg / no ASA indication
2161	813	Edoxaban	ASA indication	BAH535N	17.6.21 12:41	2021-12-31	Edoxaban 60mg / ASA indication
2161	813	Edoxaban	ASA indication	LZU667T	23.6.22 11:41	2024-04-30	Edoxaban 60mg / ASA indication
2073	813	Edoxaban	no ASA indication	FPM486D	29.4.21 9:43	2021-12-31	Edoxaban 60mg / no ASA indication
2073	813	Edoxaban	no ASA indication	LYG558D	21.10.21 11:51	2024-04-30	Edoxaban 60mg / no ASA indication
2073	813	Edoxaban	no ASA indication	LYM965P	4.5.22 7:47	2024-04-30	Edoxaban 60mg / no ASA indication
1387	815	Placebo	ASA indication	HFM418X	27.5.20 9:43	2022-08-31	Edoxaban 30mg / ASA indication
1387	815	Placebo	ASA indication	SYE946U	14.11.19 11:22	2022-08-31	Edoxaban 30mg / ASA indication
1387	815	Placebo	ASA indication	HMT948K	10.11.20 11:33	2022-08-31	Edoxaban 30mg / no ASA indication
1904	815	Placebo	ASA indication	GBS633P	14.12.20 10:23	2022-08-31	Edoxaban 30mg / ASA indication
947	815	Placebo	no ASA indication	KUM213T	22.7.19 8:03	2021-12-31	Edoxaban 60mg / no ASA indication
947	815	Placebo	no ASA indication	SKY435N	22.1.20 9:15	2022-08-31	Edoxaban 30mg / no ASA indication
947	815	Placebo	no ASA indication	XLT437S	22.1.19 12:19	2020-01-01	Edoxaban 60mg / no ASA indication
947	815	Placebo	no ASA indication	NES643F	27.1.21 12:20	2021-12-31	Edoxaban 60mg / no ASA indication
947	815	Placebo	no ASA indication	SWT855R	29.7.20 10:36	2021-12-31	Edoxaban 60mg / no ASA indication
1551	815	Placebo	no ASA indication	TDV539W	18.3.21 9:13	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1551	815	Placebo	no ASA indication	RSN977S	10.9.21 10:27	2022-08-31	Edoxaban 30mg / no ASA indication
1551	815	Placebo	no ASA indication	RMM657U	10.3.20 11:18	2022-08-31	Edoxaban 30mg / no ASA indication
1551	815	Placebo	no ASA indication	ZES971T	7.9.20 11:10	2022-08-31	Edoxaban 30mg / no ASA indication
1812	815	Placebo	no ASA indication	HDV634A	16.4.21 10:30	2022-08-31	Edoxaban 30mg / no ASA indication
1812	815	Placebo	no ASA indication	VLR591D	5.10.20 8:09	2022-08-31	Edoxaban 30mg / no ASA indication
1812	815	Placebo	no ASA indication	RTV233M	11.10.21 9:02	2022-08-31	Edoxaban 30mg / no ASA indication
1486	815	Edoxaban	ASA indication	RML532E	22.7.20 10:27	2021-12-31	Edoxaban 60mg / no ASA indication
1486	815	Edoxaban	ASA indication	VFY563K	22.1.20 9:45	2021-12-31	Edoxaban 60mg / ASA indication
1486	815	Edoxaban	ASA indication	TGG128P	20.1.21 8:47	2021-12-31	Edoxaban 60mg / no ASA indication
1486	815	Edoxaban	ASA indication	LTM771V	27.7.21 7:54	2024-04-30	Edoxaban 60mg / no ASA indication
1486	815	Edoxaban	ASA indication	LUF296L	4.2.22 9:33	2024-04-30	Edoxaban 60mg / no ASA indication
1486	815	Edoxaban	ASA indication	PHW431H	21.7.22 8:34	2024-04-30	Edoxaban 60mg / no ASA indication
1896	815	Edoxaban	ASA indication	ZAH884W	9.12.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1896	815	Edoxaban	ASA indication	VTE456E	13.12.21 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
1896	815	Edoxaban	ASA indication	VTC584Y	23.6.22 13:57	2024-04-30	Edoxaban 60mg / no ASA indication
1896	815	Edoxaban	ASA indication	LVW677D	22.6.21 8:40	2024-04-30	Edoxaban 60mg / no ASA indication
2526	815	Edoxaban	ASA indication	LUX875U	9.3.22 13:32	2024-04-30	Edoxaban 60mg / ASA indication
986	815	Edoxaban	no ASA indication	SAE364P	12.2.19 11:57	2020-01-01	Edoxaban 30mg / no ASA indication
1429	815	Edoxaban	no ASA indication	DDY372E	4.12.19 9:38	2021-12-31	Edoxaban 60mg / no ASA indication
1895	815	Edoxaban	no ASA indication	ENZ959H	9.12.20 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
2200	815	Edoxaban	no ASA indication	DFT327N	21.7.21 9:32	2022-08-31	Edoxaban 30mg / no ASA indication
2290	824	Placebo	ASA indication	NBM993D	29.9.21 10:42	2024-04-30	Edoxaban 60mg / ASA indication
2290	824	Placebo	ASA indication	VZR248L	24.3.22 13:41	2024-04-30	Edoxaban 60mg / ASA indication
1473	824	Placebo	no ASA indication	NWC219G	5.1.22 12:06	2024-04-30	Edoxaban 60mg / no ASA indication
1473	824	Placebo	no ASA indication	GYS999X	12.1.21 15:30	2021-12-31	Edoxaban 60mg / no ASA indication
1473	824	Placebo	no ASA indication	RRB865V	30.7.20 11:15	2021-12-31	Edoxaban 60mg / no ASA indication
1473	824	Placebo	no ASA indication	RWZ244M	14.1.20 15:27	2021-12-31	Edoxaban 60mg / no ASA indication
1473	824	Placebo	no ASA indication	NVK467L	9.8.22 11:55	2024-04-30	Edoxaban 60mg / no ASA indication
1473	824	Placebo	no ASA indication	KUA118L	20.7.21 10:58	2024-04-30	Edoxaban 60mg / no ASA indication
1497	824	Placebo	no ASA indication	KTV242Z	13.7.21 11:35	2024-04-30	Edoxaban 60mg / no ASA indication
1497	824	Placebo	no ASA indication	NLW747S	29.1.20 15:15	2021-12-31	Edoxaban 60mg / no ASA indication
1497	824	Placebo	no ASA indication	KXB768N	9.2.21 14:55	2021-12-31	Edoxaban 60mg / no ASA indication
1497	824	Placebo	no ASA indication	HAL365E	30.7.20 11:17	2021-12-31	Edoxaban 60mg / no ASA indication
2002	824	Edoxaban	ASA indication	VBS761R	10.3.21 15:05	2021-12-31	Edoxaban 60mg / ASA indication
2010	824	Edoxaban	ASA indication	GSE845Y	9.9.21 12:47	2024-04-30	Edoxaban 60mg / no ASA indication
2010	824	Edoxaban	ASA indication	WMD672E	16.3.21 13:14	2021-12-31	Edoxaban 60mg / ASA indication
2627	824	Edoxaban	ASA indication	MGA421H	25.5.22 9:17	2024-04-30	Edoxaban 60mg / ASA indication
2423	824	Edoxaban	no ASA indication	GPM514G	11.1.22 13:25	2024-04-30	Edoxaban 60mg / no ASA indication
2423	824	Edoxaban	no ASA indication	GYM799T	20.7.22 13:57	2024-04-30	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	YNZ624U	24.6.19 6:31	2021-12-31	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	MWW768H	10.1.20 13:24	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
892	826	Placebo	no ASA indication	UNL696R	18.12.20 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	SDY296D	11.6.21 7:41	2021-12-31	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	KBL335W	10.12.21 8:22	2024-04-30	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	DPU488F	19.6.20 7:42	2021-12-31	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	DEZ535A	14.12.18 11:34	2020-01-01	Edoxaban 60mg / no ASA indication
892	826	Placebo	no ASA indication	KEZ499F	17.6.22 8:30	2024-04-30	Edoxaban 60mg / no ASA indication
1425	826	Placebo	no ASA indication	KDL275Y	7.12.21 11:11	2024-04-30	Edoxaban 60mg / no ASA indication
1425	826	Placebo	no ASA indication	SDV398C	8.6.21 10:08	2021-12-31	Edoxaban 60mg / no ASA indication
1425	826	Placebo	no ASA indication	FPT353X	4.12.20 12:08	2021-12-31	Edoxaban 60mg / no ASA indication
1425	826	Placebo	no ASA indication	GCR185T	29.5.20 7:40	2021-12-31	Edoxaban 60mg / no ASA indication
1425	826	Placebo	no ASA indication	DTC893C	17.6.22 9:00	2024-11-30	Edoxaban 30mg / no ASA indication
1425	826	Placebo	no ASA indication	GCH844B	2.12.19 13:26	2021-12-31	Edoxaban 60mg / no ASA indication
476	826	Edoxaban	ASA indication	HSW295Y	9.3.18 12:42	2020-01-01	Edoxaban 60mg / ASA indication
476	826	Edoxaban	ASA indication	YCN783N	8.3.19 11:22	2020-01-01	Edoxaban 60mg / no ASA indication
476	826	Edoxaban	ASA indication	WNB858V	19.9.19 7:57	2021-12-31	Edoxaban 60mg / no ASA indication
476	826	Edoxaban	ASA indication	MVT127Y	7.9.18 11:54	2020-01-01	Edoxaban 60mg / ASA indication
2738	826	Edoxaban	no ASA indication	KAW757Y	19.8.22 10:08	2024-04-30	Edoxaban 60mg / no ASA indication
724	827	Placebo	ASA indication	NRD697W	17.10.19 8:08	2021-12-31	Edoxaban 60mg / no ASA indication
724	827	Placebo	ASA indication	WXF793A	13.11.19 10:50	2021-12-31	Edoxaban 60mg / ASA indication
724	827	Placebo	ASA indication	KVK425K	21.4.20 12:26	2021-12-31	Edoxaban 60mg / ASA indication
724	827	Placebo	ASA indication	TTK671D	5.10.21 6:24	2024-04-30	Edoxaban 60mg / no ASA indication
724	827	Placebo	ASA indication	CKL359T	9.4.19 12:15	2020-01-01	Edoxaban 60mg / ASA indication
724	827	Placebo	ASA indication	SSR548E	13.4.21 8:31	2021-12-31	Edoxaban 60mg / no ASA indication
724	827	Placebo	ASA indication	SKL367A	27.9.18 11:09	2020-01-01	Edoxaban 60mg / ASA indication
724	827	Placebo	ASA indication	BVZ327D	27.10.20 13:34	2021-12-31	Edoxaban 60mg / no ASA indication
724	827	Placebo	ASA indication	TSM385A	5.4.22 7:29	2024-04-30	Edoxaban 60mg / no ASA indication
770	827	Placebo	ASA indication	VPF784G	28.5.19 8:36	2020-01-01	Edoxaban 60mg / ASA indication
770	827	Placebo	ASA indication	XPW667Z	21.11.18 14:10	2020-01-01	Edoxaban 60mg / ASA indication
770	827	Placebo	ASA indication	NCP174M	19.5.21 10:52	2021-12-31	Edoxaban 60mg / no ASA indication
770	827	Placebo	ASA indication	HTC236B	27.5.20 7:28	2021-12-31	Edoxaban 60mg / ASA indication
770	827	Placebo	ASA indication	VEY476N	24.11.20 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
770	827	Placebo	ASA indication	XAG724W	27.11.19 8:30	2021-12-31	Edoxaban 60mg / ASA indication
764	827	Edoxaban	ASA indication	SLY445C	24.10.18 6:39	2020-01-01	Edoxaban 60mg / ASA indication
764	827	Edoxaban	ASA indication	WYH594Y	12.4.19 11:51	2020-01-01	Edoxaban 60mg / ASA indication
764	827	Edoxaban	ASA indication	RNC735R	15.10.19 11:36	2021-12-31	Edoxaban 60mg / ASA indication
764	827	Edoxaban	ASA indication	SVU299C	8.4.20 7:59	2021-12-31	Edoxaban 60mg / ASA indication
764	827	Edoxaban	ASA indication	GTD272A	20.10.20 12:29	2021-12-31	Edoxaban 60mg / no ASA indication
807	827	Edoxaban	ASA indication	ZPM359G	24.5.19 12:11	2020-01-01	Edoxaban 30mg / ASA indication
807	827	Edoxaban	ASA indication	BWA814V	22.11.19 12:45	2022-08-31	Edoxaban 30mg / ASA indication
807	827	Edoxaban	ASA indication	NYH572N	12.11.18 8:00	2020-01-01	Edoxaban 30mg / ASA indication
1011	828	Placebo	ASA indication	EKK741A	27.8.20 8:49	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1011	828	Placebo	ASA indication	HXW774Y	1.3.21 8:27	2022-08-31	Edoxaban 30mg / ASA indication
1011	828	Placebo	ASA indication	WWK573D	30.8.19 7:51	2022-08-31	Edoxaban 30mg / ASA indication
1011	828	Placebo	ASA indication	CZH875L	1.9.21 8:59	2022-08-31	Edoxaban 30mg / no ASA indication
1011	828	Placebo	ASA indication	PKG995A	26.2.20 12:48	2022-08-31	Edoxaban 30mg / no ASA indication
1011	828	Placebo	ASA indication	WEX443U	1.3.19 9:07	2020-01-01	Edoxaban 30mg / ASA indication
987	833	Placebo	ASA indication	HNZ524R	28.1.20 13:06	2021-12-31	Edoxaban 60mg / ASA indication
987	833	Placebo	ASA indication	XBW524Y	12.2.19 14:30	2020-01-01	Edoxaban 60mg / ASA indication
987	833	Placebo	ASA indication	YPP583E	30.7.19 11:54	2021-12-31	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	DGF667V	21.7.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	ACK386R	16.7.19 10:22	2021-12-31	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	ZXA529G	14.1.20 13:05	2021-12-31	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	FEC729B	12.7.22 13:04	2024-04-30	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	TCK841X	20.7.21 8:54	2024-04-30	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	TBR399F	25.1.22 13:20	2024-04-30	Edoxaban 60mg / ASA indication
1224	833	Placebo	ASA indication	DCK521P	11.5.21 12:25	2021-12-31	Edoxaban 60mg / ASA indication
1290	833	Placebo	ASA indication	KWH695T	17.3.20 12:53	2021-12-31	Edoxaban 60mg / ASA indication
1290	833	Placebo	ASA indication	ZCT969A	15.9.20 13:18	2021-12-31	Edoxaban 60mg / no ASA indication
1290	833	Placebo	ASA indication	BEH867A	17.9.19 14:24	2021-12-31	Edoxaban 60mg / ASA indication
1290	833	Placebo	ASA indication	NGF218U	7.9.21 12:45	2022-08-31	Edoxaban 30mg / ASA indication
1290	833	Placebo	ASA indication	FHX155Y	15.3.22 10:00	2024-11-30	Edoxaban 30mg / ASA indication
1290	833	Placebo	ASA indication	DLU867S	23.3.21 13:57	2021-12-31	Edoxaban 60mg / ASA indication
2239	833	Placebo	ASA indication	VMA543L	24.8.21 12:25	2024-04-30	Edoxaban 60mg / ASA indication
2239	833	Placebo	ASA indication	MGA735W	22.2.22 13:41	2024-04-30	Edoxaban 60mg / ASA indication
2239	833	Placebo	ASA indication	TSH343X	16.8.22 8:30	2024-04-30	Edoxaban 60mg / ASA indication
2382	833	Placebo	ASA indication	TAE698Y	7.12.21 9:15	2024-04-30	Edoxaban 60mg / ASA indication
2382	833	Placebo	ASA indication	TUW743B	14.6.22 12:08	2024-04-30	Edoxaban 60mg / no ASA indication
2458	833	Placebo	ASA indication	BYU465M	1.2.22 9:43	2022-08-31	Edoxaban 30mg / ASA indication
2458	833	Placebo	ASA indication	FNT154S	19.7.22 8:28	2024-11-30	Edoxaban 30mg / ASA indication
626	833	Edoxaban	ASA indication	LTX274B	15.1.19 13:23	2020-01-01	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	UBA341W	18.1.22 9:00	2024-04-30	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	UBA132E	20.7.21 8:24	2024-04-30	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	VCH335K	2.7.19 7:06	2021-12-31	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	NYP567X	7.1.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	GPS726M	12.7.18 8:47	2020-01-01	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	WAL849C	12.7.22 12:30	2024-04-30	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	CLL332N	12.1.21 8:38	2021-12-31	Edoxaban 60mg / ASA indication
626	833	Edoxaban	ASA indication	BCW523P	21.7.20 8:51	2021-12-31	Edoxaban 60mg / ASA indication
976	833	Edoxaban	ASA indication	KRE293M	30.7.19 14:37	2022-08-31	Edoxaban 30mg / ASA indication
976	833	Edoxaban	ASA indication	LXR936Y	28.1.20 13:33	2022-08-31	Edoxaban 30mg / ASA indication
976	833	Edoxaban	ASA indication	MPN183N	5.2.19 10:12	2020-01-01	Edoxaban 60mg / ASA indication
1277	833	Edoxaban	ASA indication	LXE691X	10.9.19 8:23	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1277	833	Edoxaban	ASA indication	CUY827S	15.9.20 13:13	2021-12-31	Edoxaban 60mg / ASA indication
1277	833	Edoxaban	ASA indication	DGW957X	10.3.20 8:56	2021-12-31	Edoxaban 60mg / ASA indication
1637	833	Edoxaban	ASA indication	FZU918C	16.6.20 13:33	2021-12-31	Edoxaban 60mg / ASA indication
1923	833	Edoxaban	ASA indication	UAV224K	13.7.21 12:57	2024-04-30	Edoxaban 60mg / ASA indication
1923	833	Edoxaban	ASA indication	WAV339V	11.1.22 14:19	2024-04-30	Edoxaban 60mg / ASA indication
1923	833	Edoxaban	ASA indication	LZM891L	12.1.21 10:48	2021-12-31	Edoxaban 60mg / ASA indication
1923	833	Edoxaban	ASA indication	KMF731T	19.7.22 7:50	2024-04-30	Edoxaban 60mg / ASA indication
2242	833	Edoxaban	no ASA indication	TMV146K	24.8.21 13:14	2024-04-30	Edoxaban 60mg / no ASA indication
2242	833	Edoxaban	no ASA indication	EMX161Y	16.8.22 8:03	2024-04-30	Edoxaban 60mg / no ASA indication
2242	833	Edoxaban	no ASA indication	TMX443T	22.2.22 14:01	2024-04-30	Edoxaban 60mg / no ASA indication
2361	833	Edoxaban	no ASA indication	TLY456K	23.11.21 8:57	2024-04-30	Edoxaban 60mg / no ASA indication
2361	833	Edoxaban	no ASA indication	ELF736U	31.5.22 7:50	2024-04-30	Edoxaban 60mg / no ASA indication
795	836	Placebo	no ASA indication	XZT549A	5.11.18 12:54	2020-01-01	Edoxaban 60mg / no ASA indication
795	836	Placebo	no ASA indication	XSZ771B	24.4.19 12:32	2020-01-01	Edoxaban 60mg / no ASA indication
795	836	Placebo	no ASA indication	LCV837H	23.10.19 11:43	2021-12-31	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	TRL186K	20.5.20 10:53	2021-12-31	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	ZMT451N	4.5.22 10:28	2024-04-30	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	RKA954M	4.11.20 11:55	2021-12-31	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	MFF966K	6.5.19 9:44	2020-01-01	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	GFY238Z	11.11.19 12:33	2021-12-31	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	SMU336B	12.11.18 13:45	2020-01-01	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	FPA974X	5.5.21 11:27	2021-12-31	Edoxaban 60mg / no ASA indication
814	836	Placebo	no ASA indication	XTW561F	3.11.21 13:25	2024-04-30	Edoxaban 60mg / no ASA indication
819	836	Placebo	no ASA indication	BFY278E	21.11.18 18:57	2020-01-01	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	HPE913Z	20.2.19 13:01	2020-01-01	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	PNT437L	17.2.21 11:54	2021-12-31	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	KCK482H	26.2.20 13:03	2021-12-31	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	KBH278T	22.2.22 12:44	2024-04-30	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	MLR124W	4.9.19 11:42	2021-12-31	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	MZX334R	26.8.20 11:52	2021-12-31	Edoxaban 60mg / no ASA indication
997	836	Placebo	no ASA indication	VRA229M	18.8.21 11:41	2024-04-30	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	HYL264U	28.4.21 14:32	2021-12-31	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	XTW557Y	14.10.20 11:54	2021-12-31	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	WYH475U	6.5.20 11:34	2021-12-31	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	FBF581K	6.11.19 12:25	2021-12-31	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	PCU749U	3.11.21 12:50	2024-04-30	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	AWB193S	27.4.22 10:40	2024-04-30	Edoxaban 60mg / no ASA indication
1103	836	Placebo	no ASA indication	ERE485B	3.5.19 9:15	2020-01-01	Edoxaban 60mg / no ASA indication
1151	836	Placebo	no ASA indication	NDY222T	27.11.19 12:52	2021-12-31	Edoxaban 60mg / no ASA indication
1151	836	Placebo	no ASA indication	DBC843U	27.5.20 12:02	2021-12-31	Edoxaban 60mg / no ASA indication
1151	836	Placebo	no ASA indication	MUY753C	29.5.19 12:12	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1151	836	Placebo	no ASA indication	AVD464Z	17.11.21 13:47	2024-04-30	Edoxaban 60mg / no ASA indication
1151	836	Placebo	no ASA indication	UVZ882M	26.5.21 11:10	2021-12-31	Edoxaban 60mg / no ASA indication
1151	836	Placebo	no ASA indication	ZRZ921P	18.5.22 10:47	2024-04-30	Edoxaban 60mg / no ASA indication
1151	836	Placebo	no ASA indication	GSW613D	25.11.20 12:26	2021-12-31	Edoxaban 60mg / no ASA indication
1489	836	Placebo	no ASA indication	PCF612T	7.7.21 11:40	2024-04-30	Edoxaban 60mg / no ASA indication
1489	836	Placebo	no ASA indication	PUT624A	13.1.21 12:30	2021-12-31	Edoxaban 60mg / no ASA indication
1489	836	Placebo	no ASA indication	ZYK989N	20.7.22 12:10	2024-04-30	Edoxaban 60mg / no ASA indication
1489	836	Placebo	no ASA indication	UZY686K	15.7.20 10:55	2021-12-31	Edoxaban 60mg / no ASA indication
1489	836	Placebo	no ASA indication	BDZ625X	5.1.22 13:06	2024-04-30	Edoxaban 60mg / no ASA indication
1489	836	Placebo	no ASA indication	DKL339A	22.1.20 13:14	2021-12-31	Edoxaban 60mg / no ASA indication
1840	836	Placebo	no ASA indication	PAM812T	20.10.21 11:56	2024-04-30	Edoxaban 60mg / no ASA indication
1840	836	Placebo	no ASA indication	RHG478M	28.10.20 12:44	2021-12-31	Edoxaban 60mg / no ASA indication
1840	836	Placebo	no ASA indication	GSB934L	21.4.21 11:32	2021-12-31	Edoxaban 60mg / no ASA indication
1840	836	Placebo	no ASA indication	TET153U	19.4.22 10:49	2024-04-30	Edoxaban 60mg / no ASA indication
2546	836	Placebo	no ASA indication	HYM484Z	21.3.22 11:47	2024-04-30	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	WXL689Z	6.5.20 11:11	2021-12-31	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	SZW864W	27.4.22 12:09	2024-04-30	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	WFC153K	7.11.18 12:56	2020-01-01	Edoxaban 60mg / ASA indication
802	836	Edoxaban	ASA indication	XEM677N	3.11.21 12:31	2024-04-30	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	SDF196X	23.10.19 12:25	2021-12-31	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	UUZ448H	4.11.20 12:56	2021-12-31	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	DHA617M	28.4.21 12:09	2021-12-31	Edoxaban 60mg / no ASA indication
802	836	Edoxaban	ASA indication	RVX582U	24.4.19 13:00	2020-01-01	Edoxaban 60mg / no ASA indication
849	836	Edoxaban	no ASA indication	MCB833K	27.5.20 13:31	2021-12-31	Edoxaban 60mg / no ASA indication
849	836	Edoxaban	no ASA indication	FDS726Z	15.5.19 11:03	2020-01-01	Edoxaban 60mg / no ASA indication
849	836	Edoxaban	no ASA indication	ARA249M	20.11.19 13:29	2022-08-31	Edoxaban 30mg / no ASA indication
849	836	Edoxaban	no ASA indication	UMS171Z	28.11.18 12:56	2020-01-01	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	TVM394C	10.7.19 12:43	2021-12-31	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	CMG297D	5.1.22 12:24	2024-04-30	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	NZT675B	7.7.21 10:22	2024-04-30	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	UWU162U	13.1.21 12:48	2021-12-31	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	CXL126B	15.7.20 11:51	2021-12-31	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	ZRL762B	20.7.22 11:50	2024-04-30	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	ZEZ782B	15.1.20 13:01	2021-12-31	Edoxaban 60mg / no ASA indication
938	836	Edoxaban	no ASA indication	VBZ811N	16.1.19 13:16	2020-01-01	Edoxaban 60mg / no ASA indication
951	836	Edoxaban	no ASA indication	DCY341E	17.7.19 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
951	836	Edoxaban	no ASA indication	KDP323K	14.7.21 11:02	2022-08-31	Edoxaban 30mg / no ASA indication
951	836	Edoxaban	no ASA indication	LAE483B	20.1.21 12:27	2021-12-31	Edoxaban 60mg / no ASA indication
951	836	Edoxaban	no ASA indication	YKV725T	15.7.20 11:21	2022-08-31	Edoxaban 30mg / no ASA indication
951	836	Edoxaban	no ASA indication	DNZ666D	1.8.22 11:35	2024-11-30	Edoxaban 30mg / no ASA indication
951	836	Edoxaban	no ASA indication	EMY843D	19.1.22 12:01	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
951	836	Edoxaban	no ASA indication	NCD953U	23.1.19 12:58	2020-01-01	Edoxaban 30mg / no ASA indication
951	836	Edoxaban	no ASA indication	DCZ525Z	15.1.20 12:08	2021-12-31	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	YSU557Y	7.9.22 11:41	2024-04-30	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	MPK993U	13.3.19 12:31	2020-01-01	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	LKA862A	2.3.22 12:27	2024-04-30	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	CPA387Z	4.3.20 12:42	2021-12-31	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	TTX785G	10.3.21 12:21	2021-12-31	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	NRW637X	11.9.19 11:30	2021-12-31	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	KYZ219P	16.9.20 12:06	2021-12-31	Edoxaban 60mg / no ASA indication
1022	836	Edoxaban	no ASA indication	VUM792T	8.9.21 14:02	2024-04-30	Edoxaban 60mg / no ASA indication
1298	836	Edoxaban	no ASA indication	DNN671V	8.4.20 11:34	2021-12-31	Edoxaban 60mg / no ASA indication
1298	836	Edoxaban	no ASA indication	TLW475M	16.9.20 11:26	2021-12-31	Edoxaban 60mg / no ASA indication
1298	836	Edoxaban	no ASA indication	SXY756H	23.3.22 12:34	2024-04-30	Edoxaban 60mg / no ASA indication
1298	836	Edoxaban	no ASA indication	CSR764L	24.3.21 13:20	2021-12-31	Edoxaban 60mg / no ASA indication
1298	836	Edoxaban	no ASA indication	MSD975F	25.9.19 11:42	2021-12-31	Edoxaban 60mg / no ASA indication
1298	836	Edoxaban	no ASA indication	VUE287B	22.9.21 11:54	2024-04-30	Edoxaban 60mg / no ASA indication
1996	836	Edoxaban	no ASA indication	PLR761T	3.3.21 12:46	2021-12-31	Edoxaban 60mg / no ASA indication
2001	836	Edoxaban	no ASA indication	ULN513B	10.3.21 13:47	2021-12-31	Edoxaban 60mg / no ASA indication
2188	836	Edoxaban	no ASA indication	NZL778H	14.7.21 14:42	2024-04-30	Edoxaban 60mg / no ASA indication
2188	836	Edoxaban	no ASA indication	LNX631L	19.1.22 12:45	2024-04-30	Edoxaban 60mg / no ASA indication
2188	836	Edoxaban	no ASA indication	AHH547B	27.7.22 11:29	2024-04-30	Edoxaban 60mg / no ASA indication
2329	836	Edoxaban	no ASA indication	YSH174G	4.5.22 11:15	2024-04-30	Edoxaban 60mg / no ASA indication
2329	836	Edoxaban	no ASA indication	NZK596X	8.11.21 10:53	2024-04-30	Edoxaban 60mg / no ASA indication
2364	836	Edoxaban	no ASA indication	XGN518M	24.11.21 12:16	2024-04-30	Edoxaban 60mg / no ASA indication
1876	857	Placebo	ASA indication	PCA326N	1.6.21 8:30	2021-12-31	Edoxaban 60mg / ASA indication
1876	857	Placebo	ASA indication	GEW892G	20.5.22 9:20	2024-11-30	Edoxaban 30mg / ASA indication
1876	857	Placebo	ASA indication	TMZ511U	4.11.21 9:51	2024-04-30	Edoxaban 60mg / ASA indication
1876	857	Placebo	ASA indication	PPB512S	20.11.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
1957	857	Placebo	ASA indication	GKC255T	11.2.21 13:28	2022-08-31	Edoxaban 30mg / ASA indication
1830	857	Placebo	no ASA indication	SMF516F	19.4.21 10:09	2021-12-31	Edoxaban 60mg / no ASA indication
1830	857	Placebo	no ASA indication	UGG181H	18.10.21 13:41	2024-04-30	Edoxaban 60mg / no ASA indication
1830	857	Placebo	no ASA indication	SRN575D	20.10.20 8:10	2021-12-31	Edoxaban 60mg / no ASA indication
1853	857	Placebo	no ASA indication	FDK561G	6.11.20 9:19	2022-08-31	Edoxaban 30mg / no ASA indication
1835	857	Edoxaban	ASA indication	NRC155F	21.10.20 8:48	2021-12-31	Edoxaban 60mg / ASA indication
2006	857	Edoxaban	ASA indication	NPU556X	12.3.21 8:43	2021-12-31	Edoxaban 60mg / ASA indication
2465	862	Edoxaban	no ASA indication	WAY299P	3.2.22 8:05	2024-04-30	Edoxaban 60mg / no ASA indication
2465	862	Edoxaban	no ASA indication	WAA214Y	10.8.22 9:38	2024-04-30	Edoxaban 60mg / no ASA indication
677	866	Placebo	ASA indication	STY369D	26.2.19 12:59	2020-01-01	Edoxaban 60mg / ASA indication
677	866	Placebo	ASA indication	BTT973L	16.3.21 11:12	2022-08-31	Edoxaban 30mg / ASA indication
677	866	Placebo	ASA indication	AFH384K	31.8.20 10:23	2022-08-31	Edoxaban 30mg / ASA indication
677	866	Placebo	ASA indication	CZF779H	26.3.20 12:17	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
677	866	Placebo	ASA indication	EGP818F	17.3.22 13:26	2024-11-30	Edoxaban 30mg / ASA indication
677	866	Placebo	ASA indication	MBW374X	19.8.22 11:11	2024-11-30	Edoxaban 30mg / ASA indication
677	866	Placebo	ASA indication	EFX244C	30.8.21 13:22	2022-08-31	Edoxaban 30mg / ASA indication
677	866	Placebo	ASA indication	VGH796U	17.8.18 11:23	2020-01-01	Edoxaban 60mg / ASA indication
677	866	Placebo	ASA indication	LXV881F	14.9.19 9:13	2021-12-31	Edoxaban 60mg / no ASA indication
742	866	Placebo	ASA indication	RKX337A	18.10.19 11:20	2021-12-31	Edoxaban 60mg / no ASA indication
742	866	Placebo	ASA indication	SLU225F	5.4.19 11:01	2020-01-01	Edoxaban 60mg / no ASA indication
742	866	Placebo	ASA indication	TMB989H	8.10.18 11:46	2020-01-01	Edoxaban 60mg / ASA indication
750	866	Placebo	ASA indication	UUH657K	15.4.19 8:16	2020-01-01	Edoxaban 60mg / no ASA indication
750	866	Placebo	ASA indication	UBT384S	12.10.18 9:42	2020-01-01	Edoxaban 60mg / ASA indication
791	866	Placebo	ASA indication	SAU969N	6.5.19 6:35	2020-01-01	Edoxaban 60mg / no ASA indication
791	866	Placebo	ASA indication	LNV698V	2.11.18 13:58	2020-01-01	Edoxaban 60mg / ASA indication
809	866	Placebo	ASA indication	HKE176R	23.5.19 9:32	2020-01-01	Edoxaban 30mg / no ASA indication
809	866	Placebo	ASA indication	LVZ134U	2.6.22 12:19	2024-11-30	Edoxaban 30mg / ASA indication
809	866	Placebo	ASA indication	TWF597V	28.11.19 11:12	2022-08-31	Edoxaban 30mg / ASA indication
809	866	Placebo	ASA indication	NLD315X	12.11.18 7:26	2020-01-01	Edoxaban 30mg / ASA indication
809	866	Placebo	ASA indication	FLH965X	4.12.21 7:17	2022-08-31	Edoxaban 30mg / ASA indication
809	866	Placebo	ASA indication	XFL587X	29.5.20 9:43	2022-08-31	Edoxaban 30mg / ASA indication
809	866	Placebo	ASA indication	DCL876F	28.5.21 8:21	2022-08-31	Edoxaban 30mg / ASA indication
809	866	Placebo	ASA indication	NAB244W	2.12.20 10:27	2022-08-31	Edoxaban 30mg / ASA indication
885	866	Placebo	ASA indication	NDC146N	11.12.18 13:04	2020-01-01	Edoxaban 60mg / ASA indication
885	866	Placebo	ASA indication	PLC237L	13.6.19 10:41	2020-01-01	Edoxaban 60mg / ASA indication
1149	866	Placebo	ASA indication	HZC977T	27.11.19 11:48	2022-08-31	Edoxaban 30mg / ASA indication
1149	866	Placebo	ASA indication	SNG659K	20.5.20 10:30	2022-08-31	Edoxaban 30mg / ASA indication
1149	866	Placebo	ASA indication	KRF961M	28.5.19 11:35	2020-01-01	Edoxaban 30mg / ASA indication
2026	866	Placebo	ASA indication	AAS984X	5.10.21 10:21	2024-04-30	Edoxaban 60mg / ASA indication
2026	866	Placebo	ASA indication	KYD927A	24.3.22 9:39	2024-04-30	Edoxaban 60mg / ASA indication
2026	866	Placebo	ASA indication	HNB515V	24.3.21 13:04	2021-12-31	Edoxaban 60mg / ASA indication
2107	866	Placebo	ASA indication	LRB363A	18.5.21 12:10	2021-12-31	Edoxaban 60mg / ASA indication
2107	866	Placebo	ASA indication	ANR335D	25.5.22 7:57	2024-04-30	Edoxaban 60mg / ASA indication
2107	866	Placebo	ASA indication	HRL582V	17.12.21 7:53	2024-04-30	Edoxaban 60mg / ASA indication
2110	866	Placebo	ASA indication	GAE499S	17.12.21 8:16	2022-08-31	Edoxaban 30mg / ASA indication
2110	866	Placebo	ASA indication	FST942S	1.7.22 7:37	2024-11-30	Edoxaban 30mg / no ASA indication
2110	866	Placebo	ASA indication	CTK186F	19.5.21 12:48	2022-08-31	Edoxaban 30mg / ASA indication
2302	866	Placebo	ASA indication	DDF828D	8.10.21 6:13	2022-08-31	Edoxaban 30mg / ASA indication
2302	866	Placebo	ASA indication	EWK297A	14.4.22 12:43	2024-11-30	Edoxaban 30mg / ASA indication
767	866	Edoxaban	ASA indication	NHY569P	4.11.19 7:28	2021-12-31	Edoxaban 60mg / ASA indication
767	866	Edoxaban	ASA indication	PXR982C	9.11.20 8:57	2021-12-31	Edoxaban 60mg / ASA indication
767	866	Edoxaban	ASA indication	FDS993E	20.5.20 9:55	2021-12-31	Edoxaban 60mg / ASA indication
767	866	Edoxaban	ASA indication	WCG175X	24.10.18 11:15	2020-01-01	Edoxaban 60mg / ASA indication
767	866	Edoxaban	ASA indication	AAB441F	26.4.19 11:12	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
775	866	Edoxaban	ASA indication	KLD423L	12.5.20 9:42	2022-08-31	Edoxaban 30mg / ASA indication
775	866	Edoxaban	ASA indication	LHE674T	25.11.19 10:39	2021-12-31	Edoxaban 60mg / ASA indication
775	866	Edoxaban	ASA indication	DPA535U	26.10.18 8:33	2020-01-01	Edoxaban 60mg / ASA indication
775	866	Edoxaban	ASA indication	PXP446Z	26.4.19 7:27	2020-01-01	Edoxaban 60mg / no ASA indication
788	866	Edoxaban	ASA indication	NXR621B	13.5.19 14:13	2020-01-01	Edoxaban 60mg / no ASA indication
788	866	Edoxaban	ASA indication	AHU258Z	2.11.18 9:03	2020-01-01	Edoxaban 60mg / ASA indication
952	866	Edoxaban	ASA indication	TGU729Z	12.11.19 9:40	2021-12-31	Edoxaban 60mg / ASA indication
952	866	Edoxaban	ASA indication	ZUA816U	5.5.20 8:20	2021-12-31	Edoxaban 60mg / ASA indication
952	866	Edoxaban	ASA indication	RFX812D	25.4.19 12:39	2020-01-01	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	NYD693T	18.2.20 15:02	2021-12-31	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	BKB667E	27.8.20 10:40	2021-12-31	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	AAL484E	19.8.21 13:37	2024-04-30	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	HBA733Y	24.1.19 13:14	2020-01-01	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	NKY966G	18.8.22 12:20	2024-04-30	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	CZA747M	24.2.21 15:38	2021-12-31	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	FUF472N	2.8.19 9:58	2021-12-31	Edoxaban 60mg / ASA indication
953	866	Edoxaban	ASA indication	FTB446B	4.2.22 11:10	2024-04-30	Edoxaban 60mg / ASA indication
1100	866	Edoxaban	ASA indication	UVR175P	4.12.19 10:52	2022-08-31	Edoxaban 30mg / ASA indication
1100	866	Edoxaban	ASA indication	BVD939C	10.6.20 10:15	2022-08-31	Edoxaban 30mg / ASA indication
1100	866	Edoxaban	ASA indication	CGK437M	27.11.20 8:58	2022-08-31	Edoxaban 30mg / ASA indication
1100	866	Edoxaban	ASA indication	NAB988K	2.5.19 12:38	2020-01-01	Edoxaban 30mg / ASA indication
1106	866	Edoxaban	ASA indication	CXH364P	4.11.19 11:54	2022-08-31	Edoxaban 30mg / ASA indication
1106	866	Edoxaban	ASA indication	EXZ754R	4.11.20 11:22	2022-08-31	Edoxaban 30mg / ASA indication
1106	866	Edoxaban	ASA indication	CSR325H	4.5.19 6:25	2020-01-01	Edoxaban 30mg / ASA indication
1106	866	Edoxaban	ASA indication	FNB384S	4.5.20 8:59	2022-08-31	Edoxaban 30mg / no ASA indication
1106	866	Edoxaban	ASA indication	CVR935V	11.5.21 6:37	2022-08-31	Edoxaban 30mg / ASA indication
1196	866	Edoxaban	ASA indication	BWU631N	21.6.19 11:22	2021-12-31	Edoxaban 60mg / ASA indication
1715	866	Edoxaban	ASA indication	GRA775H	18.2.21 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1715	866	Edoxaban	ASA indication	ACK917C	13.8.21 12:51	2024-04-30	Edoxaban 60mg / ASA indication
1715	866	Edoxaban	ASA indication	GGB954R	19.8.22 7:50	2024-11-30	Edoxaban 30mg / ASA indication
1715	866	Edoxaban	ASA indication	MEL348C	18.2.22 11:19	2024-04-30	Edoxaban 60mg / ASA indication
1715	866	Edoxaban	ASA indication	MZT828Y	31.7.20 10:36	2021-12-31	Edoxaban 60mg / ASA indication
2257	866	Edoxaban	ASA indication	MFK242E	16.3.22 11:23	2024-04-30	Edoxaban 60mg / ASA indication
2257	866	Edoxaban	ASA indication	FXD485B	7.9.21 6:49	2024-04-30	Edoxaban 60mg / ASA indication
2374	866	Edoxaban	ASA indication	ACS987X	1.12.21 13:19	2024-04-30	Edoxaban 60mg / ASA indication
2374	866	Edoxaban	ASA indication	NRY354N	2.6.22 7:22	2024-04-30	Edoxaban 60mg / ASA indication
2404	866	Edoxaban	ASA indication	LFH244Y	21.12.21 13:08	2024-04-30	Edoxaban 60mg / ASA indication
2404	866	Edoxaban	ASA indication	MUM719D	30.6.22 6:20	2024-04-30	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	YRN747G	1.2.19 11:59	2020-01-01	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	AFE623U	19.7.19 14:01	2021-12-31	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	FDE368P	15.1.21 8:07	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
630	868	Placebo	ASA indication	AXR885A	12.7.21 6:05	2024-04-30	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	PZE442E	24.6.20 7:35	2021-12-31	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	REP492U	18.7.18 9:33	2020-01-01	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	PLP681M	22.1.20 9:30	2021-12-31	Edoxaban 60mg / ASA indication
630	868	Placebo	ASA indication	PVG629F	19.1.22 13:16	2024-04-30	Edoxaban 60mg / no ASA indication
665	868	Placebo	ASA indication	FEB995B	16.8.18 8:47	2020-01-01	Edoxaban 60mg / ASA indication
665	868	Placebo	ASA indication	HAA176Z	11.2.20 12:42	2021-12-31	Edoxaban 60mg / ASA indication
665	868	Placebo	ASA indication	CNM198D	15.3.19 13:52	2020-01-01	Edoxaban 60mg / ASA indication
665	868	Placebo	ASA indication	VLS595L	26.9.19 14:01	2021-12-31	Edoxaban 60mg / ASA indication
734	868	Placebo	ASA indication	LXT648V	15.11.21 13:36	2024-04-30	Edoxaban 60mg / no ASA indication
734	868	Placebo	ASA indication	CNX348D	4.10.18 10:49	2020-01-01	Edoxaban 60mg / no ASA indication
734	868	Placebo	ASA indication	DNH716R	7.11.18 8:17	2020-01-01	Edoxaban 60mg / ASA indication
734	868	Placebo	ASA indication	CRA962P	7.10.20 13:30	2021-12-31	Edoxaban 60mg / ASA indication
734	868	Placebo	ASA indication	VVK692S	12.4.19 6:13	2020-01-01	Edoxaban 60mg / no ASA indication
734	868	Placebo	ASA indication	UHK692A	17.5.22 12:27	2024-04-30	Edoxaban 60mg / no ASA indication
734	868	Placebo	ASA indication	SHN383P	27.3.20 11:28	2021-12-31	Edoxaban 60mg / ASA indication
734	868	Placebo	ASA indication	LMN948U	2.10.19 12:47	2021-12-31	Edoxaban 60mg / ASA indication
734	868	Placebo	ASA indication	GEG561Z	15.4.21 6:28	2021-12-31	Edoxaban 60mg / no ASA indication
825	868	Placebo	ASA indication	BGY457S	26.6.20 11:39	2021-12-31	Edoxaban 60mg / ASA indication
825	868	Placebo	ASA indication	EEW424A	29.5.19 8:24	2020-01-01	Edoxaban 60mg / ASA indication
825	868	Placebo	ASA indication	UHF211X	10.6.22 17:29	2024-04-30	Edoxaban 60mg / no ASA indication
825	868	Placebo	ASA indication	VZK159M	16.11.18 12:32	2020-01-01	Edoxaban 30mg / ASA indication
825	868	Placebo	ASA indication	TTN752E	27.1.21 12:00	2021-12-31	Edoxaban 60mg / no ASA indication
825	868	Placebo	ASA indication	UWD177L	11.11.19 13:24	2021-12-31	Edoxaban 60mg / ASA indication
825	868	Placebo	ASA indication	KAA932N	5.1.22 8:30	2024-04-30	Edoxaban 60mg / no ASA indication
825	868	Placebo	ASA indication	KGD679Z	2.6.21 13:38	2021-12-31	Edoxaban 60mg / no ASA indication
965	868	Placebo	ASA indication	LTK739S	7.8.19 16:27	2022-08-31	Edoxaban 30mg / ASA indication
965	868	Placebo	ASA indication	AXL926S	4.8.20 13:22	2021-12-31	Edoxaban 60mg / ASA indication
965	868	Placebo	ASA indication	NTY694E	31.1.19 10:18	2020-01-01	Edoxaban 30mg / ASA indication
965	868	Placebo	ASA indication	GUR894H	10.8.21 6:10	2024-04-30	Edoxaban 60mg / no ASA indication
965	868	Placebo	ASA indication	PNW864H	12.2.20 7:16	2021-12-31	Edoxaban 60mg / ASA indication
965	868	Placebo	ASA indication	GBP829G	4.2.21 17:25	2021-12-31	Edoxaban 60mg / no ASA indication
1315	868	Placebo	ASA indication	REK395M	20.11.20 8:56	2022-08-31	Edoxaban 30mg / no ASA indication
1315	868	Placebo	ASA indication	CRZ355E	2.4.20 7:10	2022-08-31	Edoxaban 30mg / ASA indication
1315	868	Placebo	ASA indication	WKP198S	7.10.19 11:59	2022-08-31	Edoxaban 30mg / ASA indication
1315	868	Placebo	ASA indication	HDM871U	22.10.21 14:46	2024-04-30	Edoxaban 60mg / no ASA indication
1315	868	Placebo	ASA indication	GFL563T	28.4.21 16:31	2021-12-31	Edoxaban 60mg / no ASA indication
1669	868	Placebo	ASA indication	EYF274M	8.2.21 15:23	2021-12-31	Edoxaban 60mg / no ASA indication
1669	868	Placebo	ASA indication	KXX456S	30.6.20 11:54	2021-12-31	Edoxaban 60mg / ASA indication
1669	868	Placebo	ASA indication	MYG996Z	13.1.22 7:51	2024-04-30	Edoxaban 60mg / no ASA indication
1669	868	Placebo	ASA indication	AWZ199G	12.7.21 10:14	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
701	868	Placebo	no ASA indication	DHE519H	27.9.19 9:51	2021-12-31	Edoxaban 60mg / ASA indication
701	868	Placebo	no ASA indication	TML734F	7.10.20 13:34	2021-12-31	Edoxaban 60mg / no ASA indication
701	868	Placebo	no ASA indication	ZHF388C	26.3.20 13:41	2021-12-31	Edoxaban 60mg / ASA indication
701	868	Placebo	no ASA indication	SSZ191U	5.4.19 13:44	2020-01-01	Edoxaban 60mg / no ASA indication
701	868	Placebo	no ASA indication	KSW933C	10.9.18 15:02	2020-01-01	Edoxaban 60mg / no ASA indication
899	868	Placebo	no ASA indication	TYH553S	19.7.19 9:42	2021-12-31	Edoxaban 60mg / ASA indication
899	868	Placebo	no ASA indication	WPV817L	15.1.20 11:25	2021-12-31	Edoxaban 60mg / ASA indication
899	868	Placebo	no ASA indication	BLP627N	4.8.20 15:08	2021-12-31	Edoxaban 60mg / ASA indication
899	868	Placebo	no ASA indication	HXA661V	4.1.22 15:55	2024-04-30	Edoxaban 60mg / no ASA indication
899	868	Placebo	no ASA indication	AWG193A	10.8.21 6:00	2024-04-30	Edoxaban 60mg / no ASA indication
899	868	Placebo	no ASA indication	VAX187C	18.12.18 10:56	2020-01-01	Edoxaban 60mg / no ASA indication
899	868	Placebo	no ASA indication	CKZ437T	15.1.21 7:47	2021-12-31	Edoxaban 60mg / ASA indication
924	868	Placebo	no ASA indication	ASL187R	26.7.21 11:57	2024-04-30	Edoxaban 60mg / no ASA indication
924	868	Placebo	no ASA indication	PTN372E	17.1.22 13:38	2024-04-30	Edoxaban 60mg / no ASA indication
924	868	Placebo	no ASA indication	BPM378N	16.7.20 13:04	2021-12-31	Edoxaban 60mg / ASA indication
924	868	Placebo	no ASA indication	PDV189M	8.1.19 10:31	2020-01-01	Edoxaban 30mg / no ASA indication
924	868	Placebo	no ASA indication	PRY742G	19.7.19 9:51	2021-12-31	Edoxaban 60mg / ASA indication
924	868	Placebo	no ASA indication	UGT528N	29.8.22 16:29	2024-04-30	Edoxaban 60mg / no ASA indication
924	868	Placebo	no ASA indication	AYA712T	4.2.21 17:17	2021-12-31	Edoxaban 60mg / ASA indication
924	868	Placebo	no ASA indication	PXT721L	12.2.20 7:30	2021-12-31	Edoxaban 60mg / ASA indication
1431	868	Placebo	no ASA indication	UDA276M	5.12.19 7:50	2021-12-31	Edoxaban 60mg / no ASA indication
754	868	Edoxaban	ASA indication	AKM376E	25.4.19 9:01	2020-01-01	Edoxaban 60mg / ASA indication
754	868	Edoxaban	ASA indication	AUY833M	27.3.20 11:31	2021-12-31	Edoxaban 60mg / ASA indication
754	868	Edoxaban	ASA indication	BKS152V	22.4.21 11:03	2021-12-31	Edoxaban 60mg / no ASA indication
754	868	Edoxaban	ASA indication	BFW318D	9.10.19 14:01	2021-12-31	Edoxaban 60mg / ASA indication
754	868	Edoxaban	ASA indication	TRB476D	17.10.18 9:29	2020-01-01	Edoxaban 60mg / ASA indication
754	868	Edoxaban	ASA indication	AME566B	20.11.20 8:34	2021-12-31	Edoxaban 60mg / ASA indication
754	868	Edoxaban	ASA indication	AWT366H	12.11.21 15:00	2024-04-30	Edoxaban 60mg / no ASA indication
798	868	Edoxaban	ASA indication	UZE723X	6.11.18 13:06	2020-01-01	Edoxaban 60mg / ASA indication
798	868	Edoxaban	ASA indication	MMW699A	29.5.19 8:17	2020-01-01	Edoxaban 60mg / ASA indication
798	868	Edoxaban	ASA indication	URK554E	18.6.20 13:33	2021-12-31	Edoxaban 60mg / ASA indication
798	868	Edoxaban	ASA indication	HTR616P	14.11.19 10:52	2021-12-31	Edoxaban 60mg / ASA indication
798	868	Edoxaban	ASA indication	CFH283C	12.1.21 15:19	2021-12-31	Edoxaban 60mg / no ASA indication
800	868	Edoxaban	ASA indication	DYH434W	8.5.19 8:37	2020-01-01	Edoxaban 30mg / ASA indication
800	868	Edoxaban	ASA indication	ZPV495H	18.6.20 13:36	2022-08-31	Edoxaban 30mg / ASA indication
800	868	Edoxaban	ASA indication	FSW155A	2.6.21 13:33	2022-08-31	Edoxaban 30mg / no ASA indication
800	868	Edoxaban	ASA indication	FLF492N	4.1.22 15:51	2022-08-31	Edoxaban 30mg / no ASA indication
800	868	Edoxaban	ASA indication	XZX661K	12.1.21 15:14	2022-08-31	Edoxaban 30mg / no ASA indication
800	868	Edoxaban	ASA indication	KYD246F	7.11.18 9:11	2020-01-01	Edoxaban 30mg / ASA indication
800	868	Edoxaban	ASA indication	YHF282X	21.11.19 14:58	2022-08-31	Edoxaban 30mg / ASA indication
897	868	Edoxaban	ASA indication	GRU145T	18.12.18 10:16	2020-01-01	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
897	868	Edoxaban	ASA indication	AVZ336Z	2.7.21 14:26	2024-04-30	Edoxaban 60mg / ASA indication
897	868	Edoxaban	ASA indication	GHG728D	1.7.20 10:23	2021-12-31	Edoxaban 60mg / ASA indication
897	868	Edoxaban	ASA indication	BAE218X	5.12.19 8:03	2021-12-31	Edoxaban 60mg / ASA indication
897	868	Edoxaban	ASA indication	RDV865Z	19.7.19 9:38	2021-12-31	Edoxaban 60mg / ASA indication
897	868	Edoxaban	ASA indication	KNR871F	3.2.22 14:49	2024-04-30	Edoxaban 60mg / no ASA indication
897	868	Edoxaban	ASA indication	BHN654X	7.12.20 18:18	2021-12-31	Edoxaban 60mg / ASA indication
923	868	Edoxaban	ASA indication	ABL181E	8.1.19 10:26	2020-01-01	Edoxaban 60mg / ASA indication
923	868	Edoxaban	ASA indication	HRR274S	27.1.21 12:03	2021-12-31	Edoxaban 60mg / ASA indication
923	868	Edoxaban	ASA indication	ESC612S	19.7.19 9:46	2021-12-31	Edoxaban 60mg / ASA indication
923	868	Edoxaban	ASA indication	AZN816S	2.7.21 14:39	2024-04-30	Edoxaban 60mg / no ASA indication
923	868	Edoxaban	ASA indication	APV789X	14.7.20 14:08	2021-12-31	Edoxaban 60mg / ASA indication
923	868	Edoxaban	ASA indication	WZH112R	15.1.20 11:30	2021-12-31	Edoxaban 60mg / ASA indication
923	868	Edoxaban	ASA indication	KKU273X	19.1.22 13:19	2024-04-30	Edoxaban 60mg / no ASA indication
967	868	Edoxaban	ASA indication	GCF292P	31.1.19 16:18	2020-01-01	Edoxaban 30mg / ASA indication
967	868	Edoxaban	ASA indication	HAW969B	10.2.20 7:39	2022-08-31	Edoxaban 30mg / ASA indication
967	868	Edoxaban	ASA indication	XEG962W	10.2.21 11:37	2022-08-31	Edoxaban 30mg / no ASA indication
967	868	Edoxaban	ASA indication	HRE764F	14.4.22 12:51	2024-11-30	Edoxaban 30mg / no ASA indication
967	868	Edoxaban	ASA indication	ACX852C	4.8.20 12:54	2022-08-31	Edoxaban 30mg / ASA indication
967	868	Edoxaban	ASA indication	LTY797P	31.8.21 16:59	2022-08-31	Edoxaban 30mg / no ASA indication
967	868	Edoxaban	ASA indication	HXP295P	19.8.19 14:13	2022-08-31	Edoxaban 30mg / ASA indication
2098	868	Edoxaban	ASA indication	HMM373A	3.12.21 11:16	2024-04-30	Edoxaban 60mg / no ASA indication
2098	868	Edoxaban	ASA indication	HSP528M	13.5.21 14:50	2021-12-31	Edoxaban 60mg / ASA indication
645	868	Edoxaban	no ASA indication	FCP691T	15.3.19 9:40	2020-01-01	Edoxaban 60mg / ASA indication
645	868	Edoxaban	no ASA indication	APP751H	3.3.20 13:25	2021-12-31	Edoxaban 60mg / ASA indication
645	868	Edoxaban	no ASA indication	KHT674N	17.3.21 11:50	2021-12-31	Edoxaban 60mg / no ASA indication
645	868	Edoxaban	no ASA indication	RSY847K	26.9.19 13:53	2021-12-31	Edoxaban 60mg / ASA indication
645	868	Edoxaban	no ASA indication	FEM791A	21.10.21 13:49	2024-04-30	Edoxaban 60mg / no ASA indication
645	868	Edoxaban	no ASA indication	LRX993K	4.9.20 8:48	2021-12-31	Edoxaban 60mg / no ASA indication
645	868	Edoxaban	no ASA indication	KZG514W	7.9.18 7:21	2020-01-01	Edoxaban 60mg / no ASA indication
759	868	Edoxaban	no ASA indication	EFS851W	22.10.21 14:49	2024-04-30	Edoxaban 60mg / no ASA indication
759	868	Edoxaban	no ASA indication	PPD647F	27.3.20 11:47	2021-12-31	Edoxaban 60mg / no ASA indication
759	868	Edoxaban	no ASA indication	AXB224U	20.11.20 8:28	2021-12-31	Edoxaban 60mg / ASA indication
759	868	Edoxaban	no ASA indication	AKX471L	19.10.18 10:52	2020-01-01	Edoxaban 60mg / no ASA indication
759	868	Edoxaban	no ASA indication	BAT786L	8.5.19 8:31	2020-01-01	Edoxaban 60mg / ASA indication
759	868	Edoxaban	no ASA indication	ZUX356E	6.11.19 8:08	2021-12-31	Edoxaban 60mg / ASA indication
759	868	Edoxaban	no ASA indication	LDM732A	28.4.21 16:24	2021-12-31	Edoxaban 60mg / ASA indication
982	868	Edoxaban	no ASA indication	CMW253U	23.8.19 14:52	2022-08-31	Edoxaban 30mg / ASA indication
982	868	Edoxaban	no ASA indication	GTE514H	20.2.20 15:23	2022-08-31	Edoxaban 30mg / ASA indication
982	868	Edoxaban	no ASA indication	FBH853Z	22.2.21 15:05	2022-08-31	Edoxaban 30mg / no ASA indication
982	868	Edoxaban	no ASA indication	DAE426E	31.8.21 17:04	2022-08-31	Edoxaban 30mg / ASA indication
982	868	Edoxaban	no ASA indication	ADX293S	7.8.20 14:22	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
982	868	Edoxaban	no ASA indication	FBB834C	8.2.19 15:27	2020-01-01	Edoxaban 30mg / no ASA indication
982	868	Edoxaban	no ASA indication	FHS423D	18.3.22 9:48	2024-11-30	Edoxaban 30mg / ASA indication
1228	868	Edoxaban	no ASA indication	WWW275U	19.6.20 10:04	2021-12-31	Edoxaban 60mg / ASA indication
1228	868	Edoxaban	no ASA indication	AZN283C	26.7.21 12:04	2024-04-30	Edoxaban 60mg / no ASA indication
1228	868	Edoxaban	no ASA indication	NBH483N	22.1.20 9:21	2021-12-31	Edoxaban 60mg / ASA indication
1228	868	Edoxaban	no ASA indication	KAR498A	19.7.19 12:06	2021-12-31	Edoxaban 60mg / no ASA indication
1228	868	Edoxaban	no ASA indication	GRY848K	8.2.21 15:12	2021-12-31	Edoxaban 60mg / no ASA indication
1228	868	Edoxaban	no ASA indication	BBW626M	18.3.22 9:45	2024-04-30	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	BAX789S	9.8.21 7:56	2024-04-30	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	VWX384V	10.2.20 8:15	2021-12-31	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	ZBC752B	7.2.19 8:47	2020-01-01	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	KUV621G	9.2.22 7:38	2024-04-30	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	BFZ616U	11.8.20 6:44	2021-12-31	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	LZS785N	12.8.22 8:00	2024-04-30	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	FMR275K	10.2.21 8:31	2021-12-31	Edoxaban 60mg / ASA indication
980	869	Placebo	ASA indication	REC126T	22.8.19 6:58	2021-12-31	Edoxaban 60mg / ASA indication
1261	869	Placebo	ASA indication	KUV864Z	25.2.22 9:09	2024-04-30	Edoxaban 60mg / ASA indication
1261	869	Placebo	ASA indication	DAE195Y	21.8.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1261	869	Placebo	ASA indication	XKK633P	27.8.19 9:54	2021-12-31	Edoxaban 60mg / ASA indication
1261	869	Placebo	ASA indication	FBN565T	25.8.22 8:01	2024-11-30	Edoxaban 30mg / ASA indication
1261	869	Placebo	ASA indication	HGC878Y	26.2.21 9:29	2021-12-31	Edoxaban 60mg / ASA indication
1261	869	Placebo	ASA indication	FVG574U	3.9.21 8:12	2024-04-30	Edoxaban 60mg / ASA indication
1261	869	Placebo	ASA indication	AUX232S	12.3.20 6:56	2021-12-31	Edoxaban 60mg / ASA indication
1355	869	Placebo	ASA indication	FLK585L	29.4.21 8:37	2021-12-31	Edoxaban 60mg / ASA indication
1355	869	Placebo	ASA indication	MXC351E	28.4.22 8:35	2024-04-30	Edoxaban 60mg / ASA indication
1355	869	Placebo	ASA indication	HFU174M	5.6.20 7:44	2021-12-31	Edoxaban 60mg / ASA indication
1355	869	Placebo	ASA indication	FMV813X	4.11.21 9:19	2024-04-30	Edoxaban 60mg / ASA indication
1355	869	Placebo	ASA indication	MZA347A	28.10.19 10:31	2021-12-31	Edoxaban 60mg / ASA indication
1355	869	Placebo	ASA indication	EFM235G	30.10.20 9:37	2021-12-31	Edoxaban 60mg / ASA indication
1717	869	Placebo	ASA indication	BEL631D	9.8.21 8:06	2024-04-30	Edoxaban 60mg / ASA indication
1717	869	Placebo	ASA indication	PMV194Z	3.8.20 8:47	2021-12-31	Edoxaban 60mg / ASA indication
1717	869	Placebo	ASA indication	DKA913D	10.2.21 9:23	2021-12-31	Edoxaban 60mg / ASA indication
1867	869	Placebo	ASA indication	LNZ573G	19.5.21 8:26	2021-12-31	Edoxaban 60mg / ASA indication
1867	869	Placebo	ASA indication	HUK378U	26.11.21 10:47	2024-04-30	Edoxaban 60mg / ASA indication
1867	869	Placebo	ASA indication	EGG947A	16.11.20 10:08	2021-12-31	Edoxaban 60mg / ASA indication
1867	869	Placebo	ASA indication	LXF487M	18.5.22 9:08	2024-04-30	Edoxaban 60mg / ASA indication
2008	869	Placebo	ASA indication	BLD856H	12.3.21 10:53	2022-08-31	Edoxaban 30mg / ASA indication
780	869	Placebo	no ASA indication	BEM275X	29.10.19 9:05	2022-08-31	Edoxaban 30mg / ASA indication
780	869	Placebo	no ASA indication	NYZ927W	29.10.18 9:15	2020-01-01	Edoxaban 30mg / no ASA indication
780	869	Placebo	no ASA indication	FYT856T	3.5.19 6:46	2020-01-01	Edoxaban 30mg / ASA indication
823	869	Placebo	no ASA indication	FNG456X	15.11.18 11:34	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
823	869	Placebo	no ASA indication	WFP719Y	13.5.20 8:03	2022-08-31	Edoxaban 30mg / no ASA indication
823	869	Placebo	no ASA indication	DLW648L	14.11.19 8:11	2021-12-31	Edoxaban 60mg / no ASA indication
823	869	Placebo	no ASA indication	NEN286K	20.5.19 7:14	2020-01-01	Edoxaban 60mg / no ASA indication
1180	869	Placebo	no ASA indication	MVY121C	16.6.21 10:12	2022-08-31	Edoxaban 30mg / ASA indication
1180	869	Placebo	no ASA indication	MVK748T	16.6.22 8:28	2024-04-30	Edoxaban 60mg / ASA indication
1180	869	Placebo	no ASA indication	RVH415W	13.6.19 9:26	2020-01-01	Edoxaban 60mg / no ASA indication
1180	869	Placebo	no ASA indication	UZV248Y	25.6.20 8:16	2021-12-31	Edoxaban 60mg / ASA indication
1180	869	Placebo	no ASA indication	EFS467E	15.12.20 9:12	2021-12-31	Edoxaban 60mg / ASA indication
1180	869	Placebo	no ASA indication	LXF374L	21.1.20 7:39	2021-12-31	Edoxaban 60mg / ASA indication
1180	869	Placebo	no ASA indication	HUT611Y	16.12.21 9:12	2024-04-30	Edoxaban 60mg / ASA indication
1311	869	Placebo	no ASA indication	GNN968G	29.4.20 10:31	2021-12-31	Edoxaban 60mg / ASA indication
1311	869	Placebo	no ASA indication	KYB384K	1.4.21 9:07	2021-12-31	Edoxaban 60mg / ASA indication
1311	869	Placebo	no ASA indication	EAH778H	13.10.20 8:18	2021-12-31	Edoxaban 60mg / ASA indication
1311	869	Placebo	no ASA indication	DPW176H	3.10.19 9:20	2021-12-31	Edoxaban 60mg / no ASA indication
1360	869	Placebo	no ASA indication	HNT488E	30.10.19 11:00	2021-12-31	Edoxaban 60mg / no ASA indication
1360	869	Placebo	no ASA indication	BFT861U	3.11.20 8:13	2021-12-31	Edoxaban 60mg / ASA indication
1360	869	Placebo	no ASA indication	HFY215Y	2.11.21 8:57	2024-04-30	Edoxaban 60mg / ASA indication
1360	869	Placebo	no ASA indication	NHF271G	6.5.22 7:49	2024-04-30	Edoxaban 60mg / ASA indication
1360	869	Placebo	no ASA indication	HMA796W	29.4.21 7:53	2021-12-31	Edoxaban 60mg / ASA indication
1360	869	Placebo	no ASA indication	AYU521Y	30.4.20 9:02	2021-12-31	Edoxaban 60mg / ASA indication
1276	869	Edoxaban	ASA indication	VCF996T	19.10.20 8:39	2022-08-31	Edoxaban 30mg / ASA indication
1276	869	Edoxaban	ASA indication	HUU298A	10.3.20 11:17	2021-12-31	Edoxaban 60mg / ASA indication
1276	869	Edoxaban	ASA indication	RDU289H	9.9.19 9:27	2021-12-31	Edoxaban 60mg / ASA indication
1390	869	Edoxaban	ASA indication	FTU883W	15.11.19 7:45	2021-12-31	Edoxaban 60mg / ASA indication
1465	869	Edoxaban	ASA indication	AVA292D	15.6.20 10:19	2021-12-31	Edoxaban 60mg / ASA indication
1465	869	Edoxaban	ASA indication	GRP963M	11.1.22 11:08	2024-04-30	Edoxaban 60mg / ASA indication
1465	869	Edoxaban	ASA indication	PRR223G	30.6.22 8:46	2024-04-30	Edoxaban 60mg / ASA indication
1465	869	Edoxaban	ASA indication	CSY663W	28.12.20 13:08	2022-08-31	Edoxaban 30mg / ASA indication
1465	869	Edoxaban	ASA indication	FGE744B	15.9.21 8:30	2024-04-30	Edoxaban 60mg / ASA indication
1465	869	Edoxaban	ASA indication	HTU518G	27.12.19 11:17	2021-12-31	Edoxaban 60mg / ASA indication
1558	869	Edoxaban	ASA indication	CVX472R	11.3.21 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1558	869	Edoxaban	ASA indication	XAN434Y	12.3.20 15:31	2021-12-31	Edoxaban 60mg / ASA indication
1558	869	Edoxaban	ASA indication	MEE955P	15.3.22 7:48	2024-04-30	Edoxaban 60mg / ASA indication
1558	869	Edoxaban	ASA indication	BHB295H	17.9.20 6:39	2021-12-31	Edoxaban 60mg / ASA indication
1558	869	Edoxaban	ASA indication	BHD299Z	17.9.21 7:05	2024-04-30	Edoxaban 60mg / ASA indication
1970	869	Edoxaban	ASA indication	LNW293F	19.2.21 10:17	2021-12-31	Edoxaban 60mg / ASA indication
1970	869	Edoxaban	ASA indication	FKF193N	16.9.21 6:24	2024-04-30	Edoxaban 60mg / ASA indication
2208	869	Edoxaban	ASA indication	BKB989C	28.7.21 11:54	2024-04-30	Edoxaban 60mg / ASA indication
683	869	Edoxaban	no ASA indication	FDN536D	22.8.18 8:02	2020-01-01	Edoxaban 60mg / no ASA indication
683	869	Edoxaban	no ASA indication	ZRU743L	25.2.20 9:03	2021-12-31	Edoxaban 60mg / ASA indication
683	869	Edoxaban	no ASA indication	LBS596G	11.9.19 6:42	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
683	869	Edoxaban	no ASA indication	ZYT111T	21.8.20 8:28	2021-12-31	Edoxaban 60mg / ASA indication
683	869	Edoxaban	no ASA indication	FRV366A	27.2.19 8:25	2020-01-01	Edoxaban 60mg / ASA indication
683	869	Edoxaban	no ASA indication	DGH165F	12.3.21 9:43	2022-08-31	Edoxaban 30mg / ASA indication
730	869	Edoxaban	no ASA indication	TXM922C	6.10.20 6:03	2021-12-31	Edoxaban 60mg / no ASA indication
730	869	Edoxaban	no ASA indication	AHG799E	17.4.20 7:32	2021-12-31	Edoxaban 60mg / no ASA indication
730	869	Edoxaban	no ASA indication	MFB537F	9.4.19 6:31	2020-01-01	Edoxaban 60mg / no ASA indication
730	869	Edoxaban	no ASA indication	RTB466L	25.9.19 11:05	2021-12-31	Edoxaban 60mg / no ASA indication
730	869	Edoxaban	no ASA indication	RSY721V	1.4.21 8:01	2021-12-31	Edoxaban 60mg / no ASA indication
730	869	Edoxaban	no ASA indication	VAU183R	2.10.18 9:02	2020-01-01	Edoxaban 60mg / no ASA indication
1104	869	Edoxaban	no ASA indication	AYH514G	28.4.20 8:16	2021-12-31	Edoxaban 60mg / ASA indication
1104	869	Edoxaban	no ASA indication	YZD147E	11.5.21 10:24	2021-12-31	Edoxaban 60mg / no ASA indication
1104	869	Edoxaban	no ASA indication	AUH424T	4.11.19 11:35	2021-12-31	Edoxaban 60mg / ASA indication
1104	869	Edoxaban	no ASA indication	PVR438W	3.5.19 10:25	2020-01-01	Edoxaban 30mg / no ASA indication
1104	869	Edoxaban	no ASA indication	NZW564P	24.5.22 9:50	2024-04-30	Edoxaban 60mg / ASA indication
1104	869	Edoxaban	no ASA indication	DHZ146R	13.11.20 10:04	2021-12-31	Edoxaban 60mg / ASA indication
1104	869	Edoxaban	no ASA indication	GTL268L	9.11.21 9:27	2024-04-30	Edoxaban 60mg / ASA indication
1279	869	Edoxaban	no ASA indication	GRV341A	18.9.20 7:28	2022-08-31	Edoxaban 30mg / ASA indication
1279	869	Edoxaban	no ASA indication	DSD255A	16.9.21 6:51	2022-08-31	Edoxaban 30mg / ASA indication
1279	869	Edoxaban	no ASA indication	KHR585M	11.9.19 8:55	2021-12-31	Edoxaban 60mg / no ASA indication
1279	869	Edoxaban	no ASA indication	GLC887B	10.3.22 7:33	2024-11-30	Edoxaban 30mg / ASA indication
1279	869	Edoxaban	no ASA indication	CPM418Z	11.3.21 7:39	2022-08-31	Edoxaban 30mg / ASA indication
1279	869	Edoxaban	no ASA indication	WSM958L	12.3.20 8:09	2022-08-31	Edoxaban 30mg / no ASA indication
1481	869	Edoxaban	no ASA indication	MXB589A	20.1.20 9:29	2021-12-31	Edoxaban 60mg / no ASA indication
1481	869	Edoxaban	no ASA indication	BFA836U	20.7.21 7:34	2024-04-30	Edoxaban 60mg / ASA indication
1481	869	Edoxaban	no ASA indication	GHC536L	21.7.20 10:11	2021-12-31	Edoxaban 60mg / ASA indication
1481	869	Edoxaban	no ASA indication	KBW617L	26.1.21 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1481	869	Edoxaban	no ASA indication	LGH138G	31.1.22 8:55	2024-04-30	Edoxaban 60mg / ASA indication
850	870	Placebo	ASA indication	FKP176X	28.11.18 13:49	2020-01-01	Edoxaban 30mg / ASA indication
1028	870	Placebo	ASA indication	VYA291V	8.5.20 10:29	2021-12-31	Edoxaban 60mg / ASA indication
1028	870	Placebo	ASA indication	KUA327G	18.3.19 11:00	2020-01-01	Edoxaban 60mg / ASA indication
1028	870	Placebo	ASA indication	KKV746K	12.4.21 11:58	2021-12-31	Edoxaban 60mg / ASA indication
1028	870	Placebo	ASA indication	MRM274T	2.10.19 7:43	2021-12-31	Edoxaban 60mg / ASA indication
1028	870	Placebo	ASA indication	DUS392V	29.9.20 6:42	2021-12-31	Edoxaban 60mg / ASA indication
1030	870	Placebo	ASA indication	HRE757D	11.3.20 7:28	2021-12-31	Edoxaban 60mg / ASA indication
1030	870	Placebo	ASA indication	DYS833B	16.9.20 6:41	2021-12-31	Edoxaban 60mg / ASA indication
1030	870	Placebo	ASA indication	XTK717S	12.9.19 7:05	2021-12-31	Edoxaban 60mg / ASA indication
1030	870	Placebo	ASA indication	PWR344U	19.3.19 14:32	2020-01-01	Edoxaban 60mg / ASA indication
1073	870	Placebo	ASA indication	XRM359C	9.10.19 7:48	2021-12-31	Edoxaban 60mg / ASA indication
1073	870	Placebo	ASA indication	FER731E	10.4.19 10:47	2020-01-01	Edoxaban 60mg / ASA indication
1073	870	Placebo	ASA indication	FXZ976H	7.10.20 7:14	2021-12-31	Edoxaban 60mg / no ASA indication
1073	870	Placebo	ASA indication	VED714E	14.4.20 6:59	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1073	870	Placebo	ASA indication	KUD554Y	26.5.21 11:18	2021-12-31	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	KLR734W	20.11.19 8:10	2021-12-31	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	GXP685U	4.5.20 6:40	2021-12-31	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	LCL564L	15.5.21 7:20	2021-12-31	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	HSH679Y	20.11.21 7:31	2024-04-30	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	CZZ248V	13.11.20 7:31	2021-12-31	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	VKC991A	11.5.19 11:37	2020-01-01	Edoxaban 60mg / ASA indication
1119	870	Placebo	ASA indication	PFZ382F	21.5.22 7:46	2024-04-30	Edoxaban 60mg / ASA indication
1265	870	Placebo	ASA indication	FEL896Y	25.2.21 7:49	2021-12-31	Edoxaban 60mg / ASA indication
1265	870	Placebo	ASA indication	KKU542Z	18.2.20 8:25	2021-12-31	Edoxaban 60mg / ASA indication
1265	870	Placebo	ASA indication	AWL157Y	26.8.20 7:05	2021-12-31	Edoxaban 60mg / ASA indication
1265	870	Placebo	ASA indication	HXF255S	28.8.19 10:24	2021-12-31	Edoxaban 60mg / ASA indication
1267	870	Placebo	ASA indication	SRF158K	28.2.20 8:27	2021-12-31	Edoxaban 60mg / ASA indication
1267	870	Placebo	ASA indication	LWS814K	7.3.22 10:56	2024-04-30	Edoxaban 60mg / ASA indication
1267	870	Placebo	ASA indication	PAV344R	29.8.19 8:02	2021-12-31	Edoxaban 60mg / ASA indication
1267	870	Placebo	ASA indication	HPZ493V	9.3.21 7:40	2021-12-31	Edoxaban 60mg / ASA indication
1267	870	Placebo	ASA indication	CGA475N	10.9.20 11:11	2021-12-31	Edoxaban 60mg / ASA indication
1267	870	Placebo	ASA indication	FWU295Y	4.9.21 8:02	2024-04-30	Edoxaban 60mg / ASA indication
1303	870	Placebo	ASA indication	RMG883A	8.5.20 8:13	2021-12-31	Edoxaban 60mg / ASA indication
1303	870	Placebo	ASA indication	HWY347D	26.9.19 11:33	2021-12-31	Edoxaban 60mg / ASA indication
1303	870	Placebo	ASA indication	YFD376X	9.10.20 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
1395	870	Placebo	ASA indication	BAN824W	6.5.22 9:55	2024-11-30	Edoxaban 30mg / no ASA indication
1395	870	Placebo	ASA indication	TGM515U	11.5.21 8:02	2022-08-31	Edoxaban 30mg / no ASA indication
1395	870	Placebo	ASA indication	FUN713V	12.5.20 7:11	2021-12-31	Edoxaban 60mg / ASA indication
1395	870	Placebo	ASA indication	GYA137A	18.11.19 12:00	2021-12-31	Edoxaban 60mg / ASA indication
1395	870	Placebo	ASA indication	FSX352V	24.11.21 6:30	2022-08-31	Edoxaban 30mg / ASA indication
1395	870	Placebo	ASA indication	ECL553S	21.11.20 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
1409	870	Placebo	ASA indication	EPX498L	26.11.20 7:32	2021-12-31	Edoxaban 60mg / ASA indication
1409	870	Placebo	ASA indication	LZV794V	26.5.21 6:11	2021-12-31	Edoxaban 60mg / ASA indication
1409	870	Placebo	ASA indication	PBN445X	3.6.22 6:43	2024-04-30	Edoxaban 60mg / ASA indication
1409	870	Placebo	ASA indication	WKH224Y	2.6.20 6:54	2021-12-31	Edoxaban 60mg / ASA indication
1409	870	Placebo	ASA indication	FSN865V	26.11.19 10:49	2021-12-31	Edoxaban 60mg / ASA indication
1409	870	Placebo	ASA indication	KBK872N	3.12.21 8:57	2024-04-30	Edoxaban 60mg / ASA indication
1463	870	Placebo	ASA indication	LGM748Z	16.6.21 5:57	2021-12-31	Edoxaban 60mg / ASA indication
1463	870	Placebo	ASA indication	ENU146Y	22.12.20 7:38	2021-12-31	Edoxaban 60mg / ASA indication
1463	870	Placebo	ASA indication	XUZ239M	19.6.20 6:01	2021-12-31	Edoxaban 60mg / ASA indication
1463	870	Placebo	ASA indication	HXZ762G	17.12.21 7:47	2024-04-30	Edoxaban 60mg / ASA indication
1463	870	Placebo	ASA indication	CNB931S	24.12.19 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1463	870	Placebo	ASA indication	NWT479E	28.6.22 8:01	2024-04-30	Edoxaban 60mg / ASA indication
1480	870	Placebo	ASA indication	MDB961M	18.7.22 12:28	2024-04-30	Edoxaban 60mg / ASA indication
1480	870	Placebo	ASA indication	GFG356X	21.1.21 12:11	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1480	870	Placebo	ASA indication	LEK632F	17.1.20 8:20	2022-08-31	Edoxaban 30mg / ASA indication
1480	870	Placebo	ASA indication	VEC845U	16.7.20 6:43	2021-12-31	Edoxaban 60mg / ASA indication
1480	870	Placebo	ASA indication	KCV411V	8.1.22 7:50	2024-04-30	Edoxaban 60mg / ASA indication
1480	870	Placebo	ASA indication	APH253S	7.7.21 13:52	2024-04-30	Edoxaban 60mg / ASA indication
1514	870	Placebo	ASA indication	DZL744M	2.2.21 8:14	2021-12-31	Edoxaban 60mg / ASA indication
1514	870	Placebo	ASA indication	ZHH679W	11.2.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication
1514	870	Placebo	ASA indication	BYL885Z	5.8.20 8:26	2021-12-31	Edoxaban 60mg / ASA indication
1514	870	Placebo	ASA indication	FVT511U	27.8.21 16:30	2024-04-30	Edoxaban 60mg / ASA indication
1572	870	Placebo	ASA indication	KCR342X	29.4.21 6:28	2021-12-31	Edoxaban 60mg / ASA indication
1572	870	Placebo	ASA indication	PNY716S	13.5.22 5:57	2024-04-30	Edoxaban 60mg / ASA indication
1572	870	Placebo	ASA indication	EAZ182Y	28.10.20 7:26	2021-12-31	Edoxaban 60mg / ASA indication
1572	870	Placebo	ASA indication	HSF628D	8.11.21 9:29	2024-04-30	Edoxaban 60mg / ASA indication
1572	870	Placebo	ASA indication	UKW827Y	29.4.20 7:34	2021-12-31	Edoxaban 60mg / ASA indication
1580	870	Placebo	ASA indication	FXY923U	11.11.21 7:02	2024-04-30	Edoxaban 60mg / ASA indication
1580	870	Placebo	ASA indication	EBR596G	28.10.20 6:56	2021-12-31	Edoxaban 60mg / ASA indication
1580	870	Placebo	ASA indication	NLR533F	27.4.22 6:08	2024-04-30	Edoxaban 60mg / ASA indication
1580	870	Placebo	ASA indication	HZT752V	7.5.21 5:53	2021-12-31	Edoxaban 60mg / ASA indication
1580	870	Placebo	ASA indication	WSK422P	8.5.20 7:53	2021-12-31	Edoxaban 60mg / ASA indication
1616	870	Placebo	ASA indication	DPN142Y	9.6.20 11:13	2021-12-31	Edoxaban 60mg / ASA indication
1616	870	Placebo	ASA indication	ANU966C	29.6.21 18:40	2024-04-30	Edoxaban 60mg / ASA indication
1616	870	Placebo	ASA indication	AEH685W	15.12.20 7:49	2022-08-31	Edoxaban 30mg / ASA indication
1616	870	Placebo	ASA indication	FXP815W	20.12.21 7:01	2022-08-31	Edoxaban 30mg / ASA indication
1616	870	Placebo	ASA indication	PMG872F	18.6.22 6:30	2024-04-30	Edoxaban 60mg / ASA indication
1678	870	Placebo	ASA indication	LDP473T	12.1.22 8:04	2024-04-30	Edoxaban 60mg / ASA indication
1678	870	Placebo	ASA indication	BSE751P	8.7.20 6:34	2021-12-31	Edoxaban 60mg / ASA indication
1678	870	Placebo	ASA indication	BGB474H	19.7.21 5:45	2024-04-30	Edoxaban 60mg / ASA indication
1678	870	Placebo	ASA indication	EPE873P	12.1.21 7:07	2021-12-31	Edoxaban 60mg / ASA indication
1678	870	Placebo	ASA indication	NSK911T	19.7.22 5:13	2024-04-30	Edoxaban 60mg / ASA indication
1685	870	Placebo	ASA indication	GFW431P	24.1.21 11:57	2021-12-31	Edoxaban 60mg / ASA indication
1685	870	Placebo	ASA indication	AFP623G	31.1.22 8:40	2024-11-30	Edoxaban 30mg / ASA indication
1685	870	Placebo	ASA indication	ZLL395Y	13.7.20 9:17	2021-12-31	Edoxaban 60mg / ASA indication
1685	870	Placebo	ASA indication	PLF811U	7.9.22 7:31	2024-04-30	Edoxaban 60mg / ASA indication
1685	870	Placebo	ASA indication	ELR152Z	21.7.21 5:23	2024-04-30	Edoxaban 60mg / ASA indication
1976	870	Placebo	ASA indication	FBF929K	9.9.21 9:01	2022-08-31	Edoxaban 30mg / ASA indication
1976	870	Placebo	ASA indication	FPY223N	1.3.22 8:26	2024-11-30	Edoxaban 30mg / ASA indication
1976	870	Placebo	ASA indication	KAF996R	29.8.22 6:29	2024-11-30	Edoxaban 30mg / ASA indication
1976	870	Placebo	ASA indication	CBA128R	24.2.21 7:42	2022-08-31	Edoxaban 30mg / ASA indication
1985	870	Placebo	ASA indication	GLL633S	26.2.21 9:57	2021-12-31	Edoxaban 60mg / ASA indication
1985	870	Placebo	ASA indication	FGN179P	30.8.21 7:13	2024-04-30	Edoxaban 60mg / ASA indication
1985	870	Placebo	ASA indication	LRL232M	14.3.22 7:30	2024-04-30	Edoxaban 60mg / ASA indication
1995	870	Placebo	ASA indication	CMX837W	3.9.21 9:02	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1995	870	Placebo	ASA indication	LVN679V	9.3.22 7:45	2024-04-30	Edoxaban 60mg / ASA indication
1995	870	Placebo	ASA indication	GGW125D	3.3.21 10:45	2021-12-31	Edoxaban 60mg / ASA indication
1997	870	Placebo	ASA indication	EZX231P	20.8.21 8:58	2024-04-30	Edoxaban 60mg / ASA indication
1997	870	Placebo	ASA indication	LMY583Y	22.2.22 6:24	2024-04-30	Edoxaban 60mg / ASA indication
1997	870	Placebo	ASA indication	GHG416G	3.3.21 14:24	2021-12-31	Edoxaban 60mg / ASA indication
1997	870	Placebo	ASA indication	NRU338G	5.9.22 8:06	2024-04-30	Edoxaban 60mg / ASA indication
2043	870	Placebo	ASA indication	FVG392B	17.5.22 8:27	2024-11-30	Edoxaban 30mg / ASA indication
2043	870	Placebo	ASA indication	CTX272G	13.4.21 9:52	2022-08-31	Edoxaban 30mg / ASA indication
2043	870	Placebo	ASA indication	FGE231M	12.10.21 8:24	2022-08-31	Edoxaban 30mg / ASA indication
2047	870	Placebo	ASA indication	HXM395A	15.4.21 6:11	2021-12-31	Edoxaban 60mg / ASA indication
2047	870	Placebo	ASA indication	PBG183M	29.4.22 10:50	2024-04-30	Edoxaban 60mg / ASA indication
2047	870	Placebo	ASA indication	GPH186U	18.10.21 6:56	2024-04-30	Edoxaban 60mg / ASA indication
2151	870	Placebo	ASA indication	FDE285X	17.12.21 7:50	2024-04-30	Edoxaban 60mg / ASA indication
2151	870	Placebo	ASA indication	PFR388F	16.6.22 6:03	2024-04-30	Edoxaban 60mg / ASA indication
2151	870	Placebo	ASA indication	MFW272F	14.6.21 9:09	2021-12-31	Edoxaban 60mg / ASA indication
2198	870	Placebo	ASA indication	EKS854H	19.1.22 9:35	2024-04-30	Edoxaban 60mg / ASA indication
2198	870	Placebo	ASA indication	PFB947L	27.7.22 6:43	2024-04-30	Edoxaban 60mg / ASA indication
2198	870	Placebo	ASA indication	EGK266H	21.7.21 7:16	2024-04-30	Edoxaban 60mg / ASA indication
2201	870	Placebo	ASA indication	CWT551Y	21.7.21 10:34	2022-08-31	Edoxaban 30mg / ASA indication
2292	870	Placebo	ASA indication	GES779R	29.9.21 10:39	2024-04-30	Edoxaban 60mg / ASA indication
2292	870	Placebo	ASA indication	LEY126D	6.4.22 6:54	2024-04-30	Edoxaban 60mg / ASA indication
2369	870	Placebo	ASA indication	HZB923R	29.11.21 7:36	2024-04-30	Edoxaban 60mg / ASA indication
2369	870	Placebo	ASA indication	PDV537T	24.6.22 12:23	2024-04-30	Edoxaban 60mg / ASA indication
971	870	Placebo	no ASA indication	CFX685T	9.8.20 8:25	2021-12-31	Edoxaban 60mg / ASA indication
971	870	Placebo	no ASA indication	GPN233F	1.9.22 11:08	2024-11-30	Edoxaban 30mg / ASA indication
971	870	Placebo	no ASA indication	EUA641N	18.8.21 8:07	2024-04-30	Edoxaban 60mg / ASA indication
971	870	Placebo	no ASA indication	UDH888F	22.8.19 7:23	2022-08-31	Edoxaban 30mg / ASA indication
971	870	Placebo	no ASA indication	KVZ179T	23.2.20 7:28	2021-12-31	Edoxaban 60mg / ASA indication
971	870	Placebo	no ASA indication	GBS661M	7.2.21 8:27	2021-12-31	Edoxaban 60mg / ASA indication
971	870	Placebo	no ASA indication	AEC176U	9.2.22 7:45	2024-11-30	Edoxaban 30mg / ASA indication
971	870	Placebo	no ASA indication	KXV516F	2.2.19 7:57	2020-01-01	Edoxaban 60mg / no ASA indication
1675	870	Placebo	no ASA indication	TLA368H	2.7.20 12:23	2021-12-31	Edoxaban 60mg / no ASA indication
1675	870	Placebo	no ASA indication	AUW352C	17.1.21 9:34	2021-12-31	Edoxaban 60mg / ASA indication
1675	870	Placebo	no ASA indication	LAZ376G	22.1.22 9:05	2024-04-30	Edoxaban 60mg / ASA indication
1675	870	Placebo	no ASA indication	AXM383D	14.7.21 19:42	2024-04-30	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	FEF318R	12.8.21 6:22	2024-04-30	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	SMK518C	2.9.22 5:34	2024-04-30	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	AGL317E	12.8.20 6:43	2021-12-31	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	BDX925S	20.8.18 11:05	2020-01-01	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	ZVL731X	7.2.20 8:59	2021-12-31	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	VRU469X	20.8.19 7:23	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
680	870	Edoxaban	ASA indication	LDM233H	10.2.21 8:27	2021-12-31	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	BTY962U	26.2.19 11:20	2020-01-01	Edoxaban 60mg / ASA indication
680	870	Edoxaban	ASA indication	LVY256U	18.2.22 7:28	2024-04-30	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	ELG834U	24.10.18 13:18	2020-01-01	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	RAU548D	5.5.22 6:55	2024-04-30	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	CBM465F	8.10.20 9:56	2021-12-31	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	MSD641X	6.11.19 8:36	2021-12-31	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	FMD222R	18.11.21 13:24	2022-08-31	Edoxaban 30mg / ASA indication
769	870	Edoxaban	ASA indication	MFP611L	26.4.19 7:35	2020-01-01	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	MPD719D	19.4.21 8:40	2021-12-31	Edoxaban 60mg / ASA indication
769	870	Edoxaban	ASA indication	DZA426P	14.5.20 6:45	2021-12-31	Edoxaban 60mg / ASA indication
1032	870	Edoxaban	ASA indication	GXX675R	13.3.20 7:36	2022-08-31	Edoxaban 30mg / ASA indication
1032	870	Edoxaban	ASA indication	WLE121A	11.9.19 7:11	2021-12-31	Edoxaban 60mg / ASA indication
1032	870	Edoxaban	ASA indication	AUH364N	10.9.21 5:57	2024-04-30	Edoxaban 60mg / no ASA indication
1032	870	Edoxaban	ASA indication	SAR458S	9.9.20 6:55	2021-12-31	Edoxaban 60mg / no ASA indication
1032	870	Edoxaban	ASA indication	STL919Y	20.3.19 13:15	2020-01-01	Edoxaban 60mg / ASA indication
1032	870	Edoxaban	ASA indication	BTS963K	9.3.22 10:57	2024-04-30	Edoxaban 60mg / no ASA indication
1032	870	Edoxaban	ASA indication	LWE712A	10.3.21 7:21	2021-12-31	Edoxaban 60mg / ASA indication
1077	870	Edoxaban	ASA indication	CGU225R	5.10.20 6:51	2021-12-31	Edoxaban 60mg / ASA indication
1077	870	Edoxaban	ASA indication	FXG877Z	30.9.19 8:04	2021-12-31	Edoxaban 60mg / ASA indication
1077	870	Edoxaban	ASA indication	UAX641A	26.5.21 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
1077	870	Edoxaban	ASA indication	UAD724N	13.4.19 8:35	2020-01-01	Edoxaban 60mg / ASA indication
1077	870	Edoxaban	ASA indication	DLB529N	1.4.20 7:44	2021-12-31	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	EAV549F	3.4.20 8:44	2021-12-31	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	PUA285R	6.5.22 7:49	2024-04-30	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	CVN794X	8.10.20 8:08	2021-12-31	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	HVP665K	23.10.21 7:49	2024-04-30	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	RNG544X	22.4.19 9:15	2020-01-01	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	XHA489A	10.10.19 7:42	2021-12-31	Edoxaban 60mg / ASA indication
1093	870	Edoxaban	ASA indication	MXK959Z	19.4.21 9:08	2021-12-31	Edoxaban 60mg / ASA indication
1131	870	Edoxaban	ASA indication	AKP861Z	19.5.20 7:29	2021-12-31	Edoxaban 60mg / ASA indication
1131	870	Edoxaban	ASA indication	DWM797Y	16.11.20 8:07	2021-12-31	Edoxaban 60mg / ASA indication
1131	870	Edoxaban	ASA indication	NXR453D	14.5.21 5:50	2021-12-31	Edoxaban 60mg / ASA indication
1131	870	Edoxaban	ASA indication	CBU875V	6.11.19 8:55	2021-12-31	Edoxaban 60mg / ASA indication
1131	870	Edoxaban	ASA indication	MEY229N	17.5.19 10:05	2020-01-01	Edoxaban 60mg / ASA indication
1142	870	Edoxaban	ASA indication	PVS743D	2.12.20 7:33	2022-08-31	Edoxaban 30mg / ASA indication
1142	870	Edoxaban	ASA indication	RGT122E	4.6.22 6:56	2024-04-30	Edoxaban 60mg / ASA indication
1142	870	Edoxaban	ASA indication	FRR454F	29.11.21 8:10	2022-08-31	Edoxaban 30mg / ASA indication
1142	870	Edoxaban	ASA indication	GZU321W	24.5.19 9:05	2020-01-01	Edoxaban 60mg / ASA indication
1142	870	Edoxaban	ASA indication	TYX968A	21.11.19 7:45	2021-12-31	Edoxaban 60mg / ASA indication
1142	870	Edoxaban	ASA indication	MVS467B	13.5.21 6:47	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1142	870	Edoxaban	ASA indication	ZEN473F	2.6.20 7:22	2021-12-31	Edoxaban 60mg / ASA indication
1271	870	Edoxaban	ASA indication	MFM738S	6.3.20 18:08	2021-12-31	Edoxaban 60mg / ASA indication
1271	870	Edoxaban	ASA indication	LVC325K	1.3.21 7:52	2021-12-31	Edoxaban 60mg / ASA indication
1271	870	Edoxaban	ASA indication	HFK729Z	9.3.22 10:55	2024-04-30	Edoxaban 60mg / no ASA indication
1271	870	Edoxaban	ASA indication	MNX336F	2.9.22 5:38	2024-04-30	Edoxaban 60mg / ASA indication
1271	870	Edoxaban	ASA indication	ACY526R	9.9.20 6:50	2021-12-31	Edoxaban 60mg / ASA indication
1271	870	Edoxaban	ASA indication	AWA854F	4.9.19 7:32	2022-08-31	Edoxaban 30mg / ASA indication
1271	870	Edoxaban	ASA indication	FML823E	28.8.21 6:40	2024-04-30	Edoxaban 60mg / ASA indication
1297	870	Edoxaban	ASA indication	MRX189B	6.4.21 7:48	2021-12-31	Edoxaban 60mg / ASA indication
1297	870	Edoxaban	ASA indication	DEB552S	24.9.20 5:14	2021-12-31	Edoxaban 60mg / ASA indication
1297	870	Edoxaban	ASA indication	CAB649P	25.9.19 9:52	2021-12-31	Edoxaban 60mg / ASA indication
1297	870	Edoxaban	ASA indication	RNN851V	14.5.22 8:57	2024-04-30	Edoxaban 60mg / ASA indication
1297	870	Edoxaban	ASA indication	GRD465M	3.10.21 8:05	2024-04-30	Edoxaban 60mg / ASA indication
1297	870	Edoxaban	ASA indication	UCZ453R	1.4.20 7:21	2021-12-31	Edoxaban 60mg / ASA indication
1384	870	Edoxaban	ASA indication	PGK553U	20.5.21 11:54	2021-12-31	Edoxaban 60mg / ASA indication
1384	870	Edoxaban	ASA indication	RUM566E	28.5.22 7:17	2024-04-30	Edoxaban 60mg / ASA indication
1384	870	Edoxaban	ASA indication	YVZ622Z	21.5.20 6:28	2021-12-31	Edoxaban 60mg / ASA indication
1384	870	Edoxaban	ASA indication	DYG888L	24.11.20 7:57	2021-12-31	Edoxaban 60mg / ASA indication
1384	870	Edoxaban	ASA indication	CDR613M	19.11.19 11:05	2021-12-31	Edoxaban 60mg / ASA indication
1384	870	Edoxaban	ASA indication	KMH363K	25.11.21 12:31	2024-04-30	Edoxaban 60mg / ASA indication
1464	870	Edoxaban	ASA indication	PCH326C	23.6.20 8:03	2021-12-31	Edoxaban 60mg / ASA indication
1464	870	Edoxaban	ASA indication	EAW793S	24.12.19 9:36	2021-12-31	Edoxaban 60mg / ASA indication
1464	870	Edoxaban	ASA indication	SKA112P	4.7.22 6:51	2024-04-30	Edoxaban 60mg / ASA indication
1464	870	Edoxaban	ASA indication	FRS511P	20.12.21 10:59	2024-04-30	Edoxaban 60mg / ASA indication
1464	870	Edoxaban	ASA indication	FXF681N	8.12.20 9:43	2021-12-31	Edoxaban 60mg / ASA indication
1464	870	Edoxaban	ASA indication	PDV814H	10.6.21 8:37	2021-12-31	Edoxaban 60mg / ASA indication
1500	870	Edoxaban	ASA indication	KZY856G	2.2.21 8:35	2021-12-31	Edoxaban 60mg / ASA indication
1500	870	Edoxaban	ASA indication	RBR528G	16.8.22 9:25	2024-04-30	Edoxaban 60mg / ASA indication
1500	870	Edoxaban	ASA indication	LDU494F	9.2.22 13:21	2024-04-30	Edoxaban 60mg / ASA indication
1500	870	Edoxaban	ASA indication	DUG566H	1.2.20 11:08	2021-12-31	Edoxaban 60mg / ASA indication
1500	870	Edoxaban	ASA indication	AHN192V	7.8.21 7:35	2024-04-30	Edoxaban 60mg / ASA indication
1500	870	Edoxaban	ASA indication	PZA848D	22.7.20 8:51	2021-12-31	Edoxaban 60mg / ASA indication
1526	870	Edoxaban	ASA indication	TFD964S	10.2.21 7:56	2022-08-31	Edoxaban 30mg / no ASA indication
1526	870	Edoxaban	ASA indication	AAA248W	18.2.22 7:25	2024-11-30	Edoxaban 30mg / ASA indication
1526	870	Edoxaban	ASA indication	TXS616W	19.2.20 11:23	2021-12-31	Edoxaban 60mg / ASA indication
1526	870	Edoxaban	ASA indication	LTW938E	30.8.22 5:40	2024-11-30	Edoxaban 30mg / ASA indication
1526	870	Edoxaban	ASA indication	DBV323V	18.8.21 5:51	2022-08-31	Edoxaban 30mg / ASA indication
1526	870	Edoxaban	ASA indication	BLL662R	5.8.20 6:52	2021-12-31	Edoxaban 60mg / ASA indication
1587	870	Edoxaban	ASA indication	FAH995U	16.11.20 7:30	2021-12-31	Edoxaban 60mg / ASA indication
1587	870	Edoxaban	ASA indication	RUW834W	16.5.22 10:33	2024-04-30	Edoxaban 60mg / ASA indication
1587	870	Edoxaban	ASA indication	GKS723F	22.11.21 8:27	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1587	870	Edoxaban	ASA indication	NTE553K	14.5.21 11:59	2021-12-31	Edoxaban 60mg / ASA indication
1587	870	Edoxaban	ASA indication	CTZ864U	14.5.20 15:55	2021-12-31	Edoxaban 60mg / ASA indication
1596	870	Edoxaban	ASA indication	MGU628G	2.3.22 12:28	2024-04-30	Edoxaban 60mg / ASA indication
1596	870	Edoxaban	ASA indication	AUM635X	29.6.21 18:43	2024-04-30	Edoxaban 60mg / no ASA indication
1596	870	Edoxaban	ASA indication	DGD798M	23.5.20 7:32	2021-12-31	Edoxaban 60mg / ASA indication
1596	870	Edoxaban	ASA indication	EXZ758W	30.11.20 14:33	2021-12-31	Edoxaban 60mg / ASA indication
1618	870	Edoxaban	ASA indication	NYR427T	16.6.21 6:44	2021-12-31	Edoxaban 60mg / ASA indication
1618	870	Edoxaban	ASA indication	GFD516K	14.12.20 7:55	2021-12-31	Edoxaban 60mg / ASA indication
1618	870	Edoxaban	ASA indication	AEZ654Y	9.6.20 12:34	2021-12-31	Edoxaban 60mg / ASA indication
1618	870	Edoxaban	ASA indication	SFW892N	15.6.22 6:57	2024-04-30	Edoxaban 60mg / ASA indication
1618	870	Edoxaban	ASA indication	KST414G	14.12.21 6:50	2024-04-30	Edoxaban 60mg / ASA indication
1627	870	Edoxaban	ASA indication	RUR592T	12.6.20 7:16	2021-12-31	Edoxaban 60mg / ASA indication
1684	870	Edoxaban	ASA indication	BMN324Z	22.7.21 11:40	2024-04-30	Edoxaban 60mg / ASA indication
1684	870	Edoxaban	ASA indication	FLS676A	11.1.21 8:39	2021-12-31	Edoxaban 60mg / ASA indication
1684	870	Edoxaban	ASA indication	SVX147K	10.7.20 16:11	2021-12-31	Edoxaban 60mg / ASA indication
1722	870	Edoxaban	ASA indication	DEZ895H	5.2.21 7:25	2021-12-31	Edoxaban 60mg / ASA indication
1722	870	Edoxaban	ASA indication	AGX888S	5.8.20 8:16	2021-12-31	Edoxaban 60mg / ASA indication
1722	870	Edoxaban	ASA indication	KRU839N	6.8.21 6:22	2022-08-31	Edoxaban 30mg / ASA indication
1722	870	Edoxaban	ASA indication	AHD239X	17.2.22 8:03	2024-11-30	Edoxaban 30mg / ASA indication
1722	870	Edoxaban	ASA indication	SKA734Y	16.8.22 7:17	2024-04-30	Edoxaban 60mg / ASA indication
1967	870	Edoxaban	ASA indication	FSB931R	18.8.21 7:54	2024-04-30	Edoxaban 60mg / ASA indication
1967	870	Edoxaban	ASA indication	PUY467B	14.5.22 9:47	2024-04-30	Edoxaban 60mg / ASA indication
1967	870	Edoxaban	ASA indication	HSR879L	18.2.21 11:19	2021-12-31	Edoxaban 60mg / ASA indication
1973	870	Edoxaban	ASA indication	KAU982X	22.2.21 17:29	2021-12-31	Edoxaban 60mg / ASA indication
1994	870	Edoxaban	ASA indication	MAE494T	3.3.21 10:20	2021-12-31	Edoxaban 60mg / ASA indication
1994	870	Edoxaban	ASA indication	FYW919L	6.9.21 7:31	2024-04-30	Edoxaban 60mg / ASA indication
1994	870	Edoxaban	ASA indication	GFF461B	10.3.22 12:43	2024-04-30	Edoxaban 60mg / ASA indication
1999	870	Edoxaban	ASA indication	HZA196M	9.3.21 8:35	2021-12-31	Edoxaban 60mg / ASA indication
1999	870	Edoxaban	ASA indication	LHW523M	7.3.22 7:30	2024-04-30	Edoxaban 60mg / ASA indication
1999	870	Edoxaban	ASA indication	ANT278C	31.8.21 5:06	2024-04-30	Edoxaban 60mg / ASA indication
2000	870	Edoxaban	ASA indication	AKS447E	7.9.21 7:03	2024-04-30	Edoxaban 60mg / ASA indication
2000	870	Edoxaban	ASA indication	MPG387E	10.3.21 8:54	2021-12-31	Edoxaban 60mg / ASA indication
2000	870	Edoxaban	ASA indication	MFM532Z	10.3.22 12:41	2024-04-30	Edoxaban 60mg / ASA indication
2087	870	Edoxaban	ASA indication	HXT148E	12.11.21 7:27	2024-04-30	Edoxaban 60mg / ASA indication
2087	870	Edoxaban	ASA indication	SKB594N	24.5.22 13:57	2024-04-30	Edoxaban 60mg / ASA indication
2087	870	Edoxaban	ASA indication	MSE552X	6.5.21 9:18	2021-12-31	Edoxaban 60mg / ASA indication
2130	870	Edoxaban	ASA indication	PCS189A	31.5.21 10:17	2021-12-31	Edoxaban 60mg / ASA indication
2130	870	Edoxaban	ASA indication	SCT398U	2.6.22 12:05	2024-04-30	Edoxaban 60mg / ASA indication
2130	870	Edoxaban	ASA indication	KZS539F	1.12.21 13:37	2024-04-30	Edoxaban 60mg / ASA indication
2261	870	Edoxaban	ASA indication	FSV953R	8.9.21 13:15	2024-04-30	Edoxaban 60mg / ASA indication
2261	870	Edoxaban	ASA indication	SFN979A	7.9.22 12:10	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2261	870	Edoxaban	ASA indication	LUU365F	9.3.22 8:59	2024-04-30	Edoxaban 60mg / ASA indication
2262	870	Edoxaban	ASA indication	GDP916M	10.9.21 6:37	2024-04-30	Edoxaban 60mg / ASA indication
2262	870	Edoxaban	ASA indication	NEG178H	12.5.22 8:32	2024-04-30	Edoxaban 60mg / no ASA indication
2314	870	Edoxaban	ASA indication	FEG816P	21.10.21 9:08	2022-08-31	Edoxaban 30mg / ASA indication
977	870	Edoxaban	no ASA indication	VSX948R	9.8.19 7:35	2021-12-31	Edoxaban 60mg / ASA indication
977	870	Edoxaban	no ASA indication	URA164X	6.2.19 15:22	2020-01-01	Edoxaban 60mg / no ASA indication
1020	870	Edoxaban	no ASA indication	UGA998S	19.9.19 7:02	2021-12-31	Edoxaban 60mg / ASA indication
1020	870	Edoxaban	no ASA indication	DWX594Y	3.3.20 8:03	2022-08-31	Edoxaban 30mg / ASA indication
1020	870	Edoxaban	no ASA indication	GLG572K	12.3.19 10:34	2020-01-01	Edoxaban 30mg / no ASA indication
732	871	Placebo	ASA indication	XAF361X	4.10.18 7:48	2020-01-01	Edoxaban 30mg / ASA indication
804	871	Placebo	ASA indication	LZB234A	27.8.20 16:32	2021-12-31	Edoxaban 60mg / no ASA indication
804	871	Placebo	ASA indication	UKF267S	10.6.19 7:18	2020-01-01	Edoxaban 60mg / ASA indication
804	871	Placebo	ASA indication	CSZ758E	8.11.18 9:06	2020-01-01	Edoxaban 60mg / ASA indication
804	871	Placebo	ASA indication	FBP396Y	14.5.21 11:46	2021-12-31	Edoxaban 60mg / ASA indication
804	871	Placebo	ASA indication	LHU686L	11.2.20 11:51	2021-12-31	Edoxaban 60mg / ASA indication
874	871	Placebo	ASA indication	UZA162V	6.2.20 12:37	2021-12-31	Edoxaban 60mg / ASA indication
874	871	Placebo	ASA indication	DSV873B	14.5.21 11:53	2021-12-31	Edoxaban 60mg / ASA indication
874	871	Placebo	ASA indication	GKH925G	10.12.18 9:49	2020-01-01	Edoxaban 60mg / ASA indication
874	871	Placebo	ASA indication	MHZ937L	27.8.20 16:21	2021-12-31	Edoxaban 60mg / no ASA indication
914	871	Placebo	ASA indication	PVU865F	14.2.20 9:58	2021-12-31	Edoxaban 60mg / ASA indication
914	871	Placebo	ASA indication	EPC465S	16.7.19 10:43	2021-12-31	Edoxaban 60mg / ASA indication
914	871	Placebo	ASA indication	KND649W	14.5.21 11:55	2022-08-31	Edoxaban 30mg / ASA indication
914	871	Placebo	ASA indication	SPA782N	26.12.18 13:26	2020-01-01	Edoxaban 30mg / ASA indication
914	871	Placebo	ASA indication	RSE119V	27.8.20 16:10	2021-12-31	Edoxaban 60mg / no ASA indication
962	871	Placebo	ASA indication	DTB971E	14.5.21 11:58	2021-12-31	Edoxaban 60mg / ASA indication
962	871	Placebo	ASA indication	DSS743B	18.2.20 8:27	2021-12-31	Edoxaban 60mg / ASA indication
962	871	Placebo	ASA indication	KWW593Z	27.8.20 16:06	2021-12-31	Edoxaban 60mg / ASA indication
962	871	Placebo	ASA indication	VHD315E	30.1.19 7:43	2020-01-01	Edoxaban 60mg / ASA indication
963	871	Placebo	ASA indication	WKL566A	27.8.20 15:50	2021-12-31	Edoxaban 60mg / ASA indication
963	871	Placebo	ASA indication	SKS369F	30.1.19 9:42	2020-01-01	Edoxaban 60mg / ASA indication
963	871	Placebo	ASA indication	ZER964R	11.9.19 8:25	2021-12-31	Edoxaban 60mg / ASA indication
762	871	Edoxaban	ASA indication	ZRH739P	5.2.20 6:10	2021-12-31	Edoxaban 60mg / ASA indication
762	871	Edoxaban	ASA indication	HEH685M	22.10.18 11:57	2020-01-01	Edoxaban 60mg / ASA indication
762	871	Edoxaban	ASA indication	CXK319K	2.3.21 11:27	2021-12-31	Edoxaban 60mg / ASA indication
762	871	Edoxaban	ASA indication	GAV177H	19.4.19 10:38	2020-01-01	Edoxaban 60mg / ASA indication
762	871	Edoxaban	ASA indication	LEV182K	18.8.20 11:40	2021-12-31	Edoxaban 60mg / ASA indication
762	871	Edoxaban	ASA indication	BWY188Y	14.9.21 13:01	2024-04-30	Edoxaban 60mg / no ASA indication
762	871	Edoxaban	ASA indication	MAH749D	20.4.22 18:05	2024-04-30	Edoxaban 60mg / ASA indication
808	871	Edoxaban	ASA indication	DTH437V	9.11.18 14:23	2020-01-01	Edoxaban 60mg / ASA indication
812	871	Edoxaban	ASA indication	PWH969X	12.11.18 9:48	2020-01-01	Edoxaban 30mg / ASA indication
872	871	Edoxaban	ASA indication	BWW618B	27.8.20 16:26	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
872	871	Edoxaban	ASA indication	VUN867P	14.6.19 11:09	2020-01-01	Edoxaban 60mg / ASA indication
872	871	Edoxaban	ASA indication	FZH893D	8.12.18 9:02	2020-01-01	Edoxaban 60mg / ASA indication
872	871	Edoxaban	ASA indication	USG756L	16.1.20 9:03	2021-12-31	Edoxaban 60mg / ASA indication
880	871	Edoxaban	ASA indication	RGK228R	28.9.21 16:18	2022-08-31	Edoxaban 30mg / ASA indication
880	871	Edoxaban	ASA indication	KBH595W	9.12.19 9:18	2022-08-31	Edoxaban 30mg / ASA indication
880	871	Edoxaban	ASA indication	DPV441M	11.12.18 7:43	2020-01-01	Edoxaban 30mg / ASA indication
880	871	Edoxaban	ASA indication	YWP579K	6.6.19 11:30	2020-01-01	Edoxaban 60mg / ASA indication
880	871	Edoxaban	ASA indication	XAX765S	30.7.20 8:04	2021-12-31	Edoxaban 60mg / ASA indication
880	871	Edoxaban	ASA indication	DLV765M	2.2.21 7:35	2021-12-31	Edoxaban 60mg / ASA indication
972	871	Edoxaban	ASA indication	ETL581C	22.8.19 7:07	2021-12-31	Edoxaban 60mg / ASA indication
972	871	Edoxaban	ASA indication	DKL155Z	27.2.20 7:33	2021-12-31	Edoxaban 60mg / ASA indication
972	871	Edoxaban	ASA indication	YBL263A	3.2.19 9:43	2020-01-01	Edoxaban 60mg / ASA indication
972	871	Edoxaban	ASA indication	BMR589Z	30.11.21 13:29	2024-04-30	Edoxaban 60mg / ASA indication
972	871	Edoxaban	ASA indication	KSD749S	11.5.21 6:45	2022-08-31	Edoxaban 30mg / ASA indication
972	871	Edoxaban	ASA indication	CWU613V	6.10.20 11:40	2021-12-31	Edoxaban 60mg / ASA indication
1012	871	Edoxaban	ASA indication	BVW115V	25.1.22 12:22	2024-04-30	Edoxaban 60mg / ASA indication
1012	871	Edoxaban	ASA indication	ZXU838C	1.3.19 10:55	2020-01-01	Edoxaban 30mg / ASA indication
1012	871	Edoxaban	ASA indication	YWE275X	28.2.20 9:12	2021-12-31	Edoxaban 60mg / ASA indication
1012	871	Edoxaban	ASA indication	AMF369R	27.8.20 15:44	2022-08-31	Edoxaban 30mg / no ASA indication
1012	871	Edoxaban	ASA indication	TLR399D	24.9.20 10:16	2021-12-31	Edoxaban 60mg / ASA indication
1012	871	Edoxaban	ASA indication	EXS893P	9.4.21 14:47	2021-12-31	Edoxaban 60mg / no ASA indication
700	872	Placebo	no ASA indication	KKG431L	11.3.19 9:35	2020-01-01	Edoxaban 60mg / no ASA indication
700	872	Placebo	no ASA indication	ASY833Z	11.9.19 12:04	2021-12-31	Edoxaban 60mg / no ASA indication
700	872	Placebo	no ASA indication	ADP343D	11.9.20 10:24	2022-08-31	Edoxaban 30mg / no ASA indication
700	872	Placebo	no ASA indication	CMP335B	16.3.21 8:08	2022-08-31	Edoxaban 30mg / no ASA indication
700	872	Placebo	no ASA indication	ACB984V	24.9.21 8:25	2022-08-31	Edoxaban 30mg / no ASA indication
700	872	Placebo	no ASA indication	WKK839W	17.3.20 8:30	2022-08-31	Edoxaban 30mg / no ASA indication
700	872	Placebo	no ASA indication	VVD839P	7.9.18 11:50	2020-01-01	Edoxaban 30mg / no ASA indication
776	872	Placebo	no ASA indication	GRW624C	17.6.20 11:59	2022-08-31	Edoxaban 30mg / no ASA indication
776	872	Placebo	no ASA indication	ZUF758E	11.11.19 8:49	2022-08-31	Edoxaban 30mg / no ASA indication
776	872	Placebo	no ASA indication	MET491U	24.4.19 8:51	2020-01-01	Edoxaban 30mg / no ASA indication
776	872	Placebo	no ASA indication	LFN681T	26.10.18 8:59	2020-01-01	Edoxaban 30mg / no ASA indication
889	872	Placebo	no ASA indication	FTB646X	17.12.19 11:30	2021-12-31	Edoxaban 60mg / no ASA indication
889	872	Placebo	no ASA indication	GMA715Z	3.7.20 6:52	2021-12-31	Edoxaban 60mg / no ASA indication
889	872	Placebo	no ASA indication	LZU762Y	14.12.18 9:39	2020-01-01	Edoxaban 60mg / no ASA indication
889	872	Placebo	no ASA indication	YZB343W	28.6.19 19:56	2021-12-31	Edoxaban 60mg / no ASA indication
889	872	Placebo	no ASA indication	CUA965P	20.8.21 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
889	872	Placebo	no ASA indication	AWG398H	26.1.21 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
891	872	Placebo	no ASA indication	YYD383P	18.12.19 12:41	2021-12-31	Edoxaban 60mg / no ASA indication
891	872	Placebo	no ASA indication	XXH324W	12.6.19 18:13	2020-01-01	Edoxaban 60mg / no ASA indication
891	872	Placebo	no ASA indication	ABX619P	10.6.20 10:29	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
891	872	Placebo	no ASA indication	UWR861P	14.12.18 11:16	2020-01-01	Edoxaban 60mg / no ASA indication
1143	872	Placebo	no ASA indication	RSX399A	27.5.19 8:47	2020-01-01	Edoxaban 30mg / no ASA indication
696	872	Edoxaban	no ASA indication	TAL712Z	5.9.18 8:09	2020-01-01	Edoxaban 60mg / no ASA indication
696	872	Edoxaban	no ASA indication	GER238B	13.9.19 10:23	2021-12-31	Edoxaban 60mg / no ASA indication
696	872	Edoxaban	no ASA indication	FXE389X	19.2.19 12:41	2020-01-01	Edoxaban 60mg / no ASA indication
727	872	Edoxaban	no ASA indication	UMY582B	12.4.19 13:50	2020-01-01	Edoxaban 60mg / no ASA indication
727	872	Edoxaban	no ASA indication	LAZ481X	8.4.20 8:06	2021-12-31	Edoxaban 60mg / no ASA indication
727	872	Edoxaban	no ASA indication	NXU142F	27.9.18 16:34	2020-01-01	Edoxaban 60mg / no ASA indication
727	872	Edoxaban	no ASA indication	EDC683A	25.9.19 11:17	2021-12-31	Edoxaban 60mg / no ASA indication
727	872	Edoxaban	no ASA indication	AVN983Z	30.10.20 10:54	2021-12-31	Edoxaban 60mg / no ASA indication
755	872	Edoxaban	no ASA indication	GUG829U	8.4.19 11:56	2020-01-01	Edoxaban 60mg / no ASA indication
755	872	Edoxaban	no ASA indication	RVZ334V	17.12.20 14:17	2021-12-31	Edoxaban 60mg / no ASA indication
755	872	Edoxaban	no ASA indication	VBZ876Y	29.10.19 10:11	2021-12-31	Edoxaban 60mg / no ASA indication
755	872	Edoxaban	no ASA indication	RTZ461X	18.10.18 8:28	2020-01-01	Edoxaban 60mg / no ASA indication
755	872	Edoxaban	no ASA indication	BZN999X	23.7.21 12:54	2024-04-30	Edoxaban 60mg / no ASA indication
755	872	Edoxaban	no ASA indication	PGH957X	29.4.20 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
916	872	Edoxaban	no ASA indication	KYV167E	28.12.18 14:26	2020-01-01	Edoxaban 60mg / no ASA indication
916	872	Edoxaban	no ASA indication	CLX352Z	18.6.19 14:21	2020-01-01	Edoxaban 30mg / no ASA indication
917	872	Edoxaban	no ASA indication	MFG645R	29.12.18 8:54	2020-01-01	Edoxaban 60mg / no ASA indication
917	872	Edoxaban	no ASA indication	RAV134S	10.7.20 7:07	2021-12-31	Edoxaban 60mg / no ASA indication
917	872	Edoxaban	no ASA indication	FGF495E	5.2.21 14:06	2021-12-31	Edoxaban 60mg / no ASA indication
917	872	Edoxaban	no ASA indication	WFT253M	12.7.19 8:50	2021-12-31	Edoxaban 60mg / no ASA indication
917	872	Edoxaban	no ASA indication	EDS525S	12.2.20 11:41	2021-12-31	Edoxaban 60mg / no ASA indication
1109	872	Edoxaban	no ASA indication	VXN652K	4.11.19 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
1109	872	Edoxaban	no ASA indication	CBM166Z	30.10.20 9:00	2022-08-31	Edoxaban 30mg / no ASA indication
1109	872	Edoxaban	no ASA indication	SYY418B	6.5.19 11:43	2020-01-01	Edoxaban 60mg / no ASA indication
1109	872	Edoxaban	no ASA indication	CUG199V	7.5.20 8:08	2021-12-31	Edoxaban 60mg / no ASA indication
910	873	Edoxaban	ASA indication	GVP534Y	22.12.18 7:29	2020-01-01	Edoxaban 30mg / ASA indication
743	874	Placebo	ASA indication	YYL829P	2.5.19 15:37	2020-01-01	Edoxaban 60mg / ASA indication
743	874	Placebo	ASA indication	XRV789Y	20.10.18 8:09	2020-01-01	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	ZNZ267U	25.5.21 10:05	2021-12-31	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	BSS492S	8.12.21 10:41	2024-04-30	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	VPL258S	9.11.18 15:36	2020-01-01	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	YXB855E	9.11.20 14:31	2021-12-31	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	DBS448S	23.5.19 11:03	2020-01-01	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	TMR477S	22.5.20 11:48	2021-12-31	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	FSG332T	28.11.19 10:51	2021-12-31	Edoxaban 60mg / ASA indication
806	874	Placebo	ASA indication	BPD113A	31.5.22 10:41	2024-04-30	Edoxaban 60mg / ASA indication
827	874	Placebo	ASA indication	XBB217E	22.5.20 11:19	2022-08-31	Edoxaban 30mg / ASA indication
827	874	Placebo	ASA indication	WCU592D	17.11.18 10:04	2020-01-01	Edoxaban 30mg / ASA indication
827	874	Placebo	ASA indication	PXE871E	31.5.19 11:52	2020-01-01	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
827	874	Placebo	ASA indication	BNS627Z	26.1.22 14:56	2022-08-31	Edoxaban 30mg / ASA indication
827	874	Placebo	ASA indication	GAG194P	9.5.22 16:08	2024-11-30	Edoxaban 30mg / ASA indication
827	874	Placebo	ASA indication	NGG355Z	17.12.20 8:39	2022-08-31	Edoxaban 30mg / ASA indication
827	874	Placebo	ASA indication	CAY238D	8.6.21 5:04	2022-08-31	Edoxaban 30mg / ASA indication
827	874	Placebo	ASA indication	GSY785R	29.11.19 11:30	2022-08-31	Edoxaban 30mg / ASA indication
870	874	Placebo	ASA indication	MKC295W	18.6.19 12:03	2020-01-01	Edoxaban 60mg / ASA indication
870	874	Placebo	ASA indication	SCU476V	14.2.20 7:34	2021-12-31	Edoxaban 60mg / ASA indication
870	874	Placebo	ASA indication	HCR533E	6.12.18 12:37	2020-01-01	Edoxaban 60mg / ASA indication
912	874	Placebo	ASA indication	EDC886H	5.7.19 8:19	2022-08-31	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	KHA341R	25.12.18 11:17	2020-01-01	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	DMX834M	7.7.21 7:55	2022-08-31	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	BAK668B	11.7.22 10:13	2024-11-30	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	VME212V	13.6.20 8:37	2022-08-31	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	KTZ553B	21.12.19 13:20	2022-08-31	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	VCX927A	26.12.20 10:14	2022-08-31	Edoxaban 30mg / ASA indication
912	874	Placebo	ASA indication	CAR131K	18.1.22 17:06	2022-08-31	Edoxaban 30mg / ASA indication
994	874	Placebo	ASA indication	ZZF346W	14.9.19 16:09	2022-08-31	Edoxaban 30mg / ASA indication
994	874	Placebo	ASA indication	GDM339F	8.5.20 7:48	2022-08-31	Edoxaban 30mg / ASA indication
994	874	Placebo	ASA indication	LGU262X	19.2.19 12:59	2020-01-01	Edoxaban 30mg / ASA indication
1002	874	Placebo	ASA indication	VKP718F	22.2.20 8:52	2021-12-31	Edoxaban 60mg / ASA indication
1002	874	Placebo	ASA indication	SWL262C	30.8.19 11:00	2021-12-31	Edoxaban 60mg / ASA indication
1002	874	Placebo	ASA indication	BNZ868E	14.12.21 16:43	2024-04-30	Edoxaban 60mg / ASA indication
1002	874	Placebo	ASA indication	UVT852Y	26.8.20 10:28	2021-12-31	Edoxaban 60mg / ASA indication
1002	874	Placebo	ASA indication	VYN826L	25.2.19 11:02	2020-01-01	Edoxaban 60mg / ASA indication
1002	874	Placebo	ASA indication	CHA373L	27.5.21 12:39	2021-12-31	Edoxaban 60mg / ASA indication
792	874	Placebo	no ASA indication	MFK296A	1.5.19 12:24	2020-01-01	Edoxaban 30mg / no ASA indication
792	874	Placebo	no ASA indication	ZWX164G	4.11.18 8:04	2020-01-01	Edoxaban 30mg / no ASA indication
913	874	Placebo	no ASA indication	FPR711N	21.12.19 9:47	2022-08-31	Edoxaban 30mg / no ASA indication
913	874	Placebo	no ASA indication	PBB138M	4.7.19 8:29	2021-12-31	Edoxaban 60mg / no ASA indication
913	874	Placebo	no ASA indication	BRY982Z	20.12.21 9:03	2022-08-31	Edoxaban 30mg / no ASA indication
913	874	Placebo	no ASA indication	HCD243H	7.7.21 10:25	2022-08-31	Edoxaban 30mg / no ASA indication
913	874	Placebo	no ASA indication	NTN313Y	26.12.18 9:50	2020-01-01	Edoxaban 60mg / no ASA indication
913	874	Placebo	no ASA indication	BVZ898H	26.12.20 8:14	2022-08-31	Edoxaban 30mg / no ASA indication
913	874	Placebo	no ASA indication	XZN747C	19.6.20 8:00	2022-08-31	Edoxaban 30mg / no ASA indication
913	874	Placebo	no ASA indication	LYP182Z	11.7.22 7:49	2024-11-30	Edoxaban 30mg / no ASA indication
1158	874	Placebo	no ASA indication	BYZ597Y	5.6.20 8:38	2022-08-31	Edoxaban 30mg / no ASA indication
1158	874	Placebo	no ASA indication	MLX222E	15.6.22 10:03	2024-11-30	Edoxaban 30mg / no ASA indication
1158	874	Placebo	no ASA indication	DYC937E	8.12.21 10:04	2022-08-31	Edoxaban 30mg / no ASA indication
1158	874	Placebo	no ASA indication	KUB513P	25.12.19 9:00	2022-08-31	Edoxaban 30mg / no ASA indication
1158	874	Placebo	no ASA indication	XXC455X	10.12.20 8:42	2022-08-31	Edoxaban 30mg / no ASA indication
1158	874	Placebo	no ASA indication	EKE491M	9.6.21 10:25	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1158	874	Placebo	no ASA indication	XFX662G	4.6.19 9:58	2020-01-01	Edoxaban 30mg / no ASA indication
1208	874	Placebo	no ASA indication	DDV353V	19.1.22 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
1208	874	Placebo	no ASA indication	ELV782D	28.1.21 15:34	2021-12-31	Edoxaban 60mg / no ASA indication
1208	874	Placebo	no ASA indication	UPF429V	28.6.19 10:12	2021-12-31	Edoxaban 60mg / no ASA indication
1208	874	Placebo	no ASA indication	NFS173T	28.12.19 11:07	2021-12-31	Edoxaban 60mg / no ASA indication
1208	874	Placebo	no ASA indication	RYP161M	15.7.20 13:19	2021-12-31	Edoxaban 60mg / no ASA indication
1208	874	Placebo	no ASA indication	CVA485L	23.7.21 10:11	2024-04-30	Edoxaban 60mg / no ASA indication
1208	874	Placebo	no ASA indication	CWM128Z	9.8.22 14:07	2024-04-30	Edoxaban 60mg / no ASA indication
716	874	Edoxaban	ASA indication	FEE744N	21.9.18 16:40	2020-01-01	Edoxaban 30mg / ASA indication
716	874	Edoxaban	ASA indication	MDZ397F	4.4.19 10:19	2020-01-01	Edoxaban 60mg / ASA indication
716	874	Edoxaban	ASA indication	LNB733F	4.4.19 10:55	2020-01-01	Edoxaban 30mg / no ASA indication
716	874	Edoxaban	ASA indication	NZK985F	24.9.18 7:10	2020-01-01	Edoxaban 30mg / no ASA indication
716	874	Edoxaban	ASA indication	LHY328P	20.9.18 13:19	2020-01-01	Edoxaban 60mg / ASA indication
857	874	Edoxaban	ASA indication	ALS679X	22.5.20 13:45	2021-12-31	Edoxaban 60mg / ASA indication
857	874	Edoxaban	ASA indication	URK118M	30.11.18 14:33	2020-01-01	Edoxaban 60mg / ASA indication
857	874	Edoxaban	ASA indication	BXS745C	15.6.21 11:50	2022-08-31	Edoxaban 30mg / ASA indication
857	874	Edoxaban	ASA indication	FAN483G	29.11.19 12:28	2021-12-31	Edoxaban 60mg / ASA indication
857	874	Edoxaban	ASA indication	DGT674D	21.12.21 11:04	2024-04-30	Edoxaban 60mg / ASA indication
857	874	Edoxaban	ASA indication	GUH258G	4.6.19 11:06	2020-01-01	Edoxaban 60mg / ASA indication
857	874	Edoxaban	ASA indication	EHE645Y	11.12.20 10:16	2021-12-31	Edoxaban 60mg / ASA indication
858	874	Edoxaban	ASA indication	ZBU738G	5.6.20 9:20	2021-12-31	Edoxaban 60mg / ASA indication
858	874	Edoxaban	ASA indication	ZTT532P	12.12.18 14:55	2020-01-01	Edoxaban 60mg / ASA indication
858	874	Edoxaban	ASA indication	XRZ375V	22.6.19 9:06	2021-12-31	Edoxaban 60mg / ASA indication
858	874	Edoxaban	ASA indication	HMX646N	6.12.19 12:44	2021-12-31	Edoxaban 60mg / ASA indication
858	874	Edoxaban	ASA indication	BUW724W	18.12.20 9:55	2021-12-31	Edoxaban 60mg / ASA indication
871	874	Edoxaban	ASA indication	YPC193F	22.6.20 14:39	2021-12-31	Edoxaban 60mg / ASA indication
871	874	Edoxaban	ASA indication	KFP681Z	6.12.18 14:45	2020-01-01	Edoxaban 60mg / ASA indication
871	874	Edoxaban	ASA indication	VSW515Y	5.12.19 10:45	2021-12-31	Edoxaban 60mg / ASA indication
871	874	Edoxaban	ASA indication	UYZ198R	26.6.19 11:35	2021-12-31	Edoxaban 60mg / ASA indication
932	874	Edoxaban	ASA indication	EFS357G	15.1.19 9:43	2020-01-01	Edoxaban 30mg / ASA indication
932	874	Edoxaban	ASA indication	NSX329B	28.7.20 7:32	2022-08-31	Edoxaban 30mg / ASA indication
932	874	Edoxaban	ASA indication	BMK486L	21.1.21 9:27	2022-08-31	Edoxaban 30mg / ASA indication
932	874	Edoxaban	ASA indication	EYW112X	26.7.21 8:58	2022-08-31	Edoxaban 30mg / ASA indication
932	874	Edoxaban	ASA indication	RAH132M	15.7.19 8:44	2022-08-31	Edoxaban 30mg / ASA indication
932	874	Edoxaban	ASA indication	PGX638E	24.1.20 14:24	2022-08-31	Edoxaban 30mg / ASA indication
1171	874	Edoxaban	ASA indication	MEZ865Z	14.2.20 7:38	2021-12-31	Edoxaban 60mg / ASA indication
1171	874	Edoxaban	ASA indication	NZF725Y	11.6.19 9:53	2020-01-01	Edoxaban 60mg / ASA indication
1181	874	Edoxaban	ASA indication	ULX733H	28.12.19 9:50	2021-12-31	Edoxaban 60mg / ASA indication
1181	874	Edoxaban	ASA indication	CSY116W	21.12.21 15:27	2024-04-30	Edoxaban 60mg / ASA indication
1181	874	Edoxaban	ASA indication	KPG269R	14.6.21 13:55	2021-12-31	Edoxaban 60mg / ASA indication
1181	874	Edoxaban	ASA indication	BPE154Y	26.12.20 9:44	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1181	874	Edoxaban	ASA indication	LMW746V	8.7.20 9:27	2021-12-31	Edoxaban 60mg / ASA indication
1181	874	Edoxaban	ASA indication	PSH732U	1.7.22 11:48	2024-04-30	Edoxaban 60mg / ASA indication
1181	874	Edoxaban	ASA indication	RDR443V	26.6.19 9:48	2021-12-31	Edoxaban 60mg / ASA indication
1469	874	Edoxaban	ASA indication	PDK519N	29.7.20 7:19	2022-08-31	Edoxaban 30mg / ASA indication
1469	874	Edoxaban	ASA indication	XHV149N	10.1.20 15:07	2022-08-31	Edoxaban 30mg / ASA indication
1724	874	Edoxaban	ASA indication	YHW114Z	6.8.20 10:31	2022-08-31	Edoxaban 30mg / ASA indication
1726	874	Edoxaban	ASA indication	BNW534D	7.8.20 12:51	2022-08-31	Edoxaban 30mg / ASA indication
831	874	Edoxaban	no ASA indication	NSB256W	10.12.18 15:44	2020-01-01	Edoxaban 60mg / no ASA indication
911	874	Edoxaban	no ASA indication	ZDK561Z	3.7.20 17:25	2022-08-31	Edoxaban 30mg / no ASA indication
911	874	Edoxaban	no ASA indication	YRS794U	28.12.20 14:46	2022-08-31	Edoxaban 30mg / no ASA indication
911	874	Edoxaban	no ASA indication	ZMF573S	9.7.19 16:33	2022-08-31	Edoxaban 30mg / no ASA indication
911	874	Edoxaban	no ASA indication	KWR169F	14.1.22 9:12	2022-08-31	Edoxaban 30mg / no ASA indication
911	874	Edoxaban	no ASA indication	BCZ526U	25.1.20 9:03	2022-08-31	Edoxaban 30mg / no ASA indication
911	874	Edoxaban	no ASA indication	RGZ856V	24.12.18 10:02	2020-01-01	Edoxaban 30mg / no ASA indication
911	874	Edoxaban	no ASA indication	UYX987F	8.7.21 12:45	2022-08-31	Edoxaban 30mg / no ASA indication
646	875	Placebo	ASA indication	TAF733D	13.2.19 8:09	2020-01-01	Edoxaban 60mg / no ASA indication
646	875	Placebo	ASA indication	HHP629S	31.7.18 8:44	2020-01-01	Edoxaban 60mg / ASA indication
646	875	Placebo	ASA indication	FGY766X	11.2.21 10:03	2021-12-31	Edoxaban 60mg / no ASA indication
646	875	Placebo	ASA indication	HMN822V	15.8.19 8:18	2021-12-31	Edoxaban 60mg / no ASA indication
646	875	Placebo	ASA indication	HPA353C	19.8.21 11:38	2024-04-30	Edoxaban 60mg / no ASA indication
646	875	Placebo	ASA indication	BFB914L	10.8.20 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
646	875	Placebo	ASA indication	NBX125N	10.2.20 10:11	2021-12-31	Edoxaban 60mg / no ASA indication
646	875	Placebo	ASA indication	RWC313F	9.2.22 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	PTM287H	30.7.20 7:35	2021-12-31	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	FWT275X	4.2.21 13:29	2021-12-31	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	DXX283C	2.8.21 8:58	2024-04-30	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	PEF128D	30.1.20 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	VMN731V	8.8.22 7:39	2024-04-30	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	KWF326G	29.1.19 8:56	2020-01-01	Edoxaban 60mg / ASA indication
956	875	Placebo	ASA indication	CKL837N	25.7.19 9:18	2021-12-31	Edoxaban 60mg / no ASA indication
956	875	Placebo	ASA indication	NDZ462K	31.1.22 8:59	2024-04-30	Edoxaban 60mg / no ASA indication
751	875	Placebo	no ASA indication	KFR716M	12.10.18 13:04	2020-01-01	Edoxaban 60mg / no ASA indication
939	875	Placebo	no ASA indication	WAA373A	17.1.19 8:26	2020-01-01	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	KCS535R	6.4.20 9:25	2021-12-31	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	KDL289E	5.4.21 11:01	2021-12-31	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	ENM152X	28.9.19 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	VNB314G	18.4.22 8:36	2024-04-30	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	BGD499D	2.10.20 6:57	2021-12-31	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	LFS315N	11.10.21 9:22	2024-04-30	Edoxaban 60mg / no ASA indication
1055	875	Placebo	no ASA indication	VAX473E	3.4.19 11:04	2020-01-01	Edoxaban 60mg / no ASA indication
1144	875	Placebo	no ASA indication	UDW686Z	16.6.20 8:25	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1144	875	Placebo	no ASA indication	SRL431Z	28.5.19 7:35	2020-01-01	Edoxaban 60mg / no ASA indication
1144	875	Placebo	no ASA indication	DWB316A	5.12.19 7:38	2021-12-31	Edoxaban 60mg / no ASA indication
1608	875	Placebo	no ASA indication	DVP448K	25.6.21 14:10	2024-04-30	Edoxaban 60mg / no ASA indication
1608	875	Placebo	no ASA indication	DRH241V	7.12.20 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
1608	875	Placebo	no ASA indication	LLR895Z	3.6.20 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
1650	875	Placebo	no ASA indication	VRF132U	18.6.20 14:39	2021-12-31	Edoxaban 60mg / no ASA indication
1650	875	Placebo	no ASA indication	DPT814M	21.12.20 16:05	2021-12-31	Edoxaban 60mg / no ASA indication
1650	875	Placebo	no ASA indication	FHA821T	5.7.21 13:09	2024-04-30	Edoxaban 60mg / no ASA indication
1650	875	Placebo	no ASA indication	LFE324R	4.1.22 15:02	2024-04-30	Edoxaban 60mg / no ASA indication
1650	875	Placebo	no ASA indication	VEA998U	12.7.22 14:57	2024-04-30	Edoxaban 60mg / no ASA indication
2004	875	Placebo	no ASA indication	TFS217U	4.4.22 9:50	2024-04-30	Edoxaban 60mg / no ASA indication
2004	875	Placebo	no ASA indication	HXA754F	11.3.21 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
2004	875	Placebo	no ASA indication	HUR243A	24.9.21 6:26	2024-04-30	Edoxaban 60mg / no ASA indication
2175	875	Placebo	no ASA indication	ZBL812N	23.12.21 11:17	2022-08-31	Edoxaban 30mg / no ASA indication
2175	875	Placebo	no ASA indication	EEX662N	29.6.21 12:25	2024-04-30	Edoxaban 60mg / no ASA indication
2175	875	Placebo	no ASA indication	DNB212V	29.6.22 10:59	2024-11-30	Edoxaban 30mg / no ASA indication
638	875	Edoxaban	ASA indication	ZDW619M	30.1.20 9:47	2021-12-31	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	MWR821H	24.7.18 11:00	2020-01-01	Edoxaban 60mg / ASA indication
638	875	Edoxaban	ASA indication	YTB739K	24.1.19 12:03	2020-01-01	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	TBP971C	15.8.22 7:15	2024-04-30	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	FSP665L	29.7.19 8:07	2021-12-31	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	BXH742C	7.8.20 10:17	2021-12-31	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	HUL666K	25.1.21 7:55	2021-12-31	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	FEZ112C	16.8.21 8:18	2024-04-30	Edoxaban 60mg / no ASA indication
638	875	Edoxaban	ASA indication	LPN517B	21.2.22 9:52	2024-04-30	Edoxaban 60mg / no ASA indication
1027	875	Edoxaban	ASA indication	GUV243E	15.3.19 12:07	2020-01-01	Edoxaban 30mg / ASA indication
2167	875	Edoxaban	ASA indication	DUY824C	25.6.21 14:29	2024-04-30	Edoxaban 60mg / ASA indication
636	875	Edoxaban	no ASA indication	YDM353A	29.1.20 10:02	2021-12-31	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	PFY994F	1.8.20 9:55	2021-12-31	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	PUE613R	24.1.19 9:00	2020-01-01	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	DBG319P	26.7.21 11:13	2024-04-30	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	KZC488T	9.2.22 10:23	2024-04-30	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	SSV919Z	11.8.22 11:57	2024-04-30	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	FVM598T	24.7.18 9:58	2020-01-01	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	HUZ769F	25.1.21 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
636	875	Edoxaban	no ASA indication	XBH829Z	25.7.19 8:25	2021-12-31	Edoxaban 60mg / no ASA indication
664	875	Edoxaban	no ASA indication	VDA543L	10.8.18 10:17	2020-01-01	Edoxaban 60mg / no ASA indication
1043	875	Edoxaban	no ASA indication	GKR262Z	4.10.21 7:38	2024-04-30	Edoxaban 60mg / no ASA indication
1043	875	Edoxaban	no ASA indication	GGB139M	6.4.20 6:54	2021-12-31	Edoxaban 60mg / no ASA indication
1043	875	Edoxaban	no ASA indication	MRN824E	27.3.19 12:01	2020-01-01	Edoxaban 60mg / no ASA indication
1043	875	Edoxaban	no ASA indication	PGW197X	27.9.19 9:13	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1043	875	Edoxaban	no ASA indication	MSA326X	13.4.22 7:16	2024-04-30	Edoxaban 60mg / no ASA indication
1043	875	Edoxaban	no ASA indication	DGL646M	13.10.20 6:23	2021-12-31	Edoxaban 60mg / no ASA indication
1043	875	Edoxaban	no ASA indication	HVA893X	6.4.21 8:21	2021-12-31	Edoxaban 60mg / no ASA indication
1197	875	Edoxaban	no ASA indication	MAY358N	9.1.20 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
1197	875	Edoxaban	no ASA indication	DLG542C	21.12.20 12:54	2021-12-31	Edoxaban 60mg / no ASA indication
1197	875	Edoxaban	no ASA indication	EMK546F	21.6.19 19:07	2021-12-31	Edoxaban 60mg / no ASA indication
1197	875	Edoxaban	no ASA indication	HWW811F	16.6.21 11:33	2021-12-31	Edoxaban 60mg / no ASA indication
1197	875	Edoxaban	no ASA indication	SRR623K	2.7.20 7:06	2021-12-31	Edoxaban 60mg / no ASA indication
1284	875	Edoxaban	no ASA indication	WXV285S	12.9.19 11:59	2021-12-31	Edoxaban 60mg / no ASA indication
1676	875	Edoxaban	no ASA indication	SAH845H	3.7.20 16:56	2021-12-31	Edoxaban 60mg / no ASA indication
1676	875	Edoxaban	no ASA indication	KDU315U	21.7.22 8:29	2024-11-30	Edoxaban 30mg / no ASA indication
1676	875	Edoxaban	no ASA indication	NYE112X	5.1.22 12:29	2022-08-31	Edoxaban 30mg / no ASA indication
1676	875	Edoxaban	no ASA indication	GTG196S	15.1.21 10:59	2021-12-31	Edoxaban 60mg / no ASA indication
1676	875	Edoxaban	no ASA indication	TRD618F	8.7.21 8:42	2022-08-31	Edoxaban 30mg / no ASA indication
1931	875	Edoxaban	no ASA indication	DAW272P	4.8.21 6:42	2024-04-30	Edoxaban 60mg / no ASA indication
1931	875	Edoxaban	no ASA indication	BPX735L	19.1.21 15:00	2021-12-31	Edoxaban 60mg / no ASA indication
2388	875	Edoxaban	no ASA indication	DBE821V	10.12.21 16:18	2024-04-30	Edoxaban 60mg / no ASA indication
2388	875	Edoxaban	no ASA indication	SDV139N	6.6.22 14:08	2024-04-30	Edoxaban 60mg / no ASA indication
2415	875	Edoxaban	no ASA indication	KYS418Y	5.1.22 11:34	2024-04-30	Edoxaban 60mg / no ASA indication
2415	875	Edoxaban	no ASA indication	SAN932A	5.7.22 10:00	2024-04-30	Edoxaban 60mg / no ASA indication
744	876	Placebo	ASA indication	YMU348H	9.4.19 10:42	2020-01-01	Edoxaban 60mg / ASA indication
744	876	Placebo	ASA indication	KDC795C	2.4.20 12:03	2021-12-31	Edoxaban 60mg / ASA indication
744	876	Placebo	ASA indication	MUW634V	11.10.19 12:37	2021-12-31	Edoxaban 60mg / ASA indication
744	876	Placebo	ASA indication	WXU121L	9.10.18 18:54	2020-01-01	Edoxaban 60mg / ASA indication
859	876	Placebo	ASA indication	VRX489T	3.6.19 8:21	2020-01-01	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	CMS982T	13.6.22 8:11	2024-11-30	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	SBA967V	30.11.18 17:12	2020-01-01	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	MAT594B	10.12.19 9:58	2022-08-31	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	BXU336X	11.6.21 9:38	2022-08-31	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	FAM696B	22.6.20 16:38	2022-08-31	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	BMX712T	3.12.20 9:06	2022-08-31	Edoxaban 30mg / ASA indication
859	876	Placebo	ASA indication	ERB361D	8.12.21 9:34	2022-08-31	Edoxaban 30mg / ASA indication
896	876	Placebo	ASA indication	SAM181U	26.6.20 11:26	2022-08-31	Edoxaban 30mg / ASA indication
896	876	Placebo	ASA indication	BDT168X	23.12.20 9:59	2021-12-31	Edoxaban 60mg / ASA indication
896	876	Placebo	ASA indication	BNB125Z	28.6.19 6:15	2021-12-31	Edoxaban 60mg / ASA indication
896	876	Placebo	ASA indication	CHT645X	15.12.21 10:27	2024-04-30	Edoxaban 60mg / ASA indication
896	876	Placebo	ASA indication	LMH521U	14.6.22 9:42	2024-04-30	Edoxaban 60mg / ASA indication
896	876	Placebo	ASA indication	DTU143M	18.12.18 8:49	2020-01-01	Edoxaban 60mg / ASA indication
896	876	Placebo	ASA indication	BSK647U	19.12.19 10:20	2022-08-31	Edoxaban 30mg / ASA indication
896	876	Placebo	ASA indication	AYC833Z	24.6.21 9:04	2022-08-31	Edoxaban 30mg / ASA indication
736	876	Placebo	no ASA indication	LTC434T	29.3.19 12:09	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
736	876	Placebo	no ASA indication	ARK552T	2.4.20 11:49	2021-12-31	Edoxaban 60mg / ASA indication
736	876	Placebo	no ASA indication	AUZ534L	5.10.18 9:29	2020-01-01	Edoxaban 60mg / no ASA indication
736	876	Placebo	no ASA indication	LMN893Y	7.10.19 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
877	876	Placebo	no ASA indication	BPV423A	13.6.19 7:30	2020-01-01	Edoxaban 30mg / ASA indication
877	876	Placebo	no ASA indication	WBS866W	18.6.20 5:52	2021-12-31	Edoxaban 60mg / no ASA indication
877	876	Placebo	no ASA indication	DNA227T	5.7.21 14:43	2024-04-30	Edoxaban 60mg / no ASA indication
877	876	Placebo	no ASA indication	GPM538N	10.12.19 9:17	2021-12-31	Edoxaban 60mg / no ASA indication
877	876	Placebo	no ASA indication	HCH743Z	10.12.18 10:55	2020-01-01	Edoxaban 60mg / no ASA indication
877	876	Placebo	no ASA indication	AVF828X	1.12.20 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
1385	876	Placebo	no ASA indication	ECB824R	19.5.20 6:19	2021-12-31	Edoxaban 60mg / no ASA indication
1385	876	Placebo	no ASA indication	XYP531R	17.5.21 7:32	2022-08-31	Edoxaban 30mg / no ASA indication
1385	876	Placebo	no ASA indication	VTV627P	30.5.22 8:38	2024-04-30	Edoxaban 60mg / no ASA indication
1385	876	Placebo	no ASA indication	WSB954X	14.11.19 10:43	2021-12-31	Edoxaban 60mg / no ASA indication
1385	876	Placebo	no ASA indication	WMY777M	19.11.20 8:25	2022-08-31	Edoxaban 30mg / no ASA indication
1385	876	Placebo	no ASA indication	KPE662N	8.11.21 7:35	2022-08-31	Edoxaban 30mg / no ASA indication
1628	876	Placebo	no ASA indication	AUR112H	9.12.20 17:29	2021-12-31	Edoxaban 60mg / no ASA indication
1628	876	Placebo	no ASA indication	DPF688S	13.7.21 6:20	2024-04-30	Edoxaban 60mg / no ASA indication
1628	876	Placebo	no ASA indication	CCY879U	12.6.20 7:32	2021-12-31	Edoxaban 60mg / no ASA indication
1628	876	Placebo	no ASA indication	GNH231W	16.6.22 7:53	2024-04-30	Edoxaban 60mg / no ASA indication
1628	876	Placebo	no ASA indication	GKG457R	24.12.21 9:43	2024-04-30	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	VPN791A	19.3.19 10:44	2020-01-01	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	SXB335S	20.3.20 12:41	2021-12-31	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	DUP567E	14.9.18 13:19	2020-01-01	Edoxaban 60mg / ASA indication
708	876	Edoxaban	ASA indication	BHA915X	24.9.20 9:54	2021-12-31	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	CYP988D	24.9.19 9:58	2021-12-31	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	LCH353B	7.4.22 14:26	2024-04-30	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	HPG819E	13.3.21 6:50	2021-12-31	Edoxaban 60mg / no ASA indication
708	876	Edoxaban	ASA indication	FEH396B	15.9.21 10:06	2024-04-30	Edoxaban 60mg / no ASA indication
1732	876	Edoxaban	ASA indication	DSV632S	15.12.21 11:03	2024-04-30	Edoxaban 60mg / ASA indication
1732	876	Edoxaban	ASA indication	BMH979T	14.8.20 8:13	2021-12-31	Edoxaban 60mg / ASA indication
1732	876	Edoxaban	ASA indication	DKC935U	22.2.22 9:36	2024-04-30	Edoxaban 60mg / ASA indication
1732	876	Edoxaban	ASA indication	RGE624U	24.2.21 10:03	2021-12-31	Edoxaban 60mg / ASA indication
901	876	Edoxaban	no ASA indication	KWD837L	27.6.20 6:41	2021-12-31	Edoxaban 60mg / no ASA indication
901	876	Edoxaban	no ASA indication	VSL565Z	18.12.18 20:48	2020-01-01	Edoxaban 60mg / no ASA indication
901	876	Edoxaban	no ASA indication	FUK177U	22.12.20 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
901	876	Edoxaban	no ASA indication	CWD537F	25.12.19 8:57	2021-12-31	Edoxaban 60mg / no ASA indication
901	876	Edoxaban	no ASA indication	KWL418H	24.12.21 10:44	2024-04-30	Edoxaban 60mg / no ASA indication
901	876	Edoxaban	no ASA indication	YTR373Y	21.6.19 7:25	2021-12-31	Edoxaban 60mg / no ASA indication
901	876	Edoxaban	no ASA indication	CNU683A	26.6.21 8:22	2024-04-30	Edoxaban 60mg / no ASA indication
1145	876	Edoxaban	no ASA indication	ZNM932L	22.11.19 11:48	2021-12-31	Edoxaban 60mg / no ASA indication
1145	876	Edoxaban	no ASA indication	CCA757W	28.5.19 9:19	2020-01-01	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1145	876	Edoxaban	no ASA indication	BLP364T	26.11.20 10:24	2021-12-31	Edoxaban 60mg / no ASA indication
1145	876	Edoxaban	no ASA indication	CTZ226B	9.12.21 8:53	2024-04-30	Edoxaban 60mg / no ASA indication
1145	876	Edoxaban	no ASA indication	CKA248P	7.6.22 7:29	2024-11-30	Edoxaban 30mg / no ASA indication
1145	876	Edoxaban	no ASA indication	ANC882M	31.5.21 10:28	2021-12-31	Edoxaban 60mg / no ASA indication
1145	876	Edoxaban	no ASA indication	CLZ233D	5.6.20 7:30	2021-12-31	Edoxaban 60mg / no ASA indication
1443	876	Edoxaban	no ASA indication	WAP994D	23.6.20 10:39	2022-08-31	Edoxaban 30mg / no ASA indication
1443	876	Edoxaban	no ASA indication	TTS115B	11.6.22 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
1443	876	Edoxaban	no ASA indication	HUV358X	11.12.19 10:24	2021-12-31	Edoxaban 60mg / no ASA indication
1443	876	Edoxaban	no ASA indication	KPR164T	14.12.21 10:12	2024-04-30	Edoxaban 60mg / no ASA indication
1443	876	Edoxaban	no ASA indication	BPN531K	1.6.21 7:54	2022-08-31	Edoxaban 30mg / no ASA indication
1443	876	Edoxaban	no ASA indication	BRK947T	10.12.20 12:12	2022-08-31	Edoxaban 30mg / no ASA indication
1656	876	Edoxaban	no ASA indication	NHL516D	23.6.20 9:39	2022-08-31	Edoxaban 30mg / no ASA indication
1656	876	Edoxaban	no ASA indication	LSD148V	14.7.21 7:26	2022-08-31	Edoxaban 30mg / no ASA indication
1656	876	Edoxaban	no ASA indication	CGH186C	15.7.22 7:56	2024-11-30	Edoxaban 30mg / no ASA indication
1656	876	Edoxaban	no ASA indication	FTY194F	30.12.20 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
1656	876	Edoxaban	no ASA indication	DTD177E	6.1.22 9:22	2022-08-31	Edoxaban 30mg / no ASA indication
801	877	Placebo	ASA indication	MCC531S	7.11.18 12:41	2020-01-01	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	LLM472V	16.12.19 10:28	2021-12-31	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	VTM937D	30.6.20 7:41	2021-12-31	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	GEE155K	14.12.18 8:38	2020-01-01	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	DYT998N	30.6.21 10:31	2024-04-30	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	HHN349C	20.12.21 8:00	2024-04-30	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	LUE789H	3.12.18 10:15	2020-01-01	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	BHG487E	4.12.20 9:09	2021-12-31	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	HHE217M	21.6.19 12:09	2021-12-31	Edoxaban 60mg / ASA indication
860	877	Placebo	ASA indication	DBG218R	22.7.22 8:30	2024-04-30	Edoxaban 60mg / ASA indication
1275	877	Placebo	ASA indication	UZA415Z	9.9.19 9:38	2021-12-31	Edoxaban 60mg / ASA indication
1295	877	Placebo	ASA indication	AZW932L	24.9.20 6:56	2021-12-31	Edoxaban 60mg / ASA indication
1295	877	Placebo	ASA indication	NWL284U	2.4.20 7:00	2021-12-31	Edoxaban 60mg / ASA indication
1295	877	Placebo	ASA indication	HTC692D	24.9.19 8:57	2021-12-31	Edoxaban 60mg / ASA indication
1352	877	Placebo	ASA indication	EXM938K	11.5.21 5:46	2021-12-31	Edoxaban 60mg / ASA indication
1352	877	Placebo	ASA indication	AUS472C	20.11.20 10:18	2021-12-31	Edoxaban 60mg / ASA indication
1352	877	Placebo	ASA indication	XLT644X	5.5.20 6:22	2021-12-31	Edoxaban 60mg / ASA indication
1352	877	Placebo	ASA indication	SBU388L	28.10.19 11:31	2021-12-31	Edoxaban 60mg / ASA indication
1919	877	Placebo	ASA indication	KCM881E	5.1.21 10:25	2022-08-31	Edoxaban 30mg / ASA indication
1919	877	Placebo	ASA indication	CWG478W	18.1.22 7:30	2022-08-31	Edoxaban 30mg / ASA indication
1919	877	Placebo	ASA indication	UCC756H	8.7.21 6:01	2022-08-31	Edoxaban 30mg / ASA indication
1919	877	Placebo	ASA indication	EPT894E	21.7.22 7:23	2024-04-30	Edoxaban 60mg / ASA indication
2260	877	Placebo	ASA indication	DAP285H	8.9.21 9:53	2024-04-30	Edoxaban 60mg / ASA indication
695	877	Placebo	no ASA indication	ZCS239B	25.3.20 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
695	877	Placebo	no ASA indication	EEE113H	13.9.19 7:58	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
695	877	Placebo	no ASA indication	NAS756V	14.3.19 8:36	2020-01-01	Edoxaban 60mg / no ASA indication
695	877	Placebo	no ASA indication	ELH548F	14.9.21 7:48	2024-04-30	Edoxaban 60mg / no ASA indication
695	877	Placebo	no ASA indication	DAX424B	4.9.18 12:04	2020-01-01	Edoxaban 60mg / no ASA indication
695	877	Placebo	no ASA indication	EPG212Y	15.3.21 9:28	2021-12-31	Edoxaban 60mg / no ASA indication
695	877	Placebo	no ASA indication	ARE593W	11.9.20 8:17	2021-12-31	Edoxaban 60mg / no ASA indication
757	877	Placebo	no ASA indication	WDX519V	9.6.20 8:23	2021-12-31	Edoxaban 60mg / no ASA indication
757	877	Placebo	no ASA indication	UVN494M	18.10.19 8:40	2021-12-31	Edoxaban 60mg / no ASA indication
757	877	Placebo	no ASA indication	NHT314E	18.4.19 10:25	2020-01-01	Edoxaban 60mg / no ASA indication
757	877	Placebo	no ASA indication	HNB725D	18.10.18 10:25	2020-01-01	Edoxaban 60mg / no ASA indication
915	877	Placebo	no ASA indication	MHM488B	6.1.20 9:14	2021-12-31	Edoxaban 60mg / no ASA indication
915	877	Placebo	no ASA indication	TDP451H	4.7.20 6:23	2021-12-31	Edoxaban 60mg / no ASA indication
915	877	Placebo	no ASA indication	SPT948Z	30.12.20 12:14	2022-08-31	Edoxaban 30mg / no ASA indication
915	877	Placebo	no ASA indication	AHE478F	4.7.19 8:20	2021-12-31	Edoxaban 60mg / no ASA indication
915	877	Placebo	no ASA indication	RUP695A	28.12.18 10:30	2020-01-01	Edoxaban 60mg / no ASA indication
1092	877	Placebo	no ASA indication	XUY697D	19.4.19 9:49	2020-01-01	Edoxaban 30mg / no ASA indication
1092	877	Placebo	no ASA indication	FZV882V	21.10.19 5:32	2022-08-31	Edoxaban 30mg / no ASA indication
1092	877	Placebo	no ASA indication	BTY298M	17.4.21 8:33	2022-08-31	Edoxaban 30mg / no ASA indication
1092	877	Placebo	no ASA indication	DNL493L	6.11.20 7:16	2021-12-31	Edoxaban 60mg / no ASA indication
1092	877	Placebo	no ASA indication	GTE549Y	22.10.21 6:36	2022-08-31	Edoxaban 30mg / no ASA indication
1092	877	Placebo	no ASA indication	KFY712N	24.4.20 7:44	2021-12-31	Edoxaban 60mg / no ASA indication
1141	877	Placebo	no ASA indication	RYA293H	23.5.19 11:07	2020-01-01	Edoxaban 60mg / no ASA indication
1592	877	Placebo	no ASA indication	DLC647R	30.11.20 8:28	2021-12-31	Edoxaban 60mg / no ASA indication
1592	877	Placebo	no ASA indication	HDR267A	19.11.21 7:58	2022-08-31	Edoxaban 30mg / no ASA indication
1592	877	Placebo	no ASA indication	GCY976U	2.6.21 9:04	2022-08-31	Edoxaban 30mg / no ASA indication
1592	877	Placebo	no ASA indication	UDR633S	19.5.20 7:51	2021-12-31	Edoxaban 60mg / no ASA indication
1795	877	Placebo	no ASA indication	ESL479S	11.5.21 8:25	2021-12-31	Edoxaban 60mg / no ASA indication
1795	877	Placebo	no ASA indication	ANY579S	19.9.20 6:54	2021-12-31	Edoxaban 60mg / no ASA indication
2132	877	Placebo	no ASA indication	LGV786T	12.1.22 6:43	2024-04-30	Edoxaban 60mg / no ASA indication
2132	877	Placebo	no ASA indication	DMD734P	2.6.21 8:58	2021-12-31	Edoxaban 60mg / no ASA indication
2276	877	Placebo	no ASA indication	EGX513L	17.9.21 9:17	2024-04-30	Edoxaban 60mg / no ASA indication
2285	877	Placebo	no ASA indication	FGH215E	28.9.21 8:15	2024-04-30	Edoxaban 60mg / no ASA indication
2285	877	Placebo	no ASA indication	LMU348R	17.5.22 14:55	2024-04-30	Edoxaban 60mg / no ASA indication
706	877	Edoxaban	ASA indication	BSV417Z	18.9.19 8:50	2021-12-31	Edoxaban 60mg / ASA indication
706	877	Edoxaban	ASA indication	BDB243W	22.9.20 7:19	2022-08-31	Edoxaban 30mg / ASA indication
706	877	Edoxaban	ASA indication	YSV138A	13.3.19 9:02	2020-01-01	Edoxaban 60mg / ASA indication
706	877	Edoxaban	ASA indication	EMT394Z	14.9.18 9:46	2020-01-01	Edoxaban 60mg / ASA indication
706	877	Edoxaban	ASA indication	RFM759V	3.4.20 6:26	2021-12-31	Edoxaban 60mg / ASA indication
706	877	Edoxaban	ASA indication	CXP545S	25.3.21 7:36	2022-08-31	Edoxaban 30mg / ASA indication
853	877	Edoxaban	ASA indication	KUL477T	4.6.19 7:52	2020-01-01	Edoxaban 60mg / ASA indication
853	877	Edoxaban	ASA indication	ZXU883R	14.12.18 12:10	2020-01-01	Edoxaban 60mg / ASA indication
853	877	Edoxaban	ASA indication	TPV536D	4.12.19 10:08	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
853	877	Edoxaban	ASA indication	VYH185G	30.11.18 10:50	2020-01-01	Edoxaban 60mg / ASA indication
853	877	Edoxaban	ASA indication	AMP932E	4.6.20 8:10	2022-08-31	Edoxaban 30mg / ASA indication
876	877	Edoxaban	ASA indication	NDA918F	10.12.18 10:33	2020-01-01	Edoxaban 60mg / ASA indication
876	877	Edoxaban	ASA indication	RPL461M	10.12.19 11:42	2021-12-31	Edoxaban 60mg / ASA indication
876	877	Edoxaban	ASA indication	ACC337K	2.7.20 9:06	2022-08-31	Edoxaban 30mg / ASA indication
876	877	Edoxaban	ASA indication	TMY162V	25.5.19 9:21	2020-01-01	Edoxaban 60mg / no ASA indication
876	877	Edoxaban	ASA indication	DWB998E	6.7.21 8:56	2022-08-31	Edoxaban 30mg / ASA indication
876	877	Edoxaban	ASA indication	DMS722N	23.12.20 9:10	2022-08-31	Edoxaban 30mg / no ASA indication
876	877	Edoxaban	ASA indication	FBS258Y	29.12.21 10:21	2022-08-31	Edoxaban 30mg / ASA indication
1649	877	Edoxaban	ASA indication	BDC552A	30.12.20 10:34	2022-08-31	Edoxaban 30mg / ASA indication
1649	877	Edoxaban	ASA indication	DXS331S	7.7.21 6:21	2022-08-31	Edoxaban 30mg / ASA indication
1649	877	Edoxaban	ASA indication	EMB761P	17.1.22 9:22	2022-08-31	Edoxaban 30mg / ASA indication
1649	877	Edoxaban	ASA indication	YKP699H	18.6.20 9:33	2022-08-31	Edoxaban 30mg / ASA indication
1803	877	Edoxaban	ASA indication	ABH964H	19.5.21 7:48	2021-12-31	Edoxaban 60mg / ASA indication
1803	877	Edoxaban	ASA indication	ZUK527A	28.9.20 9:26	2021-12-31	Edoxaban 60mg / ASA indication
2003	877	Edoxaban	ASA indication	LMG635S	11.3.21 10:47	2021-12-31	Edoxaban 60mg / ASA indication
2003	877	Edoxaban	ASA indication	ECV393B	27.9.21 7:14	2024-04-30	Edoxaban 60mg / ASA indication
2050	877	Edoxaban	ASA indication	VFS837N	16.4.21 10:22	2021-12-31	Edoxaban 60mg / ASA indication
2050	877	Edoxaban	ASA indication	GZC296V	26.10.21 7:54	2024-04-30	Edoxaban 60mg / ASA indication
735	877	Edoxaban	no ASA indication	ZKZ412M	5.10.18 9:06	2020-01-01	Edoxaban 30mg / no ASA indication
737	877	Edoxaban	no ASA indication	WGV889T	5.10.18 9:31	2020-01-01	Edoxaban 60mg / no ASA indication
737	877	Edoxaban	no ASA indication	GFN831M	19.4.19 6:44	2020-01-01	Edoxaban 60mg / no ASA indication
737	877	Edoxaban	no ASA indication	MNL279P	16.10.19 9:15	2021-12-31	Edoxaban 60mg / no ASA indication
890	877	Edoxaban	no ASA indication	LSW742C	18.6.19 7:23	2020-01-01	Edoxaban 30mg / no ASA indication
890	877	Edoxaban	no ASA indication	KSU282K	14.12.18 10:36	2020-01-01	Edoxaban 30mg / no ASA indication
890	877	Edoxaban	no ASA indication	EPH472B	17.1.20 8:12	2022-08-31	Edoxaban 30mg / no ASA indication
890	877	Edoxaban	no ASA indication	SAN698C	8.7.20 7:41	2022-08-31	Edoxaban 30mg / no ASA indication
1023	877	Edoxaban	no ASA indication	EFX471X	20.9.19 5:27	2021-12-31	Edoxaban 60mg / no ASA indication
1023	877	Edoxaban	no ASA indication	BKE765X	26.2.20 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
1023	877	Edoxaban	no ASA indication	YCD978M	14.3.19 7:50	2020-01-01	Edoxaban 60mg / no ASA indication
1084	877	Edoxaban	no ASA indication	LAB291Y	18.10.21 13:33	2022-08-31	Edoxaban 30mg / no ASA indication
1084	877	Edoxaban	no ASA indication	GHY414D	7.4.20 8:18	2021-12-31	Edoxaban 60mg / no ASA indication
1084	877	Edoxaban	no ASA indication	ACB981L	10.10.19 7:47	2022-08-31	Edoxaban 30mg / no ASA indication
1084	877	Edoxaban	no ASA indication	GRF538V	16.4.19 10:15	2020-01-01	Edoxaban 30mg / no ASA indication
1084	877	Edoxaban	no ASA indication	BDN857Y	9.4.21 13:30	2022-08-31	Edoxaban 30mg / no ASA indication
1084	877	Edoxaban	no ASA indication	CZZ125P	8.10.20 7:26	2022-08-31	Edoxaban 30mg / no ASA indication
1613	877	Edoxaban	no ASA indication	HED378M	19.6.21 7:59	2022-08-31	Edoxaban 30mg / no ASA indication
1613	877	Edoxaban	no ASA indication	UMC329U	5.6.20 10:35	2021-12-31	Edoxaban 60mg / no ASA indication
1613	877	Edoxaban	no ASA indication	DBW937N	5.12.20 11:17	2021-12-31	Edoxaban 60mg / no ASA indication
1613	877	Edoxaban	no ASA indication	DFD996V	30.5.22 9:19	2024-04-30	Edoxaban 60mg / no ASA indication
1613	877	Edoxaban	no ASA indication	KTR526P	8.12.21 9:55	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1648	877	Edoxaban	no ASA indication	RFC354C	18.6.20 9:12	2022-08-31	Edoxaban 30mg / no ASA indication
1679	877	Edoxaban	no ASA indication	ECX692F	17.8.21 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
1679	877	Edoxaban	no ASA indication	EMA643V	26.1.21 9:00	2021-12-31	Edoxaban 60mg / no ASA indication
1679	877	Edoxaban	no ASA indication	ZTH566R	8.7.20 8:29	2021-12-31	Edoxaban 60mg / no ASA indication
893	881	Edoxaban	ASA indication	DYU655C	14.12.18 13:28	2020-01-01	Edoxaban 60mg / ASA indication
1495	884	Placebo	ASA indication	NBB198A	30.7.20 10:43	2021-12-31	Edoxaban 60mg / ASA indication
1495	884	Placebo	ASA indication	LEG497G	29.1.20 11:01	2021-12-31	Edoxaban 60mg / ASA indication
1495	884	Placebo	ASA indication	NXD847T	27.1.22 16:00	2024-04-30	Edoxaban 60mg / ASA indication
1495	884	Placebo	ASA indication	PHN659K	21.7.21 12:36	2024-04-30	Edoxaban 60mg / ASA indication
1495	884	Placebo	ASA indication	RVC444S	26.1.21 14:43	2021-12-31	Edoxaban 60mg / ASA indication
1377	884	Edoxaban	no ASA indication	HBA634V	5.5.20 12:25	2022-08-31	Edoxaban 30mg / no ASA indication
1377	884	Edoxaban	no ASA indication	VMS851E	4.11.21 11:11	2022-08-31	Edoxaban 30mg / no ASA indication
1377	884	Edoxaban	no ASA indication	KDX339U	16.5.22 12:30	2024-11-30	Edoxaban 30mg / no ASA indication
1377	884	Edoxaban	no ASA indication	SYU865Z	9.11.20 12:44	2022-08-31	Edoxaban 30mg / no ASA indication
1377	884	Edoxaban	no ASA indication	BKG584E	10.5.21 11:16	2022-08-31	Edoxaban 30mg / no ASA indication
1377	884	Edoxaban	no ASA indication	NHF359A	11.11.19 12:03	2022-08-31	Edoxaban 30mg / no ASA indication
984	901	Placebo	ASA indication	YHL597U	11.2.20 7:29	2021-12-31	Edoxaban 60mg / ASA indication
984	901	Placebo	ASA indication	CUD465M	11.2.22 8:45	2024-04-30	Edoxaban 60mg / ASA indication
984	901	Placebo	ASA indication	BED866A	11.2.19 9:02	2020-01-01	Edoxaban 60mg / ASA indication
984	901	Placebo	ASA indication	FCP421P	17.8.22 9:05	2024-04-30	Edoxaban 60mg / ASA indication
984	901	Placebo	ASA indication	SBX189U	9.2.21 13:15	2021-12-31	Edoxaban 60mg / ASA indication
984	901	Placebo	ASA indication	BEF735Z	26.8.19 6:48	2021-12-31	Edoxaban 60mg / no ASA indication
984	901	Placebo	ASA indication	APD912P	29.7.20 6:43	2021-12-31	Edoxaban 60mg / ASA indication
984	901	Placebo	ASA indication	TGT666L	19.8.21 6:25	2024-04-30	Edoxaban 60mg / ASA indication
1549	901	Placebo	ASA indication	APR921Z	1.9.20 6:27	2021-12-31	Edoxaban 60mg / ASA indication
1549	901	Placebo	ASA indication	KXK557W	16.3.21 13:07	2021-12-31	Edoxaban 60mg / ASA indication
1549	901	Placebo	ASA indication	XVN132R	10.3.20 8:16	2021-12-31	Edoxaban 60mg / ASA indication
1549	901	Placebo	ASA indication	UZD747L	7.9.22 7:32	2024-04-30	Edoxaban 60mg / ASA indication
1549	901	Placebo	ASA indication	SFE621K	15.3.22 11:02	2024-04-30	Edoxaban 60mg / ASA indication
1549	901	Placebo	ASA indication	TKD792M	22.9.21 12:27	2024-04-30	Edoxaban 60mg / ASA indication
1564	901	Placebo	ASA indication	TKB198B	5.10.21 10:15	2024-04-30	Edoxaban 60mg / ASA indication
1564	901	Placebo	ASA indication	LDN485C	31.3.21 6:43	2021-12-31	Edoxaban 60mg / ASA indication
1564	901	Placebo	ASA indication	FRU536C	30.9.20 6:39	2021-12-31	Edoxaban 60mg / ASA indication
1564	901	Placebo	ASA indication	CWC953Z	22.3.22 9:57	2024-04-30	Edoxaban 60mg / ASA indication
1564	901	Placebo	ASA indication	DVH164V	24.3.20 9:25	2021-12-31	Edoxaban 60mg / ASA indication
1859	901	Placebo	ASA indication	RSW379K	11.11.20 9:19	2021-12-31	Edoxaban 60mg / ASA indication
1859	901	Placebo	ASA indication	XXE276P	16.11.21 10:44	2024-04-30	Edoxaban 60mg / ASA indication
1859	901	Placebo	ASA indication	ZFE212S	30.5.22 12:26	2024-04-30	Edoxaban 60mg / ASA indication
1859	901	Placebo	ASA indication	DPG198Y	21.5.21 9:50	2021-12-31	Edoxaban 60mg / no ASA indication
2473	901	Placebo	ASA indication	XVU847R	9.2.22 11:08	2024-04-30	Edoxaban 60mg / ASA indication
2473	901	Placebo	ASA indication	VXR787T	16.8.22 9:08	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2490	901	Placebo	ASA indication	SDF123N	22.2.22 9:21	2024-04-30	Edoxaban 60mg / ASA indication
2490	901	Placebo	ASA indication	PCM375W	17.8.22 9:28	2024-04-30	Edoxaban 60mg / no ASA indication
2601	901	Placebo	ASA indication	VZN931U	28.4.22 11:32	2024-04-30	Edoxaban 60mg / ASA indication
2666	901	Placebo	ASA indication	ZGB626W	22.6.22 11:53	2024-04-30	Edoxaban 60mg / ASA indication
1217	901	Placebo	no ASA indication	LNS296R	28.6.22 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
1217	901	Placebo	no ASA indication	DBT424G	8.7.19 8:14	2021-12-31	Edoxaban 60mg / no ASA indication
1217	901	Placebo	no ASA indication	SFB524N	13.1.20 7:41	2021-12-31	Edoxaban 60mg / no ASA indication
1217	901	Placebo	no ASA indication	UBR952B	15.7.21 6:40	2024-04-30	Edoxaban 60mg / no ASA indication
1217	901	Placebo	no ASA indication	BFV976Y	25.6.20 6:30	2021-12-31	Edoxaban 60mg / no ASA indication
1217	901	Placebo	no ASA indication	VRX848M	13.1.22 11:26	2024-04-30	Edoxaban 60mg / no ASA indication
1217	901	Placebo	no ASA indication	UHK252B	7.1.21 7:55	2021-12-31	Edoxaban 60mg / no ASA indication
1566	901	Placebo	no ASA indication	BXC298U	6.10.20 6:26	2021-12-31	Edoxaban 60mg / no ASA indication
1566	901	Placebo	no ASA indication	HZG694R	24.3.20 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
1566	901	Placebo	no ASA indication	KUD443H	31.3.21 7:20	2021-12-31	Edoxaban 60mg / no ASA indication
1711	901	Placebo	no ASA indication	BWH353B	20.1.21 7:24	2021-12-31	Edoxaban 60mg / no ASA indication
1711	901	Placebo	no ASA indication	UAT983S	22.7.21 6:40	2024-04-30	Edoxaban 60mg / no ASA indication
1711	901	Placebo	no ASA indication	UCV316P	20.1.22 15:25	2024-04-30	Edoxaban 60mg / no ASA indication
1711	901	Placebo	no ASA indication	SSG768F	29.7.20 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
1711	901	Placebo	no ASA indication	PFP637P	20.7.22 8:49	2024-04-30	Edoxaban 60mg / no ASA indication
2381	901	Placebo	no ASA indication	VRT492S	3.12.21 14:16	2024-04-30	Edoxaban 60mg / no ASA indication
2476	901	Placebo	no ASA indication	LKS838H	11.2.22 11:09	2024-04-30	Edoxaban 60mg / no ASA indication
2476	901	Placebo	no ASA indication	TSE584K	24.8.22 8:49	2024-04-30	Edoxaban 60mg / no ASA indication
882	901	Edoxaban	ASA indication	WXG482T	22.6.20 7:54	2022-08-31	Edoxaban 30mg / ASA indication
882	901	Edoxaban	ASA indication	FPW156X	11.12.18 10:56	2020-01-01	Edoxaban 30mg / ASA indication
882	901	Edoxaban	ASA indication	TTZ127E	17.6.19 7:20	2020-01-01	Edoxaban 30mg / ASA indication
882	901	Edoxaban	ASA indication	NHV825K	11.12.19 7:36	2022-08-31	Edoxaban 30mg / ASA indication
1038	901	Edoxaban	ASA indication	KAP457L	15.9.20 6:36	2021-12-31	Edoxaban 60mg / ASA indication
1038	901	Edoxaban	ASA indication	ZXW484V	23.3.21 9:04	2021-12-31	Edoxaban 60mg / ASA indication
1038	901	Edoxaban	ASA indication	ALS378M	26.3.19 9:08	2020-01-01	Edoxaban 60mg / ASA indication
1038	901	Edoxaban	ASA indication	XLS194Y	24.9.19 7:10	2021-12-31	Edoxaban 60mg / ASA indication
1038	901	Edoxaban	ASA indication	TXH499A	12.3.20 7:40	2021-12-31	Edoxaban 60mg / ASA indication
1120	901	Edoxaban	ASA indication	VKL135L	13.5.19 9:30	2020-01-01	Edoxaban 30mg / ASA indication
1138	901	Edoxaban	ASA indication	MTA659N	23.5.19 8:02	2020-01-01	Edoxaban 60mg / ASA indication
1138	901	Edoxaban	ASA indication	TZG551B	19.11.19 8:27	2022-08-31	Edoxaban 30mg / ASA indication
2427	901	Edoxaban	ASA indication	UFD298W	12.1.22 15:02	2024-04-30	Edoxaban 60mg / ASA indication
2480	901	Edoxaban	ASA indication	UCF353R	15.2.22 11:26	2024-04-30	Edoxaban 60mg / ASA indication
2706	901	Edoxaban	ASA indication	UGR523E	11.7.22 8:54	2024-04-30	Edoxaban 60mg / ASA indication
2723	901	Edoxaban	ASA indication	GVN645E	21.7.22 12:46	2024-11-30	Edoxaban 30mg / ASA indication
1057	901	Edoxaban	no ASA indication	SVN383T	4.4.19 9:20	2020-01-01	Edoxaban 60mg / no ASA indication
1720	901	Edoxaban	no ASA indication	EWC563M	4.8.20 8:02	2022-08-31	Edoxaban 30mg / no ASA indication
1720	901	Edoxaban	no ASA indication	FCL472M	11.2.22 10:47	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1720	901	Edoxaban	no ASA indication	UKY674R	4.8.20 8:45	2022-08-31	Edoxaban 30mg / ASA indication
1720	901	Edoxaban	no ASA indication	KDN738V	15.2.21 13:12	2022-08-31	Edoxaban 30mg / ASA indication
1720	901	Edoxaban	no ASA indication	GUU644T	23.8.22 12:18	2024-11-30	Edoxaban 30mg / ASA indication
1720	901	Edoxaban	no ASA indication	BAZ393S	17.8.21 12:31	2022-08-31	Edoxaban 30mg / ASA indication
1880	901	Edoxaban	no ASA indication	SAF165T	7.6.21 6:21	2021-12-31	Edoxaban 60mg / no ASA indication
1880	901	Edoxaban	no ASA indication	XMV328W	25.11.20 11:18	2021-12-31	Edoxaban 60mg / no ASA indication
1880	901	Edoxaban	no ASA indication	EWP982F	2.6.22 10:04	2024-04-30	Edoxaban 60mg / no ASA indication
1880	901	Edoxaban	no ASA indication	TTK443Y	30.11.21 10:49	2024-04-30	Edoxaban 60mg / no ASA indication
2135	901	Edoxaban	no ASA indication	DPV824A	3.6.21 7:43	2021-12-31	Edoxaban 60mg / no ASA indication
2135	901	Edoxaban	no ASA indication	TTL223U	30.11.21 8:18	2024-04-30	Edoxaban 60mg / no ASA indication
2135	901	Edoxaban	no ASA indication	TTL534F	25.5.22 8:23	2024-04-30	Edoxaban 60mg / no ASA indication
2435	901	Edoxaban	no ASA indication	PYK731W	17.8.22 9:57	2024-11-30	Edoxaban 30mg / no ASA indication
2435	901	Edoxaban	no ASA indication	KCD815L	18.1.22 11:52	2022-08-31	Edoxaban 30mg / no ASA indication
2595	901	Edoxaban	no ASA indication	HSC113E	25.4.22 12:00	2024-11-30	Edoxaban 30mg / no ASA indication
2638	901	Edoxaban	no ASA indication	HRZ232U	1.6.22 14:15	2024-11-30	Edoxaban 30mg / no ASA indication
2739	901	Edoxaban	no ASA indication	EXZ897Z	22.8.22 12:49	2024-04-30	Edoxaban 60mg / no ASA indication
1273	964	Placebo	no ASA indication	HPT875Z	1.3.22 13:05	2024-11-30	Edoxaban 30mg / no ASA indication
1273	964	Placebo	no ASA indication	LHY212X	4.9.19 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
1273	964	Placebo	no ASA indication	FFA478Z	8.9.20 11:21	2021-12-31	Edoxaban 60mg / no ASA indication
1273	964	Placebo	no ASA indication	FMZ358V	7.9.21 10:53	2022-08-31	Edoxaban 30mg / no ASA indication
1273	964	Placebo	no ASA indication	ECC677E	4.3.20 11:39	2022-08-31	Edoxaban 30mg / no ASA indication
1273	964	Placebo	no ASA indication	LFF621D	17.3.21 11:51	2022-08-31	Edoxaban 30mg / no ASA indication
1049	965	Placebo	ASA indication	RXV999C	20.4.20 10:13	2021-12-31	Edoxaban 60mg / ASA indication
1049	965	Placebo	ASA indication	PXX478S	26.4.22 14:05	2024-04-30	Edoxaban 60mg / no ASA indication
1049	965	Placebo	ASA indication	GTR633K	28.10.20 10:19	2021-12-31	Edoxaban 60mg / no ASA indication
1049	965	Placebo	ASA indication	MZU921U	2.4.19 6:19	2020-01-01	Edoxaban 60mg / ASA indication
1049	965	Placebo	ASA indication	HCZ322A	19.4.21 9:17	2021-12-31	Edoxaban 60mg / no ASA indication
1049	965	Placebo	ASA indication	ACF399G	14.10.19 11:09	2021-12-31	Edoxaban 60mg / no ASA indication
1049	965	Placebo	ASA indication	UDL767H	20.10.21 10:04	2024-04-30	Edoxaban 60mg / no ASA indication
2280	965	Placebo	ASA indication	WPP577Y	23.9.21 11:17	2022-08-31	Edoxaban 30mg / ASA indication
2280	965	Placebo	ASA indication	HNR798T	23.6.22 9:39	2024-11-30	Edoxaban 30mg / ASA indication
2488	965	Placebo	no ASA indication	UCY812N	22.2.22 14:51	2024-04-30	Edoxaban 60mg / no ASA indication
2550	965	Placebo	no ASA indication	UEY777F	22.3.22 9:38	2024-04-30	Edoxaban 60mg / no ASA indication
2321	965	Edoxaban	ASA indication	GYS225G	1.11.21 13:30	2022-08-31	Edoxaban 30mg / ASA indication
2321	965	Edoxaban	ASA indication	HBK236C	27.5.22 6:29	2024-11-30	Edoxaban 30mg / ASA indication
2420	965	Edoxaban	ASA indication	LPN952K	11.1.22 7:31	2022-08-31	Edoxaban 30mg / ASA indication
2664	965	Edoxaban	ASA indication	HAY571V	22.6.22 11:32	2024-11-30	Edoxaban 30mg / ASA indication
1323	965	Edoxaban	no ASA indication	NWV648V	3.4.20 8:02	2022-08-31	Edoxaban 30mg / no ASA indication
1323	965	Edoxaban	no ASA indication	HWT265G	9.10.19 13:34	2021-12-31	Edoxaban 60mg / no ASA indication
2426	965	Edoxaban	no ASA indication	TTV448T	12.1.22 12:18	2024-04-30	Edoxaban 60mg / no ASA indication
2097	1023	Placebo	ASA indication	RYN712U	18.5.21 15:59	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2097	1023	Placebo	ASA indication	EZC817M	17.1.22 10:22	2024-04-30	Edoxaban 60mg / no ASA indication
2366	1023	Placebo	ASA indication	CNP167X	25.11.21 8:28	2022-08-31	Edoxaban 30mg / ASA indication
709	1023	Placebo	no ASA indication	ZBY547U	17.9.18 9:15	2020-01-01	Edoxaban 60mg / no ASA indication
2271	1023	Placebo	no ASA indication	ERD253U	15.9.21 10:38	2024-04-30	Edoxaban 60mg / no ASA indication
2022	1023	Edoxaban	no ASA indication	HXF625N	23.3.21 9:45	2021-12-31	Edoxaban 60mg / no ASA indication
2022	1023	Edoxaban	no ASA indication	EEZ765P	24.9.21 15:27	2024-04-30	Edoxaban 60mg / ASA indication
2022	1023	Edoxaban	no ASA indication	DVR482K	28.4.22 8:44	2024-04-30	Edoxaban 60mg / no ASA indication
1172	1028	Placebo	ASA indication	GSF719U	11.6.19 11:54	2020-01-01	Edoxaban 60mg / ASA indication
1172	1028	Placebo	ASA indication	MBL659S	10.11.21 11:17	2024-04-30	Edoxaban 60mg / no ASA indication
1172	1028	Placebo	ASA indication	FVM734U	3.11.20 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
1172	1028	Placebo	ASA indication	TMM586E	4.5.20 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
1172	1028	Placebo	ASA indication	MXH536F	5.11.19 10:39	2021-12-31	Edoxaban 60mg / no ASA indication
1172	1028	Placebo	ASA indication	RKB754F	19.5.22 8:48	2024-04-30	Edoxaban 60mg / no ASA indication
1172	1028	Placebo	ASA indication	VXN336R	27.4.21 9:28	2021-12-31	Edoxaban 60mg / no ASA indication
2573	1028	Placebo	ASA indication	RVZ813G	5.4.22 10:49	2024-04-30	Edoxaban 60mg / ASA indication
1342	1028	Placebo	no ASA indication	PKH484E	21.10.21 9:26	2022-08-31	Edoxaban 30mg / no ASA indication
1342	1028	Placebo	no ASA indication	BUB448C	27.4.21 8:54	2022-08-31	Edoxaban 30mg / no ASA indication
1342	1028	Placebo	no ASA indication	MLU522T	21.10.20 9:52	2022-08-31	Edoxaban 30mg / no ASA indication
1342	1028	Placebo	no ASA indication	FWT415L	20.4.20 10:27	2022-08-31	Edoxaban 30mg / no ASA indication
1342	1028	Placebo	no ASA indication	BTU229E	22.10.19 9:55	2022-08-31	Edoxaban 30mg / no ASA indication
1561	1028	Placebo	no ASA indication	VRY289N	9.3.21 13:29	2021-12-31	Edoxaban 60mg / no ASA indication
1561	1028	Placebo	no ASA indication	CTV294Z	17.3.20 11:19	2021-12-31	Edoxaban 60mg / no ASA indication
1561	1028	Placebo	no ASA indication	MHG253D	22.9.21 8:29	2024-04-30	Edoxaban 60mg / no ASA indication
1561	1028	Placebo	no ASA indication	GWD242A	9.9.20 8:33	2021-12-31	Edoxaban 60mg / no ASA indication
2156	1028	Placebo	no ASA indication	YBK516B	15.12.21 11:29	2022-08-31	Edoxaban 30mg / no ASA indication
2156	1028	Placebo	no ASA indication	PNZ922N	16.6.21 8:39	2022-08-31	Edoxaban 30mg / no ASA indication
2156	1028	Placebo	no ASA indication	HZZ132H	29.6.22 7:49	2024-11-30	Edoxaban 30mg / no ASA indication
2159	1028	Placebo	no ASA indication	RFV567P	7.12.21 11:05	2024-04-30	Edoxaban 60mg / no ASA indication
2159	1028	Placebo	no ASA indication	UPG682K	16.6.21 10:02	2021-12-31	Edoxaban 60mg / no ASA indication
2159	1028	Placebo	no ASA indication	MKL341C	29.6.22 9:25	2024-04-30	Edoxaban 60mg / no ASA indication
2696	1028	Placebo	no ASA indication	PNZ159V	6.7.22 10:33	2024-04-30	Edoxaban 60mg / no ASA indication
1313	1028	Edoxaban	ASA indication	RSY133E	4.10.19 10:50	2021-12-31	Edoxaban 60mg / ASA indication
1553	1028	Edoxaban	ASA indication	PVZ426R	23.3.22 11:01	2024-04-30	Edoxaban 60mg / no ASA indication
1553	1028	Edoxaban	ASA indication	RZU192F	9.3.21 11:35	2021-12-31	Edoxaban 60mg / no ASA indication
1553	1028	Edoxaban	ASA indication	GWE946B	10.3.20 11:52	2022-08-31	Edoxaban 30mg / ASA indication
1553	1028	Edoxaban	ASA indication	RCT631S	9.9.20 8:17	2021-12-31	Edoxaban 60mg / ASA indication
1553	1028	Edoxaban	ASA indication	KXP849U	15.9.21 9:22	2024-04-30	Edoxaban 60mg / no ASA indication
1314	1028	Edoxaban	no ASA indication	XLU963X	21.10.20 7:48	2021-12-31	Edoxaban 60mg / no ASA indication
1314	1028	Edoxaban	no ASA indication	SBC957F	27.4.21 10:42	2021-12-31	Edoxaban 60mg / no ASA indication
1314	1028	Edoxaban	no ASA indication	RCX943L	4.10.19 12:27	2021-12-31	Edoxaban 60mg / no ASA indication
1314	1028	Edoxaban	no ASA indication	ZGM466K	20.4.20 10:39	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1314	1028	Edoxaban	no ASA indication	PPW949M	10.11.21 10:21	2024-04-30	Edoxaban 60mg / no ASA indication
1344	1028	Edoxaban	no ASA indication	UFD988D	7.5.21 8:38	2022-08-31	Edoxaban 30mg / no ASA indication
1344	1028	Edoxaban	no ASA indication	VVR546S	22.10.19 11:34	2022-08-31	Edoxaban 30mg / no ASA indication
1344	1028	Edoxaban	no ASA indication	TPM335W	4.5.20 9:57	2022-08-31	Edoxaban 30mg / no ASA indication
1344	1028	Edoxaban	no ASA indication	FZP786X	17.5.22 5:38	2024-04-30	Edoxaban 60mg / no ASA indication
1344	1028	Edoxaban	no ASA indication	SNV516K	6.11.20 16:48	2022-08-31	Edoxaban 30mg / no ASA indication
1344	1028	Edoxaban	no ASA indication	MTZ821A	10.11.21 12:17	2024-04-30	Edoxaban 60mg / no ASA indication
1539	1028	Edoxaban	no ASA indication	RYL592T	9.9.20 8:51	2021-12-31	Edoxaban 60mg / no ASA indication
1539	1028	Edoxaban	no ASA indication	MXP734T	21.9.21 12:36	2024-04-30	Edoxaban 60mg / no ASA indication
1539	1028	Edoxaban	no ASA indication	XGL763D	3.3.20 12:01	2021-12-31	Edoxaban 60mg / no ASA indication
1539	1028	Edoxaban	no ASA indication	SYP985V	10.3.21 9:14	2021-12-31	Edoxaban 60mg / no ASA indication
1547	1028	Edoxaban	no ASA indication	NCX259G	23.3.22 12:40	2024-04-30	Edoxaban 60mg / no ASA indication
1547	1028	Edoxaban	no ASA indication	GYX227Z	5.3.20 11:59	2021-12-31	Edoxaban 60mg / no ASA indication
1547	1028	Edoxaban	no ASA indication	SNP386A	9.9.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1547	1028	Edoxaban	no ASA indication	SCW812P	9.3.21 12:47	2021-12-31	Edoxaban 60mg / no ASA indication
1547	1028	Edoxaban	no ASA indication	KTB489C	15.9.21 11:40	2024-04-30	Edoxaban 60mg / no ASA indication
2160	1028	Edoxaban	no ASA indication	SAD395P	16.6.21 10:59	2021-12-31	Edoxaban 60mg / no ASA indication
2160	1028	Edoxaban	no ASA indication	GRC469K	29.6.22 11:29	2024-04-30	Edoxaban 60mg / no ASA indication
2160	1028	Edoxaban	no ASA indication	PRR595S	15.12.21 12:23	2024-04-30	Edoxaban 60mg / no ASA indication
2251	1028	Edoxaban	no ASA indication	KXK992T	31.8.21 8:20	2024-04-30	Edoxaban 60mg / no ASA indication
2251	1028	Edoxaban	no ASA indication	PZF532V	1.3.22 11:21	2024-04-30	Edoxaban 60mg / no ASA indication
2251	1028	Edoxaban	no ASA indication	RKH878F	18.8.22 13:28	2024-04-30	Edoxaban 60mg / no ASA indication
2504	1028	Edoxaban	no ASA indication	KWM679F	1.3.22 12:24	2024-11-30	Edoxaban 30mg / no ASA indication
2694	1028	Edoxaban	no ASA indication	FCM284R	6.7.22 8:57	2024-04-30	Edoxaban 60mg / no ASA indication
949	1029	Placebo	ASA indication	ZTU673X	12.8.19 14:14	2021-12-31	Edoxaban 60mg / ASA indication
949	1029	Placebo	ASA indication	YYK136L	22.1.19 18:50	2020-01-01	Edoxaban 60mg / ASA indication
1159	1029	Placebo	ASA indication	YBM645B	4.6.19 15:48	2020-01-01	Edoxaban 30mg / ASA indication
1617	1029	Placebo	ASA indication	FBF499F	9.6.20 12:25	2021-12-31	Edoxaban 60mg / ASA indication
1986	1029	Placebo	ASA indication	FRL599D	1.3.21 9:47	2021-12-31	Edoxaban 60mg / ASA indication
2093	1029	Placebo	ASA indication	XDZ721T	11.5.21 8:30	2021-12-31	Edoxaban 60mg / ASA indication
2093	1029	Placebo	ASA indication	MPW428B	27.6.22 7:09	2024-04-30	Edoxaban 60mg / ASA indication
2093	1029	Placebo	ASA indication	LZT713R	7.12.21 15:42	2024-04-30	Edoxaban 60mg / no ASA indication
2155	1029	Placebo	ASA indication	HGP871W	15.6.21 14:39	2022-08-31	Edoxaban 30mg / ASA indication
2178	1029	Placebo	ASA indication	MSF634F	2.7.21 13:18	2024-04-30	Edoxaban 60mg / ASA indication
961	1029	Placebo	no ASA indication	PZL161R	16.3.21 13:06	2021-12-31	Edoxaban 60mg / no ASA indication
961	1029	Placebo	no ASA indication	LZK388B	22.2.22 15:36	2024-04-30	Edoxaban 60mg / no ASA indication
961	1029	Placebo	no ASA indication	GMF657C	6.8.19 15:43	2021-12-31	Edoxaban 60mg / no ASA indication
961	1029	Placebo	no ASA indication	TWU514K	27.3.20 8:16	2021-12-31	Edoxaban 60mg / no ASA indication
961	1029	Placebo	no ASA indication	KTB239R	29.1.19 17:02	2020-01-01	Edoxaban 60mg / no ASA indication
961	1029	Placebo	no ASA indication	SAA261V	16.9.20 9:42	2021-12-31	Edoxaban 60mg / no ASA indication
1236	1029	Placebo	no ASA indication	ATS595E	30.7.19 15:06	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1236	1029	Placebo	no ASA indication	GFV395R	16.3.21 13:59	2022-08-31	Edoxaban 30mg / no ASA indication
1236	1029	Placebo	no ASA indication	CMS215N	7.12.21 14:18	2022-08-31	Edoxaban 30mg / no ASA indication
1236	1029	Placebo	no ASA indication	RAG672D	8.7.22 19:47	2024-11-30	Edoxaban 30mg / no ASA indication
1236	1029	Placebo	no ASA indication	SBK196B	18.2.20 14:31	2022-08-31	Edoxaban 30mg / no ASA indication
1236	1029	Placebo	no ASA indication	CWR251A	16.9.20 9:10	2022-08-31	Edoxaban 30mg / no ASA indication
1242	1029	Placebo	no ASA indication	LXX621N	28.9.21 13:39	2024-04-30	Edoxaban 60mg / no ASA indication
1242	1029	Placebo	no ASA indication	YFK929C	6.8.19 13:35	2021-12-31	Edoxaban 60mg / no ASA indication
1242	1029	Placebo	no ASA indication	ZRA863E	10.3.20 14:50	2022-08-31	Edoxaban 30mg / no ASA indication
1242	1029	Placebo	no ASA indication	ZMN942D	25.8.20 11:55	2022-08-31	Edoxaban 30mg / no ASA indication
1242	1029	Placebo	no ASA indication	FEW752E	23.3.21 14:28	2022-08-31	Edoxaban 30mg / no ASA indication
1437	1029	Placebo	no ASA indication	MGT125H	27.4.21 13:14	2022-08-31	Edoxaban 30mg / no ASA indication
1437	1029	Placebo	no ASA indication	CYS573M	5.4.22 8:49	2024-11-30	Edoxaban 30mg / no ASA indication
1437	1029	Placebo	no ASA indication	SKC188G	6.12.19 12:01	2022-08-31	Edoxaban 30mg / no ASA indication
1437	1029	Placebo	no ASA indication	SPR582K	14.7.20 9:31	2022-08-31	Edoxaban 30mg / no ASA indication
1588	1029	Placebo	no ASA indication	VCY631B	24.11.20 9:56	2021-12-31	Edoxaban 60mg / no ASA indication
1588	1029	Placebo	no ASA indication	ELC213L	15.5.20 14:06	2021-12-31	Edoxaban 60mg / no ASA indication
1588	1029	Placebo	no ASA indication	VYL693A	9.7.21 6:04	2022-08-31	Edoxaban 30mg / no ASA indication
1588	1029	Placebo	no ASA indication	CSR699Y	27.2.22 18:53	2024-11-30	Edoxaban 30mg / no ASA indication
1878	1029	Placebo	no ASA indication	GFE373M	23.11.20 11:19	2022-08-31	Edoxaban 30mg / no ASA indication
1878	1029	Placebo	no ASA indication	VZF465V	18.10.21 10:24	2022-08-31	Edoxaban 30mg / no ASA indication
1878	1029	Placebo	no ASA indication	NFS476E	17.5.21 9:37	2022-08-31	Edoxaban 30mg / no ASA indication
2345	1029	Placebo	no ASA indication	RBZ532K	22.6.22 10:49	2024-11-30	Edoxaban 30mg / no ASA indication
2345	1029	Placebo	no ASA indication	SMB416V	15.11.21 14:05	2022-08-31	Edoxaban 30mg / no ASA indication
1243	1029	Edoxaban	ASA indication	PVY946U	28.8.20 11:19	2022-08-31	Edoxaban 30mg / ASA indication
1243	1029	Edoxaban	ASA indication	VLG349W	6.8.19 14:56	2022-08-31	Edoxaban 30mg / ASA indication
1243	1029	Edoxaban	ASA indication	FVM285Y	17.2.20 14:21	2022-08-31	Edoxaban 30mg / ASA indication
1243	1029	Edoxaban	ASA indication	CTG912M	11.4.22 9:35	2024-11-30	Edoxaban 30mg / ASA indication
1243	1029	Edoxaban	ASA indication	DZS222N	21.9.21 11:23	2022-08-31	Edoxaban 30mg / ASA indication
1243	1029	Edoxaban	ASA indication	LEL995D	10.3.21 13:55	2022-08-31	Edoxaban 30mg / ASA indication
1256	1029	Edoxaban	ASA indication	DUA772S	16.3.20 13:44	2021-12-31	Edoxaban 60mg / ASA indication
1256	1029	Edoxaban	ASA indication	WHH185K	27.9.21 11:49	2024-04-30	Edoxaban 60mg / ASA indication
1256	1029	Edoxaban	ASA indication	VDZ118F	31.8.20 10:37	2021-12-31	Edoxaban 60mg / ASA indication
1256	1029	Edoxaban	ASA indication	NCE838C	22.3.21 10:53	2021-12-31	Edoxaban 60mg / ASA indication
1917	1029	Edoxaban	ASA indication	YZB261B	11.1.22 14:30	2022-08-31	Edoxaban 30mg / ASA indication
1917	1029	Edoxaban	ASA indication	CYR613C	6.6.22 10:39	2024-11-30	Edoxaban 30mg / ASA indication
1917	1029	Edoxaban	ASA indication	KXU499T	4.1.21 11:04	2022-08-31	Edoxaban 30mg / ASA indication
1917	1029	Edoxaban	ASA indication	LUF193X	14.6.21 10:12	2022-08-31	Edoxaban 30mg / ASA indication
1936	1029	Edoxaban	ASA indication	KTM272E	25.1.21 13:06	2021-12-31	Edoxaban 60mg / ASA indication
1936	1029	Edoxaban	ASA indication	MSN485K	26.7.21 9:17	2024-04-30	Edoxaban 60mg / ASA indication
1936	1029	Edoxaban	ASA indication	MNA984T	22.8.22 7:57	2024-04-30	Edoxaban 60mg / ASA indication
1936	1029	Edoxaban	ASA indication	WFS321K	4.2.22 10:24	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2090	1029	Edoxaban	ASA indication	GHZ253T	10.5.21 11:18	2022-08-31	Edoxaban 30mg / ASA indication
2108	1029	Edoxaban	ASA indication	STH914Z	19.5.21 11:00	2021-12-31	Edoxaban 60mg / ASA indication
2180	1029	Edoxaban	ASA indication	MRC747C	5.7.21 11:54	2024-04-30	Edoxaban 60mg / ASA indication
900	1029	Edoxaban	no ASA indication	MHV285S	29.9.21 12:52	2024-04-30	Edoxaban 60mg / no ASA indication
900	1029	Edoxaban	no ASA indication	CWM846H	18.2.20 17:17	2021-12-31	Edoxaban 60mg / no ASA indication
900	1029	Edoxaban	no ASA indication	UYM779X	3.3.21 12:02	2021-12-31	Edoxaban 60mg / no ASA indication
900	1029	Edoxaban	no ASA indication	HHW357H	18.12.18 17:52	2020-01-01	Edoxaban 60mg / no ASA indication
900	1029	Edoxaban	no ASA indication	KBN164Z	30.7.19 17:42	2021-12-31	Edoxaban 60mg / no ASA indication
900	1029	Edoxaban	no ASA indication	AFT936T	15.7.20 9:17	2021-12-31	Edoxaban 60mg / no ASA indication
1053	1029	Edoxaban	no ASA indication	XMS767X	3.2.20 14:47	2021-12-31	Edoxaban 60mg / no ASA indication
1053	1029	Edoxaban	no ASA indication	GLV413H	1.9.20 12:21	2021-12-31	Edoxaban 60mg / no ASA indication
1053	1029	Edoxaban	no ASA indication	GYH157H	2.4.19 14:15	2020-01-01	Edoxaban 60mg / no ASA indication
1053	1029	Edoxaban	no ASA indication	FHA567H	7.5.21 10:49	2021-12-31	Edoxaban 60mg / no ASA indication
1177	1029	Edoxaban	no ASA indication	AHB465K	2.7.19 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
1335	1029	Edoxaban	no ASA indication	AXG269P	12.5.20 12:19	2021-12-31	Edoxaban 60mg / no ASA indication
1335	1029	Edoxaban	no ASA indication	VEV794E	15.10.19 13:33	2021-12-31	Edoxaban 60mg / no ASA indication
1441	1029	Edoxaban	no ASA indication	PZF282E	10.12.19 14:06	2021-12-31	Edoxaban 60mg / no ASA indication
1441	1029	Edoxaban	no ASA indication	LNA685F	27.7.21 12:19	2022-08-31	Edoxaban 30mg / no ASA indication
1441	1029	Edoxaban	no ASA indication	MKM695U	31.8.22 11:29	2024-04-30	Edoxaban 60mg / no ASA indication
1441	1029	Edoxaban	no ASA indication	PKZ588A	11.2.22 11:54	2022-08-31	Edoxaban 30mg / no ASA indication
1441	1029	Edoxaban	no ASA indication	FMS241G	8.1.21 12:55	2021-12-31	Edoxaban 60mg / no ASA indication
1441	1029	Edoxaban	no ASA indication	YFE329C	26.6.20 12:23	2021-12-31	Edoxaban 60mg / no ASA indication
1735	1029	Edoxaban	no ASA indication	KSX973M	18.8.20 11:25	2022-08-31	Edoxaban 30mg / no ASA indication
1735	1029	Edoxaban	no ASA indication	TRC116W	23.3.21 13:45	2022-08-31	Edoxaban 30mg / no ASA indication
1735	1029	Edoxaban	no ASA indication	DPG153U	12.4.22 10:37	2024-11-30	Edoxaban 30mg / no ASA indication
1735	1029	Edoxaban	no ASA indication	HTR379M	28.9.21 11:59	2022-08-31	Edoxaban 30mg / no ASA indication
1407	1039	Placebo	ASA indication	UEV767P	21.11.19 13:23	2021-12-31	Edoxaban 60mg / ASA indication
1407	1039	Placebo	ASA indication	RMV135D	26.5.20 13:06	2021-12-31	Edoxaban 60mg / ASA indication
1459	1039	Placebo	ASA indication	UGS965N	22.6.21 6:02	2024-04-30	Edoxaban 60mg / ASA indication
1459	1039	Placebo	ASA indication	BZU719B	16.6.20 10:14	2021-12-31	Edoxaban 60mg / ASA indication
1459	1039	Placebo	ASA indication	SYS831N	16.12.20 8:49	2021-12-31	Edoxaban 60mg / ASA indication
1459	1039	Placebo	ASA indication	BWN123F	20.12.19 7:42	2021-12-31	Edoxaban 60mg / ASA indication
2562	1039	Placebo	ASA indication	LDV351T	29.3.22 9:02	2024-11-30	Edoxaban 30mg / ASA indication
2690	1039	Placebo	no ASA indication	UYX935X	5.7.22 10:26	2024-04-30	Edoxaban 60mg / no ASA indication
1227	1039	Edoxaban	ASA indication	WPK866H	18.7.19 13:00	2022-08-31	Edoxaban 30mg / ASA indication
1227	1039	Edoxaban	ASA indication	EZS146B	22.1.20 8:56	2022-08-31	Edoxaban 30mg / ASA indication
1467	1039	Edoxaban	ASA indication	BGN567R	3.1.20 10:33	2022-08-31	Edoxaban 30mg / ASA indication
1467	1039	Edoxaban	ASA indication	ARD115B	15.12.20 10:01	2022-08-31	Edoxaban 30mg / ASA indication
1467	1039	Edoxaban	ASA indication	WAB113X	8.7.21 8:43	2022-08-31	Edoxaban 30mg / ASA indication
1467	1039	Edoxaban	ASA indication	HDW331V	23.6.20 9:55	2022-08-31	Edoxaban 30mg / ASA indication
1534	1039	Edoxaban	ASA indication	KHH935Z	16.2.21 10:46	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1534	1039	Edoxaban	ASA indication	XAU467D	28.2.20 13:35	2022-08-31	Edoxaban 30mg / ASA indication
1534	1039	Edoxaban	ASA indication	VGR468F	31.8.21 10:45	2024-04-30	Edoxaban 60mg / ASA indication
1534	1039	Edoxaban	ASA indication	USC973B	17.2.22 11:17	2024-04-30	Edoxaban 60mg / no ASA indication
1534	1039	Edoxaban	ASA indication	NAW981R	25.8.20 9:46	2021-12-31	Edoxaban 60mg / ASA indication
2503	1039	Edoxaban	ASA indication	VHK871A	1.3.22 10:43	2024-04-30	Edoxaban 60mg / ASA indication
2503	1039	Edoxaban	ASA indication	VGX162N	1.9.22 9:42	2024-04-30	Edoxaban 60mg / ASA indication
2225	1048	Placebo	ASA indication	GXW497L	16.8.21 13:21	2022-08-31	Edoxaban 30mg / ASA indication
2225	1048	Placebo	ASA indication	GUV276Z	10.2.22 9:57	2022-08-31	Edoxaban 30mg / ASA indication
2225	1048	Placebo	ASA indication	LHT331P	11.8.22 9:39	2024-11-30	Edoxaban 30mg / ASA indication
2619	1048	Placebo	ASA indication	RED116F	18.5.22 13:30	2024-04-30	Edoxaban 60mg / ASA indication
2170	1048	Edoxaban	ASA indication	RFS574N	24.6.21 10:37	2024-04-30	Edoxaban 60mg / ASA indication
2335	1049	Placebo	ASA indication	PGU941F	9.11.21 12:23	2024-04-30	Edoxaban 60mg / ASA indication
1359	1049	Placebo	no ASA indication	PLV883Z	19.4.22 10:08	2024-04-30	Edoxaban 60mg / no ASA indication
1359	1049	Placebo	no ASA indication	ZLP918Z	29.10.19 13:35	2021-12-31	Edoxaban 60mg / no ASA indication
1359	1049	Placebo	no ASA indication	TDW117A	29.4.21 6:41	2021-12-31	Edoxaban 60mg / no ASA indication
1359	1049	Placebo	no ASA indication	ZGB917Y	19.10.20 11:16	2022-08-31	Edoxaban 30mg / no ASA indication
1359	1049	Placebo	no ASA indication	MLE262R	19.10.20 13:32	2021-12-31	Edoxaban 60mg / no ASA indication
1359	1049	Placebo	no ASA indication	NLB168U	28.4.20 10:42	2021-12-31	Edoxaban 60mg / no ASA indication
1359	1049	Placebo	no ASA indication	PKK338R	18.10.21 10:57	2024-04-30	Edoxaban 60mg / no ASA indication
2231	1049	Placebo	no ASA indication	XUG447E	17.8.21 10:59	2022-08-31	Edoxaban 30mg / no ASA indication
2714	1067	Edoxaban	no ASA indication	XVD653K	19.7.22 8:28	2024-04-30	Edoxaban 60mg / no ASA indication
1240	1071	Placebo	ASA indication	NGW383L	26.7.21 12:56	2024-04-30	Edoxaban 60mg / ASA indication
1240	1071	Placebo	ASA indication	ATW245R	5.8.19 14:09	2021-12-31	Edoxaban 60mg / ASA indication
1240	1071	Placebo	ASA indication	NHV232C	5.8.22 13:00	2024-04-30	Edoxaban 60mg / ASA indication
1240	1071	Placebo	ASA indication	XNH411M	3.8.20 13:38	2021-12-31	Edoxaban 60mg / no ASA indication
1240	1071	Placebo	ASA indication	BNX941C	5.2.21 14:00	2021-12-31	Edoxaban 60mg / ASA indication
1240	1071	Placebo	ASA indication	ZZW591W	6.2.20 15:34	2021-12-31	Edoxaban 60mg / no ASA indication
1240	1071	Placebo	ASA indication	NKF861D	31.1.22 14:11	2024-04-30	Edoxaban 60mg / ASA indication
1241	1071	Edoxaban	ASA indication	ZWY298U	6.2.20 16:11	2022-08-31	Edoxaban 30mg / ASA indication
1241	1071	Edoxaban	ASA indication	EMA595F	31.1.22 13:30	2022-08-31	Edoxaban 30mg / ASA indication
1241	1071	Edoxaban	ASA indication	EDT941L	26.7.21 13:25	2022-08-31	Edoxaban 30mg / ASA indication
1241	1071	Edoxaban	ASA indication	MSE789H	5.2.21 13:05	2022-08-31	Edoxaban 30mg / ASA indication
1241	1071	Edoxaban	ASA indication	VMX535E	30.7.20 12:51	2022-08-31	Edoxaban 30mg / ASA indication
1241	1071	Edoxaban	ASA indication	RUU273F	5.8.22 11:47	2024-11-30	Edoxaban 30mg / ASA indication
1241	1071	Edoxaban	ASA indication	FKR488V	6.8.19 12:58	2022-08-31	Edoxaban 30mg / ASA indication
1838	1074	Placebo	ASA indication	MNK685G	27.4.21 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
1838	1074	Placebo	ASA indication	YBP141Y	22.10.20 12:32	2021-12-31	Edoxaban 60mg / ASA indication
2143	1074	Placebo	ASA indication	YZN614G	8.6.21 11:30	2021-12-31	Edoxaban 60mg / ASA indication
2672	1074	Placebo	ASA indication	DAC878U	28.6.22 11:43	2024-11-30	Edoxaban 30mg / ASA indication
1325	1074	Placebo	no ASA indication	UAV136M	8.10.20 11:35	2022-08-31	Edoxaban 30mg / no ASA indication
1325	1074	Placebo	no ASA indication	XHE528A	26.3.20 9:00	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1325	1074	Placebo	no ASA indication	RXN621G	29.10.21 10:07	2022-08-31	Edoxaban 30mg / no ASA indication
1325	1074	Placebo	no ASA indication	PHF541A	21.4.22 9:36	2024-11-30	Edoxaban 30mg / no ASA indication
1325	1074	Placebo	no ASA indication	LNG489K	11.10.19 10:57	2022-08-31	Edoxaban 30mg / no ASA indication
1325	1074	Placebo	no ASA indication	CVH857H	13.4.21 11:47	2022-08-31	Edoxaban 30mg / no ASA indication
1337	1074	Placebo	no ASA indication	PKN661X	8.4.22 10:03	2024-11-30	Edoxaban 30mg / no ASA indication
1337	1074	Placebo	no ASA indication	MDC272S	19.4.21 9:07	2022-08-31	Edoxaban 30mg / no ASA indication
1337	1074	Placebo	no ASA indication	AHC913L	15.4.20 10:28	2022-08-31	Edoxaban 30mg / no ASA indication
1337	1074	Placebo	no ASA indication	GZY244S	17.10.19 10:19	2022-08-31	Edoxaban 30mg / no ASA indication
1337	1074	Placebo	no ASA indication	VNE568A	29.10.21 10:10	2022-08-31	Edoxaban 30mg / no ASA indication
1337	1074	Placebo	no ASA indication	FLV632E	16.10.20 10:15	2022-08-31	Edoxaban 30mg / no ASA indication
1402	1074	Placebo	no ASA indication	FMF693D	20.11.20 10:07	2022-08-31	Edoxaban 30mg / no ASA indication
1402	1074	Placebo	no ASA indication	KNV891X	21.5.20 8:39	2022-08-31	Edoxaban 30mg / no ASA indication
1402	1074	Placebo	no ASA indication	REA124S	23.5.22 10:28	2024-11-30	Edoxaban 30mg / no ASA indication
1402	1074	Placebo	no ASA indication	CMT194P	3.12.21 10:51	2022-08-31	Edoxaban 30mg / no ASA indication
1402	1074	Placebo	no ASA indication	UGY139H	21.5.21 8:27	2022-08-31	Edoxaban 30mg / no ASA indication
1402	1074	Placebo	no ASA indication	PGG214F	20.11.19 11:36	2022-08-31	Edoxaban 30mg / no ASA indication
1403	1074	Placebo	no ASA indication	KLP849W	20.11.19 12:48	2021-12-31	Edoxaban 60mg / no ASA indication
1548	1074	Placebo	no ASA indication	MDF187U	11.3.21 12:12	2022-08-31	Edoxaban 30mg / no ASA indication
1548	1074	Placebo	no ASA indication	KFW115X	5.3.20 12:57	2022-08-31	Edoxaban 30mg / no ASA indication
1548	1074	Placebo	no ASA indication	LXD766L	7.9.20 11:14	2022-08-31	Edoxaban 30mg / no ASA indication
1548	1074	Placebo	no ASA indication	CYY668F	11.3.22 11:02	2024-11-30	Edoxaban 30mg / no ASA indication
1548	1074	Placebo	no ASA indication	TMD148G	13.9.21 10:43	2022-08-31	Edoxaban 30mg / no ASA indication
1607	1074	Placebo	no ASA indication	WRF159H	19.5.21 7:57	2021-12-31	Edoxaban 60mg / no ASA indication
1607	1074	Placebo	no ASA indication	GBU569R	1.6.20 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
1607	1074	Placebo	no ASA indication	FFR758R	1.12.20 8:59	2021-12-31	Edoxaban 60mg / no ASA indication
1696	1074	Placebo	no ASA indication	WSK173X	27.1.21 11:14	2021-12-31	Edoxaban 60mg / no ASA indication
1696	1074	Placebo	no ASA indication	BDG472E	21.1.22 11:43	2024-04-30	Edoxaban 60mg / no ASA indication
1696	1074	Placebo	no ASA indication	RFN768A	20.7.22 10:49	2024-04-30	Edoxaban 60mg / no ASA indication
1696	1074	Placebo	no ASA indication	BGA733Z	20.7.20 11:31	2021-12-31	Edoxaban 60mg / no ASA indication
1696	1074	Placebo	no ASA indication	BBV685B	28.7.21 9:00	2024-04-30	Edoxaban 60mg / no ASA indication
1697	1074	Placebo	no ASA indication	DCA492S	20.7.20 12:04	2022-08-31	Edoxaban 30mg / no ASA indication
1811	1074	Placebo	no ASA indication	KXD565X	2.10.20 10:34	2021-12-31	Edoxaban 60mg / no ASA indication
1893	1074	Placebo	no ASA indication	WRS449X	8.6.21 9:41	2021-12-31	Edoxaban 60mg / no ASA indication
1893	1074	Placebo	no ASA indication	FBE375T	8.12.20 11:23	2021-12-31	Edoxaban 60mg / no ASA indication
1893	1074	Placebo	no ASA indication	BDM948C	10.12.21 10:09	2024-04-30	Edoxaban 60mg / no ASA indication
1893	1074	Placebo	no ASA indication	GAG441X	8.6.22 10:12	2024-04-30	Edoxaban 60mg / no ASA indication
1972	1074	Placebo	no ASA indication	UBW719W	20.8.21 10:54	2022-08-31	Edoxaban 30mg / no ASA indication
1972	1074	Placebo	no ASA indication	TXA538G	23.8.22 10:06	2024-04-30	Edoxaban 60mg / no ASA indication
1972	1074	Placebo	no ASA indication	MXP364X	19.2.21 11:56	2021-12-31	Edoxaban 60mg / no ASA indication
1972	1074	Placebo	no ASA indication	CBF156L	22.2.22 11:28	2024-04-30	Edoxaban 60mg / no ASA indication
2080	1074	Placebo	no ASA indication	NTX377M	30.4.21 10:25	2022-08-31	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2080	1074	Placebo	no ASA indication	MAF282M	29.10.21 10:29	2022-08-31	Edoxaban 30mg / no ASA indication
2080	1074	Placebo	no ASA indication	RDX685T	27.4.22 10:25	2024-11-30	Edoxaban 30mg / no ASA indication
2162	1074	Placebo	no ASA indication	BES467E	21.6.21 10:38	2024-04-30	Edoxaban 60mg / no ASA indication
2235	1074	Placebo	no ASA indication	TLD423X	20.8.21 10:29	2022-08-31	Edoxaban 30mg / no ASA indication
2300	1074	Placebo	no ASA indication	VST116F	6.10.21 10:51	2024-04-30	Edoxaban 60mg / no ASA indication
2300	1074	Placebo	no ASA indication	RGZ877L	5.4.22 10:56	2024-04-30	Edoxaban 60mg / no ASA indication
2515	1074	Placebo	no ASA indication	CYX573A	4.3.22 11:32	2024-11-30	Edoxaban 30mg / no ASA indication
2665	1074	Placebo	no ASA indication	YYZ194X	22.6.22 11:55	2024-04-30	Edoxaban 60mg / no ASA indication
2720	1074	Placebo	no ASA indication	GAE649R	20.7.22 11:48	2024-04-30	Edoxaban 60mg / no ASA indication
1420	1074	Edoxaban	ASA indication	BWX281Z	28.11.19 13:13	2021-12-31	Edoxaban 60mg / ASA indication
1420	1074	Edoxaban	ASA indication	GVL524G	28.5.21 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
1420	1074	Edoxaban	ASA indication	WED387T	30.11.20 8:17	2021-12-31	Edoxaban 60mg / no ASA indication
1420	1074	Edoxaban	ASA indication	XWY243C	30.11.21 10:03	2024-04-30	Edoxaban 60mg / no ASA indication
1420	1074	Edoxaban	ASA indication	YHV867Y	28.5.20 7:25	2021-12-31	Edoxaban 60mg / ASA indication
1420	1074	Edoxaban	ASA indication	YBD552P	1.6.22 9:22	2024-04-30	Edoxaban 60mg / no ASA indication
1424	1074	Edoxaban	ASA indication	ALD741L	2.12.19 12:55	2022-08-31	Edoxaban 30mg / ASA indication
1842	1074	Edoxaban	ASA indication	SWC422T	29.10.20 12:42	2021-12-31	Edoxaban 60mg / ASA indication
2192	1074	Edoxaban	ASA indication	BTX271M	14.1.22 10:42	2024-04-30	Edoxaban 60mg / no ASA indication
2192	1074	Edoxaban	ASA indication	FUM298E	20.7.22 10:05	2024-04-30	Edoxaban 60mg / no ASA indication
2192	1074	Edoxaban	ASA indication	BGY399C	16.7.21 10:29	2024-04-30	Edoxaban 60mg / ASA indication
1294	1074	Edoxaban	no ASA indication	MAX674G	19.3.20 10:56	2021-12-31	Edoxaban 60mg / no ASA indication
1294	1074	Edoxaban	no ASA indication	YFT964Y	26.3.21 11:34	2021-12-31	Edoxaban 60mg / no ASA indication
1294	1074	Edoxaban	no ASA indication	RWC333F	18.3.22 10:30	2024-04-30	Edoxaban 60mg / no ASA indication
1294	1074	Edoxaban	no ASA indication	WZW775U	4.10.21 11:03	2024-04-30	Edoxaban 60mg / no ASA indication
1294	1074	Edoxaban	no ASA indication	RMM823B	21.9.20 12:10	2021-12-31	Edoxaban 60mg / no ASA indication
1294	1074	Edoxaban	no ASA indication	CYU228Y	20.9.19 11:17	2021-12-31	Edoxaban 60mg / no ASA indication
1305	1074	Edoxaban	no ASA indication	XYZ572T	31.3.20 11:42	2022-08-31	Edoxaban 30mg / no ASA indication
1305	1074	Edoxaban	no ASA indication	BTT531S	30.9.19 10:43	2022-08-31	Edoxaban 30mg / no ASA indication
1365	1074	Edoxaban	no ASA indication	TXL951Z	5.5.20 11:34	2022-08-31	Edoxaban 30mg / no ASA indication
1365	1074	Edoxaban	no ASA indication	NRE312L	7.6.22 10:39	2024-11-30	Edoxaban 30mg / no ASA indication
1365	1074	Edoxaban	no ASA indication	WPK437Z	5.11.20 12:18	2022-08-31	Edoxaban 30mg / no ASA indication
1365	1074	Edoxaban	no ASA indication	UKC331X	5.11.19 11:32	2022-08-31	Edoxaban 30mg / no ASA indication
1365	1074	Edoxaban	no ASA indication	BMS795H	9.11.21 11:26	2024-04-30	Edoxaban 60mg / no ASA indication
1365	1074	Edoxaban	no ASA indication	HKW931B	5.5.21 10:21	2021-12-31	Edoxaban 60mg / no ASA indication
1446	1074	Edoxaban	no ASA indication	WGT657C	14.6.22 9:19	2024-04-30	Edoxaban 60mg / no ASA indication
1446	1074	Edoxaban	no ASA indication	NHM562Z	18.6.20 8:24	2021-12-31	Edoxaban 60mg / no ASA indication
1446	1074	Edoxaban	no ASA indication	GHA424X	17.6.21 11:29	2021-12-31	Edoxaban 60mg / no ASA indication
1446	1074	Edoxaban	no ASA indication	WKP694L	12.12.19 12:11	2021-12-31	Edoxaban 60mg / no ASA indication
1446	1074	Edoxaban	no ASA indication	WEL841C	14.12.20 9:51	2021-12-31	Edoxaban 60mg / no ASA indication
1446	1074	Edoxaban	no ASA indication	BUU752A	10.12.21 10:34	2024-04-30	Edoxaban 60mg / no ASA indication
1557	1074	Edoxaban	no ASA indication	MNS428S	7.9.20 10:44	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1557	1074	Edoxaban	no ASA indication	BNV237A	13.9.21 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
1557	1074	Edoxaban	no ASA indication	GDU386A	11.3.22 11:34	2024-04-30	Edoxaban 60mg / no ASA indication
1557	1074	Edoxaban	no ASA indication	TFS318H	12.3.20 12:07	2021-12-31	Edoxaban 60mg / no ASA indication
1557	1074	Edoxaban	no ASA indication	YCE683H	11.3.21 12:26	2022-08-31	Edoxaban 30mg / no ASA indication
1565	1074	Edoxaban	no ASA indication	WGU868C	26.3.21 10:47	2021-12-31	Edoxaban 60mg / no ASA indication
1565	1074	Edoxaban	no ASA indication	WUU623L	24.3.20 11:14	2021-12-31	Edoxaban 60mg / no ASA indication
1565	1074	Edoxaban	no ASA indication	UEB131W	24.3.22 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
1565	1074	Edoxaban	no ASA indication	FEN599G	21.9.20 11:39	2021-12-31	Edoxaban 60mg / no ASA indication
1565	1074	Edoxaban	no ASA indication	XAK634D	28.9.21 11:05	2024-04-30	Edoxaban 60mg / no ASA indication
1699	1074	Edoxaban	no ASA indication	PTN616C	20.1.21 12:22	2022-08-31	Edoxaban 30mg / no ASA indication
1699	1074	Edoxaban	no ASA indication	AUA291S	21.1.22 10:24	2022-08-31	Edoxaban 30mg / no ASA indication
1699	1074	Edoxaban	no ASA indication	KNM491U	28.7.21 9:21	2022-08-31	Edoxaban 30mg / no ASA indication
1699	1074	Edoxaban	no ASA indication	YTM427L	21.7.20 8:09	2022-08-31	Edoxaban 30mg / no ASA indication
1708	1074	Edoxaban	no ASA indication	RVP416B	26.1.21 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
1708	1074	Edoxaban	no ASA indication	YXG446R	24.7.20 10:45	2022-08-31	Edoxaban 30mg / no ASA indication
1708	1074	Edoxaban	no ASA indication	GVG664S	28.7.21 8:04	2022-08-31	Edoxaban 30mg / no ASA indication
1708	1074	Edoxaban	no ASA indication	RTK958G	20.7.22 10:29	2024-11-30	Edoxaban 30mg / no ASA indication
1708	1074	Edoxaban	no ASA indication	UMC694R	21.1.22 11:17	2022-08-31	Edoxaban 30mg / no ASA indication
1756	1074	Edoxaban	no ASA indication	ZNU982M	3.9.20 11:52	2021-12-31	Edoxaban 60mg / no ASA indication
1952	1074	Edoxaban	no ASA indication	HYX285Y	16.8.21 9:28	2022-08-31	Edoxaban 30mg / no ASA indication
1952	1074	Edoxaban	no ASA indication	DRP474W	22.2.22 11:49	2024-11-30	Edoxaban 30mg / no ASA indication
1952	1074	Edoxaban	no ASA indication	SYA586K	9.8.22 10:54	2024-11-30	Edoxaban 30mg / no ASA indication
1952	1074	Edoxaban	no ASA indication	GVN168F	9.2.21 12:12	2022-08-31	Edoxaban 30mg / no ASA indication
1968	1074	Edoxaban	no ASA indication	YBC459S	18.2.21 12:57	2022-08-31	Edoxaban 30mg / no ASA indication
2009	1074	Edoxaban	no ASA indication	BPC184Y	13.9.21 10:21	2024-04-30	Edoxaban 60mg / no ASA indication
2009	1074	Edoxaban	no ASA indication	RXG851R	16.3.22 11:50	2024-04-30	Edoxaban 60mg / no ASA indication
2009	1074	Edoxaban	no ASA indication	RLK478L	12.3.21 13:16	2021-12-31	Edoxaban 60mg / no ASA indication
2075	1074	Edoxaban	no ASA indication	YHB815N	29.4.21 10:54	2022-08-31	Edoxaban 30mg / no ASA indication
2075	1074	Edoxaban	no ASA indication	DSU752S	25.4.22 10:33	2024-11-30	Edoxaban 30mg / no ASA indication
2075	1074	Edoxaban	no ASA indication	WXZ124L	27.10.21 9:43	2022-08-31	Edoxaban 30mg / no ASA indication
2246	1074	Edoxaban	no ASA indication	BHT937S	25.8.21 10:57	2024-04-30	Edoxaban 60mg / no ASA indication
2246	1074	Edoxaban	no ASA indication	GCL295P	22.2.22 11:29	2024-04-30	Edoxaban 60mg / no ASA indication
2246	1074	Edoxaban	no ASA indication	SGB561X	30.8.22 10:57	2024-04-30	Edoxaban 60mg / no ASA indication
2308	1074	Edoxaban	no ASA indication	WCL312S	8.4.22 10:23	2024-04-30	Edoxaban 60mg / no ASA indication
2308	1074	Edoxaban	no ASA indication	XZK217K	15.10.21 11:59	2024-04-30	Edoxaban 60mg / no ASA indication
2561	1074	Edoxaban	no ASA indication	UYL515Z	28.3.22 9:24	2024-04-30	Edoxaban 60mg / no ASA indication
2707	1074	Edoxaban	no ASA indication	UYU989Y	11.7.22 10:59	2024-04-30	Edoxaban 60mg / no ASA indication
1784	1080	Placebo	ASA indication	VXS329F	17.9.20 8:51	2021-12-31	Edoxaban 60mg / ASA indication
1784	1080	Placebo	ASA indication	DPM171W	13.9.21 6:54	2024-04-30	Edoxaban 60mg / ASA indication
1784	1080	Placebo	ASA indication	NME385L	9.3.21 9:15	2021-12-31	Edoxaban 60mg / ASA indication
1784	1080	Placebo	ASA indication	LHC898S	5.4.22 15:21	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1915	1080	Placebo	ASA indication	HAC756B	16.12.21 6:42	2024-04-30	Edoxaban 60mg / ASA indication
1915	1080	Placebo	ASA indication	RBW788Y	20.6.22 7:00	2024-04-30	Edoxaban 60mg / ASA indication
1915	1080	Placebo	ASA indication	WHX536E	24.12.20 11:11	2021-12-31	Edoxaban 60mg / ASA indication
1915	1080	Placebo	ASA indication	DPG183E	29.6.21 8:32	2024-04-30	Edoxaban 60mg / ASA indication
2078	1080	Placebo	ASA indication	ZXU281M	30.4.21 6:48	2022-08-31	Edoxaban 30mg / ASA indication
1396	1080	Placebo	no ASA indication	CES536C	4.12.20 13:46	2022-08-31	Edoxaban 30mg / no ASA indication
1396	1080	Placebo	no ASA indication	WZE426U	18.11.19 12:33	2021-12-31	Edoxaban 60mg / no ASA indication
1396	1080	Placebo	no ASA indication	AHS289P	3.7.20 7:35	2022-08-31	Edoxaban 30mg / no ASA indication
1445	1080	Placebo	no ASA indication	HHN162L	17.6.20 10:56	2021-12-31	Edoxaban 60mg / no ASA indication
1445	1080	Placebo	no ASA indication	ENU575W	16.12.20 8:34	2021-12-31	Edoxaban 60mg / no ASA indication
1445	1080	Placebo	no ASA indication	HEG936R	29.6.21 6:24	2022-08-31	Edoxaban 30mg / no ASA indication
1445	1080	Placebo	no ASA indication	HSP997Y	22.6.22 8:10	2024-11-30	Edoxaban 30mg / no ASA indication
1445	1080	Placebo	no ASA indication	NFD228N	11.12.19 13:23	2021-12-31	Edoxaban 60mg / no ASA indication
1445	1080	Placebo	no ASA indication	LWN833S	23.12.21 14:01	2022-08-31	Edoxaban 30mg / no ASA indication
1475	1080	Placebo	no ASA indication	AMR777H	3.7.20 8:41	2022-08-31	Edoxaban 30mg / no ASA indication
1475	1080	Placebo	no ASA indication	CXR896F	27.1.21 11:47	2022-08-31	Edoxaban 30mg / no ASA indication
1475	1080	Placebo	no ASA indication	NXX397G	1.2.22 12:36	2022-08-31	Edoxaban 30mg / no ASA indication
1475	1080	Placebo	no ASA indication	NTK218A	15.1.20 11:40	2022-08-31	Edoxaban 30mg / no ASA indication
1475	1080	Placebo	no ASA indication	HTD961R	12.7.21 11:09	2022-08-31	Edoxaban 30mg / no ASA indication
1478	1080	Placebo	no ASA indication	KKD294Z	8.9.21 12:15	2024-04-30	Edoxaban 60mg / no ASA indication
1478	1080	Placebo	no ASA indication	FUC336E	16.1.20 12:19	2022-08-31	Edoxaban 30mg / no ASA indication
1478	1080	Placebo	no ASA indication	DTR511E	10.2.21 8:50	2021-12-31	Edoxaban 60mg / no ASA indication
1478	1080	Placebo	no ASA indication	TAL738A	3.4.22 17:03	2024-04-30	Edoxaban 60mg / no ASA indication
1478	1080	Placebo	no ASA indication	BYA934Z	29.7.20 7:30	2021-12-31	Edoxaban 60mg / no ASA indication
1536	1080	Placebo	no ASA indication	GDW249C	3.3.20 8:58	2021-12-31	Edoxaban 60mg / no ASA indication
1536	1080	Placebo	no ASA indication	CTR116Y	16.9.20 7:45	2021-12-31	Edoxaban 60mg / no ASA indication
1536	1080	Placebo	no ASA indication	KKF311Y	4.3.21 11:45	2021-12-31	Edoxaban 60mg / no ASA indication
1573	1080	Placebo	no ASA indication	XYL933W	29.4.20 10:01	2022-08-31	Edoxaban 30mg / no ASA indication
1573	1080	Placebo	no ASA indication	MFA181B	14.5.21 10:14	2021-12-31	Edoxaban 60mg / no ASA indication
1573	1080	Placebo	no ASA indication	CBN118W	29.10.20 6:31	2022-08-31	Edoxaban 30mg / no ASA indication
1643	1080	Placebo	no ASA indication	TRU615G	17.6.20 10:31	2022-08-31	Edoxaban 30mg / no ASA indication
1643	1080	Placebo	no ASA indication	DWT946M	4.1.21 9:41	2022-08-31	Edoxaban 30mg / no ASA indication
1660	1080	Placebo	no ASA indication	BKV939Y	29.12.20 10:28	2022-08-31	Edoxaban 30mg / no ASA indication
1660	1080	Placebo	no ASA indication	YEV551K	25.6.20 9:57	2022-08-31	Edoxaban 30mg / no ASA indication
1661	1080	Placebo	no ASA indication	EES979B	21.12.20 9:03	2021-12-31	Edoxaban 60mg / no ASA indication
1661	1080	Placebo	no ASA indication	ABM356U	25.6.20 10:06	2022-08-31	Edoxaban 30mg / no ASA indication
1661	1080	Placebo	no ASA indication	BHC135M	15.12.21 11:28	2022-08-31	Edoxaban 30mg / no ASA indication
1661	1080	Placebo	no ASA indication	HTN834L	21.6.22 9:23	2024-11-30	Edoxaban 30mg / no ASA indication
1661	1080	Placebo	no ASA indication	FNA193C	11.6.21 5:39	2022-08-31	Edoxaban 30mg / no ASA indication
1688	1080	Placebo	no ASA indication	FNT743X	14.7.20 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
1695	1080	Placebo	no ASA indication	PZP156X	20.7.20 9:36	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1695	1080	Placebo	no ASA indication	RKG426M	25.7.22 9:02	2024-11-30	Edoxaban 30mg / no ASA indication
1695	1080	Placebo	no ASA indication	AWP134S	28.1.21 8:54	2022-08-31	Edoxaban 30mg / no ASA indication
1695	1080	Placebo	no ASA indication	NSK118D	26.1.22 9:15	2022-08-31	Edoxaban 30mg / no ASA indication
1695	1080	Placebo	no ASA indication	KWW474T	23.7.21 8:36	2022-08-31	Edoxaban 30mg / no ASA indication
1703	1080	Placebo	no ASA indication	GDG214D	21.7.21 11:41	2024-04-30	Edoxaban 60mg / no ASA indication
1703	1080	Placebo	no ASA indication	RHM353C	31.1.22 9:25	2024-04-30	Edoxaban 60mg / no ASA indication
1703	1080	Placebo	no ASA indication	FPC282T	28.1.21 8:11	2021-12-31	Edoxaban 60mg / no ASA indication
1703	1080	Placebo	no ASA indication	BAK942N	23.7.20 8:22	2021-12-31	Edoxaban 60mg / no ASA indication
1703	1080	Placebo	no ASA indication	RLT493Z	22.8.22 9:39	2024-11-30	Edoxaban 30mg / no ASA indication
1707	1080	Placebo	no ASA indication	FPN571V	16.2.21 7:36	2021-12-31	Edoxaban 60mg / no ASA indication
1707	1080	Placebo	no ASA indication	RGX974W	9.2.22 13:29	2024-04-30	Edoxaban 60mg / no ASA indication
1707	1080	Placebo	no ASA indication	YMW218R	27.7.22 6:51	2024-04-30	Edoxaban 60mg / no ASA indication
1707	1080	Placebo	no ASA indication	FFG849M	12.7.21 5:54	2024-04-30	Edoxaban 60mg / no ASA indication
1707	1080	Placebo	no ASA indication	BZF111Z	29.7.20 7:33	2021-12-31	Edoxaban 60mg / no ASA indication
1734	1080	Placebo	no ASA indication	ELP846H	17.2.21 9:05	2022-08-31	Edoxaban 30mg / no ASA indication
1734	1080	Placebo	no ASA indication	BFS991P	17.8.20 9:48	2022-08-31	Edoxaban 30mg / no ASA indication
1734	1080	Placebo	no ASA indication	FEA497Y	9.2.22 11:12	2024-11-30	Edoxaban 30mg / no ASA indication
1734	1080	Placebo	no ASA indication	RWN268W	11.8.22 10:00	2024-11-30	Edoxaban 30mg / no ASA indication
1734	1080	Placebo	no ASA indication	KUF723V	2.9.21 8:09	2022-08-31	Edoxaban 30mg / no ASA indication
1740	1080	Placebo	no ASA indication	BPA825N	20.8.20 16:26	2021-12-31	Edoxaban 60mg / no ASA indication
1740	1080	Placebo	no ASA indication	KNL126H	27.8.21 4:49	2022-08-31	Edoxaban 30mg / no ASA indication
1740	1080	Placebo	no ASA indication	GRS711Y	4.4.22 12:21	2024-11-30	Edoxaban 30mg / no ASA indication
1740	1080	Placebo	no ASA indication	GUX713Y	19.2.21 11:36	2021-12-31	Edoxaban 60mg / no ASA indication
1743	1080	Placebo	no ASA indication	HVL981M	2.3.21 8:41	2021-12-31	Edoxaban 60mg / no ASA indication
1743	1080	Placebo	no ASA indication	TEF112E	3.4.22 17:17	2024-04-30	Edoxaban 60mg / no ASA indication
1743	1080	Placebo	no ASA indication	HNZ872W	30.8.21 9:06	2024-04-30	Edoxaban 60mg / no ASA indication
1743	1080	Placebo	no ASA indication	BZM937M	25.8.20 8:24	2021-12-31	Edoxaban 60mg / no ASA indication
1746	1080	Placebo	no ASA indication	BVY811M	26.8.20 7:46	2021-12-31	Edoxaban 60mg / no ASA indication
1746	1080	Placebo	no ASA indication	SLH792N	4.4.22 12:13	2024-04-30	Edoxaban 60mg / no ASA indication
1746	1080	Placebo	no ASA indication	KKV195W	6.9.21 7:01	2024-04-30	Edoxaban 60mg / no ASA indication
1746	1080	Placebo	no ASA indication	GWS339L	24.2.21 9:01	2021-12-31	Edoxaban 60mg / no ASA indication
1749	1080	Placebo	no ASA indication	CSZ131G	27.8.20 8:19	2021-12-31	Edoxaban 60mg / no ASA indication
1749	1080	Placebo	no ASA indication	GDG696N	25.2.21 7:45	2021-12-31	Edoxaban 60mg / no ASA indication
1798	1080	Placebo	no ASA indication	CRF259Y	23.9.20 12:00	2021-12-31	Edoxaban 60mg / no ASA indication
1798	1080	Placebo	no ASA indication	LTY364S	19.10.21 11:25	2024-04-30	Edoxaban 60mg / no ASA indication
1798	1080	Placebo	no ASA indication	LGE263V	1.4.21 9:31	2021-12-31	Edoxaban 60mg / no ASA indication
1798	1080	Placebo	no ASA indication	MXX592T	4.4.22 12:32	2024-04-30	Edoxaban 60mg / no ASA indication
1814	1080	Placebo	no ASA indication	YZE283U	13.4.22 9:50	2024-04-30	Edoxaban 60mg / no ASA indication
1814	1080	Placebo	no ASA indication	CER595A	5.10.20 11:24	2021-12-31	Edoxaban 60mg / no ASA indication
1814	1080	Placebo	no ASA indication	LXP733B	15.10.21 12:24	2024-04-30	Edoxaban 60mg / no ASA indication
1814	1080	Placebo	no ASA indication	LMM167S	31.3.21 13:37	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1843	1080	Placebo	no ASA indication	CZN329L	1.11.20 7:54	2021-12-31	Edoxaban 60mg / no ASA indication
1856	1080	Placebo	no ASA indication	LVK357T	28.12.21 9:18	2022-08-31	Edoxaban 30mg / no ASA indication
1856	1080	Placebo	no ASA indication	FVX265U	3.6.21 6:42	2022-08-31	Edoxaban 30mg / no ASA indication
1856	1080	Placebo	no ASA indication	AWR543M	10.11.20 8:10	2022-08-31	Edoxaban 30mg / no ASA indication
1874	1080	Placebo	no ASA indication	KLK589V	30.12.21 10:45	2024-04-30	Edoxaban 60mg / no ASA indication
1874	1080	Placebo	no ASA indication	CUB113H	19.11.20 9:36	2021-12-31	Edoxaban 60mg / no ASA indication
1874	1080	Placebo	no ASA indication	GLB368B	10.6.21 8:26	2022-08-31	Edoxaban 30mg / no ASA indication
1888	1080	Placebo	no ASA indication	DUW413F	2.12.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1888	1080	Placebo	no ASA indication	NGS826E	22.12.21 11:35	2024-04-30	Edoxaban 60mg / no ASA indication
1888	1080	Placebo	no ASA indication	EZP649N	26.6.21 8:32	2024-04-30	Edoxaban 60mg / no ASA indication
1914	1080	Placebo	no ASA indication	FGU238N	7.7.21 5:59	2024-04-30	Edoxaban 60mg / no ASA indication
1914	1080	Placebo	no ASA indication	MAU568X	28.12.21 8:06	2024-04-30	Edoxaban 60mg / no ASA indication
1914	1080	Placebo	no ASA indication	YSE119A	7.7.22 8:03	2024-04-30	Edoxaban 60mg / no ASA indication
1914	1080	Placebo	no ASA indication	DHD483R	22.12.20 11:41	2021-12-31	Edoxaban 60mg / no ASA indication
1945	1080	Placebo	no ASA indication	FUY794D	3.2.21 8:04	2021-12-31	Edoxaban 60mg / no ASA indication
1945	1080	Placebo	no ASA indication	WWS455D	17.8.22 12:11	2024-04-30	Edoxaban 60mg / no ASA indication
1945	1080	Placebo	no ASA indication	GAL731W	9.8.21 5:49	2024-04-30	Edoxaban 60mg / no ASA indication
1945	1080	Placebo	no ASA indication	MWB752H	16.2.22 11:45	2024-04-30	Edoxaban 60mg / no ASA indication
1948	1080	Placebo	no ASA indication	FTF916V	6.8.21 5:53	2024-04-30	Edoxaban 60mg / no ASA indication
1948	1080	Placebo	no ASA indication	FGU821B	15.2.22 9:40	2024-11-30	Edoxaban 30mg / no ASA indication
1948	1080	Placebo	no ASA indication	EGD772B	4.2.21 7:21	2021-12-31	Edoxaban 60mg / no ASA indication
2012	1080	Placebo	no ASA indication	KGL391P	16.3.21 10:45	2021-12-31	Edoxaban 60mg / no ASA indication
2017	1080	Placebo	no ASA indication	HMZ724Y	16.9.21 7:48	2024-04-30	Edoxaban 60mg / no ASA indication
2017	1080	Placebo	no ASA indication	SLD145X	3.4.22 16:48	2024-04-30	Edoxaban 60mg / no ASA indication
2017	1080	Placebo	no ASA indication	KYV355W	18.3.21 8:15	2021-12-31	Edoxaban 60mg / no ASA indication
2020	1080	Placebo	no ASA indication	HDX782K	16.9.21 7:40	2024-04-30	Edoxaban 60mg / no ASA indication
2020	1080	Placebo	no ASA indication	TUX372W	13.4.22 9:39	2024-04-30	Edoxaban 60mg / no ASA indication
2020	1080	Placebo	no ASA indication	KZV729B	19.3.21 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
2024	1080	Placebo	no ASA indication	KAB472G	22.9.21 7:55	2024-04-30	Edoxaban 60mg / no ASA indication
2024	1080	Placebo	no ASA indication	YXG189Z	13.4.22 9:43	2024-04-30	Edoxaban 60mg / no ASA indication
2024	1080	Placebo	no ASA indication	MAH382Y	24.3.21 9:06	2021-12-31	Edoxaban 60mg / no ASA indication
2056	1080	Placebo	no ASA indication	KYF615F	27.10.21 10:35	2024-04-30	Edoxaban 60mg / no ASA indication
2056	1080	Placebo	no ASA indication	MDW322Z	20.4.21 11:01	2021-12-31	Edoxaban 60mg / no ASA indication
2056	1080	Placebo	no ASA indication	YXN389P	10.5.22 6:29	2024-04-30	Edoxaban 60mg / no ASA indication
2058	1080	Placebo	no ASA indication	HKU983E	17.12.21 17:24	2022-08-31	Edoxaban 30mg / no ASA indication
2058	1080	Placebo	no ASA indication	FDP762U	20.4.21 20:48	2022-08-31	Edoxaban 30mg / no ASA indication
2123	1080	Placebo	no ASA indication	KZW555M	27.5.21 6:20	2021-12-31	Edoxaban 60mg / no ASA indication
2123	1080	Placebo	no ASA indication	KMH745K	26.11.21 6:52	2024-04-30	Edoxaban 60mg / no ASA indication
2125	1080	Placebo	no ASA indication	MFV598R	27.5.21 9:36	2021-12-31	Edoxaban 60mg / no ASA indication
2126	1080	Placebo	no ASA indication	MGF219C	18.11.21 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
2126	1080	Placebo	no ASA indication	LRC617Z	28.5.21 12:03	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2144	1080	Placebo	no ASA indication	MUN181G	10.6.21 7:24	2021-12-31	Edoxaban 60mg / no ASA indication
2150	1080	Placebo	no ASA indication	FKY568C	10.6.21 10:15	2022-08-31	Edoxaban 30mg / no ASA indication
2154	1080	Placebo	no ASA indication	NXT871E	21.1.22 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
2154	1080	Placebo	no ASA indication	FDB618X	26.6.21 8:38	2024-04-30	Edoxaban 60mg / no ASA indication
2154	1080	Placebo	no ASA indication	ZXC492U	30.5.22 8:33	2024-04-30	Edoxaban 60mg / no ASA indication
2185	1080	Placebo	no ASA indication	FCV886D	12.7.21 10:06	2024-04-30	Edoxaban 60mg / no ASA indication
2194	1080	Placebo	no ASA indication	PRV872B	5.1.22 11:53	2024-04-30	Edoxaban 60mg / no ASA indication
2194	1080	Placebo	no ASA indication	ZFC866U	14.7.22 10:32	2024-04-30	Edoxaban 60mg / no ASA indication
2194	1080	Placebo	no ASA indication	FZV543L	20.7.21 10:03	2024-04-30	Edoxaban 60mg / no ASA indication
2206	1080	Placebo	no ASA indication	RLZ113B	7.2.22 13:09	2024-04-30	Edoxaban 60mg / no ASA indication
2206	1080	Placebo	no ASA indication	FUR225Y	27.7.21 11:28	2024-04-30	Edoxaban 60mg / no ASA indication
2288	1080	Placebo	no ASA indication	XCY479M	17.5.22 7:14	2024-04-30	Edoxaban 60mg / no ASA indication
2288	1080	Placebo	no ASA indication	KKZ715H	29.9.21 10:41	2024-04-30	Edoxaban 60mg / no ASA indication
2293	1080	Placebo	no ASA indication	KLD417G	29.9.21 11:19	2024-04-30	Edoxaban 60mg / no ASA indication
2293	1080	Placebo	no ASA indication	ZBP612F	17.5.22 11:05	2024-04-30	Edoxaban 60mg / no ASA indication
2320	1080	Placebo	no ASA indication	LBR223H	29.10.21 8:50	2022-08-31	Edoxaban 30mg / no ASA indication
2320	1080	Placebo	no ASA indication	RXL942X	25.4.22 19:23	2024-11-30	Edoxaban 30mg / no ASA indication
2348	1080	Placebo	no ASA indication	MCK829F	16.11.21 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
2478	1080	Placebo	no ASA indication	RYR185G	15.2.22 9:28	2024-04-30	Edoxaban 60mg / no ASA indication
2478	1080	Placebo	no ASA indication	XCZ285Z	15.8.22 9:02	2024-04-30	Edoxaban 60mg / no ASA indication
1765	1080	Edoxaban	ASA indication	ERP425W	8.9.21 7:45	2024-04-30	Edoxaban 60mg / ASA indication
1765	1080	Edoxaban	ASA indication	KUE942U	5.4.22 15:52	2024-04-30	Edoxaban 60mg / ASA indication
1765	1080	Edoxaban	ASA indication	DHR221Z	12.3.21 9:18	2021-12-31	Edoxaban 60mg / ASA indication
1765	1080	Edoxaban	ASA indication	ATD944L	9.9.20 11:33	2021-12-31	Edoxaban 60mg / ASA indication
1778	1080	Edoxaban	ASA indication	PAY828G	15.9.20 9:05	2021-12-31	Edoxaban 60mg / ASA indication
1793	1080	Edoxaban	ASA indication	ESH917F	5.4.22 16:00	2024-04-30	Edoxaban 60mg / ASA indication
1793	1080	Edoxaban	ASA indication	PXF663T	18.9.20 8:08	2021-12-31	Edoxaban 60mg / ASA indication
1793	1080	Edoxaban	ASA indication	FDC875P	22.3.21 8:41	2021-12-31	Edoxaban 60mg / ASA indication
1793	1080	Edoxaban	ASA indication	ELA856S	24.9.21 8:59	2024-04-30	Edoxaban 60mg / ASA indication
2085	1080	Edoxaban	ASA indication	NLB134G	5.5.21 8:29	2021-12-31	Edoxaban 60mg / ASA indication
2085	1080	Edoxaban	ASA indication	HXV974F	4.11.21 11:11	2024-04-30	Edoxaban 60mg / ASA indication
2310	1080	Edoxaban	ASA indication	HBB138E	19.10.21 9:28	2024-04-30	Edoxaban 60mg / ASA indication
1371	1080	Edoxaban	no ASA indication	ZGN744W	14.5.20 9:48	2021-12-31	Edoxaban 60mg / no ASA indication
1371	1080	Edoxaban	no ASA indication	HNR936C	4.11.21 7:53	2024-04-30	Edoxaban 60mg / no ASA indication
1371	1080	Edoxaban	no ASA indication	PTD133K	30.5.22 7:09	2024-04-30	Edoxaban 60mg / no ASA indication
1371	1080	Edoxaban	no ASA indication	EDK114F	29.10.20 7:36	2021-12-31	Edoxaban 60mg / no ASA indication
1371	1080	Edoxaban	no ASA indication	HLK641W	1.6.21 8:00	2021-12-31	Edoxaban 60mg / no ASA indication
1371	1080	Edoxaban	no ASA indication	TLB137R	6.11.19 12:37	2021-12-31	Edoxaban 60mg / no ASA indication
1388	1080	Edoxaban	no ASA indication	BKT122E	3.7.20 7:20	2021-12-31	Edoxaban 60mg / no ASA indication
1388	1080	Edoxaban	no ASA indication	EYB889U	23.11.20 10:34	2021-12-31	Edoxaban 60mg / no ASA indication
1388	1080	Edoxaban	no ASA indication	CBW726R	14.11.19 14:43	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1444	1080	Edoxaban	no ASA indication	MYS848B	23.12.21 14:06	2022-08-31	Edoxaban 30mg / no ASA indication
1444	1080	Edoxaban	no ASA indication	LNB492Z	26.6.21 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
1444	1080	Edoxaban	no ASA indication	HDP875S	30.12.20 7:31	2021-12-31	Edoxaban 60mg / no ASA indication
1444	1080	Edoxaban	no ASA indication	LHH313Z	10.6.22 11:49	2024-11-30	Edoxaban 30mg / no ASA indication
1444	1080	Edoxaban	no ASA indication	LTX695S	11.12.19 11:54	2022-08-31	Edoxaban 30mg / no ASA indication
1444	1080	Edoxaban	no ASA indication	FHF141G	16.6.20 8:04	2022-08-31	Edoxaban 30mg / no ASA indication
1462	1080	Edoxaban	no ASA indication	HDG978L	17.6.20 10:20	2021-12-31	Edoxaban 60mg / no ASA indication
1462	1080	Edoxaban	no ASA indication	DXP156B	23.12.19 8:18	2021-12-31	Edoxaban 60mg / no ASA indication
1538	1080	Edoxaban	no ASA indication	KDB669P	3.3.20 10:23	2021-12-31	Edoxaban 60mg / no ASA indication
1571	1080	Edoxaban	no ASA indication	KFH592E	27.7.21 8:55	2022-08-31	Edoxaban 30mg / no ASA indication
1571	1080	Edoxaban	no ASA indication	FYC765Y	28.3.22 13:49	2024-11-30	Edoxaban 30mg / no ASA indication
1571	1080	Edoxaban	no ASA indication	WAW929H	23.4.20 11:29	2022-08-31	Edoxaban 30mg / no ASA indication
1571	1080	Edoxaban	no ASA indication	EBZ891E	29.10.20 7:21	2021-12-31	Edoxaban 60mg / no ASA indication
1615	1080	Edoxaban	no ASA indication	EUL971S	10.12.20 6:59	2021-12-31	Edoxaban 60mg / no ASA indication
1615	1080	Edoxaban	no ASA indication	STD162U	9.6.20 10:15	2021-12-31	Edoxaban 60mg / no ASA indication
1636	1080	Edoxaban	no ASA indication	HSW926L	14.12.21 10:08	2024-04-30	Edoxaban 60mg / no ASA indication
1636	1080	Edoxaban	no ASA indication	DMT345C	23.12.20 8:36	2021-12-31	Edoxaban 60mg / no ASA indication
1636	1080	Edoxaban	no ASA indication	ECG756S	6.7.21 6:49	2024-04-30	Edoxaban 60mg / no ASA indication
1636	1080	Edoxaban	no ASA indication	KYT867L	16.6.20 10:25	2021-12-31	Edoxaban 60mg / no ASA indication
1636	1080	Edoxaban	no ASA indication	UFY833A	22.6.22 8:56	2024-04-30	Edoxaban 60mg / no ASA indication
1665	1080	Edoxaban	no ASA indication	GRB732H	23.12.20 10:25	2021-12-31	Edoxaban 60mg / no ASA indication
1665	1080	Edoxaban	no ASA indication	ECW246P	1.7.21 9:22	2024-04-30	Edoxaban 60mg / no ASA indication
1665	1080	Edoxaban	no ASA indication	ARD557W	26.6.20 9:15	2021-12-31	Edoxaban 60mg / no ASA indication
1671	1080	Edoxaban	no ASA indication	HBK124K	11.1.21 12:16	2021-12-31	Edoxaban 60mg / no ASA indication
1671	1080	Edoxaban	no ASA indication	DZM732G	13.7.21 6:57	2024-04-30	Edoxaban 60mg / no ASA indication
1671	1080	Edoxaban	no ASA indication	BEF759L	1.7.20 9:16	2021-12-31	Edoxaban 60mg / no ASA indication
1671	1080	Edoxaban	no ASA indication	PCG618X	12.8.22 12:30	2024-04-30	Edoxaban 60mg / no ASA indication
1671	1080	Edoxaban	no ASA indication	LBS646H	12.1.22 9:52	2024-04-30	Edoxaban 60mg / no ASA indication
1694	1080	Edoxaban	no ASA indication	WCU152L	17.7.20 7:51	2022-08-31	Edoxaban 30mg / no ASA indication
1694	1080	Edoxaban	no ASA indication	CAG153N	29.1.21 8:32	2022-08-31	Edoxaban 30mg / no ASA indication
1694	1080	Edoxaban	no ASA indication	LDA757P	21.7.22 10:35	2024-11-30	Edoxaban 30mg / no ASA indication
1694	1080	Edoxaban	no ASA indication	GVV471R	5.8.21 5:41	2022-08-31	Edoxaban 30mg / no ASA indication
1694	1080	Edoxaban	no ASA indication	PCH785Z	25.1.22 7:00	2022-08-31	Edoxaban 30mg / no ASA indication
1700	1080	Edoxaban	no ASA indication	HMT987X	28.1.21 13:01	2021-12-31	Edoxaban 60mg / no ASA indication
1700	1080	Edoxaban	no ASA indication	AWY737A	21.7.20 9:56	2021-12-31	Edoxaban 60mg / no ASA indication
1700	1080	Edoxaban	no ASA indication	DTH797W	31.1.22 12:42	2024-11-30	Edoxaban 30mg / no ASA indication
1700	1080	Edoxaban	no ASA indication	TZE133P	29.7.22 9:45	2024-04-30	Edoxaban 60mg / no ASA indication
1700	1080	Edoxaban	no ASA indication	LVS893A	23.7.21 9:57	2022-08-31	Edoxaban 30mg / no ASA indication
1721	1080	Edoxaban	no ASA indication	BYU545U	26.1.21 7:25	2022-08-31	Edoxaban 30mg / no ASA indication
1721	1080	Edoxaban	no ASA indication	LKE231E	28.7.21 9:35	2022-08-31	Edoxaban 30mg / no ASA indication
1721	1080	Edoxaban	no ASA indication	MXL848K	16.8.22 8:08	2024-11-30	Edoxaban 30mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1721	1080	Edoxaban	no ASA indication	AKA633X	5.8.20 7:41	2022-08-31	Edoxaban 30mg / no ASA indication
1721	1080	Edoxaban	no ASA indication	DSN312R	2.2.22 12:25	2024-11-30	Edoxaban 30mg / no ASA indication
1728	1080	Edoxaban	no ASA indication	ENK938U	5.8.21 8:39	2024-04-30	Edoxaban 60mg / no ASA indication
1728	1080	Edoxaban	no ASA indication	CHW956C	12.8.20 8:03	2021-12-31	Edoxaban 60mg / no ASA indication
1728	1080	Edoxaban	no ASA indication	UVF267U	16.8.22 10:58	2024-04-30	Edoxaban 60mg / no ASA indication
1728	1080	Edoxaban	no ASA indication	HEM943K	4.2.21 9:47	2021-12-31	Edoxaban 60mg / no ASA indication
1728	1080	Edoxaban	no ASA indication	LRY553L	8.2.22 10:37	2024-04-30	Edoxaban 60mg / no ASA indication
1736	1080	Edoxaban	no ASA indication	BXK353R	19.8.20 9:59	2022-08-31	Edoxaban 30mg / no ASA indication
1736	1080	Edoxaban	no ASA indication	FTX998U	12.3.21 10:27	2022-08-31	Edoxaban 30mg / no ASA indication
1736	1080	Edoxaban	no ASA indication	GSA547Y	4.4.22 13:38	2024-11-30	Edoxaban 30mg / no ASA indication
1736	1080	Edoxaban	no ASA indication	MAM462N	4.9.21 9:38	2022-08-31	Edoxaban 30mg / no ASA indication
1744	1080	Edoxaban	no ASA indication	HXV567X	25.2.21 10:00	2021-12-31	Edoxaban 60mg / no ASA indication
1744	1080	Edoxaban	no ASA indication	BYF947P	25.8.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1754	1080	Edoxaban	no ASA indication	LZR694U	3.4.22 17:48	2024-04-30	Edoxaban 60mg / no ASA indication
1754	1080	Edoxaban	no ASA indication	CHU666D	3.9.20 9:13	2021-12-31	Edoxaban 60mg / no ASA indication
1754	1080	Edoxaban	no ASA indication	KGN435A	9.3.21 11:39	2021-12-31	Edoxaban 60mg / no ASA indication
1754	1080	Edoxaban	no ASA indication	MAX985L	15.9.21 8:55	2022-08-31	Edoxaban 30mg / no ASA indication
1762	1080	Edoxaban	no ASA indication	KBH388K	5.4.22 15:15	2024-04-30	Edoxaban 60mg / no ASA indication
1762	1080	Edoxaban	no ASA indication	CUZ244T	9.9.20 8:25	2021-12-31	Edoxaban 60mg / no ASA indication
1762	1080	Edoxaban	no ASA indication	LVT149V	26.3.21 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1762	1080	Edoxaban	no ASA indication	HEZ857H	28.10.21 6:17	2024-04-30	Edoxaban 60mg / no ASA indication
1786	1080	Edoxaban	no ASA indication	DPS979W	17.9.20 9:07	2021-12-31	Edoxaban 60mg / no ASA indication
1786	1080	Edoxaban	no ASA indication	HWX667U	1.4.21 6:50	2021-12-31	Edoxaban 60mg / no ASA indication
1802	1080	Edoxaban	no ASA indication	CTR979Y	25.9.20 11:48	2021-12-31	Edoxaban 60mg / no ASA indication
1822	1080	Edoxaban	no ASA indication	CKC125R	12.10.20 7:38	2022-08-31	Edoxaban 30mg / no ASA indication
1861	1080	Edoxaban	no ASA indication	CCS685E	11.11.20 12:33	2022-08-31	Edoxaban 30mg / no ASA indication
1863	1080	Edoxaban	no ASA indication	LAG361S	27.4.21 5:21	2021-12-31	Edoxaban 60mg / no ASA indication
1863	1080	Edoxaban	no ASA indication	EKP837V	11.11.20 12:52	2021-12-31	Edoxaban 60mg / no ASA indication
1890	1080	Edoxaban	no ASA indication	EUW365W	4.12.20 8:42	2021-12-31	Edoxaban 60mg / no ASA indication
1890	1080	Edoxaban	no ASA indication	NES368C	10.6.21 5:44	2021-12-31	Edoxaban 60mg / no ASA indication
1912	1080	Edoxaban	no ASA indication	EDG142U	9.7.21 7:35	2024-04-30	Edoxaban 60mg / no ASA indication
1912	1080	Edoxaban	no ASA indication	FCK232B	12.1.22 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
1912	1080	Edoxaban	no ASA indication	GAZ911S	21.12.20 9:36	2021-12-31	Edoxaban 60mg / no ASA indication
1912	1080	Edoxaban	no ASA indication	PRF111G	6.7.22 11:24	2024-04-30	Edoxaban 60mg / no ASA indication
1937	1080	Edoxaban	no ASA indication	GWM623V	26.1.21 8:09	2021-12-31	Edoxaban 60mg / no ASA indication
1977	1080	Edoxaban	no ASA indication	FCW488S	24.2.21 8:42	2022-08-31	Edoxaban 30mg / no ASA indication
1988	1080	Edoxaban	no ASA indication	EYC364A	1.3.21 12:54	2022-08-31	Edoxaban 30mg / no ASA indication
1988	1080	Edoxaban	no ASA indication	MDE825L	13.4.22 9:52	2024-11-30	Edoxaban 30mg / no ASA indication
1988	1080	Edoxaban	no ASA indication	MUZ629K	5.10.21 10:37	2022-08-31	Edoxaban 30mg / no ASA indication
1992	1080	Edoxaban	no ASA indication	MAX825S	4.4.22 11:51	2024-04-30	Edoxaban 60mg / no ASA indication
1992	1080	Edoxaban	no ASA indication	GDE556V	2.9.21 8:16	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1992	1080	Edoxaban	no ASA indication	CMW964Y	2.3.21 10:08	2022-08-31	Edoxaban 30mg / no ASA indication
2018	1080	Edoxaban	no ASA indication	DML195C	18.3.21 11:12	2022-08-31	Edoxaban 30mg / no ASA indication
2018	1080	Edoxaban	no ASA indication	MMS627F	30.9.21 8:49	2022-08-31	Edoxaban 30mg / no ASA indication
2037	1080	Edoxaban	no ASA indication	GGV378C	8.4.21 9:08	2022-08-31	Edoxaban 30mg / no ASA indication
2037	1080	Edoxaban	no ASA indication	GSA492V	5.4.22 15:05	2024-11-30	Edoxaban 30mg / no ASA indication
2037	1080	Edoxaban	no ASA indication	MBL191Y	29.10.21 9:20	2022-08-31	Edoxaban 30mg / no ASA indication
2057	1080	Edoxaban	no ASA indication	MMU216V	20.4.21 20:20	2021-12-31	Edoxaban 60mg / no ASA indication
2084	1080	Edoxaban	no ASA indication	EXM279U	19.11.21 9:50	2024-04-30	Edoxaban 60mg / no ASA indication
2084	1080	Edoxaban	no ASA indication	UGU784S	11.5.22 7:38	2024-04-30	Edoxaban 60mg / no ASA indication
2084	1080	Edoxaban	no ASA indication	LRX593L	5.5.21 5:55	2021-12-31	Edoxaban 60mg / no ASA indication
2099	1080	Edoxaban	no ASA indication	MFR466A	14.5.21 5:27	2021-12-31	Edoxaban 60mg / no ASA indication
2099	1080	Edoxaban	no ASA indication	VKW545E	2.6.22 6:17	2024-04-30	Edoxaban 60mg / no ASA indication
2099	1080	Edoxaban	no ASA indication	GPT199V	15.11.21 9:26	2024-04-30	Edoxaban 60mg / no ASA indication
2131	1080	Edoxaban	no ASA indication	GEP147G	1.6.21 9:50	2022-08-31	Edoxaban 30mg / no ASA indication
2138	1080	Edoxaban	no ASA indication	NKH617S	30.11.21 7:22	2022-08-31	Edoxaban 30mg / no ASA indication
2138	1080	Edoxaban	no ASA indication	GXT548C	4.6.21 8:44	2022-08-31	Edoxaban 30mg / no ASA indication
2141	1080	Edoxaban	no ASA indication	NCT993F	8.6.21 17:27	2021-12-31	Edoxaban 60mg / no ASA indication
2147	1080	Edoxaban	no ASA indication	NGP524Y	13.4.22 9:48	2024-04-30	Edoxaban 60mg / no ASA indication
2147	1080	Edoxaban	no ASA indication	MZR746N	10.6.21 9:33	2021-12-31	Edoxaban 60mg / no ASA indication
2184	1080	Edoxaban	no ASA indication	LKU576L	8.2.22 9:11	2024-04-30	Edoxaban 60mg / no ASA indication
2184	1080	Edoxaban	no ASA indication	DZR598A	12.7.21 8:17	2024-04-30	Edoxaban 60mg / no ASA indication
2184	1080	Edoxaban	no ASA indication	NFS335A	12.7.22 7:10	2024-04-30	Edoxaban 60mg / no ASA indication
2215	1080	Edoxaban	no ASA indication	ESR783Y	9.8.21 8:46	2024-04-30	Edoxaban 60mg / no ASA indication
2237	1080	Edoxaban	no ASA indication	DCF683X	24.8.21 8:22	2022-08-31	Edoxaban 30mg / no ASA indication
2237	1080	Edoxaban	no ASA indication	GXL858X	13.4.22 9:46	2024-11-30	Edoxaban 30mg / no ASA indication
2244	1080	Edoxaban	no ASA indication	KER421K	4.4.22 13:21	2024-04-30	Edoxaban 60mg / no ASA indication
2244	1080	Edoxaban	no ASA indication	ENK874K	25.8.21 8:07	2024-04-30	Edoxaban 60mg / no ASA indication
2284	1080	Edoxaban	no ASA indication	VLU812P	17.5.22 11:55	2024-04-30	Edoxaban 60mg / no ASA indication
2284	1080	Edoxaban	no ASA indication	GKW983G	27.9.21 9:59	2024-04-30	Edoxaban 60mg / no ASA indication
2286	1080	Edoxaban	no ASA indication	KFZ983Z	4.4.22 13:27	2024-04-30	Edoxaban 60mg / no ASA indication
2286	1080	Edoxaban	no ASA indication	GNZ484R	28.9.21 8:53	2024-04-30	Edoxaban 60mg / no ASA indication
2305	1080	Edoxaban	no ASA indication	HBN679R	13.10.21 8:19	2024-04-30	Edoxaban 60mg / no ASA indication
2441	1080	Edoxaban	no ASA indication	PHY999T	21.1.22 8:46	2022-08-31	Edoxaban 30mg / no ASA indication
2464	1080	Edoxaban	no ASA indication	UXT883N	20.7.22 8:47	2024-04-30	Edoxaban 60mg / no ASA indication
2464	1080	Edoxaban	no ASA indication	LFK559B	2.2.22 13:33	2024-04-30	Edoxaban 60mg / no ASA indication
2484	1080	Edoxaban	no ASA indication	FWC791X	18.2.22 10:09	2024-11-30	Edoxaban 30mg / no ASA indication
2484	1080	Edoxaban	no ASA indication	TZD982S	9.8.22 7:17	2024-04-30	Edoxaban 60mg / no ASA indication
1353	1085	Placebo	ASA indication	UCX578V	28.10.19 9:58	2022-08-31	Edoxaban 30mg / ASA indication
1353	1085	Placebo	ASA indication	AWM489N	8.5.20 7:13	2022-08-31	Edoxaban 30mg / ASA indication
1433	1085	Placebo	ASA indication	GNS774M	5.12.19 10:56	2022-08-31	Edoxaban 30mg / ASA indication
1499	1085	Placebo	ASA indication	MNM494U	6.8.20 9:20	2022-08-31	Edoxaban 30mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1499	1085	Placebo	ASA indication	VSY697E	30.1.20 12:24	2022-08-31	Edoxaban 30mg / ASA indication
1529	1085	Placebo	ASA indication	SWM567W	25.2.20 9:47	2021-12-31	Edoxaban 60mg / ASA indication
2029	1085	Placebo	ASA indication	NKR425X	28.9.21 13:37	2024-04-30	Edoxaban 60mg / ASA indication
2029	1085	Placebo	ASA indication	KCL734U	26.3.21 9:59	2021-12-31	Edoxaban 60mg / ASA indication
2029	1085	Placebo	ASA indication	SVL739U	30.3.22 11:50	2024-04-30	Edoxaban 60mg / ASA indication
2115	1085	Placebo	ASA indication	NKU925N	25.11.21 11:25	2024-04-30	Edoxaban 60mg / ASA indication
2115	1085	Placebo	ASA indication	ZUS621R	16.5.22 12:15	2024-04-30	Edoxaban 60mg / ASA indication
2115	1085	Placebo	ASA indication	DZZ197W	21.5.21 10:58	2021-12-31	Edoxaban 60mg / ASA indication
2316	1085	Placebo	ASA indication	NNC966U	21.10.21 11:43	2024-04-30	Edoxaban 60mg / ASA indication
2316	1085	Placebo	ASA indication	XWM324V	28.4.22 10:56	2024-04-30	Edoxaban 60mg / ASA indication
2500	1085	Placebo	ASA indication	FPN126H	24.2.22 12:54	2024-04-30	Edoxaban 60mg / ASA indication
2625	1085	Placebo	ASA indication	FKF826G	24.5.22 12:06	2024-04-30	Edoxaban 60mg / ASA indication
1520	1085	Placebo	no ASA indication	GHB313N	24.2.21 9:40	2022-08-31	Edoxaban 30mg / no ASA indication
1520	1085	Placebo	no ASA indication	VPE247B	17.2.20 10:05	2022-08-31	Edoxaban 30mg / no ASA indication
1520	1085	Placebo	no ASA indication	WGN828S	31.8.20 10:19	2022-08-31	Edoxaban 30mg / no ASA indication
1520	1085	Placebo	no ASA indication	NBM216V	13.8.21 6:52	2024-04-30	Edoxaban 60mg / no ASA indication
1520	1085	Placebo	no ASA indication	PLA878M	18.2.22 12:49	2024-11-30	Edoxaban 30mg / no ASA indication
1520	1085	Placebo	no ASA indication	PMM841S	17.8.22 12:02	2024-11-30	Edoxaban 30mg / no ASA indication
1673	1085	Placebo	no ASA indication	MLF481P	2.7.20 9:13	2021-12-31	Edoxaban 60mg / no ASA indication
1785	1085	Placebo	no ASA indication	FEP819N	17.9.20 9:08	2021-12-31	Edoxaban 60mg / no ASA indication
1785	1085	Placebo	no ASA indication	XGZ239E	10.3.22 11:38	2024-04-30	Edoxaban 60mg / no ASA indication
1785	1085	Placebo	no ASA indication	YFX756E	30.3.21 11:22	2021-12-31	Edoxaban 60mg / no ASA indication
1785	1085	Placebo	no ASA indication	NBM958V	16.9.21 11:23	2024-04-30	Edoxaban 60mg / no ASA indication
1788	1085	Placebo	no ASA indication	AHK244P	17.9.20 9:49	2021-12-31	Edoxaban 60mg / no ASA indication
1788	1085	Placebo	no ASA indication	RLA185F	26.3.21 11:56	2021-12-31	Edoxaban 60mg / no ASA indication
1788	1085	Placebo	no ASA indication	LRM991M	18.3.22 12:41	2024-04-30	Edoxaban 60mg / no ASA indication
1788	1085	Placebo	no ASA indication	NCS522H	21.9.21 11:49	2024-04-30	Edoxaban 60mg / no ASA indication
1962	1085	Placebo	no ASA indication	SAD924W	17.2.21 11:00	2022-08-31	Edoxaban 30mg / no ASA indication
2301	1085	Placebo	no ASA indication	ZCH212Z	10.2.22 16:26	2024-04-30	Edoxaban 60mg / ASA indication
2301	1085	Placebo	no ASA indication	WYH264R	31.3.22 11:36	2024-04-30	Edoxaban 60mg / ASA indication
2301	1085	Placebo	no ASA indication	XSR216A	6.10.21 11:22	2024-04-30	Edoxaban 60mg / no ASA indication
2385	1085	Placebo	no ASA indication	VCD346R	1.6.22 10:40	2024-04-30	Edoxaban 60mg / no ASA indication
2385	1085	Placebo	no ASA indication	ZAG683B	7.12.21 13:11	2024-04-30	Edoxaban 60mg / no ASA indication
2429	1085	Placebo	no ASA indication	XTP766U	13.1.22 12:38	2024-04-30	Edoxaban 60mg / no ASA indication
2429	1085	Placebo	no ASA indication	VDB267S	26.7.22 10:50	2024-04-30	Edoxaban 60mg / no ASA indication
1477	1085	Edoxaban	ASA indication	LBV586P	16.1.20 9:52	2021-12-31	Edoxaban 60mg / ASA indication
1477	1085	Edoxaban	ASA indication	NBV496C	31.7.21 11:13	2024-04-30	Edoxaban 60mg / no ASA indication
1477	1085	Edoxaban	ASA indication	YFZ418K	24.1.22 12:47	2024-04-30	Edoxaban 60mg / no ASA indication
1477	1085	Edoxaban	ASA indication	ZAU556N	16.7.22 13:52	2024-04-30	Edoxaban 60mg / no ASA indication
1477	1085	Edoxaban	ASA indication	LBX481V	5.8.20 13:35	2021-12-31	Edoxaban 60mg / no ASA indication
1477	1085	Edoxaban	ASA indication	FEF943M	28.1.21 12:07	2021-12-31	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1537	1085	Edoxaban	ASA indication	KAN877M	9.9.20 11:16	2021-12-31	Edoxaban 60mg / ASA indication
1537	1085	Edoxaban	ASA indication	EKU314R	3.3.20 9:50	2021-12-31	Edoxaban 60mg / ASA indication
1963	1085	Edoxaban	ASA indication	NLH656M	11.8.21 14:28	2024-04-30	Edoxaban 60mg / ASA indication
1963	1085	Edoxaban	ASA indication	RDD969H	12.8.22 11:40	2024-04-30	Edoxaban 60mg / ASA indication
1963	1085	Edoxaban	ASA indication	VZL685C	17.2.21 11:38	2022-08-31	Edoxaban 30mg / ASA indication
1963	1085	Edoxaban	ASA indication	EMG626V	21.2.22 12:40	2024-04-30	Edoxaban 60mg / ASA indication
1980	1085	Edoxaban	ASA indication	MGG163U	24.2.21 11:03	2021-12-31	Edoxaban 60mg / ASA indication
1980	1085	Edoxaban	ASA indication	NWX519G	23.2.22 12:44	2024-04-30	Edoxaban 60mg / ASA indication
1980	1085	Edoxaban	ASA indication	NGY276E	9.9.21 12:14	2024-04-30	Edoxaban 60mg / ASA indication
1980	1085	Edoxaban	ASA indication	ULF676G	23.8.22 14:04	2024-04-30	Edoxaban 60mg / ASA indication
2021	1085	Edoxaban	ASA indication	CUE425E	24.9.21 17:24	2022-08-31	Edoxaban 30mg / ASA indication
2021	1085	Edoxaban	ASA indication	ESN269E	19.3.21 10:25	2022-08-31	Edoxaban 30mg / ASA indication
2021	1085	Edoxaban	ASA indication	RVH566N	25.3.22 12:48	2024-11-30	Edoxaban 30mg / ASA indication
2114	1085	Edoxaban	ASA indication	SVH114H	21.5.21 10:24	2021-12-31	Edoxaban 60mg / ASA indication
2482	1085	Edoxaban	ASA indication	XUC858V	16.2.22 12:36	2024-04-30	Edoxaban 60mg / ASA indication
2482	1085	Edoxaban	ASA indication	TSR357K	10.8.22 11:07	2024-04-30	Edoxaban 60mg / ASA indication
2511	1085	Edoxaban	ASA indication	PGC759M	3.3.22 12:39	2024-04-30	Edoxaban 60mg / ASA indication
1386	1085	Edoxaban	no ASA indication	LDD459X	19.11.20 12:52	2021-12-31	Edoxaban 60mg / no ASA indication
1386	1085	Edoxaban	no ASA indication	YGM375W	19.11.21 12:46	2024-04-30	Edoxaban 60mg / no ASA indication
1386	1085	Edoxaban	no ASA indication	AYE348V	18.5.20 10:26	2021-12-31	Edoxaban 60mg / no ASA indication
1386	1085	Edoxaban	no ASA indication	ESL697M	11.5.22 10:54	2024-04-30	Edoxaban 60mg / no ASA indication
1386	1085	Edoxaban	no ASA indication	GNT451H	11.6.21 12:39	2021-12-31	Edoxaban 60mg / no ASA indication
1386	1085	Edoxaban	no ASA indication	YMS897F	14.11.19 11:14	2021-12-31	Edoxaban 60mg / no ASA indication
1483	1085	Edoxaban	no ASA indication	HHV977E	10.7.20 10:16	2021-12-31	Edoxaban 60mg / no ASA indication
1483	1085	Edoxaban	no ASA indication	NKW968G	1.2.22 10:24	2024-04-30	Edoxaban 60mg / ASA indication
1483	1085	Edoxaban	no ASA indication	RDT128W	28.7.22 10:21	2024-04-30	Edoxaban 60mg / ASA indication
1483	1085	Edoxaban	no ASA indication	LDS828T	28.1.21 12:48	2021-12-31	Edoxaban 60mg / no ASA indication
1483	1085	Edoxaban	no ASA indication	NBT161L	26.7.21 7:17	2024-04-30	Edoxaban 60mg / no ASA indication
1483	1085	Edoxaban	no ASA indication	VYU345E	21.1.20 10:33	2021-12-31	Edoxaban 60mg / no ASA indication
1483	1085	Edoxaban	no ASA indication	XSH322C	5.11.21 12:09	2024-04-30	Edoxaban 60mg / ASA indication
1771	1085	Edoxaban	no ASA indication	LRH775N	11.9.20 9:30	2021-12-31	Edoxaban 60mg / no ASA indication
1771	1085	Edoxaban	no ASA indication	VWL574Z	19.3.21 11:51	2021-12-31	Edoxaban 60mg / no ASA indication
2032	1085	Edoxaban	no ASA indication	RVZ151N	13.4.22 11:58	2024-11-30	Edoxaban 30mg / no ASA indication
2032	1085	Edoxaban	no ASA indication	ZHH349V	30.3.21 12:15	2022-08-31	Edoxaban 30mg / no ASA indication
2032	1085	Edoxaban	no ASA indication	CKM397K	30.9.21 10:33	2022-08-31	Edoxaban 30mg / no ASA indication
2298	1085	Edoxaban	no ASA indication	KWZ328K	5.10.21 11:54	2022-08-31	Edoxaban 30mg / no ASA indication
2298	1085	Edoxaban	no ASA indication	SDH221S	19.4.22 11:06	2024-11-30	Edoxaban 30mg / no ASA indication
2307	1085	Edoxaban	no ASA indication	VYG767T	15.10.21 11:56	2024-04-30	Edoxaban 60mg / no ASA indication
2307	1085	Edoxaban	no ASA indication	NNF841B	9.5.22 11:00	2024-04-30	Edoxaban 60mg / no ASA indication
2312	1085	Edoxaban	no ASA indication	NPH539V	26.4.22 11:06	2024-04-30	Edoxaban 60mg / no ASA indication
2312	1085	Edoxaban	no ASA indication	VXV623R	19.10.21 11:40	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2440	1085	Edoxaban	no ASA indication	NBM326L	20.1.22 12:25	2024-04-30	Edoxaban 60mg / no ASA indication
2440	1085	Edoxaban	no ASA indication	ZBH279N	2.8.22 10:24	2024-04-30	Edoxaban 60mg / no ASA indication
2095	1086	Placebo	ASA indication	NPA318X	15.11.21 11:18	2024-04-30	Edoxaban 60mg / ASA indication
2095	1086	Placebo	ASA indication	NDA558P	26.5.22 12:33	2024-04-30	Edoxaban 60mg / no ASA indication
2095	1086	Placebo	ASA indication	MXT174D	12.5.21 10:46	2021-12-31	Edoxaban 60mg / ASA indication
2540	1086	Placebo	ASA indication	NPZ195U	18.3.22 9:50	2024-04-30	Edoxaban 60mg / ASA indication
2072	1086	Edoxaban	ASA indication	PHB474K	29.4.21 10:36	2021-12-31	Edoxaban 60mg / ASA indication
2072	1086	Edoxaban	ASA indication	FGM514B	29.4.21 12:00	2022-08-31	Edoxaban 30mg / ASA indication
2072	1086	Edoxaban	ASA indication	XYV366U	20.10.21 9:38	2022-08-31	Edoxaban 30mg / no ASA indication
2072	1086	Edoxaban	ASA indication	SHP153X	27.4.22 10:51	2024-11-30	Edoxaban 30mg / ASA indication
1174	1089	Placebo	no ASA indication	EGV989W	10.6.20 14:40	2021-12-31	Edoxaban 60mg / no ASA indication
1174	1089	Placebo	no ASA indication	BEB745S	17.12.19 10:22	2021-12-31	Edoxaban 60mg / no ASA indication
1174	1089	Placebo	no ASA indication	MTX382E	14.6.22 9:06	2024-04-30	Edoxaban 60mg / no ASA indication
1174	1089	Placebo	no ASA indication	NWK143D	21.12.21 10:55	2024-04-30	Edoxaban 60mg / no ASA indication
1174	1089	Placebo	no ASA indication	FDV111Z	11.6.19 12:03	2020-01-01	Edoxaban 60mg / no ASA indication
1174	1089	Placebo	no ASA indication	MMX335E	15.6.21 11:15	2021-12-31	Edoxaban 60mg / no ASA indication
1174	1089	Placebo	no ASA indication	MTY727W	22.12.20 11:43	2021-12-31	Edoxaban 60mg / no ASA indication
1358	1089	Placebo	no ASA indication	CLX946Y	29.10.19 12:59	2021-12-31	Edoxaban 60mg / no ASA indication
1364	1089	Placebo	no ASA indication	KUM641P	17.11.20 10:46	2022-08-31	Edoxaban 30mg / no ASA indication
1364	1089	Placebo	no ASA indication	EBW757A	9.11.21 10:48	2022-08-31	Edoxaban 30mg / no ASA indication
1364	1089	Placebo	no ASA indication	PSD127V	25.5.21 9:55	2022-08-31	Edoxaban 30mg / no ASA indication
1364	1089	Placebo	no ASA indication	XGX361M	27.5.20 14:11	2022-08-31	Edoxaban 30mg / no ASA indication
1364	1089	Placebo	no ASA indication	SKF824S	5.11.19 13:39	2022-08-31	Edoxaban 30mg / no ASA indication
1492	1089	Placebo	no ASA indication	BLK495Y	28.1.20 10:46	2021-12-31	Edoxaban 60mg / no ASA indication
1492	1089	Placebo	no ASA indication	GGG371C	23.7.20 13:35	2021-12-31	Edoxaban 60mg / no ASA indication
1502	1089	Placebo	no ASA indication	PXY863X	16.2.21 11:22	2022-08-31	Edoxaban 30mg / no ASA indication
1502	1089	Placebo	no ASA indication	PYA915L	5.10.21 11:49	2022-08-31	Edoxaban 30mg / no ASA indication
1502	1089	Placebo	no ASA indication	PWA432X	15.2.22 9:51	2022-08-31	Edoxaban 30mg / no ASA indication
1502	1089	Placebo	no ASA indication	FBL393Y	4.2.20 9:57	2022-08-31	Edoxaban 30mg / no ASA indication
1502	1089	Placebo	no ASA indication	KHG633X	11.8.20 11:45	2022-08-31	Edoxaban 30mg / no ASA indication
1522	1089	Placebo	no ASA indication	GLU199M	11.8.20 11:40	2021-12-31	Edoxaban 60mg / no ASA indication
1522	1089	Placebo	no ASA indication	RTA916Z	18.2.20 16:29	2021-12-31	Edoxaban 60mg / no ASA indication
2205	1089	Placebo	no ASA indication	MTG592Z	27.7.21 9:41	2024-04-30	Edoxaban 60mg / no ASA indication
2205	1089	Placebo	no ASA indication	BYL447N	26.7.22 10:15	2024-04-30	Edoxaban 60mg / no ASA indication
2205	1089	Placebo	no ASA indication	SKC796R	15.2.22 9:37	2024-04-30	Edoxaban 60mg / no ASA indication
2230	1089	Placebo	no ASA indication	SHD142M	15.3.22 11:24	2024-04-30	Edoxaban 60mg / no ASA indication
2230	1089	Placebo	no ASA indication	MMR178T	17.8.21 11:03	2024-04-30	Edoxaban 60mg / no ASA indication
2336	1089	Placebo	no ASA indication	NWE143M	18.1.22 12:47	2024-04-30	Edoxaban 60mg / no ASA indication
2336	1089	Placebo	no ASA indication	CMT123H	3.8.22 16:17	2024-04-30	Edoxaban 60mg / no ASA indication
1317	1089	Edoxaban	no ASA indication	WDX778P	20.4.21 9:14	2021-12-31	Edoxaban 60mg / no ASA indication
1317	1089	Edoxaban	no ASA indication	TYF566H	20.10.20 9:56	2021-12-31	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
1317	1089	Edoxaban	no ASA indication	KXL162N	8.10.19 11:16	2021-12-31	Edoxaban 60mg / no ASA indication
1317	1089	Edoxaban	no ASA indication	KZK574M	19.10.21 9:37	2024-04-30	Edoxaban 60mg / no ASA indication
1317	1089	Edoxaban	no ASA indication	VDB277G	30.3.20 9:39	2021-12-31	Edoxaban 60mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	KDZ658F	21.10.20 8:51	2021-12-31	Edoxaban 60mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	NUW918D	3.5.22 9:24	2024-04-30	Edoxaban 60mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	UKR919W	20.8.21 13:32	2022-08-31	Edoxaban 30mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	AWL185N	22.4.20 12:44	2021-12-31	Edoxaban 60mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	CDY581M	15.10.19 9:32	2021-12-31	Edoxaban 60mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	VLV739Y	20.4.21 10:24	2021-12-31	Edoxaban 60mg / no ASA indication
1333	1089	Edoxaban	no ASA indication	LGL299V	19.10.21 10:22	2024-04-30	Edoxaban 60mg / no ASA indication
1427	1089	Edoxaban	no ASA indication	AAM986G	17.11.20 11:19	2022-08-31	Edoxaban 30mg / no ASA indication
1427	1089	Edoxaban	no ASA indication	FDG324U	22.5.20 9:45	2021-12-31	Edoxaban 60mg / no ASA indication
1427	1089	Edoxaban	no ASA indication	SSS747S	3.12.19 13:05	2021-12-31	Edoxaban 60mg / no ASA indication
1504	1089	Edoxaban	no ASA indication	CKW829F	16.2.21 12:01	2021-12-31	Edoxaban 60mg / no ASA indication
1504	1089	Edoxaban	no ASA indication	XZW239Y	4.2.20 12:15	2021-12-31	Edoxaban 60mg / no ASA indication
1504	1089	Edoxaban	no ASA indication	FZL833V	11.8.20 11:49	2021-12-31	Edoxaban 60mg / no ASA indication
1504	1089	Edoxaban	no ASA indication	LAC916N	29.9.21 14:42	2024-04-30	Edoxaban 60mg / no ASA indication
1504	1089	Edoxaban	no ASA indication	PAA485N	1.2.22 11:11	2024-04-30	Edoxaban 60mg / no ASA indication
1523	1089	Edoxaban	no ASA indication	WVF884Y	18.2.20 12:37	2021-12-31	Edoxaban 60mg / no ASA indication
2066	1089	Edoxaban	no ASA indication	CBT467L	27.4.21 10:11	2021-12-31	Edoxaban 60mg / no ASA indication
2067	1089	Edoxaban	no ASA indication	FBC955G	27.4.21 14:03	2022-08-31	Edoxaban 30mg / no ASA indication
2344	1097	Placebo	ASA indication	FFV983B	16.11.21 6:23	2022-08-31	Edoxaban 30mg / ASA indication
1705	1097	Edoxaban	ASA indication	VFP133T	19.7.21 9:01	2024-04-30	Edoxaban 60mg / ASA indication
1705	1097	Edoxaban	ASA indication	FZN389B	11.1.21 10:46	2021-12-31	Edoxaban 60mg / no ASA indication
1705	1097	Edoxaban	ASA indication	TDU496G	20.9.21 12:04	2022-08-31	Edoxaban 30mg / no ASA indication
1705	1097	Edoxaban	ASA indication	YFE574E	24.7.20 11:39	2021-12-31	Edoxaban 60mg / ASA indication
2331	1097	Edoxaban	ASA indication	DYZ147W	8.11.21 15:13	2022-08-31	Edoxaban 30mg / ASA indication
2331	1097	Edoxaban	ASA indication	TBB896U	19.5.22 10:47	2024-11-30	Edoxaban 30mg / ASA indication
2401	1097	Edoxaban	ASA indication	TCG174G	30.6.22 11:30	2024-11-30	Edoxaban 30mg / ASA indication
2401	1097	Edoxaban	ASA indication	LFG884G	20.12.21 11:38	2022-08-31	Edoxaban 30mg / ASA indication
2651	1097	Edoxaban	no ASA indication	TKK114V	13.6.22 11:38	2024-11-30	Edoxaban 30mg / no ASA indication
2445	1104	Placebo	ASA indication	PEL953B	26.1.22 13:33	2024-04-30	Edoxaban 60mg / ASA indication
2560	1104	Placebo	ASA indication	PDN817W	24.3.22 13:06	2024-04-30	Edoxaban 60mg / ASA indication
2535	1104	Placebo	no ASA indication	PEE593U	15.3.22 14:32	2024-04-30	Edoxaban 60mg / no ASA indication
2169	1104	Edoxaban	no ASA indication	PAR136F	23.12.21 16:49	2024-04-30	Edoxaban 60mg / no ASA indication
2169	1104	Edoxaban	no ASA indication	VUV913V	12.8.22 11:51	2024-04-30	Edoxaban 60mg / no ASA indication
2169	1104	Edoxaban	no ASA indication	LAH678N	12.8.22 12:10	2024-04-30	Edoxaban 60mg / no ASA indication
2169	1104	Edoxaban	no ASA indication	NZW184V	24.6.21 14:16	2024-04-30	Edoxaban 60mg / no ASA indication
2553	1104	Edoxaban	no ASA indication	PAA325V	24.3.22 11:48	2024-04-30	Edoxaban 60mg / no ASA indication
2578	1108	Placebo	no ASA indication	NNV566W	7.4.22 14:54	2024-04-30	Edoxaban 60mg / no ASA indication
2531	1111	Edoxaban	no ASA indication	MRH434S	11.3.22 12:43	2024-04-30	Edoxaban 60mg / no ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2330	1115	Edoxaban	ASA indication	XMK792G	8.11.21 12:58	2024-04-30	Edoxaban 60mg / ASA indication
2434	1115	Edoxaban	no ASA indication	WVN426L	17.1.22 12:07	2024-04-30	Edoxaban 60mg / no ASA indication
2434	1115	Edoxaban	no ASA indication	WVT738G	21.7.22 7:53	2024-04-30	Edoxaban 60mg / no ASA indication
2538	1116	Placebo	no ASA indication	BLM812Y	17.3.22 10:25	2024-04-30	Edoxaban 60mg / no ASA indication
2576	1116	Placebo	no ASA indication	BKH487Y	7.4.22 9:43	2024-04-30	Edoxaban 60mg / no ASA indication
2646	1116	Placebo	no ASA indication	SWB261R	9.6.22 8:00	2024-11-30	Edoxaban 30mg / no ASA indication
2461	1116	Edoxaban	no ASA indication	APZ985D	2.2.22 13:38	2024-04-30	Edoxaban 60mg / no ASA indication
2461	1116	Edoxaban	no ASA indication	UXX962R	11.8.22 7:41	2024-11-30	Edoxaban 30mg / no ASA indication
2461	1116	Edoxaban	no ASA indication	DML789X	2.2.22 14:09	2022-08-31	Edoxaban 30mg / no ASA indication
2598	1116	Edoxaban	no ASA indication	XGH566B	28.4.22 7:41	2024-04-30	Edoxaban 60mg / no ASA indication
2701	1116	Edoxaban	no ASA indication	VDD529R	7.7.22 9:05	2024-11-30	Edoxaban 30mg / no ASA indication
2728	1117	Placebo	no ASA indication	LVW525D	28.7.22 9:21	2024-04-30	Edoxaban 60mg / no ASA indication
2678	1118	Placebo	ASA indication	RXN327U	29.6.22 11:44	2024-11-30	Edoxaban 30mg / ASA indication
2697	1118	Placebo	ASA indication	RZE824B	6.7.22 11:28	2024-11-30	Edoxaban 30mg / ASA indication
2657	1118	Placebo	no ASA indication	UMK182M	15.6.22 11:52	2024-04-30	Edoxaban 60mg / no ASA indication
2689	1118	Placebo	no ASA indication	PLZ136H	5.7.22 7:33	2024-11-30	Edoxaban 30mg / no ASA indication
2732	1118	Edoxaban	ASA indication	PAU259Z	8.8.22 11:30	2024-11-30	Edoxaban 30mg / ASA indication
2729	1121	Placebo	ASA indication	VAR681X	1.8.22 14:38	2024-11-30	Edoxaban 30mg / ASA indication
2587	1121	Placebo	no ASA indication	YKA197P	20.4.22 12:08	2024-04-30	Edoxaban 60mg / no ASA indication
2609	1121	Edoxaban	ASA indication	YVZ532N	9.5.22 13:15	2024-04-30	Edoxaban 60mg / ASA indication
2377	1121	Edoxaban	no ASA indication	MZR879U	2.12.21 15:30	2022-08-31	Edoxaban 30mg / no ASA indication
2377	1121	Edoxaban	no ASA indication	VWZ965K	2.12.21 16:23	2022-08-31	Edoxaban 30mg / ASA indication
2444	1121	Edoxaban	no ASA indication	YBS333V	24.5.22 12:19	2024-04-30	Edoxaban 60mg / no ASA indication
2444	1121	Edoxaban	no ASA indication	AZD946U	6.9.22 10:29	2024-04-30	Edoxaban 60mg / no ASA indication
2444	1121	Edoxaban	no ASA indication	YBC554D	25.1.22 13:59	2024-04-30	Edoxaban 60mg / no ASA indication
2359	1123	Placebo	ASA indication	TFV934N	19.11.21 13:29	2022-08-31	Edoxaban 30mg / ASA indication
2359	1123	Placebo	ASA indication	DAS989M	12.5.22 9:25	2024-11-30	Edoxaban 30mg / ASA indication
2389	1123	Edoxaban	ASA indication	WRN946Z	9.6.22 8:51	2024-04-30	Edoxaban 60mg / ASA indication
2389	1123	Edoxaban	ASA indication	WRW129W	13.12.21 10:16	2024-04-30	Edoxaban 60mg / ASA indication
2502	1127	Placebo	no ASA indication	WKS224X	10.3.22 8:34	2024-04-30	Edoxaban 60mg / no ASA indication
2502	1127	Placebo	no ASA indication	WLF147C	15.8.22 12:51	2024-04-30	Edoxaban 60mg / no ASA indication
2557	1133	Edoxaban	ASA indication	YDA829D	4.4.22 14:11	2024-04-30	Edoxaban 60mg / ASA indication
2699	1133	Edoxaban	ASA indication	UNK798D	6.7.22 12:14	2024-11-30	Edoxaban 30mg / ASA indication
2597	1133	Edoxaban	no ASA indication	XBM229H	27.4.22 12:08	2024-04-30	Edoxaban 60mg / no ASA indication
2477	1138	Edoxaban	no ASA indication	YFY778B	15.2.22 9:54	2024-04-30	Edoxaban 60mg / no ASA indication
2611	1146	Placebo	ASA indication	AVE356H	13.5.22 8:56	2024-04-30	Edoxaban 60mg / ASA indication
2713	1146	Placebo	ASA indication	VRT485P	15.7.22 11:29	2024-11-30	Edoxaban 30mg / ASA indication
2519	1146	Placebo	no ASA indication	AUH534V	8.3.22 15:50	2024-04-30	Edoxaban 60mg / no ASA indication
2519	1146	Placebo	no ASA indication	YGG859G	26.8.22 12:01	2024-04-30	Edoxaban 60mg / no ASA indication
2574	1146	Placebo	no ASA indication	ARS778D	13.4.22 6:34	2024-04-30	Edoxaban 60mg / no ASA indication
2398	1146	Edoxaban	ASA indication	AND841D	21.12.21 11:26	2024-04-30	Edoxaban 60mg / ASA indication

Patient-ID	Centre-ID	Random group	Random stratum	Med. Kit batch	Dispense date / time	Expiry date	Product type
2398	1146	Edoxaban	ASA indication	WLP911P	10.6.22 11:02	2024-04-30	Edoxaban 60mg / ASA indication
2397	1146	Edoxaban	no ASA indication	XPT269M	20.6.22 11:12	2024-04-30	Edoxaban 60mg / no ASA indication
2397	1146	Edoxaban	no ASA indication	AGA847Z	31.12.21 9:51	2024-04-30	Edoxaban 60mg / no ASA indication
2391	1147	Placebo	ASA indication	YLH823V	14.12.21 11:49	2024-04-30	Edoxaban 60mg / ASA indication
2391	1147	Placebo	ASA indication	YMB815U	16.6.22 12:02	2024-04-30	Edoxaban 60mg / ASA indication
2391	1147	Placebo	ASA indication	XST943E	16.6.22 8:11	2024-11-30	Edoxaban 30mg / ASA indication
2525	1147	Edoxaban	no ASA indication	XSG148P	9.3.22 11:47	2024-04-30	Edoxaban 60mg / no ASA indication
2525	1147	Edoxaban	no ASA indication	XRT969B	7.9.22 10:01	2024-04-30	Edoxaban 60mg / no ASA indication
2688	1148	Placebo	no ASA indication	FGR997T	4.7.22 13:04	2024-04-30	Edoxaban 60mg / no ASA indication
2737	1148	Placebo	no ASA indication	MZZ521L	16.8.22 14:08	2024-11-30	Edoxaban 30mg / no ASA indication
2603	1148	Edoxaban	ASA indication	FBG112L	3.5.22 13:12	2024-04-30	Edoxaban 60mg / ASA indication

16.1.7 Randomisation scheme and codes (patient identification and treatment assigned)

Table 23 Randomisation list

Patient-ID	Centre-ID	Random group	Random stratum (indication)
46	9	Edoxaban	no ASA
48	9	Placebo	ASA
54	9	Edoxaban	no ASA
57	9	Edoxaban	ASA
66	9	Edoxaban	ASA
75	9	Placebo	ASA
92	9	Placebo	no ASA
93	9	Edoxaban	ASA
96	9	Placebo	no ASA
100	9	Edoxaban	no ASA
118	9	Placebo	ASA
129	9	Edoxaban	ASA
153	9	Edoxaban	ASA
170	9	Placebo	ASA
192	9	Placebo	ASA
237	9	Edoxaban	ASA
288	9	Placebo	ASA
393	9	Edoxaban	ASA
410	9	Edoxaban	no ASA
434	9	Placebo	ASA
468	9	Placebo	ASA
485	9	Edoxaban	ASA
536	9	Edoxaban	no ASA
561	9	Placebo	ASA
666	9	Edoxaban	ASA
681	9	Placebo	ASA
682	9	Edoxaban	ASA
694	9	Placebo	ASA
697	9	Placebo	no ASA
719	9	Edoxaban	ASA
720	9	Placebo	ASA
731	9	Edoxaban	ASA
758	9	Placebo	ASA
830	9	Placebo	no ASA
843	9	Edoxaban	ASA
878	9	Placebo	no ASA
879	9	Placebo	ASA
908	9	Edoxaban	ASA
1126	9	Edoxaban	ASA
1127	9	Edoxaban	ASA
1178	9	Edoxaban	ASA
1192	9	Placebo	ASA
1204	9	Placebo	ASA
1213	9	Placebo	ASA
1259	9	Placebo	ASA
1278	9	Edoxaban	ASA
1338	9	Edoxaban	ASA
1346	9	Edoxaban	ASA
1570	9	Placebo	no ASA
1600	9	Placebo	ASA
1641	9	Placebo	ASA
1692	9	Edoxaban	no ASA
1816	9	Edoxaban	ASA
1817	9	Placebo	ASA
1847	9	Placebo	no ASA
1871	9	Placebo	ASA
1879	9	Edoxaban	no ASA
1897	9	Edoxaban	no ASA
1961	9	Edoxaban	ASA
1974	9	Placebo	ASA
2044	9	Edoxaban	ASA
2210	9	Edoxaban	ASA
2221	9	Placebo	ASA
2226	9	Placebo	no ASA
2297	9	Edoxaban	no ASA
2311	9	Placebo	ASA
2333	9	Edoxaban	ASA
2403	9	Placebo	no ASA
2406	9	Placebo	ASA
2408	9	Placebo	no ASA
2421	9	Edoxaban	ASA
2479	9	Edoxaban	ASA
2563	9	Placebo	no ASA
2599	9	Placebo	ASA
2615	9	Edoxaban	no ASA
2624	9	Placebo	ASA
2700	9	Edoxaban	no ASA
2741	9	Placebo	ASA
1581	12	Edoxaban	ASA
1582	12	Placebo	ASA
1651	12	Edoxaban	no ASA
1658	12	Edoxaban	no ASA
1687	12	Placebo	no ASA
1698	12	Placebo	no ASA
1701	12	Placebo	ASA
1706	12	Edoxaban	ASA
1752	12	Edoxaban	ASA
1760	12	Placebo	no ASA
1761	12	Edoxaban	ASA
1775	12	Placebo	no ASA
1787	12	Placebo	ASA
1789	12	Edoxaban	no ASA
2608	12	Edoxaban	no ASA
2622	12	Placebo	ASA
2649	12	Edoxaban	no ASA
2684	12	Placebo	ASA
2708	12	Placebo	ASA
148	16	Placebo	no ASA
385	16	Edoxaban	no ASA
440	16	Edoxaban	no ASA
1033	16	Edoxaban	no ASA
1165	16	Edoxaban	ASA
1179	16	Edoxaban	ASA
1269	16	Placebo	ASA
364	17	Edoxaban	ASA
409	17	Edoxaban	no ASA
446	17	Placebo	ASA
1598	17	Placebo	no ASA
120	19	Placebo	no ASA
203	19	Edoxaban	ASA
263	19	Placebo	ASA
329	19	Edoxaban	ASA
340	19	Edoxaban	no ASA
600	19	Placebo	ASA
805	19	Edoxaban	no ASA
1633	19	Edoxaban	ASA
608	22		
624	22	Edoxaban	ASA
927	22		
122	23	Edoxaban	no ASA
140	23	Placebo	ASA
234	23	Edoxaban	ASA
265	23	Edoxaban	ASA
504	23	Placebo	ASA
692	23	Placebo	ASA
150	33	Placebo	ASA
216	33	Placebo	ASA
221	33	Placebo	no ASA
235	33	Edoxaban	ASA
1206	33	Edoxaban	ASA
1378	33	Edoxaban	ASA
1413	33	Placebo	ASA
442	34	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
964	34		
59	35	Placebo	ASA
260	35	Edoxaban	no ASA
453	35	Placebo	ASA
301	38		
305	38	Edoxaban	no ASA
414	38	Placebo	no ASA
566	38	Placebo	ASA
1186	39	Edoxaban	ASA
1351	39	Placebo	ASA
1391	39	Placebo	ASA
2005	39	Placebo	no ASA
300	40	Placebo	ASA
861	40	Edoxaban	no ASA
567	42	Edoxaban	ASA
1953	42	Edoxaban	no ASA
2013	42	Placebo	ASA
2103	42	Edoxaban	ASA
2122	42	Placebo	ASA
2219	42	Placebo	ASA
2250	42	Placebo	no ASA
2296	42	Placebo	ASA
2376	42	Placebo	no ASA
2439	42	Placebo	ASA
2443	42	Placebo	ASA
2564	42	Edoxaban	no ASA
2683	42	Edoxaban	ASA
2692	42	Edoxaban	ASA
2698	42	Edoxaban	ASA
2733	42	Edoxaban	ASA
258	43	Edoxaban	ASA
397	43	Placebo	ASA
845	43	Placebo	ASA
472	44	Placebo	ASA
1274	44	Edoxaban	ASA
1426	44	Placebo	ASA
2019	44	Edoxaban	ASA
43	46	Edoxaban	ASA
63	46	Edoxaban	no ASA
69	46	Edoxaban	ASA
95	46	Placebo	ASA
145	46	Placebo	ASA
147	46	Placebo	ASA
243	49	Edoxaban	no ASA
272	49	Edoxaban	no ASA
287	49	Placebo	ASA
363	49	Placebo	no ASA
321	53	Edoxaban	no ASA
451	57	Edoxaban	ASA
587	57	Placebo	ASA
593	57	Edoxaban	ASA
723	57	Placebo	ASA
966	57	Edoxaban	ASA
1300	57	Placebo	ASA
1324	57	Edoxaban	ASA
1568	57	Placebo	ASA
1629	57	Edoxaban	ASA
1755	57	Edoxaban	ASA
1837	57	Edoxaban	ASA
1928	57	Placebo	ASA
2245	57	Placebo	ASA
2542	57	Placebo	no ASA
2551	57	Placebo	ASA
9	59	Placebo	no ASA
19	59	Placebo	ASA
24	59	Placebo	ASA
58	59	Edoxaban	no ASA
67	59	Placebo	ASA
98	59	Edoxaban	ASA
119	59	Placebo	ASA
149	59	Edoxaban	no ASA
186	59	Edoxaban	ASA
380	59	Edoxaban	ASA
416	59	Edoxaban	ASA
463	59	Placebo	no ASA
466	59	Placebo	ASA
467	59	Placebo	no ASA
493	59	Edoxaban	ASA
528	59	Edoxaban	ASA
541	59	Edoxaban	no ASA
615	59	Placebo	no ASA
655	59	Edoxaban	ASA
679	59	Placebo	ASA
826	59	Placebo	no ASA
1063	59	Placebo	ASA
1105	59	Edoxaban	ASA
1115	59	Edoxaban	no ASA
1140	59	Edoxaban	no ASA
1161	59	Placebo	ASA
1191	59	Placebo	no ASA
1195	59	Edoxaban	ASA
1230	59	Placebo	no ASA
1245	59	Edoxaban	ASA
1247	59	Placebo	ASA
1293	59	Edoxaban	no ASA
1422	59	Placebo	no ASA
1451	59	Placebo	ASA
1456	59	Placebo	ASA
1490	59	Edoxaban	ASA
1579	59	Edoxaban	ASA
1583	59	Placebo	ASA
1634	59	Edoxaban	no ASA
1779	59	Placebo	ASA
1801	59	Edoxaban	no ASA
1920	59	Edoxaban	no ASA
2211	59	Placebo	ASA
2442	59	Edoxaban	no ASA
2467	59	Placebo	ASA
2470	59	Edoxaban	ASA
2612	59	Placebo	no ASA
2669	59	Placebo	no ASA
16	70	Edoxaban	no ASA
105	70	Edoxaban	ASA
151	70	Placebo	no ASA
253	70	Edoxaban	no ASA
325	70	Placebo	ASA
401	70	Placebo	no ASA
402	70	Edoxaban	no ASA
418	70	Placebo	no ASA
479	70	Placebo	no ASA
511	70	Placebo	ASA
514	70	Edoxaban	no ASA
644	70	Placebo	ASA
662	70	Edoxaban	ASA
674	70	Edoxaban	ASA
765	70	Placebo	ASA
774	70	Edoxaban	ASA
881	70	Edoxaban	ASA
995	70	Placebo	ASA
1045	70	Placebo	ASA
1114	70	Placebo	no ASA
1134	70	Edoxaban	ASA
1148	70	Placebo	ASA
1304	70	Placebo	no ASA
1320	70	Edoxaban	no ASA
1485	70	Placebo	ASA
1569	70	Edoxaban	no ASA
1599	70	Edoxaban	ASA
1714	70	Placebo	no ASA
1725	70	Edoxaban	ASA
1727	70	Placebo	ASA
1730	70	Placebo	no ASA
1741	70	Edoxaban	no ASA
1751	70	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1805	70	Edoxaban	ASA
1808	70	Edoxaban	ASA
1829	70	Edoxaban	no ASA
1910	70	Placebo	no ASA
1950	70	Placebo	ASA
1964	70	Edoxaban	ASA
2014	70	Edoxaban	ASA
2028	70	Placebo	ASA
2068	70	Edoxaban	ASA
2171	70	Edoxaban	no ASA
2182	70	Edoxaban	ASA
2425	70	Placebo	ASA
2438	70	Placebo	ASA
2475	70	Placebo	ASA
2517	70	Placebo	no ASA
2529	70	Edoxaban	ASA
2554	70	Placebo	ASA
2686	70	Placebo	ASA
338	86	Edoxaban	ASA
352	86	Edoxaban	ASA
373	86	Placebo	ASA
404	86	Placebo	ASA
554	86	Placebo	no ASA
672	86	Edoxaban	no ASA
722	86	Edoxaban	ASA
1016	86	Placebo	ASA
1085	86		
1189	86	Edoxaban	no ASA
1262	86	Placebo	ASA
1263	86	Edoxaban	ASA
1374	86	Edoxaban	ASA
1379	86	Edoxaban	no ASA
1428	86	Edoxaban	ASA
1542	86	Placebo	no ASA
10	95	Edoxaban	ASA
13	95	Edoxaban	no ASA
14	95	Edoxaban	ASA
18	95	Placebo	ASA
22	95	Placebo	no ASA
26	95	Placebo	no ASA
28	95	Placebo	ASA
29	95	Edoxaban	no ASA
30	95	Placebo	no ASA
38	95	Placebo	ASA
44	95	Placebo	ASA
53	95	Edoxaban	ASA
71	95	Placebo	no ASA
117	95	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
180	95	Edoxaban	no ASA
202	95	Edoxaban	no ASA
256	95		
533	95	Edoxaban	no ASA
534	95	Placebo	no ASA
820	95	Edoxaban	no ASA
1066	95	Placebo	no ASA
1175	95	Edoxaban	ASA
1368	95	Placebo	no ASA
2287	95	Placebo	no ASA
4	100	Placebo	ASA
124	100	Edoxaban	ASA
527	100	Edoxaban	ASA
537	100	Edoxaban	ASA
846	100	Placebo	ASA
848	100	Placebo	ASA
933	100	Edoxaban	ASA
1327	100	Edoxaban	ASA
1604	100	Placebo	no ASA
1969	100	Placebo	ASA
2653	100	Placebo	no ASA
201	109	Placebo	ASA
36	113	Edoxaban	no ASA
37	113	Placebo	no ASA
39	113	Placebo	ASA
40	113	Edoxaban	no ASA
60	113	Placebo	ASA
62	113	Placebo	no ASA
65	113	Edoxaban	no ASA
154	113	Placebo	no ASA
369	113	Edoxaban	ASA
411	113	Edoxaban	no ASA
17	117	Placebo	ASA
23	117	Placebo	ASA
264	117	Edoxaban	ASA
320	117	Edoxaban	ASA
663	117	Edoxaban	ASA
943	117	Edoxaban	ASA
1155	117	Placebo	no ASA
1739	117	Placebo	no ASA
41	121	Edoxaban	ASA
56	121	Placebo	ASA
103	121	Placebo	ASA
109	121	Edoxaban	ASA
111	121	Edoxaban	no ASA
130	121	Placebo	no ASA
355	121	Placebo	ASA
359	121	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
6	132	Edoxaban	no ASA
8	132	Placebo	no ASA
51	132	Edoxaban	no ASA
70	132	Edoxaban	no ASA
73	132	Placebo	no ASA
101	132	Placebo	ASA
229	132	Placebo	ASA
266	132	Placebo	no ASA
295	132	Edoxaban	ASA
388	132	Edoxaban	ASA
739	132	Edoxaban	no ASA
1383	132	Placebo	no ASA
1436	132	Placebo	no ASA
1612	132	Placebo	ASA
1902	132	Edoxaban	ASA
1958	132	Placebo	ASA
1983	132	Edoxaban	ASA
2392	132	Edoxaban	no ASA
2629	132	Placebo	no ASA
82	133	Edoxaban	ASA
188	133	Edoxaban	ASA
400	133	Placebo	ASA
477	133	Placebo	no ASA
618	133	Placebo	ASA
634	133	Edoxaban	ASA
97	135	Placebo	no ASA
328	135	Edoxaban	ASA
339	135	Edoxaban	ASA
376	135	Placebo	no ASA
7	136	Placebo	ASA
33	136	Placebo	ASA
34	136	Edoxaban	ASA
132	136	Edoxaban	ASA
52	140	Placebo	ASA
68	140	Placebo	no ASA
74	140	Edoxaban	no ASA
85	140	Edoxaban	ASA
88	140		
99	140	Placebo	no ASA
113	140	Placebo	no ASA
114	140	Placebo	ASA
136	140	Edoxaban	ASA
160	140	Placebo	ASA
171	140	Placebo	ASA
190	140	Edoxaban	ASA
200	140	Edoxaban	no ASA
209	140	Edoxaban	ASA
212	140	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
225	140	Placebo	ASA
251	140	Edoxaban	no ASA
252	140	Edoxaban	ASA
254	140	Edoxaban	ASA
257	140	Placebo	ASA
331	140	Edoxaban	no ASA
399	140	Placebo	ASA
407	140	Edoxaban	ASA
432	140	Placebo	no ASA
436	140	Edoxaban	ASA
482	140	Placebo	ASA
506	140	Edoxaban	ASA
539	140	Placebo	no ASA
551	140	Placebo	ASA
565	140	Placebo	ASA
568	140	Edoxaban	no ASA
592	140	Edoxaban	no ASA
622	140	Edoxaban	ASA
669	140	Placebo	no ASA
713	140	Placebo	no ASA
717	140	Edoxaban	ASA
803	140	Placebo	ASA
818	140	Edoxaban	no ASA
841	140	Edoxaban	ASA
919	140	Edoxaban	no ASA
941	140	Placebo	ASA
1094	140	Placebo	ASA
1101	140	Placebo	no ASA
1266	140	Edoxaban	ASA
1389	140	Placebo	no ASA
1394	140	Edoxaban	ASA
1406	140	Edoxaban	ASA
1438	140	Placebo	ASA
1439	140	Placebo	ASA
1466	140	Placebo	ASA
1496	140	Placebo	no ASA
1576	140	Edoxaban	no ASA
1577	140	Edoxaban	ASA
1578	140	Edoxaban	ASA
1655	140	Placebo	ASA
1666	140	Placebo	ASA
1781	140	Edoxaban	ASA
1826	140	Placebo	no ASA
1889	140	Edoxaban	ASA
1926	140	Placebo	no ASA
1929	140	Edoxaban	no ASA
1930	140	Placebo	ASA
2046	140	Edoxaban	ASA
2096	140	Edoxaban	ASA
2187	140	Edoxaban	no ASA
2202	140	Placebo	no ASA
2204	140	Edoxaban	no ASA
2238	140	Placebo	no ASA
2349	140	Placebo	ASA
2357	140	Edoxaban	ASA
2617	140	Edoxaban	no ASA
2618	140	Placebo	no ASA
2631	140	Placebo	ASA
2661	140	Placebo	ASA
2691	140	Edoxaban	no ASA
671	145	Placebo	ASA
2533	151	Edoxaban	ASA
2537	151	Placebo	no ASA
2572	151	Edoxaban	no ASA
2585	151	Placebo	ASA
35	153	Edoxaban	no ASA
106	153	Edoxaban	ASA
319	153	Placebo	ASA
1098	153	Placebo	no ASA
1545	153	Placebo	no ASA
1935	153	Placebo	ASA
2142	153	Placebo	no ASA
2730	153	Edoxaban	ASA
110	154	Placebo	ASA
181	154	Edoxaban	ASA
297	154	Placebo	ASA
688	154	Edoxaban	ASA
230	161	Edoxaban	ASA
294	161	Placebo	ASA
302	161	Edoxaban	ASA
361	161	Placebo	ASA
395	161	Placebo	ASA
459	161	Edoxaban	ASA
526	161		
978	161	Placebo	ASA
1543	161	Placebo	ASA
2485	161	Placebo	ASA
2417	166	Placebo	ASA
2510	166	Edoxaban	no ASA
2626	166	Edoxaban	no ASA
2671	166	Placebo	ASA
2594	167	Edoxaban	no ASA
2621	167	Placebo	no ASA
2623	167	Edoxaban	no ASA
2640	167	Placebo	ASA
2149	171	Edoxaban	ASA
2255	171	Edoxaban	no ASA
2304	171	Edoxaban	ASA
2518	171	Placebo	no ASA
2606	171	Placebo	ASA
2709	171	Edoxaban	no ASA
2717	171	Placebo	no ASA
167	173	Placebo	no ASA
176	173	Placebo	no ASA
242	173	Edoxaban	ASA
314	173	Edoxaban	no ASA
322	173	Edoxaban	no ASA
553	173	Placebo	no ASA
585	173	Placebo	ASA
894	173	Edoxaban	no ASA
975	173	Edoxaban	no ASA
1014	173	Placebo	no ASA
1062	173	Placebo	ASA
1067	173	Placebo	no ASA
1080	173	Edoxaban	no ASA
1319	173	Placebo	no ASA
1488	173	Placebo	no ASA
1540	173	Placebo	ASA
1712	173	Edoxaban	ASA
1716	173	Edoxaban	no ASA
1758	173	Edoxaban	ASA
2042	173	Placebo	ASA
2062	173	Edoxaban	no ASA
2124	173	Placebo	ASA
2342	173	Placebo	ASA
2375	173	Edoxaban	no ASA
2453	173	Edoxaban	ASA
2506	173	Placebo	no ASA
2568	173	Edoxaban	ASA
2607	173	Edoxaban	no ASA
2675	173	Placebo	no ASA
172	174	Edoxaban	no ASA
306	174	Edoxaban	ASA
498	174	Placebo	no ASA
613	174	Edoxaban	ASA
1008	174	Placebo	ASA
1414	174	Placebo	no ASA
1487	174	Edoxaban	no ASA
1672	174	Edoxaban	no ASA
1925	174	Placebo	ASA
2069	174	Placebo	no ASA
2176	174	Placebo	ASA
2566	174	Edoxaban	no ASA
2586	174	Placebo	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2588	174	Edoxaban	ASA
487	175	Edoxaban	no ASA
515	175	Placebo	no ASA
1035	175	Edoxaban	no ASA
2456	175	Placebo	ASA
2460	175	Placebo	ASA
2523	175	Edoxaban	ASA
2530	175	Edoxaban	no ASA
2536	175	Placebo	no ASA
2745	175	Edoxaban	ASA
128	179	Placebo	ASA
296	179	Edoxaban	no ASA
308	179	Placebo	no ASA
510	179	Placebo	ASA
989	179		
1108	179		
1112	179	Edoxaban	ASA
1132	179	Edoxaban	no ASA
1147	179	Edoxaban	ASA
1182	179	Placebo	no ASA
1270	179	Edoxaban	no ASA
1868	179	Placebo	no ASA
2100	179	Edoxaban	no ASA
2101	179	Placebo	no ASA
2193	179	Edoxaban	ASA
351	189		
424	189	Edoxaban	ASA
1331	189	Edoxaban	ASA
169	195	Edoxaban	no ASA
283	195	Edoxaban	no ASA
396	195	Placebo	no ASA
398	195	Edoxaban	ASA
412	195	Placebo	ASA
519	195	Edoxaban	ASA
617	195	Edoxaban	ASA
633	195	Placebo	ASA
1004	195	Placebo	ASA
1233	195	Placebo	no ASA
1411	195	Edoxaban	ASA
144	198	Placebo	no ASA
1857	198	Placebo	ASA
2148	198	Placebo	ASA
348	202	Edoxaban	no ASA
419	202	Edoxaban	no ASA
556	202	Edoxaban	ASA
1125	202	Placebo	no ASA
1146	202	Edoxaban	ASA
1188	202	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
80	205	Edoxaban	ASA
182	205	Edoxaban	no ASA
184	205	Placebo	ASA
207	205	Placebo	no ASA
285	205	Placebo	ASA
336	205	Edoxaban	ASA
342	205		
366	205	Placebo	ASA
382	205	Edoxaban	ASA
748	205	Placebo	ASA
931	205	Placebo	ASA
946	205	Edoxaban	ASA
516	208	Placebo	no ASA
524	208	Placebo	no ASA
1036	208	Edoxaban	ASA
1306	208	Edoxaban	no ASA
1362	208	Edoxaban	ASA
1449	208	Edoxaban	no ASA
79	209	Placebo	ASA
141	209	Placebo	no ASA
1501	209	Placebo	no ASA
143	211	Placebo	ASA
204	211	Edoxaban	ASA
250	211	Placebo	ASA
356	211	Edoxaban	ASA
513	211	Placebo	no ASA
49	217	Placebo	no ASA
239	226	Edoxaban	ASA
293	226	Placebo	ASA
413	226	Edoxaban	ASA
609	226		
648	226	Placebo	ASA
1164	226	Edoxaban	no ASA
1400	226	Placebo	ASA
1404	226	Edoxaban	ASA
1434	226	Placebo	ASA
1511	226	Edoxaban	ASA
1630	226	Placebo	ASA
1638	226	Placebo	no ASA
1670	226	Edoxaban	ASA
1710	226	Placebo	no ASA
2089	226	Edoxaban	no ASA
2120	226	Edoxaban	ASA
2243	226	Edoxaban	no ASA
2259	226	Placebo	no ASA
2639	226	Edoxaban	ASA
228	232	Edoxaban	no ASA
749	232	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1019	232	Edoxaban	ASA
1152	232	Edoxaban	ASA
381	264	Edoxaban	no ASA
408	264	Placebo	no ASA
583	264	Edoxaban	ASA
747	264	Placebo	ASA
905	264	Placebo	ASA
1330	264	Edoxaban	ASA
1544	264	Placebo	no ASA
1753	264	Edoxaban	no ASA
1844	264	Placebo	ASA
2454	264	Placebo	ASA
2681	264	Placebo	no ASA
829	267	Placebo	ASA
832	267	Edoxaban	ASA
920	267	Edoxaban	ASA
937	267	Edoxaban	ASA
1219	267	Placebo	ASA
21	308	Placebo	no ASA
215	308	Placebo	ASA
217	308	Edoxaban	no ASA
267	308	Placebo	no ASA
501	326	Edoxaban	ASA
72	377	Placebo	ASA
83	377	Placebo	no ASA
175	377	Placebo	ASA
163	406	Placebo	ASA
1003	406	Placebo	ASA
220	414	Placebo	ASA
246	414	Edoxaban	no ASA
268	414	Edoxaban	ASA
346	414	Edoxaban	ASA
433	414	Placebo	ASA
584	414	Placebo	ASA
670	414	Edoxaban	ASA
704	414	Placebo	ASA
970	414	Edoxaban	ASA
988	414	Placebo	no ASA
1510	414	Edoxaban	no ASA
1541	414	Placebo	ASA
1610	414	Edoxaban	ASA
1626	414	Placebo	no ASA
1654	414	Placebo	ASA
1686	414	Placebo	no ASA
1704	414	Edoxaban	no ASA
1767	414	Edoxaban	no ASA
1777	414	Edoxaban	ASA
1783	414	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1792	414	Placebo	ASA
1845	414	Placebo	ASA
1892	414	Placebo	ASA
1941	414	Placebo	no ASA
1943	414	Edoxaban	ASA
1971	414	Edoxaban	ASA
2035	414	Placebo	no ASA
2116	414		
2174	414	Edoxaban	ASA
2183	414	Edoxaban	no ASA
2278	414		
2309	414		
2322	414		
2323	414	Placebo	ASA
2424	414	Placebo	no ASA
2469	414	Edoxaban	ASA
2481	414		
2497	414		
2507	414	Edoxaban	no ASA
2569	414		
2570	414	Edoxaban	no ASA
2571	414	Placebo	ASA
84	416	Edoxaban	no ASA
86	416	Placebo	no ASA
125	416	Placebo	no ASA
191	416		
445	416	Placebo	no ASA
449	416	Edoxaban	no ASA
469	416	Edoxaban	no ASA
547	416	Placebo	no ASA
1001	416	Edoxaban	no ASA
211	419	Edoxaban	no ASA
244	419	Placebo	no ASA
247	419	Edoxaban	ASA
323	419	Edoxaban	no ASA
441	419		
464	419	Placebo	no ASA
494	419	Placebo	ASA
637	419	Edoxaban	no ASA
690	419	Placebo	no ASA
945	419	Edoxaban	no ASA
1137	419	Placebo	no ASA
1260	419	Edoxaban	ASA
1858	419	Placebo	ASA
2083	419	Edoxaban	ASA
2172	419	Edoxaban	ASA
2207	419	Edoxaban	ASA
2303	419	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
55	421	Placebo	no ASA
77	421	Edoxaban	ASA
78	421	Placebo	no ASA
116	421	Placebo	ASA
126	421	Placebo	ASA
146	421	Edoxaban	no ASA
155	421	Edoxaban	no ASA
157	421	Placebo	ASA
161	421	Placebo	ASA
236	421	Edoxaban	ASA
279	421	Edoxaban	ASA
290	421	Edoxaban	no ASA
353	421	Edoxaban	ASA
430	421	Placebo	no ASA
500	421	Edoxaban	no ASA
503	421	Edoxaban	ASA
544	421	Placebo	no ASA
685	421	Placebo	no ASA
699	421	Edoxaban	no ASA
768	421	Placebo	no ASA
790	421	Placebo	ASA
828	421	Placebo	ASA
854	421	Edoxaban	no ASA
875	421	Edoxaban	no ASA
907	421	Edoxaban	no ASA
985	421	Edoxaban	ASA
1000	421	Placebo	ASA
1046	421	Edoxaban	ASA
1116	421	Placebo	no ASA
1216	421	Placebo	no ASA
1225	421	Edoxaban	ASA
1299	421	Placebo	ASA
1307	421	Edoxaban	ASA
1357	421	Placebo	no ASA
1380	421	Edoxaban	no ASA
1418	421	Placebo	ASA
1505	421	Placebo	no ASA
1584	421	Edoxaban	no ASA
1590	421	Edoxaban	ASA
1602	421	Edoxaban	ASA
1668	421	Edoxaban	no ASA
1729	421	Placebo	ASA
1759	421	Placebo	ASA
1804	421	Placebo	no ASA
1806	421	Placebo	no ASA
1841	421	Placebo	ASA
1882	421	Placebo	ASA
1883	421	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1884	421	Placebo	ASA
1899	421	Edoxaban	ASA
1933	421	Edoxaban	no ASA
1934	421	Edoxaban	ASA
1940	421	Edoxaban	ASA
1949	421	Placebo	ASA
1956	421	Edoxaban	ASA
1979	421	Placebo	ASA
1991	421	Edoxaban	no ASA
2023	421	Placebo	ASA
2033	421	Edoxaban	ASA
2034	421	Edoxaban	ASA
2076	421		
2109	421	Placebo	no ASA
2111	421	Placebo	ASA
2152	421	Edoxaban	no ASA
2227	421	Placebo	ASA
2228	421	Edoxaban	ASA
2232	421	Placebo	no ASA
2240	421	Edoxaban	no ASA
2241	421	Edoxaban	no ASA
2264	421	Placebo	no ASA
2265	421	Edoxaban	ASA
2283	421	Placebo	no ASA
2325	421	Placebo	ASA
2347	421	Placebo	ASA
2386	421	Edoxaban	ASA
2414	421	Placebo	ASA
2430	421	Placebo	no ASA
2449	421	Placebo	ASA
2452	421	Edoxaban	ASA
2457	421	Edoxaban	ASA
2489	421	Placebo	ASA
2508	421	Edoxaban	no ASA
2544	421	Edoxaban	ASA
2596	421	Edoxaban	ASA
2604	421	Placebo	ASA
2616	421	Placebo	no ASA
2633	421	Edoxaban	ASA
2654	421	Edoxaban	ASA
2673	421	Placebo	ASA
2702	421	Placebo	ASA
2712	421	Edoxaban	ASA
569	426	Placebo	no ASA
718	426	Edoxaban	ASA
778	426	Placebo	ASA
930	426	Edoxaban	no ASA
1235	426	Placebo	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1468	426	Edoxaban	ASA
1642	426	Placebo	ASA
1796	426	Edoxaban	no ASA
423	427	Placebo	no ASA
438	427	Edoxaban	ASA
508	427	Placebo	ASA
847	427	Placebo	ASA
1089	427	Edoxaban	ASA
326	428	Edoxaban	no ASA
721	428	Edoxaban	ASA
2350	428	Edoxaban	ASA
2534	428	Placebo	no ASA
650	445	Edoxaban	ASA
651	445	Edoxaban	ASA
652	445	Placebo	ASA
784	445	Edoxaban	no ASA
785	445	Placebo	ASA
786	445	Placebo	ASA
1506	445	Edoxaban	ASA
1507	445	Edoxaban	ASA
1574	445	Edoxaban	ASA
2209	445	Edoxaban	no ASA
2324	445	Placebo	ASA
2674	445	Placebo	ASA
159	459	Placebo	ASA
574	459		
196	470	Edoxaban	ASA
222	470	Edoxaban	ASA
304	470	Edoxaban	no ASA
529	470	Edoxaban	ASA
76	479	Placebo	ASA
107	479	Placebo	no ASA
535	479	Placebo	no ASA
2352	479	Edoxaban	ASA
2580	479	Edoxaban	ASA
405	487	Edoxaban	no ASA
1215	487	Edoxaban	no ASA
1246	487	Placebo	ASA
1652	487	Placebo	no ASA
2059	487	Placebo	no ASA
2491	487	Edoxaban	no ASA
2	488	Placebo	ASA
3	488		
5	488	Placebo	no ASA
12	488		
20	488	Edoxaban	ASA
25	488	Edoxaban	no ASA
27	488	Edoxaban	ASA
31	488	Edoxaban	ASA
32	488		
42	488	Edoxaban	no ASA
45	488	Placebo	ASA
47	488	Placebo	ASA
50	488	Edoxaban	ASA
61	488		
64	488	Placebo	ASA
90	488	Placebo	no ASA
121	488	Edoxaban	no ASA
134	488	Placebo	no ASA
135	488	Edoxaban	ASA
139	488	Edoxaban	no ASA
189	488	Placebo	ASA
206	488	Placebo	ASA
213	488	Edoxaban	ASA
218	488	Placebo	ASA
249	488	Placebo	ASA
261	488	Edoxaban	ASA
277	488		
280	488	Edoxaban	ASA
318	488	Edoxaban	ASA
327	488	Placebo	ASA
330	488		
343	488	Edoxaban	ASA
357	488	Placebo	no ASA
370	488	Placebo	ASA
390	488	Edoxaban	ASA
474	488	Placebo	ASA
766	488	Edoxaban	no ASA
810	488	Edoxaban	ASA
898	488	Edoxaban	no ASA
1099	488	Placebo	ASA
1133	488	Placebo	no ASA
1244	488	Edoxaban	ASA
1250	488	Placebo	no ASA
1361	488	Placebo	no ASA
1532	488	Placebo	ASA
1586	488	Edoxaban	no ASA
1824	488	Edoxaban	ASA
1942	488	Edoxaban	no ASA
2318	488	Placebo	ASA
2372	488	Edoxaban	no ASA
2413	488	Placebo	no ASA
2591	488		
102	502	Edoxaban	no ASA
133	502	Edoxaban	no ASA
166	502	Edoxaban	ASA
195	502	Edoxaban	ASA
198	502	Placebo	no ASA
227	502	Edoxaban	no ASA
270	502	Placebo	no ASA
309	502	Placebo	no ASA
334	502	Placebo	ASA
425	502	Edoxaban	no ASA
602	502	Placebo	no ASA
835	502	Placebo	ASA
1200	502	Edoxaban	ASA
1282	502	Placebo	ASA
1283	502	Placebo	ASA
1440	502	Edoxaban	ASA
1535	502	Placebo	ASA
1556	502	Edoxaban	ASA
1585	502	Placebo	ASA
1782	502	Edoxaban	no ASA
2081	502	Edoxaban	ASA
2496	502	Edoxaban	ASA
164	514	Placebo	no ASA
456	514	Edoxaban	ASA
2370	519	Edoxaban	ASA
2400	519	Edoxaban	no ASA
2577	519	Edoxaban	ASA
255	529	Placebo	ASA
317	529	Edoxaban	no ASA
447	529	Edoxaban	no ASA
489	529	Placebo	ASA
658	529	Edoxaban	ASA
659	529	Placebo	no ASA
703	529	Edoxaban	ASA
712	529	Placebo	no ASA
926	529	Edoxaban	no ASA
1006	529	Edoxaban	ASA
1050	529	Edoxaban	no ASA
1068	529	Placebo	no ASA
1072	529	Placebo	ASA
1083	529	Edoxaban	ASA
1121	529	Placebo	no ASA
1198	529	Edoxaban	no ASA
1199	529	Placebo	no ASA
1201	529	Edoxaban	ASA
1234	529	Edoxaban	ASA
1254	529	Placebo	ASA
1343	529	Edoxaban	no ASA
1354	529	Placebo	no ASA
1399	529	Placebo	ASA
1410	529		

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1503	529	Edoxaban	no ASA
1515	529	Placebo	ASA
1550	529	Placebo	ASA
1593	529	Edoxaban	no ASA
1594	529	Placebo	ASA
1595	529	Edoxaban	ASA
1632	529	Placebo	no ASA
1635	529	Placebo	no ASA
1689	529	Edoxaban	ASA
1709	529	Edoxaban	ASA
1745	529	Placebo	no ASA
1763	529	Edoxaban	ASA
1768	529	Edoxaban	no ASA
1780	529	Placebo	no ASA
1813	529	Placebo	no ASA
1823	529	Edoxaban	no ASA
1846	529	Edoxaban	no ASA
1848	529	Placebo	no ASA
1852	529	Placebo	ASA
1898	529	Edoxaban	no ASA
1924	529	Placebo	ASA
1927	529	Edoxaban	no ASA
1951	529	Edoxaban	no ASA
1965	529	Placebo	no ASA
1987	529	Edoxaban	ASA
2011	529	Placebo	no ASA
2104	529	Placebo	no ASA
2113	529	Placebo	ASA
2117	529	Edoxaban	no ASA
2118	529	Placebo	no ASA
2119	529	Edoxaban	no ASA
2216	529	Edoxaban	no ASA
2220	529	Placebo	ASA
2223	529	Edoxaban	no ASA
2229	529	Placebo	no ASA
2256	529	Placebo	no ASA
2258	529	Placebo	no ASA
2328	529	Edoxaban	no ASA
2334	529	Placebo	ASA
2338	529		
2451	529	Edoxaban	ASA
2459	529	Edoxaban	ASA
2545	529	Placebo	ASA
2555	529	Placebo	ASA
2643	529	Edoxaban	ASA
2644	529	Placebo	ASA
2647	529	Placebo	no ASA
2659	529	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2662	529	Placebo	no ASA
271	530	Edoxaban	ASA
315	530	Placebo	ASA
429	530	Placebo	no ASA
1010	530	Placebo	ASA
1059	530	Edoxaban	ASA
1237	530	Edoxaban	ASA
1513	530	Edoxaban	ASA
1521	530	Edoxaban	no ASA
1552	530	Placebo	no ASA
2106	530	Placebo	ASA
2163	530	Placebo	ASA
2164	530	Placebo	ASA
2279	530	Placebo	no ASA
2548	530	Edoxaban	no ASA
2652	530	Edoxaban	no ASA
241	531	Placebo	no ASA
311	532	Placebo	ASA
335	535	Edoxaban	no ASA
538	535	Edoxaban	ASA
546	535	Edoxaban	ASA
563	535	Placebo	no ASA
605	535	Placebo	no ASA
631	535	Edoxaban	no ASA
756	535	Edoxaban	no ASA
1268	535	Placebo	no ASA
1393	535	Placebo	no ASA
1589	535	Edoxaban	no ASA
1693	535	Edoxaban	ASA
1769	535	Edoxaban	no ASA
1776	535	Edoxaban	no ASA
276	536	Edoxaban	ASA
386	536	Placebo	ASA
991	536	Placebo	no ASA
1328	536	Placebo	ASA
1818	536	Edoxaban	ASA
2326	536	Edoxaban	no ASA
291	541	Placebo	no ASA
417	541	Placebo	no ASA
470	541	Edoxaban	no ASA
855	541	Edoxaban	ASA
856	541		
347	542	Edoxaban	no ASA
523	542	Placebo	no ASA
137	544	Placebo	no ASA
156	544	Placebo	no ASA
177	544	Placebo	ASA
178	544	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
179	544	Placebo	ASA
224	544	Edoxaban	no ASA
310	544	Edoxaban	no ASA
367	544	Placebo	no ASA
486	544	Edoxaban	ASA
488	544	Edoxaban	no ASA
491	544	Placebo	no ASA
575	544	Placebo	no ASA
773	544	Edoxaban	no ASA
839	544	Edoxaban	no ASA
940	544	Placebo	ASA
958	544	Edoxaban	ASA
1005	544	Edoxaban	ASA
1190	544	Edoxaban	ASA
1193	544	Placebo	no ASA
1336	544	Placebo	ASA
1345	544	Edoxaban	no ASA
1367	544	Edoxaban	no ASA
1370	544	Edoxaban	ASA
1476	544	Placebo	ASA
1482	544	Placebo	ASA
1508	544	Placebo	ASA
1606	544	Placebo	no ASA
1683	544	Edoxaban	ASA
1831	544	Placebo	no ASA
1854	544	Placebo	no ASA
273	547	Placebo	no ASA
275	547	Placebo	ASA
378	547	Edoxaban	ASA
391	547	Placebo	ASA
392	547	Edoxaban	ASA
454	547	Placebo	no ASA
499	547	Edoxaban	no ASA
573	547	Edoxaban	no ASA
702	547	Placebo	no ASA
715	547	Placebo	no ASA
864	547	Edoxaban	no ASA
909	547	Edoxaban	no ASA
918	547	Placebo	no ASA
922	547	Placebo	no ASA
936	547	Edoxaban	no ASA
996	547	Edoxaban	no ASA
1088	547	Placebo	ASA
1160	547	Edoxaban	no ASA
1238	547	Placebo	no ASA
1369	547	Edoxaban	ASA
1517	547	Placebo	ASA
1554	547	Placebo	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1622	547	Edoxaban	no ASA
1653	547	Placebo	no ASA
1663	547	Edoxaban	ASA
1903	547	Placebo	no ASA
1906	547	Placebo	ASA
1922	547	Placebo	ASA
1932	547	Edoxaban	no ASA
1938	547	Edoxaban	no ASA
1939	547	Placebo	ASA
2051	547	Placebo	no ASA
2052	547	Edoxaban	no ASA
2053	547	Placebo	no ASA
2054	547	Edoxaban	no ASA
2055	547	Edoxaban	ASA
2063	547	Edoxaban	ASA
2127	547	Placebo	no ASA
2128	547	Edoxaban	no ASA
2129	547	Edoxaban	no ASA
2213	547	Edoxaban	no ASA
2214	547	Edoxaban	ASA
2218	547	Placebo	ASA
2299	547	Edoxaban	ASA
2379	547	Placebo	no ASA
2380	547	Edoxaban	no ASA
2407	547	Placebo	no ASA
2409	547	Placebo	no ASA
2411	547	Edoxaban	ASA
2412	547	Placebo	ASA
2447	547	Placebo	ASA
2493	547	Edoxaban	no ASA
2495	547	Edoxaban	no ASA
2520	547	Placebo	no ASA
2521	547	Placebo	no ASA
2522	547	Edoxaban	ASA
2565	547	Placebo	no ASA
2605	547	Edoxaban	ASA
2628	547	Placebo	no ASA
2632	547	Placebo	no ASA
2635	547	Edoxaban	no ASA
2636	547	Edoxaban	no ASA
2658	547	Edoxaban	no ASA
2695	547	Placebo	no ASA
2718	547	Edoxaban	no ASA
2719	547	Edoxaban	ASA
2735	547	Placebo	ASA
394	557	Edoxaban	no ASA
460	557	Placebo	no ASA
502	557	Edoxaban	ASA
530	557	Placebo	no ASA
598	557	Edoxaban	no ASA
667	557	Placebo	ASA
714	557	Edoxaban	ASA
733	557	Placebo	ASA
1117	557	Placebo	no ASA
1232	557	Edoxaban	no ASA
389	564	Placebo	no ASA
462	564	Placebo	ASA
490	564	Edoxaban	ASA
548	564	Edoxaban	ASA
779	564	Edoxaban	no ASA
974	564	Edoxaban	ASA
1110	564	Placebo	ASA
1322	564		
165	566	Edoxaban	ASA
344	577	Placebo	no ASA
298	605	Edoxaban	ASA
377	605	Placebo	ASA
572	608	Placebo	ASA
816	608	Placebo	ASA
817	608	Edoxaban	ASA
868	608	Placebo	ASA
869	608	Edoxaban	ASA
903	608	Placebo	no ASA
954	608	Edoxaban	no ASA
973	608	Edoxaban	ASA
1091	608	Placebo	no ASA
1450	608	Placebo	no ASA
1471	608	Edoxaban	no ASA
1484	608	Placebo	ASA
1766	608	Edoxaban	no ASA
1774	608	Placebo	ASA
1791	608	Edoxaban	ASA
1993	608	Edoxaban	no ASA
2036	608	Edoxaban	ASA
2402	608	Placebo	no ASA
2645	608	Placebo	no ASA
601	619	Edoxaban	no ASA
115	641	Edoxaban	ASA
138	641	Placebo	no ASA
238	641	Edoxaban	ASA
262	641	Edoxaban	no ASA
274	641	Edoxaban	no ASA
286	641	Placebo	ASA
292	641	Edoxaban	no ASA
422	641	Placebo	no ASA
473	641	Placebo	no ASA
478	641	Placebo	no ASA
542	641		
552	641	Placebo	ASA
581	641	Placebo	ASA
588	641	Edoxaban	no ASA
589	641	Edoxaban	ASA
632	641	Placebo	no ASA
643	641	Placebo	ASA
746	641	Edoxaban	no ASA
1015	641	Edoxaban	no ASA
1167	641	Edoxaban	ASA
1211	641	Placebo	no ASA
1280	641	Edoxaban	no ASA
1405	641	Edoxaban	ASA
1430	641	Placebo	no ASA
1498	641	Placebo	no ASA
1691	641	Edoxaban	ASA
1719	641	Placebo	ASA
1807	641	Placebo	ASA
1828	641	Edoxaban	no ASA
1834	641	Placebo	no ASA
1855	641	Edoxaban	no ASA
1905	641	Placebo	no ASA
1944	641	Edoxaban	no ASA
1981	641	Placebo	no ASA
1990	641	Edoxaban	ASA
2016	641	Placebo	ASA
2112	641	Edoxaban	no ASA
2166	641	Placebo	ASA
2168	641	Placebo	no ASA
2196	641	Edoxaban	no ASA
2341	641	Edoxaban	no ASA
2343	641	Placebo	no ASA
2393	641	Edoxaban	ASA
2463	641	Edoxaban	ASA
2584	641	Placebo	ASA
2637	641	Placebo	no ASA
2667	641	Placebo	no ASA
2332	653	Placebo	ASA
2448	653	Edoxaban	ASA
2486	653	Edoxaban	no ASA
2487	653	Edoxaban	ASA
2498	653	Edoxaban	no ASA
2655	653	Placebo	ASA
152	655	Placebo	ASA
379	655	Edoxaban	ASA
461	655	Edoxaban	no ASA
465	655	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
549	655	Edoxaban	ASA
559	655	Edoxaban	ASA
560	655	Placebo	no ASA
580	655	Placebo	ASA
597	655	Placebo	no ASA
834	655	Edoxaban	no ASA
1457	655	Placebo	ASA
1491	655	Placebo	no ASA
2501	655	Edoxaban	no ASA
2582	655	Placebo	no ASA
2656	655	Edoxaban	ASA
223	663	Edoxaban	no ASA
579	663	Placebo	no ASA
259	669	Placebo	ASA
450	669	Edoxaban	ASA
1075	669	Edoxaban	no ASA
1220	669	Placebo	no ASA
1723	669	Edoxaban	no ASA
87	673	Placebo	no ASA
91	673	Edoxaban	no ASA
194	673	Placebo	no ASA
269	673	Placebo	ASA
324	673	Placebo	no ASA
337	673	Edoxaban	no ASA
427	673	Edoxaban	no ASA
707	673	Edoxaban	no ASA
821	673	Placebo	no ASA
833	673	Placebo	no ASA
837	673	Edoxaban	no ASA
948	673	Edoxaban	ASA
1048	673	Placebo	no ASA
1052	673	Edoxaban	no ASA
1097	673	Placebo	ASA
1136	673	Edoxaban	no ASA
1150	673	Placebo	no ASA
1168	673	Edoxaban	no ASA
1287	673	Placebo	no ASA
1302	673	Placebo	no ASA
1372	673	Edoxaban	ASA
1382	673	Edoxaban	no ASA
1533	673	Placebo	no ASA
1567	673	Placebo	no ASA
1662	673	Edoxaban	no ASA
1713	673	Edoxaban	ASA
1797	673	Edoxaban	no ASA
1849	673	Placebo	no ASA
1862	673	Edoxaban	no ASA
1864	673	Placebo	no ASA
1866	673	Edoxaban	no ASA
1875	673	Placebo	no ASA
1913	673	Edoxaban	ASA
1916	673	Placebo	ASA
2077	673	Edoxaban	no ASA
2086	673	Placebo	no ASA
2139	673	Edoxaban	no ASA
2146	673	Edoxaban	no ASA
2234	673	Placebo	ASA
2263	673	Edoxaban	no ASA
2268	673	Placebo	no ASA
2275	673	Placebo	no ASA
2337	673	Placebo	ASA
2339	673	Placebo	ASA
2433	673	Edoxaban	no ASA
2541	673	Placebo	no ASA
2575	673	Placebo	no ASA
745	674		
886	674	Placebo	no ASA
888	674	Placebo	no ASA
1448	674	Placebo	ASA
233	675	Edoxaban	no ASA
240	675	Edoxaban	no ASA
307	675	Placebo	no ASA
345	675	Placebo	no ASA
365	675	Placebo	no ASA
384	675	Edoxaban	no ASA
507	675	Edoxaban	no ASA
591	675	Placebo	no ASA
942	675	Edoxaban	no ASA
505	679	Placebo	no ASA
1078	679	Edoxaban	no ASA
623	680	Edoxaban	ASA
668	680	Edoxaban	no ASA
698	680	Edoxaban	ASA
711	680	Placebo	ASA
729	680	Edoxaban	no ASA
763	680	Edoxaban	ASA
771	680	Placebo	no ASA
772	680	Placebo	ASA
783	680	Placebo	ASA
789	680	Placebo	ASA
813	680	Edoxaban	ASA
815	680	Edoxaban	ASA
836	680	Placebo	ASA
838	680	Placebo	no ASA
851	680	Placebo	no ASA
887	680	Edoxaban	ASA
902	680	Placebo	ASA
904	680	Placebo	ASA
934	680	Edoxaban	ASA
935	680	Placebo	ASA
955	680	Edoxaban	ASA
979	680	Placebo	ASA
981	680	Placebo	ASA
993	680	Edoxaban	ASA
998	680	Edoxaban	ASA
1024	680	Placebo	ASA
1034	680	Edoxaban	ASA
1037	680	Placebo	ASA
1041	680	Edoxaban	ASA
1044	680	Placebo	ASA
1054	680	Edoxaban	ASA
1064	680	Placebo	ASA
1065	680	Edoxaban	ASA
1071	680	Edoxaban	no ASA
1079	680	Placebo	ASA
1087	680	Edoxaban	ASA
1090	680	Edoxaban	ASA
1122	680	Placebo	ASA
1129	680	Placebo	ASA
1135	680	Placebo	no ASA
1153	680	Edoxaban	ASA
1156	680	Placebo	no ASA
1210	680	Placebo	ASA
1212	680	Edoxaban	ASA
1231	680	Placebo	ASA
1248	680	Edoxaban	no ASA
1257	680	Edoxaban	ASA
1292	680	Edoxaban	ASA
1316	680	Edoxaban	ASA
1318	680	Placebo	ASA
1339	680	Placebo	ASA
1340	680	Edoxaban	ASA
1347	680	Placebo	ASA
1349	680	Edoxaban	no ASA
1363	680	Edoxaban	ASA
1417	680	Placebo	ASA
1455	680	Placebo	ASA
1474	680	Placebo	no ASA
1512	680	Edoxaban	no ASA
1530	680	Edoxaban	ASA
1531	680	Placebo	ASA
1609	680	Placebo	ASA
1640	680	Placebo	ASA
1645	680	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1657	680	Edoxaban	ASA
1664	680	Edoxaban	ASA
1681	680	Edoxaban	no ASA
1750	680	Edoxaban	ASA
1799	680	Placebo	ASA
1815	680	Placebo	ASA
1821	680	Placebo	ASA
1832	680	Edoxaban	no ASA
1887	680	Edoxaban	ASA
1891	680	Placebo	no ASA
1907	680	Edoxaban	ASA
1955	680	Placebo	no ASA
1960	680	Placebo	no ASA
1998	680	Edoxaban	ASA
2031	680	Placebo	no ASA
2045	680	Placebo	ASA
2048	680	Edoxaban	no ASA
2060	680	Edoxaban	ASA
2065	680	Edoxaban	ASA
2088	680	Edoxaban	ASA
2091	680	Edoxaban	no ASA
2092	680	Placebo	ASA
2094	680	Edoxaban	no ASA
2233	680	Placebo	ASA
2254	680	Edoxaban	ASA
2266	680	Placebo	ASA
2267	680	Edoxaban	no ASA
2306	680	Placebo	ASA
2317	680	Placebo	ASA
2346	680	Edoxaban	ASA
2356	680	Placebo	ASA
2362	680	Edoxaban	no ASA
2394	680	Placebo	no ASA
2410	680	Edoxaban	ASA
2499	680	Placebo	no ASA
2509	680	Placebo	no ASA
2516	680	Placebo	ASA
2539	680	Edoxaban	ASA
2543	680	Placebo	ASA
2547	680	Edoxaban	no ASA
2614	680	Placebo	ASA
2620	680	Placebo	no ASA
2641	680	Placebo	ASA
2705	680	Edoxaban	ASA
2715	680	Edoxaban	ASA
2721	680	Placebo	no ASA
2724	680	Edoxaban	ASA
2747	680	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
185	685	Edoxaban	no ASA
403	685	Edoxaban	no ASA
1419	685	Placebo	no ASA
1625	685	Edoxaban	no ASA
2027	685	Placebo	no ASA
2177	685	Placebo	no ASA
358	687	Placebo	ASA
691	687	Edoxaban	no ASA
1157	687	Placebo	no ASA
1611	687	Placebo	no ASA
1614	687	Edoxaban	no ASA
2061	687	Placebo	no ASA
2355	687	Placebo	no ASA
112	688	Edoxaban	ASA
123	688	Placebo	ASA
127	688	Placebo	no ASA
183	688	Edoxaban	no ASA
210	688	Edoxaban	ASA
231	688	Edoxaban	no ASA
550	688	Edoxaban	no ASA
628	688	Placebo	no ASA
640	688	Placebo	no ASA
728	688	Placebo	ASA
842	688	Placebo	no ASA
865	688	Edoxaban	ASA
983	688	Edoxaban	ASA
1209	688	Placebo	ASA
1312	688	Placebo	ASA
1373	688	Edoxaban	ASA
1447	688	Placebo	ASA
1601	688	Placebo	ASA
1833	688	Edoxaban	ASA
1877	688	Edoxaban	no ASA
1975	688	Edoxaban	ASA
2165	688	Placebo	ASA
2179	688	Edoxaban	ASA
2252	688	Placebo	ASA
2281	688	Placebo	ASA
2363	688	Edoxaban	no ASA
2677	688	Edoxaban	ASA
578	689	Edoxaban	ASA
726	689	Placebo	no ASA
906	689	Placebo	ASA
990	689	Placebo	no ASA
232	690	Placebo	no ASA
1989	690	Edoxaban	no ASA
2190	690	Edoxaban	no ASA
2419	690	Placebo	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2428	690	Edoxaban	no ASA
1229	692	Edoxaban	ASA
1453	693	Edoxaban	no ASA
1454	693	Placebo	no ASA
1461	693	Placebo	no ASA
1518	693	Edoxaban	no ASA
1519	693	Placebo	no ASA
1559	693	Edoxaban	no ASA
2282	693	Placebo	ASA
428	697	Edoxaban	ASA
162	698	Placebo	no ASA
193	698	Edoxaban	no ASA
219	698	Edoxaban	ASA
226	698	Edoxaban	ASA
303	698	Edoxaban	ASA
475	698	Placebo	ASA
621	698	Placebo	ASA
1123	698	Placebo	ASA
1176	698	Placebo	no ASA
1494	698	Edoxaban	ASA
1018	700	Edoxaban	no ASA
1310	700	Placebo	ASA
2483	700	Placebo	ASA
158	702	Edoxaban	no ASA
174	702	Edoxaban	no ASA
289	702	Placebo	no ASA
444	702	Edoxaban	ASA
950	702	Placebo	ASA
1031	702	Placebo	no ASA
1296	702	Placebo	ASA
1381	702	Edoxaban	ASA
612	704	Edoxaban	ASA
635	704	Placebo	ASA
649	704	Edoxaban	ASA
761	704	Placebo	ASA
1528	704	Placebo	no ASA
1412	705	Placebo	ASA
1416	705	Edoxaban	ASA
1479	705	Edoxaban	ASA
1509	705	Edoxaban	ASA
1621	705	Edoxaban	no ASA
1647	705	Placebo	no ASA
1677	705		
1682	705	Placebo	ASA
1748	705	Placebo	no ASA
1773	705	Placebo	ASA
1860	705	Placebo	ASA
1881	705	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1908	705	Edoxaban	ASA
2133	705	Edoxaban	no ASA
2134	705	Placebo	ASA
2137	705	Edoxaban	ASA
2153	705	Edoxaban	no ASA
2157	705	Placebo	ASA
2158	705	Edoxaban	ASA
2272	705	Edoxaban	ASA
2291	705	Placebo	no ASA
2367	705	Edoxaban	ASA
2383	705	Edoxaban	ASA
2390	705	Placebo	ASA
2395	705	Edoxaban	ASA
2396	705	Placebo	ASA
2431	705	Edoxaban	ASA
2432	705	Placebo	ASA
2437	705	Placebo	ASA
2556	705	Placebo	ASA
2579	705	Placebo	ASA
2731	705	Placebo	no ASA
2740	705	Edoxaban	ASA
2742	705	Placebo	ASA
208	706	Edoxaban	no ASA
248	706	Edoxaban	no ASA
278	706	Edoxaban	ASA
282	706	Placebo	no ASA
557	706	Edoxaban	ASA
654	706	Placebo	ASA
689	706	Edoxaban	ASA
437	707	Edoxaban	ASA
480	707	Placebo	ASA
496	707	Edoxaban	no ASA
522	707	Edoxaban	no ASA
1214	707	Placebo	ASA
1226	707	Edoxaban	ASA
1820	707	Placebo	no ASA
1873	707	Edoxaban	no ASA
374	708	Edoxaban	no ASA
492	708	Edoxaban	no ASA
512	708	Placebo	ASA
525	708	Edoxaban	ASA
360	711	Placebo	ASA
383	711	Edoxaban	ASA
439	711	Edoxaban	no ASA
443	711	Placebo	ASA
518	711	Edoxaban	no ASA
611	711	Edoxaban	no ASA
873	711	Placebo	ASA
1252	711	Edoxaban	ASA
1253	711	Placebo	no ASA
1458	711	Edoxaban	ASA
2373	713	Placebo	ASA
1013	718	Edoxaban	no ASA
2630	720	Placebo	ASA
2682	720	Edoxaban	no ASA
2726	720	Placebo	ASA
1039	724	Placebo	ASA
1040	724	Edoxaban	ASA
1061	724	Placebo	ASA
1076	724	Edoxaban	ASA
1258	724		
1286	724	Edoxaban	no ASA
1452	724	Placebo	ASA
782	725	Edoxaban	ASA
796	725	Placebo	ASA
822	725	Edoxaban	ASA
1009	725	Edoxaban	ASA
1042	725	Placebo	ASA
1107	725		
1154	725	Placebo	no ASA
1194	725	Placebo	no ASA
1203	725	Placebo	ASA
1223	725	Edoxaban	no ASA
1239	725	Placebo	ASA
1326	725	Edoxaban	no ASA
1329	725	Edoxaban	ASA
1392	725	Placebo	ASA
1442	725	Placebo	no ASA
1470	725	Edoxaban	ASA
1524	725	Edoxaban	ASA
1525	725	Placebo	no ASA
1619	725	Edoxaban	ASA
1620	725	Edoxaban	no ASA
1631	725	Placebo	ASA
1639	725	Placebo	ASA
1644	725	Edoxaban	no ASA
1742	725	Edoxaban	ASA
1839	725	Edoxaban	no ASA
1869	725	Placebo	ASA
1894	725	Placebo	ASA
1946	725	Edoxaban	ASA
1947	725	Placebo	ASA
1954	725	Edoxaban	ASA
2030	725	Edoxaban	ASA
2038	725	Placebo	ASA
2040	725	Edoxaban	ASA
2041	725	Placebo	ASA
2102	725	Placebo	no ASA
2105	725	Edoxaban	ASA
2197	725	Placebo	ASA
2277	725	Placebo	no ASA
2353	725	Edoxaban	ASA
2371	725	Placebo	ASA
2462	725	Edoxaban	ASA
2474	725	Placebo	ASA
2492	725	Edoxaban	ASA
2494	725	Edoxaban	ASA
2549	725	Edoxaban	no ASA
2600	725	Edoxaban	no ASA
2602	725	Edoxaban	ASA
2610	725	Placebo	ASA
2642	725	Placebo	ASA
2668	725	Placebo	ASA
2703	725	Placebo	ASA
2704	725	Edoxaban	ASA
2710	725	Edoxaban	no ASA
2748	725		
387	728	Edoxaban	no ASA
452	728	Edoxaban	no ASA
577	728	Edoxaban	ASA
883	728	Edoxaban	no ASA
1124	728	Placebo	no ASA
1166	728	Placebo	ASA
1202	728		
1560	730	Placebo	no ASA
2399	730	Placebo	no ASA
799	735	Placebo	ASA
431	740	Edoxaban	ASA
753	740	Edoxaban	no ASA
866	740	Edoxaban	no ASA
925	740	Placebo	ASA
1058	740	Edoxaban	ASA
1222	740	Placebo	no ASA
1886	740	Placebo	ASA
2436	740	Edoxaban	ASA
368	741	Edoxaban	no ASA
415	741	Edoxaban	no ASA
421	741	Placebo	no ASA
435	741	Edoxaban	no ASA
483	741	Placebo	no ASA
484	741	Placebo	no ASA
725	741	Edoxaban	ASA
840	741	Edoxaban	ASA
921	741	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1051	741	Placebo	no ASA
1095	741	Edoxaban	no ASA
1118	741	Edoxaban	no ASA
1207	741		
1356	741	Edoxaban	no ASA
1408	741	Edoxaban	no ASA
1737	741	Placebo	ASA
1790	741	Placebo	no ASA
1825	741	Placebo	no ASA
1836	741	Placebo	no ASA
1850	741	Placebo	no ASA
1865	741	Edoxaban	ASA
1909	741	Edoxaban	no ASA
2015	741	Placebo	no ASA
2064	741	Placebo	ASA
2253	741	Edoxaban	no ASA
2294	741	Edoxaban	no ASA
2313	741	Placebo	no ASA
2315	741	Placebo	no ASA
2319	741	Edoxaban	no ASA
2368	741	Edoxaban	ASA
2405	741	Edoxaban	ASA
2532	741	Edoxaban	no ASA
2650	741	Placebo	no ASA
2660	741	Placebo	ASA
2685	741	Placebo	ASA
521	742		
173	748	Placebo	ASA
199	748	Edoxaban	ASA
281	748	Edoxaban	ASA
332	748	Placebo	ASA
532	748	Edoxaban	ASA
555	748	Edoxaban	ASA
558	748	Placebo	ASA
564	748	Placebo	no ASA
576	748	Placebo	ASA
596	748	Edoxaban	no ASA
604	748	Placebo	ASA
610	748	Edoxaban	ASA
641	748	Edoxaban	no ASA
656	748		
675	748	Edoxaban	ASA
684	748	Placebo	ASA
687	748	Edoxaban	ASA
824	748	Placebo	no ASA
852	748	Placebo	no ASA
928	748	Edoxaban	ASA
957	748	Placebo	ASA
992	748	Edoxaban	ASA
999	748	Placebo	no ASA
1026	748	Placebo	ASA
1056	748	Placebo	ASA
1074	748	Edoxaban	ASA
1096	748	Edoxaban	ASA
1130	748	Edoxaban	ASA
1139	748	Placebo	ASA
1249	748	Edoxaban	no ASA
1251	748	Placebo	ASA
1272	748	Placebo	ASA
1285	748	Placebo	ASA
1301	748	Edoxaban	no ASA
1415	748	Edoxaban	ASA
1546	748	Edoxaban	no ASA
1575	748	Edoxaban	no ASA
1591	748	Edoxaban	ASA
1597	748	Placebo	ASA
1646	748	Edoxaban	ASA
1659	748	Placebo	ASA
1674	748	Placebo	ASA
1731	748	Placebo	ASA
1757	748	Placebo	ASA
1885	748	Edoxaban	ASA
1901	748	Placebo	no ASA
1918	748	Placebo	no ASA
1921	748	Placebo	no ASA
1966	748	Edoxaban	ASA
1982	748	Edoxaban	no ASA
2039	748	Edoxaban	ASA
2049	748	Edoxaban	ASA
2071	748	Placebo	ASA
2079	748	Placebo	no ASA
2136	748	Edoxaban	ASA
2181	748	Placebo	ASA
2186	748	Placebo	ASA
2189	748	Edoxaban	ASA
2191	748	Placebo	ASA
2195	748	Placebo	ASA
2199	748	Placebo	ASA
2203	748	Edoxaban	ASA
2222	748	Edoxaban	no ASA
2236	748	Edoxaban	ASA
2248	748	Edoxaban	ASA
2249	748	Edoxaban	ASA
2327	748	Placebo	ASA
2354	748	Placebo	ASA
2358	748	Edoxaban	no ASA
2384	748	Placebo	ASA
2422	748	Edoxaban	ASA
2455	748	Edoxaban	ASA
2466	748	Placebo	ASA
2613	748	Edoxaban	ASA
2670	748	Edoxaban	ASA
2676	748	Placebo	no ASA
2680	748	Placebo	ASA
2693	748	Placebo	ASA
2716	748	Edoxaban	ASA
2725	748	Placebo	no ASA
2734	748	Edoxaban	ASA
2746	748	Edoxaban	ASA
316	752	Placebo	no ASA
371	752	Placebo	ASA
372	752	Placebo	no ASA
406	752	Edoxaban	no ASA
457	752	Placebo	ASA
458	752	Edoxaban	no ASA
517	752	Edoxaban	no ASA
570	752	Edoxaban	ASA
607	752	Edoxaban	no ASA
657	752	Placebo	no ASA
862	752	Edoxaban	ASA
863	752	Edoxaban	no ASA
1025	752	Placebo	no ASA
1081	752	Edoxaban	ASA
1111	752	Placebo	ASA
426	756	Edoxaban	no ASA
448	756	Placebo	no ASA
495	756	Edoxaban	ASA
509	756	Placebo	no ASA
540	756	Placebo	ASA
1069	756	Placebo	ASA
1102	756	Placebo	ASA
1255	756	Edoxaban	ASA
481	758	Placebo	ASA
760	758	Edoxaban	no ASA
811	758	Edoxaban	ASA
1086	758	Placebo	no ASA
562	768	Edoxaban	no ASA
740	768	Edoxaban	no ASA
1205	768	Placebo	no ASA
1341	768	Placebo	no ASA
312	774	Placebo	no ASA
497	774	Edoxaban	ASA
619	774	Placebo	ASA
1218	774	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2505	774	Placebo	ASA
2559	774	Placebo	ASA
2581	774	Placebo	no ASA
362	775	Placebo	ASA
603	775	Edoxaban	ASA
660	775	Placebo	ASA
1060	775	Edoxaban	ASA
1350	775	Edoxaban	no ASA
1366	775	Placebo	ASA
1555	775	Placebo	ASA
1562	775	Edoxaban	ASA
1563	775	Placebo	no ASA
1851	775	Edoxaban	ASA
1959	775	Placebo	ASA
2121	775	Edoxaban	ASA
2270	775	Placebo	ASA
2524	775	Edoxaban	ASA
299	776	Edoxaban	ASA
614	776	Edoxaban	no ASA
1432	776	Edoxaban	ASA
2145	776	Placebo	ASA
2173	776	Placebo	ASA
2727	776	Edoxaban	no ASA
284	780	Placebo	no ASA
313	780	Edoxaban	ASA
354	780	Edoxaban	no ASA
625	780	Edoxaban	no ASA
673	780	Edoxaban	no ASA
781	780	Edoxaban	ASA
2663	783	Placebo	ASA
2743	783	Placebo	no ASA
1375	784	Placebo	ASA
1376	784	Edoxaban	ASA
1281	785	Edoxaban	no ASA
1605	788	Placebo	no ASA
1623	788	Edoxaban	no ASA
1624	788	Edoxaban	ASA
1718	788	Placebo	ASA
1733	788	Edoxaban	no ASA
1738	788	Placebo	no ASA
1827	788	Placebo	ASA
1872	788	Placebo	no ASA
2007	788	Edoxaban	no ASA
2212	788	Placebo	no ASA
2295	788	Edoxaban	ASA
884	799	Placebo	no ASA
1163	799	Placebo	no ASA
1291	799	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
420	800	Edoxaban	ASA
571	800	Placebo	no ASA
642	800	Edoxaban	ASA
647	800	Placebo	ASA
653	800	Edoxaban	ASA
1128	800	Edoxaban	ASA
1221	800	Placebo	ASA
1264	800	Edoxaban	no ASA
1332	800	Edoxaban	no ASA
1401	800	Placebo	ASA
1421	800	Placebo	ASA
1527	800	Placebo	ASA
1603	800	Edoxaban	ASA
1667	800	Placebo	no ASA
1984	800	Edoxaban	no ASA
2360	800	Edoxaban	no ASA
2634	800	Placebo	ASA
520	801	Edoxaban	ASA
531	801	Placebo	ASA
543	801	Edoxaban	ASA
545	801	Placebo	ASA
582	801	Edoxaban	no ASA
594	801	Edoxaban	no ASA
595	801	Placebo	no ASA
599	801	Placebo	no ASA
620	801	Placebo	ASA
639	801	Edoxaban	no ASA
693	801	Placebo	ASA
710	801	Edoxaban	no ASA
738	801	Placebo	no ASA
741	801	Edoxaban	no ASA
793	801	Placebo	no ASA
895	801	Edoxaban	ASA
968	801	Edoxaban	ASA
969	801	Placebo	no ASA
1007	801	Edoxaban	no ASA
1021	801	Edoxaban	ASA
1070	801	Placebo	ASA
1169	801	Edoxaban	no ASA
1170	801	Edoxaban	ASA
1183	801	Placebo	ASA
1184	801	Edoxaban	ASA
1187	801	Placebo	ASA
1288	801	Placebo	ASA
1289	801	Placebo	no ASA
1308	801	Edoxaban	ASA
1309	801	Placebo	ASA
1334	801	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1397	801	Placebo	no ASA
1398	801	Placebo	no ASA
1460	801	Edoxaban	no ASA
1770	801	Placebo	no ASA
1772	801	Edoxaban	no ASA
1794	801	Edoxaban	ASA
1800	801	Edoxaban	ASA
1809	801	Placebo	no ASA
1810	801	Placebo	no ASA
2247	801	Edoxaban	no ASA
2273	801	Edoxaban	ASA
2274	801	Edoxaban	no ASA
2378	801	Edoxaban	ASA
2387	801	Placebo	ASA
2513	801	Placebo	no ASA
2514	801	Placebo	ASA
2527	801	Placebo	ASA
2592	801	Edoxaban	no ASA
2593	801	Placebo	no ASA
2744	801	Placebo	no ASA
349	802	Placebo	ASA
629	802	Placebo	no ASA
705	802	Edoxaban	no ASA
1047	802	Edoxaban	no ASA
1082	802	Edoxaban	ASA
2351	802	Edoxaban	ASA
2567	802	Placebo	ASA
2679	802	Placebo	no ASA
2070	813	Placebo	ASA
2073	813	Edoxaban	no ASA
2074	813	Placebo	ASA
2161	813	Edoxaban	ASA
947	815	Placebo	no ASA
986	815	Edoxaban	no ASA
1387	815	Placebo	ASA
1429	815	Edoxaban	no ASA
1486	815	Edoxaban	ASA
1551	815	Placebo	no ASA
1812	815	Placebo	no ASA
1895	815	Edoxaban	no ASA
1896	815	Edoxaban	ASA
1904	815	Placebo	ASA
2200	815	Edoxaban	no ASA
2526	815	Edoxaban	ASA
1473	824	Placebo	no ASA
1497	824	Placebo	no ASA
2002	824	Edoxaban	ASA
2010	824	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2290	824	Placebo	ASA
2423	824	Edoxaban	no ASA
2472	824		
2627	824	Edoxaban	ASA
476	826	Edoxaban	ASA
892	826	Placebo	no ASA
1425	826	Placebo	no ASA
2738	826	Edoxaban	no ASA
724	827	Placebo	ASA
764	827	Edoxaban	ASA
770	827	Placebo	ASA
807	827	Edoxaban	ASA
1011	828	Placebo	ASA
626	833	Edoxaban	ASA
976	833	Edoxaban	ASA
987	833	Placebo	ASA
1224	833	Placebo	ASA
1277	833	Edoxaban	ASA
1290	833	Placebo	ASA
1637	833	Edoxaban	ASA
1923	833	Edoxaban	ASA
2239	833	Placebo	ASA
2242	833	Edoxaban	no ASA
2361	833	Edoxaban	no ASA
2382	833	Placebo	ASA
2458	833	Placebo	ASA
795	836	Placebo	no ASA
802	836	Edoxaban	ASA
814	836	Placebo	no ASA
819	836	Placebo	no ASA
849	836	Edoxaban	no ASA
938	836	Edoxaban	no ASA
951	836	Edoxaban	no ASA
997	836	Placebo	no ASA
1022	836	Edoxaban	no ASA
1103	836	Placebo	no ASA
1151	836	Placebo	no ASA
1298	836	Edoxaban	no ASA
1489	836	Placebo	no ASA
1840	836	Placebo	no ASA
1996	836	Edoxaban	no ASA
2001	836	Edoxaban	no ASA
2188	836	Edoxaban	no ASA
2329	836	Edoxaban	no ASA
2364	836	Edoxaban	no ASA
2546	836	Placebo	no ASA
1830	857	Placebo	no ASA
1835	857	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1853	857	Placebo	no ASA
1876	857	Placebo	ASA
1957	857	Placebo	ASA
2006	857	Edoxaban	ASA
2465	862	Edoxaban	no ASA
677	866	Placebo	ASA
742	866	Placebo	ASA
750	866	Placebo	ASA
767	866	Edoxaban	ASA
775	866	Edoxaban	ASA
788	866	Edoxaban	ASA
791	866	Placebo	ASA
809	866	Placebo	ASA
885	866	Placebo	ASA
952	866	Edoxaban	ASA
953	866	Edoxaban	ASA
1100	866	Edoxaban	ASA
1106	866	Edoxaban	ASA
1149	866	Placebo	ASA
1196	866	Edoxaban	ASA
1715	866	Edoxaban	ASA
2026	866	Placebo	ASA
2107	866	Placebo	ASA
2110	866	Placebo	ASA
2257	866	Edoxaban	ASA
2302	866	Placebo	ASA
2374	866	Edoxaban	ASA
2404	866	Edoxaban	ASA
630	868	Placebo	ASA
645	868	Edoxaban	no ASA
665	868	Placebo	ASA
701	868	Placebo	no ASA
734	868	Placebo	ASA
754	868	Edoxaban	ASA
759	868	Edoxaban	no ASA
798	868	Edoxaban	ASA
800	868	Edoxaban	ASA
825	868	Placebo	ASA
897	868	Edoxaban	ASA
899	868	Placebo	no ASA
923	868	Edoxaban	ASA
924	868	Placebo	no ASA
965	868	Placebo	ASA
967	868	Edoxaban	ASA
982	868	Edoxaban	no ASA
1228	868	Edoxaban	no ASA
1315	868	Placebo	ASA
1431	868	Placebo	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1669	868	Placebo	ASA
2098	868	Edoxaban	ASA
683	869	Edoxaban	no ASA
730	869	Edoxaban	no ASA
780	869	Placebo	no ASA
823	869	Placebo	no ASA
980	869	Placebo	ASA
1104	869	Edoxaban	no ASA
1180	869	Placebo	no ASA
1261	869	Placebo	ASA
1276	869	Edoxaban	ASA
1279	869	Edoxaban	no ASA
1311	869	Placebo	no ASA
1355	869	Placebo	ASA
1360	869	Placebo	no ASA
1390	869	Edoxaban	ASA
1465	869	Edoxaban	ASA
1481	869	Edoxaban	no ASA
1558	869	Edoxaban	ASA
1717	869	Placebo	ASA
1867	869	Placebo	ASA
1970	869	Edoxaban	ASA
2008	869	Placebo	ASA
2208	869	Edoxaban	ASA
680	870	Edoxaban	ASA
769	870	Edoxaban	ASA
850	870	Placebo	ASA
971	870	Placebo	no ASA
977	870	Edoxaban	no ASA
1020	870	Edoxaban	no ASA
1028	870	Placebo	ASA
1030	870	Placebo	ASA
1032	870	Edoxaban	ASA
1073	870	Placebo	ASA
1077	870	Edoxaban	ASA
1093	870	Edoxaban	ASA
1119	870	Placebo	ASA
1131	870	Edoxaban	ASA
1142	870	Edoxaban	ASA
1265	870	Placebo	ASA
1267	870	Placebo	ASA
1271	870	Edoxaban	ASA
1297	870	Edoxaban	ASA
1303	870	Placebo	ASA
1384	870	Edoxaban	ASA
1395	870	Placebo	ASA
1409	870	Placebo	ASA
1463	870	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1464	870	Edoxaban	ASA
1480	870	Placebo	ASA
1500	870	Edoxaban	ASA
1514	870	Placebo	ASA
1526	870	Edoxaban	ASA
1572	870	Placebo	ASA
1580	870	Placebo	ASA
1587	870	Edoxaban	ASA
1596	870	Edoxaban	ASA
1616	870	Placebo	ASA
1618	870	Edoxaban	ASA
1627	870	Edoxaban	ASA
1675	870	Placebo	no ASA
1678	870	Placebo	ASA
1684	870	Edoxaban	ASA
1685	870	Placebo	ASA
1722	870	Edoxaban	ASA
1967	870	Edoxaban	ASA
1973	870	Edoxaban	ASA
1976	870	Placebo	ASA
1985	870	Placebo	ASA
1994	870	Edoxaban	ASA
1995	870	Placebo	ASA
1997	870	Placebo	ASA
1999	870	Edoxaban	ASA
2000	870	Edoxaban	ASA
2043	870	Placebo	ASA
2047	870	Placebo	ASA
2087	870	Edoxaban	ASA
2130	870	Edoxaban	ASA
2151	870	Placebo	ASA
2198	870	Placebo	ASA
2201	870	Placebo	ASA
2261	870	Edoxaban	ASA
2262	870	Edoxaban	ASA
2292	870	Placebo	ASA
2314	870	Edoxaban	ASA
2369	870	Placebo	ASA
732	871	Placebo	ASA
762	871	Edoxaban	ASA
804	871	Placebo	ASA
808	871	Edoxaban	ASA
812	871	Edoxaban	ASA
872	871	Edoxaban	ASA
874	871	Placebo	ASA
880	871	Edoxaban	ASA
914	871	Placebo	ASA
962	871	Placebo	ASA
963	871	Placebo	ASA
972	871	Edoxaban	ASA
1012	871	Edoxaban	ASA
696	872	Edoxaban	no ASA
700	872	Placebo	no ASA
727	872	Edoxaban	no ASA
755	872	Edoxaban	no ASA
776	872	Placebo	no ASA
889	872	Placebo	no ASA
891	872	Placebo	no ASA
916	872	Edoxaban	no ASA
917	872	Edoxaban	no ASA
1109	872	Edoxaban	no ASA
1143	872	Placebo	no ASA
910	873	Edoxaban	ASA
716	874	Edoxaban	ASA
743	874	Placebo	ASA
792	874	Placebo	no ASA
806	874	Placebo	ASA
827	874	Placebo	ASA
831	874	Edoxaban	no ASA
857	874	Edoxaban	ASA
858	874	Edoxaban	ASA
870	874	Placebo	ASA
871	874	Edoxaban	ASA
911	874	Edoxaban	no ASA
912	874	Placebo	ASA
913	874	Placebo	no ASA
932	874	Edoxaban	ASA
994	874	Placebo	ASA
1002	874	Placebo	ASA
1158	874	Placebo	no ASA
1171	874	Edoxaban	ASA
1181	874	Edoxaban	ASA
1208	874	Placebo	no ASA
1469	874	Edoxaban	ASA
1724	874	Edoxaban	ASA
1726	874	Edoxaban	ASA
636	875	Edoxaban	no ASA
638	875	Edoxaban	ASA
646	875	Placebo	ASA
664	875	Edoxaban	no ASA
751	875	Placebo	no ASA
939	875	Placebo	no ASA
956	875	Placebo	ASA
1027	875	Edoxaban	ASA
1043	875	Edoxaban	no ASA
1055	875	Placebo	no ASA
1144	875	Placebo	no ASA
1197	875	Edoxaban	no ASA
1284	875	Edoxaban	no ASA
1608	875	Placebo	no ASA
1650	875	Placebo	no ASA
1676	875	Edoxaban	no ASA
1931	875	Edoxaban	no ASA
2004	875	Placebo	no ASA
2167	875	Edoxaban	ASA
2175	875	Placebo	no ASA
2388	875	Edoxaban	no ASA
2415	875	Edoxaban	no ASA
708	876	Edoxaban	ASA
736	876	Placebo	no ASA
744	876	Placebo	ASA
859	876	Placebo	ASA
877	876	Placebo	no ASA
896	876	Placebo	ASA
901	876	Edoxaban	no ASA
1145	876	Edoxaban	no ASA
1385	876	Placebo	no ASA
1443	876	Edoxaban	no ASA
1628	876	Placebo	no ASA
1656	876	Edoxaban	no ASA
1732	876	Edoxaban	ASA
695	877	Placebo	no ASA
706	877	Edoxaban	ASA
735	877	Edoxaban	no ASA
737	877	Edoxaban	no ASA
757	877	Placebo	no ASA
801	877	Placebo	ASA
853	877	Edoxaban	ASA
860	877	Placebo	ASA
876	877	Edoxaban	ASA
890	877	Edoxaban	no ASA
915	877	Placebo	no ASA
1023	877	Edoxaban	no ASA
1084	877	Edoxaban	no ASA
1092	877	Placebo	no ASA
1141	877	Placebo	no ASA
1275	877	Placebo	ASA
1295	877	Placebo	ASA
1352	877	Placebo	ASA
1592	877	Placebo	no ASA
1613	877	Edoxaban	no ASA
1648	877	Edoxaban	no ASA
1649	877	Edoxaban	ASA
1679	877	Edoxaban	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1795	877	Placebo	no ASA
1803	877	Edoxaban	ASA
1919	877	Placebo	ASA
2003	877	Edoxaban	ASA
2050	877	Edoxaban	ASA
2132	877	Placebo	no ASA
2260	877	Placebo	ASA
2276	877	Placebo	no ASA
2285	877	Placebo	no ASA
893	881	Edoxaban	ASA
1377	884	Edoxaban	no ASA
1495	884	Placebo	ASA
882	901	Edoxaban	ASA
944	901		
984	901	Placebo	ASA
1038	901	Edoxaban	ASA
1057	901	Edoxaban	no ASA
1120	901	Edoxaban	ASA
1138	901	Edoxaban	ASA
1217	901	Placebo	no ASA
1549	901	Placebo	ASA
1564	901	Placebo	ASA
1566	901	Placebo	no ASA
1711	901	Placebo	no ASA
1720	901	Edoxaban	no ASA
1859	901	Placebo	ASA
1880	901	Edoxaban	no ASA
2135	901	Edoxaban	no ASA
2381	901	Placebo	no ASA
2427	901	Edoxaban	ASA
2435	901	Edoxaban	no ASA
2473	901	Placebo	ASA
2476	901	Placebo	no ASA
2480	901	Edoxaban	ASA
2490	901	Placebo	ASA
2595	901	Edoxaban	no ASA
2601	901	Placebo	ASA
2638	901	Edoxaban	no ASA
2666	901	Placebo	ASA
2706	901	Edoxaban	ASA
2723	901	Edoxaban	ASA
2739	901	Edoxaban	no ASA
1273	964	Placebo	no ASA
1049	965	Placebo	ASA
1323	965	Edoxaban	no ASA
2280	965	Placebo	ASA
2321	965	Edoxaban	ASA
2420	965	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2426	965	Edoxaban	no ASA
2488	965	Placebo	no ASA
2550	965	Placebo	no ASA
2664	965	Edoxaban	ASA
709	1023	Placebo	no ASA
2022	1023	Edoxaban	no ASA
2097	1023	Placebo	ASA
2271	1023	Placebo	no ASA
2289	1023		
2366	1023	Placebo	ASA
797	1028		
844	1028		
1172	1028	Placebo	ASA
1313	1028	Edoxaban	ASA
1314	1028	Edoxaban	no ASA
1342	1028	Placebo	no ASA
1344	1028	Edoxaban	no ASA
1539	1028	Edoxaban	no ASA
1547	1028	Edoxaban	no ASA
1553	1028	Edoxaban	ASA
1561	1028	Placebo	no ASA
2156	1028	Placebo	no ASA
2159	1028	Placebo	no ASA
2160	1028	Edoxaban	no ASA
2251	1028	Edoxaban	no ASA
2504	1028	Edoxaban	no ASA
2573	1028	Placebo	ASA
2694	1028	Edoxaban	no ASA
2696	1028	Placebo	no ASA
900	1029	Edoxaban	no ASA
949	1029	Placebo	ASA
961	1029	Placebo	no ASA
1053	1029	Edoxaban	no ASA
1159	1029	Placebo	ASA
1177	1029	Edoxaban	no ASA
1236	1029	Placebo	no ASA
1242	1029	Placebo	no ASA
1243	1029	Edoxaban	ASA
1256	1029	Edoxaban	ASA
1335	1029	Edoxaban	no ASA
1437	1029	Placebo	no ASA
1441	1029	Edoxaban	no ASA
1588	1029	Placebo	no ASA
1617	1029	Placebo	ASA
1735	1029	Edoxaban	no ASA
1878	1029	Placebo	no ASA
1917	1029	Edoxaban	ASA
1936	1029	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1986	1029	Placebo	ASA
2090	1029	Edoxaban	ASA
2093	1029	Placebo	ASA
2108	1029	Edoxaban	ASA
2155	1029	Placebo	ASA
2178	1029	Placebo	ASA
2180	1029	Edoxaban	ASA
2345	1029	Placebo	no ASA
1227	1039	Edoxaban	ASA
1407	1039	Placebo	ASA
1459	1039	Placebo	ASA
1467	1039	Edoxaban	ASA
1534	1039	Edoxaban	ASA
2269	1039		
2503	1039	Edoxaban	ASA
2562	1039	Placebo	ASA
2690	1039	Placebo	no ASA
2170	1048	Edoxaban	ASA
2225	1048	Placebo	ASA
2619	1048	Placebo	ASA
1359	1049	Placebo	no ASA
2231	1049	Placebo	no ASA
2335	1049	Placebo	ASA
2714	1067	Edoxaban	no ASA
1240	1071	Placebo	ASA
1241	1071	Edoxaban	ASA
1294	1074	Edoxaban	no ASA
1305	1074	Edoxaban	no ASA
1325	1074	Placebo	no ASA
1337	1074	Placebo	no ASA
1365	1074	Edoxaban	no ASA
1402	1074	Placebo	no ASA
1403	1074	Placebo	no ASA
1420	1074	Edoxaban	ASA
1424	1074	Edoxaban	ASA
1446	1074	Edoxaban	no ASA
1548	1074	Placebo	no ASA
1557	1074	Edoxaban	no ASA
1565	1074	Edoxaban	no ASA
1607	1074	Placebo	no ASA
1696	1074	Placebo	no ASA
1697	1074	Placebo	no ASA
1699	1074	Edoxaban	no ASA
1708	1074	Edoxaban	no ASA
1756	1074	Edoxaban	no ASA
1811	1074	Placebo	no ASA
1838	1074	Placebo	ASA
1842	1074	Edoxaban	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
1893	1074	Placebo	no ASA
1952	1074	Edoxaban	no ASA
1968	1074	Edoxaban	no ASA
1972	1074	Placebo	no ASA
2009	1074	Edoxaban	no ASA
2075	1074	Edoxaban	no ASA
2080	1074	Placebo	no ASA
2143	1074	Placebo	ASA
2162	1074	Placebo	no ASA
2192	1074	Edoxaban	ASA
2235	1074	Placebo	no ASA
2246	1074	Edoxaban	no ASA
2300	1074	Placebo	no ASA
2308	1074	Edoxaban	no ASA
2515	1074	Placebo	no ASA
2561	1074	Edoxaban	no ASA
2665	1074	Placebo	no ASA
2672	1074	Placebo	ASA
2707	1074	Edoxaban	no ASA
2720	1074	Placebo	no ASA
1371	1080	Edoxaban	no ASA
1388	1080	Edoxaban	no ASA
1396	1080	Placebo	no ASA
1444	1080	Edoxaban	no ASA
1445	1080	Placebo	no ASA
1462	1080	Edoxaban	no ASA
1475	1080	Placebo	no ASA
1478	1080	Placebo	no ASA
1536	1080	Placebo	no ASA
1538	1080	Edoxaban	no ASA
1571	1080	Edoxaban	no ASA
1573	1080	Placebo	no ASA
1615	1080	Edoxaban	no ASA
1636	1080	Edoxaban	no ASA
1643	1080	Placebo	no ASA
1660	1080	Placebo	no ASA
1661	1080	Placebo	no ASA
1665	1080	Edoxaban	no ASA
1671	1080	Edoxaban	no ASA
1688	1080	Placebo	no ASA
1694	1080	Edoxaban	no ASA
1695	1080	Placebo	no ASA
1700	1080	Edoxaban	no ASA
1703	1080	Placebo	no ASA
1707	1080	Placebo	no ASA
1721	1080	Edoxaban	no ASA
1728	1080	Edoxaban	no ASA
1734	1080	Placebo	no ASA
1736	1080	Edoxaban	no ASA
1740	1080	Placebo	no ASA
1743	1080	Placebo	no ASA
1744	1080	Edoxaban	no ASA
1746	1080	Placebo	no ASA
1749	1080	Placebo	no ASA
1754	1080	Edoxaban	no ASA
1762	1080	Edoxaban	no ASA
1765	1080	Edoxaban	ASA
1778	1080	Edoxaban	ASA
1784	1080	Placebo	ASA
1786	1080	Edoxaban	no ASA
1793	1080	Edoxaban	ASA
1798	1080	Placebo	no ASA
1802	1080	Edoxaban	no ASA
1814	1080	Placebo	no ASA
1822	1080	Edoxaban	no ASA
1843	1080	Placebo	no ASA
1856	1080	Placebo	no ASA
1861	1080	Edoxaban	no ASA
1863	1080	Edoxaban	no ASA
1874	1080	Placebo	no ASA
1888	1080	Placebo	no ASA
1890	1080	Edoxaban	no ASA
1912	1080	Edoxaban	no ASA
1914	1080	Placebo	no ASA
1915	1080	Placebo	ASA
1937	1080	Edoxaban	no ASA
1945	1080	Placebo	no ASA
1948	1080	Placebo	no ASA
1977	1080	Edoxaban	no ASA
1988	1080	Edoxaban	no ASA
1992	1080	Edoxaban	no ASA
2012	1080	Placebo	no ASA
2017	1080	Placebo	no ASA
2018	1080	Edoxaban	no ASA
2020	1080	Placebo	no ASA
2024	1080	Placebo	no ASA
2037	1080	Edoxaban	no ASA
2056	1080	Placebo	no ASA
2057	1080	Edoxaban	no ASA
2058	1080	Placebo	no ASA
2078	1080	Placebo	ASA
2084	1080	Edoxaban	no ASA
2085	1080	Edoxaban	ASA
2099	1080	Edoxaban	no ASA
2123	1080	Placebo	no ASA
2125	1080	Placebo	no ASA
2126	1080	Placebo	no ASA
2131	1080	Edoxaban	no ASA
2138	1080	Edoxaban	no ASA
2141	1080	Edoxaban	no ASA
2144	1080	Placebo	no ASA
2147	1080	Edoxaban	no ASA
2150	1080	Placebo	no ASA
2154	1080	Placebo	no ASA
2184	1080	Edoxaban	no ASA
2185	1080	Placebo	no ASA
2194	1080	Placebo	no ASA
2206	1080	Placebo	no ASA
2215	1080	Edoxaban	no ASA
2237	1080	Edoxaban	no ASA
2244	1080	Edoxaban	no ASA
2284	1080	Edoxaban	no ASA
2286	1080	Edoxaban	no ASA
2288	1080	Placebo	no ASA
2293	1080	Placebo	no ASA
2305	1080	Edoxaban	no ASA
2310	1080	Edoxaban	ASA
2320	1080	Placebo	no ASA
2348	1080	Placebo	no ASA
2441	1080	Edoxaban	no ASA
2464	1080	Edoxaban	no ASA
2478	1080	Placebo	no ASA
2484	1080	Edoxaban	no ASA
1353	1085	Placebo	ASA
1386	1085	Edoxaban	no ASA
1433	1085	Placebo	ASA
1477	1085	Edoxaban	ASA
1483	1085	Edoxaban	no ASA
1499	1085	Placebo	ASA
1520	1085	Placebo	no ASA
1529	1085	Placebo	ASA
1537	1085	Edoxaban	ASA
1673	1085	Placebo	no ASA
1771	1085	Edoxaban	no ASA
1785	1085	Placebo	no ASA
1788	1085	Placebo	no ASA
1962	1085	Placebo	no ASA
1963	1085	Edoxaban	ASA
1980	1085	Edoxaban	ASA
2021	1085	Edoxaban	ASA
2029	1085	Placebo	ASA
2032	1085	Edoxaban	no ASA
2114	1085	Edoxaban	ASA
2115	1085	Placebo	ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2298	1085	Edoxaban	no ASA
2301	1085	Placebo	no ASA
2307	1085	Edoxaban	no ASA
2312	1085	Edoxaban	no ASA
2316	1085	Placebo	ASA
2385	1085	Placebo	no ASA
2429	1085	Placebo	no ASA
2440	1085	Edoxaban	no ASA
2482	1085	Edoxaban	ASA
2500	1085	Placebo	ASA
2511	1085	Edoxaban	ASA
2625	1085	Placebo	ASA
2072	1086	Edoxaban	ASA
2095	1086	Placebo	ASA
2540	1086	Placebo	ASA
1174	1089	Placebo	no ASA
1317	1089	Edoxaban	no ASA
1333	1089	Edoxaban	no ASA
1358	1089	Placebo	no ASA
1364	1089	Placebo	no ASA
1427	1089	Edoxaban	no ASA
1492	1089	Placebo	no ASA
1502	1089	Placebo	no ASA
1504	1089	Edoxaban	no ASA
1522	1089	Placebo	no ASA
1523	1089	Edoxaban	no ASA
2066	1089	Edoxaban	no ASA
2067	1089	Edoxaban	no ASA
2205	1089	Placebo	no ASA
2230	1089	Placebo	no ASA
2336	1089	Placebo	no ASA
1705	1097	Edoxaban	ASA
2331	1097	Edoxaban	ASA
2344	1097	Placebo	ASA
2401	1097	Edoxaban	ASA
2651	1097	Edoxaban	no ASA
2169	1104	Edoxaban	no ASA
2445	1104	Placebo	ASA
2535	1104	Placebo	no ASA
2553	1104	Edoxaban	no ASA
2560	1104	Placebo	ASA
2578	1108	Placebo	no ASA
2531	1111	Edoxaban	no ASA
2330	1115	Edoxaban	ASA
2434	1115	Edoxaban	no ASA
2461	1116	Edoxaban	no ASA
2538	1116	Placebo	no ASA
2576	1116	Placebo	no ASA

Patient-ID	Centre-ID	Random group	Random stratum (indication)
2598	1116	Edoxaban	no ASA
2646	1116	Placebo	no ASA
2701	1116	Edoxaban	no ASA
2728	1117	Placebo	no ASA
2657	1118	Placebo	no ASA
2678	1118	Placebo	ASA
2689	1118	Placebo	no ASA
2697	1118	Placebo	ASA
2732	1118	Edoxaban	ASA
2377	1121	Edoxaban	no ASA
2444	1121	Edoxaban	no ASA
2587	1121	Placebo	no ASA
2609	1121	Edoxaban	ASA
2729	1121	Placebo	ASA
2359	1123	Placebo	ASA
2389	1123	Edoxaban	ASA
2502	1127	Placebo	no ASA
2557	1133	Edoxaban	ASA
2597	1133	Edoxaban	no ASA
2699	1133	Edoxaban	ASA
2477	1138	Edoxaban	no ASA
2397	1146	Edoxaban	no ASA
2398	1146	Edoxaban	ASA
2519	1146	Placebo	no ASA
2574	1146	Placebo	no ASA
2611	1146	Placebo	ASA
2713	1146	Placebo	ASA
2391	1147	Placebo	ASA
2525	1147	Edoxaban	no ASA
2603	1148	Edoxaban	ASA
2688	1148	Placebo	no ASA
2737	1148	Placebo	no ASA

16.1.8 Audit certificates

CERTIFICATE OF GCP-AUDIT

GXP Engaged Auditing Services

Type of audit:	GCP Gap Analysis of Sponsor Quality Management System
Sponsor:	Kompetenznetz Vorhofflimmern e.V. (Atrial Fibrillation Network - AFNET) Mendelstraße 11 48149 Münster Germany
Protocol number:	AXADIA-AFNET 8
Auditee:	AFNET Mendelstraße 11 48149 Münster Germany
Audit scope:	To assess gaps and potential areas for improvement of general systems and procedures of the auditee, with focus on Quality Management and sponsor oversight activities.
Audit standards:	European Commission Directive 2001/20/EC European Commission Directive 2005/28/EC ICH E6: Guideline for Good Clinical Practice (CPMP/ICH/135/95) The Declaration of Helsinki GCP Verordnung (German GCP Ordinance), version 19 October 2012 Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz (AMG)) (German Medicinal Products Act), version 04 April 2016Enter from Audit Report

This is to certify that the above-mentioned auditee participated in the following audit:

Audit dates:	22-23 February 2017
Auditor name:	Alexander Both
Auditor signature:	A Both
Date of signature:	15 Mar 2017

16.1.9 Documentation of statistical methods

Statistical Analysis Plan

NOAH

Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial High Rate Episodes

ClinicalTrials.gov: NCT02618577, EudraCT number: 2015-003997-33, ISRCTN number: ISRCTN17309850

Version: 4 (Final Version)

Date: 21.03.2023

Author: S. Sehner, A.-K. Ozga, A. Suling

Reviewers: B. Blank, J. Haug, P. Kirchhof, M. Wolf, A. Zapf

Institution: Institute of Medical Biometry and Epidemiology, Medical Center Hamburg-Eppendorf, Hamburg

Document:	Statistical Analysis Plan for Final Analysis
Sponsor Project Code:	NOAH
Study No.	ClinicalTrials.gov: NCT02618577, EudraCT number: 2015-003997-33, ISRCTN number: ISRCTN17309850
Study short title:	Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial High Rate Episodes
Version / date:	**4 / March 21, 2023** based on study protocol version 5.1, dated October 1, 2020 **and corresponding amendment no. 4**
Author:	S. Sehner, A.-K. Ozga
Sponsor:	Kompetenznetz Vorhofflimmern e.V. (AFNET)
Statistician:	Prof. Dr. Gregory Chlouverakis 1 and Prof. Dr. Antonia Zapf 2 [1] School of Medicine, University of Crete, Rethymno, Greece [2] Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Confidential

The information contained herein is the property of Kompetenznetz Vorhofflimmern e.V. (AFNET) and may not be reproduced, published or disclosed to others without written authorization of the sponsor. The information provided in this document is strictly confidential and is available for review to investigators, potential investigators, health authorities and appropriate Ethics Committees. No disclosure should take place without written authorization from the sponsor except to the extent necessary to obtain informed consent from potential subjects. Once signed, the terms of this protocol are binding for all.

Table of Contents

Version history 6
Signature Page 7
Abbreviations 8
1 Introduction 9
1.1 Background and rationale 9
1.2 Objectives 9
1.2.1 Primary outcome 10
1.2.2 Main secondary outcomes 10
1.2.3 Patient Reported Outcome (PRO) 10
1.2.4 Safety outcome parameters 10
2 Study Methods 11
2.1 Trial design 11
2.2 Randomization and blinding 11
2.3 Sample size 11
2.4 Framework 12
2.5 Statistical interim analyses and stopping guidance 12
2.6 Timing of final analysis 12
3 Statistical Principles 13
3.1 Confidence intervals and *P* values 13
3.2 Adherence and protocol deviations 14
3.3 Analysis populations 16
3.3.1 Modified Intention to treat Population (mITT) 16
3.3.2 Per Protocol population (PP) 16
3.3.3 Safety Population 16
4 Trial Population 16
4.1 Eligibility 16
4.2 Recruitment 17
4.3 Withdrawal / follow-up 17

4.4 Baseline patient characteristics (Definition of table 1) 18
5 Analysis 18
5.1 Censoring and event definition 18
5.1.1 Trial specific censoring 18
5.1.2 Event definition 18
5.2 Primary endpoint analysis 18
5.3 Secondary endpoints analysis 19
5.3.1 Time-to-event endpoints 19
5.3.2 Continuous endpoints 19
5.3.3 Change in autonomy status 20
5.4 Missing data analysis 20
5.5 Sensitivity analyses 21
5.6 Per protocol analyses 21
5.7 Subgroup analyses 21
5.8 Additional analyses 22
5.9 Safety analyses (SAE) 22
5.10 Harms 23
5.11 Statistical software 23
6 Database Sources 23
6.1 Source data and documents 23
6.2 Direct access to data 24
6.3 Storage, transformation of data and preparation for analysis 24
7 Amendment 24
7.1 Changes in chapter *1.2.2. Main secondary outcomes* 25
7.2 Changes in chapter *2.6 Timing of final analysis* 25
7.3 Changes in chapter *3.3.2 Per Protocol population (PP)* 25
7.4 Changes in chapter *4.2 Recruitment* 25
7.5 Changes in chapter *4.4 Baseline patient characteristics (Definition of table 1) and correction of Appendix A* 26

7.6 Changes in chapter *5.1.2 Event definition* 28

7.7 Changes in chapter *5.4 Missing data analysis* 28

7.8 Changes in chapter *5.5. Sensitivity Analyses* 29

7.9 Changes in chapter *5.7. Subgroup Analyses* 29

7.10 Changes in chapter *5.8. Additional Analyses* 30

8 References 30

9 Appendix 31

Version history

Version	Date	Section number changed	Description/Changes made
1	15.10.2019		New version based on the of the former SAP prepared by Gregory Chlouverakis
2-6	29.10.2020	complete	Changes in Section 5 S,Sehner, A.Ozga • Censoring • Primary and secondary endpoint analyses • Missing data analyses • Sensitivity analyses • Per protocol analyses
7	04.05.2021	Minor things in some sections	5.4 deleted; 2.5. written in past tense; Reference section
8	06.09.2021	All	Cleaning
9	17.12.2021	2.6, 3.2, 5.7	• More description of timing of final analysis • Compliance changed to adherence • Adherence as subgroup
10	12.05.2022	3.2	Protocol deviations specified
Final Version	27.08.2022	All	Finalization
Final Version with Amendment, i.e version 2	17.10.2022	Amendment	Amendment added after first SAP version was signed (before unblinding)
Final Version with Amendment, i.e version 3	08.02.2023	Amendment	Further clarification of analysis (before unblinding), i.e. Analysis of: adherence, AHRE during the study duration, Baseline variables
Second Final Version	21.03.2023	Amendment	Finalization (typos)

Signature Page

Prof. Dr. Paulus Kirchhof

Principal Investigator Universitäres Herz- und Gefäßzentrum UKE Hamburg Klinik für Kardiologie Hamburg, Germany

27 Mar 23 — Date

Signature

Prof. Dr. Gregory Chlouverakis 1 and Prof. Dr. Antonia Zapf 2

Trial Statisticians

[1] School of Medicine, University of Crete, Rethymno, Greece

[2] Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

30-3-2023 — Date

Digitally signed by Gregory Chlouverakis
Date: 2023.03.30 14:25:27 +03'00'

Signature

27.3.23 — Date

Signature

S. Sehner, A.-K. Ozga

SAP authors

Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

21.03.2023 — Date

Signature

21.3.2023 — Date

Signature

Abbreviations

ACS	Acute coronary syndrome
AF	Atrial fibrillation
AFNET	Kompetenznetz Vorhofflimmern e.V.
AHRE	Atrial high rate episodes
ALT	Alanine aminotransferase
aPTT	Activated partial thromboplastin time
ASA	Acetylsalicylic acid
AST	Alanine aminotransferase
BMI	Body-mass-index
CABG	Coronary artery bypass graft
CONSORT	Consolidated standards of reporting trials
CRI	The Clinical Research Institute GmbH
DAPT	Dual antiplatelet therapy
DSMB	Data safety monitoring board
EC	Ethics committee
ECG	Electrocardiogram
eCRF	Electronic case report form
EDC	Electronic data capture
EHRA	European heart rhythm association
ERC	Endpoint review committee
FMI	Fraction of missing information
GOT	Glutamic-oxaloacetic transaminase
GPT	Glutamic pyruvic transaminase
I/E criteria	Inclusion/exclusion criteria
ILR	Implantable loop recorder
IMP	Investigational medicinal product
INR	International normalized ratio
IQR	Inter-quartile range
IRB	Institutional Review Board
ISTH	International society on thrombosis and haemostasis
LLT	Lowest level terms
MACE(s)	Major adverse cardiac event(s)
MedDRA	Medical dictionary for regulatory activities
MI	Myocardial infarction
MICE	Multivariate imputation by chained equations
mITT	Modified intention-to-treat
MoCA	Montreal cognitive assessment
NOAC(s)	Non-vitamin K antagonist Oral anticoagulant(s)
NOAH	Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial High Rate ^ Episodes
OD	Once daily
PCI	Percutaneous coronary intervention
PP	Per protocol
PROs	Patient-reported outcomes
PT	Preferred term
SAE(s)	Severe adverse event(s)
SAP	Statistical Analysis Plan
SC	Steering committee
SD	Standard deviation
SmPC	Summary of Product Characteristics
SOC	System organ class
TIA	Transient ischemic attack
UKE	University medical-center Hamburg-Eppendorf
VKA(s)	Vitamin K antagonist(s)

1 Introduction

This Statistical Analysis Plan (SAP) is based on the study protocol version 5.1 of October 1, 2020 and corresponding amendment no.5 and follows the guideline for statistical analysis plans (Gamble, et al., 2017). Some points of the statistical methods and of the study design are already described in the study protocol. This SAP aims to further specify the procedures and statistical methods applied during the final analysis of the study data.

1.1 Background and rationale

Atrial fibrillation (AF) is a common cause of stroke, especially ischemic stroke. So far, all available data that demonstrate a beneficial effect of oral anticoagulation for stroke prevention have been collected in populations with AF documented by conventional electrocardiogram (ECG) recordings. It is well established that a large proportion of AF episodes remain undiagnosed ("silent AF"), and many of these patients present with a stroke as the first clinical sign of AF. Earlier initiation of anticoagulation could prevent such events. Continuous monitoring of atrial rhythm by implanted devices could close this diagnostic gap. Pacemakers, defibrillators, and cardiac resynchronization devices already provide automated algorithms alerting to the occurrence of highly organized atrial tachyarrhythmia episodes, also called "subclinical atrial fibrillation" or, more commonly, "atrial high rate episodes" (AHRE). Data from large prospectively followed patient cohorts demonstrated that stroke rate is increased in patients with AHRE. A sizeable portion of these patients develops clinically detected AF over time. In these patients, AHRE can be considered as an early manifestation of paroxysmal AF. A few AHRE patients do not develop clinically overt AF, and the absolute stroke rates are lower in patients with AHRE when compared to stroke rates in patients with clinically diagnosed AF. In light of the bleeding complications associated with oral anticoagulant therapy, there is thus uncertainty about the optimal antithrombotic therapy in patients with AHREs.

The Non-vitamin K antagonist Oral anticoagulants (NOACs) provide similar or slightly better stroke prevention, and appear slightly safer compared to vitamin K antagonists (VKAs). In addition, no individual therapy adjustment of NOACs has to be performed. Edoxaban, a newly introduced NOAC, at a dose regime of 60 mg once daily (OD) has a favorable profile compared to dose-adjusted VKA therapy: In the ENGAGE-TIMI 48 trial (Giugliano, et al., 2013), edoxaban prevented strokes at least as effectively as VKA therapy but caused less major bleeding events than VKA therapy.

1.2 Objectives

To demonstrate that oral anticoagulation with the NOAC edoxaban is superior (test for difference) to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent stroke, systemic embolism, or cardiovascular death in patients with AHRE but

without overt AF and at least two stroke risk factors leading to a modified CHA_2DS_2VASc score of 2 or more.

1.2.1 Primary outcome

The primary outcome parameter of NOAH is defined as the time from randomization to the first occurrence of a composite of ischemic stroke, systemic embolism or cardiovascular death.

1.2.2 Main secondary outcomes

The secondary outcome parameters are defined as

a) time from randomization to components of the primary outcome (time to first event, i.e. for the non-fatal events (ischemic stroke and systemic embolism) only the respective first event is used),
b) time from randomization to all-cause death,
c) time from randomization to first occurrence of Major Adverse Cardiac Events (MACEs: cardiovascular death, myocardial infarction, acute coronary syndrome (ACS); percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)),
d) time from randomization to first occurrence of ischemic stroke or systemic arterial embolism (composite),
e) time to first occurrence of major bleeding event
f) number of major bleeding events according to the International Society on Thrombosis and Haemostasis (ISTH) definitions,
g) quality of life changes at 12 and 24 months compared to baseline (assessed by EQ-5D including its visual-analogue scale and by the Karnofsky scale (EuroQol Research Foundation, 2019), (van Hout & Janssen, 2012),
h) patient satisfaction changes at 12 and 24 months compared to baseline (assessed by modified EHRA score and PACT-Q2 (Prins, et al., 2009a), (Prins, et al., 2009b))
i) cognitive function changes (MoCA) at 12 and 24 months compared to baseline
j) changes of autonomy status only in patients with stroke during study participation, assessed at each clinical follow-up visit by modified Rankin scale; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed.

1.2.3 Patient Reported Outcome (PRO)

Are captured in section 1.2.2 g), h).

1.2.4 Safety outcome parameters

Are captured in section 1.2.1 and 1.2.2 c), d), e), f).

Additionally the combined outcome of time from randomization to death or time from randomization to first occurrence of major bleeding (composite endpoint) will be analyzed.

2 Study Methods

2.1 Trial design

Investigator-initiated, prospective, parallel-group, randomized, controlled, double-blind, event-driven, multi-centre trial. Although it can be argued that the indication tested is within the registered label of edoxaban, NOAH will be conducted as a phase IIIb study.

2.2 Randomization and blinding

The randomization sequence was generated using STATA12 SE (StataCorp, 2011) with blocks of variable sizes of 4 to 8 entries to ensure allocation concealment could not be breached, by guessing the sequence at the end of each block. Patients were randomized in a 1:1 ratio to one of the two parallel groups NOAC or usual care arms, stratified by indication for ASA and study site.

The randomisation was performed with the integrated randomisation service in the web-based EDC system MARVIN used as eCRF. According to protocol, requirements and design of the eCRF, randomisation could only be performed after informed consent had been obtained and all in- and exclusion criteria had been confirmed by study site staff. Multiple randomisations or pseudo-randomisations of subjects are prevented by the integrated randomisation service. Details can be found in the study protocol, section 6.2.5.

Patients, all hospital personnel performing direct care and assessments of patients and the Endpoint Review Committee (ERC) will be blinded to randomized treatment assignments until the database is locked for the primary analysis. The DSMB will be unblinded to treatment assignment throughout the study.

In case of an event which threatens the patient's health without the knowledge of the study drug identity, investigator can unblind the subject's treatment group in the MARVIN e-CRF. The identity of the person having triggered the unblinding as well as date and time of unblinding, justification of unblinding and identity of random group are stored in the data base. From timepoint of unblinding, the subject is censored for analysis in the mITT (modified intention-to-treat; see Section 3.3.1) population.

2.3 Sample size

NOAH is an event-driven trial with a planned number of randomised and treated patients of n=2,538 and an anticipated number of primary endpoints of n=220. The protocol includes an

adjustment of the sample size based on an analysis of events after 1000 observed patient-years. Details of sample size calculation can be found in the study protocol, section 12.2.

2.4 Framework

NOAH intends to demonstrate that oral anticoagulation with the NOAC edoxaban differs to current therapy (antiplatelet therapy or no therapy depending on cardio-vascular risk) to prevent the occurrence of the primary endpoint defined as the time from randomization to the first occurrence of a composite of stroke, systemic embolism or cardiovascular death. For all other (secondary) endpoints a test for difference will also be used.

2.5 Statistical interim analyses and stopping guidance

The Steering Committee (SC) has assessed pooled event rates after about 1,000 patient-years of observation in the mITT (modified intention-to-treat; see Section 3.3.1) study population (without knowledge of study group assignment or study treatment). Alternatively the interim analysis could have been conducted after about 24 months after enrolment of the first patient (this was not the case). Sample size or inclusion criteria (e.g. enrichment for patients at higher risk for events should low event rates be observed, or adaptation of sample size based on observed event rates, or alternatively reduction of the number of patients needed based on observed events) were adapted to reflect the observed event rates.

The pooled event rate was calculated as the ratio of the sum of all observed primary events until the time point of interim analysis and corresponding person-years, defined as the sum of all observed follow-up times (in years) for each patient between randomization and the event date (patients with primary events), or the date of development of overt AF, date of unblinding, or the last documented follow-up information (all other patients). The corresponding 95%-confidence interval was estimated using the quadratic approximation to the Poisson log likelihood for the log-rate parameter.

The event rate of 4.4%, assumed for the sample size calculations, was not greater than the upper 95% limit. Adjustments in the sample size or in the inclusion criteria were discussed in the SC based on this result. No changes were decided.

2.6 Timing of final analysis

NOAH is an event-driven trial with a planned number of randomised patients of n=2,538 and a fixed number of valid events (n=220). The total duration of the trial is an estimate based on observed outcome rates in other large trials with similar populations. The total number of events in the trial is depending on the time at risk that is the follow-up time of all patients. In practice, the event-driven design may result in slight variation of the expected trial duration and

of the total number of patients enrolled if observed event rates do not exactly match the assumed rates. All patients will be followed until the global end of the trial. Remaining medication will be collected at the final visit. As given in the study protocol following estimation for the study duration is made: Screening and enrolment of patients is expected to be accomplished after 71 months. Based on the sample size estimation, it is expected that the required number of adjudicated (verified primary outcome events) will be reached 12 months after enrolment of the last patient. Due to the time required to obtain follow-up information and to adjudicate events (about 3 months to perform a final study visit in all patients still in the trial plus 4 months for receiving adjudication by ERC to confirm that the required number of adjudicated endpoints have been reached), a total study duration of 71 + 12 + 3 + 4 = 90 months is expected. The total study duration of 90 months (about 7.5 years) was adapted based on an interim analysis. After that and data management the final analysis can be conducted.

Global end of study (EOS) is defined as the last Final Visit performed in a study patient. This date will be approved by the sponsor and announced by the CRI.

The global end of study will be announced by the CRI after all necessary primary endpoints have been reached.

This procedure can result in more than the anticipated primary events within the final analysis (depending on the amount of events that can be adjudicated).

The accrual time and hence the total study time was further adapted in 2022 due to loss of Ukrainian participants and the lower than expected event rate. The steering committee decided to censor all Ukrainian patients on the last documented contact before the 24th February 2022, the day of the outbreak of war in Ukraine, to protect the trial against unexpected changes in event rates due to the influence of war on Ukrainian patients.

3 Statistical Principles

3.1 Confidence intervals and *P* values

All applicable statistical tests will be two-sided and will be performed using a 5% significance level. All confidence intervals presented will be 95% and two-sided. Analyses of secondary, safety and patient reported outcomes will be performed exploratory without adjustment for multiplicity.

3.2 Adherence and protocol deviations

Adherence with study drug is defined as following (percentages refer to the period between the last documented follow-up visit and the next, ideally 6 months):

- Non-adherence: Intake of study drugs < 80% of the number of daily dosages calculated for the corresponding time period.
- Acceptable adherence: Intake of study drugs 80% to < 90% of the number of daily dosages calculated for the corresponding time period.
- Good adherence: Intake of study drugs 90% or more of the number of daily dosages calculated for the corresponding time period.

Thereby, the duration of discontinuation is not considered.

In case of non-adherence the investigator has to instruct the patient about importance of regular drug intake.

Adherence is measured by count of remaining pills in each returned medication box by the site staff. The pill count entered into the eCRF system for each blister and medication box is confirmed by a second pill count performed by Monitors during Monitoring or Site Close-Out visits at end of study. Successful intake of one daily dosage is defined as the intake of one pill of product ASA (or placebo) and one pill of product edoxaban (or placebo). Blisters and medication boxes that were disposed by the patient as being confirmed completely used by the patient, are considered as intake of all contained daily dosages in a best-case scenario.

Permanent discontinuation of study medication is documented in the eCRF. A sensitivity analysis comparing the two randomised groups during exposure to study medication will be planned. For this analysis, all patients will be censored at the time of permanent discontinuation of study medication.

Major protocol violations are any unapproved changes in the research study design and/or procedures that are within the investigator's control and not in accordance with the IRB- or EC-approved protocol that may affect the participant's rights, safety or well-being, or the completeness, accuracy and reliability of the study data. Patients with major protocol violations will be excluded from the per protocol analysis. Some major protocol violations may be reported to regulatory authorities within defined time periods as mandated. Study specific definitions of major protocol violations will be given by the SC.

The type and reason of protocol violation will be documented in this study, and the summary of protocol violations will be reported in both arms.

Following protocol deviations were specified by the SC:

- deviation from inclusion criteria is a major protocol deviation, i.e. if the following is not fulfilled:
  - Pacemaker, defibrillator or insertable cardiac monitor implanted for any reason with feature of detection of AHRE, implanted at least 2 months prior to randomisation (not major for ILR (implantable loop recorder))
  - AHRE detection feature activated for adequate detection of AHRE (not major if AHRE episodes were reviewed by site and adequate criteria found)
  - AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) documented by the implanted device via its atrial lead and stored digitally. Any AHRE episode recorded is potentially eligible, but AHRE episodes detected in the first 2 months after implantation of a new device involving placement or repositioning of atrial electrodes are not eligible. AHRE episodes recorded in the first two months after a simple "box change" operation, i.e. exchange of a pacemaker or defibrillator device without exchange or repositioning of atrial electrodes, are eligible.
  - modified CHA2DS2VASc score of 2 or more
- deviation from exclusion criteria is a major protocol deviation, i.e. if the following is observed:
  - Any disease that limits life expectancy to less than 1 year
  - Participation in another controlled clinical trial, either within the past two months or still ongoing.
  - Previous participation in the present trial NOAH - AFNET 6.
  - Drug abuse or clinically manifest alcohol abuse.
  - Any history of overt AF or atrial flutter
  - Indication for oral anticoagulation (e.g. deep venous thrombosis).
  - Contraindication for oral anticoagulation in general
  - Contraindication for edoxaban as stated in the current SmPC.
  - Indication for long-term antiplatelet therapy other than acetylsalicylic acid or a need for treatment with any antiplatelet agent in addition to edoxaban, especially dual antiplatelet therapy (DAPT). Patients with a transient requirement for DAPT (e.g. after receiving a stent) will be eligible when the need for DAPT is no longer present.
  - Acute coronary syndrome, coronary revascularisation (PCI or bypass surgery), or overt stroke within 30 days prior to randomisation.
  - End stage renal disease (creatinine clearance < 15 ml/min as calculated by the Cockcroft-Gault method).
  - All persons exempt from participation in a clinical trial by law.

- Deviation related to study therapy defined as major:
  - Intake of study drugs < 80% of the number of pills calculated for the corresponding time period
  - Permanent stop of IMP intake without indication or contraindication for oral anticoagulation
  - Measurement of creatinine value at baseline visit older 28 days if it is not measured within 6 months of therapy initiation
- Deviation related to study procedures defined as major:
  - No complete chain of medication supply if interruption is 20% or more of the planned treatment time (aligned with definition of adherence)
  - Simultaneous intake of study medication and other oral anticoagulation
  - Simultaneous intake of study medication and any antiplatelet agent

3.3 Analysis populations

3.3.1 Modified Intention to treat Population (mITT)

The modified intention to treat population (mITT) consists of all randomised patients with a qualifying AHRE and intake of at least one dose of study drug. The mITT doesn't include patients that were randomized but a) have AF onset before 1st dose of IMP, or b) die before 1st dose of IMP, c) withdrew their consent before 1st dose of IMP or d) are lost to follow up before 1st dose of the IMP.

3.3.2 Per Protocol population (PP)

The Per Protocol population consists of mITT populations patients who have no major protocol deviation. Definition of major protocol deviation are given is Section 3.2.

3.3.3 Safety Population

Safety data will be collected on all enrolled patients (i.e. all patients that signed informed consent) in this study.

4 Trial Population

4.1 Eligibility

The number of ineligible patients randomised, i.e. those randomised by not fulfilling the inclusion and exclusion criteria, will be reported, with reasons for ineligibility.

4.2 Recruitment

A CONSORT (Schulz, Altman, & Moher, 2010) flow diagram will be used to summarise the number of patients (per treatment group where appropriate) who were:

- enrolled (patients documented in MARVIN, numbers will be provided by CRI to IMBE for construction of CONSORT flow chart)
  - fulfilling I/E-Criteria at screening
  - not fulfilling I/E-Criteria at screening*
  - post-hoc violation of I/E-Criteria*
- randomised
- not randomised*
- received the randomised treatment
- did not receive the randomised treatment*
- lost to follow-up*
- randomised and included in the primary analysis
- randomised and excluded from the primary analysis*

*reasons will be provided

4.3 Withdrawal / follow-up

Information on the number and level of withdrawals/drop outs, number included in the analysis and the number died will be presented in CONSORT diagram format with numbers and reasons for withdrawal and/or exclusion from analysis given at each visit. Levels of withdrawal are defined as:

- Modification of consent (MOC):
  Patients who wish to withdraw from the study are asked to maintain consent for minimal effort follow-up, allowing to use their clinical data achieved at the clinically indicated visits. All available data will be used until the end of study (no drop out of patient).
- Withdrawal of consent (WOC):
  If patients withdraw consent to any further study participation, data will be used until time of withdrawal and censored afterwards.
- Complete withdrawal:
  Patient request deletion of all his/her data.
- Early withdrawal: Withdrawal of patient's consent (WOC) within the first month after study inclusion. Patients with early withdrawal will be included in primary analysis. Furthermore, a sensitivity analysis will be conducted without these patients.

4.4 Baseline patient characteristics (Definition of table 1)

Patients will be described with respect to age, gender, and clinical features, both overall and separately for the two randomised groups. A shell table is included in the appendix.

Categorical data will be summarised by numbers and percentages. Continuous data will be summarised by mean, SD, median, 1st and 3rd quartile, and minimum and maximum. Histograms and boxplots will be used to check the distribution and possible outliers for continuous variables. Number of available observations and number of missing observations will be presented for the treatment groups separately. Tests of statistical significance will not be undertaken for baseline characteristics; rather the clinical importance of any imbalance will be noted (Senn, 1994).

5 Analysis

5.1 Censoring and event definition

5.1.1 Trial specific censoring

Patients who develop overt AF during the trial period will be censored at that point in time but followed according to protocol until the global end of the trial.

From time point of unblinding, the subject is censored for analysis in the mITT population. Patients without an event at the end of follow-up will have their efficacy measure censored at the end of follow-up.

If a patient is lost to follow-up, the last time point of contact is used as censoring time point in case of no event, else the event time point is used for analysis.

If a patient withdraws his/her consent but accepts that data till this time point of withdrawal can be used, the time point of last contact is used as censoring time point in case of no event, else the event time point is used for analysis.

5.1.2 Event definition

No matter what, i.e. although events might occur in quick succession, the first event that was observed is used within analysis. Primary outcomes that occur within one day of unblinding will be counted as primary outcomes.

5.2 Primary endpoint analysis

The primary outcome analysis will be performed in the mITT population using the adjudicated endpoint data of the ERC. The primary endpoint is the time from randomisation to the first

occurrence of ischemic stroke, systemic embolism or cardiovascular death. Deaths of unknown cause will be classified as cardiovascular death (Hicks, et al., 2018) in all analyses. All patients who will not reach the primary endpoint by the global end of the study will be censored at that time point.

Because all-cause death acts as a competing event for the primary endpoint the following methods will be applied:

- Primary analysis: Cause-specific Cox-proportional hazards model with frailty for centers and the fixed effects random group and ASA, i.e. an adjusted estimated (cause-specific) hazard ratio (hazard ratio of edoxaban vs usual care) with two-sided 95% confidence interval, and corresponding p-value will be provided.
- Graphical display of results: cumulative incidence curves (Aalen-Johansen estimates)

The proportional hazards assumption will be checked graphically (e.g. Schoenfeld residuals, -log-log-survival).

5.3 Secondary endpoints analysis

5.3.1 Time-to-event endpoints

The following secondary endpoints will be analysed in the same way as the primary endpoint:

a) time to components of primary outcome,
c) time to first occurrence of major adverse cardiac events,
d) time to first occurrence of stroke or arterial embolism,
e) time to first major bleeding events.

b) Time to all-cause death will be analysed using an adjusted Cox-proportional hazards model (hazard ratio of edoxaban vs usual care) with the fixed effects random group and ASA and a frailty term for study side.

All results will be reported within tables with estimated hazard ratios, corresponding confidence intervals, and p-values and visualized by cumulative incidence curves (Aalen-Johansen estimates in case of the competing event all-cause death; for all-cause death Kaplan-Meier type estimates).

5.3.2 Continuous endpoints

The following continuous secondary endpoints:

g) change in quality of life (EQ-5D and Karnofsky score),

h) patient satisfaction (PACT-Q2, EHRA),

i) cognitive function (MoCA),

at 12 and 24 months will be analysed using the difference to baseline as outcome in the following model:

- baseline and randomization strata (ASA) adjusted linear mixed effects regression,
- with a time (12 and 24 months) by treatment interaction if interaction p-value <0.05; else only both main effects
- the dependency structure of the time points will be modelled by including the study side as random effect (independent identically distributed) and patient nested within study side, with an unstructured variance covariance matrix of the residuals matrix (time points).

Normal distributed residuals will be checked graphically via histogram of residuals.

Adjusted mean values and adjusted effect estimators (mean differences) with corresponding confidence intervals and p-values will be given.

f) Number of major bleeding events according to ISTH: randomization strata adjusted mixed negative binomial regression with the individual observational time as offset.

5.3.3 Change in autonomy status.

Changes in autonomy status will be quantified by comparing modified Rankin scales over time after a stroke using a shift analysis (Ganesh, Luengo-Fernandez, Wharton, & Rothwell, 2018). For this, a cumulative ordinal regression is used with random group and ASA as fixed effects and center as random effect. The joint adjusted odds ratio (OR) with two-sided 95% confidence interval, and corresponding p-value will be provided.

5.4 Missing data analysis

For the primary outcome the worst case scenario will be used for missing values, i.e. deaths of unknown cause will be classified as CVD (Hicks, et al., 2018) in all analyses.
No other imputation will be conducted for primary endpoint analysis.

Missing values for continuous secondary outcomes will be imputed using chained equations (MICE) with of at least 20 imputations (M) if the assumption of M=100**FMI* (Largest Fraction of Missing Information) is fulfilled (White & Royston, 2009). The imputation model includes simultaneously all above described variables at all measured time points and the following

clinical relevant predictors at all measured time points: age, sex, body mass index, NYHA class, documentation of overt atrial fibrillation, left ventricular ejection fraction, eligibility for aspirin therapy, estimated creatinine clearance.

If possible we will use a parametric approach depending on the measurement level of the variable, otherwise predictive mean matching with the ten nearest neighbors will be used. Imputation will be performed stratified by treatment.

If possible sum-scores will be imputed on item level. If, due to complexity of the model, the imputation on item level is not possible the sum-score will be used.

This imputation model will be used if estimateable, else a further reduction of the complexity of the model will be performed. The results of the imputed data will be primarily reported.

For outcome g) death can be imputed (with 0), but for others outcomes which are no time to event endpoints this is not possible and hence information on these patients remains missing.

5.5 Sensitivity analyses

For sensitivity analyses for the primary endpoint will be estimated:

- using the per-protocol population,
- using the mITT population with censoring of patients at the time of discontinuation of IMP ("on treatment analysis")
- without censoring for overt AF or for unblinding,
- using the Fine-and-Gray model with random group and ASA as fixed effects but without a frailty for study site,
- without patients who withdrew their consent (early or late and early only, i.e. <1 month),

For further sensitivity analyses for secondary continuous outcomes complete case analysis will be conducted, i.e. analysis without imputed data.

5.6 Per protocol analyses

The primary endpoint will be evaluated in the PP population as a sensitivity analysis in the same manner as described in Section 5.2.

5.7 Subgroup analyses

Explorative subgroup analyses with respect to the primary outcome that allow identifying determinants of treatment success will be performed by the appropriate interaction tests for each subgroup separately. Each test will be performed at a significance level of alpha=5% and within the mITT population.

Predefined subgroups are:

- Sex
- Age groups split by median as well as ≥75 years
- Maximal duration of AHRE episodes (≥24 hours vs other)
- Maximal AHRE duration split by median
- Stratified by CHA_2DS_2VASc score / factors
  - congestive heart failure history
  - hypertension history
  - diabetes history
  - Stroke/TIA/thromboembolism history
  - Vascular disease history (prior MI, peripheral artery disease, or aortic plaque)
- high comorbidity burden (CHA_2DS_2VASc score ≥5 and CHA_2DS_2VASc score > median)
- Adherence:
  - Non-adherence: Intake of study drugs < 80% of the number of daily dosages calculated for the corresponding time period.
  - Acceptable adherence: Intake of study drugs 80% to < 90% of the number of daily dosages calculated for the corresponding time period.
  - Good adherence: Intake of study drugs 90% or more of the number of daily dosages calculated for the corresponding time period.
- Patients without any AHRE during the study duration

5.8 Additional analyses

A more detailed extended analysis of the primary outcome will be performed in the mITT population after global end of the study by statistical model building based on cause-specific Cox proportional hazard models with fixed effects for random group and ASA and a frailty for study site and the inclusion of several covariates. In particular variables that differ clinically relevant between the random groups at baseline will be determined with respect to the primary outcome. In addition to clinical predictors available in the locked data base, further analyses will determine potential genetic and biomolecule-based predictors of outcomes.

5.9 Safety analyses (SAE)

Safety analyses will be performed based on the data of the safety population following the ITT principle. The primary safety outcome in this study is a composite of cardiovascular death, ischemic stroke, and systemic embolism, which will be analysed using time-to-event methodology, as described for the primary outcome analysis. Time to first occurrence of Major

Adverse Cardiac Events, time to first occurrence of stroke or systemic arterial embolism, and time to first occurrence of major bleeding event are also considered as safety outcomes and already captured in secondary endpoint analysis. Additionally the composite of time to death or time to first occurrence of major bleeding event will be analysed in the same cause-specific time-to-event manner.

SAEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA, Version 19.1) dictionary in its actual version at the start of the study by Lowest Level Terms (LLT). Treatment related SAEs will be summarized under each treatment group, by system organ class (SOC) and preferred term (PT). SAEs will be summarized by severity and relation to study treatment received.

5.10 Harms

The investigational medicinal product (edoxaban) has a known safety profile and is approved for use in patients with atrial fibrillation. Knowing that the administration of edoxaban in AHRE patients without overt non-valvular AF is not in-line with the approved label, adverse events are expected to occur in similar clinical manifestations and at a comparable rate as the known adverse events of the approved therapies applied in the trial (i.e. "low risk trial"). The safety profile includes major bleeding events. As stated in Section 5.9 we will therefore compare the secondary outcome time to first occurrence of major bleeding and a combined outcome of time to death or time to first major bleeding between the random groups.

5.11 Statistical software

- STATA 17 or newer
- R 3.4.1 or newer
- SPSS 22.0 or newer
- SAS 9.4 or newer

6 Database Sources

6.1 Source data and documents

Source data are defined as all information in original records and certified copies of original records of clinical findings, observations or other activities in a clinical study necessary for the reconstruction and evaluation of the study. Source data are contained in source documents.

Source documents are defined as original documents, data and records (e.g. hospital records, clinical and office charts, electronic patient records, laboratory notes, memoranda, patient diaries or evaluation check lists, pharmacy dispensing records, recorded data from automated

instruments, copies or transcriptions, microfiches, photographic negatives, microfilm or magnetic media, x-rays, patient files, records kept at pharmacy, at the laboratories and at medico technical departments) involved in this clinical study.
In case of data that are result of patient reporting and will not be documented in clinical routine, the e-CRF is the source document, if the patients answer is documented there without prior documentation on paper.

6.2 Direct access to data

Direct access is defined as the permission to examine, analyze, verify and reproduce any records and reports that are important to evaluation of a clinical study. Any party with direct access should take all reasonable precautions within the constraints of the applicable regulatory requirements to maintain the confidentiality of patient identities and sponsor proprietary information.

6.3 Storage, transformation of data and preparation for analysis

All study data, administrative data and relevant metadata are collected, stored and secured against deletion or unnoticed manipulation according to current regulatory requirements for electronic data capture in clinical trials. The data of the e-CRF database are extracted and transformed to structured data sets for analysis in a validated process. All structured data are prepared for statistical analysis with the statistical software package R using validated functions and scripts.

7 Amendment

On 2 September 2022, the NOAH-AFNET6 sponsor, the Atrial Fibrillation NETwork (AFNET), decided to terminate the NOAH-AFNET6 study prematurely. This decision follows a unanimous recommendation by the Data and Safety Monitoring Board (DSMB) on 26 August 2022 to terminate the study and a unanimous vote by the study's Steering Committee on 2 September 2022 to follow this recommendation.
As reasons for its recommendation to terminate NOAH-AFNET6 the DSMB cited an observed trend towards futility of efficacy combined with safety concerns.
Furthermore, on the basis of a unanimous vote of the Steering Committee, the decision was taken by the sponsor to orderly terminate the trial, i.e., the final patient visit should be performed for each patient still in follow-up as soon as possible, and all patients still taking Investigational medicinal product (IMP) should conduct a regular final visit at the study site at which the IMP intake ends.

Due to the premature study termination some changes have to be made to the first version of the signed SAP. These are described in this chapter.

7.1 Changes in chapter *1.2.2. Main secondary outcomes*

g) EQ-5D-5L: The index analysis based on the values of United Kingdom will be primarily reported. The index analysis based on the German values or values of the Netherlands as well as the analysis of the visual-analogue scale will be reported as additional analysis.

For outcome

j) changes of autonomy status only in patients with stroke during study participation, assessed at each clinical follow-up visit by modified Rankin scale; a maximum of 2 subsequent assessments in follow-up per patient with stroke should be performed

the following is added/changed:

A maximum of two assessments for patients with stroke during study participation is foreseen by Rankin Score. This information is only captured in patients with a stroke. First and last assessment will be evaluated in the analysis.

Also, the EQ-5D has been renamed EQ-5D-5L in all subsequent chapters.

7.2 Changes in chapter *2.6 Timing of final analysis*

Added information on Ukraine:

All collected data until the 23rd of February 2022 (war started in the early hours on 24th of February) will be evaluated. All outcome events occurring on or prior to 23 February will be counted in the primary analysis. Patients are lost to follow up if there is no final visit done or any contact to the patient. SC will finally decide how to handle special cases.

The SC decided on December 19, 2022 to end the study on December 31, 2022. The date is equal to end of observation.

7.3 Changes in chapter *3.3.2 Per Protocol population (PP)*

If possible patients with major protocol deviation are censored at the time of a major protocol deviation for the per protocol population. The censoring time of the major protocol deviation will be used if it occurs before a primary event or other censoring was observed.

7.4 Changes in chapter *4.2 Recruitment*

The following is added:

Lost to follow up: This will be explained if possible, e.g. withdrawn consent, including "no known reason" where this is the case. This information will be captured in the CONSORT diagram.

7.5 Changes in chapter *4.4 Baseline patient characteristics (Definition of table 1) and correction of Appendix A*

Added information on characteristics of interest, i.e. the following patients' characteristics will be given in this table (also correction of Appendix A):

- Age (years)
- Sex (female, male)
- Weight (kg)
- BMI (body-mass-index)
- AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration) (yes, no)
- CHA2DS2VASc score
- Older than 75 years (yes, no)
- Symptomatic Heart failure (yes, no)
- Hypertension (yes, no)
- Diabetes mellitus (yes, no)
- Stroke or TIA (yes, no)
- Vascular disease (yes, no)
- Indication for ASA (yes, no)
- Unstable angina pectoris (yes, no)
- Acute myocardial infarction (yes, no)
- Prevention of re-infarction (yes, no)
- After arterial vascular or general surgical interventions (e.g. after CABG or after PTCA) (yes, no)
- For prevention of transitory ischaemic attacks (TIA) and strokes (yes, no)
- Patient currently has a contraindication for ASA (yes, no)
- Hypertension (yes, no)
- NYHA (No heart failure, I, II, III, IV)
- Cardiomyopathy (No, Hypertrophic cardiomyopathy, Dilatative cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Other cardiomyopathy)
- Valvular heart disease (yes, no)
- Confirmed Coronary Artery Disease (yes, no)
- Confirmed carotid stenosis (>50% lumen reduction) (None, left side, right side, both sides)
- Arterial hypertension (yes, no)

- Diabetes mellitus (No, oral antidiabetics, insulin therapy, oral antidiabetics and insulin therapy)
- Hypercholesterinaemia (yes, no)
- Peripheral arterial vascular disease (yes, no)
- Overall heart rhythm (Sinus rhythm prevails, Atrial fibrillation prevails, Pacing prevails, Pacing and AF, Other)
- Heart rate
- QRS interval
- PR interval
- QT duration
- QT duration calculated
- Amiodarone (yes, no)
- Dronedarone (yes, no)
- Flecainide (yes, no)
- Ibutilide (yes, no)
- Propafenone (yes, no)
- Digoxin or Digitoxin (yes, no)
- Antiarrhythmic drugs (yes, no)
- Antianginal drugs (yes, no)
- Potassium channel inhibitor (yes, no)
- Sodium channel inhibitor (yes, no)
- Diuretics (yes, no)
- Loop diuretics (yes, no)
- Mineralocorticoid receptor antagonist (yes, no)
- Beta blockers (yes, no)
- Calcium channel antagonists (yes, no)
- Rate controlling calcium channel antagonist (yes, no)
- ACE inhibitors or angiotensin II receptor blocker (yes, no)
- Renin inhibitor (yes, no)
- Imidazole and triazole derivatives (yes, no)
- Non-Steroidal Anti-Inflammatory Drugs (yes, no)
- Intravenous anticoagulant (yes, no)
- NOAC (yes, no)
- Platelet inhibitors (yes, no)
- Vitamin K antagonists (yes, no)
- Insulin (yes, no)
- Oral antidiabetics (yes, no)

- SGLT2 inhibitors (yes, no)
- Statins (yes, no)
- Serum creatinine value (mg/dl)
- Creatinine clearance
- Haemoglobin (g/l)
- Hematocrit
- Red blood cells
- Leucocytes
- Thrombocytes
- INR (international normalized ratio)
- aPTT (activated partial thromboplastin time)
- ALT (alanine aminotransferase) (GPT; glutamic pyruvic transaminase) (U/l)
- AST (aspartate aminotransferase) (GOT; glutamic-oxaloacetic transaminase) (U/l)
- Total bilirubin (µmol/l)
- Cholesterol (mmol/l)
- Karnofsky score
- Atrial fibrillation symptom score (EHRA) (EHRA I, EHRA IIa, EHRA IIb, EHRA III, EHRA IV, unknown)
- Cognitive function at baseline (MoCA)
- ≤ 12 years formal education (yes, no)
- MoCA (<26) (Cognitive impairment: yes, no)
- EQ-5D-5L: Mobility
- EQ-5D-5L: Self-Care
- EQ-5D-5L: Usual Activities
- EQ-5D-5L: Pain/Discomfort:
- EQ-5D-5L: Anxiety/Depression:
- EQ-5D: State of health rate on a scale of 1 (very poor) to 100 (very good)
- EQ-5D total score

7.6 Changes in chapter *5.1.2 Event definition*

The following is added: All potential outcome events will be adjudicated by the endpoint review committee. That definition defines the nature of each event.

7.7 Changes in chapter *5.4 Missing data analysis*

No imputation for missing values for secondary endpoints will be conducted. Due to the premature termination of the trial, not all patients will be followed up until 12 months. Currently

60-65% of the patients have undergone or are scheduled to undergo a 12 months visit (n=1.680) and for less than 50% after 24 months (n=1.100). This means information is missing for the outcomes of interest. The expected number of missing values (ca 1/3) is too large to perform reliable imputation. Clinically relevant changes in quality of life can be expected to be detectable in ca 1600 patients as well.

Hence, data analysis will be done for those patients where regular 12 and/or 24 months visits and assessments have been done. Patients without 12 and 24 months follow up data (roundabout 30%) will not be included in the statistical analysis of the following secondary outcomes:

- change in quality of life (EQ-5D-5L and Karnofsky score),
- patient satisfaction (PACT-Q2, EHRA),
- cognitive function (MoCA),
- changes of autonomy status.

7.8 Changes in chapter *5.5. Sensitivity Analyses*

The point

- using the mITT population with censoring of patients at the time of discontinuation of IMP ("on treatment analysis")

changes to

- using the mITT population with censoring of patients at the time of permanent discontinuation of IMP (kind of censoring)

(which is not exactly an "on treatment analysis" but a specific kind of censoring)

7.9 Changes in chapter *5.7. Subgroup Analyses*

The cut-off for CHA2DS2VASc score is changed to ≥5.

Furthermore, the section is divided into two parts:

- Baseline subgroups, i.e. subgroups specified before randomization and which do not change over time
- Subgroups that occur over time, i.e. are not defined by data collected at baseline but by data collected after randomization during the course of the study

The subgroups that are defined by data collected during the course of the study are "Patients without any AHRE during the study duration" and "Adherence". All other subgroups are baseline subgroups.

The baseline subgroups are analyzed as described in Chapter 5.7.

For the subgroup "Patients without any AHRE during the study duration" a causal mediation analysis will be conducted. Thereby, the variables described in chapter 7.10. will be considered in the model as potential confounders.
"Adherence" as a post randomization event will be analysed as time-dependent covariate and interactor for the treatment effect with censoring at study drug discontinuation.

7.10 Changes in chapter *5.8. Additional Analyses*

Potential genetic and biomolecule-based predictors of outcomes will not be part of the current SAP analyses but part of secondary subsequent analyses. A dedicated biomolecule SAP will be written when they are quantified.
For the multiple cause-specific Cox proportional hazard models with fixed effects for random group and ASA and a frailty for study site and the inclusion of several covariates, the additional covariates were chosen by the SC and include:

- age
- sex
- congestive heart failure history
- hypertension history
- diabetes history
- stroke/TIA/thromboembolism history
- vascular disease history (prior MI, peripheral artery disease, or aortic plaque)
- aspirin intake at baseline
- Non-Steroidal Anti-Inflammatory Drugs

8 References

EuroQol Research Foundation. (2019). EQ-5D-5L User Guide.

Gamble, C., Krishan, A., Stocken, D., Lewis, S., Juszczak, E., Dore, C., . . . Loder, E. (2017, December 19). Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. *JAMA, 318*, pp. 318(23): 2337-2343.

Ganesh, A., Luengo-Fernandez, R., Wharton, R., & Rothwell, P. M. (2018, November 20). Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke. *Neurology*, pp. 91(21):e1951-e1960.

Giugliano, R., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., . . . Antman, E. M. (2013, November 28). Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, pp. 369(22): 2093-104.

Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., . . . Temple, R. T. (2018). Standardized Data Collection for Cardiovascular Trials Initiative (SCTI) (2018). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation*, pp. 137(9), 961–972.

Prins, M., Guillemin, I., Gilet, H., Gabriel, S., Essers, B., Raskob, G., & Kahn, S. (2009b, Apr 7). Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). *Health Qual Life Outcomes, 1*, p. 7:30.

Prins, M., Marrel, A., Carita, P., Anderson, D., Bousser, M., Crijns, H., . . . Arnould, B. (2009a, February 6). Multinational development of a questionnaire assessing patient satidfaction with ant-coagulant treatment: the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). *Health Qual Life Outcomes, 9*, p. 7:9.

Schulz, K. F., Altman, D. G., & Moher, D. (2010, Mar 23). CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. *BMJ, 63*, p. 340:c332.

Senn, S. (1994, Sep 15). Testing for baseline balance in clinical trials. *Stat Med, 13*(17), pp. 13(17): 1715-26.

StataCorp. (2011). Stata Statistical Software: Release 12. *College Station, TX: StataCorp LP*.

van Hout, B., & Janssen, M. (2012, Jul-Aug). Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value in Health, 15*(5), pp. 15(5):708-15.

White, I. R., & Royston, P. (2009, Jul 10). Imputing missing covariate values for the Cox model. *Stat Med, 28*(15), pp. 1982-98.

9 Appendix

Appendix A:

Shell table showing clinical characteristics.

Table 1
Baseline Characteristics and Demographics
(mITT Population)

Characteristics	Edoxaban (N = xxx)	SOC (N = xxx)	All subjects (N = xxx)
Age (yrs.)			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)

Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Sex			
Female	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Male	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Weight (kg)			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
BMI			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
AHRE (≥ 170 bpm atrial rate and ≥ 6 min duration)	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
$CHA_2DS2VASc$			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Older than 75 years	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Sympt. Heart failure	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Hypertension	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Diabetes mellitus	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Stroke or trans. isch. attack	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Vascular disease	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Indication for ASA	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Unstable angina pectoris	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Acute myocardial infarction	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Prevention of re-infarction	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
After arterial vascular or general surgical interventions (e.g. after CABG or after PTCA)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
For prevention of transitory ischaemic attacks (TIA) and strokes	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Coronary artery disease			
Other indication			
Patient currently has a contraindication for ASA	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Hypertension	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
NYHA			
I	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
II	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
III	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
IV	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)

Cardiomyopathy	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
No	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Hypertrophic cardiomyopathy ∇	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Dilatative cardiomyopathy	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Arrhythmogenic right ventricular cardiomyopathy	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Other cardiomyopathy	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Valvular heart disease	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Confirmed Coronary Artery Disease	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Confirmed carotid stenosis (>50% lumen reduction)			
None	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
left side	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
right side	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
both sides	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Arterial hypertension	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Diabetes mellitus	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
No	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
oral antidiabetics	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
insulin therapy	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
oral antidiabetics and insulin therapy	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Hypercholesterinaemia	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Peripheral arterial vascular disease	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Overall heart rhythm			
Sinus rhythm	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Atrial fibrillation	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Pacing	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Pacing and AF	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Other	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)	xxx/xxx (xx.x%)
Heart rate			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
QRS interval			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
PR interval			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
QT duration			

N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
QTc (calculated)			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Serum creatinine value (mg/dl)			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Estimated creatinine clearance			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Haemoglobin (converted to "g/l")			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Hematocrit			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Red blood cells			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Leucocytes			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Thrombocytes			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
INR			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)

Min, Max	xx, xx	xx, xx	xx, xx
aPTT			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
ALT (GPT) (converted to "U/l")			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
AST (GOT) (converted to "U/l")			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Total bilirubin (converted to "µmol/l")			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Cholesterol (converted to "mmol/l")			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
Amiodarone	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Dronedarone	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Flecainide	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Ibutilide	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Propafenone	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Digoxin or Digitoxin	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Antiarrhythmic drugs	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Antianginal drugs	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Potassium channel inhibitor	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Sodium channel inhibitor	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Diuretics	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Loop diuretics	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mineralocorticoid receptor antagonist	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Beta blockers	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Calcium channel antagonists	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Rate controlling calcium channel antagonist	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)

ACE inhibitors or angiotensin II receptor blocker	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Renin inhibitor	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Imidazole and triazole derivatives	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Non-Steroidal Anti-Inflammatory Drugs	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Intravenous anticoagulant	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
NOAC	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Platelet inhibitors	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Vitamin K antagonists	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Insulin	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Oral antidiabetics	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
SGLT2 inhibitors	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Statins	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Atrial fibrillation symptom score (EHRA) EHRA I EHRA IIa EHRA IIb EHRA III EHRA IV unknown	 xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%)	 xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%)	 xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%) xxx/xxx (xx.x%)
Cognitive function at baseline (MoCA) N Mean (SD) Median (25th, 75th) Min, Max ≤ 12 years formal education Cognitive impairment (<26)	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x) xx, xx xxx (xx.x%) xxx (xx.x%)	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x) xx, xx xxx (xx.x%) xxx (xx.x%)	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x) xx, xx xxx (xx.x%) xxx (xx.x%)
EQ-5D-5L responses at baseline			
EQ-5D-5L: Mobility N Mean (SD) Median (25th, 75th) Min, Max	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
EQ-5D-5L: Self-Care N Mean (SD) Median (25th, 75th) Min, Max	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x) xx, xx	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x) xx, xx	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x) xx, xx
EQ-5D-5L: Usual Activities N Mean (SD) Median (25th, 75th)	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x)	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x)	 xxx (xx.x%) xx.x (xx.x) xx.x (xx.x, xx.x)

Min, Max	xx, xx	xx, xx	xx, xx
EQ-5D-5L: Pain/Discomfort			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
EQ-5D-5L: Anxiety/Depression			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
EQ-5D: State of health rate on a scale of 1 (very poor) to 100 (very good)			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx
EQ-5D total score			
N	xxx (xx.x%)	xxx (xx.x%)	xxx (xx.x%)
Mean (SD)	xx.x (xx.x)	xx.x (xx.x)	xx.x (xx.x)
Median (25th, 75th)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)	xx.x (xx.x, xx.x)
Min, Max	xx, xx	xx, xx	xx, xx

Interim analysis

NOAH

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

ClinicalTrials.gov: NCT02618577, EudraCT number: 2015-003997-33, NCT number: NCT02618577, ISRCTN number: ISRCTN17309850

Version: 2

Date: 19.11.2019

Author: A. Zapf, S. Sehner, E. Freiwald-Bibiza

Institution: UKE

1 Sample Description

The transferred database contains 1270 datasets from 1264 patients.

As described in the SAP the interim analysis is based on the modified intention to treat Population (mITT). The mITT excludes patients that were randomized but a) had AF onset before 1st dose of IMP, or b) died before 1st dose of IMP, or c) withdrew their consent before 1st dose of IMP or d) were lost to follow up before 1st dose of the IMP.

Due to these conditions, 76 of 1264 patients (6.01%) are excluded.

The remaining 1194 datasets contain data from 1188 patients with the following event structure:

- 1135 patients without an event
- 47 patients with one event
- 6 patients with two events

Eleven of the 59 observed events (18.6%) were strokes, 12 (20.3%) systemic embolisms and 36 (61.0%) were cardiovascular deaths. Five of the six patients with two events had a cardiovascular death as the second event, while for two of them this event occurred on the same date as the first event. The remaining patient with two events had two systemic embolisms.

For the analysis of the event rate per year, only the first occurred event will be included in the analysis sample.

2 Censoring

There is a withdrawal of 83 patients (7.4%); three of these patients had an event, for all of them the event occurred before the date of withdrawal. The events are therefore included in the estimation. The remaining 80 withdrawal patients are censored accordingly.

One-hundred-six patients (9.5%) had a documented AF during the observational period; seven of these patients also had at least one event (one patient had two events). All events occurred after the first documented AF and are censored. The remaining 99 withdrawal patients are censored accordingly.

Censoring at the time point of the competing event of a non-cardiac death was performed for 16 patients. In total 21 patients had a non-cardiac death, five of these had an event before competing event and were not censored.

Censoring at the time point of unblinding was not performed. In total six patients were unblinded, three of them at the date of event. The other three patients were unblinded a short time before the last observation, so a censoring is not necessary for the interim analysis.

All described censoring processes and resulting patient numbers are illustrated in Figure 1.




Figure 1: Interim analysis – Flow chart

3 Event Rate

One-hundred-seventy-six patients of the remaining 1188 patients had a follow up period of zero days, so 1012 patients are included in the event rate analysis. The censuses for the interim analysis are defined as follows:

Person-years, as the sum of all observed follow-up times (in years) for each patient between randomization and the first event date (patients with primary events), or the date of development of overt AF, date of unblinding, or the last documented follow-up information (all other patients).

Based on this definition 46 events result within 997 patient years, which results in an event rate of 4.61% per year (95%-CI: 3.46%, 6.16 %) (Figure 2). This event rate is not significantly different to the assumed event rate of 4.4% per year (p=0.748).




Figure 2: Interim analysis - event rate with corresponding 95%-CI

4 Recruiting process

According to the original sample size calculation 1343 patients per group, 2686 in total, have to be randomized over 54 months resulting in a recruitment rate of 50 patients per month.

The final assumptions for the initial sample size calculations were:

- alpha=5%, power 80%,

- hazard $rate_{control}$ = 0.053, hazard $rate_{treatment}$ = 0.0364,
- accrual period 4.5 yrs, minimum follow up period 1 yr,
- hazard rates for loss to follow-up were 0.287 for both groups:
  - 5% patients per year will decided to stop the study (withdrawal)
  - 16 % patients per year will develop overt AF and be censored
  - hazard rate of 0.02 for non-cardiac death in both groups (2% patients per year will have an competing event)

In the observational period, we overserved the following rates:

- 80 withdrawal / app. 1000 patient years: 8 %
- 106 AF censorings / app. 1000 patient years: 11 %
- 16 non-cardiac death / app. 1000 years: 2 %

The interim analysis was conducted after the 40th months of recruitment. At this time point, 1188 patients with app. 1000 person years were randomized. In comparison to the planned number of 2050 randomized patients only 58% were realized (Figure 3). The assumption of uniform accrual until the interim analysis is violated, therefore the realized accrual process is approximated using a truncated exponential accrual over the interval with parameter γ=-0.5 [1].


Following scenarios are calculated: for 45, 50, or 55 patients randomized per month, the accrual distribution is assumed uniform over the intended accrual period.
The required study time and sample size to achieve the expected number of valid events (n=222) are recalculated under the assumption of exponential approximation of the previous accrual and the different accrual quotas. Further the initial settings are retained (alpha=5%, power 80%, hazard $rate_{control}$ = 0.053, hazard $rate_{treatment}$ = 0.0364, hazard rates for loss to follow-up were 0.287 for both groups).

The results for these estimations are given in table 1 and figure 3.

[1] Lachin, J. M., and M. A. Foulkes. 1986. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42: 507–519.

Table 1: Sample size recalculation – results,

Patients included per month	Accrual period (total study duration) in months	Time extension in months	Sample size	Expected number of events
45	71 (83)	17	2538	220
50	70 (82)	16	2638	222
55	68 (80)	14	2673	220



*nonuniform accrual: truncated exponential accrual with parameter -0.5

Figure 3: Recruitment process for different scenarios

16.1.10 Publications based on the study

Kirchhof, Paulus et al. “Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.” American heart journal vol. 190 (2017): 12-18. doi:10.1016/j.ahj.2017.04.015

Kirchhof, Paulus et al. “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.” The New England journal of medicine vol. 383,14 (2020): 1305-1316. doi:10.1056/NEJMoa2019422

Kirchhof, Paulus et al. “Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.” European heart journal. Cardiovascular pharmacotherapy vol. 9,1 (2022): 47-57. doi:10.1093/ehjcvp/pvac042

Kirchhof, Paulus et al. “Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.” The New England journal of medicine vol. 389,13 (2023): 1167-1179. doi:10.1056/NEJMoa2303062

16.1.11 Important publications referenced in the report

See 15.

16.2 Patient Data Listings

16.2.1 Discontinued patients

Table 24 Patients discontinued after enrolment

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
48	9	Placebo	ASA	84	m	692	Patient's request (however, patient is still being followed-up in the study)	
75	9	Placebo	ASA	77	m	163	Patient completely withdraws consent to any further study participation	
192	9	Placebo	ASA	75	f	110	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
288	9	Placebo	ASA	83	m	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
434	9	Placebo	ASA	91	f	31	Patient's request (however, patient is still being followed-up in the study)	
561	9	Placebo	ASA	68	f	772	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
681	9	Placebo	ASA	89	f	875	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
720	9	Placebo	ASA	84	m	20	Patient's request (however, patient is still being followed-up in the study)	
758	9	Placebo	ASA	88	f	798	Other reason: Patient has dementia syndrome, intake of study medication wasstopped at about June 2021.	
879	9	Placebo	ASA	72	m	183	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1192	9	Placebo	ASA	74	m	420	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1204	9	Placebo	ASA	75	m	362	Patient's request (however, patient is still being followed-up in the study)	
1213	9	Placebo	ASA	91	f	70	Patient's request (however, patient is still being followed-up in the study)	
1817	9	Placebo	ASA	74	f	377	Patient's request (however, patient is still being followed-up in the study)	
1974	9	Placebo	ASA	88	m	585	Death	
2406	9	Placebo	ASA	86	m	258	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2741	9	Placebo	ASA	72	m	37	Patient's request (however, patient is still being followed-up in the study)	
92	9	Placebo	no ASA	82	m	1521	Patient's request (however, patient is still being followed-up in the study)	
96	9	Placebo	no ASA	73	f	1088	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
697	9	Placebo	no ASA	92	m	182	Other reason: Diarrhea due to study medication intake	
830	9	Placebo	no ASA	90	m	541	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
878	9	Placebo	no ASA	84	f	27	Patient's request (however, patient is still being followed-up in the study)	
1570	9	Placebo	no ASA	73	m	736	Patient's request (however, patient is still being followed-up in the study)	
1847	9	Placebo	no ASA	75	m	590	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2408	9	Placebo	no ASA	76	f	92	Patient's request (however, patient is still being followed-up in the study)	
57	9	Edoxaban	ASA	78	m	76	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
66	9	Edoxaban	ASA	84	f	240	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
93	9	Edoxaban	ASA	84	m	722	Patient's request (however, patient is still being followed-up in the study)	
129	9	Edoxaban	ASA	77	f	305	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
153	9	Edoxaban	ASA	74	m	1256	Patient's request (however, patient is still being followed-up in the study)	
393	9	Edoxaban	ASA	88	m	365	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
485	9	Edoxaban	ASA	82	f	271	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
719	9	Edoxaban	ASA	90	f	374	Patient's request (however, patient is still being followed-up in the study)	
843	9	Edoxaban	ASA	77	m	19	Patient's request (however, patient is still being followed-up in the study)	
908	9	Edoxaban	ASA	71	m	858	Patient's request (however, patient is still being followed-up in the study)	
1126	9	Edoxaban	ASA	98	m	547	Patient completely withdraws consent to any further study participation	
1178	9	Edoxaban	ASA	82	f	599	Patient's request (however, patient is still being followed-up in the study)	
1278	9	Edoxaban	ASA	87	m	13	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1338	9	Edoxaban	ASA	88	m	115	Contraindication for oral anticoagulation in general	
1346	9	Edoxaban	ASA	80	f	14	Patient completely withdraws consent to any further study participation	
1816	9	Edoxaban	ASA	73	m	195	Patient's request (however, patient is still being followed-up in the study)	
46	9	Edoxaban	no ASA	84	f	1307	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
100	9	Edoxaban	no ASA	76	m	369	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
410	9	Edoxaban	no ASA	69	f	24	Patient's request (however, patient is still being followed-up in the study)	
536	9	Edoxaban	no ASA	80	f	392	Patient completely withdraws consent to any further study participation	
1692	9	Edoxaban	no ASA	80	m	361	Patient's request (however, patient is still being followed-up in the study)	
2297	9	Edoxaban	no ASA	80	f	19	Patient's request (however, patient is still being followed-up in the study)	
2615	9	Edoxaban	no ASA	77	m	189	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1582	12	Placebo	ASA	91	f	13	Patient's request (however, patient is still being followed-up in the study)	
1701	12	Placebo	ASA	73	m	243	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1787	12	Placebo	ASA	76	m	163	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2684	12	Placebo	ASA	67	m	6	Patient's request (however, patient is still being followed-up in the study)	
1698	12	Placebo	no ASA	85	f	0	Patient's request (however, patient is still being followed-up in the study)	
1760	12	Placebo	no ASA	94	f	546	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1775	12	Placebo	no ASA	75	m	40	Patient completely withdraws consent to any further study participation	
1581	12	Edoxaban	ASA	86	f	64	Contraindication for oral anticoagulation in general	
1706	12	Edoxaban	ASA	86	m	12	Death	
1752	12	Edoxaban	ASA	86	m	184	Death	
1651	12	Edoxaban	no ASA	78	m	362	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1789	12	Edoxaban	no ASA	91	m	25	Contraindication for oral anticoagulation in general	
1269	16	Placebo	ASA	81	m	517	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
440	16	Edoxaban	no ASA	66	m	324	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
446	17	Placebo	ASA	80	m	1490	Other reason: 4xAHRE (10Hr) on device interrogation: decision of investigator to stop studymedication and start open label NOAC (edoxaban 60 mg)	
364	17	Edoxaban	ASA	72	m	11	Other reason: macroscopic hematuria	
409	17	Edoxaban	no ASA	77	f	1343	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2021-09-23
263	19	Placebo	ASA	67	m	75	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
600	19	Placebo	ASA	90	m	1533	Contraindication for oral anticoagulation in general	
1633	19	Edoxaban	ASA	75	m	461	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
340	19	Edoxaban	no ASA	71	f	903	Patient's request (however, patient is still being followed-up in the study)	
805	19	Edoxaban	no ASA	77	m	1338	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
624	22	Edoxaban	ASA	71	m	234	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2019-03-01
504	23	Placebo	ASA	93	m	1092	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
692	23	Placebo	ASA	83	m	1072	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
234	23	Edoxaban	ASA	78	m	553	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
265	23	Edoxaban	ASA	78	m	545	Other reason: cognitive decline patient	
122	23	Edoxaban	no ASA	75	m	110	Patient's request (however, patient is still being followed-up in the study)	
150	33	Placebo	ASA	81	m	1411	Patient's request (however, patient is still being followed-up in the study)	
235	33	Edoxaban	ASA	74	m	907	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1206	33	Edoxaban	ASA	92	m	369	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1378	33	Edoxaban	ASA	82	m	8	Patient completely withdraws consent to any further study participation	
442	34	Placebo	ASA	93	f	64	Other reason: Anämia	
59	35	Placebo	ASA	92	m	8	Patient's request (however, patient is still being followed-up in the study)	
453	35	Placebo	ASA	91	m	88	Patient completely withdraws consent to any further study participation	
260	35	Edoxaban	no ASA	80	m	196	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
566	38	Placebo	ASA	72	m	8	Patient completely withdraws consent to any further study participation	
414	38	Placebo	no ASA	81	m	46	Patient's request (however, patient is still being followed-up in the study)	
305	38	Edoxaban	no ASA	79	f	12	Patient completely withdraws consent to any further study participation	
1351	39	Placebo	ASA	74	m	14	Patient's request (however, patient is still being followed-up in the study)	
1391	39	Placebo	ASA	71	m	157	Patient's request (however, patient is still being followed-up in the study)	
2005	39	Placebo	no ASA	79	m	357	Patient's request (however, patient is still being followed-up in the study)	
1186	39	Edoxaban	ASA	94	f	384	Patient completely withdraws consent to any further study participation	
300	40	Placebo	ASA	77	m	712	Other reason: The patient cannot be reached.	
861	40	Edoxaban	no ASA	82	m	14	Patient completely withdraws consent to any further study participation	
2250	42	Placebo	no ASA	80	f	365	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
567	42	Edoxaban	ASA	87	f	236	Patient's request (however, patient is still being followed-up in the study)	
2692	42	Edoxaban	ASA	75	m	7	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
397	43	Placebo	ASA	66	m	415	Patient's request (however, patient is still being followed-up in the study)	
845	43	Placebo	ASA	86	f	6	Patient completely withdraws consent to any further study participation	
258	43	Edoxaban	ASA	82	f	554	Patient's request (however, patient is still being followed-up in the study)	
472	44	Placebo	ASA	86	f	303	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1426	44	Placebo	ASA	84	m	303	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1274	44	Edoxaban	ASA	79	m	28	Patient's request (however, patient is still being followed-up in the study)	
2019	44	Edoxaban	ASA	81	m	415	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
95	46	Placebo	ASA	67	f	672	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
147	46	Placebo	ASA	86	m	220	Patient completely withdraws consent to any further study participation	
43	46	Edoxaban	ASA	78	m	917	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
69	46	Edoxaban	ASA	81	f	211	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
287	49	Placebo	ASA	78	m	196	Patient's request (however, patient is still being followed-up in the study)	
363	49	Placebo	no ASA	82	f	95	Patient's request (however, patient is still being followed-up in the study)	
321	53	Edoxaban	no ASA	83	f	300	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
587	57	Placebo	ASA	79	m	907	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
723	57	Placebo	ASA	83	m	955	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1300	57	Placebo	ASA	76	m	487	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1568	57	Placebo	ASA	81	m	9	Patient's request (however, patient is still being followed-up in the study)	
1928	57	Placebo	ASA	81	f	102	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2021-04-27
2551	57	Placebo	ASA	84	m	177	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
593	57	Edoxaban	ASA	83	m	887	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1324	57	Edoxaban	ASA	82	f	910	Patient's request (however, patient is still being followed-up in the study)	
1755	57	Edoxaban	ASA	81	m	283	Death	
24	59	Placebo	ASA	67	m	166	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
67	59	Placebo	ASA	79	m	384	Contraindication for oral anticoagulation in general	
119	59	Placebo	ASA	83	f	249	Patient completely withdraws consent to any further study participation	
466	59	Placebo	ASA	77	m	545	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
679	59	Placebo	ASA	77	m	43	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1161	59	Placebo	ASA	83	m	1105	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1451	59	Placebo	ASA	81	m	126	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1583	59	Placebo	ASA	93	m	195	Patient completely withdraws consent to any further study participation	
2211	59	Placebo	ASA	83	m	159	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
463	59	Placebo	no ASA	79	f	294	Patient's request (however, patient is still being followed-up in the study)	
467	59	Placebo	no ASA	78	f	849	Patient's request (however, patient is still being followed-up in the study)	
615	59	Placebo	no ASA	81	f	135	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
826	59	Placebo	no ASA	83	f	487	Other reason: unknown reason. in demission letter of sae 903 no reason explained. suspected because risk of falling.	
1230	59	Placebo	no ASA	78	m	131	Patient's request (however, patient is still being followed-up in the study)	
1422	59	Placebo	no ASA	84	m	653	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
98	59	Edoxaban	ASA	73	m	6	Death	
186	59	Edoxaban	ASA	65	m	195	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
380	59	Edoxaban	ASA	79	m	753	Contraindication for oral anticoagulation in general	
416	59	Edoxaban	ASA	90	f	553	Death	
493	59	Edoxaban	ASA	79	m	1512	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
528	59	Edoxaban	ASA	83	f	1408	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
655	59	Edoxaban	ASA	88	f	832	Contraindication for oral anticoagulation in general	
1105	59	Edoxaban	ASA	70	f	199	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1245	59	Edoxaban	ASA	90	m	883	Death	
1490	59	Edoxaban	ASA	86	m	187	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1579	59	Edoxaban	ASA	66	f	558	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
58	59	Edoxaban	no ASA	79	m	1414	Death	
149	59	Edoxaban	no ASA	79	m	909	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1140	59	Edoxaban	no ASA	82	f	179	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1634	59	Edoxaban	no ASA	85	f	356	Patient's request (however, patient is still being followed-up in the study)	
1920	59	Edoxaban	no ASA	87	f	372	Patient's request (however, patient is still being followed-up in the study)	
325	70	Placebo	ASA	80	m	617	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
511	70	Placebo	ASA	82	m	688	Death	
644	70	Placebo	ASA	80	f	1160	Patient completely withdraws consent to any further study participation	
765	70	Placebo	ASA	82	m	262	Patient's request (however, patient is still being followed-up in the study)	
995	70	Placebo	ASA	79	m	183	Patient's request (however, patient is still being followed-up in the study)	
1045	70	Placebo	ASA	77	m	182	Patient completely withdraws consent to any further study participation	
1148	70	Placebo	ASA	82	m	102	Patient's request (however, patient is still being followed-up in the study)	
1485	70	Placebo	ASA	81	f	778	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1751	70	Placebo	ASA	82	m	13	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1950	70	Placebo	ASA	76	m	353	Death	
2425	70	Placebo	ASA	85	m	8	Patient's request (however, patient is still being followed-up in the study)	
2686	70	Placebo	ASA	72	f	108	Patient's request (however, patient is still being followed-up in the study)	
151	70	Placebo	no ASA	89	f	365	Patient completely withdraws consent to any further study participation	
401	70	Placebo	no ASA	80	m	888	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
418	70	Placebo	no ASA	82	f	741	Patient completely withdraws consent to any further study participation	
479	70	Placebo	no ASA	88	f	205	Patient completely withdraws consent to any further study participation	
1114	70	Placebo	no ASA	76	m	341	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1714	70	Placebo	no ASA	87	m	321	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1730	70	Placebo	no ASA	84	m	45	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
105	70	Edoxaban	ASA	70	f	1150	Patient completely withdraws consent to any further study participation	
662	70	Edoxaban	ASA	81	m	5	Other reason: OP	
881	70	Edoxaban	ASA	85	m	97	Patient's request (however, patient is still being followed-up in the study)	
1808	70	Edoxaban	ASA	77	m	351	Patient completely withdraws consent to any further study participation	
2068	70	Edoxaban	ASA	74	m	151	Patient's request (however, patient is still being followed-up in the study)	
2182	70	Edoxaban	ASA	82	m	55	Patient's request (however, patient is still being followed-up in the study)	
16	70	Edoxaban	no ASA	77	m	1370	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
253	70	Edoxaban	no ASA	69	m	587	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
402	70	Edoxaban	no ASA	79	m	215	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
514	70	Edoxaban	no ASA	75	f	362	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1320	70	Edoxaban	no ASA	67	f	8	Patient completely withdraws consent to any further study participation	
1569	70	Edoxaban	no ASA	80	m	153	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1741	70	Edoxaban	no ASA	89	m	499	Death	
373	86	Placebo	ASA	75	m	9	Patient's request (however, patient is still being followed-up in the study)	
554	86	Placebo	no ASA	68	f	5	Patient's request (however, patient is still being followed-up in the study)	
1542	86	Placebo	no ASA	76	f	839	Patient's request (however, patient is still being followed-up in the study)	
338	86	Edoxaban	ASA	77	m	370	Patient's request (however, patient is still being followed-up in the study)	
352	86	Edoxaban	ASA	82	m	184	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1428	86	Edoxaban	ASA	84	m	899	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1189	86	Edoxaban	no ASA	80	f	48	Patient's request (however, patient is still being followed-up in the study)	
18	95	Placebo	ASA	78	f	197	Patient's request (however, patient is still being followed-up in the study)	
28	95	Placebo	ASA	73	f	15	Death	
38	95	Placebo	ASA	81	f	742	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
44	95	Placebo	ASA	80	m	1623	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
22	95	Placebo	no ASA	73	m	596	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
30	95	Placebo	no ASA	82	m	893	Other reason: Patient has dementia. His wife is scared to make something wrong with study medication and rejected new study medication	
71	95	Placebo	no ASA	77	m	872	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
534	95	Placebo	no ASA	65	m	51	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1368	95	Placebo	no ASA	79	f	421	Death	
10	95	Edoxaban	ASA	88	m	167	Patient's request (however, patient is still being followed-up in the study)	
14	95	Edoxaban	ASA	72	m	1775	Death	
53	95	Edoxaban	ASA	83	m	382	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1175	95	Edoxaban	ASA	83	f	1153	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
29	95	Edoxaban	no ASA	81	f	490	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
117	95	Edoxaban	no ASA	77	m	912	Other reason: indication for ASS and Clopidogrel in case of an stentimplantation	
202	95	Edoxaban	no ASA	72	m	163	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
533	95	Edoxaban	no ASA	81	f	653	Patient's request (however, patient is still being followed-up in the study)	
820	95	Edoxaban	no ASA	77	m	69	Patient's request (however, patient is still being followed-up in the study)	
4	100	Placebo	ASA	77	f	353	Patient's request (however, patient is still being followed-up in the study)	
846	100	Placebo	ASA	73	m	276	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
848	100	Placebo	ASA	71	f	1391	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
124	100	Edoxaban	ASA	77	m	1073	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
537	100	Edoxaban	ASA	94	m	558	Patient's request (however, patient is still being followed-up in the study)	
933	100	Edoxaban	ASA	83	m	1132	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1327	100	Edoxaban	ASA	78	f	910	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
201	109	Placebo	ASA	83	f	7	Patient's request (however, patient is still being followed-up in the study)	
39	113	Placebo	ASA	85	m	449	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
60	113	Placebo	ASA	88	m	343	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
37	113	Placebo	no ASA	75	m	870	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
62	113	Placebo	no ASA	85	m	1081	Patient completely withdraws consent to any further study participation	
154	113	Placebo	no ASA	80	m	895	Patient completely withdraws consent to any further study participation	
369	113	Edoxaban	ASA	86	f	728	Patient completely withdraws consent to any further study participation	
36	113	Edoxaban	no ASA	80	m	7	Patient's request (however, patient is still being followed-up in the study)	
40	113	Edoxaban	no ASA	80	m	71	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
65	113	Edoxaban	no ASA	80	m	724	Patient completely withdraws consent to any further study participation	
411	113	Edoxaban	no ASA	78	m	184	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
17	117	Placebo	ASA	66	f	179	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
23	117	Placebo	ASA	91	m	1292	Patient's request (however, patient is still being followed-up in the study)	
1155	117	Placebo	no ASA	86	m	450	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1739	117	Placebo	no ASA	85	f	368	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
264	117	Edoxaban	ASA	80	m	547	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
320	117	Edoxaban	ASA	83	m	246	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
663	117	Edoxaban	ASA	79	m	542	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
943	117	Edoxaban	ASA	83	m	416	Death	
56	121	Placebo	ASA	92	m	1418	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
103	121	Placebo	ASA	88	f	188	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
355	121	Placebo	ASA	84	m	896	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
130	121	Placebo	no ASA	82	f	336	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
41	121	Edoxaban	ASA	72	f	84	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
109	121	Edoxaban	ASA	76	m	150	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	2017-08-15
359	121	Edoxaban	ASA	81	m	13	Patient completely withdraws consent to any further study participation	
111	121	Edoxaban	no ASA	79	m	370	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1612	132	Placebo	ASA	74	m	458	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1958	132	Placebo	ASA	84	m	285	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
8	132	Placebo	no ASA	77	m	219	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
266	132	Placebo	no ASA	77	m	106	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1383	132	Placebo	no ASA	85	m	909	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
295	132	Edoxaban	ASA	85	f	903	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1902	132	Edoxaban	ASA	81	m	556	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
6	132	Edoxaban	no ASA	69	f	88	Patient completely withdraws consent to any further study participation	
51	132	Edoxaban	no ASA	79	f	420	Other reason: PI descision due to worsening dementia	
70	132	Edoxaban	no ASA	78	m	428	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
400	133	Placebo	ASA	75	m	25	Patient completely withdraws consent to any further study participation	
618	133	Placebo	ASA	81	m	732	Patient completely withdraws consent to any further study participation	
477	133	Placebo	no ASA	75	m	181	Patient completely withdraws consent to any further study participation	
82	133	Edoxaban	ASA	84	m	1096	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
188	133	Edoxaban	ASA	78	m	1645	Patient's request (however, patient is still being followed-up in the study)	
97	135	Placebo	no ASA	82	m	30	Patient completely withdraws consent to any further study participation	
376	135	Placebo	no ASA	81	m	131	Patient completely withdraws consent to any further study participation	
328	135	Edoxaban	ASA	80	m	567	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
339	135	Edoxaban	ASA	77	m	167	Patient completely withdraws consent to any further study participation	
7	136	Placebo	ASA	72	m	3	Death	
33	136	Placebo	ASA	79	m	15	Patient completely withdraws consent to any further study participation	
34	136	Edoxaban	ASA	87	f	1448	Patient completely withdraws consent to any further study participation	
132	136	Edoxaban	ASA	79	m	504	Patient completely withdraws consent to any further study participation	
114	140	Placebo	ASA	87	f	1933	Death	
171	140	Placebo	ASA	82	m	553	Contraindication for oral anticoagulation in general	
257	140	Placebo	ASA	81	f	5	Patient's request (however, patient is still being followed-up in the study)	
399	140	Placebo	ASA	75	m	196	Patient's request (however, patient is still being followed-up in the study)	
482	140	Placebo	ASA	82	m	84	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
551	140	Placebo	ASA	81	m	1220	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
565	140	Placebo	ASA	72	m	1172	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
803	140	Placebo	ASA	82	f	1160	Patient's request (however, patient is still being followed-up in the study)	
1094	140	Placebo	ASA	82	m	16	Other reason: Due to an esophageal stenosis, the patient has severe swallowing problems and therefore can not continue to take the medication	
1655	140	Placebo	ASA	72	m	364	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1930	140	Placebo	ASA	84	f	358	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
68	140	Placebo	no ASA	75	f	368	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
99	140	Placebo	no ASA	76	m	0	Patient completely withdraws consent to any further study participation	
113	140	Placebo	no ASA	85	m	491	Patient completely withdraws consent to any further study participation	
539	140	Placebo	no ASA	89	m	1057	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
669	140	Placebo	no ASA	78	f	461	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1101	140	Placebo	no ASA	83	f	700	Patient's request (however, patient is still being followed-up in the study)	
1826	140	Placebo	no ASA	82	m	658	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1926	140	Placebo	no ASA	70	f	88	Death	
136	140	Edoxaban	ASA	72	m	815	Patient's request (however, patient is still being followed-up in the study)	
252	140	Edoxaban	ASA	86	m	10	Patient completely withdraws consent to any further study participation	
254	140	Edoxaban	ASA	84	f	354	Other reason: no high-frequency episodes and multiple morbidities with recurrent interventions at peripher aterial disease	
436	140	Edoxaban	ASA	78	f	570	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
717	140	Edoxaban	ASA	87	m	1174	Other reason: Progressive dementia after the death of the wife - study medication ended in consultation with the general practitioner	
841	140	Edoxaban	ASA	85	m	129	Patient's request (however, patient is still being followed-up in the study)	
1266	140	Edoxaban	ASA	86	m	204	Patient completely withdraws consent to any further study participation	
1394	140	Edoxaban	ASA	86	f	471	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1406	140	Edoxaban	ASA	82	m	545	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1781	140	Edoxaban	ASA	81	f	497	Patient's request (however, patient is still being followed-up in the study)	
2357	140	Edoxaban	ASA	74	m	175	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
200	140	Edoxaban	no ASA	75	f	364	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
212	140	Edoxaban	no ASA	88	m	883	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
251	140	Edoxaban	no ASA	81	m	21	Patient's request (however, patient is still being followed-up in the study)	
331	140	Edoxaban	no ASA	85	m	133	Patient's request (however, patient is still being followed-up in the study)	
568	140	Edoxaban	no ASA	75	m	7	Patient's request (however, patient is still being followed-up in the study)	
592	140	Edoxaban	no ASA	85	f	909	Patient's request (however, patient is still being followed-up in the study)	
919	140	Edoxaban	no ASA	76	m	709	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1929	140	Edoxaban	no ASA	83	m	181	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2691	140	Edoxaban	no ASA	81	m	140	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
671	145	Placebo	ASA	89	m	358	Patient completely withdraws consent to any further study participation	
319	153	Placebo	ASA	75	m	80	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1935	153	Placebo	ASA	74	m	141	Patient completely withdraws consent to any further study participation	
1545	153	Placebo	no ASA	85	m	368	Patient completely withdraws consent to any further study participation	
106	153	Edoxaban	ASA	79	m	76	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
35	153	Edoxaban	no ASA	84	m	80	Other reason: the patient lost his medication. he was in such a poor condition that the end of life was in the foreseeable future	
110	154	Placebo	ASA	82	m	1397	Patient's request (however, patient is still being followed-up in the study)	
297	154	Placebo	ASA	92	f	350	Patient completely withdraws consent to any further study participation	
181	154	Edoxaban	ASA	77	m	4	Patient's request (however, patient is still being followed-up in the study)	
688	154	Edoxaban	ASA	87	m	57	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
294	161	Placebo	ASA	71	m	1450	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
361	161	Placebo	ASA	78	m	4	Patient completely withdraws consent to any further study participation	
395	161	Placebo	ASA	66	m	553	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
978	161	Placebo	ASA	78	m	146	Patient's request (however, patient is still being followed-up in the study)	
2485	161	Placebo	ASA	67	m	20	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
230	161	Edoxaban	ASA	84	m	462	Patient's request (however, patient is still being followed-up in the study)	
302	161	Edoxaban	ASA	80	f	757	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
459	161	Edoxaban	ASA	86	m	1178	Death	
2304	171	Edoxaban	ASA	76	m	5	Patient's request (however, patient is still being followed-up in the study)	
2255	171	Edoxaban	no ASA	71	m	358	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
585	173	Placebo	ASA	75	m	371	Patient completely withdraws consent to any further study participation	
2124	173	Placebo	ASA	73	m	459	Patient's request (however, patient is still being followed-up in the study)	
2342	173	Placebo	ASA	77	m	22	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
167	173	Placebo	no ASA	68	m	370	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
553	173	Placebo	no ASA	84	m	23	Patient's request (however, patient is still being followed-up in the study)	
1014	173	Placebo	no ASA	87	m	13	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1067	173	Placebo	no ASA	68	m	481	Patient completely withdraws consent to any further study participation	
1319	173	Placebo	no ASA	85	m	650	Death	
242	173	Edoxaban	ASA	73	m	548	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1712	173	Edoxaban	ASA	66	m	494	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1758	173	Edoxaban	ASA	71	m	293	Death	
2453	173	Edoxaban	ASA	77	m	13	Patient's request (however, patient is still being followed-up in the study)	
314	173	Edoxaban	no ASA	72	f	851	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
322	173	Edoxaban	no ASA	92	m	15	Patient completely withdraws consent to any further study participation	
975	173	Edoxaban	no ASA	88	m	744	Patient's request (however, patient is still being followed-up in the study)	
1716	173	Edoxaban	no ASA	84	m	718	Patient's request (however, patient is still being followed-up in the study)	
1008	174	Placebo	ASA	73	f	362	Death	
306	174	Edoxaban	ASA	84	m	57	Patient's request (however, patient is still being followed-up in the study)	
613	174	Edoxaban	ASA	65	m	97	Contraindication for oral anticoagulation in general	
1672	174	Edoxaban	no ASA	76	f	453	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2456	175	Placebo	ASA	78	m	167	Other reason: PATIENT FEELS TIRED AND HAS DIFICULTIES TO WALK. PRIVATE DOCTOR RECOMMENDS TO STOP STUDY MEDICATION	
515	175	Placebo	no ASA	81	f	5	Patient's request (however, patient is still being followed-up in the study)	
2536	175	Placebo	no ASA	76	f	15	Patient's request (however, patient is still being followed-up in the study)	
487	175	Edoxaban	no ASA	75	f	712	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1035	175	Edoxaban	no ASA	86	m	557	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
128	179	Placebo	ASA	68	f	165	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1182	179	Placebo	no ASA	83	f	184	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1868	179	Placebo	no ASA	72	m	113	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2193	179	Edoxaban	ASA	81	m	15	Patient completely withdraws consent to any further study participation	
1132	179	Edoxaban	no ASA	78	f	175	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1331	189	Edoxaban	ASA	82	f	98	Other reason: study treatment intolerance with nausea dizziness headache and sleep disorder	
412	195	Placebo	ASA	81	m	1359	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
633	195	Placebo	ASA	84	f	347	Patient's request (however, patient is still being followed-up in the study)	
1004	195	Placebo	ASA	72	m	990	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
396	195	Placebo	no ASA	71	m	68	Patient's request (however, patient is still being followed-up in the study)	
1233	195	Placebo	no ASA	82	m	23	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
398	195	Edoxaban	ASA	71	m	181	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
519	195	Edoxaban	ASA	84	m	1018	Patient completely withdraws consent to any further study participation	
617	195	Edoxaban	ASA	70	m	270	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1411	195	Edoxaban	ASA	72	m	531	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
283	195	Edoxaban	no ASA	82	m	37	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1857	198	Placebo	ASA	73	m	197	Patient's request (however, patient is still being followed-up in the study)	
144	198	Placebo	no ASA	73	f	722	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1125	202	Placebo	no ASA	79	m	177	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
556	202	Edoxaban	ASA	88	f	14	Other reason: the patient has stomach and leg pain after the start of the study treatment and does not want to continue taking this treatment	
348	202	Edoxaban	no ASA	80	f	63	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
419	202	Edoxaban	no ASA	71	f	1084	Patient completely withdraws consent to any further study participation	
184	205	Placebo	ASA	88	m	16	Patient's request (however, patient is still being followed-up in the study)	
285	205	Placebo	ASA	71	m	749	Patient completely withdraws consent to any further study participation	
366	205	Placebo	ASA	98	f	32	Death	
748	205	Placebo	ASA	88	f	846	Other reason: Patient admitted to hospital and medication stopped by medical team	
207	205	Placebo	no ASA	82	m	1093	Contraindication for oral anticoagulation in general	
80	205	Edoxaban	ASA	88	f	365	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
336	205	Edoxaban	ASA	77	m	363	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
946	205	Edoxaban	ASA	72	m	22	Patient's request (however, patient is still being followed-up in the study)	
182	205	Edoxaban	no ASA	76	m	182	Patient completely withdraws consent to any further study participation	
516	208	Placebo	no ASA	83	m	1016	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
524	208	Placebo	no ASA	83	m	1184	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1036	208	Edoxaban	ASA	72	m	62	Patient completely withdraws consent to any further study participation	
1306	208	Edoxaban	no ASA	83	m	415	Death	
1449	208	Edoxaban	no ASA	66	m	6	Patient's request (however, patient is still being followed-up in the study)	
79	209	Placebo	ASA	86	m	1480	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
143	211	Placebo	ASA	81	m	940	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
250	211	Placebo	ASA	82	m	34	Patient's request (however, patient is still being followed-up in the study)	
204	211	Edoxaban	ASA	90	m	3	Patient completely withdraws consent to any further study participation	
356	211	Edoxaban	ASA	88	m	376	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
49	217	Placebo	no ASA	79	m	2041	Patient's request (however, patient is still being followed-up in the study)	
293	226	Placebo	ASA	79	m	1388	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
648	226	Placebo	ASA	74	m	18	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1400	226	Placebo	ASA	78	m	815	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1434	226	Placebo	ASA	89	f	845	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1630	226	Placebo	ASA	79	f	589	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1710	226	Placebo	no ASA	79	m	368	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2259	226	Placebo	no ASA	75	m	373	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
413	226	Edoxaban	ASA	84	m	553	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1670	226	Edoxaban	ASA	90	m	162	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2120	226	Edoxaban	ASA	77	m	108	Patient's request (however, patient is still being followed-up in the study)	
1164	226	Edoxaban	no ASA	70	f	173	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1019	232	Edoxaban	ASA	83	m	900	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
749	232	Edoxaban	no ASA	72	m	405	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
747	264	Placebo	ASA	74	m	1106	Patient's request (however, patient is still being followed-up in the study)	
905	264	Placebo	ASA	72	m	1007	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1544	264	Placebo	no ASA	81	m	573	Patient's request (however, patient is still being followed-up in the study)	
583	264	Edoxaban	ASA	78	m	353	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1330	264	Edoxaban	ASA	67	f	979	Death	
381	264	Edoxaban	no ASA	78	m	738	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1219	267	Placebo	ASA	66	m	280	Death	
832	267	Edoxaban	ASA	94	m	770	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
937	267	Edoxaban	ASA	86	f	324	Patient completely withdraws consent to any further study participation	
215	308	Placebo	ASA	79	m	186	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
267	308	Placebo	no ASA	83	m	1830	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
217	308	Edoxaban	no ASA	72	m	238	Patient's request (however, patient is still being followed-up in the study)	
501	326	Edoxaban	ASA	79	m	505	Patient completely withdraws consent to any further study participation	
72	377	Placebo	ASA	84	m	934	Patient's request (however, patient is still being followed-up in the study)	
175	377	Placebo	ASA	86	f	735	Patient's request (however, patient is still being followed-up in the study)	
83	377	Placebo	no ASA	84	m	170	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
163	406	Placebo	ASA	86	f	330	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1003	406	Placebo	ASA	86	m	1	Patient completely withdraws consent to any further study participation	
220	414	Placebo	ASA	81	m	352	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
433	414	Placebo	ASA	79	m	1298	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
704	414	Placebo	ASA	85	f	434	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1541	414	Placebo	ASA	77	m	15	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1654	414	Placebo	ASA	85	m	217	Death	
2571	414	Placebo	ASA	68	m	7	Patient's request (however, patient is still being followed-up in the study)	
988	414	Placebo	no ASA	77	m	812	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1626	414	Placebo	no ASA	89	f	459	Patient's request (however, patient is still being followed-up in the study)	
1941	414	Placebo	no ASA	73	m	49	Patient's request (however, patient is still being followed-up in the study)	
2424	414	Placebo	no ASA	92	m	164	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
268	414	Edoxaban	ASA	79	m	347	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
970	414	Edoxaban	ASA	95	m	972	Contraindication for oral anticoagulation in general	
1783	414	Edoxaban	ASA	89	m	280	Death	
1943	414	Edoxaban	ASA	88	m	178	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2174	414	Edoxaban	ASA	72	m	157	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2469	414	Edoxaban	ASA	75	m	152	Contraindication for oral anticoagulation in general	
246	414	Edoxaban	no ASA	102	f	1473	Death	
1510	414	Edoxaban	no ASA	69	m	400	Other reason: hematuria in NOAH, we interrupted the protocol, with immediate cessation of hematuria	
2183	414	Edoxaban	no ASA	73	m	215	Contraindication for oral anticoagulation in general	
2570	414	Edoxaban	no ASA	75	m	39	Contraindication for oral anticoagulation in general	
86	416	Placebo	no ASA	84	f	50	Patient's request (however, patient is still being followed-up in the study)	
125	416	Placebo	no ASA	77	f	543	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
445	416	Placebo	no ASA	78	f	75	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
547	416	Placebo	no ASA	85	f	1240	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
84	416	Edoxaban	no ASA	80	f	36	Patient's request (however, patient is still being followed-up in the study)	
469	416	Edoxaban	no ASA	79	f	31	Patient completely withdraws consent to any further study participation	
494	419	Placebo	ASA	79	f	1483	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1858	419	Placebo	ASA	85	m	98	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
244	419	Placebo	no ASA	70	m	731	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
464	419	Placebo	no ASA	70	m	1093	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
690	419	Placebo	no ASA	66	m	342	Death	
1137	419	Placebo	no ASA	89	f	194	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
247	419	Edoxaban	ASA	75	f	1081	Other reason: We didn't supply a new study mdication because the 36 month visit was supposed to be the end of the study. The last dose of medication was taken approximately the day before the visit	
1260	419	Edoxaban	ASA	70	m	78	Patient completely withdraws consent to any further study participation	
2083	419	Edoxaban	ASA	80	m	379	Other reason: sublavian stenosis, advised ASA	2022-12-28
2207	419	Edoxaban	ASA	82	m	112	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
211	419	Edoxaban	no ASA	65	m	337	Patient's request (however, patient is still being followed-up in the study)	
323	419	Edoxaban	no ASA	81	f	1133	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
637	419	Edoxaban	no ASA	89	f	1464	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2022-12-28
2303	419	Edoxaban	no ASA	77	f	365	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
116	421	Placebo	ASA	67	m	42	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	2017-05-08
157	421	Placebo	ASA	83	m	25	Death	
161	421	Placebo	ASA	79	f	188	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
828	421	Placebo	ASA	82	m	118	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1000	421	Placebo	ASA	78	m	179	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1841	421	Placebo	ASA	84	m	14	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1884	421	Placebo	ASA	86	m	10	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1949	421	Placebo	ASA	72	m	553	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2227	421	Placebo	ASA	87	m	183	Patient completely withdraws consent to any further study participation	
2325	421	Placebo	ASA	78	m	7	Patient's request (however, patient is still being followed-up in the study)	
2414	421	Placebo	ASA	92	f	74	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2604	421	Placebo	ASA	75	m	6	Patient's request (however, patient is still being followed-up in the study)	
55	421	Placebo	no ASA	78	m	761	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
78	421	Placebo	no ASA	80	f	4	Patient completely withdraws consent to any further study participation	
544	421	Placebo	no ASA	79	m	13	Patient's request (however, patient is still being followed-up in the study)	
685	421	Placebo	no ASA	71	m	1462	Patient's request (however, patient is still being followed-up in the study)	
768	421	Placebo	no ASA	86	m	167	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1216	421	Placebo	no ASA	83	m	954	Other reason: received enoxaparin s.c. instead of study med. as far as traceable, the reason for this change is not traceable	
1357	421	Placebo	no ASA	70	m	30	Patient's request (however, patient is still being followed-up in the study)	
1505	421	Placebo	no ASA	76	m	4	Patient's request (however, patient is still being followed-up in the study)	
1806	421	Placebo	no ASA	67	f	438	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2021-12-13
2232	421	Placebo	no ASA	73	m	0	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2264	421	Placebo	no ASA	69	f	0	Patient's request (however, patient is still being followed-up in the study)	
2283	421	Placebo	no ASA	88	m	160	Death	
77	421	Edoxaban	ASA	67	m	888	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
236	421	Edoxaban	ASA	70	f	210	Patient's request (however, patient is still being followed-up in the study)	
353	421	Edoxaban	ASA	78	m	722	Other reason: Physican's decision after evaluation of risk of another bleeding	
503	421	Edoxaban	ASA	76	m	392	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
985	421	Edoxaban	ASA	81	m	737	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1046	421	Edoxaban	ASA	73	m	371	Patient completely withdraws consent to any further study participation	
1225	421	Edoxaban	ASA	87	m	409	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1307	421	Edoxaban	ASA	84	m	633	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1590	421	Edoxaban	ASA	90	m	839	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1602	421	Edoxaban	ASA	72	m	64	Other reason: After intense discussion with neurologic specialists, expressed wish for unblinding, so anblinding was done and open label medication was administered.	2020-09-23

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1883	421	Edoxaban	ASA	73	m	279	Patient's request (however, patient is still being followed-up in the study)	
1899	421	Edoxaban	ASA	92	m	557	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1940	421	Edoxaban	ASA	88	f	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1956	421	Edoxaban	ASA	75	m	15	Patient's request (however, patient is still being followed-up in the study)	
2033	421	Edoxaban	ASA	81	m	118	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2021-07-27
2034	421	Edoxaban	ASA	93	m	187	Patient's request (however, patient is still being followed-up in the study)	
2228	421	Edoxaban	ASA	69	m	352	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2457	421	Edoxaban	ASA	74	m	188	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2544	421	Edoxaban	ASA	80	m	79	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2596	421	Edoxaban	ASA	84	f	5	Patient's request (however, patient is still being followed-up in the study)	
2654	421	Edoxaban	ASA	77	m	69	Patient's request (however, patient is still being followed-up in the study)	
155	421	Edoxaban	no ASA	80	f	185	Patient's request (however, patient is still being followed-up in the study)	
290	421	Edoxaban	no ASA	71	m	18	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
500	421	Edoxaban	no ASA	83	m	29	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
854	421	Edoxaban	no ASA	77	m	26	Patient's request (however, patient is still being followed-up in the study)	
907	421	Edoxaban	no ASA	72	m	27	Patient's request (however, patient is still being followed-up in the study)	
1668	421	Edoxaban	no ASA	72	m	368	Death	
1991	421	Edoxaban	no ASA	81	f	520	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2152	421	Edoxaban	no ASA	84	m	359	Patient's request (however, patient is still being followed-up in the study)	
778	426	Placebo	ASA	83	m	103	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1642	426	Placebo	ASA	75	f	687	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1235	426	Placebo	no ASA	83	f	317	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
718	426	Edoxaban	ASA	72	f	194	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1468	426	Edoxaban	ASA	79	m	706	Patient's request (however, patient is still being followed-up in the study)	
1796	426	Edoxaban	no ASA	81	m	370	Contraindication for oral anticoagulation in general	
508	427	Placebo	ASA	86	m	3	Patient's request (however, patient is still being followed-up in the study)	
423	427	Placebo	no ASA	71	f	188	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
438	427	Edoxaban	ASA	72	m	188	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1089	427	Edoxaban	ASA	89	m	587	Patient's request (however, patient is still being followed-up in the study)	
721	428	Edoxaban	ASA	73	m	168	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2350	428	Edoxaban	ASA	68	m	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
326	428	Edoxaban	no ASA	84	f	279	Patient's request (however, patient is still being followed-up in the study)	
652	445	Placebo	ASA	92	f	363	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
785	445	Placebo	ASA	82	m	170	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
786	445	Placebo	ASA	78	m	474	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2674	445	Placebo	ASA	87	m	91	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
650	445	Edoxaban	ASA	79	f	112	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
651	445	Edoxaban	ASA	96	m	916	Patient's request (however, patient is still being followed-up in the study)	
1506	445	Edoxaban	ASA	81	m	735	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
784	445	Edoxaban	no ASA	85	f	650	Patient completely withdraws consent to any further study participation	
529	470	Edoxaban	ASA	82	m	1402	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
304	470	Edoxaban	no ASA	83	m	1457	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
76	479	Placebo	ASA	70	f	1269	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
535	479	Placebo	no ASA	91	m	156	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1246	487	Placebo	ASA	82	m	550	Patient's request (however, patient is still being followed-up in the study)	
1652	487	Placebo	no ASA	87	m	545	Patient's request (however, patient is still being followed-up in the study)	
405	487	Edoxaban	no ASA	80	m	159	Patient completely withdraws consent to any further study participation	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
2	488	Placebo	ASA	81	m	611	Other reason: anemia	
45	488	Placebo	ASA	87	m	34	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
47	488	Placebo	ASA	86	f	1087	Patient completely withdraws consent to any further study participation	
189	488	Placebo	ASA	83	f	716	Death	
206	488	Placebo	ASA	83	f	1147	Death	
370	488	Placebo	ASA	78	m	956	Other reason: PI Decision. During the trial, the patient developed dementia. His legal guardian (the wife) confirmed the ongoing of the study. But when the legal guardian died, the PI decided to stop the interventional product.	
1099	488	Placebo	ASA	87	f	235	Patient's request (however, patient is still being followed-up in the study)	
1532	488	Placebo	ASA	85	f	355	Patient's request (however, patient is still being followed-up in the study)	
5	488	Placebo	no ASA	68	f	706	Other reason: regulatory action	
134	488	Placebo	no ASA	89	m	1867	Death	
357	488	Placebo	no ASA	81	m	1092	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1361	488	Placebo	no ASA	82	f	1	Patient completely withdraws consent to any further study participation	
20	488	Edoxaban	ASA	80	m	418	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
27	488	Edoxaban	ASA	80	m	730	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
31	488	Edoxaban	ASA	89	m	1321	Contraindication for oral anticoagulation in general	
50	488	Edoxaban	ASA	74	m	465	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
135	488	Edoxaban	ASA	83	m	233	Patient completely withdraws consent to any further study participation	
213	488	Edoxaban	ASA	87	f	382	Patient's request (however, patient is still being followed-up in the study)	
261	488	Edoxaban	ASA	70	m	833	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
280	488	Edoxaban	ASA	79	m	86	Death	
318	488	Edoxaban	ASA	94	f	1519	Death	
343	488	Edoxaban	ASA	79	f	1169	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
390	488	Edoxaban	ASA	85	m	48	Patient completely withdraws consent to any further study participation	
810	488	Edoxaban	ASA	93	f	893	Death	
1244	488	Edoxaban	ASA	78	m	1010	Patient's request (however, patient is still being followed-up in the study)	
25	488	Edoxaban	no ASA	78	m	1981	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
42	488	Edoxaban	no ASA	66	m	587	Death	
121	488	Edoxaban	no ASA	90	m	732	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
139	488	Edoxaban	no ASA	86	m	10	Patient completely withdraws consent to any further study participation	
898	488	Edoxaban	no ASA	86	f	723	Patient's request (however, patient is still being followed-up in the study)	
2372	488	Edoxaban	no ASA	82	m	43	Patient completely withdraws consent to any further study participation	
334	502	Placebo	ASA	68	m	157	Patient's request (however, patient is still being followed-up in the study)	
835	502	Placebo	ASA	88	f	235	Patient completely withdraws consent to any further study participation	
1282	502	Placebo	ASA	69	m	739	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1283	502	Placebo	ASA	76	f	211	Patient's request (however, patient is still being followed-up in the study)	
1535	502	Placebo	ASA	82	m	100	Patient's request (however, patient is still being followed-up in the study)	
1585	502	Placebo	ASA	68	m	51	Patient's request (however, patient is still being followed-up in the study)	
270	502	Placebo	no ASA	92	m	181	Patient completely withdraws consent to any further study participation	
309	502	Placebo	no ASA	72	f	212	Patient's request (however, patient is still being followed-up in the study)	
602	502	Placebo	no ASA	75	m	156	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
166	502	Edoxaban	ASA	87	m	26	Patient's request (however, patient is still being followed-up in the study)	
195	502	Edoxaban	ASA	83	m	2	Patient completely withdraws consent to any further study participation	
2081	502	Edoxaban	ASA	76	m	81	Patient's request (however, patient is still being followed-up in the study)	
2496	502	Edoxaban	ASA	83	f	68	Patient's request (however, patient is still being followed-up in the study)	
102	502	Edoxaban	no ASA	76	m	599	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
133	502	Edoxaban	no ASA	80	m	364	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
227	502	Edoxaban	no ASA	86	m	1505	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
425	502	Edoxaban	no ASA	78	m	49	Patient's request (however, patient is still being followed-up in the study)	
1782	502	Edoxaban	no ASA	80	f	8	Patient completely withdraws consent to any further study participation	
456	514	Edoxaban	ASA	71	m	552	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2577	519	Edoxaban	ASA	75	f	172	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
255	529	Placebo	ASA	80	m	417	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1254	529	Placebo	ASA	85	m	56	Patient's request (however, patient is still being followed-up in the study)	
1399	529	Placebo	ASA	85	m	315	Death	
659	529	Placebo	no ASA	65	f	355	Other reason: Patient doesn´t want to continue with the study, despite this she acepts minimun monitoring	
1199	529	Placebo	no ASA	79	m	1024	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1635	529	Placebo	no ASA	78	f	189	Patient's request (however, patient is still being followed-up in the study)	
1813	529	Placebo	no ASA	83	m	388	Patient's request (however, patient is still being followed-up in the study)	
1848	529	Placebo	no ASA	78	m	387	Contraindication for oral anticoagulation in general	
2104	529	Placebo	no ASA	83	m	478	Patient's request (however, patient is still being followed-up in the study)	
2229	529	Placebo	no ASA	80	f	399	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
658	529	Edoxaban	ASA	72	f	19	Patient's request (however, patient is still being followed-up in the study)	
703	529	Edoxaban	ASA	86	m	1117	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1006	529	Edoxaban	ASA	76	m	181	Patient's request (however, patient is still being followed-up in the study)	
1083	529	Edoxaban	ASA	87	m	730	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1201	529	Edoxaban	ASA	69	f	3	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1234	529	Edoxaban	ASA	70	m	575	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1987	529	Edoxaban	ASA	84	m	13	Patient's request (however, patient is still being followed-up in the study)	
2459	529	Edoxaban	ASA	69	m	129	Other reason: wrong diagnosis of AHRE	
2659	529	Edoxaban	ASA	77	m	150	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
317	529	Edoxaban	no ASA	70	m	1281	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
447	529	Edoxaban	no ASA	73	m	158	Patient's request (however, patient is still being followed-up in the study)	
926	529	Edoxaban	no ASA	77	m	90	Patient's request (however, patient is still being followed-up in the study)	
1050	529	Edoxaban	no ASA	77	f	60	Patient completely withdraws consent to any further study participation	
1198	529	Edoxaban	no ASA	80	m	178	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1593	529	Edoxaban	no ASA	86	f	703	Patient's request (however, patient is still being followed-up in the study)	
1823	529	Edoxaban	no ASA	73	m	165	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1846	529	Edoxaban	no ASA	76	m	126	Patient completely withdraws consent to any further study participation	
1927	529	Edoxaban	no ASA	88	f	567	Patient's request (however, patient is still being followed-up in the study)	
2328	529	Edoxaban	no ASA	79	m	116	Patient's request (however, patient is still being followed-up in the study)	
315	530	Placebo	ASA	68	f	531	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
429	530	Placebo	no ASA	75	f	54	Patient's request (however, patient is still being followed-up in the study)	
1059	530	Edoxaban	ASA	77	m	888	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1513	530	Edoxaban	ASA	81	m	33	Death	
1521	530	Edoxaban	no ASA	83	f	3	Contraindication for oral anticoagulation in general	
241	531	Placebo	no ASA	81	m	728	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
311	532	Placebo	ASA	76	m	809	Death	
563	535	Placebo	no ASA	86	f	916	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
538	535	Edoxaban	ASA	84	f	178	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
335	535	Edoxaban	no ASA	76	m	1695	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
631	535	Edoxaban	no ASA	81	f	726	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
756	535	Edoxaban	no ASA	81	f	0	Patient's request (however, patient is still being followed-up in the study)	
1769	535	Edoxaban	no ASA	77	m	193	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
386	536	Placebo	ASA	84	m	707	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1328	536	Placebo	ASA	85	m	25	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
991	536	Placebo	no ASA	92	f	965	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
276	536	Edoxaban	ASA	77	m	63	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2017-11-16
417	541	Placebo	no ASA	78	m	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
855	541	Edoxaban	ASA	90	f	1284	Death	
347	542	Edoxaban	no ASA	74	f	1782	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
177	544	Placebo	ASA	70	f	721	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1336	544	Placebo	ASA	87	f	257	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2020-07-01
1476	544	Placebo	ASA	83	f	147	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1508	544	Placebo	ASA	73	m	184	Death	
137	544	Placebo	no ASA	85	f	0	Patient's request (however, patient is still being followed-up in the study)	
1854	544	Placebo	no ASA	82	f	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
178	544	Edoxaban	ASA	88	f	455	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
486	544	Edoxaban	ASA	85	f	571	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
958	544	Edoxaban	ASA	76	f	540	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1190	544	Edoxaban	ASA	73	m	874	Death	
1370	544	Edoxaban	ASA	71	m	907	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1683	544	Edoxaban	ASA	86	f	550	Patient's request (however, patient is still being followed-up in the study)	
773	544	Edoxaban	no ASA	75	f	178	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
839	544	Edoxaban	no ASA	67	f	189	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1345	544	Edoxaban	no ASA	80	m	394	Death	
1367	544	Edoxaban	no ASA	75	m	259	Contraindication for oral anticoagulation in general	
1517	547	Placebo	ASA	87	f	159	Patient's request (however, patient is still being followed-up in the study)	
273	547	Placebo	no ASA	84	m	727	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
715	547	Placebo	no ASA	78	f	434	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
918	547	Placebo	no ASA	84	m	350	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
922	547	Placebo	no ASA	84	m	1306	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1653	547	Placebo	no ASA	88	f	682	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2053	547	Placebo	no ASA	82	f	38	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
378	547	Edoxaban	ASA	74	m	29	Patient completely withdraws consent to any further study participation	
392	547	Edoxaban	ASA	83	m	812	Death	
1369	547	Edoxaban	ASA	86	m	276	Contraindication for oral anticoagulation in general	
2055	547	Edoxaban	ASA	83	m	26	Contraindication for oral anticoagulation in general	
2214	547	Edoxaban	ASA	67	m	40	Patient's request (however, patient is still being followed-up in the study)	
2411	547	Edoxaban	ASA	84	m	64	Patient's request (however, patient is still being followed-up in the study)	
2605	547	Edoxaban	ASA	79	m	150	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
573	547	Edoxaban	no ASA	80	m	12	Patient's request (however, patient is still being followed-up in the study)	
936	547	Edoxaban	no ASA	81	f	574	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
996	547	Edoxaban	no ASA	70	f	97	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1938	547	Edoxaban	no ASA	87	f	621	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
667	557	Placebo	ASA	85	m	145	Contraindication for oral anticoagulation in general	
733	557	Placebo	ASA	79	f	182	Other reason: New diagnosis of JAK2 myeloproliferative disorder hence has to be on aspirin.	
460	557	Placebo	no ASA	69	m	1647	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
530	557	Placebo	no ASA	80	m	1062	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1117	557	Placebo	no ASA	89	m	452	Patient's request (however, patient is still being followed-up in the study)	
502	557	Edoxaban	ASA	86	f	1129	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
714	557	Edoxaban	ASA	75	m	185	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
598	557	Edoxaban	no ASA	78	f	78	Patient's request (however, patient is still being followed-up in the study)	
1232	557	Edoxaban	no ASA	76	f	103	Patient's request (however, patient is still being followed-up in the study)	
462	564	Placebo	ASA	89	f	8	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1110	564	Placebo	ASA	84	m	270	Other reason: SAE (reason for study drug not conform to protocole)	
389	564	Placebo	no ASA	84	f	59	Death	
490	564	Edoxaban	ASA	69	m	205	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
974	564	Edoxaban	ASA	82	f	647	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
779	564	Edoxaban	no ASA	69	m	57	Other reason: minor bleeding of the gums	
165	566	Edoxaban	ASA	79	m	545	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
344	577	Placebo	no ASA	80	m	29	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
377	605	Placebo	ASA	69	m	1189	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
298	605	Edoxaban	ASA	81	m	1076	Patient completely withdraws consent to any further study participation	
572	608	Placebo	ASA	77	m	34	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
816	608	Placebo	ASA	80	m	782	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
868	608	Placebo	ASA	81	m	1273	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1484	608	Placebo	ASA	88	m	899	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
903	608	Placebo	no ASA	77	f	543	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1091	608	Placebo	no ASA	93	f	533	Patient's request (however, patient is still being followed-up in the study)	
2402	608	Placebo	no ASA	82	m	230	Other reason: altered general condition due to Parkinson desease	
869	608	Edoxaban	ASA	70	m	1098	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
973	608	Edoxaban	ASA	85	m	898	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2036	608	Edoxaban	ASA	88	f	4	Patient's request (however, patient is still being followed-up in the study)	
954	608	Edoxaban	no ASA	81	m	184	Patient completely withdraws consent to any further study participation	
1471	608	Edoxaban	no ASA	86	m	178	Patient's request (however, patient is still being followed-up in the study)	
601	619	Edoxaban	no ASA	89	f	1053	Other reason: atrial flutter	
286	641	Placebo	ASA	73	m	212	Patient completely withdraws consent to any further study participation	
643	641	Placebo	ASA	89	f	164	Death	
478	641	Placebo	no ASA	82	f	37	Death	
632	641	Placebo	no ASA	78	m	301	Death	
1430	641	Placebo	no ASA	78	m	216	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1498	641	Placebo	no ASA	67	f	181	Patient completely withdraws consent to any further study participation	
115	641	Edoxaban	ASA	75	m	743	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
238	641	Edoxaban	ASA	76	m	178	Patient completely withdraws consent to any further study participation	
1167	641	Edoxaban	ASA	83	m	182	Patient completely withdraws consent to any further study participation	
262	641	Edoxaban	no ASA	73	m	1317	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
274	641	Edoxaban	no ASA	67	m	775	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
292	641	Edoxaban	no ASA	81	f	1379	Patient's request (however, patient is still being followed-up in the study)	
1015	641	Edoxaban	no ASA	78	m	20	Death	
1828	641	Edoxaban	no ASA	77	m	562	Patient's request (however, patient is still being followed-up in the study)	
1855	641	Edoxaban	no ASA	70	m	665	Patient's request (however, patient is still being followed-up in the study)	
2448	653	Edoxaban	ASA	89	f	174	Patient's request (however, patient is still being followed-up in the study)	
152	655	Placebo	ASA	71	f	1294	Patient's request (however, patient is still being followed-up in the study)	
465	655	Placebo	ASA	90	m	709	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
560	655	Placebo	no ASA	75	m	1000	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
597	655	Placebo	no ASA	85	m	549	Patient completely withdraws consent to any further study participation	
379	655	Edoxaban	ASA	84	m	193	Patient completely withdraws consent to any further study participation	
549	655	Edoxaban	ASA	76	m	538	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
559	655	Edoxaban	ASA	81	m	1478	Other reason: patient and our decision, because of his extra-cardiological disease and limits	
461	655	Edoxaban	no ASA	80	f	897	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
579	663	Placebo	no ASA	75	f	560	Patient completely withdraws consent to any further study participation	
223	663	Edoxaban	no ASA	75	m	576	Death	
259	669	Placebo	ASA	70	m	1026	Patient completely withdraws consent to any further study participation	
1220	669	Placebo	no ASA	83	m	147	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
450	669	Edoxaban	ASA	72	f	1202	Patient completely withdraws consent to any further study participation	
1075	669	Edoxaban	no ASA	71	m	915	Patient completely withdraws consent to any further study participation	
1723	669	Edoxaban	no ASA	78	f	81	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
269	673	Placebo	ASA	92	m	811	Other reason: Patient is not willing to continue intake study medication. Due to impaired cognitive status patient is not able to came study visits. On 25 November 2019 patient's family member brought back the study medication.	
2234	673	Placebo	ASA	84	m	267	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
87	673	Placebo	no ASA	82	f	512	Death	
194	673	Placebo	no ASA	84	m	968	Other reason: Clinical decission due to end-stage disease	
821	673	Placebo	no ASA	82	f	545	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1150	673	Placebo	no ASA	83	m	492	Death	
1287	673	Placebo	no ASA	81	m	911	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1302	673	Placebo	no ASA	79	f	183	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1567	673	Placebo	no ASA	84	f	108	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1875	673	Placebo	no ASA	85	f	254	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2086	673	Placebo	no ASA	92	m	182	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2268	673	Placebo	no ASA	83	m	332	Other reason: Interrupted after scheduled Percutaneous Coronary Interventions (PCI) and stent implated on 12AUG2022.	
948	673	Edoxaban	ASA	84	m	170	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1372	673	Edoxaban	ASA	83	m	735	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1713	673	Edoxaban	ASA	85	m	565	Death	
91	673	Edoxaban	no ASA	82	m	6	Contraindication for oral anticoagulation in general	
337	673	Edoxaban	no ASA	79	m	1064	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
427	673	Edoxaban	no ASA	90	m	12	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
707	673	Edoxaban	no ASA	90	f	213	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
837	673	Edoxaban	no ASA	78	m	1092	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1136	673	Edoxaban	no ASA	90	f	217	Patient's request (however, patient is still being followed-up in the study)	
1382	673	Edoxaban	no ASA	71	m	911	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1662	673	Edoxaban	no ASA	84	f	180	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1862	673	Edoxaban	no ASA	84	f	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1866	673	Edoxaban	no ASA	73	f	415	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2263	673	Edoxaban	no ASA	90	m	344	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2433	673	Edoxaban	no ASA	78	m	182	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1448	674	Placebo	ASA	77	m	369	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
886	674	Placebo	no ASA	70	m	916	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
307	675	Placebo	no ASA	74	m	291	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
345	675	Placebo	no ASA	81	f	127	Other reason: During the verification of source data it was noticed this patient had an episode of atrial flutter in 2010 and it was indicated he had to stop the participation on the study due to this (and the atrial rate of qualifiying episode) as he did not fulfill all inclusion criteria	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
240	675	Edoxaban	no ASA	75	m	437	Contraindication for oral anticoagulation in general	
507	675	Edoxaban	no ASA	82	m	183	Contraindication for oral anticoagulation in general	
1078	679	Edoxaban	no ASA	79	m	497	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
711	680	Placebo	ASA	83	m	1094	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
772	680	Placebo	ASA	70	m	105	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
783	680	Placebo	ASA	73	m	609	Death	
789	680	Placebo	ASA	79	m	134	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
836	680	Placebo	ASA	81	m	10	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
902	680	Placebo	ASA	78	f	316	Death	
1024	680	Placebo	ASA	72	m	1279	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1037	680	Placebo	ASA	74	m	92	Patient's request (however, patient is still being followed-up in the study)	
1079	680	Placebo	ASA	81	f	1101	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1129	680	Placebo	ASA	85	m	183	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1210	680	Placebo	ASA	66	m	340	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1339	680	Placebo	ASA	88	f	10	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1347	680	Placebo	ASA	71	m	67	Contraindication for oral anticoagulation in general	
1417	680	Placebo	ASA	91	m	14	Patient completely withdraws consent to any further study participation	
1455	680	Placebo	ASA	81	m	542	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1609	680	Placebo	ASA	76	m	362	Death	
1799	680	Placebo	ASA	91	m	546	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1821	680	Placebo	ASA	80	m	116	Other reason: itchy skin	
2317	680	Placebo	ASA	78	f	311	Patient's request (however, patient is still being followed-up in the study)	
851	680	Placebo	no ASA	80	f	756	Patient's request (however, patient is still being followed-up in the study)	
1156	680	Placebo	no ASA	83	m	186	Patient's request (however, patient is still being followed-up in the study)	
1474	680	Placebo	no ASA	74	f	179	Patient's request (however, patient is still being followed-up in the study)	
1955	680	Placebo	no ASA	76	m	222	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1960	680	Placebo	no ASA	72	f	57	Patient's request (however, patient is still being followed-up in the study)	
2031	680	Placebo	no ASA	76	m	352	Death	
2394	680	Placebo	no ASA	69	f	47	Other reason: AE	
2509	680	Placebo	no ASA	74	m	42	Patient's request (however, patient is still being followed-up in the study)	
623	680	Edoxaban	ASA	68	m	183	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
698	680	Edoxaban	ASA	89	f	511	Death	
887	680	Edoxaban	ASA	83	m	177	Patient's request (however, patient is still being followed-up in the study)	
934	680	Edoxaban	ASA	80	m	628	Patient's request (however, patient is still being followed-up in the study)	
993	680	Edoxaban	ASA	70	m	678	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
998	680	Edoxaban	ASA	86	f	0	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1034	680	Edoxaban	ASA	84	m	1256	Patient's request (however, patient is still being followed-up in the study)	
1054	680	Edoxaban	ASA	69	m	991	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1065	680	Edoxaban	ASA	80	f	544	Contraindication for oral anticoagulation in general	
1087	680	Edoxaban	ASA	70	m	460	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1153	680	Edoxaban	ASA	70	m	160	Contraindication for oral anticoagulation in general	
1292	680	Edoxaban	ASA	73	m	337	Death	
1363	680	Edoxaban	ASA	87	m	381	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1530	680	Edoxaban	ASA	82	f	612	Other reason: Doctors wanted the patient to take acetylsalicylic acid	
1657	680	Edoxaban	ASA	77	m	28	Other reason: ID intolerance - stomachache, meteorismus	
1664	680	Edoxaban	ASA	69	m	7	Other reason: intolerance of study drug - stomach ache, nausea	
1887	680	Edoxaban	ASA	88	m	333	Contraindication for oral anticoagulation in general	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
2065	680	Edoxaban	ASA	86	m	366	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2254	680	Edoxaban	ASA	77	f	0	Patient's request (however, patient is still being followed-up in the study)	
2410	680	Edoxaban	ASA	81	f	64	Patient's request (however, patient is still being followed-up in the study)	
2539	680	Edoxaban	ASA	71	m	128	Patient's request (however, patient is still being followed-up in the study)	
1071	680	Edoxaban	no ASA	69	m	370	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1349	680	Edoxaban	no ASA	88	m	424	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1512	680	Edoxaban	no ASA	73	f	485	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1681	680	Edoxaban	no ASA	77	f	545	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1419	685	Placebo	no ASA	77	m	558	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
403	685	Edoxaban	no ASA	85	f	13	Patient's request (however, patient is still being followed-up in the study)	
358	687	Placebo	ASA	72	m	181	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1157	687	Placebo	no ASA	74	f	173	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1614	687	Edoxaban	no ASA	75	f	785	Patient completely withdraws consent to any further study participation	
123	688	Placebo	ASA	78	m	113	Patient's request (however, patient is still being followed-up in the study)	
728	688	Placebo	ASA	73	m	382	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1209	688	Placebo	ASA	66	m	364	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1447	688	Placebo	ASA	77	f	607	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1601	688	Placebo	ASA	79	f	333	Patient's request (however, patient is still being followed-up in the study)	
2165	688	Placebo	ASA	83	m	272	Patient's request (however, patient is still being followed-up in the study)	
2281	688	Placebo	ASA	80	f	264	Contraindication for oral anticoagulation in general	
127	688	Placebo	no ASA	81	f	173	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
628	688	Placebo	no ASA	77	m	358	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
640	688	Placebo	no ASA	79	f	833	Patient's request (however, patient is still being followed-up in the study)	
842	688	Placebo	no ASA	82	m	157	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
112	688	Edoxaban	ASA	74	m	565	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
865	688	Edoxaban	ASA	70	m	894	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
983	688	Edoxaban	ASA	77	m	92	Patient's request (however, patient is still being followed-up in the study)	
1373	688	Edoxaban	ASA	83	m	222	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1833	688	Edoxaban	ASA	72	m	321	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2677	688	Edoxaban	ASA	80	m	38	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
231	688	Edoxaban	no ASA	82	m	1	Patient's request (however, patient is still being followed-up in the study)	
550	688	Edoxaban	no ASA	81	m	1449	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1877	688	Edoxaban	no ASA	73	m	88	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
726	689	Placebo	no ASA	74	f	1288	Patient's request (however, patient is still being followed-up in the study)	
578	689	Edoxaban	ASA	76	m	378	Patient completely withdraws consent to any further study participation	
232	690	Placebo	no ASA	83	m	1593	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1989	690	Edoxaban	no ASA	83	f	189	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1229	692	Edoxaban	ASA	67	m	48	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
475	698	Placebo	ASA	76	m	685	Patient completely withdraws consent to any further study participation	
1123	698	Placebo	ASA	66	m	672	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
162	698	Placebo	no ASA	75	m	729	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1176	698	Placebo	no ASA	83	m	1094	Patient's request (however, patient is still being followed-up in the study)	
219	698	Edoxaban	ASA	85	f	133	Contraindication for oral anticoagulation in general	
226	698	Edoxaban	ASA	77	m	1629	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
303	698	Edoxaban	ASA	74	m	344	Patient's request (however, patient is still being followed-up in the study)	
193	698	Edoxaban	no ASA	80	f	899	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2483	700	Placebo	ASA	72	m	130	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1296	702	Placebo	ASA	86	m	35	Patient's request (however, patient is still being followed-up in the study)	
289	702	Placebo	no ASA	79	m	1036	Patient completely withdraws consent to any further study participation	
1031	702	Placebo	no ASA	66	m	196	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
444	702	Edoxaban	ASA	88	m	908	Patient completely withdraws consent to any further study participation	
1381	702	Edoxaban	ASA	79	f	32	Patient completely withdraws consent to any further study participation	
158	702	Edoxaban	no ASA	84	m	298	Patient completely withdraws consent to any further study participation	
174	702	Edoxaban	no ASA	88	m	650	Patient completely withdraws consent to any further study participation	
635	704	Placebo	ASA	92	f	1410	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
761	704	Placebo	ASA	79	m	186	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1528	704	Placebo	no ASA	72	m	908	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
612	704	Edoxaban	ASA	74	m	164	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
649	704	Edoxaban	ASA	75	m	581	Patient completely withdraws consent to any further study participation	
1412	705	Placebo	ASA	72	m	370	Patient completely withdraws consent to any further study participation	
1682	705	Placebo	ASA	83	m	105	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1860	705	Placebo	ASA	86	m	22	Patient completely withdraws consent to any further study participation	
2437	705	Placebo	ASA	88	f	252	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2556	705	Placebo	ASA	75	m	147	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1748	705	Placebo	no ASA	76	m	573	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2731	705	Placebo	no ASA	85	f	22	Other reason: Mamma CA, Surgery Inv. duct. G2, ER90%; PR60%, Her2-	
1416	705	Edoxaban	ASA	80	m	412	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1509	705	Edoxaban	ASA	70	f	764	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1908	705	Edoxaban	ASA	76	f	540	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2137	705	Edoxaban	ASA	70	f	348	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2272	705	Edoxaban	ASA	70	m	186	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2367	705	Edoxaban	ASA	69	m	258	Patient's request (however, patient is still being followed-up in the study)	
2740	705	Edoxaban	ASA	78	m	5	Patient's request (however, patient is still being followed-up in the study)	
1621	705	Edoxaban	no ASA	75	f	69	Patient's request (however, patient is still being followed-up in the study)	
2153	705	Edoxaban	no ASA	66	f	54	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
282	706	Placebo	no ASA	94	m	178	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
689	706	Edoxaban	ASA	84	m	752	Patient's request (however, patient is still being followed-up in the study)	
208	706	Edoxaban	no ASA	73	m	875	Patient's request (however, patient is still being followed-up in the study)	
248	706	Edoxaban	no ASA	81	m	1146	Patient's request (however, patient is still being followed-up in the study)	
480	707	Placebo	ASA	81	m	636	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2019-12-24
437	707	Edoxaban	ASA	75	m	624	Contraindication for oral anticoagulation in general	
1226	707	Edoxaban	ASA	79	m	172	Contraindication for oral anticoagulation in general	
496	707	Edoxaban	no ASA	83	f	1036	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
522	707	Edoxaban	no ASA	80	f	540	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1873	707	Edoxaban	no ASA	73	m	280	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
512	708	Placebo	ASA	75	f	0	Patient completely withdraws consent to any further study participation	
525	708	Edoxaban	ASA	85	f	364	Patient's request (however, patient is still being followed-up in the study)	
374	708	Edoxaban	no ASA	94	f	823	Patient's request (however, patient is still being followed-up in the study)	
492	708	Edoxaban	no ASA	89	f	327	Patient's request (however, patient is still being followed-up in the study)	
360	711	Placebo	ASA	79	f	460	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2019-03-09
873	711	Placebo	ASA	84	m	510	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1253	711	Placebo	no ASA	79	m	1098	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
383	711	Edoxaban	ASA	76	m	1461	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
439	711	Edoxaban	no ASA	73	f	27	Patient's request (however, patient is still being followed-up in the study)	
518	711	Edoxaban	no ASA	86	m	172	Contraindication for oral anticoagulation in general	
611	711	Edoxaban	no ASA	86	m	827	Death	
1013	718	Edoxaban	no ASA	81	f	722	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1039	724	Placebo	ASA	80	f	555	Patient's request (however, patient is still being followed-up in the study)	
1061	724	Placebo	ASA	70	f	551	Other reason: Lost of the follow-up - NOAH put these acronyms	
1452	724	Placebo	ASA	70	m	533	Patient's request (however, patient is still being followed-up in the study)	
1076	724	Edoxaban	ASA	77	m	203	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2019-12-01
1286	724	Edoxaban	no ASA	74	m	900	Patient's request (however, patient is still being followed-up in the study)	
1042	725	Placebo	ASA	78	m	69	Other reason: patient reports that since March 2019 (since he started the drug), the presence of eczematous skin lesions in the limbs and trunk. patient reports that he has no itch. These lesions were initially treated with dermatological care without benefit (no documentation available).	
1392	725	Placebo	ASA	89	m	177	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1631	725	Placebo	ASA	76	m	728	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1947	725	Placebo	ASA	84	m	231	Contraindication for oral anticoagulation in general	
2041	725	Placebo	ASA	82	m	84	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2197	725	Placebo	ASA	95	m	198	Contraindication for oral anticoagulation in general	
2474	725	Placebo	ASA	77	m	182	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1154	725	Placebo	no ASA	79	m	332	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2102	725	Placebo	no ASA	77	f	358	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
782	725	Edoxaban	ASA	88	m	1424	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
822	725	Edoxaban	ASA	68	m	35	Other reason: Erytema left leg and left chest	
1470	725	Edoxaban	ASA	76	m	153	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1742	725	Edoxaban	ASA	83	f	547	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1954	725	Edoxaban	ASA	85	m	544	Patient's request (however, patient is still being followed-up in the study)	
2105	725	Edoxaban	ASA	69	m	7	Contraindication for oral anticoagulation in general	
2462	725	Edoxaban	ASA	73	m	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2494	725	Edoxaban	ASA	70	m	3	Contraindication for oral anticoagulation in general	
1223	725	Edoxaban	no ASA	88	m	1	Patient completely withdraws consent to any further study participation	
1326	725	Edoxaban	no ASA	86	f	78	Patient's request (however, patient is still being followed-up in the study)	
1620	725	Edoxaban	no ASA	73	m	175	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1839	725	Edoxaban	no ASA	77	m	49	Death	
1124	728	Placebo	no ASA	78	m	1141	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
387	728	Edoxaban	no ASA	82	m	664	Other reason: On advice of his cancer specialist.	
452	728	Edoxaban	no ASA	77	m	2	Patient's request (however, patient is still being followed-up in the study)	
883	728	Edoxaban	no ASA	75	f	1295	Patient's request (however, patient is still being followed-up in the study)	
1560	730	Placebo	no ASA	90	f	521	Death	
799	735	Placebo	ASA	73	m	371	Contraindication for oral anticoagulation in general	
925	740	Placebo	ASA	88	m	923	Patient's request (however, patient is still being followed-up in the study)	
1886	740	Placebo	ASA	78	f	304	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
431	740	Edoxaban	ASA	89	m	539	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1058	740	Edoxaban	ASA	79	f	185	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
866	740	Edoxaban	no ASA	79	f	278	Patient's request (however, patient is still being followed-up in the study)	
483	741	Placebo	no ASA	79	m	744	Patient's request (however, patient is still being followed-up in the study)	
484	741	Placebo	no ASA	87	m	1114	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1825	741	Placebo	no ASA	80	m	357	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1836	741	Placebo	no ASA	79	m	182	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1850	741	Placebo	no ASA	85	m	688	Other reason: trial medication not taken following SAE 02023	
2315	741	Placebo	no ASA	77	m	128	Patient's request (however, patient is still being followed-up in the study)	
840	741	Edoxaban	ASA	79	m	529	Patient's request (however, patient is still being followed-up in the study)	
368	741	Edoxaban	no ASA	86	m	726	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
415	741	Edoxaban	no ASA	85	f	1040	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
435	741	Edoxaban	no ASA	78	m	166	Other reason: Investigator decision - gastrointestinal side-effects were affecting patient's quality of life and the patient was not complying with the drug regimen as a result.	
1356	741	Edoxaban	no ASA	78	m	531	Patient's request (however, patient is still being followed-up in the study)	
1909	741	Edoxaban	no ASA	79	m	17	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2253	741	Edoxaban	no ASA	74	m	17	Patient's request (however, patient is still being followed-up in the study)	
332	748	Placebo	ASA	75	m	1413	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
576	748	Placebo	ASA	84	f	1	Patient completely withdraws consent to any further study participation	
604	748	Placebo	ASA	82	f	317	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
957	748	Placebo	ASA	88	m	586	Death	
1026	748	Placebo	ASA	94	f	1182	Patient's request (however, patient is still being followed-up in the study)	
1056	748	Placebo	ASA	90	f	502	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1139	748	Placebo	ASA	90	m	26	Patient's request (however, patient is still being followed-up in the study)	
1251	748	Placebo	ASA	94	m	1081	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1272	748	Placebo	ASA	85	f	300	Death	
1285	748	Placebo	ASA	90	m	1007	Death	
1659	748	Placebo	ASA	83	f	764	Other reason: uncertainty of the patient due to the present symptoms. the patient then no longer wishes to participate in the study.	
1674	748	Placebo	ASA	89	f	21	Patient's request (however, patient is still being followed-up in the study)	
1731	748	Placebo	ASA	84	m	320	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2021-06-30
1757	748	Placebo	ASA	87	m	174	Patient completely withdraws consent to any further study participation	
2195	748	Placebo	ASA	71	m	42	Other reason: The treating cardiologist wants to give a NOAC because of the HOCM + AHRE. The patient is now taking Eliquis again.	
2199	748	Placebo	ASA	85	m	172	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2354	748	Placebo	ASA	87	m	354	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2384	748	Placebo	ASA	87	m	218	Death	
564	748	Placebo	no ASA	83	f	963	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
824	748	Placebo	no ASA	81	f	1446	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
852	748	Placebo	no ASA	87	f	702	Patient completely withdraws consent to any further study participation	
199	748	Edoxaban	ASA	84	m	1455	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
281	748	Edoxaban	ASA	76	m	1758	Death	
532	748	Edoxaban	ASA	82	f	672	Patient's request (however, patient is still being followed-up in the study)	
555	748	Edoxaban	ASA	69	m	110	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
610	748	Edoxaban	ASA	84	m	488	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
687	748	Edoxaban	ASA	80	m	4	Patient's request (however, patient is still being followed-up in the study)	
928	748	Edoxaban	ASA	84	f	172	Other reason: doctor's decision	
992	748	Edoxaban	ASA	80	m	1276	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1096	748	Edoxaban	ASA	89	f	29	Patient's request (however, patient is still being followed-up in the study)	
1415	748	Edoxaban	ASA	87	f	854	Other reason: The patient is very demented and stopped taking the study medication on her own in about April. She cannot give an exact date. The relatives cannot either. Unfortunately, the medication package cannot be found either.	
1591	748	Edoxaban	ASA	81	f	546	Patient's request (however, patient is still being followed-up in the study)	
1646	748	Edoxaban	ASA	84	m	350	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1885	748	Edoxaban	ASA	78	f	354	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
2136	748	Edoxaban	ASA	81	m	354	Patient's request (however, patient is still being followed-up in the study)	
2236	748	Edoxaban	ASA	80	m	54	Patient's request (however, patient is still being followed-up in the study)	
2734	748	Edoxaban	ASA	88	f	5	Patient's request (however, patient is still being followed-up in the study)	
1249	748	Edoxaban	no ASA	77	f	230	Death	
1301	748	Edoxaban	no ASA	96	f	65	Patient's request (however, patient is still being followed-up in the study)	
1982	748	Edoxaban	no ASA	72	f	168	Patient's request (however, patient is still being followed-up in the study)	
371	752	Placebo	ASA	81	m	447	Patient completely withdraws consent to any further study participation	
457	752	Placebo	ASA	86	f	1222	Patient's request (however, patient is still being followed-up in the study)	
316	752	Placebo	no ASA	86	f	755	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
657	752	Placebo	no ASA	84	m	330	Contraindication for oral anticoagulation in general	
1025	752	Placebo	no ASA	86	m	50	Patient completely withdraws consent to any further study participation	
570	752	Edoxaban	ASA	86	f	43	Patient completely withdraws consent to any further study participation	
862	752	Edoxaban	ASA	90	f	717	Patient completely withdraws consent to any further study participation	
406	752	Edoxaban	no ASA	89	f	461	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
458	752	Edoxaban	no ASA	81	m	466	Contraindication for oral anticoagulation in general	
517	752	Edoxaban	no ASA	93	m	820	Patient's request (however, patient is still being followed-up in the study)	
607	752	Edoxaban	no ASA	89	m	539	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
863	752	Edoxaban	no ASA	75	m	538	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1069	756	Placebo	ASA	76	m	226	Patient's request (however, patient is still being followed-up in the study)	
1102	756	Placebo	ASA	80	f	1101	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
448	756	Placebo	no ASA	81	m	1612	Patient's request (however, patient is still being followed-up in the study)	
509	756	Placebo	no ASA	72	m	341	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
495	756	Edoxaban	ASA	78	m	1456	Patient's request (however, patient is still being followed-up in the study)	
1255	756	Edoxaban	ASA	81	m	106	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
426	756	Edoxaban	no ASA	76	m	1650	Patient's request (however, patient is still being followed-up in the study)	
760	758	Edoxaban	no ASA	89	m	371	Patient completely withdraws consent to any further study participation	
1341	768	Placebo	no ASA	89	f	821	Death	
312	774	Placebo	no ASA	73	m	203	Patient's request (however, patient is still being followed-up in the study)	
497	774	Edoxaban	ASA	70	m	1112	Patient's request (however, patient is still being followed-up in the study)	
362	775	Placebo	ASA	84	m	519	Patient completely withdraws consent to any further study participation	
660	775	Placebo	ASA	72	f	180	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1366	775	Placebo	ASA	82	m	194	Patient's request (however, patient is still being followed-up in the study)	
1555	775	Placebo	ASA	77	m	288	Death	
1959	775	Placebo	ASA	93	f	541	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2270	775	Placebo	ASA	73	m	218	Other reason: Pat lost his medication, dont know were, dont want take another medication	
1563	775	Placebo	no ASA	83	m	545	Patient's request (however, patient is still being followed-up in the study)	
603	775	Edoxaban	ASA	81	m	948	Patient completely withdraws consent to any further study participation	
1060	775	Edoxaban	ASA	82	f	698	Patient's request (however, patient is still being followed-up in the study)	
1562	775	Edoxaban	ASA	68	m	508	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1851	775	Edoxaban	ASA	82	f	447	Patient's request (however, patient is still being followed-up in the study)	
2145	776	Placebo	ASA	77	m	4	Patient's request (however, patient is still being followed-up in the study)	
299	776	Edoxaban	ASA	85	m	7	Patient's request (however, patient is still being followed-up in the study)	
614	776	Edoxaban	no ASA	79	f	81	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
313	780	Edoxaban	ASA	75	m	1056	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2018-06-15
781	780	Edoxaban	ASA	68	m	1102	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
354	780	Edoxaban	no ASA	75	m	183	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
625	780	Edoxaban	no ASA	79	m	48	Patient's request (however, patient is still being followed-up in the study)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
673	780	Edoxaban	no ASA	84	m	619	Patient's request (however, patient is still being followed-up in the study)	
1376	784	Edoxaban	ASA	77	m	362	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1827	788	Placebo	ASA	77	m	22	Death	
1738	788	Placebo	no ASA	70	m	195	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2212	788	Placebo	no ASA	72	m	80	Patient completely withdraws consent to any further study participation	
1624	788	Edoxaban	ASA	81	f	205	Patient completely withdraws consent to any further study participation	
1733	788	Edoxaban	no ASA	76	f	10	Patient completely withdraws consent to any further study participation	
884	799	Placebo	no ASA	76	f	544	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1163	799	Placebo	no ASA	76	m	159	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1401	800	Placebo	ASA	82	m	845	Other reason: worsening of demention	
1421	800	Placebo	ASA	75	m	3	Patient's request (however, patient is still being followed-up in the study)	
1527	800	Placebo	ASA	84	f	92	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1667	800	Placebo	no ASA	81	m	164	Patient's request (however, patient is still being followed-up in the study)	
420	800	Edoxaban	ASA	89	m	572	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
642	800	Edoxaban	ASA	84	m	1	Patient's request (however, patient is still being followed-up in the study)	
653	800	Edoxaban	ASA	68	m	553	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1128	800	Edoxaban	ASA	77	m	222	Death	
1603	800	Edoxaban	ASA	86	m	127	Contraindication for oral anticoagulation in general	
1332	800	Edoxaban	no ASA	80	m	43	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
531	801	Placebo	ASA	84	m	932	Patient's request (however, patient is still being followed-up in the study)	
545	801	Placebo	ASA	78	f	1447	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
620	801	Placebo	ASA	67	m	520	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
693	801	Placebo	ASA	65	m	45	Other reason: The patient has just presented with chest-pain and SOB. hs Troponin T is 52 ng/L. ECG: SR, knonw LBBB, no STE. Echo LVEF 48%, diffuse hypokinesis. Pacemaker interrogation shows good device sensing and pacing, no new EHRA. Since the pat. has known 3 VD, CABG will be performed due to NSTEMI.	2018-10-18
1183	801	Placebo	ASA	67	m	723	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1187	801	Placebo	ASA	79	f	380	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1288	801	Placebo	ASA	84	m	545	Patient completely withdraws consent to any further study participation	
1309	801	Placebo	ASA	75	m	175	Patient's request (however, patient is still being followed-up in the study)	
599	801	Placebo	no ASA	74	m	381	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
738	801	Placebo	no ASA	86	m	365	Patient's request (however, patient is still being followed-up in the study)	
969	801	Placebo	no ASA	78	m	120	Patient's request (however, patient is still being followed-up in the study)	
1289	801	Placebo	no ASA	71	m	491	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1809	801	Placebo	no ASA	85	f	559	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2513	801	Placebo	no ASA	67	f	182	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
520	801	Edoxaban	ASA	84	m	420	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
543	801	Edoxaban	ASA	76	f	1406	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2022-03-08
1021	801	Edoxaban	ASA	77	m	1094	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1184	801	Edoxaban	ASA	79	m	36	Contraindication for oral anticoagulation in general	
2273	801	Edoxaban	ASA	82	m	166	Contraindication for oral anticoagulation in general	
639	801	Edoxaban	no ASA	78	m	22	Patient completely withdraws consent to any further study participation	
741	801	Edoxaban	no ASA	83	m	1268	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1007	801	Edoxaban	no ASA	79	f	431	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1334	801	Edoxaban	no ASA	81	m	191	Contraindication for oral anticoagulation in general	
1772	801	Edoxaban	no ASA	78	f	45	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2247	801	Edoxaban	no ASA	84	f	369	Patient completely withdraws consent to any further study participation	
349	802	Placebo	ASA	83	m	108	Contraindication for oral anticoagulation in general	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
629	802	Placebo	no ASA	82	f	547	Contraindication for oral anticoagulation in general	
1082	802	Edoxaban	ASA	83	m	83	Patient's request (however, patient is still being followed-up in the study)	
705	802	Edoxaban	no ASA	67	f	714	Patient's request (however, patient is still being followed-up in the study)	
2070	813	Placebo	ASA	78	m	201	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1387	815	Placebo	ASA	82	m	468	Patient completely withdraws consent to any further study participation	
1904	815	Placebo	ASA	87	m	99	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
947	815	Placebo	no ASA	79	f	917	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1551	815	Placebo	no ASA	90	f	744	Patient's request (however, patient is still being followed-up in the study)	
1812	815	Placebo	no ASA	88	f	374	Contraindication for oral anticoagulation in general	
1896	815	Edoxaban	ASA	78	m	707	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
986	815	Edoxaban	no ASA	73	f	123	Patient's request (however, patient is still being followed-up in the study)	
1429	815	Edoxaban	no ASA	75	m	176	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1895	815	Edoxaban	no ASA	74	m	182	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2200	815	Edoxaban	no ASA	84	m	125	Death	
1497	824	Placebo	no ASA	68	f	748	Patient completely withdraws consent to any further study participation	
2002	824	Edoxaban	ASA	83	m	179	Patient's request (however, patient is still being followed-up in the study)	
2010	824	Edoxaban	ASA	76	m	178	Patient's request (however, patient is still being followed-up in the study)	
476	826	Edoxaban	ASA	81	m	655	Contraindication for oral anticoagulation in general	
770	827	Placebo	ASA	75	m	1046	Patient's request (however, patient is still being followed-up in the study)	
764	827	Edoxaban	ASA	81	f	778	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
807	827	Edoxaban	ASA	78	f	569	Patient's request (however, patient is still being followed-up in the study)	
1011	828	Placebo	ASA	81	m	1021	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
987	833	Placebo	ASA	76	m	354	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
976	833	Edoxaban	ASA	83	m	528	Other reason: Patient had progressive dementia development.	
1277	833	Edoxaban	ASA	85	m	374	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1637	833	Edoxaban	ASA	78	m	34	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
795	836	Placebo	no ASA	80	m	554	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
819	836	Placebo	no ASA	77	m	180	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
997	836	Placebo	no ASA	82	m	1281	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
849	836	Edoxaban	no ASA	80	f	549	Death	
1996	836	Edoxaban	no ASA	69	f	20	Patient's request (however, patient is still being followed-up in the study)	
2001	836	Edoxaban	no ASA	81	m	93	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2364	836	Edoxaban	no ASA	73	m	174	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1876	857	Placebo	ASA	72	f	717	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1957	857	Placebo	ASA	81	f	123	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1830	857	Placebo	no ASA	72	f	445	Patient completely withdraws consent to any further study participation	
1853	857	Placebo	no ASA	91	f	179	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1835	857	Edoxaban	ASA	81	m	47	Patient completely withdraws consent to any further study participation	
2006	857	Edoxaban	ASA	77	m	20	Patient's request (however, patient is still being followed-up in the study)	
742	866	Placebo	ASA	67	m	571	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
750	866	Placebo	ASA	69	m	284	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
791	866	Placebo	ASA	71	m	385	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
885	866	Placebo	ASA	66	f	370	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1149	866	Placebo	ASA	80	m	559	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
767	866	Edoxaban	ASA	67	f	939	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
775	866	Edoxaban	ASA	70	m	760	Patient's request (however, patient is still being followed-up in the study)	
788	866	Edoxaban	ASA	78	m	390	Other reason: The drug is over	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
952	866	Edoxaban	ASA	84	m	572	Patient's request (however, patient is still being followed-up in the study)	
1100	866	Edoxaban	ASA	80	f	755	Patient completely withdraws consent to any further study participation	
1106	866	Edoxaban	ASA	80	f	1243	Other reason: Has not answered phone calls for over 7 months	
1196	866	Edoxaban	ASA	70	m	202	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
630	868	Placebo	ASA	78	f	1475	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
665	868	Placebo	ASA	77	m	722	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
965	868	Placebo	ASA	77	f	1074	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1315	868	Placebo	ASA	73	f	884	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
701	868	Placebo	no ASA	70	m	925	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
899	868	Placebo	no ASA	72	m	1101	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
754	868	Edoxaban	ASA	76	m	1353	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
798	868	Edoxaban	ASA	81	f	931	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
800	868	Edoxaban	ASA	77	m	1387	Patient's request (however, patient is still being followed-up in the study)	
2098	868	Edoxaban	ASA	70	f	413	Patient's request (however, patient is still being followed-up in the study)	
645	868	Edoxaban	no ASA	81	m	1321	Patient's request (however, patient is still being followed-up in the study)	
759	868	Edoxaban	no ASA	82	m	1306	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1717	869	Placebo	ASA	74	m	562	Patient's request (however, patient is still being followed-up in the study)	
2008	869	Placebo	ASA	72	f	195	Patient's request (however, patient is still being followed-up in the study)	
780	869	Placebo	no ASA	82	f	534	Patient's request (however, patient is still being followed-up in the study)	
823	869	Placebo	no ASA	79	m	637	Patient completely withdraws consent to any further study participation	
1311	869	Placebo	no ASA	76	m	736	Patient's request (however, patient is still being followed-up in the study)	
1276	869	Edoxaban	ASA	67	m	548	Other reason: due to the epidemiological situation, fear of contracting a coronovirus infection, the patient cannot come to the research center	
1390	869	Edoxaban	ASA	74	m	195	Patient's request (however, patient is still being followed-up in the study)	
1970	869	Edoxaban	ASA	72	f	379	Other reason: the patient left the country due to military operations. cannot come to visits according to the schedule	
2208	869	Edoxaban	ASA	72	f	195	Patient's request (however, patient is still being followed-up in the study)	
683	869	Edoxaban	no ASA	80	f	1134	Patient completely withdraws consent to any further study participation	
730	869	Edoxaban	no ASA	70	f	1091	Patient's request (however, patient is still being followed-up in the study)	
1481	869	Edoxaban	no ASA	79	f	924	Patient's request (however, patient is still being followed-up in the study)	
850	870	Placebo	ASA	80	f	11	Death	
1028	870	Placebo	ASA	74	f	922	Patient completely withdraws consent to any further study participation	
1030	870	Placebo	ASA	68	f	562	Death	
1073	870	Placebo	ASA	74	f	920	Patient completely withdraws consent to any further study participation	
1265	870	Placebo	ASA	71	m	772	Patient completely withdraws consent to any further study participation	
1303	870	Placebo	ASA	72	f	559	Patient's request (however, patient is still being followed-up in the study)	
1077	870	Edoxaban	ASA	73	f	920	Patient completely withdraws consent to any further study participation	
1131	870	Edoxaban	ASA	76	f	916	Patient completely withdraws consent to any further study participation	
1596	870	Edoxaban	ASA	82	m	846	Patient completely withdraws consent to any further study participation	
1627	870	Edoxaban	ASA	78	m	172	Patient completely withdraws consent to any further study participation	
1684	870	Edoxaban	ASA	80	m	514	Death	
1973	870	Edoxaban	ASA	71	m	72	Death	
977	870	Edoxaban	no ASA	67	f	369	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1020	870	Edoxaban	no ASA	93	m	563	Patient completely withdraws consent to any further study participation	
732	871	Placebo	ASA	70	f	179	Patient completely withdraws consent to any further study participation	
804	871	Placebo	ASA	64	f	1153	Patient's request (however, patient is still being followed-up in the study)	
874	871	Placebo	ASA	78	m	926	Other reason: patient request	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
962	871	Placebo	ASA	83	m	824	Patient's request (however, patient is still being followed-up in the study)	
963	871	Placebo	ASA	78	f	390	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
808	871	Edoxaban	ASA	77	m	140	Contraindication for oral anticoagulation in general	
812	871	Edoxaban	ASA	86	f	176	Patient completely withdraws consent to any further study participation	
872	871	Edoxaban	ASA	71	f	808	Patient's request (however, patient is still being followed-up in the study)	
880	871	Edoxaban	ASA	80	f	1024	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
700	872	Placebo	no ASA	82	f	1290	Other reason: The last contact with the patient was on 03/21/22, she reported that the last dose of the drug was on 03/20/2022. Later, the contact was interrupted.	
776	872	Placebo	no ASA	83	m	649	Death	
889	872	Placebo	no ASA	79	m	1170	Other reason: The visit was by telephone due to the coronavirus pandemic 19	
891	872	Placebo	no ASA	80	m	597	Death	
1143	872	Placebo	no ASA	79	f	210	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
696	872	Edoxaban	no ASA	67	m	568	Patient completely withdraws consent to any further study participation	
727	872	Edoxaban	no ASA	68	m	965	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
755	872	Edoxaban	no ASA	78	f	1136	Other reason: due to the coronavirus pandemic 19, the patient is outside the area and is temporarily unable to visit the center. Suspended the study drug. After returning to the city, ready to continue research.	
916	872	Edoxaban	no ASA	78	f	584	Patient completely withdraws consent to any further study participation	
917	872	Edoxaban	no ASA	68	m	926	Other reason: Due to the coronavirus pandemic 19, the patient refused to continue to participate in the study.	
1109	872	Edoxaban	no ASA	67	f	736	Patient's request (however, patient is still being followed-up in the study)	
910	873	Edoxaban	ASA	83	m	268	Patient completely withdraws consent to any further study participation	
743	874	Placebo	ASA	73	m	297	Patient completely withdraws consent to any further study participation	
870	874	Placebo	ASA	82	m	656	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
994	874	Placebo	ASA	78	m	522	Patient's request (however, patient is still being followed-up in the study)	
1002	874	Placebo	ASA	75	f	1213	Patient's request (however, patient is still being followed-up in the study)	
792	874	Placebo	no ASA	94	f	348	Death	
913	874	Placebo	no ASA	78	f	1375	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
716	874	Edoxaban	ASA	71	m	245	Other reason: anemia due to suspected cancer prostata	
857	874	Edoxaban	ASA	84	m	1318	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
858	874	Edoxaban	ASA	73	m	872	Other reason: on the recommendation of a doctor	
871	874	Edoxaban	ASA	83	m	780	Patient completely withdraws consent to any further study participation	
932	874	Edoxaban	ASA	89	f	935	Other reason: severe weakness	
1171	874	Edoxaban	ASA	76	m	360	Patient completely withdraws consent to any further study participation	
1469	874	Edoxaban	ASA	83	f	296	Death	
1724	874	Edoxaban	ASA	82	m	194	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1726	874	Edoxaban	ASA	71	f	176	Death	
831	874	Edoxaban	no ASA	72	f	177	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
646	875	Placebo	ASA	69	m	1382	Death	
751	875	Placebo	no ASA	75	f	95	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
939	875	Placebo	no ASA	70	f	186	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1144	875	Placebo	no ASA	67	m	575	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1608	875	Placebo	no ASA	66	f	553	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1027	875	Edoxaban	ASA	76	m	205	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2167	875	Edoxaban	ASA	77	m	21	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
664	875	Edoxaban	no ASA	76	m	193	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1197	875	Edoxaban	no ASA	70	m	915	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1284	875	Edoxaban	no ASA	77	m	185	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1931	875	Edoxaban	no ASA	65	m	363	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
744	876	Placebo	ASA	76	m	673	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
736	876	Placebo	no ASA	79	m	678	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
877	876	Placebo	no ASA	73	f	1103	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1443	876	Edoxaban	no ASA	81	m	1028	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
801	877	Placebo	ASA	71	f	181	Patient completely withdraws consent to any further study participation	
1275	877	Placebo	ASA	84	m	193	Patient completely withdraws consent to any further study participation	
1295	877	Placebo	ASA	73	m	547	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1352	877	Placebo	ASA	81	f	746	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2260	877	Placebo	ASA	80	f	205	Other reason: 01.04.2022 - the day the patient took last dose of IP, later she could not receive IP because of war (not able to visit center)	
757	877	Placebo	no ASA	75	m	726	Patient completely withdraws consent to any further study participation	
915	877	Placebo	no ASA	69	f	848	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1141	877	Placebo	no ASA	70	m	208	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
706	877	Edoxaban	ASA	85	m	931	Death	
853	877	Edoxaban	ASA	69	m	735	Death	
1803	877	Edoxaban	ASA	86	m	371	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
735	877	Edoxaban	no ASA	81	f	159	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
737	877	Edoxaban	no ASA	73	m	504	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
890	877	Edoxaban	no ASA	81	f	617	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1023	877	Edoxaban	no ASA	70	f	420	Patient completely withdraws consent to any further study participation	
1648	877	Edoxaban	no ASA	83	f	2	Patient's request (however, patient is still being followed-up in the study)	
893	881	Edoxaban	ASA	74	f	178	Patient completely withdraws consent to any further study participation	
1495	884	Placebo	ASA	67	m	905	Patient's request (however, patient is still being followed-up in the study)	
1566	901	Placebo	no ASA	83	m	509	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2381	901	Placebo	no ASA	70	f	178	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
882	901	Edoxaban	ASA	89	f	638	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1038	901	Edoxaban	ASA	73	m	757	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1120	901	Edoxaban	ASA	89	m	5	Patient's request (however, patient is still being followed-up in the study)	
1138	901	Edoxaban	ASA	77	m	250	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2427	901	Edoxaban	ASA	81	m	29	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1057	901	Edoxaban	no ASA	72	f	54	Patient's request (however, patient is still being followed-up in the study)	
2550	965	Placebo	no ASA	86	m	157	Death	
2420	965	Edoxaban	ASA	83	f	45	Patient's request (however, patient is still being followed-up in the study)	
1323	965	Edoxaban	no ASA	81	f	351	Patient completely withdraws consent to any further study participation	
2426	965	Edoxaban	no ASA	81	m	122	Patient's request (however, patient is still being followed-up in the study)	
2366	1023	Placebo	ASA	66	f	0	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
709	1023	Placebo	no ASA	70	f	177	Patient completely withdraws consent to any further study participation	
1342	1028	Placebo	no ASA	83	f	875	Patient's request (however, patient is still being followed-up in the study)	
1561	1028	Placebo	no ASA	74	m	668	Patient's request (however, patient is still being followed-up in the study)	
2696	1028	Placebo	no ASA	83	m	41	Patient's request (however, patient is still being followed-up in the study)	
1313	1028	Edoxaban	ASA	66	m	1	Patient's request (however, patient is still being followed-up in the study)	
1314	1028	Edoxaban	no ASA	82	m	867	Patient's request (however, patient is still being followed-up in the study)	
1539	1028	Edoxaban	no ASA	83	f	744	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
949	1029	Placebo	ASA	83	m	384	Death	
1159	1029	Placebo	ASA	88	f	171	Patient's request (however, patient is still being followed-up in the study)	
1617	1029	Placebo	ASA	69	m	80	Patient completely withdraws consent to any further study participation	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
1986	1029	Placebo	ASA	70	f	176	Patient's request (however, patient is still being followed-up in the study)	
2155	1029	Placebo	ASA	81	f	397	Patient's request (however, patient is still being followed-up in the study)	
2178	1029	Placebo	ASA	89	m	178	Patient completely withdraws consent to any further study participation	
1256	1029	Edoxaban	ASA	70	m	939	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
2090	1029	Edoxaban	ASA	87	f	125	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2021-09-12
2108	1029	Edoxaban	ASA	85	f	13	Patient's request (however, patient is still being followed-up in the study)	
2180	1029	Edoxaban	ASA	74	m	256	Patient's request (however, patient is still being followed-up in the study)	
1177	1029	Edoxaban	no ASA	71	m	327	Patient's request (however, patient is still being followed-up in the study)	
1335	1029	Edoxaban	no ASA	78	m	406	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1407	1039	Placebo	ASA	78	m	189	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1459	1039	Placebo	ASA	87	m	632	Patient completely withdraws consent to any further study participation	
1227	1039	Edoxaban	ASA	80	m	125	Patient completely withdraws consent to any further study participation	
1467	1039	Edoxaban	ASA	81	m	682	Death	
1534	1039	Edoxaban	ASA	80	m	828	Patient completely withdraws consent to any further study participation	
2170	1048	Edoxaban	ASA	81	f	5	Patient's request (however, patient is still being followed-up in the study)	
2335	1049	Placebo	ASA	80	f	84	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2231	1049	Placebo	no ASA	87	m	29	Patient's request (however, patient is still being followed-up in the study)	
2143	1074	Placebo	ASA	74	m	153	Patient's request (however, patient is still being followed-up in the study)	
1403	1074	Placebo	no ASA	75	m	5	Patient's request (however, patient is still being followed-up in the study)	
1607	1074	Placebo	no ASA	83	m	517	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1697	1074	Placebo	no ASA	77	m	71	Patient's request (however, patient is still being followed-up in the study)	
2162	1074	Placebo	no ASA	81	m	54	Patient completely withdraws consent to any further study participation	
2235	1074	Placebo	no ASA	81	f	165	Patient's request (however, patient is still being followed-up in the study)	
2720	1074	Placebo	no ASA	72	m	28	Patient's request (however, patient is still being followed-up in the study)	
1424	1074	Edoxaban	ASA	68	m	13	Patient's request (however, patient is still being followed-up in the study)	
1842	1074	Edoxaban	ASA	68	m	90	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1305	1074	Edoxaban	no ASA	85	f	365	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1699	1074	Edoxaban	no ASA	92	f	729	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1756	1074	Edoxaban	no ASA	79	m	65	Patient's request (however, patient is still being followed-up in the study)	
1968	1074	Edoxaban	no ASA	84	f	155	Death	
2308	1074	Edoxaban	no ASA	81	f	137	Patient's request (however, patient is still being followed-up in the study)	
2561	1074	Edoxaban	no ASA	68	m	13	Death	
2078	1080	Placebo	ASA	84	f	224	Death	
1396	1080	Placebo	no ASA	86	f	556	Patient completely withdraws consent to any further study participation	
1536	1080	Placebo	no ASA	68	f	563	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1573	1080	Placebo	no ASA	78	f	524	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1643	1080	Placebo	no ASA	82	f	358	Patient completely withdraws consent to any further study participation	
1660	1080	Placebo	no ASA	70	f	375	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1688	1080	Placebo	no ASA	73	m	190	Death	
1749	1080	Placebo	no ASA	66	f	371	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1843	1080	Placebo	no ASA	67	f	173	Patient's request (however, patient is still being followed-up in the study)	
1856	1080	Placebo	no ASA	88	f	668	Patient completely withdraws consent to any further study participation	
1888	1080	Placebo	no ASA	67	f	646	Patient completely withdraws consent to any further study participation	
1948	1080	Placebo	no ASA	77	m	557	Patient's request (however, patient is still being followed-up in the study)	
2125	1080	Placebo	no ASA	71	m	195	Patient completely withdraws consent to any further study participation	
2126	1080	Placebo	no ASA	72	f	355	Patient completely withdraws consent to any further study participation	
2144	1080	Placebo	no ASA	71	f	188	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
2150	1080	Placebo	no ASA	75	f	244	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2320	1080	Placebo	no ASA	83	f	238	Patient completely withdraws consent to any further study participation	
1778	1080	Edoxaban	ASA	83	m	117	Patient's request (however, patient is still being followed-up in the study)	
1388	1080	Edoxaban	no ASA	67	f	726	Patient completely withdraws consent to any further study participation	
1462	1080	Edoxaban	no ASA	81	f	377	Death	
1538	1080	Edoxaban	no ASA	81	f	0	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1615	1080	Edoxaban	no ASA	73	f	373	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1665	1080	Edoxaban	no ASA	68	m	577	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1744	1080	Edoxaban	no ASA	66	f	367	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1786	1080	Edoxaban	no ASA	78	m	368	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1802	1080	Edoxaban	no ASA	73	f	194	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1822	1080	Edoxaban	no ASA	78	f	210	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1861	1080	Edoxaban	no ASA	82	f	175	Patient completely withdraws consent to any further study participation	
1863	1080	Edoxaban	no ASA	71	f	196	Contraindication for oral anticoagulation in general	
1890	1080	Edoxaban	no ASA	68	m	367	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1937	1080	Edoxaban	no ASA	74	f	287	Other reason: We have no contact with patient. Phone is of for more than 3 months	
1977	1080	Edoxaban	no ASA	73	m	258	Other reason: We have no contact with patient.	
2057	1080	Edoxaban	no ASA	82	f	194	Patient completely withdraws consent to any further study participation	
2131	1080	Edoxaban	no ASA	70	f	247	Patient completely withdraws consent to any further study participation	
2141	1080	Edoxaban	no ASA	68	m	255	Patient completely withdraws consent to any further study participation	
2237	1080	Edoxaban	no ASA	78	f	228	Patient completely withdraws consent to any further study participation	
1353	1085	Placebo	ASA	82	m	274	Contraindication for edoxaban or ASA (as given in the current investigator's brochure)	
1433	1085	Placebo	ASA	87	f	18	Patient's request (however, patient is still being followed-up in the study)	
1499	1085	Placebo	ASA	83	f	371	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2500	1085	Placebo	ASA	82	m	5	Patient completely withdraws consent to any further study participation	
1673	1085	Placebo	no ASA	85	f	196	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1962	1085	Placebo	no ASA	79	f	64	Patient's request (however, patient is still being followed-up in the study)	
2301	1085	Placebo	no ASA	85	m	132	Patient's request (however, patient is still being followed-up in the study)	
1537	1085	Edoxaban	ASA	78	m	288	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2114	1085	Edoxaban	ASA	80	f	2	Patient completely withdraws consent to any further study participation	
1771	1085	Edoxaban	no ASA	84	f	304	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2298	1085	Edoxaban	no ASA	86	f	269	Patient's request (however, patient is still being followed-up in the study)	
1358	1089	Placebo	no ASA	82	m	91	Death	
1364	1089	Placebo	no ASA	93	m	951	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1492	1089	Placebo	no ASA	74	f	359	Patient completely withdraws consent to any further study participation	
1502	1089	Placebo	no ASA	76	m	655	Other reason: social reason patient on open label	
1522	1089	Placebo	no ASA	85	m	176	Death	
2230	1089	Placebo	no ASA	80	m	349	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1317	1089	Edoxaban	no ASA	88	m	743	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1427	1089	Edoxaban	no ASA	83	m	484	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2066	1089	Edoxaban	no ASA	78	m	0	Patient completely withdraws consent to any further study participation	
2344	1097	Placebo	ASA	81	f	9	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
1705	1097	Edoxaban	ASA	75	m	538	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2578	1108	Placebo	no ASA	73	m	159	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2330	1115	Edoxaban	ASA	83	f	86	Other reason: Patient observed blood per rectum in febuary 2022 (started study medication in november 2021). patient is known with hemorides, she told us that she was sure it was not from hemorides but rectum. It is not examineded closer hens the patient do not want that. The bleeding stopped after the study medication was interrupted and she i not interrested in starting again.	

Patient-ID	Centre-ID	Random group	Random stratum (indication)	Age at discont.	Sex	Duration of drug exposure [d]	Drug discontinuation reason	Unblinding date
2678	1118	Placebo	ASA	83	f	126	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	2022-11-04
2689	1118	Placebo	no ASA	91	f	92	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2587	1121	Placebo	no ASA	87	m	68	Patient's request (however, patient is still being followed-up in the study)	
2377	1121	Edoxaban	no ASA	91	m	25	Death	
2444	1121	Edoxaban	no ASA	81	m	238	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2477	1138	Edoxaban	no ASA	79	m	185	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	
2713	1146	Placebo	ASA	80	f	0	Clinical indication for oral anticoagulation (e.g. new diagnosis of overt AF)	

16.2.2 Protocol deviations

Table 25 Summary of protocol deviations by study centre

Centre-ID	12-lead ECG at baseline not performed	Any history of overt AF or atrial flutter	Drug abuse or clinically manifest alcohol abuse	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	Measurement of creatinine value at baseline visit older 28 days	No complete chain of medication supply	No detection feature activated for adequate detection of AHRE	No eligible AHRE episodes documented (($\geq$ 170 bpm atrial rate and $\geq$ 6 min duration))	No eligible device (exempt ILR) with AHRE detection implanted at least 2 months prior randomisation	Participation in another clinical trial (within the past 2 months or still ongoing)	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	Previous participation in the present trial NOAH - AFNET 6	Simultaneous intake of study medication and any antiplatelet agent	Simultaneous intake of study medication and other oral anticoagulation
9	6	1	0	14	4	6	0	2	0	0	26	0	1	1
12	0	0	0	3	0	0	0	0	0	0	4	0	0	0
17	0	0	0	0	0	1	0	0	0	0	0	0	0	0
19	0	0	0	1	0	1	0	0	0	0	1	0	0	0
23	0	0	0	1	1	1	0	1	0	0	1	0	0	0
33	0	0	0	0	0	1	0	0	0	0	2	0	1	0
35	0	0	0	1	0	1	0	0	0	0	2	0	0	0
38	0	0	0	0	2	0	0	0	0	0	3	0	0	0
39	2	0	0	3	3	1	0	1	0	0	4	0	0	0
40	0	0	0	1	0	0	0	0	0	0	1	0	0	0
42	0	0	0	3	0	2	0	0	0	0	1	0	0	0
43	0	0	0	1	0	0	0	0	0	0	3	0	0	0
44	2	0	0	0	0	0	0	1	0	0	1	0	0	0
46	0	0	0	0	0	0	0	1	0	0	1	0	0	2
49	0	0	0	0	0	2	0	0	0	0	2	0	0	0
53	0	0	0	0	0	1	0	0	0	0	0	0	0	0
57	0	0	0	3	5	2	0	3	0	0	2	0	0	0
59	2	0	0	7	0	4	0	4	0	0	7	0	1	0
70	0	0	0	12	0	11	0	3	0	0	16	0	0	0
86	1	0	0	0	0	2	0	0	0	0	5	0	1	0
95	0	0	0	6	3	5	0	2	0	0	4	0	0	1
100	0	0	0	0	1	1	0	1	0	0	2	0	0	0
109	0	0	0	0	0	0	0	0	0	0	1	0	0	0
113	0	0	0	2	0	0	0	0	0	0	6	0	0	0
117	0	0	0	0	3	0	0	1	0	0	1	0	0	0
121	0	0	0	0	0	1	0	0	0	0	1	0	0	0
132	1	0	0	1	2	4	0	0	0	0	1	0	0	0
133	0	0	0	0	0	1	0	0	0	0	4	0	0	0
135	0	0	0	0	3	0	0	0	0	0	3	0	0	0
136	0	0	0	0	2	1	0	0	0	0	3	0	0	0
140	0	0	1	7	0	1	0	1	0	0	16	0	0	0
145	0	0	0	0	0	0	0	0	0	0	1	0	0	0
153	0	0	0	3	6	0	0	0	0	0	2	0	0	1
154	0	0	0	0	0	0	0	0	0	0	3	0	0	0
161	0	0	0	0	1	0	0	0	0	0	3	0	0	0
166	0	0	0	1	0	0	0	0	0	0	0	0	0	0
171	0	0	0	0	0	0	0	0	0	0	1	0	0	0
173	1	0	0	3	0	4	0	2	0	0	8	0	0	0
174	0	0	0	3	0	2	0	0	0	0	1	0	0	0
175	0	0	0	1	0	0	0	0	0	0	2	0	0	0
179	0	0	0	2	0	0	0	1	0	0	1	0	0	0
189	0	0	0	0	0	0	0	1	0	0	0	0	0	0
195	0	0	0	3	0	0	0	0	0	0	4	1	0	1
198	0	0	0	0	0	0	0	1	0	0	1	0	0	0
202	0	0	0	0	0	0	0	1	0	0	1	0	1	0
205	0	0	0	5	0	0	0	0	0	0	4	0	0	0
208	0	0	0	2	0	0	0	0	0	0	2	0	0	1
209	0	0	0	1	0	1	0	0	0	0	0	0	0	0
211	0	0	0	0	0	0	0	0	0	0	2	0	0	0
217	0	0	0	0	0	1	0	0	0	0	1	0	0	0
226	0	0	0	1	1	2	0	0	0	0	1	0	0	0

Centre-ID	12-lead ECG at baseline not performed	Any history of overt AF or atrial flutter	Drug abuse or clinically manifest alcohol abuse	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	Measurement of creatinine value at baseline visit older 28 days	No complete chain of medication supply	No detection feature activated for adequate detection of AHRE	No eligible AHRE episodes documented (≥ 170 bpm atrial rate and ≥ 6 min duration))	No eligible device (exempt ILR) with AHRE detection implanted at least 2 months prior randomisation	Participation in another clinical trial (within the past 2 months or still ongoing)	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	Previous participation in the present trial NOAH - AFNET 6	Simultaneous intake of study medication and any antiplatelet agent	Simultaneous intake of study medication and other oral anticoagulation
232	0	0	0	0	1	1	0	0	0	0	0	0	0	0
264	0	0	0	0	0	2	0	0	0	0	2	0	0	0
267	0	0	0	1	0	3	0	0	0	0	1	0	0	0
308	0	0	0	0	0	0	0	0	0	0	1	0	0	0
326	0	0	0	0	1	0	0	0	0	0	1	0	0	0
377	0	0	0	0	0	0	0	0	0	0	2	0	0	0
406	0	0	0	0	0	0	0	0	0	0	1	0	0	0
414	14	0	0	7	2	10	0	2	0	1	3	1	0	0
416	0	0	0	1	0	1	0	0	0	0	3	0	0	0
419	0	0	0	1	0	7	0	0	0	0	2	0	0	0
421	0	0	0	15	0	3	0	1	0	0	20	0	0	4
426	0	0	0	0	0	4	0	0	0	0	1	0	0	0
427	0	0	0	0	0	2	0	0	0	0	2	0	0	0
428	0	0	0	0	0	0	0	1	0	0	1	0	0	0
445	0	0	0	3	4	2	0	0	0	0	2	0	1	0
470	0	0	0	0	0	1	0	0	0	0	0	0	0	0
479	1	0	0	0	0	1	0	0	0	0	0	0	0	0
487	0	0	0	1	0	0	0	1	0	0	3	0	0	0
488	0	0	1	4	1	0	0	3	0	0	11	0	0	0
502	0	0	0	2	0	1	0	1	0	0	13	0	0	0
529	0	1	0	6	0	22	0	1	0	0	14	0	0	1
530	0	0	0	3	0	1	0	0	0	0	1	0	0	0
531	0	0	0	0	1	0	0	0	0	0	0	0	0	0
532	0	0	0	0	0	1	0	0	0	0	0	0	0	0
535	0	0	0	1	0	3	0	0	0	0	1	0	0	0
536	0	0	0	2	1	2	0	0	0	0	0	0	0	0
541	0	0	0	1	0	1	0	0	0	0	0	0	0	0
544	0	1	0	8	4	3	0	2	0	0	2	0	0	0
547	0	0	0	5	0	6	0	0	0	0	5	0	0	0
557	0	0	0	0	0	2	0	0	0	0	3	0	0	0
564	0	0	0	2	0	0	0	1	0	0	0	0	0	1
605	0	0	0	0	1	0	0	0	0	0	1	0	0	0
608	3	0	0	4	2	5	0	2	0	0	4	0	0	0
641	0	0	0	16	3	26	0	0	0	0	7	1	0	0
653	0	0	0	0	0	0	0	0	0	0	1	0	0	0
655	0	0	0	1	0	2	0	0	0	0	4	0	0	0
663	0	0	1	2	0	1	0	1	0	0	1	0	0	0
669	0	0	0	0	0	0	0	0	0	0	3	0	0	1
673	0	0	0	3	6	3	0	2	0	0	1	0	0	0
674	0	0	0	0	0	1	0	0	0	0	0	0	0	0
675	0	1	0	1	0	2	0	0	0	0	0	0	0	0
679	0	0	0	0	0	0	0	1	0	0	0	0	0	0
680	0	0	0	15	0	13	0	1	0	0	14	0	0	0
685	0	0	0	0	0	0	0	0	0	0	1	0	0	0
687	0	0	0	0	0	1	0	0	0	0	1	0	0	0
688	0	0	0	2	0	4	0	0	0	0	6	0	1	0
689	0	0	0	0	0	1	0	1	0	0	2	0	0	0
690	0	0	0	1	0	0	0	0	0	0	0	0	0	0
693	0	0	0	1	0	5	0	0	0	0	0	0	0	0
697	0	0	0	0	0	1	0	0	0	0	0	0	1	0
698	0	0	0	2	0	0	0	0	0	0	3	0	0	0
700	0	0	0	0	0	1	0	0	0	0	0	0	0	0
702	0	0	0	1	0	1	0	1	0	0	6	0	0	0
704	2	0	0	2	0	2	0	0	0	0	1	0	0	0
705	0	0	0	9	0	8	0	2	0	0	5	0	0	0
706	0	0	0	2	0	3	0	0	0	0	3	0	0	0
707	0	0	0	1	0	0	0	0	0	0	0	0	0	0
708	0	0	0	1	4	3	0	0	0	0	4	0	0	0
711	0	0	0	3	0	1	0	1	0	0	1	0	1	0

Centre-ID	12-lead ECG at baseline not performed	Any history of overt AF or atrial flutter	Drug abuse or clinically manifest alcohol abuse	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	Measurement of creatinine value at baseline visit older 28 days	No complete chain of medication supply	No detection feature activated for adequate detection of AHRE	No eligible AHRE episodes documented (≥ 170 bpm atrial rate and ≥ 6 min duration))	No eligible device (exempt ILR) with AHRE detection implanted at least 2 months prior randomisation	Participation in another clinical trial (within the past 2 months or still ongoing)	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	Previous participation in the present trial NOAH - AFNET 6	Simultaneous intake of study medication and any antiplatelet agent	Simultaneous intake of study medication and other oral anticoagulation
724	0	0	0	4	2	2	0	0	0	0	3	0	0	0
725	0	0	0	3	0	3	0	0	0	0	3	0	0	1
728	0	0	0	2	0	3	0	0	0	0	2	0	0	0
730	0	0	0	1	0	1	0	0	0	0	0	0	0	0
740	0	0	0	0	0	2	0	1	0	0	2	0	0	0
741	0	0	0	6	0	8	0	0	0	0	5	0	0	1
748	0	0	0	11	0	3	0	0	0	0	16	0	0	0
752	0	0	0	2	0	2	0	0	0	0	6	0	0	0
756	0	0	0	0	0	2	0	0	0	0	4	0	1	0
758	0	0	0	3	0	3	0	1	0	0	1	0	0	0
768	0	0	0	0	0	3	0	0	0	0	0	0	0	0
774	0	0	0	0	0	2	0	0	0	0	2	0	0	0
775	5	0	0	2	9	6	0	0	0	0	6	0	1	1
776	0	0	0	0	5	0	0	0	0	0	2	0	0	0
780	0	0	0	0	0	0	0	0	0	0	2	0	0	0
784	0	0	0	0	0	2	0	0	0	0	0	0	0	0
788	0	0	0	2	0	3	0	1	0	0	3	0	0	0
799	0	0	0	0	0	1	0	0	0	0	0	0	0	0
800	0	0	0	0	1	1	0	0	0	0	3	0	0	1
801	0	0	0	9	0	9	0	2	0	0	7	0	0	0
802	0	0	0	1	0	0	0	0	0	0	2	0	0	0
815	0	0	0	2	0	0	0	0	0	0	3	0	0	0
824	0	0	0	0	0	2	0	0	0	0	3	0	0	0
826	0	0	0	1	0	1	0	0	0	0	0	0	0	1
827	0	0	0	1	0	0	0	0	0	0	2	0	0	0
833	0	0	0	1	1	0	0	0	0	0	0	0	1	0
836	0	0	0	2	0	1	0	1	0	0	1	0	0	0
857	0	0	0	0	0	1	0	1	0	0	3	0	0	0
862	0	0	0	0	1	0	0	0	0	0	0	0	0	0
866	0	0	0	1	0	14	0	3	0	0	3	0	1	0
868	5	0	0	8	1	20	0	4	0	0	3	0	0	0
869	0	0	0	5	0	9	0	1	0	0	10	0	0	0
870	0	0	0	13	0	27	0	0	0	0	9	0	0	0
871	0	0	0	7	0	10	0	3	0	0	5	0	0	0
872	0	0	0	4	0	8	0	1	0	0	3	0	0	0
873	0	0	0	0	0	1	1	1	0	0	1	0	0	0
874	1	0	0	5	0	13	0	4	0	0	5	0	0	1
875	0	0	0	0	0	9	0	1	0	0	0	0	0	0
876	0	0	0	4	1	3	0	1	0	0	0	0	0	0
877	0	0	0	8	0	17	0	0	0	0	5	0	0	0
881	0	0	0	0	0	0	0	0	0	0	1	0	0	0
884	0	0	0	0	1	0	0	0	0	0	1	0	0	0
901	0	0	0	1	12	1	0	0	0	0	2	0	2	0
965	2	0	0	2	0	2	0	2	0	0	3	0	0	0
1023	2	1	0	2	0	3	0	0	1	0	1	0	0	0
1028	0	0	0	3	1	8	0	1	0	0	5	0	0	0
1029	1	0	0	12	2	21	0	3	0	0	8	0	0	0
1039	1	0	0	0	0	1	0	1	0	0	3	0	0	0
1048	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1049	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1067	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1074	0	0	0	12	0	3	0	1	0	0	9	0	0	0
1080	0	0	0	36	0	66	0	0	0	0	16	0	0	1
1085	0	0	0	2	0	5	0	1	0	0	6	0	0	0
1089	0	0	0	8	1	7	0	0	0	0	2	0	0	0
1097	1	0	0	1	0	0	0	1	0	0	0	0	0	0
1104	0	0	0	0	0	4	0	0	0	0	0	0	0	0
1111	0	0	0	1	0	0	0	0	0	0	0	0	0	0
1116	0	0	0	1	0	0	0	1	0	0	0	0	0	0

Centre-ID	12-lead ECG at baseline not performed	Any history of overt AF or atrial flutter	Drug abuse or clinically manifest alcohol abuse	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	Measurement of creatinine value at baseline visit older 28 days	No complete chain of medication supply	No detection feature activated for adequate detection of AHRE	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	No eligible device (exempt ILR) with AHRE detection implanted at least 2 months prior randomisation	Participation in another clinical trial (within the past 2 months or still ongoing)	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	Previous participation in the present trial NOAH - AFNET 6	Simultaneous intake of study medication and any antiplatelet agent	Simultaneous intake of study medication and other oral anticoagulation
1121	0	0	0	2	0	0	0	1	0	0	1	0	1	0
1133	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1138	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1146	0	0	0	0	0	0	0	0	0	0	0	0	1	0
1147	0	0	0	0	0	0	0	0	0	0	0	0	0	1

Table 26 Individual patients with protocol deviations as summarised in the previous table

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
9	48	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.11.2018
9	48	P	ASA	Simultaneous intake of study medication and any antiplatelet agent	25.07.2018
9	54	E	no ASA	No complete chain of medication supply	12.12.2017
9	66	E	ASA	Any history of overt AF or atrial flutter	21.12.2016
9	66	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.08.2017
9	75	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.06.2017
9	92	P	no ASA	12-lead ECG at baseline not performed	08.02.2017
9	92	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.04.2021
9	93	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.02.2019
9	153	E	ASA	Measurement of creatinine value at baseline visit older 28 days	04.05.2017
9	153	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.11.2020
9	410	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.02.2018
9	434	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.03.2018
9	434	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.03.2018
9	468	P	ASA	No complete chain of medication supply	10.03.2022
9	468	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	28.02.2018
9	536	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.05.2019
9	697	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.03.2019
9	719	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.10.2019
9	720	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.10.2018
9	731	E	ASA	No complete chain of medication supply	29.09.2020
9	758	P	ASA	No complete chain of medication supply	29.09.2020
9	758	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.10.2019
9	843	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.12.2018
9	843	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.12.2018
9	878	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.01.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
9	878	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	18.12.2018
9	908	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.05.2021
9	1126	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.11.2020
9	1178	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.06.2021
9	1204	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.06.2020
9	1213	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.09.2019
9	1278	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.09.2019
9	1346	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.11.2019
9	1570	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.04.2022
9	1692	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.07.2021
9	1692	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.07.2021
9	1692	E	no ASA	12-lead ECG at baseline not performed	16.07.2020
9	1816	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.04.2021
9	1817	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.10.2021
9	1847	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.05.2021
9	1879	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.06.2021
9	1897	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.06.2021
9	1961	E	ASA	12-lead ECG at baseline not performed	16.02.2021
9	2210	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.11.2022
9	2226	P	no ASA	12-lead ECG at baseline not performed	17.08.2021
9	2226	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	17.08.2021
9	2297	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.10.2021
9	2333	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	09.11.2021
9	2403	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.11.2022
9	2406	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.09.2022
9	2408	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.03.2022
9	2408	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.03.2022
9	2421	E	ASA	No complete chain of medication supply	26.07.2022
9	2563	P	no ASA	12-lead ECG at baseline not performed	30.03.2022
9	2599	P	ASA	No complete chain of medication supply	10.11.2022
9	2624	P	ASA	Measurement of creatinine value at baseline visit older 28 days	24.05.2022
9	2741	P	ASA	Measurement of creatinine value at baseline visit older 28 days	24.08.2022
9	2741	P	ASA	12-lead ECG at baseline not performed	24.08.2022
9	2741	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.10.2022
9	2741	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.10.2022
12	1581	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.07.2020
12	1582	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.05.2020
12	1582	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.05.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
12	1698	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.07.2020
12	1775	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.10.2020
12	1787	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.03.2021
12	2684	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.07.2022
17	446	P	ASA	No complete chain of medication supply	30.08.2018
19	329	E	ASA	No complete chain of medication supply	18.11.2021
19	340	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.05.2020
19	1633	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.09.2021
23	122	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.07.2017
23	234	E	ASA	Measurement of creatinine value at baseline visit older 28 days	26.07.2017
23	234	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	19.07.2017
23	265	E	ASA	No complete chain of medication supply	29.08.2018
23	265	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.02.2018
33	150	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.03.2021
33	1206	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	26.06.2020
33	1206	E	ASA	No complete chain of medication supply	30.06.2020
33	1378	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.11.2019
35	59	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.12.2016
35	260	E	no ASA	No complete chain of medication supply	06.03.2018
35	453	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.05.2018
35	453	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.05.2018
38	305	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.10.2017
38	305	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	17.10.2017
38	414	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.03.2018
38	414	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	24.01.2018
38	566	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.06.2018
39	1186	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.12.2019
39	1186	E	ASA	Measurement of creatinine value at baseline visit older 28 days	18.06.2019
39	1186	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.07.2020
39	1186	E	ASA	No complete chain of medication supply	01.07.2020
39	1351	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	24.10.2019
39	1351	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.11.2019
39	1351	P	ASA	Measurement of creatinine value at baseline visit older 28 days	24.10.2019
39	1351	P	ASA	12-lead ECG at baseline not performed	24.10.2019
39	1351	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.11.2019
39	1391	P	ASA	12-lead ECG at baseline not performed	25.11.2019
39	1391	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.04.2020
39	1391	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.04.2020
39	1391	P	ASA	Measurement of creatinine value at baseline visit older 28 days	25.11.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
39	2005	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.03.2022
40	300	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.04.2018
40	861	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.12.2018
42	567	E	ASA	No complete chain of medication supply	06.12.2018
42	567	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.01.2019
42	567	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.12.2018
42	1953	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.09.2022
42	1953	E	no ASA	No complete chain of medication supply	19.08.2022
42	2013	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.09.2021
43	258	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.02.2019
43	397	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.03.2019
43	845	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.12.2018
43	845	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.12.2018
44	472	P	ASA	12-lead ECG at baseline not performed	07.03.2018
44	1274	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.10.2019
44	1426	P	ASA	12-lead ECG at baseline not performed	03.12.2019
44	2019	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	18.03.2021
46	43	E	ASA	Simultaneous intake of study medication and other oral anticoagulation	27.02.2017
46	69	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	11.01.2017
46	95	P	ASA	Simultaneous intake of study medication and other oral anticoagulation	11.12.2018
46	147	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.12.2017
49	243	E	no ASA	No complete chain of medication supply	15.02.2018
49	287	P	ASA	No complete chain of medication supply	12.04.2018
49	287	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.04.2018
49	363	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.03.2018
53	321	E	no ASA	No complete chain of medication supply	20.11.2018
57	587	P	ASA	Measurement of creatinine value at baseline visit older 28 days	12.06.2018
57	593	E	ASA	Measurement of creatinine value at baseline visit older 28 days	14.06.2018
57	966	E	ASA	Measurement of creatinine value at baseline visit older 28 days	31.01.2019
57	966	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.11.2022
57	966	E	ASA	No complete chain of medication supply	16.07.2020
57	1324	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.04.2022
57	1568	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.04.2020
57	1755	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.06.2021
57	1837	E	ASA	Measurement of creatinine value at baseline visit older 28 days	22.10.2020
57	1837	E	ASA	No complete chain of medication supply	03.11.2022
57	1837	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	22.10.2020
57	1928	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	14.01.2021
57	1928	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.04.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
57	2542	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	18.03.2022
57	2542	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	18.03.2022
59	19	P	ASA	No complete chain of medication supply	12.09.2018
59	67	P	ASA	No complete chain of medication supply	15.01.2018
59	119	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.11.2017
59	119	P	ASA	No complete chain of medication supply	04.10.2017
59	119	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.11.2017
59	149	E	no ASA	12-lead ECG at baseline not performed	02.05.2017
59	186	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	09.06.2017
59	186	E	ASA	12-lead ECG at baseline not performed	09.06.2017
59	463	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.12.2018
59	467	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.06.2020
59	493	E	ASA	No complete chain of medication supply	07.10.2019
59	541	E	no ASA	Simultaneous intake of study medication and any antiplatelet agent	25.06.2019
59	615	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.11.2018
59	655	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.11.2020
59	1195	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	21.06.2019
59	1230	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.12.2019
59	1583	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.11.2020
59	1634	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.06.2021
59	1920	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.01.2022
59	2211	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.01.2022
59	2442	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.08.2022
59	2467	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	03.02.2022
59	2612	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.09.2022
59	2669	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.09.2022
59	2669	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	23.06.2022
70	16	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	31.08.2016
70	105	E	ASA	No complete chain of medication supply	20.03.2019
70	105	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.04.2020
70	151	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.05.2018
70	325	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.07.2019
70	418	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.02.2020
70	418	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	29.01.2018
70	479	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.10.2018
70	479	P	no ASA	No complete chain of medication supply	24.09.2018
70	511	P	ASA	No complete chain of medication supply	18.10.2018
70	644	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.10.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
70	644	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.02.2019
70	644	P	ASA	No complete chain of medication supply	04.03.2020
70	662	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.08.2018
70	765	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.07.2019
70	881	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.03.2019
70	995	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.09.2019
70	995	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.09.2019
70	1045	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.09.2019
70	1148	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.09.2019
70	1304	P	no ASA	No complete chain of medication supply	09.04.2021
70	1320	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	08.10.2019
70	1320	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.10.2019
70	1485	P	ASA	No complete chain of medication supply	08.02.2022
70	1569	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.09.2020
70	1599	E	ASA	No complete chain of medication supply	13.12.2021
70	1714	P	no ASA	No complete chain of medication supply	12.02.2021
70	1714	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.02.2021
70	1727	P	ASA	No complete chain of medication supply	18.02.2022
70	1805	E	ASA	No complete chain of medication supply	13.10.2021
70	1808	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.09.2021
70	1829	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.04.2021
70	1950	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.08.2021
70	1964	E	ASA	No complete chain of medication supply	26.08.2022
70	1964	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.08.2021
70	2068	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.09.2021
70	2182	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.09.2021
70	2182	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.09.2021
70	2425	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.01.2022
70	2425	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.01.2022
70	2438	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.07.2022
70	2686	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.10.2022
86	338	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.11.2018
86	373	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.12.2017
86	404	P	ASA	No complete chain of medication supply	20.07.2021
86	404	P	ASA	12-lead ECG at baseline not performed	15.01.2018
86	554	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.05.2018
86	1189	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.08.2019
86	1379	E	no ASA	No complete chain of medication supply	26.05.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
86	1428	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	28.04.2022
86	1542	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.06.2022
95	10	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.01.2017
95	10	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.01.2017
95	14	E	ASA	No complete chain of medication supply	15.03.2017
95	18	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.03.2017
95	18	P	ASA	No complete chain of medication supply	21.03.2017
95	18	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.03.2017
95	22	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	30.04.2018
95	22	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.03.2017
95	26	P	no ASA	No complete chain of medication supply	17.08.2021
95	28	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.10.2016
95	38	P	ASA	No complete chain of medication supply	17.10.2017
95	71	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.06.2017
95	117	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	21.03.2017
95	117	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.09.2019
95	180	E	no ASA	No complete chain of medication supply	29.10.2019
95	180	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	07.06.2017
95	533	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.02.2020
95	820	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.01.2019
95	1368	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	06.11.2019
95	2287	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	28.09.2021
95	2287	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	28.09.2021
100	4	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.06.2017
100	537	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.11.2019
100	537	E	ASA	No complete chain of medication supply	30.10.2019
100	933	E	ASA	Measurement of creatinine value at baseline visit older 28 days	15.01.2019
100	1969	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	18.02.2021
109	201	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.07.2017
113	36	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.10.2016
113	39	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.10.2017
113	40	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.01.2017
113	62	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.12.2019
113	65	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.12.2018
113	65	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.06.2017
113	154	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.10.2019
113	369	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.12.2019
117	23	P	ASA	Measurement of creatinine value at baseline visit older 28 days	16.09.2016

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
117	23	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.03.2020
117	264	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	24.08.2017
117	943	E	ASA	Measurement of creatinine value at baseline visit older 28 days	18.01.2019
117	1739	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	20.08.2020
121	130	P	no ASA	No complete chain of medication supply	13.10.2017
121	359	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.12.2017
132	6	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	08.07.2016
132	6	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.10.2016
132	8	P	no ASA	12-lead ECG at baseline not performed	18.07.2016
132	8	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	18.07.2016
132	51	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.01.2018
132	73	P	no ASA	No complete chain of medication supply	29.01.2018
132	101	P	ASA	No complete chain of medication supply	05.09.2017
132	229	P	ASA	No complete chain of medication supply	08.08.2018
132	1383	P	no ASA	No complete chain of medication supply	02.06.2021
133	188	E	ASA	No complete chain of medication supply	21.07.2020
133	188	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.12.2021
133	400	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.02.2018
133	477	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.09.2018
133	618	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.07.2020
135	97	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.03.2017
135	328	E	ASA	Measurement of creatinine value at baseline visit older 28 days	07.11.2017
135	339	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.05.2018
135	339	E	ASA	Measurement of creatinine value at baseline visit older 28 days	15.11.2017
135	376	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.04.2018
135	376	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	20.12.2017
136	33	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.10.2016
136	33	P	ASA	Measurement of creatinine value at baseline visit older 28 days	30.09.2016
136	34	E	ASA	No complete chain of medication supply	11.11.2019
136	34	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.10.2020
136	34	E	ASA	Measurement of creatinine value at baseline visit older 28 days	30.09.2016
136	132	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.08.2018
140	99	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	07.02.2017
140	99	P	no ASA	Drug abuse or clinically manifest alcohol abuse	07.02.2017
140	99	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.02.2017
140	113	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.09.2017
140	113	P	no ASA	No complete chain of medication supply	06.04.2018
140	113	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.07.2018
140	136	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.07.2019
140	251	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.09.2017

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
140	252	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.08.2017
140	252	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.08.2017
140	254	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.02.2018
140	257	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.08.2017
140	331	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.03.2018
140	399	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.07.2018
140	551	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.09.2021
140	568	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.05.2018
140	592	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.12.2020
140	592	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.12.2018
140	717	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.03.2020
140	803	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.01.2022
140	841	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.03.2019
140	1101	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.11.2019
140	1101	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.05.2021
140	1266	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.05.2020
140	1781	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.01.2022
140	2349	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.05.2022
145	671	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.08.2019
153	35	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.12.2016
153	35	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	06.10.2016
153	106	E	ASA	Simultaneous intake of study medication and other oral anticoagulation	18.05.2017
153	319	P	ASA	Measurement of creatinine value at baseline visit older 28 days	26.10.2017
153	1098	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	29.04.2019
153	1545	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.03.2021
153	1545	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.03.2021
153	1935	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.06.2021
153	1935	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.06.2021
153	1935	P	ASA	Measurement of creatinine value at baseline visit older 28 days	21.01.2021
153	2142	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	08.06.2021
153	2730	E	ASA	Measurement of creatinine value at baseline visit older 28 days	08.08.2022
154	110	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.03.2021
154	181	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.06.2017
154	297	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.09.2018
161	230	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.10.2018
161	361	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.12.2017
161	978	P	ASA	Measurement of creatinine value at baseline visit older 28 days	07.02.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
161	978	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.07.2019
166	2671	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.11.2022
171	2304	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.10.2021
173	176	P	no ASA	No complete chain of medication supply	08.12.2020
173	242	E	ASA	12-lead ECG at baseline not performed	02.08.2017
173	322	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.11.2017
173	322	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.11.2017
173	553	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	15.05.2018
173	553	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.06.2018
173	585	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.06.2019
173	975	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.05.2021
173	1062	P	ASA	No complete chain of medication supply	30.04.2021
173	1067	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.08.2020
173	1067	P	no ASA	No complete chain of medication supply	27.04.2020
173	1319	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.10.2020
173	1716	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.07.2022
173	1758	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.07.2021
173	2124	P	ASA	No complete chain of medication supply	14.06.2022
173	2124	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.08.2022
173	2453	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.02.2022
173	2453	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	27.01.2022
174	306	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.12.2017
174	1008	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.09.2019
174	1008	P	ASA	No complete chain of medication supply	11.09.2019
174	1672	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.09.2021
174	2176	P	ASA	No complete chain of medication supply	06.07.2022
174	2566	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.10.2022
175	515	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.04.2018
175	2536	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.04.2022
175	2536	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.04.2022
179	308	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	19.10.2017
179	1868	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.03.2021
179	2193	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.08.2021
179	2193	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.08.2021
189	1331	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	15.10.2019
195	283	E	no ASA	Previous participation in the present trial NOAH - AFNET 6	26.09.2017
195	396	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.03.2018

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
195	398	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.07.2018
195	412	P	ASA	Simultaneous intake of study medication and other oral anticoagulation	15.10.2021
195	519	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.03.2020
195	519	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.01.2021
195	633	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.07.2019
195	1233	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.08.2019
195	1233	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.08.2019
198	144	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	25.04.2017
198	1857	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.05.2021
202	419	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.01.2021
202	419	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	30.01.2018
202	556	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	31.05.2018
205	182	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.12.2017
205	182	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.12.2017
205	184	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.06.2017
205	207	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.06.2018
205	285	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.10.2019
205	366	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.01.2018
205	748	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.10.2019
205	946	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.02.2019
205	946	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.02.2019
208	516	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	06.01.2021
208	524	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.10.2018
208	1036	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.05.2019
208	1036	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.05.2019
208	1449	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.12.2019
209	79	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.12.2018
209	141	P	no ASA	No complete chain of medication supply	08.11.2018
211	204	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.06.2017
211	250	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.09.2017
217	49	P	no ASA	No complete chain of medication supply	11.06.2018
217	49	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.06.2022
226	293	P	ASA	Measurement of creatinine value at baseline visit older 28 days	05.10.2017
226	1404	E	ASA	No complete chain of medication supply	01.06.2022
226	1670	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.12.2020
226	2089	E	no ASA	No complete chain of medication supply	13.05.2022
226	2120	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.09.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
232	228	E	no ASA	No complete chain of medication supply	31.01.2018
232	1152	E	ASA	Measurement of creatinine value at baseline visit older 28 days	29.05.2019
264	408	P	no ASA	No complete chain of medication supply	02.08.2022
264	747	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.10.2021
264	1544	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.09.2021
264	1753	E	no ASA	No complete chain of medication supply	17.03.2022
267	829	P	ASA	No complete chain of medication supply	04.06.2019
267	832	E	ASA	No complete chain of medication supply	29.12.2020
267	937	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.01.2020
267	937	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.01.2020
267	937	E	ASA	No complete chain of medication supply	31.07.2019
308	217	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.03.2018
326	501	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.08.2019
326	501	E	ASA	Measurement of creatinine value at baseline visit older 28 days	28.03.2018
377	72	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.08.2019
377	175	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.06.2019
406	1003	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.02.2019
414	246	E	no ASA	12-lead ECG at baseline not performed	08.08.2017
414	246	E	no ASA	No complete chain of medication supply	04.09.2018
414	268	E	ASA	12-lead ECG at baseline not performed	05.09.2017
414	433	P	ASA	No complete chain of medication supply	18.09.2020
414	433	P	ASA	12-lead ECG at baseline not performed	05.02.2018
414	584	P	ASA	Previous participation in the present trial NOAH - AFNET 6	31.05.2018
414	584	P	ASA	12-lead ECG at baseline not performed	31.05.2018
414	670	E	ASA	No complete chain of medication supply	26.02.2019
414	670	E	ASA	12-lead ECG at baseline not performed	14.08.2018
414	970	E	ASA	No complete chain of medication supply	04.02.2021
414	988	P	no ASA	No complete chain of medication supply	02.03.2021
414	1510	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.03.2021
414	1541	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	29.01.2020
414	1541	P	ASA	12-lead ECG at baseline not performed	29.01.2020
414	1610	E	ASA	Measurement of creatinine value at baseline visit older 28 days	05.03.2020
414	1610	E	ASA	No complete chain of medication supply	30.12.2021
414	1610	E	ASA	12-lead ECG at baseline not performed	05.03.2020
414	1626	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.09.2021
414	1686	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.01.2021
414	1767	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.03.2021
414	1777	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	24.06.2020
414	1777	E	ASA	12-lead ECG at baseline not performed	24.06.2020
414	1777	E	ASA	No complete chain of medication supply	19.09.2022
414	1783	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.04.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
414	1783	E	ASA	No complete chain of medication supply	01.04.2021
414	1845	P	ASA	Participation in another clinical trial (within the past 2 months or still ongoing)	27.10.2020
414	1941	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.03.2021
414	1943	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.08.2021
414	1943	E	ASA	12-lead ECG at baseline not performed	25.01.2021
414	2174	E	ASA	12-lead ECG at baseline not performed	18.06.2021
414	2183	E	no ASA	No complete chain of medication supply	01.02.2022
414	2183	E	no ASA	12-lead ECG at baseline not performed	01.07.2021
414	2323	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.05.2022
414	2424	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.06.2022
414	2469	E	ASA	Measurement of creatinine value at baseline visit older 28 days	03.02.2022
414	2507	E	no ASA	12-lead ECG at baseline not performed	02.03.2022
414	2507	E	no ASA	No complete chain of medication supply	19.09.2022
414	2570	E	no ASA	12-lead ECG at baseline not performed	30.03.2022
414	2571	P	ASA	12-lead ECG at baseline not performed	01.04.2022
414	2571	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.04.2022
416	84	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.03.2017
416	84	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.03.2017
416	86	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.03.2017
416	469	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.04.2018
416	1001	E	no ASA	No complete chain of medication supply	09.09.2019
419	211	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.06.2018
419	247	E	ASA	No complete chain of medication supply	03.02.2020
419	323	E	no ASA	No complete chain of medication supply	19.05.2020
419	323	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.05.2019
419	464	P	no ASA	No complete chain of medication supply	05.03.2019
419	494	P	ASA	No complete chain of medication supply	05.04.2022
419	637	E	no ASA	No complete chain of medication supply	02.02.2021
419	945	E	no ASA	No complete chain of medication supply	28.07.2020
419	1260	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.11.2019
419	2172	E	ASA	No complete chain of medication supply	22.07.2022
421	77	E	ASA	Simultaneous intake of study medication and other oral anticoagulation	12.01.2019
421	78	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.01.2017
421	126	P	ASA	No complete chain of medication supply	28.09.2020
421	155	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.11.2017
421	157	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.06.2017
421	236	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.01.2018
421	236	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.02.2019
421	290	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.10.2017
421	430	P	no ASA	No complete chain of medication supply	18.02.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
421	544	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.05.2018
421	685	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.08.2022
421	828	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.03.2019
421	854	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.12.2018
421	854	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.12.2018
421	907	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.02.2019
421	985	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.08.2019
421	1046	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.04.2020
421	1046	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.04.2020
421	1216	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.01.2020
421	1307	E	ASA	No complete chain of medication supply	28.09.2020
421	1357	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.11.2019
421	1505	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.02.2020
421	1584	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	12.05.2020
421	1584	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.11.2020
421	1602	E	ASA	Simultaneous intake of study medication and other oral anticoagulation	30.07.2020
421	1602	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.09.2020
421	1806	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.12.2021
421	1841	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.11.2020
421	1883	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.09.2021
421	1956	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.02.2021
421	1991	E	no ASA	Simultaneous intake of study medication and other oral anticoagulation	19.04.2021
421	2033	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.07.2021
421	2034	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.10.2021
421	2152	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.06.2022
421	2227	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.02.2022
421	2228	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.08.2022
421	2232	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	31.08.2021
421	2232	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.08.2021
421	2264	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.09.2021
421	2325	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.11.2021
421	2596	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.05.2022
421	2604	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.05.2022
421	2654	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.08.2022
426	569	P	no ASA	No complete chain of medication supply	24.06.2022
426	930	E	no ASA	No complete chain of medication supply	13.08.2021
426	1468	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.12.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
426	1468	E	ASA	No complete chain of medication supply	21.07.2020
426	1642	P	ASA	No complete chain of medication supply	28.06.2021
427	508	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.04.2018
427	847	P	ASA	No complete chain of medication supply	10.06.2019
427	1089	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.11.2020
427	1089	E	ASA	No complete chain of medication supply	30.10.2019
428	326	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	01.11.2017
428	326	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.08.2018
445	651	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.07.2021
445	652	P	ASA	Measurement of creatinine value at baseline visit older 28 days	01.08.2018
445	784	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	31.10.2018
445	784	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.08.2020
445	784	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.08.2020
445	785	P	ASA	Measurement of creatinine value at baseline visit older 28 days	31.10.2018
445	786	P	ASA	Measurement of creatinine value at baseline visit older 28 days	31.10.2018
445	1507	E	ASA	No complete chain of medication supply	09.08.2022
445	1507	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	17.02.2020
445	2209	E	no ASA	No complete chain of medication supply	05.08.2022
445	2209	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.09.2022
445	2324	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.04.2022
470	529	E	ASA	No complete chain of medication supply	29.10.2019
479	76	P	ASA	No complete chain of medication supply	15.01.2018
479	535	P	no ASA	12-lead ECG at baseline not performed	25.04.2018
487	405	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.06.2018
487	1246	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.02.2021
487	1246	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.03.2021
487	1652	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.04.2022
487	2059	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	21.04.2021
488	5	P	no ASA	Drug abuse or clinically manifest alcohol abuse	06.07.2016
488	25	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.02.2022
488	47	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.11.2019
488	134	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	10.04.2017
488	135	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.11.2017
488	135	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.11.2017
488	139	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.05.2017
488	206	P	ASA	Measurement of creatinine value at baseline visit older 28 days	28.06.2017
488	206	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	28.06.2017
488	213	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.07.2018
488	370	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.06.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
488	390	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.02.2018
488	898	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.12.2020
488	1099	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.12.2019
488	1133	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.11.2019
488	1244	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.05.2022
488	1361	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.11.2019
488	1532	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.03.2021
488	1824	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	13.10.2020
488	2372	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.01.2022
502	166	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.06.2017
502	195	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.06.2017
502	227	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.07.2020
502	227	E	no ASA	No complete chain of medication supply	30.01.2019
502	270	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.03.2018
502	309	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.05.2018
502	334	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.04.2018
502	425	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.03.2018
502	835	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.08.2019
502	1283	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.04.2020
502	1283	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.04.2020
502	1440	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	09.12.2019
502	1535	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.06.2020
502	1585	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.07.2020
502	1782	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.09.2020
502	2081	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.07.2021
502	2496	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.05.2022
529	317	E	no ASA	No complete chain of medication supply	12.11.2019
529	447	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.07.2018
529	489	P	ASA	No complete chain of medication supply	18.10.2022
529	658	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.08.2018
529	703	E	ASA	No complete chain of medication supply	15.10.2020
529	926	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.04.2019
529	1006	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.08.2019
529	1050	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.06.2019
529	1068	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	20.04.2021
529	1072	P	ASA	No complete chain of medication supply	26.10.2022
529	1072	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.04.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
529	1121	P	no ASA	No complete chain of medication supply	29.06.2022
529	1199	P	no ASA	No complete chain of medication supply	29.12.2021
529	1234	E	ASA	No complete chain of medication supply	10.02.2020
529	1254	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.10.2019
529	1343	E	no ASA	No complete chain of medication supply	01.12.2021
529	1354	P	no ASA	No complete chain of medication supply	05.11.2020
529	1399	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.05.2020
529	1550	P	ASA	Any history of overt AF or atrial flutter	10.03.2020
529	1593	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.05.2022
529	1635	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.12.2020
529	1780	P	no ASA	No complete chain of medication supply	05.10.2022
529	1813	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	05.10.2020
529	1813	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.10.2021
529	1813	P	no ASA	No complete chain of medication supply	19.04.2021
529	1846	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.03.2021
529	1846	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.03.2021
529	1898	E	no ASA	No complete chain of medication supply	23.06.2021
529	1898	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.11.2022
529	1927	E	no ASA	No complete chain of medication supply	03.08.2022
529	1927	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.08.2022
529	1951	E	no ASA	No complete chain of medication supply	23.08.2021
529	1965	P	no ASA	No complete chain of medication supply	02.09.2021
529	1987	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.03.2021
529	1987	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.03.2021
529	2104	P	no ASA	No complete chain of medication supply	03.06.2022
529	2104	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.09.2022
529	2104	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.06.2022
529	2216	E	no ASA	No complete chain of medication supply	21.02.2022
529	2220	P	ASA	No complete chain of medication supply	23.02.2022
529	2256	P	no ASA	No complete chain of medication supply	21.03.2022
529	2258	P	no ASA	No complete chain of medication supply	04.10.2022
529	2328	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.03.2022
529	2545	P	ASA	No complete chain of medication supply	03.10.2022
529	2555	P	ASA	No complete chain of medication supply	05.10.2022
530	429	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.03.2018
530	429	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.03.2018
530	1059	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.04.2020
530	1513	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.03.2020
530	1552	P	no ASA	No complete chain of medication supply	20.09.2022
531	241	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	27.07.2017

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
532	311	P	ASA	No complete chain of medication supply	05.11.2019
535	605	P	no ASA	No complete chain of medication supply	31.12.2020
535	756	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.10.2018
535	1268	P	no ASA	No complete chain of medication supply	05.09.2022
535	1393	P	no ASA	No complete chain of medication supply	03.12.2020
535	1393	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.05.2022
536	991	P	no ASA	No complete chain of medication supply	30.08.2019
536	1328	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.11.2019
536	1818	E	ASA	No complete chain of medication supply	21.04.2021
536	1818	E	ASA	Measurement of creatinine value at baseline visit older 28 days	07.10.2020
536	1818	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.10.2021
541	470	E	no ASA	No complete chain of medication supply	23.03.2021
541	470	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.04.2021
544	137	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.04.2017
544	156	P	no ASA	No complete chain of medication supply	01.11.2022
544	179	P	ASA	No complete chain of medication supply	03.06.2021
544	310	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.05.2018
544	958	E	ASA	Measurement of creatinine value at baseline visit older 28 days	29.01.2019
544	1005	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	26.02.2019
544	1005	E	ASA	Measurement of creatinine value at baseline visit older 28 days	26.02.2019
544	1005	E	ASA	No complete chain of medication supply	10.03.2020
544	1190	E	ASA	Measurement of creatinine value at baseline visit older 28 days	19.06.2019
544	1190	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.06.2020
544	1193	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	20.06.2019
544	1336	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.04.2020
544	1336	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	17.10.2019
544	1367	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.08.2020
544	1482	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.01.2022
544	1508	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.08.2020
544	1606	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.11.2020
544	1683	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.01.2021
544	1683	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.01.2022
544	1831	P	no ASA	Any history of overt AF or atrial flutter	20.10.2020
547	378	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.01.2018
547	378	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.01.2018
547	392	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.03.2020
547	392	E	ASA	No complete chain of medication supply	23.01.2019
547	454	P	no ASA	No complete chain of medication supply	05.09.2018
547	573	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.06.2018
547	864	E	no ASA	No complete chain of medication supply	17.11.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
547	922	P	no ASA	No complete chain of medication supply	04.01.2021
547	1517	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.07.2020
547	1922	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	02.11.2022
547	1922	P	ASA	No complete chain of medication supply	03.08.2022
547	2214	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.09.2021
547	2214	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.09.2021
547	2380	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.07.2022
547	2380	E	no ASA	No complete chain of medication supply	17.06.2022
547	2411	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.03.2022
557	394	E	no ASA	No complete chain of medication supply	28.07.2020
557	502	E	ASA	No complete chain of medication supply	06.04.2020
557	598	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.09.2018
557	1117	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.12.2020
557	1232	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.11.2019
564	462	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.03.2018
564	548	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	09.05.2018
564	548	E	ASA	Simultaneous intake of study medication and other oral anticoagulation	07.05.2022
564	1110	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.11.2019
605	298	E	ASA	Measurement of creatinine value at baseline visit older 28 days	10.10.2017
605	298	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.09.2020
608	572	P	ASA	Measurement of creatinine value at baseline visit older 28 days	29.05.2018
608	572	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	02.07.2018
608	816	P	ASA	No complete chain of medication supply	13.10.2020
608	816	P	ASA	12-lead ECG at baseline not performed	13.11.2018
608	816	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.03.2019
608	869	E	ASA	12-lead ECG at baseline not performed	05.12.2018
608	869	E	ASA	No complete chain of medication supply	03.06.2020
608	954	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.07.2019
608	973	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	04.02.2019
608	1091	P	no ASA	12-lead ECG at baseline not performed	18.04.2019
608	1091	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.10.2020
608	1471	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.07.2020
608	1484	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.02.2021
608	1766	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	09.09.2020
608	1774	P	ASA	No complete chain of medication supply	29.09.2021
608	1791	E	ASA	No complete chain of medication supply	01.04.2021
608	1993	E	no ASA	No complete chain of medication supply	16.09.2022
608	2036	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.04.2021
608	2645	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.12.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
608	2645	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	08.06.2022
641	138	P	no ASA	No complete chain of medication supply	03.11.2021
641	238	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.01.2018
641	238	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.01.2018
641	274	E	no ASA	No complete chain of medication supply	15.04.2019
641	274	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	08.09.2017
641	286	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.04.2018
641	286	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.04.2018
641	286	P	ASA	No complete chain of medication supply	11.04.2018
641	292	E	no ASA	No complete chain of medication supply	08.05.2019
641	292	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.07.2021
641	422	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.11.2022
641	422	P	no ASA	No complete chain of medication supply	13.09.2022
641	473	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.11.2022
641	473	P	no ASA	No complete chain of medication supply	19.09.2018
641	478	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.04.2018
641	552	P	ASA	No complete chain of medication supply	11.12.2019
641	552	P	ASA	Previous participation in the present trial NOAH - AFNET 6	15.05.2018
641	581	P	ASA	No complete chain of medication supply	15.01.2020
641	588	E	no ASA	No complete chain of medication supply	25.12.2018
641	588	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.04.2019
641	643	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.01.2019
641	746	E	no ASA	No complete chain of medication supply	24.04.2019
641	1015	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.03.2019
641	1167	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.12.2019
641	1280	E	no ASA	No complete chain of medication supply	07.10.2020
641	1430	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.07.2020
641	1430	P	no ASA	No complete chain of medication supply	17.06.2020
641	1498	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.07.2020
641	1691	E	ASA	No complete chain of medication supply	27.01.2021
641	1691	E	ASA	Measurement of creatinine value at baseline visit older 28 days	15.07.2020
641	1719	P	ASA	No complete chain of medication supply	15.02.2021
641	1719	P	ASA	Measurement of creatinine value at baseline visit older 28 days	03.08.2020
641	1807	P	ASA	No complete chain of medication supply	14.04.2021
641	1807	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.05.2021
641	1828	E	no ASA	No complete chain of medication supply	29.12.2021
641	1828	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.06.2021
641	1828	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.11.2022
641	1855	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.09.2022
641	1855	E	no ASA	No complete chain of medication supply	24.05.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
641	1905	P	no ASA	No complete chain of medication supply	15.07.2022
641	1944	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.08.2021
641	1944	E	no ASA	No complete chain of medication supply	17.08.2021
641	1981	P	no ASA	No complete chain of medication supply	08.09.2021
641	1990	E	ASA	No complete chain of medication supply	21.03.2022
641	2016	P	ASA	No complete chain of medication supply	29.09.2021
641	2112	E	no ASA	No complete chain of medication supply	01.12.2021
641	2166	P	ASA	No complete chain of medication supply	05.01.2022
641	2168	P	no ASA	No complete chain of medication supply	05.01.2022
641	2196	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.02.2022
641	2343	P	no ASA	No complete chain of medication supply	30.05.2022
641	2343	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.11.2022
641	2637	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.11.2022
641	2667	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.11.2022
653	2448	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.07.2022
655	152	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.11.2020
655	379	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.07.2018
655	379	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.07.2018
655	560	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.02.2021
655	597	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.03.2020
655	597	P	no ASA	No complete chain of medication supply	03.07.2019
655	1457	P	ASA	No complete chain of medication supply	30.12.2021
663	223	E	no ASA	No complete chain of medication supply	18.01.2019
663	223	E	no ASA	Drug abuse or clinically manifest alcohol abuse	12.07.2017
663	223	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.02.2019
663	579	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	05.06.2018
663	579	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.12.2018
663	579	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.12.2019
669	259	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.07.2020
669	450	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.08.2021
669	1075	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.10.2021
669	1723	E	no ASA	Simultaneous intake of study medication and other oral anticoagulation	21.10.2020
673	91	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	08.02.2017
673	269	P	ASA	No complete chain of medication supply	26.09.2019
673	269	P	ASA	Measurement of creatinine value at baseline visit older 28 days	05.09.2017
673	324	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	31.10.2017
673	427	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.02.2018
673	833	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	20.11.2018
673	1048	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	01.04.2019
673	1097	P	ASA	No complete chain of medication supply	12.05.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
673	1136	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.12.2019
673	1136	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.12.2019
673	1287	P	no ASA	No complete chain of medication supply	30.03.2020
673	1866	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	12.11.2020
673	1875	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	19.11.2020
673	2139	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	07.06.2021
673	2146	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.12.2021
674	888	P	no ASA	No complete chain of medication supply	29.12.2021
675	233	E	no ASA	No complete chain of medication supply	10.08.2022
675	307	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.08.2018
675	345	P	no ASA	Any history of overt AF or atrial flutter	22.11.2017
675	384	E	no ASA	No complete chain of medication supply	23.01.2019
679	1078	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	15.04.2019
680	711	P	ASA	No complete chain of medication supply	01.04.2020
680	851	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.12.2020
680	851	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.05.2019
680	851	P	no ASA	No complete chain of medication supply	23.12.2020
680	887	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.06.2019
680	902	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.06.2019
680	934	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.10.2020
680	934	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	16.01.2019
680	955	E	ASA	No complete chain of medication supply	27.07.2021
680	979	P	ASA	No complete chain of medication supply	02.02.2021
680	1034	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.08.2022
680	1034	E	ASA	No complete chain of medication supply	06.10.2021
680	1037	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.06.2019
680	1037	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.06.2019
680	1041	E	ASA	No complete chain of medication supply	06.10.2021
680	1065	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.03.2020
680	1071	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.04.2020
680	1156	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.12.2019
680	1316	E	ASA	No complete chain of medication supply	09.10.2020
680	1318	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
680	1318	P	ASA	No complete chain of medication supply	21.04.2020
680	1340	E	ASA	No complete chain of medication supply	05.05.2020
680	1417	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.12.2019
680	1474	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.07.2020
680	1474	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.07.2020
680	1530	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.02.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
680	1609	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.06.2021
680	1664	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.07.2020
680	1815	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.10.2021
680	1960	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.04.2021
680	2045	P	ASA	No complete chain of medication supply	27.10.2021
680	2048	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.10.2021
680	2091	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.11.2022
680	2092	P	ASA	No complete chain of medication supply	06.06.2022
680	2233	P	ASA	No complete chain of medication supply	15.09.2022
680	2254	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.09.2021
680	2306	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.04.2022
680	2306	P	ASA	No complete chain of medication supply	25.10.2022
680	2317	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.08.2022
680	2410	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.02.2022
680	2509	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.04.2022
680	2509	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.04.2022
680	2539	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.07.2022
685	403	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.02.2018
687	1614	E	no ASA	No complete chain of medication supply	27.06.2022
687	1614	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.08.2022
688	112	E	ASA	No complete chain of medication supply	28.09.2017
688	112	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	21.06.2017
688	112	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.03.2018
688	123	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.07.2017
688	231	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.07.2017
688	550	E	no ASA	No complete chain of medication supply	14.05.2019
688	640	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.02.2021
688	983	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.05.2019
688	1373	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.06.2020
688	1601	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.04.2021
688	1975	E	ASA	No complete chain of medication supply	06.09.2022
688	2165	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.03.2022
688	2252	P	ASA	No complete chain of medication supply	13.09.2022
689	578	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.06.2019
689	726	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.04.2022
689	990	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	14.02.2019
689	990	P	no ASA	No complete chain of medication supply	27.08.2020
690	2190	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.10.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
693	1453	E	no ASA	No complete chain of medication supply	29.06.2020
693	1454	P	no ASA	No complete chain of medication supply	08.01.2021
693	1518	E	no ASA	No complete chain of medication supply	26.08.2020
693	1519	P	no ASA	No complete chain of medication supply	13.09.2021
693	1559	E	no ASA	No complete chain of medication supply	28.09.2021
693	2282	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.05.2022
697	428	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	14.05.2018
697	428	E	ASA	No complete chain of medication supply	05.08.2022
698	219	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.11.2017
698	303	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.09.2018
698	475	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.08.2018
698	475	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.01.2020
698	1176	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.06.2022
700	1018	E	no ASA	No complete chain of medication supply	09.03.2020
702	158	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.03.2018
702	174	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.03.2019
702	289	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.08.2020
702	444	E	ASA	No complete chain of medication supply	21.08.2019
702	444	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.08.2020
702	1296	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.10.2019
702	1296	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.10.2019
702	1381	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	07.11.2019
702	1381	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.12.2019
704	612	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.12.2018
704	635	P	ASA	No complete chain of medication supply	05.02.2019
704	649	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.03.2020
704	649	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.02.2019
704	761	P	ASA	12-lead ECG at baseline not performed	22.10.2018
704	1528	P	no ASA	No complete chain of medication supply	11.12.2020
704	1528	P	no ASA	12-lead ECG at baseline not performed	21.02.2020
705	1412	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.12.2020
705	1416	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.01.2021
705	1416	E	ASA	No complete chain of medication supply	16.12.2020
705	1479	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	16.01.2020
705	1479	E	ASA	No complete chain of medication supply	09.02.2022
705	1479	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.07.2020
705	1509	E	ASA	No complete chain of medication supply	07.03.2022
705	1621	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.08.2020
705	1647	P	no ASA	No complete chain of medication supply	31.12.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
705	1748	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.03.2021
705	1773	P	ASA	No complete chain of medication supply	29.09.2022
705	1860	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.12.2020
705	1860	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.12.2020
705	2137	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	04.06.2021
705	2158	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.06.2022
705	2158	E	ASA	No complete chain of medication supply	21.12.2022
705	2272	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.03.2022
705	2367	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.08.2022
705	2367	E	ASA	No complete chain of medication supply	09.06.2022
705	2396	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.06.2022
705	2579	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.10.2022
705	2579	P	ASA	No complete chain of medication supply	21.10.2022
705	2740	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.08.2022
705	2742	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
706	208	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.11.2019
706	248	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.10.2020
706	278	E	ASA	No complete chain of medication supply	15.09.2022
706	557	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.11.2018
706	557	E	ASA	No complete chain of medication supply	08.06.2020
706	654	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.02.2019
706	689	E	ASA	No complete chain of medication supply	16.09.2020
706	689	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.09.2020
707	1214	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.01.2020
708	374	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	13.12.2017
708	374	E	no ASA	No complete chain of medication supply	27.06.2018
708	374	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.03.2020
708	374	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.03.2020
708	492	E	no ASA	No complete chain of medication supply	02.10.2018
708	492	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	20.03.2018
708	492	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.02.2019
708	512	P	ASA	Measurement of creatinine value at baseline visit older 28 days	06.04.2018
708	512	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.04.2018
708	525	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.04.2019
708	525	E	ASA	No complete chain of medication supply	29.10.2018
708	525	E	ASA	Measurement of creatinine value at baseline visit older 28 days	16.04.2018
711	439	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.03.2018
711	439	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.03.2018

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
711	518	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.09.2018
711	611	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.06.2019
711	1253	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	16.08.2019
711	1253	P	no ASA	Simultaneous intake of study medication and any antiplatelet agent	19.04.2022
711	1458	E	ASA	No complete chain of medication supply	01.07.2021
724	1039	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.10.2020
724	1039	P	ASA	Measurement of creatinine value at baseline visit older 28 days	26.03.2019
724	1040	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.10.2019
724	1061	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.10.2019
724	1061	P	ASA	Measurement of creatinine value at baseline visit older 28 days	05.04.2019
724	1076	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.11.2019
724	1286	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.03.2020
724	1286	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.03.2022
724	1286	E	no ASA	No complete chain of medication supply	29.09.2020
724	1452	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.06.2021
724	1452	P	ASA	No complete chain of medication supply	05.01.2021
725	1223	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.07.2019
725	1326	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.12.2019
725	1442	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	20.12.2021
725	1631	P	ASA	No complete chain of medication supply	14.12.2021
725	1839	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.12.2020
725	1954	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.02.2022
725	1954	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.08.2022
725	2038	P	ASA	No complete chain of medication supply	26.10.2021
725	2040	E	ASA	No complete chain of medication supply	26.10.2021
725	2197	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	02.02.2022
728	387	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.11.2019
728	452	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.02.2018
728	577	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.12.2018
728	883	E	no ASA	No complete chain of medication supply	15.12.2020
728	883	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.06.2022
728	1124	P	no ASA	No complete chain of medication supply	03.12.2020
728	1166	P	ASA	No complete chain of medication supply	30.06.2021
730	1560	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.10.2020
730	1560	P	no ASA	No complete chain of medication supply	25.09.2020
740	753	E	no ASA	No complete chain of medication supply	01.10.2021
740	866	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.09.2019
740	925	P	ASA	No complete chain of medication supply	19.07.2021
740	925	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.07.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
740	2436	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	18.01.2022
741	421	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	15.07.2022
741	483	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.03.2020
741	483	P	no ASA	No complete chain of medication supply	26.03.2020
741	484	P	no ASA	No complete chain of medication supply	23.03.2021
741	840	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.05.2020
741	921	P	ASA	No complete chain of medication supply	20.07.2020
741	1095	E	no ASA	No complete chain of medication supply	08.05.2020
741	1118	E	no ASA	No complete chain of medication supply	27.05.2020
741	1356	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	12.04.2021
741	1356	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.03.2020
741	1408	E	no ASA	No complete chain of medication supply	08.06.2020
741	1825	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.10.2021
741	2253	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.09.2021
741	2253	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.09.2021
741	2294	E	no ASA	No complete chain of medication supply	27.09.2022
741	2315	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.02.2022
741	2319	E	no ASA	No complete chain of medication supply	11.05.2022
741	2368	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.05.2022
741	2650	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.10.2022
741	2660	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.10.2022
748	532	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.02.2020
748	576	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.06.2018
748	687	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.08.2018
748	852	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.11.2020
748	957	P	ASA	No complete chain of medication supply	28.07.2020
748	957	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.09.2020
748	1026	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.06.2022
748	1096	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.05.2019
748	1139	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.06.2019
748	1249	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.02.2020
748	1272	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.07.2020
748	1301	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.12.2019
748	1546	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.09.2020
748	1591	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.11.2020
748	1591	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.11.2021
748	1674	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.07.2020
748	1674	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.07.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
748	1757	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.02.2021
748	1757	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.02.2021
748	1885	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.11.2021
748	1982	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.08.2021
748	2136	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.05.2022
748	2222	E	no ASA	No complete chain of medication supply	24.02.2022
748	2222	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
748	2236	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.10.2021
748	2384	P	ASA	No complete chain of medication supply	21.06.2022
748	2384	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.07.2022
748	2466	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.07.2022
748	2676	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.09.2022
748	2734	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.08.2022
752	316	P	no ASA	No complete chain of medication supply	14.05.2019
752	371	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.03.2019
752	371	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.03.2019
752	457	P	ASA	No complete chain of medication supply	24.02.2021
752	457	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.09.2021
752	517	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.07.2020
752	570	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.07.2018
752	862	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.11.2020
752	863	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.06.2019
752	1025	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.05.2019
756	426	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.08.2022
756	426	E	no ASA	No complete chain of medication supply	20.08.2019
756	448	P	no ASA	No complete chain of medication supply	22.02.2022
756	448	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.08.2022
756	495	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	22.06.2018
756	495	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.09.2022
756	1069	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.11.2019
758	481	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.03.2020
758	481	P	ASA	No complete chain of medication supply	26.09.2022
758	760	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.10.2019
758	760	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	22.10.2018
758	811	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	13.05.2019
758	811	E	ASA	No complete chain of medication supply	21.11.2022
758	1086	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.10.2019
758	1086	P	no ASA	No complete chain of medication supply	11.11.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
768	740	E	no ASA	No complete chain of medication supply	22.04.2019
768	1205	P	no ASA	No complete chain of medication supply	08.01.2020
768	1341	P	no ASA	No complete chain of medication supply	05.05.2020
774	312	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.05.2018
774	497	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.04.2021
774	497	E	ASA	No complete chain of medication supply	14.04.2020
774	619	P	ASA	No complete chain of medication supply	11.08.2021
775	362	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.05.2019
775	362	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.05.2018
775	603	E	ASA	No complete chain of medication supply	05.02.2019
775	603	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.03.2021
775	1060	E	ASA	Measurement of creatinine value at baseline visit older 28 days	05.04.2019
775	1060	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.03.2021
775	1350	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	23.10.2019
775	1350	E	no ASA	No complete chain of medication supply	22.09.2021
775	1350	E	no ASA	12-lead ECG at baseline not performed	23.10.2019
775	1366	P	ASA	12-lead ECG at baseline not performed	06.11.2019
775	1366	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.05.2020
775	1555	P	ASA	Measurement of creatinine value at baseline visit older 28 days	12.03.2020
775	1555	P	ASA	Simultaneous intake of study medication and other oral anticoagulation	22.12.2020
775	1555	P	ASA	12-lead ECG at baseline not performed	12.03.2020
775	1555	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.09.2020
775	1562	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	21.10.2020
775	1562	E	ASA	Measurement of creatinine value at baseline visit older 28 days	18.03.2020
775	1562	E	ASA	12-lead ECG at baseline not performed	18.03.2020
775	1562	E	ASA	No complete chain of medication supply	15.09.2021
775	1563	P	no ASA	No complete chain of medication supply	08.09.2021
775	1563	P	no ASA	12-lead ECG at baseline not performed	19.03.2020
775	1563	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	19.03.2020
775	1563	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.09.2021
775	1851	E	ASA	No complete chain of medication supply	20.10.2021
775	1851	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.01.2022
775	1851	E	ASA	Measurement of creatinine value at baseline visit older 28 days	05.11.2020
775	1959	P	ASA	Measurement of creatinine value at baseline visit older 28 days	15.02.2021
775	2121	E	ASA	Measurement of creatinine value at baseline visit older 28 days	26.05.2021
775	2270	P	ASA	No complete chain of medication supply	30.03.2022
775	2270	P	ASA	Measurement of creatinine value at baseline visit older 28 days	15.09.2021
776	299	E	ASA	Measurement of creatinine value at baseline visit older 28 days	12.10.2017
776	299	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.10.2017
776	614	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	05.07.2018
776	2145	P	ASA	Measurement of creatinine value at baseline visit older 28 days	10.06.2021
776	2145	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.06.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
776	2173	P	ASA	Measurement of creatinine value at baseline visit older 28 days	29.06.2021
776	2727	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	28.07.2022
780	625	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.08.2018
780	673	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.04.2020
784	1375	P	ASA	No complete chain of medication supply	25.05.2020
784	1376	E	ASA	No complete chain of medication supply	25.05.2020
788	1623	E	no ASA	No complete chain of medication supply	24.12.2021
788	1623	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
788	1624	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.01.2021
788	1718	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.02.2021
788	1718	P	ASA	No complete chain of medication supply	19.08.2022
788	1733	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.08.2020
788	2212	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.10.2021
788	2295	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	30.09.2021
788	2295	E	ASA	No complete chain of medication supply	27.10.2022
799	1291	E	no ASA	No complete chain of medication supply	01.04.2021
800	642	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.08.2018
800	653	E	ASA	Simultaneous intake of study medication and other oral anticoagulation	22.01.2020
800	1421	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.12.2019
800	1667	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.12.2020
800	1984	E	no ASA	No complete chain of medication supply	31.08.2022
800	1984	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	26.02.2021
801	531	P	ASA	No complete chain of medication supply	21.04.2020
801	531	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.11.2020
801	531	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.10.2018
801	543	E	ASA	No complete chain of medication supply	13.05.2019
801	543	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	02.05.2018
801	639	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.08.2018
801	693	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	03.09.2018
801	693	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.10.2018
801	710	E	no ASA	No complete chain of medication supply	27.09.2021
801	738	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.10.2019
801	741	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.04.2019
801	969	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.06.2019
801	1007	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.10.2020
801	1007	E	no ASA	No complete chain of medication supply	11.09.2019
801	1288	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.03.2021
801	1288	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.03.2020
801	1309	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.03.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
801	1772	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.10.2020
801	1794	E	ASA	No complete chain of medication supply	27.09.2021
801	1800	E	ASA	No complete chain of medication supply	27.09.2021
801	1810	P	no ASA	No complete chain of medication supply	27.10.2022
801	2247	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.08.2022
801	2247	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	30.08.2022
801	2273	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.03.2022
801	2378	E	ASA	No complete chain of medication supply	17.06.2022
801	2514	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	02.09.2022
801	2593	P	no ASA	No complete chain of medication supply	04.11.2022
802	349	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.03.2018
802	705	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.08.2020
802	1082	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.07.2019
815	986	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.06.2019
815	986	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.06.2019
815	1387	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.02.2021
815	1551	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.03.2022
815	2200	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.11.2021
824	1473	P	no ASA	No complete chain of medication supply	28.07.2020
824	1497	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.02.2022
824	1497	P	no ASA	No complete chain of medication supply	25.01.2022
824	2002	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	06.09.2021
824	2010	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.09.2021
826	892	P	no ASA	No complete chain of medication supply	06.01.2020
826	1425	P	no ASA	Simultaneous intake of study medication and other oral anticoagulation	29.06.2021
826	2738	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.09.2022
827	764	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.04.2019
827	770	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.10.2021
827	807	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.06.2020
833	976	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.07.2019
833	1224	P	ASA	Simultaneous intake of study medication and any antiplatelet agent	03.11.2020
833	1923	E	ASA	Measurement of creatinine value at baseline visit older 28 days	12.01.2021
836	795	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.04.2019
836	795	P	no ASA	No complete chain of medication supply	06.05.2020
836	802	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.10.2019
836	1996	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.03.2021
836	2329	E	no ASA	No eligible AHRE episodes documented (($\geq$ 170 bpm atrial rate and $\geq$ 6 min duration))	08.11.2021
857	1830	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.01.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
857	1835	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.12.2020
857	1876	P	ASA	No complete chain of medication supply	19.05.2022
857	1957	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	11.02.2021
857	2006	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	02.04.2021
862	2465	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	03.02.2022
866	677	P	ASA	No complete chain of medication supply	10.09.2019
866	767	E	ASA	No complete chain of medication supply	18.05.2020
866	775	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	26.10.2018
866	775	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.11.2020
866	775	E	ASA	No complete chain of medication supply	08.11.2019
866	788	E	ASA	No complete chain of medication supply	25.11.2019
866	791	P	ASA	No complete chain of medication supply	18.11.2019
866	952	E	ASA	No complete chain of medication supply	07.11.2019
866	952	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.11.2020
866	953	E	ASA	No complete chain of medication supply	14.02.2020
866	1100	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.05.2021
866	1100	E	ASA	No complete chain of medication supply	14.11.2019
866	1100	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	02.05.2019
866	1106	E	ASA	No complete chain of medication supply	23.11.2021
866	1106	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.05.2020
866	1149	P	ASA	No complete chain of medication supply	02.12.2020
866	1196	E	ASA	No complete chain of medication supply	03.01.2020
866	1715	E	ASA	No complete chain of medication supply	12.02.2021
866	2026	P	ASA	Simultaneous intake of study medication and any antiplatelet agent	24.03.2021
866	2107	P	ASA	No complete chain of medication supply	30.11.2021
866	2110	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	19.05.2021
866	2110	P	ASA	No complete chain of medication supply	01.12.2021
868	630	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.02.2019
868	630	P	ASA	No complete chain of medication supply	30.01.2019
868	645	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	30.07.2018
868	645	E	no ASA	No complete chain of medication supply	29.09.2021
868	645	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.04.2022
868	645	E	no ASA	12-lead ECG at baseline not performed	30.07.2018
868	665	P	ASA	No complete chain of medication supply	28.02.2019
868	701	P	no ASA	No complete chain of medication supply	25.03.2019
868	734	P	ASA	No complete chain of medication supply	28.10.2021
868	754	E	ASA	No complete chain of medication supply	09.10.2020
868	759	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	19.10.2018
868	759	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.11.2020
868	759	E	no ASA	No complete chain of medication supply	03.05.2019
868	798	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.05.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
868	798	E	ASA	No complete chain of medication supply	21.05.2019
868	800	E	ASA	No complete chain of medication supply	20.11.2019
868	800	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.11.2019
868	800	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.08.2022
868	825	P	ASA	12-lead ECG at baseline not performed	16.11.2018
868	825	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	16.11.2018
868	825	P	ASA	No complete chain of medication supply	25.05.2020
868	897	E	ASA	No complete chain of medication supply	02.07.2019
868	899	P	no ASA	No complete chain of medication supply	02.07.2019
868	923	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.01.2020
868	923	E	ASA	No complete chain of medication supply	26.01.2021
868	924	P	no ASA	No complete chain of medication supply	31.01.2020
868	967	E	ASA	No complete chain of medication supply	15.08.2019
868	982	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.08.2020
868	982	E	no ASA	No complete chain of medication supply	19.02.2021
868	982	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	07.02.2019
868	1228	E	no ASA	No complete chain of medication supply	01.01.2021
868	1228	E	no ASA	12-lead ECG at baseline not performed	19.07.2019
868	1315	P	ASA	12-lead ECG at baseline not performed	07.10.2019
868	1315	P	ASA	No complete chain of medication supply	15.10.2020
868	1315	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	02.04.2020
868	1315	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	07.10.2019
868	1669	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.07.2022
868	1669	P	ASA	No complete chain of medication supply	12.01.2021
868	2098	E	ASA	12-lead ECG at baseline not performed	13.05.2021
868	2098	E	ASA	No complete chain of medication supply	25.11.2021
868	2098	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.07.2022
869	683	E	no ASA	No complete chain of medication supply	05.03.2021
869	683	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.09.2021
869	730	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.10.2021
869	730	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	02.10.2018
869	780	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.04.2020
869	823	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.08.2020
869	1104	E	no ASA	No complete chain of medication supply	10.11.2020
869	1180	P	no ASA	No complete chain of medication supply	26.12.2019
869	1261	P	ASA	No complete chain of medication supply	10.03.2020
869	1276	E	ASA	No complete chain of medication supply	22.09.2020
869	1276	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.03.2021
869	1311	P	no ASA	No complete chain of medication supply	16.04.2020
869	1311	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.10.2021
869	1355	P	ASA	No complete chain of medication supply	11.05.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
869	1390	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.05.2020
869	1465	E	ASA	No complete chain of medication supply	12.07.2021
869	1481	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.07.2020
869	1481	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.08.2022
869	1717	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.02.2022
869	1717	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.02.2021
869	1970	E	ASA	No complete chain of medication supply	03.09.2021
869	1970	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.09.2021
869	2008	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.09.2021
869	2208	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.02.2022
869	2208	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.02.2022
870	769	E	ASA	No complete chain of medication supply	01.11.2021
870	971	P	no ASA	No complete chain of medication supply	17.08.2019
870	1020	E	no ASA	No complete chain of medication supply	15.09.2020
870	1020	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.09.2019
870	1020	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.09.2020
870	1028	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.10.2021
870	1028	P	ASA	No complete chain of medication supply	30.09.2019
870	1073	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.04.2020
870	1073	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.10.2021
870	1073	P	ASA	No complete chain of medication supply	21.04.2021
870	1077	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.09.2019
870	1077	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.10.2021
870	1077	E	ASA	No complete chain of medication supply	19.04.2021
870	1131	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.11.2021
870	1131	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.11.2021
870	1142	E	ASA	No complete chain of medication supply	25.11.2021
870	1265	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.10.2021
870	1265	P	ASA	No complete chain of medication supply	09.09.2021
870	1265	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.02.2020
870	1267	P	ASA	No complete chain of medication supply	19.09.2022
870	1271	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.03.2020
870	1297	E	ASA	No complete chain of medication supply	17.04.2022
870	1303	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.04.2021
870	1303	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.05.2020
870	1303	P	ASA	No complete chain of medication supply	09.04.2020
870	1395	P	ASA	No complete chain of medication supply	23.11.2021
870	1464	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.06.2020
870	1514	P	ASA	No complete chain of medication supply	17.08.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
870	1596	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.09.2022
870	1596	E	ASA	No complete chain of medication supply	14.06.2021
870	1596	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	02.03.2022
870	1627	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.12.2020
870	1627	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.12.2020
870	1675	P	no ASA	No complete chain of medication supply	14.01.2021
870	1684	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.01.2021
870	1685	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.01.2021
870	1685	P	ASA	No complete chain of medication supply	15.08.2022
870	1967	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.08.2021
870	1967	E	ASA	No complete chain of medication supply	02.03.2022
870	1976	P	ASA	No complete chain of medication supply	08.09.2021
870	1994	E	ASA	No complete chain of medication supply	22.09.2022
870	1999	E	ASA	No complete chain of medication supply	19.09.2022
870	2000	E	ASA	No complete chain of medication supply	22.09.2022
870	2043	P	ASA	No complete chain of medication supply	26.04.2022
870	2201	P	ASA	No complete chain of medication supply	02.02.2022
870	2262	E	ASA	No complete chain of medication supply	25.03.2022
870	2292	P	ASA	No complete chain of medication supply	19.10.2022
870	2314	E	ASA	No complete chain of medication supply	05.05.2022
870	2369	P	ASA	No complete chain of medication supply	13.06.2022
871	732	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.04.2019
871	732	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.04.2019
871	732	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	04.10.2018
871	762	E	ASA	No complete chain of medication supply	01.11.2019
871	804	P	ASA	No complete chain of medication supply	23.05.2019
871	804	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.01.2022
871	804	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	08.11.2018
871	808	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.03.2019
871	812	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.05.2019
871	872	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.06.2019
871	872	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.02.2021
871	872	E	ASA	No complete chain of medication supply	27.12.2019
871	874	P	ASA	No complete chain of medication supply	24.06.2019
871	874	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.02.2020
871	880	E	ASA	No complete chain of medication supply	22.06.2020
871	880	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.06.2019
871	914	P	ASA	No complete chain of medication supply	10.07.2019
871	914	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	26.12.2018
871	914	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.07.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
871	962	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.02.2020
871	962	P	ASA	No complete chain of medication supply	14.08.2019
871	962	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.11.2021
871	963	P	ASA	No complete chain of medication supply	14.08.2019
871	972	E	ASA	No complete chain of medication supply	18.08.2019
871	1012	E	ASA	No complete chain of medication supply	13.09.2019
872	696	E	no ASA	No complete chain of medication supply	03.09.2019
872	696	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	26.03.2020
872	700	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.03.2020
872	727	E	no ASA	No complete chain of medication supply	11.04.2019
872	755	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.04.2019
872	755	E	no ASA	No complete chain of medication supply	21.10.2019
872	776	P	no ASA	No complete chain of medication supply	06.11.2019
872	889	P	no ASA	No complete chain of medication supply	30.06.2020
872	916	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.06.2019
872	916	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	28.12.2018
872	916	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.08.2020
872	916	E	no ASA	No complete chain of medication supply	31.12.2019
872	917	E	no ASA	No complete chain of medication supply	24.01.2020
872	1109	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.11.2019
872	1109	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.05.2021
872	1143	P	no ASA	No complete chain of medication supply	09.12.2019
873	910	E	ASA	No detection feature activated for adequate detection of AHRE	22.12.2018
873	910	E	ASA	No complete chain of medication supply	06.07.2019
873	910	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	22.12.2018
873	910	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.09.2019
874	743	P	ASA	12-lead ECG at baseline not performed	09.10.2018
874	743	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	13.08.2019
874	806	P	ASA	No complete chain of medication supply	24.05.2021
874	827	P	ASA	No complete chain of medication supply	04.12.2020
874	831	E	no ASA	Simultaneous intake of study medication and other oral anticoagulation	14.06.2019
874	831	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	20.11.2018
874	857	E	ASA	No complete chain of medication supply	04.12.2020
874	858	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	30.11.2018
874	870	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	06.12.2018
874	870	P	ASA	No complete chain of medication supply	31.12.2019
874	871	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.01.2021
874	871	E	ASA	No complete chain of medication supply	20.06.2019
874	911	E	no ASA	No complete chain of medication supply	08.07.2019
874	913	P	no ASA	No complete chain of medication supply	04.07.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
874	932	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	15.01.2019
874	994	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.07.2020
874	994	P	ASA	No complete chain of medication supply	03.09.2019
874	1002	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.07.2022
874	1002	P	ASA	No complete chain of medication supply	10.03.2021
874	1158	P	no ASA	No complete chain of medication supply	17.12.2019
874	1171	E	ASA	No complete chain of medication supply	24.12.2019
874	1171	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.02.2020
874	1171	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.06.2020
874	1181	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.06.2021
874	1208	P	no ASA	No complete chain of medication supply	11.07.2020
874	1208	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.09.2022
874	1469	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.07.2020
874	1469	E	ASA	No complete chain of medication supply	24.07.2020
874	1726	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.01.2021
875	636	E	no ASA	No complete chain of medication supply	07.02.2022
875	638	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	24.07.2018
875	638	E	ASA	No complete chain of medication supply	09.08.2021
875	646	P	ASA	No complete chain of medication supply	12.02.2019
875	1027	E	ASA	No complete chain of medication supply	27.09.2019
875	1197	E	no ASA	No complete chain of medication supply	03.01.2020
875	1608	P	no ASA	No complete chain of medication supply	21.06.2021
875	1676	E	no ASA	No complete chain of medication supply	20.07.2022
875	1931	E	no ASA	No complete chain of medication supply	03.08.2021
875	2004	P	no ASA	No complete chain of medication supply	23.09.2021
876	708	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.09.2021
876	736	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.03.2019
876	744	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.04.2019
876	859	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	30.11.2018
876	877	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	10.12.2018
876	877	P	no ASA	No complete chain of medication supply	15.06.2021
876	896	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	19.12.2019
876	1385	P	no ASA	No complete chain of medication supply	23.05.2022
876	1628	P	no ASA	No complete chain of medication supply	23.06.2021
877	695	P	no ASA	No complete chain of medication supply	29.03.2022
877	706	E	ASA	No complete chain of medication supply	01.04.2020
877	757	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.11.2020
877	757	P	no ASA	No complete chain of medication supply	01.05.2020
877	757	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.11.2020
877	801	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.05.2019

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
877	801	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.05.2019
877	853	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.12.2018
877	860	P	ASA	No complete chain of medication supply	29.06.2020
877	876	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.12.2020
877	876	E	ASA	No complete chain of medication supply	07.12.2019
877	890	E	no ASA	No complete chain of medication supply	31.12.2019
877	1023	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.05.2020
877	1084	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	24.02.2022
877	1141	P	no ASA	No complete chain of medication supply	05.12.2019
877	1141	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.12.2019
877	1275	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.03.2020
877	1275	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.03.2020
877	1352	P	ASA	No complete chain of medication supply	17.11.2020
877	1592	P	no ASA	No complete chain of medication supply	03.06.2022
877	1648	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.06.2020
877	1649	E	ASA	No complete chain of medication supply	01.08.2022
877	1679	E	no ASA	No complete chain of medication supply	20.01.2021
877	1679	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.01.2021
877	1795	P	no ASA	No complete chain of medication supply	03.04.2021
877	1803	E	ASA	No complete chain of medication supply	12.04.2021
877	2003	E	ASA	No complete chain of medication supply	23.09.2021
877	2132	P	no ASA	No complete chain of medication supply	15.12.2021
877	2260	P	ASA	No complete chain of medication supply	23.03.2022
877	2285	P	no ASA	No complete chain of medication supply	12.04.2022
881	893	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	11.06.2019
884	1377	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	11.11.2019
884	1495	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.08.2022
901	882	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	05.09.2019
901	984	P	ASA	Measurement of creatinine value at baseline visit older 28 days	11.02.2019
901	1038	E	ASA	Measurement of creatinine value at baseline visit older 28 days	26.03.2019
901	1038	E	ASA	Simultaneous intake of study medication and any antiplatelet agent	28.10.2020
901	1057	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	04.04.2019
901	1057	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.05.2019
901	1120	E	ASA	Measurement of creatinine value at baseline visit older 28 days	13.05.2019
901	1120	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	19.05.2019
901	1138	E	ASA	Measurement of creatinine value at baseline visit older 28 days	23.05.2019
901	1564	P	ASA	Measurement of creatinine value at baseline visit older 28 days	24.03.2020
901	1566	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	24.03.2020
901	1711	P	no ASA	Measurement of creatinine value at baseline visit older 28 days	29.07.2020
901	1720	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	04.08.2020
901	1859	P	ASA	Measurement of creatinine value at baseline visit older 28 days	11.11.2020

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
901	1880	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	25.11.2020
901	2135	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	03.06.2021
901	2435	E	no ASA	No complete chain of medication supply	02.08.2022
901	2723	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.09.2022
965	1323	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.09.2020
965	2280	P	ASA	No complete chain of medication supply	07.04.2022
965	2321	E	ASA	No complete chain of medication supply	16.05.2022
965	2420	E	ASA	12-lead ECG at baseline not performed	10.01.2022
965	2420	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.02.2022
965	2420	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	10.01.2022
965	2426	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.05.2022
965	2426	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	12.01.2022
965	2426	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.05.2022
965	2550	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.08.2022
965	2664	E	ASA	12-lead ECG at baseline not performed	22.06.2022
1023	709	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.03.2019
1023	709	P	no ASA	No eligible device (exempt ILR) with AHRE detection implanted at least 2 months prior randomisation	14.09.2018
1023	2022	E	no ASA	12-lead ECG at baseline not performed	23.03.2021
1023	2022	E	no ASA	No complete chain of medication supply	08.04.2022
1023	2097	P	ASA	No complete chain of medication supply	30.11.2021
1023	2097	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.01.2022
1023	2097	P	ASA	12-lead ECG at baseline not performed	13.05.2021
1023	2271	P	no ASA	No complete chain of medication supply	30.03.2022
1023	2271	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.09.2022
1023	2366	P	ASA	Any history of overt AF or atrial flutter	25.11.2021
1028	1172	P	ASA	No complete chain of medication supply	09.11.2021
1028	1313	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.10.2019
1028	1314	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	04.03.2022
1028	1314	E	no ASA	No complete chain of medication supply	09.11.2021
1028	1342	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.03.2022
1028	1547	E	no ASA	No complete chain of medication supply	05.10.2022
1028	1553	E	ASA	No complete chain of medication supply	05.10.2022
1028	1561	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.09.2021
1028	1561	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.01.2022
1028	1561	P	no ASA	No complete chain of medication supply	21.09.2021
1028	2159	P	no ASA	No complete chain of medication supply	21.06.2022
1028	2160	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	16.06.2021
1028	2251	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	31.08.2021
1028	2504	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.10.2022
1028	2504	E	no ASA	No complete chain of medication supply	13.09.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1028	2573	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.11.2022
1028	2573	P	ASA	No complete chain of medication supply	18.10.2022
1028	2696	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	16.08.2022
1029	900	E	no ASA	No complete chain of medication supply	02.07.2019
1029	900	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.09.2021
1029	949	P	ASA	No complete chain of medication supply	06.08.2019
1029	949	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.02.2020
1029	961	P	no ASA	No complete chain of medication supply	18.02.2020
1029	961	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	06.08.2019
1029	1053	E	no ASA	No complete chain of medication supply	17.08.2020
1029	1053	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.02.2020
1029	1159	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.11.2019
1029	1159	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.11.2019
1029	1177	E	no ASA	No complete chain of medication supply	14.01.2020
1029	1177	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	11.06.2019
1029	1177	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.06.2020
1029	1177	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.06.2020
1029	1236	P	no ASA	No complete chain of medication supply	11.02.2020
1029	1242	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.03.2020
1029	1242	P	no ASA	No complete chain of medication supply	18.02.2020
1029	1243	E	ASA	No complete chain of medication supply	05.04.2022
1029	1256	E	ASA	No complete chain of medication supply	15.03.2021
1029	1335	E	no ASA	No complete chain of medication supply	28.04.2020
1029	1437	P	no ASA	No complete chain of medication supply	26.01.2021
1029	1437	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	14.07.2020
1029	1437	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	06.12.2019
1029	1441	E	no ASA	No complete chain of medication supply	23.06.2020
1029	1588	P	no ASA	No complete chain of medication supply	08.06.2021
1029	1617	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.08.2020
1029	1735	E	no ASA	No complete chain of medication supply	02.03.2021
1029	1878	P	no ASA	No complete chain of medication supply	02.05.2022
1029	1878	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.10.2022
1029	1917	E	ASA	No complete chain of medication supply	27.12.2021
1029	1936	E	ASA	No complete chain of medication supply	19.08.2022
1029	1936	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	25.01.2021
1029	1986	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.09.2021
1029	1986	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.09.2021
1029	2090	E	ASA	Measurement of creatinine value at baseline visit older 28 days	10.05.2021
1029	2090	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	12.09.2021
1029	2093	P	ASA	No complete chain of medication supply	23.11.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1029	2108	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.06.2021
1029	2108	E	ASA	Measurement of creatinine value at baseline visit older 28 days	19.05.2021
1029	2108	E	ASA	12-lead ECG at baseline not performed	19.05.2021
1029	2155	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.07.2022
1029	2155	P	ASA	No complete chain of medication supply	28.12.2021
1029	2178	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.12.2021
1029	2180	E	ASA	No complete chain of medication supply	17.01.2022
1029	2180	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	18.03.2022
1029	2180	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.03.2022
1029	2345	P	no ASA	No complete chain of medication supply	30.05.2022
1039	1227	E	ASA	12-lead ECG at baseline not performed	18.07.2019
1039	1227	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.01.2020
1039	1459	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	20.09.2021
1039	1459	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	17.12.2019
1039	1467	E	ASA	No complete chain of medication supply	29.06.2021
1039	1534	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.06.2022
1048	2170	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.06.2021
1049	2231	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.09.2021
1067	2714	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	19.07.2022
1074	1325	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.10.2020
1074	1325	P	no ASA	No complete chain of medication supply	26.10.2021
1074	1365	E	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	05.11.2019
1074	1365	E	no ASA	No complete chain of medication supply	24.05.2022
1074	1403	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	25.11.2019
1074	1424	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.12.2019
1074	1607	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.12.2020
1074	1697	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	29.09.2020
1074	1756	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	07.11.2020
1074	1756	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	07.11.2020
1074	1838	P	ASA	No complete chain of medication supply	09.11.2021
1074	1838	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.04.2021
1074	1842	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.01.2021
1074	1893	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	08.06.2022
1074	1968	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.07.2021
1074	2143	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.11.2021
1074	2162	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	14.08.2021
1074	2235	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.02.2022
1074	2235	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	01.02.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1074	2246	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	22.02.2022
1074	2308	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.03.2022
1074	2561	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.04.2022
1074	2665	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.10.2022
1074	2707	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1074	2720	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	17.08.2022
1080	1371	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.10.2020
1080	1371	E	no ASA	No complete chain of medication supply	13.05.2021
1080	1388	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.11.2021
1080	1388	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.07.2020
1080	1388	E	no ASA	No complete chain of medication supply	28.05.2020
1080	1396	P	no ASA	No complete chain of medication supply	01.06.2020
1080	1396	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.05.2021
1080	1444	E	no ASA	No complete chain of medication supply	29.12.2020
1080	1462	E	no ASA	No complete chain of medication supply	30.12.2020
1080	1475	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	03.07.2020
1080	1475	P	no ASA	No complete chain of medication supply	15.01.2021
1080	1478	P	no ASA	No complete chain of medication supply	25.08.2021
1080	1536	P	no ASA	No complete chain of medication supply	15.09.2020
1080	1538	E	no ASA	Simultaneous intake of study medication and other oral anticoagulation	03.03.2020
1080	1571	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.10.2020
1080	1571	E	no ASA	No complete chain of medication supply	13.05.2021
1080	1573	P	no ASA	No complete chain of medication supply	13.05.2021
1080	1643	P	no ASA	No complete chain of medication supply	30.12.2020
1080	1643	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.06.2021
1080	1660	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.12.2020
1080	1665	E	no ASA	No complete chain of medication supply	13.01.2022
1080	1671	E	no ASA	No complete chain of medication supply	27.07.2022
1080	1695	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	1703	P	no ASA	No complete chain of medication supply	15.08.2022
1080	1707	P	no ASA	No complete chain of medication supply	10.02.2021
1080	1721	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	1734	P	no ASA	No complete chain of medication supply	01.09.2021
1080	1736	E	no ASA	No complete chain of medication supply	03.03.2021
1080	1740	P	no ASA	No complete chain of medication supply	11.03.2022
1080	1740	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.08.2021
1080	1743	P	no ASA	No complete chain of medication supply	14.03.2022
1080	1744	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.08.2021
1080	1746	P	no ASA	No complete chain of medication supply	21.03.2022
1080	1754	E	no ASA	No complete chain of medication supply	30.03.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1080	1762	E	no ASA	No complete chain of medication supply	24.03.2021
1080	1765	E	ASA	No complete chain of medication supply	23.03.2022
1080	1778	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	10.01.2021
1080	1784	P	ASA	No complete chain of medication supply	28.03.2022
1080	1798	P	no ASA	No complete chain of medication supply	14.10.2021
1080	1814	P	no ASA	No complete chain of medication supply	13.10.2021
1080	1814	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	1822	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.05.2021
1080	1822	E	no ASA	No complete chain of medication supply	26.04.2021
1080	1843	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.04.2021
1080	1856	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.09.2022
1080	1856	P	no ASA	No complete chain of medication supply	25.05.2021
1080	1861	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	05.05.2021
1080	1874	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	1874	P	no ASA	No complete chain of medication supply	03.06.2021
1080	1888	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	09.09.2022
1080	1888	P	no ASA	No complete chain of medication supply	16.06.2021
1080	1912	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	1912	E	no ASA	No complete chain of medication supply	05.07.2021
1080	1914	P	no ASA	No complete chain of medication supply	06.07.2021
1080	1937	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.11.2021
1080	1937	E	no ASA	No complete chain of medication supply	10.08.2021
1080	1948	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	15.08.2022
1080	1977	E	no ASA	No complete chain of medication supply	08.09.2021
1080	1977	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.11.2021
1080	1988	E	no ASA	No complete chain of medication supply	13.09.2021
1080	1988	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.10.2021
1080	1992	E	no ASA	No complete chain of medication supply	17.03.2022
1080	2017	P	no ASA	No complete chain of medication supply	31.03.2022
1080	2018	E	no ASA	No complete chain of medication supply	14.04.2022
1080	2018	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2020	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	16.09.2021
1080	2020	P	no ASA	No complete chain of medication supply	31.03.2022
1080	2024	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2024	P	no ASA	No complete chain of medication supply	06.04.2022
1080	2037	E	no ASA	No complete chain of medication supply	21.10.2021
1080	2057	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.11.2021
1080	2058	P	no ASA	No complete chain of medication supply	02.11.2021
1080	2058	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.12.2021
1080	2078	P	ASA	No complete chain of medication supply	12.11.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1080	2084	E	no ASA	No complete chain of medication supply	17.11.2021
1080	2085	E	ASA	No complete chain of medication supply	19.05.2022
1080	2085	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.11.2021
1080	2099	E	no ASA	No complete chain of medication supply	30.05.2022
1080	2099	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2123	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	26.11.2021
1080	2123	P	no ASA	No complete chain of medication supply	10.06.2022
1080	2125	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	08.12.2021
1080	2126	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.05.2022
1080	2131	E	no ASA	No complete chain of medication supply	14.12.2021
1080	2131	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	03.02.2022
1080	2138	E	no ASA	No complete chain of medication supply	14.06.2022
1080	2138	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2141	E	no ASA	No complete chain of medication supply	21.12.2021
1080	2141	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	18.02.2022
1080	2147	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2147	E	no ASA	No complete chain of medication supply	23.12.2021
1080	2150	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.02.2022
1080	2150	P	no ASA	No complete chain of medication supply	23.12.2021
1080	2154	P	no ASA	No complete chain of medication supply	08.01.2022
1080	2154	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	21.01.2022
1080	2184	E	no ASA	No complete chain of medication supply	24.01.2022
1080	2185	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2185	P	no ASA	No complete chain of medication supply	24.01.2022
1080	2194	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2206	P	no ASA	No complete chain of medication supply	22.08.2022
1080	2215	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2215	E	no ASA	No complete chain of medication supply	21.02.2022
1080	2237	E	no ASA	No complete chain of medication supply	08.03.2022
1080	2237	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.06.2022
1080	2244	E	no ASA	No complete chain of medication supply	09.03.2022
1080	2284	E	no ASA	No complete chain of medication supply	11.04.2022
1080	2288	P	no ASA	No complete chain of medication supply	13.04.2022
1080	2293	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	17.05.2022
1080	2293	P	no ASA	No complete chain of medication supply	13.04.2022
1080	2305	E	no ASA	No complete chain of medication supply	27.04.2022
1080	2305	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2310	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2310	E	ASA	No complete chain of medication supply	03.05.2022
1080	2320	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	25.04.2022

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1080	2320	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	24.06.2022
1080	2348	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1080	2348	P	no ASA	No complete chain of medication supply	31.05.2022
1080	2441	E	no ASA	No complete chain of medication supply	05.08.2022
1080	2441	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.12.2022
1085	1386	E	no ASA	No complete chain of medication supply	03.06.2021
1085	1433	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.12.2019
1085	1433	P	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	23.12.2019
1085	1483	E	no ASA	No complete chain of medication supply	22.01.2021
1085	1483	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	10.07.2020
1085	1962	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	22.04.2021
1085	1980	E	ASA	No complete chain of medication supply	08.09.2021
1085	2114	E	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	23.05.2021
1085	2298	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.07.2022
1085	2301	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	31.03.2022
1085	2307	E	no ASA	No complete chain of medication supply	29.04.2022
1085	2500	P	ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	01.03.2022
1085	2511	E	ASA	No complete chain of medication supply	15.09.2022
1085	2625	P	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	24.05.2022
1089	1317	E	no ASA	No complete chain of medication supply	12.10.2020
1089	1333	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.04.2021
1089	1333	E	no ASA	No complete chain of medication supply	15.11.2022
1089	1358	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	28.01.2020
1089	1364	P	no ASA	No complete chain of medication supply	24.05.2022
1089	1364	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.05.2020
1089	1427	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	31.03.2021
1089	1492	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	21.01.2021
1089	1502	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	05.10.2021
1089	1504	E	no ASA	No complete chain of medication supply	16.08.2022
1089	1504	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	04.02.2020
1089	1504	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	29.09.2021
1089	1522	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	11.08.2020
1089	2066	E	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	28.04.2021
1089	2205	P	no ASA	No complete chain of medication supply	08.02.2022
1089	2230	P	no ASA	No complete chain of medication supply	01.03.2022
1089	2230	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	15.03.2022
1089	2336	P	no ASA	No complete chain of medication supply	02.08.2022
1097	2331	E	ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	08.11.2021
1097	2331	E	ASA	12-lead ECG at baseline not performed	08.11.2021

Centre -ID	Patient -ID	Random group[1]	Random stratum (indication)[2]	Deviation type	Deviation date
1097	2401	E	ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	30.06.2022
1104	2169	E	no ASA	No complete chain of medication supply	07.07.2022
1104	2535	P	no ASA	No complete chain of medication supply	27.09.2022
1104	2553	E	no ASA	No complete chain of medication supply	06.10.2022
1104	2560	P	ASA	No complete chain of medication supply	06.10.2022
1111	2531	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	09.09.2022
1116	2576	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	07.04.2022
1116	2646	P	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	04.11.2022
1121	2377	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	27.12.2021
1121	2444	E	no ASA	Intake of study drugs < 80% of the number of pills calculated for the corresponding time period	20.09.2022
1121	2444	E	no ASA	Simultaneous intake of study medication and any antiplatelet agent	19.09.2022
1121	2587	P	no ASA	Permanent stop of IMP intake without indication or contraindication for oral anticoagulation	27.06.2022
1121	2587	P	no ASA	No eligible AHRE episodes documented ((≥ 170 bpm atrial rate and ≥ 6 min duration))	20.04.2022
1133	2699	E	ASA	Measurement of creatinine value at baseline visit older 28 days	06.07.2022
1138	2477	E	no ASA	Measurement of creatinine value at baseline visit older 28 days	15.02.2022
1146	2713	P	ASA	Simultaneous intake of study medication and any antiplatelet agent	15.07.2022
1147	2525	E	no ASA	Simultaneous intake of study medication and other oral anticoagulation	13.08.2022

[1] P = Placebo, E = Edoxaban

[2] ASA = Acetylsalicylic acid

16.2.3 Patients excluded from the efficacy analysis

Table 27 Patients excluded from the efficacy analysis

Patient-ID	Centre-ID	Sex	Age	Random group	Random stratum	Reason
118	9	Male	86	Placebo	ASA indication	No intake of IMP
170	9	Male	78	Placebo	ASA indication	No intake of IMP
237	9	Female	70	Edoxaban	ASA indication	No intake of IMP
694	9	Male	78	Placebo	ASA indication	No intake of IMP
1687	12	Female	81	Placebo	no ASA indication	No intake of IMP
148	16	Male	81	Placebo	no ASA indication	No intake of IMP
1033	16	Male	85	Edoxaban	no ASA indication	No intake of IMP
608	22	Male	73			Not randomised
927	22	Male	77			Not randomised
140	23	Female	81	Placebo	ASA indication	Not randomised
964	34	Male	84			Not randomised
301	38	Male	85			Not randomised
63	46	Male	75	Edoxaban	no ASA indication	No intake of IMP
451	57	Male	71	Edoxaban	ASA indication	No intake of IMP
2470	59	Female	92	Edoxaban	ASA indication	No intake of IMP
674	70	Male	89	Edoxaban	ASA indication	No intake of IMP
1910	70	Female	84	Placebo	no ASA indication	No intake of IMP
2028	70	Male	88	Placebo	ASA indication	No intake of IMP
672	86	Female	86	Edoxaban	no ASA indication	No intake of IMP
1085	86	Female	71			Not randomised
13	95	Female	85	Edoxaban	no ASA indication	No intake of IMP
256	95	Female	84			Not randomised
1604	100	Female	65	Placebo	no ASA indication	No intake of IMP
634	133	Male	76	Edoxaban	ASA indication	No intake of IMP
88	140	Male	79			Not randomised
209	140	Male	92	Edoxaban	ASA indication	No intake of IMP
1889	140	Male	78	Edoxaban	ASA indication	No intake of IMP
526	161	Male	78			Not randomised
296	179	Female	69	Edoxaban	no ASA indication	No intake of IMP
989	179	Male	74			Not randomised
1108	179	Male	89			Not randomised

Patient-ID	Centre-ID	Sex	Age	Random group	Random stratum	Reason
351	189	Female	88			Not randomised
424	189	Female	69	Edoxaban	ASA indication	No intake of IMP
169	195	Male	82	Edoxaban	no ASA indication	No intake of IMP
1146	202	Male	69	Edoxaban	ASA indication	No intake of IMP
342	205	Female	88			Not randomised
382	205	Female	76	Edoxaban	ASA indication	No intake of IMP
931	205	Male	68	Placebo	ASA indication	No intake of IMP
609	226	Male	76			Not randomised
346	414	Female	75	Edoxaban	ASA indication	No intake of IMP
2035	414	Male	80	Placebo	no ASA indication	No intake of IMP
2116	414	Male	73			Not randomised
2278	414	Female	80			Not randomised
2309	414	Male	89			Not randomised
2322	414	Female	87			Not randomised
2481	414	Female	88			Not randomised
2497	414	Male	83			Not randomised
2569	414	Male	77			Not randomised
191	416	Male	80			Not randomised
441	419	Male	87			Not randomised
279	421	Male	77	Edoxaban	ASA indication	No intake of IMP
500	421	Male	83	Edoxaban	no ASA indication	AF onset before 1st dose of IMP
699	421	Female	69	Edoxaban	no ASA indication	No intake of IMP
1299	421	Female	85	Placebo	ASA indication	No intake of IMP
2076	421	Female	86			Not randomised
574	459	Male	85			Not randomised
3	488	Male	66			Not randomised
12	488	Male	82			Not randomised
32	488	Female	68			Not randomised
61	488	Female	80			Not randomised
64	488	Male	80	Placebo	ASA indication	No intake of IMP
249	488	Male	85	Placebo	ASA indication	No intake of IMP
277	488	Female	89			Not randomised
327	488	Female	86	Placebo	ASA indication	No intake of IMP
330	488	Male	74			Not randomised
766	488	Female	75	Edoxaban	no ASA indication	No intake of IMP
2591	488	Male	69			Not randomised
198	502	Female	84	Placebo	no ASA indication	No intake of IMP
712	529	Female	76	Placebo	no ASA indication	No intake of IMP
1410	529	Male	73			Not randomised
1763	529	Male	72	Edoxaban	ASA indication	No intake of IMP
1924	529	Male	83	Placebo	ASA indication	No intake of IMP
2334	529	Male	87	Placebo	ASA indication	No intake of IMP
2338	529	Female	77			Not randomised
291	541	Male	77	Placebo	no ASA indication	Not randomised
856	541	Male	72			Not randomised
488	544	Male	73	Edoxaban	no ASA indication	No intake of IMP
940	544	Male	76	Placebo	ASA indication	No intake of IMP
2718	547	Female	82	Edoxaban	no ASA indication	No intake of IMP
2735	547	Female	78	Placebo	ASA indication	No intake of IMP
1322	564	Male	96			Not randomised
817	608	Male	76	Edoxaban	ASA indication	No intake of IMP
542	641	Male	82			Not randomised
1211	641	Female	79	Placebo	no ASA indication	No intake of IMP
2656	655	Male	85	Edoxaban	ASA indication	No intake of IMP
745	674	Male	81			Not randomised
942	675	Male	84	Edoxaban	no ASA indication	No intake of IMP
505	679	Female	85	Placebo	no ASA indication	No intake of IMP
1461	693	Male	83	Placebo	no ASA indication	No intake of IMP
950	702	Male	82	Placebo	ASA indication	No intake of IMP
1677	705	Male	83			Not randomised
2134	705	Female	76	Placebo	ASA indication	No intake of IMP
2291	705	Female	97	Placebo	no ASA indication	No intake of IMP
2432	705	Male	76	Placebo	ASA indication	No intake of IMP
1252	711	Male	72	Edoxaban	ASA indication	No intake of IMP
1258	724	Male	73			Not randomised
1009	725	Male	81	Edoxaban	ASA indication	No intake of IMP
1107	725	Male	67			Not randomised
1524	725	Male	81	Edoxaban	ASA indication	No intake of IMP
2748	725	Female	77			Not randomised
1202	728	Male	91			Not randomised
1207	741	Male	90			Not randomised

Patient-ID	Centre-ID	Sex	Age	Random group	Random stratum	Reason
521	742	Male	73			Not randomised
656	748	Male	80			Not randomised
675	748	Female	92	Edoxaban	ASA indication	No intake of IMP
1597	748	Male	88	Placebo	ASA indication	No intake of IMP
1901	748	Male	82	Placebo	no ASA indication	No intake of IMP
2079	748	Female	83	Placebo	no ASA indication	No intake of IMP
2716	748	Male	80	Edoxaban	ASA indication	No intake of IMP
372	752	Female	88	Placebo	no ASA indication	No intake of IMP
2472	824	Male	69			Not randomised
1431	868	Male	72	Placebo	no ASA indication	No intake of IMP
944	901	Female	78			Not randomised
2480	901	Female	70	Edoxaban	ASA indication	No intake of IMP
2706	901	Male	84	Edoxaban	ASA indication	No intake of IMP
2488	965	Male	79	Placebo	no ASA indication	No intake of IMP
2289	1023	Male	77			Not randomised
797	1028	Male	77			Not randomised
844	1028	Female	69			Not randomised
2269	1039	Male	82			Not randomised
1811	1074	Male	85	Placebo	no ASA indication	No intake of IMP
2012	1080	Female	77	Placebo	no ASA indication	No intake of IMP
1529	1085	Male	70	Placebo	ASA indication	No intake of IMP
1523	1089	Female	84	Edoxaban	no ASA indication	No intake of IMP
2067	1089	Male	96	Edoxaban	no ASA indication	No intake of IMP

16.2.4 Demographic data

Table 28 Individual patient demographics

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	9	46	81	f	PM	184	296	1	4	n	y	n	n	n	n	n	n	30 mg	49,11	69	y	y	y	n	n	n	n
P	ASA	9	48	83	m	PM	2021	545	7	7	y	y	n	y	n	y	n	n	60 mg	72,94	72	n	n	y	n	n	n	n
E	no ASA	9	54	71	m	PM	40	375	1	3	y	y	n	n	n	n	n	n	60 mg	72,06	82	y	n	y	n	n	n	n
E	ASA	9	57	78	m	ICD-CRT	55	284	8	8	y	y	y, it	n	y	y	n	y	30 mg	26,93	69	y	y	n	n	n	n	n
E	ASA	9	66	84	f	PM	729	600	2	6	n	y	n	n	y	n	n	n	30 mg	36,62	80	n	y	n	n	n	n	n
P	ASA	9	75	77	m	ICD-CRT	2880	252	1	6	y	y	n	y	n	n	n	n	30 mg	31,02	72	y	n	n	n	y	n	n
P	no ASA	9	92	78	m	PM	158	400	5	2	n	n	n	n	n	n	n	n	60 mg	103,98		y	n	y	n	n	y	n
E	ASA	9	93	83	m	PM	320	545	12	3	n	y	n	n	n	n	n	n	60 mg	53,85	68	n	n	y	n	n	n	n
P	no ASA	9	96	70	f	PM	1157	594	1	3	n	y	n	n	n	n	n	n	60 mg	67,08	84	n	n	y	n	n	n	n
E	no ASA	9	100	75	m	PM	405	400	8	3	n	y	n	n	n	n	n	n	60 mg	71,6	89	n	n	y	n	n	n	n
P	ASA	9	118	86	m	PM	1635	405	5	4	n	y	n	n	n	n	n	n	30 mg	46,79		n	n	n	n	n	n	n
E	ASA	9	129	77	f	PM	235	405	3	3	n	n	n	n	n	n	n	n	60 mg	55,32	75	y	n	n	n	n	n	n
E	ASA	9	153	71	m	PM	28	591	2	4	n	y	y, oa	n	n	y	y	y	60 mg	63,25	79	y	n	y	n	n	n	n
P	ASA	9	170	78	m	ICD-CRT	153	600	4	5	y	y	n	n	n	n	n	n	30 mg	37,77	71	y	n	n	n	n	n	n
P	ASA	9	192	75	f	PM	1167	231	10	3	n	n	n	n	n	n	n	n	60 mg	76,6	87	n	n	n	n	n	n	n
E	ASA	9	237	70	f	PM	511	230	2	3	n	y	n	n	n	n	n	n	30 mg	54,47	75	y	n	y	n	n	n	n
P	ASA	9	288	83	m	PM	9999	640	236	3	n	y	n	n	n	n	n	n	60 mg	75,32	78	n	y	y	n	n	n	n
E	ASA	9	393	87	m	ICD	284	545	1	5	y	y	n	n	n	y	y	n	30 mg	43,12	77	y	n	y	n	n	n	n
E	no ASA	9	410	69	f	PM	147	600	14	4	n	y	y, oa	n	n	n	n	n	60 mg	123,96	78	n	n	y	n	n	n	n
P	ASA	9	434	91	f	PM	13	400	1	4	n	y	n	n	n	n	n	n	30 mg	21	91	n	n	y	n	n	n	n
P	ASA	9	468	66	m	ICD-CRT	880	500	1	4	y	y	n	n	n	n	y	n	60 mg	60,12	62	n	n	y	n	n	n	n
E	ASA	9	485	82	f	PM	20	280	2	5	n	y	n	n	n	y	n	n	30 mg	29,27	60	y	y	n	n	n	n	n
E	no ASA	9	536	79	f	ICD-CRT	543	600	1	5	y	y	n	n	n	n	n	n	30 mg	50,52	82	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	9	561	66	f	PM-CRT	335	273	5	4	y	y	n	n	n	n	n	n	60 mg	56,56	63	y	n	n	n	n	n	n
E	ASA	9	666	86	m	PM	86	462	22	4	n	y	n	n	n	n	n	n	30 mg	38,36	83	n	n	y	n	n	n	n
P	ASA	9	681	87	f	PM	567	286	12	7	n	y	n	y	y	n	n	n	30 mg	45,57	60	n	y	y	n	n	n	n
E	ASA	9	682	78	m	PM	25	600	2	2	n	n	n	n	n	n	n	n	30 mg	37,21	75	y	n	n	n	n	n	n
P	ASA	9	694	78	m	PM	50	462	1	5	n	y	y, oa	n	n	n	n	n	60 mg	59,34	74	y	n	n	n	n	n	n
P	no ASA	9	697	92	m	PM	1296	600	8	3	n	y	n	n	n	n	n	n	30 mg	33,15	110	n	n	y	n	n	n	n
E	ASA	9	719	89	f	PM	196	545	6	5	n	y	n	n	n	n	n	y	30 mg	47,37	60	n	n	n	n	n	n	n
P	ASA	9	720	84	m	ICD-CRT	1982	349	2	8	y	y	y, oa	n	y	n	y	n	60 mg	60,1	60	y	n	y	n	n	n	n
E	ASA	9	731	71	m	PM	127	343	14	4	n	y	n	n	y	n	n	n	60 mg	77,01	82	n	n	y	n	n	n	n
P	ASA	9	758	85	f	PM	491	545	14	3	n	n	n	n	n	n	n	n	30 mg	62,43	82	n	n	n	n	n	n	y
P	no ASA	9	830	89	m	PM	9999	600	3	3	n	y	n	n	n	n	n	n	30 mg	47,83	64	n	n	y	n	n	n	n
E	ASA	9	843	77	m	PM	16	462	2	2	n	n	n	n	n	n	n	n	60 mg	58,84	80	n	n	n	n	n	n	n
P	no ASA	9	878	84	f	PM	7	286	1	4	n	y	n	n	n	n	n	n	60 mg	54,65	71	n	n	y	n	n	n	n
P	ASA	9	879	72	m	PM	265	640	2	4	y	y	n	n	n	y	y	y	60 mg	98,01	77	y	n	y	n	n	n	n
E	ASA	9	908	69	m	PM	12	293	1	2	n	y	n	n	n	n	n	n	60 mg	101,05	83	n	y	y	n	n	n	n
E	ASA	9	1126	97	m	PM	28	232	5	5	y	y	n	n	n	y	n	n	30 mg	21,69	68	y	n	n	n	n	n	n
E	ASA	9	1127	71	m	PM	532	600	1	3	n	y	n	n	n	n	n	n	30 mg	37,81	76	n	y	y	n	n	n	n
E	ASA	9	1178	80	f	ICD-CRT	483	365	1	7	y	y	y, oa	n	n	y	n	n	30 mg	44,27	86	y	n	y	n	n	n	n
P	ASA	9	1192	73	m	ICD-CRT	599	286	1	4	y	y	n	n	n	n	n	n	30 mg	29,67	84	y	n	n	n	n	n	n
P	ASA	9	1204	75	m	PM	7200	300	1	7	n	y	y, oa	n	y	n	n	n	30 mg	42,8	91	y	y	y	n	n	n	n
P	ASA	9	1213	91	f	PM	207	600	24	8	y	y	n	y	n	n	n	n	30 mg	36,38	86	n	n	n	n	n	n	n
P	ASA	9	1259	75	m	ICM	16	300	1	4	n	y	n	n	n	n	y	y	60 mg	64,89	46	y	n	y	n	n	n	n
E	ASA	9	1278	87	m	PM	209	545	6	5	n	y	n	n	y	n	y	n	30 mg	48,65	79	y	n	n	n	n	n	n
E	ASA	9	1338	88	m	PM	210	400	6	5	n	y	n	n	y	n	n	n	30 mg	47,1	84	n	n	n	n	n	n	n
E	ASA	9	1346	80	f	PM	439	545	4	5	n	y	n	n	n	n	n	n	30 mg	50	85	n	y	n	n	n	y	n
P	no ASA	9	1570	71	m	PM	132		6	2	n	y	n	n	n	n	n	n	60 mg	62,09	76	n	n	y	n	n	n	n
P	ASA	9	1600	77	m	ICD-CRT	249	640	2	4	y	y	n	n	n	n	n	n	60 mg	64,39	60	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	9	1641	86	m	ICM	60		1	6	n	y	n	y	n	y	y	n	30 mg	48,16	90	n	n	y	n	n	n	n
E	no ASA	9	1692	79	m	PM	94	545	2	2	n	n	n	n	n	n	n	n	60 mg	68,8		n	n	n	n	n	n	n
E	ASA	9	1816	73	m	PM	57	545	8	2	n	y	n	n	n	n	n	n	60 mg	62,53	101	n	n	n	n	n	n	n
P	ASA	9	1817	73	f	PM	1174	301	13	3	n	n	y, it	n	n	n	n	y	60 mg	59,54	60	n	n	n	n	n	n	n
P	no ASA	9	1847	74	m	PM	10	200	2	3	y	y	n	n	n	n	n	n	30 mg	43,39	68	y	n	n	n	n	n	n
P	ASA	9	1871	89	f	PM	283	600	1	5	n	y	n	n	n	n	y	n	30 mg	26,56	63	n	y	y	n	n	n	n
E	no ASA	9	1879	73	m	PM	572		7	3	y	y	n	n	n	n	n	n	60 mg	84,09	103	n	y	n	n	n	n	n
E	no ASA	9	1897	65	m	ICD-CRT	1102		1	3	y	y	n	n	n	n	n	n	60 mg	85,91	75	y	n	y	n	n	n	n
E	ASA	9	1961	86	m	PM	10		2	3	n	y	n	n	n	n	y	n	60 mg	50,79		n	n	y	n	n	n	n
P	ASA	9	1974	87	m	PM	46		3	4	y	y	n	n	n	n	n	n	30 mg	45,6	72	n	n	n	n	n	n	n
E	ASA	9	2044	84	m	PM	412		1	4	n	y	n	n	n	y	y	n	60 mg	55,77	86	n	n	y	n	n	n	n
E	ASA	9	2210	73	m	PM	192	640	2	3	n	y	n	n	n	n	n	n	60 mg	95,79	71	n	y	y	n	n	n	n
P	ASA	9	2221	68	m	PM	7	231	1	5	n	y	n	n	y	y	y	y	60 mg	75,22	60	y	n	y	n	n	n	n
P	no ASA	9	2226	86	f	PM	41	545	3	4	n	y	n	n	n	n	n	n	30 mg	42,76		y	n	n	n	n	n	n
E	no ASA	9	2297	80	f	PM	213	600	2	5	y	y	n	n	n	n	n	n	60 mg	53,76	79	n	n	y	n	n	n	n
P	ASA	9	2311	83	f	PM	24	640	1	5	n	y	n	n	n	n	n	n	30 mg	59,26	62	n	n	y	n	n	n	n
E	ASA	9	2333	83	m	PM	597	545	11	4	n	y	n	n	n	n	n	n	60 mg	54,87	67	n	y	y	n	n	n	n
P	no ASA	9	2403	75	m	PM	12		1	3	n	y	n	n	n	n	n	n	60 mg	67,06	68	n	n	n	n	n	n	n
P	ASA	9	2406	86	m	PM	38	500	15	4	n	y	n	n	n	y	y	n	60 mg	58,33	65	n	n	y	n	n	n	n
P	no ASA	9	2408	76	f	PM	107		2	3	n	n	n	n	n	n	n	n	60 mg	80,28	66	n	y	n	n	n	n	n
E	ASA	9	2421	81	f	PM-CRT			1	5	y	y	n	n	n	n	n	n	60 mg	75,9	94	y	y	y	n	n	n	n
E	ASA	9	2479	77	m	PM	74	400	1	4	n	y	y, oa	n	n	n	y	n	60 mg	52,99	89	n	y	y	n	n	n	n
P	no ASA	9	2563	86	m	PM	110	640	2	2	n	n	n	n	n	n	n	n	60 mg	72,7		n	n	n	n	n	n	n
P	ASA	9	2599	81	m	PM	12	273	1	4	n	y	n	n	n	n	y	n	60 mg	56,25	66	n	y	y	n	n	n	n
E	no ASA	9	2615	77	m	PM	1665	600	6	3	n	y	n	n	n	n	n	n	60 mg	98,57	66	n	y	y	n	n	n	n
P	ASA	9	2624	74	m	PM	632		8	3	n	y	n	n	n	n	n	y	60 mg	67,87	52	y	n	y	n	n	n	n
E	no ASA	9	2700	66	f	PM	56		5	3	n	y	n	n	n	n	n	n	60 mg	122,03	73	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	9	2741	72	m	PM	623	600	2	6	n	y	y, oa	y	n	n	n	n	60 mg	70,57		n	n	n	n	n	n	n
E	ASA	12	1581	86	f	PM	83	333	8	6	y	y	y, it	n	n	n	y	y	30 mg	44,82	63	y	n	y	n	n	n	n
P	ASA	12	1582	91	f	PM	619	400	4	5	n	y	n	n	n	y	n	n	30 mg	34,71	80	n	y	y	n	n	n	n
E	no ASA	12	1651	78	m	PM	659	640	1	3	n	y	n	n	n	n	n	n	60 mg	77,02	74	y	y	y	n	n	n	n
E	no ASA	12	1658	81	f	PM	36		1	4	n	y	n	n	n	n	n	n	60 mg	55,07	75	y	y	y	n	n	n	n
P	no ASA	12	1687	81	f	PM	611		4	3	n	n	n	n	n	n	n	n	30 mg	32,74	81	n	n	n	n	n	n	n
P	no ASA	12	1698	85	f	PM	357		1	3	n	n	n	n	n	n	n	n	60 mg	50,5	62	n	n	n	n	n	n	n
P	ASA	12	1701	73	m	PM	37		2	4	n	y	n	n	y	n	n	n	60 mg	83,47	60	y	n	n	n	n	n	n
E	ASA	12	1706	86	m	PM	33		5	3	n	y	n	n	n	n	n	y	30 mg	45,57	89	n	y	n	n	n	n	n
E	ASA	12	1752	86	m	PM	223		2	4	y	y	n	n	n	n	n	n	60 mg	53,98	78	n	n	y	n	n	n	n
P	no ASA	12	1760	93	f	PM	220		3	3	n	n	n	n	n	n	n	n	30 mg	43,35	94	n	n	n	n	n	n	n
E	ASA	12	1761	85	m	PM	241		3	4	n	y	n	n	n	n	n	n	30 mg	35,71	73	y	n	y	n	n	n	n
P	no ASA	12	1775	75	m	PM	56		1	2	n	n	n	n	n	n	n	n	60 mg	92,41	60	y	n	n	n	n	n	n
P	ASA	12	1787	76	m	ICD	9999	640	6	3	y	n	n	n	n	n	n	y	60 mg	56,87	62	y	n	n	n	n	n	n
E	no ASA	12	1789	91	m	PM	9	439	1	2	n	n	n	n	n	n	n	n	30 mg	44,87	80	n	n	n	n	n	n	n
E	no ASA	12	2608	73	m	ICD-CRT	72	640	5	3	y	n	y, oa	n	n	n	n	n	60 mg	63,67	101	y	n	y	n	n	n	n
P	ASA	12	2622	72	m	ICD	180		1	3	y	y	n	n	n	n	n	n	60 mg	73,67	56	y	n	y	n	n	n	n
E	no ASA	12	2649	78	m	PM	915	320	1	4	n	y	y, oa	n	n	n	n	n	60 mg	87,87	79	n	y	y	n	n	n	n
P	ASA	12	2684	67	m	ICD-CRT	47	640	1	5	y	y	y, oa	n	n	y	y	n	60 mg	59,38	60	y	n	y	n	y	n	n
P	ASA	12	2708	66	f	PM-CRT	59		5	4	y	y	n	n	n	n	n	n	60 mg	68,73	55	y	n	y	n	n	n	n
P	no ASA	16	148	81	m	PM	98	340	1	2	n	n	n	n	n	n	n	n	30 mg	38,81		n	n	n	n	n	n	n
E	no ASA	16	385	78	f	PM	1440		4	4	n	y	n	n	n	n	n	n	30 mg	53,11	66	n	n	n	n	n	n	n
E	no ASA	16	440	66	m	PM	14	300	1	2	n	y	n	n	n	n	n	n	60 mg	86,18	85	y	y	y	n	n	n	n
E	no ASA	16	1033	85	m	PM	210	600	9	3	n	y	n	n	n	n	n	n	60 mg	75	75	n	y	y	n	n	n	n
E	ASA	16	1165	68	m	ICD	20	353	3	4	y	y	n	n	n	y	n	n	60 mg	134,29	84	n	n	y	n	n	n	n
E	ASA	16	1179	74	m	ICD-CRT	1390	300	2	3	y	n	n	n	n	y	y	n	60 mg	51,49		y	n	y	n	y	n	n
P	ASA	16	1269	80	m	PM	149	327	1	4	n	y	n	n	n	y	n	y	30 mg	33,17	60	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	17	364	72	m	ICD-CRT	74	343	1	4	y	y	n	n	n	y	y	n	60 mg	79,9	68	y	n	y	n	n	n	n
E	no ASA	17	409	74	f	PM	55	600	1	3	n	y	n	n	n	n	n	n	60 mg	68,21	69	n	n	y	n	n	n	n
P	ASA	17	446	76	m	PM	187	465	1	3	n	y	n	n	n	n	n	n	60 mg	90,26	32	y	y	n	n	n	n	n
P	no ASA	17	1598	67	m	PM	355	640	1	2	n	n	n	n	n	n	n	n	60 mg	68,13	60	n	n	n	n	n	n	n
P	no ASA	19	120	82	m	PM	21	205	3	3	n	y	n	n	n	n	n	n	30 mg	38,76	60	n	y	n	n	n	n	n
E	ASA	19	203	84	f	PM	17	214	1	5	n	y	n	n	n	n	n	n	60 mg	65,85	80	y	n	y	n	n	n	n
P	ASA	19	263	67	m	PM	684	429	4	2	n	y	n	n	n	n	n	n	60 mg	88,16	70	n	n	n	n	n	n	n
E	ASA	19	329	77	m	PM	261	366	1	3	n	n	n	n	n	n	n	y	60 mg	67,81	62	y	n	n	n	n	n	n
E	no ASA	19	340	69	f	PM	28	550	4	3	n	y	n	n	n	n	n	n	30 mg	42,61	60	y	n	n	n	n	n	n
P	ASA	19	600	86	m	PM	193	545	1	4	n	y	n	n	n	n	y	n	60 mg	56,16	68	n	n	n	n	n	n	n
E	no ASA	19	805	74	m	PM	121	600	1	2	n	y	n	n	n	n	n	n	60 mg	62,5	60	n	y	n	n	n	n	n
E	ASA	19	1633	74	m	PM	591		5	2	n	n	n	n	n	n	n	n	60 mg	67,52	67	y	n	n	y	n	n	n
		22	608	73	m					3									60 mg	99,7								
E	ASA	22	624	71	m	ICD	1493	500	2	4	y	y	n	n	n	y	n	y	60 mg	74,61	56	n	n	y	n	n	n	n
		22	927	77	m					4																		
E	no ASA	23	122	75	m	PM	5760	600	1700	6	y	y	y, oa	n	n	n	n	n	60 mg	58,75	61	y	y	n	n	n	n	n
P	ASA	23	140	81	f		6	429	1	4									30 mg	52,22								
E	ASA	23	234	77	m	PM	24	331	1	4	n	y	n	n	n	y	y	y	30 mg	46,78	70	y	n	y	n	n	n	n
E	ASA	23	265	77	m	ICD-CRT	249	545	3	4	y	n	n	n	n	y	n	n	60 mg	67,08	65	n	n	y	y	n	n	n
P	ASA	23	504	90	m	PM	1685	600	7	3	n	y	n	n	n	n	n	n	30 mg	35,53	52	n	y	y	n	n	n	n
P	ASA	23	692	80	m	ICD-CRT	167	462	1	4	y	n	y, oa	n	n	n	n	n	30 mg	41,44	56	y	n	y	n	n	n	n
P	ASA	33	150	78	m	PM	322	400	1	4	n	y	n	n	n	n	n	n	60 mg	54,28	58	y	n	n	n	n	n	n
P	ASA	33	216	81	m	PM	13	264	1	3	n	n	n	n	n	n	n	n	60 mg	69,27	68	n	n	n	n	n	n	n
P	no ASA	33	221	77	m	ICD-CRT	108	600	1	4	y	y	n	n	n	n	n	n	30 mg	48,46	60	y	n	y	n	n	n	n
E	ASA	33	235	72	m	PM	140	362	1	2	n	y	n	n	n	n	n	n	60 mg	100,39	66	y	y	y	n	n	n	n
E	ASA	33	1206	91	m	ICD-CRT	288		9	5	y	y	n	n	n	y	y	y	30 mg	19,23	70	y	n	n	n	n	n	n
E	ASA	33	1378	82	m	ICD-CRT	35	284	2	5	y	y	n	n	n	y	y	n	60 mg	58,94	58	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	33	1413	92	f	PM	145	640	1	5	n	y	y, oa	n	n	n	y	n	30 mg	41,75	60	y	n	n	n	n	n	n
P	ASA	34	442	93	f	PM	261	400	1	5	n	y	n	n	n	n	n	n	30 mg	33,71	74	y	n	y	n	n	n	n
		34	964	84	m		13	264	2	4									60 mg	56,85								
P	ASA	35	59	92	m	PM	8	400	1	3	n	y	n	n	n	n	y	n	30 mg	21,88	83	n	n	y	n	n	n	n
E	no ASA	35	260	80	m	PM	47	273	1	3	n	y	n	n	n	n	n	n	30 mg	48,2	77	n	n	y	n	n	n	n
P	ASA	35	453	91	m	PM	1475	600	1	5	n	y	n	n	y	n	n	n	30 mg	40,55	85	n	n	n	n	n	n	n
		38	301	85	m					5																		
E	no ASA	38	305	79	f	ICD-CRT	535	640	1	7	y	y	y, it	n	n	n	y	n	30 mg	31,91	64	y	n	y	n	n	n	n
P	no ASA	38	414	81	m	PM-CRT	7	600	1	3	n	y	n	n	n	n	n	n	60 mg	69,87	65	y	n	y	n	n	n	n
P	ASA	38	566	72	m	ICD-CRT	18	549	1	6	y	y	n	y	n	n	n	n	60 mg	86,89	70	y	n	y	n	n	n	n
E	ASA	39	1186	93	f	PM	18	400	4	6	n	y	y, oa	n	n	n	n	n	30 mg	22,06	70	y	n	n	n	n	n	n
P	ASA	39	1351	74	m	ICD-CRT	116	500	3	5	y	y	y, oa	n	n	y	y	y	60 mg	65,22		y	y	y	n	n	n	n
P	ASA	39	1391	71	m	PM	23	353	2	4	n	y	y, it	n	n	n	y	y	30 mg	40,3		n	n	y	n	n	n	n
P	no ASA	39	2005	78	m	PM	6	175	1	4	n	y	y, oa	n	n	n	n	n	60 mg	95,18	84	n	n	y	n	n	n	n
P	ASA	40	300	76	m	PM	63	513	1	5	n	y	y, oa	n	n	y	y	y	60 mg	53,33	71	y	n	y	n	n	n	n
E	no ASA	40	861	82	m	ICD	152	600	1	3	n	y	n	n	n	n	n	n	30 mg	45,78		y	n	y	n	n	n	n
E	ASA	42	567	87	f	PM-CRT	126	640	1	5	n	y	n	n	n	y	n	n	30 mg	42,25	62	y	y	y	n	n	n	n
E	no ASA	42	1953	76	f	PM-CRT	117		1	4	n	y	n	n	n	n	n	n	30 mg	44,63		n	n	y	n	n	n	n
P	ASA	42	2013	71	m	ICD-CRT	74	614	4	5	y	y	y, oa	n	n	y	y	n	60 mg	63,21	73	y	n	n	n	n	n	n
E	ASA	42	2103	81	m	PM	64	640	3	4	n	y	n	n	n	n	y	n	60 mg	58,52	109	y	n	y	n	n	n	n
P	ASA	42	2122	66	f	ICD	7		1	4	y	y	n	n	n	n	n	n	60 mg	74,35	65	y	n	n	n	n	n	n
P	ASA	42	2219	71	m	PM	81	199	2	4	n	y	y, oa	n	n	y	n	y	60 mg	54,57	63	n	y	y	n	n	n	n
P	no ASA	42	2250	79	f	PM	155	293	1	3	n	n	n	n	n	n	n	n	60 mg	50,62	85	y	n	n	n	n	n	n
P	ASA	42	2296	79	f	PM	75		2	6	n	n	n	y	n	n	n	n	60 mg	69,24	85	n	n	y	n	n	n	n
P	no ASA	42	2376	75	f	PM	37		3	4	n	y	n	n	n	n	n	n	30 mg	37,44	59	n	n	y	n	n	n	n
P	ASA	42	2439	72	m	PM	42	400	1	2	n	n	n	n	n	n	n	n	60 mg	70,27	85	n	n	n	n	n	n	n
P	ASA	42	2443	81	m	PM	240		2	3	n	y	n	n	n	n	n	n	60 mg	78,11	60	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	42	2564	77	f	PM	247	400	1	3	n	n	n	n	n	n	n	n	30 mg	69,06	49	y	y	y	n	n	n	n
E	ASA	42	2683	82	m	PM	24	545	2	3	n	n	n	n	n	n	y	n	60 mg	77,58	68	n	n	n	n	n	n	n
E	ASA	42	2692	75	m	PM	669	640	1	5	n	y	n	y	n	n	n	n	60 mg	87,43	80	n	y	y	n	n	n	n
E	ASA	42	2698	73	m	ICM				3	n	n	y, oa	n	n	n	n	n	60 mg	98,72	57	y	n	y	n	n	n	n
E	ASA	42	2733	82	m	ICD	186	545	1	4	n	y	n	n	n	n	y	n	30 mg	41,77	62	y	y	y	n	n	n	n
E	ASA	43	258	81	f	PM	1219	480	1	5	n	y	n	n	n	n	n	n	60 mg	50,66	61	n	n	y	n	n	n	n
P	ASA	43	397	65	m	PM	61	400	1	4	y	y	n	n	n	n	y	n	60 mg	69,29	91	y	n	y	n	n	n	n
P	ASA	43	845	86	f	PM	37	455	3	7	n	y	y, oa	y	n	n	n	n	30 mg	24,11	65	n	n	n	n	n	n	n
P	ASA	44	472	86	f	PM	2880	600	1	6	n	y	y, it	n	n	y	y	n	30 mg	47,81		y	y	n	n	n	n	n
E	ASA	44	1274	79	m	ICD-CRT	156		1	5	y	y	n	n	n	y	n	y	60 mg	59,31	64	n	n	y	n	n	n	n
P	ASA	44	1426	84	m	PM	12	500	1	4	n	y	n	n	n	n	n	n	60 mg	62,22		n	n	n	n	n	n	n
E	ASA	44	2019	80	m	PM	23	175	1	5	n	y	y, oa	n	n	n	n	y	30 mg	39,81	120	n	n	y	n	n	n	n
E	ASA	46	43	76	m	PM	293	400	5	7	y	y	n	n	y	y	y	y	60 mg	80	90	y	n	y	n	n	n	n
E	no ASA	46	63	75	m	PM	38	331	1	2	n	n	n	n	n	n	n	n	60 mg	76,74	99	n	n	n	n	n	n	n
E	ASA	46	69	81	f	PM-CRT	51	375	3	6	y	y	n	n	n	n	y	n	30 mg	47,93	59	n	n	n	n	n	n	n
P	ASA	46	95	66	f	PM	587	293	1	6	n	y	y, oa	n	y	n	y	n	60 mg	89,41	86	n	n	y	n	n	n	n
P	ASA	46	145	67	m	PM	7	400	1	2	n	n	n	n	n	n	n	n	60 mg	97,78	66	y	n	y	n	n	n	n
P	ASA	46	147	86	m	PM	71	400	2	4	y	y	n	n	n	n	n	n	60 mg	56,88	70	y	y	n	n	n	n	n
E	no ASA	49	243	85	f	PM	51	400	1	4	n	y	n	n	n	n	n	n	30 mg	48,7	82	n	n	y	n	n	n	n
E	no ASA	49	272	72	f	PM	16	488	1	3	n	y	n	n	n	n	n	n	60 mg	71,6	67	n	y	y	n	n	n	n
P	ASA	49	287	78	m	PM	6000	545	8	7	n	y	y, oa	n	y	n	n	n	60 mg	123,78	63	n	y	y	n	n	n	n
P	no ASA	49	363	82	f	PM	139	591	2	4	n	y	n	n	n	n	n	n	60 mg	54,31	59	y	n	y	n	n	n	n
E	no ASA	53	321	82	f	PM	251	640	1	4	n	y	n	n	n	n	n	n	60 mg	66,76	60	y	n	n	n	n	n	n
E	ASA	57	451	71	m	ICD-CRT	621	375	1	4	y	y	n	n	n	y	y	y	60 mg	63,54	74	y	n	y	n	n	n	n
P	ASA	57	587	77	m	PM	1049	600	10	3	n	y	n	n	n	n	n	n	60 mg	147,75	79	n	y	y	n	n	n	n
E	ASA	57	593	81	m	PM	609	400	1	4	n	y	y, oa	n	n	n	y	n	60 mg	53,11	76	y	n	y	n	n	n	n
P	ASA	57	723	81	m	ICD	429	308	1	4	y	y	n	n	n	n	y	y	60 mg	98,33	75	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	57	966	79	f	PM	25	400	1	4	n	n	n	n	n	y	y	n	30 mg	43,21	72	n	n	n	n	n	n	n
P	ASA	57	1300	75	m	ICD-CRT	44		1	8	y	y	y, oa AND it	n	y	y	y	n	60 mg	83,83	80	y	y	y	n	n	n	n
E	ASA	57	1324	80	f	ICM	130		2	4	n	y	n	n	n	n	n	n	30 mg	60,71	53	n	n	y	n	n	n	n
P	ASA	57	1568	81	m	ICD-CRT	156		2	5	y	y	n	n	n	y	y	y	30 mg	31,75	65	y	n	y	n	n	n	n
E	ASA	57	1629	82	f	PM	30	640	4	4	n	y	n	n	n	n	n	n	60 mg	74,99	60	n	y	y	n	n	n	n
E	ASA	57	1755	81	m	ICM	51		32	4	n	y	n	n	n	n	n	n	60 mg	74,8		n	y	y	n	n	n	n
E	ASA	57	1837	81	m	PM	309		3	4	n	y	y, oa	n	n	n	y	n	60 mg	86,6	64	y	y	y	n	n	n	n
P	ASA	57	1928	81	f	PM	94		6	7	n	y	y, it	n	y	n	n	n	60 mg	62,39	59	y	n	y	n	n	n	n
P	ASA	57	2245	83	m	PM	574		2	2	n	n	n	n	n	n	y	n	60 mg	51,98	61	n	n	n	n	n	n	n
P	no ASA	57	2542	83	m	PM	330		1	4	n	y	y, it	n	n	n	n	n	30 mg	34,19	60	y	y	y	n	n	n	n
P	ASA	57	2551	84	m	PM	1440		4	6	y	y	y, oa	n	n	n	y	n	60 mg	88,07	61	n	n	y	n	n	n	n
P	no ASA	59	9	80	m	PM-CRT	34		3	4	y	y	n	n	n	n	n	n	60 mg	71,91	79	n	n	y	n	n	n	n
P	ASA	59	19	81	f	PM-CRT	47	226	2	4	n	y	n	n	n	n	n	n	60 mg	65,91	70	y	n	y	n	n	n	n
P	ASA	59	24	67	m	PM	7200	300	12	3	n	y	y, it	n	n	n	n	n	60 mg	56,84	74	y	n	y	n	n	n	n
E	no ASA	59	58	76	m	PM	1440	460	3	5	y	y	y, it	n	n	n	n	n	60 mg	50,64	71	y	n	y	n	n	n	n
P	ASA	59	67	78	m	PM	1087	400	5	4	y	y	n	n	n	n	y	n	60 mg	100,13	60	y	y	y	n	n	n	n
E	ASA	59	98	73	m	PM	9	208	1	4	y	y	n	n	n	y	y	y	60 mg	76,02	59	y	n	y	n	n	n	n
P	ASA	59	119	83	f	PM	68	273	3	3	n	n	n	n	n	n	y	y	60 mg	63,19	60	y	n	n	n	n	n	n
E	no ASA	59	149	77	m	PM	2880	400	12	3	n	y	n	n	n	n	n	n	60 mg	72,33		n	n	y	n	n	n	n
E	ASA	59	186	65	m	PM	75	324	2	3	n	y	n	n	n	y	y	n	60 mg	79,29		y	n	n	n	y	n	n
E	ASA	59	380	77	m	PM	104	429	1	3	n	y	n	n	n	n	y	n	60 mg	79,75	65	n	n	y	n	n	n	n
E	ASA	59	416	89	f	PM	70	500	3	8	y	y	n	y	n	n	n	n	30 mg	17,27	70	y	y	y	n	n	n	n
P	no ASA	59	463	79	f	PM	482	375	3	5	n	y	y, oa	n	n	n	n	n	60 mg	60,82	84	y	n	y	n	n	n	n
P	ASA	59	466	76	m	PM	670	400	7	6	n	y	n	y	n	y	n	n	60 mg	66,75	85	y	n	y	n	n	n	n
P	no ASA	59	467	76	f	PM	446	600	3	4	n	y	n	n	n	n	n	n	30 mg	76,86	64	n	n	y	n	n	n	n
E	ASA	59	493	75	m	PM	15	273	1	5	y	y	n	n	n	y	y	y	60 mg	124,13	61	y	n	y	n	n	n	n
E	ASA	59	528	80	f	PM	367	500	3	5	n	y	n	n	n	y	y	n	60 mg	87,26	59	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	59	541	74	m	PM	288	600	2	2	n	y	n	n	n	n	n	n	60 mg	90,28	60	n	y	y	n	n	n	n
P	no ASA	59	615	81	f	PM	13	300	1	4	n	y	n	n	n	n	n	n	60 mg	71,33	62	n	n	y	n	n	n	n
E	ASA	59	655	86	f	PM	195	600	10	5	y	y	n	n	n	n	y	n	60 mg	65,38	76	y	y	n	n	n	n	n
P	ASA	59	679	77	m	PM	1274	375	3	3	n	y	n	n	n	n	n	y	30 mg	42,74	69	n	n	y	n	y	n	n
P	no ASA	59	826	82	f	PM	57	300	1	5	y	y	n	n	n	n	n	n	60 mg	52,32	60	y	n	y	n	n	n	n
P	ASA	59	1063	67	m	PM	9999	500	11	5	y	y	y, oa	n	n	y	y	n	60 mg	84,68	63	y	n	y	n	n	n	n
E	ASA	59	1105	70	f	PM	192	333	6	4	n	y	n	n	n	y	y	n	60 mg	61,84	76	y	n	y	n	n	n	n
E	no ASA	59	1115	80	f	PM	236	333	2	4	n	y	n	n	n	n	n	n	60 mg	84,26	70	n	n	y	n	n	n	n
E	no ASA	59	1140	82	f	PM	39	375	3	4	n	y	n	n	n	n	n	n	30 mg	46,93	60	y	n	y	n	n	n	n
P	ASA	59	1161	80	m	PM	26	300	2	3	n	y	n	n	n	n	y	n	60 mg	89,74	68	y	y	y	n	n	n	n
P	no ASA	59	1191	67	m	PM	9	350	1	2	n	y	n	n	n	n	n	n	60 mg	107,87	79	n	n	y	n	n	n	n
E	ASA	59	1195	65	f	PM	23	214	1	4	n	y	y, oa	n	n	n	n	n	60 mg	82,83	74	y	n	y	n	n	n	n
P	no ASA	59	1230	78	m	PM	216	500	7	3	n	y	n	n	n	n	n	n	60 mg	79,2	60	n	y	y	n	n	n	n
E	ASA	59	1245	88	m	PM	311	300	5	3	n	y	n	n	n	n	n	n	30 mg	44,2	65	y	y	y	n	n	n	n
P	ASA	59	1247	67	f	PM	589	600	15	4	n	y	y, oa	n	n	n	n	n	60 mg	73,38	72	y	y	y	n	n	n	n
E	no ASA	59	1293	87	m	PM	1440	375	2	3	n	y	n	n	n	n	n	n	30 mg	42,37	87	y	y	y	n	n	n	n
P	no ASA	59	1422	83	m	PM	22	232	1	3	n	y	n	n	n	n	n	n	60 mg	55,42	60	y	y	n	n	n	n	n
P	ASA	59	1451	81	m	PM	756	600	12	4	n	y	n	n	n	n	y	n	30 mg	43,31	77	n	y	y	n	n	n	n
P	ASA	59	1456	77	m	PM	52	300	1	4	n	y	y, oa	n	n	n	y	n	60 mg	64,05	82	y	n	y	n	n	n	n
E	ASA	59	1490	86	m	PM	17	250	2	4	n	y	n	n	n	y	y	n	60 mg	56,94	75	y	n	n	n	n	n	n
E	ASA	59	1579	65	f	PM	1029		4	3	n	y	n	n	n	n	n	n	60 mg	91,28	70	y	n	y	n	n	n	n
P	ASA	59	1583	93	m	PM	90		3	5	y	y	n	n	n	n	n	y	30 mg	26,18	70	n	n	n	n	n	n	n
E	no ASA	59	1634	85	f	PM	507		3	4	n	y	n	n	n	n	n	n	60 mg	70,83	69	n	y	y	n	n	n	n
P	ASA	59	1779	83	m	PM	36		2	5	n	y	n	n	y	n	n	n	60 mg	57,65	71	y	n	n	n	n	n	n
E	no ASA	59	1801	80	m	PM	34		1	4	y	y	n	n	n	n	n	n	60 mg	72,82	59	y	n	y	n	n	n	n
E	no ASA	59	1920	86	f	PM	21		2	4	n	y	n	n	n	n	n	n	30 mg	32,4	60	y	n	y	n	n	n	n
P	ASA	59	2211	83	m	ICD	850		1	6	y	y	y, it	n	n	y	y	n	30 mg	36,2	58	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	59	2442	79	m	PM	9999		9	3	n	y	n	n	n	n	n	n	60 mg	84,39	63	n	n	y	n	n	n	n
P	ASA	59	2467	79	f	PM	455		1	4	n	y	n	n	n	n	y	n	60 mg	51,73	63	n	y	n	n	n	n	n
E	ASA	59	2470	92	f	PM	30		1	4	n	y	n	n	n	n	n	n	30 mg	43,52	60	n	y	y	n	n	n	n
P	no ASA	59	2612	82	f	PM	17		1	4	n	y	n	n	n	n	n	n	60 mg	68,97	60	y	y	y	n	n	n	n
P	no ASA	59	2669	77	m	PM	5760		6	2	n	n	n	n	n	n	n	n	60 mg	101,97	80	n	n	n	n	n	n	n
E	no ASA	70	16	74	m	PM	14	400	1	2	n	y	n	n	n	n	n	n	60 mg	86,53	68	n	y	y	n	n	n	n
E	ASA	70	105	67	f	ICD	108	594	2	4	y	y	n	n	n	n	y	n	60 mg	74,49	68	y	n	y	y	n	n	n
P	no ASA	70	151	88	f	PM	50	246	4	4	n	y	n	n	n	n	n	n	30 mg	35,42	70	n	n	y	n	n	n	n
E	no ASA	70	253	68	m	ICD-CRT	13	214	1	3	y	y	n	n	n	n	n	n	60 mg	116,5	68	y	n	y	n	n	n	n
P	ASA	70	325	79	m	ICD	19	600	1	4	n	y	n	n	n	y	y	n	60 mg	63	69	y	n	y	n	n	n	n
P	no ASA	70	401	78	m	PM	1087	400	11	4	n	y	y, oa	n	n	n	n	n	60 mg	71,4		y	y	y	n	n	n	n
E	no ASA	70	402	79	m	PM	280	400	4	3	n	y	n	n	n	n	n	n	30 mg	43,01	56	y	n	y	n	n	n	n
P	no ASA	70	418	80	f	PM	341	429	3	4	n	y	n	n	n	n	n	n	60 mg	58,62	82	y	y	y	n	n	n	n
P	no ASA	70	479	88	f	PM	5760	400	3	4	n	y	n	n	n	n	n	n	30 mg	28,82	71	y	n	n	n	n	n	n
P	ASA	70	511	81	m	PM-CRT	8	495	1	6	y	y	y, oa	n	n	y	y	n	60 mg	62,57	78	y	y	y	n	n	n	n
E	no ASA	70	514	74	f	PM	1627	600	3	3	n	y	n	n	n	n	n	n	60 mg	125,57	69	n	n	y	n	n	n	n
P	ASA	70	644	77	f	PM	302	400	1	6	y	y	y, it	n	n	n	y	n	60 mg	54,5	67	n	y	y	n	n	n	n
E	ASA	70	662	81	m	PM	690	400	2	3	n	y	n	n	n	n	n	n	30 mg	29,54	62	y	n	y	n	n	n	n
E	ASA	70	674	89	m	PM	6	400	1	4	n	y	n	n	n	y	y	n	30 mg	38,35	64	n	n	y	n	n	n	n
P	ASA	70	765	82	m	PM	5760	400	1	3	n	y	n	n	n	n	n	n	30 mg	28,75	50	y	n	y	n	n	n	n
E	ASA	70	774	86	m	PM	73	225	1	4	n	y	y, it	n	n	n	n	n	30 mg	39,24	60	y	n	y	n	n	n	n
E	ASA	70	881	85	m	PM	333	400	3	3	n	y	n	n	n	n	n	n	30 mg	39,01	92	y	n	y	n	n	n	n
P	ASA	70	995	79	m	ICD-CRT	52	214	1	7	y	n	y, it	y	n	y	y	n	60 mg	70,92	70	y	n	y	n	n	n	n
P	ASA	70	1045	77	m	ICD	64	640	1	4	n	y	n	n	n	y	y	y	60 mg	72,62	68	y	n	y	n	n	n	n
P	no ASA	70	1114	75	m	PM	5760	400	1	4	n	y	y, oa	n	n	n	n	n	60 mg	63,16	93	y	n	y	n	n	n	n
E	ASA	70	1134	82	m	PM	345	400	3	4	y	n	n	n	n	y	y	n	60 mg	58,25	60	y	n	y	n	n	n	n
P	ASA	70	1148	82	m	PM	13	300	3	4	n	y	n	n	n	n	n	n	60 mg	63,5	63	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	70	1304	75	m	PM	130	380	2	2	n	n	n	n	n	n	n	n	60 mg	66,67	62	n	n	n	n	n	n	n
E	no ASA	70	1320	67	f	PM	26	429	9	3	n	y	n	n	n	n	n	n	30 mg	44,95	64	n	n	y	n	n	n	n
P	ASA	70	1485	79	f	PM	7	331	1	6	n	y	y, it	n	n	n	n	n	30 mg	34,49	72	y	y	y	n	n	n	n
E	no ASA	70	1569	80	m	PM	4749	333	3	4	n	y	y, it	n	n	n	n	n	60 mg	57,06	85	n	y	n	n	n	n	n
E	ASA	70	1599	71	f	PM	211	545	4	5	n	y	n	y	n	n	n	n	60 mg	61,45	58	y	n	y	n	n	n	n
P	no ASA	70	1714	87	m	PM	183	462	1	4	n	y	y, it	n	n	n	n	n	60 mg	54,61	79	n	y	y	n	n	n	n
E	ASA	70	1725	69	f	ICD-CRT	206	640	1	4	y	y	n	n	n	n	n	n	60 mg	88,15	69	y	n	n	n	n	n	n
P	ASA	70	1727	77	m	ICD-CRT	196	640	1	7	y	y	n	n	y	y	y	n	60 mg	77,21	68	y	n	n	n	n	n	n
P	no ASA	70	1730	84	m	PM	19	261	1	3	n	y	n	n	n	n	n	n	60 mg	63,49	76	n	n	y	n	n	n	n
E	no ASA	70	1741	88	m	PM	141	500	1	3	n	y	n	n	n	n	n	n	30 mg	37,29	74	n	y	y	n	n	n	n
P	ASA	70	1751	82	m	PM	629	400	13	5	y	y	y, oa AND it	n	n	n	n	n	30 mg	49,23	94	y	n	y	n	n	n	n
E	ASA	70	1805	83	f	PM	192	400	8	4	n	y	n	n	n	n	n	n	60 mg	54,14	65	n	n	y	n	n	n	n
E	ASA	70	1808	77	m	PM	146	545	2	3	n	y	n	n	n	n	n	n	60 mg	84,55	68	n	y	y	n	n	n	n
E	no ASA	70	1829	78	m	PM	445	400	2	3	n	y	n	n	n	n	n	n	30 mg	49,92	58	n	y	y	n	n	n	n
P	no ASA	70	1910	84	f	PM	9	400	2	4	n	y	n	n	n	n	n	n	30 mg	45,08	66	y	y	y	n	n	n	n
P	ASA	70	1950	76	m	ICD	620	500	1	4	y	n	n	n	n	n	y	n	60 mg	78,92	63	y	n	y	n	n	n	n
E	ASA	70	1964	79	m	ICD-CRT	28		1	5	y	y	n	n	n	y	y	y	60 mg	65,74	87	y	n	y	n	n	n	n
E	ASA	70	2014	76	f	PM	586	545	12	5	n	y	y, oa	n	n	n	y	n	30 mg	45,68	77	y	y	y	n	n	n	n
P	ASA	70	2028	88	m	PM-CRT	802	545	4	6	y	n	y, oa AND it	n	y	n	y	n	30 mg	27,87	73	y	n	y	n	n	n	n
E	ASA	70	2068	74	m	ICD-CRT	13	591	1	7	y	y	y, it	y	n	y	y	y	60 mg	74,98	85	y	n	y	n	n	n	n
E	no ASA	70	2171	81	m	PM	9	240	2	3	n	y	n	n	n	n	n	n	30 mg	43,88	63	n	y	y	n	n	n	n
E	ASA	70	2182	82	m	PM-CRT	110	614	1	5	y	n	y, it	n	n	y	y	n	60 mg	53,97	67	y	n	n	n	n	n	n
P	ASA	70	2425	85	m	PM	22	282	2	3	n	y	n	n	n	n	n	n	30 mg	46,15	85	n	y	y	n	n	n	n
P	ASA	70	2438	70	f	PM	80	380	1	3	n	y	n	n	n	n	n	n	60 mg	127,41	71	n	y	y	n	n	n	n
P	ASA	70	2475	65	m	ICD	2580		1	4	y	n	n	y	n	n	n	n	30 mg	77,08	60	y	n	y	n	n	n	n
P	no ASA	70	2517	81	m	PM	34		2	2	n	n	n	n	n	n	n	n	60 mg	63,1	96	n	n	n	n	n	n	n
E	ASA	70	2529	75	m	ICD-CRT	22	500	1	6	y	y	y, it	n	n	y	y	n	30 mg	41,03	74	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	70	2554	71	m	ICD-CRT	474	462	2	4	y	y	n	n	n	y	n	y	60 mg	68,61	67	y	n	y	n	n	n	n
P	ASA	70	2686	72	f	PM	150	400	2	5	n	y	n	y	n	n	n	n	60 mg	59,1	71	n	y	y	n	n	n	n
E	ASA	86	338	76	m	ICD	80	353	1	6	y	y	y, oa	n	n	y	y	n	60 mg	112,59	82	y	n	y	n	n	n	n
E	ASA	86	352	82	m	PM	5760	400	11	4	n	y	n	n	n	y	y	y	60 mg	60,2	79	n	n	y	n	n	n	n
P	ASA	86	373	75	m	PM	849	316	5	4	n	y	n	n	n	n	n	n	60 mg	103,82	60	n	n	y	n	n	n	n
P	ASA	86	404	71	f	ICD	140	400	1	5	y	n	n	n	n	y	y	n	30 mg	36,91		y	n	y	n	n	n	n
P	no ASA	86	554	68	f	PM	104	272	2	3	n	y	n	n	n	n	n	n	60 mg	91,99	69	y	n	n	n	n	n	n
E	no ASA	86	672	86	f	PM	39	400	1	5	n	y	y, oa	n	n	n	n	n	60 mg	78,88	87	n	n	n	n	n	n	n
E	ASA	86	722	71	m	PM	9999	600	12	3	n	y	n	n	n	n	n	y	60 mg	117,66	60	y	n	y	n	n	n	n
P	ASA	86	1016	87	m	PM	7	180	1	4	n	n	y, it	n	n	n	y	n	60 mg	52,92	77	n	n	y	n	n	n	n
		86	1085	71	f					2																		
E	no ASA	86	1189	80	f	PM	109	400	4	4	n	y	n	n	n	n	n	n	30 mg	26,82	84	n	y	y	n	n	n	n
P	ASA	86	1262	82	m	PM	19		1	5	n	y	n	y	n	n	n	n	60 mg	64,44	62	n	n	y	n	n	n	n
E	ASA	86	1263	79	m	PM	606	400	4	5	n	n	n	n	y	n	y	n	60 mg	63,11	73	y	n	n	n	n	n	n
E	ASA	86	1374	67	f	PM	194	400	7	4	n	y	n	n	n	n	n	y	60 mg	87,39	80	n	y	y	n	n	n	n
E	no ASA	86	1379	66	m	PM	176		9	3	n	y	y, oa AND it	n	n	n	n	n	60 mg	99,97	60	y	y	y	n	n	n	n
E	ASA	86	1428	82	m	PM	11	273	1	4	n	y	n	n	n	y	y	n	60 mg	89,51	96	n	n	n	n	n	n	n
P	no ASA	86	1542	74	f	PM	61	400	7	3	n	y	n	n	n	n	n	n	60 mg	93,24	72	y	n	y	n	n	n	n
E	ASA	95	10	88	m	PM	448		1	4	y	y	n	n	n	n	n	n	60 mg	57,62	80	y	n	n	n	n	n	n
E	no ASA	95	13	85	f	PM	1661		1	4	n	y	n	n	n	n	n	n	30 mg	29,94	78	n	n	n	n	n	n	n
E	ASA	95	14	68	m	ICD-CRT	6	192	1	3	y	y	n	n	n	n	n	n	60 mg	66,94	68	y	y	y	n	n	y	n
P	ASA	95	18	78	f	PM	3428	296	1	5	y	y	n	n	n	n	n	n	60 mg	50,23	73	y	n	y	n	n	n	n
P	no ASA	95	22	72	m	PM	438	321	1	3	y	y	n	n	n	n	y	n	60 mg	78,28	79	y	y	y	n	n	n	n
P	no ASA	95	26	69	f	PM	235	275	2	3	n	y	n	n	n	n	n	n	60 mg	61,98	69	n	n	n	n	n	n	n
P	ASA	95	28	73	f	PM	968	296	2	4	y	y	n	n	n	n	n	n	60 mg	73,45	60	n	y	y	n	n	n	n
E	no ASA	95	29	80	f	PM	518	405	1	6	y	y	n	n	n	y	y	n	60 mg	64,22	87	y	y	y	n	n	n	n
P	no ASA	95	30	80	m	PM	259	335	2	6	y	y	n	y	n	n	n	n	60 mg	79,99	83	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	95	38	79	f	PM	1186	513	3	4	n	y	n	n	n	n	n	n	60 mg	55,02	61	y	n	n	n	n	n	n
P	ASA	95	44	76	m	PM	1082	286	1	4	y	y	n	n	n	n	y	n	60 mg	65,19	60	y	n	n	n	n	n	n
E	ASA	95	53	82	m	PM	155	321	3	5	y	y	y, oa AND it	n	n	n	n	n	60 mg	56,86	75	y	n	y	n	n	n	n
P	no ASA	95	71	75	m	PM	144	321	1	3	n	y	n	n	n	n	n	n	60 mg	73,47		n	y	y	n	n	n	n
E	no ASA	95	117	75	m	PM	7	240	1	3	n	y	n	n	n	n	n	n	60 mg	116,67	69	n	n	y	n	n	n	n
E	no ASA	95	180	75	f	PM	1253	275	1	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	68,89	71	n	y	y	n	n	n	n
E	no ASA	95	202	72	m	PM	9	549	1	3	y	y	n	n	n	n	n	n	60 mg	64,7	70	y	n	y	n	n	n	n
		95	256	84	f					4									30 mg	32,55								
E	no ASA	95	533	80	f	PM				5	y	y	n	n	n	n	n	n	60 mg	60,28	80	y	y	y	n	n	n	n
P	no ASA	95	534	65	m	PM				4	y	y	y, oa AND it	n	n	n	n	n	60 mg	122,46	67	y	n	n	n	n	n	n
E	no ASA	95	820	77	m	PM				4	n	y	n	n	n	n	n	n	60 mg	80,5	88	n	n	y	n	n	n	n
P	no ASA	95	1066	75	m	PM	834	308	3	5	y	y	n	n	n	y	n	y	60 mg	59,74	61	y	n	y	n	n	n	n
E	ASA	95	1175	80	f	PM	511	308	1	5	y	y	n	n	n	n	n	n	60 mg	73,59	68	y	y	y	n	n	n	n
P	no ASA	95	1368	78	f	PM	568	256	1	5	y	y	n	n	n	n	n	n	30 mg	39,46	77	n	n	n	y	n	n	n
P	no ASA	95	2287	67	f	PM	72		1	3	y	n	n	n	n	n	n	n	60 mg	95,93	71	n	n	n	y	n	n	n
P	ASA	100	4	77	f	PM	150	380	5	4	n	y	n	n	n	n	n	n	30 mg	54,09	100	y	y	n	n	n	n	n
E	ASA	100	124	75	m	PM	468	429	9	7	n	y	y, it	y	n	n	y	n	30 mg	47,69	66	y	n	y	n	n	n	n
E	ASA	100	527	66	f	PM	85	500	1	3	n	n	n	n	n	n	n	n	30 mg	52,67	59	y	n	n	n	n	n	n
E	ASA	100	537	93	m	PM	315	480	9	4	n	y	n	n	n	n	n	n	60 mg	50,06	83	n	y	y	n	n	n	n
P	ASA	100	846	73	m	PM	584		3	4	n	y	y, oa	n	n	y	n	y	60 mg	89,95	56	y	y	y	n	n	n	n
P	ASA	100	848	68	f	ICD	65	640	1	4	n	y	n	n	n	n	y	n	60 mg	93,5	84	y	n	y	n	n	n	n
E	ASA	100	933	80	m	PM	47	430	2	4	n	y	y, it	n	n	n	n	n	30 mg	31,66	59	y	y	y	n	n	n	n
E	ASA	100	1327	76	f	PM	94		3	5	n	n	n	y	n	n	n	n	30 mg	53,26	94	y	n	n	n	n	n	n
P	no ASA	100	1604	65	f	PM	525		11	3	n	n	n	n	n	n	n	n	60 mg	97,9	60	n	n	n	n	n	n	n
P	ASA	100	1969	86	m	PM	642		4	3	n	y	n	n	n	n	n	n	30 mg	40,66	89	y	n	y	n	n	n	n
P	no ASA	100	2653	78	m	PM	508	640	1	3	n	y	n	n	n	n	n	n	30 mg	37,56	57	n	y	y	n	n	n	n
P	ASA	109	201	83	f	PM				6	n	y	y, it	n	n	y	y	y	30 mg	34,83	65	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	113	36	80	m	PM	115	300	3	4	n	y	y, oa	n	n	n	n	n	60 mg	68,11	60	n	y	y	n	n	n	n
P	no ASA	113	37	73	m	PM	185	317	4	2	n	y	n	n	n	n	n	n	60 mg	77,55	92	y	n	y	n	n	n	n
P	ASA	113	39	84	m	PM	129	500	2	5	n	y	n	y	n	n	n	n	30 mg	34,05	70	n	n	n	n	n	n	n
E	no ASA	113	40	80	m	PM	87	375	3	2	n	n	n	n	n	n	n	n	60 mg	69,44	70	n	n	n	n	n	n	n
P	ASA	113	60	88	m	PM	58		3	3	n	y	n	n	n	n	y	n	60 mg	79,14	60	n	n	y	n	n	n	n
P	no ASA	113	62	83	m	PM	331		3	3	n	y	n	n	n	n	n	n	60 mg	57,88	71	n	y	y	n	n	n	n
E	no ASA	113	65	78	m	PM				3	n	y	n	n	n	n	n	n	60 mg	65,02	115	y	n	y	n	n	n	n
P	no ASA	113	154	78	m	ICD-CRT	16	500	2	3	y	n	n	n	n	n	n	n	60 mg	65,97	77	y	n	y	n	n	n	n
E	ASA	113	369	84	f	PM	152	600	6	8	y	y	n	n	y	n	n	n	30 mg	43,59	63	y	n	y	n	n	n	n
E	no ASA	113	411	78	m	PM	60	550	3	2	n	n	n	n	n	n	n	n	60 mg	59,07	52	y	n	n	n	n	n	n
P	ASA	117	17	66	f	ICD	390	201	5	6	y	y	y, it	n	n	n	n	y	60 mg	54,68	59	y	y	y	n	n	y	n
P	ASA	117	23	88	m	PM	45	375	3	4	n	y	n	n	n	y	y	n	60 mg	66,26	74	y	n	y	n	n	n	n
E	ASA	117	264	79	m	PM	998	400	9	3	n	y	n	n	n	n	n	y	60 mg	66,83	60	y	n	y	n	n	n	n
E	ASA	117	320	83	m	ICD	190	545	2	4	n	y	n	n	n	y	y	n	30 mg	29,51	57	y	n	y	n	n	n	n
E	ASA	117	663	78	m	PM	561	462	17	4	n	y	n	n	n	y	y	n	60 mg	60,52	74	y	n	y	n	n	n	n
E	ASA	117	943	82	m	ICD		352	14	6	y	y	y, it	n	n	y	n	y	60 mg	59,84	77	y	n	y	n	n	n	n
P	no ASA	117	1155	85	m	ICD-CRT	572	290	3	4	y	y	n	n	n	n	n	n	60 mg	77,45	54	y	n	y	n	n	y	n
P	no ASA	117	1739	84	f	PM	138		8	4	n	y	n	n	n	n	n	n	30 mg	38,75	62	y	n	y	n	n	n	n
E	ASA	121	41	72	f	PM	123	375	2	3	n	y	n	n	n	n	n	y	30 mg	48,17	64	y	n	y	n	n	n	n
P	ASA	121	56	89	m	PM	86	264	2	3	n	y	n	n	n	n	y	y	30 mg	47,7	70	y	y	y	n	n	n	n
P	ASA	121	103	88	f	PM	14	265	2	7	y	y	n	y	n	n	n	n	60 mg	71,57	61	n	y	y	n	n	n	n
E	ASA	121	109	76	m	ICD-CRT	15	235	1	4	y	y	n	n	n	n	y	n	30 mg	41,83	64	y	n	y	n	y	n	n
E	no ASA	121	111	78	m	ICD-CRT	114	275	2	4	y	y	n	n	n	n	n	n	60 mg	52,79	60	y	n	y	n	n	n	n
P	no ASA	121	130	82	f	PM-CRT	1325	300	12	5	y	y	n	n	n	n	n	n	30 mg	24,74	60	y	n	y	n	n	n	n
P	ASA	121	355	82	m	PM	10	286	1	6	y	y	y, oa	n	n	n	n	n	60 mg	71,77	72	y	n	y	n	n	n	n
E	ASA	121	359	81	m	PM	624	500	4	3	n	y	n	n	n	n	n	n	60 mg	83,62	60	y	n	y	n	n	n	n
E	no ASA	132	6	69	f	ICD-CRT	1816	545	4	3	y	n	n	n	n	n	n	n	60 mg	62,24	93	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	132	8	77	m	ICD-CRT	31	400	1	4	y	y	n	n	n	n	n	n	30 mg	50		y	n	y	n	y	n	n
E	no ASA	132	51	78	f	ICD-CRT	91	545	2	4	y	n	n	n	n	n	n	n	30 mg	43,92	64	y	n	y	n	n	n	n
E	no ASA	132	70	77	m	PM	937	400	1	3	n	y	n	n	n	n	n	n	60 mg	61,62	82	n	y	y	n	n	n	n
P	no ASA	132	73	68	m	PM	29	400	1	2	n	y	n	n	n	n	n	n	60 mg	80,59	70	n	n	n	n	n	n	n
P	ASA	132	101	74	m	PM	47	640	1	2	n	y	n	n	n	n	n	n	60 mg	82,38	50	y	n	y	n	n	n	n
P	ASA	132	229	80	m	ICD-CRT	53	353	30	5	y	y	n	n	n	y	y	y	30 mg	50	63	y	n	y	n	n	n	n
P	no ASA	132	266	77	m	PM	1267	353	7	2	n	n	n	n	n	n	n	n	60 mg	64,83	72	n	n	n	n	n	n	n
E	ASA	132	295	83	f	PM	60	300	23	4	n	y	n	n	n	n	n	n	30 mg	39,03	63	y	n	y	n	n	n	n
E	ASA	132	388	76	m	PM	41	353	1	3	n	y	n	n	n	n	n	n	60 mg	66,18	81	n	n	y	n	n	n	n
E	no ASA	132	739	70	f	ICD-CRT	631	462	1	4	y	y	n	n	n	n	n	n	60 mg	59,22	65	y	y	y	n	n	n	n
P	no ASA	132	1383	83	m	PM	287	300	4	3	n	y	n	n	n	n	n	n	60 mg	66,93	52	n	n	y	n	n	n	n
P	no ASA	132	1436	65	f	ICD-CRT	15	500	1	3	y	n	n	n	n	n	n	n	30 mg	49,58	65	y	n	y	n	n	n	n
P	ASA	132	1612	73	m	PM	175	188	9	3	n	y	n	n	n	y	n	n	60 mg	73,51	60	n	y	y	n	n	n	n
E	ASA	132	1902	80	m	ICD-CRT	43	375	1	7	y	y	n	y	n	y	y	y	30 mg	48,28	72	y	n	y	n	n	n	n
P	ASA	132	1958	84	m	ICD-CRT	6000	600	3	4	y	n	n	n	n	y	n	y	30 mg	41,89	77	y	n	y	n	n	n	n
E	ASA	132	1983	73	m	PM	77		8	3	y	y	n	n	n	n	n	n	30 mg	45,83	60	y	y	y	n	n	n	n
E	no ASA	132	2392	78	f	PM	230		2	4	n	y	n	n	n	n	n	n	60 mg	73,19	76	n	y	y	n	n	n	n
P	no ASA	132	2629	83	f	PM	57		3	4	n	y	n	n	n	n	n	n	60 mg	54,67	60	y	n	y	n	n	n	n
E	ASA	133	82	81	m	PM	63	250	6	4	n	y	n	n	n	y	y	n	30 mg	32,22	60	y	y	y	n	n	n	n
E	ASA	133	188	74	m	PM	11	317	1	2	n	y	n	n	n	n	n	y	60 mg	53,77	54	n	y	y	n	n	n	n
P	ASA	133	400	75	m	ICD-CRT	9999	400	1	5	y	y	y, oa	n	n	n	y	n	30 mg	50	80	y	n	y	n	n	n	n
P	no ASA	133	477	75	m	PM	518	600	2	3	n	y	n	n	n	n	n	n	60 mg	92,84	78	y	n	y	n	n	n	n
P	ASA	133	618	79	m	ICD-CRT	669	600	1	4	y	y	n	n	n	n	n	n	60 mg	55,1	62	y	n	y	n	n	n	n
E	ASA	133	634	76	m	PM	25	200	2	3	n	n	n	n	n	n	n	n	30 mg	41,18	70	y	n	n	n	n	n	n
P	no ASA	135	97	82	m	PM	144	250	3	2	n	n	n	n	n	n	n	n	60 mg	55,83	74	n	n	n	n	n	n	n
E	ASA	135	328	79	m	PM	2875	308	2	3	n	y	n	n	n	n	n	n	30 mg	38,51	80	n	y	y	n	n	n	n
E	ASA	135	339	77	m	PM	216		8	5	y	y	y, oa	n	n	n	n	n	60 mg	108,87	60	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	135	376	81	m	PM	351	333	4	5	n	y	y, it	n	n	y	n	y	30 mg	47,8	62	y	n	n	n	n	n	n
P	ASA	136	7	72	m	PM	1204	214	3	3	y	y	n	n	n	n	n	n	60 mg	66,47	60	y	y	y	n	n	n	n
P	ASA	136	33	79	m	PM	600		1	5	y	y	y, oa	n	n	n	n	n	60 mg	118,98		y	n	n	n	n	n	n
E	ASA	136	34	83	f	PM		380		4	n	y	n	n	n	n	n	n	60 mg	69,5	59	n	n	y	n	n	n	n
E	ASA	136	132	78	m	PM	57		2	3	n	y	n	n	n	n	n	n	60 mg	57,63	62	n	n	y	n	n	n	n
P	ASA	140	52	78	m	PM	14	300	1	3	n	y	n	n	n	n	n	n	60 mg	58,36	66	y	y	y	n	n	n	n
P	no ASA	140	68	74	f	ICD-CRT	135	400	2	4	y	y	n	n	n	n	n	n	60 mg	62,98	60	y	n	y	n	n	n	n
E	no ASA	140	74	72	f	PM	104	256	1	3	n	y	n	n	n	n	n	n	60 mg	113,9	70	n	n	y	n	n	n	n
E	ASA	140	85	83	m	PM	24	308	1	3	n	y	n	n	n	n	n	n	60 mg	70,97	65	n	n	n	n	n	n	n
		140	88	79	m					4									60 mg	67,49								
P	no ASA	140	99	76	m	PM	1348	353	2	3	n	y	n	n	n	n	n	n	60 mg	55,61	68	y	y	y	n	n	n	n
P	no ASA	140	113	84	m	PM	41	375	1	3	n	y	n	n	n	n	n	n	60 mg	67,19	61	n	y	y	n	n	n	n
P	ASA	140	114	82	f	PM	353	452	2	6	n	y	n	n	y	n	n	n	60 mg	52,8	63	n	n	y	n	n	n	n
E	ASA	140	136	70	m	PM	7	340	1	4	n	y	y, oa	n	n	y	y	y	60 mg	101,81	84	y	n	y	n	n	n	n
P	ASA	140	160	74	m	PM	169	380	2	4	y	y	n	n	n	y	y	n	60 mg	50,08	50	y	y	y	n	n	n	n
P	ASA	140	171	81	m	ICD	198	400	1	7	y	y	y, it	y	n	n	n	n	30 mg	36	65	y	n	y	n	n	n	n
E	ASA	140	190	81	m	PM	7	316	1	3	n	y	n	n	n	n	n	n	60 mg	77,46	60	y	n	y	n	n	n	n
E	no ASA	140	200	75	f	PM	464	321	1	4	n	y	n	n	n	n	n	n	60 mg	50,9	63	y	n	n	n	n	n	n
E	ASA	140	209	92	m	PM				4	y	y	n	n	n	n	n	n	30 mg	40,26	76	n	y	y	n	n	n	n
E	no ASA	140	212	86	m	PM	264	300	1	3	n	y	n	n	n	n	n	n	30 mg	33,56	60	y	n	n	n	n	n	n
P	ASA	140	225	72	m	PM	183	385	1	2	n	y	n	n	n	n	n	n	60 mg	83,21	70	n	y	y	n	n	n	n
E	no ASA	140	251	81	m	PM	218		7	4	y	y	n	n	n	n	n	n	60 mg	88,5	60	y	n	y	n	n	n	n
E	ASA	140	252	86	m	PM	293	188	5	3	n	y	n	n	n	n	n	n	60 mg	71,05	77	y	y	y	n	n	n	n
E	ASA	140	254	83	f	PM	319		1	7	y	y	y, it	n	n	y	n	y	30 mg	39,99	83	n	y	y	n	n	n	n
P	ASA	140	257	81	f	PM	122		6	7	n	y	y, oa	n	y	n	n	n	30 mg	41,32	60	y	n	y	n	n	n	n
E	no ASA	140	331	85	m	PM	52	220	1	3	n	y	n	n	n	n	n	n	60 mg	64,63	83	n	y	y	n	n	n	n
P	ASA	140	399	75	m	ICD-CRT	8	273	1	4	y	y	n	n	n	n	n	n	60 mg	73,37	62	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	140	407	75	m	ICD	186	551	1	5	y	y	n	n	n	y	y	y	60 mg	75,36	60	y	n	y	n	n	n	n
P	no ASA	140	432	77	f	PM	57	640	2	5	n	y	n	n	n	n	n	n	60 mg	57,79	76	y	n	y	n	n	n	n
E	ASA	140	436	77	f	PM	276	640	1	5	y	y	n	n	n	n	n	n	60 mg	106,36	76	y	n	y	n	n	n	n
P	ASA	140	482	82	m	PM	5760	550	17	3	n	y	n	n	n	n	n	n	60 mg	68,84	67	n	n	y	n	n	n	n
E	ASA	140	506	84	m	ICD-CRT	90	300	7	5	y	y	n	n	n	y	y	y	60 mg	69,04	69	y	n	y	n	n	n	n
P	no ASA	140	539	86	m	PM	442	400	53	3	y	n	n	n	n	n	n	n	30 mg	35,75	74	n	n	n	n	n	n	n
P	ASA	140	551	78	m	PM	16	600	2	4	n	y	y, oa	n	n	n	n	n	30 mg	46,1	60	y	y	y	n	n	n	n
P	ASA	140	565	69	m	PM-CRT	8	366	1	4	y	y	y, oa AND it	n	n	n	n	n	30 mg	44,96	68	y	n	y	n	n	n	n
E	no ASA	140	568	75	m	PM	62	600	5	6	y	y	y, oa	n	n	n	n	n	30 mg	40,24	55	n	n	y	n	n	n	n
E	no ASA	140	592	83	f	PM	19	400	1	5	n	y	y, oa	n	n	n	n	n	30 mg	34	66	y	y	y	n	n	n	n
E	ASA	140	622	83	f	PM	82	366	1	5	n	y	n	n	n	n	n	n	30 mg	42,44	60	n	y	n	n	n	n	n
P	no ASA	140	669	77	f	PM	494	600	6	4	n	y	n	n	n	n	n	n	60 mg	85,76	65	n	n	y	n	n	n	n
P	no ASA	140	713	83	m	PM	203	480	1	3	n	y	n	n	n	n	n	n	60 mg	54,51	91	n	n	y	n	n	n	n
E	ASA	140	717	84	m	PM	15	305	1	6	n	y	y, oa	n	y	n	n	y	30 mg	49,22	67	y	n	y	n	n	n	n
P	ASA	140	803	79	f	PM	93	333	1	4	n	y	n	n	n	n	n	n	60 mg	70,3	63	y	n	y	n	n	n	n
E	no ASA	140	818	86	f	PM	81	480	1	4	n	y	n	n	n	n	n	n	30 mg	25,15	72	y	y	y	n	n	n	n
E	ASA	140	841	85	m	PM	1437		1	7	y	y	y, oa	y	n	n	n	n	60 mg	68,35	89	y	n	y	n	n	n	n
E	no ASA	140	919	74	m	PM	29	240	3	2	n	y	n	n	n	n	n	n	60 mg	96,84	90	n	n	y	n	n	n	n
P	ASA	140	941	73	m	PM	1233	380	1	2	n	y	n	n	n	n	n	n	60 mg	98,29	94	n	n	y	n	n	n	n
P	ASA	140	1094	82	m	PM	120	600	8	5	y	y	y, oa	n	n	n	y	n	60 mg	56,25	72	n	y	y	n	n	n	n
P	no ASA	140	1101	81	f	ICD	28	330	1	6	y	y	y, oa	n	n	n	n	n	60 mg	51,94	78	y	y	y	n	n	n	n
E	ASA	140	1266	86	m	PM	138	400	1	4	n	y	y, oa	n	n	n	n	n	60 mg	62,5	85	n	y	y	n	n	n	n
P	no ASA	140	1389	65	m	PM	1443		4	2	n	y	n	n	n	n	n	n	60 mg	77,71	73	y	n	y	n	n	n	n
E	ASA	140	1394	85	f	PM	696		10	5	y	y	n	n	n	n	y	n	60 mg	63,42	60	y	n	y	n	n	n	n
E	ASA	140	1406	81	m	PM	17	600	1	4	y	y	n	n	n	n	y	n	60 mg	79,21	76	y	n	y	n	n	n	n
P	ASA	140	1438	75	f	PM	201	300	1	5	y	y	n	n	n	n	n	n	60 mg	50,2	85	n	n	y	n	n	n	n
P	ASA	140	1439	85	m	PM	372		1	3	n	y	n	n	n	n	y	n	60 mg	66,43	60	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	140	1466	78	m	PM	34	240	3	5	n	y	n	y	n	n	n	n	60 mg	62,18	69	n	n	y	n	n	n	n
P	no ASA	140	1496	81	m	PM	44	400	1	5	y	y	y, oa	n	n	n	n	n	60 mg	51,53	68	y	n	y	n	n	n	n
E	no ASA	140	1576	78	m	ICD-CRT	14			4	y	y	n	n	n	n	n	n	60 mg	59,17	69	y	n	y	n	n	n	n
E	ASA	140	1577	79	m	PM	264		7	3	n	y	n	n	n	n	n	n	60 mg	120,5	76	n	n	y	n	n	n	n
E	ASA	140	1578	86	m	PM	14		1	5	y	y	y, it	n	n	n	y	n	60 mg	74,19	56	y	n	y	n	n	n	n
P	ASA	140	1655	71	m	PM	222		1	2	n	y	n	n	n	n	y	n	60 mg	66,35	60	y	n	y	n	n	n	n
P	ASA	140	1666	75	m	ICD-CRT	294		1	4	y	y	n	n	n	n	n	n	60 mg	89,19	50	y	n	y	n	n	n	n
E	ASA	140	1781	80	f	PM	12		1	6	y	y	y, oa	n	n	n	n	n	60 mg	63,84	75	n	n	y	n	n	n	n
P	no ASA	140	1826	81	m	ICD	36	260	1	5	y	y	y, oa	n	n	n	n	n	60 mg	56,76	65	y	n	y	n	y	n	n
E	ASA	140	1889	78	m		1440		5	5									60 mg	93,94		n	n	n	n	n	n	n
P	no ASA	140	1926	70	f	PM	9		1	5	y	y	y, oa	n	n	n	n	n	60 mg	59,65	65	n	n	y	n	n	n	n
E	no ASA	140	1929	83	m	PM	1046	265	604	4	n	y	y, oa	n	n	n	n	n	30 mg	40,3	60	n	y	y	n	n	n	n
P	ASA	140	1930	84	f	PM	279		3	5	n	y	y, it	n	n	n	y	n	30 mg	45,14	67	y	n	y	n	n	n	n
E	ASA	140	2046	81	m	PM	160		7	4	n	y	y, oa AND it	n	n	n	n	n	30 mg	42,12	80	n	n	y	n	n	n	n
E	ASA	140	2096	67	m	PM	56		1	2	n	y	n	n	n	n	n	n	60 mg	106,84	60	y	y	y	n	n	n	n
E	no ASA	140	2187	82	f	PM	291	640	2	4	n	y	n	n	n	n	n	n	60 mg	52,34	66	y	n	y	n	n	n	n
P	no ASA	140	2202	69	m	PM	36		2	2	n	y	n	n	n	n	n	n	60 mg	74,94	78	y	n	y	n	n	n	n
E	no ASA	140	2204	90	f	PM	256		5	4	n	y	n	n	n	n	n	n	30 mg	49,19	67	n	y	y	n	n	n	n
P	no ASA	140	2238	81	f	PM	298		4	4	n	y	n	n	n	n	n	n	60 mg	80,62	81	y	y	y	n	n	n	n
P	ASA	140	2349	82	m	PM	244		6	4	n	y	n	n	n	y	y	n	30 mg	44,13	60	y	n	y	n	n	n	n
E	ASA	140	2357	74	m	PM	293		5	3	n	y	n	n	n	n	n	n	60 mg	57,34	60	y	n	n	n	n	n	n
E	no ASA	140	2617	74	m	PM	178		4	4	y	y	y, oa	n	n	n	n	n	60 mg	105,98	66	n	y	y	n	n	n	n
P	no ASA	140	2618	84	m	PM	163	530	6	5	y	y	y, oa	n	n	n	n	n	30 mg	49,28	66	y	n	y	n	n	n	n
P	ASA	140	2631	82	m	PM	12	346	1	3	n	y	n	n	n	n	n	n	60 mg	76,12	69	n	y	y	n	n	n	n
P	ASA	140	2661	86	m	PM	1440		16	3	n	y	n	n	n	n	n	n	30 mg	44,63	73	y	n	n	n	y	n	n
E	no ASA	140	2691	81	m	PM	329		1	3	n	y	n	n	n	n	n	n	60 mg	51,26	85	n	n	y	n	n	n	n
P	ASA	145	671	89	m	PM	16	385	2	3	n	n	n	n	n	n	n	n	30 mg	41,23	73	n	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	151	2533	80	f	PM	112	400	9	3	n	n	n	n	n	n	n	n	60 mg	91,65	77	y	n	y	n	n	n	n
P	no ASA	151	2537	81	m	PM	32		1	3	n	y	n	n	n	n	n	n	60 mg	68,59	60	y	y	y	n	n	n	n
E	no ASA	151	2572	76	f	PM	359	400	2	3	n	n	n	n	n	n	n	n	30 mg	74,02	60	n	n	n	n	n	n	n
P	ASA	151	2585	78	m	PM	161	640	1	3	n	y	n	n	n	n	y	n	60 mg	60,22	60	y	y	y	n	n	n	n
E	no ASA	153	35	84	m	PM	133	400	1	3	y	y	n	n	n	n	n	n	60 mg	54,68	70	y	y	y	n	n	n	n
E	ASA	153	106	79	m	ICD-CRT	2113	295	53	7	y	y	y, it	y	n	n	n	n	60 mg	69,44	71	y	n	y	n	n	n	n
P	ASA	153	319	75	m	PM	57	248	1	4	y	y	n	n	n	n	n	y	30 mg	40,18	74	y	n	n	n	n	n	n
P	no ASA	153	1098	67	m	PM	450	545	12	3	n	y	y, oa	n	n	n	n	n	60 mg	65,46	68	y	n	n	n	n	n	n
P	no ASA	153	1545	84	m	PM	2146	400	9	3	n	y	n	n	n	n	n	n	60 mg	90,71	63	y	y	y	n	n	n	n
P	ASA	153	1935	74	m	PM	4334	400	3	4	n	y	n	y	n	n	n	n	60 mg	80,25	80	y	y	y	n	n	n	n
P	no ASA	153	2142	68	m	PM	75		1	2	n	y	n	n	n	n	n	n	60 mg	79,66	75	y	n	y	n	n	n	n
E	ASA	153	2730	86	m	PM	203	400	1	4	n	y	y, oa	n	n	n	y	n	60 mg	64,9	61	y	n	y	n	n	n	n
P	ASA	154	110	78	m	ICD	240	240	4	3	y	n	n	n	n	n	n	n	30 mg	29,19	73	n	n	y	n	y	n	n
E	ASA	154	181	77	m	ICD-CRT	220	545	1	4	y	y	n	n	n	n	n	y	30 mg	45,89	60	y	n	y	n	n	n	n
P	ASA	154	297	92	f	PM	5760	400	2	6	y	y	n	n	n	n	n	n	30 mg	31,08	66	y	y	y	n	n	n	n
E	ASA	154	688	87	m	ICD-CRT	539	240	1	7	y	y	n	n	y	y	y	n	30 mg	29,11	51	y	n	y	n	n	n	n
E	ASA	161	230	83	m	PM	120	400	4	5	n	y	y, it	n	n	n	n	y	30 mg	44,76	62	y	y	y	n	n	n	n
P	ASA	161	294	67	m	PM	11	248	1	3	y	y	n	n	n	n	n	n	60 mg	71,45	61	n	n	y	n	n	n	n
E	ASA	161	302	78	f	PM	275	550	6	4	n	y	n	n	n	n	y	n	60 mg	64,48	87	y	n	n	n	n	n	n
P	ASA	161	361	78	m	ICD-CRT	481	214	1	6	y	y	y, oa	n	n	y	y	n	30 mg	40,82	62	y	n	y	n	n	n	n
P	ASA	161	395	65	m	PM	164	308	1	3	n	y	y, it	n	n	n	n	n	60 mg	121,9	62	y	y	y	n	n	n	n
E	ASA	161	459	83	m	PM	6	308	1	4	n	y	y, oa	n	n	n	n	n	60 mg	69,8	90	y	n	y	n	n	n	n
		161	526	78	m					4																		
P	ASA	161	978	78	m	PM	435	275	1	3	n	y	n	n	n	n	n	n	60 mg	77,6	74	n	y	y	n	n	n	n
P	ASA	161	1543	68	f	ICD-CRT	156	333	2	4	y	y	n	n	n	n	n	n	60 mg	62,86	67	y	n	n	n	n	n	n
P	ASA	161	2485	67	m	ICD	1020	545	2	4	y	y	n	n	n	y	y	y	60 mg	139,98	65	y	n	y	n	n	n	n
P	ASA	166	2417	68	f	PM-CRT	99	640	3	4	y	y	y, oa AND it	n	n	n	n	n	60 mg	139,7	81	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	166	2510	78	m	PM-CRT	312	640	9	2	y	n	n	n	n	n	n	n	60 mg	94,82	68	y	n	y	n	n	n	n
E	no ASA	166	2626	70	m	PM	151		1	2	n	y	n	n	n	n	n	n	60 mg	125,7	61	n	y	y	n	n	n	n
P	ASA	166	2671	84	m	PM				3	n	n	n	n	n	n	y	n	30 mg	40,94	53	n	n	n	n	n	n	n
E	no ASA	167	2594	74	f	PM	72		1	3	n	y	n	n	n	n	n	n	60 mg	85,71	73	n	n	y	n	n	n	n
P	no ASA	167	2621	84	m	PM-CRT	969		15	3	y	n	n	n	n	n	n	n	30 mg	41,09	75	y	n	y	n	n	n	n
E	no ASA	167	2623	76	m	PM-CRT	238		1	3	y	n	n	n	n	n	n	n	60 mg	84,09	50	y	n	y	n	n	n	n
P	ASA	167	2640	91	m	PM	40		1	5	y	y	n	n	n	y	y	n	30 mg	35,82	61	y	n	y	n	n	n	n
E	ASA	171	2149	75	m	PM	148		1	2	n	n	n	n	n	n	n	n	60 mg	73,33	75	n	n	n	n	n	n	n
E	no ASA	171	2255	71	m	PM-CRT	83	640	1	2	y	n	n	n	n	n	n	n	60 mg	78,15	60	y	n	y	n	n	n	n
E	ASA	171	2304	76	m	PM	51	640	1	5	n	y	y, it	n	n	y	y	n	30 mg	44,44	64	n	y	y	n	n	n	n
P	no ASA	171	2518	76	f	PM	211		1	3	n	n	n	n	n	n	n	n	30 mg	74,79	64	n	n	n	n	n	n	n
P	ASA	171	2606	77	m	PM	303	400	1	3	n	y	n	n	n	n	n	n	60 mg	121,56	61	n	y	n	n	n	n	n
E	no ASA	171	2709	85	m	PM	38		2	3	n	y	n	n	n	n	n	n	60 mg	67,59	61	n	n	y	n	n	n	n
P	no ASA	171	2717	85	f	PM	32	640	1	4	n	y	n	n	n	n	n	n	60 mg	68,41	63	y	n	n	n	n	n	n
P	no ASA	173	167	67	m	PM				2	n	y	n	n	n	n	n	n	60 mg	179,25	60	n	n	y	n	n	n	n
P	no ASA	173	176	76	m	PM	84	569	7	3	n	y	n	n	n	n	n	n	60 mg	86,42	60	y	y	n	n	n	n	n
E	ASA	173	242	72	m	ICD-CRT	92	500	2	4	y	y	n	n	n	y	n	y	30 mg	42,99		y	n	y	n	n	n	n
E	no ASA	173	314	70	f	ICD-CRT	583	450	1	4	y	y	n	n	n	n	n	n	60 mg	62,88	60	y	n	y	n	n	y	n
E	no ASA	173	322	92	m	PM	3576	380	5	4	n	y	y, oa	n	n	n	n	n	60 mg	53,85	65	n	n	y	n	n	n	n
P	no ASA	173	553	84	m	PM	252	256	1	3	n	y	n	n	n	n	n	n	60 mg	67,95	63	y	n	n	n	n	n	n
P	ASA	173	585	74	m	ICD-CRT	26	600	2	5	y	y	n	n	n	n	n	y	60 mg	54,57	60	y	n	y	n	n	n	n
E	no ASA	173	894	69	m	PM	219	549	14	2	n	n	y, it	n	n	n	n	n	30 mg	63,62	50	n	n	n	n	n	n	n
E	no ASA	173	975	86	m	PM	7	202	2	3	n	y	n	n	n	n	n	n	30 mg	34,51	60	n	n	y	n	n	n	n
P	no ASA	173	1014	87	m	PM				3	n	y	n	n	n	n	n	n	30 mg	46,97	72	n	n	y	n	n	n	n
P	ASA	173	1062	79	f	PM	269	640	31	6	n	y	y, oa	n	n	n	n	n	30 mg	45,99	66	n	y	y	n	n	n	n
P	no ASA	173	1067	67	m	PM	2880	680	3	3	n	y	y, oa	n	n	n	n	n	60 mg	83	60	y	n	y	n	n	n	n
E	no ASA	173	1080	69	f	PM	16	366	3	3	n	y	n	n	n	n	n	n	60 mg	81,39	60	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	173	1319	84	m	PM	9	175	1	3	n	y	n	n	n	n	n	n	30 mg	33,76	91	n	n	n	n	n	n	n
P	no ASA	173	1488	75	f	PM	11	182	1	4	n	y	n	n	n	n	n	n	30 mg	77,69	64	n	n	y	n	n	n	n
P	ASA	173	1540	71	m	PM	96		1	3	n	y	n	n	n	n	n	n	60 mg	73,67	63	n	n	y	n	n	n	n
E	ASA	173	1712	65	m	ICD-CRT	66	640	3	4	y	y	y, oa	n	n	n	n	n	60 mg	82,19	50	y	n	y	n	n	n	n
E	no ASA	173	1716	83	m	PM	22	640	1	3	n	y	n	n	n	n	n	n	60 mg	53,9	100	n	n	y	n	n	n	n
E	ASA	173	1758	71	m	ICD-CRT	2304		2	5	y	y	y, oa	n	n	n	n	n	60 mg	62,34	60	y	n	y	n	n	n	n
P	ASA	173	2042	85	f	PM-CRT	66	640	2	4	y	n	n	n	n	n	n	n	60 mg	53,91	81	y	n	y	n	n	n	n
E	no ASA	173	2062	77	m	PM	195	400	12	2	n	n	n	n	n	n	n	n	60 mg	51,67	64	y	n	n	y	n	n	n
P	ASA	173	2124	72	m	ICD-CRT	581	600	1	3	y	n	n	n	n	y	y	n	60 mg	76,14	66	y	n	y	n	n	n	n
P	ASA	173	2342	77	m	ICD-CRT				5	y	y	n	n	n	y	y	n	60 mg	62,6	58	y	n	y	n	n	n	n
E	no ASA	173	2375	67	f	PM	6	213	1	3	n	y	n	n	n	n	n	n	30 mg	49,05	80	n	n	y	n	n	n	n
E	ASA	173	2453	77	m	PM	170	640	1	5	n	y	n	n	y	n	n	n	60 mg	76,36	69	n	n	y	n	n	n	n
P	no ASA	173	2506	77	f	PM	23	252	3	5	n	y	y, oa	n	n	n	n	n	30 mg	40,48	60	y	y	y	n	n	n	n
E	ASA	173	2568	84	m	ICD-CRT	7		1	6	y	y	y, oa	n	n	y	y	n	30 mg	41,72	51	y	n	y	n	n	n	n
E	no ASA	173	2607	87	m	PM	3855	640	1	3	n	y	n	n	n	n	n	n	60 mg	59,22	69	n	n	y	n	n	n	n
P	no ASA	173	2675	86	m	PM	386	640	6	6	n	y	y, it	n	y	n	n	n	30 mg	34,9	60	y	y	y	n	n	n	n
E	no ASA	174	172	78	f	PM		300		4	n	y	n	n	n	n	n	n	60 mg	72,11	71	n	n	n	n	n	n	n
E	ASA	174	306	84	m	PM	6	400	1	5	y	y	n	n	n	y	n	n	60 mg	69,75	57	y	n	y	n	n	n	n
P	no ASA	174	498	75	m	PM	32	316	1	3	n	y	n	n	n	n	n	n	60 mg	100,61	63	n	n	y	n	n	n	n
E	ASA	174	613	65	m	PM	490	325	1	4	n	y	y, oa	n	n	n	n	n	60 mg	67,18	102	n	n	n	n	n	n	n
P	ASA	174	1008	72	f	PM	26	334	1	6	y	y	y, oa AND it	n	n	y	n	n	30 mg	42,77	60	n	n	y	n	n	n	n
P	no ASA	174	1414	84	f	PM	16	400	4	4	n	y	n	n	n	n	n	n	60 mg	64,37	60	y	y	n	n	n	n	n
E	no ASA	174	1487	74	m	PM	988	600	2	2	n	y	n	n	n	n	n	n	60 mg	112,39	71	n	y	y	n	n	n	n
E	no ASA	174	1672	75	f	PM	107	375	10	4	n	y	n	n	n	n	n	n	60 mg	56,64	70	n	y	y	n	n	n	n
P	ASA	174	1925	74	m	ICD-CRT	39	640	1	4	y	y	n	n	n	y	n	n	60 mg	79,56	70	y	y	y	n	n	n	n
P	no ASA	174	2069	75	m	PM	40	240	1	3	n	y	n	n	n	n	n	n	60 mg	106,73	52	n	y	y	n	n	n	n
P	ASA	174	2176	67	f	PM	118	640	1	4	n	y	n	n	n	n	n	n	30 mg	66,99	60	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	174	2566	80	m	PM	34	400	3	3	n	y	n	n	n	n	n	n	60 mg	68,94	61	y	n	n	n	n	n	n
P	no ASA	174	2586	81	m	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	69,26	70	y	y	y	y	n	n	n
E	ASA	174	2588	75	m	PM	10		1	3	n	y	n	n	n	n	y	n	60 mg	98,44	69	y	y	y	n	n	n	n
E	no ASA	175	487	74	f	PM	177	321	2	3	n	y	n	n	n	n	n	n	60 mg	103,02	75	y	y	y	n	n	n	n
P	no ASA	175	515	81	f	ICD-CRT	24	480	1	5	y	y	n	n	n	n	n	n	30 mg	36,92	55	y	y	y	n	n	n	n
E	no ASA	175	1035	85	m	PM	589	640	3	2	n	n	n	n	n	n	n	n	60 mg	79,75	61	n	n	n	n	n	n	n
P	ASA	175	2456	78	m	PM	422		9	3	n	y	n	n	n	n	n	n	60 mg	81,38	61	n	y	y	n	n	n	n
P	ASA	175	2460	79	m	PM	43	640	1	3	n	n	n	n	n	n	n	n	60 mg	75,66	50	n	n	n	n	n	n	n
E	ASA	175	2523	87	m	PM	102	614	1	3	n	y	n	n	n	n	n	n	30 mg	40,12	61	n	n	y	n	n	n	n
E	no ASA	175	2530	88	m	PM	706	545	22	3	n	y	n	n	n	n	n	n	60 mg	54,01	62	n	y	y	n	n	n	n
P	no ASA	175	2536	76	f	PM	21	512	1	4	n	y	n	n	n	n	n	n	60 mg	87,36	60	n	y	y	n	n	n	n
E	ASA	175	2745	80	m	PM	60	545	1	4	n	y	y, oa	n	n	n	n	n	60 mg	112,12	66	n	y	y	n	n	n	n
P	ASA	179	128	68	f	ICD-CRT	88	522	1	6	y	y	y, oa AND it	n	n	n	n	n	60 mg	62,86	63	y	n	y	n	n	n	n
E	no ASA	179	296	69	f	PM				3	n	y	n	n	n	n	n	n	60 mg	86,37	59	n	n	y	n	n	n	n
P	no ASA	179	308	82	f	PM	2152	640	1	4	n	y	n	n	n	n	n	n	60 mg	56,42	49	n	y	y	n	n	n	n
P	ASA	179	510	85	m	PM	19	351	1	6	n	y	y, oa	y	n	n	n	n	60 mg	86,39	74	n	y	y	n	n	n	n
		179	989	74	m					3																		
		179	1108	89	m					6																		
E	ASA	179	1112	68	m	PM	28	370	1	2	n	n	n	n	n	y	y	n	60 mg	108,99	62	n	n	y	n	n	n	n
E	no ASA	179	1132	78	f	PM	751	375	6	4	n	y	n	n	n	n	n	n	60 mg	92,32	60	y	y	y	n	n	n	n
E	ASA	179	1147	85	m	PM	12	455	1	3	n	y	n	n	n	n	n	n	60 mg	59,72	64	y	n	y	n	n	n	n
P	no ASA	179	1182	83	f	PM	113	640	1	4	n	y	n	n	n	n	n	n	60 mg	62,48	53	y	n	y	n	n	n	n
E	no ASA	179	1270	84	f	PM				4	n	y	n	n	n	n	n	n	30 mg	40,48	60	y	n	y	n	n	n	n
P	no ASA	179	1868	72	m	PM	33	614	1	5	n	y	y, oa	y	n	n	n	n	60 mg	73,41	60	n	n	n	n	n	n	n
E	no ASA	179	2100	80	f	PM	239	462	1	4	n	y	n	n	n	n	n	n	60 mg	82,48	60	n	n	y	n	n	n	n
P	no ASA	179	2101	77	f	PM	11	400	1	4	n	y	n	n	n	n	n	n	60 mg	65,67	60	n	n	y	n	n	n	n
E	ASA	179	2193	81	m	PM-CRT	249	640	1	6	y	y	y, oa	n	n	n	n	n	60 mg	59,98	67	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
		189	351	88	f					4																		
E	ASA	189	424	69	f		12	183	1	3									30 mg	52,1		n	n	y	n	n	n	n
E	ASA	189	1331	82	f	ICD-CRT	8	300	1	4	y	n	n	n	n	n	n	n	30 mg	41,22	59	y	n	n	n	n	n	n
E	no ASA	195	169	82	m	PM				4	n	y	y, it	n	n	n	n	n	60 mg	70,15		y	n	y	n	n	n	n
E	no ASA	195	283	82	m	PM	6000	500	2	4	n	y	y, it	n	n	n	n	n	60 mg	62,27		y	n	y	n	n	n	n
P	no ASA	195	396	71	m	ICD-CRT	9	375	1	3	y	y	n	n	n	n	n	n	60 mg	57,11	63	n	y	n	n	n	n	n
E	ASA	195	398	71	m	PM	9999	600	10	3	n	y	n	n	n	n	n	n	30 mg	51,99	60	y	y	y	n	n	n	n
P	ASA	195	412	78	m	PM	1029	357	1	2	n	n	n	n	n	n	n	n	60 mg	70,42		y	n	n	n	n	n	n
E	ASA	195	519	82	m	PM	170	600	1	4	y	n	n	n	n	y	n	n	30 mg	43,46	74	y	n	n	n	n	n	n
E	ASA	195	617	70	m	ICD	22	192	1	4	n	y	y, oa AND it	n	n	y	n	n	60 mg	75	55	y	n	y	n	n	n	n
P	ASA	195	633	84	f	PM	281	260	1	5	n	y	n	n	n	y	n	n	30 mg	20,83	123	y	y	n	n	n	n	n
P	ASA	195	1004	70	m	PM	608	545	5	2	n	n	n	n	n	n	n	n	60 mg	76,87	60	n	n	n	n	n	n	n
P	no ASA	195	1233	82	m	PM	17	375	2	3	n	y	n	n	n	n	n	n	60 mg	76,48	75	n	n	n	n	n	n	n
E	ASA	195	1411	71	m	PM	458	190	1	2	n	n	n	n	n	y	y	n	60 mg	78,51	65	n	n	n	n	n	n	n
P	no ASA	198	144	72	f	PM	108	248	3	4	n	n	n	y	n	n	n	n	30 mg	46,65	71	n	n	y	n	n	n	n
P	ASA	198	1857	73	m	PM	2621	392	2	3	n	y	n	n	n	y	n	n	60 mg	74,9	61	y	n	n	n	n	n	n
P	ASA	198	2148	81	m	PM	37		4	4	n	y	n	n	n	n	n	n	30 mg	61,29	109	n	y	y	n	n	n	n
E	no ASA	202	348	80	f	PM	795	320	6	5	y	y	n	n	n	n	n	n	60 mg	62,69	86	n	n	y	n	n	n	n
E	no ASA	202	419	69	f	PM	131	300	1	4	n	y	y, oa	n	n	n	n	n	60 mg	113,98	72	n	y	y	n	n	n	n
E	ASA	202	556	88	f	PM	35	197	1	6	y	y	y, oa	n	n	n	n	n	60 mg	76,74	71	n	n	y	n	n	n	n
P	no ASA	202	1125	79	m	PM	450	400	1	3	n	y	n	n	n	n	n	n	60 mg	74,13	66	n	n	y	n	n	n	n
E	ASA	202	1146	69	m	ICD-CRT	420	640	1	4	y	n	y, oa	n	n	y	y	n	60 mg	80,12	63	y	n	y	n	n	n	n
P	ASA	202	1188	76	m	PM	9	614	1	2	n	n	n	n	n	n	n	n	60 mg	103,75	68	y	n	n	n	n	n	n
E	ASA	205	80	87	f	PM	486	429	1	4	n	y	n	n	n	n	n	n	60 mg	51,45	61	n	n	y	n	n	n	n
E	no ASA	205	182	76	m	ICD-CRT	87	462	8	5	y	y	y, oa	n	n	n	n	n	60 mg	73,98	61	y	n	y	n	n	n	n
P	ASA	205	184	88	m	PM	13	462	1	4	n	y	n	n	n	y	y	n	30 mg	40,9	67	n	n	n	n	n	n	n
P	no ASA	205	207	80	m	PM	435	500	1	3	n	y	n	n	n	n	n	n	30 mg	27,05	60	n	y	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	205	285	69	m	PM	355	400	3	3	n	y	n	n	n	y	y	n	60 mg	83,65	59	y	n	y	n	n	n	n
E	ASA	205	336	77	m	PM	265	640	16	5	y	y	n	n	n	y	y	n	60 mg	85,52	80	n	n	y	n	n	n	n
		205	342	88	f					5																		
P	ASA	205	366	98	f	PM	2095	400	6	6	n	y	n	n	y	n	n	n	30 mg	28,69	61	y	y	y	n	n	n	n
E	ASA	205	382	76	f	PM	871	500	2	5	n	y	y, it	n	n	n	n	n	60 mg	50,4	61	n	y	y	n	n	n	n
P	ASA	205	748	86	f	PM	540		2	5	n	y	n	n	n	n	n	n	60 mg	57,43	63	n	n	n	n	n	n	n
P	ASA	205	931	68	m	PM	1109	600	2	3	n	y	n	n	n	n	y	n	60 mg	76,96		n	n	n	n	n	n	n
E	ASA	205	946	72	m	PM	129	387	1	3	n	y	n	n	n	n	n	y	60 mg	105,4	81	n	n	n	n	n	n	n
P	no ASA	208	516	81	m	PM	180	400	3	3	n	y	n	n	n	n	n	n	60 mg	56,99	69	y	n	y	n	n	n	n
P	no ASA	208	524	80	m	PM	12	380	1	2	n	n	n	n	n	n	n	n	60 mg	74,49	62	n	n	n	n	n	n	n
E	ASA	208	1036	72	m	PM	1092	545	1	7	y	y	y, oa	n	y	y	n	y	60 mg	93,23	62	n	y	y	n	n	n	n
E	no ASA	208	1306	82	m	PM	9	353	2	3	n	y	n	n	n	n	n	n	60 mg	62,96	93	n	y	y	n	n	n	n
E	ASA	208	1362	72	m	PM	778		1	3	n	n	n	n	y	n	n	n	60 mg	75,85	58	y	n	n	n	n	n	n
E	no ASA	208	1449	66	m	ICD-CRT	27	462	1	2	y	n	n	n	n	n	n	n	60 mg	126,33	61	y	n	y	n	n	n	n
P	ASA	209	79	82	m	PM	485	640	1	2	n	n	n	n	n	n	y	y	60 mg	64,58	53	y	n	y	n	n	n	n
P	no ASA	209	141	74	f	PM	361	400	2	3	n	y	n	n	n	n	n	n	60 mg	86,63	77	n	y	n	n	n	n	n
P	no ASA	209	1501	75	m	PM				3	n	y	n	n	n	n	n	n	60 mg	62,9	74	n	n	y	n	n	n	n
P	ASA	211	143	79	m	PM	12	300	2	4	n	y	y, oa	n	n	n	n	n	60 mg	61,28	91	n	y	y	n	n	n	n
E	ASA	211	204	90	m	PM	170	400	2	4	n	n	n	n	y	n	n	n	60 mg	52,46		n	n	n	n	n	n	n
P	ASA	211	250	82	m	ICD-CRT	115	295	3	4	y	n	n	n	n	n	n	y	30 mg	42,17	60	y	n	y	n	n	n	n
E	ASA	211	356	87	m	PM	13	274	2	3	n	n	n	n	n	y	n	y	30 mg	43,9	70	y	n	n	n	n	n	n
P	no ASA	211	513	74	m	PM	180	513	1	3	y	y	n	n	n	n	n	n	60 mg	60,99	63	y	n	y	n	n	n	n
P	no ASA	217	49	74	m	PM	55	202	8	2	n	y	n	n	n	n	n	n	60 mg	59,91	69	n	y	n	n	n	n	n
E	ASA	226	239	67	m	ICD-CRT	94	333	2	4	n	y	y, oa	n	n	y	n	n	60 mg	80,04	55	y	y	y	n	n	n	n
P	ASA	226	293	76	m	PM	288	480	8	3	n	y	n	n	n	n	n	n	60 mg	138,43	62	y	n	y	n	n	n	n
E	ASA	226	413	83	m	PM	154	545	1	4	n	y	n	n	n	y	n	y	60 mg	65,5	60	n	n	y	n	n	n	n
		226	609	76	m					4																		

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	226	648	74	m	PM	1001	600	1	4	n	y	n	n	n	n	n	n	60 mg	58,26	64	y	y	y	n	n	n	n
E	no ASA	226	1164	70	f	PM-CRT	2812		8	4	y	n	n	n	n	n	n	n	30 mg	46,04	72	n	n	y	n	n	n	n
P	ASA	226	1400	76	m	PM	963	545	1	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	94,09	79	n	n	y	n	n	n	n
E	ASA	226	1404	89	m	PM	77	380	2	6	y	y	y, oa	n	n	y	y	n	30 mg	32,9	62	y	n	y	n	n	n	n
P	ASA	226	1434	87	f	PM	59	265	1	5	n	y	n	n	n	n	y	n	60 mg	70,3	76	n	n	y	n	n	n	n
E	ASA	226	1511	75	m	PM	46		1	3	n	n	n	n	n	n	y	n	60 mg	52,53	80	y	n	y	n	n	n	n
P	ASA	226	1630	78	f	PM	15		5	5	n	y	n	n	n	n	n	n	60 mg	92,17	60	y	y	n	n	n	n	n
P	no ASA	226	1638	83	f	PM	10	375	3	4	n	y	n	n	n	n	n	n	30 mg	48,07	77	n	n	y	n	n	n	n
E	ASA	226	1670	90	m	PM	360	600	1	5	n	y	y, oa	n	n	n	n	n	30 mg	37,39	68	y	n	y	n	n	n	n
P	no ASA	226	1710	78	m	PM	117	300	3	3	n	y	n	n	n	n	n	n	60 mg	84,24	55	n	n	y	n	n	n	n
E	no ASA	226	2089	81	f	PM	2579	640	6	4	n	y	n	n	n	n	n	n	30 mg	50,27	80	y	n	y	n	n	n	n
E	ASA	226	2120	77	m	PM	63	400	3	6	y	y	y, oa	n	n	n	n	n	60 mg	61,22	61	n	y	y	n	n	n	n
E	no ASA	226	2243	81	m	PM	428	400	3	3	n	y	n	n	n	n	n	n	60 mg	62,25	56	y	n	y	n	n	n	n
P	no ASA	226	2259	74	m	PM-CRT	175	400	7	3	y	n	y, oa	n	n	n	n	n	60 mg	55,71	55	y	n	y	n	n	n	n
E	ASA	226	2639	74	m	PM-CRT	420	640	2	3	y	y	n	n	n	n	n	n	60 mg	100,13	63	y	n	y	n	y	n	n
E	no ASA	232	228	81	f	ICD-CRT	766	480	1	5	y	y	n	n	n	n	n	n	60 mg	51	64	y	n	y	n	n	n	n
E	no ASA	232	749	71	m	PM	120	600	1	2	n	y	n	n	n	n	n	n	60 mg	90,33	73	n	n	y	n	n	n	n
E	ASA	232	1019	81	m	PM	16	232	2	5	n	y	y, oa	n	n	n	n	n	60 mg	62,32	68	n	y	y	n	n	n	n
E	ASA	232	1152	83	m	PM	6	333	1	3	n	n	n	n	n	y	y	n	60 mg	63,33	85	y	n	y	n	n	n	n
E	no ASA	264	381	76	m	PM	1494	240	4	3	n	n	n	n	n	n	n	n	60 mg	68,76	50	n	n	n	n	n	n	n
P	no ASA	264	408	81	f	PM	7	347	1	4	y	n	n	n	n	n	n	n	60 mg	71,9		y	n	y	n	n	n	n
E	ASA	264	583	77	m	PM	323	640	1	3	n	n	n	n	n	n	n	n	60 mg	68,8	60	n	n	n	n	n	n	n
P	ASA	264	747	71	m	PM	25	444	1	4	n	y	y, oa	n	n	y	y	n	60 mg	85,68	79	y	n	y	n	n	n	n
P	ASA	264	905	70	m	ICD-CRT	76	600	2	5	y	y	y, oa	n	n	y	y	n	60 mg	96,47	65	y	n	y	n	n	n	n
E	ASA	264	1330	65	f	PM	24	400	1	3	n	n	n	n	n	n	n	n	60 mg	106,55		y	n	n	n	n	n	n
P	no ASA	264	1544	80	m	PM	86	640	1	3	n	y	n	n	n	n	n	n	60 mg	60,46	54	n	n	n	n	n	n	n
E	no ASA	264	1753	80	f	ICM	58		1	4	y	n	n	n	n	n	n	n	60 mg	61,44	73	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	264	1844	73	m	ICD	39	199	1	4	y	n	y, it	n	n	y	n	n	60 mg	60,22	50	y	n	y	n	y	n	n
P	ASA	264	2454	67	m	PM	14	512	24	5	n	y	y, oa	n	y	n	n	n	60 mg	113,22		n	y	y	n	n	n	n
P	no ASA	264	2681	82	m	PM	646		4	2	n	n	n	n	n	n	n	n	60 mg	80,93	92	n	n	n	n	n	n	n
P	ASA	267	829	80	m	PM	105	600	4	5	n	y	n	n	y	n	n	n	60 mg	62,01	60	y	n	y	n	n	n	n
E	ASA	267	832	92	m	PM	580	250	1	4	n	y	n	n	n	y	y	n	30 mg	45,75	62	y	n	y	n	n	n	n
E	ASA	267	920	68	m	ICD-CRT	1085	510	2	4	y	y	n	n	n	y	y	n	60 mg	117,79	71	y	y	y	n	n	n	n
E	ASA	267	937	86	f	PM	829	320	4	4	n	y	n	n	n	n	n	n	30 mg	34,88	70	y	n	y	n	n	n	n
P	ASA	267	1219	65	m	PM	91	267	1	3	y	y	n	n	n	n	n	n	60 mg	104,17	70	y	n	y	n	n	n	n
P	no ASA	308	21	68	f	PM	6	400	1	3	n	y	n	n	n	n	n	n	30 mg	49,3	60	y	n	y	n	n	n	n
P	ASA	308	215	79	m	PM	15	280	1	4	n	y	n	n	n	y	n	n	60 mg	76,53	82	n	n	y	n	n	n	n
E	no ASA	308	217	72	m	PM	735	591	3	4	y	y	y, it	n	n	n	n	n	60 mg	77,95	65	y	y	y	n	n	n	n
P	no ASA	308	267	78	m	PM	7	201	1	4	n	y	y, oa	n	n	n	n	n	60 mg	70,3	73	y	n	y	n	n	n	n
E	ASA	326	501	78	m	PM	540	640	15	5	n	y	y, oa AND it	n	n	n	n	y	60 mg	68,2	77	y	n	y	n	n	n	n
P	ASA	377	72	82	m	PM	128	400	1	3	n	y	n	n	n	n	y	n	30 mg	32,99	71	n	n	y	n	n	n	n
P	no ASA	377	83	84	m	PM	515	591	1	3	n	y	n	n	n	n	n	n	60 mg	81,77	64	n	n	y	n	n	n	n
P	ASA	377	175	84	f	PM	111	400	2	8	y	y	n	y	n	n	y	n	60 mg	50,65	64	y	n	y	n	n	n	n
P	ASA	406	163	85	f	PM	42	300	2	5	y	y	n	n	n	n	n	n	60 mg	91,43		y	y	y	n	n	n	n
P	ASA	406	1003	86	m	PM				4	y	y	n	n	n	n	y	y	30 mg	48,01	60	n	n	y	n	n	n	n
P	ASA	414	220	81	m	PM	18	233	1	3	n	y	n	n	n	n	n	n	60 mg	56,51		y	n	y	n	n	n	n
E	no ASA	414	246	98	f	PM	2851	640	3	4	n	y	n	n	n	n	n	n	30 mg	36,75		n	y	n	n	n	n	n
E	ASA	414	268	79	m	PM	472	231	1	3	n	n	y, oa	n	n	n	y	n	60 mg	81,4		y	y	y	n	n	n	n
E	ASA	414	346	75	f	PM				4	n	y	n	n	n	n	n	n	30 mg	38,98		y	y	n	n	y	n	n
P	ASA	414	433	76	m	PM	70	310	1	3	n	y	n	n	n	n	y	n	60 mg	68,23		n	y	y	n	n	n	n
P	ASA	414	584	75	f	PM	14	600	1	4	n	y	n	n	n	n	n	n	60 mg	55,11		y	n	y	n	n	n	n
E	ASA	414	670	83	f	PM	45	600	1	3	n	n	n	n	n	n	y	n	30 mg	32,48		y	n	n	n	n	n	n
P	ASA	414	704	84	f	PM	255	286	6	4	n	y	n	n	n	n	n	n	30 mg	34,6	69	n	n	y	y	n	n	n
E	ASA	414	970	93	m	PM	74	438	1	2	n	n	n	n	n	n	n	n	30 mg	44,92	65	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	414	988	75	m	PM	607	333	12	2	n	n	n	n	n	n	n	n	30 mg	42,08	59	y	n	n	n	n	n	n
E	no ASA	414	1510	68	m	PM	987		3	2	y	n	n	n	n	n	n	n	60 mg	74,22	60	y	n	n	n	n	n	n
P	ASA	414	1541	77	m	PM	984		1	6	y	y	y, it	n	n	y	n	n	60 mg	60,22		y	y	y	n	n	n	n
E	ASA	414	1610	85	m	PM	607		16	5	n	y	y, it	n	n	y	y	n	30 mg	19,26		n	y	y	n	n	n	n
P	no ASA	414	1626	88	f	ICM	30		2	4	n	y	n	n	n	n	n	n	30 mg	34,7	66	n	y	n	n	n	n	n
P	ASA	414	1654	85	m	PM	45		1	4	y	y	n	n	n	n	n	n	60 mg	66,43	69	y	y	y	n	n	n	n
P	no ASA	414	1686	66	m	PM	159		5	3	n	y	y, oa	n	n	n	n	n	60 mg	93,17	102	n	n	y	n	n	n	n
E	no ASA	414	1704	75	m	ICM	474		1	2	n	n	n	n	n	n	n	n	60 mg	63,91	64	n	n	n	n	n	n	n
E	no ASA	414	1767	67	m	ICD	687	545	2	2	n	y	n	n	n	n	n	n	60 mg	106,46	74	n	y	y	n	n	n	n
E	ASA	414	1777	84	m	PM	108		1	3	n	n	n	n	n	y	y	n	60 mg	52,66		y	n	n	n	n	n	n
E	ASA	414	1783	88	m	PM	340		1	6	n	n	y, it	n	y	y	y	n	60 mg	61,84	78	y	y	y	n	n	n	n
P	ASA	414	1792	87	m	PM	64		1	3	n	y	n	n	n	n	y	n	30 mg	42,42	60	y	y	n	n	n	n	n
P	ASA	414	1845	81	m	PM	587	640	1	4	n	y	n	n	n	n	y	n	30 mg	29,36	56	y	n	y	n	y	n	n
P	ASA	414	1892	66	m	ICD	18		1	3	n	y	y, oa	n	n	n	n	n	60 mg	74,81	53	y	n	y	n	n	n	n
P	no ASA	414	1941	73	m	ICD-CRT	84	640	2	2	y	n	n	n	n	n	n	n	30 mg	41,98	64	y	n	y	n	n	n	n
E	ASA	414	1943	88	m	PM	36	187	1	4	n	n	n	y	n	n	n	n	30 mg	35,69		y	n	n	n	n	n	n
E	ASA	414	1971	91	f	PM	29		1	3	n	n	n	n	n	n	n	n	30 mg	34,85	70	n	n	n	n	n	n	n
P	no ASA	414	2035	80	m	PM	325		1	2	n	n	n	n	n	n	n	n	30 mg	53,44	60	y	n	n	n	y	n	n
		414	2116	73	m					2																		
E	ASA	414	2174	72	m	ICM	312		1	4	n	y	y, it	n	n	n	y	n	60 mg	84,19		n	y	y	n	n	n	n
E	no ASA	414	2183	72	m	PM	102	600	1	2	n	y	n	n	n	n	n	n	60 mg	127,78		n	n	y	n	n	n	n
		414	2278	80	f		183		2	5																		
		414	2309	89	m					3																		
		414	2322	87	f					4																		
P	ASA	414	2323	83	m	PM	668	500	1	4	n	y	y, it	n	n	n	y	n	60 mg	62,67	68	y	y	y	n	n	n	n
P	no ASA	414	2424	92	m	PM				4	y	y	n	n	n	n	n	n	30 mg	34,36	68	n	n	y	n	n	n	n
E	ASA	414	2469	75	m	ICD	639		2	5	y	n	n	n	y	n	y	n	60 mg	54,7	84	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
		414	2481	88	f		38		3	3																		
		414	2497	83	m		272		1	4																		
E	no ASA	414	2507	69	m	PM	883	282	9	3	y	y	n	n	n	n	n	n	60 mg	106,94		y	n	n	n	n	n	n
		414	2569	77	m					2																		
E	no ASA	414	2570	75	m	ICM				4	n	y	y, it	n	n	n	n	n	30 mg	25,66		n	n	y	n	n	n	n
P	ASA	414	2571	68	m	ICM	10		1	4	y	y	y, oa	n	n	n	y	n	60 mg	97,39		n	y	n	n	n	n	n
E	no ASA	416	84	80	f	PM	5760	400	1	5	n	y	y, it	n	n	n	n	n	60 mg	53,22	86	y	n	n	n	n	n	n
P	no ASA	416	86	84	f	PM	144	400	1	5	n	y	y, oa	n	n	n	n	n	60 mg	55,68	90	y	n	y	n	n	n	n
P	no ASA	416	125	76	f	PM	47	263	1	4	n	y	n	n	n	n	n	n	60 mg	75,61	65	n	y	n	n	n	n	n
		416	191	80	m					8																		
P	no ASA	416	445	78	f	PM	25	500	2	5	n	y	y, oa	n	n	n	n	n	30 mg	48,81	66	n	n	y	n	n	n	n
E	no ASA	416	449	80	m	PM	1261	400	3	6	n	y	y, oa	y	n	n	n	n	30 mg	47,36	66	y	n	y	n	n	n	n
E	no ASA	416	469	79	f	PM	69	429	11	4	n	y	n	n	n	n	n	n	60 mg	58,87	69	n	y	y	n	n	n	n
P	no ASA	416	547	82	f	PM	25	600	2	4	n	y	n	n	n	n	n	n	30 mg	40,78	55	y	y	n	n	n	n	n
E	no ASA	416	1001	82	f	PM				4	n	y	n	n	n	n	n	n	30 mg	40,53	76	n	n	y	n	n	n	n
E	no ASA	419	211	65	m	PM	23	316	1	2	n	y	n	n	n	n	n	n	60 mg	117,31	60	y	y	n	n	n	n	n
P	no ASA	419	244	68	m	ICD	312	545	1	3	y	y	n	n	n	n	n	n	60 mg	84,83	50	y	n	y	n	n	n	n
E	ASA	419	247	73	f	ICD	666	462	2	4	n	n	n	y	n	n	n	n	60 mg	63,45	80	y	n	n	n	n	n	n
E	no ASA	419	323	78	f	ICD-CRT	74	387	1	4	n	y	n	n	n	n	n	n	60 mg	65,06	74	y	n	y	n	n	n	n
		419	441	87	m					5									30 mg	47,2								
P	no ASA	419	464	68	m	PM	541	335	1	2	n	y	n	n	n	n	n	n	60 mg	63,32	83	n	n	y	n	n	n	n
P	ASA	419	494	75	f	PM	179	333	4	5	n	y	n	n	n	y	n	n	30 mg	45,9	60	n	n	y	n	n	n	n
E	no ASA	419	637	85	f	PM	288	250	2	4	n	y	n	n	n	n	n	n	30 mg	33,15	62	n	n	n	n	n	n	n
P	no ASA	419	690	66	m	PM	601	231	8	3	n	y	y, oa	n	n	n	n	n	60 mg	150,09		n	y	y	n	n	n	n
E	no ASA	419	945	74	f	ICD-CRT	67	500	2	3	y	n	n	n	n	n	n	n	30 mg	48,18	58	y	n	y	n	n	n	n
P	no ASA	419	1137	89	f	PM	55	300	3	4	n	y	n	n	n	n	n	n	30 mg	42,01	66	y	y	n	n	n	n	n
E	ASA	419	1260	70	m	ICD-CRT	323	240	1	5	y	y	y, oa	n	n	y	n	n	60 mg	89,29	67	y	n	y	n	y	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	419	1858	85	m	ICD-CRT	395		1	5	y	y	n	n	n	y	y	n	60 mg	63,66	89	y	n	y	n	n	n	n
E	ASA	419	2083	79	m	PM				3	n	n	n	n	n	n	n	n	60 mg	88,96	60	y	n	n	n	n	n	n
E	ASA	419	2172	80	m	PM	82		2	3	n	y	n	n	n	n	n	n	60 mg	59,72	65	y	n	n	n	n	n	n
E	ASA	419	2207	82	m	ICD	92		1	5	y	y	n	n	n	y	y	y	30 mg	48,86	60	y	n	y	n	n	n	n
E	no ASA	419	2303	76	f	PM	101		4	4	n	y	n	n	n	n	n	n	60 mg	63,28	70	n	n	n	n	n	n	n
P	no ASA	421	55	76	m	PM	65	455	3	4	n	y	y, oa	n	n	n	n	n	60 mg	71,53	84	y	n	n	n	n	n	n
E	ASA	421	77	65	m	PM	496	400	1	4	y	y	y, oa AND it	n	n	n	n	n	60 mg	91,77	85	y	n	y	n	n	n	n
P	no ASA	421	78	80	f	PM	52	328	1	4	n	y	n	n	n	n	n	n	60 mg	77,03	62	n	y	y	n	n	n	n
P	ASA	421	116	67	m	PM	639	375	7	2	n	y	n	n	n	n	n	n	60 mg	73,68	65	y	n	n	n	n	n	n
P	ASA	421	126	77	f	PM	134	400	3	4	n	y	n	n	n	n	n	n	60 mg	69,13	66	n	n	y	n	n	n	n
E	no ASA	421	146	87	m	PM	1260	400	1	3	n	y	n	n	n	n	n	n	30 mg	44,07	81	n	n	n	n	n	n	n
E	no ASA	421	155	80	f	PM	72	400	5	4	n	y	n	n	n	n	n	n	60 mg	69,46	85	y	n	y	n	n	n	n
P	ASA	421	157	83	m	PM	21	400	2	6	y	y	y, oa	n	n	y	n	n	30 mg	26,25	85	y	n	y	n	n	n	n
P	ASA	421	161	79	f	PM	165	233	8	4	n	y	n	n	n	n	n	n	30 mg	25,13	60	y	n	y	n	n	n	n
E	ASA	421	236	69	f	PM	29	600	7	5	n	y	n	n	y	n	n	n	60 mg	64,96	71	y	n	n	n	n	n	n
E	ASA	421	279	77	m	PM	127	220	2	5	n	y	y, it	n	n	y	n	n	60 mg	109,38	60	n	n	n	n	n	n	n
E	no ASA	421	290	71	m	PM	696	462	11	2	n	y	n	n	n	n	n	n	60 mg	98,8	68	n	y	n	n	n	n	n
E	ASA	421	353	77	m	PM	75	460	4	6	n	y	n	y	n	n	n	n	60 mg	58,03	87	n	y	y	n	n	n	n
P	no ASA	421	430	72	m	PM	34	429	10	2	n	y	n	n	n	n	n	n	60 mg	84,96	64	y	y	y	n	n	n	n
E	no ASA	421	500	83	m	PM	2880	600	6	3	n	y	n	n	n	n	n	n	60 mg	91,72	76	n	y	y	n	n	n	n
E	ASA	421	503	75	m	PM	119	429	5	5	y	y	n	n	n	y	y	n	60 mg	71	79	y	n	y	n	n	n	n
P	no ASA	421	544	79	m	PM	691	600	7	3	n	y	n	n	n	n	n	n	60 mg	75,21	51	n	y	y	n	n	n	n
P	no ASA	421	685	67	m	PM	132	500	1	3	n	y	y, oa	n	n	n	n	n	30 mg	38,25	60	n	y	y	n	n	n	n
E	no ASA	421	699	69	f	PM	13	375	1	3	n	y	n	n	n	n	n	n	60 mg	64,15	65	n	n	n	n	n	n	n
P	no ASA	421	768	86	m	PM	155	273	4	3	n	y	n	n	n	n	n	n	60 mg	60	83	y	n	n	n	n	n	n
P	ASA	421	790	65	m	PM	206	600	5	2	n	y	n	n	n	n	n	n	60 mg	102,97	52	y	n	y	n	n	n	n
P	ASA	421	828	82	m	PM	9	191	1	4	n	y	n	n	n	n	n	n	60 mg	84,53	84	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	421	854	77	m	PM	519	600	1	3	n	y	n	n	n	n	n	n	60 mg	66,53	72	y	n	y	n	n	n	n
E	no ASA	421	875	83	f	PM	36	462	1	4	n	y	n	n	n	n	n	n	60 mg	64,53	63	y	n	y	n	n	n	n
E	no ASA	421	907	72	m	PM	582	300	4	2	n	y	n	n	n	n	n	n	60 mg	84,03	61	n	n	y	n	n	n	n
E	ASA	421	985	79	m	PM	264	500	5	4	n	y	n	n	n	n	n	n	60 mg	57,8		y	y	y	n	n	n	n
P	ASA	421	1000	78	m	PM	229	640	1	5	y	y	n	n	n	n	n	n	60 mg	56,48	66	y	y	y	n	n	n	n
E	ASA	421	1046	72	m	PM	164	382	1	4	n	y	y, oa	n	n	y	y	n	60 mg	61,39	60	n	n	y	n	n	n	n
P	no ASA	421	1116	75	f	PM	16	231	2	5	n	y	y, it	n	n	n	n	n	60 mg	67,78	73	n	y	y	n	n	n	n
P	no ASA	421	1216	81	m	PM	221	600	6	5	n	y	y, oa	n	n	n	n	n	30 mg	46,21	71	n	y	y	n	n	n	n
E	ASA	421	1225	86	m	PM	266	176	5	3	n	y	n	n	n	n	n	n	30 mg	34,49	67	y	n	n	n	n	n	n
P	ASA	421	1299	85	f	PM	372	351	3	6	n	y	n	y	n	n	n	n	30 mg	26,45	72	y	n	y	n	n	n	n
E	ASA	421	1307	82	m	PM	2880		8	5	n	y	n	n	n	y	y	n	60 mg	59,99	74	y	y	y	n	n	n	n
P	no ASA	421	1357	70	m	PM	144	640	2	2	n	y	n	n	n	n	n	n	60 mg	54,25	56	n	y	y	n	n	n	n
E	no ASA	421	1380	66	m	ICD	196	316	5	2	n	n	y, oa	n	n	n	n	n	60 mg	72,74	60	y	n	n	n	n	n	n
P	ASA	421	1418	80	f	PM	447	300	8	4	n	y	n	n	n	n	n	n	30 mg	49,58	80	y	n	y	n	n	n	n
P	no ASA	421	1505	76	m	PM	46	640	5	4	y	y	n	n	n	n	n	n	60 mg	98,94	67	y	n	n	n	n	n	n
E	no ASA	421	1584	82	f	PM	653		4	4	n	y	n	n	n	n	n	n	60 mg	55,42	80	n	y	y	n	n	n	n
E	ASA	421	1590	88	m	PM	124		1	3	n	n	y, oa	n	n	n	n	n	60 mg	57,21	66	n	n	y	n	n	n	n
E	ASA	421	1602	72	m	PM	629		3	5	n	y	n	y	n	y	y	n	60 mg	60,71	77	n	n	n	n	n	n	n
E	no ASA	421	1668	71	m	PM	1268	462	1	4	n	y	y, it	n	n	n	n	n	60 mg	80,24	66	y	y	n	n	n	n	n
P	ASA	421	1729	71	f	PM	3475	600	1	4	n	y	n	n	n	n	n	n	60 mg	73,88	70	y	y	y	n	n	n	n
P	ASA	421	1759	77	m	PM	6		1	6	n	y	n	y	n	n	n	n	60 mg	65,38	67	y	n	y	n	n	n	n
P	no ASA	421	1804	81	f	PM	989	240	3	5	n	y	y, oa	n	n	n	n	n	60 mg	58,2	81	y	n	y	n	n	n	n
P	no ASA	421	1806	66	f	PM	68		3	3	n	y	n	n	n	n	n	n	60 mg	121,04	83	y	n	n	n	n	n	n
P	ASA	421	1841	84	m	PM	1038		15	6	n	y	y, it	y	n	n	n	n	30 mg	47,13	80	y	y	y	n	n	n	n
P	ASA	421	1882	87	f	PM	126		6	5	n	y	y, oa	n	n	n	n	n	30 mg	48,49	63	y	n	y	n	n	n	n
E	ASA	421	1883	73	m	ICD	22		2	4	y	y	n	n	n	y	n	y	60 mg	52,58	66	y	n	n	n	n	n	n
P	ASA	421	1884	86	m	PM	101	500	1	4	n	y	n	n	n	y	n	n	60 mg	83,33	67	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	421	1899	91	m	PM	209		5	3	n	n	n	n	n	n	n	n	30 mg	43,06	68	y	n	y	n	n	n	n
E	no ASA	421	1933	75	f	PM	406		13	8	y	y	y, oa	y	n	n	n	y	30 mg	31,08	65	y	n	y	n	n	n	n
E	ASA	421	1934	71	m	PM	39		2	3	n	y	n	n	n	n	n	n	60 mg	54,53	64	y	n	n	n	n	n	n
E	ASA	421	1940	88	f	PM	9999		10	7	y	y	y, it	n	n	y	n	y	30 mg	26,16	81	y	n	y	n	n	n	n
P	ASA	421	1949	71	m	PM	192		5	4	y	y	n	n	n	n	n	n	60 mg	134,09	71	y	n	y	n	n	n	n
E	ASA	421	1956	75	m	PM	1843	366	1	5	n	y	n	y	n	n	n	n	60 mg	81,87	64	n	n	y	n	n	n	n
P	ASA	421	1979	76	m	PM	41		2	4	n	y	n	n	n	n	y	n	30 mg	48,46	62	y	n	n	n	n	n	n
E	no ASA	421	1991	80	f	PM	276	640	1	4	n	y	n	n	n	n	n	n	30 mg	48,99	60	y	n	n	n	n	n	n
P	ASA	421	2023	85	f	PM	891		19	5	n	y	n	n	n	n	n	n	60 mg	89,62	68	y	n	y	n	n	n	n
E	ASA	421	2033	81	m	PM	1713	279	81	4	n	n	y, oa	n	n	n	n	n	60 mg	55,58	75	n	n	n	n	n	n	n
E	ASA	421	2034	93	m	PM	50		3	3	n	n	n	n	n	n	n	n	30 mg	40,79	91	n	n	n	n	n	n	n
		421	2076	86	f					6																		
P	no ASA	421	2109	76	m	PM	348	462	3	3	n	y	n	n	n	n	n	n	60 mg	75,97	77	n	n	y	n	n	n	n
P	ASA	421	2111	79	f	PM	120	545	1	5	n	y	n	n	n	n	y	n	60 mg	84,39	73	n	n	y	n	n	n	n
E	no ASA	421	2152	84	m	PM	4417	600	2	3	n	y	n	n	n	n	n	n	30 mg	35,45	68	n	n	y	n	n	n	n
P	ASA	421	2227	87	m	PM	3854	614	3	4	n	y	n	n	n	n	n	n	30 mg	46,56	65	y	y	n	n	n	n	n
E	ASA	421	2228	69	m	ICD-CRT	533		8	4	y	y	n	n	n	n	y	n	60 mg	55,11	69	y	n	y	n	n	n	n
P	no ASA	421	2232	73	m	PM	216		1	3	y	y	n	n	n	n	n	n	60 mg	50,05	81	n	y	y	n	n	n	n
E	no ASA	421	2240	80	m	PM	17		2	5	n	y	y, it	n	n	n	n	n	30 mg	43,33	68	y	y	y	n	n	n	n
E	no ASA	421	2241	79	f	PM-CRT	571	640	5	6	y	y	y, oa	n	n	n	n	n	30 mg	49,51	72	y	n	y	n	n	n	n
P	no ASA	421	2264	69	f	PM	98	545	1	3	n	y	n	n	n	n	n	n	60 mg	65,25	60	n	n	y	n	n	n	n
E	ASA	421	2265	85	m	PM	22		1	4	n	y	n	n	n	n	n	n	60 mg	54,56	75	n	y	y	n	n	n	n
P	no ASA	421	2283	88	m	PM	167		2	3	n	y	n	n	n	n	n	n	30 mg	39,12	100	n	y	y	n	n	n	n
P	ASA	421	2325	78	m	PM	10	261	4	3	n	n	n	n	n	n	n	n	60 mg	62,29	72	n	n	n	n	n	n	n
P	ASA	421	2347	77	m	PM	37	640	1	4	n	y	n	n	n	n	n	n	60 mg	59,87	65	n	n	n	n	n	n	n
E	ASA	421	2386	74	f	PM	116		9	4	n	y	y, it	n	n	n	y	n	60 mg	60,85	73	n	y	y	n	n	n	n
P	ASA	421	2414	92	f	PM	129		1	6	y	y	n	n	n	n	n	n	30 mg	23,01	70	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	421	2430	86	f	PM	35		1	4	n	y	n	n	n	n	n	n	30 mg	30,9	63	y	y	n	n	n	n	n
P	ASA	421	2449	75	f	PM	346		5	4	n	y	n	n	n	n	n	n	30 mg	37,01	62	y	n	y	n	n	n	n
E	ASA	421	2452	91	m	PM				4	y	y	n	n	n	n	n	n	30 mg	25,89	63	y	n	y	n	n	n	n
E	ASA	421	2457	74	m	PM	262	327	4	2	n	y	n	n	n	n	y	n	60 mg	78,56	64	y	y	y	n	n	n	n
P	ASA	421	2489	85	f	PM	20	200	11	5	n	y	y, oa	n	n	n	n	n	30 mg	33,03	75	n	y	y	n	n	n	n
E	no ASA	421	2508	80	m	PM	26		2	4	n	y	y, oa	n	n	n	n	n	60 mg	70,24	74	n	n	y	n	n	n	n
E	ASA	421	2544	80	m	PM	1440		19	5	n	y	n	n	n	n	n	n	60 mg	70,08	72	y	y	y	n	n	n	n
E	ASA	421	2596	84	f	PM	142	640	1	6	n	y	n	n	y	n	n	n	60 mg	57,97	56	n	n	y	n	n	n	n
P	ASA	421	2604	75	m	PM	491		1	5	n	y	n	y	n	n	n	n	30 mg	48,1	60	n	n	y	n	n	n	n
P	no ASA	421	2616	86	f	PM	51		2	4	n	y	n	n	n	n	n	n	30 mg	44,4	74	n	y	n	n	n	n	n
E	ASA	421	2633	76	m	ICD	65	500	21	3	n	y	n	n	n	n	y	n	60 mg	99,68	65	n	n	n	n	n	n	n
E	ASA	421	2654	77	m	ICD	6000	600	1	4	n	y	n	n	n	y	n	n	30 mg	38,17	47	y	y	y	n	n	n	n
P	ASA	421	2673	85	m	ICD-CRT	11		1	5	y	y	n	n	n	y	y	n	30 mg	43,06	74	y	n	y	n	n	n	n
P	ASA	421	2702	87	m	PM-CRT	30	462	1	8	y	y	y, oa	y	n	y	n	y	60 mg	58,62	71	y	n	y	n	n	n	n
E	ASA	421	2712	75	m	PM	149	400	2	3	n	y	n	n	n	n	n	n	60 mg	80,1	82	n	n	y	n	n	n	n
P	no ASA	426	569	78	m	PM	44	405	4	2	n	n	n	n	n	n	n	n	60 mg	80,54	65	n	n	n	n	n	n	n
E	ASA	426	718	72	f	PM	2020	400	1	6	n	y	y, oa	n	y	n	n	n	60 mg	61,44	75	n	n	y	n	n	n	n
P	ASA	426	778	83	m	ICD	525	270	5	7	y	y	n	n	y	y	y	n	60 mg	52,09	75	y	n	y	n	n	n	n
E	no ASA	426	930	70	m	PM	51	333	3	2	n	y	n	n	n	n	n	n	60 mg	73,16	82	n	y	y	n	n	n	n
P	no ASA	426	1235	83	f	PM	26	320	2	3	n	n	n	n	n	n	n	n	30 mg	39,99	65	n	n	y	n	n	n	n
E	ASA	426	1468	78	m	PM	259	400	5	5	n	y	y, oa	n	n	y	y	n	60 mg	111,18		y	y	y	n	n	n	n
P	ASA	426	1642	73	f	PM	733		5	4	n	y	n	n	n	n	n	n	30 mg	60,21	60	y	n	y	n	n	n	n
E	no ASA	426	1796	80	m	PM	34	400	8	2	n	n	n	n	n	n	n	n	60 mg	100,53	60	n	n	n	n	n	n	n
P	no ASA	427	423	71	f	PM	2880		2	3	n	y	n	n	n	n	n	n	60 mg	147,18	60	n	n	y	n	n	n	n
E	ASA	427	438	72	m	ICD	14	530	4	2	y	n	n	n	n	n	n	n	60 mg	82,82	64	y	n	y	n	n	n	n
P	ASA	427	508	86	m	PM	660	250	34	2	n	n	n	n	n	n	y	n	60 mg	56,14	65	n	n	n	n	n	n	n
P	ASA	427	847	72	f	PM	600	400	1	3	n	y	n	n	n	n	n	n	60 mg	76,84	65	n	y	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	427	1089	88	m	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	70,62	72	y	n	y	n	n	n	n
E	no ASA	428	326	84	f	PM	8	236	1	3	n	n	n	n	n	n	n	n	60 mg	76,66	93	n	n	n	n	n	n	n
E	ASA	428	721	73	m	PM	9999	290	3	5	n	y	n	n	y	n	n	n	60 mg	86,14	70	y	n	n	n	n	n	n
E	ASA	428	2350	68	m	PM	9696	640	1	3	n	n	y, oa AND it	n	n	y	y	n	60 mg	108,66	61	y	y	y	n	n	n	n
P	no ASA	428	2534	68	m	ICD-CRT	270	545	1	3	y	y	n	n	n	n	n	n	60 mg	79,07	53	y	n	y	n	n	n	n
E	ASA	445	650	79	f	PM	119		7	4	n	y	n	n	n	n	n	n	30 mg	45,1		y	n	y	n	n	n	n
E	ASA	445	651	94	m	PM	187	545	2	6	n	y	n	n	y	n	n	n	30 mg	39,82	66	y	n	n	n	n	n	n
P	ASA	445	652	92	f	PM	229	429	11	4	n	y	n	n	n	n	n	n	30 mg	34,31	86	n	y	y	n	n	n	n
E	no ASA	445	784	84	f	PM	61	400	2	4	n	y	n	n	n	n	n	n	30 mg	44,6	77	y	n	n	n	n	n	n
P	ASA	445	785	82	m	PM	203	400	6	5	n	y	y, oa	n	n	n	n	n	60 mg	64,83	60	y	n	y	n	n	n	n
P	ASA	445	786	77	m	PM	721	400	4	5	n	y	y, oa	n	n	n	n	n	60 mg	69,27	73	y	n	y	n	n	n	n
E	ASA	445	1506	79	m	PM	414	640	3	4	n	y	y, oa	n	n	n	n	n	60 mg	93,04	62	y	y	y	n	n	n	n
E	ASA	445	1507	85	m	PM	46	500	7	5	n	y	y, oa	n	n	y	y	y	30 mg	46,64	74	y	n	y	n	n	n	n
E	ASA	445	1574	82	f	PM	152	545	2	3	n	n	n	n	n	n	y	n	60 mg	56,49	60	y	n	n	n	n	n	n
E	no ASA	445	2209	84	f	PM	1440		2	4	n	y	n	n	n	n	n	n	60 mg	50,85	69	y	y	y	n	n	n	n
P	ASA	445	2324	75	f	PM	12		2	3	n	n	n	n	n	n	n	n	30 mg	58,53	60	y	y	n	n	n	y	n
P	ASA	445	2674	87	m	ICD-CRT	1088	545	1	5	y	y	n	n	n	y	n	y	30 mg	36,36	50	y	n	n	n	n	n	n
P	ASA	459	159	65	m	PM	9	265	1	3	n	y	y, oa	n	n	n	y	n	60 mg	100,45	61	y	n	y	n	n	n	n
		459	574	85	m					4																		
E	ASA	470	196	84	f	PM	94	279	1	4	n	y	n	n	n	n	n	y	60 mg	63,08	67	n	y	y	n	n	n	n
E	ASA	470	222	80	m	PM	500	400	6	5	y	y	n	n	n	y	y	n	60 mg	79,64	56	n	n	n	n	n	n	n
E	no ASA	470	304	80	m	PM	80	261	7	3	n	y	n	n	n	n	n	n	60 mg	94,94	103	n	n	y	n	n	n	n
E	ASA	470	529	79	m	PM	564	400	2	3	n	y	n	n	n	n	n	n	60 mg	63,24	67	n	n	n	n	n	n	n
P	ASA	479	76	67	f	ICD-CRT	55	640	2	6	y	y	y, oa AND it	n	n	y	y	y	30 mg	39,45		y	n	y	n	n	n	n
P	no ASA	479	107	75	f	ICD	708	640	1	6	y	y	n	n	n	y	y	n	60 mg	63,95	55	y	n	y	n	n	n	n
P	no ASA	479	535	91	m	ICD-CRT	25	244	1	5	y	y	y, it	n	n	n	n	n	30 mg	21,65		y	n	n	n	n	n	n
E	ASA	479	2352	80	m	PM	16	199	1	4	n	y	n	n	n	y	y	y	60 mg	56,31	52	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	479	2580	81	m	PM	23		2	4	n	y	y, oa AND it	n	n	n	y	n	60 mg	57,18	60	y	n	y	n	n	n	n
E	no ASA	487	405	80	m	PM	21	300	2	3	n	y	n	n	n	n	n	n	60 mg	93,89	64	y	y	n	n	n	n	n
E	no ASA	487	1215	68	f	PM	19	300	1	4	n	y	y, it	n	n	n	n	n	60 mg	88,31	55	y	n	y	n	n	n	n
P	ASA	487	1246	81	m	PM	119	400	2	3	n	y	n	n	n	n	n	n	60 mg	78,3	61	y	n	n	n	n	n	n
P	no ASA	487	1652	86	m	PM	1440		3	4	n	y	y, oa	n	n	n	n	n	60 mg	77,7	77	n	n	y	n	n	n	n
P	no ASA	487	2059	67	m	PM	1391		3	2	n	y	n	n	n	n	n	n	60 mg	77,59	60	n	n	y	n	n	n	n
E	no ASA	487	2491	82	f	PM	112	400	1	4	n	y	n	n	n	n	n	n	30 mg	48,07	63	y	n	y	n	n	n	n
P	ASA	488	2	80	m	PM	21	380		3	n	y	n	n	n	n	n	n	30 mg	26,86	66	n	y	y	n	n	n	n
		488	3	66	m					3									30 mg	29,57								
P	no ASA	488	5	67	f	ICD	8	188		3	n	y	n	n	n	n	n	n	60 mg	80,02	74	y	n	n	n	n	n	n
		488	12	82	m					4																		
E	ASA	488	20	79	m	ICD	18	223	1	8	y	y	y, oa	y	n	y	n	y	60 mg	57,05	82	n	n	n	n	n	n	n
E	no ASA	488	25	73	m	PM	9643	321	1	2	n	y	n	n	n	n	n	n	60 mg	68,75	75	n	n	n	n	n	n	n
E	ASA	488	27	78	m	PM	7	286	1	4	y	y	n	n	n	n	n	n	60 mg	92,96	61	n	n	y	n	n	n	n
E	ASA	488	31	86	m	PM	76	400	2	6	n	y	y, oa	y	n	n	n	n	60 mg	65,73	60	y	y	n	n	n	n	n
		488	32	68	f		145	349	1	3									60 mg	89,59								
E	no ASA	488	42	65	m	ICD	319	640	2	3	y	y	n	n	n	n	n	n	60 mg	53,93	65	y	n	y	n	n	n	n
P	ASA	488	45	87	m	PM	115	400	1	3	n	y	n	n	n	n	y	n	30 mg	49,74	87	n	y	y	n	n	n	n
P	ASA	488	47	83	f	ICD-CRT	23	333	1	6	y	y	y, oa AND it	n	n	n	y	n	30 mg	46,04	65	y	n	y	n	n	n	n
E	ASA	488	50	73	m	ICD	72	321	1	4	y	y	y, oa	n	n	n	n	y	60 mg	64,96	60	y	n	n	n	n	n	n
		488	61	80	f					5																		
P	ASA	488	64	80	m	PM	2160	400	3	6	y	y	y, oa	n	n	y	n	y	60 mg	66,82	108	y	y	y	n	n	n	n
P	no ASA	488	90	78	m	PM	14	219	2	4	y	y	n	n	n	n	n	n	60 mg	54,22	67	n	y	n	n	n	n	n
E	no ASA	488	121	88	m	PM	211	250	1	3	n	y	n	n	n	n	n	n	30 mg	38,5	68	n	n	n	n	n	n	n
P	no ASA	488	134	84	m	PM	38	220	1	3	y	n	n	n	n	n	n	n	60 mg	74,16	74	y	n	y	n	n	n	n
E	ASA	488	135	83	m	ICD-CRT	12	600	1	4	y	y	n	n	n	n	n	n	30 mg	49,71	69	y	n	y	n	n	n	n
E	no ASA	488	139	86	m	ICD	13	282	1	4	y	n	n	n	n	y	n	y	30 mg	33,37	61	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	488	189	82	f	PM	156	275	1	4	n	y	n	n	n	n	n	n	30 mg	41,72	68	n	n	y	n	n	n	n
P	ASA	488	206	80	f	PM	45	414	5	4	n	y	n	n	n	n	n	n	60 mg	88,54	67	n	y	y	n	n	n	n
E	ASA	488	213	86	f	PM	464	192	1	4	n	y	n	n	n	n	n	n	30 mg	47,61	86	n	n	y	y	n	n	n
P	ASA	488	218	80	f	PM	1589	591	3	7	n	y	y, oa	y	n	n	n	n	60 mg	75,46	69	n	y	y	n	n	n	n
P	ASA	488	249	85	m	PM	136	191	13	3	n	y	n	n	n	n	y	n	30 mg	38,45	79	y	n	y	n	n	n	n
E	ASA	488	261	68	m	PM	58	400	7	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	87,04	60	n	y	y	n	n	n	n
		488	277	89	f					4																		
E	ASA	488	280	79	m	PM	170	400	1	4	n	y	n	n	n	y	y	n	60 mg	74,03	61	y	n	y	n	n	n	n
E	ASA	488	318	90	f	PM	157	321	1	4	n	y	n	n	n	n	n	n	30 mg	38,62	70	n	y	n	n	n	n	n
P	ASA	488	327	86	f	PM	763	591	4	5	n	y	y, it	n	n	n	y	n	30 mg	43,42	80	y	n	n	n	n	n	n
		488	330	74	m		116	480	1	2									60 mg	100								
E	ASA	488	343	76	f	PM	250	256	8	4	n	y	n	n	n	n	n	n	60 mg	57,45	70	n	y	n	y	n	n	n
P	no ASA	488	357	79	m	PM	505	550	8	3	n	y	n	n	n	n	n	n	30 mg	46,74	60	y	n	y	n	n	n	n
P	ASA	488	370	76	m	PM	424	273	1	4	n	y	n	n	n	y	y	n	30 mg	47,41	60	y	n	y	n	n	n	n
E	ASA	488	390	85	m	PM	92	400	2	3	n	y	n	n	n	n	n	n	60 mg	60,79	64	y	n	n	n	n	n	n
P	ASA	488	474	79	m	PM	12	300	1	4	n	y	y, oa	n	n	n	y	n	60 mg	77,16	80	n	y	y	n	n	n	n
E	no ASA	488	766	75	f	PM				5	n	y	y, oa	n	n	n	n	n	60 mg	52,83	90	y	n	n	n	n	n	n
E	ASA	488	810	91	f	PM	60	333	23	5	n	y	y, oa	n	n	n	n	n	60 mg	57,85	60	y	y	n	n	n	n	n
E	no ASA	488	898	85	f	PM	195	400	9	3	n	n	n	n	n	n	n	n	30 mg	43,52	73	n	n	n	n	n	n	n
P	ASA	488	1099	87	f	PM	128	500	7	4	n	y	n	n	n	n	y	n	30 mg	40,67	71	n	n	y	n	n	n	n
P	no ASA	488	1133	86	f	PM	80	335	6	4	n	y	n	n	n	n	n	n	30 mg	19,97	60	y	n	n	n	n	n	n
E	ASA	488	1244	76	m	PM	51	240	1	3	n	n	n	n	n	n	y	n	60 mg	53,85	73	n	n	n	n	n	n	n
P	no ASA	488	1250	65	m	PM	331	450	9	4	n	y	y, oa	n	n	n	y	n	60 mg	132,81	75	y	n	y	n	n	n	n
P	no ASA	488	1361	82	f	PM	171	256	1	4	n	y	n	n	n	n	n	n	60 mg	65,9	54	n	n	y	n	n	n	n
P	ASA	488	1532	84	f	PM	6	175	1	5	n	y	n	n	n	n	n	n	30 mg	38,12	86	n	n	y	n	n	n	n
E	no ASA	488	1586	82	f	PM	13		4	4	n	y	n	n	n	n	n	n	30 mg	30,32	52	y	y	y	n	n	n	n
E	ASA	488	1824	76	m	PM	450		10	4	n	y	y, it	n	n	n	n	n	60 mg	50,48	69	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	488	1942	73	f	PM	6		1	4	n	y	y, it	n	n	n	n	n	30 mg	41,63	84	n	y	y	n	n	n	n
P	ASA	488	2318	78	m	PM	67	495	1	5	n	y	n	n	n	n	n	n	60 mg	80,04	59	n	n	y	n	n	n	n
E	no ASA	488	2372	82	m	PM	154		5	3	n	y	n	n	n	n	n	n	60 mg	54,81	69	n	y	y	n	n	n	n
P	no ASA	488	2413	75	m	PM	89		7	3	n	y	n	n	n	n	n	n	60 mg	50,79	70	y	n	y	n	n	n	n
		488	2591	69	m					1																		
E	no ASA	502	102	75	m	PM				3	n	y	n	n	n	n	n	n	60 mg	95,58	60	y	n	y	n	n	n	n
E	no ASA	502	133	80	m	PM	440	335	3	3	n	y	n	n	n	n	n	n	60 mg	51,49	60	y	n	y	n	n	n	n
E	ASA	502	166	87	m	ICD	252	545	14	5	y	y	n	n	n	y	y	y	30 mg	21,82		n	n	n	n	n	n	n
E	ASA	502	195	83	m	PM	33	300	1	4	y	n	n	n	n	y	y	y	60 mg	55,85	63	y	n	y	n	n	n	n
P	no ASA	502	198	84	f	PM	14	252	6	4	n	y	n	n	n	n	n	n	30 mg	37,38	69	n	y	n	n	n	n	n
E	no ASA	502	227	82	m	PM	290	640	1	4	y	y	n	n	n	n	n	n	30 mg	49,8	65	y	n	y	n	n	n	n
P	no ASA	502	270	92	m	PM	9	500	1	3	n	y	n	n	n	n	n	n	30 mg	37,63	59	n	n	y	n	n	n	n
P	no ASA	502	309	72	f	ICD	10	545	1	3	n	y	n	n	n	n	n	n	60 mg	60,7	69	n	y	n	n	n	n	n
P	ASA	502	334	68	m	ICD	41	545	3	4	y	y	n	n	n	y	n	n	60 mg	92,79	56	y	n	y	n	n	n	n
E	no ASA	502	425	78	m	PM	196	240	2	3	n	y	n	n	n	n	n	n	60 mg	89,71	65	y	n	n	n	n	n	n
P	no ASA	502	602	75	m	PM	107	600	4	2	n	n	n	n	n	n	n	n	60 mg	60,45	57	n	n	n	n	n	n	n
P	ASA	502	835	88	f	PM	1218	375	2	6	n	y	n	n	y	n	n	n	60 mg	54,54		y	n	n	n	n	n	n
E	ASA	502	1200	77	m	PM	350	265	3	4	n	y	n	n	n	y	y	n	60 mg	89,98		n	n	y	n	n	n	n
P	ASA	502	1282	67	m	PM	1440	430	17	3	n	y	n	n	n	n	n	n	60 mg	89,46	49	n	n	n	n	n	n	n
P	ASA	502	1283	76	f	PM	8	265	1	5	n	y	n	n	n	n	n	n	60 mg	88,75	60	y	n	y	n	n	n	n
E	ASA	502	1440	70	m	PM	166		3	4	y	y	n	n	n	y	n	n	60 mg	73,55	71	n	y	y	n	n	n	n
P	ASA	502	1535	82	m	ICD-CRT	634	640	1	4	y	y	n	n	n	n	y	n	60 mg	50,8	61	n	n	n	n	n	n	n
E	ASA	502	1556	68	m	ICD	339	640	6	5	y	y	y, oa	n	n	y	y	n	60 mg	74,56	59	y	n	y	n	n	n	n
P	ASA	502	1585	68	m	ICD-CRT	120	500	16	4	y	y	n	n	n	y	y	n	60 mg	95,74	54	y	n	y	n	n	n	n
E	no ASA	502	1782	80	f	ICD	751	545	3	5	y	y	n	n	n	n	y	n	30 mg	44,9	58	y	n	y	n	n	n	n
E	ASA	502	2081	76	m	ICD	475	545	1	3	n	y	n	n	n	n	y	y	60 mg	57,3		y	y	y	n	n	n	n
E	ASA	502	2496	83	f	PM	116		6	4	n	y	n	n	n	n	n	n	60 mg	75,97	66	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	514	164	67	m	PM-CRT	19	183	1	4	y	y	y, oa	n	n	n	n	n	30 mg	66,12	74	y	n	y	n	n	n	n
E	ASA	514	456	70	m	ICD-CRT	1265	640	2	2	y	n	n	n	n	n	n	n	60 mg	77,15	60	y	n	y	n	n	n	n
E	ASA	519	2370	65	m	ICD-CRT	52	640	2	5	y	y	y, oa	n	n	y	y	n	60 mg	81,52	81	y	n	y	n	n	n	n
E	no ASA	519	2400	76	m	ICD-CRT	189	640	1	3	y	n	n	n	n	n	n	n	60 mg	77,37	78	y	n	y	n	n	n	n
E	ASA	519	2577	75	f	ICD	24		1	4	y	n	n	n	n	n	n	n	60 mg	154,89		y	n	y	n	y	n	n
P	ASA	529	255	79	m	PM	5760	400	14	3	n	n	n	n	n	y	n	y	60 mg	59,8	60	n	n	y	n	n	n	n
E	no ASA	529	317	67	m	PM	5760	400	7	3	n	y	y, oa	n	n	n	n	n	60 mg	63,56	60	n	y	y	n	n	n	n
E	no ASA	529	447	73	m	PM	321	614	1	3	n	y	y, oa	n	n	n	n	n	60 mg	108,68	100	n	n	y	n	n	n	n
P	ASA	529	489	75	m	PM	2550	640	2	4	n	y	y, oa	n	n	n	n	n	30 mg	42,35	68	y	n	y	n	n	n	n
E	ASA	529	658	72	f	PM	56	614	1	3	n	y	n	n	n	n	n	n	60 mg	55,73	60	n	n	n	n	n	n	n
P	no ASA	529	659	65	f	PM-CRT	14	640	1	3	n	y	n	n	n	n	n	n	60 mg	70,67	65	y	n	y	n	n	n	n
E	ASA	529	703	83	m	PM	565	600	7	4	n	y	y, oa	n	n	n	n	n	60 mg	57,29	68	n	y	y	n	n	n	n
P	no ASA	529	712	76	f	PM	13	305	1	4	n	y	n	n	n	n	n	n	30 mg	55,89	70	n	n	y	n	n	n	n
E	no ASA	529	926	77	m	PM-CRT	9823	640	1	4	y	y	n	n	n	n	n	n	60 mg	86,11	68	y	n	y	n	n	n	n
E	ASA	529	1006	76	m	PM	6000	600	27	4	n	y	y, oa	n	n	n	n	n	30 mg	32,81	61	n	n	y	n	n	n	n
E	no ASA	529	1050	77	f	ICD-CRT	13		1	4	y	n	n	n	n	n	n	n	60 mg	61,55	61	y	n	n	n	n	n	n
P	no ASA	529	1068	83	m	PM				3	n	y	n	n	n	n	n	n	60 mg	75,86	63	n	y	n	n	n	n	n
P	ASA	529	1072	78	m	PM	5760	400	13	3	n	y	n	n	n	n	n	n	60 mg	84,72	62	y	n	y	n	n	n	n
E	ASA	529	1083	85	m	PM	155	400	1	6	n	y	y, oa	n	y	n	n	n	60 mg	63,79	73	n	n	y	n	n	n	n
P	no ASA	529	1121	66	m	PM	138	462	1	2	n	y	n	n	n	n	n	n	60 mg	87,79	68	n	n	n	n	n	n	n
E	no ASA	529	1198	80	m	PM	5760		1	3	n	y	n	n	n	n	n	n	60 mg	69,44	60	n	n	n	n	n	n	n
P	no ASA	529	1199	77	m	PM	961	640	7	3	n	y	n	n	n	n	n	n	60 mg	92,59	67	n	y	n	n	n	n	n
E	ASA	529	1201	69	f	PM	108		1	5	n	y	n	y	n	n	n	n	60 mg	82,6	54	n	n	y	n	n	n	n
E	ASA	529	1234	69	m	PM	170	400	1	3	y	y	n	n	n	n	n	n	60 mg	109,05	61	y	n	n	n	n	n	n
P	ASA	529	1254	85	m	PM	12	175	1	3	n	y	n	n	n	n	n	n	30 mg	49,36	66	y	n	n	n	n	n	n
E	no ASA	529	1343	87	f	PM	728	300	1	4	n	y	n	n	n	n	n	n	30 mg	20,21	60	n	y	y	n	n	n	n
P	no ASA	529	1354	67	m	PM	22	640	1	2	n	y	n	n	n	n	n	n	60 mg	67,95	72	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	529	1399	85	m	PM	273	600	9	4	n	y	y, it	n	n	n	n	n	30 mg	37,24	60	n	n	y	n	n	n	n
		529	1410	73	m					1																		
E	no ASA	529	1503	77	m	PM	5760	246	6	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	74,53	81	n	y	y	n	n	n	n
P	ASA	529	1515	71	m	PM	6		1	2	n	n	n	n	n	n	n	n	30 mg	48,52	50	n	n	n	n	n	n	n
P	ASA	529	1550	77	m	PM	942		1	3	n	n	n	n	n	y	y	n	60 mg	51,25	60	n	n	n	n	n	n	n
E	no ASA	529	1593	84	f	PM	482	214	20	3	n	n	n	n	n	n	n	n	30 mg	20,95	82	n	n	n	n	n	n	n
P	ASA	529	1594	77	m	PM	810	400		5	n	n	y, it	y	n	n	n	n	30 mg	40,31	60	n	n	n	n	n	n	n
E	ASA	529	1595	77	m	PM	439	500	1	5	n	y	y, oa	n	n	n	n	n	60 mg	91,43	72	n	n	y	n	n	n	n
P	no ASA	529	1632	86	m	PM	41	260	2	4	n	y	y, oa	n	n	n	n	n	30 mg	37,82	77	n	y	y	n	n	n	n
P	no ASA	529	1635	78	f	PM	9	231	1	3	n	n	n	n	n	n	n	n	30 mg	37,63	72	n	n	n	n	n	n	n
E	ASA	529	1689	81	f	PM	152		1	7	n	y	y, oa	n	y	n	n	n	60 mg	72,3	60	y	n	y	n	n	n	n
E	ASA	529	1709	65	m	ICD	226		18	2	n	y	n	n	n	n	n	n	60 mg	112,85	66	n	n	y	n	n	n	n
P	no ASA	529	1745	73	f	PM	194	400	3	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	62,24	60	n	y	y	n	n	n	n
E	ASA	529	1763	72	m	PM	300		1	3	n	y	y, oa	n	n	n	n	n	60 mg	89,72	71	n	n	y	n	n	n	n
E	no ASA	529	1768	73	m	PM	60	569		3	n	y	y, oa	n	n	n	n	n	60 mg	67,9	75	n	n	y	n	n	n	n
P	no ASA	529	1780	82	f	PM	91		4	4	n	y	n	n	n	n	n	n	60 mg	58,45	74	y	n	y	n	n	n	n
P	no ASA	529	1813	82	m	PM	105	640	1	3	n	y	n	n	n	n	n	n	60 mg	61,7	59	n	n	n	n	n	n	n
E	no ASA	529	1823	73	m	PM	1666	404	7	3	n	y	y, oa	n	n	n	n	n	60 mg	105,85	68	n	y	y	n	n	n	n
E	no ASA	529	1846	76	m	PM	120	500	1	4	n	y	y, oa	n	n	n	n	n	60 mg	86,8	65	y	n	n	n	n	n	n
P	no ASA	529	1848	77	m	PM	5254		8	3	y	y	n	n	n	n	n	n	60 mg	68,42	50	n	y	y	n	n	n	n
P	ASA	529	1852	85	m	PM	219	640	7	5	n	y	y, oa	n	n	n	n	n	30 mg	40,38	61	n	n	n	n	n	n	n
E	no ASA	529	1898	67	m	PM	9	273	1	2	n	y	n	n	n	n	n	n	60 mg	87,28	64	n	y	y	n	n	n	n
P	ASA	529	1924	83	m	PM	106		2	4	n	y	y, oa	n	n	n	n	n	60 mg	62,96	78	n	n	n	n	n	n	n
E	no ASA	529	1927	87	f	PM	64	640	3	3	n	n	n	n	n	n	n	n	30 mg	28,52	66	n	n	n	n	n	n	n
E	no ASA	529	1951	73	m	PM	831	530	1	3	n	y	y, oa	n	n	n	n	n	60 mg	70,51	67	y	n	y	n	n	n	n
P	no ASA	529	1965	67	m	PM	10	222	1	2	n	y	n	n	n	n	n	n	60 mg	64,46	60	n	n	y	n	n	n	n
E	ASA	529	1987	84	m	PM	1925	545	1	3	y	n	n	n	n	n	y	n	60 mg	51,47	61	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	529	2011	77	m	PM	7	207	1	3	n	y	n	n	n	n	n	n	60 mg	62,13	74	n	y	n	n	n	n	n
P	no ASA	529	2104	82	m	PM-CRT	330	600	1	4	y	y	n	n	n	n	n	n	60 mg	83,61	53	n	n	n	n	n	n	n
P	ASA	529	2113	76	m	PM	28	212		3	n	y	n	n	n	n	n	n	60 mg	87,5	56	n	n	y	n	n	n	n
E	no ASA	529	2117	80	m	PM	51	400	3	3	n	y	n	n	n	n	n	n	60 mg	73,68	59	n	n	y	n	n	n	n
P	no ASA	529	2118	78	m	PM	506	600	1	3	n	y	n	n	n	n	n	n	60 mg	66,78	69	n	n	y	n	n	n	n
E	no ASA	529	2119	75	f	PM	154	400	3	3	n	n	n	n	n	n	n	n	60 mg	70,09	60	n	n	n	n	n	n	n
E	no ASA	529	2216	80	m	PM	11	291	1	3	n	y	n	n	n	n	n	n	60 mg	69,77	97	n	n	y	n	n	n	n
P	ASA	529	2220	86	f	PM	280	640	1	6	n	y	y, oa	n	n	n	n	n	30 mg	33,55	66	y	y	n	n	n	n	n
E	no ASA	529	2223	81	m	PM	395		2	2	n	n	n	n	n	n	n	n	60 mg	50,08	60	n	n	n	n	n	n	n
P	no ASA	529	2229	79	f	PM	443	366	1	4	n	y	n	n	n	n	n	n	60 mg	63,01	50	n	y	n	n	n	n	n
P	no ASA	529	2256	68	m	PM	6		1	2	n	y	n	n	n	n	n	n	60 mg	85,06	74	y	y	y	n	n	n	n
P	no ASA	529	2258	82	m	PM	96		3	3	n	y	n	n	n	n	n	n	30 mg	48,98	63	n	y	y	n	n	n	n
E	no ASA	529	2328	79	m	PM	70	334	1	3	n	y	n	n	n	n	n	n	60 mg	80,44	63	n	n	y	n	n	n	n
P	ASA	529	2334	87	m	PM	1287	640	1	4	n	y	y, it	n	n	n	n	n	60 mg	72,63	65	n	n	y	n	n	n	n
		529	2338	77	f		283	545	1	4									60 mg	110,07								
E	ASA	529	2451	82	m	PM	20		3	5	n	y	y, oa AND it	n	n	y	y	n	30 mg	47,39	61	n	n	y	n	n	n	n
E	ASA	529	2459	69	m	ICD	7	366	1	5	y	y	y, oa	n	n	y	y	n	60 mg	106,27	47	y	n	y	n	n	n	n
P	ASA	529	2545	73	f	PM	62	415	2	3	n	y	n	n	n	n	n	n	30 mg	43,29	60	y	n	y	n	n	n	n
P	ASA	529	2555	70	m	PM	75		1	2	n	y	n	n	n	n	n	n	30 mg	72,33	57	y	n	y	n	n	n	n
E	ASA	529	2643	71	m	PM	347	640	1	6	y	y	y, oa	y	n	n	n	n	60 mg	97,05	74	n	y	y	n	n	n	n
P	ASA	529	2644	76	m	PM	112	375	1	6	n	y	n	y	n	n	n	n	30 mg	80,41	67	n	n	n	n	n	n	n
P	no ASA	529	2647	86	f	PM	758	500	1	4	n	y	n	n	n	n	n	n	60 mg	68,92	68	n	n	y	n	n	n	n
E	ASA	529	2659	77	m	PM	9	286	1	5	y	y	y, oa AND it	n	n	n	n	n	30 mg	44,35	70	n	y	y	n	n	n	n
P	no ASA	529	2662	83	m	PM	5760	400	2	5	n	y	y, oa	n	n	n	n	n	30 mg	51,42	63	y	y	y	n	n	n	n
E	ASA	530	271	74	m	ICD	15	375	3	5	y	y	y, oa AND it	n	n	y	n	n	60 mg	60,03	58	y	n	y	n	n	n	n
P	ASA	530	315	67	f	PM	246	429	9	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	60,33	60	y	n	y	n	n	n	n
P	no ASA	530	429	75	f	PM	70	500	1	5	n	y	y, oa	n	n	n	n	n	60 mg	51,38	70	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	530	1010	76	m	ICD	58	308	1	5	y	y	n	n	n	y	n	y	60 mg	92,31	65	y	n	y	n	n	n	n
E	ASA	530	1059	75	m	PM	639	428	10	3	n	y	n	n	n	n	n	n	30 mg	46,41	60	n	n	n	n	n	n	n
E	ASA	530	1237	76	m	ICD	149	405	1	4	n	y	n	n	n	y	n	n	60 mg	73,31	55	y	n	y	n	n	n	n
E	ASA	530	1513	81	m	PM	1124	319	5	3	n	y	n	n	n	n	n	n	60 mg	60,78	75	y	n	y	n	n	n	n
E	no ASA	530	1521	83	f	PM	57	614	3	4	n	y	n	n	n	n	n	n	60 mg	77,84	59	n	n	y	n	n	n	n
P	no ASA	530	1552	70	f	PM	438	545	3	4	n	y	y, oa	n	n	n	n	n	60 mg	78,44	67	n	y	y	n	n	n	n
P	ASA	530	2106	76	m	PM	135	600	4	6	n	y	y, oa	n	y	n	n	n	60 mg	114,42	70	n	n	n	n	n	n	n
P	ASA	530	2163	68	f	PM	220	500	7	3	n	y	n	n	n	n	n	n	60 mg	54,52	70	y	n	y	n	n	n	n
P	ASA	530	2164	76	m	PM	288	600	1	3	n	y	n	n	n	n	n	n	60 mg	84,31	55	n	n	y	n	n	n	n
P	no ASA	530	2279	70	m	PM	119	500	14	3	n	y	y, oa	n	n	n	n	n	60 mg	79,8	86	n	n	n	n	n	n	n
E	no ASA	530	2548	73	m	ICD	307		2	2	n	y	n	n	n	n	n	n	60 mg	94,16	60	n	n	y	n	n	n	n
E	no ASA	530	2652	69	m	PM	71		8	2	n	y	n	n	n	n	n	n	60 mg	65,46	60	n	n	n	n	n	n	n
P	no ASA	531	241	79	m	PM				3	n	y	n	n	n	n	n	n	60 mg	105,28	60	y	n	n	n	n	n	n
P	ASA	532	311	74	m	ICD-CRT	475	366	1	4	y	y	y, oa	n	n	n	n	y	60 mg	59,15	78	n	y	y	n	n	n	n
E	no ASA	535	335	72	m	PM	25	385	1	5	n	y	y, oa	n	y	n	n	n	60 mg	111,36		n	y	y	n	n	n	n
E	ASA	535	538	84	f	PM	858	291	2	6	y	y	n	n	n	y	n	n	30 mg	45,95		y	y	y	n	n	n	n
E	ASA	535	546	81	f	PM	146	308	1	4	n	y	n	n	n	n	n	n	30 mg	48	62	n	y	y	n	n	n	n
P	no ASA	535	563	84	f	PM	188	286	1	5	n	y	y, oa	n	n	n	n	n	60 mg	52,96	61	n	n	y	n	n	n	n
P	no ASA	535	605	70	m	PM	9	500	1	2	n	y	n	n	n	n	n	n	60 mg	88,98	52	n	y	y	n	n	n	n
E	no ASA	535	631	80	f	PM	1393	400	1	4	n	y	n	n	n	n	n	n	30 mg	47,57	64	y	y	y	n	n	n	n
E	no ASA	535	756	81	f	PM	558	400	1	4	n	y	n	n	n	n	n	n	60 mg	65,89	67	n	n	n	n	n	n	n
P	no ASA	535	1268	76	f	PM	23		7	4	n	y	n	n	n	n	n	n	60 mg	103,71	70	n	y	y	n	n	n	n
P	no ASA	535	1393	88	f	PM	230	265	1	4	n	y	n	n	n	n	n	n	60 mg	70,03	66	n	y	y	n	n	n	n
E	no ASA	535	1589	81	f	PM	103	341	1	4	n	y	n	n	n	n	n	n	60 mg	66,12	73	n	n	y	n	n	n	n
E	ASA	535	1693	80	m	PM	131		1	6	n	y	y, oa AND it	y	n	n	n	n	60 mg	68,13	64	n	n	y	n	n	n	n
E	no ASA	535	1769	77	m	PM	100		3	4	n	y	y, oa	n	n	n	n	n	60 mg	64,6	68	n	n	n	n	n	n	n
E	no ASA	535	1776	77	m	PM	587		2	3	n	y	n	n	n	n	n	n	60 mg	83,33	59	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	536	276	77	m	ICD-CRT	18	186	1	6	y	y	y, it	n	n	y	n	n	60 mg	70,71	53	y	y	y	n	n	n	n
P	ASA	536	386	83	m	ICD-CRT	786	296	3	6	y	y	y, oa	n	n	y	y	y	30 mg	47,36	55	y	n	y	n	n	n	n
P	no ASA	536	991	90	f	PM	54	333	3	5	y	y	n	n	n	n	n	n	60 mg	53,22	60	y	y	y	n	n	y	n
P	ASA	536	1328	85	m	ICD-CRT	337	300	1	6	y	y	y, it	n	n	n	y	n	60 mg	102,63	65	n	n	y	n	n	n	n
E	ASA	536	1818	75	m	ICD	30		1	5	n	y	y, it	n	n	y	y	n	60 mg	81,96	67	y	n	y	n	n	n	n
E	no ASA	536	2326	67	m	ICD-CRT	6000	375	1	6	y	y	y, it	y	y	n	n	n	30 mg	51,47	70	y	n	y	n	n	n	n
P	no ASA	541	291	77	m					4									30 mg	40,83								
P	no ASA	541	417	78	m	PM	23	336	1	3	n	y	n	n	n	n	n	n	60 mg	65,9	55	n	y	y	n	n	n	n
E	no ASA	541	470	78	f	PM	9	600	1	6	y	y	y, oa	n	n	n	n	n	60 mg	86,08	70	n	n	y	n	n	n	n
E	ASA	541	855	87	f	PM				5	y	n	y, oa	n	n	n	n	n	60 mg	50,59	94	n	y	y	n	n	n	n
		541	856	72	m					1																		
E	no ASA	542	347	70	f	PM	65	600	1	3	n	y	n	n	n	n	n	n	60 mg	75,97	60	n	n	y	n	n	n	n
P	no ASA	542	523	77	m	PM				3	n	y	n	n	n	n	n	n	60 mg	67,54	68	n	y	y	n	n	n	n
P	no ASA	544	137	85	f	PM	192	286	1	3	n	n	n	n	n	n	n	n	60 mg	73,7	54	n	n	n	n	n	n	n
P	no ASA	544	156	91	m	PM	777	400	7	3	n	y	n	n	n	n	n	n	30 mg	24,88	60	n	n	n	n	n	n	n
P	ASA	544	177	69	f	ICD	16	351	1	8	y	y	y, oa	n	y	y	n	n	60 mg	92,91	68	y	n	y	n	n	n	n
E	ASA	544	178	87	f	PM	7	480	1	4	n	y	n	n	n	n	n	n	30 mg	44,55	77	n	y	y	n	n	n	n
P	ASA	544	179	82	f	PM	146	591	1	5	n	y	n	n	n	y	y	n	60 mg	67,71	70	y	n	y	n	n	n	n
E	no ASA	544	224	80	f	PM	10	461	1	5	n	y	y, oa	n	n	n	n	n	60 mg	63,65	64	y	n	y	n	n	n	n
E	no ASA	544	310	69	f	PM	96	640	2	3	n	y	n	n	n	n	n	n	30 mg	45,47	61	n	n	y	n	n	n	n
P	no ASA	544	367	81	m	PM	106	308	3	4	y	y	n	n	n	n	n	n	30 mg	48,34	69	n	n	y	n	n	y	n
E	ASA	544	486	84	f	PM	195	591	3	5	n	y	y, oa	n	n	n	y	n	60 mg	75,23	58	n	y	n	n	n	n	n
E	no ASA	544	488	73	m	PM	302	545	1	2	n	y	n	n	n	n	n	n	60 mg	110,2	65	n	y	y	n	n	n	n
P	no ASA	544	491	80	f	PM	237	266	1	4	n	y	n	n	n	n	n	n	60 mg	105,52		y	n	y	n	n	n	n
P	no ASA	544	575	91	m	PM	123	600	13	2	n	n	n	n	n	n	n	n	30 mg	39,92	72	y	n	n	n	n	n	n
E	no ASA	544	773	75	f	PM	565	591	2	5	n	y	y, oa	n	n	n	n	n	60 mg	115,33	70	n	n	y	n	n	n	n
E	no ASA	544	839	67	f	PM	110	366	3	3	n	y	n	n	n	n	n	n	60 mg	70,97	75	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	544	940	76	m					3									60 mg	86,42		n	n	n	n	n	n	n
E	ASA	544	958	75	f	PM	16	404	1	6	n	y	y, oa	n	n	n	n	n	60 mg	72,23	60	n	n	y	n	n	n	n
E	ASA	544	1005	82	m	ICD-CRT	270	286	1	5	y	y	n	n	n	y	y	y	30 mg	36,52		y	n	y	n	n	n	n
E	ASA	544	1190	71	m	PM	117	640	1	6	n	y	y, oa	y	n	n	n	n	60 mg	85,95	65	y	n	n	n	n	n	n
P	no ASA	544	1193	82	m	PM	1458	400	5	4	n	y	y, oa	n	n	n	n	n	30 mg	38	57	n	n	y	n	n	n	n
P	ASA	544	1336	87	f	PM	54	462	1	7	y	y	n	n	y	n	n	n	60 mg	50,53	61	n	n	y	n	n	n	n
E	no ASA	544	1345	79	m	PM	194		1	4	n	y	n	n	n	n	n	n	60 mg	76,25		n	n	y	n	n	n	n
E	no ASA	544	1367	75	m	PM	214	462	1	3	n	y	n	n	n	n	n	n	60 mg	133,43		n	n	y	n	n	n	n
E	ASA	544	1370	69	m	PM	515	640	1	4	n	y	y, oa	n	n	y	y	n	60 mg	122,89		y	n	y	n	n	n	n
P	ASA	544	1476	83	f	PM	244	405	1	4	n	y	n	n	n	n	n	n	60 mg	61,09	59	n	n	y	n	n	n	n
P	ASA	544	1482	75	m	PM	163	279	1	5	y	y	y, oa	n	n	n	y	y	60 mg	52,36	60	y	n	y	n	n	n	n
P	ASA	544	1508	73	m	PM	94	366	2	5	y	y	y, oa AND it	n	n	y	y	y	30 mg	41,33	60	y	n	y	n	n	n	n
P	no ASA	544	1606	69	f	PM	96		1	3	n	y	n	n	n	n	n	n	60 mg	88,4		n	n	y	n	n	n	n
E	ASA	544	1683	85	f	PM	49		1	6	y	y	y, oa AND it	n	n	n	n	n	30 mg	33,9	65	y	y	y	n	n	n	n
P	no ASA	544	1831	68	m	PM	975	591	2	2	n	y	n	n	n	n	n	n	60 mg	107,97	60	y	n	y	n	n	n	n
P	no ASA	544	1854	82	f	PM	16	549	1	5	n	y	y, oa	n	n	n	n	n	30 mg	48,85	76	n	y	y	n	n	n	n
P	no ASA	547	273	83	m	PM	138	351	2	3	n	y	n	n	n	n	n	n	60 mg	70,65	64	n	n	n	n	n	n	n
P	ASA	547	275	85	f	PM	6	248	1	6	n	y	n	y	n	n	n	n	60 mg	53,35	62	n	n	y	n	n	n	n
E	ASA	547	378	74	m	PM	1036	351	2	3	n	y	n	n	n	n	n	n	60 mg	56,71	68	n	y	y	n	n	n	n
P	ASA	547	391	78	m	PM	10	400	3	4	n	y	y, it	n	n	n	y	n	60 mg	53,71	63	y	n	y	n	n	n	n
E	ASA	547	392	81	m	PM	10	286	1	5	n	n	y, it	y	y	n	n	n	30 mg	46,45	86	n	y	y	n	n	n	n
P	no ASA	547	454	81	m	PM	341	300	1	2	n	n	n	n	n	n	n	n	60 mg	65,91	62	n	n	n	n	n	n	n
E	no ASA	547	499	73	f	PM	112	366	2	3	n	y	n	n	n	n	n	n	60 mg	92,28	60	n	n	n	n	n	n	n
E	no ASA	547	573	80	m	PM	626	296	1	3	n	y	n	n	n	n	n	n	60 mg	88,89	64	n	y	n	n	n	n	n
P	no ASA	547	702	67	m	PM	567	321	1	3	n	y	y, it	n	n	n	n	n	60 mg	115,21	67	y	n	y	n	n	n	n
P	no ASA	547	715	77	f	PM	1137	265	1	3	n	n	n	n	n	n	n	n	30 mg	47,26	65	y	n	n	n	n	n	n
E	no ASA	547	864	75	m	PM	1015	351	1	4	n	y	y, oa	n	n	n	n	n	60 mg	103,09	79	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	547	909	76	m	PM	1192	296	2	3	n	y	n	n	n	n	n	n	60 mg	76,73	60	n	y	y	n	n	n	n
P	no ASA	547	918	84	m	PM	896	333	1	3	n	y	n	n	n	n	n	n	60 mg	81,45	64	y	n	y	n	n	n	n
P	no ASA	547	922	81	m	ICD	476	375	1	4	n	y	y, oa	n	n	n	n	n	60 mg	82,54	60	n	y	y	n	y	n	n
E	no ASA	547	936	80	f	PM	211	307	2	4	n	y	n	n	n	n	n	n	30 mg	45,85	70	n	n	y	n	n	n	n
E	no ASA	547	996	70	f	PM	250	248	1	4	n	y	y, it	n	n	n	n	n	60 mg	72,85	76	n	n	y	n	n	n	n
P	ASA	547	1088	75	m	ICD-CRT	624	545	1	6	y	y	y, it	n	n	y	y	n	30 mg	35,99	63	y	y	y	n	n	y	n
E	no ASA	547	1160	72	m	PM-CRT	589	640	8	2	y	n	n	n	n	n	n	n	60 mg	89,63	73	y	n	y	n	n	n	n
P	no ASA	547	1238	77	m	PM	1109	321	1	3	n	y	n	n	n	n	n	n	60 mg	88,45	78	n	n	y	n	n	n	n
E	ASA	547	1369	85	m	ICD	797	279	1	6	y	y	y, it	n	n	y	y	n	30 mg	30,21	70	y	n	n	n	n	n	n
P	ASA	547	1517	87	f	PM-CRT	70	600	2	9	y	y	y, it	y	n	n	n	n	60 mg	67,14	60	n	n	y	n	n	n	n
P	no ASA	547	1554	74	m	PM	1373		1	2	n	y	n	n	n	n	n	n	60 mg	61,12	62	n	y	n	n	n	n	n
E	no ASA	547	1622	69	m	PM	462		1	2	n	y	n	n	n	n	n	n	60 mg	77,41	96	n	n	y	n	n	n	n
P	no ASA	547	1653	87	f	PM	6000	545	10	5	n	y	y, oa	n	n	n	n	n	30 mg	41,71	77	n	n	y	n	n	n	n
E	ASA	547	1663	73	m	ICD-CRT	32		1	3	y	n	n	n	n	n	y	n	60 mg	59,99	64	n	n	y	n	n	n	n
P	no ASA	547	1903	77	f	PM	6		1	4	n	y	n	n	n	n	n	n	30 mg	31,88	74	n	n	y	n	n	n	n
P	ASA	547	1906	72	m	ICD	289	284	1	4	y	y	n	n	n	y	n	n	60 mg	70,83	80	y	n	y	n	n	n	n
P	ASA	547	1922	73	m	ICD	207		1	5	y	y	y, it	n	n	y	y	n	30 mg	48,14	65	y	n	y	n	n	n	n
E	no ASA	547	1932	66	f	PM	83	614	1	3	n	n	y, oa	n	n	n	n	n	60 mg	158,34	70	n	n	n	n	n	n	n
E	no ASA	547	1938	86	f	PM	113	640	1	4	n	y	n	n	n	n	n	n	60 mg	72,01	70	n	y	y	n	n	n	n
P	ASA	547	1939	83	m	PM	52	360	1	6	y	y	y, oa	n	n	y	y	n	30 mg	37,59	60	y	n	y	n	n	n	n
P	no ASA	547	2051	68	f	PM	9999	640	3	3	n	y	n	n	n	n	n	n	60 mg	53,03	67	n	n	y	n	n	n	n
E	no ASA	547	2052	80	m	PM	1440		8	3	n	y	n	n	n	n	n	n	60 mg	58,94	59	n	n	y	n	n	n	n
P	no ASA	547	2053	82	f	PM	933	341	1	3	n	n	n	n	n	n	n	n	30 mg	42,22	74	n	n	n	n	n	n	n
E	no ASA	547	2054	84	m	PM	208		1	3	n	y	n	n	n	n	n	n	30 mg	38,5	60	y	n	y	n	n	n	n
E	ASA	547	2055	83	m	PM	21		1	3	n	n	n	n	n	n	n	n	60 mg	52,23	75	n	n	n	n	n	n	n
E	ASA	547	2063	78	f	PM	22		1	6	n	y	y, oa	n	n	y	y	n	60 mg	71,16	78	y	y	y	n	n	n	n
P	no ASA	547	2127	80	m	PM	455	640	2	3	n	y	n	n	n	n	n	n	60 mg	97,66	60	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	547	2128	80	f	PM	46	415	2	5	n	y	y, oa	n	n	n	n	n	60 mg	66,13	72	n	y	y	n	n	n	n
E	no ASA	547	2129	82	m	PM	25	380	1	2	n	n	n	n	n	n	n	n	60 mg	55,48	54	y	n	n	n	n	n	n
E	no ASA	547	2213	82	m	PM	424	250	1	3	n	y	n	n	n	n	n	n	60 mg	67,13	90	n	n	y	n	n	n	n
E	ASA	547	2214	67	m	PM	518	250	2	4	n	y	y, oa	n	n	n	n	n	60 mg	58,23	64	n	n	y	n	n	n	n
P	ASA	547	2218	70	m	PM	42	300	1	4	n	y	y, oa	n	n	n	n	n	60 mg	77,96	78	n	y	y	n	n	n	n
E	ASA	547	2299	74	m	ICD	100	661	2	2	n	n	n	n	n	y	y	n	60 mg	74,16	50	y	n	y	n	n	n	n
P	no ASA	547	2379	77	f	PM	212		1	5	n	y	n	n	n	n	n	n	60 mg	73,43	60	n	n	y	n	n	n	n
E	no ASA	547	2380	67	m	ICD-CRT	73	640	1	2	y	n	n	n	n	n	n	n	60 mg	69,73	60	y	n	y	n	n	n	n
P	no ASA	547	2407	73	f	PM	173		3	3	n	y	n	n	n	n	n	n	60 mg	63,74	61	n	n	y	n	n	n	n
P	no ASA	547	2409	77	f	PM	65		1	3	n	n	n	n	n	n	n	n	60 mg	74,27	68	n	n	n	n	n	n	n
E	ASA	547	2411	84	m	PM				4	n	y	n	n	n	n	n	y	30 mg	49,18	60	y	n	n	n	n	n	n
P	ASA	547	2412	75	f	PM	477		1	6	n	y	y, oa AND it	n	n	n	y	n	60 mg	74,79	55	y	n	y	n	n	n	n
P	ASA	547	2447	72	f	ICD	11		1	4	y	y	n	n	n	n	n	n	60 mg	80,13	68	n	n	y	n	n	n	n
E	no ASA	547	2493	77	f	PM	22		1	4	n	y	n	n	n	n	n	n	30 mg	36,44	60	n	y	y	n	n	n	n
E	no ASA	547	2495	79	f	PM	270		1	4	n	y	n	n	n	n	n	n	60 mg	58,73	60	y	n	y	n	n	n	n
P	no ASA	547	2520	81	m	PM	110		85	4	n	y	y, oa	n	n	n	n	n	60 mg	73,75	59	n	y	y	y	n	n	n
P	no ASA	547	2521	85	f	PM	267		1	4	n	y	n	n	n	n	n	n	60 mg	68,06	65	n	y	y	n	n	n	n
E	ASA	547	2522	71	m	ICD-CRT				3	y	y	n	n	n	n	y	n	60 mg	84,16	60	y	n	y	n	n	n	n
P	no ASA	547	2565	77	m	PM	10		1	3	n	y	n	n	n	n	n	n	30 mg	42,13	78	n	n	y	n	n	n	n
E	ASA	547	2605	79	m	PM	618		4	5	n	y	y, oa	n	n	y	y	n	60 mg	88,46	79	n	y	y	n	n	n	n
P	no ASA	547	2628	85	f	PM	89		2	5	n	y	y, oa	n	n	n	n	n	60 mg	53,04	62	n	n	y	n	n	n	n
P	no ASA	547	2632	86	f	ICD-CRT	303	600	1	5	y	y	n	n	n	n	n	n	30 mg	42,28	66	y	n	y	n	n	n	n
E	no ASA	547	2635	74	m	PM	182		9	2	n	y	n	n	n	n	n	n	60 mg	56,31	68	y	n	n	n	n	n	n
E	no ASA	547	2636	81	f	PM	36	220	1	5	n	y	y, oa	n	n	n	n	n	60 mg	59,8	93	n	n	y	n	n	n	n
E	no ASA	547	2658	84	f	PM	94	500	4	4	n	y	n	n	n	n	n	n	30 mg	33,73	64	y	n	y	n	n	n	n
P	no ASA	547	2695	78	m	PM	119		2	4	n	y	y, oa	n	n	n	n	n	60 mg	59,05	89	n	y	y	n	n	n	n
E	no ASA	547	2718	82	f	PM	309		3	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	55,67	70	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	547	2719	76	m	PM	15	640	3	3	n	y	n	n	n	n	y	n	60 mg	54,33	60	n	n	y	n	n	n	n
P	ASA	547	2735	78	f	PM	244	640	3	4	n	y	n	n	n	n	n	n	60 mg	89,36	60	y	n	y	n	n	n	n
E	no ASA	557	394	78	f	PM	120	400	1	3	n	n	n	n	n	n	n	n	60 mg	86,81	80	n	n	n	n	n	n	n
P	no ASA	557	460	65	m	PM	313	351	1	3	n	y	y, oa	n	n	n	n	n	60 mg	130,19	66	y	y	y	n	n	n	n
E	ASA	557	502	83	f	PM	713	640	9	6	n	y	y, oa	n	n	n	n	n	60 mg	60,85	60	n	n	y	n	n	n	n
P	no ASA	557	530	77	m	PM	1082	640	4	3	n	y	n	n	n	n	n	n	60 mg	136,99	62	y	n	n	n	n	n	n
E	no ASA	557	598	78	f	PM	207	429	1	4	n	y	n	n	n	n	n	n	60 mg	76,38	72	n	y	n	n	n	n	n
P	ASA	557	667	85	m	PM	64	357	1	3	n	n	n	n	n	y	y	n	60 mg	52,05	60	n	n	n	n	n	n	n
E	ASA	557	714	75	m	PM	9999	640	1	5	y	y	n	n	n	y	n	y	60 mg	53,35	76	y	n	y	n	n	n	n
P	ASA	557	733	79	f	PM	205	640	1	5	n	y	y, oa	n	n	n	n	y	60 mg	80		n	y	y	n	n	n	n
P	no ASA	557	1117	88	m	PM	69	275	1	3	n	y	n	n	n	n	n	n	30 mg	36,41	67	n	n	y	n	n	n	n
E	no ASA	557	1232	76	f	PM	12	500	1	4	n	y	n	n	n	n	n	n	30 mg	52,33		y	n	y	n	n	n	n
P	no ASA	564	389	84	f	PM	498		12	4	y	n	n	n	n	n	n	n	30 mg	31,42	88	y	n	y	n	n	n	n
P	ASA	564	462	89	f	PM	33	200	4	7	n	y	n	n	y	n	y	n	30 mg	17,53	86	y	n	y	n	n	n	n
E	ASA	564	490	70	m	PM	389	640	1	2	n	y	n	n	n	n	n	n	60 mg	119,79	60	n	n	y	n	n	n	n
E	ASA	564	548	81	f	PM				4	n	y	n	n	n	n	y	n	30 mg	43,96	98	n	n	y	n	n	n	n
E	no ASA	564	779	69	m	PM	73	591	1	3	y	y	n	n	n	n	n	n	30 mg	30,53	77	n	y	n	n	n	n	n
E	ASA	564	974	81	f	PM	6	256	1	5	n	y	n	n	n	n	y	n	60 mg	67,48		y	n	y	n	n	n	n
P	ASA	564	1110	84	m	ICD-CRT	11	357	2	4	y	n	n	n	n	y	n	n	60 mg	62,03	60	y	n	y	n	y	n	n
		564	1322	96	m					3																		
E	ASA	566	165	78	m	PM	434	640	1	5	n	y	n	y	n	n	n	n	60 mg	87,91	65	y	n	y	n	n	n	n
P	no ASA	577	344	80	m	PM	920	513	1	2	n	n	n	n	n	n	n	n	60 mg	60,44	66	y	n	n	n	n	n	n
E	ASA	605	298	79	m	PM	92	400	3	3	n	y	n	n	n	n	n	n	60 mg	60,28	86	n	y	y	n	n	n	n
P	ASA	605	377	66	m	ICD	127	600	1	5	n	y	n	y	n	y	y	n	60 mg	72,94	62	n	y	y	n	n	n	n
P	ASA	608	572	77	m	PM				5	n	y	y, oa	n	n	y	y	n	60 mg	61,39	60	y	n	y	n	n	n	n
P	ASA	608	816	78	m	ICD	4167	221	1	5	n	y	y, oa	n	n	n	y	y	60 mg	68,69		y	n	y	n	n	n	n
E	ASA	608	817	76	m	PM	6	250	1	3	n	y	n	n	n	n	n	n	60 mg	54,22		n	y	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	608	868	78	m	PM	506	296	1	3	n	y	n	n	n	n	n	n	60 mg	90,77	65	n	n	y	n	n	n	n
E	ASA	608	869	67	m	PM	592	366	1	3	n	y	y, oa	n	n	n	n	n	60 mg	109,45		y	y	y	n	n	n	n
P	no ASA	608	903	76	f	PM	653	333	1	5	n	y	y, oa	n	n	n	n	n	60 mg	76,46	100	y	n	y	n	n	n	n
E	no ASA	608	954	81	m	PM	1440	190	7	3	n	y	n	n	n	n	n	n	60 mg	64,12	63	n	n	y	n	n	n	n
E	ASA	608	973	83	m	PM	8595	640	1	4	n	y	n	n	n	y	y	n	60 mg	55,33	60	y	n	n	n	n	n	n
P	no ASA	608	1091	92	f	PM	562	265	2	4	n	y	n	n	n	n	n	n	30 mg	30,83		y	n	n	n	n	n	n
P	no ASA	608	1450	75	f	PM	37	330	1	4	n	y	n	n	n	n	n	n	60 mg	79,29	65	y	n	y	n	n	n	n
E	no ASA	608	1471	86	m	PM	81	400	1	3	n	y	n	n	n	n	n	n	60 mg	63,66	70	n	n	n	n	n	n	n
P	ASA	608	1484	86	m	PM	1237	640	1	4	n	y	n	n	n	n	n	y	30 mg	47,92	60	n	y	y	n	n	n	n
E	no ASA	608	1766	83	f	PM	62	614	17	4	n	y	n	n	n	n	n	n	30 mg	41,15	61	n	n	y	n	n	n	n
P	ASA	608	1774	85	f	PM	573		1	4	n	y	n	n	n	n	n	n	30 mg	43,79	72	y	y	y	n	n	n	n
E	ASA	608	1791	81	m	PM	2756		3	3	n	y	n	n	n	n	n	n	60 mg	80,56		y	y	n	n	n	n	n
E	no ASA	608	1993	82	m	PM	142	640	5	5	n	y	y, it	n	n	n	n	n	60 mg	67,13	87	n	y	y	n	n	n	n
E	ASA	608	2036	88	f	PM	743		5	6	y	y	n	n	n	n	n	y	30 mg	34,99	61	y	n	y	n	n	n	n
P	no ASA	608	2402	82	m	PM	2880		2	3	n	y	n	n	n	n	n	n	60 mg	60,2	70	n	n	n	n	n	n	n
P	no ASA	608	2645	82	m	PM	401	640	3	2	n	n	n	n	n	n	n	n	60 mg	100,69	70	n	n	n	n	n	n	n
E	no ASA	619	601	87	f	PM	1262	400	7	4	n	y	n	n	n	n	n	n	30 mg	36,38	67	n	y	y	n	n	n	n
E	ASA	641	115	73	m	ICD-CRT	52	201	1	5	y	y	y, it	n	n	y	n	n	60 mg	59,4	63	y	y	y	n	n	n	n
P	no ASA	641	138	67	m	PM	7	240	4	3	n	y	y, oa	n	n	n	n	n	60 mg	66,95	62	y	y	y	n	n	n	n
E	ASA	641	238	76	m	ICD	732	500	1	3	y	y	n	n	n	n	n	n	60 mg	50,51	60	y	y	y	n	y	n	n
E	no ASA	641	262	70	m	ICD	19	232	1	4	y	y	n	n	n	y	y	n	30 mg	48,52	84	n	n	y	n	y	n	n
E	no ASA	641	274	65	m	ICD-CRT	13	199	1	3	y	y	n	n	n	n	n	n	60 mg	76,06	60	y	n	y	n	n	n	n
P	ASA	641	286	73	m	PM				3	n	y	n	n	n	y	n	y	60 mg	74,44	60	y	y	y	n	n	n	n
E	no ASA	641	292	78	f	PM	10	455	2	4	n	y	n	n	n	n	n	n	60 mg	71,1	66	n	y	n	n	n	n	n
P	no ASA	641	422	85	m	ICD	308	550	1	4	y	y	n	n	n	n	n	n	60 mg	61,88	61	y	y	y	n	n	n	n
P	no ASA	641	473	66	m	PM	190	550	1	2	n	y	n	n	n	n	n	n	60 mg	112,65	60	n	n	y	n	n	n	n
P	no ASA	641	478	82	f	PM	16	321	1	4	y	y	n	n	n	n	n	n	30 mg	63,09	60	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
		641	542	82	m					5																		
P	ASA	641	552	81	m	ICD	11	569	1	5	y	y	n	n	n	y	y	n	30 mg	57,96	60	y	n	y	n	n	n	n
P	ASA	641	581	88	m	PM	382	265	3	7	y	y	n	n	y	y	y	n	60 mg	84,71	76	y	n	y	n	n	n	n
E	no ASA	641	588	71	m	ICD-CRT	35	256	1	3	y	y	n	n	n	n	n	n	60 mg	74,54	65	y	n	y	n	n	n	n
E	ASA	641	589	70	f	ICD-CRT	7	275	1	3	n	y	n	n	n	n	n	y	30 mg	39,47	75	n	n	y	n	n	n	n
P	no ASA	641	632	78	m	PM				3	n	y	n	n	n	n	n	n	30 mg	42,36	67	y	n	n	n	n	n	n
P	ASA	641	643	89	f	PM	89	351	1	5	n	y	n	n	n	n	n	n	30 mg	24,9		y	n	y	n	n	n	n
E	no ASA	641	746	84	m	ICD	281	495	1	5	y	y	n	n	n	n	n	n	60 mg	68,06	79	n	n	y	n	n	n	n
E	no ASA	641	1015	78	m	PM	11	231	1	5	n	y	y, oa	n	n	n	n	n	60 mg	60,76	65	n	n	y	n	n	n	n
E	ASA	641	1167	83	m	ICD	52	300	1	3	y	n	n	n	n	n	n	n	30 mg	51,41	66	y	n	y	n	n	n	n
P	no ASA	641	1211	79	f	PM				5	y	y	n	n	n	n	n	n	30 mg	44,27	60	y	n	y	n	n	n	n
E	no ASA	641	1280	84	f	PM	27	233	1	4	n	y	n	n	n	n	n	n	30 mg	28,39	69	y	n	y	n	n	n	n
E	ASA	641	1405	73	m	ICD	1872	545	1	5	y	y	y, oa	n	n	y	y	y	60 mg	82,84	64	y	n	y	n	n	n	n
P	no ASA	641	1430	78	m	PM	1238	320	1	3	n	y	n	n	n	n	n	n	60 mg	91,06	60	y	y	y	n	n	n	n
P	no ASA	641	1498	67	f	ICD-CRT	2044	640	1	4	y	y	n	n	n	n	n	n	60 mg	55,78	66	y	n	y	n	n	n	n
E	ASA	641	1691	68	m	PM	338		1	5	y	y	y, oa	n	n	y	y	y	30 mg	32,61	60	y	n	n	n	y	n	n
P	ASA	641	1719	68	m	PM				4	n	y	y, oa	n	n	n	n	y	60 mg	84,79	60	y	n	y	n	n	n	n
P	ASA	641	1807	71	f	ICD-CRT	31	301	1	6	y	y	y, it	n	n	n	n	n	30 mg	43,16	93	y	n	y	n	n	n	n
E	no ASA	641	1828	75	m	PM	447		1	3	n	y	n	n	n	n	n	n	60 mg	83,56	68	n	n	n	n	n	n	n
P	no ASA	641	1834	65	f	PM	78	462	1	3	n	y	n	n	n	n	n	n	60 mg	77,47	62	n	n	y	n	n	n	n
E	no ASA	641	1855	69	m	PM	574		8	3	n	y	n	n	n	n	n	n	60 mg	88,1	74	n	n	y	n	n	n	n
P	no ASA	641	1905	78	f	PM	192		1	3	n	n	n	n	n	n	n	n	30 mg	54,22	66	n	n	n	n	n	n	n
E	no ASA	641	1944	80	m	PM	17	545	1	4	n	y	y, oa	n	n	n	n	n	30 mg	29,76	60	y	n	y	n	n	n	n
P	no ASA	641	1981	83	m	PM	220		1	3	n	y	n	n	n	n	n	n	30 mg	40,42	71	y	n	y	n	n	n	n
E	ASA	641	1990	77	m	PM	63		1	5	n	y	y, oa	n	n	n	n	n	60 mg	79,08	60	y	n	n	n	n	n	n
P	ASA	641	2016	69	m	PM	438		1	2	n	y	n	n	n	n	n	n	60 mg	78,18	66	n	y	n	n	n	n	n
E	no ASA	641	2112	81	m	PM-CRT	916		1	5	y	y	y, oa	n	n	n	n	n	60 mg	63,73	60	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	641	2166	77	m	PM	735		1	5	y	y	n	n	n	y	y	n	60 mg	74,29	69	y	y	y	n	n	n	n
P	no ASA	641	2168	68	m	PM	42	640	1	4	y	y	y, oa	n	n	n	n	n	60 mg	77,48	61	y	n	y	n	n	n	n
E	no ASA	641	2196	75	m	PM	1440		5	4	n	y	y, oa	n	n	n	n	n	60 mg	128,97	72	n	n	y	n	n	n	n
E	no ASA	641	2341	78	f	PM	53		3	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	64,88	87	y	n	y	n	n	n	n
P	no ASA	641	2343	80	f	PM				4	n	y	n	n	n	n	n	n	30 mg	58,85	83	y	n	n	n	n	n	n
E	ASA	641	2393	76	m	ICD-CRT	178	233	1	5	y	y	n	n	n	y	n	y	60 mg	66,17	60	y	n	n	n	n	n	n
E	ASA	641	2463	83	m	PM	95		1	4	n	y	n	n	n	n	n	n	60 mg	64,81	60	y	n	y	n	n	n	n
P	ASA	641	2584	68	m	PM				3	n	y	n	n	n	n	y	n	60 mg	112,5	60	n	n	y	n	n	n	n
P	no ASA	641	2637	86	m	PM				3	n	y	n	n	n	n	n	n	60 mg	62,25	66	y	y	y	n	n	n	n
P	no ASA	641	2667	65	m	ICD-CRT				3	y	y	n	n	n	n	n	n	60 mg	136,5	75	y	n	n	n	n	n	n
P	ASA	653	2332	86	f	PM	239		12	6	n	y	y, oa	n	n	n	n	n	30 mg	25,19	54	y	y	n	n	n	n	n
E	ASA	653	2448	89	f	PM	198	640	6	6	n	y	n	y	n	n	n	n	30 mg	33,54	60	y	n	y	n	n	n	n
E	no ASA	653	2486	82	m	PM	7	231	1	3	n	y	n	n	n	n	n	n	30 mg	48,09	60	y	y	y	n	n	n	n
E	ASA	653	2487	83	m	PM	108		1	3	n	y	n	n	n	n	n	n	60 mg	80,81	75	n	n	y	n	n	n	n
E	no ASA	653	2498	67	f	PM	995		1	3	n	y	n	n	n	n	n	n	60 mg	116,28	75	n	n	n	n	n	n	n
P	ASA	653	2655	82	m	ICD-CRT	13	400	1	4	y	y	n	n	n	n	n	n	60 mg	68,02	75	y	n	y	n	n	n	n
P	ASA	655	152	68	f	ICD	11	213	1	5	y	y	n	n	n	y	y	y	60 mg	72,64	48	y	n	y	n	n	n	n
E	ASA	655	379	84	m	PM	295	429	1	5	n	y	y, oa	n	n	n	n	n	30 mg	29,63	80	n	n	n	n	n	n	n
E	no ASA	655	461	78	f	PM	99	640	1	5	n	y	y, oa	n	n	n	n	n	60 mg	72,01	65	y	n	y	n	n	n	n
P	ASA	655	465	89	m	PM	34	240	1	3	n	y	n	n	n	n	n	n	30 mg	38,19	90	n	n	y	n	n	n	n
E	ASA	655	549	75	m	ICD	468	600	1	6	y	y	y, oa	n	n	y	y	n	60 mg	50,04	71	y	y	n	n	n	n	n
E	ASA	655	559	77	m	ICD	22	640	1	5	n	y	y, oa	n	n	y	y	n	30 mg	41,33	60	y	n	n	n	y	n	n
P	no ASA	655	560	73	m	PM	2880	311		2	n	y	n	n	n	n	n	n	60 mg	89,83	66	n	n	y	n	n	n	n
P	ASA	655	580	85	m	PM	1465	392	2	4	n	y	n	n	n	n	n	n	60 mg	76,7	62	y	y	y	n	n	n	n
P	no ASA	655	597	84	m	PM	4358	380	4	3	n	y	n	n	n	n	y	n	60 mg	58,33	74	n	n	y	n	n	n	n
E	no ASA	655	834	79	m	PM	126	404	1	3	n	y	n	n	n	n	n	n	60 mg	51,6	60	n	n	y	n	n	n	n
P	ASA	655	1457	76	m	PM	1128		1	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	60,44	70	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	655	1491	72	m	PM	627	640	2	2	n	y	n	n	n	n	n	n	60 mg	159,52	68	y	y	y	n	n	n	n
E	no ASA	655	2501	85	m	PM	21		1	3	n	y	n	n	n	n	n	n	60 mg	51,43	64	n	n	y	n	n	n	n
P	no ASA	655	2582	66	f	PM	7		1	3	n	y	n	n	n	n	n	n	60 mg	128,13	61	y	y	y	n	n	n	n
E	ASA	655	2656	85	m	ICD-CRT	157	400	1	4	y	y	n	n	n	n	n	n	30 mg	27,78	60	y	n	y	n	y	n	n
E	no ASA	663	223	74	m	PM	186	400	1	2	n	y	n	n	n	n	n	n	60 mg	78,77	75	n	y	y	n	n	n	n
P	no ASA	663	579	74	f	PM	9	400	1	5	n	y	n	y	n	n	n	n	60 mg	60,29		n	y	y	n	n	n	n
P	ASA	669	259	68	m	PM	862	600	1	3	n	y	y, oa	n	n	n	n	n	60 mg	165,37	69	y	n	y	n	n	n	n
E	ASA	669	450	69	f	PM	73		1	3	n	n	n	n	n	n	y	n	60 mg	97,18	55	y	n	y	n	n	n	n
E	no ASA	669	1075	69	m	ICD-CRT	9999	600	2	3	y	y	n	n	n	n	n	n	60 mg	71,99	72	y	y	y	n	n	n	n
P	no ASA	669	1220	83	m	PM	5817	640	3	4	n	y	y, oa	n	n	n	n	n	60 mg	66,37	52	y	n	n	n	n	n	n
E	no ASA	669	1723	78	f	PM	9	218	1	4	n	y	n	n	n	n	y	n	60 mg	79,52	100	n	n	y	n	n	n	n
P	no ASA	673	87	81	f	PM	48	400	1	4	n	n	y, oa	n	n	n	n	n	60 mg	60,1	66	n	n	n	n	n	n	n
E	no ASA	673	91	82	m	ICD-CRT	186	316	1	4	n	y	n	n	n	y	y	n	30 mg	38,74	78	n	n	y	n	n	n	n
P	no ASA	673	194	82	m	PM	96	640	1	2	n	n	n	n	n	n	n	n	60 mg	52,78	60	y	n	y	n	n	n	n
P	ASA	673	269	90	m	PM	340	400	3	4	n	y	y, oa	n	n	n	n	n	30 mg	30,06	71	n	y	y	n	n	n	n
P	no ASA	673	324	71	f	PM				3	n	y	n	n	n	n	n	n	60 mg	84,85	66	n	n	y	n	n	n	n
E	no ASA	673	337	77	m	PM				3	n	y	n	n	n	n	n	n	60 mg	88,53	80	n	y	n	n	n	n	n
E	no ASA	673	427	90	m	PM		400	1	3	n	y	n	n	n	n	n	n	30 mg	28,14	116	y	n	y	n	n	n	n
E	no ASA	673	707	90	f	PM	9999	600	6	4	n	y	n	n	n	n	n	n	30 mg	33,02	70	y	n	y	n	n	n	n
P	no ASA	673	821	81	f	PM	122	308	2	5	n	y	y, oa	n	n	n	n	n	60 mg	74,46	75	n	n	y	n	n	n	n
P	no ASA	673	833	73	f	PM-CRT	77	333	9	3	y	n	n	n	n	n	n	n	30 mg	45,9	81	y	n	y	n	n	n	n
E	no ASA	673	837	76	m	PM	29	429	1	2	n	n	n	n	n	n	n	n	60 mg	62,63	67	n	n	n	n	n	n	n
E	ASA	673	948	84	m	PM	9999	366	6	5	y	y	n	n	n	n	y	n	60 mg	50,4	75	n	n	y	n	n	n	n
P	no ASA	673	1048	83	m	PM				3	n	y	n	n	n	n	n	n	60 mg	82,81	79	n	n	y	n	n	n	n
E	no ASA	673	1052	75	m	PM	185	462	2	3	n	y	n	n	n	n	n	n	60 mg	62,14	70	n	n	y	n	n	n	n
P	ASA	673	1097	70	m	ICD-CRT	33	207	14	4	y	n	y, oa	n	n	y	n	n	60 mg	77,11	69	y	n	y	n	n	n	n
E	no ASA	673	1136	90	f	PM	210	429	1	4	n	y	n	n	n	n	n	n	30 mg	34,56	80	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	673	1150	82	m	PM				5	y	y	y, oa AND it	n	n	n	n	n	30 mg	44,98	65	n	n	y	n	n	n	n
E	no ASA	673	1168	76	m	PM	914	640	1	2	n	n	n	n	n	n	n	n	60 mg	65,88	63	n	n	n	n	n	n	n
P	no ASA	673	1287	79	m	PM	1018	300	4	2	n	n	n	n	n	n	n	n	60 mg	79,17	66	n	n	n	n	n	n	n
P	no ASA	673	1302	79	f	PM	420	275	1	5	n	y	y, oa	n	n	n	n	n	60 mg	54,05	68	n	n	y	n	n	n	n
E	ASA	673	1372	81	m	PM	3493	500	9	4	n	y	y, oa	n	n	n	n	n	30 mg	48,51	68	n	y	y	n	n	n	n
E	no ASA	673	1382	69	m	PM	221	640	167	2	n	y	n	n	n	n	n	n	60 mg	89,24	67	n	n	n	n	n	n	n
P	no ASA	673	1533	70	m	ICD	21	545	1	3	y	y	n	n	n	n	n	n	60 mg	84,62	62	y	n	y	n	n	n	n
P	no ASA	673	1567	84	f	PM				4	n	y	n	n	n	n	n	n	60 mg	69,94	72	y	n	n	n	n	n	n
E	no ASA	673	1662	84	f	PM	606	640	1	4	n	y	n	n	n	n	n	n	30 mg	45,03	68	n	n	y	n	n	n	n
E	ASA	673	1713	84	m	PM-CRT	18	300	1	4	y	y	n	n	n	n	n	n	30 mg	49,74	60	y	n	y	n	n	n	n
E	no ASA	673	1797	73	m	ICD	289	640	1	3	y	y	n	n	n	n	n	n	60 mg	64,66	73	y	n	y	n	n	n	n
P	no ASA	673	1849	72	f	PM	494	545	5	4	n	y	y, oa	n	n	n	n	n	60 mg	86,27	86	n	y	y	n	n	n	n
E	no ASA	673	1862	84	f	PM	139	591	4	4	n	y	n	n	n	n	n	n	30 mg	59,5	65	n	n	y	n	n	n	n
P	no ASA	673	1864	78	f	ICD	787	545	11	5	y	n	n	n	n	y	n	n	30 mg	53,82	74	y	n	y	n	n	n	n
E	no ASA	673	1866	72	f	PM-CRT	12	353	2	4	y	n	y, oa	n	n	n	n	n	30 mg	64,93	72	y	n	y	n	n	n	n
P	no ASA	673	1875	85	f	PM	66	462	1	4	n	y	n	n	n	n	n	n	60 mg	51,31	72	n	y	y	n	n	n	n
E	ASA	673	1913	90	m	PM	72		2	3	n	y	n	n	n	n	n	n	30 mg	44,07	76	y	n	n	n	n	n	n
P	ASA	673	1916	79	f	PM	35	375	3	7	y	y	y, oa	n	n	y	n	n	30 mg	48,23	61	n	n	n	n	n	n	n
E	no ASA	673	2077	78	m	PM	1882	500	2	4	n	y	y, oa	n	n	n	n	n	30 mg	38,33	62	n	n	n	n	n	n	n
P	no ASA	673	2086	92	m	PM	64	640	3	4	n	y	y, oa	n	n	n	n	n	30 mg	36,32	66	n	y	n	n	n	n	n
E	no ASA	673	2139	82	m	PM				4	n	y	y, oa	n	n	n	n	n	30 mg	32,2	83	n	n	y	n	n	n	n
E	no ASA	673	2146	86	m	PM	314		3	2	n	n	n	n	n	n	n	n	60 mg	72,63	69	n	n	n	n	n	n	n
P	ASA	673	2234	84	m	PM	390	545	1	4	n	y	n	n	n	n	n	n	30 mg	44,05	67	n	n	y	n	n	n	n
E	no ASA	673	2263	90	m	PM	725		4	3	n	y	n	n	n	n	n	n	30 mg	25,22	129	n	y	n	n	n	n	n
P	no ASA	673	2268	83	m	PM	754		5	4	n	y	n	n	n	n	y	n	60 mg	105,56	73	y	n	y	n	n	n	n
P	no ASA	673	2275	80	m	PM	166		5	4	n	y	y, oa	n	n	n	n	n	60 mg	79,07	78	n	n	n	n	n	n	n
P	ASA	673	2337	65	m	ICD	16	640	1	3	n	y	n	n	n	y	y	n	60 mg	82,97	50	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	673	2339	71	m	ICD	15	240	3	3	n	y	n	n	n	y	y	n	60 mg	89,84	72	y	n	y	n	y	n	n
E	no ASA	673	2433	78	m	PM	832		5	6	n	y	y, oa	y	n	n	n	n	60 mg	80,66	77	n	y	y	n	n	n	n
P	no ASA	673	2541	86	f	PM-CRT	17	462	2	5	y	y	n	n	n	n	n	n	30 mg	39,78	57	y	n	y	n	n	n	n
P	no ASA	673	2575	91	f	PM	836	640	15	4	n	y	n	n	n	n	n	n	30 mg	51,42	60	n	n	y	n	n	n	n
		674	745	81	m					5									60 mg	69,65								
P	no ASA	674	886	68	m	ICD-CRT	531	545	1	2	n	y	n	n	n	n	n	n	60 mg	113,75	61	y	n	y	n	n	n	n
P	no ASA	674	888	80	f	PM	95	600	5	4	n	y	n	n	n	n	n	n	30 mg	47,65	63	y	n	y	n	n	n	n
P	ASA	674	1448	76	m	ICD	29		2	4	n	y	n	n	n	n	y	n	60 mg	60,44	62	n	n	y	n	n	n	n
E	no ASA	675	233	72	m	ICD	321	520	1	3	n	y	y, oa	n	n	n	n	n	60 mg	59,22	64	n	y	y	n	n	n	n
E	no ASA	675	240	74	m	PM	56	545	10	2	n	y	n	n	n	n	n	n	60 mg	61,43	67	y	n	y	n	n	n	n
P	no ASA	675	307	74	m	PM	489	351	2	3	n	n	n	y	n	n	n	n	60 mg	68,75	60	n	y	n	n	n	n	n
P	no ASA	675	345	81	f	PM				3	n	n	n	n	n	n	n	n	30 mg	40,79	67	y	n	n	n	n	n	n
P	no ASA	675	365	79	m	PM	7		1	3	n	y	n	n	n	n	n	n	30 mg	41,3	88	n	y	y	n	n	n	n
E	no ASA	675	384	76	f	ICD-CRT	357	545	6	5	n	y	y, oa	n	n	n	n	n	60 mg	82,88	62	y	n	y	n	n	n	n
E	no ASA	675	507	82	m	ICD	172	545	14	6	y	y	y, oa	n	n	y	n	n	60 mg	55,27	56	y	n	n	n	n	n	n
P	no ASA	675	591	67	m	PM	352	600	7	2	n	y	n	n	n	n	n	n	60 mg	98,26	64	n	n	y	n	n	n	n
E	no ASA	675	942	84	m	PM				4	y	y	n	n	n	n	n	n	60 mg	111,86	62	y	n	y	n	n	n	n
P	no ASA	679	505	85	f	PM	1903	480	2	4	n	y	n	n	n	n	n	y	30 mg	43,68	71	n	n	n	n	n	n	n
E	no ASA	679	1078	78	m	PM	94	275	1	4	n	y	n	n	n	n	n	n	60 mg	58,57	70	n	n	n	n	n	n	n
E	ASA	680	623	68	m	PM	631	400	1	3	n	y	y, oa	n	n	n	n	n	60 mg	70,27	55	y	y	y	n	n	n	n
E	no ASA	680	668	79	f	PM	40	400	3	4	n	y	n	n	n	n	n	n	60 mg	50,5	62	y	n	n	y	n	n	n
E	ASA	680	698	88	f	PM	264	400	4	4	n	y	n	n	n	n	n	n	30 mg	32,77	75	y	n	n	n	n	n	n
P	ASA	680	711	81	m	ICD	25	500	1	3	y	n	n	n	n	n	y	n	30 mg	39,64	60	y	n	y	n	n	n	n
E	no ASA	680	729	79	m	PM-CRT	115	429	1	3	y	n	n	n	n	n	n	n	60 mg	106,77	60	y	n	n	n	n	n	n
E	ASA	680	763	75	m	ICD-CRT	1291	640	11	8	y	y	n	n	y	y	y	y	60 mg	59,47	60	y	y	y	n	n	n	n
P	no ASA	680	771	88	f	PM	276	500	1	4	n	y	n	n	n	n	n	n	30 mg	47,5	60	y	y	y	n	n	n	n
P	ASA	680	772	70	m	ICD	166	300	1	4	y	y	n	n	n	y	y	n	60 mg	53,57	60	y	n	y	n	y	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	680	783	72	m	PM-CRT	16	640	2	4	y	y	n	n	n	y	y	n	60 mg	81,67	65	y	n	y	n	n	n	n
P	ASA	680	789	79	m	PM	501	400	3	4	n	y	n	n	n	y	y	n	60 mg	63,54	60	y	y	y	n	n	n	n
E	ASA	680	813	84	f	PM	185	400	10	7	n	y	y, oa	y	n	n	n	n	30 mg	36,06	75	y	y	n	n	n	n	n
E	ASA	680	815	67	m	PM	1633	400	2	5	y	y	y, oa	n	n	y	y	y	60 mg	81,99	60	y	y	y	n	n	n	n
P	ASA	680	836	81	m	PM	40	400	4	4	n	y	n	n	n	n	n	n	60 mg	56,07	75	n	y	y	n	n	n	n
P	no ASA	680	838	68	m	PM	176	600	2	2	n	y	n	n	n	n	n	n	60 mg	91,96	65	n	n	y	n	n	n	n
P	no ASA	680	851	78	f	PM	175	600	1	4	n	y	n	n	n	n	n	n	30 mg	36,6	70	y	y	y	n	n	n	n
E	ASA	680	887	83	m	PM-CRT	85	269	1	7	y	y	y, oa	y	n	n	n	n	60 mg	76,82	60	y	n	y	n	n	n	n
P	ASA	680	902	78	f	PM	229	400	1	5	n	y	y, oa	n	n	n	n	n	30 mg	44,6	64	y	n	y	n	n	n	n
P	ASA	680	904	80	m	ICD	23	333	1	5	y	y	n	n	n	y	y	y	60 mg	52,42	70	y	n	y	n	n	n	n
E	ASA	680	934	79	m	PM	271	400	10	5	n	y	y, oa	n	n	y	n	y	30 mg	46,88	85	y	n	y	n	n	n	n
P	ASA	680	935	72	m	ICD	105	429	1	5	y	y	y, oa	n	n	y	n	y	60 mg	82,82	60	y	n	y	n	n	n	n
E	ASA	680	955	85	f	ICD	1309	545	2	5	n	y	y, oa	n	n	n	n	n	30 mg	27,53	70	y	n	y	n	n	n	n
P	ASA	680	979	75	f	PM	147	400	3	5	n	y	n	n	n	n	n	n	60 mg	103,39		y	n	n	n	n	n	n
P	ASA	680	981	80	m	PM	88	462	2	3	n	y	n	n	n	n	n	n	30 mg	46,84	68	y	n	y	n	n	n	n
E	ASA	680	993	69	m	PM	1764	400	6	3	n	y	n	n	n	y	y	n	60 mg	99,56	60	y	n	y	n	n	n	n
E	ASA	680	998	86	f	PM	142	400	2	5	n	y	y, it	n	n	n	y	n	30 mg	27,63	65	y	n	n	n	n	n	n
P	ASA	680	1024	69	m	ICD	27	480	4	5	y	y	y, it	n	n	y	y	y	60 mg	85,2	57	y	y	y	n	n	n	n
E	ASA	680	1034	81	m	PM	87	500	1	3	y	n	n	n	n	n	n	n	60 mg	68,6	60	y	n	y	n	n	n	n
P	ASA	680	1037	74	m	ICD	1949	600	1	2	n	y	n	n	n	n	y	n	60 mg	97,33	60	y	n	y	n	n	n	n
E	ASA	680	1041	73	m	ICD	207	640	1	4	y	y	n	n	n	y	n	n	60 mg	83,16		y	n	y	n	n	n	n
P	ASA	680	1044	65	m	PM	628	400	5	3	n	y	y, oa	n	n	n	n	n	60 mg	108,97		n	n	y	n	n	n	n
E	ASA	680	1054	67	m	PM	5760	400	1	3	n	y	n	n	n	y	y	n	60 mg	100,63	60	y	n	y	n	n	n	n
P	ASA	680	1064	69	m	PM	398	400	1	3	n	y	n	n	n	n	n	n	60 mg	118,45		y	y	n	n	n	n	n
E	ASA	680	1065	79	f	PM	7	400	1	6	y	y	n	n	n	y	n	n	60 mg	55,6	70	y	n	y	n	n	n	n
E	no ASA	680	1071	68	m	PM	252	317	1	2	n	y	n	n	n	n	n	n	60 mg	90,43	60	n	n	y	n	n	n	n
P	ASA	680	1079	78	f	PM	27	600	1	4	n	y	n	n	n	n	n	n	60 mg	50,08	84	y	n	n	y	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	680	1087	69	m	ICD-CRT	116	640	2	5	y	y	y, oa	n	n	y	y	y	60 mg	118,66		y	n	n	n	n	n	n
E	ASA	680	1090	70	f	PM	145	282	8	4	n	y	y, oa	n	n	n	n	n	60 mg	134,5	70	n	y	y	n	n	n	n
P	ASA	680	1122	77	m	ICD-CRT	1083	640	1	6	y	y	y, oa	n	n	y	y	n	60 mg	73,23	68	y	n	y	n	n	n	n
P	ASA	680	1129	85	m	PM	5701	545	1	4	n	y	y, oa	n	n	n	n	n	60 mg	50,69	60	y	y	y	n	n	n	n
P	no ASA	680	1135	72	f	PM	2154	400	2	4	n	y	y, oa	n	n	n	n	n	60 mg	74,68	64	y	n	n	n	n	n	n
E	ASA	680	1153	70	m	ICD	342	600	1	3	y	n	n	n	n	y	y	n	60 mg	71,96	60	y	n	y	n	n	n	n
P	no ASA	680	1156	83	m	PM	598	346	1	3	n	y	n	n	n	n	n	n	30 mg	36,03	60	y	n	n	n	n	n	n
P	ASA	680	1210	66	m	PM	647	400	5	5	y	y	y, oa	n	n	y	y	y	60 mg	68,8	84	y	y	y	n	n	n	n
E	ASA	680	1212	68	m	PM	125	400	1	6	n	y	y, oa	y	n	y	y	n	60 mg	78,26	60	y	y	y	n	n	n	n
P	ASA	680	1231	74	m	PM	7	331	1	6	n	y	y, oa	n	y	n	y	n	60 mg	57,87	82	y	y	y	n	n	n	n
E	no ASA	680	1248	82	f	PM	71	346	3	4	n	y	n	n	n	n	n	n	60 mg	60,71	70	y	y	y	n	n	n	n
E	ASA	680	1257	91	f	PM	230	600	11	6	n	y	n	y	n	n	n	n	30 mg	25,89	85	y	n	y	n	n	n	n
E	ASA	680	1292	73	m	PM	482	400	6	3	n	y	y, oa	n	n	n	n	n	60 mg	68,6	61	n	y	y	n	n	n	n
E	ASA	680	1316	66	m	PM	39	400	6	3	n	y	n	n	n	y	n	y	60 mg	55,26	60	y	n	y	n	n	n	n
P	ASA	680	1318	82	f	PM	40	331	3	5	n	y	n	n	n	n	n	n	60 mg	66,14	60	n	n	y	n	n	n	n
P	ASA	680	1339	88	f	PM	115	400	2	5	n	y	n	n	n	y	n	n	60 mg	60,49	70	y	y	n	n	n	n	n
E	ASA	680	1340	88	f	PM	11	305	1	6	n	y	n	y	n	n	n	n	30 mg	40,26	60	y	n	y	n	n	y	n
P	ASA	680	1347	71	m	PM	58		1	5	y	y	y, it	n	n	y	y	y	60 mg	102,93	60	y	n	n	n	n	n	n
E	no ASA	680	1349	87	m	PM	134	400	3	3	n	y	n	n	n	n	n	n	60 mg	51,74	60	n	n	n	n	n	n	n
E	ASA	680	1363	86	m	PM	202	545	1	3	n	y	n	n	n	n	n	n	30 mg	42,33		y	n	y	n	n	n	n
P	ASA	680	1417	91	m	PM-CRT	6	208	1	4	y	y	n	n	n	n	n	n	30 mg	41,42	65	y	n	y	n	n	n	n
P	ASA	680	1455	80	m	PM	894	400	1	3	n	y	n	n	n	n	n	n	60 mg	67,15	63	y	n	y	n	n	n	n
P	no ASA	680	1474	74	f	PM	8	305	1	4	n	y	y, oa	n	n	n	n	n	60 mg	56,78	60	y	y	n	y	n	y	n
E	no ASA	680	1512	72	f	PM	10	201	1	4	n	y	y, oa	n	n	n	n	n	30 mg	46,14	64	n	y	y	n	n	n	n
E	ASA	680	1530	81	f	PM	1508	250	31	5	n	y	y, oa	n	n	n	y	n	30 mg	31,79	62	y	n	y	y	n	n	n
P	ASA	680	1531	87	m	PM	1292	400	5	4	y	y	n	n	n	n	n	n	30 mg	48,57	60	y	y	y	n	n	n	n
P	ASA	680	1609	76	m	PM	9999	300	1	5	n	y	y, it	n	n	y	y	n	60 mg	86,02	83	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	680	1640	73	m	PM	245	400	1	2	n	y	n	n	n	n	n	n	60 mg	55,25		y	y	n	n	n	n	n
E	ASA	680	1645	84	f	PM	45	400	1	5	n	y	n	n	n	n	n	y	30 mg	42,63	60	y	y	n	n	n	n	n
E	ASA	680	1657	77	m	PM	7	254	1	5	n	y	n	n	y	n	n	n	60 mg	60,43	60	y	y	n	n	n	n	n
E	ASA	680	1664	69	m	ICD	7	261	1	5	y	y	y, oa	n	n	y	y	y	60 mg	88,28	60	y	y	y	n	n	n	n
E	no ASA	680	1681	76	f	PM	14	400	1	6	y	y	y, oa	n	n	n	n	n	60 mg	132,61	60	y	n	y	n	n	n	n
E	ASA	680	1750	90	m	PM	182	400	1	4	n	y	y, oa	n	n	n	n	n	30 mg	47,37	60	y	n	n	n	n	n	n
P	ASA	680	1799	90	m	PM	4780	400	4	4	n	y	n	n	n	y	y	n	30 mg	43,93	70	y	y	y	n	n	n	n
P	ASA	680	1815	84	f	ICD-CRT	335	640	1	5	y	n	y, oa	n	n	n	y	n	30 mg	49,36		y	y	y	n	n	n	n
P	ASA	680	1821	80	m	ICD	12		3	5	y	y	n	n	n	y	y	n	30 mg	49,24	75	y	n	n	n	n	n	n
E	no ASA	680	1832	69	m	ICD-CRT	763	640	5	2	y	n	n	n	n	n	n	n	60 mg	71,96		y	n	y	n	n	n	n
E	ASA	680	1887	88	m	PM	22	400	2	6	n	y	n	y	n	y	y	y	60 mg	51,16	80	y	y	y	n	n	n	n
P	no ASA	680	1891	67	m	PM	55	400	3	3	n	y	y, oa	n	n	n	n	n	60 mg	78,55	62	y	n	n	y	n	n	n
E	ASA	680	1907	77	m	ICD	1983		2	4	y	n	n	n	n	y	y	n	60 mg	69,31	56	y	n	n	n	n	n	n
P	no ASA	680	1955	76	m	PM	34	429	2	3	n	y	n	n	n	n	n	n	60 mg	62,1		y	n	y	n	n	n	n
P	no ASA	680	1960	72	f	PM	38	400	1	3	n	y	n	n	n	n	n	n	30 mg	53,71	63	n	n	y	n	n	n	n
E	ASA	680	1998	76	f	ICD-CRT	96	640	1	7	y	y	y, oa	n	n	y	y	n	60 mg	81,29		y	n	y	n	n	n	n
P	no ASA	680	2031	76	m	PM	126	400	1	4	n	y	y, oa	n	n	n	n	n	60 mg	93,38		y	y	y	n	n	n	n
P	ASA	680	2045	81	m	PM	1746	400	2	6	n	y	n	y	n	y	y	n	60 mg	67,8	60	y	y	y	n	n	n	n
E	no ASA	680	2048	80	f	ICD-CRT	541	640	2	5	y	y	n	n	n	n	n	n	60 mg	87,07	72	y	y	y	n	n	n	n
E	ASA	680	2060	69	m	ICD-CRT	513	640	3	4	y	y	n	n	n	y	y	n	60 mg	82,99	70	y	n	y	n	n	n	n
E	ASA	680	2065	85	m	ICD-CRT	107	375	1	6	y	y	y, oa	n	n	y	n	y	60 mg	56,58		y	n	y	n	n	n	n
E	ASA	680	2088	71	f	ICD-CRT	34	640	6	4	y	n	n	n	n	y	y	n	60 mg	58,76	65	y	n	y	n	n	n	n
E	no ASA	680	2091	73	f	PM	304	400	4	4	n	y	y, oa	n	n	n	n	n	60 mg	106,89		y	y	y	n	n	n	n
P	ASA	680	2092	88	m	ICD-CRT	736	640	1	6	y	y	y, oa AND it	n	n	y	n	n	60 mg	57,08		y	n	n	n	n	y	n
E	no ASA	680	2094	77	f	PM	10	400	1	5	n	n	y, oa	n	n	n	n	n	60 mg	78,42	75	n	n	n	n	n	n	n
P	ASA	680	2233	78	m	PM	48	400	4	5	n	y	y, oa	n	n	n	n	n	30 mg	33	70	y	n	y	n	n	n	n
E	ASA	680	2254	77	f	ICD	722	640	1	6	y	y	y, oa	n	n	n	n	n	60 mg	81,42	62	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	680	2266	70	m	PM	1886	640	1	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	132,58	60	y	n	y	n	n	n	n
E	no ASA	680	2267	67	m	ICD-CRT	53	640	1	3	y	y	n	n	n	n	n	n	60 mg	110,89	65	y	n	y	n	n	n	n
P	ASA	680	2306	65	f	ICD	13	429	1	5	y	y	n	n	n	y	y	n	60 mg	62,68		y	n	y	n	n	n	n
P	ASA	680	2317	78	f	PM	277	273	1	5	n	y	y, it	n	n	n	n	n	60 mg	66,54	65	n	n	y	n	n	n	n
E	ASA	680	2346	70	f	PM				6	y	y	y, oa	n	n	n	n	y	30 mg	42,06	60	y	y	y	n	n	n	n
P	ASA	680	2356	68	f	PM	715	400	7	3	n	y	n	n	n	n	n	n	60 mg	131,69	60	y	y	y	n	n	n	n
E	no ASA	680	2362	79	m	PM	510	400	1	3	n	y	n	n	n	n	n	n	30 mg	38,51	60	y	n	n	n	n	n	n
P	no ASA	680	2394	69	f	PM	27	346	3	4	n	y	y, oa	n	n	n	n	n	60 mg	75,62	68	y	n	y	n	n	n	n
E	ASA	680	2410	81	f	PM	9	400	1	4	n	y	n	n	n	n	n	n	30 mg	42,86		y	y	n	n	n	n	n
P	no ASA	680	2499	73	f	PM	221	400	2	4	n	y	y, oa	n	n	n	n	n	60 mg	64,21	69	y	n	y	n	n	n	n
P	no ASA	680	2509	74	m	ICD-CRT	11	400	10	3	y	y	n	n	n	n	n	n	30 mg	48,71	95	y	n	y	n	y	n	n
P	ASA	680	2516	79	m	ICD-CRT	123	640	1	6	y	y	y, oa	n	n	y	y	n	60 mg	103,57		y	n	y	n	n	n	n
E	ASA	680	2539	71	m	PM	31	400	3	3	n	y	y, it	n	n	n	n	n	60 mg	113,82	60	y	y	y	n	n	n	n
P	ASA	680	2543	79	m	PM	549	400	12	5	n	y	y, oa AND it	n	n	y	y	n	60 mg	60,48	70	y	y	y	y	n	n	n
E	no ASA	680	2547	69	m	PM	795	640	21	2	n	y	n	n	n	n	n	n	60 mg	128,62	70	y	y	y	n	n	n	n
P	ASA	680	2614	88	m	PM	453	549	47	5	n	n	n	n	y	y	n	y	30 mg	37,14	80	y	n	y	n	n	n	n
P	no ASA	680	2620	85	f	PM	5760	400	4	4	n	y	n	n	n	n	n	n	30 mg	40,02	60	y	n	y	n	n	n	n
P	ASA	680	2641	83	m	PM	721	400	1	5	n	y	y, oa	n	n	n	n	y	60 mg	58,1		y	y	y	n	n	n	n
E	ASA	680	2705	82	f	PM	72	400	3	8	n	y	y, it	n	y	n	n	y	60 mg	53,15		y	n	y	n	n	n	n
E	ASA	680	2715	74	f	PM	1376	400	5	4	n	y	n	n	n	n	n	n	60 mg	51,43		n	n	y	n	n	n	n
P	no ASA	680	2721	83	m	PM	1192	400	1	3	n	y	n	n	n	n	n	n	60 mg	52,35	70	n	y	y	n	n	n	n
E	ASA	680	2724	81	m	PM	205	400	1	8	y	y	y, it	y	n	n	n	n	30 mg	56,55	70	y	y	y	n	n	n	n
P	ASA	680	2747	86	f	PM	18	400	1	6	n	y	y, oa AND it	n	n	n	n	n	30 mg	54,03	70	y	y	y	n	n	n	n
E	no ASA	685	185	68	f	PM	48	362	3	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	112,65	56	y	y	n	n	n	n	n
E	no ASA	685	403	85	f	PM	294	640	1	3	n	n	n	n	n	n	n	n	30 mg	47,44	71	y	n	n	n	n	n	n
P	no ASA	685	1419	76	m	PM	311	333	1	5	n	y	n	n	y	n	n	n	60 mg	57,91	68	n	n	y	n	n	n	n
E	no ASA	685	1625	81	m	PM	412	640	1	2	n	n	n	n	n	n	n	n	60 mg	67,26	60	n	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	685	2027	76	f	PM	794	640	1	4	n	y	n	n	n	n	n	n	30 mg	53,72	60	y	n	y	n	n	n	n
P	no ASA	685	2177	77	f	PM	126	640	4	4	n	y	n	n	n	n	n	n	60 mg	84,75	60	n	n	y	n	n	n	n
P	ASA	687	358	72	m	PM-CRT	293	400	2	5	y	y	y, oa	n	n	y	n	n	60 mg	62,96	71	y	n	y	n	y	n	n
E	no ASA	687	691	76	f	PM	312	640	1	4	n	y	n	n	n	n	n	n	60 mg	56,23	60	y	n	y	n	n	n	n
P	no ASA	687	1157	74	f	PM	28	265	1	4	n	y	y, oa	n	n	n	n	n	60 mg	90,14	68	y	y	y	n	n	n	n
P	no ASA	687	1611	71	m	PM	40	394	1	3	y	y	n	n	n	n	n	n	60 mg	101,97	88	n	n	n	n	y	n	n
E	no ASA	687	1614	73	f	PM	45	327	1	6	n	y	n	y	n	n	n	n	60 mg	72,48	68	n	y	y	n	n	n	n
P	no ASA	687	2061	73	m	PM	230		2	3	y	y	n	n	n	n	n	n	60 mg	71,82	60	n	n	y	n	n	n	n
P	no ASA	687	2355	77	m	PM	299		2	5	y	y	n	n	n	y	n	n	60 mg	72,25	60	y	n	y	n	n	n	n
E	ASA	688	112	73	m	ICD	3011	640	4	3	y	y	n	n	n	n	n	n	60 mg	73,33	68	y	n	y	n	n	n	n
P	ASA	688	123	78	m	ICD	2880	405	1	5	y	y	n	n	n	y	y	n	30 mg	37,78	60	y	n	y	n	n	n	n
P	no ASA	688	127	81	f	PM	2901	400	4	5	n	y	y, oa	n	n	n	n	n	30 mg	36,58	79	y	y	n	n	n	n	n
E	no ASA	688	183	76	m	PM-CRT	484	545	2	4	y	y	n	n	n	n	n	n	60 mg	66,82	57	y	n	y	n	n	n	n
E	ASA	688	210	70	f	ICD-CRT	23	640	3	3	y	n	n	n	n	n	n	n	30 mg	44,32	60	y	y	y	n	n	n	n
E	no ASA	688	231	82	m	PM	78	400	1	3	n	y	n	n	n	n	n	n	60 mg	72,5	80	n	n	y	n	n	n	n
E	no ASA	688	550	78	m	ICD	2880	280	2	4	y	y	n	n	n	n	n	n	60 mg	82,75	60	y	n	y	n	n	n	n
P	no ASA	688	628	76	m	PM	343	400	3	3	n	y	n	n	n	n	n	n	60 mg	76,19	78	y	y	y	n	n	n	n
P	no ASA	688	640	77	f	ICD	83	400	2	4	n	y	n	n	n	n	n	n	60 mg	60,47	57	n	n	y	n	n	n	n
P	ASA	688	728	72	m	PM	169	319	15	5	n	y	y, oa	y	n	n	n	n	60 mg	69,55	62	y	y	n	n	n	n	n
P	no ASA	688	842	82	m	PM	394	260	4	4	n	y	n	n	n	n	n	n	60 mg	64,01	61	n	n	n	n	n	n	n
E	ASA	688	865	68	m	PM	584	331	3	4	n	y	y, oa	n	n	n	n	n	60 mg	116,67	67	n	y	y	n	n	n	n
E	ASA	688	983	77	m	PM	112	500	3	3	n	y	n	n	n	n	n	n	60 mg	66,88	62	n	n	y	n	n	n	n
P	ASA	688	1209	65	m	ICD-CRT	252	545	1	7	y	y	y, it	y	n	y	n	y	60 mg	98,48	70	y	n	y	n	n	n	n
P	ASA	688	1312	65	f	ICD	10	400	1	4	n	y	n	n	n	n	y	n	60 mg	84,58	61	y	n	y	n	n	n	n
E	ASA	688	1373	83	m	ICD	153	400	2	7	y	y	n	y	n	n	y	n	30 mg	44,69	77	y	n	y	n	n	n	n
P	ASA	688	1447	76	f	ICD	171	400	1	5	n	y	n	n	n	n	n	n	30 mg	37,54	84	n	y	y	n	n	n	n
P	ASA	688	1601	79	f	ICD	491	640	7	5	n	y	n	n	n	n	n	n	60 mg	70,51	65	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	688	1833	72	m	ICD	554	353	3	3	n	y	n	n	n	n	n	n	60 mg	92,28	96	n	y	y	n	n	n	n
E	no ASA	688	1877	73	m	PM	565	400	4	2	n	y	n	n	n	n	n	n	60 mg	64,18	85	n	n	y	n	n	n	n
E	ASA	688	1975	69	m	ICD	139	400	1	3	n	y	n	n	n	y	y	n	60 mg	159,62	87	y	n	y	n	n	n	n
P	ASA	688	2165	83	m	ICD	265		3	4	n	y	y, oa	n	n	n	n	n	60 mg	55,86	79	y	n	y	n	n	n	n
E	ASA	688	2179	79	m	ICD	2052	400	1	3	n	y	n	n	n	n	n	y	60 mg	59,44	82	y	y	y	n	n	n	n
P	ASA	688	2252	77	m	ICD	811	225	5	4	n	y	n	n	n	y	y	n	60 mg	59,5	66	y	n	y	n	n	n	n
P	ASA	688	2281	80	f	PM	2894	640	1	4	n	y	n	n	n	n	n	n	30 mg	39,46	60	y	y	y	n	n	n	n
E	no ASA	688	2363	72	m	ICD	530	400	4	2	n	y	n	n	n	n	n	n	60 mg	81,85	54	n	n	y	n	n	n	n
E	ASA	688	2677	80	m	PM	1128		2	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	104,71	67	y	n	y	n	n	n	n
E	ASA	689	578	75	m	PM	39	273	1	5	n	y	y, oa	n	n	n	n	n	60 mg	77,72	68	n	n	y	n	n	n	n
P	no ASA	689	726	71	f	PM	180	300	2	4	n	y	n	n	n	n	n	n	60 mg	81,46	65	n	n	y	n	n	n	n
P	ASA	689	906	79	m	PM	123		2	4	n	y	n	n	n	y	n	y	60 mg	51,09	60	y	n	y	n	n	n	n
P	no ASA	689	990	84	f	PM				4	n	y	n	n	n	n	n	n	60 mg	95,49	60	n	y	y	n	n	n	n
P	no ASA	690	232	79	m	PM	981	308	1	2	n	n	n	n	n	n	n	n	60 mg	70,6	69	n	n	n	n	n	n	n
E	no ASA	690	1989	83	f	PM-CRT	236		2	3	n	n	n	n	n	n	n	n	60 mg	56,41	67	y	n	n	n	n	n	n
E	no ASA	690	2190	75	f	PM	88		12	4	n	y	n	n	n	n	n	n	60 mg	87,9	65	y	y	y	n	n	n	n
P	no ASA	690	2419	77	m	PM	175	640	2	2	n	n	n	n	n	n	n	n	60 mg	71,76	67	n	n	n	n	n	n	n
E	no ASA	690	2428	79	f	PM	53		1	5	y	y	n	n	n	n	n	n	60 mg	52,46	73	y	n	y	n	n	n	n
E	ASA	692	1229	67	m	PM	1538	400	7	4	y	n	y, it	n	n	n	n	n	60 mg	82,12	91	y	n	y	n	n	n	n
E	no ASA	693	1453	78	m	ICD	7	320	1	5	y	y	y, it	n	n	n	n	n	60 mg	56,01	65	y	n	y	n	n	n	n
P	no ASA	693	1454	73	m	PM	966	400	6	2	n	y	n	n	n	n	n	n	60 mg	76,14	84	n	n	n	n	n	n	n
P	no ASA	693	1461	83	m	PM	303	600	3	3	n	y	n	n	n	n	n	n	60 mg	87,96	65	y	n	y	n	n	n	n
E	no ASA	693	1518	80	f	PM	269	400	7	4	n	y	n	n	n	n	n	n	60 mg	70,83	73	n	n	y	n	n	n	n
P	no ASA	693	1519	72	m	ICD	47		4	3	y	y	n	n	n	n	n	n	60 mg	101,33	60	n	n	y	y	n	n	n
E	no ASA	693	1559	75	f	PM	142	400	2	4	n	y	n	n	n	n	n	n	60 mg	71,25	60	n	n	n	n	n	n	n
P	ASA	693	2282	83	m	PM	111	400	7	5	y	y	n	n	n	y	y	n	60 mg	55,09	81	y	n	y	n	n	n	n
E	ASA	697	428	80	f	PM	158	550	2	6	n	y	n	n	y	n	n	n	60 mg	55,57	59	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	698	162	74	m	ICD	166	426	1	3	y	y	n	n	n	n	n	n	60 mg	69,21	101	y	n	y	n	n	n	n
E	no ASA	698	193	78	f	ICD-CRT	174	640	2	5	y	y	n	n	n	n	n	n	60 mg	51,01	67	y	n	y	n	n	n	n
E	ASA	698	219	85	f	PM	16	460	1	5	n	y	y, oa	n	n	n	n	n	60 mg	76,06	68	y	n	y	n	n	n	n
E	ASA	698	226	73	m	PM	104	272	3	5	y	y	y, oa	n	n	y	y	n	60 mg	60,49	80	y	n	y	n	n	n	n
E	ASA	698	303	74	m	ICD-CRT	2583	640	14	4	y	y	y, it	n	n	n	n	n	60 mg	50,93	66	y	y	y	n	n	n	n
P	ASA	698	475	75	m	PM	51	366	1	3	n	y	n	n	n	n	n	n	60 mg	77,33	74	n	n	y	n	n	n	n
P	ASA	698	621	79	m	PM	275	264	1	3	n	y	n	n	n	n	n	n	60 mg	76,25	60	n	y	y	n	n	n	n
P	ASA	698	1123	65	m	ICD	404	295	1	4	y	y	n	n	n	y	y	n	60 mg	87,83	67	y	n	y	n	n	n	n
P	no ASA	698	1176	81	m	PM	276	300	4	2	n	n	n	n	n	n	n	n	60 mg	64,44	98	y	n	n	n	n	n	n
E	ASA	698	1494	80	m	PM	240		7	4	y	y	n	n	n	n	n	n	60 mg	52,15	60	n	n	y	n	n	n	n
E	no ASA	700	1018	78	m	PM	7	282	3	3	n	y	n	n	n	n	n	n	60 mg	69,03	61	n	y	n	n	n	n	n
P	ASA	700	1310	74	m	PM	24	192	1	2	n	n	n	n	n	y	y	n	60 mg	85,71	69	n	n	n	n	n	n	n
P	ASA	700	2483	72	m	PM	2880		6	4	n	y	y, it	n	n	y	y	n	60 mg	78,3	55	y	y	y	n	n	n	n
E	no ASA	702	158	84	m	PM	1340	430	10	3	n	y	n	n	n	n	n	n	30 mg	34,98	59	n	n	y	n	n	n	n
E	no ASA	702	174	87	m	PM	135	640	1	3	n	y	n	n	n	n	n	n	60 mg	54,17	55	y	n	n	y	n	n	n
P	no ASA	702	289	77	m	PM	25	640	1	3	n	y	n	n	n	n	n	n	60 mg	108,33	60	y	n	n	n	n	n	n
E	ASA	702	444	86	m	PM	323	640	1	4	n	y	y, oa	n	n	n	n	n	60 mg	56,09	60	y	y	y	n	n	n	n
P	ASA	702	950	82	m	PM-CRT	72	640	1	4	n	y	y, it	n	n	n	n	n	60 mg	75,8	61	y	n	y	n	n	n	n
P	no ASA	702	1031	66	m	PM	313	400	1	3	n	y	y, oa	n	n	n	n	n	60 mg	93,28	72	y	n	n	n	n	n	n
P	ASA	702	1296	86	m	PM	17	313	1	6	y	y	y, it	n	n	y	y	n	30 mg	49,32	60	y	n	n	n	n	n	n
E	ASA	702	1381	79	f	ICD	1328	640	1	6	n	y	n	y	n	n	n	n	60 mg	65,98	64	y	y	y	n	n	n	n
E	ASA	704	612	74	m	PM	803	400	6	5	y	y	y, oa	n	n	y	y	n	60 mg	68,91	70	y	n	n	n	n	n	n
P	ASA	704	635	89	f	PM	246	400	13	5	n	y	n	n	n	n	n	n	60 mg	54,81	60	y	y	y	n	n	n	n
E	ASA	704	649	74	m	ICD	15	640	1	4	y	y	n	n	n	y	y	n	60 mg	106,63	70	y	n	n	n	n	n	n
P	ASA	704	761	79	m	ICD	1128	545	11	6	y	n	n	y	n	n	n	n	60 mg	69,39		y	n	y	n	n	n	n
P	no ASA	704	1528	70	m	ICD-CRT	578	462	1	3	y	y	n	n	n	n	n	n	60 mg	95,83		y	n	y	n	n	n	n
P	ASA	705	1412	71	m	ICD-CRT	166	300	1	4	y	y	n	n	n	y	y	n	30 mg	44,49		y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	705	1416	79	m	PM	5760	600	2	3	n	y	n	n	n	n	n	n	60 mg	71,01	75	y	n	y	n	n	n	n
E	ASA	705	1479	74	m	PM-CRT	258	640	1	2	n	n	n	n	n	y	n	y	60 mg	60,13	65	n	n	y	n	n	n	n
E	ASA	705	1509	68	f	PM	593		2	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	112,08	71	y	y	y	n	n	n	n
E	no ASA	705	1621	75	f	PM	88	400	1	4	n	y	n	n	n	n	n	n	60 mg	65,13	79	n	n	y	n	n	n	n
P	no ASA	705	1647	78	m	PM				3	n	y	n	n	n	n	n	n	60 mg	65,98	60	y	y	y	n	n	n	n
		705	1677	83	m		190		7	3									60 mg	52,63								
P	ASA	705	1682	83	m	PM	127	429	1	4	n	y	n	n	n	y	n	y	60 mg	56,99	87	y	n	y	n	n	n	n
P	no ASA	705	1748	75	m	PM	236		4	3	n	y	n	n	n	n	n	n	60 mg	62,9	55	n	y	n	n	n	n	n
P	ASA	705	1773	75	m	ICD-CRT	27		3	4	y	n	n	n	n	y	y	n	60 mg	70,37	65	y	n	n	n	n	n	n
P	ASA	705	1860	86	m	PM	586		4	3	n	y	n	n	n	n	n	y	30 mg	26,23		y	n	n	n	n	n	n
P	ASA	705	1881	78	m	PM	4454	260	589	6	y	y	y, oa	n	n	y	n	y	30 mg	45,26	60	y	n	y	n	n	n	n
E	ASA	705	1908	75	f	PM	309		1	5	n	y	n	n	n	n	n	n	30 mg	45,61	83	n	n	y	n	n	n	n
E	no ASA	705	2133	75	m	PM	645		1	3	n	y	n	n	n	n	n	n	60 mg	87,89	87	n	n	y	n	n	n	n
P	ASA	705	2134	76	f	ICD-CRT	10		2	7	y	y	y, oa	n	n	y	n	y	60 mg	69,08	85	y	n	y	n	n	n	n
E	ASA	705	2137	70	f	PM				3	n	y	n	n	n	n	n	n	60 mg	132,61	66	y	n	y	n	n	n	n
E	no ASA	705	2153	66	f	PM	14	214	1	3	n	y	n	n	n	n	n	n	30 mg	83,2	101	n	n	y	n	n	n	n
P	ASA	705	2157	67	m	PM	49		3	4	y	y	n	n	n	n	n	n	60 mg	80,7	60	n	n	y	n	n	n	n
E	ASA	705	2158	88	f	ICM				7	y	y	n	y	n	n	n	n	30 mg	38,7	65	n	n	y	n	n	n	n
E	ASA	705	2272	70	m	ICD				4	y	y	n	n	n	n	n	n	60 mg	74,92	52	y	n	y	n	n	n	n
P	no ASA	705	2291	97	f	PM	67		2	4	n	y	n	n	n	n	n	n	30 mg	27,25	65	n	n	y	n	n	n	n
E	ASA	705	2367	69	m	PM	322		2	3	n	y	n	n	n	n	y	n	60 mg	90,13	75	y	n	y	n	n	n	n
E	ASA	705	2383	78	m	ICD-CRT				5	y	y	n	n	n	n	n	n	60 mg	78,36	62	y	n	y	n	n	n	n
P	ASA	705	2390	85	f	PM	101		3	5	n	y	n	n	n	n	n	n	60 mg	64,93	73	n	n	y	n	n	n	n
E	ASA	705	2395	81	f	PM				7	n	y	n	y	y	n	n	y	30 mg	34,24	93	n	y	n	n	n	n	n
P	ASA	705	2396	74	m	PM	7		1	4	y	y	n	n	n	n	n	n	60 mg	58,76	67	n	n	y	n	n	n	n
E	ASA	705	2431	71	m	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	122,78	67	y	y	y	n	n	n	n
P	ASA	705	2432	76	m					4									30 mg	43,98		n	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	705	2437	88	f	PM				7	y	y	y, oa	n	n	y	y	n	30 mg	38,03	88	y	n	y	n	n	n	n
P	ASA	705	2556	75	m	PM	112		1	4	n	y	n	n	n	y	n	n	60 mg	67,88	68	n	n	y	n	n	n	n
P	ASA	705	2579	68	m	ICM	184		3	5	n	y	n	y	n	n	n	n	60 mg	80,5	57	n	n	y	n	n	n	n
P	no ASA	705	2731	85	f	PM	281	549	45	5	y	y	n	n	n	n	n	n	30 mg	25,9	62	n	n	y	n	n	n	n
E	ASA	705	2740	78	m	PM	11		2	4	n	y	n	n	n	n	y	n	60 mg	83,71	80	y	y	y	n	n	n	n
P	ASA	705	2742	72	m	PM	184		11	5	n	y	n	n	y	n	n	n	60 mg	126,67	68	y	n	y	n	n	n	n
E	no ASA	706	208	71	m	PM	146	591	3	4	n	y	n	n	y	n	n	n	60 mg	74,48	87	n	n	y	n	n	n	n
E	no ASA	706	248	78	m	PM	557		10	2	n	n	n	n	n	n	n	n	60 mg	83,84	68	n	n	n	n	n	n	n
E	ASA	706	278	84	f	PM	60	300	5	5	n	y	y, oa	n	n	n	n	n	30 mg	36,66	69	y	y	y	n	n	n	n
P	no ASA	706	282	94	m	PM	1440		18	3	n	n	n	n	n	n	n	n	30 mg	44,03		n	n	n	n	n	n	n
E	ASA	706	557	77	m	PM	59	591	1	3	n	n	n	n	n	y	n	y	60 mg	86,32	66	n	n	y	n	n	n	n
P	ASA	706	654	82	m	PM	912	591	2	2	n	n	n	n	n	n	n	n	60 mg	54,97	60	y	n	n	n	n	n	n
E	ASA	706	689	82	m	PM	60	614	22	3	n	y	n	n	n	n	n	n	60 mg	66,61	60	y	n	n	n	n	n	n
E	ASA	707	437	74	m	ICD	20	429	1	2	n	y	n	n	n	n	n	n	60 mg	76,02	81	y	y	y	n	n	n	n
P	ASA	707	480	80	m	PM	12	214	1	3	n	y	n	n	n	n	n	n	60 mg	68,57	104	n	n	y	n	n	n	n
E	no ASA	707	496	81	f	PM	319	545	2	4	n	y	n	n	n	n	n	n	60 mg	61,14	74	n	n	y	n	n	n	n
E	no ASA	707	522	79	f	PM	230	429	4	4	n	y	n	n	n	n	n	n	30 mg	34,06	69	y	n	y	n	n	n	n
P	ASA	707	1214	76	f	PM	357		1	6	n	y	y, it	n	n	n	y	y	60 mg	59,26	60	y	y	y	n	n	n	n
E	ASA	707	1226	79	m	ICD	90	545	12	7	y	y	n	y	n	y	y	y	30 mg	34,49	81	y	n	y	n	n	n	n
P	no ASA	707	1820	80	m	PM	40		6	3	n	y	n	n	n	n	n	n	60 mg	83,33	72	n	n	y	n	n	n	n
E	no ASA	707	1873	73	m	PM	1515	462	12	2	y	n	n	n	n	n	n	n	60 mg	111,03	77	n	n	n	n	n	n	n
E	no ASA	708	374	92	f	PM				5	n	y	y, oa	n	n	n	n	n	60 mg	58,29	75	n	n	y	n	n	n	n
E	no ASA	708	492	89	f	PM	47	400	2	6	y	y	n	n	n	y	n	n	30 mg	45,01	80	n	n	n	n	n	n	n
P	ASA	708	512	75	f	PM	15		1	6	y	y	y, oa	n	n	n	n	n	60 mg	103,62	70	n	n	y	n	n	n	n
E	ASA	708	525	85	f	PM	667		3	6	y	y	n	n	n	y	n	n	30 mg	28,98	60	y	n	y	n	n	n	n
P	ASA	711	360	78	f	ICD	14	300	1	7	y	y	y, it	n	n	y	n	n	30 mg	47,17	70	y	n	y	n	n	n	n
E	ASA	711	383	72	m	PM	427	500	3	3	n	y	n	n	n	y	y	n	60 mg	78,53	60	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	711	439	73	f	PM	391	640	1	4	n	y	y, it	n	n	n	n	n	60 mg	73,82	75	y	y	y	n	n	n	n
P	ASA	711	443	70	m	ICD	660		4	3	n	n	y, oa	n	n	n	n	n	60 mg	89,84	60	y	n	y	n	n	n	n
E	no ASA	711	518	86	m	PM	510	240	2	3	n	y	n	n	n	n	n	n	60 mg	65,43	60	n	y	y	n	n	n	n
E	no ASA	711	611	84	m	PM	8	273	1	3	n	y	n	n	n	n	n	n	30 mg	39,27	70	y	y	y	n	n	n	n
P	ASA	711	873	83	m	PM	1440	600	2	3	n	y	n	n	n	n	n	n	60 mg	59,84	60	n	n	y	n	n	n	n
E	ASA	711	1252	72	m	PM	18	400	2	2	n	y	n	n	n	n	n	n	60 mg	85,86	98	y	y	y	n	n	n	n
P	no ASA	711	1253	76	m	PM	863	300	8	4	n	y	y, it	n	n	n	n	n	60 mg	112,5	60	y	n	y	n	n	n	n
E	ASA	711	1458	75	m	PM	10	300	1	4	n	y	n	n	n	n	y	y	60 mg	90,28	60	n	n	n	n	n	n	n
P	ASA	713	2373	84	f	PM	455		7	6	n	y	n	y	n	n	n	n	30 mg	46,21	80	n	y	n	n	n	n	n
E	no ASA	718	1013	80	f	PM	16	640	3	3	n	n	n	n	n	n	n	n	60 mg	65,35	66	n	n	n	n	n	n	n
P	ASA	720	2630	79	m	PM	7	210	1	5	n	y	y, it	n	n	y	y	n	30 mg	29,92	74	y	n	n	n	n	n	n
E	no ASA	720	2682	80	m	ICD-CRT	24	173	2	3	n	n	y, oa	n	n	n	n	n	60 mg	55,6	70	n	n	n	n	n	n	n
P	ASA	720	2726	80	f	PM	22	200	1	4	n	y	n	n	n	n	n	n	60 mg	54,01	77	n	n	y	n	n	n	n
P	ASA	724	1039	79	f	PM	16	219	2	7	n	y	y, oa	n	y	n	n	n	30 mg	48,21	70	y	y	y	n	n	n	n
E	ASA	724	1040	86	f	PM				6	n	y	n	n	y	n	n	n	60 mg	53,27	65	n	n	y	n	n	n	n
P	ASA	724	1061	69	f	PM	201	400	2	6	n	y	n	n	y	y	n	n	60 mg	56,85	65	y	n	n	n	n	n	n
E	ASA	724	1076	77	m	PM	3724	400	2	5	n	y	y, oa	n	n	y	y	n	30 mg	49,77	35	y	y	n	n	n	n	n
		724	1258	73	m					3																		
E	no ASA	724	1286	72	m	PM	455		3	2	y	n	n	n	n	n	n	n	60 mg	65,04	60	y	n	y	n	n	n	n
P	ASA	724	1452	69	m	PM	120	375	1	3	y	n	n	n	n	n	n	n	60 mg	106,93	60	y	n	y	n	n	n	n
E	ASA	725	782	85	m	PM	89	429	2	5	y	y	y, oa	n	n	n	y	n	30 mg	50	75	y	n	y	n	n	n	n
P	ASA	725	796	85	m	PM	163	591	1	3	n	y	n	n	n	n	y	n	60 mg	52,62	60	y	n	y	n	n	n	n
E	ASA	725	822	68	m	ICD	18	316	1	3	n	y	n	n	n	n	n	n	60 mg	104,17	102	n	y	y	n	n	n	n
E	ASA	725	1009	81	m	PM	524	375	1	4	n	y	n	n	n	n	n	n	60 mg	62,82	51	n	y	y	n	n	n	n
P	ASA	725	1042	78	m	PM	72	640	1	3	n	y	n	n	n	n	n	n	60 mg	74,24		n	n	y	n	n	n	n
		725	1107	67	m					3																		
P	no ASA	725	1154	79	m	PM	527	640	1	3	n	y	n	n	n	n	n	n	60 mg	69,7	64	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	725	1194	83	m	PM	90		1	3	n	y	n	n	n	n	n	n	60 mg	75,3	61	n	n	y	n	n	n	n
P	ASA	725	1203	71	m	PM	17	380	1	4	y	y	y, oa	n	n	n	n	n	60 mg	107,81	119	y	n	y	n	n	n	n
E	no ASA	725	1223	88	m	PM	25		1	3	n	y	n	n	n	n	n	n	60 mg	65,5	72	n	y	y	n	n	n	n
P	ASA	725	1239	82	m	PM	120	380	15	5	n	y	y, oa	n	n	n	n	n	60 mg	88,7	53	n	n	y	n	n	n	n
E	no ASA	725	1326	86	f	PM	12	185	1	4	n	y	n	n	n	n	n	n	30 mg	41,58	67	n	n	y	n	n	n	n
E	ASA	725	1329	69	m	ICD	225	614	2	5	y	y	y, oa	n	n	y	y	n	60 mg	83,68	64	y	n	y	n	n	n	n
P	ASA	725	1392	89	m	PM	5084	380	30	5	y	y	n	n	n	y	y	n	60 mg	63,48	60	n	n	y	n	n	n	n
P	no ASA	725	1442	75	m	PM	181	190	1	2	n	n	n	n	n	n	n	n	60 mg	68,13	58	n	n	n	n	n	n	n
E	ASA	725	1470	76	m	PM	27	640	1	6	y	y	y, oa	n	n	n	y	n	30 mg	48,13	55	y	n	n	n	n	n	n
E	ASA	725	1524	81	m	PM	60	214	3	5	n	y	n	n	n	y	y	n	60 mg	63,44	55	n	n	y	n	n	n	n
P	no ASA	725	1525	75	f	PM			2	4	n	y	n	n	n	n	n	n	60 mg	72,72	77	n	n	y	n	n	n	n
E	ASA	725	1619	72	m	PM	28	640	1	3	n	y	n	n	n	y	y	n	60 mg	77,37	64	n	n	y	n	n	n	n
E	no ASA	725	1620	73	m	PM	782		2	2	n	y	n	n	n	n	n	n	60 mg	66,86	50	n	n	y	y	n	n	n
P	ASA	725	1631	75	m	PM	2255		4	4	n	y	n	n	n	y	y	n	60 mg	61,93	60	n	y	y	n	n	n	n
P	ASA	725	1639	73	m	PM	32		1	4	y	n	y, it	n	n	y	y	n	30 mg	42,56	63	y	n	y	n	n	n	n
E	no ASA	725	1644	69	m	PM	9		1	2	n	y	n	n	n	n	n	n	60 mg	60,76	53	n	n	n	n	n	n	n
E	ASA	725	1742	82	f	PM	22		1	5	n	y	n	n	n	y	n	n	30 mg	38,85	66	y	y	y	n	n	n	n
E	no ASA	725	1839	77	m	PM	691	640	1	6	n	y	y, it	y	n	n	n	y	60 mg	62,36	66	n	y	y	n	n	n	n
P	ASA	725	1869	71	m	PM	303		15	4	y	y	n	n	n	y	y	n	60 mg	74,37	64	y	n	y	n	n	n	n
P	ASA	725	1894	74	m	PM	26		2	2	n	y	n	n	n	n	n	y	60 mg	77,19	74	n	y	y	n	n	n	n
E	ASA	725	1946	72	m	PM	116		34	3	n	y	y, it	n	n	n	n	n	60 mg	93,85	99	y	y	y	n	n	n	n
P	ASA	725	1947	84	m	PM	3150	313	30	3	n	y	n	n	n	n	n	n	30 mg	35,29	70	y	n	y	n	n	n	n
E	ASA	725	1954	84	m	PM	67		1	3	n	y	n	n	n	n	n	n	60 mg	61,43	60	n	n	n	n	n	n	n
E	ASA	725	2030	83	f	PM	81	640	2	6	n	y	y, oa	n	n	y	y	n	60 mg	71,36	73	n	y	n	n	n	n	n
P	ASA	725	2038	77	m	PM-CRT	1033	545	1	6	y	y	y, oa	n	n	n	y	n	30 mg	43,29	70	y	n	y	n	n	n	n
E	ASA	725	2040	81	m	PM	137	380	7	3	n	y	n	n	n	n	n	n	30 mg	46,12	90	n	n	y	n	n	n	n
P	ASA	725	2041	82	m	ICD	293		1	5	y	y	n	n	n	y	y	y	30 mg	33,88	65	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	725	2102	77	f	PM	1347	400	4	4	n	y	n	n	n	n	n	n	30 mg	49,83	79	n	y	y	n	n	n	n
E	ASA	725	2105	69	m	PM	16		1	4	y	n	y, oa	n	n	y	y	n	60 mg	54,35	74	y	n	y	n	n	n	n
P	ASA	725	2197	95	m	PM	2544		1	4	n	y	n	n	n	y	y	y	30 mg	50	70	y	y	y	n	n	n	n
P	no ASA	725	2277	83	m	PM	104		1	4	y	y	n	n	n	n	n	n	60 mg	60,24	72	n	n	y	n	n	n	n
E	ASA	725	2353	86	m	PM	392	545	1	4	n	y	n	n	n	y	y	n	30 mg	42,86	60	y	n	y	n	n	n	n
P	ASA	725	2371	77	m	PM	338		1	4	n	y	n	n	n	n	n	n	60 mg	58,06	60	n	n	n	n	n	n	n
E	ASA	725	2462	73	m	PM	48	247	3	3	n	y	n	n	n	y	y	n	60 mg	73,17	65	y	n	y	n	n	n	n
P	ASA	725	2474	77	m	PM	286	240	6	4	y	n	n	n	n	y	y	n	60 mg	54,49	70	y	n	y	n	n	n	n
E	ASA	725	2492	86	f	PM	57		1	3	n	n	n	n	n	n	n	n	30 mg	49,76	65	n	n	n	n	n	n	n
E	ASA	725	2494	70	m	ICD	181		1	7	y	y	y, it	y	n	y	y	y	60 mg	55,24	45	y	n	y	n	n	n	n
E	no ASA	725	2549	81	f	PM	60	452	2	3	n	n	n	n	n	n	n	n	60 mg	60,67	82	n	n	n	n	n	n	n
E	no ASA	725	2600	83	f	PM				4	n	y	n	n	n	n	n	n	30 mg	36,36	73	n	n	n	n	n	n	n
E	ASA	725	2602	84	m	PM	28	640	1	4	n	y	y, oa	n	n	n	n	n	30 mg	21,91	60	y	y	n	n	n	n	n
P	ASA	725	2610	95	m	PM	25	201	2	5	n	y	y, oa	n	n	y	n	n	60 mg	61,79	78	n	y	n	n	n	n	n
P	ASA	725	2642	69	m	ICD	1298		1	4	y	y	n	n	n	y	y	n	30 mg	42,01	65	y	y	y	n	n	n	n
P	ASA	725	2668	79	f	PM	228		1	5	n	y	y, oa	n	n	n	n	n	60 mg	59,74	60	n	y	y	n	n	n	n
P	ASA	725	2703	75	m	PM	89		1	4	n	y	n	n	n	n	n	y	60 mg	52,99	55	n	y	y	n	n	n	n
E	ASA	725	2704	82	f	PM	384		2	5	n	y	n	n	n	y	n	n	30 mg	49,8	50	y	n	y	n	n	n	n
E	no ASA	725	2710	86	f	PM	992	400	3	4	n	y	n	n	n	n	n	n	30 mg	16,84	50	y	y	n	n	n	n	n
		725	2748	77	f		31	300	4	4																		
E	no ASA	728	387	81	m	PM	113	250	3	2	n	n	n	n	n	n	n	n	60 mg	98,91	60	y	n	n	n	n	n	n
E	no ASA	728	452	77	m	PM	23	218	1	2	n	n	n	n	n	n	n	n	60 mg	79,31	75	n	n	n	n	n	n	n
E	ASA	728	577	85	m	PM	4586	591	1	3	n	y	n	n	n	n	n	n	30 mg	43,82	61	y	n	y	n	n	n	n
E	no ASA	728	883	72	f	PM	29	400	3	3	n	y	n	n	n	n	n	n	60 mg	72,1		n	n	y	n	n	n	n
P	no ASA	728	1124	75	m	PM	256	569	16	4	n	y	y, oa	n	n	n	n	n	60 mg	78,12	72	n	n	y	n	n	n	n
P	ASA	728	1166	87	f	PM	136	400	5	4	n	y	n	n	n	n	n	n	30 mg	31,24	75	n	y	y	n	n	n	n
		728	1202	91	m		12	400	3	5									30 mg	29								

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	730	1560	89	f	PM	32	375	6	3	n	n	n	n	n	n	n	n	30 mg	46,17	88	n	n	n	n	n	n	n
P	no ASA	730	2399	75	m	PM	109	400	1	5	n	y	n	n	y	n	n	n	60 mg	103,07	53	n	y	y	n	n	n	n
P	ASA	735	799	72	m	PM				3	n	y	y, it	n	n	n	n	n	60 mg	82,93	61	n	y	n	n	n	n	n
E	ASA	740	431	88	m	ICD	151	550	1	5	y	y	n	n	n	y	n	y	30 mg	33,48	54	y	n	y	n	n	n	n
E	no ASA	740	753	78	m	PM	828	286	1	2	n	n	n	n	n	n	n	n	60 mg	75,68	85	n	n	n	n	n	n	n
E	no ASA	740	866	79	f	PM	141	545	8	4	n	y	n	n	n	n	n	n	60 mg	61,08		n	n	y	n	n	n	n
P	ASA	740	925	86	m	PM	181	400	3	5	y	y	n	n	n	n	n	n	30 mg	35,55	64	y	n	y	n	n	n	n
E	ASA	740	1058	79	f	PM	190	521	1	5	n	y	y, oa	n	n	n	n	n	60 mg	79,8	91	n	n	y	n	n	n	n
P	no ASA	740	1222	67	f	PM	52	500	1	3	n	y	n	n	n	n	n	n	60 mg	105,61	86	n	n	n	n	n	n	n
P	ASA	740	1886	78	f	ICD	6000		1	5	n	n	n	n	y	n	n	n	30 mg	39,64		n	n	n	n	n	n	n
E	ASA	740	2436	68	m	PM	50	545	7	4	n	n	y, oa	n	y	n	n	n	60 mg	147,22	82	n	n	n	n	n	n	n
E	no ASA	741	368	84	m	PM	30	300	3	3	n	y	n	n	n	n	n	n	60 mg	58,63	85	n	n	y	n	n	n	n
E	no ASA	741	415	83	f	PM	102	591	1	5	n	y	y, oa	n	n	n	n	n	30 mg	40,57	60	n	y	y	n	n	n	n
P	no ASA	741	421	74	f	PM	408	429	3	3	n	y	n	n	n	n	n	n	60 mg	95,64	71	n	n	n	n	n	n	n
E	no ASA	741	435	78	m	PM	9999	591	1	2	n	n	n	n	n	n	n	n	60 mg	72,21	80	n	n	n	n	n	n	n
P	no ASA	741	483	77	m	PM	320	640	12	2	n	n	n	n	n	n	n	n	60 mg	61,41	70	n	n	n	n	n	n	n
P	no ASA	741	484	84	m	PM	2880	300	11	3	n	y	n	n	n	n	n	n	60 mg	69,14	80	n	y	y	n	n	n	n
E	ASA	741	725	70	m	PM	145	591	1	4	n	y	n	y	n	n	y	n	60 mg	91,04	73	y	n	n	n	n	n	n
E	ASA	741	840	78	m	PM	9999	640	1	4	n	y	n	n	n	y	y	y	60 mg	94,15	67	n	y	y	n	n	n	n
P	ASA	741	921	75	m	PM	9	233	1	3	n	y	n	n	n	n	n	y	60 mg	70,8	46	n	n	y	n	n	n	n
P	no ASA	741	1051	69	m	PM	402	640	2	2	n	n	y, oa AND it	n	n	n	n	n	60 mg	106,11	71	n	n	n	n	n	n	n
E	no ASA	741	1095	83	f	PM-CRT	74	314	45	5	y	y	n	n	n	n	n	n	30 mg	58,88	74	n	n	y	n	n	n	n
E	no ASA	741	1118	81	m	ICM	430		29	3	n	y	n	n	n	n	n	n	60 mg	51,63	66	n	n	y	n	n	n	n
		741	1207	90	m					3									30 mg	44,03								
E	no ASA	741	1356	77	m	ICD	266	591	1	5	y	y	y, oa	n	n	n	n	n	30 mg	49,19		y	n	y	n	n	n	n
E	no ASA	741	1408	77	m	PM	536	640	1	3	n	y	n	n	n	n	n	n	60 mg	57,93	60	n	n	y	n	n	n	n
P	ASA	741	1737	67	m	ICM	154		3	2	n	n	n	n	n	y	y	n	60 mg	116,29	63	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	741	1790	87	m	PM	71	545	1	3	y	n	n	n	n	n	n	n	30 mg	40,71	67	n	n	n	n	n	n	n
P	no ASA	741	1825	80	m	PM	244	452	3	4	y	y	n	n	n	n	n	n	60 mg	74,29	60	n	n	n	n	n	n	n
P	no ASA	741	1836	79	m	PM	1230	640	4	3	n	y	n	n	n	n	n	n	60 mg	82,21	60	n	y	n	n	n	n	n
P	no ASA	741	1850	84	m	ICM	236		1	2	n	n	n	n	n	n	n	n	60 mg	87,24	58	n	n	n	n	n	n	n
E	ASA	741	1865	66	m	ICD-CRT	35	341	1	6	y	n	y, oa AND it	n	y	y	y	y	60 mg	96,04	68	y	n	y	n	n	n	n
E	no ASA	741	1909	79	m	ICM	172		10	2	n	n	n	n	n	n	n	n	60 mg	57,64	60	n	n	n	n	n	n	n
P	no ASA	741	2015	70	f	PM	2636	640	1	3	n	y	n	n	n	n	n	n	30 mg	41,68	60	y	n	y	n	n	n	n
P	ASA	741	2064	65	m	PM	137	640	8	2	n	y	n	n	n	n	n	n	60 mg	102,71	59	n	y	y	n	n	n	n
E	no ASA	741	2253	74	m	PM	3502	600	1	3	n	y	y, oa	n	n	n	n	n	60 mg	66,67	61	y	y	y	n	n	n	n
E	no ASA	741	2294	79	m	PM	777	614	1	3	n	y	n	n	n	n	n	n	60 mg	77,75	68	n	y	y	n	n	n	n
P	no ASA	741	2313	83	m	PM	811	600	4	3	n	y	n	n	n	n	n	n	60 mg	54,11	71	n	y	y	n	n	n	n
P	no ASA	741	2315	77	m	PM	321	614	68	4	n	n	n	n	y	n	n	n	30 mg	43,75	50	n	n	n	n	n	n	n
E	no ASA	741	2319	78	m	PM	2236	400	5	4	n	y	y, oa	n	n	n	n	n	30 mg	45,31	85	n	n	y	n	n	n	n
E	ASA	741	2368	79	m	ICM	2478		1	3	n	y	n	n	n	n	n	y	60 mg	86,6	66	n	y	y	n	n	n	n
E	ASA	741	2405	73	m	PM	108	353	8	3	n	y	n	n	n	y	y	n	60 mg	128,35	52	n	n	y	n	n	n	n
E	no ASA	741	2532	75	m	PM	240		1	3	n	y	n	n	n	n	n	n	60 mg	79,01	59	y	n	y	n	n	n	n
P	no ASA	741	2650	82	f	ICD	360		1	5	y	y	n	n	n	n	n	n	30 mg	33,65		y	n	y	n	n	n	n
P	ASA	741	2660	83	m	PM	655	480	2	4	n	y	y, oa	n	n	n	n	y	60 mg	64,98	74	y	y	y	n	n	n	n
P	ASA	741	2685	76	m	PM	731	640	1	4	n	y	y, oa	n	n	n	n	n	60 mg	80,78	69	y	y	y	n	n	n	n
		742	521	73	m					3									30 mg	43,92								
P	ASA	748	173	68	f	PM	104	280	4	4	n	y	n	n	n	n	n	n	60 mg	112,5	60	y	y	n	n	n	n	n
E	ASA	748	199	81	m	ICD	78	260	2	4	y	y	n	n	n	n	y	n	60 mg	94,62	71	y	y	n	n	n	n	n
E	ASA	748	281	72	m	PM-CRT	8	545	1	6	y	n	y, oa	y	n	n	y	n	60 mg	85,99	92	y	n	y	n	n	n	n
P	ASA	748	332	72	m	PM-CRT	11	462	1	3	y	y	n	n	n	n	n	n	60 mg	73,35	81	y	y	y	n	n	n	n
E	ASA	748	532	81	f	PM	18	245	1	6	n	y	y, it	n	n	y	n	y	60 mg	50,39	70	n	n	y	n	n	n	n
E	ASA	748	555	69	m	PM	400	400	5	5	y	y	y, oa	n	n	y	y	y	60 mg	63,34	60	y	n	y	n	n	n	n
P	ASA	748	558	71	f	ICD	334	545	3	4	y	y	n	n	n	n	n	n	60 mg	87,08	62	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	748	564	81	f	PM	51	400	1	3	n	n	n	n	n	n	n	n	60 mg	57,58	60	y	n	n	n	n	n	n
P	ASA	748	576	84	f	PM	102	600	1	4	n	y	n	n	n	n	n	n	30 mg	41,89	66	n	y	y	n	n	n	n
E	no ASA	748	596	73	m	PM	391	400	1	3	y	y	n	n	n	n	n	n	60 mg	101,92	62	y	n	n	n	n	n	n
P	ASA	748	604	82	f	PM	739	600	7	6	n	y	n	y	n	n	n	n	60 mg	61,17	68	y	n	n	n	n	n	n
E	ASA	748	610	83	m	ICD	153	545	7	4	n	y	n	n	n	y	y	y	60 mg	64,7	70	y	n	n	n	n	n	n
E	no ASA	748	641	88	m	PM	152	400	3	3	n	y	n	n	n	n	n	n	60 mg	50,27	70	y	n	y	n	n	n	n
		748	656	80	m					3																		
E	ASA	748	675	92	f	PM				5	n			n	n	n	n	n	30 mg	40,35		n	n	n	n	n	n	n
P	ASA	748	684	87	f	PM	108	273	1	4	n	y	n	n	n	n	n	n	30 mg	41,98	80	y	y	y	n	n	n	n
E	ASA	748	687	80	m	PM	160	600	4	4	n	y	n	n	n	n	y	n	60 mg	82,51	80	y	n	y	n	n	n	n
P	no ASA	748	824	78	f	PM	660	324	3	5	n	y	y, oa	n	n	n	n	n	60 mg	51,55	88	y	n	y	n	n	n	n
P	no ASA	748	852	86	f	PM	71	600	2	4	n	y	n	n	n	n	n	n	60 mg	68,65	77	y	n	y	n	n	n	n
E	ASA	748	928	84	f	PM	6		1	4	n	y	n	n	n	n	n	n	60 mg	51,94	65	n	y	y	n	n	n	n
P	ASA	748	957	87	m	PM	7	305	1	5	n	y	n	n	n	y	y	n	30 mg	44,83	75	y	n	y	n	n	n	n
E	ASA	748	992	77	m	PM	41	250	4	4	n	y	n	n	n	y	n	n	60 mg	122,92		y	y	y	n	n	n	n
P	no ASA	748	999	80	m	PM	27	400	5	3	n	y	n	n	n	n	n	n	60 mg	78,95	90	n	n	y	n	n	n	n
P	ASA	748	1026	91	f	PM	132	362	6	3	n	n	n	n	n	n	n	n	60 mg	64,83	72	y	y	n	n	n	n	n
P	ASA	748	1056	89	f	PM	606	400	2	4	n	y	n	n	n	n	n	n	30 mg	22,62	63	y	y	y	n	n	n	n
E	ASA	748	1074	76	m	PM	291	400	3	3	n	y	n	n	n	n	n	n	60 mg	66,67	60	y	n	y	n	n	n	n
E	ASA	748	1096	89	f	PM	97	300	1	5	n	y	n	n	n	n	n	n	30 mg	47,68	60	y	n	n	n	n	n	n
E	ASA	748	1130	76	m	PM	113	600	1	3	n	y	n	n	n	n	n	n	60 mg	80,57	50	n	y	n	n	n	n	n
P	ASA	748	1139	90	m	PM	5447	400	1	5	n	y	y, oa	n	n	n	y	n	60 mg	74,4	68	n	y	y	n	n	n	n
E	no ASA	748	1249	77	f	PM	602	400	1	5	y	y	n	n	n	n	n	n	30 mg	30,54	60	y	n	y	n	n	n	n
P	ASA	748	1251	92	m	PM	143	214	7	7	y	y	n	n	y	y	y	n	30 mg	28,14	60	y	n	n	n	n	n	n
P	ASA	748	1272	85	f	PM	5760	375	2	5	y	y	n	n	n	n	n	n	30 mg	40,58	100	y	n	y	n	n	n	n
P	ASA	748	1285	88	m	PM	1707	317	1	2	n	n	n	n	n	n	y	n	30 mg	19,41	85	n	n	n	n	n	n	n
E	no ASA	748	1301	96	f	PM	623	400	1	4	n	y	n	n	n	n	n	n	30 mg	27,69	85	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	748	1415	85	f	PM	40	300	1	4	n	y	n	n	n	n	n	n	60 mg	96,71	70	y	n	n	n	n	n	n
E	no ASA	748	1546	81	f	PM	7	380	1	5	n	y	y, oa AND it	n	n	n	n	n	30 mg	37,21	81	n	n	y	n	n	n	n
E	no ASA	748	1575	65	m	PM	203	400	1	2	n	y	n	n	n	n	n	n	60 mg	105,35	60	y	n	n	n	n	n	n
E	ASA	748	1591	80	f	PM	132	400	4	3	n	n	n	n	n	n	n	n	60 mg	75,18	63	n	n	n	n	n	n	n
P	ASA	748	1597	88	m	PM	216		3	4	n	y	n	n	n	n	n	n	30 mg	27,92	60	n	n	n	n	n	n	n
E	ASA	748	1646	84	m	ICD	9999	640	1	5	y	y	n	n	n	y	y	y	30 mg	37,67	68	y	n	y	n	n	n	n
P	ASA	748	1659	81	f	PM	59		3	4	n	y	n	n	n	n	n	n	60 mg	63,96	60	y	y	y	n	n	n	n
P	ASA	748	1674	89	f	PM	68		1	7	n	y	n	y	y	y	y	n	30 mg	28,28	60	y	n	y	n	y	n	n
P	ASA	748	1731	84	m	PM	300			3	n	y	n	n	n	n	y	n	60 mg	55,56	80	y	n	y	n	n	n	n
P	ASA	748	1757	87	m	PM	306	400	1	5	y	y	y, it	n	n	n	n	y	60 mg	66,56	82	y	n	y	n	n	n	n
E	ASA	748	1885	78	f	PM	14		1	4	n	y	n	n	n	n	n	n	30 mg	61,53	68	y	y	y	n	n	n	n
P	no ASA	748	1901	82	m	PM	6	175	1	3	n	y	n	n	n	n	n	n	60 mg	82,29	75	y	n	n	y	n	n	n
P	no ASA	748	1918	66	f	PM	172		1	3	n	y	n	n	n	n	n	n	60 mg	106,16	71	n	n	y	n	n	n	n
P	no ASA	748	1921	82	f	PM	63		1	4	n	n	n	n	n	n	n	n	30 mg	42,82	102	y	n	n	n	n	n	n
E	ASA	748	1966	84	m	PM	5760	400	1	4	n	y	y, oa	n	n	n	y	n	60 mg	65,94	73	y	y	y	n	n	n	n
E	no ASA	748	1982	72	f	ICD-CRT	4738		3	4	y	y	n	n	n	n	n	n	60 mg	63,66	60	y	n	y	n	n	n	n
E	ASA	748	2039	79	f	ICD	268		1	5	y	y	n	n	n	n	n	n	60 mg	50,08	65	y	n	y	n	n	n	n
E	ASA	748	2049	73	m	PM	90		3	2	n	y	n	n	n	n	n	n	60 mg	83,61	64	y	n	y	n	n	n	n
P	ASA	748	2071	84	m	PM	338		3	5	n	y	n	n	y	n	n	n	60 mg	61,11	83	n	n	y	n	n	n	n
P	no ASA	748	2079	83	f	PM	12		1	4	n	y	n	n	n	n	n	n	60 mg	63,12	60	n	n	y	n	n	n	n
E	ASA	748	2136	81	m	PM	462		1	3	n	y	n	n	n	n	y	y	60 mg	82,52	69	y	y	y	n	n	n	n
P	ASA	748	2181	84	f	PM	598		2	5	n	y	n	n	n	n	n	n	30 mg	42,34	90	y	y	y	n	n	n	n
P	ASA	748	2186	82	m	PM	262		3	3	n	y	n	n	n	n	n	n	60 mg	63,79	70	y	y	y	n	n	n	n
E	ASA	748	2189	86	f	PM	533	400	1	4	n	y	n	n	n	n	n	n	30 mg	32,69	84	y	n	y	n	n	n	n
P	ASA	748	2191	65	m	PM	262		1	2	n	y	n	n	n	n	n	n	60 mg	73,67	63	y	n	y	n	n	n	n
P	ASA	748	2195	71	m	ICD	560		1	2	n	y	n	n	n	n	y	n	60 mg	106,25	65	y	y	y	n	n	n	n
P	ASA	748	2199	85	m	ICD	520		5	5	n	y	n	n	y	n	n	n	30 mg	48,1	61	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	748	2203	86	m	PM	53		1	3	n	y	n	n	n	n	y	n	60 mg	67,43	75	y	n	n	n	n	n	n
E	no ASA	748	2222	67	f	PM	31		2	3	n	y	n	n	n	n	n	n	60 mg	75,6	60	y	n	y	n	n	n	n
E	ASA	748	2236	80	m	ICD	6162		1	5	y	y	n	n	n	y	y	n	60 mg	58,67	63	y	y	y	n	n	n	n
E	ASA	748	2248	73	f	PM	19	400	11	4	n	n	n	n	y	n	n	n	60 mg	80,39	73	n	n	n	n	n	n	n
E	ASA	748	2249	86	f	PM	649	400	7	5	n	y	y, it	n	n	n	n	n	60 mg	75,94	86	y	n	y	n	n	n	n
P	ASA	748	2327	82	m	PM	95		1	5	y	y	y, oa	n	n	n	y	n	30 mg	26,85	60	y	n	y	n	n	n	n
P	ASA	748	2354	87	m	PM	346		4	6	n	y	y, it	y	n	n	n	n	30 mg	41,92	84	n	n	y	n	n	n	n
E	no ASA	748	2358	81	f	PM	179		3	4	n	y	n	n	n	n	n	n	30 mg	56,72	73	y	y	y	n	n	n	n
P	ASA	748	2384	87	m	ICD	1749	500	1	3	n	y	n	n	n	n	y	n	60 mg	55,57	65	y	n	y	n	y	n	n
E	ASA	748	2422	81	m	PM	22		1	3	n	y	n	n	n	n	n	n	60 mg	102,53	60	y	n	y	n	n	n	n
E	ASA	748	2455	84	f	ICD	51		1	5	y	y	n	n	n	n	n	n	30 mg	22,92	64	y	n	y	n	n	n	n
P	ASA	748	2466	92	m	PM	2872	400	5	4	n	y	n	n	n	y	y	n	30 mg	49,11	60	y	n	n	n	n	n	n
E	ASA	748	2613	73	m	PM	37		3	2	n	y	n	n	n	n	y	n	60 mg	101,85	61	y	n	n	n	n	n	n
E	ASA	748	2670	72	f	ICD	34		1	5	y	y	n	n	n	y	y	y	30 mg	42,51	60	y	n	y	n	n	n	n
P	no ASA	748	2676	76	m	PM	238	400	1	2	n	n	n	n	n	n	n	n	60 mg	72,1	60	y	y	y	n	n	n	n
P	ASA	748	2680	86	m	PM	1110	400	4	7	n	y	y, it	y	n	n	n	n	60 mg	61,59	74	y	n	y	n	n	n	n
P	ASA	748	2693	75	m	PM	577	400	2	3	n	y	n	n	n	n	n	y	60 mg	119,85	62	y	n	n	n	n	n	n
E	ASA	748	2716	80	m	PM	693		3	4	n	y	y, oa	n	n	n	n	y	60 mg	82,76	67	y	y	y	n	n	n	n
P	no ASA	748	2725	66	m	PM	9		1	2	n	y	n	n	n	n	n	n	60 mg	99,31	71	y	y	y	n	n	n	n
E	ASA	748	2734	88	f	PM-CRT	541		10	5	y	y	n	n	n	n	n	n	60 mg	58,79	72	y	y	y	n	n	n	n
E	ASA	748	2746	83	m	ICD	6		1	4	y	y	n	n	n	n	n	n	30 mg	31,8	61	n	n	y	n	y	n	n
P	no ASA	752	316	84	f	PM	14	191	1	4	n	y	n	n	n	n	n	n	60 mg	64,37	64	y	n	y	n	n	n	n
P	ASA	752	371	80	m	PM	730	256	1	4	n	y	n	n	n	n	n	n	30 mg	43,48	60	n	y	n	n	n	n	n
P	no ASA	752	372	88	f	PM	8	331	2	4	n	y	n	n	n	n	n	n	60 mg	58,28	63	n	n	y	n	n	n	n
E	no ASA	752	406	88	f	PM	22	400	3	4	n	y	n	n	n	n	n	n	30 mg	63,75	80	n	n	y	n	n	n	n
P	ASA	752	457	83	f	PM	451	400	1	6	n	y	n	n	y	n	n	n	60 mg	60,19	82	n	y	y	n	n	n	n
E	no ASA	752	458	80	m	PM	198	400	1	3	n	y	n	n	n	n	n	n	60 mg	63,16	66	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	752	517	91	m	PM	9	429	1	3	n	y	n	n	n	n	n	n	60 mg	61,54	85	n	n	y	n	n	n	n
E	ASA	752	570	86	f	PM	30	600	2	5	n	y	n	n	n	y	n	n	30 mg	50,06	55	y	y	y	n	n	n	n
E	no ASA	752	607	88	m	PM	1007	400	2	3	n	y	n	n	n	n	n	n	60 mg	71,47	82	n	n	y	n	n	n	n
P	no ASA	752	657	84	m	PM	219	429	4	2	n	n	n	n	n	n	n	n	30 mg	48,69	60	n	n	n	n	n	n	n
E	ASA	752	862	89	f	PM	327	331	10	4	n	y	n	n	n	n	n	n	30 mg	28,26	60	n	y	y	n	n	n	n
E	no ASA	752	863	74	m	PM	805	429	8	2	n	y	n	n	n	n	n	n	60 mg	78,57	78	y	y	y	n	n	n	n
P	no ASA	752	1025	86	m	PM	179	480	1	2	n	n	n	n	n	n	n	n	60 mg	79,62	69	n	n	n	n	n	n	n
E	ASA	752	1081	86	m	PM	57	600	1	3	n	n	y, oa	n	n	n	n	n	30 mg	49,46	62	n	n	n	n	n	n	n
P	ASA	752	1111	79	f	PM	240		1	4	n	y	n	n	n	n	n	n	30 mg	48,5	69	n	y	y	n	n	n	n
E	no ASA	756	426	72	m	PM	24	337	1	3	n	y	y, oa	n	n	n	n	n	60 mg	107,63	61	n	n	y	n	n	n	n
P	no ASA	756	448	77	m	ICD-CRT	18	308	1	5	y	y	n	n	n	y	n	n	60 mg	51,87	69	y	n	y	n	n	n	n
E	ASA	756	495	74	m	ICD-CRT	185	440	1	5	y	y	y, oa	n	n	y	n	n	60 mg	60,75	58	y	n	y	n	n	n	n
P	no ASA	756	509	72	m	PM	514	640	1	2	n	y	n	n	n	n	n	n	60 mg	85,65	87	n	n	y	n	n	n	n
P	ASA	756	540	74	f	ICD-CRT	325	632	1	5	y	n	n	n	y	n	n	n	60 mg	56,83	60	y	n	y	n	n	n	n
P	ASA	756	1069	76	m	ICD-CRT	53	275	1	5	y	n	y, oa	n	n	y	y	n	60 mg	61,87	60	y	n	y	n	n	n	n
P	ASA	756	1102	77	f	PM	167		6	4	n	y	n	n	n	n	n	n	30 mg	47,88	60	n	n	n	n	n	n	n
E	ASA	756	1255	81	m	ICD	816	640	1	4	n	y	n	n	n	y	y	n	60 mg	58,13	60	y	n	y	n	n	n	n
P	ASA	758	481	77	f	PM	48	600	1	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	90,78	95	y	n	y	n	n	n	n
E	no ASA	758	760	88	m	PM	66	351	1	3	n	y	n	n	n	n	n	n	30 mg	42,92	69	y	n	n	n	n	n	n
E	ASA	758	811	66	m	PM	66	429	4	3	n	n	y, oa	n	n	y	n	y	60 mg	152,54	128	n	n	n	n	n	n	n
P	no ASA	758	1086	68	m	ICD-CRT	41	640	1	2	y	n	n	n	n	n	n	n	60 mg	75,15	67	y	n	y	n	n	n	n
E	no ASA	768	562	76	m	PM	872	400	1	3	n	y	n	n	n	n	n	n	60 mg	75,27	87	n	y	y	n	n	n	n
E	no ASA	768	740	74	f	PM	51	591	1	3	n	y	n	n	n	n	n	n	60 mg	63,67	64	n	n	y	n	n	n	n
P	no ASA	768	1205	75	f	PM			1	5	n	y	y, oa	n	n	n	n	n	30 mg	58,36	71	y	y	y	n	n	n	n
P	no ASA	768	1341	87	f	PM			3	4	n	y	n	n	n	n	n	n	60 mg	63,5	63	y	n	n	n	n	n	n
P	no ASA	774	312	73	m	PM	349	417	2	3	n	y	y, oa AND it	n	n	n	n	n	60 mg	71,52	75	n	y	y	n	n	n	n
E	ASA	774	497	67	m	ICD-CRT	337		1	7	y	y	y, it	y	n	y	n	y	60 mg	95,01		y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	774	619	78	m	PM	1186	286	1	5	n	y	n	n	y	n	n	n	60 mg	63,67	60	n	n	y	n	n	n	n
E	ASA	774	1218	83	m	PM	43		1	4	n	y	n	n	n	n	n	y	30 mg	43,13	81	n	n	y	n	n	n	n
P	ASA	774	2505	91	f	PM	6		1	5	n	y	n	n	n	y	n	n	30 mg	39,92	72	y	y	y	n	n	n	n
P	ASA	774	2559	78	m	PM	85		3	5	n	y	y, oa	n	n	n	n	n	60 mg	70,96	73	n	y	n	n	n	n	n
P	no ASA	774	2581	77	m	PM	50	640	1	4	n	y	n	n	n	n	n	n	60 mg	64,71	69	n	y	y	n	n	n	n
P	ASA	775	362	83	m	PM	258	640	3	4	n	y	y, oa	n	n	n	y	n	30 mg	48,59	63	y	n	y	n	n	n	n
E	ASA	775	603	79	m	ICD-CRT	123	640	17	6	n	y	n	n	y	n	n	y	60 mg	64,51	64	n	y	y	n	n	n	n
P	ASA	775	660	72	f	PM	399	640	1	5	y	y	n	n	n	n	y	n	60 mg	101,89	60	n	y	y	n	n	n	n
E	ASA	775	1060	81	f	ICD	21	640	4	4	n	y	n	n	n	n	n	n	60 mg	72,71	64	y	n	y	n	n	n	n
E	no ASA	775	1350	82	f	PM	44	640	1	6	n	y	y, oa	n	n	n	n	n	60 mg	95,86		y	y	y	n	n	n	n
P	ASA	775	1366	82	m	PM	332	640	1	4	n	y	n	n	n	n	y	n	60 mg	53,97		y	n	n	n	n	n	n
P	ASA	775	1555	77	m	PM	113		4	3	n	y	n	n	n	n	n	n	60 mg	123,02		n	n	y	n	n	n	n
E	ASA	775	1562	67	m	ICD	61	640	28	3	n	y	n	n	n	y	n	y	30 mg	105		y	n	y	n	n	n	n
P	no ASA	775	1563	82	m	PM	103	301	1	2	n	n	n	n	n	n	n	n	60 mg	65,97		n	n	n	n	n	n	n
E	ASA	775	1851	81	f	PM	31	614	4	6	n	y	y, oa	n	n	y	n	n	60 mg	62,86	76	y	n	y	n	n	n	n
P	ASA	775	1959	92	f	PM	36	640	1	5	n	y	n	n	n	y	n	n	60 mg	50,09	60	n	n	y	n	n	n	n
E	ASA	775	2121	66	f	ICD	117	640	1	3	n	y	n	n	n	n	y	n	60 mg	84,97	79	y	n	y	n	n	n	n
P	ASA	775	2270	73	m	PM	20	256	1	4	n	y	n	y	y	n	n	n	60 mg	77,19	74	n	n	y	n	n	n	n
E	ASA	775	2524	69	m	PM	30		1	4	y	y	y, oa	n	n	n	n	n	60 mg	70,34	85	y	n	y	n	n	n	n
E	ASA	776	299	85	m	PM	131	269	9	5	n	y	y, oa	n	n	y	n	y	30 mg	47,67	60	y	n	y	n	n	n	n
E	no ASA	776	614	79	f	PM-CRT	1107	600	1	9	y	y	y, it	n	y	y	n	n	60 mg	57,6	62	y	n	y	n	n	y	n
E	ASA	776	1432	74	m	PM	80	250	1	3	y	y	n	n	n	n	n	n	60 mg	68,75	67	n	n	y	n	n	n	n
P	ASA	776	2145	77	m	PM	27		1	4	n	y	n	n	n	n	n	n	60 mg	67,98	92	y	n	y	n	n	n	n
P	ASA	776	2173	74	m	ICD-CRT	46	400	1	2	n	n	n	n	n	y	n	n	60 mg	76,67	69	y	n	n	n	n	n	n
E	no ASA	776	2727	82	m	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	67,44	66	y	y	y	n	n	n	n
P	no ASA	780	284	77	m	PM	47	296	1	4	n	y	y, oa	n	n	n	n	n	60 mg	78,75	54	y	y	y	n	n	n	n
E	ASA	780	313	73	m	ICD	1382	640	1	3	y	n	n	n	n	y	y	n	60 mg	68,72	60	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	780	354	75	m	ICD-CRT	1136	640	1	5	y	y	n	n	n	n	n	n	60 mg	86,67	54	y	n	y	n	n	n	n
E	no ASA	780	625	79	m	PM	1618	600	2	4	n	y	y, oa	n	n	n	n	n	60 mg	93,19	79	y	y	y	n	n	n	n
E	no ASA	780	673	83	m	PM	857	600	3	2	n	n	n	n	n	n	n	n	60 mg	74,77	61	n	n	n	n	n	n	n
E	ASA	780	781	65	m	PM	30	415	5	2	n	y	n	n	n	n	n	n	60 mg	94,7	60	y	n	y	n	n	n	n
P	ASA	783	2663	79	f	PM	319		11	4	n	y	n	n	n	n	n	n	60 mg	87,9	60	y	n	n	n	n	n	n
P	no ASA	783	2743	88	f	PM	25		1	3	n	n	n	n	n	n	n	n	30 mg	55,35	64	n	n	n	n	n	n	n
P	ASA	784	1375	70	m	PM	830	480	1	2	n	y	n	n	n	n	n	n	60 mg	52,17	64	y	n	y	n	n	n	n
E	ASA	784	1376	77	m	PM	350	400	3	4	y	y	n	n	n	n	n	n	60 mg	57,94	60	y	y	y	n	n	n	n
E	no ASA	785	1281	72	m	PM	782	300	4	2	n	y	n	n	n	n	n	n	60 mg	112,85	63	n	y	y	n	n	n	n
P	no ASA	788	1605	68	m	PM	253		3	2	n	y	n	n	n	n	n	n	60 mg	83,33	62	y	n	y	n	n	n	n
E	no ASA	788	1623	65	m	PM-CRT	579		11	2	y	n	n	n	n	n	n	n	60 mg	69,97	60	y	n	y	n	n	n	n
E	ASA	788	1624	81	f	PM	220		2	4	n	y	n	n	n	n	n	n	60 mg	88,29	60	y	n	y	n	n	n	n
P	ASA	788	1718	82	m	PM	1008		1	5	n	y	n	y	n	n	n	n	60 mg	58,64	60	n	n	y	n	n	n	n
E	no ASA	788	1733	76	f	PM-CRT	105		6	6	y	y	n	n	n	n	n	n	30 mg	30,57	75	y	n	y	n	n	n	n
P	no ASA	788	1738	70	m	PM	281	203	8	3	n	y	y, oa	n	n	n	n	n	60 mg	108,2		y	n	y	n	n	n	n
P	ASA	788	1827	77	m	PM	64		2	7	y	y	y, it	y	n	n	n	n	60 mg	79,09	60	y	n	y	n	n	n	n
P	no ASA	788	1872	66	m	PM	15		1	3	n	y	y, oa	n	n	n	n	n	60 mg	169,19	60	n	n	y	n	n	n	n
E	no ASA	788	2007	65	f	PM	442		3	3	n	y	n	n	n	n	n	n	60 mg	67,85	63	y	y	y	n	n	n	n
P	no ASA	788	2212	72	m	PM	577		2	2	n	y	n	n	n	n	n	n	60 mg	100,35	60	y	y	y	n	n	n	n
E	ASA	788	2295	78	f	PM	2880		1	5	n	y	y, oa	n	n	n	y	n	60 mg	61,35	78	n	y	y	n	n	n	n
P	no ASA	799	884	75	f	PM	78	400	6	4	n	y	n	n	n	n	n	n	60 mg	87,42	78	n	y	n	n	n	n	n
P	no ASA	799	1163	76	m	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	66,02	78	y	n	n	n	n	n	n
E	no ASA	799	1291	68	m	PM	390		1	3	n	y	y, oa	n	n	n	n	n	60 mg	109,2	78	y	y	y	n	n	n	n
E	ASA	800	420	88	m	PM	117	333	11	4	n	y	n	n	n	y	n	y	60 mg	56,81	77	n	y	y	n	n	n	n
P	no ASA	800	571	69	m	PM	36		3	2	n	y	n	n	n	n	n	n	60 mg	110,21	69	y	n	y	n	n	n	n
E	ASA	800	642	84	m	PM	84	600	2	4	n	y	n	n	n	n	n	n	60 mg	56,37	64	n	y	y	n	n	n	n
P	ASA	800	647	85	f	PM	88	400	2	7	n	y	y, oa	n	y	n	n	n	30 mg	40,65	79	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	800	653	67	m	PM	9999	400	142	3	y	y	y, it	n	n	n	n	n	60 mg	147,83	70	y	y	y	n	n	n	n
E	ASA	800	1128	77	m	PM	56	400	1	4	y	y	n	n	n	n	n	n	60 mg	52,8	76	y	n	y	n	n	n	n
P	ASA	800	1221	77	f	PM	24	264	1	6	n	y	n	y	n	n	n	n	30 mg	40,87	60	y	n	y	n	n	n	n
E	no ASA	800	1264	68	m	PM	530	400	2	3	y	y	n	n	n	n	n	n	60 mg	142,12	67	n	y	y	n	n	n	n
E	no ASA	800	1332	80	m	PM	180		13	2	n	n	n	n	n	n	n	n	60 mg	69,18	107	y	n	n	n	n	n	n
P	ASA	800	1401	80	m	PM	541	600	4	4	n	y	n	n	n	n	y	n	60 mg	71,73	60	y	n	y	n	n	n	n
P	ASA	800	1421	75	m	PM	751	400	7	4	n	y	y, oa	n	n	n	n	n	60 mg	60,48	78	y	y	n	n	n	n	n
P	ASA	800	1527	84	f	PM	416		13	4	y	y	n	n	n	n	n	y	30 mg	47,57	66	y	y	y	n	n	n	n
E	ASA	800	1603	86	m	PM	20		2	6	y	y	y, oa AND it	n	n	n	n	n	60 mg	54,31	70	y	y	y	n	n	n	n
P	no ASA	800	1667	81	m	PM	239		12	4	y	y	n	n	n	n	n	n	30 mg	49,42	64	y	n	n	n	n	n	n
E	no ASA	800	1984	72	f	PM	24	400	5	6	y	y	y, it	n	n	n	n	n	60 mg	65	61	y	y	y	n	n	n	n
E	no ASA	800	2360	78	m	PM	4042	545	2	3	n	y	n	n	n	n	n	n	60 mg	68,27	65	y	y	y	n	n	n	n
P	ASA	800	2634	79	m	PM	9		1	6	n	y	n	n	y	n	n	n	60 mg	62,89	73	n	y	y	n	n	n	n
E	ASA	801	520	83	m	PM	1440	429	3	4	n	y	n	n	n	n	n	y	30 mg	45,32	59	y	y	y	n	n	n	n
P	ASA	801	531	82	m	PM	1472	640	45	3	n	y	n	n	n	n	n	n	60 mg	55,82	70	y	n	y	n	n	n	n
E	ASA	801	543	73	f	PM	301	375	1	4	n	y	n	n	n	n	n	n	60 mg	115,32	80	n	y	n	n	n	n	n
P	ASA	801	545	75	f	PM	156	375	4	4	n	y	n	n	n	n	n	n	60 mg	66,57	68	y	n	y	n	n	n	n
E	no ASA	801	582	82	m	PM	254	600	1	3	n	y	n	n	n	n	n	n	30 mg	49,57	69	y	n	y	n	n	n	n
E	no ASA	801	594	76	f	PM-CRT	105	600	1	4	y	n	n	n	n	n	n	n	60 mg	65,73	73	y	n	y	n	n	n	n
P	no ASA	801	595	71	m	ICD-CRT	255	480	12	3	n	y	n	n	n	n	n	n	60 mg	87,63	72	y	n	y	n	n	n	n
P	no ASA	801	599	73	m	PM-CRT	4658	400	1	4	y	y	y, oa	n	n	n	n	n	60 mg	104,31	59	y	y	y	n	n	n	n
P	ASA	801	620	66	m	PM	1120	400	4	3	n	y	y, oa	n	n	n	n	n	60 mg	143,52	68	y	n	y	n	n	n	n
E	no ASA	801	639	78	m	PM	5760	400	1	3	n	y	n	n	n	n	n	n	60 mg	60,01	60	y	y	n	n	n	n	n
P	ASA	801	693	65	m	PM	244	640	2	4	y	y	n	n	n	n	n	n	60 mg	112	60	y	n	y	n	n	n	n
E	no ASA	801	710	80	f	PM	781	455	10	4	n	y	n	n	n	n	n	n	60 mg	63,42	60	y	n	y	n	n	n	n
P	no ASA	801	738	85	m	PM	11	400	2	4	n	y	n	n	n	n	n	n	60 mg	58,47	72	n	y	y	n	n	n	n
E	no ASA	801	741	80	m	PM	9999	480	1	3	n	y	n	n	n	n	n	n	60 mg	83,33	60	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	801	793	75	f	PM	126	400	1	6	y	y	y, it	n	n	n	n	n	60 mg	60,46	70	y	y	y	n	n	n	n
E	ASA	801	895	78	m	PM	485	269	2	4	n	y	n	n	n	n	n	n	60 mg	110,55	65	n	n	y	n	n	n	n
E	ASA	801	968	84	m	PM	10	500	2	3	n	y	n	n	n	n	n	n	60 mg	68,89	83	y	n	y	n	n	n	n
P	no ASA	801	969	78	m	PM	110	461	2	3	n	y	n	n	n	n	n	n	30 mg	44,56	60	y	y	y	n	n	n	n
E	no ASA	801	1007	78	f	PM	113	400	4	5	n	y	n	n	n	n	n	n	60 mg	64,23	70	n	n	y	n	n	n	n
E	ASA	801	1021	75	m	PM	540	315	2	4	n	y	n	n	n	y	y	n	60 mg	76,98	76	y	y	y	n	n	n	n
P	ASA	801	1070	68	m	PM	630	400	1	3	n	y	n	n	n	y	n	y	60 mg	119,93	54	y	n	y	n	n	n	n
E	no ASA	801	1169	70	m	PM	25	500	1	3	n	y	y, oa	n	n	n	n	n	60 mg	70,34	62	y	n	y	n	n	n	n
E	ASA	801	1170	82	f	PM	188	350	2	7	y	y	y, oa	n	n	y	y	n	60 mg	68,05	71	y	n	y	n	n	n	n
P	ASA	801	1183	66	m	ICD-CRT			4	6	y	y	n	y	n	y	y	y	60 mg	68,52	93	y	n	y	n	n	y	n
E	ASA	801	1184	79	m	PM		375		4	n	y	y, oa	n	n	n	n	n	60 mg	50,41	82	y	n	y	n	n	n	n
P	ASA	801	1187	78	f	PM	41	400	3	6	n	y	y, oa AND it	n	n	y	y	n	30 mg	46,16	74	n	n	y	n	n	n	n
P	ASA	801	1288	83	m	PM	1986	300	9	5	n	y	y, oa	n	n	y	y	y	60 mg	107,11	81	y	y	y	n	n	n	n
P	no ASA	801	1289	70	m	PM	186		13	3	n	y	n	n	n	n	n	n	60 mg	123,24	70	y	y	y	n	n	n	n
E	ASA	801	1308	75	f	ICD-CRT	483	271	3	6	y	y	n	n	n	y	n	n	60 mg	52,32	61	y	n	y	n	y	n	n
P	ASA	801	1309	75	m	PM	609		12	5	n	y	y, oa	n	n	n	n	n	60 mg	109,62	63	y	y	y	n	n	n	n
E	no ASA	801	1334	81	m	ICD-CRT	9999	640	3	4	y	y	n	n	n	n	n	n	60 mg	69,58	85	y	n	y	n	n	n	n
P	no ASA	801	1397	87	f	PM				4	n	y	n	n	n	n	n	n	30 mg	39,51	76	y	n	y	n	n	n	n
P	no ASA	801	1398	75	m	PM	25	400	2	3	n	y	n	n	n	n	n	n	60 mg	55,69	60	y	n	n	n	n	n	n
E	no ASA	801	1460	74	m	PM	302	300	1	3	n	y	y, oa	n	n	n	n	n	60 mg	66,31	70	y	n	n	n	n	n	n
P	no ASA	801	1770	69	m	PM	11	186	1	2	n	y	n	n	n	n	n	n	60 mg	82,75	59	y	n	n	n	n	n	n
E	no ASA	801	1772	78	f	PM	2880		3	5	n	y	n	n	n	n	n	n	60 mg	77,43	86	n	n	y	n	n	n	n
E	ASA	801	1794	76	m	PM	271		2	4	n	y	n	n	n	n	n	n	60 mg	80,59	78	y	n	y	n	n	n	n
E	ASA	801	1800	68	f	PM	125		1	3	n	y	n	n	n	n	n	n	60 mg	103,21	66	n	y	y	n	n	n	n
P	no ASA	801	1809	84	f	ICD	6000		22	4	n	y	n	n	n	n	n	n	30 mg	44,07	64	y	n	n	n	n	n	n
P	no ASA	801	1810	76	f	PM	50		9	5	n	y	y, oa	n	n	n	n	n	60 mg	104,89	64	y	n	y	n	n	n	n
E	no ASA	801	2247	83	f	PM	190	462	2	5	n	y	y, oa	n	n	n	n	n	30 mg	43,65	70	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	801	2273	82	m	PM	112	462	1	4	n	y	n	n	n	y	y	n	30 mg	46,99	70	n	y	y	n	n	n	n
E	no ASA	801	2274	85	m	PM	17	400	4	3	n	y	n	n	n	n	n	n	60 mg	75,56	70	y	n	n	n	n	n	n
E	ASA	801	2378	78	f	ICD-CRT	546	614	2	7	y	y	y, oa	n	n	y	y	n	30 mg	45,34	75	y	n	y	n	n	n	n
P	ASA	801	2387	76	f	ICD	113	462	2	5	n	y	y, oa	n	n	n	n	n	30 mg	59,65	75	y	n	n	n	n	n	n
P	no ASA	801	2513	67	f	PM	167		7	3	n	y	n	n	n	n	n	n	30 mg	50,87	65	y	n	y	n	n	n	n
P	ASA	801	2514	79	f	PM	59		1	6	n	y	y, oa AND it	n	n	y	y	n	30 mg	43,67	72	y	y	y	n	n	n	n
P	ASA	801	2527	81	m	PM	123		20	5	n	y	y, oa AND it	n	n	y	y	n	30 mg	36,14	60	y	y	y	n	n	n	n
E	no ASA	801	2592	71	m	PM	614		1	2	n	y	n	n	n	n	n	n	60 mg	93,81	93	n	y	y	n	n	n	n
P	no ASA	801	2593	83	m	PM	66		1	3	n	y	n	n	n	n	n	n	60 mg	67,02	63	n	n	y	n	n	n	n
P	no ASA	801	2744	77	f	PM	13		3	4	n	y	n	n	n	n	n	n	60 mg	62,29	62	y	n	n	n	n	n	n
P	ASA	802	349	83	m	PM-CRT	1440	375	122	5	y	n	y, it	n	n	y	n	y	30 mg	35,48	63	n	n	y	n	n	n	n
P	no ASA	802	629	81	f	PM	1440	232	9	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	71,8	60	n	y	n	n	n	n	n
E	no ASA	802	705	66	f	PM	6	362	2	3	n	n	y, it	n	n	n	n	n	60 mg	77,25	65	n	n	n	n	n	n	n
E	no ASA	802	1047	72	m	PM	44	400	1	2	n	y	n	n	n	n	n	n	60 mg	103,3	62	y	n	y	n	n	n	n
E	ASA	802	1082	83	m	PM	136	400	2	3	n	y	n	n	n	n	n	n	60 mg	52,73	61	n	n	y	n	n	n	n
E	ASA	802	2351	83	m	PM	645			2	n	n	n	n	n	n	n	n	60 mg	65,41	69	y	n	n	n	n	n	n
P	ASA	802	2567	84	f	PM-CRT	250	500	1	6	y	y	n	n	n	y	y	n	60 mg	76,54	74	y	y	y	n	n	n	n
P	no ASA	802	2679	74	m	PM	74		2	2	n	y	n	n	n	n	n	n	60 mg	87,04	78	n	n	n	n	n	n	n
P	ASA	813	2070	78	m	PM	323		1	4	n	y	n	n	n	y	y	n	60 mg	60,46	64	y	n	n	n	n	n	n
E	no ASA	813	2073	65	m	PM	13		2	2	n	y	n	n	n	n	n	n	60 mg	107,29	75	y	n	y	n	n	n	n
P	ASA	813	2074	83	f	PM	2206	400	1	5	n	y	n	n	n	y	n	n	60 mg	68,72	81	y	n	n	n	n	n	n
E	ASA	813	2161	72	m	PM-CRT	201		1	5	y	y	y, oa	n	n	n	n	n	60 mg	79,03	70	y	n	y	n	n	n	n
P	no ASA	815	947	77	f	PM	394	320	3	5	n	y	y, oa	n	n	n	n	n	60 mg	74,15	75	y	n	n	n	n	n	n
E	no ASA	815	986	73	f	PM				4	n	y	y, oa	n	n	n	n	n	30 mg	37,4	62	n	y	y	n	n	n	n
P	ASA	815	1387	81	m	PM	27	600	5	4	n	y	n	n	n	n	n	n	30 mg	36,94	60	n	n	y	n	n	n	n
E	no ASA	815	1429	75	m	PM	42	600	4	4	y	y	n	n	n	n	n	n	60 mg	91,16	60	y	y	y	n	n	n	n
E	ASA	815	1486	71	m	PM	44	640	10	3	y	y	n	n	n	n	n	n	60 mg	104,49	75	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	815	1551	88	f	PM	27		1	4	n	y	n	n	n	n	n	n	30 mg	31,31	60	y	y	n	n	n	n	n
P	no ASA	815	1812	87	f	PM	474		7	4	n	y	n	n	n	n	n	n	30 mg	31,18	75	y	n	y	n	n	n	n
E	no ASA	815	1895	74	m	PM	785		8	3	y	y	n	n	n	n	n	n	60 mg	65,48	75	y	n	y	n	n	n	n
E	ASA	815	1896	77	m	PM	774		6	3	y	n	n	n	n	n	n	n	60 mg	77,78	65	y	n	y	n	n	n	n
P	ASA	815	1904	87	m	PM	45	362	1	4	n	n	n	y	y	n	n	n	30 mg	45,3	85	n	n	n	n	n	n	n
E	no ASA	815	2200	84	m	PM	9999		6	3	n	y	n	n	n	n	n	n	30 mg	34,42	60	y	n	y	n	n	n	n
E	ASA	815	2526	75	f	PM	151		2	7	y	y	y, oa	n	n	n	y	n	60 mg	53,46	75	y	n	y	n	n	n	n
P	no ASA	824	1473	88	m	PM	42	640	11	2	n	n	n	n	n	n	n	n	60 mg	65,01	60	n	n	n	n	n	n	n
P	no ASA	824	1497	66	f	ICM	92		1	3	n	y	n	n	n	n	n	n	60 mg	74,03	63	n	y	n	n	n	n	n
E	ASA	824	2002	83	m	PM	24	640	1	4	n	y	n	n	n	y	y	n	60 mg	53,03	70	y	n	y	n	n	n	n
E	ASA	824	2010	76	m	PM-CRT	93	591	1	6	y	y	n	n	n	y	n	n	60 mg	64,34	57	y	n	y	n	n	n	n
P	ASA	824	2290	74	m	PM	148	400	2	3	y	y	n	n	n	n	n	n	60 mg	79,66	61	y	n	y	n	n	n	n
E	no ASA	824	2423	75	m	ICM	228		1	4	n	y	y, oa	n	n	n	n	n	60 mg	95,8	52	n	n	y	n	n	n	n
		824	2472	69	m					2									60 mg									
E	ASA	824	2627	70	m	ICD-CRT	872	640	1	3	y	n	n	n	n	y	y	n	60 mg	56,18	60	y	n	y	n	n	n	n
E	ASA	826	476	80	m	PM	40	380	4	5	n	y	n	y	n	n	n	n	60 mg	67,39	75	y	n	n	n	n	n	n
P	no ASA	826	892	69	m	PM	113	640	1	2	n	y	n	n	n	n	n	n	60 mg	82,01	61	y	n	y	n	n	n	n
P	no ASA	826	1425	90	f	PM	47	400	1	3	n	n	n	n	n	n	n	n	60 mg	56,26	60	y	n	n	n	n	n	n
E	no ASA	826	2738	73	m	PM	598	640	1	2	n	y	n	n	n	n	n	n	60 mg	69,24	57	n	n	y	n	n	n	n
P	ASA	827	724	78	f	PM	36	600	3	5	n	y	y, oa	n	n	n	n	n	60 mg	81,33	68	y	y	n	n	n	n	n
E	ASA	827	764	79	f	PM	71	600	2	5	n	y	y, oa	n	n	n	n	n	60 mg	63,01	60	n	y	y	n	n	n	n
P	ASA	827	770	73	m	ICD	381	600	1	4	y	y	y, oa	n	n	n	n	n	60 mg	87,77	62	y	n	y	n	n	n	n
E	ASA	827	807	77	f	ICD	39	429	1	5	y	n	n	n	n	y	y	n	30 mg	37,19	60	y	n	y	n	n	n	n
P	ASA	828	1011	79	m	PM	9	569	4	4	n	n	n	n	y	n	n	n	30 mg	48,46	61	y	n	y	n	n	n	n
E	ASA	833	626	67	m	ICD-CRT	79	384	1	5	y	y	y, it	n	n	y	y	n	60 mg	73,89	64	y	n	y	n	n	n	n
E	ASA	833	976	82	m	PM	136	180	10	4	n	y	n	n	n	y	y	y	60 mg	58,94	74	n	n	y	n	n	n	n
P	ASA	833	987	76	m	PM	12	313	1	6	n	y	y, oa	n	y	n	n	n	60 mg	71,59	81	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	833	1224	74	m	PM	13	640	1	4	n	y	y, oa	n	n	n	y	n	60 mg	70,46	64	n	y	y	n	n	n	n
E	ASA	833	1277	84	m	PM	328	350	16	3	n	y	n	n	n	n	n	n	60 mg	63,66	66	y	n	y	n	n	n	n
P	ASA	833	1290	80	m	PM	275	500	6	7	n	y	n	n	y	y	y	n	60 mg	69,31	60	n	n	y	n	n	n	n
E	ASA	833	1637	78	m	PM	35	307	1	3	n	n	n	n	n	n	y	y	60 mg	68,43	61	y	n	n	n	n	n	n
E	ASA	833	1923	77	m	PM	6	207	1	4	n	y	n	n	n	n	n	n	60 mg	62,15	68	n	n	y	n	n	n	n
P	ASA	833	2239	70	f	PM	104		5	4	n	y	n	n	n	n	y	n	60 mg	76,27	76	n	y	y	n	n	n	n
E	no ASA	833	2242	66	f	PM	216	640	2	3	n	y	n	n	n	n	n	n	60 mg	74,84	60	y	n	n	n	n	n	n
E	no ASA	833	2361	82	m	PM	437		1	3	n	y	n	n	n	n	n	n	60 mg	71,29	68	y	n	y	n	n	n	n
P	ASA	833	2382	75	m	PM	88		4	3	n	n	n	n	n	y	y	y	60 mg	68,13	82	n	n	n	n	n	n	n
P	ASA	833	2458	75	f	ICD	6		1	5	y	y	n	n	n	n	n	n	30 mg	39,58	67	y	n	y	n	n	n	n
P	no ASA	836	795	79	m	PM	4885	640	1	3	n	y	n	n	n	n	n	n	60 mg	66,08	73	n	n	n	n	n	n	n
E	ASA	836	802	73	f	PM	72	600	1	4	n	y	n	n	n	y	y	n	60 mg	107,57	83	n	n	y	n	n	n	n
P	no ASA	836	814	76	f	PM				4	n	y	n	n	n	n	n	n	60 mg	61,98	70	y	n	y	n	n	n	n
P	no ASA	836	819	77	m	PM	61	380	3	4	n	y	y, oa	n	n	n	n	n	60 mg	109,38	60	n	y	n	n	n	n	n
E	no ASA	836	849	79	f	PM	7	396	1	6	n	y	n	n	y	n	n	n	60 mg	69,31	60	y	n	y	n	n	n	n
E	no ASA	836	938	75	f	PM	230	400	1	4	n	y	n	n	n	n	n	n	60 mg	71,24	74	n	y	y	n	n	n	n
E	no ASA	836	951	85	m	PM	124	380	2	4	n	y	y, oa	n	n	n	n	n	30 mg	49,38	58	n	n	y	n	n	n	n
P	no ASA	836	997	79	m	PM	24	295	1	4	n	y	y, oa	n	n	n	n	n	60 mg	78,7	73	n	y	y	n	n	n	n
E	no ASA	836	1022	66	f	PM	17	487	1	4	n	y	n	n	n	n	n	n	60 mg	172,36	57	n	n	y	n	n	n	n
P	no ASA	836	1103	68	m	PM	57	380	12	2	n	y	n	n	n	n	n	n	60 mg	68,18	60	y	y	y	n	n	n	n
P	no ASA	836	1151	77	m	PM	698	333	1	4	n	y	y, oa	n	n	n	n	n	60 mg	87,2	61	n	y	y	n	n	n	n
E	no ASA	836	1298	72	f	PM	262	640	2	3	n	y	n	n	n	n	n	n	60 mg	87,01	64	n	y	y	n	n	n	n
P	no ASA	836	1489	73	m	PM	839	352	1	2	n	y	n	n	n	n	n	n	60 mg	71,3	61	y	y	y	n	n	n	n
P	no ASA	836	1840	79	m	PM	123	500	1	3	n	y	n	n	n	n	n	n	60 mg	68,46	71	n	n	y	n	n	n	n
E	no ASA	836	1996	69	f	PM				3	n	y	n	n	n	n	n	n	60 mg	85,39	60	n	n	y	n	n	n	n
E	no ASA	836	2001	81	m	PM	94	614	4	4	n	y	y, oa	n	n	n	n	n	60 mg	104,72	58	n	y	y	n	n	n	n
E	no ASA	836	2188	67	m	PM	882	640	4	3	n	y	y, oa	n	n	n	n	n	60 mg	101,39	72	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	836	2329	83	m	PM	17		1	3	n	y	n	n	n	n	y	n	60 mg	68,61	65	n	n	y	n	n	n	n
E	no ASA	836	2364	73	m	PM	817	640	6	3	n	y	y, it	n	n	n	n	n	60 mg	116,32	67	n	n	y	n	n	n	n
P	no ASA	836	2546	79	m	PM	145		2	3	n	y	n	n	n	n	n	n	60 mg	68,94	90	y	n	y	n	n	n	n
P	no ASA	857	1830	71	f	PM	304	640	1	3	n	y	n	n	n	n	n	n	60 mg	77,81	90	y	n	n	n	n	n	n
E	ASA	857	1835	81	m	PM	13	357	1	5	n	y	y, oa	n	n	n	y	n	60 mg	72,63	71	n	y	y	n	n	n	n
P	no ASA	857	1853	91	f	PM	43		2	4	n	y	n	n	n	n	n	n	30 mg	39,24	87	y	y	y	n	n	n	n
P	ASA	857	1876	71	f	PM	61		1	4	n	y	y, oa	n	n	n	y	n	60 mg	63,84	60	y	n	y	n	n	n	n
P	ASA	857	1957	81	f	PM	108		1	4	n	y	n	n	n	n	n	n	30 mg	27,77	29	n	n	y	n	n	n	n
E	ASA	857	2006	77	m	PM	90	462	1	2	n	n	n	n	n	n	n	n	60 mg	72,21	84	n	n	n	n	n	n	n
E	no ASA	862	2465	76	m	PM	13		1	2	n	n	n	n	n	n	n	n	60 mg	100,11	64	n	n	n	n	n	n	n
P	ASA	866	677	73	f	PM	130		7	5	n	y	n	n	y	n	n	n	60 mg	56,16	60	y	n	y	n	n	n	n
P	ASA	866	742	66	m	PM	347	400	1	5	n	y	y, oa	y	n	n	n	n	60 mg	80,68	70	n	n	y	n	y	n	n
P	ASA	866	750	69	m	PM	524	640	142	3	y	y	n	n	n	n	n	n	60 mg	69,5	84	y	n	y	n	y	n	n
E	ASA	866	767	65	f	PM	9999		1	3	n	y	n	n	n	n	n	n	60 mg	70,47	63	y	n	y	n	n	n	n
E	ASA	866	775	68	m	PM	3137	400	1	4	y	y	n	n	n	y	n	n	60 mg	54,69	69	y	y	n	n	n	n	n
E	ASA	866	788	77	m	ICD	1518	400	2	3	y	n	n	n	n	n	n	n	60 mg	64,64	83	y	n	n	n	y	n	n
P	ASA	866	791	70	m	PM	188	400	51	2	n	y	n	n	n	n	n	n	60 mg	76,39	67	y	n	y	n	n	n	n
P	ASA	866	809	75	m	PM	247	400	1	5	y	y	n	n	n	y	y	y	30 mg	49,13	77	y	n	y	n	n	n	n
P	ASA	866	885	65	f	PM	1952	512	10	4	n	y	y, oa	n	n	n	n	n	60 mg	88,54	70	y	y	y	n	n	n	n
E	ASA	866	952	83	m	PM	68		1	3	n	y	n	n	n	n	n	n	60 mg	69,85	65	y	n	n	n	n	n	n
E	ASA	866	953	66	f	PM	35	400	1	3	n	y	n	n	n	n	n	n	60 mg	81,55	68	y	y	y	n	n	n	n
E	ASA	866	1100	78	f	PM	68	400	3	4	n	y	n	n	n	n	n	n	30 mg	48,48	66	y	y	n	n	n	n	n
E	ASA	866	1106	77	f	PM	9	400	1	5	n	y	y, oa	n	n	n	n	n	30 mg	35,92	56	n	y	n	n	n	n	n
P	ASA	866	1149	79	m	PM				4	y	y	n	n	n	n	n	n	30 mg	37,78	90	n	n	y	n	n	n	n
E	ASA	866	1196	70	m	PM	192	640	6	2	n	y	n	n	n	n	n	n	60 mg	77,37	56	y	y	y	n	n	n	n
E	ASA	866	1715	72	f	PM	88	212	3	3	n	y	n	n	n	n	n	n	60 mg	61,06	83	n	n	y	n	n	n	n
P	ASA	866	2026	65	m	PM	640	400	3	2	n	y	n	n	n	n	y	n	60 mg	84,46	60	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	866	2107	74	m	PM	126	400	3	2	n	y	n	n	n	n	n	n	60 mg	55,89	82	y	y	y	n	n	n	n
P	ASA	866	2110	84	f	PM	5760	400	3	4	n	y	n	n	n	n	n	n	30 mg	21,78	88	n	y	n	n	n	n	n
E	ASA	866	2257	73	m	PM	217	180	4	2	n	y	n	n	n	n	n	n	60 mg	64,07	82	y	n	n	n	n	n	n
P	ASA	866	2302	76	f	PM				4	n	y	n	n	n	n	y	n	30 mg	47,91	86	y	n	y	n	n	n	n
E	ASA	866	2374	71	m	PM	855	400	3	2	n	y	n	n	n	n	n	n	60 mg	53,16	60	n	n	y	n	n	n	n
E	ASA	866	2404	75	m	PM				3	n	y	n	n	n	n	n	n	60 mg	56,5	60	n	n	y	n	n	n	n
P	ASA	868	630	74	f	ICD	221	250	1	6	y	y	y, oa	n	n	n	n	y	60 mg	63,68	70	n	n	y	n	n	n	n
E	no ASA	868	645	78	m	ICD				4	n	y	n	n	n	n	n	n	60 mg	77,5		y	n	y	n	n	n	n
P	ASA	868	665	76	m	PM	10	400	1	5	y	y	n	n	n	n	n	n	60 mg	86,82	62	n	n	y	n	n	n	n
P	no ASA	868	701	68	m	PM	256	248	1	6	n	y	y, oa	y	y	y	y	y	60 mg	73,51	70	y	n	y	n	n	n	n
P	ASA	868	734	72	f	ICD				5	n	y	y, oa	n	n	y	n	n	60 mg	54,86		n	n	y	n	n	n	n
E	ASA	868	754	73	m	ICD-CRT	470	300	1	3	n	y	n	n	n	y	n	n	60 mg	62,04		n	y	y	n	n	n	n
E	no ASA	868	759	79	m	ICD				7	n	y	y, oa	y	n	y	n	n	60 mg	61		y	n	y	n	n	n	n
E	ASA	868	798	79	f	PM-CRT	1440		3	5	n	y	n	n	n	n	n	n	60 mg	57,61	85	y	y	n	n	n	n	n
E	ASA	868	800	74	m	ICD	165	400	8	4	n	y	y, oa	n	n	n	n	n	30 mg	49,28	62	n	n	y	n	n	n	n
P	ASA	868	825	71	m	PM				3	n	y	n	n	n	n	n	n	30 mg	61,88		n	n	y	n	n	n	n
E	ASA	868	897	67	m	ICD-CRT	192	400	2	4	n	y	y, oa	n	n	n	n	n	60 mg	77,99		n	n	y	n	n	n	n
P	no ASA	868	899	69	m	ICD	11	400	2	4	n	y	n	y	n	n	n	n	60 mg	72,48	66	y	n	y	n	n	n	n
E	ASA	868	923	71	m	ICD	20	304	1	5	n	y	n	y	y	y	n	n	60 mg	83,2	90	n	n	y	n	n	n	n
P	no ASA	868	924	78	f	ICD	360	400	1	5	n	y	y, oa	n	n	n	y	n	30 mg	45,91		y	n	n	n	n	n	n
P	ASA	868	965	75	f	ICD	12	400	1	7	n	y	y, oa	y	n	n	n	n	30 mg	47,73	66	y	n	y	n	n	n	n
E	ASA	868	967	79	f	PM	21	242	2	6	n	y	n	n	y	n	n	n	30 mg	28,07		y	n	y	n	n	n	n
E	no ASA	868	982	71	f	PM	526	400	2	6	n	y	y, oa	y	n	n	n	n	30 mg	47,02	72	y	n	y	n	n	n	n
E	no ASA	868	1228	69	f	ICD	61	296	3	4	n	y	y, oa	n	n	n	n	n	60 mg	66,81		y	n	y	n	n	n	n
P	ASA	868	1315	71	f	ICD				7	n	y	y, oa	y	y	n	n	n	30 mg	38,98		y	y	n	n	n	n	n
P	no ASA	868	1431	72	m	ICD				7	y	y	y, oa	y	y	y	n	n	60 mg	74,1		n	y	y	n	n	n	n
P	ASA	868	1669	67	m	ICD	7	545	1	3	n	y	n	n	n	n	y	n	60 mg	78,46	64	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	868	2098	69	f	ICD	1670	400	3	4	n	y	y, oa	n	n	n	n	n	60 mg	64,03		n	n	y	n	n	n	n
E	no ASA	869	683	77	f	PM	279	429	6	6	y	y	n	n	n	y	y	n	60 mg	59,34	70	n	n	n	n	y	n	n
E	no ASA	869	730	67	f	PM				6	y	y	y, oa	n	n	y	y	n	60 mg	138,94	76	y	n	n	n	n	n	n
P	no ASA	869	780	81	f	PM	48	265	1	5	y	y	n	n	n	n	n	n	30 mg	40,57	70	y	n	n	n	n	n	n
P	no ASA	869	823	78	m	PM	1471	400	6	4	y	y	n	n	n	n	n	n	60 mg	52,47	70	y	y	y	n	y	n	n
P	ASA	869	980	71	f	PM				5	y	y	n	n	n	y	y	n	60 mg	81,22	70	n	y	y	n	n	n	n
E	no ASA	869	1104	71	f	PM	32		1	5	y	y	y, oa	n	n	n	n	n	30 mg	66,05	70	y	y	y	n	n	n	n
P	no ASA	869	1180	72	f	PM	3228	320	4	4	y	y	n	n	n	n	n	n	60 mg	70,35	69	y	y	n	n	n	n	n
P	ASA	869	1261	71	m	PM	14		1	5	y	y	n	y	n	n	n	n	60 mg	77,66	76	n	y	y	n	n	n	n
E	ASA	869	1276	66	m	PM	892	400	3	5	y	y	y, oa	n	n	y	y	y	60 mg	95,76	70	y	n	n	n	n	n	n
E	no ASA	869	1279	72	f	PM				4	y	y	n	n	n	n	n	n	60 mg	50,62	70	n	y	n	n	n	n	n
P	no ASA	869	1311	74	m	PM	1048	312	5	3	y	y	n	n	n	n	n	n	60 mg	59,22	60	n	n	n	n	n	n	n
P	ASA	869	1355	71	f	PM	9999	640	1	5	y	y	y, oa	n	n	n	n	n	60 mg	77,06	70	y	n	n	n	n	n	n
P	no ASA	869	1360	70	f	PM	1293	640	3	4	y	y	n	n	n	n	n	n	60 mg	93,91	85	n	y	y	n	n	n	n
E	ASA	869	1390	74	m	PM			2	3	y	y	n	n	n	n	n	n	60 mg	79,75	67	y	n	y	n	n	n	n
E	ASA	869	1465	72	m	PM	142	330	3	4	y	y	y, oa AND it	n	n	n	n	n	60 mg	113,33	70	y	n	y	n	n	n	n
E	no ASA	869	1481	77	f	PM			1	6	y	y	y, oa	n	n	n	n	n	60 mg	67,31	70	n	y	y	n	n	n	n
E	ASA	869	1558	65	f	PM	480	300	4	4	y	y	n	n	n	n	n	n	60 mg	78,3	60	y	y	y	n	n	n	n
P	ASA	869	1717	73	m	PM	9	186	4	7	y	y	y, oa	y	n	y	n	n	60 mg	77,15	70	y	n	n	n	n	n	n
P	ASA	869	1867	72	f	PM				5	y	y	y, oa	n	n	n	n	n	60 mg	59,78	70	n	n	y	n	n	n	n
E	ASA	869	1970	71	f	PM				4	y	y	n	n	n	n	n	n	60 mg	100,35	63	y	n	n	n	n	n	n
P	ASA	869	2008	72	f	PM				7	y	y	y, oa	y	n	n	n	n	30 mg	40,02	87	y	n	y	n	n	n	n
E	ASA	869	2208	72	f	PM				4	n	y	n	n	n	y	n	n	60 mg	73,77	66	y	n	n	n	n	n	n
E	ASA	870	680	68	m	PM				3	y	y	n	n	n	n	n	n	60 mg	61,72	60	y	n	n	n	n	n	n
E	ASA	870	769	73	f	PM	30		6	4	n	y	n	n	n	n	n	n	60 mg	52,5	65	y	n	n	y	n	n	n
P	ASA	870	850	80	f	PM				5	y	y	n	n	n	n	n	n	30 mg	33,18	60	y	n	y	n	n	n	n
P	no ASA	870	971	79	f	PM	504		4	7	y	y	n	n	y	n	n	n	60 mg	50,83	85	n	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	870	977	66	f	PM	541	400	6	5	y	y	y, oa	n	n	n	n	n	60 mg	77,31	70	y	y	y	n	n	n	n
E	no ASA	870	1020	92	m	PM	278	640	11	4	n	y	n	n	n	y	n	n	30 mg	46,63	60	y	n	n	n	n	n	n
P	ASA	870	1028	72	f	PM	1103	400	4	4	n	y	n	n	n	n	n	n	60 mg	83,75	67	y	n	n	n	n	n	n
P	ASA	870	1030	67	f	PM	73		2	3	n	y	n	n	n	n	n	n	60 mg	59,32	60	y	n	n	n	y	n	n
E	ASA	870	1032	66	m	PM	6	640	1	5	n	y	y, oa	n	y	n	n	n	60 mg	109,34	65	y	y	y	n	n	n	n
P	ASA	870	1073	72	f	PM	5149	400	12	4	n	y	y, oa	n	n	n	n	n	60 mg	65,31	73	y	y	y	n	n	n	n
E	ASA	870	1077	71	f	PM	26	380	2	4	y	y	n	n	n	n	n	n	60 mg	88,94	67	y	y	y	n	n	n	n
E	ASA	870	1093	68	f	PM	1106	495	25	5	n	y	n	y	n	n	n	n	60 mg	85,62	60	y	y	n	n	n	n	n
P	ASA	870	1119	66	f	PM	330	400	3	3	n	y	n	n	n	n	n	n	60 mg	72,8	78	y	y	y	n	n	n	n
E	ASA	870	1131	74	f	PM		600	2	6	n	y	y, oa	y	n	n	n	n	60 mg	71,05	98	n	y	y	n	n	n	n
E	ASA	870	1142	79	f	PM	108	400	2	4	n	y	n	n	n	n	n	n	60 mg	62,23	81	y	n	n	n	n	n	n
P	ASA	870	1265	69	m	PM	1440		5	3	n	y	y, it	n	n	n	n	n	60 mg	78,53	63	y	n	y	n	n	n	n
P	ASA	870	1267	82	m	PM			2	4	n	y	y, oa	n	n	n	n	n	60 mg	76,4	65	y	n	n	n	n	n	n
E	ASA	870	1271	70	m	PM				4	n	y	n	n	y	n	n	n	30 mg	48,03	60	y	n	y	n	n	n	n
E	ASA	870	1297	65	f	PM	59	614	1	4	y	y	n	n	n	n	n	n	60 mg	91,7	65	y	n	n	n	n	n	n
P	ASA	870	1303	71	f	PM	16	600	3	4	y	y	n	n	n	n	n	n	60 mg	83,18	75	y	n	n	n	n	n	n
E	ASA	870	1384	71	m	PM	9999	400	4	4	y	y	y, oa	n	n	n	n	n	60 mg	68,78	65	y	y	y	n	n	n	n
P	ASA	870	1395	80	f	PM	17	295		5	y	y	n	n	n	n	n	n	60 mg	67,61	88	y	y	y	n	n	n	n
P	ASA	870	1409	74	f	PM	3186	400	8	6	y	y	n	n	y	n	n	n	60 mg	64,79	85	y	y	y	n	n	n	n
P	ASA	870	1463	67	f	PM	1573	400	16	4	y	y	n	n	n	n	n	n	60 mg	79,17	70	n	n	y	n	y	n	n
E	ASA	870	1464	68	f	PM	7	404	4	5	y	y	n	n	n	y	n	n	60 mg	76,74	60	y	n	y	n	n	n	n
P	ASA	870	1480	83	m	PM	722	640	7	5	y	y	n	n	n	y	y	n	30 mg	42,97	60	y	n	n	n	n	n	n
E	ASA	870	1500	71	m	ICD-CRT	251	275	6	4	y	y	n	n	n	y	n	n	60 mg	88,04	85	y	y	y	n	n	n	n
P	ASA	870	1514	69	m	PM	1440		6	4	y	y	y, oa	n	n	n	n	n	60 mg	101,64	54	y	y	y	n	n	n	n
E	ASA	870	1526	81	f	PM	38	182	2	4	n	y	n	n	n	n	n	n	60 mg	52,21	67	y	n	n	n	n	n	n
P	ASA	870	1572	70	m	PM	184		1	4	y	y	y, oa	n	n	n	n	n	60 mg	91,18	63	y	y	y	n	n	n	n
P	ASA	870	1580	69	m	PM	235	640	3	3	y	y	n	n	n	n	n	n	60 mg	92,59	60	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	870	1587	69	f	PM	38	182	1	4	y	y	n	n	n	n	n	n	60 mg	75,13	88	n	y	y	n	n	n	n
E	ASA	870	1596	80	m	PM	3471	400	5	5	y	y	n	n	n	y	y	n	60 mg	63,08	60	y	n	n	n	n	n	n
P	ASA	870	1616	76	f	PM	27		1	5	y	y	n	n	n	n	n	n	60 mg	73,51	60	y	y	y	n	n	n	n
E	ASA	870	1618	71	f	PM				7	y	y	n	y	n	y	n	n	60 mg	69,82	71	y	y	n	n	n	n	n
E	ASA	870	1627	78	m	PM				4	y	y	n	n	n	n	n	n	60 mg	61,78	60	y	n	n	n	n	n	n
P	no ASA	870	1675	78	f	PM			41	5	y	y	n	n	n	n	n	n	60 mg	77,42	63	y	n	y	n	n	n	n
P	ASA	870	1678	75	m	PM	18	175	1	4	y	y	n	n	n	n	n	n	60 mg	94,12	60	y	y	y	n	n	n	n
E	ASA	870	1684	79	m	PM	590	400	6	7	y	y	y, oa	y	y	n	n	n	60 mg	65,08	69	y	y	n	n	n	n	n
P	ASA	870	1685	80	f	PM	5760	400	6	5	y	y	n	n	n	n	n	n	60 mg	67	66	y	n	n	n	n	n	n
E	ASA	870	1722	68	f	PM	16		1	3	n	y	n	n	n	n	n	n	60 mg	55,88	60	y	n	n	n	n	n	n
E	ASA	870	1967	66	m	PM	6849	591	3	4	n	n	y, oa	y	n	n	n	n	60 mg	85,96	53	y	n	n	n	y	n	n
E	ASA	870	1973	71	m	ICD-CRT	14	295	3	3	y	n	n	n	n	n	n	n	60 mg	73,46	68	y	n	y	n	y	n	n
P	ASA	870	1976	67	f	PM	935	415	713	3	n	y	n	n	n	n	n	n	30 mg	51,19	60	y	n	y	n	n	n	n
P	ASA	870	1985	68	f	PM	8		1	5	n	y	n	y	n	n	n	n	60 mg	69,85	62	y	n	n	n	n	n	n
E	ASA	870	1994	75	m	PM	440	400	2	5	y	y	n	n	n	y	y	n	60 mg	71,87	70	y	y	y	n	y	n	n
P	ASA	870	1995	72	f	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	80,94	60	y	y	y	n	n	n	n
P	ASA	870	1997	79	f	PM				4	n	y	n	n	n	n	n	n	60 mg	54,17	114	y	n	n	n	n	n	n
E	ASA	870	1999	68	m	PM				3	n	y	y, oa	n	n	n	n	n	60 mg	102,64	68	y	n	y	n	n	n	n
E	ASA	870	2000	65	m	PM				3	y	y	n	n	n	n	n	n	60 mg	68,22	70	y	y	n	n	n	n	n
P	ASA	870	2043	75	f	PM				5	y	y	n	n	n	n	n	n	30 mg	36,77	75	y	n	y	n	y	n	n
P	ASA	870	2047	67	m	PM				2	n	y	n	n	n	n	n	n	60 mg	86,36	82	y	n	y	n	n	n	n
E	ASA	870	2087	69	f	PM	12	400	3	4	y	y	n	n	n	n	n	n	60 mg	76,28	61	y	n	n	n	n	n	n
E	ASA	870	2130	71	f	PM	204	400	3	4	y	y	n	n	n	n	n	n	60 mg	59,76	60	y	n	n	n	n	n	n
P	ASA	870	2151	67	f	PM	682	400	5	3	n	y	n	n	n	n	n	n	60 mg	92,4	77	y	n	y	n	n	n	n
P	ASA	870	2198	65	m	PM	2065	400	3	2	n	y	n	n	n	n	n	n	60 mg	103,35	63	y	n	n	n	n	n	n
P	ASA	870	2201	71	m	PM	5760	400	6	2	n	y	n	n	n	n	n	n	30 mg	49,28	63	n	n	y	n	n	n	n
E	ASA	870	2261	76	m	PM	29	206	3	6	y	y	n	y	n	n	n	n	60 mg	93,72	77	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	870	2262	81	m	PM	2880		3	4	y	y	n	n	n	n	n	n	60 mg	59,05	80	y	n	n	n	n	n	n
P	ASA	870	2292	70	m	PM				2	n	y	n	n	n	n	n	n	60 mg	79,72	60	y	n	n	n	n	n	n
E	ASA	870	2314	83	m	PM	1033	400	2	6	y	y	n	n	y	n	n	n	30 mg	35,07	65	y	y	n	n	n	n	n
P	ASA	870	2369	79	m	PM	210	400	3	4	y	y	n	n	n	n	n	n	60 mg	59,94	65	y	n	n	n	n	n	n
P	ASA	871	732	70	f	PM	11	246	1	4	n	y	y, oa	n	n	n	n	n	60 mg	67,88	87	y	n	n	n	n	n	n
E	ASA	871	762	66	m	PM-CRT	61	600	1	3	n	y	n	n	n	n	n	n	60 mg	80,04	60	n	n	y	n	n	n	n
P	ASA	871	804	61	f	PM				3	n	y	n	n	n	n	n	n	60 mg	82,46	77	y	n	n	n	n	n	n
E	ASA	871	808	77	m	PM	625	400	1	3	n	y	n	n	n	n	n	n	60 mg	83,17	62	y	n	n	n	n	n	n
E	ASA	871	812	86	f	PM	18	304	2	4	n	y	n	n	n	n	n	n	30 mg	42,71	81	y	n	n	n	n	n	n
E	ASA	871	872	69	f	PM	8	210	2	3	n	y	n	n	n	n	n	n	60 mg	59,75	59	y	n	n	n	n	n	n
P	ASA	871	874	75	m	PM	14	187	1	3	n	y	n	n	n	n	n	n	60 mg	52,21	60	y	n	n	n	n	n	n
E	ASA	871	880	78	f	PM	136	400	10	4	n	y	n	n	n	n	n	n	30 mg	46,23	72	y	n	y	n	n	n	n
P	ASA	871	914	80	m	PM	11	400	1	3	n	y	n	n	n	n	n	n	30 mg	47,44	92	n	n	y	n	n	n	n
P	ASA	871	962	81	m	PM	11	375	2	4	n	y	n	n	n	n	y	n	60 mg	82,81	60	y	n	n	n	n	n	n
P	ASA	871	963	77	f	PM	10	390	1	5	n	y	n	n	n	n	n	n	60 mg	81,33	80	n	n	n	n	n	n	n
E	ASA	871	972	80	f	PM	16	312	2	5	n	y	n	n	n	n	n	n	60 mg	57,06	62	y	n	y	n	n	n	n
E	ASA	871	1012	72	m	PM	11	234	2	2	n	y	n	n	n	n	n	n	30 mg	47,12	60	n	n	y	n	n	n	n
E	no ASA	872	696	66	m	PM	1440	480		3	y	y	n	n	n	n	n	n	60 mg	87,85	65	y	n	n	n	n	n	n
P	no ASA	872	700	79	f	PM	949	400	6	5	y	y	n	n	n	n	n	n	30 mg	22,29	69	y	n	n	n	y	n	n
E	no ASA	872	727	66	m	PM				3	y	y	n	n	n	n	n	n	60 mg	60,46	55	n	n	y	n	n	n	n
E	no ASA	872	755	75	f	PM	61	400	2	5	y	y	n	n	n	n	n	n	60 mg	66,06	71	y	n	y	n	n	n	n
P	no ASA	872	776	82	m	PM	34	400	3	3	y	n	n	n	n	n	n	n	30 mg	46,91	62	n	n	n	n	n	n	n
P	no ASA	872	889	76	m	PM	1360		3	3	y	n	n	n	n	n	n	n	60 mg	56,64	60	y	n	n	n	n	n	n
P	no ASA	872	891	79	m	PM	5760	280	1	4	y	y	n	n	n	n	n	n	60 mg	65,28	80	y	n	n	n	n	n	n
E	no ASA	872	916	77	f	PM	67	400	6	5	y	y	n	n	n	n	n	n	60 mg	78,97	67	y	n	y	n	n	n	n
E	no ASA	872	917	66	m	PM				3	y	y	n	n	n	n	n	n	60 mg	85,48	60	n	y	y	n	n	n	n
E	no ASA	872	1109	65	f	PM				6	y	y	n	y	n	n	n	n	60 mg	89,71	60	y	y	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	872	1143	79	f	PM				4	n	y	n	n	n	n	n	n	30 mg	46,29		y	y	y	n	n	n	n
E	ASA	873	910	83	m	PM				4	n	y	n	n	n	n	n	y	30 mg	40,32	66	y	n	n	n	n	n	n
E	ASA	874	716	71	m	PM	80	400	8	4	n	y	y, oa	n	n	y	y	n	30 mg	42,7	60	n	n	y	n	n	n	n
P	ASA	874	743	73	m	PM	357		3	3	y	y	n	n	n	n	n	n	60 mg	76,63		y	n	y	n	n	n	n
P	no ASA	874	792	94	f	PM	13		3	5	n	y	n	n	n	y	y	n	30 mg	17,07	70	y	n	y	n	n	n	n
P	ASA	874	806	74	m	PM	43	320	5	5	n	y	n	y	y	n	n	n	60 mg	95,88	60	n	n	y	n	n	n	n
P	ASA	874	827	83	f	PM	101	400	4	7	n	y	n	n	y	y	n	n	30 mg	43,65	60	n	y	y	n	n	n	n
E	no ASA	874	831	72	f	PM	9999	400	6	5	n	y	y, oa	n	n	n	n	n	60 mg	69	70	y	n	y	n	n	n	n
E	ASA	874	857	81	m	PM	9999	400	10	5	y	y	n	n	n	y	n	n	60 mg	78,98	80	n	y	y	n	n	n	n
E	ASA	874	858	71	m	PM	114	346	3	5	n	y	n	n	y	n	n	n	60 mg	75,24	80	y	n	y	n	n	n	n
P	ASA	874	870	81	m	PM	372	400	3	6	n	y	n	n	y	n	n	n	60 mg	62,71	64	y	n	y	n	n	n	n
E	ASA	874	871	81	m	PM	282	600	9	6	n	y	n	n	y	n	n	n	60 mg	64,13	80	y	n	y	n	n	n	n
E	no ASA	874	911	79	f	PM	318	400	2	7	n	y	n	y	y	n	n	n	30 mg	41,67	80	y	n	y	n	n	n	n
P	ASA	874	912	80	m	PM	42	400	2	6	n	y	n	n	y	n	n	n	30 mg	39,68	50	y	n	y	n	n	n	n
P	no ASA	874	913	75	f	PM	218	400	4	7	n	y	n	n	y	n	n	n	60 mg	63,53	60	y	n	y	n	n	n	n
E	ASA	874	932	87	f	PM	47	400	1	7	n	y	n	n	y	n	n	n	30 mg	31,79	60	n	n	y	n	n	n	n
P	ASA	874	994	77	m	PM	234	400	4	4	n	y	n	n	n	y	n	n	30 mg	48,47	60	y	n	y	n	y	n	n
P	ASA	874	1002	72	f	PM	861	400	8	7	n	y	y, oa	n	y	n	n	n	60 mg	85,51	72	n	y	y	n	n	n	n
P	no ASA	874	1158	84	f	PM	185	400	1	6	y	y	n	n	n	n	n	n	30 mg	38,58	60	n	n	y	n	n	n	n
E	ASA	874	1171	76	m	PM	599	400	8	5	y	y	n	n	n	n	n	n	60 mg	69,69	60	y	n	y	n	n	n	n
E	ASA	874	1181	78	m	PM	102	600	8	6	y	y	y, oa	n	n	y	y	n	60 mg	63,54	70	n	n	y	n	n	n	n
P	no ASA	874	1208	73	f	PM	928	400	6	6	y	y	n	n	y	n	n	n	60 mg	84,15	60	n	n	y	n	n	n	n
E	ASA	874	1469	83	f	PM	302	400	4	5	y	y	n	n	n	n	n	n	30 mg	28,25	60	y	n	y	n	n	n	n
E	ASA	874	1724	82	m	PM	4292	640	318	3	n	y	n	n	n	n	y	n	30 mg	42,88	60	y	n	y	n	n	n	n
E	ASA	874	1726	71	f	PM				4	n	y	y, it	n	n	n	n	n	30 mg	37,38	60	y	y	y	n	n	n	n
E	no ASA	875	636	79	f	PM	649	400	8	4	n	y	n	n	n	n	n	n	60 mg	61,85	56	y	y	y	n	n	n	n
E	ASA	875	638	65	f	PM	12	180	1	3	n	y	n	n	n	n	n	n	60 mg	56,35	64	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	875	646	66	m	PM	561	400	3	2	n	y	n	n	n	n	n	n	60 mg	71,15	77	y	n	y	n	n	n	n
E	no ASA	875	664	76	m	PM	23	233	1	3	n	y	n	n	n	n	n	n	60 mg	77,19	65	n	n	y	n	n	n	n
P	no ASA	875	751	75	f	PM	239	400	2	4	n	y	n	n	n	n	n	n	60 mg	53,04	63	y	n	y	n	n	n	n
P	no ASA	875	939	70	f	PM	190	400	1	4	y	y	n	n	n	n	n	n	60 mg	80,82	62	y	n	y	n	n	n	n
P	ASA	875	956	71	m	ICD	117	202	1	5	y	y	y, oa AND it	n	n	y	y	n	60 mg	79,04	65	y	n	y	n	n	n	n
E	ASA	875	1027	76	m	PM	1512	400	12	6	n	y	n	y	n	n	y	n	30 mg	41,93	68	y	y	y	n	n	n	n
E	no ASA	875	1043	65	m	PM	2265	400	15	3	y	y	n	n	n	n	n	n	60 mg	118,49	84	y	n	y	n	n	n	n
P	no ASA	875	1055	66	f	PM	8	175	1	3	n	y	n	n	n	n	n	n	60 mg	68,85	62	y	y	y	n	n	n	n
P	no ASA	875	1144	66	m	PM	126	400	1	4	y	y	y, oa	n	n	n	n	n	60 mg	108,11	74	y	n	y	n	n	n	n
E	no ASA	875	1197	68	m	PM	322	600	2	3	y	y	n	n	n	n	n	n	60 mg	126,95	79	y	n	y	n	n	n	n
E	no ASA	875	1284	77	m	PM	24	239	2	5	y	y	n	n	n	n	n	n	60 mg	107,3	67	y	n	y	n	n	n	n
P	no ASA	875	1608	65	f	PM	284	400	14	3	n	y	n	n	n	n	n	n	60 mg	109,44	71	y	y	n	n	n	n	n
P	no ASA	875	1650	65	m	PM	129		1	2	n	y	n	n	n	n	n	n	60 mg	110,95	60	n	n	y	n	n	n	n
E	no ASA	875	1676	65	f	PM	5760	346	2	3	y	n	n	n	n	n	n	n	60 mg	52,45	65	y	n	n	n	n	n	n
E	no ASA	875	1931	65	m	PM	399	175	7	3	y	y	n	n	n	n	n	n	60 mg	90,43	69	y	n	y	n	n	n	n
P	no ASA	875	2004	68	m	PM	1543	400	2	3	n	y	n	n	n	n	n	n	60 mg	82,5	98	y	n	y	n	n	n	n
E	ASA	875	2167	77	m	PM	345		3	5	y	y	n	n	n	y	n	n	60 mg	55	77	y	n	y	n	n	n	n
P	no ASA	875	2175	67	f	PM	600	400	4	3	n	y	n	n	n	n	n	n	60 mg	81,7	52	y	n	y	n	n	n	n
E	no ASA	875	2388	65	m	PM	901	400	7	4	y	y	y, oa AND it	n	n	n	n	n	60 mg	71,2	63	n	y	y	n	n	n	n
E	no ASA	875	2415	65	m	PM	148	400	3	3	y	y	n	n	n	n	n	n	60 mg	123,61	66	y	n	y	n	n	n	n
E	ASA	876	708	75	m	PM	36	640	2	5	n	n	n	y	n	n	n	n	60 mg	59,62	60	y	n	n	n	n	n	n
P	no ASA	876	736	78	m	PM	9999	380	7	4	n	y	n	n	n	n	n	n	60 mg	84,24	66	y	y	y	n	n	n	n
P	ASA	876	744	75	m	PM	31	308	1	3	n	y	n	n	n	n	n	n	60 mg	68,78	60	y	y	n	n	n	n	n
P	ASA	876	859	79	f	PM	418	640	1	6	y	y	y, oa	n	n	n	n	n	30 mg	37,65	60	n	y	y	n	n	n	n
P	no ASA	876	877	70	f	PM	273	400	10	4	n	y	y, oa	n	n	n	n	n	60 mg	54,85	80	n	y	y	n	n	n	n
P	ASA	876	896	71	m	PM-CRT				7	y	y	y, oa	y	n	y	n	n	60 mg	73,02	68	y	n	y	n	n	n	n
E	no ASA	876	901	79	f	PM	97	309	1	5	n	y	y, oa	n	n	n	n	n	60 mg	58,79	66	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	876	1145	83	m	PM	229	405	2	4	y	y	n	n	n	n	n	n	60 mg	56,86	54	n	n	y	n	n	n	n
P	no ASA	876	1385	78	f	PM	162	384	1	5	y	y	n	n	n	n	n	n	60 mg	63,72	78	n	y	y	n	n	n	n
E	no ASA	876	1443	79	m	PM	44		2	3	n	y	n	n	n	n	n	n	60 mg	53,32	75	y	n	y	n	n	n	n
P	no ASA	876	1628	75	f	PM				5	y	y	n	n	n	n	n	n	60 mg	69,76	64	n	n	y	n	n	n	n
E	no ASA	876	1656	81	f	PM	609	400	7	4	n	y	n	n	n	n	n	n	30 mg	42,69	60	n	y	y	n	n	n	n
E	ASA	876	1732	80	m	PM	5760	400	11	4	n	y	n	n	n	n	y	n	60 mg	91	72	y	n	n	n	n	n	n
P	no ASA	877	695	66	m	PM	126	214	6	2	n	y	n	n	n	n	n	n	60 mg	82,22	70	y	n	n	n	n	n	n
E	ASA	877	706	83	m	PM	633	600	1	5	y	y	y, oa	n	n	n	n	n	60 mg	58,76	68	y	n	y	n	n	n	n
E	no ASA	877	735	81	f	PM	119	321	1	5	y	y	n	n	n	n	n	n	30 mg	22,52	76	y	n	y	n	n	n	n
E	no ASA	877	737	72	m	PM	175	400	4	2	n	y	n	n	n	n	n	n	60 mg	63,24	65	y	y	n	n	n	n	n
P	no ASA	877	757	73	m	PM	1311	380	15	3	y	y	n	n	n	n	n	n	60 mg	65,69	65	y	n	n	n	n	n	n
P	ASA	877	801	71	f	PM	66	320	82	4	y	y	n	n	n	n	n	n	60 mg	57,1	70	y	n	y	n	n	n	n
E	ASA	877	853	67	m	PM-CRT	270		2	4	y	n	y, oa	n	n	y	y	y	60 mg	62,45	71	y	n	y	n	n	n	n
P	ASA	877	860	75	m	PM	16	321	1	5	y	y	n	n	n	y	n	y	60 mg	74,23	70	y	n	y	n	n	n	n
E	ASA	877	876	70	f	PM	3628	400	6	4	y	y	n	n	n	n	n	n	60 mg	62,22	60	y	y	y	n	n	n	n
E	no ASA	877	890	79	f	PM	1094	385	6	5	y	y	n	n	n	n	n	n	30 mg	33,65	69	y	n	n	n	n	n	n
P	no ASA	877	915	67	f	PM	1609	400	5	5	y	y	y, oa	n	n	n	n	n	60 mg	59,99	79	n	n	y	n	n	n	n
E	no ASA	877	1023	69	f	PM	695	308	1	4	y	y	n	n	n	n	n	n	60 mg	107,43	83	y	y	y	n	n	n	n
E	no ASA	877	1084	93	m	PM	606	400	13	4	y	y	n	n	n	n	n	n	30 mg	47,33	60	y	n	n	n	n	n	n
P	no ASA	877	1092	79	f	PM	725	275	1	5	y	y	n	n	n	n	n	n	30 mg	49,82	60	y	n	y	n	n	n	n
P	no ASA	877	1141	70	m	PM	9999	400	6	3	y	y	n	n	n	n	n	n	60 mg	87,77	90	n	y	y	n	n	n	n
P	ASA	877	1275	84	m	PM	15	600	1	7	y	y	y, oa	y	n	n	n	n	60 mg	52,23	89	n	n	y	n	n	n	n
P	ASA	877	1295	72	m	PM	17	400	3	4	y	y	n	n	n	y	n	n	60 mg	73,91	60	y	n	y	n	n	n	n
P	ASA	877	1352	79	f	PM	119	400	1	5	y	y	n	n	n	n	n	n	60 mg	72,01	82	y	n	y	n	n	n	n
P	no ASA	877	1592	78	f	PM	7	174	1	5	y	y	n	n	n	n	n	n	60 mg	57,44	70	y	n	y	n	n	n	n
E	no ASA	877	1613	81	m	PM	5760	400	11	4	y	y	n	n	n	n	n	n	60 mg	58,4	60	n	n	y	n	n	n	n
E	no ASA	877	1648	83	f	PM	48	346		5	y	y	n	n	n	n	n	n	30 mg	47,22	86	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	877	1649	65	f	PM	26	175	1	6	y	y	n	y	n	n	n	n	30 mg	32,49	64	n	y	y	n	n	n	n
E	no ASA	877	1679	69	f	PM	463		1	5	y	y	y, oa	n	n	n	n	n	60 mg	96,09	65	y	y	y	n	n	n	n
P	no ASA	877	1795	66	m	PM	126	400	2	2	n	y	n	n	n	n	n	n	60 mg	65,5	54	y	n	n	n	n	n	n
E	ASA	877	1803	85	m	PM	1673	380	26	4	y	y	n	n	n	n	n	n	60 mg	78,25	65	y	y	n	n	n	n	n
P	ASA	877	1919	73	m	PM	6348		1	5	y	y	y, oa	n	n	y	n	n	30 mg	43,14	60	y	n	y	n	n	n	n
E	ASA	877	2003	75	m	PM	9999		1	7	y	y	n	y	n	y	y	n	60 mg	61,87	62	y	y	y	n	n	n	n
E	ASA	877	2050	79	m	PM	31		2	4	y	y	n	n	n	n	n	n	60 mg	57,12	80	y	n	y	n	n	n	n
P	no ASA	877	2132	80	f	PM	1110	400	9	5	y	y	n	n	n	n	n	n	60 mg	52,57	68	y	n	y	n	n	n	n
P	ASA	877	2260	80	f	PM	84	400	3	6	y	y	y, oa	n	n	n	n	n	60 mg	77,74	82	y	n	y	n	n	n	n
P	no ASA	877	2276	69	m	PM	2994		3	3	y	y	n	n	n	n	n	n	60 mg	84,63	60	y	y	n	n	n	n	n
P	no ASA	877	2285	77	m	PM	172		3	4	y	y	n	n	n	n	n	n	60 mg	58,54	65	n	y	y	n	n	n	n
E	ASA	881	893	74	f	PM				7	y	y	n	n	y	y	n	n	60 mg	64,93	66	n	n	y	n	n	n	n
E	no ASA	884	1377	88	f	PM	20	357	1	4	n	y	n	n	n	n	n	n	30 mg	47,01		y	y	y	n	n	n	n
P	ASA	884	1495	65	m	ICD	20		1	4	y	n	n	n	n	y	y	n	60 mg	89,88	53	y	n	y	n	n	n	n
E	ASA	901	882	88	f	PM	24	300	2	5	n	y	n	n	n	n	y	n	30 mg	37,78	67	y	y	n	n	n	n	n
		901	944	78	f					4																		
P	ASA	901	984	75	m	PM	2153	600	1	3	n	y	n	n	n	n	y	n	60 mg	91,43	79	y	n	n	n	n	n	n
E	ASA	901	1038	71	m	PM-CRT	1260	500	1	4	n	y	y, it	n	n	y	y	n	60 mg	92,64	59	n	y	y	n	n	n	n
E	no ASA	901	1057	72	f	PM	28	300	1	3	n	y	n	n	n	n	n	n	60 mg	88,33	71	n	y	y	n	n	n	n
E	ASA	901	1120	89	m	PM	420		1	7	n	y	y, oa	n	y	n	y	y	30 mg	47,05	83	y	y	n	n	n	n	n
E	ASA	901	1138	77	m	PM	540	400	2	6	n	y	n	y	n	n	n	y	60 mg	68,41	63	y	y	y	n	n	n	n
P	no ASA	901	1217	80	m	PM	198	300	3	3	y	n	n	n	n	n	n	n	60 mg	79,55	61	y	n	n	n	n	n	n
P	ASA	901	1549	65	m	PM-CRT	106	545	1	5	y	y	y, it	n	n	y	y	y	60 mg	77,33		y	n	y	n	n	n	n
P	ASA	901	1564	68	m	PM	68			3	n	y	y, it	n	n	n	y	n	60 mg	140,87	93	n	n	y	n	n	n	n
P	no ASA	901	1566	82	m	PM	1459	545	2	3	n	y	n	n	n	n	n	n	60 mg	72,13	82	n	y	y	n	n	n	n
P	no ASA	901	1711	77	m	PM	187	545	1	2	n	n	n	n	n	n	n	n	60 mg	90,59	69	n	n	n	n	n	n	n
E	no ASA	901	1720	87	f	PM	22	400	1	6	n	y	n	n	n	y	y	n	30 mg	39,43	72	y	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	901	1859	78	m	PM	78		7	3	n	n	n	n	n	n	n	n	60 mg	78,04	61	y	n	n	n	n	n	n
E	no ASA	901	1880	65	m	PM	141	400	1	2	n	y	n	n	n	n	n	n	60 mg	139,6	67	y	n	y	n	n	n	n
E	no ASA	901	2135	74	m	PM	17	362	3	2	n	y	n	n	n	n	n	n	60 mg	79,71	81	y	n	n	n	n	n	n
P	no ASA	901	2381	70	f	PM	5760	400	2	3	n	y	n	n	n	n	n	n	60 mg	87,8	79	n	y	y	n	n	n	n
E	ASA	901	2427	81	m	PM	783	400	1	6	y	y	y, oa	n	n	y	y	y	60 mg	89,38	60	y	n	y	n	n	n	n
E	no ASA	901	2435	83	m	PM				3	n	n	y, oa	n	n	n	n	n	30 mg	43,65		n	n	n	n	n	n	n
P	ASA	901	2473	70	f	PM				4	n	n	n	y	n	n	n	n	60 mg	58,73	69	n	n	n	n	n	n	n
P	no ASA	901	2476	75	f	PM	505		2	4	n	y	n	n	n	n	n	n	60 mg	96,1	69	n	n	y	n	n	n	n
E	ASA	901	2480	70	f	PM	2224	261	1	4	n	y	n	n	n	n	n	n	60 mg	62,14	63	n	n	n	n	n	n	n
P	ASA	901	2490	66	m	PM	250	400	1	4	n	n	n	n	y	n	n	n	60 mg	74,66	66	y	n	n	n	n	n	n
E	no ASA	901	2595	83	f	PM	239	400	3	7	n	y	y, oa	n	y	n	n	n	30 mg	49,38	68	n	n	n	n	n	n	n
P	ASA	901	2601	85	m	PM	782	400	3	4	n	y	y, oa	n	n	n	n	n	60 mg	78,63	116	y	n	y	n	n	n	n
E	no ASA	901	2638	86	f	PM				4	n	y	n	n	n	n	n	n	30 mg	40,55	71	n	y	n	n	n	n	n
P	ASA	901	2666	74	m	PM				3	n	y	n	n	n	n	y	n	60 mg	72,39	65	y	n	y	n	n	n	n
E	ASA	901	2706	84	m	PM	278		3	4	n	y	n	n	n	n	y	n	60 mg	50,93	66	y	n	y	n	n	n	n
E	ASA	901	2723	79	m	PM	50	400	1	4	n	y	y, oa AND it	n	n	n	y	n	30 mg	49,58	106	y	n	y	n	n	n	n
E	no ASA	901	2739	81	m	PM	9	270	1	3	n	y	n	n	n	n	n	n	60 mg	99,5	68	n	y	n	n	n	n	n
P	no ASA	964	1273	75	f	PM				5	n	y	n	n	n	y	n	n	60 mg	57,81	60	n	y	n	n	n	n	n
P	ASA	965	1049	67	m	PM	46	640	1	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	67,97	78	y	n	y	n	n	n	n
E	no ASA	965	1323	81	f	PM	87	272	2	5	n	y	n	n	n	n	n	n	30 mg	47,79	60	y	y	y	n	n	n	n
P	ASA	965	2280	86	m	PM	7		1	5	n	y	n	y	n	n	n	n	60 mg	50,78	66	y	n	n	n	n	n	n
E	ASA	965	2321	79	f	PM	24		1	7	n	y	n	y	y	n	n	n	60 mg	58,42	66	n	y	y	n	n	n	n
E	ASA	965	2420	83	f	PM	19	394	1	4	y	n	n	n	n	n	y	n	30 mg	27,8		y	n	n	n	n	n	n
E	no ASA	965	2426	81	m	PM	661		1	3	n	y	n	n	n	n	n	n	60 mg	65,12	49	n	n	y	n	n	n	n
P	no ASA	965	2488	79	m	PM	47		3	3	n	y	n	n	n	n	n	n	60 mg	77,72	65	n	y	y	n	n	n	n
P	no ASA	965	2550	86	m	PM	15		2	3	n	y	n	n	n	n	n	n	60 mg	57,49	62	n	y	y	n	n	n	n
E	ASA	965	2664	73	f	PM				3	n	y	n	n	n	n	n	n	30 mg	38,09		y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	1023	709	70	f	PM	192	400	1	4	n	n	y, oa	n	n	n	n	n	60 mg	55,37	68	y	y	n	n	n	n	n
E	no ASA	1023	2022	74	m	ICD				2	n	y	n	n	n	n	n	n	60 mg	69,21		n	n	y	n	n	n	n
P	ASA	1023	2097	73	m	ICD	361	355	2	3	n	y	n	n	n	y	y	n	60 mg	59,71		n	y	y	n	n	n	n
P	no ASA	1023	2271	66	f	PM	8	400	2	5	n	y	n	n	y	n	n	n	60 mg	80,17	84	n	y	n	n	n	n	n
		1023	2289	77	m					5																		
P	ASA	1023	2366	66	f	ICD-CRT				5	y	y	n	n	n	n	y	n	60 mg	65,52	62	n	n	y	n	n	n	n
		1028	797	77	m					5																		
		1028	844	69	f					4									60 mg	56,36								
P	ASA	1028	1172	82	m	ICD-CRT	26	500	1	3	n	n	n	n	n	n	n	y	60 mg	55,22	51	y	n	n	n	n	n	n
E	ASA	1028	1313	66	m	PM	92	400	2	2	n	y	n	n	n	n	n	n	60 mg	115,54	78	y	n	y	n	n	n	n
E	no ASA	1028	1314	80	m	PM	30	500	1	3	n	y	n	n	n	n	n	n	60 mg	98,77	95	n	y	y	n	n	n	n
P	no ASA	1028	1342	81	f	PM	431	640	1	5	n	y	y, oa	n	n	n	n	n	30 mg	60,34	80	n	n	y	n	n	n	n
E	no ASA	1028	1344	80	m	ICD-CRT	372	600	3	4	y	y	n	n	n	n	n	n	60 mg	51,1	62	y	n	y	n	n	n	n
E	no ASA	1028	1539	81	f	ICM	402		2	3	n	n	n	n	n	n	n	n	60 mg	50,76	57	n	n	n	n	n	n	n
E	no ASA	1028	1547	84	f	PM	47	400	3	4	n	y	n	n	n	n	n	n	60 mg	60,79	67	n	y	n	n	n	n	n
E	ASA	1028	1553	87	m	PM	1181	253	1	4	n	y	n	n	n	y	y	n	30 mg	42,06	80	n	y	n	n	n	n	n
P	no ASA	1028	1561	73	m	PM	97	640	1	2	n	y	n	n	n	n	n	n	60 mg	110,44	66	n	y	n	n	n	n	n
P	no ASA	1028	2156	77	m	PM-CRT				4	y	n	n	n	n	n	n	n	30 mg	39,54	65	y	n	n	n	n	n	n
P	no ASA	1028	2159	67	m	PM	266		1	2	n	y	n	n	n	n	n	n	60 mg	107,06	90	n	y	y	n	n	n	n
E	no ASA	1028	2160	72	f	PM	16		1	3	n	y	n	n	n	n	n	n	60 mg	80,42	69	n	y	n	n	n	n	n
E	no ASA	1028	2251	73	m	ICD	1185	545	1	3	y	y	n	n	n	n	n	n	60 mg	90,9	58	y	n	y	n	n	n	n
E	no ASA	1028	2504	87	f	PM	84	640	1	4	n	y	n	n	n	n	n	n	30 mg	46,87	86	y	n	y	n	n	n	n
P	ASA	1028	2573	73	m	PM	689	545	1	3	y	y	n	n	n	n	n	n	60 mg	88,55	71	y	n	y	n	n	n	n
E	no ASA	1028	2694	77	m	PM	21		1	4	n	y	y, oa	n	n	n	n	n	60 mg	55	90	n	n	n	n	n	n	n
P	no ASA	1028	2696	83	m	PM	36	500	1	3	n	y	n	n	n	n	n	n	60 mg	70,49	90	n	y	y	n	n	n	n
E	no ASA	1029	900	79	f	PM	159	320	10	5	y	y	n	n	n	n	n	n	60 mg	65,47	75	y	n	y	n	n	n	n
P	ASA	1029	949	82	m	PM	124	305	3	5	n	y	n	y	n	n	n	n	60 mg	63,77	65	n	n	n	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	1029	961	74	m	PM				2	n	y	n	n	n	n	n	n	60 mg	76,74	65	y	n	n	n	n	n	n
E	no ASA	1029	1053	80	f	PM	901	400	6	4	n	y	n	n	n	n	n	n	60 mg	56,42	60	y	y	y	n	n	n	n
P	ASA	1029	1159	88	f	PM	666	640	6	7	n	y	n	y	n	n	n	n	30 mg	46,66	60	y	n	y	n	n	n	n
E	no ASA	1029	1177	70	m	PM	241	500	3	2	n	y	n	n	n	n	n	n	60 mg	112,6	77	y	y	y	n	n	n	n
P	no ASA	1029	1236	81	f	PM	9	400	2	4	n	y	n	n	n	n	n	n	30 mg	44,58	72	y	n	y	n	n	n	n
P	no ASA	1029	1242	79	f	PM	159	320	10	4	n	y	n	n	n	n	n	n	60 mg	50,29	75	y	y	y	n	n	n	n
E	ASA	1029	1243	87	m	PM	376	400	2	4	n	n	n	y	n	n	n	n	30 mg	34,64	90	n	n	n	n	n	n	n
E	ASA	1029	1256	68	m	ICD	169	640	2	4	n	y	y, oa	n	n	y	n	n	60 mg	91,82	90	y	n	y	n	n	n	n
E	no ASA	1029	1335	77	m	PM	36	175	1	4	n	y	y, oa	n	n	n	n	n	60 mg	83,85	75	n	n	y	n	n	n	n
P	no ASA	1029	1437	77	f	PM	19	300	3	4	n	y	n	n	n	n	n	n	30 mg	42,5	75	y	y	y	n	n	n	n
E	no ASA	1029	1441	69	m	PM	470	400	3	2	n	y	n	n	n	n	n	n	60 mg	63,14	80	y	y	n	n	n	n	n
P	no ASA	1029	1588	82	m	PM	21		5	5	n	y	y, oa	n	n	n	n	n	60 mg	58,71	75	y	n	y	n	n	n	n
P	ASA	1029	1617	69	m	PM	818		3	4	y	y	y, oa	n	n	n	n	n	60 mg	79,55	75	y	n	y	n	n	n	n
E	no ASA	1029	1735	85	f	PM	908		10	4	n	y	n	n	n	n	n	n	30 mg	32,47	70	y	n	n	n	n	n	n
P	no ASA	1029	1878	88	f	PM	12	178	1	3	n	n	n	n	n	n	n	n	30 mg	24,86	80	y	n	n	n	n	n	n
E	ASA	1029	1917	84	f	PM	142		3	6	y	y	n	n	n	y	y	n	30 mg	34,96	60	y	n	n	n	n	n	n
E	ASA	1029	1936	82	m	ICD	1041	600	3	5	y	y	n	n	n	n	n	n	60 mg	142,5	70	y	n	y	n	n	n	n
P	ASA	1029	1986	70	f	PM				5	y	y	n	n	n	n	n	n	60 mg	95,03	60	y	n	y	y	n	n	n
E	ASA	1029	2090	87	f	PM	1440		2	4	n	y	n	n	n	n	n	n	30 mg	36,83	65	y	y	y	n	n	n	n
P	ASA	1029	2093	76	f	PM	28	182	11	5	n	y	n	n	n	y	n	n	60 mg	83,33	65	y	n	y	n	n	n	n
E	ASA	1029	2108	85	f	PM	622	400	10	3	n	n	n	n	n	n	n	n	60 mg	72,44		y	n	y	n	n	n	n
P	ASA	1029	2155	80	f	PM				4	n	y	n	n	n	n	n	n	30 mg	43,12	70	y	y	y	n	n	n	n
P	ASA	1029	2178	89	m	PM	88		2	5	y	y	n	n	n	y	y	n	60 mg	62,5	78	y	y	y	n	n	n	n
E	ASA	1029	2180	74	m	PM	428		1	4	n	y	n	y	n	n	n	n	60 mg	69,67	65	y	n	y	n	n	n	n
P	no ASA	1029	2345	86	f	PM	161		3	4	n	y	n	n	n	n	n	n	30 mg	55,92	75	n	n	y	n	n	n	n
E	ASA	1039	1227	80	m	ICD-CRT	14		1	5	y	y	n	n	n	y	y	y	30 mg	40,09		y	n	n	n	y	n	n
P	ASA	1039	1407	78	m	PM	6	207	1	5	n	y	y, oa	n	n	n	n	n	60 mg	58,87	141	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	1039	1459	86	m	PM	98	400	1	3	n	y	n	n	n	n	n	n	60 mg	84,38	73	n	n	y	n	n	n	n
E	ASA	1039	1467	80	m	ICD-CRT	628	545	1	6	y	y	y, it	n	n	y	n	y	30 mg	24,58	73	y	n	n	n	n	y	n
E	ASA	1039	1534	78	m	PM-CRT	223	640	1	4	y	y	n	n	n	n	y	n	60 mg	57,82		y	n	n	n	n	n	n
		1039	2269	82	m		365	400	1	5																		
E	ASA	1039	2503	69	f	PM				3	n	y	n	n	n	n	n	n	60 mg	112,15	60	n	n	n	n	n	n	n
P	ASA	1039	2562	84	f	PM	78	263	1	6	y	y	y, oa	n	n	n	y	n	30 mg	35,42	73	y	n	y	n	n	n	n
P	no ASA	1039	2690	75	f	ICD	7		1	5	n	y	y, oa	n	n	n	n	n	60 mg	54,41	82	y	n	y	n	n	n	n
E	ASA	1048	2170	81	f	PM	163		1	5	n	y	y, it	n	n	n	n	n	60 mg	52,87	95	n	n	y	n	n	n	n
P	ASA	1048	2225	88	f	PM	310	640	7	6	n	y	n	n	y	n	n	n	30 mg	40,16	77	y	n	y	n	n	n	n
P	ASA	1048	2619	78	m	PM	10		3	3	n	y	n	n	n	n	n	n	60 mg	54,52	71	n	y	y	n	n	n	n
P	no ASA	1049	1359	68	f	PM	77		1	3	n	y	n	n	n	n	n	n	60 mg	84,54	60	y	n	y	n	n	n	n
P	no ASA	1049	2231	87	m	PM				3	n	y	n	n	n	n	n	n	30 mg	33,89	80	y	n	y	n	n	n	n
P	ASA	1049	2335	80	f	PM	216	400	2	7	y	y	y, oa	n	n	y	n	n	60 mg	68,77	72	y	n	y	n	n	n	n
E	no ASA	1067	2714	77	f	ICM				4	n	y	n	n	n	n	n	n	60 mg	73,19	62	y	y	y	n	n	n	n
P	ASA	1071	1240	77	m	PM	599	400	84	3	n	n	n	n	n	n	n	n	60 mg	85,2	75	n	n	n	n	n	n	n
E	ASA	1071	1241	65	m	ICD	258	500	1	4	y	y	n	n	n	y	y	n	30 mg	33,68	60	y	n	y	n	n	n	n
E	no ASA	1074	1294	66	m	PM	17	400	3	2	n	n	y, it	n	n	n	n	n	60 mg	111,34	80	n	n	n	n	n	n	n
E	no ASA	1074	1305	84	f	PM	313	640	11	5	n	y	y, oa	n	n	n	n	n	30 mg	36,33	60	y	y	y	n	n	n	n
P	no ASA	1074	1325	91	m	PM	158		3	5	n	y	n	y	y	n	n	n	30 mg	38,75	66	n	y	n	n	n	n	n
P	no ASA	1074	1337	87	f	PM	341	430	1	5	y	y	n	n	n	n	n	n	30 mg	48,9	60	y	n	y	n	n	n	n
E	no ASA	1074	1365	67	f	PM				3	n	y	n	n	n	n	n	n	30 mg	56,2	80	y	n	n	n	n	n	n
P	no ASA	1074	1402	77	f	PM	182	307	1	5	n	y	n	n	n	n	n	n	30 mg	36,06	60	y	y	y	n	n	n	n
P	no ASA	1074	1403	75	m	PM	45	400	1	3	n	n	n	n	n	n	n	n	60 mg	58,42	60	n	n	n	n	n	n	n
E	ASA	1074	1420	68	m	PM	92	400	1	4	n	y	y, oa	n	n	n	y	n	60 mg	87,96	75	y	n	y	n	n	n	n
E	ASA	1074	1424	68	m	PM	357	300	2	4	n	y	y, it	n	n	n	y	n	60 mg	50,6	106	y	y	n	n	n	n	n
E	no ASA	1074	1446	79	f	PM	814		1	4	n	y	n	n	n	n	n	n	60 mg	66,97	60	y	y	y	n	n	n	n
P	no ASA	1074	1548	83	f	PM	20	320	2	4	n	y	n	n	n	n	n	n	30 mg	40,17	70	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	1074	1557	72	m	PM	49		7	3	n	y	n	n	n	n	n	y	60 mg	56,51	62	n	y	y	n	n	n	n
E	no ASA	1074	1565	76	m	PM	11	346	2	3	n	y	n	n	n	n	n	n	60 mg	88,91	74	n	n	y	n	n	n	n
P	no ASA	1074	1607	82	m	PM	332	400	2	4	n	y	n	n	n	n	n	n	60 mg	64,77	80	n	n	y	n	n	n	n
P	no ASA	1074	1696	72	f	PM	321	400	10	3	n	y	n	n	n	n	n	n	60 mg	80,28	60	y	n	y	n	n	n	n
P	no ASA	1074	1697	77	m	PM	53	384		4	n	y	n	n	n	y	y	n	30 mg	48,47	60	y	y	n	n	n	n	n
E	no ASA	1074	1699	91	f	PM	8090	614	9	5	n	y	n	n	n	y	n	n	30 mg	24,08	60	y	n	n	n	n	n	n
E	no ASA	1074	1708	91	f	PM	82		1	5	n	y	n	n	n	y	y	n	30 mg	39,58	60	y	y	y	n	n	n	n
E	no ASA	1074	1756	79	m	PM	1440		2	5	n	n	n	y	n	n	y	n	60 mg	75,22	60	y	n	n	n	n	n	n
P	no ASA	1074	1811	85	m	PM				3	n	y	n	n	n	n	n	n	60 mg	74,57	75	y	n	n	n	n	n	n
P	ASA	1074	1838	75	f	PM	280	500	1	6	n	y	y, oa	n	n	y	y	n	60 mg	89,86	60	y	n	y	n	n	n	n
E	ASA	1074	1842	68	m	PM	67	545	4	4	y	y	n	n	n	n	y	n	60 mg	126,21	60	y	n	y	n	n	n	n
P	no ASA	1074	1893	88	m	PM	196	439	1	3	n	y	n	n	n	n	n	n	60 mg	59,88	75	n	y	y	n	n	n	n
E	no ASA	1074	1952	82	m	PM	516	400	7	3	n	y	n	n	n	n	n	n	30 mg	45,42	60	y	n	n	n	n	n	n
E	no ASA	1074	1968	84	f	PM	1381	400	12	9	y	y	y, it	n	y	y	y	n	30 mg	29,51	80	y	n	n	n	n	n	n
P	no ASA	1074	1972	79	f	PM	177		1	4	n	y	n	n	n	n	n	n	60 mg	55,97	70	n	n	y	n	n	n	n
E	no ASA	1074	2009	72	m	PM	46	545	2	3	y	y	n	n	n	n	n	n	60 mg	85,05	75	n	n	y	n	n	n	n
E	no ASA	1074	2075	87	f	PM				4	n	y	n	n	n	n	n	n	30 mg	47,91	60	n	n	y	n	n	n	n
P	no ASA	1074	2080	81	f	PM	262	400	1	5	y	y	n	n	n	n	n	n	30 mg	43,63	75	y	y	y	n	n	n	n
P	ASA	1074	2143	74	m	PM	99	591	1	4	y	y	n	n	n	y	y	n	60 mg	53,1	60	y	y	y	n	n	n	n
P	no ASA	1074	2162	81	m	PM	155	400	2	3	n	y	n	n	n	n	n	n	60 mg	66,4	70	n	n	y	n	n	n	n
E	ASA	1074	2192	76	f	PM	686	400	8	6	n	y	y, oa	n	n	y	y	y	60 mg	62,2	70	y	n	y	n	n	n	n
P	no ASA	1074	2235	81	f	PM	10	208	1	5	y	y	n	n	n	n	n	n	30 mg	43,97	75	y	y	y	n	n	n	n
E	no ASA	1074	2246	80	m	PM	632	640	5	2	n	n	n	n	n	n	n	n	60 mg	77,72	65	n	n	n	n	n	n	n
P	no ASA	1074	2300	81	m	PM	2713	640	4	4	n	y	n	n	n	n	n	n	60 mg	79,82	60	y	n	n	n	n	n	n
E	no ASA	1074	2308	81	f	PM	32	205	1	3	n	n	n	n	n	n	n	n	30 mg	65,3	75	n	n	n	n	n	n	n
P	no ASA	1074	2515	74	f	PM	11		1	4	n	y	y, oa	n	n	n	n	n	30 mg	43,06	68	y	y	y	n	n	n	n
E	no ASA	1074	2561	68	m	PM	274	400	15	3	n	y	y, oa	n	n	n	n	y	60 mg	65,74	85	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	1074	2665	83	m	PM	676	341	1	4	n	y	y, oa	n	n	n	n	n	60 mg	84,11	70	n	y	n	n	n	n	n
P	ASA	1074	2672	76	f	PM	1061	400	7	6	n	y	y, it	n	n	y	y	n	30 mg	54,95	60	n	n	n	n	n	n	n
E	no ASA	1074	2707	76	m	PM	63	591	2	4	n	n	n	n	y	n	n	n	60 mg	55,89	60	y	n	n	n	n	n	n
P	no ASA	1074	2720	72	m	PM	1811	640	4	2	n	y	n	n	n	n	n	n	60 mg	58,73	93	n	n	y	n	n	n	n
E	no ASA	1080	1371	65	f	PM	87		4	3	n	y	n	n	n	n	n	n	60 mg	94,03	70	y	n	n	n	n	n	n
E	no ASA	1080	1388	66	f	PM				3	n	y	n	n	n	n	n	n	60 mg	104,83	60	n	n	y	n	n	n	n
P	no ASA	1080	1396	85	f	PM				4	n	y	n	n	n	n	n	n	60 mg	64,93	110	y	y	y	n	n	n	n
E	no ASA	1080	1444	79	f	PM	294	400	10	4	y	n	n	n	n	n	n	n	30 mg	45,89	70	y	n	y	n	n	n	n
P	no ASA	1080	1445	84	m	PM	13	400	1	3	n	y	n	n	n	n	n	n	60 mg	64,81	70	y	n	n	n	n	n	n
E	no ASA	1080	1462	80	f	PM	455	400	12	3	n	n	n	n	n	n	n	n	60 mg	52,22	60	y	n	n	n	n	n	n
P	no ASA	1080	1475	78	f	PM				4	n	y	n	n	n	n	n	n	30 mg	27,35	75	n	n	y	n	n	n	n
P	no ASA	1080	1478	73	f	PM	6	317	1	3	n	y	n	n	n	n	n	n	30 mg	45,24	80	n	n	y	n	n	n	n
P	no ASA	1080	1536	67	f	PM	720	640	5	3	n	y	n	n	n	n	n	n	60 mg	96,84	65	n	y	y	n	n	n	n
E	no ASA	1080	1538	81	f	PM	270	640	2	4	n	y	n	n	n	n	n	n	60 mg	71,66		n	n	y	n	n	n	n
E	no ASA	1080	1571	89	f	PM	783	400	12	4	n	y	n	n	n	n	n	n	30 mg	34,21	55	y	n	n	n	n	n	n
P	no ASA	1080	1573	77	f	PM	111	400	2	4	n	y	n	n	n	n	n	n	30 mg	49,23	60	y	n	n	n	n	n	n
E	no ASA	1080	1615	72	f	PM	21	614	1	3	n	y	n	n	n	n	n	n	60 mg	72,95	60	n	y	y	n	n	n	n
E	no ASA	1080	1636	70	f	PM				3	n	y	n	n	n	n	n	n	60 mg	68,48	60	n	n	y	n	n	n	n
P	no ASA	1080	1643	82	f	PM	885	640	1	4	n	y	n	n	n	n	n	n	30 mg	37,4	62	y	n	n	n	n	n	n
P	no ASA	1080	1660	69	f	ICD	114	429	16	3	y	n	n	n	n	n	n	n	30 mg	27,36	70	y	n	y	n	n	n	n
P	no ASA	1080	1661	83	f	PM	55	400	4	4	n	y	n	n	n	n	n	n	30 mg	38,03	60	y	n	y	n	n	n	n
E	no ASA	1080	1665	67	m	PM				3	n	n	n	y	n	n	n	n	60 mg	67,29	60	y	n	n	n	n	n	n
E	no ASA	1080	1671	73	f	PM	50	317	1	3	n	y	n	n	n	n	n	y	60 mg	69,79	70	n	y	n	n	n	n	n
P	no ASA	1080	1688	73	m	PM	829		3	2	n	y	n	n	n	n	n	n	60 mg	67,33	65	n	n	y	n	n	n	n
E	no ASA	1080	1694	67	f	PM	450	400	6	3	n	y	n	n	n	n	n	n	30 mg	49	60	n	n	y	n	n	n	n
P	no ASA	1080	1695	67	f	PM	312	375	7	3	n	y	n	n	n	n	n	n	60 mg	65,83	80	y	n	n	n	n	n	n
E	no ASA	1080	1700	67	f	PM	36	400	4	3	n	y	n	n	n	n	n	n	60 mg	64,39	80	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	1080	1703	65	m	PM	545	240	181	2	n	y	n	n	n	n	n	n	60 mg	75,59	70	n	y	y	n	n	n	n
P	no ASA	1080	1707	69	f	PM	4674	640	1951	3	n	y	n	n	n	n	n	n	60 mg	84,83	88	n	n	y	n	n	n	n
E	no ASA	1080	1721	80	f	PM	5134	400	10	6	n	y	n	y	n	n	n	n	30 mg	33,18	65	y	n	n	n	n	n	n
E	no ASA	1080	1728	67	m	PM	863	400	10	2	n	y	n	n	n	n	n	n	60 mg	79,52	65	y	n	y	n	n	n	n
P	no ASA	1080	1734	77	f	PM	3940	400	7	4	n	y	n	n	n	n	n	n	30 mg	32,89	65	y	n	y	n	n	n	n
E	no ASA	1080	1736	83	f	PM	61	400	7	4	n	y	n	n	n	n	n	n	30 mg	41,69	85	n	n	y	n	n	n	n
P	no ASA	1080	1740	80	f	PM	5760	400	11	6	n	y	n	n	y	n	n	n	60 mg	56,99	56	y	y	y	n	n	n	n
P	no ASA	1080	1743	65	m	PM	297	400	5	2	n	y	n	n	n	n	n	n	60 mg	71,9	70	y	n	y	n	n	n	n
E	no ASA	1080	1744	65	f	PM	3905	480	1	3	n	y	n	n	n	n	n	n	60 mg	63,37	65	y	n	y	n	n	n	n
P	no ASA	1080	1746	66	m	PM	925	600	4	2	n	y	n	n	n	n	n	n	60 mg	154,01	66	n	y	y	n	n	n	n
P	no ASA	1080	1749	65	f	PM				3	n	y	n	n	n	n	n	n	60 mg	108,51	85	n	n	y	n	n	n	n
E	no ASA	1080	1754	74	f	PM	1954		2	3	n	y	n	n	n	n	n	n	60 mg	60,06	60	n	n	y	n	n	n	n
E	no ASA	1080	1762	80	f	PM	41		1	4	n	y	n	n	n	n	n	n	60 mg	56,42	60	n	y	y	n	n	n	n
E	ASA	1080	1765	66	m	PM	1002	400	7	3	n	y	n	n	n	y	n	n	60 mg	89,13	75	y	n	y	n	n	n	n
E	ASA	1080	1778	83	m	PM				4	n	y	n	n	n	y	n	n	60 mg	52,54	90	y	n	y	n	n	n	n
P	ASA	1080	1784	80	m	PM	69	400	3	4	n	y	n	n	n	y	n	y	60 mg	65,27	60	y	n	y	n	n	n	n
E	no ASA	1080	1786	77	m	PM	1012		53	3	n	y	n	n	n	n	n	n	60 mg	67,97	55	y	n	y	n	n	n	n
E	ASA	1080	1793	82	m	PM	5760	400	4	4	n	y	n	n	n	y	y	n	60 mg	86,48	60	y	n	y	n	n	n	n
P	no ASA	1080	1798	65	f	PM	63	400	1	3	n	y	n	n	n	n	n	n	60 mg	65,1	67	n	y	y	n	n	n	n
E	no ASA	1080	1802	73	f	PM	15	640	1	3	n	y	n	n	n	n	n	n	60 mg	80,15	55	n	n	y	n	n	n	n
P	no ASA	1080	1814	65	f	PM	147		2	3	n	y	n	n	n	n	n	n	60 mg	58,77	60	n	y	y	n	n	n	n
E	no ASA	1080	1822	78	f	PM	2413	400	835	7	n	y	y, oa	y	n	n	n	n	30 mg	44,7	60	y	n	y	n	n	n	n
P	no ASA	1080	1843	67	f	PM	4421	600	38	3	n	y	n	n	n	n	n	n	60 mg	76,6	90	y	n	n	n	n	n	n
P	no ASA	1080	1856	87	f	PM				4	n	y	n	n	n	n	n	n	30 mg	41,27	90	n	n	y	n	n	n	n
E	no ASA	1080	1861	82	f	PM	631	400	2	4	n	y	n	n	n	n	n	n	30 mg	35,2	80	n	y	n	n	n	n	n
E	no ASA	1080	1863	71	f	PM	9999	512	8	4	n	y	y, oa	n	n	n	n	n	60 mg	55,15	80	n	n	y	n	n	n	n
P	no ASA	1080	1874	71	f	PM	66	331	1	3	n	y	n	n	n	n	n	n	30 mg	40,73	85	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	no ASA	1080	1888	66	f	PM	1581	400	2	3	n	y	n	n	n	n	n	n	60 mg	93,09	60	y	n	n	n	n	n	n
E	no ASA	1080	1890	67	m	PM	783	400	6	3	n	y	y, oa	n	n	n	n	n	60 mg	90,67	70	y	y	n	n	n	n	n
E	no ASA	1080	1912	75	f	PM	1838	400	12	4	n	y	n	n	n	n	n	n	60 mg	59,68	60	y	n	y	n	n	n	n
P	no ASA	1080	1914	71	m	PM	900	400	4	2	n	y	n	n	n	n	n	n	60 mg	73,28	60	y	n	y	n	n	n	n
P	ASA	1080	1915	84	m	PM	1156	400	3	3	n	y	n	n	n	n	y	n	60 mg	55,2	65	y	n	y	n	n	n	n
E	no ASA	1080	1937	74	f	PM			2	3	n	y	n	n	n	n	n	n	60 mg	89,35	69	y	n	y	n	n	n	n
P	no ASA	1080	1945	65	f	PM	1238	640	15	4	y	y	n	n	n	n	n	n	60 mg	85,46	60	y	n	y	n	n	n	n
P	no ASA	1080	1948	76	m	PM	14		1	3	n	y	n	n	n	n	n	n	60 mg	55,76	90	n	n	y	n	n	n	n
E	no ASA	1080	1977	73	m	ICD-CRT	9	182	1	4	y	y	n	n	n	y	n	n	30 mg	41,89	80	y	n	y	n	n	n	n
E	no ASA	1080	1988	86	m	ICD-CRT	2166	640	1	3	y	n	n	n	n	n	n	n	30 mg	41,06	76	y	n	y	n	n	n	n
E	no ASA	1080	1992	72	f	PM	21		2	3	n	y	n	n	n	n	n	n	30 mg	48,05	60	n	n	y	n	n	n	n
P	no ASA	1080	2012	77	f	PM	286	400	4	4	n	y	n	n	n	n	n	n	60 mg	61,54	60	n	n	y	n	n	n	n
P	no ASA	1080	2017	67	f	PM	15	614	1	3	n	y	n	n	n	n	n	n	60 mg	58,57	60	y	n	y	n	n	n	n
E	no ASA	1080	2018	85	f	PM	54	530	1	4	n	y	n	n	n	n	n	n	30 mg	48,38	60	n	y	y	n	n	n	n
P	no ASA	1080	2020	71	f	PM	429	400	13	3	n	y	n	n	n	n	n	n	60 mg	55,28	79	n	n	y	n	n	n	n
P	no ASA	1080	2024	68	m	PM	77	400	3	2	n	y	n	n	n	n	n	n	60 mg	51,13	60	y	n	y	n	n	n	n
E	no ASA	1080	2037	66	f	PM	178		3	3	n	y	n	n	n	n	n	n	30 mg	60,83	66	n	n	y	n	n	n	n
P	no ASA	1080	2056	69	f	PM	2182	400	13	3	n	y	n	n	n	n	n	n	60 mg	57,96	60	y	n	n	n	n	n	n
E	no ASA	1080	2057	82	f	PM	39	591	1	4	n	y	n	n	n	n	n	n	60 mg	53,7	60	n	y	n	n	n	n	n
P	no ASA	1080	2058	87	m	PM	747	400	6	3	n	y	n	n	n	n	n	n	30 mg	26,56	88	y	y	n	n	n	n	n
P	ASA	1080	2078	84	f	PM	281		4	6	n	y	y, oa	n	n	n	n	n	30 mg	36,77	90	y	y	n	n	n	n	n
E	no ASA	1080	2084	76	f	PM	480		1	5	n	y	y, oa	n	n	n	n	n	60 mg	64,12	80	y	n	y	n	n	n	n
E	ASA	1080	2085	68	m	ICD-CRT	8355	640	1	4	y	y	n	n	n	y	n	y	60 mg	76,93	67	y	n	y	n	n	n	n
E	no ASA	1080	2099	74	f	PM	27	174	2	3	n	y	n	n	n	n	n	n	60 mg	80,17	50	n	n	y	n	n	n	n
P	no ASA	1080	2123	71	f	PM	2880		2	3	n	y	n	n	n	n	n	n	60 mg	59,5	70	n	n	y	n	n	n	n
P	no ASA	1080	2125	71	m	PM-CRT	9999	640	2	2	y	n	n	n	n	n	n	n	60 mg	57,24	60	y	n	y	n	n	n	n
P	no ASA	1080	2126	72	f	PM	84	400	19	3	n	y	n	n	n	n	n	n	60 mg	56,89	81	n	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	1080	2131	70	f	PM	5760	400	12	3	n	y	n	n	n	n	n	n	30 mg	49,93	70	n	n	y	n	n	n	n
E	no ASA	1080	2138	86	f	PM	55	225	1	5	y	y	n	n	n	n	n	n	30 mg	40,49	60	y	n	y	n	n	n	n
E	no ASA	1080	2141	68	m	ICD	6000	600	1	2	n	y	n	n	n	n	n	n	60 mg	55,84	60	y	n	y	n	n	n	n
P	no ASA	1080	2144	71	f	PM	1244	640	70	4	n	y	y, oa	n	n	n	n	n	60 mg	69,62	60	y	n	y	n	n	n	n
E	no ASA	1080	2147	68	f	PM	940	400	2	4	n	y	y, oa	n	n	n	n	n	60 mg	70,76	60	n	n	y	n	n	n	n
P	no ASA	1080	2150	75	f	PM	762	400	5	5	n	y	y, oa	n	n	n	n	n	30 mg	94,44	60	n	n	y	n	n	n	n
P	no ASA	1080	2154	73	f	PM	144	400	6	3	n	y	n	n	n	n	n	n	60 mg	65,91	60	n	n	y	n	n	n	n
E	no ASA	1080	2184	72	f	PM	288		5	3	n	y	n	n	n	n	n	n	60 mg	62,07	80	y	n	n	n	n	n	n
P	no ASA	1080	2185	83	m	PM	261		2	6	y	y	n	y	n	n	n	n	60 mg	58,9	70	y	n	y	n	n	n	n
P	no ASA	1080	2194	72	f	PM	89		1	3	n	y	n	n	n	n	n	n	60 mg	95,46	60	n	n	y	n	n	n	n
P	no ASA	1080	2206	73	m	PM	3931	640	1	2	n	y	n	n	n	n	n	n	60 mg	69,79	90	n	n	y	n	n	n	n
E	no ASA	1080	2215	66	f	PM	326	400	4	5	n	y	n	y	n	n	n	n	60 mg	65,06	60	y	y	y	n	n	n	n
E	no ASA	1080	2237	78	f	PM	104	254	2	4	n	y	n	n	n	n	n	n	30 mg	45,45	65	n	y	n	n	n	n	n
E	no ASA	1080	2244	72	f	PM	85	400	6	3	n	y	n	n	n	n	n	n	60 mg	54,62	60	y	n	y	n	n	n	n
E	no ASA	1080	2284	66	f	PM	2269	400	2	3	n	y	n	n	n	n	n	n	60 mg	88,29	60	y	n	y	n	n	n	n
E	no ASA	1080	2286	69	f	PM	10	400	1	5	n	y	n	y	y	n	n	n	60 mg	97,61	75	n	n	y	n	n	n	n
P	no ASA	1080	2288	70	f	PM	151	400	7	3	n	y	n	n	n	n	n	n	60 mg	76,74	65	n	n	y	n	n	n	n
P	no ASA	1080	2293	69	m	PM-CRT	6000	600	40	2	n	y	n	n	n	n	n	n	60 mg	58,33	60	y	n	n	n	n	n	n
E	no ASA	1080	2305	81	f	PM-CRT		640	8	4	n	y	n	n	n	n	n	n	60 mg	56,78	60	y	n	y	n	n	n	n
E	ASA	1080	2310	75	m	PM				3	y	n	n	n	n	n	y	y	60 mg	67,49	76	y	n	y	n	n	n	n
P	no ASA	1080	2320	83	f	PM	1364	400	4	4	n	y	n	n	n	n	n	n	30 mg	49,39	65	n	y	n	n	n	n	n
P	no ASA	1080	2348	81	f	PM	46	400	2	4	n	y	n	n	n	n	n	n	60 mg	55,17	60	n	n	y	n	n	n	n
E	no ASA	1080	2441	86	m	PM	341	284		3	n	y	n	n	n	n	n	n	30 mg	32,72	78	n	y	n	n	n	n	n
E	no ASA	1080	2464	65	f	PM	216		2	3	n	y	n	n	n	n	n	n	60 mg	69,68	60	n	n	y	n	n	n	n
P	no ASA	1080	2478	65	m	PM	356	640	3	3	n	y	y, oa	n	n	n	n	n	60 mg	118,9	67	y	n	n	n	n	n	n
E	no ASA	1080	2484	69	m	PM	4159	640	6	2	n	y	n	n	n	n	n	n	30 mg	70,07	60	n	n	y	n	n	n	n
P	ASA	1085	1353	82	m	PM	845	640	2	6	n	y	y, it	y	n	n	n	n	30 mg	25,99	60	y	n	y	n	y	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	1085	1386	81	m	PM	113	400	1	5	n	y	y, oa	n	n	n	n	n	60 mg	77,39	76	y	n	n	n	n	n	n
P	ASA	1085	1433	87	f	PM	27	208	1	5	n	n	y, oa	n	n	n	y	n	30 mg	29,41	70	n	n	n	n	n	n	n
E	ASA	1085	1477	69	f	PM	332	480	1	3	n	y	n	n	n	n	n	n	60 mg	87,68	60	n	y	y	n	n	n	n
E	no ASA	1085	1483	75	f	PM	71	384	4	3	n	n	n	n	n	n	n	n	60 mg	70,77	60	y	n	n	n	n	n	n
P	ASA	1085	1499	82	f	PM	62	269	1	8	y	y	y, it	y	n	n	n	n	30 mg	30,87	70	y	y	y	n	n	n	n
P	no ASA	1085	1520	85	f	PM	10	549	8	3	n	n	n	n	n	n	n	n	30 mg	61,63	80	n	n	n	n	n	n	n
P	ASA	1085	1529	70	m	PM	34	640	1	4	n	y	y, oa AND it	n	n	n	n	n	60 mg	118,01	60	n	n	y	n	n	n	n
E	ASA	1085	1537	78	m	PM	143	272	3	6	y	y	y, it	n	n	n	n	y	60 mg	66,02	76	n	n	y	n	n	n	n
P	no ASA	1085	1673	85	f	PM	452	640	1	5	y	y	n	n	n	n	n	n	60 mg	66,87	70	y	y	n	n	n	n	n
E	no ASA	1085	1771	84	f	PM	161	591	12	4	n	y	n	n	n	n	n	n	60 mg	55,19	60	y	n	y	y	n	n	n
P	no ASA	1085	1785	73	m	PM	8431	640	3	2	n	y	n	n	n	n	n	n	60 mg	115,73	65	y	n	y	n	n	n	n
P	no ASA	1085	1788	69	m	PM	99	640	3	2	n	y	n	n	n	n	n	n	60 mg	97,22	92	y	n	y	n	n	n	n
P	no ASA	1085	1962	79	f	PM	31		2	4	n	y	n	n	n	n	n	n	30 mg	97,82	86	y	n	n	n	n	n	n
E	ASA	1085	1963	80	m	PM	2964	400	1	5	y	y	n	n	n	n	n	n	30 mg	54,63	80	y	y	y	n	n	n	n
E	ASA	1085	1980	84	m	PM	738	512	8	6	n	y	n	y	n	n	y	n	60 mg	64,34	60	y	n	y	n	n	n	n
E	ASA	1085	2021	81	f	PM	278		1	7	y	y	y, oa	n	n	n	y	n	30 mg	40,03	64	y	n	y	n	n	n	n
P	ASA	1085	2029	82	m	PM	30		4	4	n	y	n	n	n	y	y	n	60 mg	60,9	65	y	y	y	n	n	n	n
E	no ASA	1085	2032	81	f	PM	506	179	1	4	n	y	n	n	n	n	n	n	30 mg	44,82	87	y	y	y	n	n	n	n
E	ASA	1085	2114	80	f	PM	27	640	2	6	n	y	y, oa	n	n	y	y	n	60 mg	66,79	60	y	n	y	n	n	n	n
P	ASA	1085	2115	78	m	PM	8	549	1	3	n	n	y, oa	n	n	n	n	n	60 mg	88,57	65	n	n	n	n	n	n	n
E	no ASA	1085	2298	86	f	PM	53	240	12	4	n	y	n	n	n	n	n	n	30 mg	31,88	72	n	y	y	n	n	n	n
P	no ASA	1085	2301	85	m	PM	22		3	2	n	n	n	n	n	n	n	n	60 mg	54,75	70	y	n	n	y	n	n	n
E	no ASA	1085	2307	84	f	PM	17	640	1	4	n	y	n	n	n	n	n	n	60 mg	81,37	60	y	n	y	n	n	n	n
E	no ASA	1085	2312	87	f	PM	542	640	19	3	n	n	n	n	n	n	n	n	60 mg	55,62	70	y	n	n	n	n	n	n
P	ASA	1085	2316	83	f	PM	9999	404	1	6	n	y	y, oa	n	n	n	n	n	60 mg	61,24	73	y	n	y	n	n	n	n
P	no ASA	1085	2385	75	f	PM	153	640	11	4	n	y	n	n	n	n	n	n	60 mg	70,02	60	y	n	y	n	n	n	n
P	no ASA	1085	2429	79	f	PM	78	640	1	4	n	y	n	n	n	n	n	n	60 mg	72,86	60	y	n	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	no ASA	1085	2440	77	f	PM	180	640	3	4	n	y	n	n	n	n	n	n	60 mg	73,19		n	y	y	n	n	n	n
E	ASA	1085	2482	70	m	PM	664	591	10	6	n	y	y, oa	y	n	n	n	n	60 mg	88,17	67	y	n	n	y	n	n	n
P	ASA	1085	2500	82	m	PM	192	640	14	4	n	y	n	n	n	n	n	n	60 mg	54,7	60	y	y	y	n	n	n	n
E	ASA	1085	2511	77	m	PM	383		6	4	y	n	n	n	n	y	n	y	60 mg	86,11	60	y	n	y	n	n	n	n
P	ASA	1085	2625	74	m	PM	29	341	3	2	n	y	n	n	n	n	n	n	60 mg	130,95	65	y	y	y	n	y	n	n
E	ASA	1086	2072	85	f	PM				5	n	y	n	n	n	y	y	n	30 mg	33,67	60	y	y	y	n	n	n	n
P	ASA	1086	2095	69	f	PM	160	640	1	3	n	y	n	n	n	n	n	n	60 mg	61,04	60	n	y	y	n	n	n	n
P	ASA	1086	2540	75	m	ICD	21	640	1	5	y	n	y, oa	n	n	y	n	n	60 mg	83,83	66	y	n	y	n	n	n	n
P	no ASA	1089	1174	81	f	PM	133	600	1	4	n	y	n	n	n	n	n	n	60 mg	84,45	73	n	n	y	n	n	n	n
E	no ASA	1089	1317	86	m	PM	111	305	1	3	n	y	n	n	n	n	n	n	60 mg	83,53	74	n	n	y	n	n	n	n
E	no ASA	1089	1333	72	m	PM	160	400		2	n	y	n	n	n	n	n	n	60 mg	107,67	80	n	y	y	n	n	n	n
P	no ASA	1089	1358	82	m	PM	162		1	7	n	y	y, oa	y	n	y	n	n	30 mg	37,86	72	n	n	y	n	n	n	n
P	no ASA	1089	1364	91	m	PM	62	591	1	3	n	y	n	n	n	n	n	n	30 mg	22,57	50	n	y	y	n	n	n	n
E	no ASA	1089	1427	82	m	PM	1643	591	3	3	n	y	n	n	n	n	n	n	60 mg	54,75	62	y	y	n	n	n	n	n
P	no ASA	1089	1492	74	f	PM	89	400		4	n	y	y, oa	n	n	n	n	n	60 mg	54,01	61	y	n	y	n	n	n	n
P	no ASA	1089	1502	75	m	PM	92		1	4	n	y	y, oa	n	n	n	n	n	30 mg	36,18	98	y	n	y	n	n	n	n
E	no ASA	1089	1504	70	m	PM	100	640	1	3	n	y	n	n	n	n	n	n	60 mg	102,44	62	n	n	y	n	n	n	n
P	no ASA	1089	1522	85	m	PM	297	400	7	4	n	y	y, oa	n	n	n	n	n	60 mg	71,08		n	n	y	n	n	n	n
E	no ASA	1089	1523	84	f	ICM	222		1	3	n	n	n	n	n	n	n	n	60 mg	60,72	74	n	n	n	n	n	n	n
E	no ASA	1089	2066	78	m	PM	1015	400	2	3	n	y	n	n	n	n	n	n	60 mg	84,14	61	n	y	y	n	n	n	n
E	no ASA	1089	2067	96	m	PM	2440		57	3	y	n	n	n	n	n	n	n	30 mg	27,6		y	n	y	n	n	n	n
P	no ASA	1089	2205	85	m	PM				3	n	y	n	n	n	n	n	n	60 mg	78,75	50	n	y	y	n	n	n	n
P	no ASA	1089	2230	80	m	PM	37	316	1	2	n	n	n	n	n	n	n	n	60 mg	69,55	92	n	n	n	n	n	n	n
P	no ASA	1089	2336	79	m	ICD	93		1	5	y	y	n	n	n	y	y	y	60 mg	56,45	72	y	n	n	n	n	n	n
E	ASA	1097	1705	74	m	PM	7		2	3	n	y	n	n	n	n	n	y	60 mg	65,66	109	y	n	y	n	n	n	n
E	ASA	1097	2331	77	f	PM	100	400	5	5	n	y	n	n	n	n	n	n	30 mg	43,56		n	y	y	n	n	n	n
P	ASA	1097	2344	81	f	PM	69	261	2	6	n	y	y, oa	n	n	y	y	n	30 mg	44,45	72	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
E	ASA	1097	2401	68	m	PM	40		7	4	n	y	y, it	n	n	y	y	y	30 mg	35,12	63	y	n	y	n	n	n	n
E	no ASA	1097	2651	78	f	PM	1564	500	2	4	n	y	n	n	n	n	n	n	30 mg	49,02	60	n	n	y	n	n	n	n
E	no ASA	1104	2169	77	m	PM	55		5	3	n	y	n	n	n	n	n	n	60 mg	78,1	64	n	n	y	n	n	n	n
P	ASA	1104	2445	72	m	PM	183		1	3	n	y	n	n	n	n	n	n	60 mg	84,81	65	n	n	y	n	n	n	n
P	no ASA	1104	2535	76	m	PM	107	640	2	3	n	y	n	n	n	n	n	n	60 mg	87,5	72	n	n	y	n	n	n	n
E	no ASA	1104	2553	72	m	PM	7		1	2	n	y	n	n	n	n	n	n	60 mg	88,52	82	y	y	y	n	n	n	n
P	ASA	1104	2560	71	m	PM	6026	614	2	3	y	n	n	n	n	n	y	n	60 mg	88,89	64	y	n	y	n	n	n	n
P	no ASA	1108	2578	73	m	PM	6	210	1	2	n	y	n	n	n	n	n	n	60 mg	102,13	72	n	n	n	n	n	n	n
E	no ASA	1111	2531	83	m	PM	9	429	1	3	n	y	n	n	n	n	n	n	60 mg	69,91	74	n	n	y	n	n	n	n
E	ASA	1115	2330	83	f	PM	85		1	5	n	y	y, oa AND it	n	n	n	n	n	60 mg	51,2	66	n	y	y	n	n	n	n
E	no ASA	1115	2434	75	m	PM	137		5	3	n	y	n	n	n	n	n	n	60 mg	75,29	89	n	y	y	n	n	n	n
E	no ASA	1116	2461	75	f	PM	117	400	1	4	n	y	n	n	n	n	n	n	30 mg	46,26	62	y	y	y	n	n	n	n
P	no ASA	1116	2538	80	f	ICM	102		1	5	n	y	y, oa	n	n	n	n	n	60 mg	61,67	81	y	n	y	n	n	n	n
P	no ASA	1116	2576	77	m	PM-CRT	659		1	4	y	y	n	n	n	n	n	n	60 mg	92,39	57	y	n	y	n	n	n	n
E	no ASA	1116	2598	85	f	PM	542		7	4	n	y	n	n	n	n	n	n	60 mg	54,98	60	y	n	y	n	n	n	n
P	no ASA	1116	2646	86	m	PM	291	400	2	3	n	y	n	n	n	n	n	n	30 mg	29,94	90	n	n	y	n	n	n	n
E	no ASA	1116	2701	84	f	PM	200		3	4	n	y	n	n	n	n	n	n	30 mg	33,07	94	y	y	y	n	n	n	n
P	no ASA	1117	2728	79	f	PM	605	400	1	7	n	y	n	n	y	n	n	n	60 mg	82,72	60	y	y	y	n	n	n	n
P	no ASA	1118	2657	86	f	PM	166	640	3	4	n	y	n	n	n	n	n	n	60 mg	56,46	60	y	y	n	n	n	n	n
P	ASA	1118	2678	83	f	PM	385	500	9	5	n	y	n	n	n	n	n	n	30 mg	45,36	59	y	y	y	n	n	n	n
P	no ASA	1118	2689	91	f	PM	84	316	1	4	n	y	n	n	n	n	n	n	30 mg	33,58	73	n	n	y	n	n	n	n
P	ASA	1118	2697	85	f	PM	172		4	5	n	y	n	n	n	n	n	n	30 mg	31,83	57	y	n	y	n	n	n	n
E	ASA	1118	2732	83	m	PM	340	500	24	4	n	y	n	n	n	n	n	n	30 mg	42,3	48	n	n	y	n	y	n	n
E	no ASA	1121	2377	91	m	PM-CRT	2733			6	y	y	y, oa	n	n	y	n	y	30 mg	24,38	69	y	n	y	n	n	n	n
E	no ASA	1121	2444	81	m	ICM	138		1	3	n	n	y, oa	n	n	n	n	n	60 mg	85,64	53	y	y	y	n	n	n	n
P	no ASA	1121	2587	87	m	PM	5760	400	1	2	n	n	n	n	n	n	n	n	60 mg	52,96	68	n	n	n	n	n	n	n
E	ASA	1121	2609	80	f	PM	217	500	2	5	n	y	n	n	n	y	y	n	60 mg	82,52	55	y	y	y	n	n	n	n

Random group[1]	Random stratum (indication)[2]	Centre-ID	Patient-ID	Age	Sex	Device implanted[3]	Max. AHRE episode duration [min]	Max. AHRE bpm	No. of adequ. AHRE	CHA2DS2-VASc Sc.	Heart failure	Hypertension	Diabetes mellitus[4]	Prior stroke	Prior TIA	Prior myocardial infarction	Prior PCI	Prior CABG	Edoxaban dose recomm. at randomisation (OD)	Creatinine clearance [ml/min]	Heart rate [bpm]	Beta blocking agents	Calcium channel blockers	Agents acting on the renin-angiotensin system	Antiarrhythm. class Ic	Antiarrhythm. class III	Cardiac glycosides	Cardiac stimulants excl. cardiac glycosides
P	ASA	1121	2729	89	f	PM	497	400	1	3	n	n	n	n	n	n	n	n	30 mg	31,95	63	y	n	n	n	n	n	n
P	ASA	1123	2359	76	f	PM	271	545	2	5	n	y	n	n	n	y	y	n	30 mg	47,63	68	n	y	y	n	n	n	n
E	ASA	1123	2389	68	m	PM	847	640	3	3	n	y	n	n	n	n	n	n	60 mg	93,83	61	n	y	y	n	n	n	n
P	no ASA	1127	2502	84	f	PM	304	640	1	4	n	y	n	n	n	n	n	n	60 mg	56,27	73	y	n	y	n	n	n	n
E	ASA	1133	2557	76	m	ICD	54	545	3	6	y	y	y, it	n	n	y	y	y	60 mg	52,29	65	y	y	y	n	n	n	n
E	no ASA	1133	2597	71	f	PM				3	n	y	n	n	n	n	n	n	60 mg	91,95	75	n	y	n	n	n	n	n
E	ASA	1133	2699	78	m	ICD-CRT	277	429	1	5	y	n	y, oa AND it	n	n	y	y	y	60 mg	51,57	59	y	n	y	n	n	n	n
E	no ASA	1138	2477	79	m	PM-CRT	9999	640	2	5	y	y	y, oa	n	n	n	n	n	60 mg	66,59	71	y	n	y	n	n	n	n
E	no ASA	1146	2397	78	m	PM				4	n	y	y, oa	n	n	n	n	n	60 mg	80,02	78	n	n	y	n	n	n	n
E	ASA	1146	2398	79	m	PM	152		2	4	n	n	n	n	y	n	n	n	60 mg	92,42	93	n	n	n	n	n	n	n
P	no ASA	1146	2519	87	f	PM	137	640	2	4	n	y	n	n	n	n	n	n	60 mg	53,52	72	y	n	y	n	n	n	n
P	no ASA	1146	2574	78	m	PM	6	175	1	2	n	n	n	n	n	n	n	n	60 mg	89,43	57	n	n	n	n	n	n	n
P	ASA	1146	2611	75	m	PM	438		1	4	n	y	n	n	n	n	y	n	60 mg	86,55	88	n	y	y	n	n	n	n
P	ASA	1146	2713	80	f	PM	141	301	2	4	n	y	n	n	n	n	n	n	30 mg	41,59		y	y	y	n	n	n	n
P	ASA	1147	2391	76	m	ICD-CRT	180	640	1	4	y	n	n	n	n	y	y	n	60 mg	64,4	75	y	n	y	n	n	n	n
E	no ASA	1147	2525	69	f	PM	143	545	13	3	n	y	n	n	n	n	n	n	60 mg	120,3	75	n	n	y	n	n	n	n
E	ASA	1148	2603	69	m	ICD	156	640	1	4	y	n	y, oa	n	n	y	y	n	60 mg	70,71	65	y	n	y	n	n	n	n
P	no ASA	1148	2688	75	f	ICM	473		5	4	n	y	n	n	n	n	n	n	60 mg	54,88	89	n	n	y	n	n	n	n
P	no ASA	1148	2737	73	m	ICD-CRT	21	195	1	3	y	y	n	n	n	n	n	n	30 mg	39,48	60	y	n	y	n	y	n	n

[1] E = Edoxaban; P = Placebo

[2] ASA = Acetylsalicylic acid

[3] PM = pace maker; ICD = implantable cardioverter-defibrillator; CRT = cardiac resynchronization therapy; ICM = implantable cardiac monitor

[4] it = insulin therapy; oa = oral antidiabetics

16.2.5 Compliance and/or Drug Concentration Data (if available)

Table 29 Individual treatment compliance

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
48	9	Placebo	ASA	2016-11-16	Good compliance (>= 90%)
75	9	Placebo	ASA	2017-01-18	Good compliance (>= 90%)
118	9	Placebo	ASA		
170	9	Placebo	ASA		
192	9	Placebo	ASA	2017-06-14	Good compliance (>= 90%)
288	9	Placebo	ASA	2017-09-30	Good compliance (>= 90%)
434	9	Placebo	ASA	2018-02-13	Non-compliance (< 80%)
468	9	Placebo	ASA	2018-03-01	Good compliance (>= 90%)
561	9	Placebo	ASA	2018-05-19	Good compliance (>= 90%)
681	9	Placebo	ASA	2018-08-22	Good compliance (>= 90%)
694	9	Placebo	ASA		
720	9	Placebo	ASA	2018-09-22	Good compliance (>= 90%)
758	9	Placebo	ASA	2019-04-18	Good compliance (>= 90%)
879	9	Placebo	ASA	2018-12-11	Good compliance (>= 90%)
1192	9	Placebo	ASA	2019-06-20	Good compliance (>= 90%)
1204	9	Placebo	ASA	2019-06-27	Good compliance (>= 90%)
1213	9	Placebo	ASA	2019-07-12	Good compliance (>= 90%)
1259	9	Placebo	ASA	2019-08-28	Good compliance (>= 90%)
1600	9	Placebo	ASA	2020-05-29	Good compliance (>= 90%)
1641	9	Placebo	ASA	2020-06-18	Good compliance (>= 90%)
1817	9	Placebo	ASA	2020-10-07	Good compliance (>= 90%)
1871	9	Placebo	ASA	2020-11-19	Good compliance (>= 90%)
1974	9	Placebo	ASA	2021-02-24	Good compliance (>= 90%)
2221	9	Placebo	ASA	2021-08-13	Good compliance (>= 90%)
2311	9	Placebo	ASA	2021-10-20	Good compliance (>= 90%)
2406	9	Placebo	ASA	2021-12-23	Good compliance (>= 90%)
2599	9	Placebo	ASA	2022-04-29	Good compliance (>= 90%)
2624	9	Placebo	ASA	2022-05-25	Good compliance (>= 90%)
2741	9	Placebo	ASA	2022-08-25	Non-compliance (< 80%)
92	9	Placebo	no ASA	2017-02-09	Good compliance (>= 90%)
96	9	Placebo	no ASA	2017-02-11	Good compliance (>= 90%)
697	9	Placebo	no ASA	2018-09-06	Non-compliance (< 80%)
830	9	Placebo	no ASA	2018-11-20	Good compliance (>= 90%)
878	9	Placebo	no ASA	2018-12-11	
1570	9	Placebo	no ASA	2020-04-15	Good compliance (>= 90%)
1847	9	Placebo	no ASA	2020-11-04	Good compliance (>= 90%)
2226	9	Placebo	no ASA	2021-08-18	Good compliance (>= 90%)
2403	9	Placebo	no ASA	2021-12-22	Non-compliance (< 80%)
2408	9	Placebo	no ASA	2021-12-23	Non-compliance (< 80%)
2563	9	Placebo	no ASA	2022-03-31	Acceptable compliance (80% to < 90%)
57	9	Edoxaban	ASA	2016-12-07	Good compliance (>= 90%)
66	9	Edoxaban	ASA	2016-12-28	Acceptable compliance (80% to < 90%)
93	9	Edoxaban	ASA	2017-02-09	Good compliance (>= 90%)
129	9	Edoxaban	ASA	2017-04-01	Good compliance (>= 90%)
153	9	Edoxaban	ASA	2017-05-18	Good compliance (>= 90%)
237	9	Edoxaban	ASA		
393	9	Edoxaban	ASA	2018-01-10	Good compliance (>= 90%)
485	9	Edoxaban	ASA	2018-03-16	Good compliance (>= 90%)
666	9	Edoxaban	ASA	2018-08-14	Good compliance (>= 90%)
682	9	Edoxaban	ASA	2018-08-22	Good compliance (>= 90%)
719	9	Edoxaban	ASA	2018-09-22	Good compliance (>= 90%)
731	9	Edoxaban	ASA	2018-10-04	Good compliance (>= 90%)
843	9	Edoxaban	ASA	2018-11-24	Non-compliance (< 80%)
908	9	Edoxaban	ASA	2018-12-22	Good compliance (>= 90%)
1126	9	Edoxaban	ASA	2019-05-15	Good compliance (>= 90%)
1127	9	Edoxaban	ASA	2019-05-16	Good compliance (>= 90%)
1178	9	Edoxaban	ASA	2019-06-13	Good compliance (>= 90%)
1278	9	Edoxaban	ASA	2019-09-12	Good compliance (>= 90%)
1338	9	Edoxaban	ASA	2019-10-18	Good compliance (>= 90%)
1346	9	Edoxaban	ASA	2019-10-24	Good compliance (>= 90%)
1816	9	Edoxaban	ASA	2020-10-07	Good compliance (>= 90%)
1961	9	Edoxaban	ASA	2021-02-17	Good compliance (>= 90%)
2044	9	Edoxaban	ASA	2021-04-15	Good compliance (>= 90%)
2210	9	Edoxaban	ASA	2021-11-24	Non-compliance (< 80%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2333	9	Edoxaban	ASA	2021-11-10	Good compliance (>= 90%)
2421	9	Edoxaban	ASA	2022-01-12	Good compliance (>= 90%)
2479	9	Edoxaban	ASA	2022-02-16	Good compliance (>= 90%)
46	9	Edoxaban	no ASA	2016-11-10	Good compliance (>= 90%)
54	9	Edoxaban	no ASA	2016-11-25	Good compliance (>= 90%)
100	9	Edoxaban	no ASA	2017-02-18	Good compliance (>= 90%)
410	9	Edoxaban	no ASA	2018-01-19	Good compliance (>= 90%)
536	9	Edoxaban	no ASA	2018-04-27	Good compliance (>= 90%)
1692	9	Edoxaban	no ASA	2020-07-17	Acceptable compliance (80% to < 90%)
1879	9	Edoxaban	no ASA	2020-11-25	Non-compliance (< 80%)
1897	9	Edoxaban	no ASA	2020-12-10	
2297	9	Edoxaban	no ASA	2021-10-06	Good compliance (>= 90%)
2615	9	Edoxaban	no ASA	2022-05-18	Acceptable compliance (80% to < 90%)
2700	9	Edoxaban	no ASA	2022-07-08	Good compliance (>= 90%)
1582	12	Placebo	ASA	2020-05-12	Non-compliance (< 80%)
1701	12	Placebo	ASA	2020-07-23	Good compliance (>= 90%)
1787	12	Placebo	ASA	2020-09-18	Acceptable compliance (80% to < 90%)
2622	12	Placebo	ASA	2022-05-21	Good compliance (>= 90%)
2684	12	Placebo	ASA	2022-07-01	Acceptable compliance (80% to < 90%)
2708	12	Placebo	ASA	2022-07-12	Acceptable compliance (80% to < 90%)
1687	12	Placebo	no ASA		
1698	12	Placebo	no ASA	2020-07-21	
1760	12	Placebo	no ASA	2020-09-08	Good compliance (>= 90%)
1775	12	Placebo	no ASA	2020-09-15	Good compliance (>= 90%)
1581	12	Edoxaban	ASA	2020-05-08	Non-compliance (< 80%)
1706	12	Edoxaban	ASA	2020-07-25	
1752	12	Edoxaban	ASA	2020-09-03	Acceptable compliance (80% to < 90%)
1761	12	Edoxaban	ASA	2020-09-09	Good compliance (>= 90%)
1651	12	Edoxaban	no ASA	2020-06-20	Good compliance (>= 90%)
1658	12	Edoxaban	no ASA	2020-06-26	Good compliance (>= 90%)
1789	12	Edoxaban	no ASA	2020-09-18	
2608	12	Edoxaban	no ASA	2022-05-08	Good compliance (>= 90%)
2649	12	Edoxaban	no ASA	2022-06-10	Good compliance (>= 90%)
1269	16	Placebo	ASA	2019-08-30	Good compliance (>= 90%)
148	16	Placebo	no ASA		
1165	16	Edoxaban	ASA	2019-06-12	Good compliance (>= 90%)
1179	16	Edoxaban	ASA	2019-06-14	Good compliance (>= 90%)
385	16	Edoxaban	no ASA	2018-01-17	Good compliance (>= 90%)
440	16	Edoxaban	no ASA	2018-02-14	Good compliance (>= 90%)
1033	16	Edoxaban	no ASA		
446	17	Placebo	ASA	2018-02-16	Good compliance (>= 90%)
1598	17	Placebo	no ASA	2020-05-28	Good compliance (>= 90%)
364	17	Edoxaban	ASA	2017-12-07	Good compliance (>= 90%)
409	17	Edoxaban	no ASA	2018-01-19	Good compliance (>= 90%)
263	19	Placebo	ASA	2017-08-24	Good compliance (>= 90%)
600	19	Placebo	ASA	2018-06-20	Good compliance (>= 90%)
120	19	Placebo	no ASA	2017-03-22	Good compliance (>= 90%)
203	19	Edoxaban	ASA	2017-06-27	Good compliance (>= 90%)
329	19	Edoxaban	ASA	2017-11-07	Good compliance (>= 90%)
1633	19	Edoxaban	ASA	2020-06-16	Good compliance (>= 90%)
340	19	Edoxaban	no ASA	2017-11-16	Good compliance (>= 90%)
805	19	Edoxaban	no ASA	2018-11-08	Good compliance (>= 90%)
624	22	Edoxaban	ASA	2018-07-12	Good compliance (>= 90%)
608	22				
927	22				
140	23	Placebo	ASA		
504	23	Placebo	ASA	2018-03-28	Good compliance (>= 90%)
692	23	Placebo	ASA	2018-08-31	Good compliance (>= 90%)
234	23	Edoxaban	ASA	2017-07-27	Good compliance (>= 90%)
265	23	Edoxaban	ASA	2017-08-31	Good compliance (>= 90%)
122	23	Edoxaban	no ASA	2017-03-24	Good compliance (>= 90%)
150	33	Placebo	ASA	2017-05-04	Good compliance (>= 90%)
216	33	Placebo	ASA	2017-07-11	Good compliance (>= 90%)
1413	33	Placebo	ASA	2019-11-28	Good compliance (>= 90%)
221	33	Placebo	no ASA	2017-07-11	Good compliance (>= 90%)
235	33	Edoxaban	ASA	2017-07-29	Good compliance (>= 90%)
1206	33	Edoxaban	ASA	2019-06-28	Good compliance (>= 90%)
1378	33	Edoxaban	ASA	2019-11-21	Good compliance (>= 90%)
442	34	Placebo	ASA	2018-02-13	Good compliance (>= 90%)
964	34				

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
59	35	Placebo	ASA	2016-12-09	Acceptable compliance (80% to < 90%)
453	35	Placebo	ASA	2018-02-28	Non-compliance (< 80%)
260	35	Edoxaban	no ASA	2017-08-23	Good compliance (>= 90%)
566	38	Placebo	ASA	2018-05-24	Acceptable compliance (80% to < 90%)
414	38	Placebo	no ASA	2018-01-25	Good compliance (>= 90%)
305	38	Edoxaban	no ASA	2017-10-17	Good compliance (>= 90%)
301	38				
1351	39	Placebo	ASA	2019-10-25	Non-compliance (< 80%)
1391	39	Placebo	ASA	2019-11-25	
2005	39	Placebo	no ASA	2021-03-22	Good compliance (>= 90%)
1186	39	Edoxaban	ASA	2019-06-18	Non-compliance (< 80%)
300	40	Placebo	ASA	2017-10-18	Acceptable compliance (80% to < 90%)
861	40	Edoxaban	no ASA	2018-12-04	Good compliance (>= 90%)
2013	42	Placebo	ASA	2021-03-16	Non-compliance (< 80%)
2122	42	Placebo	ASA	2021-05-26	Good compliance (>= 90%)
2219	42	Placebo	ASA	2021-08-10	Good compliance (>= 90%)
2296	42	Placebo	ASA	2021-10-01	Good compliance (>= 90%)
2439	42	Placebo	ASA	2022-01-20	Good compliance (>= 90%)
2443	42	Placebo	ASA	2022-01-24	Acceptable compliance (80% to < 90%)
2250	42	Placebo	no ASA	2021-08-30	Good compliance (>= 90%)
2376	42	Placebo	no ASA	2021-12-02	Good compliance (>= 90%)
567	42	Edoxaban	ASA	2018-05-25	Non-compliance (< 80%)
2103	42	Edoxaban	ASA	2021-05-17	Good compliance (>= 90%)
2683	42	Edoxaban	ASA	2022-07-01	Acceptable compliance (80% to < 90%)
2692	42	Edoxaban	ASA	2022-07-05	Good compliance (>= 90%)
2698	42	Edoxaban	ASA	2022-07-06	Good compliance (>= 90%)
2733	42	Edoxaban	ASA	2022-08-10	Good compliance (>= 90%)
1953	42	Edoxaban	no ASA	2021-02-10	Acceptable compliance (80% to < 90%)
2564	42	Edoxaban	no ASA	2022-03-30	Good compliance (>= 90%)
397	43	Placebo	ASA	2018-01-16	Good compliance (>= 90%)
845	43	Placebo	ASA	2018-11-27	Non-compliance (< 80%)
258	43	Edoxaban	ASA	2017-08-21	Good compliance (>= 90%)
472	44	Placebo	ASA	2018-03-08	Good compliance (>= 90%)
1426	44	Placebo	ASA	2019-12-04	Good compliance (>= 90%)
1274	44	Edoxaban	ASA	2019-09-06	Good compliance (>= 90%)
2019	44	Edoxaban	ASA	2021-03-18	Good compliance (>= 90%)
95	46	Placebo	ASA	2017-02-10	Good compliance (>= 90%)
145	46	Placebo	ASA	2017-04-27	Good compliance (>= 90%)
147	46	Placebo	ASA	2017-04-29	Good compliance (>= 90%)
43	46	Edoxaban	ASA	2016-11-04	Good compliance (>= 90%)
69	46	Edoxaban	ASA	2017-01-11	Good compliance (>= 90%)
63	46	Edoxaban	no ASA		
287	49	Placebo	ASA	2017-09-29	Good compliance (>= 90%)
363	49	Placebo	no ASA	2017-12-07	Good compliance (>= 90%)
243	49	Edoxaban	no ASA	2017-08-04	Good compliance (>= 90%)
272	49	Edoxaban	no ASA	2017-09-07	Good compliance (>= 90%)
321	53	Edoxaban	no ASA	2017-10-27	Good compliance (>= 90%)
587	57	Placebo	ASA	2018-06-12	Good compliance (>= 90%)
723	57	Placebo	ASA	2018-09-27	Good compliance (>= 90%)
1300	57	Placebo	ASA	2019-09-26	Good compliance (>= 90%)
1568	57	Placebo	ASA	2020-03-31	Good compliance (>= 90%)
1928	57	Placebo	ASA	2021-01-14	Non-compliance (< 80%)
2245	57	Placebo	ASA	2021-08-25	Good compliance (>= 90%)
2551	57	Placebo	ASA	2022-03-22	
2542	57	Placebo	no ASA	2022-03-18	Good compliance (>= 90%)
451	57	Edoxaban	ASA		
593	57	Edoxaban	ASA	2018-06-14	Good compliance (>= 90%)
966	57	Edoxaban	ASA	2019-01-31	Good compliance (>= 90%)
1324	57	Edoxaban	ASA	2019-10-10	Good compliance (>= 90%)
1629	57	Edoxaban	ASA	2020-06-12	Good compliance (>= 90%)
1755	57	Edoxaban	ASA	2020-09-03	Good compliance (>= 90%)
1837	57	Edoxaban	ASA	2020-10-22	Good compliance (>= 90%)
19	59	Placebo	ASA	2016-09-07	Good compliance (>= 90%)
24	59	Placebo	ASA	2016-09-17	Good compliance (>= 90%)
67	59	Placebo	ASA	2017-01-04	Good compliance (>= 90%)
119	59	Placebo	ASA	2017-03-22	Non-compliance (< 80%)
466	59	Placebo	ASA	2018-02-28	Good compliance (>= 90%)
679	59	Placebo	ASA	2018-08-20	Good compliance (>= 90%)
1063	59	Placebo	ASA	2019-04-08	Good compliance (>= 90%)
1161	59	Placebo	ASA	2019-06-05	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1247	59	Placebo	ASA	2019-08-08	Good compliance (>= 90%)
1451	59	Placebo	ASA	2019-12-16	Good compliance (>= 90%)
1456	59	Placebo	ASA	2019-12-19	Good compliance (>= 90%)
1583	59	Placebo	ASA	2020-05-11	
1779	59	Placebo	ASA	2020-09-16	Good compliance (>= 90%)
2211	59	Placebo	ASA	2021-08-03	
2467	59	Placebo	ASA	2022-02-03	Good compliance (>= 90%)
9	59	Placebo	no ASA	2016-08-08	Good compliance (>= 90%)
463	59	Placebo	no ASA	2018-02-26	Good compliance (>= 90%)
467	59	Placebo	no ASA	2018-02-28	Good compliance (>= 90%)
615	59	Placebo	no ASA	2018-07-05	Non-compliance (< 80%)
826	59	Placebo	no ASA	2018-11-16	Good compliance (>= 90%)
1191	59	Placebo	no ASA	2019-06-19	Good compliance (>= 90%)
1230	59	Placebo	no ASA	2019-07-24	Acceptable compliance (80% to < 90%)
1422	59	Placebo	no ASA	2019-12-02	Good compliance (>= 90%)
2612	59	Placebo	no ASA	2022-05-11	Non-compliance (< 80%)
2669	59	Placebo	no ASA	2022-06-23	Non-compliance (< 80%)
98	59	Edoxaban	ASA	2017-02-14	Acceptable compliance (80% to < 90%)
186	59	Edoxaban	ASA	2017-06-09	Good compliance (>= 90%)
380	59	Edoxaban	ASA	2017-12-21	Good compliance (>= 90%)
416	59	Edoxaban	ASA	2018-01-26	Good compliance (>= 90%)
493	59	Edoxaban	ASA	2018-03-20	Good compliance (>= 90%)
528	59	Edoxaban	ASA	2018-04-16	Good compliance (>= 90%)
655	59	Edoxaban	ASA	2018-08-06	Good compliance (>= 90%)
1105	59	Edoxaban	ASA	2019-05-03	Good compliance (>= 90%)
1195	59	Edoxaban	ASA	2019-06-21	Good compliance (>= 90%)
1245	59	Edoxaban	ASA	2019-08-07	Good compliance (>= 90%)
1490	59	Edoxaban	ASA	2020-01-23	Good compliance (>= 90%)
1579	59	Edoxaban	ASA	2020-05-07	Good compliance (>= 90%)
2470	59	Edoxaban	ASA		
58	59	Edoxaban	no ASA	2016-12-07	Good compliance (>= 90%)
149	59	Edoxaban	no ASA	2017-05-02	Good compliance (>= 90%)
541	59	Edoxaban	no ASA	2018-04-30	Good compliance (>= 90%)
1115	59	Edoxaban	no ASA	2019-05-08	Good compliance (>= 90%)
1140	59	Edoxaban	no ASA	2019-05-23	Good compliance (>= 90%)
1293	59	Edoxaban	no ASA	2019-09-18	Good compliance (>= 90%)
1634	59	Edoxaban	no ASA	2020-06-16	Good compliance (>= 90%)
1801	59	Edoxaban	no ASA	2020-09-25	Good compliance (>= 90%)
1920	59	Edoxaban	no ASA	2021-01-06	Good compliance (>= 90%)
2442	59	Edoxaban	no ASA	2022-01-24	Non-compliance (< 80%)
325	70	Placebo	ASA	2017-11-02	Good compliance (>= 90%)
511	70	Placebo	ASA	2018-04-11	Good compliance (>= 90%)
644	70	Placebo	ASA	2018-08-15	Acceptable compliance (80% to < 90%)
765	70	Placebo	ASA	2018-10-24	Good compliance (>= 90%)
995	70	Placebo	ASA	2019-03-04	
1045	70	Placebo	ASA	2019-03-29	Good compliance (>= 90%)
1148	70	Placebo	ASA	2019-05-31	Good compliance (>= 90%)
1485	70	Placebo	ASA	2020-01-22	Good compliance (>= 90%)
1727	70	Placebo	ASA	2020-08-12	Good compliance (>= 90%)
1751	70	Placebo	ASA	2020-09-03	Good compliance (>= 90%)
1950	70	Placebo	ASA	2021-02-15	
2028	70	Placebo	ASA		
2425	70	Placebo	ASA	2022-01-14	Non-compliance (< 80%)
2438	70	Placebo	ASA	2022-01-25	Acceptable compliance (80% to < 90%)
2475	70	Placebo	ASA	2022-02-14	Good compliance (>= 90%)
2554	70	Placebo	ASA	2022-03-25	Good compliance (>= 90%)
2686	70	Placebo	ASA	2022-07-05	Good compliance (>= 90%)
151	70	Placebo	no ASA	2017-05-03	Good compliance (>= 90%)
401	70	Placebo	no ASA	2018-01-16	Good compliance (>= 90%)
418	70	Placebo	no ASA	2018-01-30	Good compliance (>= 90%)
479	70	Placebo	no ASA	2018-03-12	Good compliance (>= 90%)
1114	70	Placebo	no ASA	2019-05-09	Good compliance (>= 90%)
1304	70	Placebo	no ASA	2019-10-01	Good compliance (>= 90%)
1714	70	Placebo	no ASA	2020-08-01	Good compliance (>= 90%)
1730	70	Placebo	no ASA	2020-08-17	Good compliance (>= 90%)
1910	70	Placebo	no ASA		
2517	70	Placebo	no ASA	2022-03-11	Good compliance (>= 90%)
105	70	Edoxaban	ASA	2017-03-01	Good compliance (>= 90%)
662	70	Edoxaban	ASA	2018-08-15	Non-compliance (< 80%)
674	70	Edoxaban	ASA		

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
774	70	Edoxaban	ASA	2018-11-01	Good compliance (>= 90%)
881	70	Edoxaban	ASA	2018-12-12	Good compliance (>= 90%)
1134	70	Edoxaban	ASA	2019-05-22	Good compliance (>= 90%)
1599	70	Edoxaban	ASA	2020-05-30	Good compliance (>= 90%)
1725	70	Edoxaban	ASA	2020-08-17	Good compliance (>= 90%)
1805	70	Edoxaban	ASA	2020-10-05	Good compliance (>= 90%)
1808	70	Edoxaban	ASA	2020-10-05	Good compliance (>= 90%)
1964	70	Edoxaban	ASA	2021-02-18	Good compliance (>= 90%)
2014	70	Edoxaban	ASA	2021-03-22	Good compliance (>= 90%)
2068	70	Edoxaban	ASA	2021-04-29	Good compliance (>= 90%)
2182	70	Edoxaban	ASA	2021-07-12	Non-compliance (< 80%)
2529	70	Edoxaban	ASA	2022-03-14	Good compliance (>= 90%)
16	70	Edoxaban	no ASA	2016-09-01	Good compliance (>= 90%)
253	70	Edoxaban	no ASA	2017-08-17	Good compliance (>= 90%)
402	70	Edoxaban	no ASA	2018-01-13	Good compliance (>= 90%)
514	70	Edoxaban	no ASA	2018-04-12	Good compliance (>= 90%)
1320	70	Edoxaban	no ASA	2019-10-09	Good compliance (>= 90%)
1569	70	Edoxaban	no ASA	2020-09-19	Good compliance (>= 90%)
1741	70	Edoxaban	no ASA	2020-08-25	Good compliance (>= 90%)
1829	70	Edoxaban	no ASA	2020-10-20	Good compliance (>= 90%)
2171	70	Edoxaban	no ASA	2021-07-01	Good compliance (>= 90%)
373	86	Placebo	ASA	2017-12-12	Good compliance (>= 90%)
404	86	Placebo	ASA	2018-01-15	Good compliance (>= 90%)
1016	86	Placebo	ASA	2019-03-05	Good compliance (>= 90%)
1262	86	Placebo	ASA	2019-08-27	Good compliance (>= 90%)
554	86	Placebo	no ASA	2018-05-15	Acceptable compliance (80% to < 90%)
1542	86	Placebo	no ASA	2020-03-03	Good compliance (>= 90%)
338	86	Edoxaban	ASA	2017-11-14	Good compliance (>= 90%)
352	86	Edoxaban	ASA	2017-11-28	Good compliance (>= 90%)
722	86	Edoxaban	ASA	2018-09-25	Good compliance (>= 90%)
1263	86	Edoxaban	ASA	2019-08-27	Good compliance (>= 90%)
1374	86	Edoxaban	ASA	2019-11-11	Good compliance (>= 90%)
1428	86	Edoxaban	ASA	2019-12-03	Good compliance (>= 90%)
672	86	Edoxaban	no ASA		
1189	86	Edoxaban	no ASA	2019-06-18	Good compliance (>= 90%)
1379	86	Edoxaban	no ASA	2019-11-12	Good compliance (>= 90%)
1085	86				
18	95	Placebo	ASA	2016-09-07	Non-compliance (< 80%)
28	95	Placebo	ASA	2016-09-22	
38	95	Placebo	ASA	2016-10-20	Good compliance (>= 90%)
44	95	Placebo	ASA	2016-11-09	Good compliance (>= 90%)
22	95	Placebo	no ASA	2016-09-14	Non-compliance (< 80%)
26	95	Placebo	no ASA	2016-09-20	Good compliance (>= 90%)
30	95	Placebo	no ASA	2016-09-22	Good compliance (>= 90%)
71	95	Placebo	no ASA	2017-01-13	Non-compliance (< 80%)
534	95	Placebo	no ASA	2018-04-25	Good compliance (>= 90%)
1066	95	Placebo	no ASA	2019-04-10	Good compliance (>= 90%)
1368	95	Placebo	no ASA	2019-11-07	Good compliance (>= 90%)
2287	95	Placebo	no ASA	2021-09-28	Good compliance (>= 90%)
10	95	Edoxaban	ASA	2016-08-10	Non-compliance (< 80%)
14	95	Edoxaban	ASA	2016-09-01	Good compliance (>= 90%)
53	95	Edoxaban	ASA	2016-11-24	Good compliance (>= 90%)
1175	95	Edoxaban	ASA	2019-06-12	Good compliance (>= 90%)
13	95	Edoxaban	no ASA		
29	95	Edoxaban	no ASA	2016-09-22	Good compliance (>= 90%)
117	95	Edoxaban	no ASA	2017-03-21	Good compliance (>= 90%)
180	95	Edoxaban	no ASA	2017-06-07	Good compliance (>= 90%)
202	95	Edoxaban	no ASA	2017-06-27	Good compliance (>= 90%)
533	95	Edoxaban	no ASA	2018-04-25	Good compliance (>= 90%)
820	95	Edoxaban	no ASA	2018-11-16	Good compliance (>= 90%)
256	95				
4	100	Placebo	ASA	2016-07-08	Good compliance (>= 90%)
846	100	Placebo	ASA	2018-11-27	Good compliance (>= 90%)
848	100	Placebo	ASA	2018-11-28	Good compliance (>= 90%)
1969	100	Placebo	ASA	2021-02-18	Good compliance (>= 90%)
1604	100	Placebo	no ASA		
2653	100	Placebo	no ASA	2022-06-14	Acceptable compliance (80% to < 90%)
124	100	Edoxaban	ASA	2017-03-29	Good compliance (>= 90%)
527	100	Edoxaban	ASA	2018-04-16	Good compliance (>= 90%)
537	100	Edoxaban	ASA	2018-04-26	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
933	100	Edoxaban	ASA	2019-01-16	Good compliance (>= 90%)
1327	100	Edoxaban	ASA	2019-11-14	Good compliance (>= 90%)
201	109	Placebo	ASA	2017-06-27	Good compliance (>= 90%)
39	113	Placebo	ASA	2016-10-25	Non-compliance (< 80%)
60	113	Placebo	ASA	2016-12-13	Good compliance (>= 90%)
37	113	Placebo	no ASA	2016-10-14	Good compliance (>= 90%)
62	113	Placebo	no ASA	2016-12-15	Good compliance (>= 90%)
154	113	Placebo	no ASA	2017-05-04	Good compliance (>= 90%)
369	113	Edoxaban	ASA	2017-12-11	Good compliance (>= 90%)
36	113	Edoxaban	no ASA	2016-10-12	Good compliance (>= 90%)
40	113	Edoxaban	no ASA	2016-10-25	Good compliance (>= 90%)
65	113	Edoxaban	no ASA	2016-12-20	Non-compliance (< 80%)
411	113	Edoxaban	no ASA	2018-01-23	Good compliance (>= 90%)
17	117	Placebo	ASA	2016-09-02	Good compliance (>= 90%)
23	117	Placebo	ASA	2016-09-16	Good compliance (>= 90%)
1155	117	Placebo	no ASA	2019-06-01	Good compliance (>= 90%)
1739	117	Placebo	no ASA	2020-08-20	Good compliance (>= 90%)
264	117	Edoxaban	ASA	2017-08-24	Good compliance (>= 90%)
320	117	Edoxaban	ASA	2017-10-26	Good compliance (>= 90%)
663	117	Edoxaban	ASA	2018-08-11	Good compliance (>= 90%)
943	117	Edoxaban	ASA	2019-01-19	Good compliance (>= 90%)
56	121	Placebo	ASA	2016-12-06	Good compliance (>= 90%)
103	121	Placebo	ASA	2017-03-02	Good compliance (>= 90%)
355	121	Placebo	ASA	2017-11-30	Good compliance (>= 90%)
130	121	Placebo	no ASA	2017-04-01	Good compliance (>= 90%)
41	121	Edoxaban	ASA	2016-10-26	Good compliance (>= 90%)
109	121	Edoxaban	ASA	2017-03-13	Good compliance (>= 90%)
359	121	Edoxaban	ASA	2017-12-05	Good compliance (>= 90%)
111	121	Edoxaban	no ASA	2017-03-15	Good compliance (>= 90%)
101	132	Placebo	ASA	2017-02-21	Good compliance (>= 90%)
229	132	Placebo	ASA	2017-07-19	Good compliance (>= 90%)
1612	132	Placebo	ASA	2020-06-05	Good compliance (>= 90%)
1958	132	Placebo	ASA	2021-02-12	Good compliance (>= 90%)
8	132	Placebo	no ASA	2016-07-19	Good compliance (>= 90%)
73	132	Placebo	no ASA	2017-01-16	Good compliance (>= 90%)
266	132	Placebo	no ASA	2017-08-31	Good compliance (>= 90%)
1383	132	Placebo	no ASA	2019-11-13	Good compliance (>= 90%)
1436	132	Placebo	no ASA	2019-12-06	Good compliance (>= 90%)
2629	132	Placebo	no ASA	2022-05-30	Good compliance (>= 90%)
295	132	Edoxaban	ASA	2017-10-09	Good compliance (>= 90%)
388	132	Edoxaban	ASA	2018-01-09	Good compliance (>= 90%)
1902	132	Edoxaban	ASA	2020-12-11	Good compliance (>= 90%)
1983	132	Edoxaban	ASA	2021-02-26	Good compliance (>= 90%)
6	132	Edoxaban	no ASA	2016-07-09	Good compliance (>= 90%)
51	132	Edoxaban	no ASA	2016-11-21	Non-compliance (< 80%)
70	132	Edoxaban	no ASA	2017-01-13	Good compliance (>= 90%)
739	132	Edoxaban	no ASA	2018-10-08	Good compliance (>= 90%)
2392	132	Edoxaban	no ASA	2021-12-15	Good compliance (>= 90%)
400	133	Placebo	ASA	2018-01-13	Good compliance (>= 90%)
618	133	Placebo	ASA	2018-07-06	Good compliance (>= 90%)
477	133	Placebo	no ASA	2018-03-09	Good compliance (>= 90%)
82	133	Edoxaban	ASA	2017-01-27	Good compliance (>= 90%)
188	133	Edoxaban	ASA	2017-06-09	Good compliance (>= 90%)
634	133	Edoxaban	ASA		
97	135	Placebo	no ASA	2017-02-13	Good compliance (>= 90%)
376	135	Placebo	no ASA	2017-12-20	Good compliance (>= 90%)
328	135	Edoxaban	ASA	2017-11-07	Good compliance (>= 90%)
339	135	Edoxaban	ASA	2017-11-15	Good compliance (>= 90%)
7	136	Placebo	ASA	2016-07-15	
33	136	Placebo	ASA	2016-10-01	Good compliance (>= 90%)
34	136	Edoxaban	ASA	2016-10-01	Good compliance (>= 90%)
132	136	Edoxaban	ASA	2017-04-05	Good compliance (>= 90%)
52	140	Placebo	ASA	2016-11-22	Good compliance (>= 90%)
114	140	Placebo	ASA	2017-03-20	Good compliance (>= 90%)
160	140	Placebo	ASA	2017-05-16	Good compliance (>= 90%)
171	140	Placebo	ASA	2017-05-31	Good compliance (>= 90%)
225	140	Placebo	ASA	2017-07-13	Good compliance (>= 90%)
257	140	Placebo	ASA	2017-08-17	Good compliance (>= 90%)
399	140	Placebo	ASA	2018-01-11	Good compliance (>= 90%)
482	140	Placebo	ASA	2018-03-14	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
551	140	Placebo	ASA	2018-05-15	Good compliance (>= 90%)
565	140	Placebo	ASA	2018-05-23	Good compliance (>= 90%)
803	140	Placebo	ASA	2018-11-07	Good compliance (>= 90%)
941	140	Placebo	ASA	2019-01-17	Good compliance (>= 90%)
1094	140	Placebo	ASA	2019-04-24	Good compliance (>= 90%)
1438	140	Placebo	ASA	2019-12-09	Good compliance (>= 90%)
1439	140	Placebo	ASA	2019-12-09	Good compliance (>= 90%)
1466	140	Placebo	ASA	2020-01-02	Good compliance (>= 90%)
1655	140	Placebo	ASA	2020-06-23	Good compliance (>= 90%)
1666	140	Placebo	ASA	2020-06-29	Good compliance (>= 90%)
1930	140	Placebo	ASA	2021-01-18	Good compliance (>= 90%)
2349	140	Placebo	ASA	2021-11-16	Non-compliance (< 80%)
2631	140	Placebo	ASA	2022-05-31	Good compliance (>= 90%)
2661	140	Placebo	ASA	2022-06-21	Good compliance (>= 90%)
68	140	Placebo	no ASA	2017-01-09	Good compliance (>= 90%)
99	140	Placebo	no ASA	2017-02-16	
113	140	Placebo	no ASA	2017-03-20	
432	140	Placebo	no ASA	2018-02-07	Good compliance (>= 90%)
539	140	Placebo	no ASA	2018-04-26	Good compliance (>= 90%)
669	140	Placebo	no ASA	2018-08-14	Good compliance (>= 90%)
713	140	Placebo	no ASA	2018-09-19	Good compliance (>= 90%)
1101	140	Placebo	no ASA	2019-05-02	Non-compliance (< 80%)
1389	140	Placebo	no ASA	2019-11-19	Good compliance (>= 90%)
1496	140	Placebo	no ASA	2020-01-29	Good compliance (>= 90%)
1826	140	Placebo	no ASA	2020-10-14	Good compliance (>= 90%)
1926	140	Placebo	no ASA	2021-01-13	Good compliance (>= 90%)
2202	140	Placebo	no ASA	2021-07-21	Good compliance (>= 90%)
2238	140	Placebo	no ASA	2021-08-24	Good compliance (>= 90%)
2618	140	Placebo	no ASA	2022-05-17	Good compliance (>= 90%)
85	140	Edoxaban	ASA	2017-01-31	Good compliance (>= 90%)
136	140	Edoxaban	ASA	2017-04-12	Good compliance (>= 90%)
190	140	Edoxaban	ASA	2017-06-12	Good compliance (>= 90%)
209	140	Edoxaban	ASA		
252	140	Edoxaban	ASA	2017-08-16	Acceptable compliance (80% to < 90%)
254	140	Edoxaban	ASA	2017-08-23	Good compliance (>= 90%)
407	140	Edoxaban	ASA	2018-01-17	Good compliance (>= 90%)
436	140	Edoxaban	ASA	2018-02-08	Good compliance (>= 90%)
506	140	Edoxaban	ASA	2018-04-03	Good compliance (>= 90%)
622	140	Edoxaban	ASA	2018-07-10	Good compliance (>= 90%)
717	140	Edoxaban	ASA	2018-09-20	Good compliance (>= 90%)
841	140	Edoxaban	ASA	2018-11-22	Non-compliance (< 80%)
1266	140	Edoxaban	ASA	2019-08-28	Good compliance (>= 90%)
1394	140	Edoxaban	ASA	2019-11-18	Good compliance (>= 90%)
1406	140	Edoxaban	ASA	2019-11-21	Good compliance (>= 90%)
1577	140	Edoxaban	ASA	2020-04-30	Good compliance (>= 90%)
1578	140	Edoxaban	ASA	2020-05-05	Good compliance (>= 90%)
1781	140	Edoxaban	ASA	2020-09-16	Good compliance (>= 90%)
1889	140	Edoxaban	ASA		
2046	140	Edoxaban	ASA	2021-04-14	Good compliance (>= 90%)
2096	140	Edoxaban	ASA	2021-05-12	Good compliance (>= 90%)
2357	140	Edoxaban	ASA	2021-11-19	Good compliance (>= 90%)
74	140	Edoxaban	no ASA	2017-01-17	Good compliance (>= 90%)
200	140	Edoxaban	no ASA	2017-06-26	Good compliance (>= 90%)
212	140	Edoxaban	no ASA	2017-07-12	Good compliance (>= 90%)
251	140	Edoxaban	no ASA	2017-08-14	Good compliance (>= 90%)
331	140	Edoxaban	no ASA	2017-11-08	Good compliance (>= 90%)
568	140	Edoxaban	no ASA	2018-05-24	Non-compliance (< 80%)
592	140	Edoxaban	no ASA	2018-06-14	Non-compliance (< 80%)
818	140	Edoxaban	no ASA	2018-11-14	Good compliance (>= 90%)
919	140	Edoxaban	no ASA	2019-01-09	Good compliance (>= 90%)
1576	140	Edoxaban	no ASA	2020-04-30	Good compliance (>= 90%)
1929	140	Edoxaban	no ASA	2021-01-14	Good compliance (>= 90%)
2187	140	Edoxaban	no ASA	2021-07-14	Good compliance (>= 90%)
2204	140	Edoxaban	no ASA	2021-07-27	Good compliance (>= 90%)
2617	140	Edoxaban	no ASA	2022-05-17	Good compliance (>= 90%)
2691	140	Edoxaban	no ASA	2022-07-05	Acceptable compliance (80% to < 90%)
88	140				
671	145	Placebo	ASA	2018-08-16	Good compliance (>= 90%)
2585	151	Placebo	ASA	2022-04-19	Good compliance (>= 90%)
2537	151	Placebo	no ASA	2022-03-16	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2533	151	Edoxaban	ASA	2022-03-14	Good compliance (>= 90%)
2572	151	Edoxaban	no ASA	2022-04-05	Good compliance (>= 90%)
319	153	Placebo	ASA	2017-10-27	Good compliance (>= 90%)
1935	153	Placebo	ASA	2021-01-21	
1098	153	Placebo	no ASA	2019-04-29	Good compliance (>= 90%)
1545	153	Placebo	no ASA	2020-03-05	Good compliance (>= 90%)
2142	153	Placebo	no ASA	2021-06-08	Good compliance (>= 90%)
106	153	Edoxaban	ASA	2017-03-07	Good compliance (>= 90%)
2730	153	Edoxaban	ASA	2022-08-08	Good compliance (>= 90%)
35	153	Edoxaban	no ASA	2016-10-08	
110	154	Placebo	ASA	2017-03-14	Good compliance (>= 90%)
297	154	Placebo	ASA	2017-10-11	
181	154	Edoxaban	ASA	2017-06-08	Good compliance (>= 90%)
688	154	Edoxaban	ASA	2018-08-29	Good compliance (>= 90%)
294	161	Placebo	ASA	2017-10-09	Good compliance (>= 90%)
361	161	Placebo	ASA	2017-12-05	Acceptable compliance (80% to < 90%)
395	161	Placebo	ASA	2018-01-11	Good compliance (>= 90%)
978	161	Placebo	ASA	2019-02-08	Good compliance (>= 90%)
1543	161	Placebo	ASA	2020-03-05	Good compliance (>= 90%)
2485	161	Placebo	ASA	2022-02-18	Good compliance (>= 90%)
230	161	Edoxaban	ASA	2017-07-20	Good compliance (>= 90%)
302	161	Edoxaban	ASA	2017-10-16	Good compliance (>= 90%)
459	161	Edoxaban	ASA	2018-02-26	Good compliance (>= 90%)
526	161				
2417	166	Placebo	ASA	2022-01-07	Good compliance (>= 90%)
2671	166	Placebo	ASA	2022-06-27	Non-compliance (< 80%)
2510	166	Edoxaban	no ASA	2022-03-03	Good compliance (>= 90%)
2626	166	Edoxaban	no ASA	2022-05-25	Good compliance (>= 90%)
2640	167	Placebo	ASA	2022-06-03	Good compliance (>= 90%)
2621	167	Placebo	no ASA	2022-05-19	Good compliance (>= 90%)
2594	167	Edoxaban	no ASA	2022-04-22	Good compliance (>= 90%)
2623	167	Edoxaban	no ASA	2022-05-23	Good compliance (>= 90%)
2606	171	Placebo	ASA	2022-05-07	Good compliance (>= 90%)
2518	171	Placebo	no ASA	2022-03-08	Good compliance (>= 90%)
2717	171	Placebo	no ASA	2022-07-20	Good compliance (>= 90%)
2149	171	Edoxaban	ASA	2021-06-11	Good compliance (>= 90%)
2304	171	Edoxaban	ASA	2021-10-13	Good compliance (>= 90%)
2255	171	Edoxaban	no ASA	2021-09-07	Good compliance (>= 90%)
2709	171	Edoxaban	no ASA	2022-07-12	Good compliance (>= 90%)
585	173	Placebo	ASA	2018-06-11	Good compliance (>= 90%)
1062	173	Placebo	ASA	2019-04-08	Good compliance (>= 90%)
1540	173	Placebo	ASA	2020-03-03	Good compliance (>= 90%)
2042	173	Placebo	ASA	2021-04-12	Good compliance (>= 90%)
2124	173	Placebo	ASA	2021-05-27	Acceptable compliance (80% to < 90%)
2342	173	Placebo	ASA	2021-11-11	Good compliance (>= 90%)
167	173	Placebo	no ASA	2017-05-22	Good compliance (>= 90%)
176	173	Placebo	no ASA	2017-05-31	Good compliance (>= 90%)
553	173	Placebo	no ASA	2018-05-15	Good compliance (>= 90%)
1014	173	Placebo	no ASA	2019-03-05	Good compliance (>= 90%)
1067	173	Placebo	no ASA	2019-04-09	Good compliance (>= 90%)
1319	173	Placebo	no ASA	2019-10-08	Good compliance (>= 90%)
1488	173	Placebo	no ASA	2020-01-22	Good compliance (>= 90%)
2506	173	Placebo	no ASA	2022-03-01	Good compliance (>= 90%)
2675	173	Placebo	no ASA	2022-06-28	Good compliance (>= 90%)
242	173	Edoxaban	ASA	2017-08-03	Good compliance (>= 90%)
1712	173	Edoxaban	ASA	2020-07-30	Good compliance (>= 90%)
1758	173	Edoxaban	ASA	2020-09-04	Good compliance (>= 90%)
2453	173	Edoxaban	ASA	2022-01-27	Good compliance (>= 90%)
2568	173	Edoxaban	ASA	2022-03-31	Good compliance (>= 90%)
314	173	Edoxaban	no ASA	2017-10-24	Good compliance (>= 90%)
322	173	Edoxaban	no ASA	2017-10-31	
894	173	Edoxaban	no ASA	2018-12-17	Good compliance (>= 90%)
975	173	Edoxaban	no ASA	2019-02-04	Acceptable compliance (80% to < 90%)
1080	173	Edoxaban	no ASA	2019-04-15	Good compliance (>= 90%)
1716	173	Edoxaban	no ASA	2020-07-31	Good compliance (>= 90%)
2062	173	Edoxaban	no ASA	2021-04-22	Good compliance (>= 90%)
2375	173	Edoxaban	no ASA	2021-12-02	Good compliance (>= 90%)
2607	173	Edoxaban	no ASA	2022-05-06	Good compliance (>= 90%)
1008	174	Placebo	ASA	2019-02-28	Good compliance (>= 90%)
1925	174	Placebo	ASA	2021-01-13	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2176	174	Placebo	ASA	2021-06-30	Good compliance (>= 90%)
498	174	Placebo	no ASA	2018-03-23	Good compliance (>= 90%)
1414	174	Placebo	no ASA	2019-11-27	Good compliance (>= 90%)
2069	174	Placebo	no ASA	2021-04-28	Good compliance (>= 90%)
2586	174	Placebo	no ASA	2022-04-20	Good compliance (>= 90%)
306	174	Edoxaban	ASA	2017-10-18	Good compliance (>= 90%)
613	174	Edoxaban	ASA	2018-07-05	Good compliance (>= 90%)
2588	174	Edoxaban	ASA	2022-04-20	Good compliance (>= 90%)
172	174	Edoxaban	no ASA	2017-05-29	Good compliance (>= 90%)
1487	174	Edoxaban	no ASA	2020-01-22	Good compliance (>= 90%)
1672	174	Edoxaban	no ASA	2020-07-01	Good compliance (>= 90%)
2566	174	Edoxaban	no ASA	2022-03-30	Non-compliance (< 80%)
2456	175	Placebo	ASA	2022-02-01	Good compliance (>= 90%)
2460	175	Placebo	ASA	2022-02-02	Good compliance (>= 90%)
515	175	Placebo	no ASA	2018-04-07	Good compliance (>= 90%)
2536	175	Placebo	no ASA	2022-03-17	Non-compliance (< 80%)
2523	175	Edoxaban	ASA	2022-03-10	Good compliance (>= 90%)
2745	175	Edoxaban	ASA	2022-09-06	Good compliance (>= 90%)
487	175	Edoxaban	no ASA	2018-03-23	Good compliance (>= 90%)
1035	175	Edoxaban	no ASA	2019-03-23	Good compliance (>= 90%)
2530	175	Edoxaban	no ASA	2022-03-12	Good compliance (>= 90%)
128	179	Placebo	ASA	2017-03-30	Acceptable compliance (80% to < 90%)
510	179	Placebo	ASA	2018-04-05	Good compliance (>= 90%)
308	179	Placebo	no ASA	2017-10-19	Good compliance (>= 90%)
1182	179	Placebo	no ASA	2019-06-17	Good compliance (>= 90%)
1868	179	Placebo	no ASA	2020-11-18	
2101	179	Placebo	no ASA	2021-05-15	Good compliance (>= 90%)
1112	179	Edoxaban	ASA	2019-05-06	Good compliance (>= 90%)
1147	179	Edoxaban	ASA	2019-06-11	Good compliance (>= 90%)
2193	179	Edoxaban	ASA	2021-07-20	
296	179	Edoxaban	no ASA		
1132	179	Edoxaban	no ASA	2019-05-20	Good compliance (>= 90%)
1270	179	Edoxaban	no ASA	2019-09-02	Good compliance (>= 90%)
2100	179	Edoxaban	no ASA	2021-05-15	Good compliance (>= 90%)
989	179				
1108	179				
424	189	Edoxaban	ASA		
1331	189	Edoxaban	ASA	2019-10-16	Good compliance (>= 90%)
351	189				
412	195	Placebo	ASA	2018-01-26	Good compliance (>= 90%)
633	195	Placebo	ASA	2018-07-20	Good compliance (>= 90%)
1004	195	Placebo	ASA	2019-02-26	Good compliance (>= 90%)
396	195	Placebo	no ASA	2018-01-12	Good compliance (>= 90%)
1233	195	Placebo	no ASA	2019-07-31	Good compliance (>= 90%)
398	195	Edoxaban	ASA	2018-01-12	Non-compliance (< 80%)
519	195	Edoxaban	ASA	2018-04-10	Good compliance (>= 90%)
617	195	Edoxaban	ASA	2018-07-06	Good compliance (>= 90%)
1411	195	Edoxaban	ASA	2019-11-27	Good compliance (>= 90%)
169	195	Edoxaban	no ASA		
283	195	Edoxaban	no ASA	2017-09-26	Good compliance (>= 90%)
1857	198	Placebo	ASA	2020-11-11	Good compliance (>= 90%)
2148	198	Placebo	ASA	2021-06-11	Good compliance (>= 90%)
144	198	Placebo	no ASA	2017-04-26	Good compliance (>= 90%)
1188	202	Placebo	ASA	2019-06-19	Good compliance (>= 90%)
1125	202	Placebo	no ASA	2019-05-15	Good compliance (>= 90%)
556	202	Edoxaban	ASA	2018-05-18	Good compliance (>= 90%)
1146	202	Edoxaban	ASA		
348	202	Edoxaban	no ASA	2017-11-24	
419	202	Edoxaban	no ASA	2018-01-31	Good compliance (>= 90%)
184	205	Placebo	ASA	2017-06-08	Acceptable compliance (80% to < 90%)
285	205	Placebo	ASA	2017-09-28	Good compliance (>= 90%)
366	205	Placebo	ASA	2017-12-09	Non-compliance (< 80%)
748	205	Placebo	ASA	2018-10-11	Non-compliance (< 80%)
931	205	Placebo	ASA		
207	205	Placebo	no ASA	2017-06-29	Non-compliance (< 80%)
80	205	Edoxaban	ASA	2017-02-02	Good compliance (>= 90%)
336	205	Edoxaban	ASA	2017-11-10	Good compliance (>= 90%)
382	205	Edoxaban	ASA		
946	205	Edoxaban	ASA	2019-01-21	Non-compliance (< 80%)
182	205	Edoxaban	no ASA	2017-06-08	

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
342	205				
516	208	Placebo	no ASA	2018-04-07	Good compliance (>= 90%)
524	208	Placebo	no ASA	2018-04-14	Non-compliance (< 80%)
1036	208	Edoxaban	ASA	2019-03-23	
1362	208	Edoxaban	ASA	2019-11-09	Good compliance (>= 90%)
1306	208	Edoxaban	no ASA	2019-10-05	Good compliance (>= 90%)
1449	208	Edoxaban	no ASA	2019-12-14	Acceptable compliance (80% to < 90%)
79	209	Placebo	ASA	2017-01-27	Good compliance (>= 90%)
141	209	Placebo	no ASA	2017-04-21	Good compliance (>= 90%)
1501	209	Placebo	no ASA	2020-02-04	Good compliance (>= 90%)
143	211	Placebo	ASA	2017-04-22	Good compliance (>= 90%)
250	211	Placebo	ASA	2017-08-15	Good compliance (>= 90%)
513	211	Placebo	no ASA	2018-04-06	Good compliance (>= 90%)
204	211	Edoxaban	ASA	2017-06-27	Non-compliance (< 80%)
356	211	Edoxaban	ASA	2017-12-01	Good compliance (>= 90%)
49	217	Placebo	no ASA	2016-11-18	Good compliance (>= 90%)
293	226	Placebo	ASA	2017-10-05	Good compliance (>= 90%)
648	226	Placebo	ASA	2018-07-31	Good compliance (>= 90%)
1400	226	Placebo	ASA	2019-11-19	Good compliance (>= 90%)
1434	226	Placebo	ASA	2019-12-05	Good compliance (>= 90%)
1630	226	Placebo	ASA	2020-06-12	Good compliance (>= 90%)
1638	226	Placebo	no ASA	2020-06-17	Good compliance (>= 90%)
1710	226	Placebo	no ASA	2020-07-27	Good compliance (>= 90%)
2259	226	Placebo	no ASA	2021-09-08	Good compliance (>= 90%)
239	226	Edoxaban	ASA	2017-07-28	Good compliance (>= 90%)
413	226	Edoxaban	ASA	2018-01-24	Good compliance (>= 90%)
1404	226	Edoxaban	ASA	2019-11-20	Good compliance (>= 90%)
1511	226	Edoxaban	ASA	2020-02-10	Good compliance (>= 90%)
1670	226	Edoxaban	ASA	2020-06-30	
2120	226	Edoxaban	ASA	2021-05-25	
2639	226	Edoxaban	ASA	2022-06-01	Good compliance (>= 90%)
1164	226	Edoxaban	no ASA	2019-06-06	Good compliance (>= 90%)
2089	226	Edoxaban	no ASA	2021-05-07	Good compliance (>= 90%)
2243	226	Edoxaban	no ASA	2021-08-25	Good compliance (>= 90%)
609	226				
1019	232	Edoxaban	ASA	2019-03-11	Good compliance (>= 90%)
1152	232	Edoxaban	ASA	2019-05-29	Good compliance (>= 90%)
228	232	Edoxaban	no ASA	2017-07-22	Good compliance (>= 90%)
749	232	Edoxaban	no ASA	2018-10-11	Good compliance (>= 90%)
747	264	Placebo	ASA	2018-10-11	Good compliance (>= 90%)
905	264	Placebo	ASA	2018-12-21	Good compliance (>= 90%)
1844	264	Placebo	ASA	2020-11-03	Good compliance (>= 90%)
2454	264	Placebo	ASA	2022-01-29	Good compliance (>= 90%)
408	264	Placebo	no ASA	2018-01-18	Good compliance (>= 90%)
1544	264	Placebo	no ASA	2020-03-05	Acceptable compliance (80% to < 90%)
2681	264	Placebo	no ASA	2022-06-30	Good compliance (>= 90%)
583	264	Edoxaban	ASA	2018-06-08	Good compliance (>= 90%)
1330	264	Edoxaban	ASA	2019-10-15	Good compliance (>= 90%)
381	264	Edoxaban	no ASA	2017-12-22	Good compliance (>= 90%)
1753	264	Edoxaban	no ASA	2020-09-03	Good compliance (>= 90%)
829	267	Placebo	ASA	2018-11-21	Good compliance (>= 90%)
1219	267	Placebo	ASA	2019-07-09	Good compliance (>= 90%)
832	267	Edoxaban	ASA	2018-11-22	Good compliance (>= 90%)
920	267	Edoxaban	ASA	2019-01-05	Good compliance (>= 90%)
937	267	Edoxaban	ASA	2019-01-17	Non-compliance (< 80%)
215	308	Placebo	ASA	2017-07-10	Acceptable compliance (80% to < 90%)
21	308	Placebo	no ASA	2016-09-11	Good compliance (>= 90%)
267	308	Placebo	no ASA	2017-09-05	Good compliance (>= 90%)
217	308	Edoxaban	no ASA	2017-07-10	Good compliance (>= 90%)
501	326	Edoxaban	ASA	2018-03-28	Good compliance (>= 90%)
72	377	Placebo	ASA	2017-01-16	Good compliance (>= 90%)
175	377	Placebo	ASA	2017-06-01	Good compliance (>= 90%)
83	377	Placebo	no ASA	2017-01-30	Good compliance (>= 90%)
163	406	Placebo	ASA	2017-05-18	Good compliance (>= 90%)
1003	406	Placebo	ASA	2019-02-25	Non-compliance (< 80%)
220	414	Placebo	ASA	2017-07-12	Good compliance (>= 90%)
433	414	Placebo	ASA	2018-03-15	Good compliance (>= 90%)
584	414	Placebo	ASA	2018-06-11	Good compliance (>= 90%)
704	414	Placebo	ASA	2018-09-13	Good compliance (>= 90%)
1541	414	Placebo	ASA	2020-03-03	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1654	414	Placebo	ASA	2020-06-23	Good compliance (>= 90%)
1792	414	Placebo	ASA	2020-09-28	Good compliance (>= 90%)
1845	414	Placebo	ASA	2020-11-28	Good compliance (>= 90%)
1892	414	Placebo	ASA	2021-09-24	Good compliance (>= 90%)
2323	414	Placebo	ASA	2021-11-08	Good compliance (>= 90%)
2571	414	Placebo	ASA	2022-04-12	Acceptable compliance (80% to < 90%)
988	414	Placebo	no ASA	2019-02-14	Good compliance (>= 90%)
1626	414	Placebo	no ASA	2020-06-11	Good compliance (>= 90%)
1686	414	Placebo	no ASA	2020-07-16	Good compliance (>= 90%)
1941	414	Placebo	no ASA	2021-02-04	Good compliance (>= 90%)
2035	414	Placebo	no ASA		
2424	414	Placebo	no ASA	2022-01-12	
268	414	Edoxaban	ASA	2017-09-15	Acceptable compliance (80% to < 90%)
346	414	Edoxaban	ASA		
670	414	Edoxaban	ASA	2018-08-15	Good compliance (>= 90%)
970	414	Edoxaban	ASA	2019-02-02	Good compliance (>= 90%)
1610	414	Edoxaban	ASA	2020-06-04	Good compliance (>= 90%)
1777	414	Edoxaban	ASA	2020-09-29	Good compliance (>= 90%)
1783	414	Edoxaban	ASA	2020-09-18	
1943	414	Edoxaban	ASA	2021-02-23	
1971	414	Edoxaban	ASA	2021-10-17	Acceptable compliance (80% to < 90%)
2174	414	Edoxaban	ASA	2021-07-02	Good compliance (>= 90%)
2469	414	Edoxaban	ASA	2022-03-19	Good compliance (>= 90%)
246	414	Edoxaban	no ASA	2017-08-09	Good compliance (>= 90%)
1510	414	Edoxaban	no ASA	2020-02-11	Acceptable compliance (80% to < 90%)
1704	414	Edoxaban	no ASA	2020-07-24	Good compliance (>= 90%)
1767	414	Edoxaban	no ASA	2020-09-11	Acceptable compliance (80% to < 90%)
2183	414	Edoxaban	no ASA	2021-07-21	
2507	414	Edoxaban	no ASA	2022-03-07	Good compliance (>= 90%)
2570	414	Edoxaban	no ASA	2022-07-22	Good compliance (>= 90%)
2116	414				
2278	414				
2309	414				
2322	414				
2481	414				
2497	414				
2569	414				
86	416	Placebo	no ASA	2017-02-03	Good compliance (>= 90%)
125	416	Placebo	no ASA	2017-03-30	Good compliance (>= 90%)
445	416	Placebo	no ASA	2018-02-16	Good compliance (>= 90%)
547	416	Placebo	no ASA	2018-05-28	Good compliance (>= 90%)
84	416	Edoxaban	no ASA	2017-01-31	
449	416	Edoxaban	no ASA	2018-02-20	Good compliance (>= 90%)
469	416	Edoxaban	no ASA	2018-03-02	Good compliance (>= 90%)
1001	416	Edoxaban	no ASA	2019-02-26	Good compliance (>= 90%)
191	416				
494	419	Placebo	ASA	2018-03-21	Good compliance (>= 90%)
1858	419	Placebo	ASA	2020-11-10	Good compliance (>= 90%)
244	419	Placebo	no ASA	2017-08-07	Good compliance (>= 90%)
464	419	Placebo	no ASA	2018-02-27	Good compliance (>= 90%)
690	419	Placebo	no ASA	2018-08-31	Good compliance (>= 90%)
1137	419	Placebo	no ASA	2019-05-22	Good compliance (>= 90%)
247	419	Edoxaban	ASA	2017-08-10	Good compliance (>= 90%)
1260	419	Edoxaban	ASA	2019-08-27	Acceptable compliance (80% to < 90%)
2083	419	Edoxaban	ASA	2021-05-04	Good compliance (>= 90%)
2172	419	Edoxaban	ASA	2021-06-28	Good compliance (>= 90%)
2207	419	Edoxaban	ASA	2021-07-28	Good compliance (>= 90%)
211	419	Edoxaban	no ASA	2017-07-05	Good compliance (>= 90%)
323	419	Edoxaban	no ASA	2017-10-31	Good compliance (>= 90%)
637	419	Edoxaban	no ASA	2018-07-24	Good compliance (>= 90%)
945	419	Edoxaban	no ASA	2019-01-21	Good compliance (>= 90%)
2303	419	Edoxaban	no ASA	2021-10-12	Good compliance (>= 90%)
441	419				
116	421	Placebo	ASA	2017-03-22	
126	421	Placebo	ASA	2017-03-30	Good compliance (>= 90%)
157	421	Placebo	ASA	2017-05-10	
161	421	Placebo	ASA	2017-05-17	Good compliance (>= 90%)
790	421	Placebo	ASA	2018-11-12	Good compliance (>= 90%)
828	421	Placebo	ASA	2018-11-21	Non-compliance (< 80%)
1000	421	Placebo	ASA	2019-02-23	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1299	421	Placebo	ASA		
1418	421	Placebo	ASA	2019-11-29	Good compliance (>= 90%)
1729	421	Placebo	ASA	2020-08-13	Good compliance (>= 90%)
1759	421	Placebo	ASA	2020-09-09	Good compliance (>= 90%)
1841	421	Placebo	ASA	2020-10-30	
1882	421	Placebo	ASA	2020-11-26	Good compliance (>= 90%)
1884	421	Placebo	ASA	2020-11-27	Good compliance (>= 90%)
1949	421	Placebo	ASA	2021-02-05	Good compliance (>= 90%)
1979	421	Placebo	ASA	2021-02-25	Good compliance (>= 90%)
2023	421	Placebo	ASA	2021-04-02	Good compliance (>= 90%)
2111	421	Placebo	ASA	2021-05-20	Good compliance (>= 90%)
2227	421	Placebo	ASA	2021-08-18	Good compliance (>= 90%)
2325	421	Placebo	ASA	2021-11-05	Good compliance (>= 90%)
2347	421	Placebo	ASA	2021-11-17	Good compliance (>= 90%)
2414	421	Placebo	ASA	2022-01-06	Good compliance (>= 90%)
2449	421	Placebo	ASA	2022-01-28	Good compliance (>= 90%)
2489	421	Placebo	ASA	2022-02-22	Good compliance (>= 90%)
2604	421	Placebo	ASA	2022-05-05	Good compliance (>= 90%)
2673	421	Placebo	ASA	2022-06-28	Good compliance (>= 90%)
2702	421	Placebo	ASA	2022-07-08	Good compliance (>= 90%)
55	421	Placebo	no ASA	2016-12-02	Good compliance (>= 90%)
78	421	Placebo	no ASA	2017-01-25	Acceptable compliance (80% to < 90%)
430	421	Placebo	no ASA	2018-02-06	Good compliance (>= 90%)
544	421	Placebo	no ASA	2018-05-04	Good compliance (>= 90%)
685	421	Placebo	no ASA	2018-08-24	Good compliance (>= 90%)
768	421	Placebo	no ASA	2018-10-25	Good compliance (>= 90%)
1116	421	Placebo	no ASA	2019-05-09	Good compliance (>= 90%)
1216	421	Placebo	no ASA	2019-07-06	Acceptable compliance (80% to < 90%)
1357	421	Placebo	no ASA	2019-10-29	Good compliance (>= 90%)
1505	421	Placebo	no ASA	2020-02-06	Acceptable compliance (80% to < 90%)
1804	421	Placebo	no ASA	2020-10-01	Good compliance (>= 90%)
1806	421	Placebo	no ASA	2020-10-01	Good compliance (>= 90%)
2109	421	Placebo	no ASA	2021-05-20	Good compliance (>= 90%)
2232	421	Placebo	no ASA	2021-08-31	Good compliance (>= 90%)
2264	421	Placebo	no ASA	2021-09-14	Good compliance (>= 90%)
2283	421	Placebo	no ASA	2021-09-28	
2430	421	Placebo	no ASA	2022-01-15	Good compliance (>= 90%)
2616	421	Placebo	no ASA	2022-05-24	Good compliance (>= 90%)
77	421	Edoxaban	ASA	2017-01-24	Good compliance (>= 90%)
236	421	Edoxaban	ASA	2017-07-28	Non-compliance (< 80%)
279	421	Edoxaban	ASA		
353	421	Edoxaban	ASA	2017-11-30	Good compliance (>= 90%)
503	421	Edoxaban	ASA	2018-03-29	Good compliance (>= 90%)
985	421	Edoxaban	ASA	2019-02-12	Good compliance (>= 90%)
1046	421	Edoxaban	ASA	2019-04-10	Good compliance (>= 90%)
1225	421	Edoxaban	ASA	2019-07-19	Good compliance (>= 90%)
1307	421	Edoxaban	ASA	2019-10-02	Good compliance (>= 90%)
1590	421	Edoxaban	ASA	2020-05-19	Good compliance (>= 90%)
1602	421	Edoxaban	ASA	2020-07-02	Good compliance (>= 90%)
1883	421	Edoxaban	ASA	2020-11-26	Good compliance (>= 90%)
1899	421	Edoxaban	ASA	2020-12-10	Good compliance (>= 90%)
1934	421	Edoxaban	ASA	2021-01-21	Good compliance (>= 90%)
1940	421	Edoxaban	ASA	2021-01-28	Good compliance (>= 90%)
1956	421	Edoxaban	ASA	2021-02-12	Good compliance (>= 90%)
2033	421	Edoxaban	ASA	2021-03-31	
2034	421	Edoxaban	ASA	2021-04-02	Good compliance (>= 90%)
2228	421	Edoxaban	ASA	2021-08-18	Good compliance (>= 90%)
2265	421	Edoxaban	ASA	2021-09-14	Good compliance (>= 90%)
2386	421	Edoxaban	ASA	2021-12-10	Good compliance (>= 90%)
2452	421	Edoxaban	ASA	2022-01-28	Good compliance (>= 90%)
2457	421	Edoxaban	ASA	2022-02-01	Good compliance (>= 90%)
2544	421	Edoxaban	ASA	2022-03-22	Acceptable compliance (80% to < 90%)
2596	421	Edoxaban	ASA	2022-04-28	Good compliance (>= 90%)
2633	421	Edoxaban	ASA	2022-06-02	Good compliance (>= 90%)
2654	421	Edoxaban	ASA	2022-06-16	Good compliance (>= 90%)
2712	421	Edoxaban	ASA	2022-07-15	Good compliance (>= 90%)
146	421	Edoxaban	no ASA	2017-04-27	Good compliance (>= 90%)
155	421	Edoxaban	no ASA	2017-05-09	
290	421	Edoxaban	no ASA	2017-10-05	Non-compliance (< 80%)
500	421	Edoxaban	no ASA	2018-03-28	Non-compliance (< 80%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
699	421	Edoxaban	no ASA		
854	421	Edoxaban	no ASA	2018-12-04	Non-compliance (< 80%)
875	421	Edoxaban	no ASA	2018-12-11	Good compliance (>= 90%)
907	421	Edoxaban	no ASA	2019-01-22	Good compliance (>= 90%)
1380	421	Edoxaban	no ASA	2019-11-14	Good compliance (>= 90%)
1584	421	Edoxaban	no ASA	2020-05-12	Non-compliance (< 80%)
1668	421	Edoxaban	no ASA	2020-07-01	Good compliance (>= 90%)
1933	421	Edoxaban	no ASA	2021-01-21	Good compliance (>= 90%)
1991	421	Edoxaban	no ASA	2021-03-03	Good compliance (>= 90%)
2152	421	Edoxaban	no ASA	2021-06-15	Good compliance (>= 90%)
2240	421	Edoxaban	no ASA	2021-08-25	Good compliance (>= 90%)
2241	421	Edoxaban	no ASA	2021-08-25	Good compliance (>= 90%)
2508	421	Edoxaban	no ASA	2022-03-03	Good compliance (>= 90%)
2076	421				
778	426	Placebo	ASA	2018-10-26	Good compliance (>= 90%)
1642	426	Placebo	ASA	2020-06-18	Good compliance (>= 90%)
569	426	Placebo	no ASA	2018-05-25	Good compliance (>= 90%)
1235	426	Placebo	no ASA	2019-07-31	Good compliance (>= 90%)
718	426	Edoxaban	ASA	2018-09-22	Good compliance (>= 90%)
1468	426	Edoxaban	ASA	2020-01-08	Acceptable compliance (80% to < 90%)
930	426	Edoxaban	no ASA	2019-01-12	Good compliance (>= 90%)
1796	426	Edoxaban	no ASA	2020-09-22	Good compliance (>= 90%)
508	427	Placebo	ASA	2018-04-03	Good compliance (>= 90%)
847	427	Placebo	ASA	2018-11-26	Good compliance (>= 90%)
423	427	Placebo	no ASA	2018-01-31	Good compliance (>= 90%)
438	427	Edoxaban	ASA	2018-02-08	Good compliance (>= 90%)
1089	427	Edoxaban	ASA	2019-04-17	Good compliance (>= 90%)
2534	428	Placebo	no ASA	2022-03-16	Good compliance (>= 90%)
721	428	Edoxaban	ASA	2018-09-26	Good compliance (>= 90%)
2350	428	Edoxaban	ASA	2021-11-18	Good compliance (>= 90%)
326	428	Edoxaban	no ASA	2017-11-02	Good compliance (>= 90%)
652	445	Placebo	ASA	2018-08-02	Good compliance (>= 90%)
785	445	Placebo	ASA	2018-11-05	Good compliance (>= 90%)
786	445	Placebo	ASA	2018-11-01	Good compliance (>= 90%)
2324	445	Placebo	ASA	2021-11-04	Acceptable compliance (80% to < 90%)
2674	445	Placebo	ASA	2022-06-28	Good compliance (>= 90%)
650	445	Edoxaban	ASA	2018-08-02	Good compliance (>= 90%)
651	445	Edoxaban	ASA	2018-08-02	Good compliance (>= 90%)
1506	445	Edoxaban	ASA	2020-02-06	Good compliance (>= 90%)
1507	445	Edoxaban	ASA	2020-02-17	Good compliance (>= 90%)
1574	445	Edoxaban	ASA	2020-04-30	Good compliance (>= 90%)
784	445	Edoxaban	no ASA	2018-11-01	Good compliance (>= 90%)
2209	445	Edoxaban	no ASA	2021-07-30	Acceptable compliance (80% to < 90%)
159	459	Placebo	ASA	2017-05-12	Good compliance (>= 90%)
574	459				
196	470	Edoxaban	ASA	2017-06-20	Good compliance (>= 90%)
222	470	Edoxaban	ASA	2017-07-11	Good compliance (>= 90%)
529	470	Edoxaban	ASA	2018-04-18	Good compliance (>= 90%)
304	470	Edoxaban	no ASA	2017-10-17	Good compliance (>= 90%)
76	479	Placebo	ASA	2017-01-17	Good compliance (>= 90%)
107	479	Placebo	no ASA	2017-03-06	Good compliance (>= 90%)
535	479	Placebo	no ASA	2018-04-25	Good compliance (>= 90%)
2352	479	Edoxaban	ASA	2021-11-18	Good compliance (>= 90%)
2580	479	Edoxaban	ASA	2022-04-08	Good compliance (>= 90%)
1246	487	Placebo	ASA	2019-08-08	Good compliance (>= 90%)
1652	487	Placebo	no ASA	2020-06-23	Good compliance (>= 90%)
2059	487	Placebo	no ASA	2021-04-26	Good compliance (>= 90%)
405	487	Edoxaban	no ASA	2018-01-17	Good compliance (>= 90%)
1215	487	Edoxaban	no ASA	2019-07-18	Good compliance (>= 90%)
2491	487	Edoxaban	no ASA	2022-02-23	Good compliance (>= 90%)
2	488	Placebo	ASA	2016-06-29	Good compliance (>= 90%)
45	488	Placebo	ASA	2016-11-15	Good compliance (>= 90%)
47	488	Placebo	ASA	2016-11-16	Good compliance (>= 90%)
64	488	Placebo	ASA		
189	488	Placebo	ASA	2017-06-15	Good compliance (>= 90%)
206	488	Placebo	ASA	2017-06-29	Good compliance (>= 90%)
218	488	Placebo	ASA	2017-07-15	Good compliance (>= 90%)
249	488	Placebo	ASA		
327	488	Placebo	ASA		
370	488	Placebo	ASA	2017-12-12	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
474	488	Placebo	ASA	2018-03-09	Good compliance (>= 90%)
1099	488	Placebo	ASA	2019-04-29	Good compliance (>= 90%)
1532	488	Placebo	ASA	2020-02-27	Good compliance (>= 90%)
2318	488	Placebo	ASA	2021-10-22	Good compliance (>= 90%)
5	488	Placebo	no ASA	2016-07-09	Good compliance (>= 90%)
90	488	Placebo	no ASA	2017-03-21	Good compliance (>= 90%)
134	488	Placebo	no ASA	2017-04-11	Good compliance (>= 90%)
357	488	Placebo	no ASA	2017-12-05	Good compliance (>= 90%)
1133	488	Placebo	no ASA	2019-05-21	Good compliance (>= 90%)
1250	488	Placebo	no ASA	2019-08-08	Good compliance (>= 90%)
1361	488	Placebo	no ASA	2019-11-04	Non-compliance (< 80%)
2413	488	Placebo	no ASA	2022-01-06	Good compliance (>= 90%)
20	488	Edoxaban	ASA	2016-09-14	Good compliance (>= 90%)
27	488	Edoxaban	ASA	2016-09-24	Good compliance (>= 90%)
31	488	Edoxaban	ASA	2016-10-01	Good compliance (>= 90%)
50	488	Edoxaban	ASA	2016-11-25	Good compliance (>= 90%)
135	488	Edoxaban	ASA	2017-04-11	Good compliance (>= 90%)
213	488	Edoxaban	ASA	2017-07-08	Good compliance (>= 90%)
261	488	Edoxaban	ASA	2017-08-24	Good compliance (>= 90%)
280	488	Edoxaban	ASA	2017-09-21	Good compliance (>= 90%)
318	488	Edoxaban	ASA	2017-10-27	Good compliance (>= 90%)
343	488	Edoxaban	ASA	2017-11-21	Good compliance (>= 90%)
390	488	Edoxaban	ASA	2018-01-10	Good compliance (>= 90%)
810	488	Edoxaban	ASA	2018-11-12	Good compliance (>= 90%)
1244	488	Edoxaban	ASA	2019-08-06	Good compliance (>= 90%)
1824	488	Edoxaban	ASA	2020-10-13	Good compliance (>= 90%)
25	488	Edoxaban	no ASA	2016-09-20	Good compliance (>= 90%)
42	488	Edoxaban	no ASA	2016-11-09	Good compliance (>= 90%)
121	488	Edoxaban	no ASA	2017-03-24	Good compliance (>= 90%)
139	488	Edoxaban	no ASA	2017-04-26	Good compliance (>= 90%)
766	488	Edoxaban	no ASA		
898	488	Edoxaban	no ASA	2018-12-18	Good compliance (>= 90%)
1586	488	Edoxaban	no ASA	2020-05-14	Good compliance (>= 90%)
1942	488	Edoxaban	no ASA	2021-02-01	Good compliance (>= 90%)
2372	488	Edoxaban	no ASA	2021-12-02	Good compliance (>= 90%)
3	488				
12	488				
32	488				
61	488				
277	488				
330	488				
2591	488				
334	502	Placebo	ASA	2017-11-10	Good compliance (>= 90%)
835	502	Placebo	ASA	2018-11-21	Good compliance (>= 90%)
1282	502	Placebo	ASA	2019-09-12	Good compliance (>= 90%)
1283	502	Placebo	ASA	2019-09-12	Good compliance (>= 90%)
1535	502	Placebo	ASA	2020-03-02	Good compliance (>= 90%)
1585	502	Placebo	ASA	2020-05-12	Good compliance (>= 90%)
198	502	Placebo	no ASA		
270	502	Placebo	no ASA	2017-09-05	Good compliance (>= 90%)
309	502	Placebo	no ASA	2017-10-20	Good compliance (>= 90%)
602	502	Placebo	no ASA	2018-06-21	Good compliance (>= 90%)
166	502	Edoxaban	ASA	2017-05-19	Good compliance (>= 90%)
195	502	Edoxaban	ASA	2017-06-16	Good compliance (>= 90%)
1200	502	Edoxaban	ASA	2019-06-24	Good compliance (>= 90%)
1440	502	Edoxaban	ASA	2019-12-09	Good compliance (>= 90%)
1556	502	Edoxaban	ASA	2020-03-12	Good compliance (>= 90%)
2081	502	Edoxaban	ASA	2021-05-03	Good compliance (>= 90%)
2496	502	Edoxaban	ASA	2022-02-23	Good compliance (>= 90%)
102	502	Edoxaban	no ASA	2017-03-01	Good compliance (>= 90%)
133	502	Edoxaban	no ASA	2017-04-05	Good compliance (>= 90%)
227	502	Edoxaban	no ASA	2017-07-18	Good compliance (>= 90%)
425	502	Edoxaban	no ASA	2018-02-01	Good compliance (>= 90%)
1782	502	Edoxaban	no ASA	2020-09-16	Good compliance (>= 90%)
164	514	Placebo	no ASA	2017-05-18	Good compliance (>= 90%)
456	514	Edoxaban	ASA	2018-02-22	Good compliance (>= 90%)
2370	519	Edoxaban	ASA	2021-11-30	Good compliance (>= 90%)
2577	519	Edoxaban	ASA	2022-04-07	Good compliance (>= 90%)
2400	519	Edoxaban	no ASA	2021-12-23	Good compliance (>= 90%)
255	529	Placebo	ASA	2017-08-17	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
489	529	Placebo	ASA	2018-03-19	Good compliance (>= 90%)
1072	529	Placebo	ASA	2019-04-10	Good compliance (>= 90%)
1254	529	Placebo	ASA	2019-08-19	Good compliance (>= 90%)
1399	529	Placebo	ASA	2019-11-19	Acceptable compliance (80% to < 90%)
1515	529	Placebo	ASA	2020-02-16	Good compliance (>= 90%)
1550	529	Placebo	ASA	2020-03-10	Good compliance (>= 90%)
1594	529	Placebo	ASA	2020-05-20	Good compliance (>= 90%)
1852	529	Placebo	ASA	2020-11-05	Good compliance (>= 90%)
1924	529	Placebo	ASA		
2113	529	Placebo	ASA	2021-05-20	Good compliance (>= 90%)
2220	529	Placebo	ASA	2021-08-11	Good compliance (>= 90%)
2334	529	Placebo	ASA		
2545	529	Placebo	ASA	2022-03-21	Good compliance (>= 90%)
2555	529	Placebo	ASA	2022-03-23	Acceptable compliance (80% to < 90%)
2644	529	Placebo	ASA	2022-06-09	Good compliance (>= 90%)
659	529	Placebo	no ASA	2018-08-09	Good compliance (>= 90%)
712	529	Placebo	no ASA		
1068	529	Placebo	no ASA	2019-04-09	Good compliance (>= 90%)
1121	529	Placebo	no ASA	2019-05-14	Acceptable compliance (80% to < 90%)
1199	529	Placebo	no ASA	2019-06-24	Good compliance (>= 90%)
1354	529	Placebo	no ASA	2019-10-28	Good compliance (>= 90%)
1632	529	Placebo	no ASA	2020-06-15	Good compliance (>= 90%)
1635	529	Placebo	no ASA	2020-06-16	Good compliance (>= 90%)
1745	529	Placebo	no ASA	2020-08-31	Good compliance (>= 90%)
1780	529	Placebo	no ASA	2020-09-17	Good compliance (>= 90%)
1813	529	Placebo	no ASA	2020-10-05	Good compliance (>= 90%)
1848	529	Placebo	no ASA	2020-11-04	Good compliance (>= 90%)
1965	529	Placebo	no ASA	2021-02-18	Good compliance (>= 90%)
2011	529	Placebo	no ASA	2021-03-16	Good compliance (>= 90%)
2104	529	Placebo	no ASA	2021-05-17	Good compliance (>= 90%)
2118	529	Placebo	no ASA	2021-05-25	Good compliance (>= 90%)
2229	529	Placebo	no ASA	2021-08-17	Good compliance (>= 90%)
2256	529	Placebo	no ASA	2021-09-06	Good compliance (>= 90%)
2258	529	Placebo	no ASA	2021-09-07	Good compliance (>= 90%)
2647	529	Placebo	no ASA	2022-06-18	Good compliance (>= 90%)
2662	529	Placebo	no ASA	2022-06-21	Good compliance (>= 90%)
658	529	Edoxaban	ASA	2018-08-08	Good compliance (>= 90%)
703	529	Edoxaban	ASA	2018-09-12	Good compliance (>= 90%)
1006	529	Edoxaban	ASA	2019-02-27	Good compliance (>= 90%)
1083	529	Edoxaban	ASA	2019-04-16	Good compliance (>= 90%)
1201	529	Edoxaban	ASA	2019-06-25	Non-compliance (< 80%)
1234	529	Edoxaban	ASA	2019-07-29	Good compliance (>= 90%)
1595	529	Edoxaban	ASA	2020-05-21	Good compliance (>= 90%)
1689	529	Edoxaban	ASA	2020-07-15	Good compliance (>= 90%)
1709	529	Edoxaban	ASA	2020-08-01	Good compliance (>= 90%)
1763	529	Edoxaban	ASA		
1987	529	Edoxaban	ASA	2021-03-15	Good compliance (>= 90%)
2451	529	Edoxaban	ASA	2022-01-27	Good compliance (>= 90%)
2459	529	Edoxaban	ASA	2022-02-01	Good compliance (>= 90%)
2643	529	Edoxaban	ASA	2022-06-07	Good compliance (>= 90%)
2659	529	Edoxaban	ASA	2022-06-20	Good compliance (>= 90%)
317	529	Edoxaban	no ASA	2017-10-26	Good compliance (>= 90%)
447	529	Edoxaban	no ASA	2018-02-16	Good compliance (>= 90%)
926	529	Edoxaban	no ASA	2019-01-10	Good compliance (>= 90%)
1050	529	Edoxaban	no ASA	2019-04-03	Good compliance (>= 90%)
1198	529	Edoxaban	no ASA	2019-06-24	Good compliance (>= 90%)
1343	529	Edoxaban	no ASA	2019-10-22	Good compliance (>= 90%)
1503	529	Edoxaban	no ASA	2020-02-04	Good compliance (>= 90%)
1593	529	Edoxaban	no ASA	2020-05-19	Good compliance (>= 90%)
1768	529	Edoxaban	no ASA	2020-09-10	Good compliance (>= 90%)
1823	529	Edoxaban	no ASA	2020-10-13	Acceptable compliance (80% to < 90%)
1846	529	Edoxaban	no ASA	2020-11-03	
1898	529	Edoxaban	no ASA	2020-12-09	Acceptable compliance (80% to < 90%)
1927	529	Edoxaban	no ASA	2021-01-14	Good compliance (>= 90%)
1951	529	Edoxaban	no ASA	2021-02-13	Good compliance (>= 90%)
2117	529	Edoxaban	no ASA	2021-05-28	Good compliance (>= 90%)
2119	529	Edoxaban	no ASA	2021-05-25	Good compliance (>= 90%)
2216	529	Edoxaban	no ASA	2021-08-09	Good compliance (>= 90%)
2223	529	Edoxaban	no ASA	2021-08-16	Good compliance (>= 90%)
2328	529	Edoxaban	no ASA	2021-11-08	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1410	529				
2338	529				
315	530	Placebo	ASA	2017-10-26	Good compliance (>= 90%)
1010	530	Placebo	ASA	2019-03-01	Good compliance (>= 90%)
2106	530	Placebo	ASA	2021-05-18	Good compliance (>= 90%)
2163	530	Placebo	ASA	2021-06-22	Good compliance (>= 90%)
2164	530	Placebo	ASA	2021-06-22	Good compliance (>= 90%)
429	530	Placebo	no ASA	2018-02-03	
1552	530	Placebo	no ASA	2020-03-10	Good compliance (>= 90%)
2279	530	Placebo	no ASA	2021-09-22	Good compliance (>= 90%)
271	530	Edoxaban	ASA	2017-09-06	Good compliance (>= 90%)
1059	530	Edoxaban	ASA	2019-04-05	Good compliance (>= 90%)
1237	530	Edoxaban	ASA	2019-07-31	Good compliance (>= 90%)
1513	530	Edoxaban	ASA	2020-02-11	
1521	530	Edoxaban	no ASA	2020-02-18	Good compliance (>= 90%)
2548	530	Edoxaban	no ASA	2022-03-22	Good compliance (>= 90%)
2652	530	Edoxaban	no ASA	2022-06-14	Good compliance (>= 90%)
241	531	Placebo	no ASA	2017-08-01	Good compliance (>= 90%)
311	532	Placebo	ASA	2017-10-23	Good compliance (>= 90%)
563	535	Placebo	no ASA	2018-05-22	Good compliance (>= 90%)
605	535	Placebo	no ASA	2018-06-22	Acceptable compliance (80% to < 90%)
1268	535	Placebo	no ASA	2019-08-29	Good compliance (>= 90%)
1393	535	Placebo	no ASA	2019-11-18	Acceptable compliance (80% to < 90%)
538	535	Edoxaban	ASA	2018-04-26	Good compliance (>= 90%)
546	535	Edoxaban	ASA	2018-05-08	Good compliance (>= 90%)
1693	535	Edoxaban	ASA	2020-07-16	Good compliance (>= 90%)
335	535	Edoxaban	no ASA	2017-11-13	Good compliance (>= 90%)
631	535	Edoxaban	no ASA	2018-07-18	Good compliance (>= 90%)
756	535	Edoxaban	no ASA	2018-10-18	Good compliance (>= 90%)
1589	535	Edoxaban	no ASA	2020-05-18	Good compliance (>= 90%)
1769	535	Edoxaban	no ASA	2020-09-10	Good compliance (>= 90%)
1776	535	Edoxaban	no ASA	2020-09-14	Good compliance (>= 90%)
386	536	Placebo	ASA	2018-01-05	Good compliance (>= 90%)
1328	536	Placebo	ASA	2019-10-14	
991	536	Placebo	no ASA	2019-02-18	Acceptable compliance (80% to < 90%)
276	536	Edoxaban	ASA	2017-09-13	
1818	536	Edoxaban	ASA	2020-10-08	Good compliance (>= 90%)
2326	536	Edoxaban	no ASA	2021-11-06	Good compliance (>= 90%)
291	541	Placebo	no ASA		
417	541	Placebo	no ASA	2018-01-27	
855	541	Edoxaban	ASA	2018-11-30	Good compliance (>= 90%)
470	541	Edoxaban	no ASA	2018-03-01	Good compliance (>= 90%)
856	541				
523	542	Placebo	no ASA	2018-04-14	Good compliance (>= 90%)
347	542	Edoxaban	no ASA	2017-11-23	Good compliance (>= 90%)
177	544	Placebo	ASA	2017-06-06	Good compliance (>= 90%)
179	544	Placebo	ASA	2017-06-06	Good compliance (>= 90%)
940	544	Placebo	ASA		
1336	544	Placebo	ASA	2019-10-17	Non-compliance (< 80%)
1476	544	Placebo	ASA	2020-01-17	Good compliance (>= 90%)
1482	544	Placebo	ASA	2020-01-22	Good compliance (>= 90%)
1508	544	Placebo	ASA	2020-02-07	
137	544	Placebo	no ASA	2017-04-20	Good compliance (>= 90%)
156	544	Placebo	no ASA	2017-05-09	Good compliance (>= 90%)
367	544	Placebo	no ASA	2017-12-11	Good compliance (>= 90%)
491	544	Placebo	no ASA	2018-03-19	Good compliance (>= 90%)
575	544	Placebo	no ASA	2018-05-30	Good compliance (>= 90%)
1193	544	Placebo	no ASA	2019-06-21	Good compliance (>= 90%)
1606	544	Placebo	no ASA	2020-05-30	Good compliance (>= 90%)
1831	544	Placebo	no ASA	2020-10-21	Good compliance (>= 90%)
1854	544	Placebo	no ASA	2020-11-07	Acceptable compliance (80% to < 90%)
178	544	Edoxaban	ASA	2017-06-06	Good compliance (>= 90%)
486	544	Edoxaban	ASA	2018-03-16	Good compliance (>= 90%)
958	544	Edoxaban	ASA	2019-01-30	Good compliance (>= 90%)
1005	544	Edoxaban	ASA	2019-02-27	Good compliance (>= 90%)
1190	544	Edoxaban	ASA	2019-06-20	Good compliance (>= 90%)
1370	544	Edoxaban	ASA	2019-11-07	Good compliance (>= 90%)
1683	544	Edoxaban	ASA	2020-07-11	Acceptable compliance (80% to < 90%)
224	544	Edoxaban	no ASA	2017-07-12	Good compliance (>= 90%)
310	544	Edoxaban	no ASA	2017-10-23	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
488	544	Edoxaban	no ASA		
773	544	Edoxaban	no ASA	2018-10-27	Good compliance (>= 90%)
839	544	Edoxaban	no ASA	2018-11-23	Good compliance (>= 90%)
1345	544	Edoxaban	no ASA	2019-10-24	Good compliance (>= 90%)
1367	544	Edoxaban	no ASA	2019-11-07	Acceptable compliance (80% to < 90%)
275	547	Placebo	ASA	2017-09-12	Good compliance (>= 90%)
391	547	Placebo	ASA	2018-01-09	Good compliance (>= 90%)
1088	547	Placebo	ASA	2019-04-17	Good compliance (>= 90%)
1517	547	Placebo	ASA	2020-02-12	Good compliance (>= 90%)
1906	547	Placebo	ASA	2020-12-15	Good compliance (>= 90%)
1922	547	Placebo	ASA	2021-01-11	Acceptable compliance (80% to < 90%)
1939	547	Placebo	ASA	2021-01-27	Good compliance (>= 90%)
2218	547	Placebo	ASA	2021-08-23	Good compliance (>= 90%)
2412	547	Placebo	ASA	2021-12-27	Good compliance (>= 90%)
2447	547	Placebo	ASA	2022-01-26	Good compliance (>= 90%)
2735	547	Placebo	ASA		
273	547	Placebo	no ASA	2017-09-07	Good compliance (>= 90%)
454	547	Placebo	no ASA	2018-02-21	Good compliance (>= 90%)
702	547	Placebo	no ASA	2018-09-12	Good compliance (>= 90%)
715	547	Placebo	no ASA	2018-09-20	Good compliance (>= 90%)
918	547	Placebo	no ASA	2019-01-02	Good compliance (>= 90%)
922	547	Placebo	no ASA	2019-01-08	Good compliance (>= 90%)
1238	547	Placebo	no ASA	2019-08-01	Good compliance (>= 90%)
1554	547	Placebo	no ASA	2020-03-12	Good compliance (>= 90%)
1653	547	Placebo	no ASA	2020-06-22	Good compliance (>= 90%)
1903	547	Placebo	no ASA	2020-12-14	Good compliance (>= 90%)
2051	547	Placebo	no ASA	2021-04-19	Good compliance (>= 90%)
2053	547	Placebo	no ASA	2021-04-19	Good compliance (>= 90%)
2127	547	Placebo	no ASA	2021-05-31	Good compliance (>= 90%)
2379	547	Placebo	no ASA	2021-12-03	Good compliance (>= 90%)
2407	547	Placebo	no ASA	2021-12-22	Good compliance (>= 90%)
2409	547	Placebo	no ASA	2021-12-22	Good compliance (>= 90%)
2520	547	Placebo	no ASA	2022-03-09	Good compliance (>= 90%)
2521	547	Placebo	no ASA	2022-03-09	Good compliance (>= 90%)
2565	547	Placebo	no ASA	2022-03-30	Good compliance (>= 90%)
2628	547	Placebo	no ASA	2022-05-25	Good compliance (>= 90%)
2632	547	Placebo	no ASA	2022-06-01	Good compliance (>= 90%)
2695	547	Placebo	no ASA	2022-07-06	Good compliance (>= 90%)
378	547	Edoxaban	ASA	2017-12-20	
392	547	Edoxaban	ASA	2018-01-09	Acceptable compliance (80% to < 90%)
1369	547	Edoxaban	ASA	2019-11-06	Good compliance (>= 90%)
1663	547	Edoxaban	ASA	2020-06-26	Good compliance (>= 90%)
2055	547	Edoxaban	ASA	2021-04-19	Good compliance (>= 90%)
2063	547	Edoxaban	ASA	2021-04-26	Good compliance (>= 90%)
2214	547	Edoxaban	ASA	2021-08-05	Non-compliance (< 80%)
2299	547	Edoxaban	ASA	2021-10-06	Good compliance (>= 90%)
2411	547	Edoxaban	ASA	2021-12-27	Good compliance (>= 90%)
2522	547	Edoxaban	ASA	2022-03-09	Good compliance (>= 90%)
2605	547	Edoxaban	ASA	2022-05-04	Good compliance (>= 90%)
2719	547	Edoxaban	ASA	2022-07-20	Good compliance (>= 90%)
499	547	Edoxaban	no ASA	2018-03-26	Good compliance (>= 90%)
573	547	Edoxaban	no ASA	2018-05-30	Non-compliance (< 80%)
864	547	Edoxaban	no ASA	2018-12-05	Good compliance (>= 90%)
909	547	Edoxaban	no ASA	2018-12-21	Good compliance (>= 90%)
936	547	Edoxaban	no ASA	2019-01-16	Good compliance (>= 90%)
996	547	Edoxaban	no ASA	2019-02-20	Good compliance (>= 90%)
1160	547	Edoxaban	no ASA	2019-06-19	Good compliance (>= 90%)
1622	547	Edoxaban	no ASA	2020-06-10	Good compliance (>= 90%)
1932	547	Edoxaban	no ASA	2021-01-20	Acceptable compliance (80% to < 90%)
1938	547	Edoxaban	no ASA	2021-01-27	Good compliance (>= 90%)
2052	547	Edoxaban	no ASA	2021-04-19	Acceptable compliance (80% to < 90%)
2054	547	Edoxaban	no ASA	2021-04-19	Good compliance (>= 90%)
2128	547	Edoxaban	no ASA	2021-05-31	Good compliance (>= 90%)
2129	547	Edoxaban	no ASA	2021-05-31	Good compliance (>= 90%)
2213	547	Edoxaban	no ASA	2021-08-11	Good compliance (>= 90%)
2380	547	Edoxaban	no ASA	2021-12-03	Non-compliance (< 80%)
2493	547	Edoxaban	no ASA	2022-02-23	Good compliance (>= 90%)
2495	547	Edoxaban	no ASA	2022-02-23	Good compliance (>= 90%)
2635	547	Edoxaban	no ASA	2022-06-01	Good compliance (>= 90%)
2636	547	Edoxaban	no ASA	2022-06-01	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2658	547	Edoxaban	no ASA	2022-06-20	Good compliance (>= 90%)
2718	547	Edoxaban	no ASA		
667	557	Placebo	ASA	2018-08-14	Good compliance (>= 90%)
733	557	Placebo	ASA	2018-10-05	Good compliance (>= 90%)
460	557	Placebo	no ASA	2018-02-27	Good compliance (>= 90%)
530	557	Placebo	no ASA	2018-04-19	Good compliance (>= 90%)
1117	557	Placebo	no ASA	2019-05-09	Good compliance (>= 90%)
502	557	Edoxaban	ASA	2018-03-29	Good compliance (>= 90%)
714	557	Edoxaban	ASA	2018-09-21	Good compliance (>= 90%)
394	557	Edoxaban	no ASA	2018-01-10	Good compliance (>= 90%)
598	557	Edoxaban	no ASA	2018-06-20	Good compliance (>= 90%)
1232	557	Edoxaban	no ASA	2019-07-26	Good compliance (>= 90%)
462	564	Placebo	ASA	2018-02-28	Non-compliance (< 80%)
1110	564	Placebo	ASA	2019-05-06	
389	564	Placebo	no ASA	2018-01-09	Good compliance (>= 90%)
490	564	Edoxaban	ASA	2018-03-20	Good compliance (>= 90%)
548	564	Edoxaban	ASA	2018-05-09	Good compliance (>= 90%)
974	564	Edoxaban	ASA	2019-02-04	Good compliance (>= 90%)
779	564	Edoxaban	no ASA	2018-10-27	Good compliance (>= 90%)
1322	564				
165	566	Edoxaban	ASA	2017-05-19	Good compliance (>= 90%)
344	577	Placebo	no ASA	2017-11-22	Good compliance (>= 90%)
377	605	Placebo	ASA	2017-12-21	Good compliance (>= 90%)
298	605	Edoxaban	ASA	2017-10-14	Good compliance (>= 90%)
572	608	Placebo	ASA	2018-05-29	
816	608	Placebo	ASA	2018-11-14	Good compliance (>= 90%)
868	608	Placebo	ASA	2018-12-06	Good compliance (>= 90%)
1484	608	Placebo	ASA	2020-01-21	Good compliance (>= 90%)
1774	608	Placebo	ASA	2020-09-12	Good compliance (>= 90%)
903	608	Placebo	no ASA	2018-12-20	Good compliance (>= 90%)
1091	608	Placebo	no ASA	2019-04-18	Good compliance (>= 90%)
1450	608	Placebo	no ASA	2019-12-13	Good compliance (>= 90%)
2402	608	Placebo	no ASA	2021-12-20	Good compliance (>= 90%)
2645	608	Placebo	no ASA	2022-06-09	
817	608	Edoxaban	ASA		
869	608	Edoxaban	ASA	2018-12-06	Good compliance (>= 90%)
973	608	Edoxaban	ASA	2019-02-04	Good compliance (>= 90%)
1791	608	Edoxaban	ASA	2020-09-18	Good compliance (>= 90%)
2036	608	Edoxaban	ASA	2021-04-08	Acceptable compliance (80% to < 90%)
954	608	Edoxaban	no ASA	2019-01-28	Good compliance (>= 90%)
1471	608	Edoxaban	no ASA	2020-01-14	Good compliance (>= 90%)
1766	608	Edoxaban	no ASA	2020-09-10	Good compliance (>= 90%)
1993	608	Edoxaban	no ASA	2021-03-04	Good compliance (>= 90%)
601	619	Edoxaban	no ASA	2018-06-21	Good compliance (>= 90%)
286	641	Placebo	ASA	2017-09-27	
552	641	Placebo	ASA	2018-05-15	Good compliance (>= 90%)
581	641	Placebo	ASA	2018-06-06	Good compliance (>= 90%)
643	641	Placebo	ASA	2018-07-30	
1719	641	Placebo	ASA	2020-08-03	Good compliance (>= 90%)
1807	641	Placebo	ASA	2020-09-30	Acceptable compliance (80% to < 90%)
2016	641	Placebo	ASA	2021-03-17	Good compliance (>= 90%)
2166	641	Placebo	ASA	2021-06-23	Good compliance (>= 90%)
2584	641	Placebo	ASA	2022-04-13	Good compliance (>= 90%)
138	641	Placebo	no ASA	2017-04-18	Good compliance (>= 90%)
422	641	Placebo	no ASA	2018-01-31	Acceptable compliance (80% to < 90%)
473	641	Placebo	no ASA	2018-04-07	Good compliance (>= 90%)
478	641	Placebo	no ASA	2018-03-12	
632	641	Placebo	no ASA	2018-07-18	Good compliance (>= 90%)
1211	641	Placebo	no ASA		
1430	641	Placebo	no ASA	2019-12-05	
1498	641	Placebo	no ASA	2020-01-30	
1834	641	Placebo	no ASA		
1905	641	Placebo	no ASA	2020-12-14	Good compliance (>= 90%)
1981	641	Placebo	no ASA	2021-02-24	Acceptable compliance (80% to < 90%)
2168	641	Placebo	no ASA	2021-06-23	Good compliance (>= 90%)
2343	641	Placebo	no ASA	2021-11-15	
2637	641	Placebo	no ASA	2022-06-01	
2667	641	Placebo	no ASA	2022-06-22	Non-compliance (< 80%)
115	641	Edoxaban	ASA	2017-03-21	Good compliance (>= 90%)
238	641	Edoxaban	ASA	2017-07-28	

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
589	641	Edoxaban	ASA	2018-06-13	Good compliance (>= 90%)
1167	641	Edoxaban	ASA	2019-06-11	
1405	641	Edoxaban	ASA	2019-11-20	Good compliance (>= 90%)
1691	641	Edoxaban	ASA	2020-07-15	Good compliance (>= 90%)
1990	641	Edoxaban	ASA	2021-03-01	Good compliance (>= 90%)
2393	641	Edoxaban	ASA	2021-12-15	Good compliance (>= 90%)
2463	641	Edoxaban	ASA	2022-02-02	Good compliance (>= 90%)
262	641	Edoxaban	no ASA	2017-08-24	Good compliance (>= 90%)
274	641	Edoxaban	no ASA	2017-09-08	Good compliance (>= 90%)
292	641	Edoxaban	no ASA	2017-10-04	Good compliance (>= 90%)
588	641	Edoxaban	no ASA	2018-06-12	Good compliance (>= 90%)
746	641	Edoxaban	no ASA	2018-10-10	Good compliance (>= 90%)
1015	641	Edoxaban	no ASA	2019-03-05	Non-compliance (< 80%)
1280	641	Edoxaban	no ASA	2019-09-12	Good compliance (>= 90%)
1828	641	Edoxaban	no ASA	2020-10-17	Non-compliance (< 80%)
1855	641	Edoxaban	no ASA	2020-11-09	Acceptable compliance (80% to < 90%)
1944	641	Edoxaban	no ASA	2021-02-02	Good compliance (>= 90%)
2112	641	Edoxaban	no ASA	2021-05-19	Good compliance (>= 90%)
2196	641	Edoxaban	no ASA	2021-07-20	
2341	641	Edoxaban	no ASA	2021-11-10	Good compliance (>= 90%)
542	641				
2332	653	Placebo	ASA	2021-11-08	Good compliance (>= 90%)
2655	653	Placebo	ASA	2022-06-15	Good compliance (>= 90%)
2448	653	Edoxaban	ASA	2022-01-26	Good compliance (>= 90%)
2487	653	Edoxaban	ASA	2022-02-18	Acceptable compliance (80% to < 90%)
2486	653	Edoxaban	no ASA	2022-02-18	Good compliance (>= 90%)
2498	653	Edoxaban	no ASA	2022-02-24	Good compliance (>= 90%)
152	655	Placebo	ASA	2017-05-11	Good compliance (>= 90%)
465	655	Placebo	ASA	2018-02-28	Good compliance (>= 90%)
580	655	Placebo	ASA	2018-06-06	Good compliance (>= 90%)
1457	655	Placebo	ASA	2019-12-19	Acceptable compliance (80% to < 90%)
560	655	Placebo	no ASA	2018-05-18	Good compliance (>= 90%)
597	655	Placebo	no ASA	2018-06-19	Good compliance (>= 90%)
1491	655	Placebo	no ASA	2020-01-23	Good compliance (>= 90%)
2582	655	Placebo	no ASA	2022-04-13	Good compliance (>= 90%)
379	655	Edoxaban	ASA	2017-12-20	Non-compliance (< 80%)
549	655	Edoxaban	ASA	2018-05-10	Good compliance (>= 90%)
559	655	Edoxaban	ASA	2018-05-18	Good compliance (>= 90%)
2656	655	Edoxaban	ASA		
461	655	Edoxaban	no ASA	2018-02-26	Good compliance (>= 90%)
834	655	Edoxaban	no ASA	2018-11-20	Good compliance (>= 90%)
2501	655	Edoxaban	no ASA	2022-02-25	Acceptable compliance (80% to < 90%)
579	663	Placebo	no ASA	2018-06-06	Good compliance (>= 90%)
223	663	Edoxaban	no ASA	2017-07-13	Good compliance (>= 90%)
259	669	Placebo	ASA	2017-09-04	Good compliance (>= 90%)
1220	669	Placebo	no ASA	2019-07-09	Good compliance (>= 90%)
450	669	Edoxaban	ASA	2018-04-20	Good compliance (>= 90%)
1075	669	Edoxaban	no ASA	2019-04-11	Good compliance (>= 90%)
1723	669	Edoxaban	no ASA	2020-08-06	Good compliance (>= 90%)
269	673	Placebo	ASA	2017-09-05	Acceptable compliance (80% to < 90%)
1097	673	Placebo	ASA	2019-04-27	Good compliance (>= 90%)
1916	673	Placebo	ASA	2020-12-31	Good compliance (>= 90%)
2234	673	Placebo	ASA	2021-08-19	Good compliance (>= 90%)
2337	673	Placebo	ASA	2021-11-10	Good compliance (>= 90%)
2339	673	Placebo	ASA	2021-11-10	Good compliance (>= 90%)
87	673	Placebo	no ASA	2017-02-02	Good compliance (>= 90%)
194	673	Placebo	no ASA	2017-06-15	Good compliance (>= 90%)
324	673	Placebo	no ASA	2017-10-31	Good compliance (>= 90%)
821	673	Placebo	no ASA	2018-11-16	Good compliance (>= 90%)
833	673	Placebo	no ASA	2018-11-21	Good compliance (>= 90%)
1048	673	Placebo	no ASA	2019-04-01	Good compliance (>= 90%)
1150	673	Placebo	no ASA	2019-05-29	Good compliance (>= 90%)
1287	673	Placebo	no ASA	2019-09-17	Good compliance (>= 90%)
1302	673	Placebo	no ASA	2019-09-26	
1533	673	Placebo	no ASA	2020-02-28	Good compliance (>= 90%)
1567	673	Placebo	no ASA	2020-03-26	Good compliance (>= 90%)
1849	673	Placebo	no ASA	2020-11-04	Good compliance (>= 90%)
1864	673	Placebo	no ASA	2020-11-11	Good compliance (>= 90%)
1875	673	Placebo	no ASA	2020-11-19	Good compliance (>= 90%)
2086	673	Placebo	no ASA	2021-05-05	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2268	673	Placebo	no ASA	2021-09-14	Good compliance (>= 90%)
2275	673	Placebo	no ASA	2021-09-16	Good compliance (>= 90%)
2541	673	Placebo	no ASA	2022-03-18	Good compliance (>= 90%)
2575	673	Placebo	no ASA	2022-04-06	Good compliance (>= 90%)
948	673	Edoxaban	ASA	2019-01-22	Good compliance (>= 90%)
1372	673	Edoxaban	ASA	2019-11-07	Good compliance (>= 90%)
1713	673	Edoxaban	ASA	2020-07-30	Good compliance (>= 90%)
1913	673	Edoxaban	ASA	2020-12-21	Good compliance (>= 90%)
91	673	Edoxaban	no ASA	2017-02-08	Non-compliance (< 80%)
337	673	Edoxaban	no ASA	2017-11-10	Good compliance (>= 90%)
427	673	Edoxaban	no ASA	2018-02-01	
707	673	Edoxaban	no ASA	2018-09-14	Good compliance (>= 90%)
837	673	Edoxaban	no ASA	2018-11-22	Good compliance (>= 90%)
1052	673	Edoxaban	no ASA	2019-04-02	Good compliance (>= 90%)
1136	673	Edoxaban	no ASA	2019-05-23	Acceptable compliance (80% to < 90%)
1168	673	Edoxaban	no ASA	2019-06-10	Good compliance (>= 90%)
1382	673	Edoxaban	no ASA	2019-11-13	Good compliance (>= 90%)
1662	673	Edoxaban	no ASA	2020-06-25	Good compliance (>= 90%)
1797	673	Edoxaban	no ASA	2020-09-23	Good compliance (>= 90%)
1862	673	Edoxaban	no ASA	2020-11-11	Good compliance (>= 90%)
1866	673	Edoxaban	no ASA	2020-11-12	Good compliance (>= 90%)
2077	673	Edoxaban	no ASA	2021-04-29	Good compliance (>= 90%)
2139	673	Edoxaban	no ASA	2021-06-07	Good compliance (>= 90%)
2146	673	Edoxaban	no ASA	2021-06-10	Acceptable compliance (80% to < 90%)
2263	673	Edoxaban	no ASA	2021-09-10	Good compliance (>= 90%)
2433	673	Edoxaban	no ASA	2022-01-17	Good compliance (>= 90%)
1448	674	Placebo	ASA	2019-12-13	Good compliance (>= 90%)
886	674	Placebo	no ASA	2018-12-13	Good compliance (>= 90%)
888	674	Placebo	no ASA	2018-12-14	Good compliance (>= 90%)
745	674				
307	675	Placebo	no ASA	2017-10-19	Good compliance (>= 90%)
345	675	Placebo	no ASA	2017-11-22	Good compliance (>= 90%)
365	675	Placebo	no ASA	2017-12-07	Good compliance (>= 90%)
591	675	Placebo	no ASA	2018-06-14	Good compliance (>= 90%)
233	675	Edoxaban	no ASA	2017-07-25	Good compliance (>= 90%)
240	675	Edoxaban	no ASA	2017-07-31	Good compliance (>= 90%)
384	675	Edoxaban	no ASA	2018-01-04	Good compliance (>= 90%)
507	675	Edoxaban	no ASA	2018-04-03	
942	675	Edoxaban	no ASA		
505	679	Placebo	no ASA		
1078	679	Edoxaban	no ASA	2019-04-16	Good compliance (>= 90%)
711	680	Placebo	ASA	2018-09-18	Good compliance (>= 90%)
772	680	Placebo	ASA	2018-10-25	Good compliance (>= 90%)
783	680	Placebo	ASA	2018-10-31	Good compliance (>= 90%)
789	680	Placebo	ASA	2018-11-15	Good compliance (>= 90%)
836	680	Placebo	ASA	2018-11-21	Good compliance (>= 90%)
902	680	Placebo	ASA	2018-12-20	Good compliance (>= 90%)
904	680	Placebo	ASA	2018-12-21	Good compliance (>= 90%)
935	680	Placebo	ASA	2019-01-17	Good compliance (>= 90%)
979	680	Placebo	ASA	2019-02-07	Good compliance (>= 90%)
981	680	Placebo	ASA	2019-02-07	Good compliance (>= 90%)
1024	680	Placebo	ASA	2019-03-14	Good compliance (>= 90%)
1037	680	Placebo	ASA	2019-03-26	Non-compliance (< 80%)
1044	680	Placebo	ASA	2019-03-28	Good compliance (>= 90%)
1064	680	Placebo	ASA	2019-04-09	Good compliance (>= 90%)
1079	680	Placebo	ASA	2019-04-15	Good compliance (>= 90%)
1122	680	Placebo	ASA	2019-05-14	Good compliance (>= 90%)
1129	680	Placebo	ASA	2019-05-15	Good compliance (>= 90%)
1210	680	Placebo	ASA	2019-07-03	Good compliance (>= 90%)
1231	680	Placebo	ASA	2019-07-25	Good compliance (>= 90%)
1318	680	Placebo	ASA	2019-10-10	
1339	680	Placebo	ASA	2019-10-22	Non-compliance (< 80%)
1347	680	Placebo	ASA	2019-10-24	Acceptable compliance (80% to < 90%)
1417	680	Placebo	ASA	2019-11-28	Acceptable compliance (80% to < 90%)
1455	680	Placebo	ASA	2019-12-22	Good compliance (>= 90%)
1531	680	Placebo	ASA	2020-02-27	Good compliance (>= 90%)
1609	680	Placebo	ASA	2020-06-04	Good compliance (>= 90%)
1640	680	Placebo	ASA	2020-06-17	Good compliance (>= 90%)
1799	680	Placebo	ASA	2020-09-24	Acceptable compliance (80% to < 90%)
1815	680	Placebo	ASA	2020-10-06	Non-compliance (< 80%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1821	680	Placebo	ASA	2020-10-08	Good compliance (>= 90%)
2045	680	Placebo	ASA	2021-04-14	Good compliance (>= 90%)
2092	680	Placebo	ASA	2021-05-11	Good compliance (>= 90%)
2233	680	Placebo	ASA	2021-08-19	Good compliance (>= 90%)
2266	680	Placebo	ASA	2021-09-14	Good compliance (>= 90%)
2306	680	Placebo	ASA	2021-10-14	Good compliance (>= 90%)
2317	680	Placebo	ASA	2021-10-22	Good compliance (>= 90%)
2356	680	Placebo	ASA	2021-11-19	Good compliance (>= 90%)
2516	680	Placebo	ASA	2022-03-07	Good compliance (>= 90%)
2543	680	Placebo	ASA	2022-03-21	Good compliance (>= 90%)
2614	680	Placebo	ASA	2022-05-14	Good compliance (>= 90%)
2641	680	Placebo	ASA	2022-06-06	Good compliance (>= 90%)
2747	680	Placebo	ASA	2022-09-07	Good compliance (>= 90%)
771	680	Placebo	no ASA	2018-10-25	Good compliance (>= 90%)
838	680	Placebo	no ASA	2018-11-22	Good compliance (>= 90%)
851	680	Placebo	no ASA	2018-11-29	Good compliance (>= 90%)
1135	680	Placebo	no ASA	2019-05-22	Good compliance (>= 90%)
1156	680	Placebo	no ASA	2019-06-04	Acceptable compliance (80% to < 90%)
1474	680	Placebo	no ASA	2020-01-15	Non-compliance (< 80%)
1891	680	Placebo	no ASA	2020-12-07	Good compliance (>= 90%)
1955	680	Placebo	no ASA	2021-02-11	Good compliance (>= 90%)
1960	680	Placebo	no ASA	2021-02-17	Acceptable compliance (80% to < 90%)
2031	680	Placebo	no ASA	2021-03-30	Good compliance (>= 90%)
2394	680	Placebo	no ASA	2021-12-16	Acceptable compliance (80% to < 90%)
2499	680	Placebo	no ASA	2022-02-24	Good compliance (>= 90%)
2509	680	Placebo	no ASA	2022-03-03	Non-compliance (< 80%)
2620	680	Placebo	no ASA	2022-05-19	Good compliance (>= 90%)
2721	680	Placebo	no ASA	2022-07-21	Good compliance (>= 90%)
623	680	Edoxaban	ASA	2018-07-11	Good compliance (>= 90%)
698	680	Edoxaban	ASA	2018-09-06	Good compliance (>= 90%)
763	680	Edoxaban	ASA	2018-10-23	Good compliance (>= 90%)
813	680	Edoxaban	ASA	2018-11-13	Good compliance (>= 90%)
815	680	Edoxaban	ASA	2018-11-13	Good compliance (>= 90%)
887	680	Edoxaban	ASA	2018-12-13	Good compliance (>= 90%)
934	680	Edoxaban	ASA	2019-01-16	Good compliance (>= 90%)
955	680	Edoxaban	ASA	2019-01-29	Good compliance (>= 90%)
993	680	Edoxaban	ASA	2019-02-19	Good compliance (>= 90%)
998	680	Edoxaban	ASA	2019-02-23	
1034	680	Edoxaban	ASA	2019-03-24	Good compliance (>= 90%)
1041	680	Edoxaban	ASA	2019-03-27	Good compliance (>= 90%)
1054	680	Edoxaban	ASA	2019-04-03	Good compliance (>= 90%)
1065	680	Edoxaban	ASA	2019-04-09	Acceptable compliance (80% to < 90%)
1087	680	Edoxaban	ASA	2019-04-17	Good compliance (>= 90%)
1090	680	Edoxaban	ASA	2019-04-18	Good compliance (>= 90%)
1153	680	Edoxaban	ASA	2019-05-30	Acceptable compliance (80% to < 90%)
1212	680	Edoxaban	ASA	2019-07-04	Good compliance (>= 90%)
1257	680	Edoxaban	ASA	2019-08-22	Good compliance (>= 90%)
1292	680	Edoxaban	ASA	2019-09-18	Good compliance (>= 90%)
1316	680	Edoxaban	ASA	2019-10-08	Good compliance (>= 90%)
1340	680	Edoxaban	ASA	2019-10-22	Good compliance (>= 90%)
1363	680	Edoxaban	ASA	2019-11-05	Good compliance (>= 90%)
1530	680	Edoxaban	ASA	2020-02-27	Good compliance (>= 90%)
1645	680	Edoxaban	ASA	2020-06-18	Good compliance (>= 90%)
1657	680	Edoxaban	ASA	2020-06-25	Good compliance (>= 90%)
1664	680	Edoxaban	ASA	2020-06-27	Non-compliance (< 80%)
1750	680	Edoxaban	ASA	2020-09-01	Good compliance (>= 90%)
1887	680	Edoxaban	ASA	2020-12-01	Good compliance (>= 90%)
1907	680	Edoxaban	ASA	2020-12-15	Good compliance (>= 90%)
1998	680	Edoxaban	ASA	2021-03-09	Good compliance (>= 90%)
2060	680	Edoxaban	ASA	2021-04-22	Good compliance (>= 90%)
2065	680	Edoxaban	ASA	2021-04-27	Good compliance (>= 90%)
2088	680	Edoxaban	ASA	2021-05-07	Good compliance (>= 90%)
2254	680	Edoxaban	ASA	2021-09-02	Good compliance (>= 90%)
2346	680	Edoxaban	ASA	2021-11-16	Good compliance (>= 90%)
2410	680	Edoxaban	ASA	2021-12-24	Good compliance (>= 90%)
2539	680	Edoxaban	ASA	2022-03-18	Good compliance (>= 90%)
2705	680	Edoxaban	ASA	2022-07-08	Good compliance (>= 90%)
2715	680	Edoxaban	ASA	2022-07-20	Good compliance (>= 90%)
2724	680	Edoxaban	ASA	2022-07-26	Good compliance (>= 90%)
668	680	Edoxaban	no ASA	2018-08-14	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
729	680	Edoxaban	no ASA	2018-10-01	Good compliance (>= 90%)
1071	680	Edoxaban	no ASA	2019-04-10	Acceptable compliance (80% to < 90%)
1248	680	Edoxaban	no ASA	2019-08-08	Good compliance (>= 90%)
1349	680	Edoxaban	no ASA	2019-10-23	Good compliance (>= 90%)
1512	680	Edoxaban	no ASA	2020-02-11	Good compliance (>= 90%)
1681	680	Edoxaban	no ASA	2020-07-09	Good compliance (>= 90%)
1832	680	Edoxaban	no ASA	2020-10-20	Good compliance (>= 90%)
2048	680	Edoxaban	no ASA	2021-04-15	Good compliance (>= 90%)
2091	680	Edoxaban	no ASA	2021-05-11	Acceptable compliance (80% to < 90%)
2094	680	Edoxaban	no ASA	2021-05-12	Good compliance (>= 90%)
2267	680	Edoxaban	no ASA	2021-09-14	Good compliance (>= 90%)
2362	680	Edoxaban	no ASA	2021-11-30	Good compliance (>= 90%)
2547	680	Edoxaban	no ASA	2022-03-22	Acceptable compliance (80% to < 90%)
1419	685	Placebo	no ASA	2019-12-05	Good compliance (>= 90%)
2027	685	Placebo	no ASA	2021-03-25	Good compliance (>= 90%)
2177	685	Placebo	no ASA	2021-07-01	Good compliance (>= 90%)
185	685	Edoxaban	no ASA	2017-06-09	Good compliance (>= 90%)
403	685	Edoxaban	no ASA	2018-01-19	Good compliance (>= 90%)
1625	685	Edoxaban	no ASA	2020-06-11	Good compliance (>= 90%)
358	687	Placebo	ASA	2017-12-05	Good compliance (>= 90%)
1157	687	Placebo	no ASA	2019-06-04	Good compliance (>= 90%)
1611	687	Placebo	no ASA	2020-06-05	Good compliance (>= 90%)
2061	687	Placebo	no ASA	2021-04-22	Good compliance (>= 90%)
2355	687	Placebo	no ASA	2021-11-19	Good compliance (>= 90%)
691	687	Edoxaban	no ASA	2018-08-31	Good compliance (>= 90%)
1614	687	Edoxaban	no ASA	2020-06-08	Good compliance (>= 90%)
123	688	Placebo	ASA	2017-03-31	Good compliance (>= 90%)
728	688	Placebo	ASA	2018-09-28	Good compliance (>= 90%)
1209	688	Placebo	ASA	2019-07-02	Good compliance (>= 90%)
1312	688	Placebo	ASA	2019-10-05	Good compliance (>= 90%)
1447	688	Placebo	ASA	2019-12-13	Good compliance (>= 90%)
1601	688	Placebo	ASA	2020-05-29	Good compliance (>= 90%)
2165	688	Placebo	ASA	2021-06-24	Acceptable compliance (80% to < 90%)
2252	688	Placebo	ASA	2021-09-02	Good compliance (>= 90%)
2281	688	Placebo	ASA	2021-09-24	Good compliance (>= 90%)
127	688	Placebo	no ASA	2017-03-31	Good compliance (>= 90%)
628	688	Placebo	no ASA	2018-07-19	Acceptable compliance (80% to < 90%)
640	688	Placebo	no ASA	2018-07-27	Good compliance (>= 90%)
842	688	Placebo	no ASA	2018-11-23	Good compliance (>= 90%)
112	688	Edoxaban	ASA	2017-03-16	Non-compliance (< 80%)
210	688	Edoxaban	ASA	2017-06-29	Good compliance (>= 90%)
865	688	Edoxaban	ASA	2018-12-06	Good compliance (>= 90%)
983	688	Edoxaban	ASA	2019-02-11	Good compliance (>= 90%)
1373	688	Edoxaban	ASA	2019-11-08	Good compliance (>= 90%)
1833	688	Edoxaban	ASA	2020-10-21	Good compliance (>= 90%)
1975	688	Edoxaban	ASA	2021-02-25	Good compliance (>= 90%)
2179	688	Edoxaban	ASA	2021-07-08	Good compliance (>= 90%)
2677	688	Edoxaban	ASA	2022-07-01	Good compliance (>= 90%)
183	688	Edoxaban	no ASA	2017-06-09	Good compliance (>= 90%)
231	688	Edoxaban	no ASA	2017-07-20	Non-compliance (< 80%)
550	688	Edoxaban	no ASA	2018-05-15	Good compliance (>= 90%)
1877	688	Edoxaban	no ASA	2020-11-24	Good compliance (>= 90%)
2363	688	Edoxaban	no ASA	2021-11-25	Good compliance (>= 90%)
906	689	Placebo	ASA	2018-12-20	Good compliance (>= 90%)
726	689	Placebo	no ASA	2018-09-27	Good compliance (>= 90%)
990	689	Placebo	no ASA	2019-02-14	Good compliance (>= 90%)
578	689	Edoxaban	ASA	2018-06-05	Good compliance (>= 90%)
232	690	Placebo	no ASA	2017-07-20	Good compliance (>= 90%)
2419	690	Placebo	no ASA	2022-01-10	Good compliance (>= 90%)
1989	690	Edoxaban	no ASA	2021-03-01	Good compliance (>= 90%)
2190	690	Edoxaban	no ASA	2021-07-15	Good compliance (>= 90%)
2428	690	Edoxaban	no ASA	2022-01-13	Good compliance (>= 90%)
1229	692	Edoxaban	ASA	2019-07-23	Good compliance (>= 90%)
2282	693	Placebo	ASA	2021-09-24	Good compliance (>= 90%)
1454	693	Placebo	no ASA	2019-12-17	Good compliance (>= 90%)
1461	693	Placebo	no ASA		
1519	693	Placebo	no ASA	2020-02-17	Good compliance (>= 90%)
1453	693	Edoxaban	no ASA	2019-12-16	Good compliance (>= 90%)
1518	693	Edoxaban	no ASA	2020-02-12	Good compliance (>= 90%)
1559	693	Edoxaban	no ASA	2020-03-12	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
428	697	Edoxaban	ASA	2018-02-02	Good compliance (>= 90%)
475	698	Placebo	ASA	2018-03-08	Good compliance (>= 90%)
621	698	Placebo	ASA	2018-07-09	Good compliance (>= 90%)
1123	698	Placebo	ASA	2019-05-14	Good compliance (>= 90%)
162	698	Placebo	no ASA	2017-05-16	Good compliance (>= 90%)
1176	698	Placebo	no ASA	2019-06-11	Good compliance (>= 90%)
219	698	Edoxaban	ASA	2017-07-10	
226	698	Edoxaban	ASA	2017-07-12	Good compliance (>= 90%)
303	698	Edoxaban	ASA	2017-10-16	Good compliance (>= 90%)
1494	698	Edoxaban	ASA	2020-01-28	Good compliance (>= 90%)
193	698	Edoxaban	no ASA	2017-06-13	Good compliance (>= 90%)
1310	700	Placebo	ASA	2019-10-03	Good compliance (>= 90%)
2483	700	Placebo	ASA	2022-02-17	Good compliance (>= 90%)
1018	700	Edoxaban	no ASA	2019-03-08	Good compliance (>= 90%)
950	702	Placebo	ASA		
1296	702	Placebo	ASA	2019-09-25	Non-compliance (< 80%)
289	702	Placebo	no ASA	2017-10-18	Good compliance (>= 90%)
1031	702	Placebo	no ASA	2019-03-20	Good compliance (>= 90%)
444	702	Edoxaban	ASA	2018-02-22	Good compliance (>= 90%)
1381	702	Edoxaban	ASA	2019-11-14	Good compliance (>= 90%)
158	702	Edoxaban	no ASA	2017-05-10	Good compliance (>= 90%)
174	702	Edoxaban	no ASA	2017-05-31	Good compliance (>= 90%)
635	704	Placebo	ASA	2018-07-24	Good compliance (>= 90%)
761	704	Placebo	ASA	2018-10-22	
1528	704	Placebo	no ASA	2020-02-21	Good compliance (>= 90%)
612	704	Edoxaban	ASA	2018-07-12	
649	704	Edoxaban	ASA	2018-07-31	Good compliance (>= 90%)
1412	705	Placebo	ASA	2019-11-28	Good compliance (>= 90%)
1682	705	Placebo	ASA	2020-07-10	Good compliance (>= 90%)
1773	705	Placebo	ASA	2020-09-11	Good compliance (>= 90%)
1860	705	Placebo	ASA	2020-11-11	Non-compliance (< 80%)
1881	705	Placebo	ASA	2020-11-26	Good compliance (>= 90%)
2134	705	Placebo	ASA		
2157	705	Placebo	ASA	2021-06-17	Good compliance (>= 90%)
2390	705	Placebo	ASA	2021-12-15	Acceptable compliance (80% to < 90%)
2396	705	Placebo	ASA	2021-12-17	Non-compliance (< 80%)
2432	705	Placebo	ASA		
2437	705	Placebo	ASA	2022-01-20	Good compliance (>= 90%)
2556	705	Placebo	ASA	2022-03-24	Good compliance (>= 90%)
2579	705	Placebo	ASA	2022-04-09	
2742	705	Placebo	ASA	2022-08-25	
1647	705	Placebo	no ASA	2020-06-18	Good compliance (>= 90%)
1748	705	Placebo	no ASA	2020-08-26	Good compliance (>= 90%)
2291	705	Placebo	no ASA		
2731	705	Placebo	no ASA	2022-09-01	Good compliance (>= 90%)
1416	705	Edoxaban	ASA	2019-11-28	Acceptable compliance (80% to < 90%)
1479	705	Edoxaban	ASA	2020-01-17	Good compliance (>= 90%)
1509	705	Edoxaban	ASA	2020-02-10	Good compliance (>= 90%)
1908	705	Edoxaban	ASA	2020-12-22	Good compliance (>= 90%)
2137	705	Edoxaban	ASA	2021-06-05	Good compliance (>= 90%)
2158	705	Edoxaban	ASA	2021-06-17	Good compliance (>= 90%)
2272	705	Edoxaban	ASA	2021-09-16	
2367	705	Edoxaban	ASA	2021-11-26	Good compliance (>= 90%)
2383	705	Edoxaban	ASA	2021-12-08	Good compliance (>= 90%)
2395	705	Edoxaban	ASA	2021-12-17	Good compliance (>= 90%)
2431	705	Edoxaban	ASA	2022-01-15	Good compliance (>= 90%)
2740	705	Edoxaban	ASA	2022-08-24	Acceptable compliance (80% to < 90%)
1621	705	Edoxaban	no ASA	2020-06-10	Good compliance (>= 90%)
2133	705	Edoxaban	no ASA	2021-06-03	Acceptable compliance (80% to < 90%)
2153	705	Edoxaban	no ASA	2021-06-16	Acceptable compliance (80% to < 90%)
1677	705				
654	706	Placebo	ASA	2018-08-03	Non-compliance (< 80%)
282	706	Placebo	no ASA	2017-09-25	Good compliance (>= 90%)
278	706	Edoxaban	ASA	2017-09-18	Good compliance (>= 90%)
557	706	Edoxaban	ASA	2018-05-18	Non-compliance (< 80%)
689	706	Edoxaban	ASA	2018-08-31	Good compliance (>= 90%)
208	706	Edoxaban	no ASA	2017-07-04	Good compliance (>= 90%)
248	706	Edoxaban	no ASA	2017-08-14	Good compliance (>= 90%)
480	707	Placebo	ASA	2018-03-13	Good compliance (>= 90%)
1214	707	Placebo	ASA	2019-07-04	Acceptable compliance (80% to < 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1820	707	Placebo	no ASA	2020-10-08	Good compliance (>= 90%)
437	707	Edoxaban	ASA	2018-02-08	Acceptable compliance (80% to < 90%)
1226	707	Edoxaban	ASA	2019-07-18	Good compliance (>= 90%)
496	707	Edoxaban	no ASA	2018-03-22	Good compliance (>= 90%)
522	707	Edoxaban	no ASA	2018-04-12	Good compliance (>= 90%)
1873	707	Edoxaban	no ASA	2020-11-19	Good compliance (>= 90%)
512	708	Placebo	ASA	2018-04-06	
525	708	Edoxaban	ASA	2018-04-16	
374	708	Edoxaban	no ASA	2017-12-13	Acceptable compliance (80% to < 90%)
492	708	Edoxaban	no ASA	2018-03-20	Non-compliance (< 80%)
360	711	Placebo	ASA	2017-12-04	Good compliance (>= 90%)
443	711	Placebo	ASA	2018-02-14	Good compliance (>= 90%)
873	711	Placebo	ASA	2018-12-08	Good compliance (>= 90%)
1253	711	Placebo	no ASA	2019-08-16	Good compliance (>= 90%)
383	711	Edoxaban	ASA	2017-12-30	Good compliance (>= 90%)
1252	711	Edoxaban	ASA		
1458	711	Edoxaban	ASA	2019-12-20	Good compliance (>= 90%)
439	711	Edoxaban	no ASA	2018-02-09	Non-compliance (< 80%)
518	711	Edoxaban	no ASA	2018-04-09	Good compliance (>= 90%)
611	711	Edoxaban	no ASA	2018-06-28	Good compliance (>= 90%)
2373	713	Placebo	ASA	2021-12-01	Good compliance (>= 90%)
1013	718	Edoxaban	no ASA	2019-03-05	Good compliance (>= 90%)
2630	720	Placebo	ASA	2022-05-31	Good compliance (>= 90%)
2726	720	Placebo	ASA	2022-07-26	Good compliance (>= 90%)
2682	720	Edoxaban	no ASA	2022-07-11	Good compliance (>= 90%)
1039	724	Placebo	ASA	2019-03-26	Good compliance (>= 90%)
1061	724	Placebo	ASA	2019-04-05	Good compliance (>= 90%)
1452	724	Placebo	ASA	2019-12-16	Good compliance (>= 90%)
1040	724	Edoxaban	ASA	2019-03-26	Good compliance (>= 90%)
1076	724	Edoxaban	ASA	2019-04-12	Good compliance (>= 90%)
1286	724	Edoxaban	no ASA	2019-09-13	Good compliance (>= 90%)
1258	724				
796	725	Placebo	ASA	2018-11-07	Good compliance (>= 90%)
1042	725	Placebo	ASA	2019-03-27	Good compliance (>= 90%)
1203	725	Placebo	ASA	2019-06-26	Good compliance (>= 90%)
1239	725	Placebo	ASA	2019-08-05	Good compliance (>= 90%)
1392	725	Placebo	ASA	2019-11-18	Good compliance (>= 90%)
1631	725	Placebo	ASA	2020-06-15	Good compliance (>= 90%)
1639	725	Placebo	ASA	2020-06-22	Good compliance (>= 90%)
1869	725	Placebo	ASA	2020-11-18	Good compliance (>= 90%)
1894	725	Placebo	ASA	2020-12-09	Good compliance (>= 90%)
1947	725	Placebo	ASA	2021-02-04	Good compliance (>= 90%)
2038	725	Placebo	ASA	2021-04-13	Good compliance (>= 90%)
2041	725	Placebo	ASA	2021-04-13	Good compliance (>= 90%)
2197	725	Placebo	ASA	2021-07-21	Non-compliance (< 80%)
2371	725	Placebo	ASA	2021-12-02	Good compliance (>= 90%)
2474	725	Placebo	ASA	2022-02-10	Good compliance (>= 90%)
2610	725	Placebo	ASA	2022-05-10	Good compliance (>= 90%)
2642	725	Placebo	ASA	2022-06-07	Acceptable compliance (80% to < 90%)
2668	725	Placebo	ASA	2022-06-24	Good compliance (>= 90%)
2703	725	Placebo	ASA	2022-07-08	Good compliance (>= 90%)
1154	725	Placebo	no ASA	2019-05-31	Acceptable compliance (80% to < 90%)
1194	725	Placebo	no ASA	2019-06-21	Good compliance (>= 90%)
1442	725	Placebo	no ASA	2019-12-12	Good compliance (>= 90%)
1525	725	Placebo	no ASA	2020-02-19	Good compliance (>= 90%)
2102	725	Placebo	no ASA	2021-05-17	Good compliance (>= 90%)
2277	725	Placebo	no ASA	2021-09-21	Good compliance (>= 90%)
782	725	Edoxaban	ASA	2018-10-30	Good compliance (>= 90%)
822	725	Edoxaban	ASA	2018-11-15	Good compliance (>= 90%)
1009	725	Edoxaban	ASA		
1329	725	Edoxaban	ASA	2019-10-14	Good compliance (>= 90%)
1470	725	Edoxaban	ASA	2020-01-14	Good compliance (>= 90%)
1524	725	Edoxaban	ASA		
1619	725	Edoxaban	ASA	2020-06-11	Good compliance (>= 90%)
1742	725	Edoxaban	ASA	2020-08-25	Good compliance (>= 90%)
1946	725	Edoxaban	ASA	2021-02-04	Good compliance (>= 90%)
1954	725	Edoxaban	ASA	2021-02-11	Good compliance (>= 90%)
2030	725	Edoxaban	ASA	2021-03-30	Good compliance (>= 90%)
2040	725	Edoxaban	ASA	2021-04-13	Good compliance (>= 90%)
2105	725	Edoxaban	ASA	2021-05-18	Non-compliance (< 80%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2353	725	Edoxaban	ASA	2021-12-07	Good compliance (>= 90%)
2462	725	Edoxaban	ASA	2022-02-04	Good compliance (>= 90%)
2492	725	Edoxaban	ASA	2022-02-24	Good compliance (>= 90%)
2494	725	Edoxaban	ASA	2022-02-24	
2602	725	Edoxaban	ASA	2022-04-29	Good compliance (>= 90%)
2704	725	Edoxaban	ASA	2022-07-11	Good compliance (>= 90%)
1223	725	Edoxaban	no ASA	2019-07-16	Good compliance (>= 90%)
1326	725	Edoxaban	no ASA	2019-10-14	Good compliance (>= 90%)
1620	725	Edoxaban	no ASA	2020-06-11	Good compliance (>= 90%)
1644	725	Edoxaban	no ASA	2020-06-18	Good compliance (>= 90%)
1839	725	Edoxaban	no ASA	2020-10-27	
2549	725	Edoxaban	no ASA	2022-03-22	Acceptable compliance (80% to < 90%)
2600	725	Edoxaban	no ASA	2022-04-29	Good compliance (>= 90%)
2710	725	Edoxaban	no ASA	2022-07-12	Good compliance (>= 90%)
1107	725				
2748	725				
1166	728	Placebo	ASA	2019-06-08	Good compliance (>= 90%)
1124	728	Placebo	no ASA	2019-05-15	Good compliance (>= 90%)
577	728	Edoxaban	ASA	2018-06-01	Acceptable compliance (80% to < 90%)
387	728	Edoxaban	no ASA	2018-01-06	Good compliance (>= 90%)
452	728	Edoxaban	no ASA	2018-02-21	Good compliance (>= 90%)
883	728	Edoxaban	no ASA	2018-12-12	Good compliance (>= 90%)
1202	728				
1560	730	Placebo	no ASA	2020-03-14	Non-compliance (< 80%)
2399	730	Placebo	no ASA	2022-01-08	Good compliance (>= 90%)
799	735	Placebo	ASA	2018-11-09	Good compliance (>= 90%)
925	740	Placebo	ASA	2019-01-09	Good compliance (>= 90%)
1886	740	Placebo	ASA	2020-12-04	Acceptable compliance (80% to < 90%)
1222	740	Placebo	no ASA	2019-07-15	Good compliance (>= 90%)
431	740	Edoxaban	ASA	2018-02-06	Good compliance (>= 90%)
1058	740	Edoxaban	ASA	2019-04-05	Good compliance (>= 90%)
2436	740	Edoxaban	ASA	2022-01-24	Good compliance (>= 90%)
753	740	Edoxaban	no ASA	2018-10-17	Good compliance (>= 90%)
866	740	Edoxaban	no ASA	2018-12-06	Good compliance (>= 90%)
921	741	Placebo	ASA	2019-01-04	Good compliance (>= 90%)
1737	741	Placebo	ASA	2020-08-22	Good compliance (>= 90%)
2064	741	Placebo	ASA	2021-04-28	Good compliance (>= 90%)
2660	741	Placebo	ASA	2022-06-23	Non-compliance (< 80%)
2685	741	Placebo	ASA	2022-07-02	Good compliance (>= 90%)
421	741	Placebo	no ASA	2018-02-02	Good compliance (>= 90%)
483	741	Placebo	no ASA	2018-03-16	Good compliance (>= 90%)
484	741	Placebo	no ASA	2018-03-15	Good compliance (>= 90%)
1051	741	Placebo	no ASA	2019-04-03	Good compliance (>= 90%)
1790	741	Placebo	no ASA	2020-09-18	Good compliance (>= 90%)
1825	741	Placebo	no ASA	2020-10-15	Non-compliance (< 80%)
1836	741	Placebo	no ASA	2020-10-23	Good compliance (>= 90%)
1850	741	Placebo	no ASA	2020-11-06	Good compliance (>= 90%)
2015	741	Placebo	no ASA	2021-03-19	Good compliance (>= 90%)
2313	741	Placebo	no ASA	2021-10-23	Good compliance (>= 90%)
2315	741	Placebo	no ASA	2021-10-23	Good compliance (>= 90%)
2650	741	Placebo	no ASA	2022-06-14	Acceptable compliance (80% to < 90%)
725	741	Edoxaban	ASA	2018-09-28	Good compliance (>= 90%)
840	741	Edoxaban	ASA	2018-11-23	Good compliance (>= 90%)
1865	741	Edoxaban	ASA	2020-11-14	Good compliance (>= 90%)
2368	741	Edoxaban	ASA	2021-11-27	Non-compliance (< 80%)
2405	741	Edoxaban	ASA	2021-12-23	Good compliance (>= 90%)
368	741	Edoxaban	no ASA	2017-12-15	Good compliance (>= 90%)
415	741	Edoxaban	no ASA	2018-01-26	Good compliance (>= 90%)
435	741	Edoxaban	no ASA	2018-02-09	Good compliance (>= 90%)
1095	741	Edoxaban	no ASA	2019-04-26	Good compliance (>= 90%)
1118	741	Edoxaban	no ASA	2019-05-10	Good compliance (>= 90%)
1356	741	Edoxaban	no ASA	2019-10-29	Good compliance (>= 90%)
1408	741	Edoxaban	no ASA	2019-11-26	Good compliance (>= 90%)
1909	741	Edoxaban	no ASA	2020-12-18	Good compliance (>= 90%)
2253	741	Edoxaban	no ASA	2021-09-03	Non-compliance (< 80%)
2294	741	Edoxaban	no ASA	2021-10-01	Acceptable compliance (80% to < 90%)
2319	741	Edoxaban	no ASA	2021-10-28	
2532	741	Edoxaban	no ASA	2022-03-12	Good compliance (>= 90%)
1207	741				
521	742				

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
173	748	Placebo	ASA	2017-06-01	Good compliance (>= 90%)
332	748	Placebo	ASA	2017-11-10	Good compliance (>= 90%)
558	748	Placebo	ASA	2018-05-19	Good compliance (>= 90%)
576	748	Placebo	ASA	2018-06-01	Good compliance (>= 90%)
604	748	Placebo	ASA	2018-06-22	Good compliance (>= 90%)
684	748	Placebo	ASA	2018-08-24	Good compliance (>= 90%)
957	748	Placebo	ASA	2019-01-30	Good compliance (>= 90%)
1026	748	Placebo	ASA	2019-03-15	Good compliance (>= 90%)
1056	748	Placebo	ASA	2019-04-05	Good compliance (>= 90%)
1139	748	Placebo	ASA	2019-05-24	Good compliance (>= 90%)
1251	748	Placebo	ASA	2019-08-16	Good compliance (>= 90%)
1272	748	Placebo	ASA	2019-09-05	Acceptable compliance (80% to < 90%)
1285	748	Placebo	ASA	2019-09-13	Good compliance (>= 90%)
1597	748	Placebo	ASA		
1659	748	Placebo	ASA	2020-06-26	Good compliance (>= 90%)
1674	748	Placebo	ASA	2020-07-03	Non-compliance (< 80%)
1731	748	Placebo	ASA	2020-08-14	Good compliance (>= 90%)
1757	748	Placebo	ASA	2020-09-04	Non-compliance (< 80%)
2071	748	Placebo	ASA	2021-04-30	Good compliance (>= 90%)
2181	748	Placebo	ASA	2021-07-09	Good compliance (>= 90%)
2186	748	Placebo	ASA	2021-07-14	Good compliance (>= 90%)
2191	748	Placebo	ASA	2021-07-17	Good compliance (>= 90%)
2195	748	Placebo	ASA	2021-07-21	Good compliance (>= 90%)
2199	748	Placebo	ASA	2021-07-22	Good compliance (>= 90%)
2327	748	Placebo	ASA	2021-11-06	Good compliance (>= 90%)
2354	748	Placebo	ASA	2021-11-19	Good compliance (>= 90%)
2384	748	Placebo	ASA	2021-12-08	Acceptable compliance (80% to < 90%)
2466	748	Placebo	ASA	2022-07-29	Good compliance (>= 90%)
2680	748	Placebo	ASA	2022-07-01	Good compliance (>= 90%)
2693	748	Placebo	ASA	2022-07-07	Good compliance (>= 90%)
564	748	Placebo	no ASA	2018-05-25	Good compliance (>= 90%)
824	748	Placebo	no ASA	2018-11-16	Good compliance (>= 90%)
852	748	Placebo	no ASA	2018-11-30	Acceptable compliance (80% to < 90%)
999	748	Placebo	no ASA	2019-02-22	Good compliance (>= 90%)
1901	748	Placebo	no ASA		
1918	748	Placebo	no ASA	2021-01-06	Good compliance (>= 90%)
1921	748	Placebo	no ASA	2021-01-08	Good compliance (>= 90%)
2079	748	Placebo	no ASA		
2676	748	Placebo	no ASA	2022-06-30	Non-compliance (< 80%)
2725	748	Placebo	no ASA	2022-07-27	Good compliance (>= 90%)
199	748	Edoxaban	ASA	2017-06-24	Good compliance (>= 90%)
281	748	Edoxaban	ASA	2017-09-22	Good compliance (>= 90%)
532	748	Edoxaban	ASA	2018-04-20	Good compliance (>= 90%)
555	748	Edoxaban	ASA	2018-05-25	Good compliance (>= 90%)
610	748	Edoxaban	ASA	2018-06-29	Good compliance (>= 90%)
675	748	Edoxaban	ASA		
687	748	Edoxaban	ASA	2018-08-24	Good compliance (>= 90%)
928	748	Edoxaban	ASA	2019-01-11	Good compliance (>= 90%)
992	748	Edoxaban	ASA	2019-02-19	Good compliance (>= 90%)
1074	748	Edoxaban	ASA	2019-04-12	Good compliance (>= 90%)
1096	748	Edoxaban	ASA	2019-04-26	Good compliance (>= 90%)
1130	748	Edoxaban	ASA	2019-05-18	Good compliance (>= 90%)
1415	748	Edoxaban	ASA	2019-11-29	Acceptable compliance (80% to < 90%)
1591	748	Edoxaban	ASA	2020-05-19	Non-compliance (< 80%)
1646	748	Edoxaban	ASA	2020-06-19	Good compliance (>= 90%)
1885	748	Edoxaban	ASA	2020-11-27	Good compliance (>= 90%)
1966	748	Edoxaban	ASA	2021-02-19	Good compliance (>= 90%)
2039	748	Edoxaban	ASA	2021-04-13	Good compliance (>= 90%)
2049	748	Edoxaban	ASA	2021-04-16	Good compliance (>= 90%)
2136	748	Edoxaban	ASA	2021-06-04	Good compliance (>= 90%)
2189	748	Edoxaban	ASA	2021-07-16	Good compliance (>= 90%)
2203	748	Edoxaban	ASA	2021-07-27	Good compliance (>= 90%)
2236	748	Edoxaban	ASA	2021-08-24	Good compliance (>= 90%)
2248	748	Edoxaban	ASA	2021-08-27	Good compliance (>= 90%)
2249	748	Edoxaban	ASA	2021-08-28	Good compliance (>= 90%)
2422	748	Edoxaban	ASA	2022-01-12	Good compliance (>= 90%)
2455	748	Edoxaban	ASA	2022-01-29	Good compliance (>= 90%)
2613	748	Edoxaban	ASA	2022-05-13	Good compliance (>= 90%)
2670	748	Edoxaban	ASA	2022-06-24	Good compliance (>= 90%)
2716	748	Edoxaban	ASA		

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2734	748	Edoxaban	ASA	2022-08-11	Good compliance (>= 90%)
2746	748	Edoxaban	ASA	2022-09-07	Good compliance (>= 90%)
596	748	Edoxaban	no ASA	2018-06-19	Good compliance (>= 90%)
641	748	Edoxaban	no ASA	2018-07-28	Good compliance (>= 90%)
1249	748	Edoxaban	no ASA	2019-08-09	Good compliance (>= 90%)
1301	748	Edoxaban	no ASA	2019-09-27	Good compliance (>= 90%)
1546	748	Edoxaban	no ASA	2020-03-05	Non-compliance (< 80%)
1575	748	Edoxaban	no ASA	2020-05-01	Good compliance (>= 90%)
1982	748	Edoxaban	no ASA	2021-02-26	Good compliance (>= 90%)
2222	748	Edoxaban	no ASA	2021-08-13	
2358	748	Edoxaban	no ASA	2021-11-20	Good compliance (>= 90%)
656	748				
371	752	Placebo	ASA	2017-12-12	Good compliance (>= 90%)
457	752	Placebo	ASA	2018-02-22	Good compliance (>= 90%)
1111	752	Placebo	ASA	2019-05-06	Good compliance (>= 90%)
316	752	Placebo	no ASA	2017-10-26	Good compliance (>= 90%)
372	752	Placebo	no ASA		
657	752	Placebo	no ASA	2018-08-09	Good compliance (>= 90%)
1025	752	Placebo	no ASA	2019-03-14	Good compliance (>= 90%)
570	752	Edoxaban	ASA	2018-05-25	Good compliance (>= 90%)
862	752	Edoxaban	ASA	2018-12-04	Good compliance (>= 90%)
1081	752	Edoxaban	ASA	2019-04-15	Good compliance (>= 90%)
406	752	Edoxaban	no ASA	2018-01-18	Good compliance (>= 90%)
458	752	Edoxaban	no ASA	2018-02-22	Good compliance (>= 90%)
517	752	Edoxaban	no ASA	2018-04-06	Good compliance (>= 90%)
607	752	Edoxaban	no ASA	2018-06-26	Good compliance (>= 90%)
863	752	Edoxaban	no ASA	2018-12-04	Good compliance (>= 90%)
540	756	Placebo	ASA	2018-04-27	Good compliance (>= 90%)
1069	756	Placebo	ASA	2019-04-09	Acceptable compliance (80% to < 90%)
1102	756	Placebo	ASA	2019-05-03	Good compliance (>= 90%)
448	756	Placebo	no ASA	2018-02-16	Good compliance (>= 90%)
509	756	Placebo	no ASA	2018-04-04	Good compliance (>= 90%)
495	756	Edoxaban	ASA	2018-03-22	Good compliance (>= 90%)
1255	756	Edoxaban	ASA	2019-08-20	Good compliance (>= 90%)
426	756	Edoxaban	no ASA	2018-02-02	Good compliance (>= 90%)
481	758	Placebo	ASA	2018-03-14	Good compliance (>= 90%)
1086	758	Placebo	no ASA	2019-04-17	Good compliance (>= 90%)
811	758	Edoxaban	ASA	2018-11-12	Good compliance (>= 90%)
760	758	Edoxaban	no ASA	2018-10-22	Good compliance (>= 90%)
1205	768	Placebo	no ASA	2019-06-26	Acceptable compliance (80% to < 90%)
1341	768	Placebo	no ASA	2019-10-22	Good compliance (>= 90%)
562	768	Edoxaban	no ASA	2018-05-21	Good compliance (>= 90%)
740	768	Edoxaban	no ASA	2018-10-08	Good compliance (>= 90%)
619	774	Placebo	ASA	2018-07-10	Good compliance (>= 90%)
2505	774	Placebo	ASA	2022-03-03	Good compliance (>= 90%)
2559	774	Placebo	ASA	2022-03-26	Acceptable compliance (80% to < 90%)
312	774	Placebo	no ASA	2017-10-26	Good compliance (>= 90%)
2581	774	Placebo	no ASA	2022-04-15	Good compliance (>= 90%)
497	774	Edoxaban	ASA	2018-03-24	Good compliance (>= 90%)
1218	774	Edoxaban	ASA	2019-07-09	Good compliance (>= 90%)
362	775	Placebo	ASA	2017-12-07	Non-compliance (< 80%)
660	775	Placebo	ASA	2018-08-17	Good compliance (>= 90%)
1366	775	Placebo	ASA	2019-11-06	Good compliance (>= 90%)
1555	775	Placebo	ASA	2020-03-16	Good compliance (>= 90%)
1959	775	Placebo	ASA	2021-02-15	Good compliance (>= 90%)
2270	775	Placebo	ASA	2021-09-15	
1563	775	Placebo	no ASA	2020-03-19	Good compliance (>= 90%)
603	775	Edoxaban	ASA	2018-08-03	Good compliance (>= 90%)
1060	775	Edoxaban	ASA	2019-04-05	Good compliance (>= 90%)
1562	775	Edoxaban	ASA	2020-03-18	Good compliance (>= 90%)
1851	775	Edoxaban	ASA	2020-11-05	Good compliance (>= 90%)
2121	775	Edoxaban	ASA	2021-05-26	Good compliance (>= 90%)
2524	775	Edoxaban	ASA	2022-03-09	Good compliance (>= 90%)
1350	775	Edoxaban	no ASA	2019-10-24	Good compliance (>= 90%)
2145	776	Placebo	ASA	2021-06-10	Acceptable compliance (80% to < 90%)
2173	776	Placebo	ASA	2021-06-29	Good compliance (>= 90%)
299	776	Edoxaban	ASA	2017-10-12	Non-compliance (< 80%)
1432	776	Edoxaban	ASA	2019-12-05	Good compliance (>= 90%)
614	776	Edoxaban	no ASA	2018-07-06	Good compliance (>= 90%)
2727	776	Edoxaban	no ASA	2022-07-28	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
284	780	Placebo	no ASA	2017-09-26	Good compliance (>= 90%)
313	780	Edoxaban	ASA	2017-10-24	Good compliance (>= 90%)
781	780	Edoxaban	ASA	2018-10-29	Acceptable compliance (80% to < 90%)
354	780	Edoxaban	no ASA	2017-11-29	Good compliance (>= 90%)
625	780	Edoxaban	no ASA	2018-07-12	Good compliance (>= 90%)
673	780	Edoxaban	no ASA	2018-08-16	Good compliance (>= 90%)
2663	783	Placebo	ASA	2022-06-21	Acceptable compliance (80% to < 90%)
2743	783	Placebo	no ASA	2022-09-01	Good compliance (>= 90%)
1375	784	Placebo	ASA	2019-11-11	Good compliance (>= 90%)
1376	784	Edoxaban	ASA	2019-11-11	Good compliance (>= 90%)
1281	785	Edoxaban	no ASA	2019-09-12	Good compliance (>= 90%)
1718	788	Placebo	ASA	2020-08-03	Good compliance (>= 90%)
1827	788	Placebo	ASA	2020-10-16	Good compliance (>= 90%)
1605	788	Placebo	no ASA	2020-05-29	Good compliance (>= 90%)
1738	788	Placebo	no ASA	2020-08-20	Good compliance (>= 90%)
1872	788	Placebo	no ASA	2020-11-18	Good compliance (>= 90%)
2212	788	Placebo	no ASA	2021-08-04	Good compliance (>= 90%)
1624	788	Edoxaban	ASA	2020-06-10	Good compliance (>= 90%)
2295	788	Edoxaban	ASA	2021-09-30	Good compliance (>= 90%)
1623	788	Edoxaban	no ASA	2020-06-10	Good compliance (>= 90%)
1733	788	Edoxaban	no ASA	2020-08-17	Good compliance (>= 90%)
2007	788	Edoxaban	no ASA	2021-03-12	Good compliance (>= 90%)
884	799	Placebo	no ASA	2018-12-12	Good compliance (>= 90%)
1163	799	Placebo	no ASA	2019-06-07	Good compliance (>= 90%)
1291	799	Edoxaban	no ASA	2019-09-18	Good compliance (>= 90%)
647	800	Placebo	ASA	2018-07-31	Good compliance (>= 90%)
1221	800	Placebo	ASA	2019-07-10	Good compliance (>= 90%)
1401	800	Placebo	ASA	2019-11-20	Acceptable compliance (80% to < 90%)
1421	800	Placebo	ASA	2019-11-29	Non-compliance (< 80%)
1527	800	Placebo	ASA	2020-02-20	Good compliance (>= 90%)
2634	800	Placebo	ASA	2022-06-01	Acceptable compliance (80% to < 90%)
571	800	Placebo	no ASA	2018-05-29	Good compliance (>= 90%)
1667	800	Placebo	no ASA	2020-06-30	Good compliance (>= 90%)
420	800	Edoxaban	ASA	2018-01-31	Good compliance (>= 90%)
642	800	Edoxaban	ASA	2018-08-03	Non-compliance (< 80%)
653	800	Edoxaban	ASA	2018-08-02	Good compliance (>= 90%)
1128	800	Edoxaban	ASA	2019-05-15	Good compliance (>= 90%)
1603	800	Edoxaban	ASA	2020-05-28	Good compliance (>= 90%)
1264	800	Edoxaban	no ASA	2019-08-28	Good compliance (>= 90%)
1332	800	Edoxaban	no ASA	2019-10-15	Good compliance (>= 90%)
1984	800	Edoxaban	no ASA	2021-02-26	Good compliance (>= 90%)
2360	800	Edoxaban	no ASA	2021-11-23	Good compliance (>= 90%)
531	801	Placebo	ASA	2018-04-18	Good compliance (>= 90%)
545	801	Placebo	ASA	2018-05-03	Good compliance (>= 90%)
620	801	Placebo	ASA	2018-07-09	Good compliance (>= 90%)
693	801	Placebo	ASA	2018-09-03	Non-compliance (< 80%)
1070	801	Placebo	ASA	2019-04-10	Good compliance (>= 90%)
1183	801	Placebo	ASA	2019-06-18	Good compliance (>= 90%)
1187	801	Placebo	ASA	2019-06-18	Good compliance (>= 90%)
1288	801	Placebo	ASA	2019-09-17	Good compliance (>= 90%)
1309	801	Placebo	ASA	2019-10-01	Good compliance (>= 90%)
2387	801	Placebo	ASA	2021-12-10	Good compliance (>= 90%)
2514	801	Placebo	ASA	2022-03-04	Non-compliance (< 80%)
2527	801	Placebo	ASA	2022-03-10	Good compliance (>= 90%)
595	801	Placebo	no ASA	2018-06-18	Good compliance (>= 90%)
599	801	Placebo	no ASA	2018-06-20	Good compliance (>= 90%)
738	801	Placebo	no ASA	2018-10-08	Good compliance (>= 90%)
793	801	Placebo	no ASA	2018-11-05	Good compliance (>= 90%)
969	801	Placebo	no ASA	2019-02-01	Good compliance (>= 90%)
1289	801	Placebo	no ASA	2019-09-17	Good compliance (>= 90%)
1397	801	Placebo	no ASA	2019-11-19	Good compliance (>= 90%)
1398	801	Placebo	no ASA	2019-11-19	Good compliance (>= 90%)
1770	801	Placebo	no ASA	2020-09-11	Good compliance (>= 90%)
1809	801	Placebo	no ASA	2020-10-02	Acceptable compliance (80% to < 90%)
1810	801	Placebo	no ASA	2020-10-02	Good compliance (>= 90%)
2513	801	Placebo	no ASA	2022-03-04	Good compliance (>= 90%)
2593	801	Placebo	no ASA	2022-04-22	Good compliance (>= 90%)
2744	801	Placebo	no ASA		
520	801	Edoxaban	ASA	2018-04-11	Good compliance (>= 90%)
543	801	Edoxaban	ASA	2018-05-02	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
895	801	Edoxaban	ASA	2018-12-17	Good compliance (>= 90%)
968	801	Edoxaban	ASA	2019-02-01	Good compliance (>= 90%)
1021	801	Edoxaban	ASA	2019-03-13	Good compliance (>= 90%)
1170	801	Edoxaban	ASA	2019-06-18	Good compliance (>= 90%)
1184	801	Edoxaban	ASA	2019-06-18	Good compliance (>= 90%)
1308	801	Edoxaban	ASA	2019-10-01	Good compliance (>= 90%)
1794	801	Edoxaban	ASA	2020-09-18	Acceptable compliance (80% to < 90%)
1800	801	Edoxaban	ASA	2020-09-25	Good compliance (>= 90%)
2273	801	Edoxaban	ASA	2021-09-16	
2378	801	Edoxaban	ASA	2021-12-03	Good compliance (>= 90%)
582	801	Edoxaban	no ASA	2018-06-06	Good compliance (>= 90%)
594	801	Edoxaban	no ASA	2018-06-15	Good compliance (>= 90%)
639	801	Edoxaban	no ASA	2018-07-25	Good compliance (>= 90%)
710	801	Edoxaban	no ASA	2018-09-17	Good compliance (>= 90%)
741	801	Edoxaban	no ASA	2018-10-08	Good compliance (>= 90%)
1007	801	Edoxaban	no ASA	2019-02-27	Good compliance (>= 90%)
1169	801	Edoxaban	no ASA	2019-06-11	Good compliance (>= 90%)
1334	801	Edoxaban	no ASA	2019-10-15	Good compliance (>= 90%)
1460	801	Edoxaban	no ASA	2019-12-20	Good compliance (>= 90%)
1772	801	Edoxaban	no ASA	2020-09-11	
2247	801	Edoxaban	no ASA	2021-08-26	Good compliance (>= 90%)
2274	801	Edoxaban	no ASA	2021-09-16	Good compliance (>= 90%)
2592	801	Edoxaban	no ASA	2022-04-22	Good compliance (>= 90%)
349	802	Placebo	ASA	2017-11-28	
2567	802	Placebo	ASA	2022-03-30	Good compliance (>= 90%)
629	802	Placebo	no ASA	2018-07-18	Good compliance (>= 90%)
2679	802	Placebo	no ASA	2022-06-29	Good compliance (>= 90%)
1082	802	Edoxaban	ASA	2019-04-16	Good compliance (>= 90%)
2351	802	Edoxaban	ASA	2021-11-17	Good compliance (>= 90%)
705	802	Edoxaban	no ASA	2018-09-12	Good compliance (>= 90%)
1047	802	Edoxaban	no ASA	2019-04-02	Good compliance (>= 90%)
2070	813	Placebo	ASA	2021-04-29	Good compliance (>= 90%)
2074	813	Placebo	ASA	2021-04-29	Good compliance (>= 90%)
2161	813	Edoxaban	ASA	2021-06-17	Acceptable compliance (80% to < 90%)
2073	813	Edoxaban	no ASA	2021-04-29	Good compliance (>= 90%)
1387	815	Placebo	ASA	2019-11-14	Good compliance (>= 90%)
1904	815	Placebo	ASA	2020-12-14	Good compliance (>= 90%)
947	815	Placebo	no ASA	2019-01-22	Good compliance (>= 90%)
1551	815	Placebo	no ASA	2020-03-10	Good compliance (>= 90%)
1812	815	Placebo	no ASA	2020-10-05	Good compliance (>= 90%)
1486	815	Edoxaban	ASA	2020-01-22	Acceptable compliance (80% to < 90%)
1896	815	Edoxaban	ASA	2020-12-09	Acceptable compliance (80% to < 90%)
2526	815	Edoxaban	ASA	2022-03-09	Good compliance (>= 90%)
986	815	Edoxaban	no ASA	2019-02-12	
1429	815	Edoxaban	no ASA	2019-12-04	Good compliance (>= 90%)
1895	815	Edoxaban	no ASA	2020-12-09	Good compliance (>= 90%)
2200	815	Edoxaban	no ASA	2021-07-21	
2290	824	Placebo	ASA	2021-10-03	Good compliance (>= 90%)
1473	824	Placebo	no ASA	2020-01-17	Acceptable compliance (80% to < 90%)
1497	824	Placebo	no ASA	2020-01-30	Good compliance (>= 90%)
2002	824	Edoxaban	ASA	2021-03-11	Good compliance (>= 90%)
2010	824	Edoxaban	ASA	2021-03-17	Good compliance (>= 90%)
2627	824	Edoxaban	ASA	2022-05-25	Good compliance (>= 90%)
2423	824	Edoxaban	no ASA	2022-01-14	Acceptable compliance (80% to < 90%)
2472	824				
892	826	Placebo	no ASA	2018-12-15	Good compliance (>= 90%)
1425	826	Placebo	no ASA	2019-12-02	Good compliance (>= 90%)
476	826	Edoxaban	ASA	2018-03-09	Good compliance (>= 90%)
2738	826	Edoxaban	no ASA	2022-08-19	Non-compliance (< 80%)
724	827	Placebo	ASA	2018-10-01	Good compliance (>= 90%)
770	827	Placebo	ASA	2018-11-26	Good compliance (>= 90%)
764	827	Edoxaban	ASA	2018-10-28	Non-compliance (< 80%)
807	827	Edoxaban	ASA	2018-11-14	Good compliance (>= 90%)
1011	828	Placebo	ASA	2019-03-01	Good compliance (>= 90%)
987	833	Placebo	ASA	2019-02-12	Good compliance (>= 90%)
1224	833	Placebo	ASA	2019-07-16	Good compliance (>= 90%)
1290	833	Placebo	ASA	2019-09-17	Good compliance (>= 90%)
2239	833	Placebo	ASA	2021-08-24	Good compliance (>= 90%)
2382	833	Placebo	ASA	2021-12-07	Good compliance (>= 90%)
2458	833	Placebo	ASA	2022-02-01	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
626	833	Edoxaban	ASA	2018-07-12	Good compliance (>= 90%)
976	833	Edoxaban	ASA	2019-02-05	Non-compliance (< 80%)
1277	833	Edoxaban	ASA	2019-09-10	Good compliance (>= 90%)
1637	833	Edoxaban	ASA	2020-06-16	Good compliance (>= 90%)
1923	833	Edoxaban	ASA	2021-01-12	Good compliance (>= 90%)
2242	833	Edoxaban	no ASA	2021-08-24	Good compliance (>= 90%)
2361	833	Edoxaban	no ASA	2021-11-23	Good compliance (>= 90%)
795	836	Placebo	no ASA	2018-11-06	Acceptable compliance (80% to < 90%)
814	836	Placebo	no ASA	2018-11-13	Good compliance (>= 90%)
819	836	Placebo	no ASA	2018-11-23	Good compliance (>= 90%)
997	836	Placebo	no ASA	2019-02-20	Good compliance (>= 90%)
1103	836	Placebo	no ASA	2019-05-03	Good compliance (>= 90%)
1151	836	Placebo	no ASA	2019-05-29	Good compliance (>= 90%)
1489	836	Placebo	no ASA	2020-01-22	Good compliance (>= 90%)
1840	836	Placebo	no ASA	2020-10-28	Good compliance (>= 90%)
2546	836	Placebo	no ASA	2022-03-21	Good compliance (>= 90%)
802	836	Edoxaban	ASA	2018-11-08	Acceptable compliance (80% to < 90%)
849	836	Edoxaban	no ASA	2018-11-29	Good compliance (>= 90%)
938	836	Edoxaban	no ASA	2019-01-17	Good compliance (>= 90%)
951	836	Edoxaban	no ASA	2019-01-23	Good compliance (>= 90%)
1022	836	Edoxaban	no ASA	2019-03-13	Good compliance (>= 90%)
1298	836	Edoxaban	no ASA	2019-09-25	Good compliance (>= 90%)
1996	836	Edoxaban	no ASA	2021-03-03	Good compliance (>= 90%)
2001	836	Edoxaban	no ASA	2021-03-10	Good compliance (>= 90%)
2188	836	Edoxaban	no ASA	2021-07-14	Good compliance (>= 90%)
2329	836	Edoxaban	no ASA	2021-11-08	Good compliance (>= 90%)
2364	836	Edoxaban	no ASA	2021-11-24	Acceptable compliance (80% to < 90%)
1876	857	Placebo	ASA	2020-11-21	Good compliance (>= 90%)
1957	857	Placebo	ASA	2021-02-12	Good compliance (>= 90%)
1830	857	Placebo	no ASA	2020-10-22	Good compliance (>= 90%)
1853	857	Placebo	no ASA	2020-11-07	Good compliance (>= 90%)
1835	857	Edoxaban	ASA	2020-10-22	Good compliance (>= 90%)
2006	857	Edoxaban	ASA	2021-03-13	Good compliance (>= 90%)
2465	862	Edoxaban	no ASA	2022-02-03	Good compliance (>= 90%)
677	866	Placebo	ASA	2018-08-17	Good compliance (>= 90%)
742	866	Placebo	ASA	2018-10-08	Good compliance (>= 90%)
750	866	Placebo	ASA	2018-10-12	Good compliance (>= 90%)
791	866	Placebo	ASA	2018-11-02	Good compliance (>= 90%)
809	866	Placebo	ASA	2018-11-12	Good compliance (>= 90%)
885	866	Placebo	ASA	2018-12-11	Good compliance (>= 90%)
1149	866	Placebo	ASA	2019-05-28	Good compliance (>= 90%)
2026	866	Placebo	ASA	2021-03-24	Acceptable compliance (80% to < 90%)
2107	866	Placebo	ASA	2021-05-18	Good compliance (>= 90%)
2110	866	Placebo	ASA	2021-05-19	Good compliance (>= 90%)
2302	866	Placebo	ASA	2021-10-08	Good compliance (>= 90%)
767	866	Edoxaban	ASA	2018-10-24	Good compliance (>= 90%)
775	866	Edoxaban	ASA	2018-10-26	Good compliance (>= 90%)
788	866	Edoxaban	ASA	2018-11-02	Good compliance (>= 90%)
952	866	Edoxaban	ASA	2019-04-25	Good compliance (>= 90%)
953	866	Edoxaban	ASA	2019-01-24	Good compliance (>= 90%)
1100	866	Edoxaban	ASA	2019-05-02	Good compliance (>= 90%)
1106	866	Edoxaban	ASA	2019-05-04	Good compliance (>= 90%)
1196	866	Edoxaban	ASA	2019-06-21	Good compliance (>= 90%)
1715	866	Edoxaban	ASA	2020-07-31	Good compliance (>= 90%)
2257	866	Edoxaban	ASA	2021-09-07	Good compliance (>= 90%)
2374	866	Edoxaban	ASA	2021-12-01	Good compliance (>= 90%)
2404	866	Edoxaban	ASA	2021-12-21	Good compliance (>= 90%)
630	868	Placebo	ASA	2018-07-18	Good compliance (>= 90%)
665	868	Placebo	ASA	2018-08-16	Good compliance (>= 90%)
734	868	Placebo	ASA	2018-10-04	Good compliance (>= 90%)
825	868	Placebo	ASA	2018-11-16	Good compliance (>= 90%)
965	868	Placebo	ASA	2019-02-01	Good compliance (>= 90%)
1315	868	Placebo	ASA	2019-10-10	Acceptable compliance (80% to < 90%)
1669	868	Placebo	ASA	2020-06-30	Non-compliance (< 80%)
701	868	Placebo	no ASA	2018-09-10	Good compliance (>= 90%)
899	868	Placebo	no ASA	2018-12-18	Good compliance (>= 90%)
924	868	Placebo	no ASA	2019-01-08	Acceptable compliance (80% to < 90%)
1431	868	Placebo	no ASA		
754	868	Edoxaban	ASA	2018-10-17	Good compliance (>= 90%)
798	868	Edoxaban	ASA	2018-11-06	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
800	868	Edoxaban	ASA	2018-11-07	Acceptable compliance (80% to < 90%)
897	868	Edoxaban	ASA	2018-12-18	Good compliance (>= 90%)
923	868	Edoxaban	ASA	2019-01-08	Acceptable compliance (80% to < 90%)
967	868	Edoxaban	ASA	2019-01-31	Good compliance (>= 90%)
2098	868	Edoxaban	ASA	2021-05-14	Good compliance (>= 90%)
645	868	Edoxaban	no ASA	2018-09-07	Good compliance (>= 90%)
759	868	Edoxaban	no ASA	2018-10-19	Good compliance (>= 90%)
982	868	Edoxaban	no ASA	2019-02-08	Non-compliance (< 80%)
1228	868	Edoxaban	no ASA	2019-07-19	Acceptable compliance (80% to < 90%)
980	869	Placebo	ASA	2019-02-07	Good compliance (>= 90%)
1261	869	Placebo	ASA	2019-08-27	Good compliance (>= 90%)
1355	869	Placebo	ASA	2019-10-28	Good compliance (>= 90%)
1717	869	Placebo	ASA	2020-08-03	Good compliance (>= 90%)
1867	869	Placebo	ASA	2020-11-16	Good compliance (>= 90%)
2008	869	Placebo	ASA	2021-03-12	Good compliance (>= 90%)
780	869	Placebo	no ASA	2018-10-29	Good compliance (>= 90%)
823	869	Placebo	no ASA	2018-11-15	Good compliance (>= 90%)
1180	869	Placebo	no ASA	2019-06-13	Good compliance (>= 90%)
1311	869	Placebo	no ASA	2019-10-03	Good compliance (>= 90%)
1360	869	Placebo	no ASA	2019-10-30	Good compliance (>= 90%)
1276	869	Edoxaban	ASA	2019-09-09	Good compliance (>= 90%)
1390	869	Edoxaban	ASA	2019-11-15	Good compliance (>= 90%)
1465	869	Edoxaban	ASA	2019-12-27	Good compliance (>= 90%)
1558	869	Edoxaban	ASA	2020-03-12	Good compliance (>= 90%)
1970	869	Edoxaban	ASA	2021-02-19	Good compliance (>= 90%)
2208	869	Edoxaban	ASA	2021-07-28	
683	869	Edoxaban	no ASA	2018-08-22	Good compliance (>= 90%)
730	869	Edoxaban	no ASA	2018-10-02	Good compliance (>= 90%)
1104	869	Edoxaban	no ASA	2019-05-03	Acceptable compliance (80% to < 90%)
1279	869	Edoxaban	no ASA	2019-09-11	Good compliance (>= 90%)
1481	869	Edoxaban	no ASA	2020-01-20	Good compliance (>= 90%)
850	870	Placebo	ASA	2018-11-28	Good compliance (>= 90%)
1028	870	Placebo	ASA	2019-03-18	Good compliance (>= 90%)
1030	870	Placebo	ASA	2019-03-19	Good compliance (>= 90%)
1073	870	Placebo	ASA	2019-04-10	Good compliance (>= 90%)
1119	870	Placebo	ASA	2019-05-11	Good compliance (>= 90%)
1265	870	Placebo	ASA	2019-08-28	Non-compliance (< 80%)
1267	870	Placebo	ASA	2019-08-29	Good compliance (>= 90%)
1303	870	Placebo	ASA	2019-09-26	Good compliance (>= 90%)
1395	870	Placebo	ASA	2019-11-18	Good compliance (>= 90%)
1409	870	Placebo	ASA	2019-11-26	Good compliance (>= 90%)
1463	870	Placebo	ASA	2019-12-24	Good compliance (>= 90%)
1480	870	Placebo	ASA	2020-01-17	Good compliance (>= 90%)
1514	870	Placebo	ASA	2020-02-11	Good compliance (>= 90%)
1572	870	Placebo	ASA	2020-04-29	Good compliance (>= 90%)
1580	870	Placebo	ASA	2020-05-08	Good compliance (>= 90%)
1616	870	Placebo	ASA	2020-06-09	Good compliance (>= 90%)
1678	870	Placebo	ASA	2020-07-08	Acceptable compliance (80% to < 90%)
1685	870	Placebo	ASA	2020-07-13	Acceptable compliance (80% to < 90%)
1976	870	Placebo	ASA	2021-02-24	Good compliance (>= 90%)
1985	870	Placebo	ASA	2021-02-26	Good compliance (>= 90%)
1995	870	Placebo	ASA	2021-03-03	Good compliance (>= 90%)
1997	870	Placebo	ASA	2021-03-03	Good compliance (>= 90%)
2043	870	Placebo	ASA	2021-04-13	Good compliance (>= 90%)
2047	870	Placebo	ASA	2021-04-15	Good compliance (>= 90%)
2151	870	Placebo	ASA	2021-06-14	Good compliance (>= 90%)
2198	870	Placebo	ASA	2021-07-21	Good compliance (>= 90%)
2201	870	Placebo	ASA	2021-07-21	
2292	870	Placebo	ASA	2021-09-29	Good compliance (>= 90%)
2369	870	Placebo	ASA	2021-11-29	Good compliance (>= 90%)
971	870	Placebo	no ASA	2019-02-02	Good compliance (>= 90%)
1675	870	Placebo	no ASA	2020-07-02	Good compliance (>= 90%)
680	870	Edoxaban	ASA	2018-08-20	Good compliance (>= 90%)
769	870	Edoxaban	ASA	2018-10-24	Good compliance (>= 90%)
1032	870	Edoxaban	ASA	2019-03-20	Good compliance (>= 90%)
1077	870	Edoxaban	ASA	2019-04-13	Good compliance (>= 90%)
1093	870	Edoxaban	ASA	2019-04-22	Good compliance (>= 90%)
1131	870	Edoxaban	ASA	2019-05-17	Good compliance (>= 90%)
1142	870	Edoxaban	ASA	2019-05-24	Good compliance (>= 90%)
1271	870	Edoxaban	ASA	2019-09-04	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1297	870	Edoxaban	ASA	2019-09-25	Good compliance (>= 90%)
1384	870	Edoxaban	ASA	2019-11-19	Good compliance (>= 90%)
1464	870	Edoxaban	ASA	2019-12-24	Good compliance (>= 90%)
1500	870	Edoxaban	ASA	2020-02-01	Good compliance (>= 90%)
1526	870	Edoxaban	ASA	2020-02-19	Good compliance (>= 90%)
1587	870	Edoxaban	ASA	2020-05-14	Good compliance (>= 90%)
1596	870	Edoxaban	ASA	2020-05-23	Acceptable compliance (80% to < 90%)
1618	870	Edoxaban	ASA	2020-06-09	Good compliance (>= 90%)
1627	870	Edoxaban	ASA	2020-06-12	
1684	870	Edoxaban	ASA	2020-07-10	Good compliance (>= 90%)
1722	870	Edoxaban	ASA	2020-08-05	Good compliance (>= 90%)
1967	870	Edoxaban	ASA	2021-02-18	Good compliance (>= 90%)
1973	870	Edoxaban	ASA	2021-02-22	
1994	870	Edoxaban	ASA	2021-03-03	Good compliance (>= 90%)
1999	870	Edoxaban	ASA	2021-03-09	Good compliance (>= 90%)
2000	870	Edoxaban	ASA	2021-03-10	Good compliance (>= 90%)
2087	870	Edoxaban	ASA	2021-05-06	Good compliance (>= 90%)
2130	870	Edoxaban	ASA	2021-05-31	Good compliance (>= 90%)
2261	870	Edoxaban	ASA	2021-09-08	Good compliance (>= 90%)
2262	870	Edoxaban	ASA	2021-09-10	Acceptable compliance (80% to < 90%)
2314	870	Edoxaban	ASA	2021-10-21	
977	870	Edoxaban	no ASA	2019-02-06	Good compliance (>= 90%)
1020	870	Edoxaban	no ASA	2019-03-12	Good compliance (>= 90%)
732	871	Placebo	ASA	2018-10-04	
804	871	Placebo	ASA	2018-11-08	Acceptable compliance (80% to < 90%)
874	871	Placebo	ASA	2018-12-10	Good compliance (>= 90%)
914	871	Placebo	ASA	2018-12-26	Good compliance (>= 90%)
962	871	Placebo	ASA	2019-01-30	Good compliance (>= 90%)
963	871	Placebo	ASA	2019-01-30	Good compliance (>= 90%)
762	871	Edoxaban	ASA	2018-10-22	Good compliance (>= 90%)
808	871	Edoxaban	ASA	2018-11-09	
812	871	Edoxaban	ASA	2018-11-12	
872	871	Edoxaban	ASA	2018-12-08	Good compliance (>= 90%)
880	871	Edoxaban	ASA	2018-12-11	Good compliance (>= 90%)
972	871	Edoxaban	ASA	2019-02-03	Good compliance (>= 90%)
1012	871	Edoxaban	ASA	2019-03-01	Good compliance (>= 90%)
700	872	Placebo	no ASA	2018-09-07	Good compliance (>= 90%)
776	872	Placebo	no ASA	2018-10-26	Acceptable compliance (80% to < 90%)
889	872	Placebo	no ASA	2018-12-14	Good compliance (>= 90%)
891	872	Placebo	no ASA	2018-12-14	Good compliance (>= 90%)
1143	872	Placebo	no ASA	2019-05-27	Good compliance (>= 90%)
696	872	Edoxaban	no ASA	2018-09-05	Good compliance (>= 90%)
727	872	Edoxaban	no ASA	2018-09-27	Good compliance (>= 90%)
755	872	Edoxaban	no ASA	2018-10-18	Good compliance (>= 90%)
916	872	Edoxaban	no ASA	2018-12-28	Good compliance (>= 90%)
917	872	Edoxaban	no ASA	2018-12-29	Good compliance (>= 90%)
1109	872	Edoxaban	no ASA	2019-05-06	Non-compliance (< 80%)
910	873	Edoxaban	ASA	2018-12-22	
743	874	Placebo	ASA	2018-10-20	Good compliance (>= 90%)
806	874	Placebo	ASA	2018-11-10	Good compliance (>= 90%)
827	874	Placebo	ASA	2018-11-17	Good compliance (>= 90%)
870	874	Placebo	ASA	2018-12-07	Acceptable compliance (80% to < 90%)
912	874	Placebo	ASA	2018-12-26	Good compliance (>= 90%)
994	874	Placebo	ASA	2019-02-19	Acceptable compliance (80% to < 90%)
1002	874	Placebo	ASA	2019-02-25	Good compliance (>= 90%)
792	874	Placebo	no ASA	2018-11-05	Good compliance (>= 90%)
913	874	Placebo	no ASA	2018-12-27	Good compliance (>= 90%)
1158	874	Placebo	no ASA	2019-06-04	Good compliance (>= 90%)
1208	874	Placebo	no ASA	2019-06-28	Good compliance (>= 90%)
716	874	Edoxaban	ASA	2018-09-24	Good compliance (>= 90%)
857	874	Edoxaban	ASA	2018-12-01	Good compliance (>= 90%)
858	874	Edoxaban	ASA	2018-12-13	Good compliance (>= 90%)
871	874	Edoxaban	ASA	2018-12-07	Good compliance (>= 90%)
932	874	Edoxaban	ASA	2019-01-16	Good compliance (>= 90%)
1171	874	Edoxaban	ASA	2019-06-11	Non-compliance (< 80%)
1181	874	Edoxaban	ASA	2019-06-26	Good compliance (>= 90%)
1469	874	Edoxaban	ASA	2020-01-10	Good compliance (>= 90%)
1724	874	Edoxaban	ASA	2020-08-06	Acceptable compliance (80% to < 90%)
1726	874	Edoxaban	ASA	2020-08-07	
831	874	Edoxaban	no ASA	2018-12-11	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
911	874	Edoxaban	no ASA	2018-12-25	Good compliance (>= 90%)
646	875	Placebo	ASA	2018-07-31	Good compliance (>= 90%)
956	875	Placebo	ASA	2019-01-29	Good compliance (>= 90%)
751	875	Placebo	no ASA	2018-10-12	Good compliance (>= 90%)
939	875	Placebo	no ASA	2019-01-17	Good compliance (>= 90%)
1055	875	Placebo	no ASA	2019-04-03	Good compliance (>= 90%)
1144	875	Placebo	no ASA	2019-05-28	Good compliance (>= 90%)
1608	875	Placebo	no ASA	2020-06-03	Good compliance (>= 90%)
1650	875	Placebo	no ASA	2020-06-18	Good compliance (>= 90%)
2004	875	Placebo	no ASA	2021-03-11	Good compliance (>= 90%)
2175	875	Placebo	no ASA	2021-06-29	Good compliance (>= 90%)
638	875	Edoxaban	ASA	2018-07-24	Good compliance (>= 90%)
1027	875	Edoxaban	ASA	2019-03-15	Good compliance (>= 90%)
2167	875	Edoxaban	ASA	2021-06-25	Good compliance (>= 90%)
636	875	Edoxaban	no ASA	2018-07-24	Good compliance (>= 90%)
664	875	Edoxaban	no ASA	2018-08-10	Good compliance (>= 90%)
1043	875	Edoxaban	no ASA	2019-03-27	Good compliance (>= 90%)
1197	875	Edoxaban	no ASA	2019-06-22	Good compliance (>= 90%)
1284	875	Edoxaban	no ASA	2019-09-12	Good compliance (>= 90%)
1676	875	Edoxaban	no ASA	2020-07-03	Good compliance (>= 90%)
1931	875	Edoxaban	no ASA	2021-01-19	Good compliance (>= 90%)
2388	875	Edoxaban	no ASA	2021-12-10	Good compliance (>= 90%)
2415	875	Edoxaban	no ASA	2022-01-05	Good compliance (>= 90%)
744	876	Placebo	ASA	2018-10-09	Good compliance (>= 90%)
859	876	Placebo	ASA	2018-11-30	Good compliance (>= 90%)
896	876	Placebo	ASA	2018-12-19	Good compliance (>= 90%)
736	876	Placebo	no ASA	2018-10-05	Good compliance (>= 90%)
877	876	Placebo	no ASA	2018-12-11	Good compliance (>= 90%)
1385	876	Placebo	no ASA	2019-11-14	Good compliance (>= 90%)
1628	876	Placebo	no ASA	2020-06-12	Good compliance (>= 90%)
708	876	Edoxaban	ASA	2018-09-14	Good compliance (>= 90%)
1732	876	Edoxaban	ASA	2020-08-14	Good compliance (>= 90%)
901	876	Edoxaban	no ASA	2018-12-19	Good compliance (>= 90%)
1145	876	Edoxaban	no ASA	2019-05-28	Good compliance (>= 90%)
1443	876	Edoxaban	no ASA	2019-12-11	Good compliance (>= 90%)
1656	876	Edoxaban	no ASA	2020-06-23	Good compliance (>= 90%)
801	877	Placebo	ASA	2018-11-07	
860	877	Placebo	ASA	2018-12-03	Good compliance (>= 90%)
1275	877	Placebo	ASA	2019-09-09	
1295	877	Placebo	ASA	2019-09-24	Good compliance (>= 90%)
1352	877	Placebo	ASA	2019-10-28	Good compliance (>= 90%)
1919	877	Placebo	ASA	2021-01-05	Good compliance (>= 90%)
2260	877	Placebo	ASA	2021-09-08	
695	877	Placebo	no ASA	2018-09-04	Good compliance (>= 90%)
757	877	Placebo	no ASA	2018-10-18	Good compliance (>= 90%)
915	877	Placebo	no ASA	2018-12-28	Good compliance (>= 90%)
1092	877	Placebo	no ASA	2019-04-19	Good compliance (>= 90%)
1141	877	Placebo	no ASA	2019-05-23	Non-compliance (< 80%)
1592	877	Placebo	no ASA	2020-05-19	Good compliance (>= 90%)
1795	877	Placebo	no ASA	2020-09-19	Acceptable compliance (80% to < 90%)
2132	877	Placebo	no ASA	2021-06-02	Acceptable compliance (80% to < 90%)
2276	877	Placebo	no ASA	2021-09-17	
2285	877	Placebo	no ASA	2021-09-28	
706	877	Edoxaban	ASA	2018-09-14	Good compliance (>= 90%)
853	877	Edoxaban	ASA	2018-11-30	Good compliance (>= 90%)
876	877	Edoxaban	ASA	2018-12-10	Acceptable compliance (80% to < 90%)
1649	877	Edoxaban	ASA	2020-06-18	Good compliance (>= 90%)
1803	877	Edoxaban	ASA	2020-09-28	Good compliance (>= 90%)
2003	877	Edoxaban	ASA	2021-03-11	Good compliance (>= 90%)
2050	877	Edoxaban	ASA	2021-04-16	Acceptable compliance (80% to < 90%)
735	877	Edoxaban	no ASA	2018-10-05	
737	877	Edoxaban	no ASA	2018-10-05	Good compliance (>= 90%)
890	877	Edoxaban	no ASA	2018-12-14	Good compliance (>= 90%)
1023	877	Edoxaban	no ASA	2019-03-14	Good compliance (>= 90%)
1084	877	Edoxaban	no ASA	2019-04-16	Acceptable compliance (80% to < 90%)
1613	877	Edoxaban	no ASA	2020-06-05	Good compliance (>= 90%)
1648	877	Edoxaban	no ASA	2020-06-18	Non-compliance (< 80%)
1679	877	Edoxaban	no ASA	2020-07-08	Acceptable compliance (80% to < 90%)
893	881	Edoxaban	ASA	2018-12-15	
1495	884	Placebo	ASA	2020-01-30	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1377	884	Edoxaban	no ASA	2019-11-11	Good compliance (>= 90%)
984	901	Placebo	ASA	2019-02-12	Good compliance (>= 90%)
1549	901	Placebo	ASA	2020-03-10	Good compliance (>= 90%)
1564	901	Placebo	ASA	2020-03-24	Good compliance (>= 90%)
1859	901	Placebo	ASA	2020-11-12	Good compliance (>= 90%)
2473	901	Placebo	ASA	2022-02-09	Good compliance (>= 90%)
2490	901	Placebo	ASA	2022-02-22	Good compliance (>= 90%)
2601	901	Placebo	ASA	2022-04-29	Good compliance (>= 90%)
2666	901	Placebo	ASA	2022-06-22	Good compliance (>= 90%)
1217	901	Placebo	no ASA	2019-07-08	Good compliance (>= 90%)
1566	901	Placebo	no ASA	2020-03-25	Good compliance (>= 90%)
1711	901	Placebo	no ASA	2020-07-29	Good compliance (>= 90%)
2381	901	Placebo	no ASA	2021-12-03	Good compliance (>= 90%)
2476	901	Placebo	no ASA	2022-02-11	Good compliance (>= 90%)
882	901	Edoxaban	ASA	2018-12-15	Good compliance (>= 90%)
1038	901	Edoxaban	ASA	2019-03-27	Good compliance (>= 90%)
1120	901	Edoxaban	ASA	2019-05-14	Good compliance (>= 90%)
1138	901	Edoxaban	ASA	2019-05-23	Good compliance (>= 90%)
2427	901	Edoxaban	ASA	2022-01-12	Good compliance (>= 90%)
2480	901	Edoxaban	ASA		
2706	901	Edoxaban	ASA		
2723	901	Edoxaban	ASA	2022-07-22	Non-compliance (< 80%)
1057	901	Edoxaban	no ASA	2019-04-04	Good compliance (>= 90%)
1720	901	Edoxaban	no ASA	2020-08-05	Good compliance (>= 90%)
1880	901	Edoxaban	no ASA	2020-11-25	Good compliance (>= 90%)
2135	901	Edoxaban	no ASA	2021-06-04	Good compliance (>= 90%)
2435	901	Edoxaban	no ASA	2022-01-18	Good compliance (>= 90%)
2595	901	Edoxaban	no ASA	2022-04-26	Good compliance (>= 90%)
2638	901	Edoxaban	no ASA	2022-06-02	Good compliance (>= 90%)
2739	901	Edoxaban	no ASA	2022-08-23	Good compliance (>= 90%)
944	901				
1273	964	Placebo	no ASA	2019-09-04	Good compliance (>= 90%)
1049	965	Placebo	ASA	2019-04-02	Good compliance (>= 90%)
2280	965	Placebo	ASA	2021-09-24	Good compliance (>= 90%)
2488	965	Placebo	no ASA		
2550	965	Placebo	no ASA	2022-03-22	
2321	965	Edoxaban	ASA	2021-11-01	Acceptable compliance (80% to < 90%)
2420	965	Edoxaban	ASA	2022-01-11	Good compliance (>= 90%)
2664	965	Edoxaban	ASA	2022-06-23	Good compliance (>= 90%)
1323	965	Edoxaban	no ASA	2019-10-10	Good compliance (>= 90%)
2426	965	Edoxaban	no ASA	2022-01-13	Non-compliance (< 80%)
2097	1023	Placebo	ASA	2021-05-19	Non-compliance (< 80%)
2366	1023	Placebo	ASA	2021-11-25	
709	1023	Placebo	no ASA	2018-09-28	
2271	1023	Placebo	no ASA	2021-11-25	
2022	1023	Edoxaban	no ASA	2021-03-23	Good compliance (>= 90%)
2289	1023				
1172	1028	Placebo	ASA	2019-06-11	Acceptable compliance (80% to < 90%)
2573	1028	Placebo	ASA	2022-04-05	
1342	1028	Placebo	no ASA	2019-10-22	Good compliance (>= 90%)
1561	1028	Placebo	no ASA	2020-03-17	Good compliance (>= 90%)
2156	1028	Placebo	no ASA	2021-06-16	Good compliance (>= 90%)
2159	1028	Placebo	no ASA	2021-06-16	Good compliance (>= 90%)
2696	1028	Placebo	no ASA	2022-07-06	Acceptable compliance (80% to < 90%)
1313	1028	Edoxaban	ASA	2019-10-04	
1553	1028	Edoxaban	ASA	2020-03-10	Good compliance (>= 90%)
1314	1028	Edoxaban	no ASA	2019-10-04	Good compliance (>= 90%)
1344	1028	Edoxaban	no ASA	2019-10-22	Good compliance (>= 90%)
1539	1028	Edoxaban	no ASA	2020-03-03	Good compliance (>= 90%)
1547	1028	Edoxaban	no ASA	2020-03-05	Good compliance (>= 90%)
2160	1028	Edoxaban	no ASA	2021-06-16	Good compliance (>= 90%)
2251	1028	Edoxaban	no ASA	2021-08-31	Good compliance (>= 90%)
2504	1028	Edoxaban	no ASA	2022-03-01	
2694	1028	Edoxaban	no ASA	2022-07-06	Good compliance (>= 90%)
797	1028				
844	1028				
949	1029	Placebo	ASA	2019-01-22	Non-compliance (< 80%)
1159	1029	Placebo	ASA	2019-06-04	Non-compliance (< 80%)
1617	1029	Placebo	ASA	2020-06-09	
1986	1029	Placebo	ASA	2021-03-01	

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2093	1029	Placebo	ASA	2021-05-11	Good compliance (>= 90%)
2155	1029	Placebo	ASA	2021-06-15	
2178	1029	Placebo	ASA	2021-07-02	
961	1029	Placebo	no ASA	2019-01-29	Non-compliance (< 80%)
1236	1029	Placebo	no ASA	2019-07-30	Good compliance (>= 90%)
1242	1029	Placebo	no ASA	2019-08-06	Non-compliance (< 80%)
1437	1029	Placebo	no ASA	2019-12-06	Non-compliance (< 80%)
1588	1029	Placebo	no ASA	2020-05-15	Acceptable compliance (80% to < 90%)
1878	1029	Placebo	no ASA	2020-11-23	Non-compliance (< 80%)
2345	1029	Placebo	no ASA	2021-11-15	Good compliance (>= 90%)
1243	1029	Edoxaban	ASA	2019-08-06	Good compliance (>= 90%)
1256	1029	Edoxaban	ASA	2019-08-20	Good compliance (>= 90%)
1917	1029	Edoxaban	ASA	2021-01-04	Good compliance (>= 90%)
1936	1029	Edoxaban	ASA	2021-01-25	Good compliance (>= 90%)
2090	1029	Edoxaban	ASA	2021-05-10	
2108	1029	Edoxaban	ASA	2021-05-19	Good compliance (>= 90%)
2180	1029	Edoxaban	ASA	2021-07-05	Non-compliance (< 80%)
900	1029	Edoxaban	no ASA	2018-12-19	Non-compliance (< 80%)
1053	1029	Edoxaban	no ASA	2019-04-02	Non-compliance (< 80%)
1177	1029	Edoxaban	no ASA	2019-07-24	Non-compliance (< 80%)
1335	1029	Edoxaban	no ASA	2019-10-15	Good compliance (>= 90%)
1441	1029	Edoxaban	no ASA	2019-12-10	Good compliance (>= 90%)
1735	1029	Edoxaban	no ASA	2020-08-18	Good compliance (>= 90%)
1407	1039	Placebo	ASA	2019-11-22	Good compliance (>= 90%)
1459	1039	Placebo	ASA	2019-12-20	Good compliance (>= 90%)
2562	1039	Placebo	ASA	2022-03-29	Good compliance (>= 90%)
2690	1039	Placebo	no ASA	2022-07-05	Good compliance (>= 90%)
1227	1039	Edoxaban	ASA	2019-07-19	Good compliance (>= 90%)
1467	1039	Edoxaban	ASA	2020-01-03	Good compliance (>= 90%)
1534	1039	Edoxaban	ASA	2020-02-28	Good compliance (>= 90%)
2503	1039	Edoxaban	ASA	2022-03-01	Good compliance (>= 90%)
2269	1039				
2225	1048	Placebo	ASA	2021-08-16	Good compliance (>= 90%)
2619	1048	Placebo	ASA	2022-05-19	Good compliance (>= 90%)
2170	1048	Edoxaban	ASA	2021-06-24	Non-compliance (< 80%)
2335	1049	Placebo	ASA	2021-11-09	Good compliance (>= 90%)
1359	1049	Placebo	no ASA	2019-10-30	Good compliance (>= 90%)
2231	1049	Placebo	no ASA	2021-08-17	Good compliance (>= 90%)
2714	1067	Edoxaban	no ASA	2022-07-19	Good compliance (>= 90%)
1240	1071	Placebo	ASA	2019-08-06	Good compliance (>= 90%)
1241	1071	Edoxaban	ASA	2019-08-07	Good compliance (>= 90%)
1838	1074	Placebo	ASA	2020-10-22	Good compliance (>= 90%)
2143	1074	Placebo	ASA	2021-06-08	Acceptable compliance (80% to < 90%)
2672	1074	Placebo	ASA	2022-06-28	Good compliance (>= 90%)
1325	1074	Placebo	no ASA	2019-10-11	Good compliance (>= 90%)
1337	1074	Placebo	no ASA	2019-10-17	Good compliance (>= 90%)
1402	1074	Placebo	no ASA	2019-11-20	Good compliance (>= 90%)
1403	1074	Placebo	no ASA	2019-11-20	Good compliance (>= 90%)
1548	1074	Placebo	no ASA	2020-03-05	Good compliance (>= 90%)
1607	1074	Placebo	no ASA	2020-06-01	Good compliance (>= 90%)
1696	1074	Placebo	no ASA	2020-07-20	Good compliance (>= 90%)
1697	1074	Placebo	no ASA	2020-07-20	Good compliance (>= 90%)
1811	1074	Placebo	no ASA		
1893	1074	Placebo	no ASA	2020-12-08	Acceptable compliance (80% to < 90%)
1972	1074	Placebo	no ASA	2021-02-19	Good compliance (>= 90%)
2080	1074	Placebo	no ASA	2021-04-30	Good compliance (>= 90%)
2162	1074	Placebo	no ASA	2021-06-21	Good compliance (>= 90%)
2235	1074	Placebo	no ASA	2021-08-20	Non-compliance (< 80%)
2300	1074	Placebo	no ASA	2021-10-06	Acceptable compliance (80% to < 90%)
2515	1074	Placebo	no ASA	2022-03-04	Good compliance (>= 90%)
2665	1074	Placebo	no ASA	2022-06-22	Non-compliance (< 80%)
2720	1074	Placebo	no ASA	2022-07-20	Good compliance (>= 90%)
1420	1074	Edoxaban	ASA	2019-11-28	Good compliance (>= 90%)
1424	1074	Edoxaban	ASA	2019-12-02	Acceptable compliance (80% to < 90%)
1842	1074	Edoxaban	ASA	2020-10-29	
2192	1074	Edoxaban	ASA	2021-07-16	Good compliance (>= 90%)
1294	1074	Edoxaban	no ASA	2019-09-20	Good compliance (>= 90%)
1305	1074	Edoxaban	no ASA	2019-09-30	Good compliance (>= 90%)
1365	1074	Edoxaban	no ASA	2019-11-06	Good compliance (>= 90%)
1446	1074	Edoxaban	no ASA	2019-12-12	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1557	1074	Edoxaban	no ASA	2020-03-12	Good compliance (>= 90%)
1565	1074	Edoxaban	no ASA	2020-03-24	Good compliance (>= 90%)
1699	1074	Edoxaban	no ASA	2020-07-21	Good compliance (>= 90%)
1708	1074	Edoxaban	no ASA	2020-07-24	Good compliance (>= 90%)
1756	1074	Edoxaban	no ASA	2020-09-03	Non-compliance (< 80%)
1952	1074	Edoxaban	no ASA	2021-02-09	Good compliance (>= 90%)
1968	1074	Edoxaban	no ASA	2021-02-18	
2009	1074	Edoxaban	no ASA	2021-03-12	Good compliance (>= 90%)
2075	1074	Edoxaban	no ASA	2021-04-29	Good compliance (>= 90%)
2246	1074	Edoxaban	no ASA	2021-08-25	Non-compliance (< 80%)
2308	1074	Edoxaban	no ASA	2021-10-15	Acceptable compliance (80% to < 90%)
2561	1074	Edoxaban	no ASA	2022-03-28	
2707	1074	Edoxaban	no ASA	2022-07-11	
1784	1080	Placebo	ASA	2020-09-17	Good compliance (>= 90%)
1915	1080	Placebo	ASA	2020-12-24	Good compliance (>= 90%)
2078	1080	Placebo	ASA	2021-04-30	
1396	1080	Placebo	no ASA	2019-11-18	Good compliance (>= 90%)
1445	1080	Placebo	no ASA	2019-12-11	Non-compliance (< 80%)
1475	1080	Placebo	no ASA	2020-01-15	Good compliance (>= 90%)
1478	1080	Placebo	no ASA	2020-01-16	Acceptable compliance (80% to < 90%)
1536	1080	Placebo	no ASA	2020-03-03	Good compliance (>= 90%)
1573	1080	Placebo	no ASA	2020-04-29	Good compliance (>= 90%)
1643	1080	Placebo	no ASA	2020-06-17	Good compliance (>= 90%)
1660	1080	Placebo	no ASA	2020-06-25	
1661	1080	Placebo	no ASA	2020-06-25	Acceptable compliance (80% to < 90%)
1688	1080	Placebo	no ASA	2020-07-14	
1695	1080	Placebo	no ASA	2020-07-20	Acceptable compliance (80% to < 90%)
1703	1080	Placebo	no ASA	2020-07-23	Good compliance (>= 90%)
1707	1080	Placebo	no ASA	2020-07-29	Good compliance (>= 90%)
1734	1080	Placebo	no ASA	2020-08-17	Acceptable compliance (80% to < 90%)
1740	1080	Placebo	no ASA	2020-08-21	Non-compliance (< 80%)
1743	1080	Placebo	no ASA	2020-08-25	Good compliance (>= 90%)
1746	1080	Placebo	no ASA	2020-08-26	Good compliance (>= 90%)
1749	1080	Placebo	no ASA	2020-08-27	Good compliance (>= 90%)
1798	1080	Placebo	no ASA	2020-09-23	Good compliance (>= 90%)
1814	1080	Placebo	no ASA	2020-10-05	Acceptable compliance (80% to < 90%)
1843	1080	Placebo	no ASA	2020-11-01	
1856	1080	Placebo	no ASA	2020-11-10	Good compliance (>= 90%)
1874	1080	Placebo	no ASA	2020-11-19	Good compliance (>= 90%)
1888	1080	Placebo	no ASA	2020-12-02	Good compliance (>= 90%)
1914	1080	Placebo	no ASA	2020-12-22	Good compliance (>= 90%)
1945	1080	Placebo	no ASA	2021-02-03	Good compliance (>= 90%)
1948	1080	Placebo	no ASA	2021-02-04	Good compliance (>= 90%)
2012	1080	Placebo	no ASA		
2017	1080	Placebo	no ASA	2021-03-18	Good compliance (>= 90%)
2020	1080	Placebo	no ASA	2021-03-19	Non-compliance (< 80%)
2024	1080	Placebo	no ASA	2021-03-24	Good compliance (>= 90%)
2056	1080	Placebo	no ASA	2021-04-20	Acceptable compliance (80% to < 90%)
2058	1080	Placebo	no ASA	2021-04-20	Non-compliance (< 80%)
2123	1080	Placebo	no ASA	2021-05-27	Good compliance (>= 90%)
2125	1080	Placebo	no ASA	2021-05-27	Good compliance (>= 90%)
2126	1080	Placebo	no ASA	2021-05-28	Acceptable compliance (80% to < 90%)
2144	1080	Placebo	no ASA	2021-06-10	Good compliance (>= 90%)
2150	1080	Placebo	no ASA	2021-06-10	Acceptable compliance (80% to < 90%)
2154	1080	Placebo	no ASA	2021-06-26	Non-compliance (< 80%)
2185	1080	Placebo	no ASA	2021-07-12	
2194	1080	Placebo	no ASA	2021-07-20	Good compliance (>= 90%)
2206	1080	Placebo	no ASA	2021-07-27	Acceptable compliance (80% to < 90%)
2288	1080	Placebo	no ASA	2021-09-29	Non-compliance (< 80%)
2293	1080	Placebo	no ASA	2021-09-29	Acceptable compliance (80% to < 90%)
2320	1080	Placebo	no ASA	2021-10-29	Non-compliance (< 80%)
2348	1080	Placebo	no ASA	2021-11-16	
2478	1080	Placebo	no ASA	2022-02-15	Good compliance (>= 90%)
1765	1080	Edoxaban	ASA	2020-09-09	Good compliance (>= 90%)
1778	1080	Edoxaban	ASA	2020-09-15	Good compliance (>= 90%)
1793	1080	Edoxaban	ASA	2020-09-18	Good compliance (>= 90%)
2085	1080	Edoxaban	ASA	2021-05-05	Non-compliance (< 80%)
2310	1080	Edoxaban	ASA	2021-10-19	
1371	1080	Edoxaban	no ASA	2019-11-06	Acceptable compliance (80% to < 90%)
1388	1080	Edoxaban	no ASA	2019-11-14	

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
1444	1080	Edoxaban	no ASA	2019-12-11	Good compliance (>= 90%)
1462	1080	Edoxaban	no ASA	2019-12-23	
1538	1080	Edoxaban	no ASA	2020-03-03	
1571	1080	Edoxaban	no ASA	2020-04-23	
1615	1080	Edoxaban	no ASA	2020-06-09	
1636	1080	Edoxaban	no ASA	2020-06-16	Good compliance (>= 90%)
1665	1080	Edoxaban	no ASA	2020-06-26	Acceptable compliance (80% to < 90%)
1671	1080	Edoxaban	no ASA	2020-07-01	Good compliance (>= 90%)
1694	1080	Edoxaban	no ASA	2020-07-17	Good compliance (>= 90%)
1700	1080	Edoxaban	no ASA	2020-07-21	Good compliance (>= 90%)
1721	1080	Edoxaban	no ASA	2020-08-05	Good compliance (>= 90%)
1728	1080	Edoxaban	no ASA	2020-08-13	Good compliance (>= 90%)
1736	1080	Edoxaban	no ASA	2020-08-19	Good compliance (>= 90%)
1744	1080	Edoxaban	no ASA	2020-08-25	Non-compliance (< 80%)
1754	1080	Edoxaban	no ASA	2020-09-03	Acceptable compliance (80% to < 90%)
1762	1080	Edoxaban	no ASA	2020-09-09	Good compliance (>= 90%)
1786	1080	Edoxaban	no ASA	2020-09-17	Acceptable compliance (80% to < 90%)
1802	1080	Edoxaban	no ASA	2020-09-25	
1822	1080	Edoxaban	no ASA	2020-10-12	Non-compliance (< 80%)
1861	1080	Edoxaban	no ASA	2020-11-11	
1863	1080	Edoxaban	no ASA	2020-11-11	Good compliance (>= 90%)
1890	1080	Edoxaban	no ASA	2020-12-04	Good compliance (>= 90%)
1912	1080	Edoxaban	no ASA	2020-12-21	Good compliance (>= 90%)
1937	1080	Edoxaban	no ASA	2021-01-26	
1977	1080	Edoxaban	no ASA	2021-02-24	
1988	1080	Edoxaban	no ASA	2021-03-01	Non-compliance (< 80%)
1992	1080	Edoxaban	no ASA	2021-03-02	Good compliance (>= 90%)
2018	1080	Edoxaban	no ASA	2021-03-18	Good compliance (>= 90%)
2037	1080	Edoxaban	no ASA	2021-04-08	Acceptable compliance (80% to < 90%)
2057	1080	Edoxaban	no ASA	2021-04-21	Good compliance (>= 90%)
2084	1080	Edoxaban	no ASA	2021-05-05	Good compliance (>= 90%)
2099	1080	Edoxaban	no ASA	2021-05-14	Good compliance (>= 90%)
2131	1080	Edoxaban	no ASA	2021-06-01	
2138	1080	Edoxaban	no ASA	2021-06-04	Good compliance (>= 90%)
2141	1080	Edoxaban	no ASA	2021-06-08	
2147	1080	Edoxaban	no ASA	2021-06-10	
2184	1080	Edoxaban	no ASA	2021-07-12	Good compliance (>= 90%)
2215	1080	Edoxaban	no ASA	2021-08-09	
2237	1080	Edoxaban	no ASA	2021-08-24	Non-compliance (< 80%)
2244	1080	Edoxaban	no ASA	2021-08-25	Good compliance (>= 90%)
2284	1080	Edoxaban	no ASA	2021-09-27	Acceptable compliance (80% to < 90%)
2286	1080	Edoxaban	no ASA	2021-09-28	Acceptable compliance (80% to < 90%)
2305	1080	Edoxaban	no ASA	2021-10-13	
2441	1080	Edoxaban	no ASA	2022-01-21	
2464	1080	Edoxaban	no ASA	2022-02-02	
2484	1080	Edoxaban	no ASA	2022-02-18	Good compliance (>= 90%)
1353	1085	Placebo	ASA	2019-10-28	Good compliance (>= 90%)
1433	1085	Placebo	ASA	2019-12-05	Non-compliance (< 80%)
1499	1085	Placebo	ASA	2020-01-30	Good compliance (>= 90%)
1529	1085	Placebo	ASA		
2029	1085	Placebo	ASA	2021-03-26	Good compliance (>= 90%)
2115	1085	Placebo	ASA	2021-05-21	Good compliance (>= 90%)
2316	1085	Placebo	ASA	2021-10-21	Good compliance (>= 90%)
2500	1085	Placebo	ASA	2022-02-24	Non-compliance (< 80%)
2625	1085	Placebo	ASA	2022-05-24	Good compliance (>= 90%)
1520	1085	Placebo	no ASA	2020-02-17	Good compliance (>= 90%)
1673	1085	Placebo	no ASA	2020-07-02	Good compliance (>= 90%)
1785	1085	Placebo	no ASA	2020-09-17	Good compliance (>= 90%)
1788	1085	Placebo	no ASA	2020-09-17	Good compliance (>= 90%)
1962	1085	Placebo	no ASA	2021-02-17	Acceptable compliance (80% to < 90%)
2301	1085	Placebo	no ASA	2021-10-06	Acceptable compliance (80% to < 90%)
2385	1085	Placebo	no ASA	2021-12-07	Good compliance (>= 90%)
2429	1085	Placebo	no ASA	2022-01-13	Good compliance (>= 90%)
1477	1085	Edoxaban	ASA	2020-01-16	Acceptable compliance (80% to < 90%)
1537	1085	Edoxaban	ASA	2020-03-03	Good compliance (>= 90%)
1963	1085	Edoxaban	ASA	2021-02-17	Good compliance (>= 90%)
1980	1085	Edoxaban	ASA	2021-02-24	Good compliance (>= 90%)
2021	1085	Edoxaban	ASA	2021-03-19	Good compliance (>= 90%)
2114	1085	Edoxaban	ASA	2021-05-21	Good compliance (>= 90%)
2482	1085	Edoxaban	ASA	2022-02-16	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2511	1085	Edoxaban	ASA	2022-03-03	Good compliance (>= 90%)
1386	1085	Edoxaban	no ASA	2019-11-14	Good compliance (>= 90%)
1483	1085	Edoxaban	no ASA	2020-01-21	Non-compliance (< 80%)
1771	1085	Edoxaban	no ASA	2020-09-11	Good compliance (>= 90%)
2032	1085	Edoxaban	no ASA	2021-03-30	Good compliance (>= 90%)
2298	1085	Edoxaban	no ASA	2021-10-05	Good compliance (>= 90%)
2307	1085	Edoxaban	no ASA	2021-10-15	Good compliance (>= 90%)
2312	1085	Edoxaban	no ASA	2021-10-19	Good compliance (>= 90%)
2440	1085	Edoxaban	no ASA	2022-01-20	Good compliance (>= 90%)
2095	1086	Placebo	ASA	2021-05-12	Good compliance (>= 90%)
2540	1086	Placebo	ASA	2022-03-18	Good compliance (>= 90%)
2072	1086	Edoxaban	ASA	2021-04-29	Good compliance (>= 90%)
1174	1089	Placebo	no ASA	2019-06-11	Good compliance (>= 90%)
1358	1089	Placebo	no ASA	2019-10-29	
1364	1089	Placebo	no ASA	2019-11-05	
1492	1089	Placebo	no ASA	2020-01-28	Good compliance (>= 90%)
1502	1089	Placebo	no ASA	2020-02-04	Good compliance (>= 90%)
1522	1089	Placebo	no ASA	2020-02-19	
2205	1089	Placebo	no ASA	2021-07-27	Good compliance (>= 90%)
2230	1089	Placebo	no ASA	2021-08-17	Non-compliance (< 80%)
2336	1089	Placebo	no ASA	2022-01-18	Good compliance (>= 90%)
1317	1089	Edoxaban	no ASA	2019-10-08	Good compliance (>= 90%)
1333	1089	Edoxaban	no ASA	2019-10-15	Good compliance (>= 90%)
1427	1089	Edoxaban	no ASA	2019-12-03	Good compliance (>= 90%)
1504	1089	Edoxaban	no ASA	2020-02-04	Good compliance (>= 90%)
1523	1089	Edoxaban	no ASA		
2066	1089	Edoxaban	no ASA	2021-04-28	
2067	1089	Edoxaban	no ASA		
2344	1097	Placebo	ASA	2021-11-16	Good compliance (>= 90%)
1705	1097	Edoxaban	ASA	2020-07-28	Good compliance (>= 90%)
2331	1097	Edoxaban	ASA	2021-11-09	Good compliance (>= 90%)
2401	1097	Edoxaban	ASA	2021-12-21	Non-compliance (< 80%)
2651	1097	Edoxaban	no ASA	2022-06-13	Good compliance (>= 90%)
2445	1104	Placebo	ASA	2022-01-28	Good compliance (>= 90%)
2560	1104	Placebo	ASA	2022-03-25	Good compliance (>= 90%)
2535	1104	Placebo	no ASA	2022-03-17	Acceptable compliance (80% to < 90%)
2169	1104	Edoxaban	no ASA	2021-06-25	Good compliance (>= 90%)
2553	1104	Edoxaban	no ASA	2022-03-28	Good compliance (>= 90%)
2578	1108	Placebo	no ASA	2022-04-07	Good compliance (>= 90%)
2531	1111	Edoxaban	no ASA	2022-03-15	Non-compliance (< 80%)
2330	1115	Edoxaban	ASA	2021-11-09	Good compliance (>= 90%)
2434	1115	Edoxaban	no ASA	2022-01-17	Good compliance (>= 90%)
2538	1116	Placebo	no ASA	2022-03-17	Good compliance (>= 90%)
2576	1116	Placebo	no ASA	2022-04-07	Good compliance (>= 90%)
2646	1116	Placebo	no ASA	2022-06-09	Non-compliance (< 80%)
2461	1116	Edoxaban	no ASA	2022-02-02	Good compliance (>= 90%)
2598	1116	Edoxaban	no ASA	2022-04-28	Good compliance (>= 90%)
2701	1116	Edoxaban	no ASA	2022-07-07	Good compliance (>= 90%)
2728	1117	Placebo	no ASA	2022-07-28	Good compliance (>= 90%)
2678	1118	Placebo	ASA	2022-06-29	Good compliance (>= 90%)
2697	1118	Placebo	ASA	2022-07-06	Good compliance (>= 90%)
2657	1118	Placebo	no ASA	2022-06-15	Good compliance (>= 90%)
2689	1118	Placebo	no ASA	2022-07-05	Good compliance (>= 90%)
2732	1118	Edoxaban	ASA	2022-08-08	Good compliance (>= 90%)
2729	1121	Placebo	ASA	2022-08-01	Good compliance (>= 90%)
2587	1121	Placebo	no ASA	2022-04-20	Good compliance (>= 90%)
2609	1121	Edoxaban	ASA	2022-05-09	Good compliance (>= 90%)
2377	1121	Edoxaban	no ASA	2021-12-02	
2444	1121	Edoxaban	no ASA	2022-01-25	Acceptable compliance (80% to < 90%)
2359	1123	Placebo	ASA	2021-11-19	Good compliance (>= 90%)
2389	1123	Edoxaban	ASA	2021-12-13	Good compliance (>= 90%)
2502	1127	Placebo	no ASA	2022-03-10	Good compliance (>= 90%)
2557	1133	Edoxaban	ASA	2022-04-04	Good compliance (>= 90%)
2699	1133	Edoxaban	ASA	2022-07-06	Good compliance (>= 90%)
2597	1133	Edoxaban	no ASA	2022-04-27	Good compliance (>= 90%)
2477	1138	Edoxaban	no ASA	2022-02-15	Good compliance (>= 90%)
2611	1146	Placebo	ASA	2022-05-14	Good compliance (>= 90%)
2713	1146	Placebo	ASA	2022-07-15	Good compliance (>= 90%)
2519	1146	Placebo	no ASA	2022-03-09	Good compliance (>= 90%)
2574	1146	Placebo	no ASA	2022-04-13	Good compliance (>= 90%)

Patient-ID	Centre-ID	Random group	Random stratum (indication)[1]	Treatment start date	Compliance[2]
2398	1146	Edoxaban	ASA	2021-12-21	Acceptable compliance (80% to < 90%)
2397	1146	Edoxaban	no ASA	2021-12-31	Good compliance (>= 90%)
2391	1147	Placebo	ASA	2021-12-14	Good compliance (>= 90%)
2525	1147	Edoxaban	no ASA	2022-03-09	Good compliance (>= 90%)
2688	1148	Placebo	no ASA	2022-07-04	Good compliance (>= 90%)
2737	1148	Placebo	no ASA	2022-08-16	Good compliance (>= 90%)
2603	1148	Edoxaban	ASA	2022-05-03	

[1] ASA = Acetylsalicylic acid

[2] missing values = either treatment not started or pill count not performed

16.2.6 Adverse event listings (each patient)

Table 30 Individual adverse events listing

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
468	9	P	ASA	66	m	0468-00829	2019-08-01	2019-10-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
468	9	P	ASA	66	m	0468-01383	2021-02-18	2021-02-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074312	Diaphragmatic spasm
561	9	P	ASA	66	f	0561-01156	2020-06-09	2020-06-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047393	Vestibular neuronitis
561	9	P	ASA	66	f	0561-01012	2020-06-09	2020-06-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10028813	Dizziness, Nausea
681	9	P	ASA	87	f	0681-02068	2021-01-01	2021-01-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
681	9	P	ASA	87	f	0681-02366	2022-03-01	2022-03-01	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10027458, 10027455	Metastases to lung, Metastases to kidney
681	9	P	ASA	87	f	0681-01389	2020-08-27	2020-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10065929	Cardiovascular insufficiency
1192	9	P	ASA	73	m	1192-01511	2020-08-10	2020-08-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017853	Gastritis
1213	9	P	ASA	91	f	1213-02063	2020-01-06	2020-01-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10016173	Dizziness, Fall
1259	9	P	ASA	75	m	1259-01660	2021-02-24	2021-02-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1259	9	P	ASA	75	m	1259-01661	2021-02-11	2021-02-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10016173, 10025482	Dizziness, Fall, Malaise
1259	9	P	ASA	75	m	1259-01662	2020-02-27	2021-12-15	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10006093	Bradycardia
1259	9	P	ASA	75	m	1259-02064	2021-06-01	2021-06-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
1259	9	P	ASA	75	m	1259-02400	2022-05-20	2022-05-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10036105	Polyneuropathy
1641	9	P	ASA	86	m	1641-01337	2020-09-01	2020-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10064990	Fall, Skin abrasion
1641	9	P	ASA	86	m	1641-01490	2021-05-04	2021-05-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074431	Cancer surgery
1817	9	P	ASA	73	f	1817-01351	2021-02-16	2021-02-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
1817	9	P	ASA	73	f	1817-02386	2021-10-18	2021-10-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10028813	Dizziness, Nausea
1871	9	P	ASA	89	f	1871-02364	2022-08-25	2022-08-25	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	related	related	Recovered/resolved	10016173, 10019196	Fall, Head injury
2221	9	P	ASA	68	m	2221-02365	2022-09-04	2022-09-06	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2406	9	P	ASA	86	m	2406-02457	2022-06-20	2022-06-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013578	Dizziness postural
2406	9	P	ASA	86	m	2406-02458	2022-09-07	2022-09-07	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10047249	Venous thrombosis
2741	9	P	ASA	72	m	2741-02438	2022-10-01	2022-10-01	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10020772	Hypertension
92	9	P	no ASA	78	m	0092-01471	2020-08-06	2020-08-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058179	Hypertensive emergency
96	9	P	no ASA	70	f	0096-01386	2020-02-28	2020-02-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
96	9	P	no ASA	70	f	0096-01387	2020-02-28	2020-11-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
697	9	P	no ASA	92	m	0697-00260	2018-09-06	2019-03-07	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10012735	Diarrhoea
697	9	P	no ASA	92	m	0697-02071	2019-09-01	2019-09-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10009033	Dyspnoea, Chronic obstructive pulmonary disease
697	9	P	no ASA	92	m	0697-02358	2020-08-11	2020-08-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479	Chest pain
830	9	P	no ASA	89	m	0830-02377	2021-06-30	2021-06-30	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
1570	9	P	no ASA	71	m	1570-01557	2020-07-01	2020-10-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10065929, 10013578	Cardiovascular insufficiency, Dizziness postural
2408	9	P	no ASA	76	f	2408-02296	2022-01-11	2022-03-25	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10012735	Diarrhoea
93	9	E	ASA	83	m	0093-00053	2018-01-31	2018-01-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
129	9	E	ASA	77	f	0129-01489	2020-11-19	2020-11-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557, 10025482	Palpitations, Malaise
153	9	E	ASA	71	m	0153-00390	2018-07-19	2018-09-10	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10060862	Prostate cancer
153	9	E	ASA	71	m	0153-01379	2020-11-05	2020-11-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
485	9	E	ASA	82	f	0485-01384	2020-09-17	2020-09-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
485	9	E	ASA	82	f	0485-01385	2021-03-18	2021-03-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048334, 10003239	Mobility decreased, Arthralgia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
666	9	E	ASA	86	m	0666-01349	2020-08-20	2020-08-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10033425, 10062585	Pain in extremity, Peripheral arterial occlusive disease
731	9	E	ASA	71	m	0731-02482	2022-03-01	2022-03-01	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
843	9	E	ASA	77	m	0843-00324	2018-12-13	2019-01-08	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
843	9	E	ASA	77	m	0843-01350	2021-05-25	2021-05-25	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10033557	Palpitations
843	9	E	ASA	77	m	0843-02378	2022-05-15	2022-05-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028334, 10033775	Muscle spasms, Paraesthesia
1178	9	E	ASA	80	f	1178-00600	2019-10-23	2019-10-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10069861	Device stimulation issue
1178	9	E	ASA	80	f	1178-01354	2020-12-22	2020-12-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074312	Diaphragmatic spasm
1178	9	E	ASA	80	f	1178-02176	2022-08-30	2022-08-31	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10069861, 10028347	Device stimulation issue, Muscle twitching
1178	9	E	ASA	80	f	1178-00974	2020-05-24	2020-05-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020635	Hyperglycaemia
1816	9	E	ASA	73	m	1816-01275	2021-03-25	2021-03-25	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10038063	Rectal haemorrhage
1961	9	E	ASA	86	m	1961-02060	2021-12-10	2022-02-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028347	Muscle twitching
2044	9	E	ASA	84	m	2044-02620	2022-02-01	2022-02-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2044	9	E	ASA	84	m	2044-02621	2021-12-06	2021-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
2210	9	E	ASA	73	m	2210-02388	2022-11-01	2022-11-10	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10016173, 10018852	Fall, Haematoma
2333	9	E	ASA	83	m	2333-02056	2022-05-01	2022-05-07	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10005140, 10040882	Bleeding time prolonged, Skin lesion
2421	9	E	ASA	81	f	2421-02225	2022-06-01	2022-06-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2421	9	E	ASA	81	f	2421-02417	2022-09-20	2022-09-20	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
2479	9	E	ASA	77	m	2479-02622	2022-08-21	2022-08-21	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
46	9	E	no ASA	81	f	0046-00220	2018-05-23	2022-05-30	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10050584	Contusion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
46	9	E	no ASA	81	f	0046-02077	2021-11-01	2021-11-23	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10037383	Pulmonary fibrosis
100	9	E	no ASA	75	m	0100-00883	2020-06-02	2020-06-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013538	Diverticulitis
100	9	E	no ASA	75	m	0100-01380	2020-06-27	2020-06-27	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011781, 10018867	Cystitis, Haematuria
100	9	E	no ASA	75	m	0100-01381	2021-03-03	2021-03-03	Other event	Mild	None, i.e. still ongoing	related	not related	Recovered/resolved	10008479	Chest pain
100	9	E	no ASA	75	m	0100-01382	2021-03-03	2021-03-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013971	Dyspnoea exertional
536	9	E	no ASA	79	f	0536-00592	2019-05-24	2019-05-24	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10046910	Vaginal haemorrhage
1897	9	E	no ASA	65	m	1897-01343	2020-12-10	2021-12-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025482	Malaise
2297	9	E	no ASA	80	f	2297-02521	2021-10-25	2021-10-25	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10017577, 10013573	Gait disturbance, Dizziness
2615	9	E	no ASA	77	m	2615-02446	2022-10-01	2022-10-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10071697	Periorbital haemorrhage
1582	12	P	ASA	91	f	1582-01291	2020-05-23	2020-05-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058179	Hypertensive emergency
1760	12	P	no ASA	93	f	1760-01124	2020-12-22	2020-12-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
1651	12	E	no ASA	78	m	1651-02483	2022-07-20	2022-07-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1269	16	P	ASA	80	m	1269-00634	2019-08-29	2019-09-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10002034	Anaemia
1269	16	P	ASA	80	m	1269-01540	2020-05-05		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10033425	Pain in extremity
1165	16	E	ASA	68	m	1165-02350	2022-10-13	2022-10-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
1165	16	E	ASA	68	m	1165-00748	2020-03-11	2020-03-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
1179	16	E	ASA	74	m	1179-00749	2020-04-30	2020-04-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
385	16	E	no ASA	78	f	0385-00377	2019-02-22	2019-02-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
385	16	E	no ASA	78	f	0385-00379	2019-03-25	2019-04-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
385	16	E	no ASA	78	f	0385-00776	2020-04-03	2020-04-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
385	16	E	no ASA	78	f	0385-01749	2021-08-27	2021-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
385	16	E	no ASA	78	f	0385-00228	2018-07-26	2018-08-02	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10028813	Nausea
385	16	E	no ASA	78	f	0385-00568	2019-10-15	2019-10-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
385	16	E	no ASA	78	f	0385-00569	2019-09-15	2019-11-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024774	Localised infection
440	16	E	no ASA	66	m	0440-00147	2018-02-13	2019-09-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
440	16	E	no ASA	66	m	0440-00148	2018-02-13	2019-09-03	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10037549, 10034754	Purpura, Petechiae
440	16	E	no ASA	66	m	0440-00149	2018-02-13	2018-12-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340, 10031127	Vertigo, Orthostatic hypotension
440	16	E	no ASA	66	m	0440-00419	2019-07-31	2019-10-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047340	Vertigo
446	17	P	ASA	76	m	0446-00409	2019-07-30	2019-07-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
364	17	E	ASA	72	m	0364-00044	2017-12-07	2017-12-18	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
364	17	E	ASA	72	m	0364-00158	2018-05-23		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Unknown	10030095	Oedema
364	17	E	ASA	72	m	0364-00203	2018-12-03	2018-12-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
364	17	E	ASA	72	m	0364-00562	2019-11-19	2020-09-09	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
364	17	E	ASA	72	m	0364-01143	2020-10-07	2020-10-07	Other event	Very severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
409	17	E	no ASA	74	f	0409-01341	2021-03-04	2021-03-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
409	17	E	no ASA	74	f	0409-01342	2021-05-05	2021-05-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
409	17	E	no ASA	74	f	0409-01060	2020-11-10	2020-11-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
263	19	P	ASA	67	m	0263-01807	2022-01-01	2022-03-15	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10003211, 10008479	Arteriosclerosis coronary artery, Chest pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
120	19	P	no ASA	82	m	0120-00077	2017-06-21	2017-07-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015145, 10043873	Erysipelas, Tinea pedis
120	19	P	no ASA	82	m	0120-00439	2019-04-10	2019-04-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10041834, 10074431	Squamous cell carcinoma of skin, Cancer surgery
120	19	P	no ASA	82	m	0120-00662	2020-02-24	2020-02-25	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10046555	Urinary retention
203	19	E	ASA	84	f	0203-00083	2018-01-01	2018-06-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037087, 10046735	Pruritus, Urticaria
203	19	E	ASA	84	f	0203-00344	2019-06-17	2019-06-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772, 10021097	Syncope, Hypotension
329	19	E	ASA	77	m	0329-00340	2018-12-06	2018-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10060820	Fall, Joint injury
340	19	E	no ASA	69	f	0340-00710	2020-01-01	2021-02-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735, 10013946	Diarrhoea, Dyspepsia
340	19	E	no ASA	69	f	0340-00967	2020-05-07	2020-06-01	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10019211, 10012735, 10057071	Headache, Diarrhoea, Rectal tenesmus
624	22	E	ASA	71	m	0624-00221	2018-09-20	2018-09-20	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062132	Tooth extraction
624	22	E	ASA	71	m	0624-00645	2019-09-19	2019-10-10	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658, 10007661	Atrial fibrillation, Cardioversion
624	22	E	ASA	71	m	0624-00901	2020-08-02	2020-08-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
624	22	E	ASA	71	m	0624-00902	2020-08-17	2020-08-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
624	22	E	ASA	71	m	0624-01285	2021-02-23	2021-04-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003668	Atrial tachycardia
624	22	E	ASA	71	m	0624-01284	2021-04-14	2021-04-14	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
692	23	P	ASA	80	m	0692-00490	2018-12-27	2018-12-29	Other event	Moderate	Temporarily discontinued	not related	not related	Recovered/resolved	10062242	Shoulder operation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
692	23	P	ASA	80	m	0692-02582	2020-01-22	2020-01-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020850	Hyperthyroidism
692	23	P	ASA	80	m	0692-01776	2020-07-13	2020-07-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005156	Blepharoplasty
692	23	P	ASA	80	m	0692-01912	2022-04-20	2022-04-20	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
234	23	E	ASA	77	m	0234-02572	2022-03-07	2022-09-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10007554	Cardiac failure
234	23	E	ASA	77	m	0234-02567	2021-07-26	2021-07-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479, 10000081	Chest pain, Abdominal pain
234	23	E	ASA	77	m	0234-02570	2020-06-11	2020-06-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063797	Cataract operation
234	23	E	ASA	77	m	0234-02571	2020-06-23	2020-06-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063797	Cataract operation
234	23	E	ASA	77	m	0234-02568	2022-02-07	2022-09-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10013968	Dyspnoea
234	23	E	ASA	77	m	0234-02569	2022-03-07	2023-04-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030095	Oedema
122	23	E	no ASA	75	m	0122-00024	2017-07-12	2017-07-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
150	33	P	ASA	78	m	0150-00095	2017-05-17	2017-05-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058818	Skin laceration
150	33	P	ASA	78	m	0150-00941	2020-08-31	2022-05-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10042862	Synovial rupture
150	33	P	ASA	78	m	0150-01144	2020-01-13		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10012271	Dementia Alzheimer's type
235	33	E	ASA	72	m	0235-00608	2019-12-03	2019-12-04	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10022013	Ingrowing nail
235	33	E	ASA	72	m	0235-00609	2019-12-26	2019-12-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1206	33	E	ASA	91	m	1206-00555	2019-07-05	2019-07-05	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
1206	33	E	ASA	91	m	1206-01686	2021-12-17	2022-01-04	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1378	33	E	ASA	82	m	1378-00538	2019-11-22	2019-11-29	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10000081	Abdominal pain
442	34	P	ASA	93	f	0442-00121	2018-04-18	2018-04-19	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10002034	Anaemia
59	35	P	ASA	92	m	0059-00004	2016-12-10	2016-12-17	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10012735	Diarrhoea
414	38	P	no ASA	81	m	0414-00174	2018-04-03	2018-04-03	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1391	39	P	ASA	71	m	1391-00738	2019-12-17	2020-05-25	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10037087	Pruritus
2005	39	P	no ASA	78	m	2005-01398	2021-04-07	2021-05-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015150	Erythema
845	43	P	ASA	86	f	0845-00319	2018-12-03	2018-12-03	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10002855	Anxiety
1274	44	E	ASA	79	m	1274-00484	2019-09-23	2019-10-14	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10028641	Myopathy
95	46	P	ASA	66	f	0095-00023	2017-06-21	2017-07-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048762	Tooth infection
95	46	P	ASA	66	f	0095-01366	2020-07-16	2021-01-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047340	Vertigo
95	46	P	ASA	66	f	0095-01365	2020-01-23	2021-01-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047340	Vertigo
145	46	P	ASA	67	m	0145-02342	2019-06-17	2019-06-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025650	Malignant melanoma

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
145	46	P	ASA	67	m	0145-01368	2020-05-07	2020-05-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10009887	Dizziness, Colitis
43	46	E	ASA	76	m	0043-02555	2019-02-15	2019-02-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10057668	Cognitive disorder
363	49	P	no ASA	82	f	0363-00161	2018-01-30	2018-03-19	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10013573	Dizziness
243	49	E	no ASA	85	f	0243-00347	2018-08-22	2018-08-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003399	Arthropod bite
243	49	E	no ASA	85	f	0243-01834	2022-02-04	2022-02-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
243	49	E	no ASA	85	f	0243-02407	2022-08-13	2022-09-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058818, 10016173, 10048959, 10061637	Skin laceration, Fall, Peripheral swelling, Angiogram
272	49	E	no ASA	72	f	0272-00271	2019-01-15	2019-03-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10050296	Intervertebral disc protrusion
272	49	E	no ASA	72	f	0272-00272	2018-12-11	2018-12-19	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037464	Pulpitis dental
272	49	E	no ASA	72	f	0272-00273	2019-02-27	2019-02-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037464	Pulpitis dental
272	49	E	no ASA	72	f	0272-00346	2019-04-08	2019-05-27	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
272	49	E	no ASA	72	f	0272-00670	2019-09-07		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10011781	Cystitis
272	49	E	no ASA	72	f	0272-01125	2021-02-15	2021-02-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
272	49	E	no ASA	72	f	0272-02419	2022-08-25	2022-09-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037464	Pulpitis dental
272	49	E	no ASA	72	f	0272-02374	2022-03-29	2022-04-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
272	49	E	no ASA	72	f	0272-02432	2022-06-15	2022-06-21	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10038077	Rectal prolapse
272	49	E	no ASA	72	f	0272-00433	2019-07-05	2019-08-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040943	Skin ulcer
272	49	E	no ASA	72	f	0272-00434	2019-08-08	2019-08-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037464	Pulpitis dental
272	49	E	no ASA	72	f	0272-00435	2019-07-11	2019-07-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011781	Cystitis
723	57	P	ASA	81	m	0723-02319	2022-09-02	2022-09-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013887	Dysarthria
966	57	E	ASA	79	f	0966-02054	2022-07-26	2022-07-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
966	57	E	ASA	79	f	0966-00359	2019-06-10	2019-07-04	Other event	Moderate	Temporarily discontinued	related	related	Recovered/resolved	10037087	Pruritus

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1324	57	E	ASA	80	f	1324-00935	2020-09-01		Other event	Mild	Temporarily discontinued due to this event	not related	not related	Event ongoing	10037087	Pruritus
1629	57	E	ASA	82	f	1629-01292	2021-02-12	2021-02-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018852	Haematoma
19	59	P	ASA	81	f	0019-00047	2016-09-23	2016-09-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
19	59	P	ASA	81	f	0019-01512	2021-01-01	2021-03-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007558	Cardiac failure chronic
24	59	P	ASA	67	m	0024-00008	2016-09-20	2017-03-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
67	59	P	ASA	78	m	0067-01685	2020-10-01	2021-01-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
679	59	P	ASA	77	m	0679-00245	2018-10-02	2018-12-03	Other event	Severe	Permanently discontinued due to this event	related	related	Recovered/resolved	10002034	Anaemia
463	59	P	no ASA	79	f	0463-00211	2018-03-01	2018-12-18	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10012735	Diarrhoea
463	59	P	no ASA	79	f	0463-00252	2018-12-03	2018-12-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012735	Diarrhoea
615	59	P	no ASA	81	f	0615-02080	2021-11-05	2021-11-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
615	59	P	no ASA	81	f	0615-02081	2021-10-05	2021-10-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10051942	Peritoneal cyst
615	59	P	no ASA	81	f	0615-01037	2019-03-16	2019-03-30	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10077666	Joint microhaemorrhage
1230	59	P	no ASA	78	m	1230-00653	2019-11-25	2019-12-06	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10053196	Eyelid bleeding
186	59	E	ASA	65	m	0186-00171	2017-07-01	2017-12-21	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10037844	Rash
541	59	E	no ASA	74	m	0541-01977	2020-10-01	2021-10-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000614	Actinic keratosis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1634	59	E	no ASA	85	f	1634-01315	2021-02-01	2021-06-07	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
325	70	P	ASA	79	m	0325-01296	2020-05-28	2020-05-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
511	70	P	ASA	81	m	0511-00205	2018-10-04	2018-10-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
644	70	P	ASA	77	f	0644-01120	2021-02-26	2021-03-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
765	70	P	ASA	82	m	0765-01584	2021-04-22		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013968	Dyspnoea
1727	70	P	ASA	77	m	1727-01745	2021-06-01	2022-08-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1751	70	P	ASA	82	m	1751-01122	2020-09-16	2020-09-16	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10007661	Cardioversion
1751	70	P	ASA	82	m	1751-01123	2021-02-17	2021-03-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033557	Palpitations
1751	70	P	ASA	82	m	1751-01582	2021-03-02	2021-03-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
1751	70	P	ASA	82	m	1751-02163	2021-03-12		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10004446	Benign prostatic hyperplasia
401	70	P	no ASA	78	m	0401-01297	2020-07-28	2020-07-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
401	70	P	no ASA	78	m	0401-01583	2020-11-30	2020-12-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1304	70	P	no ASA	75	m	1304-02014	2022-04-21	2022-04-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1714	70	P	no ASA	87	m	1714-01419	2021-05-01	2021-08-13	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10018852	Haematoma
1714	70	P	no ASA	87	m	1714-01420	2021-05-01	2021-08-13	Other event	Mild	Permanently discontinued	not related	not related	Recovered/resolved	10006811	Bursitis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1730	70	P	no ASA	84	m	1730-01096	2020-10-01	2021-02-10	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10060795	Hepatic enzyme increased
105	70	E	ASA	67	f	0105-00184	2018-03-12	2018-03-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037596	Pyelonephritis
105	70	E	ASA	67	f	0105-00320	2019-03-07	2019-03-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014819	Endoscopy upper gastrointestinal tract
774	70	E	ASA	86	m	0774-00927	2020-08-01	2021-04-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1805	70	E	ASA	83	f	1805-01585	2021-09-29		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10007558	Cardiac failure chronic
1964	70	E	ASA	79	m	1964-01439	2021-08-17	2021-08-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10008469	Dyspnoea, Chest discomfort
2182	70	E	ASA	82	m	2182-01789	2021-08-07	2021-12-22	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10012735, 10020993	Diarrhoea, Hypoglycaemia
16	70	E	no ASA	74	m	0016-00834	2020-06-22	2020-06-24	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
16	70	E	no ASA	74	m	0016-00835	2020-07-20	2020-07-22	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
253	70	E	no ASA	68	m	0253-00977	2020-05-18	2020-05-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661, 10003658	Cardioversion, Atrial fibrillation
253	70	E	no ASA	68	m	0253-00537	2019-03-29	2020-01-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10028813	Nausea
514	70	E	no ASA	74	f	0514-00166	2018-04-19		Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Event ongoing	10015090, 10064265	Epistaxis, Skin haemorrhage
514	70	E	no ASA	74	f	0514-00167	2018-04-23		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10028813, 10037087	Nausea, Pruritus
1320	70	E	no ASA	67	f	1320-00485	2019-10-11	2019-11-18	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10019211	Headache
1320	70	E	no ASA	67	f	1320-00486	2019-10-11	2019-11-18	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000087	Abdominal pain upper
1569	70	E	no ASA	80	m	1569-01704	2021-09-15		Other event	Mild	Not applicable (no	not related	not related	Event ongoing	10013971	Dyspnoea exertional

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
373	86	P	ASA	75	m	0373-00055	2017-12-12	2018-04-04	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10038743, 10008479	Restlessness, Chest pain
1016	86	P	ASA	87	m	1016-01006	2020-02-21	2020-08-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1262	86	P	ASA	82	m	1262-01790	2021-12-13	2021-12-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
1262	86	P	ASA	82	m	1262-01007	2020-03-01	2020-08-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211, 10037912, 10047571	Headache, Raynaud's phenomenon, Visual impairment
554	86	P	no ASA	68	f	0554-00082	2018-05-16	2018-05-22	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10022437, 10033557, 10012735	Insomnia, Palpitations, Diarrhoea
554	86	P	no ASA	68	f	0554-00246	2018-11-01	2019-01-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479	Chest pain
1542	86	P	no ASA	74	f	1542-01328	2021-01-01	2021-07-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016256	Fatigue
338	86	E	ASA	76	m	0338-00539	2019-09-15	2019-09-20	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
722	86	E	ASA	71	m	0722-00565	2019-08-15	2019-09-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1374	86	E	ASA	67	f	1374-01896	2022-04-01	2022-05-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030095	Oedema
1374	86	E	ASA	67	f	1374-01008	2020-05-01	2020-10-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1374	86	E	ASA	67	f	1374-01656	2021-10-19	2021-10-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018852	Haematoma
1428	86	E	ASA	82	m	1428-00950	2020-05-19	2020-11-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
18	95	P	ASA	78	f	0018-00757	2019-06-26	2019-06-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
44	95	P	ASA	76	m	0044-01594	2021-11-06	2021-11-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
30	95	P	no ASA	80	m	0030-00395	2019-06-18	2019-06-18	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10035664	Pneumonia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
71	95	P	no ASA	75	m	0071-00857	2020-08-26	2020-08-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
10	95	E	ASA	88	m	0010-00006	2016-08-24	2017-01-23	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
10	95	E	ASA	88	m	0010-00007	2016-08-24	2017-01-23	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10059175	Intestinal haemorrhage
29	95	E	no ASA	80	f	0029-01524	2018-01-25	2018-01-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040984	Sleep disorder
4	100	P	ASA	77	f	0004-02590	2022-08-01	2022-08-01	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10019196, 10055798	Head injury, Haemorrhage
848	100	P	ASA	68	f	0848-00736	2020-03-31	2020-04-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019974	Herpes zoster
124	100	E	ASA	75	m	0124-00665	2019-02-26	2019-02-26	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10061853	Eyelid operation
124	100	E	ASA	75	m	0124-00312	2019-03-19	2019-04-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10022970	Iron deficiency
527	100	E	ASA	66	f	0527-00906	2020-04-28	2020-04-28	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10052971	Medical device removal
527	100	E	ASA	66	f	0527-00685	2020-02-05	2020-02-05	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10023204	Joint dislocation
537	100	E	ASA	93	m	0537-00311	2018-09-01	2019-05-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
201	109	P	ASA	83	f	0201-00022	2017-06-28	2017-07-06	Other event	Severe	Permanently discontinued due to this event	not related	related	Recovered/resolved	10028813, 10000081	Nausea, Abdominal pain
201	109	P	ASA	83	f	0201-00100	2017-07-05	2017-07-05	Other event	Severe	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000081	Abdominal pain
37	113	P	no ASA	73	m	0037-00041	2016-10-24	2017-03-10	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10037844	Rash
36	113	E	no ASA	80	m	0036-00002	2016-10-13	2016-10-19	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10008479, 10022437	Chest pain, Insomnia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
40	113	E	no ASA	80	m	0040-00003	2016-12-18	2017-01-05	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
40	113	E	no ASA	80	m	0040-00048	2017-10-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10002942	Apathy
411	113	E	no ASA	78	m	0411-00118	2018-05-26	2018-07-27	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10010719	Conjunctival haemorrhage
17	117	P	ASA	66	f	0017-01821	2022-01-03	2022-02-09	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
23	117	P	ASA	88	m	0023-00909	2020-03-31	2020-09-18	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10060862	Prostate cancer
23	117	P	ASA	88	m	0023-01429	2021-03-26	2021-03-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10016256	Dizziness, Fatigue
23	117	P	ASA	88	m	0023-01822	2022-01-24		Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Unknown	10010305, 10024733	Confusional state, Living in residential institution
23	117	P	ASA	88	m	0023-00845	2019-09-17	2019-09-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010774	Constipation
1155	117	P	no ASA	85	m	1155-01069	2020-11-10	2020-11-13	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
1739	117	P	no ASA	84	f	1739-01428	2020-09-07	2021-02-26	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10018852, 10064990	Fall, Haematoma, Skin abrasion
1739	117	P	no ASA	84	f	1739-02563	2021-02-26	2021-08-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10023644	Lacrimation increased
1739	117	P	no ASA	84	f	1739-01444	2021-02-26	2021-08-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10023644	Lacrimation increased
1739	117	P	no ASA	84	f	1739-01445	2021-08-21	2021-08-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008469, 10020772	Chest discomfort, Hypertension
943	117	E	ASA	82	m	0943-00375	2019-07-15	2019-07-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037087	Pruritus
56	121	P	ASA	89	m	0056-00014	2017-01-30	2017-02-14	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10017964	Gastrointestinal infection
56	121	P	ASA	89	m	0056-00016	2017-04-28	2017-05-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
56	121	P	ASA	89	m	0056-00085	2018-05-01		Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Event ongoing	10018867	Haematuria
56	121	P	ASA	89	m	0056-00942	2020-10-05	2020-11-05	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved with sequelae	10015090	Epistaxis
56	121	P	ASA	89	m	0056-01641	2021-08-25	2021-08-26	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007390	Carcinoma in situ of skin
56	121	P	ASA	89	m	0056-00330	2017-06-30	2017-08-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
56	121	P	ASA	89	m	0056-00331	2018-12-05	2019-02-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
56	121	P	ASA	89	m	0056-00332	2018-12-05	2019-01-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
56	121	P	ASA	89	m	0056-00333	2018-12-05	2019-01-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
355	121	P	ASA	82	m	0355-01797	2021-09-09	2021-09-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063797	Cataract operation
130	121	P	no ASA	82	f	0130-00058	2017-12-27	2018-01-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
130	121	P	no ASA	82	f	0130-00059	2018-02-01	2018-03-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005746	Blood pressure fluctuation
130	121	P	no ASA	82	f	0130-00060	2018-03-03	2018-03-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019196	Head injury
41	121	E	ASA	72	f	0041-00322	2018-10-10	2018-10-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479, 10033425	Chest pain, Pain in extremity
41	121	E	ASA	72	f	0041-00371	2019-04-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Unknown	10030124	Oedema peripheral
109	121	E	ASA	76	m	0109-00025	2017-08-11	2017-08-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10069339	Acute kidney injury
109	121	E	ASA	76	m	0109-00026	2017-08-29		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10012601	Diabetes mellitus
359	121	E	ASA	81	m	0359-00035	2017-12-05		Other event	Mild	Permanently discontinued due to this event	not related	not related	Unknown	10038490	Renal pain
111	121	E	no ASA	78	m	0111-00056	2017-11-13	2017-11-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062132	Tooth extraction

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
229	132	P	ASA	80	m	0229-00629	2020-01-28	2020-01-28	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved with sequelae	10040808	Skin cancer
229	132	P	ASA	80	m	0229-00630	2019-07-09	2019-07-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040808	Skin cancer
1612	132	P	ASA	73	m	1612-01286	2020-12-10	2020-12-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10080276	Trichoglossia
8	132	P	no ASA	77	m	0008-01418	2021-02-02	2021-02-02	Other event	Mild	None, i.e. still ongoing	related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
73	132	P	no ASA	68	m	0073-00631	2019-12-06	2019-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10027805	Mole excision
1436	132	P	no ASA	65	f	1436-01959	2022-03-11	2022-03-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383, 10013968	Angina pectoris, Dyspnoea
6	132	E	no ASA	69	f	0006-00001	2016-09-16	2016-10-05	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10008786	Choroidal haemorrhage
739	132	E	no ASA	70	f	0739-00937	2020-10-10	2020-11-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019974	Herpes zoster
400	133	P	ASA	75	m	0400-00064	2018-03-15	2018-04-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012735, 10003246	Diarrhoea, Arthritis
82	133	E	ASA	81	m	0082-00880	2018-11-21	2018-11-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10008479, 10013573	Dyspnoea, Chest pain, Dizziness
82	133	E	ASA	81	m	0082-00881	2018-11-28	2018-11-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10064848	Chronic kidney disease
188	133	E	ASA	74	m	0188-01009	2020-11-14	2020-11-14	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
188	133	E	ASA	74	m	0188-01311	2021-03-23	2021-03-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
188	133	E	ASA	74	m	0188-01312	2020-10-23	2020-10-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10060862	Prostate cancer
52	140	P	ASA	78	m	0052-01925	2021-12-01	2022-11-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895	Weight decreased
114	140	P	ASA	82	f	0114-00416	2019-03-21	2019-09-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
160	140	P	ASA	74	m	0160-01232	2021-01-13	2021-01-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
160	140	P	ASA	74	m	0160-01233	2021-03-09	2021-05-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
160	140	P	ASA	74	m	0160-02376	2022-10-12	2022-11-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
160	140	P	ASA	74	m	0160-00704	2020-04-05	2020-06-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028411	Myalgia
225	140	P	ASA	72	m	0225-00759	2020-03-04	2020-03-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
257	140	P	ASA	81	f	0257-00052	2017-08-18	2017-08-24	Other event	Mild	Permanently discontinued	not related	not related	Recovered/resolved with sequelae	10020802	Hypertensive crisis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
257	140	P	ASA	81	f	0257-01572	2019-09-10	2019-09-10	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10011078	Coronary artery disease
257	140	P	ASA	81	f	0257-01271	2020-11-01	2021-01-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10037844	Rash
257	140	P	ASA	81	f	0257-01493	2020-09-01	2021-01-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479	Chest pain
257	140	P	ASA	81	f	0257-00369	2018-02-02	2018-09-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10037844	Rash
399	140	P	ASA	75	m	0399-00407	2018-01-13	2018-07-28	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10012735	Diarrhoea
399	140	P	ASA	75	m	0399-00751	2020-02-26	2020-02-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014819	Endoscopy upper gastrointestinal tract
482	140	P	ASA	82	m	0482-00591	2018-08-21	2019-03-21	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10014665	Endocarditis
551	140	P	ASA	78	m	0551-00703	2020-04-07	2020-04-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061478	Radioisotope scan
803	140	P	ASA	79	f	0803-01931	2021-12-07	2022-02-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017999	Gastrointestinal pain
1094	140	P	ASA	82	m	1094-00367	2019-05-10	2019-10-24	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013950	Dysphagia
1094	140	P	ASA	82	m	1094-00567	2019-09-01	2019-10-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1094	140	P	ASA	82	m	1094-01165	2020-10-15	2021-04-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10035484	Plasmacytoma
1094	140	P	ASA	82	m	1094-01679	2021-10-18	2021-10-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10007687	Carotid artery stenosis
1438	140	P	ASA	75	f	1438-01320	2020-12-14	2021-06-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10048334	Mobility decreased
1930	140	P	ASA	84	f	1930-01825	2022-01-05	2022-01-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013971, 10018706	Dyspnoea exertional, Graves' disease
68	140	P	no ASA	74	f	0068-00939	2020-10-13	2020-11-03	Other event	Moderate	Not applicable (no	not related	not related	Recovered/resolved with sequelae	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
68	140	P	no ASA	74	f	0068-01138	2021-01-13	2021-01-22	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10021097	Dizziness, Hypotension
68	140	P	no ASA	74	f	0068-00299	2019-03-14	2021-06-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10008479	Chest pain
68	140	P	no ASA	74	f	0068-00769	2020-06-05	2020-06-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
68	140	P	no ASA	74	f	0068-00940	2019-11-27	2019-11-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
432	140	P	no ASA	77	f	0432-00824	2019-04-29	2020-08-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895, 10046543	Weight decreased, Urinary incontinence
432	140	P	no ASA	77	f	0432-01323	2019-01-08	2019-08-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058267	Troponin increased
432	140	P	no ASA	77	f	0432-00626	2019-11-18	2020-02-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058179	Hypertensive emergency
432	140	P	no ASA	77	f	0432-01322	2020-01-20	2020-04-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
432	140	P	no ASA	77	f	0432-01078	2020-12-07	2021-01-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
539	140	P	no ASA	86	m	0539-00415	2018-08-02	2019-04-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10020772	Dizziness, Hypertension
539	140	P	no ASA	86	m	0539-01542	2021-04-17	2021-04-18	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10038063	Rectal haemorrhage
539	140	P	no ASA	86	m	0539-00414	2019-03-29	2019-04-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
539	140	P	no ASA	86	m	0539-01154	2021-03-16	2021-03-21	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10038063	Rectal haemorrhage
669	140	P	no ASA	77	f	0669-00644	2019-12-13	2019-12-13	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661, 10003658	Cardioversion, Atrial fibrillation
1101	140	P	no ASA	81	f	1101-00948	2020-10-14	2020-11-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013968	Dyspnoea
1101	140	P	no ASA	81	f	1101-01772	2020-04-01	2020-04-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020903, 10048959, 10033425	Hyperuricaemia, Peripheral swelling, Pain in extremity

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1101	140	P	no ASA	81	f	1101-01239	2021-05-19	2021-06-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1496	140	P	no ASA	81	m	1496-01375	2021-03-23	2021-03-23	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10007815	Catheterisation cardiac
1496	140	P	no ASA	81	m	1496-02528	2021-02-12	2021-07-21	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10050528	Ejection fraction decreased
1826	140	P	no ASA	81	m	1826-01163	2021-04-07	2021-04-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension
1826	140	P	no ASA	81	m	1826-01680	2021-10-05	2021-10-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013971	Dyspnoea exertional
85	140	E	ASA	83	m	0085-00617	2019-12-30	2020-01-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
136	140	E	ASA	70	m	0136-00468	2019-06-28	2019-07-05	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10018867	Haematuria
136	140	E	ASA	70	m	0136-00587	2018-03-21	2018-04-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239, 10031161	Arthralgia, Osteoarthritis
136	140	E	ASA	70	m	0136-00586	2017-12-08	2018-01-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028334	Muscle spasms
136	140	E	ASA	70	m	0136-00295	2019-03-26	2019-04-16	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
190	140	E	ASA	81	m	0190-01001	2019-06-07	2019-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10007554	Cardiac failure
407	140	E	ASA	75	m	0407-01360	2021-03-29	2021-07-14	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10016173	Fall
407	140	E	ASA	75	m	0407-02216	2022-05-19	2022-05-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10053319, 10006093, 10021143	Sleep study, Bradycardia, Hypoxia
407	140	E	ASA	75	m	0407-01067	2021-01-12	2021-03-17	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10020462, 10018852	Humerus fracture, Haematoma
436	140	E	ASA	77	f	0436-00639	2020-01-30	2020-03-30	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10060795	Hepatic enzyme increased
506	140	E	ASA	84	m	0506-00595	2018-08-20	2018-08-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
622	140	E	ASA	83	f	0622-00613	2019-11-21	2019-11-21	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007739	Cataract
622	140	E	ASA	83	f	0622-00614	2020-01-08	2020-01-08	Other event	Mild	Temporarily discontinued	not related	not related	Recovered/resolved	10007739	Cataract

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
622	140	E	ASA	83	f	0622-01068	2020-08-13	2020-12-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
622	140	E	ASA	83	f	0622-01573	2020-09-22	2020-09-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
622	140	E	ASA	83	f	0622-02459	2022-11-15		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10059650	Implant site infection
622	140	E	ASA	83	f	0622-00800	2020-05-20	2020-05-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
622	140	E	ASA	83	f	0622-00801	2020-06-25	2020-07-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
717	140	E	ASA	84	m	0717-02566	2021-12-07	2022-03-08	Other event	Severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10012267	Dementia
841	140	E	ASA	85	m	0841-00326	2019-03-31	2019-11-27	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10000087, 10013950, 10042682	Abdominal pain upper, Dysphagia, Swelling face
1266	140	E	ASA	86	m	1266-00707	2020-02-10	2020-02-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035664	Pneumonia
1266	140	E	ASA	86	m	1266-02507	2020-11-11	2020-11-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10012267	Dementia
1394	140	E	ASA	85	f	1394-02486	2022-11-11	2022-11-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020772	Hypertension
1406	140	E	ASA	81	m	1406-01234	2021-01-04	2021-05-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013971	Dyspnoea exertional
1781	140	E	ASA	80	f	1781-01907	2021-12-20	2022-02-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10037087, 10003549	Dyspnoea, Pruritus, Asthenia
1781	140	E	ASA	80	f	1781-01491	2021-07-07	2021-09-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013971	Dyspnoea exertional
74	140	E	no ASA	72	f	0074-01768	2021-07-05	2022-01-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
74	140	E	no ASA	72	f	0074-00229	2018-10-01	2020-01-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
200	140	E	no ASA	75	f	0200-00589	2019-06-25	2019-08-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
212	140	E	no ASA	86	m	0212-00368	2018-07-12	2018-10-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10077107	Complication associated with device
331	140	E	no ASA	85	m	0331-00051	2017-11-09	2019-06-20	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10037087	Pruritus

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
568	140	E	no ASA	75	m	0568-00098	2018-05-30	2018-05-31	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10018867	Haematuria
592	140	E	no ASA	83	f	0592-01771	2021-07-21	2021-07-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
592	140	E	no ASA	83	f	0592-02596	2021-07-22	2021-07-22	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
919	140	E	no ASA	74	m	0919-00357	2019-04-13	2019-04-26	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
919	140	E	no ASA	74	m	0919-01326	2021-06-01	2021-08-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013971	Dyspnoea exertional
919	140	E	no ASA	74	m	0919-02552	2021-06-01	2021-09-28	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10003662	Atrial flutter
919	140	E	no ASA	74	m	0919-00596	2019-10-06	2019-10-22	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved with sequelae	10005144	Bleeding varicose vein
2204	140	E	no ASA	90	f	2204-01721	2021-12-08	2022-01-25	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
2572	151	E	no ASA	76	f	2572-02535	2022-06-01	2022-06-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037884	Rash pruritic
106	153	E	ASA	79	m	0106-01923	2018-05-07	2018-09-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211, 10016173	Headache, Fall
35	153	E	no ASA	84	m	0035-00009	2016-12-15	2016-12-27	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003988	Back pain
110	154	P	ASA	78	m	0110-00427	2019-08-08	2019-08-08	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062251	Skin operation
110	154	P	ASA	78	m	0110-02217	2022-09-23	2022-09-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10080131	Skin lesion removal
110	154	P	ASA	78	m	0110-00262	2019-01-16	2019-01-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047700	Vomiting
110	154	P	ASA	78	m	0110-00263	2019-01-16	2019-01-20	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10012735	Diarrhoea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
110	154	P	ASA	78	m	0110-00655	2019-12-15	2020-04-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
297	154	P	ASA	92	f	0297-00159	2018-07-23	2018-09-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10050584	Contusion
181	154	E	ASA	77	m	0181-00042	2017-12-01	2017-12-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
181	154	E	ASA	77	m	0181-00244	2018-09-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10008479	Chest pain
181	154	E	ASA	77	m	0181-00417	2018-11-01	2019-10-16	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007739	Cataract
181	154	E	ASA	77	m	0181-01983	2022-05-31		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10058116	Nephrogenic anaemia
688	154	E	ASA	87	m	0688-00254	2018-11-13	2019-02-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
688	154	E	ASA	87	m	0688-00649	2020-02-15	2020-04-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
688	154	E	ASA	87	m	0688-00650	2019-10-21	2019-10-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
688	154	E	ASA	87	m	0688-01110	2021-01-30	2021-02-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
688	154	E	ASA	87	m	0688-01111	2021-02-01	2021-02-08	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10069339	Acute kidney injury
688	154	E	ASA	87	m	0688-01112	2021-02-08	2021-02-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011985	Decubitus ulcer
688	154	E	ASA	87	m	0688-01113	2021-02-08	2021-08-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
688	154	E	ASA	87	m	0688-01801	2022-01-24	2022-02-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10003239	Arthralgia
688	154	E	ASA	87	m	0688-02202	2022-08-16	2022-08-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007695	Carpal tunnel decompression
688	154	E	ASA	87	m	0688-00873	2020-04-28	2020-04-30	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554, 10030124	Cardiac failure, Oedema peripheral
688	154	E	ASA	87	m	0688-00874	2020-05-07		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10025005	Lumbar spinal stenosis
688	154	E	ASA	87	m	0688-00885	2020-05-07		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10025005, 10020937	Lumbar spinal stenosis, Hypoaesthesia
294	161	P	ASA	67	m	0294-00124	2018-04-10		Other event	Moderate	None, i.e. still ongoing	not related	not related	Unknown	10047340	Vertigo
294	161	P	ASA	67	m	0294-00752	2020-03-11	2020-03-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
294	161	P	ASA	67	m	0294-01869	2021-10-22	2022-05-17	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10003658, 10008479, 10050528	Atrial fibrillation, Chest pain, Ejection fraction decreased
294	161	P	ASA	67	m	0294-01873	2022-03-11	2022-03-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
294	161	P	ASA	67	m	0294-01877	2022-04-24	2022-04-24	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10069844	Device electrical impedance issue
294	161	P	ASA	67	m	0294-00170	2018-09-01	2019-01-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10072736	Rheumatic disorder
361	161	P	ASA	78	m	0361-00125	2017-12-07	2017-12-09	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10018836	Haematochezia
395	161	P	ASA	65	m	0395-01506	2021-09-13	2021-09-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011089	Coronary artery stenosis
978	161	P	ASA	78	m	0978-00384	2019-04-09	2020-06-16	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved with sequelae	10043554	Thrombocytopenia
1543	161	P	ASA	68	f	1543-01786	2021-08-24	2021-08-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2485	161	P	ASA	67	m	2485-01804	2022-03-03	2022-03-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003658, 10025482, 10043071	Atrial fibrillation, Malaise, Tachycardia
302	161	E	ASA	78	f	0302-00499	2019-11-01	2019-11-01	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10003662	Atrial flutter
302	161	E	ASA	78	f	0302-00681	2020-03-23	2020-06-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10037844	Rash
302	161	E	ASA	78	f	0302-00754	2020-01-10	2020-01-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
302	161	E	ASA	78	f	0302-01566	2021-09-20	2021-09-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10015090	Epistaxis
302	161	E	ASA	78	f	0302-00185	2018-10-01	2019-01-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
302	161	E	ASA	78	f	0302-01424	2020-10-12	2020-11-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10048959, 10013968	Peripheral swelling, Dyspnoea
459	161	E	ASA	83	m	0459-00255	2019-02-14		Other event	Moderate	None, i.e. still ongoing	not related	not related	Unknown	10028810	Nasopharyngitis
2640	167	P	ASA	91	m	2640-02144	2022-06-24	2022-09-08	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10018852	Haematoma
2518	171	P	no ASA	76	f	2518-02177	2022-09-21	2022-09-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2717	171	P	no ASA	85	f	2717-02235	2022-07-27	2022-07-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2149	171	E	ASA	75	m	2149-01650	2021-07-01	2021-12-15	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10037087	Pruritus
2149	171	E	ASA	75	m	2149-02248	2022-07-17	2022-08-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015145	Erysipelas
2149	171	E	ASA	75	m	2149-02561	2022-05-06	2022-10-06	Other event	Moderate	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10002882	Aortic aneurysm
2304	171	E	ASA	76	m	2304-01620	2021-10-15	2021-10-28	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10037087	Pruritus
2255	171	E	no ASA	71	m	2255-01798	2021-10-08	2022-06-15	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10028411	Myalgia
2255	171	E	no ASA	71	m	2255-02254	2022-09-21	2022-10-05	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10013968	Dyspnoea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1062	173	P	ASA	79	f	1062-02382	2022-07-07	2022-07-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1062	173	P	ASA	79	f	1062-02383	2022-08-23	2022-08-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10023644	Lacrimation increased
1540	173	P	ASA	71	m	1540-01327	2020-05-21	2022-06-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10057666	Anxiety disorder
2042	173	P	ASA	85	f	2042-02300	2022-06-11	2022-06-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2124	173	P	ASA	72	m	2124-02442	2022-08-28	2022-08-29	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
2342	173	P	ASA	77	m	2342-02347	2021-12-09	2021-12-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
2342	173	P	ASA	77	m	2342-02348	2022-04-13	2022-04-13	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
2342	173	P	ASA	77	m	2342-02349	2022-03-23	2022-03-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007739	Cataract
167	173	P	no ASA	67	m	0167-02341	2022-10-27	2022-10-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
176	173	P	no ASA	76	m	0176-02111	2021-06-28	2022-06-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10064930	Age-related macular degeneration
176	173	P	no ASA	76	m	0176-02112	2021-12-27	2021-12-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
176	173	P	no ASA	76	m	0176-02113	2022-05-31	2022-07-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10069200	Eyelid injury
176	173	P	no ASA	76	m	0176-02299	2022-06-20	2022-06-20	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10074431	Cancer surgery
553	173	P	no ASA	84	m	0553-00101	2018-05-16	2018-06-07	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10013946	Dyspepsia
553	173	P	no ASA	84	m	0553-02380	2022-04-14	2022-04-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
553	173	P	no ASA	84	m	0553-02381	2022-04-27	2022-05-01	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10013968	Dyspnoea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
553	173	P	no ASA	84	m	0553-02058	2021-11-15	2021-11-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025482, 10019301, 10003658, 10047289	Malaise, Heart rate decreased, Atrial fibrillation, Ventricular extrasystoles
1014	173	P	no ASA	87	m	1014-02295	2022-06-16	2022-06-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
1014	173	P	no ASA	87	m	1014-00745	2020-03-05	2020-03-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037660	Pyrexia
1014	173	P	no ASA	87	m	1014-01913	2020-12-09	2020-12-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003988	Back pain
1014	173	P	no ASA	87	m	1014-02281	2021-10-07	2021-10-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
1014	173	P	no ASA	87	m	1014-00269	2019-03-07	2019-03-18	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10017853	Gastritis
1067	173	P	no ASA	67	m	1067-01324	2020-02-11	2020-02-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
1319	173	P	no ASA	84	m	1319-01409	2020-11-12	2020-11-12	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
2506	173	P	no ASA	77	f	2506-02384	2022-05-10	2022-05-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
2506	173	P	no ASA	77	f	2506-02385	2022-10-19	2022-10-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
1712	173	E	ASA	65	m	1712-01901	2022-03-07	2022-03-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10074625	Large intestinal polypectomy
2568	173	E	ASA	84	m	2568-02244	2022-03-31		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10047895	Weight decreased
314	173	E	no ASA	70	f	0314-00641	2020-02-25	2020-02-25	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
314	173	E	no ASA	70	f	0314-01293	2020-02-25	2020-02-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
975	173	E	no ASA	86	m	0975-02530	2021-01-01	2021-05-17	Bleeding event/haematoma	Mild	Permanently discontinued	related	related	Recovered/resolved	10018852, 10015090	Haematoma, Epistaxis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
975	173	E	no ASA	86	m	0975-01102	2021-01-04	2021-02-07	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
1080	173	E	no ASA	69	f	1080-01547	2021-09-29	2021-09-29	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1080	173	E	no ASA	69	f	1080-02261	2022-09-21	2022-09-21	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10011844	Dacryocystitis
1716	173	E	no ASA	83	m	1716-02345	2022-07-22		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10057668	Cognitive disorder
1716	173	E	no ASA	83	m	1716-02346	2022-10-22	2022-10-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10005911, 10013968	Body temperature increased, Dyspnoea
2062	173	E	no ASA	77	m	2062-02114	2021-11-10	2021-11-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10004146	Basal cell carcinoma
2062	173	E	no ASA	77	m	2062-02518	2021-10-28	2022-10-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013968	Dyspnoea
2062	173	E	no ASA	77	m	2062-02278	2022-06-02	2022-06-02	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
2062	173	E	no ASA	77	m	2062-02279	2022-09-29	2022-09-29	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
2062	173	E	no ASA	77	m	2062-02280	2022-10-02	2022-10-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047571	Visual impairment
2375	173	E	no ASA	67	f	2375-02558	2022-03-01	2022-03-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1008	174	P	ASA	72	f	1008-00429	2019-07-09	2019-07-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1008	174	P	ASA	72	f	1008-00430	2019-07-09		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10037032	Proteinuria
1925	174	P	ASA	74	m	1925-02418	2022-07-13		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10012601	Diabetes mellitus
2176	174	P	ASA	67	f	2176-02403	2021-10-29	2022-11-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10044565	Tremor
2176	174	P	ASA	67	f	2176-02404	2022-06-28		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10013573	Dizziness
498	174	P	no ASA	75	m	0498-00891	2020-07-24	2020-07-24	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
498	174	P	no ASA	75	m	0498-01367	2020-04-27	2020-04-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
498	174	P	no ASA	75	m	0498-02110	2021-04-28	2021-09-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1414	174	P	no ASA	84	f	1414-01369	2020-12-14	2020-12-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
613	174	E	ASA	65	m	0613-00406	2019-06-03	2019-06-03	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10023825	Laryngeal cancer
613	174	E	ASA	65	m	0613-01100	2020-05-16	2020-05-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10064685	Device occlusion
613	174	E	ASA	65	m	0613-02532	2020-06-03	2020-06-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047700	Vomiting
613	174	E	ASA	65	m	0613-02533	2020-06-08	2020-06-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10069339	Acute kidney injury
2588	174	E	ASA	75	m	2588-02401	2022-09-15	2022-09-15	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
2588	174	E	ASA	75	m	2588-02402	2022-06-15	2022-06-15	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
172	174	E	no ASA	78	f	0172-01364	2021-04-24	2021-04-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10050819	Musculoskeletal chest pain
172	174	E	no ASA	78	f	0172-01999	2022-04-28	2022-04-28	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062132	Tooth extraction
172	174	E	no ASA	78	f	0172-00015	2017-06-09	2017-11-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1487	174	E	no ASA	74	m	1487-00778	2020-06-03	2020-06-25	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10038019	Rectal adenocarcinoma
1487	174	E	no ASA	74	m	1487-02298	2021-05-01	2021-05-01	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062132	Tooth extraction
1487	174	E	no ASA	74	m	1487-01095	2020-12-16	2020-12-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
1487	174	E	no ASA	74	m	1487-02310	2022-01-25	2022-06-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10036975, 10004857, 10060862, 10061544	Prostatic specific antigen increased, Biopsy prostate, Prostate cancer, Radiotherapy to prostate
1672	174	E	no ASA	75	f	1672-01373	2020-10-26	2020-10-31	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10047700, 10028813	Vomiting, Nausea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1672	174	E	no ASA	75	f	1672-01525	2021-07-15	2021-09-29	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10018358	Glomerular filtration rate decreased
1672	174	E	no ASA	75	f	1672-02423	2022-09-07		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10002855	Anxiety
1672	174	E	no ASA	75	f	1672-02421	2021-02-08	2021-02-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2456	175	P	ASA	78	m	2456-02039	2022-06-01	2022-09-20	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10016256, 10017577	Fatigue, Gait disturbance
515	175	P	no ASA	81	f	0515-02541	2019-03-29	2019-03-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
2536	175	P	no ASA	76	f	2536-01833	2022-03-23	2022-09-12	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10016256	Fatigue
487	175	E	no ASA	74	f	0487-00440	2019-04-12	2019-05-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007739	Cataract
487	175	E	no ASA	74	f	0487-02540	2021-07-21	2021-07-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1035	175	E	no ASA	85	m	1035-00930	2020-06-03	2020-12-02	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10003662	Atrial flutter
510	179	P	ASA	85	m	0510-01530	2021-07-20	2021-09-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
510	179	P	ASA	85	m	0510-01531	2021-09-17	2021-11-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10022116	Fall, Injury
510	179	P	ASA	85	m	0510-00676	2019-12-04	2019-12-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046306	Upper respiratory tract infection
510	179	P	ASA	85	m	0510-01160	2021-01-07	2021-04-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554, 10062352	Cardiac failure, Respiratory tract infection
308	179	P	no ASA	82	f	0308-01182	2020-12-22	2021-05-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10044055	Toothache
1182	179	P	no ASA	83	f	1182-01028	2020-07-13	2020-12-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
1182	179	P	no ASA	83	f	1182-00763	2020-01-10	2020-06-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022592	International normalised ratio abnormal

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1182	179	P	no ASA	83	f	1182-00764	2020-01-10	2020-06-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
1868	179	P	no ASA	72	m	1868-01133	2021-03-04	2021-03-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549, 10022437	Asthenia, Insomnia
2101	179	P	no ASA	77	f	2101-02387	2022-10-26	2022-10-27	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10012431	Dermatitis
1112	179	E	ASA	68	m	1112-00943	2020-10-27	2020-10-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002515, 10037660	Animal bite, Pyrexia
1112	179	E	ASA	68	m	1112-00944	2020-11-02	2020-11-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048762	Tooth infection
1147	179	E	ASA	85	m	1147-00543	2019-09-24	2019-09-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059242	Jaw operation
1147	179	E	ASA	85	m	1147-01019	2020-08-14	2020-09-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039674	Sciatica
1147	179	E	ASA	85	m	1147-01020	2020-08-21	2020-09-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741	Conjunctivitis
1147	179	E	ASA	85	m	1147-01021	2020-09-26	2020-10-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
1147	179	E	ASA	85	m	1147-01025	2020-12-10	2020-12-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1147	179	E	ASA	85	m	1147-01274	2020-07-01	2020-07-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025482	Malaise
1147	179	E	ASA	85	m	1147-01277	2020-06-15	2020-06-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
2193	179	E	ASA	81	m	2193-01442	2021-07-26	2021-07-26	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10001903	Amaurosis fugax
1132	179	E	no ASA	78	f	1132-00698	2019-11-28	2020-04-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1132	179	E	no ASA	78	f	1132-01240	2021-05-11	2021-05-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1270	179	E	no ASA	84	f	1270-01482	2021-06-07		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10046851	Uveitis
1331	189	E	ASA	82	f	1331-00911	2020-01-20	2020-01-27	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10019211, 10013573, 10028813	Headache, Dizziness, Nausea
633	195	P	ASA	84	f	0633-01451	2020-09-22		Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10057668	Cognitive disorder
1004	195	P	ASA	70	m	1004-01099	2021-02-10	2021-02-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003411	Arthroscopy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
396	195	P	no ASA	71	m	0396-00267	2018-07-17	2019-01-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012735	Diarrhoea
396	195	P	no ASA	71	m	0396-02230	2022-06-01	2023-01-17	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10038435	Renal failure
396	195	P	no ASA	71	m	0396-02553	2021-12-14	2022-10-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016256	Fatigue
396	195	P	no ASA	71	m	0396-00087	2018-03-21	2018-03-21	Other event	Mild	Permanently discontinued due to this event	related	not related	Recovered/resolved	10000087	Abdominal pain upper
1233	195	P	no ASA	82	m	1233-00576	2019-12-29	2019-12-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10006451	Bronchitis
398	195	E	ASA	71	m	0398-01449	2021-02-15	2021-08-27	Other event	Very severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10040808	Skin cancer
519	195	E	ASA	82	m	0519-01450	2021-01-22		Other event	Very severe	Permanently discontinued due to this event	not related	not related	Event ongoing	10049438	General physical health deterioration
519	195	E	ASA	82	m	0519-01456	2020-10-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10049947	Lumbar vertebral fracture
617	195	E	ASA	70	m	0617-00910	2020-08-01	2020-12-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003662	Atrial flutter
617	195	E	ASA	70	m	0617-00291	2019-04-02	2019-06-30	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10050584	Contusion
283	195	E	no ASA	82	m	0283-00028	2017-10-24	2017-11-02	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10008786	Choroidal haemorrhage
283	195	E	no ASA	82	m	0283-00029	2017-10-24	2017-10-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
283	195	E	no ASA	82	m	0283-00281	2019-01-24	2019-02-15	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002034	Anaemia
283	195	E	no ASA	82	m	0283-00282	2019-02-21	2019-03-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
1857	198	P	ASA	73	m	1857-01684	2021-01-05	2021-01-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062132	Tooth extraction

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2148	198	P	ASA	81	m	2148-01665	2021-10-15	2021-10-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
144	198	P	no ASA	72	f	0144-00297	2019-03-21		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10067116, 10003210	Carotid arteriosclerosis, Arteriosclerosis
1188	202	P	ASA	76	m	1188-00844	2020-05-28	2020-05-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
1125	202	P	no ASA	79	m	1125-01481	2019-08-16	2019-08-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061852	Eye operation
556	202	E	ASA	88	f	0556-00115	2018-05-20	2018-06-16	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10000087, 10033425	Abdominal pain upper, Pain in extremity
556	202	E	ASA	88	f	0556-00116	2018-05-19	2018-05-20	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
348	202	E	no ASA	80	f	0348-00111	2017-12-28	2018-01-27	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10046910	Vaginal haemorrhage
348	202	E	no ASA	80	f	0348-00112	2017-12-28	2018-01-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000087	Abdominal pain upper
348	202	E	no ASA	80	f	0348-00113	2017-12-28	2018-01-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037549	Purpura
419	202	E	no ASA	69	f	0419-00425	2019-01-24	2019-01-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
419	202	E	no ASA	69	f	0419-00426	2019-01-01	2019-08-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
184	205	P	ASA	88	m	0184-00019	2017-06-20	2017-06-24	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10027141	Melaena
285	205	P	ASA	69	m	0285-00625	2018-12-24	2018-12-24	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
336	205	E	ASA	77	m	0336-00321	2019-04-25	2019-04-26	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10038063	Rectal haemorrhage
946	205	E	ASA	72	m	0946-00473	2019-01-29	2019-02-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
516	208	P	no ASA	81	m	0516-01136	2020-12-15	2021-02-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10047895, 10000081, 10061428	Weight decreased, Abdominal pain, Decreased appetite
524	208	P	no ASA	80	m	0524-00498	2019-09-20		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10012378	Depression
524	208	P	no ASA	80	m	0524-00986	2020-08-16	2020-08-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074414	Catheter management
1362	208	E	ASA	72	m	1362-01909	2022-02-11	2022-02-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074625	Large intestinal polypectomy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1362	208	E	ASA	72	m	1362-01603	2021-11-12	2021-11-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1306	208	E	no ASA	82	m	1306-00926	2020-09-18		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10040943	Skin ulcer
1449	208	E	no ASA	66	m	1449-02548	2019-12-20	2019-12-20	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10012735	Diarrhoea
79	209	P	ASA	82	m	0079-00604	2019-03-05	2019-03-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
79	209	P	ASA	82	m										10007661	Cardioversion
79	209	P	ASA	82	m	0079-00593	2019-11-29	2019-11-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061536	Parkinson's disease
141	209	P	no ASA	74	f	0141-02546	2018-05-22	2018-05-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049548	Knee operation
141	209	P	no ASA	74	f	0141-00966	2020-08-18	2020-10-19	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006187	Breast cancer
141	209	P	no ASA	74	f	0141-00979	2020-10-19	2020-10-19	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10004797	Biopsy lymph gland
141	209	P	no ASA	74	f	0141-00530	2019-03-07	2019-03-07	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049548	Knee operation
1501	209	P	no ASA	75	m	1501-02454	2022-02-25	2022-11-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10027175	Memory impairment
1501	209	P	no ASA	75	m	1501-01088	2020-08-01	2020-12-01	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10019211	Headache
1501	209	P	no ASA	75	m	1501-01743	2021-09-09	2021-09-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10009033, 10013395	Chronic obstructive pulmonary disease, Disorientation
143	211	P	ASA	79	m	0143-02562	2019-11-18		Other event	Severe	Permanently discontinued due to this event	not related	not related	Event ongoing	10027457	Metastases to liver
250	211	P	ASA	82	m	0250-00045	2017-12-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Unknown	10021097	Hypotension
250	211	P	ASA	82	m	0250-00046	2018-01-15	2018-02-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
250	211	P	ASA	82	m	0250-00180	2018-08-16	2019-02-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10007554	Cardiac failure
513	211	P	no ASA	74	m	0513-00163	2018-04-10	2019-04-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895	Weight decreased

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
513	211	P	no ASA	74	m	0513-00164	2018-05-01	2019-04-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010774	Constipation
513	211	P	no ASA	74	m	0513-02243	2022-03-04	2022-03-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
356	211	E	ASA	87	m	0356-00088	2018-01-02	2018-01-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
49	217	P	no ASA	74	m	0049-00012	2017-01-23	2017-05-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
49	217	P	no ASA	74	m	0049-00013	2017-03-13	2017-11-27	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049128	Shoulder fracture
49	217	P	no ASA	74	m	0049-00556	2018-12-25	2019-12-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
49	217	P	no ASA	74	m	0049-00980	2020-05-18	2020-06-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988, 10003239	Back pain, Arthralgia
49	217	P	no ASA	74	m	0049-02266	2022-06-21	2022-06-24	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10058818, 10005140	Skin laceration, Bleeding time prolonged
293	226	P	ASA	76	m	0293-00811	2020-04-23	2020-04-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383, 10013968	Angina pectoris, Dyspnoea
1434	226	P	ASA	87	f	1434-00813	2020-06-10	2020-06-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
2120	226	E	ASA	77	m	2120-01523	2021-06-01	2021-09-28	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10019211	Headache
2639	226	E	ASA	74	m	2639-02556	2022-07-01	2022-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049565, 10070255	Muscle fatigue, Coronavirus test positive
1164	226	E	no ASA	70	f	1164-00812	2019-12-06	2019-12-06	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10006187	Breast cancer
1019	232	E	ASA	81	m	1019-00442	2019-04-01	2019-07-02	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018836	Haematochezia
749	232	E	no ASA	71	m	0749-01289	2019-11-17	2019-12-04	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10047249	Venous thrombosis
747	264	P	ASA	71	m	0747-00289	2019-01-29	2019-02-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
747	264	P	ASA	71	m	0747-00287	2019-04-03	2019-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
747	264	P	ASA	71	m	0747-00288	2019-01-01	2019-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
747	264	P	ASA	71	m	0747-00668	2020-02-28	2020-03-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10036099	Polymyalgia rheumatica
747	264	P	ASA	71	m	0747-00463	2019-05-10	2019-05-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
905	264	P	ASA	70	m	0905-02577	2022-06-02	2022-06-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037660	Pyrexia
905	264	P	ASA	70	m	0905-02578	2022-08-29	2022-09-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017533	Fungal infection
408	264	P	no ASA	81	f	0408-00231	2018-04-06	2018-04-06	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062132	Tooth extraction
408	264	P	no ASA	81	f	0408-01642	2019-05-15	2019-05-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010774	Constipation
408	264	P	no ASA	81	f	0408-00779	2020-04-07	2020-04-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015929	Eye infection
408	264	P	no ASA	81	f	0408-00780	2020-07-01	2020-07-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10015929	Eye infection
408	264	P	no ASA	81	f	0408-02263	2022-04-05	2022-04-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019196	Head injury
408	264	P	no ASA	81	f	0408-01056	2020-07-01	2020-10-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10041541	Spinal compression fracture
408	264	P	no ASA	81	f	0408-01058	2020-04-06	2021-01-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10025409	Macular degeneration
1544	264	P	no ASA	80	m	1544-01539	2021-09-23	2021-10-20	Other event	Very severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10027457, 10009944	Metastases to liver, Colon cancer
1544	264	P	no ASA	80	m	1544-01648	2020-05-29	2020-08-17	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007697	Carpal tunnel syndrome
1544	264	P	no ASA	80	m	1544-01649	2021-07-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10031161	Osteoarthritis
583	264	E	ASA	77	m	0583-00212	2018-10-10	2018-12-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10019196	Fall, Head injury
583	264	E	ASA	77	m	0583-00551	2019-11-15	2019-12-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10002034	Anaemia
583	264	E	ASA	77	m	0583-00552	2019-10-19	2019-12-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10003882	Axonal neuropathy
583	264	E	ASA	77	m	0583-00553	2019-11-18	2019-12-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
583	264	E	ASA	77	m	0583-00554	2019-11-12	2019-11-17	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10006451	Bronchitis
583	264	E	ASA	77	m	0583-01691	2018-10-28	2018-10-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10019196	Fall, Head injury
583	264	E	ASA	77	m	0583-01694	2018-10-28	2018-11-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10058818	Fall, Skin laceration

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
583	264	E	ASA	77	m	0583-01695	2019-07-02	2019-07-02	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
583	264	E	ASA	77	m	0583-01005	2020-12-03	2020-12-10	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
583	264	E	ASA	77	m	0583-01698	2020-03-12	2020-12-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10019641, 10053219	Hepatic cirrhosis, Non-alcoholic steatohepatitis
583	264	E	ASA	77	m	0583-01668	2021-09-30	2021-10-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10000614	Actinic keratosis
583	264	E	ASA	77	m	0583-01669	2018-06-01	2021-05-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10025650	Malignant melanoma
583	264	E	ASA	77	m	0583-00335	2019-03-15	2019-06-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
583	264	E	ASA	77	m	0583-00336	2019-04-09	2019-11-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10011224	Cough
583	264	E	ASA	77	m	0583-00337	2019-04-16	2019-04-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002034	Anaemia
583	264	E	ASA	77	m	0583-00338	2019-06-06	2020-06-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
583	264	E	ASA	77	m	0583-00733	2020-02-11	2020-05-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10056091	Varices oesophageal
583	264	E	ASA	77	m	0583-00735	2019-12-27	2020-01-07	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011224	Cough
583	264	E	ASA	77	m	0583-00737	2019-07-01	2020-12-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018852	Haematoma
583	264	E	ASA	77	m	0583-01700	2021-03-17		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10028334	Muscle spasms
1330	264	E	ASA	65	f	1330-00671	2019-11-22	2020-01-10	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
1330	264	E	ASA	65	f	1330-01681	2021-02-12	2021-03-20	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018867	Haematuria
381	264	E	no ASA	76	m	0381-00089	2018-02-01	2018-07-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
381	264	E	no ASA	76	m	0381-00768	2020-06-17		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10017367	Frequent bowel movements
381	264	E	no ASA	76	m	0381-01591	2020-01-02	2020-01-02	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020751	Hypersensitivity
381	264	E	no ASA	76	m	0381-01592	2020-03-31	2020-04-07	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063188	Post procedural haematoma
381	264	E	no ASA	76	m	0381-01339	2021-04-09		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10002882	Aortic aneurysm
381	264	E	no ASA	76	m	0381-01593	2021-01-14	2021-03-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10048218, 10000614	Xeroderma, Actinic keratosis
381	264	E	no ASA	76	m	0381-01664	2021-11-11	2021-12-01	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016256	Fatigue
381	264	E	no ASA	76	m	0381-01759	2021-11-11	2021-11-24	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
381	264	E	no ASA	76	m	0381-02576	2022-01-10		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10060862	Prostate cancer
381	264	E	no ASA	76	m	0381-00264	2018-10-16		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10061761	Chondrocalcinosis
381	264	E	no ASA	76	m	0381-00517	2019-11-01	2019-11-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10003239	Arthralgia
381	264	E	no ASA	76	m	0381-01029	2020-12-01	2020-12-15	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10015090	Epistaxis
1753	264	E	no ASA	80	f	1753-02575	2022-06-15	2022-09-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
937	267	E	ASA	86	f	0937-00719	2019-06-25	2019-07-09	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015926	Eye haemorrhage
215	308	P	ASA	79	m	0215-02429	2020-02-01		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10007554	Cardiac failure
21	308	P	no ASA	68	f	0021-00858	2019-10-10	2020-01-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
21	308	P	no ASA	68	f	0021-00034	2017-09-04	2021-05-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
21	308	P	no ASA	68	f	0021-00138	2018-05-18	2018-05-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
267	308	P	no ASA	78	m	0267-00854	2019-09-01	2020-09-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007739	Cataract
217	308	E	no ASA	72	m	0217-00038	2017-12-08		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10020903	Hyperuricaemia
72	377	P	ASA	82	m	0072-00398	2019-03-05		Other event	Mild	None, i.e. still ongoing	not related	not related	Death	10030194	Oesophageal stenosis
72	377	P	ASA	82	m	0072-01494	2017-04-05	2021-07-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10027733	Mitral valve stenosis
72	377	P	ASA	82	m	0072-01495	2017-04-05	2021-07-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002918	Aortic valve stenosis
72	377	P	ASA	82	m	0072-00424	2019-03-05	2021-07-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006895	Cachexia
175	377	P	ASA	84	f	0175-02161	2022-06-16	2022-06-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
175	377	P	ASA	84	f	0175-02119	2022-05-23	2022-06-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
83	377	P	no ASA	84	m	0083-00110	2018-06-01	2018-06-10	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10058818	Skin laceration
83	377	P	no ASA	84	m	0083-00637	2019-12-24	2019-12-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
163	406	P	ASA	85	f	0163-02516	2021-08-01	2021-08-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10051085	Endodontic procedure
163	406	P	ASA	85	f	0163-02515	2021-10-06	2021-10-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018627	Gout
220	414	P	ASA	81	m	0220-01663	2021-06-29	2021-06-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1541	414	P	ASA	77	m	1541-01116	2020-10-29	2020-11-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1541	414	P	ASA	77	m	1541-01709	2021-05-12	2022-03-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1845	414	P	ASA	81	m	1845-01974	2022-05-10	2022-09-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1892	414	P	ASA	66	m	1892-01813	2022-01-18	2022-01-18	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018276	Gingival bleeding
1892	414	P	ASA	66	m	1892-02180	2022-05-11	2022-05-11	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028024	Mouth haemorrhage
2571	414	P	ASA	68	m	2571-02508	2022-04-19	2022-11-17	Other event	Moderate	Permanently discontinued	not related	not related	Recovered/resolved	10016256	Fatigue

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
988	414	P	no ASA	75	m	0988-00767	2020-01-29	2020-01-29	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015926	Eye haemorrhage
1626	414	P	no ASA	88	f	1626-01555	2021-07-07	2021-09-13	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10006187	Breast cancer
1626	414	P	no ASA	88	f	1626-01757	2021-12-06	2021-12-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10047513	Dizziness, Vision blurred
1626	414	P	no ASA	88	f	1626-01712	2021-06-04		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10057668	Cognitive disorder
1626	414	P	no ASA	88	f	1626-01802	2021-05-22	2021-05-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239, 10018735	Arthralgia, Groin pain
1941	414	P	no ASA	73	m	1941-01404	2021-03-23	2021-06-26	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013946	Dyspepsia
670	414	E	ASA	83	f	0670-02509	2022-10-12	2022-10-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
970	414	E	ASA	93	m	0970-00505	2019-04-08	2019-04-08	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10062132, 10055798	Tooth extraction, Haemorrhage
970	414	E	ASA	93	m	0970-00766	2019-05-29	2019-06-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039099	Rhinoplasty
970	414	E	ASA	93	m	0970-01706	2021-02-18		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10013968	Dyspnoea
1610	414	E	ASA	85	m	1610-01711	2021-12-09	2022-01-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016256	Fatigue
2469	414	E	ASA	75	m	2469-02178	2022-08-18	2022-08-19	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10018867, 10015090	Haematuria, Epistaxis
246	414	E	no ASA	98	f	0246-00765	2020-02-25	2020-08-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
246	414	E	no ASA	98	f	0246-00856	2020-05-22	2021-08-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10002034	Anaemia
1510	414	E	no ASA	68	m	1510-01707	2021-03-03	2021-03-17	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10018867	Haematuria
125	416	P	no ASA	76	f	0125-00162	2018-05-10	2018-05-20	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10015090	Epistaxis
494	419	P	ASA	75	f	0494-02146	2020-11-10	2020-11-20	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10035664	Pneumonia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
244	419	P	no ASA	68	m	0244-01394	2019-03-08	2019-03-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1260	419	E	ASA	70	m	1260-00572	2019-09-27	2019-12-13	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10019705	Hepatic pain
2083	419	E	ASA	79	m	2083-02597	2021-11-09	2021-11-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
323	419	E	no ASA	78	f	0323-01791	2021-09-01		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Unknown	10016256, 10013968	Fatigue, Dyspnoea
790	421	P	ASA	65	m	0790-01314	2020-06-24	2020-06-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018852	Haematoma
1000	421	P	ASA	78	m	1000-02264	2022-03-28	2022-03-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968, 10013573	Dyspnoea, Dizziness
1000	421	P	ASA	78	m	1000-02265	2022-06-29	2022-07-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10040943	Skin ulcer
1418	421	P	ASA	80	f	1418-02450	2022-08-31	2022-09-02	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015926	Eye haemorrhage
1729	421	P	ASA	71	f	1729-02075	2022-03-16	2022-03-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772, 10016173	Syncope, Fall
1759	421	P	ASA	77	m	1759-01121	2020-10-27	2020-10-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010007	Colonoscopy
1759	421	P	ASA	77	m	1759-01793	2022-03-04	2022-03-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10061544	Radiotherapy to prostate
1759	421	P	ASA	77	m	1759-02138	2022-03-12	2022-03-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1759	421	P	ASA	77	m	1759-01478	2021-06-10	2021-06-10	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10056619, 10004857, 10078223	Rectal ultrasound, Biopsy prostate, Magnetic resonance imaging
1979	421	P	ASA	76	m	1979-02181	2022-09-13	2022-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1979	421	P	ASA	76	m	1979-01769	2021-09-07	2021-09-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010007	Colonoscopy
2111	421	P	ASA	79	f	2111-02448	2022-09-15	2022-09-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
2111	421	P	ASA	79	f	2111-02449	2022-09-16	2022-09-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10019196, 10018852	Fall, Head injury, Haematoma
2325	421	P	ASA	78	m	2325-01627	2021-11-05	2021-11-12	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10016256, 10037087, 10005746	Fatigue, Pruritus, Blood pressure fluctuation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2489	421	P	ASA	85	f	2489-02287	2022-09-05	2022-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772, 10013968, 10008479	Hypertension, Dyspnoea, Chest pain
55	421	P	no ASA	76	m	0055-02424	2022-06-09	2022-06-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10074414	Catheter management
55	421	P	no ASA	76	m	0055-02425	2022-06-23	2022-06-23	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867, 10000081, 10074414	Haematuria, Abdominal pain, Catheter management
55	421	P	no ASA	76	m	0055-02426	2022-07-07	2022-07-07	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867	Haematuria
544	421	P	no ASA	79	m	0544-00081	2018-05-07	2018-05-18	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10003239	Arthralgia
544	421	P	no ASA	79	m	0544-02361	2022-10-23	2022-10-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173, 10019196	Fall, Head injury
1116	421	P	no ASA	75	f	1116-02362	2022-06-23	2022-06-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000087, 10028813, 10047700, 10016766	Abdominal pain upper, Nausea, Vomiting, Flatulence
1116	421	P	no ASA	75	f	1116-02363	2022-10-06	2022-10-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005156, 10012493	Blepharoplasty, Dermatochalasis
1116	421	P	no ASA	75	f	1116-02559	2022-03-07	2022-03-07	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10006586	Bunion operation
2264	421	P	no ASA	69	f	2264-02153	2022-08-09	2022-08-09	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10064210, 10050584, 10003239	Bone fissure, Contusion, Arthralgia
2616	421	P	no ASA	86	f	2616-02379	2022-09-03	2022-09-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017888, 10020772	Gastroenteritis, Hypertension
77	421	E	ASA	65	m	0077-00021	2017-03-22	2017-07-13	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10005140	Bleeding time prolonged
77	421	E	ASA	65	m	0077-00817	2020-06-29	2020-06-29	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10043913	Toe amputation
77	421	E	ASA	65	m	0077-02481	2022-01-16	2022-01-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
77	421	E	ASA	65	m	0077-02256	2022-08-05		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10011985, 10041955	Decubitus ulcer, Stasis dermatitis
503	421	E	ASA	75	m	0503-02240	2022-06-17	2022-06-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968, 10011224	Dyspnoea, Cough
1602	421	E	ASA	72	m	1602-01313	2020-07-29	2020-08-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10033425, 10033775	Pain in extremity, Paraesthesia
1883	421	E	ASA	73	m	1883-02102	2021-03-17	2021-03-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895	Weight decreased
1899	421	E	ASA	91	m	1899-02152	2022-09-19		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013971, 10040984	Dyspnoea exertional, Sleep disorder
1899	421	E	ASA	91	m	1899-02184	2022-07-13	2022-08-16	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013971, 10033557	Dyspnoea exertional, Palpitations
1934	421	E	ASA	71	m	1934-01736	2021-10-04	2021-10-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003119	Arrhythmia
1956	421	E	ASA	75	m	1956-01316	2021-02-14	2021-02-28	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10013573, 10025482, 10019211	Dizziness, Malaise, Headache
2033	421	E	ASA	81	m	2033-02343	2022-05-10	2022-05-10	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173, 10019196	Fall, Head injury
2034	421	E	ASA	93	m	2034-02245	2022-05-20	2022-05-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003549, 10016256	Asthenia, Fatigue
2034	421	E	ASA	93	m	2034-02246	2022-09-22	2022-09-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479	Chest pain
2034	421	E	ASA	93	m	2034-02247	2022-05-17	2022-05-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10010774	Constipation
2544	421	E	ASA	80	m	2544-02165	2022-04-27	2022-04-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10022562	Intermittent claudication
2544	421	E	ASA	80	m	2544-02166	2022-05-12	2022-05-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10003800, 10033371	Auricular swelling, Pain
2596	421	E	ASA	84	f	2596-02028	2022-04-28	2022-05-03	Other event	Mild	Permanently discontinued	not related	related	Recovered/resolved	10028813	Nausea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
155	421	E	no ASA	80	f	0155-00129	2017-11-11	2017-11-11	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10047340	Vertigo
290	421	E	no ASA	71	m	0290-02226	2022-04-11		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10028756	Nasal polyps
290	421	E	no ASA	71	m	0290-02227	2022-05-23		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10009137	Chronic sinusitis
907	421	E	no ASA	72	m	0907-02078	2022-07-06	2022-07-06	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10023204, 10016173	Joint dislocation, Fall
1380	421	E	no ASA	66	m	1380-02354	2022-05-12	2022-05-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039674	Sciatica
1380	421	E	no ASA	66	m	1380-02355	2022-07-13	2022-07-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10009192	Circulatory collapse
1380	421	E	no ASA	66	m	1380-02356	2022-06-14	2022-06-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031127, 10042772	Orthostatic hypotension, Syncope
1380	421	E	no ASA	66	m	1380-02357	2022-07-20	2022-07-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10028372, 10016173	Dizziness, Muscular weakness, Fall
1584	421	E	no ASA	82	f	1584-02372	2022-10-11	2022-10-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000381	Accidental overdose
1584	421	E	no ASA	82	f	1584-02373	2022-06-03	2022-06-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
1933	421	E	no ASA	75	f	1933-02041	2021-07-03	2021-07-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
778	426	P	ASA	83	m	0778-00275	2019-02-05	2019-02-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772, 10047290	Syncope, Ventricular fibrillation
569	426	P	no ASA	78	m	0569-00533	2019-04-01	2020-01-02	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10010774	Constipation
569	426	P	no ASA	78	m	0569-00995	2020-10-22	2020-11-22	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867, 10005003	Haematuria, Bladder cancer
2534	428	P	no ASA	68	m	2534-02154	2022-06-11	2022-08-15	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10075322	Device inappropriate shock delivery
721	428	E	ASA	73	m	0721-02410	2022-11-17	2022-11-17	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10043071	Tachycardia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
721	428	E	ASA	73	m	0721-01818	2021-06-15	2022-02-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10022562	Intermittent claudication
2350	428	E	ASA	68	m	2350-01930	2022-05-04	2022-05-04	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10017955, 10074625	Gastrointestinal haemorrhage, Large intestinal polypectomy
2350	428	E	ASA	68	m	2350-02398	2022-06-14	2022-06-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003662, 10007661	Atrial flutter, Cardioversion
2350	428	E	ASA	68	m	2350-02399	2022-09-07	2022-09-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003662, 10031127	Atrial flutter, Orthostatic hypotension
326	428	E	no ASA	84	f	0326-00192	2018-01-03	2018-08-13	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10019022	Haemorrhoids
326	428	E	no ASA	84	f	0326-00076	2017-11-14	2018-08-08	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10019022	Haemorrhoids
326	428	E	no ASA	84	f	0326-00193	2018-01-03	2018-08-13	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10019022	Haemorrhoids
652	445	P	ASA	92	f	0652-02543	2020-06-08	2022-03-08	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
785	445	P	ASA	82	m	0785-00597	2019-04-24		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10002034	Anaemia
786	445	P	ASA	77	m	0786-01267	2019-12-02	2020-02-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047340	Vertigo
2324	445	P	ASA	75	f	2324-02434	2021-11-30	2021-11-30	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10003239	Arthralgia
2324	445	P	ASA	75	f	2324-02435	2022-10-14	2022-10-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2674	445	P	ASA	87	m	2674-02436	2022-08-30	2022-09-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
650	445	E	ASA	79	f	0650-00197	2018-11-22	2018-11-22	Other event	Mild	Permanently discontinued	not related	not related	Recovered/resolved	10033557	Palpitations

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
650	445	E	ASA	79	f	0650-01279	2021-02-26	2021-03-13	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
650	445	E	ASA	79	f	0650-00421	2019-03-02	2019-03-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10065608	Percutaneous coronary intervention
650	445	E	ASA	79	f	0650-00879	2020-07-01	2020-09-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049447	Tachyarrhythmia
650	445	E	ASA	79	f	0650-01265	2020-05-04	2021-06-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002034	Anaemia
651	445	E	ASA	94	m	0651-00599	2019-02-03	2019-02-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211, 10025482	Headache, Malaise
651	445	E	ASA	94	m	0651-00636	2020-01-27	2020-01-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047289	Ventricular extrasystoles
651	445	E	ASA	94	m	0651-01266	2020-10-01	2020-10-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10047289	Dyspnoea, Ventricular extrasystoles
651	445	E	ASA	94	m	0651-00878	2020-06-01	2020-06-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension
651	445	E	ASA	94	m	0651-01476	2021-06-14	2021-06-25	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10018867	Haematuria
1506	445	E	ASA	79	m	1506-02542	2021-12-13		Other event	Severe	None, i.e. still ongoing	not related	not related	Event ongoing	10020039, 10047895, 10017853	Hiccups, Weight decreased, Gastritis
1507	445	E	ASA	85	m	1507-02430	2021-04-27	2021-04-27	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062132	Tooth extraction
1574	445	E	ASA	82	f	1574-00933	2020-06-22	2020-06-22	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10025005	Lumbar spinal stenosis
1574	445	E	ASA	82	f	1574-02431	2021-10-17	2021-10-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028334, 10008479	Muscle spasms, Chest pain
1574	445	E	ASA	82	f	1574-01283	2020-06-22		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10003988	Back pain
2209	445	E	no ASA	84	f	2209-02433	2022-01-21	2022-02-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
196	470	E	ASA	84	f	0196-00126	2017-11-06	2017-11-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
196	470	E	ASA	84	f	0196-00127	2018-05-01	2018-06-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10060820	Joint injury
196	470	E	ASA	84	f	0196-00364	2019-04-29	2019-05-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011781	Cystitis
196	470	E	ASA	84	f	0196-00760	2020-05-23	2020-05-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10075049	Peripheral venous disease

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
222	470	E	ASA	80	m	0222-00108	2018-02-07	2018-04-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048038, 10061225	Wound infection, Limb injury
529	470	E	ASA	79	m	0529-00179	2018-09-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10004446	Benign prostatic hyperplasia
529	470	E	ASA	79	m	0529-00924	2020-10-06	2020-10-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10004146	Basal cell carcinoma
529	470	E	ASA	79	m	0529-00925	2020-09-24	2020-10-19	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
529	470	E	ASA	79	m	0529-00296	2019-04-17		Other event	Mild	None, i.e. still ongoing	related	related	Event ongoing	10043554	Thrombocytopenia
304	470	E	no ASA	80	m	0304-00173	2018-09-01	2021-10-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040984	Sleep disorder
304	470	E	no ASA	80	m	0304-00487	2019-09-30	2019-10-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012601	Diabetes mellitus
76	479	P	ASA	67	f	0076-00020	2017-01-26	2017-02-05	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10039580	Scar
76	479	P	ASA	67	f	0076-01427	2017-01-31	2017-02-05	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10051373	Wound haemorrhage
76	479	P	ASA	67	f	0076-01074	2020-10-15	2021-03-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012735	Diarrhoea
76	479	P	ASA	67	f	0076-01708	2021-11-15	2022-01-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10028810, 10011224	Nasopharyngitis, Cough
76	479	P	ASA	67	f	0076-02116	2022-08-13	2022-08-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
107	479	P	no ASA	75	f	0107-00091	2017-03-08	2017-03-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
107	479	P	no ASA	75	f	0107-01426	2018-09-06	2018-09-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10013971	Dizziness, Dyspnoea exertional
107	479	P	no ASA	75	f	0107-00257	2019-03-06		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10047571	Visual impairment
107	479	P	no ASA	75	f	0107-00258	2019-03-06		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10013968	Dyspnoea
2352	479	E	ASA	80	m	2352-01911	2022-04-06	2022-05-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
2352	479	E	ASA	80	m	2352-01910	2022-02-15	2022-02-16	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
1246	487	P	ASA	81	m	1246-01087	2020-12-16	2020-12-16	Other event	Mild	Temporarily discontinued	not related	not related	Recovered/resolved	10039674	Sciatica

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1246	487	P	ASA	81	m	1246-00929	2020-06-24	2020-11-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031264	Osteonecrosis
1215	487	E	no ASA	68	f	1215-01718	2021-08-30	2021-08-30	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007739	Cataract
1215	487	E	no ASA	68	f	1215-01719	2021-09-27	2021-09-27	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
2	488	P	ASA	80	m	0002-00080	2018-04-17		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10033425	Pain in extremity
2	488	P	ASA	80	m	0002-00057	2016-12-20	2017-05-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
206	488	P	ASA	80	f	0206-00535	2019-08-01	2019-09-20	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10043554	Thrombocytopenia
206	488	P	ASA	80	f	0206-00536	2019-11-28	2019-11-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019022	Haemorrhoids
1532	488	P	ASA	84	f	1532-01117	2020-05-07	2020-05-07	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10062585	Peripheral arterial occlusive disease
1532	488	P	ASA	84	f	1532-01118	2021-03-03	2021-09-10	Other event	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10060795	Hepatic enzyme increased
90	488	P	no ASA	78	m	0090-00249	2018-04-24	2018-04-24	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10049434	Cardiac pacemaker replacement
90	488	P	no ASA	78	m	0090-02291	2022-10-14	2022-11-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
357	488	P	no ASA	79	m	0357-00546	2019-11-28	2020-06-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10022758	Intracranial aneurysm
1133	488	P	no ASA	86	f	1133-01625	2021-11-18	2021-11-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042604	Supraventricular tachycardia
1250	488	P	no ASA	65	m	1250-01391	2021-04-01	2021-04-07	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10057518	Peripheral artery angioplasty
31	488	E	ASA	86	m	0031-00150	2018-09-18	2018-12-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035598	Pleural effusion
31	488	E	ASA	86	m	0031-00432	2019-09-17	2019-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10035598	Pleural effusion
31	488	E	ASA	86	m	0031-00469	2019-08-29	2019-08-29	Other event	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
50	488	E	ASA	73	m	0050-00033	2017-11-23	2017-11-23	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
213	488	E	ASA	86	f	0213-01334	2021-03-22	2021-03-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
318	488	E	ASA	90	f	0318-00478	2019-08-12	2019-08-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1824	488	E	ASA	76	m	1824-01596	2021-04-06	2021-04-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
25	488	E	no ASA	73	m	0025-00266	2018-11-08	2018-11-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000087	Abdominal pain upper
25	488	E	no ASA	73	m	0025-00654	2019-11-14	2019-11-14	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10028813, 10017853	Nausea, Gastritis
25	488	E	no ASA	73	m	0025-00820	2020-01-07	2020-01-11	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10062132, 10055798	Tooth extraction, Haemorrhage
25	488	E	no ASA	73	m	0025-00872	2020-04-13	2020-04-21	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10062132, 10055798	Tooth extraction, Haemorrhage
25	488	E	no ASA	73	m	0025-01824	2022-02-19	2022-02-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039117	Rib fracture
25	488	E	no ASA	73	m	0025-02042	2022-05-20	2022-05-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
121	488	E	no ASA	88	m	0121-01868	2022-03-24	2022-04-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
139	488	E	no ASA	86	m	0139-00017	2017-05-07	2017-05-10	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
1942	488	E	no ASA	73	f	1942-01597	2021-02-23	2021-02-25	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
334	502	P	ASA	68	m	0334-00069	2018-01-12	2018-12-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011224	Cough
334	502	P	ASA	68	m	0334-00072	2018-04-13	2018-04-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10050031	Muscle strain
835	502	P	ASA	88	f	0835-00318	2019-04-09	2019-05-02	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10018852	Haematoma
1282	502	P	ASA	67	m	1282-00659	2020-01-27	2020-01-27	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040808	Skin cancer
1282	502	P	ASA	67	m	1282-00875	2020-05-01	2020-07-31	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10037087	Pruritus
1282	502	P	ASA	67	m	1282-01568	2021-09-20	2021-09-27	Bleeding event/haematoma	Moderate	Not applicable (no	not related	not related	Recovered/resolved with sequelae	10018867	Haematuria

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1283	502	P	ASA	76	f	1283-00679	2020-04-03	2020-04-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1283	502	P	ASA	76	f	1283-00658	2019-11-01	2020-04-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
1535	502	P	ASA	82	m	1535-00846	2020-03-02	2020-08-31	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10030124, 10047899	Oedema peripheral, Weight increased
1535	502	P	ASA	82	m	1535-01400	2020-11-16		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10016766	Flatulence
309	502	P	no ASA	72	f	0309-00062	2017-10-20		Other event	Mild	None, i.e. still ongoing	not related	related	Event ongoing	10037884	Rash pruritic
309	502	P	no ASA	72	f	0309-00063	2018-04-09		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10043882	Tinnitus
602	502	P	no ASA	75	m	0602-00219	2019-01-07	2021-12-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
602	502	P	no ASA	75	m	0602-00602	2020-01-21	2020-06-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
602	502	P	no ASA	75	m	0602-00603	2020-01-21	2020-06-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10028836	Neck pain
166	502	E	ASA	87	m	0166-00018	2017-06-14	2017-06-19	Other event	Moderate	Permanently discontinued due to this event	related	not related	Recovered/resolved	10028813	Nausea
1200	502	E	ASA	77	m	1200-00847	2019-07-01	2019-07-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10080743	Angiocardiogram
1200	502	E	ASA	77	m	1200-01655	2021-11-30	2021-11-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
1200	502	E	ASA	77	m	1200-01303	2021-06-14	2021-12-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
1200	502	E	ASA	77	m	1200-01304	2021-06-14		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10013573	Dizziness
1200	502	E	ASA	77	m	1200-02539	2022-06-14	2022-06-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025425, 10047571	Maculopathy, Visual impairment
1440	502	E	ASA	70	m	1440-01290	2020-12-09		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10016256	Fatigue
1440	502	E	ASA	70	m	1440-01972	2022-05-15	2022-05-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1440	502	E	ASA	70	m	1440-01973	2022-05-15	2022-05-20	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10025482	Malaise
1440	502	E	ASA	70	m	1440-02428	2022-09-24	2022-10-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1440	502	E	ASA	70	m	1440-00993	2020-09-08	2021-08-05	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
1440	502	E	ASA	70	m	1440-01401	2020-08-23	2020-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000087	Abdominal pain upper
1556	502	E	ASA	68	m	1556-00861	2020-05-05	2020-05-05	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10064143	Dental implantation
1556	502	E	ASA	68	m	1556-00862	2020-04-01	2020-04-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013990	Dysuria
1556	502	E	ASA	68	m	1556-00863	2020-07-01	2021-03-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1556	502	E	ASA	68	m	1556-01114	2020-12-07	2020-12-07	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10021547	Implantation complication
1556	502	E	ASA	68	m	1556-01932	2021-11-11	2021-11-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2081	502	E	ASA	76	m	2081-01411	2021-07-23	2021-07-30	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10012735	Diarrhoea
2081	502	E	ASA	76	m	2081-01412	2021-05-11	2021-07-30	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10037087	Pruritus
2081	502	E	ASA	76	m	2081-01413	2021-06-07	2021-07-30	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10016766	Flatulence
2081	502	E	ASA	76	m	2081-01414	2021-06-07	2021-07-30	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10048959	Peripheral swelling
2081	502	E	ASA	76	m	2081-01415	2021-06-14	2021-07-30	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10028334	Muscle spasms
2496	502	E	ASA	83	f	2496-01897	2022-03-02	2022-05-06	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10000081, 10028813, 10002855	Abdominal pain, Nausea, Anxiety
102	502	E	no ASA	75	m	0102-00144	2017-02-28	2017-09-05	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10018852	Haematoma
102	502	E	no ASA	75	m	0102-00145	2018-04-13	2018-04-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062132	Tooth extraction
102	502	E	no ASA	75	m	0102-00096	2017-03-01	2019-07-09	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10018852	Haematoma
227	502	E	no ASA	82	m	0227-02564	2021-08-31	2021-09-21	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10002034	Anaemia
227	502	E	no ASA	82	m	0227-01090	2020-01-01		Other event	Mild	None, i.e. still ongoing	related	related	Unknown	10020631	Hypergammaglobulinaemia benign monoclonal
227	502	E	no ASA	82	m	0227-01079	2021-01-10	2021-01-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037660	Pyrexia
1782	502	E	no ASA	80	f	1782-00894	2020-09-21	2020-09-29	Other event	Mild	Permanently discontinued	not related	not related	Recovered/resolved	10019211	Headache

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1782	502	E	no ASA	80	f	1782-00895	2020-09-21	2020-09-29	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10047513	Vision blurred
1782	502	E	no ASA	80	f	1782-00896	2020-09-21	2020-09-29	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10028372	Muscular weakness
1782	502	E	no ASA	80	f	1782-00897	2020-09-21	2020-09-29	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10020112	Hirsutism
164	514	P	no ASA	67	m	0164-00200	2018-07-01	2018-07-01	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062132	Tooth extraction
164	514	P	no ASA	67	m	0164-01231	2021-05-04	2022-05-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895	Weight decreased
164	514	P	no ASA	67	m	0164-00084	2018-05-21	2018-05-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012174	Dehydration
456	514	E	ASA	70	m	0456-00133	2018-04-01		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10012601	Diabetes mellitus
255	529	P	ASA	79	m	0255-02617	2021-09-11		Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10009944	Colon cancer
489	529	P	ASA	75	m	0489-01836	2022-01-29	2022-01-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
489	529	P	ASA	75	m	0489-01837	2022-02-24	2022-02-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1254	529	P	ASA	85	m	1254-00635	2019-10-14	2019-10-25	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10003549	Asthenia
1550	529	P	ASA	77	m	1550-02472	2022-07-05	2022-07-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1550	529	P	ASA	77	m	1550-02473	2022-11-09	2022-11-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
1594	529	P	ASA	77	m	1594-01674	2021-09-21	2021-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1594	529	P	ASA	77	m	1594-01673	2021-03-23	2021-04-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061218, 10048959	Inflammation, Peripheral swelling
2113	529	P	ASA	76	m	2113-02463	2022-11-15	2022-11-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
2545	529	P	ASA	73	f	2545-02260	2022-07-01	2022-08-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10019974	Herpes zoster
1068	529	P	no ASA	83	m	1068-01957	2022-03-17	2022-03-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1121	529	P	no ASA	66	m	1121-00584	2019-07-06	2019-07-12	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10018852, 10016173	Haematoma, Fall
1635	529	P	no ASA	78	f	1635-01675	2020-12-22	2021-04-30	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013573	Dizziness
1745	529	P	no ASA	73	f	1745-01677	2020-09-24	2021-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
1745	529	P	no ASA	73	f	1745-01678	2020-09-02	2021-10-02	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007882	Cellulitis
1745	529	P	no ASA	73	f	1745-01780	2022-01-14	2022-01-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1745	529	P	no ASA	73	f	1745-01458	2021-03-30	2021-04-09	Other event	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10007882	Cellulitis
1745	529	P	no ASA	73	f	1745-02127	2022-08-29	2022-08-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002034	Anaemia
1965	529	P	no ASA	67	m	1965-01827	2022-02-27	2022-04-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
2229	529	P	no ASA	79	f	2229-02120	2022-03-15	2022-03-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2229	529	P	no ASA	79	f	2229-02121	2022-04-14	2022-04-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003399	Arthropod bite
2258	529	P	no ASA	82	m	2258-02292	2022-07-08	2022-07-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2258	529	P	no ASA	82	m	2258-02293	2022-09-16	2022-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
2662	529	P	no ASA	83	m	2662-02618	2022-08-11	2022-08-26	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10010741	Conjunctivitis
703	529	E	ASA	83	m	0703-01955	2021-05-03	2021-10-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1006	529	E	ASA	76	m	1006-00431	2019-03-04	2019-08-28	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10012735	Diarrhoea
1006	529	E	ASA	76	m	1006-01782	2022-01-09	2022-01-09	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1083	529	E	ASA	85	m	1083-01167	2021-04-12	2021-04-19	Bleeding event/haematoma	Moderate	Permanently discontinued	related	related	Recovered/resolved	10038063, 10064848	Rectal haemorrhage, Chronic kidney disease

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1201	529	E	ASA	69	f	1201-01672	2020-12-17	2020-12-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063797	Cataract operation
1201	529	E	ASA	69	f	1201-02619	2021-01-20	2021-01-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063797	Cataract operation
1595	529	E	ASA	77	m	1595-02317	2022-10-19	2022-12-04	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	related	related	Recovered/resolved with sequelae	10018867	Haematuria
1595	529	E	ASA	77	m	1595-01956	2021-12-16	2021-12-16	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867, 10046571	Haematuria, Urinary tract infection
1689	529	E	ASA	81	f	1689-01676	2021-04-14	2021-04-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013968	Dyspnoea
1689	529	E	ASA	81	f	1689-02047	2022-06-25	2022-06-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
1709	529	E	ASA	65	m	1709-02474	2022-10-04	2022-10-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
1709	529	E	ASA	65	m	1709-02053	2022-07-23	2022-08-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016062	Facial paralysis
1987	529	E	ASA	84	m	1987-01521	2021-03-28	2021-03-28	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018276	Gingival bleeding
1987	529	E	ASA	84	m	1987-02475	2022-08-01	2022-08-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030302	Oliguria
2451	529	E	ASA	82	m	2451-02044	2022-07-13	2022-07-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2459	529	E	ASA	69	m	2459-02460	2022-03-30	2022-03-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
2459	529	E	ASA	69	m	2459-02461	2022-09-29	2022-09-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10014805	Endoscopy
317	529	E	no ASA	67	m	0317-01840	2021-04-29	2021-04-29	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10003662	Atrial flutter
317	529	E	no ASA	67	m	0317-01841	2022-03-14	2022-03-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10003239	Arthralgia
447	529	E	no ASA	73	m	0447-02124	2022-05-02	2022-05-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
926	529	E	no ASA	77	m	0926-00378	2019-04-10	2019-04-12	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10038063	Rectal haemorrhage
926	529	E	no ASA	77	m	0926-01781	2022-02-25	2022-03-04	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
926	529	E	no ASA	77	m	0926-02309	2021-12-21	2021-12-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1050	529	E	no ASA	77	f	1050-00475	2019-06-02	2019-06-16	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10037844	Rash
1198	529	E	no ASA	80	m	1198-00616	2019-07-10	2019-07-12	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741, 10030041	Conjunctivitis, Ocular hyperaemia
1343	529	E	no ASA	87	f	1343-01950	2022-02-18	2022-04-18	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10002034	Anaemia
1503	529	E	no ASA	77	m	1503-01777	2022-01-17	2022-01-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10070255	Coronavirus test positive
1927	529	E	no ASA	87	f	1927-02262	2022-08-26	2022-09-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2216	529	E	no ASA	80	m	2216-02294	2021-10-18	2021-10-28	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10017955	Gastrointestinal haemorrhage
2328	529	E	no ASA	79	m	2328-02015	2022-03-04	2022-04-11	Other event	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved with sequelae	10002034	Anaemia
271	530	E	ASA	74	m	0271-00049	2018-02-01	2018-02-04	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018276	Gingival bleeding
271	530	E	ASA	74	m	0271-01335	2019-01-24	2019-01-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062132	Tooth extraction
1237	530	E	ASA	76	m	1237-02547	2020-09-22	2020-09-22	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
1521	530	E	no ASA	83	f	1521-01336	2020-02-21	2020-02-24	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10038063	Rectal haemorrhage
241	531	P	no ASA	79	m	0241-00472	2019-03-28	2019-04-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
311	532	P	ASA	74	m	0311-00189	2018-09-19	2018-10-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
563	535	P	no ASA	84	f	0563-01942	2022-02-18	2022-02-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
563	535	P	no ASA	84	f	0563-01249	2021-01-10		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013968	Dyspnoea
563	535	P	no ASA	84	f	0563-01250	2021-05-13	2021-11-22	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002034, 10017955	Anaemia, Gastrointestinal haemorrhage
605	535	P	no ASA	70	m	0605-00544	2018-12-14	2018-12-20	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10061225	Limb injury
605	535	P	no ASA	70	m	0605-01204	2019-12-19	2020-06-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018888	Haemoglobin increased
605	535	P	no ASA	70	m	0605-02031	2022-06-13	2022-06-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048709	Urosepsis
605	535	P	no ASA	70	m	0605-01205	2020-04-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10041349	Somnolence
1268	535	P	no ASA	76	f	1268-02143	2022-07-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10030124	Oedema peripheral
1393	535	P	no ASA	88	f	1393-01226	2020-03-14		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10057668	Cognitive disorder
1393	535	P	no ASA	88	f	1393-02600	2020-12-19	2020-12-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010305, 10013887	Confusional state, Dysarthria
1393	535	P	no ASA	88	f	1393-01939	2021-11-24	2021-11-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
1393	535	P	no ASA	88	f	1393-01969	2021-11-20	2021-11-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
1393	535	P	no ASA	88	f	1393-01227	2020-05-26	2020-05-27	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10027141	Melaena
538	535	E	ASA	84	f	0538-01203	2020-10-05	2022-04-13	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
538	535	E	ASA	84	f	0538-00724	2020-03-25	2020-05-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013538	Diverticulitis
538	535	E	ASA	84	f	0538-01747	2021-04-29	2022-04-13	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008629	Cholelithiasis
546	535	E	ASA	81	f	0546-00196	2018-07-10	2018-11-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
546	535	E	ASA	81	f	0546-00496	2019-09-11	2019-09-12	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007739	Cataract
546	535	E	ASA	81	f	0546-00497	2019-10-02	2019-10-02	Other event	Moderate	Temporarily discontinued	not related	not related	Recovered/resolved	10007739	Cataract

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1693	535	E	ASA	80	m	1693-02030	2022-06-19	2022-06-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
335	535	E	no ASA	72	m	0335-01924	2022-03-21	2022-03-21	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
631	535	E	no ASA	80	f	0631-02025	2022-05-04	2022-06-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002544	Ankle fracture
631	535	E	no ASA	80	f	0631-01687	2021-06-10		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013971	Dyspnoea exertional
1776	535	E	no ASA	77	m	1776-01128	2021-01-20	2021-01-20	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
1776	535	E	no ASA	77	m	1776-01129	2020-11-03	2020-11-03	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
1776	535	E	no ASA	77	m	1776-01799	2021-11-21	2021-11-21	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018276	Gingival bleeding
991	536	P	no ASA	90	f	0991-02529	2020-10-13	2021-11-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10028836	Neck pain
2326	536	E	no ASA	67	m	2326-01929	2022-03-16	2022-05-17	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10018852	Haematoma
417	541	P	no ASA	78	m	0417-01905	2019-02-13	2021-02-04	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10060862	Prostate cancer
347	542	E	no ASA	70	f	0347-02573	2022-03-22	2022-07-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10066091	Bronchial hyperreactivity
179	544	P	ASA	82	f	0179-00532	2019-10-31	2019-10-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007739	Cataract
179	544	P	ASA	82	f	0179-01635	2021-06-30	2021-06-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
179	544	P	ASA	82	f	0179-00090	2018-06-09	2018-08-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10038907	Retinal vein occlusion
179	544	P	ASA	82	f	0179-00741	2020-05-23	2020-05-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
1336	544	P	ASA	87	f	1336-00687	2019-11-19	2019-12-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048038	Wound infection
1336	544	P	ASA	87	f	1336-00688	2019-10-28	2019-10-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1336	544	P	ASA	87	f	1336-00689	2019-12-05		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10002882	Aortic aneurysm

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1336	544	P	ASA	87	f	1336-00690	2020-01-16	2020-01-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046306	Upper respiratory tract infection
1336	544	P	ASA	87	f	1336-00691	2020-01-23	2020-01-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10069510	Subgaleal haematoma
1336	544	P	ASA	87	f	1336-00692	2020-01-29	2020-02-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007559	Cardiac failure congestive
1336	544	P	ASA	87	f	1336-00693	2020-02-16	2022-03-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024453	Ligament sprain
1336	544	P	ASA	87	f	1336-01188	2020-12-30	2021-01-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10050584	Contusion
1336	544	P	ASA	87	f	1336-01189	2021-03-26	2021-04-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061225	Limb injury
1336	544	P	ASA	87	f	1336-01891	2022-04-05	2022-04-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1336	544	P	ASA	87	f	1336-01892	2021-12-03	2021-12-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011224	Cough
1336	544	P	ASA	87	f	1336-01893	2021-12-09	2022-03-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061225	Limb injury
1336	544	P	ASA	87	f	1336-01894	2022-03-21	2022-04-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007697	Carpal tunnel syndrome
1336	544	P	ASA	87	f	1336-01895	2022-03-31	2022-04-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1336	544	P	ASA	87	f	1336-00916	2020-04-30	2020-05-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10048038	Wound infection
1336	544	P	ASA	87	f	1336-00917	2020-07-02	2020-07-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
1336	544	P	ASA	87	f	1336-00918	2020-07-03	2020-07-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10069339	Acute kidney injury
1336	544	P	ASA	87	f	1336-00919	2020-07-14	2020-07-25	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10046571	Urinary tract infection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1336	544	P	ASA	87	f	1336-00920	2020-08-04	2020-08-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003988	Back pain
1336	544	P	ASA	87	f	1336-00921	2020-09-07	2020-09-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10010774	Constipation
1336	544	P	ASA	87	f	1336-01545	2021-05-01	2021-05-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061386	Chest injury
1336	544	P	ASA	87	f	1336-01546	2021-08-04	2021-08-17	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018852	Haematoma
1476	544	P	ASA	83	f	1476-00783	2020-01-28	2020-02-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081	Abdominal pain
1476	544	P	ASA	83	f	1476-00784	2020-03-13	2020-03-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018627	Gout
1476	544	P	ASA	83	f	1476-00785	2020-03-31	2020-03-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020802	Hypertensive crisis
1476	544	P	ASA	83	f	1476-00786	2020-04-28	2020-05-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081	Abdominal pain
1476	544	P	ASA	83	f	1476-01371	2021-01-29		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10022016	Inguinal hernia
1476	544	P	ASA	83	f	1476-01372	2021-05-03	2022-02-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081	Abdominal pain
1476	544	P	ASA	83	f	1476-02024	2022-03-08	2022-03-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003988	Back pain
1476	544	P	ASA	83	f	1476-01061	2020-08-15	2020-08-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003399	Arthropod bite
1476	544	P	ASA	83	f	1476-01062	2020-09-09	2020-09-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
1476	544	P	ASA	83	f	1476-01063	2020-10-20	2021-01-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10006895	Cachexia
1476	544	P	ASA	83	f	1476-01870	2021-08-28	2021-09-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1476	544	P	ASA	83	f	1476-01871	2021-09-26	2021-10-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
1476	544	P	ASA	83	f	1476-01872	2021-09-26	2021-10-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10019196	Head injury
1482	544	P	ASA	75	m	1482-00798	2020-06-19	2020-06-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
1482	544	P	ASA	75	m	1482-01363	2021-01-26	2021-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061128	Eye injury
1482	544	P	ASA	75	m	1482-02322	2022-10-13	2022-10-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10067251	Lead dislodgement
1482	544	P	ASA	75	m	1482-02323	2022-10-20		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10012267	Dementia
1482	544	P	ASA	75	m	1482-01070	2020-09-15	2020-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1482	544	P	ASA	75	m	1482-01071	2020-12-15	2020-12-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741	Conjunctivitis
1482	544	P	ASA	75	m	1482-01072	2020-12-21	2020-12-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017533	Fungal infection
1482	544	P	ASA	75	m	1482-01073	2020-12-21	2020-12-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10050584	Fall, Contusion
137	544	P	no ASA	85	f	0137-00027	2017-09-15	2017-10-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
137	544	P	no ASA	85	f	0137-00188	2018-10-30	2018-10-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
137	544	P	no ASA	85	f	0137-00524	2019-09-10	2019-09-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10043255	Tendonitis
137	544	P	no ASA	85	f	0137-00525	2019-10-19	2019-10-19	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
137	544	P	no ASA	85	f	0137-00526	2019-10-11	2019-10-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007695	Carpal tunnel decompression
137	544	P	no ASA	85	f	0137-00074	2017-11-14	2017-11-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
137	544	P	no ASA	85	f	0137-00696	2020-02-18		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10033425	Pain in extremity

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
137	544	P	no ASA	85	f	0137-00697	2020-04-22	2020-04-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10004663	Biliary colic
156	544	P	no ASA	91	m	0156-00030	2017-11-04	2017-11-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
156	544	P	no ASA	91	m	0156-00031	2017-09-30	2017-11-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048762	Tooth infection
156	544	P	no ASA	91	m	0156-00191	2018-11-06	2018-11-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
156	544	P	no ASA	91	m	0156-00968	2020-07-03	2020-07-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061386	Chest injury
156	544	P	no ASA	91	m	0156-00969	2020-10-06	2020-10-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
156	544	P	no ASA	91	m	0156-00970	2020-09-25	2021-03-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016880	Folate deficiency
156	544	P	no ASA	91	m	0156-00971	2020-09-25	2021-03-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040249	Serum ferritin decreased
156	544	P	no ASA	91	m	0156-01221	2020-12-01	2021-01-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061386	Chest injury
156	544	P	no ASA	91	m	0156-01222	2021-01-06	2021-01-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
156	544	P	no ASA	91	m	0156-01223	2021-03-24	2021-03-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046306	Upper respiratory tract infection
156	544	P	no ASA	91	m	0156-01224	2021-05-06	2022-02-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007739	Cataract
156	544	P	no ASA	91	m	0156-01598	2021-11-10	2021-11-18	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10018852	Haematoma
156	544	P	no ASA	91	m	0156-01852	2022-02-16	2022-02-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
156	544	P	no ASA	91	m	0156-01853	2021-12-28	2022-01-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10052251	Respiratory tract congestion
156	544	P	no ASA	91	m	0156-01854	2022-03-26	2022-04-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030041	Ocular hyperaemia
156	544	P	no ASA	91	m	0156-02369	2022-06-01	2022-06-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
156	544	P	no ASA	91	m	0156-02370	2022-08-27	2022-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
156	544	P	no ASA	91	m	0156-02371	2022-09-05	2022-10-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
156	544	P	no ASA	91	m	0156-00325	2018-12-31	2019-01-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061225	Limb injury
156	544	P	no ASA	91	m	0156-00711	2020-05-11	2020-05-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
367	544	P	no ASA	81	m	0367-02005	2021-10-14	2021-10-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015150	Erythema
367	544	P	no ASA	81	m	0367-02002	2022-01-04	2022-03-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011224	Cough

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
367	544	P	no ASA	81	m	0367-02003	2022-03-21	2022-03-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10036653	Presyncope
367	544	P	no ASA	81	m	0367-02004	2022-03-27	2022-03-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048762	Tooth infection
367	544	P	no ASA	81	m	0367-02487	2022-11-28		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10062352	Respiratory tract infection
367	544	P	no ASA	81	m	0367-02488	2022-11-15	2022-11-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension
367	544	P	no ASA	81	m	0367-00206	2018-08-30	2018-09-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
367	544	P	no ASA	81	m	0367-00207	2018-12-04	2018-12-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
367	544	P	no ASA	81	m	0367-00558	2019-09-11	2019-09-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002515	Animal bite
367	544	P	no ASA	81	m	0367-00559	2019-09-17	2019-09-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10044565	Tremor
367	544	P	no ASA	81	m	0367-00998	2020-06-10	2020-06-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024453	Ligament sprain
491	544	P	no ASA	80	f	0491-00869	2020-05-04	2020-05-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
491	544	P	no ASA	80	f	0491-00870	2020-05-04	2020-05-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017888	Gastroenteritis
491	544	P	no ASA	80	f	0491-01518	2021-06-23	2021-07-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
491	544	P	no ASA	80	f	0491-01519	2021-08-23		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10006272	Breast mass
491	544	P	no ASA	80	f	0491-01811	2021-10-24	2021-10-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017918	Gastroenteritis viral
491	544	P	no ASA	80	f	0491-02196	2022-04-14	2022-04-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
491	544	P	no ASA	80	f	0491-02197	2022-05-28	2022-06-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047700	Vomiting
491	544	P	no ASA	80	f	0491-02198	2022-09-16	2022-09-27	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010719	Conjunctival haemorrhage
491	544	P	no ASA	80	f	0491-00307	2019-02-20	2019-04-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10044055	Toothache
491	544	P	no ASA	80	f	0491-01141	2021-03-10	2021-03-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011224	Cough
575	544	P	no ASA	91	m	0575-00201	2018-06-19		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10006811	Bursitis
575	544	P	no ASA	91	m	0575-00202	2018-09-28	2018-09-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
575	544	P	no ASA	91	m	0575-00541	2019-07-05	2019-07-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
575	544	P	no ASA	91	m	0575-01628	2021-11-18	2021-11-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015150	Erythema
575	544	P	no ASA	91	m	0575-02527	2022-10-26	2022-10-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
575	544	P	no ASA	91	m	0575-01245	2021-05-03	2021-06-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10029446, 10036142	Nocturia, Polyuria

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1193	544	P	no ASA	82	m	1193-02420	2022-02-23	2022-09-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007739	Cataract
1193	544	P	no ASA	82	m	1193-00564	2019-09-19	2019-09-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1193	544	P	no ASA	82	m	1193-01996	2021-07-30	2021-09-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1193	544	P	no ASA	82	m	1193-01995	2022-05-04	2022-05-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018627	Gout
1606	544	P	no ASA	69	f	1606-00959	2020-07-02	2020-10-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037087	Pruritus
1606	544	P	no ASA	69	f	1606-01396	2020-09-28	2020-09-28	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1606	544	P	no ASA	69	f	1606-02497	2022-08-11	2022-08-18	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10004663	Biliary colic
1606	544	P	no ASA	69	f	1606-02498	2022-08-14	2022-08-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1606	544	P	no ASA	69	f	1606-01259	2020-12-23	2021-04-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
1606	544	P	no ASA	69	f	1606-01260	2021-01-11	2021-02-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
1606	544	P	no ASA	69	f	1606-01261	2021-03-12	2021-03-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1606	544	P	no ASA	69	f	1606-01262	2020-11-19	2021-01-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1606	544	P	no ASA	69	f	1606-01397	2021-01-21	2021-01-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1606	544	P	no ASA	69	f	1606-01936	2021-12-13	2021-12-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014971	Epicondylitis
1606	544	P	no ASA	69	f	1606-01937	2021-12-29	2022-01-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1606	544	P	no ASA	69	f	1606-01938	2022-03-31		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003988	Back pain
1831	544	P	no ASA	68	m	1831-01186	2021-03-17	2021-03-17	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10004146	Basal cell carcinoma
1831	544	P	no ASA	68	m	1831-01567	2021-05-18	2021-05-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10044016	Tooth abscess
1854	544	P	no ASA	82	f	1854-01216	2021-02-12	2021-03-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1854	544	P	no ASA	82	f	1854-01921	2021-12-16	2022-04-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10057668	Cognitive disorder
1854	544	P	no ASA	82	f	1854-01922	2022-04-04	2022-04-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063797	Cataract operation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1854	544	P	no ASA	82	f	1854-01587	2021-05-12		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003988	Back pain
1854	544	P	no ASA	82	f	1854-01588	2021-05-12		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia
178	544	E	ASA	87	f	0178-00210	2018-11-21		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10017533	Fungal infection
178	544	E	ASA	87	f	0178-01636	2021-06-14	2021-06-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007882	Cellulitis
178	544	E	ASA	87	f	0178-01637	2021-07-09	2021-07-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012431, 10016936	Dermatitis, Folliculitis
178	544	E	ASA	87	f	0178-01638	2021-08-06	2021-08-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003988	Back pain
178	544	E	ASA	87	f	0178-01639	2021-09-02	2021-09-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
178	544	E	ASA	87	f	0178-01640	2021-09-30	2022-06-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022972	Iron deficiency anaemia
178	544	E	ASA	87	f	0178-01980	2022-04-29	2022-06-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022972	Iron deficiency anaemia
178	544	E	ASA	87	f	0178-01984	2022-05-05		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10057668	Cognitive disorder
178	544	E	ASA	87	f	0178-01985	2022-04-27	2022-08-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10064848	Chronic kidney disease
178	544	E	ASA	87	f	0178-01986	2022-03-30		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10062189	Vitamin D decreased
178	544	E	ASA	87	f	0178-01987	2022-05-23	2022-05-31	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10038695	Respiratory failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
178	544	E	ASA	87	f	0178-01988	2022-05-26	2022-05-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000381	Accidental overdose
178	544	E	ASA	87	f	0178-01989	2021-12-10	2021-12-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
178	544	E	ASA	87	f	0178-01990	2022-01-05	2022-01-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10037087	Pruritus
178	544	E	ASA	87	f	0178-01991	2022-02-11	2022-02-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007882	Cellulitis
178	544	E	ASA	87	f	0178-01992	2022-02-25	2022-03-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
178	544	E	ASA	87	f	0178-01993	2022-03-22	2022-04-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
178	544	E	ASA	87	f	0178-01994	2022-05-18	2022-05-19	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000381	Accidental overdose
178	544	E	ASA	87	f	0178-02494	2022-08-19	2022-09-05	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
178	544	E	ASA	87	f	0178-02495	2022-10-18	2022-10-21	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
178	544	E	ASA	87	f	0178-00729	2019-12-31	2022-03-31	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020603	Hypercholesterolaemia
178	544	E	ASA	87	f	0178-00730	2019-12-31	2022-04-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020869	Hypertriglyceridaemia
486	544	E	ASA	84	f	0486-00152	2018-08-21	2018-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741	Conjunctivitis
486	544	E	ASA	84	f	0486-00153	2018-05-13	2018-05-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
486	544	E	ASA	84	f	0486-00460	2019-05-09	2019-05-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10081453	Bronchial aspiration procedure
486	544	E	ASA	84	f	0486-00461	2019-05-09	2019-05-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
486	544	E	ASA	84	f	0486-00850	2020-04-07	2020-04-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
486	544	E	ASA	84	f	0486-00851	2020-06-19	2020-06-19	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000381	Accidental overdose
486	544	E	ASA	84	f	0486-00852	2020-07-21	2021-03-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011985	Decubitus ulcer
486	544	E	ASA	84	f	0486-00853	2020-08-10	2021-03-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061225	Limb injury
486	544	E	ASA	84	f	0486-01516	2021-04-12	2021-04-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
486	544	E	ASA	84	f	0486-01517	2021-07-12	2021-07-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061225	Limb injury
486	544	E	ASA	84	f	0486-02236	2022-03-31	2022-05-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10040943	Skin ulcer
486	544	E	ASA	84	f	0486-02237	2022-09-21	2022-09-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
486	544	E	ASA	84	f	0486-00285	2018-10-21	2018-10-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
486	544	E	ASA	84	f	0486-00286	2019-03-25	2019-03-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
486	544	E	ASA	84	f	0486-00646	2019-12-11	2019-12-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
486	544	E	ASA	84	f	0486-00647	2020-01-24	2020-01-31	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061225, 10018852	Limb injury, Haematoma
486	544	E	ASA	84	f	0486-00648	2020-01-27	2020-01-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
486	544	E	ASA	84	f	0486-01145	2021-02-10	2021-02-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
486	544	E	ASA	84	f	0486-01146	2020-10-18	2020-10-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
958	544	E	ASA	75	f	0958-00795	2020-02-14		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003239	Arthralgia
958	544	E	ASA	75	f	0958-00796	2020-07-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003239	Arthralgia
958	544	E	ASA	75	f	0958-00830	2020-07-21	2020-07-21	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10003662	Atrial flutter
958	544	E	ASA	75	f	0958-02045	2022-03-16	2022-03-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10043255	Tendonitis
958	544	E	ASA	75	f	0958-02046	2022-06-15		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia
958	544	E	ASA	75	f	0958-02496	2022-08-03	2022-08-03	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015926	Eye haemorrhage
958	544	E	ASA	75	f	0958-00619	2019-08-26		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003239	Arthralgia
958	544	E	ASA	75	f	0958-00620	2020-02-04		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003988	Back pain
958	544	E	ASA	75	f	0958-00621	2020-02-04	2020-02-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014020	Ear pain
958	544	E	ASA	75	f	0958-01082	2020-11-30	2021-01-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
958	544	E	ASA	75	f	0958-01083	2020-11-30	2020-12-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia
1005	544	E	ASA	82	m	1005-00506	2019-08-27		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10060954	Abdominal hernia
1005	544	E	ASA	82	m	1005-00843	2020-07-13	2020-07-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension
1005	544	E	ASA	82	m	1005-01452	2021-05-27	2021-05-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1005	544	E	ASA	82	m	1005-01453	2021-08-02	2021-08-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010725	Conjunctival irritation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1005	544	E	ASA	82	m	1005-02586	2022-08-27	2022-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1005	544	E	ASA	82	m	1005-02587	2022-08-27	2022-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
1005	544	E	ASA	82	m	1005-00656	2019-11-24	2019-12-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741	Conjunctivitis
1005	544	E	ASA	82	m	1005-00657	2020-03-03	2020-03-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1005	544	E	ASA	82	m	1005-01783	2021-10-16	2021-11-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
1190	544	E	ASA	71	m	1190-00561	2019-12-02	2019-12-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040678	Silicosis
1190	544	E	ASA	71	m	1190-00743	2020-01-16	2020-01-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1190	544	E	ASA	71	m	1190-00744	2020-04-13	2020-04-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1370	544	E	ASA	69	m	1370-02304	2022-07-27		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia
1370	544	E	ASA	69	m	1370-00947	2020-05-27	2020-06-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741	Conjunctivitis
1683	544	E	ASA	85	f	1683-01040	2020-08-10	2020-08-26	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010719	Conjunctival haemorrhage
1683	544	E	ASA	85	f	1683-01041	2020-08-10	2020-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
1683	544	E	ASA	85	f	1683-01042	2020-08-10	2020-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
1683	544	E	ASA	85	f	1683-01043	2020-08-26	2020-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1683	544	E	ASA	85	f	1683-01044	2020-08-26	2020-08-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10058181	Hypertensive urgency
1683	544	E	ASA	85	f	1683-01344	2021-01-22	2021-02-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10034879	Phlebitis
1683	544	E	ASA	85	f	1683-01345	2021-03-01	2021-03-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1683	544	E	ASA	85	f	1683-01347	2021-03-31	2021-04-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1683	544	E	ASA	85	f	1683-01348	2021-05-19	2021-05-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1683	544	E	ASA	85	f	1683-02588	2022-07-21	2022-09-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021114	Hypothyroidism
224	544	E	no ASA	80	f	0224-00573	2019-07-23	2019-07-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
224	544	E	no ASA	80	f	0224-01395	2020-10-16	2020-10-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
224	544	E	no ASA	80	f	0224-00376	2019-01-28	2019-02-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017888	Gastroenteritis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
224	544	E	no ASA	80	f	0224-00771	2020-02-26	2020-03-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011224	Cough
224	544	E	no ASA	80	f	0224-00772	2020-02-26	2020-02-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
224	544	E	no ASA	80	f	0224-00773	2020-03-06	2020-03-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020802	Hypertensive crisis
224	544	E	no ASA	80	f	0224-00774	2020-06-04	2020-07-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006895	Cachexia
224	544	E	no ASA	80	f	0224-00775	2020-06-15	2020-06-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
310	544	E	no ASA	69	f	0310-00075	2018-03-17	2018-03-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019196	Head injury
310	544	E	no ASA	69	f	0310-00700	2019-12-30	2020-01-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074170	Candida infection
310	544	E	no ASA	69	f	0310-01166	2021-01-21	2021-02-15	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10064848	Chronic kidney disease
310	544	E	no ASA	69	f	0310-01565	2021-08-19	2021-08-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
310	544	E	no ASA	69	f	0310-02589	2021-05-06		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10030216	Oesophagitis
310	544	E	no ASA	69	f	0310-02303	2022-09-02	2022-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048762	Tooth infection
310	544	E	no ASA	69	f	0310-00509	2019-06-29	2019-07-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014011	Ear infection
310	544	E	no ASA	69	f	0310-00510	2019-07-08	2019-07-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040753	Sinusitis
310	544	E	no ASA	69	f	0310-00511	2019-07-22	2019-10-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10064848	Chronic kidney disease
310	544	E	no ASA	69	f	0310-00512	2019-09-02	2019-09-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
773	544	E	no ASA	75	f	0773-00701	2020-02-20	2020-02-25	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10038063	Rectal haemorrhage
773	544	E	no ASA	75	f	0773-00702	2019-12-08	2019-12-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011224	Cough
773	544	E	no ASA	75	f	0773-01183	2021-01-13		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10028411	Myalgia
773	544	E	no ASA	75	f	0773-01184	2021-02-16	2021-02-23	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10051625	Conjunctival hyperaemia
773	544	E	no ASA	75	f	0773-01185	2021-03-05	2021-03-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
773	544	E	no ASA	75	f	0773-01866	2022-04-11	2022-04-30	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10034544	Periorbital haematoma
773	544	E	no ASA	75	f	0773-01867	2022-04-11	2022-04-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
773	544	E	no ASA	75	f	0773-00488	2019-09-16		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia
773	544	E	no ASA	75	f	0773-00928	2020-10-14	2020-10-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000381	Accidental overdose
773	544	E	no ASA	75	f	0773-01599	2021-05-27	2021-05-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
839	544	E	no ASA	67	f	0839-00709	2020-01-21	2020-08-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021114	Hypothyroidism
839	544	E	no ASA	67	f	0839-00961	2020-09-24	2020-11-25	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10050854	Breast prosthesis user
839	544	E	no ASA	67	f	0839-01615	2021-08-18	2021-09-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124, 10033371	Oedema peripheral, Pain
1345	544	E	no ASA	79	m	1345-00682	2019-12-29	2020-01-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061225	Limb injury
1345	544	E	no ASA	79	m	1345-00683	2020-03-02		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10075049	Peripheral venous disease
1345	544	E	no ASA	79	m	1345-00684	2020-03-06	2020-03-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
1345	544	E	no ASA	79	m	1345-00945	2020-07-04	2020-07-06	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10050584	Contusion
1345	544	E	no ASA	79	m	1345-00946	2020-09-21		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10075049	Peripheral venous disease
1367	544	E	no ASA	75	m	1367-00720	2019-12-12	2019-12-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10051589	Large intestine polyp
1367	544	E	no ASA	75	m	1367-00721	2020-02-17		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10002153	Anal fissure
1367	544	E	no ASA	75	m	1367-00722	2020-02-24	2020-03-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013554	Diverticulum
1367	544	E	no ASA	75	m	1367-00723	2020-02-26	2020-05-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010774	Constipation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1367	544	E	no ASA	75	m	1367-01199	2021-01-24	2021-01-31	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021531	Impetigo
1367	544	E	no ASA	75	m	1367-01454	2020-09-03	2020-09-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10074625	Large intestinal polypectomy
275	547	P	ASA	85	f	0275-00050	2018-03-01	2018-03-01	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
275	547	P	ASA	85	f	0275-01496	2021-08-31	2021-08-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10062352	Dizziness, Respiratory tract infection
275	547	P	ASA	85	f	0275-01497	2021-09-01	2021-09-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501, 10002855	Non-cardiac chest pain, Anxiety
391	547	P	ASA	78	m	0391-02019	2022-05-19	2022-05-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10052693	Transurethral bladder resection
391	547	P	ASA	78	m	0391-02020	2022-05-22	2022-05-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
391	547	P	ASA	78	m	0391-00224	2018-07-16	2018-07-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
391	547	P	ASA	78	m	0391-00236	2018-08-31	2018-08-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062132	Tooth extraction
1517	547	P	ASA	87	f	1517-00821	2020-07-01	2020-07-04	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
1517	547	P	ASA	87	f	1517-01408	2021-02-24	2021-02-24	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
1922	547	P	ASA	73	m	1922-02336	2022-05-09	2022-05-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
1922	547	P	ASA	73	m	1922-01713	2021-08-04	2021-08-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010774	Constipation
1922	547	P	ASA	73	m	1922-01714	2021-12-24	2021-12-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020635	Hyperglycaemia
1922	547	P	ASA	73	m	1922-01715	2022-01-16	2022-01-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002515	Animal bite
2412	547	P	ASA	75	f	2412-02469	2022-09-20	2022-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735, 10047700	Diarrhoea, Vomiting
2447	547	P	ASA	72	f	2447-02051	2022-03-15	2022-03-15	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
2447	547	P	ASA	72	f	2447-02052	2022-06-15	2022-06-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10025482, 10019332	Malaise, Heat exhaustion
2447	547	P	ASA	72	f	2447-02201	2022-08-07	2022-08-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
273	547	P	no ASA	83	m	0273-00256	2019-01-29	2019-01-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046555	Urinary retention
273	547	P	no ASA	83	m	0273-02145	2022-07-11	2022-07-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033425	Pain in extremity
273	547	P	no ASA	83	m	0273-00139	2018-04-10	2018-04-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
273	547	P	no ASA	83	m	0273-00528	2018-09-04	2019-06-25	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10043554	Thrombocytopenia
454	547	P	no ASA	81	m	0454-01788	2021-11-25	2021-11-25	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014113	Echocardiogram
454	547	P	no ASA	81	m	0454-02117	2022-04-30	2022-04-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003246	Arthritis
702	547	P	no ASA	67	m	0702-02443	2022-10-26	2022-10-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
702	547	P	no ASA	67	m	0702-02444	2022-10-29	2022-10-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
702	547	P	no ASA	67	m	0702-02445	2022-11-04	2022-11-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
715	547	P	no ASA	77	f	0715-00280	2018-12-21	2018-12-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061422	Abnormal behaviour
715	547	P	no ASA	77	f	0715-00441	2019-07-25	2019-07-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
918	547	P	no ASA	84	m	0918-00996	2020-11-12	2020-11-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
922	547	P	no ASA	81	m	0922-02021	2022-01-28	2022-01-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047654	Vitreous floaters
922	547	P	no ASA	81	m	0922-02022	2022-02-11	2022-02-11	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10047655	Vitreous haemorrhage
922	547	P	no ASA	81	m	0922-02023	2022-04-19	2022-04-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040882	Skin lesion
922	547	P	no ASA	81	m	0922-02126	2022-08-03	2022-08-03	Other event	Severe	None, i.e. still ongoing	not related	related	Recovered/resolved	10061256	Ischaemic stroke
922	547	P	no ASA	81	m	0922-01059	2020-10-26	2020-12-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020462, 10016173	Humerus fracture, Fall
1238	547	P	no ASA	77	m	1238-01084	2020-10-31	2020-10-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1554	547	P	no ASA	74	m	1554-01486	2021-05-07	2021-05-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1554	547	P	no ASA	74	m	1554-01487	2021-05-14	2021-05-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1653	547	P	no ASA	87	f	1653-01904	2022-04-29	2022-04-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081	Abdominal pain
1653	547	P	no ASA	87	f	1653-02598	2022-05-02	2022-11-09	Other event	Severe	Permanently discontinued due to this event	not related	related	Recovered/resolved	10062546, 10061593	Thrombosis in device, Echocardiogram abnormal

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1653	547	P	no ASA	87	f	1653-02277	2022-10-11	2022-10-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10010305, 10017577	Confusional state, Gait disturbance
1903	547	P	no ASA	77	f	1903-02151	2022-08-14	2022-08-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081, 10010774	Abdominal pain, Constipation
2051	547	P	no ASA	68	f	2051-02259	2022-07-09	2022-07-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
2379	547	P	no ASA	77	f	2379-02470	2022-09-03	2022-09-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005148	Blepharitis
2407	547	P	no ASA	73	f	2407-02389	2022-11-02	2022-11-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007759	Cataract nuclear
2520	547	P	no ASA	81	m	2520-02134	2022-08-25	2022-08-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
2521	547	P	no ASA	85	f	2521-02135	2022-08-16	2022-08-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037802, 10016173	Radius fracture, Fall
2565	547	P	no ASA	77	m	2565-02164	2022-06-23	2022-06-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10042772	Coronavirus test positive, Syncope
2632	547	P	no ASA	86	f	2632-02468	2022-09-21	2022-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081	Abdominal pain
378	547	E	ASA	74	m	0378-00040	2018-01-17	2018-01-19	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10049555	Anal haemorrhage
392	547	E	ASA	81	m	0392-00103	2018-02-12	2018-02-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
392	547	E	ASA	81	m	0392-00104	2018-03-18	2018-03-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
392	547	E	ASA	81	m	0392-00105	2018-06-01	2018-06-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020635	Hyperglycaemia
392	547	E	ASA	81	m	0392-00106	2018-06-22	2018-06-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039906	Seizure
392	547	E	ASA	81	m	0392-00387	2019-02-20	2019-02-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039906	Seizure
392	547	E	ASA	81	m	0392-00388	2019-05-19	2019-05-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
392	547	E	ASA	81	m	0392-00232	2018-10-27	2018-10-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
392	547	E	ASA	81	m	0392-00233	2018-12-03	2018-12-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
392	547	E	ASA	81	m	0392-00234	2018-12-24	2018-12-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020635	Hyperglycaemia
392	547	E	ASA	81	m	0392-00235	2019-01-10	2019-01-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
392	547	E	ASA	81	m	0392-00582	2019-08-08	2019-08-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012601, 10020635	Diabetes mellitus, Hyperglycaemia
392	547	E	ASA	81	m	0392-00583	2019-10-29	2019-10-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1369	547	E	ASA	85	m	1369-00794	2020-02-18	2020-05-27	Other event	Severe	Temporarily discontinued	not related	not related	Recovered/resolved	10002034	Anaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1369	547	E	ASA	85	m	1369-01608	2021-11-08	2021-11-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020993, 10012373	Hypoglycaemia, Depressed level of consciousness
2055	547	E	ASA	83	m	2055-01268	2021-05-12	2021-05-12	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
2055	547	E	ASA	83	m	2055-01269	2021-05-17	2021-05-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013990	Dysuria
2055	547	E	ASA	83	m	2055-02087	2021-05-26	2021-05-28	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
2055	547	E	ASA	83	m	2055-01883	2021-10-23	2021-10-23	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867, 10013990	Haematuria, Dysuria
2055	547	E	ASA	83	m	2055-01884	2021-12-08	2021-12-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013990	Dysuria
2055	547	E	ASA	83	m	2055-01885	2021-12-26	2021-12-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033371	Pain
2055	547	E	ASA	83	m	2055-01886	2021-12-30	2021-12-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10006451	Bronchitis
2055	547	E	ASA	83	m	2055-01887	2022-03-26	2022-03-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10029223	Neuralgia
2055	547	E	ASA	83	m	2055-02090	2022-05-03	2022-05-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015958	Eye pain
2055	547	E	ASA	83	m	2055-02091	2022-05-15	2022-05-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
2055	547	E	ASA	83	m	2055-02092	2022-05-28	2022-05-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061623, 10013573, 10028813	Adverse drug reaction, Dizziness, Nausea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2055	547	E	ASA	83	m	2055-02093	2022-06-05	2022-06-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033425, 10002855	Pain in extremity, Anxiety
2055	547	E	ASA	83	m	2055-02094	2022-06-18	2022-06-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000081	Abdominal pain
2055	547	E	ASA	83	m	2055-02095	2022-06-20	2022-06-20	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867	Haematuria
2063	547	E	ASA	78	f	2063-02288	2022-09-02	2022-09-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10034835	Pharyngitis
2063	547	E	ASA	78	f	2063-01856	2021-11-16	2021-11-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10007554	Dyspnoea, Cardiac failure
2063	547	E	ASA	78	f	2063-01857	2021-12-03	2021-12-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
2214	547	E	ASA	67	m	2214-01483	2021-09-14	2021-09-14	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018964, 10012735, 10037087, 10061461	Haemoptysis, Diarrhoea, Pruritus, Erectile dysfunction
2214	547	E	ASA	67	m	2214-02525	2021-11-11	2021-11-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2411	547	E	ASA	84	m	2411-02013	2022-06-16	2022-06-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061225	Limb injury
2411	547	E	ASA	84	m	2411-02334	2022-07-10	2022-07-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
2411	547	E	ASA	84	m	2411-02335	2022-08-09	2022-08-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
573	547	E	no ASA	80	m	0573-00092	2018-06-07	2018-06-07	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
864	547	E	no ASA	75	m	0864-00954	2020-02-03	2020-02-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035664	Pneumonia
936	547	E	no ASA	80	f	0936-01081	2021-01-20	2021-01-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10003549	Dizziness, Asthenia
996	547	E	no ASA	70	f	0996-00848	2020-06-09	2020-06-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall

Patient-ID	Centre-ID	Random group[1]	Random stratum (Indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
996	547	E	no ASA	70	f	0996-02289	2022-09-11	2022-09-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015958	Eye pain
996	547	E	no ASA	70	f	0996-02290	2022-10-04	2022-10-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
996	547	E	no ASA	70	f	0996-01761	2021-12-25	2021-12-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
996	547	E	no ASA	70	f	0996-01762	2021-12-26	2021-12-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
996	547	E	no ASA	70	f	0996-01763	2021-12-27	2021-12-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
1160	547	E	no ASA	72	m	1160-00982	2020-07-07	2020-07-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
1160	547	E	no ASA	72	m	1160-01657	2021-07-15	2021-07-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772, 10021097	Syncope, Hypotension
1160	547	E	no ASA	72	m	1160-01305	2020-12-18	2020-12-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10050584	Fall, Contusion
1622	547	E	no ASA	69	m	1622-01658	2021-08-10	2021-08-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10035664	Coronavirus test positive, Pneumonia
1932	547	E	no ASA	66	f	1932-02200	2022-09-05	2022-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1932	547	E	no ASA	66	f	1932-01710	2021-08-31	2021-08-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019974	Herpes zoster
1938	547	E	no ASA	86	f	1938-01770	2021-08-20	2021-08-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
2054	547	E	no ASA	84	m	2054-01878	2022-01-09	2022-01-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
2129	547	E	no ASA	82	m	2129-02524	2022-11-22	2022-11-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037660	Pyrexia
2129	547	E	no ASA	82	m	2129-01949	2022-01-24	2022-01-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2213	547	E	no ASA	82	m	2213-01750	2021-12-17	2021-12-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479, 10036978	Chest pain, Prostatitis
2380	547	E	no ASA	67	m	2380-02018	2022-04-26	2022-04-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024453	Ligament sprain
2380	547	E	no ASA	67	m	2380-02526	2022-01-25	2022-01-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
667	557	P	ASA	85	m	0667-00240	2019-01-02	2019-01-29	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10008479	Chest pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
667	557	P	ASA	85	m	0667-01773	2021-10-07	2021-11-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10063354	Charles Bonnet syndrome
667	557	P	ASA	85	m	0667-01774	2022-02-12	2022-02-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
667	557	P	ASA	85	m	0667-01775	2022-01-11		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10008479	Chest pain
667	557	P	ASA	85	m	0667-02076	2022-03-20	2022-03-20	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10019196	Head injury
667	557	P	ASA	85	m	0667-00403	2019-08-13	2019-08-13	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002906	Aortic stenosis
667	557	P	ASA	85	m	0667-01535	2021-10-05	2021-10-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047571	Visual impairment
733	557	P	ASA	79	f	0733-00443	2019-09-05	2019-04-05	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10077465	Myeloproliferative neoplasm
733	557	P	ASA	79	f	0733-01845	2021-10-18	2021-10-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046306	Upper respiratory tract infection
733	557	P	ASA	79	f	0733-02330	2022-09-19		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia
733	557	P	ASA	79	f	0733-00960	2020-09-12	2020-09-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10021097	Dizziness, Hypotension
460	557	P	no ASA	65	m	0460-02150	2022-03-01	2022-06-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
460	557	P	no ASA	65	m	0460-02160	2020-03-02	2020-09-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
460	557	P	no ASA	65	m	0460-02174	2021-03-03		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10030095	Oedema
530	557	P	no ASA	77	m	0530-00172	2018-07-18	2018-09-18	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1117	557	P	no ASA	88	m	1117-02167	2020-12-31	2021-03-24	Other event	Moderate	Permanently discontinued	related	related	Recovered/resolved	10037844	Rash

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1117	557	P	no ASA	88	m	1117-02168	2022-04-01	2022-04-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
502	557	E	ASA	83	f	0502-00156	2018-09-10	2018-09-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
502	557	E	ASA	83	f	0502-00157	2018-03-28	2018-04-04	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10050584	Contusion
502	557	E	ASA	83	f	0502-02169	2021-09-21	2022-03-22	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018852	Haematoma
502	557	E	ASA	83	f	0502-01814	2021-12-22	2022-02-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10002034	Anaemia
502	557	E	ASA	83	f	0502-02171	2022-07-20		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013950	Dysphagia
502	557	E	ASA	83	f	0502-02172	2022-09-11		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10015958, 10030041	Eye pain, Ocular hyperaemia
394	557	E	no ASA	78	f	0394-02157	2020-09-01	2021-03-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028411	Myalgia
394	557	E	no ASA	78	f	0394-02158	2021-09-21	2022-06-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
394	557	E	no ASA	78	f	0394-01702	2021-10-10	2021-10-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003399	Arthropod bite
394	557	E	no ASA	78	f	0394-01703	2021-11-25	2021-12-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
394	557	E	no ASA	78	f	0394-02159	2022-06-16	2022-09-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
394	557	E	no ASA	78	f	0394-00216	2018-07-08	2019-05-04	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10013946	Dyspepsia
394	557	E	no ASA	78	f	0394-00217	2019-01-04	2019-01-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
394	557	E	no ASA	78	f	0394-02156	2019-10-01	2020-09-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
598	557	E	no ASA	78	f	0598-00182	2018-06-20	2018-06-27	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10013573	Dizziness
598	557	E	no ASA	78	f	0598-00183	2018-08-31	2018-09-14	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10050584	Contusion
598	557	E	no ASA	78	f	0598-02170	2019-06-18	2019-06-18	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10016173	Fall

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1232	557	E	no ASA	76	f	1232-00492	2019-11-06	2019-11-13	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved with sequelae	10000081	Abdominal pain
1110	564	P	ASA	84	m	1110-00753	2020-01-06	2020-01-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019196	Head injury
490	564	E	ASA	70	m	0490-00169	2018-06-15	2019-12-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048959, 10033425	Peripheral swelling, Pain in extremity
490	564	E	ASA	70	m	0490-01861	2021-12-12	2022-06-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10048768	Dermatosis
490	564	E	ASA	70	m	0490-02297	2022-10-05		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10070255	Coronavirus test positive
490	564	E	ASA	70	m	0490-00265	2019-02-17	2019-02-27	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022000	Influenza
490	564	E	ASA	70	m	0490-01142	2020-12-01		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10030095	Oedema
548	564	E	ASA	81	f	0548-00226	2018-07-05		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10003239	Arthralgia
548	564	E	ASA	81	f	0548-00545	2019-10-31	2020-04-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011781	Cystitis
548	564	E	ASA	81	f	0548-01862	2021-10-21	2021-10-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
548	564	E	ASA	81	f	0548-01981	2022-04-15	2022-04-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
548	564	E	ASA	81	f	0548-01982	2022-03-01	2022-03-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
548	564	E	ASA	81	f	0548-02437	2022-11-03	2022-11-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
548	564	E	ASA	81	f	0548-00316	2019-05-17	2019-05-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
548	564	E	ASA	81	f	0548-00317	2019-04-10	2019-04-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
548	564	E	ASA	81	f	0548-01254	2020-11-24	2020-11-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
974	564	E	ASA	81	f	0974-00393	2019-04-15	2019-05-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
974	564	E	ASA	81	f	0974-00394	2019-05-31	2019-06-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011781	Cystitis
974	564	E	ASA	81	f	0974-01097	2020-10-22	2020-11-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
779	564	E	no ASA	69	m	0779-00214	2018-12-21	2018-12-23	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10018276	Gingival bleeding
779	564	E	no ASA	69	m	0779-00215	2018-12-14	2018-12-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018627	Gout
779	564	E	no ASA	69	m	0779-01863	2022-03-01	2022-03-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
165	566	E	ASA	78	m	0165-00190	2018-06-22	2018-06-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
165	566	E	ASA	78	m	0165-00237	2017-07-01	2017-07-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
344	577	P	no ASA	80	m	0344-00186	2017-12-18	2018-05-15	Other event	Severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10060862	Prostate cancer
344	577	P	no ASA	80	m	0344-00187	2018-02-19	2018-05-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013990	Dysuria
377	605	P	ASA	66	m	0377-00358	2019-07-04	2019-07-04	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007661	Cardioversion
377	605	P	ASA	66	m	0377-01431	2019-07-03	2019-07-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061225	Limb injury
377	605	P	ASA	66	m	0377-01430	2020-05-12		Other event	Moderate	None, i.e. still ongoing	not related	not related	Unknown	10034464	Periarthritis
298	605	E	ASA	79	m	0298-00992	2020-06-10		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10061536	Parkinson's disease
298	605	E	ASA	79	m	0298-01033	2020-09-24	2020-12-01	Other event	Severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10016454	Femur fracture
572	608	P	ASA	77	m	0572-00154	2018-07-04	2018-07-04	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10006480, 10037383	Bronchoscopy abnormal, Pulmonary fibrosis
816	608	P	ASA	78	m	0816-00466	2019-03-20	2019-05-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003662	Atrial flutter
868	608	P	ASA	78	m	0868-01816	2021-12-01	2021-12-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
903	608	P	no ASA	76	f	0903-00994	2019-12-18	2020-06-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040979	Sleep apnoea syndrome
1450	608	P	no ASA	75	f	1450-00988	2020-06-10	2020-06-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10041349	Somnolence
1450	608	P	no ASA	75	f	1450-01815	2021-12-15	2022-02-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
869	608	E	ASA	67	m	0869-01109	2020-12-17	2020-12-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10041629	Spirometry

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
869	608	E	ASA	67	m	0869-01647	2021-11-03	2021-11-03	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10010007	Colonoscopy
1791	608	E	ASA	81	m	1791-01538	2021-01-22	2021-03-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047531	Visual acuity reduced
1471	608	E	no ASA	86	m	1471-01190	2020-07-10	2020-07-10	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
601	619	E	no ASA	87	f	0601-00758	2019-07-09	2019-08-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037802	Radius fracture
601	619	E	no ASA	87	f	0601-01024	2020-11-19	2020-11-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
601	619	E	no ASA	87	f	0601-00350	2019-05-02	2019-10-31	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
601	619	E	no ASA	87	f	0601-00362	2019-05-03		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10031282	Osteoporosis
138	641	P	no ASA	67	m	0138-00181	2017-10-23	2017-10-25	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
138	641	P	no ASA	67	m	0138-00385	2018-11-29	2018-11-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
422	641	P	no ASA	85	m	0422-02616	2020-01-15	2020-01-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
1905	641	P	no ASA	78	f	1905-02549	2021-05-12	2021-05-14	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10052925	Cholelithotomy
262	641	E	no ASA	70	m	0262-00898	2020-04-22	2020-04-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
588	641	E	no ASA	71	m	0588-00882	2019-04-10	2019-04-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002034	Anaemia
1828	641	E	no ASA	75	m	1828-02550	2020-11-17	2021-06-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10027183	Meniere's disease
152	655	P	ASA	68	f	0152-00132	2018-04-20	2018-05-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020462	Humerus fracture
465	655	P	ASA	89	m	0465-00913	2020-02-27		Other event	Mild	Permanently discontinued due to this event	not related	not related	Event ongoing	10003662	Atrial flutter
465	655	P	ASA	89	m	0465-00922	2020-02-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10013968, 10031123	Dyspnoea, Orthopnoea
580	655	P	ASA	85	m	0580-01954	2022-01-01		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10002383	Angina pectoris
580	655	P	ASA	85	m	0580-02316	2022-06-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10013971	Dyspnoea exertional
580	655	P	ASA	85	m	0580-00915	2020-05-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10003988	Back pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1457	655	P	ASA	76	m	1457-01399	2021-05-10	2021-05-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
560	655	P	no ASA	73	m	0560-01340	2020-12-01	2021-02-15	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013950	Dysphagia
597	655	P	no ASA	84	m	0597-00370	2019-01-24	2019-01-24	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
379	655	E	ASA	84	m	0379-00151	2018-02-26	2018-02-28	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
549	655	E	ASA	75	m	0549-00989	2019-10-26	2019-10-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10003549	Dyspnoea, Asthenia
549	655	E	ASA	75	m	0549-00363	2019-05-03	2019-05-17	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10002034	Anaemia
549	655	E	ASA	75	m	0549-01034	2020-09-15	2020-11-03	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10013968	Dyspnoea
559	655	E	ASA	77	m	0559-02133	2022-06-16		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10049848, 10016173	Balance disorder, Fall
559	655	E	ASA	77	m	0559-00923	2020-05-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10013968	Dyspnoea
461	655	E	no ASA	78	f	0461-00983	2020-08-01	2020-08-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011224	Cough
269	673	P	ASA	90	m	0269-00581	2019-01-16	2020-07-23	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10057678	Vascular dementia
269	673	P	ASA	90	m	0269-00303	2019-01-16	2019-03-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10057678	Vascular dementia
269	673	P	ASA	90	m	0269-00140	2018-05-22	2020-07-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10016059	Facial pain
269	673	P	ASA	90	m	0269-00261	2018-08-05	2019-03-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031064	Orchitis
1916	673	P	ASA	79	f	1916-02026	2022-03-14	2022-03-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10022972	Iron deficiency anaemia
1916	673	P	ASA	79	f	1916-02451	2022-07-30	2022-11-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10019196	Fall, Head injury
2234	673	P	ASA	84	m	2234-02072	2022-04-12	2022-08-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
2234	673	P	ASA	84	m	2234-02073	2022-05-08	2022-08-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002855	Anxiety
2337	673	P	ASA	65	m	2337-01918	2022-01-20	2022-01-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10002882, 10002910	Aortic aneurysm, Aortic thrombosis
2339	673	P	ASA	71	m	2339-01945	2022-05-10	2022-05-18	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
2339	673	P	ASA	71	m	2339-01946	2022-05-10	2022-05-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006482	Bronchospasm

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
194	673	P	no ASA	82	m	0194-00345	2019-04-12	2019-05-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
324	673	P	no ASA	71	f	0324-00301	2019-04-03	2019-04-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10060820	Joint injury
324	673	P	no ASA	71	f	0324-01198	2021-01-22	2021-02-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
821	673	P	no ASA	81	f	0821-00955	2020-05-19	2020-08-09	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10038063	Rectal haemorrhage
821	673	P	no ASA	81	f	0821-00965	2020-07-29	2020-08-09	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10038019	Rectal adenocarcinoma
833	673	P	no ASA	73	f	0833-01255	2021-01-05	2021-05-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
833	673	P	no ASA	73	f	0833-01256	2021-04-24	2021-05-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003246	Arthritis
833	673	P	no ASA	73	f	0833-01944	2021-12-30	2021-12-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1048	673	P	no ASA	83	m	1048-01168	2021-01-14	2021-07-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
1150	673	P	no ASA	82	m	1150-01331	2020-05-07	2020-05-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10002855, 10022437, 10003239	Anxiety, Insomnia, Arthralgia
1287	673	P	no ASA	79	m	1287-01515	2021-09-06	2021-09-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10067585	Type 2 diabetes mellitus
1533	673	P	no ASA	70	m	1533-01795	2021-11-09	2021-11-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
1875	673	P	no ASA	85	f	1875-01263	2021-02-02	2022-11-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
1875	673	P	no ASA	85	f	1875-01616	2021-07-28	2021-11-17	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10017853	Gastritis
2086	673	P	no ASA	92	m	2086-02599	2022-04-24	2022-05-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2268	673	P	no ASA	83	m	2268-01810	2022-03-14	2022-03-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10002383	Angina pectoris
2268	673	P	no ASA	83	m	2268-02190	2022-08-12	2022-08-12	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10002383, 10052086, 10065608	Angina pectoris, Coronary arterial stent insertion, Percutaneous coronary intervention
2575	673	P	no ASA	91	f	2575-02242	2022-06-20	2022-10-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
948	673	E	ASA	84	m	0948-01085	2020-08-19	2020-08-29	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1372	673	E	ASA	81	m	1372-01934	2022-01-04	2022-01-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1713	673	E	ASA	84	m	1713-01728	2021-09-15	2021-09-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1713	673	E	ASA	84	m	1713-01730	2021-11-11	2021-11-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1713	673	E	ASA	84	m	1713-01731	2021-11-11	2021-11-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046306	Upper respiratory tract infection
1713	673	E	ASA	84	m	1713-01732	2022-01-16	2022-01-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10038848	Retinal detachment
1713	673	E	ASA	84	m	1713-01733	2022-01-16	2022-01-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007739	Cataract
1913	673	E	ASA	90	m	1913-01670	2021-10-15	2021-10-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020802	Hypertensive crisis
91	673	E	no ASA	82	m	0091-00128	2018-05-22	2018-05-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479	Chest pain
337	673	E	no ASA	77	m	0337-01962	2021-12-06	2022-05-09	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10024652	Liver abscess
337	673	E	no ASA	77	m	0337-00493	2019-08-22	2019-11-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061761	Chondrocalcinosis
427	673	E	no ASA	90	m	0427-01147	2021-01-06	2021-01-25	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
707	673	E	no ASA	90	f	0707-00351	2018-10-03	2019-04-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10050584	Fall, Contusion
707	673	E	no ASA	90	f	0707-00352	2018-10-26	2018-11-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10002855	Anxiety
837	673	E	no ASA	76	m	0837-01236	2020-12-16	2021-05-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
837	673	E	no ASA	76	m	0837-01237	2021-03-24	2021-03-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039083	Rhinitis
837	673	E	no ASA	76	m	0837-01238	2021-01-01	2021-01-07	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
837	673	E	no ASA	76	m	0837-01943	2022-05-17	2022-05-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
837	673	E	no ASA	76	m	0837-00513	2019-10-01	2019-11-16	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10019022	Haemorrhoids

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
837	673	E	no ASA	76	m	0837-01613	2021-05-21	2021-11-18	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10015090, 10028024, 10005144	Epistaxis, Mouth haemorrhage, Bleeding varicose vein
1052	673	E	no ASA	75	m	1052-01172	2020-11-02		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10043882	Tinnitus
1052	673	E	no ASA	75	m	1052-01173	2021-03-04	2021-03-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10031161	Osteoarthritis
1052	673	E	no ASA	75	m	1052-01330	2021-02-26	2021-02-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10047340	Vertigo
1052	673	E	no ASA	75	m	1052-01843	2022-03-05	2022-03-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1136	673	E	no ASA	90	f	1136-00516	2019-11-08	2019-12-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1136	673	E	no ASA	90	f	1136-00962	2020-08-23	2020-08-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000081	Abdominal pain
1136	673	E	no ASA	90	f	1136-00963	2020-08-23	2020-08-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002383	Angina pectoris
1136	673	E	no ASA	90	f	1136-00964	2020-08-23	2020-08-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020802	Hypertensive crisis
1136	673	E	no ASA	90	f	1136-01251	2021-02-24	2022-11-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012378	Depression
1136	673	E	no ASA	90	f	1136-01252	2021-02-24	2022-11-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003549	Asthenia
1136	673	E	no ASA	90	f	1136-01940	2022-03-23	2022-05-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10022972	Iron deficiency anaemia
1136	673	E	no ASA	90	f	1136-01941	2022-04-29	2022-05-20	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10003988	Back pain
1168	673	E	no ASA	76	m	1168-00560	2019-12-09	2022-11-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10039674	Sciatica
1168	673	E	no ASA	76	m	1168-00622	2019-11-26	2019-11-30	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049548, 10031161	Knee operation, Osteoarthritis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1168	673	E	no ASA	76	m	1168-01003	2020-10-10	2020-11-23	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
1168	673	E	no ASA	76	m	1168-01004	2020-12-11	2020-12-12	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved with sequelae	10018867	Haematuria
1168	673	E	no ASA	76	m	1168-01332	2020-04-07	2020-04-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1168	673	E	no ASA	76	m	1168-01295	2021-01-13	2021-06-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10027538	Microcytic anaemia
1382	673	E	no ASA	69	m	1382-01960	2022-03-25	2022-04-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1662	673	E	no ASA	84	f	1662-01030	2020-12-11	2020-12-11	Other event	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved with sequelae	10022970, 10002034	Iron deficiency, Anaemia
1662	673	E	no ASA	84	f	1662-01031	2020-08-27	2020-11-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10048877	Vertebral lesion
1662	673	E	no ASA	84	f	1662-01333	2021-01-27	2021-05-18	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10017816	Gastric polypectomy
1662	673	E	no ASA	84	f	1662-01633	2021-05-18	2021-05-18	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10074625	Large intestinal polypectomy
1797	673	E	no ASA	73	m	1797-01819	2022-02-16	2022-03-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10020903	Hyperuricaemia
1797	673	E	no ASA	73	m	1797-02183	2022-04-04	2022-09-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039085	Rhinitis allergic
1797	673	E	no ASA	73	m	1797-01513	2021-04-15	2021-05-18	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
1797	673	E	no ASA	73	m	1797-01514	2021-09-06	2021-09-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10039085	Rhinitis allergic
1862	673	E	no ASA	84	f	1862-01219	2021-02-04	2021-02-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1862	673	E	no ASA	84	f	1862-01796	2021-06-28	2021-06-28	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2433	673	E	no ASA	78	m	2433-02132	2022-06-21	2022-07-18	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10003239	Arthralgia
307	675	P	no ASA	74	m	0307-00380	2018-03-18	2018-03-20	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018867	Haematuria
365	675	P	no ASA	79	m	0365-01206	2019-04-29	2019-04-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037087	Pruritus

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
365	675	P	no ASA	79	m	0365-01207	2019-09-12	2019-11-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012442	Dermatitis contact
365	675	P	no ASA	79	m	0365-01208	2019-06-03	2019-06-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10009033	Chronic obstructive pulmonary disease
365	675	P	no ASA	79	m	0365-01209	2019-09-30	2019-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10049088	Osteopenia
365	675	P	no ASA	79	m	0365-02580	2019-11-12		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10004446	Benign prostatic hyperplasia
365	675	P	no ASA	79	m	0365-00975	2020-08-04	2020-12-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10066065	Device lead damage
365	675	P	no ASA	79	m	0365-01152	2020-12-04	2020-12-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007598	Cardiac pacemaker insertion
240	675	E	no ASA	74	m	0240-00175	2018-10-09	2018-10-11	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10010007, 10009944	Colonoscopy, Colon cancer
240	675	E	no ASA	74	m	0240-00109	2018-07-01	2018-10-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10018852	Haematoma
384	675	E	no ASA	76	f	0384-01153	2018-07-09	2018-07-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10077407	Rhizolysis
384	675	E	no ASA	76	f	0384-01210	2019-06-26	2019-07-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10025409	Macular degeneration
384	675	E	no ASA	76	f	0384-02536	2021-07-14	2021-07-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
384	675	E	no ASA	76	f	0384-02537	2021-08-25	2021-11-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059650	Implant site infection
507	675	E	no ASA	82	m	0507-00480	2018-07-10	2018-07-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10025482, 10018836	Malaise, Haematochezia
507	675	E	no ASA	82	m	0507-01212	2020-05-11	2020-05-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047302	Ventricular tachycardia
507	675	E	no ASA	82	m	0507-01211	2020-05-11	2020-05-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
942	675	E	no ASA	84	m	0942-01213	2019-01-30	2019-07-17	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10027141	Melaena
942	675	E	no ASA	84	m	0942-01214	2019-06-28	2019-06-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003988	Back pain
942	675	E	no ASA	84	m	0942-02604	2019-03-12	2019-03-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013559, 10061636	Diverticulum intestinal, Angiodysplasia
772	680	P	ASA	70	m	0772-00444	2019-08-31	2019-08-31	Other event	Moderate	Not applicable (no	not related	not related	Recovered/resolved	10003658	Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
789	680	P	ASA	79	m	0789-00310	2019-01-21	2019-01-27	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049548	Knee operation
789	680	P	ASA	79	m	0789-01225	2021-02-17	2021-02-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024855, 10039203	Loss of consciousness, Road traffic accident
979	680	P	ASA	75	f	0979-00391	2019-02-18	2019-04-26	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
979	680	P	ASA	75	f	0979-00392	2019-05-05	2019-05-05	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
979	680	P	ASA	75	f	0979-00790	2020-04-01	2020-07-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10012601	Diabetes mellitus
981	680	P	ASA	80	m	0981-01080	2020-12-30		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10020903	Hyperuricaemia
981	680	P	ASA	80	m	0981-01738	2022-01-01	2022-09-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10036909	Prostate cancer metastatic
1037	680	P	ASA	74	m	1037-00408	2019-06-25	2019-06-27	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10013573, 10012735, 10019211	Dizziness, Diarrhoea, Headache
1037	680	P	ASA	74	m	1037-02155	2019-06-25	2019-06-27	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
1037	680	P	ASA	74	m	1037-01507	2021-01-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia
1037	680	P	ASA	74	m	1037-01139	2021-01-16	2021-03-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10039674	Sciatica
1122	680	P	ASA	77	m	1122-00728	2019-12-18	2019-12-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
1129	680	P	ASA	85	m	1129-00718	2020-04-01	2020-06-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1347	680	P	ASA	71	m	1347-00936	2020-10-13	2020-11-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10086210	Superficial vein thrombosis
1417	680	P	ASA	91	m	1417-00628	2019-12-12	2020-01-22	Other event	Mild	Permanently discontinued	related	not related	Recovered/resolved	10000081, 10017853	Abdominal pain, Gastritis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1531	680	P	ASA	87	m	1531-01106	2021-02-25	2022-08-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006272	Breast mass
1640	680	P	ASA	73	m	1640-01325	2021-04-01	2021-04-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002515	Animal bite
1815	680	P	ASA	84	f	1815-01164	2020-12-16	2020-12-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
1821	680	P	ASA	80	m	1821-01086	2021-01-07	2021-02-06	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10037087	Pruritus
1821	680	P	ASA	80	m	1821-01157	2021-02-18	2021-03-04	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10023204	Joint dislocation
1821	680	P	ASA	80	m	1821-01874	2022-04-01	2022-04-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10064990	Skin abrasion
1821	680	P	ASA	80	m	1821-01550	2021-08-05	2021-08-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10038419	Renal colic
2317	680	P	ASA	78	f	2317-02332	2022-08-29	2022-08-30	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10046528	Urinary bladder haemorrhage
771	680	P	no ASA	88	f	0771-01875	2022-04-13	2022-04-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10018852	Fall, Haematoma
838	680	P	no ASA	68	m	0838-01235	2021-04-15	2021-05-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10056997	Impaired fasting glucose
838	680	P	no ASA	68	m	0838-01970	2022-01-15	2022-05-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012378	Depression
838	680	P	no ASA	68	m	0838-00531	2019-07-26	2020-03-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10036975	Prostatic specific antigen increased
838	680	P	no ASA	68	m	0838-00981	2020-10-11	2020-10-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1156	680	P	no ASA	83	m	1156-00566	2019-12-09	2022-08-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021114	Hypothyroidism
1156	680	P	no ASA	83	m	1156-01652	2021-10-21	2021-10-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1474	680	P	no ASA	74	f	1474-00788	2020-02-20	2020-07-13	Other event	Moderate	Temporarily discontinued	related	related	Recovered/resolved	10017853	Gastritis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1960	680	P	no ASA	72	f	1960-01492	2021-04-01	2021-04-20	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000081, 10028813	Abdominal pain, Nausea
2394	680	P	no ASA	69	f	2394-02006	2022-03-03	2022-06-23	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10033645	Pancreatitis
2394	680	P	no ASA	69	f	2394-02551	2022-01-05	2022-06-23	Other event	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10000059	Abdominal discomfort
2394	680	P	no ASA	69	f	2394-02007	2022-03-03	2022-06-23	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10033645	Pancreatitis
763	680	E	ASA	75	m	0763-01202	2021-01-29	2021-02-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
763	680	E	ASA	75	m	0763-01575	2021-10-19	2021-10-19	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000081	Abdominal pain
813	680	E	ASA	84	f	0813-00305	2019-01-21	2019-01-21	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10015090	Epistaxis
813	680	E	ASA	84	f	0813-00306	2019-02-15	2019-02-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10012735	Diarrhoea
813	680	E	ASA	84	f	0813-01622	2021-11-16	2021-11-16	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
887	680	E	ASA	83	m	0887-00610	2020-01-06	2020-01-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020802, 10003549	Hypertensive crisis, Asthenia
993	680	E	ASA	69	m	0993-01423	2021-07-15	2021-07-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479	Chest pain
1034	680	E	ASA	81	m	1034-00445	2019-09-13	2019-09-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1034	680	E	ASA	81	m	1034-02396	2022-08-31	2022-09-02	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10046528	Urinary bladder haemorrhage
1041	680	E	ASA	73	m	1041-01536	2021-09-22	2021-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1065	680	E	ASA	79	f	1065-01017	2020-09-27	2020-09-27	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10016173	Fall

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1363	680	E	ASA	86	m	1363-01076	2020-11-13	2021-01-03	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1363	680	E	ASA	86	m	1363-01623	2021-06-01	2021-06-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
1657	680	E	ASA	77	m	1657-01026	2020-07-23	2020-08-02	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10017853, 10013864, 10014819, 10061816	Gastritis, Duodenitis, Endoscopy upper gastrointestinal tract, Diagnostic procedure
1657	680	E	ASA	77	m	1657-02012	2022-01-05	2022-04-27	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10051055	Deep vein thrombosis
1664	680	E	ASA	69	m	1664-01015	2020-06-27	2020-07-05	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10017853, 10028813	Gastritis, Nausea
1664	680	E	ASA	69	m	1664-01318	2021-03-01	2021-03-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2410	680	E	ASA	81	f	2410-02008	2022-01-01	2022-02-26	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
2539	680	E	ASA	71	m	2539-02270	2022-07-21	2022-07-25	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10013946	Dyspepsia
668	680	E	no ASA	79	f	0668-00241	2018-10-10	2018-10-10	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
1681	680	E	no ASA	76	f	1681-01047	2020-11-07	2020-11-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
2094	680	E	no ASA	77	f	2094-01653	2021-09-21	2021-10-12	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10020751	Hypersensitivity
1419	685	P	no ASA	76	m	1419-00900	2020-07-21	2020-07-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
1419	685	P	no ASA	76	m	1419-02592	2022-10-03		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10012267	Dementia
1419	685	P	no ASA	76	m	1419-01632	2021-11-11	2022-01-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020642	Hyperhidrosis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1419	685	P	no ASA	76	m	1419-01634	2021-06-05	2021-06-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10016173, 10019196	Dizziness, Fall, Head injury
185	685	E	no ASA	68	f	0185-01258	2021-03-22	2022-05-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
403	685	E	no ASA	85	f	0403-00276	2018-01-22	2018-02-05	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10012735	Diarrhoea
403	685	E	no ASA	85	f	0403-02591	2021-06-01	2021-06-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
403	685	E	no ASA	85	f	0403-01510	2019-02-04		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013968, 10033557, 10008469	Dyspnoea, Palpitations, Chest discomfort
1625	685	E	no ASA	81	m	1625-02593	2022-06-22		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10039101	Rhinorrhoea
728	688	P	ASA	72	m	0728-00695	2020-02-17	2020-05-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
728	688	P	ASA	72	m	0728-01472	2021-03-18	2021-04-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124, 10013968	Oedema peripheral, Dyspnoea
728	688	P	ASA	72	m	0728-01475	2020-10-29	2020-10-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10025197	Lymphadenopathy
728	688	P	ASA	72	m	0728-01846	2021-11-30	2022-01-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10022972	Iron deficiency anaemia
728	688	P	ASA	72	m	0728-01847	2022-01-13	2022-06-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020903	Hyperuricaemia
728	688	P	ASA	72	m	0728-01177	2020-06-16	2020-10-23	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
728	688	P	ASA	72	m	0728-02544	2020-06-18	2020-06-19	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10004797	Biopsy lymph gland
1209	688	P	ASA	65	m	1209-01433	2021-01-08	2021-04-15	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1312	688	P	ASA	65	f	1312-00661	2019-12-13	2020-03-17	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10037844	Rash
1312	688	P	ASA	65	f	1312-01170	2020-12-11	2020-12-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007739	Cataract
1312	688	P	ASA	65	f	1312-01171	2021-01-11	2021-01-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007739	Cataract
1312	688	P	ASA	65	f	1312-01838	2022-03-15	2022-08-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1312	688	P	ASA	65	f	1312-01839	2022-03-18	2022-04-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
1312	688	P	ASA	65	f	1312-00890	2020-09-22	2020-10-23	Other event	Mild	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10060795, 10037844	Hepatic enzyme increased, Rash
1312	688	P	ASA	65	f	1312-01522	2021-09-26	2021-10-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
1447	688	P	ASA	76	f	1447-01175	2020-12-15	2021-06-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1601	688	P	ASA	79	f	1601-01437	2021-04-27	2021-05-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
1601	688	P	ASA	79	f	1601-01468	2020-11-09	2020-11-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
2165	688	P	ASA	83	m	2165-01631	2021-11-24	2022-08-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005425	Blood cholesterol increased
2165	688	P	ASA	83	m	2165-01646	2021-08-02	2021-11-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
2165	688	P	ASA	83	m	2165-01978	2022-03-01	2022-06-07	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10049848	Balance disorder
2252	688	P	ASA	77	m	2252-01835	2021-11-30	2022-05-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
2281	688	P	ASA	80	f	2281-02485	2022-01-27	2022-02-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
2281	688	P	ASA	80	f	2281-02142	2022-06-23	2022-07-17	Other event	Severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10016173	Fall
127	688	P	no ASA	81	f	0127-01464	2021-03-22		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013968, 10003549	Dyspnoea, Asthenia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
127	688	P	no ASA	81	f	0127-01541	2021-08-24	2021-09-16	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10017577, 10049438	Gait disturbance, General physical health deterioration
127	688	P	no ASA	81	f	0127-01666	2021-09-03		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10041591	Spinal osteoarthritis
127	688	P	no ASA	81	f	0127-01667	2021-08-25	2021-09-16	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10084058	Congestive hepatopathy
127	688	P	no ASA	81	f	0127-02579	2021-09-03		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10031233	Osteochondrosis
628	688	P	no ASA	76	m	0628-00570	2019-10-07	2020-02-03	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10037844	Rash
628	688	P	no ASA	76	m	0628-01696	2022-01-11	2022-02-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015943	Eye inflammation
640	688	P	no ASA	77	f	0640-00290	2019-04-04		Other event	Severe	Temporarily discontinued due to this event	not related	not related	Event ongoing	10006187	Breast cancer
640	688	P	no ASA	77	f	0640-01169	2020-12-17	2020-12-17	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10022576	Internal fixation of fracture
640	688	P	no ASA	77	f	0640-01174	2021-02-19	2021-02-20	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013573	Dizziness
640	688	P	no ASA	77	f	0640-01462	2021-01-20	2021-01-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772, 10002383	Hypertension, Angina pectoris
640	688	P	no ASA	77	f	0640-01463	2021-02-19	2021-02-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10016173	Dizziness, Fall
842	688	P	no ASA	82	m	0842-00739	2019-12-18	2020-02-25	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
842	688	P	no ASA	82	m	0842-01967	2022-05-24	2022-06-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
112	688	E	ASA	73	m	0112-02131	2022-07-07	2022-09-15	Other event	Moderate	Not applicable (no	not related	not related	Recovered/resolved	10022970	Iron deficiency

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
112	688	E	ASA	73	m	0112-02179	2022-09-12	2022-09-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022970	Iron deficiency
210	688	E	ASA	70	f	0210-01466	2021-06-15	2021-07-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018627	Gout
865	688	E	ASA	68	m	0865-01467	2021-05-03	2021-05-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062237	Renal impairment
2179	688	E	ASA	79	m	2179-02212	2022-09-23	2022-10-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10029782	Normochromic anaemia
183	688	E	no ASA	76	m	0183-01317	2021-06-23	2021-07-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10020903	Hyperuricaemia
183	688	E	no ASA	76	m	0183-01465	2021-02-01	2021-02-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
550	688	E	no ASA	78	m	0550-00204	2018-08-13	2018-10-30	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018852	Haematoma
550	688	E	no ASA	78	m	0550-01626	2021-05-18	2022-08-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1877	688	E	no ASA	73	m	1877-01215	2021-02-20	2021-04-28	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1877	688	E	no ASA	73	m	1877-01473	2021-04-28	2021-04-28	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10054787	Haemorrhoidal haemorrhage
2363	688	E	no ASA	72	m	2363-01927	2022-01-08	2022-01-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10044055, 10062132	Toothache, Tooth extraction
2363	688	E	no ASA	72	m	2363-01928	2022-01-20	2022-01-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
232	690	P	no ASA	79	m	0232-00039	2017-11-22	2018-01-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002959	Aphthous ulcer
232	690	P	no ASA	79	m	0232-02517	2019-01-14	2019-01-21	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015926, 10063797	Eye haemorrhage, Cataract operation
232	690	P	no ASA	79	m	0232-00578	2020-01-04	2020-01-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810, 10037660	Nasopharyngitis, Pyrexia
232	690	P	no ASA	79	m	0232-00579	2019-09-04	2020-02-20	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025005	Lumbar spinal stenosis
232	690	P	no ASA	79	m	0232-00580	2020-01-06	2020-01-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
232	690	P	no ASA	79	m	0232-01045	2020-08-16	2020-08-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
232	690	P	no ASA	79	m	0232-01046	2020-08-20	2020-12-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
232	690	P	no ASA	79	m	0232-01590	2018-05-23	2018-05-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007695	Carpal tunnel decompression

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1229	692	E	ASA	67	m	1229-00606	2019-12-27		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10048667	Restrictive pulmonary disease
1229	692	E	ASA	67	m	1229-00607	2019-10-18		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10037153	Psoriasis
1229	692	E	ASA	67	m	1229-01064	2021-01-11	2021-01-19	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10038435	Renal failure
1229	692	E	ASA	67	m	1229-01065	2021-01-11	2021-01-19	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020646	Hyperkalaemia
1229	692	E	ASA	67	m	1229-00797	2020-04-27		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10021114	Hypothyroidism
1229	692	E	ASA	67	m	1229-00952	2020-02-05	2020-02-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2282	693	P	ASA	83	m	2282-02512	2022-04-07	2022-05-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10037660	Coronavirus test positive, Pyrexia
1454	693	P	no ASA	73	m	1454-02514	2022-01-13	2022-01-27	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10037660	Coronavirus test positive, Pyrexia
1453	693	E	no ASA	78	m	1453-02513	2022-07-23	2022-08-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10037660	Coronavirus test positive, Pyrexia
428	697	E	ASA	80	f	0428-00122	2018-04-01	2018-11-15	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10024429, 10037844	Lichen planus, Rash
428	697	E	ASA	80	f	0428-01359	2021-06-25	2021-07-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
428	697	E	ASA	80	f	0428-02069	2022-07-18	2022-07-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10014184	Eczema
428	697	E	ASA	80	f	0428-00243	2018-08-21	2018-08-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
428	697	E	ASA	80	f	0428-00247	2018-10-26	2019-02-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
428	697	E	ASA	80	f	0428-00248	2018-11-21	2018-12-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
475	698	P	ASA	75	m	0475-00423	2019-09-03	2019-09-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
621	698	P	ASA	79	m	0621-01321	2021-01-01	2021-12-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895	Weight decreased
1123	698	P	ASA	65	m	1123-01601	2021-03-08	2021-05-04	Other event	Moderate	Not applicable (no	not related	not related	Recovered/resolved	10013968	Dyspnoea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1123	698	P	ASA	65	m	1123-00938	2020-08-10	2020-09-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10021097	Dizziness, Hypotension
1123	698	P	ASA	65	m	1123-01563	2020-06-23	2020-06-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028594	Myocardial fibrosis
1123	698	P	ASA	65	m	1123-01564	2020-07-24	2022-03-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1123	698	P	ASA	65	m	1123-01499	2021-09-04	2021-09-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
162	698	P	no ASA	74	m	0162-00746	2019-11-18	2019-11-18	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018964	Haemoptysis
162	698	P	no ASA	74	m	0162-01220	2021-04-19	2021-07-01	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10008479, 10013968	Chest pain, Dyspnoea
162	698	P	no ASA	74	m	0162-01605	2021-08-31	2021-11-24	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
162	698	P	no ASA	74	m	0162-00068	2018-04-02	2018-04-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549, 10030095	Asthenia, Oedema
162	698	P	no ASA	74	m	0162-00418	2019-04-01	2019-06-19	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
226	698	E	ASA	73	m	0226-01055	2020-08-15	2021-02-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
226	698	E	ASA	73	m	0226-01377	2021-04-22	2021-06-16	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10076454, 10051449	Chronic papillomatous dermatitis, Biopsy intestine
226	698	E	ASA	73	m	0226-00114	2018-07-03	2022-07-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011078	Coronary artery disease
303	698	E	ASA	74	m	0303-01193	2021-04-08	2021-04-08	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061853	Eyelid operation
303	698	E	ASA	74	m	0303-01194	2021-04-22	2021-04-22	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061853	Eyelid operation
303	698	E	ASA	74	m	0303-01561	2020-12-25	2021-01-14	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090, 10039721	Epistaxis, Sclerotherapy
303	698	E	ASA	74	m	0303-01562	2021-07-20	2021-08-17	Other event	Moderate	Not applicable (no	not related	not related	Recovered/resolved	10063797	Cataract operation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
303	698	E	ASA	74	m	0303-01855	2022-02-22	2022-02-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061853	Eyelid operation
303	698	E	ASA	74	m	0303-00176	2018-10-17	2018-10-24	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
303	698	E	ASA	74	m	0303-00949	2020-09-24	2020-11-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
303	698	E	ASA	74	m	0303-01560	2020-09-15	2020-09-16	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
1494	698	E	ASA	80	m	1494-01392	2021-01-26	2021-08-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017885	Gastrooesophageal reflux disease
1494	698	E	ASA	80	m	1494-02351	2022-07-28		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10027175	Memory impairment
1494	698	E	ASA	80	m	1494-00706	2020-05-06	2022-06-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10064848	Dyspnoea, Chronic kidney disease
1494	698	E	ASA	80	m	1494-01725	2021-09-15	2022-01-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10060800	Hot flush
1494	698	E	ASA	80	m	1494-01726	2021-01-01	2022-02-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10027175	Memory impairment
1494	698	E	ASA	80	m	1494-01727	2022-01-31	2022-01-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10057453	Aortic dilatation
1494	698	E	ASA	80	m	1494-01729	2021-09-10	2021-09-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10060862	Prostate cancer
193	698	E	no ASA	78	f	0193-00549	2019-09-01	2019-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
193	698	E	no ASA	78	f	0193-00747	2019-10-11	2019-11-05	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10048049	Wrist fracture
193	698	E	no ASA	78	f	0193-01558	2020-09-21	2020-11-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021114	Hypothyroidism
193	698	E	no ASA	78	f	0193-01559	2020-11-25	2020-12-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003591	Ataxia
193	698	E	no ASA	78	f	0193-01270	2021-04-08	2021-05-18	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003239	Arthralgia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
193	698	E	no ASA	78	f	0193-01543	2020-04-08	2020-12-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10010774	Dizziness, Constipation
193	698	E	no ASA	78	f	0193-00849	2020-09-01	2020-10-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10021097	Dizziness, Hypotension
1310	700	P	ASA	74	m	1310-01148	2020-11-02	2020-11-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension
2483	700	P	ASA	72	m	2483-02493	2022-06-27	2022-12-01	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
2483	700	P	ASA	72	m	2483-02122	2022-08-11	2022-08-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2483	700	P	ASA	72	m	2483-02123	2022-08-11	2022-09-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
2483	700	P	ASA	72	m	2483-02214	2022-09-11	2022-09-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1018	700	E	no ASA	78	m	1018-02213	2022-09-26	2022-10-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10044055	Toothache
1018	700	E	no ASA	78	m	1018-01805	2021-09-30	2021-10-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046555	Urinary retention
1296	702	P	ASA	86	m	1296-00491	2019-10-05	2019-10-30	Other event	Severe	Permanently discontinued due to this event	related	related	Recovered/resolved	10037087	Pruritus
289	702	P	no ASA	77	m	0289-00097	2017-12-12	2017-12-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10043607	Thrombosis
289	702	P	no ASA	77	m	0289-00061	2017-09-27	2017-10-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003119	Arrhythmia
1682	705	P	ASA	83	m	1682-02565	2022-09-07	2022-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
1860	705	P	ASA	86	m	1860-01288	2020-11-12	2020-12-03	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10064265	Skin haemorrhage
1416	705	E	ASA	79	m	1416-01459	2020-10-14	2021-01-20	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
1509	705	E	ASA	68	f	1509-01460	2020-06-18	2020-06-18	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10028024	Mouth haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2272	705	E	ASA	70	m	2272-02538	2022-01-12	2022-04-04	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10007815	Coronavirus test positive, Catheterisation cardiac
2367	705	E	ASA	69	m	2367-02082	2022-08-06	2022-08-06	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10005140	Bleeding time prolonged
1621	705	E	no ASA	75	f	1621-00831	2020-07-06	2020-08-26	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10018852, 10046996, 10055798	Haematoma, Varicose vein, Haemorrhage
2133	705	E	no ASA	75	m	2133-01958	2022-01-30	2022-01-30	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
654	706	P	ASA	82	m	0654-01098	2021-02-16	2021-05-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
654	706	P	ASA	82	m	0654-01246	2021-02-18	2022-08-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013971	Dyspnoea exertional
278	706	E	ASA	84	f	0278-01135	2019-07-05	2019-07-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014011	Ear infection
278	706	E	ASA	84	f	0278-02141	2022-07-25	2022-07-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030919	Optic disc haemorrhage
278	706	E	ASA	84	f	0278-00889	2019-07-08	2019-09-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014011	Ear infection
278	706	E	ASA	84	f	0278-00887	2020-09-04	2020-09-30	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007695	Carpal tunnel decompression
278	706	E	ASA	84	f	0278-00888	2020-09-01	2020-10-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047340	Vertigo
689	706	E	ASA	82	m	0689-00871	2020-01-14	2020-06-19	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
689	706	E	ASA	82	m	0689-01253	2021-03-10	2021-04-23	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10024855, 10016173, 10041291	Loss of consciousness, Fall, Soft tissue injury
689	706	E	ASA	82	m	0689-01881	2022-02-18	2022-10-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173, 10039117	Fall, Rib fracture
689	706	E	ASA	82	m	0689-01574	2021-10-13	2021-12-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10048049	Wrist fracture
208	706	E	no ASA	71	m	0208-00037	2017-11-30	2017-11-30	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10051077	Post procedural haemorrhage
208	706	E	no ASA	71	m	0208-00218	2018-08-21	2019-09-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020649	Hyperkeratosis
208	706	E	no ASA	71	m	0208-01571	2021-07-24	2023-01-23	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10018884	Haemoglobin decreased

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
208	706	E	no ASA	71	m	0208-01570	2021-06-19	2021-07-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033714, 10059443	Papilloma excision, Skin neoplasm excision
208	706	E	no ASA	71	m	0208-00102	2018-04-30	2018-04-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
208	706	E	no ASA	71	m	0208-00373	2019-03-07	2019-03-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
208	706	E	no ASA	71	m	0208-00374	2019-07-01	2019-07-26	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10050584	Contusion
248	706	E	no ASA	78	m	0248-00117	2018-01-11	2018-04-03	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	related	Recovered/resolved with sequelae	10015090	Epistaxis
248	706	E	no ASA	78	m	0248-00119	2017-09-19	2017-09-20	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018867	Haematuria
248	706	E	no ASA	78	m	0248-01151	2020-09-27	2020-10-03	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
248	706	E	no ASA	78	m	0248-02282	2022-07-12	2022-10-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
248	706	E	no ASA	78	m	0248-00136	2018-08-17	2018-08-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
248	706	E	no ASA	78	m	0248-00137	2018-03-07	2018-08-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037383	Pulmonary fibrosis
480	707	P	ASA	80	m	0480-00453	2019-03-22	2019-04-25	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10086210	Superficial vein thrombosis
480	707	P	ASA	80	m	0480-01528	2021-01-30	2021-01-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011814	Cystoscopy
1820	707	P	no ASA	80	m	1820-01548	2021-04-27	2021-04-28	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
1820	707	P	no ASA	80	m	1820-01549	2021-06-03	2021-06-14	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059443	Skin neoplasm excision
437	707	E	ASA	74	m	0437-00686	2019-10-24	2019-10-25	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1226	707	E	ASA	79	m	1226-02594	2022-01-18	2022-01-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016256, 10023232, 10028411	Fatigue, Joint swelling, Myalgia
1226	707	E	ASA	79	m	1226-01529	2020-06-10	2020-07-17	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10009944, 10010007	Colon cancer, Colonoscopy
439	711	E	no ASA	73	f	0439-00130	2018-02-10	2018-03-31	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10017853	Gastritis
439	711	E	no ASA	73	f	0439-00198	2018-02-10	2018-03-31	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000087	Abdominal pain upper
611	711	E	no ASA	84	m	0611-00770	2020-01-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10028980	Neoplasm
2630	720	P	ASA	79	m	2630-02148	2022-09-05	2022-09-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1039	724	P	ASA	79	f	1039-00699	2019-08-06	2019-08-14	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10017955	Gastrointestinal haemorrhage
1039	724	P	ASA	79	f	1039-01039	2020-08-30	2021-01-01	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10038063	Rectal haemorrhage
1040	724	E	ASA	86	f	1040-00458	2019-07-22	2019-07-22	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10062501, 10021015	Non-cardiac chest pain, Hypokalaemia
796	725	P	ASA	85	m	0796-00315	2019-04-01	2019-05-17	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10039674	Sciatica
796	725	P	ASA	85	m	0796-00832	2020-05-13	2020-05-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1042	725	P	ASA	78	m	1042-00334	2019-03-30	2019-07-17	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10037844	Rash
1239	725	P	ASA	82	m	1239-00611	2019-11-20	2019-11-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
1239	725	P	ASA	82	m	1239-01746	2021-02-03	2022-08-15	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018852	Haematoma
1239	725	P	ASA	82	m	1239-02258	2022-09-21	2022-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1239	725	P	ASA	82	m	1239-01370	2021-05-01	2021-07-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030095	Oedema
1392	725	P	ASA	89	m	1392-00833	2020-05-13	2020-05-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10022000	Influenza

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1947	725	P	ASA	84	m	1947-02066	2022-05-01	2022-05-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
1947	725	P	ASA	84	m	1947-01503	2021-09-20	2021-10-02	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	not related	Recovered/resolved	10015090, 10018836	Epistaxis, Haematochezia
2041	725	P	ASA	82	m	2041-01338	2021-05-01	2021-05-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018867	Haematuria
2041	725	P	ASA	82	m	2041-02306	2022-06-15	2022-10-19	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10038435	Renal failure
2041	725	P	ASA	82	m	2041-02307	2022-10-14	2022-10-19	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2197	725	P	ASA	95	m	2197-01737	2022-01-26	2022-01-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005911	Body temperature increased
2474	725	P	ASA	77	m	2474-02084	2022-05-15	2022-06-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
2642	725	P	ASA	69	m	2642-02359	2022-08-01	2022-10-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018800	Gynaecomastia
1154	725	P	no ASA	79	m	1154-01013	2020-12-15	2022-09-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033425	Pain in extremity
1154	725	P	no ASA	79	m	1154-01014	2020-12-15	2020-12-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
1154	725	P	no ASA	79	m	1154-01611	2021-09-04	2021-09-04	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1154	725	P	no ASA	79	m	1154-01614	2021-09-04	2021-09-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10018359	Glomerular filtration rate increased
1154	725	P	no ASA	79	m	1154-00436	2019-09-02	2019-12-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1154	725	P	no ASA	79	m	1154-00822	2020-04-25	2020-04-27	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10003662	Atrial flutter
1154	725	P	no ASA	79	m	1154-01247	2021-05-14	2022-09-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10048959	Peripheral swelling
1154	725	P	no ASA	79	m	1154-01248	2021-05-18	2021-05-20	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1154	725	P	no ASA	79	m	1154-01374	2021-02-10	2021-02-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
1154	725	P	no ASA	79	m	1154-01966	2022-02-04	2022-02-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10069204	Electrocauterisation
1442	725	P	no ASA	75	m	1442-01264	2021-03-16	2021-05-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10065558	Aortic arteriosclerosis
1442	725	P	no ASA	75	m	1442-01963	2022-06-02	2022-06-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1442	725	P	no ASA	75	m	1442-02615	2021-12-15	2021-12-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
1525	725	P	no ASA	75	f	1525-00836	2020-08-10	2020-10-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
1525	725	P	no ASA	75	f	1525-01794	2020-06-17	2020-06-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1525	725	P	no ASA	75	f	1525-02085	2022-07-08	2022-07-21	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
1525	725	P	no ASA	75	f	1525-01093	2020-12-01	2022-10-26	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10031161	Osteoarthritis
782	725	E	ASA	85	m	0782-02608	2021-01-05	2021-01-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
782	725	E	ASA	85	m	0782-01864	2022-04-01	2022-10-03	Other event	Mild	None, i.e. still ongoing	related	not related	Recovered/resolved with sequelae	10029784	Normocytic anaemia
822	725	E	ASA	68	m	0822-00222	2018-12-20	2019-03-25	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10015150	Erythema
1329	725	E	ASA	69	m	1329-01865	2022-02-18	2022-02-18	Other event	Mild	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
1470	725	E	ASA	76	m	1470-02000	2020-06-27	2022-01-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
1470	725	E	ASA	76	m	1470-02001	2020-06-27	2022-01-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003549, 10013573	Asthenia, Dizziness
1470	725	E	ASA	76	m	1470-01329	2021-06-30	2021-06-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003549, 10013573	Asthenia, Dizziness
1470	725	E	ASA	76	m	1470-01077	2021-01-27	2021-01-27	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10003549, 10013573	Asthenia, Dizziness

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1619	725	E	ASA	72	m	1619-01964	2022-03-18	2022-03-18	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062003	Hernia repair
1742	725	E	ASA	82	f	1742-02096	2022-07-01	2022-08-01	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030095	Oedema
1742	725	E	ASA	82	f	1742-02097	2022-05-01	2022-10-18	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10038435	Renal failure
1742	725	E	ASA	82	f	1742-02098	2022-07-01	2022-07-30	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
1946	725	E	ASA	72	m	1946-01480	2021-07-12	2021-08-09	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10047895	Weight decreased
1946	725	E	ASA	72	m	1946-01438	2021-07-12	2022-10-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10029784	Normocytic anaemia
1946	725	E	ASA	72	m	1946-02062	2022-08-01	2022-08-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension
1946	725	E	ASA	72	m	1946-02607	2022-01-26	2022-01-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
1954	725	E	ASA	84	m	1954-01435	2021-08-01	2021-09-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018852	Haematoma
1954	725	E	ASA	84	m	1954-01436	2021-08-18	2021-08-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049235	Nocturnal dyspnoea
2030	725	E	ASA	83	f	2030-01498	2021-09-20	2022-03-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
2030	725	E	ASA	83	f	2030-02605	2022-03-22	2022-03-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
2040	725	E	ASA	81	m	2040-01849	2022-03-01	2022-03-10	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10054787	Haemorrhoidal haemorrhage
2040	725	E	ASA	81	m	2040-01848	2022-03-01	2022-03-10	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10054787	Haemorrhoidal haemorrhage
2105	725	E	ASA	69	m	2105-01257	2021-05-18	2021-06-16	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10018964	Haemoptysis
2105	725	E	ASA	69	m	2105-01617	2021-06-21	2021-06-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2353	725	E	ASA	86	m	2353-01951	2022-02-15	2022-05-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013971	Dyspnoea exertional
2353	725	E	ASA	86	m	2353-01952	2022-05-01	2022-09-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030095	Oedema
2492	725	E	ASA	86	f	2492-02083	2022-07-19	2022-07-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10042772	Syncope
1620	725	E	no ASA	73	m	1620-00997	2020-09-01	2020-12-09	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10077107, 10018852	Complication associated with device, Haematoma
1620	725	E	no ASA	73	m	1620-01298	2021-06-14	2021-06-14	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10033557	Palpitations
1620	725	E	no ASA	73	m	1620-01965	2022-05-30	2022-05-30	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015926	Eye haemorrhage
1620	725	E	no ASA	73	m	1620-02397	2022-04-04	2022-04-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003658	Atrial fibrillation
1644	725	E	no ASA	69	m	1644-01299	2021-06-07	2021-06-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1644	725	E	no ASA	69	m	1644-01300	2021-06-14	2021-06-14	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10018852	Haematoma
1644	725	E	no ASA	69	m	1644-01898	2022-04-21	2022-06-10	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090, 10038867	Epistaxis, Retinal haemorrhage
1644	725	E	no ASA	69	m	1644-01899	2022-04-01	2022-04-28	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018852	Haematoma
1166	728	P	ASA	87	f	1166-01016	2020-10-12	2021-02-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10004146	Basal cell carcinoma
1166	728	P	ASA	87	f	1166-01778	2021-10-19	2021-11-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019974	Herpes zoster
1166	728	P	ASA	87	f	1166-01779	2021-11-06	2021-11-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1166	728	P	ASA	87	f	1166-02440	2022-08-17	2022-08-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1166	728	P	ASA	87	f	1166-02464	2022-10-10	2022-10-10	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1166	728	P	ASA	87	f	1166-01352	2021-01-04	2021-01-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10009192	Circulatory collapse
1166	728	P	ASA	87	f	1166-01353	2021-03-30	2021-04-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018627	Gout
1166	728	P	ASA	87	f	1166-01355	2021-07-02	2021-07-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024855	Loss of consciousness
1166	728	P	ASA	87	f	1166-01356	2021-02-26	2021-03-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048959	Peripheral swelling
1166	728	P	ASA	87	f	1166-01357	2020-12-18	2021-03-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10059443, 10048038	Skin neoplasm excision, Wound infection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1166	728	P	ASA	87	f	1166-02036	2022-05-25	2022-09-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012267	Dementia
1166	728	P	ASA	87	f	1166-02037	2022-03-01	2022-11-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10004146	Basal cell carcinoma
1124	728	P	no ASA	75	m	1124-02465	2022-10-18	2022-11-27	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10010774	Constipation
1124	728	P	no ASA	75	m	1124-02466	2022-06-30	2022-10-24	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022016	Inguinal hernia
1124	728	P	no ASA	75	m	1124-02040	2021-12-14	2022-07-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10057678	Vascular dementia
1124	728	P	no ASA	75	m	1124-02049	2021-12-14	2022-07-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10061590	Blood disorder
577	728	E	ASA	85	m	0577-01784	2021-08-10	2021-08-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
577	728	E	ASA	85	m	0577-02308	2022-07-24	2022-07-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
387	728	E	no ASA	81	m	0387-00361	2019-06-18	2019-06-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062132	Tooth extraction
387	728	E	no ASA	81	m	0387-00489	2019-06-14	2019-06-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10025310	Lymphoma
883	728	E	no ASA	72	f	0883-00341	2019-02-21	2019-02-21	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
883	728	E	no ASA	72	f	0883-00342	2019-01-07	2019-01-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010774	Constipation
883	728	E	no ASA	72	f	0883-02016	2021-12-21	2022-10-18	Other event	Severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10010774	Constipation
883	728	E	no ASA	72	f	0883-02218	2022-09-26	2022-10-18	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10043071	Tachycardia
883	728	E	no ASA	72	f	0883-02231	2022-07-05	2022-07-05	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10047461	Viral infection
883	728	E	no ASA	72	f	0883-00605	2019-06-22	2019-06-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
883	728	E	no ASA	72	f	0883-00987	2020-06-28	2022-10-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
1560	730	P	no ASA	89	f	1560-00893	2020-07-28	2020-09-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
925	740	P	ASA	86	m	0925-02611	2022-08-11		Other event	Severe	Not applicable (no	not related	not related	Event ongoing	10012267	Dementia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
431	740	E	ASA	88	m	0431-02612	2020-04-27	2020-04-27	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1058	740	E	ASA	79	f	1058-02614	2021-03-30	2021-03-30	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10012735, 10047895	Diarrhoea, Weight decreased
1058	740	E	ASA	79	f	1058-02414	2021-04-26		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10002882	Aortic aneurysm
1058	740	E	ASA	79	f	1058-02415	2021-06-29		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10064930	Age-related macular degeneration
1058	740	E	ASA	79	f	1058-02408	2022-08-04	2022-08-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1058	740	E	ASA	79	f	1058-02409	2022-11-02	2022-11-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1058	740	E	ASA	79	f	1058-02613	2020-10-06	2020-10-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10031127, 10042772	Orthostatic hypotension, Syncope
753	740	E	no ASA	78	m	0753-02271	2022-09-18	2022-09-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
1737	741	P	ASA	67	m	1737-02609	2022-07-05	2022-07-05	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
421	741	P	no ASA	74	f	0421-01407	2021-04-01	2021-04-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
421	741	P	no ASA	74	f	0421-02065	2022-07-15	2022-07-18	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10051055, 10012735	Deep vein thrombosis, Diarrhoea
484	741	P	no ASA	84	m	0484-00864	2020-08-10	2020-08-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028347	Muscle twitching
484	741	P	no ASA	84	m	0484-02118	2022-03-14	2022-06-17	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10003988	Back pain
484	741	P	no ASA	84	m	0484-00284	2018-12-31	2018-12-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013946	Dyspepsia
484	741	P	no ASA	84	m	0484-01161	2020-11-13	2020-11-13	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	related	related	Recovered/resolved	10038063	Rectal haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1051	741	P	no ASA	69	m	1051-00454	2019-09-16	2019-09-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033775, 10020642	Paraesthesia, Hyperhidrosis
1051	741	P	no ASA	69	m	1051-00455	2019-09-20	2019-09-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1790	741	P	no ASA	87	m	1790-01469	2021-06-09	2021-06-10	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173	Fall
1825	741	P	no ASA	80	m	1825-01586	2021-09-28	2021-10-08	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10003662	Atrial flutter
1836	741	P	no ASA	79	m	1836-01187	2020-12-14	2021-05-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
1836	741	P	no ASA	79	m	1836-01556	2021-04-01	2021-04-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013554	Diverticulum
1850	741	P	no ASA	84	m	1850-01230	2020-12-09	2020-12-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013950	Dysphagia
2015	741	P	no ASA	70	f	2015-01844	2021-09-23	2022-09-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10039674	Sciatica
2313	741	P	no ASA	83	m	2313-02344	2022-09-06	2022-09-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031127	Orthostatic hypotension
2315	741	P	no ASA	77	m	2315-01961	2022-02-25	2022-02-28	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000081, 10019211	Abdominal pain, Headache
725	741	E	ASA	70	m	0725-01860	2021-10-01	2021-10-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
725	741	E	ASA	70	m	0725-00876	2020-06-07	2020-09-29	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10010030	Colorectal cancer recurrent
725	741	E	ASA	70	m	0725-00877	2020-07-06	2020-09-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10060862	Prostate cancer
840	741	E	ASA	78	m	0840-02531	2022-06-09	2022-06-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10057525	Peripheral artery occlusion
840	741	E	ASA	78	m	0840-00481	2019-05-16	2019-05-16	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10022020	Inguinal hernia repair
840	741	E	ASA	78	m	0840-00482	2019-06-18	2019-06-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
840	741	E	ASA	78	m	0840-00483	2019-06-14	2019-06-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10047513	Dizziness, Vision blurred
840	741	E	ASA	78	m	0840-01682	2020-08-20	2020-08-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020772	Hypertension
840	741	E	ASA	78	m	0840-01953	2021-10-25	2021-10-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
840	741	E	ASA	78	m	0840-00827	2020-05-16	2020-05-16	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
840	741	E	ASA	78	m	0840-00828	2020-08-01	2020-08-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
368	741	E	no ASA	84	m	0368-00209	2018-12-03	2018-12-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048959	Peripheral swelling
415	741	E	no ASA	83	f	0415-01410	2021-08-12	2021-08-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10044565	Tremor
415	741	E	no ASA	83	f	0415-02606	2020-11-06	2020-11-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
435	741	E	no ASA	78	m	0435-00123	2018-02-09	2018-07-26	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10012735	Diarrhoea
435	741	E	no ASA	78	m	0435-00470	2019-10-03	2019-10-03	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003662	Atrial flutter
435	741	E	no ASA	78	m	0435-00298	2019-02-04	2019-02-04	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061284	Mental disorder
435	741	E	no ASA	78	m	0435-02610	2020-11-17	2020-11-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1118	741	E	no ASA	81	m	1118-00712	2020-01-08	2020-01-08	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062008	Hydrocele operation
1356	741	E	no ASA	77	m	1356-02522	2022-10-19	2022-10-19	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10022687	Intestinal obstruction
1408	741	E	no ASA	77	m	1408-01228	2021-04-07	2021-04-07	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10061683	Arthrodesis
1408	741	E	no ASA	77	m	1408-01229	2021-04-26	2021-04-26	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10010007	Colonoscopy
2253	741	E	no ASA	74	m	2253-01720	2021-09-13	2021-09-22	Other event	Moderate	Permanently discontinued	not related	related	Recovered/resolved	10017944	Gastrointestinal disorder

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
2253	741	E	no ASA	74	m	2253-02511	2022-06-04	2022-06-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2319	741	E	no ASA	78	m	2319-01968	2021-12-22	2021-12-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015090	Epistaxis
576	748	P	ASA	84	f	0576-00086	2018-06-01	2018-06-03	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10037087, 10000081, 10019211	Pruritus, Abdominal pain, Headache
957	748	P	ASA	87	m	0957-00382	2019-02-17	2019-02-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017888, 10012174	Gastroenteritis, Dehydration
957	748	P	ASA	87	m	0957-00383	2019-06-15	2019-06-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10071367	Infected dermal cyst
1026	748	P	ASA	91	f	1026-01792	2022-01-28	2022-01-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1139	748	P	ASA	90	m	1139-00381	2019-06-25	2019-06-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003549	Asthenia
1251	748	P	ASA	92	m	1251-01089	2020-12-31	2020-12-31	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046995	Varicose ulceration
1285	748	P	ASA	88	m	1285-01785	2021-12-13	2021-12-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1659	748	P	ASA	81	f	1659-01010	2020-08-19	2020-08-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
1659	748	P	ASA	81	f	1659-01011	2020-09-16	2020-09-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
1659	748	P	ASA	81	f	1659-01671	2021-11-08	2021-12-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020462	Humerus fracture
1659	748	P	ASA	81	f	1659-01979	2022-03-01	2022-03-15	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10015145, 10025197	Erysipelas, Lymphadenopathy
1674	748	P	ASA	89	f	1674-00884	2020-07-13	2020-07-24	Other event	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10013573	Dizziness
1731	748	P	ASA	84	m	1731-01094	2020-10-01	2021-04-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735, 10017853, 10013946	Diarrhoea, Gastritis, Dyspepsia
1731	748	P	ASA	84	m	1731-01766	2021-09-01	2021-09-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10047700	Dizziness, Vomiting
2186	748	P	ASA	82	m	2186-01717	2021-12-22	2021-12-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10060862	Prostate cancer

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
564	748	P	no ASA	81	f	0564-01604	2021-05-11	2021-05-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
564	748	P	no ASA	81	f	0564-01218	2021-01-13	2021-01-13	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10007661	Cardioversion
824	748	P	no ASA	78	f	0824-01902	2022-03-08	2022-03-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
824	748	P	no ASA	78	f	0824-01903	2022-04-26	2022-04-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063797	Cataract operation
999	748	P	no ASA	80	m	0999-00825	2020-02-12	2020-02-12	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
999	748	P	no ASA	80	m	0999-00826	2020-05-05	2020-05-05	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10063797	Cataract operation
199	748	E	ASA	81	m	0199-01630	2021-08-20	2021-08-20	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007661	Cardioversion
610	748	E	ASA	83	m	0610-00550	2019-10-01	2019-10-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
610	748	E	ASA	83	m	0610-01362	2021-07-06	2021-07-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10036105, 10017577	Polyneuropathy, Gait disturbance
687	748	E	ASA	80	m	0687-00160	2018-08-24	2018-08-29	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10033557, 10013573, 10012735	Palpitations, Dizziness, Diarrhoea
928	748	E	ASA	84	f	0928-00366	2019-06-28	2019-07-09	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173	Fall
1096	748	E	ASA	89	f	1096-00495	2019-05-26	2019-05-27	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10047340	Vertigo
1130	748	E	ASA	76	m	1130-00507	2019-11-15	2019-11-15	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018276	Gingival bleeding
1966	748	E	ASA	84	m	1966-01406	2021-05-03	2021-05-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2136	748	E	ASA	81	m	2136-01629	2021-10-11	2021-10-18	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10069472	Vaccination site haematoma
2236	748	E	ASA	80	m	2236-01609	2021-10-01	2021-10-17	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10016256, 10012374	Fatigue, Depressed mood

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2236	748	E	ASA	80	m	2236-02115	2021-10-01	2021-11-12	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10012374	Depressed mood
2734	748	E	ASA	88	f	2734-02108	2022-08-12	2022-08-18	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013573, 10019303, 10040984, 10025482	Dizziness, Heart rate increased, Sleep disorder, Malaise
641	748	E	no ASA	88	m	0641-00227	2019-01-18	2019-01-19	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
641	748	E	no ASA	88	m	0641-02057	2022-04-13	2022-04-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1982	748	E	no ASA	72	f	1982-01425	2021-08-13	2021-08-13	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10037844	Rash
1982	748	E	no ASA	72	f	1982-01502	2021-08-13	2021-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735, 10047700, 10033557	Diarrhoea, Vomiting, Palpitations
371	752	P	ASA	80	m	0371-00343	2019-05-22	2019-07-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10072140	Bladder wall calcification
371	752	P	ASA	80	m	0371-00199	2018-11-30	2019-01-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002034	Anaemia
457	752	P	ASA	83	f	0457-00142	2018-03-15	2018-03-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063550	Spondylolisthesis
457	752	P	ASA	83	f	0457-00143	2018-09-02	2018-09-07	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019196, 10016173, 10018852	Head injury, Fall, Haematoma
1111	752	P	ASA	79	f	1111-00503	2019-06-20	2019-06-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047571	Visual impairment
1111	752	P	ASA	79	f	1111-00504	2019-07-10	2019-07-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10016173	Fall
1111	752	P	ASA	79	f	1111-00951	2020-11-09	2020-11-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10018852	Fall, Haematoma
316	752	P	no ASA	84	f	0316-00066	2017-11-20	2018-04-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10042772	Fall, Syncope
316	752	P	no ASA	84	f	0316-00067	2018-04-16	2018-05-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011781	Cystitis
316	752	P	no ASA	84	f	0316-00099	2017-11-20	2017-11-20	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10050392	Face injury
316	752	P	no ASA	84	f	0316-00093	2017-12-04	2017-12-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10070878	Cerebral small vessel ischaemic disease
316	752	P	no ASA	84	f	0316-00094	2018-05-16	2018-10-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047571	Visual impairment
316	752	P	no ASA	84	f	0316-00348	2018-11-28	2018-11-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
316	752	P	no ASA	84	f	0316-00349	2019-04-10	2019-04-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10050819	Musculoskeletal chest pain
316	752	P	no ASA	84	f	0316-00520	2018-11-13	2019-04-01	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10004056	Bacteriuria

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
316	752	P	no ASA	84	f	0316-00521	2019-03-15	2019-03-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003553	Asthma
316	752	P	no ASA	84	f	0316-00522	2019-04-13	2019-04-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003553	Asthma
316	752	P	no ASA	84	f	0316-00523	2019-04-10	2019-05-22	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10003988	Back pain
316	752	P	no ASA	84	f	0316-00476	2019-08-22	2019-09-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
657	752	P	no ASA	84	m	0657-00242	2019-01-21	2019-02-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
1025	752	P	no ASA	86	m	1025-00353	2019-04-19	2019-05-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988, 10016173	Back pain, Fall
1025	752	P	no ASA	86	m	1025-00354	2019-05-03	2019-05-03	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10042772	Syncope
1025	752	P	no ASA	86	m	1025-00355	2019-05-11	2019-07-31	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020462	Humerus fracture
862	752	E	ASA	89	f	0862-00715	2019-12-25	2019-12-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
862	752	E	ASA	89	f	0862-00716	2020-02-04	2020-02-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10007554	Dyspnoea, Cardiac failure
1081	752	E	ASA	86	m	1081-00464	2019-07-10	2020-04-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1081	752	E	ASA	86	m	1081-00675	2019-10-17	2019-12-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10009245	Clavicle fracture
406	752	E	no ASA	88	f	0406-00107	2018-06-22	2018-06-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
406	752	E	no ASA	88	f	0406-00356	2019-04-24	2019-04-24	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10042772	Syncope
458	752	E	no ASA	80	m	0458-00141	2018-05-29	2018-05-29	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10010007	Colonoscopy
517	752	E	no ASA	91	m	0517-00168	2018-07-01	2018-08-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007882	Cellulitis
517	752	E	no ASA	91	m	0517-00908	2020-07-04	2020-07-05	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10038063	Rectal haemorrhage
517	752	E	no ASA	91	m	0517-00674	2019-11-05	2019-11-05	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
517	752	E	no ASA	91	m	0517-01179	2021-02-22	2021-05-24	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013950	Dysphagia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
517	752	E	no ASA	91	m	0517-01180	2021-02-14	2021-05-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10040808	Skin cancer
607	752	E	no ASA	88	m	0607-00673	2018-11-15	2018-11-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10049438, 10013573, 10013968	General physical health deterioration, Dizziness, Dyspnoea
607	752	E	no ASA	88	m	0607-02584	2019-12-02	2019-12-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005191	Blister
1069	756	P	ASA	76	m	1069-00479	2019-04-09	2019-10-07	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10012735	Diarrhoea
1069	756	P	ASA	76	m	1069-01075	2020-11-06		Other event	Severe	None, i.e. still ongoing	not related	not related	Event ongoing	10035226	Plasma cell myeloma
1102	756	P	ASA	77	f	1102-02585	2022-05-17		Other event	Mild	None, i.e. still ongoing	not related	not related	Unknown	10062237	Renal impairment
495	756	E	ASA	74	m	0495-01577	2020-09-17	2020-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017853	Gastritis
495	756	E	ASA	74	m	0495-01576	2019-10-11	2020-10-15	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved with sequelae	10000087, 10022972	Abdominal pain upper, Iron deficiency anaemia
495	756	E	ASA	74	m	0495-01578	2021-03-15		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10002383	Angina pectoris
1255	756	E	ASA	81	m	1255-00984	2019-12-04		Other event	Mild	Permanently discontinued due to this event	not related	not related	Event ongoing	10003662	Atrial flutter
481	758	P	ASA	77	f	0481-00447	2019-09-23	2019-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988	Back pain
481	758	P	ASA	77	f	0481-00448	2019-08-05	2019-09-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061225	Limb injury
481	758	P	ASA	77	f	0481-01307	2021-02-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10002034	Anaemia
481	758	P	ASA	77	f	0481-01308	2021-02-01	2022-03-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239	Arthralgia
1086	758	P	no ASA	68	m	1086-02603	2021-12-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10062585	Peripheral arterial occlusive disease
811	758	E	ASA	66	m	0811-01309	2019-05-13	2019-11-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033775	Paraesthesia
760	758	E	no ASA	88	m	0760-00293	2019-04-16	2019-07-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
760	758	E	no ASA	88	m	0760-00294	2019-04-16	2019-07-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
619	774	P	ASA	78	m	0619-00588	2019-10-10	2019-10-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
619	774	P	ASA	78	m	0619-01724	2021-12-26	2022-01-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10018852	Fall, Haematoma
312	774	P	no ASA	73	m	0312-00178	2018-05-17	2018-05-17	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10028813	Nausea

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
312	774	P	no ASA	73	m	0312-01602	2020-08-12	2020-08-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020462	Humerus fracture
497	774	E	ASA	67	m	0497-00450	2019-05-31	2019-05-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
497	774	E	ASA	67	m	0497-00907	2020-10-03	2020-10-07	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10016173	Fall
497	774	E	ASA	67	m	0497-01919	2021-11-26	2021-11-27	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10064990	Skin abrasion
497	774	E	ASA	67	m	0497-01920	2022-03-06	2022-03-13	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
497	774	E	ASA	67	m	0497-00677	2020-03-29	2020-03-29	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10016173	Fall
660	775	P	ASA	72	f	0660-00459	2019-02-13	2019-02-19	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10058467	Lung neoplasm malignant
660	775	P	ASA	72	f	0660-00660	2019-02-13		Other event	Severe	Permanently discontinued due to this event	not related	not related	Event ongoing	10058467	Lung neoplasm malignant
1851	775	E	ASA	81	f	1851-01722	2021-04-07	2022-04-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
1851	775	E	ASA	81	f	1851-02029	2022-04-20	2022-04-20	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10037844	Rash
1432	776	E	ASA	74	m	1432-01455	2020-01-13	2020-06-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10072736	Rheumatic disorder
1432	776	E	ASA	74	m	1432-02416	2022-10-31	2022-11-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005746	Blood pressure fluctuation
614	776	E	no ASA	79	f	0614-01461	2019-07-22	2021-08-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
614	776	E	no ASA	79	f	0614-01457	2021-04-30	2021-05-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007661	Cardioversion
2727	776	E	no ASA	82	m	2727-02453	2022-07-29	2022-11-24	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10018852	Haematoma
284	780	P	no ASA	77	m	0284-02471	2021-10-22	2021-10-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
313	780	E	ASA	73	m	0313-02128	2022-05-02	2022-05-31	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10013971	Dyspnoea exertional

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
313	780	E	ASA	73	m	0313-02011	2020-09-01	2022-06-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011224	Cough
313	780	E	ASA	73	m	0313-02554	2020-09-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013968	Dyspnoea
781	780	E	ASA	65	m	0781-00386	2019-04-01	2019-07-19	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10047571	Visual impairment
781	780	E	ASA	65	m	0781-00666	2020-03-09	2020-03-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
781	780	E	ASA	65	m	0781-01149	2021-03-21	2021-03-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047571	Visual impairment
781	780	E	ASA	65	m	0781-00467	2019-08-09	2019-09-11	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10047571	Visual impairment
781	780	E	ASA	65	m	0781-00623	2019-11-14	2019-11-14	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10007739	Cataract
781	780	E	ASA	65	m	0781-00627	2020-01-29	2020-01-29	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10047571	Visual impairment
781	780	E	ASA	65	m	0781-01242	2020-09-01	2020-09-02	Other event	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10047571	Visual impairment
781	780	E	ASA	65	m	0781-01532	2021-10-01	2021-10-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047571, 10033775	Visual impairment, Paraesthesia
781	780	E	ASA	65	m	0781-01533	2021-10-01	2021-10-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
354	780	E	no ASA	75	m	0354-00563	2019-10-29	2019-11-20	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007739	Cataract
354	780	E	no ASA	75	m	0354-01022	2020-12-09	2021-01-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
354	780	E	no ASA	75	m	0354-01035	2020-12-20	2021-01-13	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
673	780	E	no ASA	83	m	0673-01581	2020-07-17	2020-09-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10011224	Cough
1605	788	P	no ASA	68	m	1605-01976	2022-06-13	2022-06-30	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010719	Conjunctival haemorrhage
1872	788	P	no ASA	66	m	1872-02484	2022-10-14	2022-10-21	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10038063	Rectal haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1733	788	E	no ASA	76	f	1733-01107	2020-08-26	2020-08-28	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10000081	Abdominal pain
884	799	P	no ASA	75	f	0884-00329	2019-03-03		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10013968	Dyspnoea
1163	799	P	no ASA	76	m	1163-00405	2019-08-21		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10061536	Parkinson's disease
647	800	P	ASA	85	f	0647-00624	2019-08-26	2019-08-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019196	Head injury
647	800	P	ASA	85	f	0647-01739	2021-11-24		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10031282	Osteoporosis
647	800	P	ASA	85	f	0647-01740	2020-11-24		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10062189	Vitamin D decreased
647	800	P	ASA	85	f	0647-01741	2021-11-24		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10063550	Spondylolisthesis
647	800	P	ASA	85	f	0647-00389	2019-02-07		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10012713	Diaphragmatic hernia
647	800	P	ASA	85	f	0647-01421	2021-03-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003239	Arthralgia
647	800	P	ASA	85	f	0647-01422	2021-07-28	2022-08-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024910	Low density lipoprotein increased
1221	800	P	ASA	77	f	1221-00574	2019-11-01	2019-11-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046571	Urinary tract infection
1221	800	P	ASA	77	f	1221-00575	2019-12-02		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10021114	Hypothyroidism
1221	800	P	ASA	77	f	1221-02239	2022-08-01	2022-10-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10019211	Headache
1221	800	P	ASA	77	f	1221-01500	2021-06-08	2022-07-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10030124	Oedema peripheral
1221	800	P	ASA	77	f	1221-01501	2021-05-08	2022-07-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10043570	Thrombophlebitis
1401	800	P	ASA	80	m	1401-00731	2019-12-01	2021-05-20	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10055798, 10058818	Haemorrhage, Skin laceration
1401	800	P	ASA	80	m	1401-01241	2021-05-05		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003549	Asthenia
1401	800	P	ASA	80	m	1401-01947	2022-02-10	2022-02-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047895	Weight decreased
1401	800	P	ASA	80	m	1401-01948	2022-02-22		Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Event ongoing	10012267	Dementia
1401	800	P	ASA	80	m	1401-00957	2020-08-01	2022-02-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10047895	Weight decreased
1401	800	P	ASA	80	m	1401-00958	2020-08-24		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10021114	Hypothyroidism
1401	800	P	ASA	80	m	1401-01612	2021-06-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003239	Arthralgia
1421	800	P	ASA	75	m	1421-00652	2019-11-30	2019-12-04	Bleeding event/haematoma	Mild	Permanently discontinued	related	related	Recovered/resolved	10015090	Epistaxis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1421	800	P	ASA	75	m	1421-00742	2020-05-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10013968	Dyspnoea
1527	800	P	ASA	84	f	1527-00838	2020-05-29		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10022970	Iron deficiency
1527	800	P	ASA	84	f	1527-01103	2020-12-01	2020-12-04	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046735	Urticaria
1527	800	P	ASA	84	f	1527-01104	2021-01-11	2021-01-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020802	Hypertensive crisis
571	800	P	no ASA	69	m	0571-00527	2019-10-20	2020-01-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061428	Decreased appetite
571	800	P	no ASA	69	m	0571-00327	2019-02-04	2019-02-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10062040	Liver operation
571	800	P	no ASA	69	m	0571-00328	2019-05-22	2019-05-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061225, 10016678	Limb injury, Finger amputation
571	800	P	no ASA	69	m	0571-00740	2020-05-04	2020-08-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019646	Hepatic cyst
1667	800	P	no ASA	81	m	1667-01018	2020-06-30	2020-12-11	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013573	Dizziness
420	800	E	ASA	88	m	0420-00799	2020-05-12		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10008629	Cholelithiasis
420	800	E	ASA	88	m	0420-00807	2020-06-05	2022-08-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
420	800	E	ASA	88	m	0420-00808	2020-05-16		Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10064265	Skin haemorrhage
420	800	E	ASA	88	m	0420-00809	2020-05-16		Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10038019	Rectal adenocarcinoma
420	800	E	ASA	88	m	0420-00810	2020-06-09	2020-06-15	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10021097	Hypotension

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
420	800	E	ASA	88	m	0420-00411	2019-08-24	2019-08-25	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
420	800	E	ASA	88	m	0420-00412	2019-08-24	2019-08-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
420	800	E	ASA	88	m	0420-00413	2019-08-24	2019-08-24	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
420	800	E	ASA	88	m	0420-00632	2019-09-01	2019-12-02	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000087	Abdominal pain upper
420	800	E	ASA	88	m	0420-00633	2020-02-11	2020-02-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002383	Angina pectoris
642	800	E	ASA	84	m	0642-00131	2018-08-04	2018-08-05	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10018867	Haematuria
653	800	E	ASA	67	m	0653-01091	2021-01-05	2021-01-25	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
653	800	E	ASA	67	m	0653-01092	2021-02-02		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10004446	Benign prostatic hyperplasia
653	800	E	ASA	67	m	0653-01748	2022-02-08		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10049694	Left ventricular dysfunction
653	800	E	ASA	67	m	0653-02479	2022-02-16	2022-02-16	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554	Cardiac failure
653	800	E	ASA	67	m	0653-02504	2022-02-23	2022-02-23	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554, 10080743	Cardiac failure, Angiocardiogram
1128	800	E	ASA	77	m	1128-00501	2019-09-06	2019-09-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016256	Fatigue
1128	800	E	ASA	77	m	1128-00502	2019-09-25		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10048612	Hydrothorax
1603	800	E	ASA	86	m	1603-02253	2020-08-04	2020-10-05	Other event	Mild	Not applicable (no	not related	not related	Recovered/resolved	10012601	Diabetes mellitus

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1603	800	E	ASA	86	m	1603-00791	2020-06-02		Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Event ongoing	10015090	Epistaxis
1603	800	E	ASA	86	m	1603-00792	2020-06-06		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10007554	Cardiac failure
1603	800	E	ASA	86	m	1603-00793	2020-07-03	2021-01-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10038435	Renal failure
1264	800	E	no ASA	68	m	1264-00837	2020-08-04	2022-02-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1332	800	E	no ASA	80	m	1332-00680	2020-02-13	2021-06-08	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10006451	Bronchitis
1332	800	E	no ASA	80	m	1332-02241	2019-11-07	2022-10-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047289	Ventricular extrasystoles
1332	800	E	no ASA	80	m	1332-01551	2021-06-08	2021-06-17	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10006458	Bronchitis chronic
1332	800	E	no ASA	80	m	1332-01552	2021-06-04		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003988	Back pain
1332	800	E	no ASA	80	m	1332-01553	2021-09-17		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10062060	Hyperlipidaemia
1984	800	E	no ASA	72	f	1984-02136	2022-04-03	2022-05-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061599	Lower limb fracture
1984	800	E	no ASA	72	f	1984-02137	2022-08-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10033775	Paraesthesia
1984	800	E	no ASA	72	f	1984-01764	2022-01-19		Other event	Mild	Temporarily discontinued due to this event	not related	not related	Event ongoing	10024453	Ligament sprain
2360	800	E	no ASA	78	m	2360-02480	2022-05-30	2022-10-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
620	801	P	ASA	66	m	0620-00601	2019-09-22	2019-09-22	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
620	801	P	ASA	66	m	0620-01132	2019-08-15	2019-12-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
620	801	P	ASA	66	m	0620-01742	2021-12-01	2022-01-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
1187	801	P	ASA	78	f	1187-01273	2020-06-25	2020-07-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124, 10013968	Oedema peripheral, Dyspnoea
595	801	P	no ASA	71	m	0595-01131	2020-10-30	2021-03-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013573	Dizziness
793	801	P	no ASA	75	f	0793-00308	2019-05-06	2019-05-06	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
793	801	P	no ASA	75	f	0793-00309	2019-05-09	2019-05-09	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012601	Diabetes mellitus
793	801	P	no ASA	75	f	0793-01800	2021-10-20	2021-12-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
793	801	P	no ASA	75	f	0793-02476	2022-03-28	2022-04-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554, 10013573, 10013968	Cardiac failure, Dizziness, Dyspnoea
793	801	P	no ASA	75	f	0793-01508	2020-10-13	2020-11-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
793	801	P	no ASA	75	f	0793-01509	2020-10-13	2020-11-13	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
969	801	P	no ASA	78	m	0969-00401	2019-06-01	2019-06-01	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10000087	Abdominal pain upper
969	801	P	no ASA	78	m	0969-00402	2019-06-01	2019-06-01	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10015090	Epistaxis
1397	801	P	no ASA	87	f	1397-02478	2022-05-19	2022-05-19	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035664	Pneumonia
1809	801	P	no ASA	84	f	1809-02456	2022-08-24		Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10007554	Cardiac failure
543	801	E	ASA	73	f	0543-00238	2018-05-04	2018-05-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10010741	Conjunctivitis
543	801	E	ASA	73	f	0543-02074	2022-03-06	2022-03-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
543	801	E	ASA	73	f	0543-00323	2018-12-12	2019-01-04	Other event	Moderate	None, i.e. still ongoing	related	not related	Recovered/resolved	10002383	Angina pectoris
895	801	E	ASA	78	m	0895-01803	2021-12-23	2021-12-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10012601	Diabetes mellitus
1170	801	E	ASA	82	f	1170-01809	2021-09-23	2021-10-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017885	Gastrooesophageal reflux disease
582	801	E	no ASA	82	m	0582-01130	2019-03-05	2019-12-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
594	801	E	no ASA	76	f	0594-00239	2018-11-11	2018-11-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
1007	801	E	no ASA	78	f	1007-01243	2020-10-01	2020-10-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10025482	Dyspnoea, Malaise
1007	801	E	no ASA	78	f	1007-01244	2020-10-01	2020-10-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047899	Weight increased
1007	801	E	no ASA	78	f	1007-01200	2021-01-01	2021-04-06	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10051267, 10019465	Dizziness, Facial paresis, Hemiparesis
1334	801	E	no ASA	81	m	1334-02455	2022-11-21	2022-11-21	Other event	Moderate	Not applicable (no	not related	not related	Recovered/resolved with sequelae	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
1334	801	E	no ASA	81	m	1334-01294	2020-10-05	2020-11-05	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013971	Dyspnoea exertional
1460	801	E	no ASA	74	m	1460-00762	2020-03-04	2020-03-13	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
629	802	P	no ASA	81	f	0629-00230	2018-09-07	2019-07-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10005654	Blood magnesium decreased
629	802	P	no ASA	81	f	0629-01057	2020-12-30	2021-02-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10013968	Dyspnoea
1082	802	E	ASA	83	m	1082-00372	2019-07-08	2019-07-11	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
1082	802	E	ASA	83	m	1082-00471	2019-10-08	2019-10-13	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867	Haematuria
1082	802	E	ASA	83	m	1082-00474	2019-08-15	2019-08-18	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867	Haematuria
2351	802	E	ASA	83	m	2351-01933	2022-03-23	2022-03-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
705	802	E	no ASA	66	f	0705-00268	2018-11-01	2019-07-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10014020	Ear pain
705	802	E	no ASA	66	f	0705-00274	2018-10-01	2019-09-11	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10019022	Haemorrhoids
705	802	E	no ASA	66	f	0705-00278	2019-03-24	2019-04-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003239, 10028836	Arthralgia, Neck pain
705	802	E	no ASA	66	f	0705-00279	2019-03-24	2019-03-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035598	Pleural effusion
705	802	E	no ASA	66	f	0705-02327	2022-10-20	2022-10-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10019211	Headache
705	802	E	no ASA	66	f	0705-02328	2022-10-28	2022-10-28	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573, 10016173, 10064990	Dizziness, Fall, Skin abrasion
705	802	E	no ASA	66	f	0705-02329	2022-09-01	2022-10-31	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10013573	Dizziness

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
705	802	E	no ASA	66	f	0705-00508	2019-11-09	2019-11-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10013573, 10058818	Fall, Dizziness, Skin laceration
705	802	E	no ASA	66	f	0705-00855	2020-04-01	2020-10-01	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10000060, 10024264	Abdominal distension, Lethargy
705	802	E	no ASA	66	f	0705-01108	2021-02-08	2022-03-29	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10041823	Squamous cell carcinoma
1047	802	E	no ASA	72	m	1047-00446	2019-05-01	2019-06-30	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
1047	802	E	no ASA	72	m	1047-01504	2021-08-06	2021-08-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097, 10013573	Hypotension, Dizziness
1047	802	E	no ASA	72	m	1047-01505	2021-07-01	2021-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003553	Asthma
1047	802	E	no ASA	72	m	1047-02228	2022-09-06	2022-09-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
1047	802	E	no ASA	72	m	1047-02233	2022-09-30	2022-09-30	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10025652, 10059443	Malignant melanoma in situ, Skin neoplasm excision
1047	802	E	no ASA	72	m	1047-00663	2019-12-01	2019-12-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	related	Recovered/resolved	10015090	Epistaxis
1047	802	E	no ASA	72	m	1047-00664	2019-12-21	2020-01-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1047	802	E	no ASA	72	m	1047-01140	2021-02-01	2021-02-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10053990	Dacryostenosis acquired
1047	802	E	no ASA	72	m	1047-01830	2022-01-11	2022-01-25	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10038063	Rectal haemorrhage
1047	802	E	no ASA	72	m	1047-01832	2021-12-26	2022-03-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
947	815	P	no ASA	77	f	0947-01758	2021-11-01	2022-05-01	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10048334, 10060820	Mobility decreased, Joint injury
986	815	E	no ASA	73	f	0986-00477	2019-06-15	2019-08-15	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10013968, 10047899, 10048959	Dyspnoea, Weight increased, Peripheral swelling
1497	824	P	no ASA	66	f	1497-01826	2021-09-14	2022-04-26	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037802	Radius fracture
1497	824	P	no ASA	66	f	1497-02545	2022-04-26	2022-04-26	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007601	Cardiac pacemaker removal
2010	824	E	ASA	76	m	2010-01485	2021-09-07	2021-09-12	Bleeding event/haematoma	Mild	Permanently discontinued	related	related	Recovered/resolved	10027141	Melaena

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
2423	824	E	no ASA	75	m	2423-02502	2022-05-17	2022-09-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10004857	Biopsy prostate
2423	824	E	no ASA	75	m	2423-02503	2022-06-13	2022-09-28	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10060862	Prostate cancer
892	826	P	no ASA	69	m	0892-01023	2020-10-01	2020-12-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10060862	Prostate cancer
476	826	E	ASA	80	m	0476-00146	2018-03-11	2018-03-28	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10013573	Dizziness
476	826	E	ASA	80	m	0476-00672	2020-01-10	2020-02-10	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10001167	Adenocarcinoma of colon
770	827	P	ASA	73	m	0770-00519	2019-08-27		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10006002, 10003549, 10003239	Bone pain, Asthenia, Arthralgia
770	827	P	ASA	73	m	0770-01447	2019-10-02		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10057969, 10051589, 10013538, 10019022	Reflux gastritis, Large intestine polyp, Diverticulitis, Haemorrhoids
770	827	P	ASA	73	m	0770-01448	2020-11-17		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10049438	General physical health deterioration
764	827	E	ASA	79	f	0764-00304	2019-01-21	2019-01-21	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007695	Carpal tunnel decompression
764	827	E	ASA	79	f	0764-02187	2022-09-02	2022-09-02	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10016173	Fall
764	827	E	ASA	79	f	0764-01446	2019-04-12	2019-04-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10031161	Osteoarthritis
987	833	P	ASA	76	m	0987-00618	2019-08-07		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10013968	Dyspnoea
987	833	P	ASA	76	m	0987-00678	2019-10-22	2019-10-22	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10080743	Angiocardiogram
987	833	P	ASA	76	m	0987-00842	2019-12-30	2020-02-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10037383	Pulmonary fibrosis
1224	833	P	ASA	74	m	1224-00789	2020-04-02	2020-04-02	Bleeding event/haematoma	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10061225	Limb injury
626	833	E	ASA	67	m	0626-02027	2022-02-01	2022-02-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255, 10011224	Coronavirus test positive, Cough
976	833	E	ASA	82	m	0976-00839	2020-06-19	2020-07-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097	Hypotension

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
976	833	E	ASA	82	m	0976-00840	2020-06-23	2020-07-17	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10012267	Dementia
976	833	E	ASA	82	m	0976-00841	2019-07-30	2020-06-23	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018867	Haematuria
1277	833	E	ASA	84	m	1277-02055	2020-09-01	2020-09-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1277	833	E	ASA	84	m	1277-01534	2021-08-06	2021-08-06	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10061637	Angiogram
1637	833	E	ASA	78	m	1637-02360	2022-07-07	2022-07-07	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1637	833	E	ASA	78	m	1637-01477	2021-04-29	2021-05-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
795	836	P	no ASA	79	m	0795-00713	2019-11-11	2019-11-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
819	836	P	no ASA	77	m	0819-01755	2020-05-26	2020-05-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10063829	Device malfunction
1103	836	P	no ASA	68	m	1103-01195	2021-01-15	2021-01-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
802	836	E	ASA	73	f	0802-00892	2020-02-12	2020-03-18	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10028813	Nausea
802	836	E	ASA	73	f	0802-01879	2021-11-23	2021-11-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
938	836	E	no ASA	75	f	0938-00640	2019-04-11	2019-04-12	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007739	Cataract
1876	857	P	ASA	71	f	1876-01935	2022-03-07	2022-03-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1957	857	P	ASA	81	f	1957-01358	2021-06-08	2022-07-27	Other event	Moderate	Temporarily discontinued due to this event	not related	related	Recovered/resolved with sequelae	10005483	Blood creatinine increased
1830	857	P	no ASA	71	f	1830-01310	2020-11-22	2020-11-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030867	Ophthalmic migraine
2006	857	E	ASA	77	m	2006-01178	2021-03-22	2021-04-03	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10015090	Epistaxis
2465	862	E	no ASA	76	m	2465-02079	2022-07-25	2022-07-29	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
775	866	E	ASA	68	m	0775-02207	2021-05-26		Other event	Mild	Not applicable (no	not related	not related	Unknown	10003549	Asthenia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											intake of study drug)					
630	868	P	ASA	74	f	0630-02340	2022-07-28	2022-09-02	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10007554, 10013968	Cardiac failure, Dyspnoea
630	868	P	ASA	74	f	0630-00500	2019-10-23	2019-11-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10013968, 10048959	Dyspnoea, Peripheral swelling
630	868	P	ASA	74	f	0630-01643	2021-07-01	2021-12-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10003549	Dyspnoea, Asthenia
665	868	P	ASA	76	m	0665-00277	2019-02-10	2019-02-21	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10039674	Sciatica
665	868	P	ASA	76	m	0665-00814	2020-02-03	2020-02-05	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
665	868	P	ASA	76	m	0665-00815	2020-07-10	2020-08-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
665	868	P	ASA	76	m	0665-01644	2021-10-09	2021-12-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124, 10003549	Oedema peripheral, Asthenia
734	868	P	ASA	72	f	0734-00708	2020-03-01	2020-03-03	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10003549	Asthenia
825	868	P	ASA	71	m	0825-01618	2021-05-28	2021-11-19	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
965	868	P	ASA	75	f	0965-00542	2019-11-04	2019-11-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035664	Pneumonia
965	868	P	ASA	75	f	0965-00816	2020-01-16	2020-01-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10006451	Bronchitis
1315	868	P	ASA	71	f	1315-01645	2021-10-02	2021-12-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479	Chest pain
701	868	P	no ASA	68	m	0701-00726	2020-03-14	2020-03-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033664	Panic attack
701	868	P	no ASA	68	m	0701-00756	2020-06-01	2020-12-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012601	Diabetes mellitus
701	868	P	no ASA	68	m	0701-00990	2020-10-06	2020-10-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
701	868	P	no ASA	68	m	0701-01600	2021-10-20	2021-11-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10030124, 10013968	Oedema peripheral, Dyspnoea
899	868	P	no ASA	69	m	0899-01405	2021-08-01	2021-08-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425, 10043570	Pain in extremity, Thrombophlebitis
899	868	P	no ASA	69	m	0899-00999	2020-01-01	2020-01-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10033425	Pain in extremity
924	868	P	no ASA	78	f	0924-00437	2019-09-14	2019-09-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
924	868	P	no ASA	78	f	0924-01378	2021-06-01	2021-06-01	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
924	868	P	no ASA	78	f	0924-00404	2019-07-03	2019-07-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211, 10020772	Headache, Hypertension
924	868	P	no ASA	78	f	0924-00438	2019-09-16	2019-09-23	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
924	868	P	no ASA	78	f	0924-00515	2019-11-18		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10003549	Asthenia
924	868	P	no ASA	78	f	0924-00787	2020-02-10	2020-02-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
924	868	P	no ASA	78	f	0924-02130	2022-01-07	2022-01-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549, 10002383	Asthenia, Angina pectoris
754	868	E	ASA	73	m	0754-02232	2022-07-01	2022-08-17	Other event	Severe	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10035664	Pneumonia
754	868	E	ASA	73	m	0754-00991	2020-09-20	2020-12-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10007554	Cardiac failure
798	868	E	ASA	79	f	0798-01272	2021-05-01	2021-06-02	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10070255	Coronavirus test positive
800	868	E	ASA	74	m	0800-00518	2019-11-02	2019-11-09	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
800	868	E	ASA	74	m	0800-02162	2022-01-01	2022-01-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
897	868	E	ASA	67	m	0897-02175	2021-06-10	2021-07-01	Other event	Severe	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10045285	Ulcer
923	868	E	ASA	71	m	0923-01619	2021-06-17	2021-11-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549, 10008479	Asthenia, Chest pain
923	868	E	ASA	71	m	0923-00585	2019-12-13	2020-01-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008120	Cerebral ischaemia
645	868	E	no ASA	78	m	0645-00456	2019-05-01	2019-06-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019114	Hand fracture
645	868	E	no ASA	78	m	0645-00725	2020-03-01	2020-03-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10022437	Insomnia
645	868	E	no ASA	78	m	0645-02129	2021-03-01	2021-03-08	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
645	868	E	no ASA	78	m	0645-02238	2021-03-21	2021-04-27	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10008479, 10002388	Chest pain, Angina unstable
645	868	E	no ASA	78	m	0645-02186	2021-11-01	2021-12-15	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10046995, 10043570	Varicose ulceration, Thrombophlebitis
645	868	E	no ASA	78	m	0645-02173	2020-08-08	2020-09-01	Bleeding event/haematoma	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016173, 10037802, 10060820, 10019196	Fall, Radius fracture, Joint injury, Head injury
759	868	E	no ASA	79	m	0759-00514	2019-11-06	2019-11-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
982	868	E	no ASA	71	f	0982-00534	2019-11-14	2020-08-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10033425	Pain in extremity
1228	868	E	no ASA	69	f	1228-00777	2020-01-10	2020-07-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1228	868	E	no ASA	69	f	1228-00494	2019-11-01	2019-11-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10033557	Dyspnoea, Palpitations
1276	869	E	ASA	66	m	1276-00914	2020-08-05	2020-08-19	Bleeding event/haematoma	Moderate	Temporarily discontinued due to this event	not related	related	Recovered/resolved	10018867	Haematuria
1279	869	E	no ASA	72	f	1279-01127	2021-01-04	2021-01-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1267	870	P	ASA	82	m	1267-02209	2021-07-12	2021-07-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016256	Fatigue
1463	870	P	ASA	67	f	1463-02211	2021-09-09	2021-09-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016256	Fatigue
1985	870	P	ASA	68	f	1985-02205	2021-07-14	2021-07-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1997	870	P	ASA	79	f	1997-02206	2021-07-15	2021-07-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
1032	870	E	ASA	66	m	1032-02210	2021-06-03	2021-06-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
1384	870	E	ASA	71	m	1384-02203	2022-03-09	2022-03-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
2261	870	E	ASA	76	m	2261-02204	2022-01-13	2022-01-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
874	871	P	ASA	75	m	0874-02601	2021-07-01	2021-07-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
914	871	P	ASA	80	m	0914-02192	2021-10-01	2021-11-03	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
962	871	P	ASA	81	m	0962-02560	2019-02-01	2021-12-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10033425	Pain in extremity
762	871	E	ASA	66	m	0762-01155	2019-08-29	2019-09-11	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10016454	Femur fracture
808	871	E	ASA	77	m	0808-00292	2019-03-29	2019-04-25	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10018867	Haematuria
872	871	E	ASA	69	f	0872-02595	2021-02-23	2021-02-23	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
872	871	E	ASA	69	f	0872-02602	2021-01-02	2021-02-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10007554	Cardiac failure
1012	871	E	ASA	72	m	1012-01159	2020-08-27	2020-09-01	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
994	874	P	ASA	77	m	0994-02505	2021-01-06	2021-01-21	Other event	Severe	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007739	Cataract
857	874	E	ASA	81	m	0857-02283	2022-03-01	2022-04-15	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10035664, 10007554	Pneumonia, Cardiac failure
831	874	E	no ASA	72	f	0831-02199	2020-01-12	2020-01-22	Other event	Moderate	Temporarily discontinued	not related	not related	Recovered/resolved	10017865	Gastritis erosive

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
1055	875	P	no ASA	66	f	1055-00457	2019-09-02	2019-09-04	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1650	875	P	no ASA	65	m	1650-02059	2022-02-02	2022-07-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10061536	Parkinson's disease
638	875	E	ASA	65	f	0638-01828	2022-02-07	2022-02-17	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
664	875	E	no ASA	76	m	0664-00250	2019-02-19	2019-03-01	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10007554	Cardiac failure
664	875	E	no ASA	76	m	0664-00410	2019-07-17	2019-07-31	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10068630	Ear infection fungal
1197	875	E	no ASA	68	m	1197-01036	2020-12-21	2021-06-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10012601	Diabetes mellitus
1197	875	E	no ASA	68	m	1197-01319	2021-04-07	2021-04-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
744	876	P	ASA	75	m	0744-00714	2019-10-01	2019-10-04	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10019211	Headache
1732	876	E	ASA	80	m	1732-02149	2022-08-14	2022-09-01	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
706	877	E	ASA	83	m	0706-00283	2019-03-11	2019-03-12	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018276	Gingival bleeding
876	877	E	ASA	70	f	0876-01032	2020-08-01	2020-08-14	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10020772	Hypertension
1649	877	E	ASA	65	f	1649-01705	2022-01-01	2022-01-07	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018852	Haematoma
2050	877	E	ASA	79	m	2050-01580	2021-06-08	2021-06-11	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1648	877	E	no ASA	83	f	1648-01038	2020-06-20	2020-06-20	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
1495	884	P	ASA	65	m	1495-00802	2020-04-20	2020-05-15	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
1495	884	P	ASA	65	m	1495-01361	2021-02-01	2021-11-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211, 10052904	Headache, Musculoskeletal stiffness

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1495	884	P	ASA	65	m	1495-02422	2022-11-17	2022-11-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046306	Upper respiratory tract infection
1495	884	P	ASA	65	m	1495-02534	2022-11-21	2022-11-21	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10028810, 10011224	Nasopharyngitis, Cough
1495	884	P	ASA	65	m	1495-01101	2021-01-08	2021-06-14	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040943	Skin ulcer
1495	884	P	ASA	65	m	1495-01900	2021-10-06	2021-10-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
1377	884	E	no ASA	88	f	1377-00705	2019-12-29	2020-01-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10062352	Respiratory tract infection
984	901	P	ASA	75	m	0984-00803	2019-04-30	2020-02-11	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011224	Cough
984	901	P	ASA	75	m	0984-02188	2022-08-01		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10008479	Chest pain
1549	901	P	ASA	65	m	1549-01527	2021-09-22		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10057668	Cognitive disorder
1549	901	P	ASA	65	m	1549-02220	2022-09-26	2022-09-28	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012735	Diarrhoea
1549	901	P	ASA	65	m	1549-01137	2021-01-11	2021-01-25	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10012426	Dermal cyst
1564	901	P	ASA	68	m	1564-00903	2020-04-01		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10017543	Fungal skin infection
1564	901	P	ASA	68	m	1564-00904	2020-07-11	2020-07-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033775	Paraesthesia
1564	901	P	ASA	68	m	1564-00905	2020-07-11	2020-07-16	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea
1859	901	P	ASA	78	m	1859-01606	2021-11-03	2021-11-03	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007695	Carpal tunnel decompression
2473	901	P	ASA	70	f	2473-02191	2022-09-01	2022-09-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1217	901	P	no ASA	80	m	1217-00577	2020-01-11	2020-02-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10048959	Peripheral swelling
1217	901	P	no ASA	80	m	1217-00761	2020-01-15	2020-01-15	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10000381	Accidental overdose
1217	901	P	no ASA	80	m	1217-01376	2021-03-15		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10030124	Oedema peripheral
1711	901	P	no ASA	77	m	1711-01066	2020-08-04	2020-08-04	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10050316	Dental examination
2476	901	P	no ASA	75	f	2476-02107	2022-06-01	2022-06-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10025169	Lyme disease
882	901	E	ASA	88	f	0882-01000	2020-09-01	2020-09-13	Other event	Mild	Permanently discontinued	not related	not related	Recovered/resolved	10041466	Speech disorder

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
											due to this event					
882	901	E	ASA	88	f	0882-01654	2021-10-12	2022-06-13	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018735	Groin pain
1038	901	E	ASA	71	m	1038-02224	2022-03-07	2022-03-25	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
1120	901	E	ASA	89	m	1120-00365	2019-05-19	2019-05-19	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10012735	Diarrhoea
1138	901	E	ASA	77	m	1138-00804	2019-07-29		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10062585	Peripheral arterial occlusive disease
1138	901	E	ASA	77	m	1138-00805	2019-08-22	2021-11-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10030124	Dyspnoea, Oedema peripheral
1138	901	E	ASA	77	m	1138-00806	2019-11-19	2020-06-12	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10013950	Dysphagia
1138	901	E	ASA	77	m	1138-00953	2020-06-09	2020-09-11	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10002383	Angina pectoris
1138	901	E	ASA	77	m	1138-02523	2022-01-05	2022-01-05	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007815	Catheterisation cardiac
1057	901	E	no ASA	72	f	1057-01624	2021-10-13	2021-10-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003988, 10062501	Back pain, Non-cardiac chest pain
2435	901	E	no ASA	83	m	2435-02189	2022-09-26	2022-09-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573, 10021097	Dizziness, Hypotension
1273	964	P	no ASA	75	f	1273-02147	2022-08-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10045210	Tympanic membrane perforation
1273	964	P	no ASA	75	f	1273-01150	2020-03-06	2020-03-06	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10080429	Primary biliary cholangitis
2420	965	E	ASA	83	f	2420-02352	2022-01-12	2022-01-12	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040882	Skin lesion
2664	965	E	ASA	73	f	2664-02477	2022-11-28		Other event	Moderate	None, i.e. still ongoing	not related	not related	Unknown	10003988	Back pain
2426	965	E	no ASA	81	m	2426-02101	2022-05-15	2022-07-15	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10028813, 10013573, 10033775	Nausea, Dizziness, Paraesthesia
709	1023	P	no ASA	70	f	0709-00782	2019-01-12	2019-01-20	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033425	Pain in extremity
2022	1023	E	no ASA	74	m	2022-02193	2022-08-03	2022-09-01	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017853	Gastritis
1172	1028	P	ASA	82	m	1172-02583	2020-04-30	2020-11-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10060800	Hot flush

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1172	1028	P	ASA	82	m	1172-01196	2020-11-11		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10067585	Type 2 diabetes mellitus
2573	1028	P	ASA	73	m	2573-02447	2022-10-02		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10003988	Back pain
1342	1028	P	no ASA	81	f	1342-01192	2020-12-17	2020-12-17	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
1561	1028	P	no ASA	73	m	1561-02353	2022-04-27	2022-05-31	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10036978	Prostatitis
2696	1028	P	no ASA	83	m	2696-02103	2022-08-13	2022-08-13	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
1313	1028	E	ASA	66	m	1313-00642	2019-10-05	2019-10-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10019211	Headache
1313	1028	E	ASA	66	m	1313-00643	2019-10-05	2019-10-10	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10028813	Nausea
1313	1028	E	ASA	66	m	1313-00669	2019-10-10	2019-10-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10025482	Malaise
1313	1028	E	ASA	66	m	1313-01115	2020-10-02	2020-10-02	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013968	Dyspnoea
1313	1028	E	ASA	66	m	1313-01544	2021-07-12	2021-07-21	Bleeding event/haematoma	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018867	Haematuria
1553	1028	E	ASA	87	m	1553-00860	2020-07-14	2020-09-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1553	1028	E	ASA	87	m	1553-01484	2020-07-14		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10013573	Dizziness
1553	1028	E	ASA	87	m	1553-02467	2021-03-09	2022-10-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
1553	1028	E	ASA	87	m	1553-01817	2021-10-04	2022-10-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10004146	Basal cell carcinoma
1314	1028	E	no ASA	80	m	1314-00694	2019-11-12	2019-11-14	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10023469	Knee arthroplasty
1314	1028	E	no ASA	80	m	1314-01197	2020-12-24	2023-02-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10056284	Lymph node calcification

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1314	1028	E	no ASA	80	m	1314-00931	2020-06-24	2020-07-21	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10041823	Squamous cell carcinoma
1314	1028	E	no ASA	80	m	1314-00932	2020-07-16	2020-07-21	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10074431	Cancer surgery
1344	1028	E	no ASA	80	m	1344-01595	2021-06-11	2021-06-11	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10059862	Cardiac resynchronisation therapy
1539	1028	E	no ASA	81	f	1539-01808	2022-03-03	2022-03-03	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007601	Cardiac pacemaker removal
1547	1028	E	no ASA	84	f	1547-00886	2020-09-01	2020-09-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10018627	Gout
1547	1028	E	no ASA	84	f	1547-01488	2021-02-16	2021-02-17	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved with sequelae	10015090	Epistaxis
1547	1028	E	no ASA	84	f	1547-01134	2020-11-20	2020-11-20	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10049434, 10065064	Cardiac pacemaker replacement, Device lead issue
1547	1028	E	no ASA	84	f	1547-02452	2021-12-07	2021-12-12	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1242	1029	P	no ASA	79	f	1242-02109	2022-03-01	2022-03-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810	Nasopharyngitis
1437	1029	P	no ASA	77	f	1437-00781	2019-12-13	2019-12-13	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10062501	Non-cardiac chest pain
1735	1029	E	no ASA	85	f	1735-02035	2022-04-12	2022-04-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10003549	Asthenia
1407	1039	P	ASA	78	m	1407-01683	2021-11-23	2021-12-10	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1227	1039	E	ASA	80	m	1227-00638	2019-08-06	2019-10-08	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10061599	Lower limb fracture
2225	1048	P	ASA	88	f	2225-01753	2022-01-20		Other event	Mild	None, i.e. still ongoing	related	not related	Event ongoing	10013573	Dizziness
2225	1048	P	ASA	88	f	2225-01754	2022-02-01	2022-07-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
2170	1048	E	ASA	81	f	2170-02411	2022-05-18		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10003239	Arthralgia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2170	1048	E	ASA	81	f	2170-02412	2022-03-12	2022-03-26	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10046571	Urinary tract infection
2170	1048	E	ASA	81	f	2170-01716	2021-06-25	2021-07-05	Other event	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10012735	Diarrhoea
2231	1049	P	no ASA	87	m	2231-01760	2021-09-16	2022-02-15	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10016173, 10039117, 10018852	Fall, Rib fracture, Haematoma
2231	1049	P	no ASA	87	m	2231-01767	2021-09-16	2022-02-15	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10016173, 10039117	Fall, Rib fracture
2231	1049	P	no ASA	87	m	2231-01787	2021-09-16	2021-09-16	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10035598, 10060733	Pleural effusion, Haematoma evacuation
2143	1074	P	ASA	74	m	2143-01651	2021-11-06	2021-11-22	Other event	Mild	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000081	Abdominal pain
1325	1074	P	no ASA	91	m	1325-01162	2021-02-22	2021-02-26	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10016256	Fatigue
1337	1074	P	no ASA	87	f	1337-01176	2021-03-25	2021-05-24	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020462	Humerus fracture
1403	1074	P	no ASA	75	m	1403-00548	2019-11-22	2019-11-26	Other event	Moderate	Permanently discontinued due to this event	not related	related	Recovered/resolved	10000081	Abdominal pain
1403	1074	P	no ASA	75	m	1403-01621	2021-11-01	2021-11-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10020802	Hypertensive crisis
1548	1074	P	no ASA	83	f	1548-01126	2020-07-20	2020-07-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10020772	Hypertension
1548	1074	P	no ASA	83	f	1548-01812	2022-01-28	2022-03-11	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10016173	Fall
1697	1074	P	no ASA	77	m	1697-00899	2020-09-01	2021-08-18	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10003239	Arthralgia
2080	1074	P	no ASA	81	f	2080-02255	2022-08-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10001760	Alopecia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2162	1074	P	no ASA	81	m	2162-01554	2021-08-14	2021-08-16	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10018852	Haematoma
2235	1074	P	no ASA	81	f	2235-01831	2021-08-21	2021-11-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10021097, 10001760	Hypotension, Alopecia
2235	1074	P	no ASA	81	f	2235-02125	2022-02-01	2022-09-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10001760	Alopecia
2300	1074	P	no ASA	81	m	2300-01842	2022-03-22	2022-03-29	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
2720	1074	P	no ASA	72	m	2720-02106	2022-08-01	2022-08-19	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10037844, 10000081	Rash, Abdominal pain
1424	1074	E	ASA	68	m	1424-00594	2019-12-13	2019-12-16	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10000081, 10006002	Abdominal pain, Bone pain
2192	1074	E	ASA	76	f	2192-02043	2022-03-01	2022-03-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1446	1074	E	no ASA	79	f	1446-01526	2021-06-01	2021-06-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018276	Gingival bleeding
1756	1074	E	no ASA	79	m	1756-01119	2020-11-06	2020-11-07	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10008479	Chest pain
2075	1074	E	no ASA	87	f	2075-01579	2021-05-06	2021-05-31	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10077603, 10016173	Craniofacial fracture, Fall
2308	1074	E	no ASA	81	f	2308-02009	2022-03-01	2022-03-08	Other event	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10000087, 10012735	Abdominal pain upper, Diarrhoea
2308	1074	E	no ASA	81	f	2308-02010	2022-03-01	2022-03-08	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10037087	Pruritus
1784	1080	P	ASA	80	m	1784-02252	2022-08-15	2022-08-29	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
1478	1080	P	no ASA	73	f	1478-02499	2022-10-10	2022-10-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1703	1080	P	no ASA	65	m	1703-02286	2022-09-06	2022-09-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10080284	Illness
1707	1080	P	no ASA	69	f	1707-02500	2022-09-05	2022-09-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1734	1080	P	no ASA	77	f	1734-02276	2022-09-19	2022-09-20	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10018276	Gingival bleeding

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1743	1080	P	no ASA	65	m	1743-02333	2022-09-10	2022-09-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10043071	Tachycardia
1746	1080	P	no ASA	66	m	1746-02139	2022-09-01	2022-09-08	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved with sequelae	10019211	Headache
1945	1080	P	no ASA	65	f	1945-02302	2022-09-12	2022-09-13	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1948	1080	P	no ASA	76	m	1948-02272	2022-08-15	2022-08-15	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10015090	Epistaxis
2017	1080	P	no ASA	67	f	2017-02250	2022-08-08	2022-08-12	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10019211	Headache
2020	1080	P	no ASA	71	f	2020-02405	2022-11-01	2022-11-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
2056	1080	P	no ASA	69	f	2056-02339	2022-08-01	2022-08-02	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
2288	1080	P	no ASA	70	f	2288-02249	2022-07-04	2022-07-18	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10037844	Rash
2293	1080	P	no ASA	69	m	2293-02338	2022-10-04	2022-10-05	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10003549	Asthenia
1765	1080	E	ASA	66	m	1765-02326	2022-09-19	2022-09-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
1444	1080	E	no ASA	79	f	1444-02305	2022-10-03	2022-10-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1636	1080	E	no ASA	70	f	1636-02275	2022-08-09	2022-08-10	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1671	1080	E	no ASA	73	f	1671-02267	2022-06-06	2022-06-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1694	1080	E	no ASA	67	f	1694-02325	2022-10-10	2022-10-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1700	1080	E	no ASA	67	f	1700-02337	2022-10-17	2022-10-17	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
1736	1080	E	no ASA	83	f	1736-02268	2022-08-15	2022-08-20	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
1754	1080	E	no ASA	74	f	1754-02285	2022-09-07	2022-09-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
1762	1080	E	no ASA	80	f	1762-02301	2022-09-05	2022-09-06	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
1992	1080	E	no ASA	72	f	1992-02251	2022-05-10	2022-05-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
2037	1080	E	no ASA	66	f	2037-02413	2022-10-17	2022-10-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10033557	Palpitations
2057	1080	E	no ASA	82	f	2057-01589	2021-10-27	2021-10-29	Bleeding event/haematoma	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10015090	Epistaxis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2084	1080	E	no ASA	76	f	2084-02406	2022-10-10	2022-10-11	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013573	Dizziness
2184	1080	E	no ASA	72	f	2184-02331	2022-08-02	2022-08-04	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
2244	1080	E	no ASA	72	f	2244-02269	2022-06-04	2022-06-07	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037844	Rash
2284	1080	E	no ASA	66	f	2284-02195	2022-08-01	2022-08-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028813	Nausea
1433	1085	P	ASA	87	f	1433-00612	2019-12-19	2020-02-19	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10017853	Gastritis
1499	1085	P	ASA	82	f	1499-01416	2021-06-10	2021-06-24	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10018852	Haematoma
2316	1085	P	ASA	83	f	2316-01890	2022-04-01	2022-06-01	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10000081	Abdominal pain
1520	1085	P	no ASA	85	f	1520-02105	2022-08-12	2022-08-31	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10019211	Headache
1673	1085	P	no ASA	85	f	1673-02311	2022-09-01	2022-10-05	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10021097	Hypotension
1962	1085	P	no ASA	79	f	1962-01217	2021-04-05	2021-04-26	Other event	Moderate	Permanently discontinued due to this event	related	related	Recovered/resolved	10017853	Gastritis
1962	1085	P	no ASA	79	f	1962-02324	2022-09-27	2022-09-27	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10042772	Syncope
2301	1085	P	no ASA	85	m	2301-01756	2021-11-01	2021-12-31	Other event	Moderate	None, i.e. still ongoing	related	related	Recovered/resolved	10013573, 10016256	Dizziness, Fatigue
2301	1085	P	no ASA	85	m	2301-01765	2021-12-01	2022-01-15	Other event	Moderate	Temporarily discontinued due to this event	related	related	Recovered/resolved	10012267, 10049848	Dementia, Balance disorder
2301	1085	P	no ASA	85	m	2301-01829	2022-03-14	2022-04-14	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10007554, 10048959, 10013971	Cardiac failure, Peripheral swelling, Dyspnoea exertional
1477	1085	E	ASA	69	f	1477-01393	2021-06-01	2021-06-06	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018852	Haematoma
1477	1085	E	ASA	69	f	1477-01723	2021-10-20	2021-10-20	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	related	related	Recovered/resolved	10018867	Haematuria
1980	1085	E	ASA	84	m	1980-02229	2022-06-01	2022-10-03	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2021	1085	E	ASA	81	f	2021-02208	2022-04-01		Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Event ongoing	10018852	Haematoma
2021	1085	E	ASA	81	f	2021-01820	2022-03-21	2022-04-01	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
2482	1085	E	ASA	70	m	2482-02104	2022-04-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10049438	General physical health deterioration
2482	1085	E	ASA	70	m	2482-02273	2022-09-15	2022-09-16	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10015090	Epistaxis
2482	1085	E	ASA	70	m	2482-02274	2022-10-12	2022-10-13	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10005140	Bleeding time prolonged
1386	1085	E	no ASA	81	m	1386-01914	2022-01-01	2022-01-31	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018852	Haematoma
1386	1085	E	no ASA	81	m	1386-00978	2020-08-01	2021-06-11	Bleeding event/haematoma	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10018852	Haematoma
1483	1085	E	no ASA	75	f	1483-01607	2021-11-02	2022-03-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10002383	Angina pectoris
1771	1085	E	no ASA	84	f	1771-01520	2021-07-12	2021-09-08	Bleeding event/haematoma	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10050953	Lower gastrointestinal haemorrhage
2032	1085	E	no ASA	81	f	2032-01850	2021-11-05	2022-09-12	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10036099	Polymyalgia rheumatica
2298	1085	E	no ASA	86	f	2298-01858	2022-02-01	2022-07-01	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013573	Dizziness
2298	1085	E	no ASA	86	f	2298-01859	2022-04-13	2022-07-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10047531	Visual acuity reduced
2307	1085	E	no ASA	84	f	2307-01906	2021-11-01		Other event	Mild	None, i.e. still ongoing	related	related	Event ongoing	10013781	Dry mouth
2307	1085	E	no ASA	84	f	2307-02215	2022-07-01		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10043189	Telangiectasia
2312	1085	E	no ASA	87	f	2312-01876	2022-02-01	2022-10-11	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1174	1089	P	no ASA	81	f	1174-02314	2021-12-01	2022-06-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10030124	Oedema peripheral
1174	1089	P	no ASA	81	f	1174-02439	2022-10-22	2022-11-22	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10028810, 10011224	Nasopharyngitis, Cough
1502	1089	P	no ASA	75	m	1502-00818	2020-03-15	2020-03-22	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
1502	1089	P	no ASA	75	m	1502-02501	2022-03-29	2022-03-29	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10009033	Chronic obstructive pulmonary disease
1502	1089	P	no ASA	75	m	1502-01181	2021-02-14	2022-08-09	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10017577	Gait disturbance

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1522	1089	P	no ASA	85	m	1522-02390	2020-08-11		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10011078	Coronary artery disease
1522	1089	P	no ASA	85	m	1522-02315	2020-06-10		Other event	Moderate	None, i.e. still ongoing	not related	not related	Event ongoing	10028600	Myocardial ischaemia
1522	1089	P	no ASA	85	m	1522-02391	2020-02-21	2020-03-02	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10013968	Dyspnoea
1522	1089	P	no ASA	85	m	1522-02392	2020-02-20	2020-03-02	Other event	Severe	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10013946	Dyspepsia
2205	1089	P	no ASA	85	m	2205-02312	2022-05-27	2022-05-27	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1317	1089	E	no ASA	86	m	1317-02313	2022-04-01	2022-04-12	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10013578, 10048959	Dizziness postural, Peripheral swelling
1333	1089	E	no ASA	72	m	1333-02441	2022-05-03	2022-05-04	Bleeding event/haematoma	Severe	Temporarily discontinued due to this event	related	related	Recovered/resolved	10015090	Epistaxis
1333	1089	E	no ASA	72	m	1333-02395	2022-05-03	2022-05-03	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10009192	Circulatory collapse
1427	1089	E	no ASA	82	m	1427-02367	2020-01-28	2020-02-18	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968, 10011224	Dyspnoea, Cough
1427	1089	E	no ASA	82	m	1427-02321	2022-03-17	2022-03-17	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10015090	Epistaxis
1427	1089	E	no ASA	82	m	1427-01998	2022-06-01		Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Event ongoing	10029446	Nocturia
1427	1089	E	no ASA	82	m	1427-02320	2020-04-01	2020-04-30	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
1427	1089	E	no ASA	82	m	1427-01806	2022-02-11	2022-03-15	Other event	Mild	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved	10014011	Ear infection
1504	1089	E	no ASA	70	m	1504-02318	2020-04-26	2021-09-14	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10040943	Skin ulcer
1504	1089	E	no ASA	70	m	1504-02393	2020-06-30	2020-07-07	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10024968	Lower respiratory tract infection
1504	1089	E	no ASA	70	m	1504-02394	2021-05-12	2021-07-20	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10064272	Bladder neoplasm surgery

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
1705	1097	E	ASA	74	m	1705-01403	2020-12-16	2020-12-20	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10055798, 10061225	Haemorrhage, Limb injury
1705	1097	E	ASA	74	m	1705-02520	2021-09-17	2021-11-09	Other event	Mild	None, i.e. still ongoing	related	related	Recovered/resolved	10005483	Blood creatinine increased
1705	1097	E	ASA	74	m	1705-01440	2021-07-19	2022-02-01	Other event	Mild	None, i.e. still ongoing	related	not related	Recovered/resolved	10055798, 10003399	Haemorrhage, Arthropod bite
1705	1097	E	ASA	74	m	1705-01441	2021-07-19		Other event	Mild	None, i.e. still ongoing	not related	not related	Event ongoing	10035528	Platelet count decreased
2331	1097	E	ASA	77	f	2331-02221	2022-05-23	2022-05-30	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037884	Rash pruritic
2331	1097	E	ASA	77	f	2331-02222	2022-06-11	2022-06-18	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037884	Rash pruritic
2331	1097	E	ASA	77	f	2331-02223	2022-08-28	2022-09-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10037884	Rash pruritic
2401	1097	E	ASA	68	m	2401-02182	2022-08-25	2022-09-01	Other event	Severe	None, i.e. still ongoing	not related	not related	Recovered/resolved	10038897	Retinal tear
2401	1097	E	ASA	68	m	2401-02519	2022-07-13	2022-07-14	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10007815	Catheterisation cardiac
2531	1111	E	no ASA	83	m	2531-02140	2022-07-09	2022-09-09	Other event	Moderate	Not applicable (no intake of study drug)	not related	not related	Recovered/resolved with sequelae	10028334	Muscle spasms
2330	1115	E	ASA	83	f	2330-01926	2022-02-03	2022-02-11	Bleeding event/haematoma	Mild	Permanently discontinued due to this event	related	related	Recovered/resolved	10038063	Rectal haemorrhage
2461	1116	E	no ASA	75	f	2461-02086	2022-08-09	2022-08-13	Bleeding event/haematoma	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10016173, 10049297	Fall, Lip haemorrhage
2461	1116	E	no ASA	75	f	2461-02100	2022-06-08	2022-06-10	Other event	Mild	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10064774, 10003239	Infusion site extravasation, Arthralgia
2689	1118	P	no ASA	91	f	2689-02375	2022-10-04	2022-11-14	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved with sequelae	10061161	Pelvic fracture
2587	1121	P	no ASA	87	m	2587-02017	2022-04-20	2022-07-04	Other event	Severe	Permanently discontinued due to this event	related	related	Recovered/resolved	10000081	Abdominal pain
2609	1121	E	ASA	80	f	2609-02506	2022-05-30	2022-06-08	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10015145	Erysipelas
2359	1123	P	ASA	76	f	2359-01916	2022-02-14	2022-02-21	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10011781	Cystitis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age	Sex	AE number	Onset date	Stop date	AE type	Intensity	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome	Preferred term (code)	Preferred term (name)
2359	1123	P	ASA	76	f	2359-01917	2022-03-12	2022-03-16	Other event	Mild	None, i.e. still ongoing	not related	not related	Recovered/resolved	10070255	Coronavirus test positive
2398	1146	E	ASA	79	m	2398-02032	2022-05-23	2022-05-24	Other event	Moderate	Temporarily discontinued due to this event	not related	not related	Recovered/resolved	10061917	Prostatic operation
2397	1146	E	no ASA	78	m	2397-01997	2022-05-30	2022-08-04	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10055890, 10016173	Haematoma muscle, Fall
2397	1146	E	no ASA	78	m	2397-02368	2022-09-07	2022-09-07	Other event	Moderate	Permanently discontinued due to this event	not related	not related	Recovered/resolved	10049434	Cardiac pacemaker replacement
2525	1147	E	no ASA	69	f	2525-02219	2022-09-07	2022-10-05	Other event	Moderate	None, i.e. still ongoing	not related	not related	Recovered/resolved	10013968	Dyspnoea

[1] P = Placebo; E= Edoxaban

[2] ASA = Acetylsalicylic acid

16.2.7 Serious adverse event listings (each patient)

Table 31 Individual serious adverse events listing

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
48	9	P	ASA	84	m	00144	28.01.2018	31.01.2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10022016	Inguinal hernia
48	9	P	ASA	84	m	00145	20.02.2018	02.03.2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10022016, 10062003	Inguinal hernia, Hernia repair
48	9	P	ASA	84	m	00223-1	19.07.2018	01.08.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10003011, 10003010	Appendicitis, Appendicectomy
48	9	P	ASA	84	m	00223-2	25.07.2018	01.08.2018	Worsening of heart failure	Moderate	Prolongation of existing hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
75	9	P	ASA	77	m	00015	18.04.2017	22.04.2017	Worsening of heart failure	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10069339	Cardiac failure, Acute kidney injury
75	9	P	ASA	77	m	00032	06.05.2017	16.05.2017	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10021789, 10064848	Cardiac failure, Infection, Chronic kidney disease
75	9	P	ASA	77	m	00033-1	12.06.2017	30.06.2017	Worsening of heart failure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10056419, 10069339, 10064848	Cardiac failure, Dilated cardiomyopathy, Acute kidney injury, Chronic kidney disease
75	9	P	ASA	77	m	00033-2	12.06.2017	30.06.2017	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10035664	Pneumonia
192	9	P	ASA	75	f	00060	02.10.2017	02.10.2017	Pulmonary embolism	Mild	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10037377	Pulmonary embolism
288	9	P	ASA	87	m	01892	14.01.2022		Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.20.2022	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
434	9	P	ASA	94	f	02043	22.10.2021	03.11.2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
434	9	P	ASA	95	f	02044	10.08. 2022	05.10. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571, 10062362	Urinary tract infection, Viral test negative
468	9	P	ASA	67	m	00718	17.10. 2019	25.10. 2019	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
561	9	P	ASA	67	f	00604	18.12. 2019	20.12. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
561	9	P	ASA	68	f	00824	08.07. 2020	13.07. 2020	Pulmonary embolism	Moderate	Life threatening event	Permanently discontinued due to this event	n	n	r/r			Main reason for hospital admission	10037377, 10051055	Pulmonary embolism, Deep vein thrombosis
681	9	P	ASA	87	f	00448	15.04. 2019	16.04. 2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10004873, 10000614	Biopsy skin, Actinic keratosis
681	9	P	ASA	88	f	00658	16.09. 2019	18.09. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10074431	Cancer surgery
681	9	P	ASA	88	f	00669	26.11. 2019	27.11. 2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10048956	Lymphadenectomy
681	9	P	ASA	88	f	00670	03.02. 2020	14.02. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10081204, 10041823	Neck dissection, Squamous cell carcinoma
681	9	P	ASA	88	f	00705	14.02. 2020	28.02. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10021519, 10041823	Impaired healing, Squamous cell carcinoma
681	9	P	ASA	89	f	01267	28.10. 2020	07.11. 2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062501	Non-cardiac chest pain
681	9	P	ASA	89	f	02045	13.06. 2021	15.06. 2021	ACS	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002388, 10051592, 10080743	Angina unstable, Acute coronary syndrome, Angiocardiogram
681	9	P	ASA	90	f	02046	05.11. 2021	10.11. 2021	Major Bleeding in non-surgical patients (according ISTH,	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10061816, 10014819, 10017955, 10062362	Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Gastrointestinal

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									including haemorrhagic stroke)											haemorrhage, Viral test negative
681	9	P	ASA	90	f	02047	16.11.2021	18.11.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10071360, 10002034	Capsule endoscopy, Anaemia
681	9	P	ASA	90	f	02048	19.01.2022	21.01.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
720	9	P	ASA	84	m	00701	14.09.2019	29.11.2019	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
720	9	P	ASA	85	m	02090	23.12.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.23.2019	Death of unknown cause		10011906	Death
758	9	P	ASA	86	f	00872	06.02.2020	26.02.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10078098, 10028836	Chronic idiopathic pain syndrome, Neck pain
758	9	P	ASA	88	f	02092	05.09.2022	15.09.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016450, 10022576, 10062362	Femoral neck fracture, Internal fixation of fracture, Viral test negative
879	9	P	ASA	73	m	01269	06.12.2020	08.12.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
879	9	P	ASA	75	m	01969	11.07.2022		Non-cardiovascular event				n	n	Death	7.11.2022	No cardiovascular cause		10011906, 10039203, 10028224, 10028200	Death, Road traffic accident, Multiple injuries, Multiple fractures
879	9	P	ASA	74	m	02050	30.10.2021	10.11.2021	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038695, 10007554, 10009033	Respiratory failure, Cardiac failure, Chronic obstructive pulmonary disease

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1192	9	P	ASA	74	m	01272	07.09. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	9.7.2020	Death of unknown cause		10011906	Death
1213	9	P	ASA	91	f	00484	19.09. 2019	08.10. 2019	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10047340	Vertigo
1213	9	P	ASA	91	f	00693	22.10. 2019	04.11. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10047340	Vertigo
1213	9	P	ASA	91	f	00694	28.11. 2019	02.12. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10041569, 10061161, 10017308	Spinal fracture, Pelvic fracture, Fractured sacrum
1213	9	P	ASA	92	f	02052	08.01. 2021	13.01. 2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571, 10035664, 10066152, 10062362	Urinary tract infection, Pneumonia, Transfusion, Viral test negative
1213	9	P	ASA	92	f	02053	24.01. 2021	25.01. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10022116, 10019196, 10016173	Injury, Head injury, Fall
1213	9	P	ASA	93	f	02078	31.05. 2022	01.06. 2022	Minor Bleeding	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016173, 10044522, 10066152, 10062362	Fall, Traumatic haematoma, Transfusion, Viral test negative
1600	9	P	ASA	78	m	02054	13.12. 2021	16.12. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1641	9	P	ASA	86	m	01273	21.03. 2021	23.03. 2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1641	9	P	ASA	88	m	01888	04.07. 2022	07.07. 2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued	n	n	r/r			Hospitalisation	10004146, 10059443,	Basal cell carcinoma, Skin neoplasm excision,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event							10041823, 10074431	Squamous cell carcinoma, Cancer surgery
1817	9	P	ASA	74	f	01978	17.05. 2022	18.05. 2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10051592, 10052086, 10003658	Percutaneous coronary intervention, Acute coronary syndrome, Coronary arterial stent insertion, Atrial fibrillation
1871	9	P	ASA	90	f	01881	10.12. 2021	17.12. 2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016173, 10061161	Fall, Pelvic fracture
1974	9	P	ASA	88	m	01889	10.05. 2022	17.05. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016173, 10077603, 10062362, 10007554	Fall, Craniofacial fracture, Viral test negative, Cardiac failure
1974	9	P	ASA	88	m	02093	02.10. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.2.2022	Death of unknown cause		10011906	Death
92	9	P	no ASA	82	m	02042	22.04. 2021	27.04. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10013554, 10010007, 10062362	Diverticulum, Colonoscopy, Viral test negative
96	9	P	no ASA	71	f	00194	03.10. 2018	05.10. 2018	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
697	9	P	no ASA	96	m	02049	02.11. 2022	04.11. 2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
878	9	P	no ASA	84	f	00265	18.12. 2018	24.12. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
878	9	P	no ASA	85	f	00737	14.05. 2020	18.05. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10048038	Wound infection
878	9	P	no ASA	87	f	01957	02.02. 2022	04.02. 2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1570	9	P	no ASA	73	m	02114	16.09. 2022	22.09. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10044445	Transurethral prostatectomy
1847	9	P	no ASA	74	m	01483	29.10. 2021	10.11. 2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062362, 10007509	Cardiac failure, Viral test negative, Cardiac amyloidosis
1847	9	P	no ASA	74	m	01484	27.08. 2021	06.09. 2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10007554, 10007509	Viral test negative, Cardiac failure, Cardiac amyloidosis
1847	9	P	no ASA	75	m	01821	17.06. 2022		Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	Death	8.24.2022	No cardiovascular cause	Hospitalisation	10015145, 10011906, 10069339, 10060738, 10070255	Erysipelas, Death, Acute kidney injury, Intervertebral discitis, Coronavirus test positive
1847	9	P	no ASA	75	m	02134	23.01. 2022	02.02. 2022	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10007509, 10042772	Cardiac failure, Cardiac amyloidosis, Syncope
2408	9	P	no ASA	76	f	02113	31.08. 2022	02.09. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017853, 10013538, 10014819, 10010007, 10074625	Gastritis, Diverticulitis, Endoscopy upper gastrointestinal tract, Colonoscopy, Large intestinal polypectomy
57	9	E	ASA	78	m	00007	05.02. 2017	15.02. 2017	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10048858, 10007554	Ischaemic cardiomyopathy, Cardiac failure
57	9	E	ASA	78	m	00016	19.03. 2017	28.03. 2017	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
57	9	E	ASA	78	m	00073	16.06.2017	27.06.2017	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
57	9	E	ASA	78	m	00074	26.11.2017	30.12.2017	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10006451, 10038435	Bronchitis, Renal failure
57	9	E	ASA	79	m	00091	07.01.2018	16.01.2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10009033	Pneumonia, Chronic obstructive pulmonary disease
57	9	E	ASA	79	m	00142	28.03.2018	04.04.2018	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10009033	Pneumonia, Chronic obstructive pulmonary disease
57	9	E	ASA	79	m	00143	07.05.2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	5.7.2018	Death of unknown cause		10011906	Death
66	9	E	ASA	86	f	00638	18.11.2019		Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	Event ongoing			Hospitalisation	10041823, 10062194	Squamous cell carcinoma, Metastasis
66	9	E	ASA	86	f	00639	02.12.2019	14.12.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10034036, 10041823	Parotidectomy, Squamous cell carcinoma
66	9	E	ASA	88	f	01245	27.05.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	5.27.2021	Death of unknown cause		10011906	Death
66	9	E	ASA	88	f	01251	09.05.2021	12.05.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035598, 10062362	Pleural effusion, Viral test negative
66	9	E	ASA	88	f	01266	17.02.2021	19.02.2021	Change of a pacemaker, ICD or any other	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
93	9	E	ASA	85	m	00505	30.07. 2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	7.30.2019	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
153	9	E	ASA	72	m	00219	03.09. 2018	10.09. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10044445	Transurethral prostatectomy
153	9	E	ASA	74	m	01209	24.11. 2020	30.11. 2020	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10041569	Spinal fracture
393	9	E	ASA	88	m	00641	31.01. 2019	02.02. 2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061853	Eyelid operation
393	9	E	ASA	88	m	00646	20.10. 2019	21.10. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
393	9	E	ASA	89	m	00695	29.02. 2020		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.14.2020	No cardiovascular cause	Hospitalisation	10011906, 10046571, 10038435	Death, Urinary tract infection, Renal failure
485	9	E	ASA	82	f	00280	05.02. 2019	07.02. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
682	9	E	ASA	81	m	01912	11.07. 2022	13.07. 2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10057900, 10028767, 10033081, 10033849	Ear tube insertion, Nasal sinus cancer, Otitis media chronic, Paranasal biopsy
719	9	E	ASA	89	f	00610	31.07. 2019	14.08. 2019	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
719	9	E	ASA	90	f	00703	21.02.2020	24.02.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
719	9	E	ASA	90	f	00704	27.02.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.27.2020	Sudden cardiac death		10049418	Sudden cardiac death
731	9	E	ASA	74	m	02010	03.08.2022	04.08.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10045458, 10045462	Umbilical hernia, Umbilical hernia repair
843	9	E	ASA	77	m	00368	04.03.2019	08.03.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020705, 10033968	Hyperparathyroidism, Parathyroidectomy
908	9	E	ASA	69	m	00292	18.02.2019	19.02.2019	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007636, 10007554	Cardiomyopathy, Cardiac failure
908	9	E	ASA	69	m	00449-1	10.03.2019	15.03.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062003	Hernia repair
908	9	E	ASA	69	m	00449-2	13.03.2019	15.03.2019	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Prolongation of existing hospitalisation	None, i.e. still ongoing	y	y	r/r			Hospitalisation	10062003, 10055798, 10039749	Hernia repair, Haemorrhage, Scrotal haematoma
908	9	E	ASA	71	m	01231-1	05.05.2021	06.05.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10054787	Haemorrhoidal haemorrhage
908	9	E	ASA	71	m	01231-2	07.05.2021	08.05.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Prolongation of existing hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10054787	Gastrointestinal haemorrhage, Haemorrhoidal haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
908	9	E	ASA	71	m	01242	19.05.2021	21.05.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10038063, 10002034, 10019022	Rectal haemorrhage, Anaemia, Haemorrhoids
908	9	E	ASA	71	m	01243	13.04.2021	16.04.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
1127	9	E	ASA	74	m	02086	08.11.2022	09.11.2022	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10047340, 10037660, 10062362, 10017577, 10021432	Vertigo, Pyrexia, Viral test negative, Gait disturbance, Immunisation reaction
1178	9	E	ASA	80	f	00613	21.07.2019	23.07.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
1178	9	E	ASA	82	f	02051	07.10.2021	11.10.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038528, 10029148	Renal stone removal, Nephrolithiasis
1338	9	E	ASA	88	m	00651	10.02.2020	21.02.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10014819, 10053757, 10061816	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Therapeutic procedure, Diagnostic procedure
1338	9	E	ASA	88	m	00743	16.04.2020	22.04.2020	Major Bleeding in non-surgical patients (according ISTH, including	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10017955, 10014819, 10010007, 10061816, 10066152, 10001150	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Transfusion,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									haemorrhagic stroke)											Adenocarcinoma gastric
1338	9	E	ASA	88	m	00795	26.05.2020	28.05.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014819, 10010007, 10017955, 10066152, 10053757, 10061816, 10001150	Endoscopy upper gastrointestinal tract, Colonoscopy, Gastrointestinal haemorrhage, Transfusion, Therapeutic procedure, Diagnostic procedure, Adenocarcinoma gastric
1338	9	E	ASA	88	m	00848	05.06.2020	10.09.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10017955, 10061965, 10053757, 10062362	Gastrointestinal haemorrhage, Gastrectomy, Therapeutic procedure, Viral test negative
1338	9	E	ASA	88	m	02091	25.09.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	9.25.2020	No cardiovascular cause		10011906, 10017758, 10062194	Death, Gastric cancer, Metastasis
1346	9	E	ASA	80	f	00739	09.03.2020	16.03.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10013538, 10003011, 10003010	Diverticulitis, Appendicitis, Appendicectomy
1816	9	E	ASA	73	m	00955	18.10.2020	21.10.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10009033, 10062362	Chronic obstructive pulmonary disease, Viral test negative
1816	9	E	ASA	73	m	01161	26.04.2021	29.04.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	y	y	r/r			Hospitalisation	10014819, 10010007, 10061816, 10017955, 10062362	Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Gastrointestinal haemorrhage, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1816	9	E	ASA	74	m	01977	25.01.2022	27.01.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10074431	Cancer surgery
1816	9	E	ASA	73	m	02056-1	25.05.2021	02.06.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038038, 10077252, 10062362	Rectal cancer, Proctectomy, Viral test negative
1816	9	E	ASA	73	m	02056-2	03.06.2021	25.06.2021	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
2333	9	E	ASA	83	m	01748	26.11.2021	26.04.2022	Non-cardiovascular event	Moderate	Other medically important event	None, i.e. still ongoing	n	n	r/r			No hospital stay	10060862, 10037794	Prostate cancer, Radiotherapy
46	9	E	no ASA	84	f	00797	24.06.2020	26.06.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
46	9	E	no ASA	85	f	01271	13.05.2021	21.05.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10025005, 10062262	Lumbar spinal stenosis, Spinal operation
46	9	E	no ASA	86	f	01541	22.11.2021	23.11.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10037383	Pulmonary fibrosis
54	9	E	no ASA	71	m	00027	16.03.2017	18.03.2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10006811, 10006807	Bursitis, Bursa removal
54	9	E	no ASA	75	m	01549	12.10.2021	13.10.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007697, 10042609	Carpal tunnel syndrome, Surgery
410	9	E	no ASA	70	f	00642	01.07.2019	05.07.2019	Syncope	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10042772	Syncope
410	9	E	no ASA	70	f	00643	11.05.2019	17.05.2019	Syncope	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10042772	Syncope
410	9	E	no ASA	70	f	00644	04.02.2019	11.02.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
410	9	E	no ASA	70	f	00645	26.05. 2019	14.06. 2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038695	Respiratory failure
410	9	E	no ASA	71	f	00698	12.02. 2020		Other cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.18.2020	Sudden cardiac death	Hospitalisation	10049418, 10007515	Sudden cardiac death, Cardiac arrest
1692	9	E	no ASA	79	m	01274	08.06. 2021	17.06. 2021	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10034474	Pericardial effusion
1692	9	E	no ASA	81	m	01966	30.08. 2022	07.09. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10008313, 10062262	Cervical spinal stenosis, Spinal operation
1879	9	E	no ASA	74	m	02057	28.09. 2022	03.10. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10022020	Inguinal hernia repair
2297	9	E	no ASA	80	f	01699	22.02. 2022	22.02. 2022	Pulmonary embolism	Moderate	Life threatening event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10037377	Pulmonary embolism
1701	12	P	ASA	73	m	01129	23.03. 2021	25.03. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10014498, 10061256, 10043568	Embolic stroke, Ischaemic stroke, Thrombolysis
1701	12	P	ASA	74	m	01644	31.01. 2022	03.02. 2022	Hospitalisation due to AF	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10003662, 10007554	Atrial fibrillation, Atrial flutter, Cardiac failure
1701	12	P	ASA	74	m	01697	03.04. 2022	05.04. 2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10080743, 10062362	Angiocardiogram, Viral test negative
1787	12	P	ASA	76	m	01139	15.03. 2021	26.03. 2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008611, 10008614	Cholecystectomy, Cholecystitis acute
1698	12	P	no ASA	86	f	01670	24.01. 2022	10.03. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016450, 10037802, 10066152, 10062362, 10020096	Femoral neck fracture, Radius fracture, Transfusion, Viral test negative, Hip arthroplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1581	12	E	ASA	86	f	00774	05.06.2020	12.06.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10066152	Gastrointestinal haemorrhage, Transfusion
1706	12	E	ASA	86	m	00855	06.08.2020		Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	8.17.2020	No cardiovascular cause	Hospitalisation	10011906, 10014665, 10040070	Death, Endocarditis, Septic shock
1752	12	E	ASA	86	m	01344	06.03.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	3.6.2021	Sudden cardiac death		10049418	Sudden cardiac death
1789	12	E	no ASA	91	m	01162	13.10.2020	15.10.2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10019196, 10061225, 10062362	Head injury, Limb injury, Viral test negative
1789	12	E	no ASA	91	m	01163	15.10.2020	28.10.2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016173, 10062362	Fall, Viral test negative
1789	12	E	no ASA	91	m	01190	11.11.2020	24.11.2020	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061256, 10062362	Ischaemic stroke, Viral test negative
1789	12	E	no ASA	92	m	02118	19.04.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	4.19.2022	No cardiovascular cause		10011906, 10003549	Death, Asthenia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1269	16	P	ASA	80	m	00492	24.09. 2019	25.09. 2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002475, 10072563	Angioplasty, Peripheral artery stenosis
1269	16	P	ASA	80	m	00673	27.02. 2020	02.03. 2020	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1269	16	P	ASA	81	m	01067	29.01. 2021	30.01. 2021	Peripheral (limb) embolism	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061340, 10043530	Peripheral embolism, Thrombectomy
1179	16	E	ASA	75	m	01240	07.05. 2021	10.05. 2021	Worsening of heart failure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
440	16	E	no ASA	66	m	00252	03.01. 2019	04.01. 2019	Hospitalisation due to AF	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
440	16	E	no ASA	66	m	00259	04.12. 2018	05.12. 2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10022020, 10058468	Inguinal hernia repair, Laparoscopic surgery
440	16	E	no ASA	68	m	00880	10.07. 2020	13.07. 2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
364	17	E	ASA	75	m	01649	28.10. 2021	08.11. 2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10051060, 10020100	Hip surgery, Hip fracture
409	17	E	no ASA	77	f	01324	05.08. 2021	07.08. 2021	ACS	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002388	Angina unstable
409	17	E	no ASA	77	f	01399	23.09. 2021	23.09. 2021		Severe	Life threatening event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10008479, 10033425	Chest pain, Pain in extremity
263	19	P	ASA	67	m	00063	07.11. 2017	08.11. 2017	Hospitalisation due to AF	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003662, 10007661	Atrial flutter, Cardioversion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
600	19	P	ASA	90	m	01938	31.08.2022	12.09.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10039203, 10022116, 10042316, 10042364, 10061249, 10059486, 10008111	Road traffic accident, Injury, Subarachnoid haemorrhage, Subdural haemorrhage, Intra-abdominal haemorrhage, Abdominal cavity drainage, Cerebral haemorrhage
120	19	P	no ASA	84	m	00498	24.09.2019	26.09.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10041834, 10061934	Squamous cell carcinoma of skin, Salivary gland cancer
120	19	P	no ASA	86	m	01646	03.03.2022	08.03.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035664, 10080743, 10062362	Pneumonia, Angiocardiogram, Viral test negative
1633	19	E	ASA	74	m	01011	29.07.2020	07.08.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10039674, 10003988	Sciatica, Back pain
1633	19	E	ASA	75	m	01413	28.09.2021		Other cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.16.2021	Death due to other cardiovascular causes	Hospitalisation	10011906, 10007649, 10002916, 10011077, 10066152, 10052989, 10051379, 10014665, 10049434	Death, Cardiovascular disorder, Aortic valve replacement, Coronary artery bypass, Transfusion, Intra-aortic balloon placement, Systemic inflammatory response syndrome, Endocarditis, Cardiac pacemaker replacement
624	22	E	ASA	71	m	00325	26.03.2019	29.03.2019	Stable AP (no ACS)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10007661	Cardiac failure, Cardioversion
624	22	E	ASA	71	m	00326	04.03.2019	05.03.2019	Hospitalisation due to AF	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
624	22	E	ASA	71	m	00365	23.05.2019	23.05.2019	Hospitalisation due to AF	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10007661, 10047302, 10003658	Cardioversion, Ventricular tachycardia, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
624	22	E	ASA	72	m	00788	10.06.2020	11.06.2020	Hospitalisation due to AF	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
692	23	P	ASA	81	m	00541	12.11.2019	15.11.2019	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r with sequelae			Hospitalisation	10018852, 10055798, 10051077	Haematoma, Haemorrhage, Post procedural haemorrhage
692	23	P	ASA	81	m	00542	28.10.2019	01.11.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062242	Shoulder operation
692	23	P	ASA	82	m	01122-1	01.03.2021	02.03.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020462	Humerus fracture
692	23	P	ASA	82	m	01122-2	02.03.2021	15.03.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Prolongation of existing hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10071229, 10022576	Procedural haemorrhage, Internal fixation of fracture
692	23	P	ASA	83	m	01556	23.12.2021	17.01.2022	Syncope	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10042772, 10048709, 10038695, 10077361, 10027141, 10014819, 10013839	Syncope, Urosepsis, Respiratory failure, Multiple organ dysfunction syndrome, Melaena, Endoscopy upper gastrointestinal tract, Duodenal ulcer haemorrhage
265	23	E	ASA	78	m	00187	30.08.2018	10.09.2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10057668	Cognitive disorder
265	23	E	ASA	79	m	00480	26.08.2019		Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	9.5.2019	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
122	23	E	no ASA	76	m	00338	07.10.2018		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable	n	n	Death	10.8.2018	Sudden cardiac death	Hospitalisation	10049418, 10017964	Sudden cardiac death,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								Gastrointestinal infection
216	33	P	ASA	84	m	00834	18.07.2020	20.07.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10024968, 10061494	Lower respiratory tract infection, Rhinovirus infection
221	33	P	no ASA	79	m	00560	05.11.2019	07.11.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
221	33	P	no ASA	78	m	00661	06.11.2018	08.11.2018	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
235	33	E	ASA	75	m	00944	21.10.2020	22.10.2020	Stable AP (no ACS)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10002383	Viral test negative, Angina pectoris
1206	33	E	ASA	92	m	00793	26.06.2020	01.07.2020	Stable AP (no ACS)	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10002383, 10080743	Angina pectoris, Angiocardiogram
1206	33	E	ASA	92	m	01145	24.03.2021	29.03.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10003658, 10007661	Cardiac failure, Atrial fibrillation, Cardioversion
442	34	P	ASA	93	f	00167-1	05.06.2018	10.06.2018	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062585, 10002475	Peripheral arterial occlusive disease, Angioplasty
442	34	P	ASA	93	f	00167-2	10.06.2018		Non-cardiovascular event	Very severe	Other medically important event	Not applicable (no intake of study drug)	n	n	Death	6.16.2018	No cardiovascular cause	Reason for prolongation of existing hospital stay	10062585, 10040047, 10011906	Peripheral arterial occlusive disease, Sepsis, Death
260	35	E	no ASA	81	m	00331	03.04.2019	09.04.2019	Major Bleeding in non-	Severe	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10046274, 10014819, 10053757,	Upper gastrointestinal haemorrhage,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									surgical patients (according ISTH, including haemorrhagic stroke)			(no intake of study drug)							10066152, 10061636	Endoscopy upper gastrointestinal tract, Therapeutic procedure, Transfusion, Angiodysplasia
414	38	P	no ASA	81	m	00186	11.07. 2018	17.07. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10058467	Lung neoplasm malignant
414	38	P	no ASA	81	m	00262	23.12. 2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.23.2018	No cardiovascular cause		10011906, 10058467	Death, Lung neoplasm malignant
414	38	P	no ASA	81	m	00263	05.11. 2018	23.11. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10058467, 10027459, 10027452, 10059282	Lung neoplasm malignant, Metastases to lymph nodes, Metastases to bone, Metastases to central nervous system
414	38	P	no ASA	81	m	00264 -1	19.10. 2018	30.10. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
414	38	P	no ASA	81	m	00264 -2	29.10. 2018	30.10. 2018	Non-cardiovascular event	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			Reason for prolongation of existing hospital stay	10003162, 10042464	Arterial injury, Suicide attempt
1351	39	P	ASA	74	m	00582	16.12. 2019		Abdominal embolism	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	12.16.2019	Death due to other cardiovascular causes	Hospitalisation	10011906, 10007649, 10027395	Death, Cardiovascular disorder, Mesenteric artery embolism
300	40	P	ASA	77	m	00581	30.09. 2019	04.10. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10069339	Acute kidney injury
861	40	E	no ASA	82	m	00253	18.12. 2018	20.12. 2018	Minor Bleeding	Moderate	Hospitalisation	Permanently discontinued due to this event	n	y	r/r			Hospitalisation	10017955, 10027141, 10010007,	Gastrointestinal haemorrhage, Melaena, Colonoscopy,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																			10053757, 10061636	Therapeutic procedure, Angiodysplasia
2122	42	P	ASA	66	f	01567	10.12. 2021	14.12. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10001949, 10062362	Amnesia, Viral test negative
2376	42	P	no ASA	75	f	01866	15.07. 2022	19.07. 2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10014819, 10050703, 10017822, 10072280	Endoscopy upper gastrointestinal tract, Oesophageal manometry, Gastric ulcer, Oesophageal mucosa erythema
397	43	P	ASA	66	m	00305	12.03. 2019	25.03. 2019	Any type of cardiovascular surgery	Moderate	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			Main reason for hospital admission	10011078, 10011077, 10021328, 10015856, 10075685	Coronary artery disease, Coronary artery bypass, Ileus, Extrasystoles, Cardiac pacemaker adjustment
397	43	P	ASA	66	m	00363	03.04. 2019	06.04. 2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10036778, 10018836, 10055798	Proctitis haemorrhagic, Haematochezia, Haemorrhage
258	43	E	ASA	86	f	02069	25.08. 2022	28.08. 2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10062362, 10007598	Cardiac pacemaker replacement, Viral test negative, Cardiac pacemaker insertion
472	44	P	ASA	86	f	00298	26.12. 2018	14.02. 2019	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10007554, 10003658, 10021036	Cardiac failure, Atrial fibrillation, Hyponatraemia
1426	44	P	ASA	84	m	00960	02.10. 2020	05.10. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									peripheral procedure											
1274	44	E	ASA	79	m	01753	23.03.2020	24.03.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
2019	44	E	ASA	81	m	01890	05.07.2022	10.07.2022	Other cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007687, 10007692	Carotid artery stenosis, Carotid endarterectomy
95	46	P	ASA	67	f	00346	11.12.2018	14.12.2018	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10063835, 10075685, 10053486	Undersensing, Cardiac pacemaker adjustment, Pacemaker generated arrhythmia
95	46	P	ASA	70	f	01548	06.09.2021	17.09.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
95	46	P	ASA	71	f	01816	31.05.2022	15.06.2022	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014665, 10007601, 10062362	Endocarditis, Cardiac pacemaker removal, Viral test negative
145	46	P	ASA	67	m	00057	11.05.2017	12.05.2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10024855, 10015037	Loss of consciousness, Epilepsy
145	46	P	ASA	67	m	00139	28.11.2017	30.11.2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10036774	Proctitis
145	46	P	ASA	71	m	01727	13.04.2022	15.04.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10036774, 10009887, 10014819, 10010007	Proctitis, Colitis, Endoscopy upper gastrointestinal tract, Colonoscopy
43	46	E	ASA	76	m	00018	27.02.2017	02.03.2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013573	Dizziness
43	46	E	ASA	78	m	00358	03.12.2018	07.12.2018	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10049447	Tachyarrhythmia
43	46	E	ASA	78	m	00531	19.10.2019	22.10.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10022116, 10039203	Injury, Road traffic accident

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
43	46	E	ASA	81	m	02135	25.04. 2022	27.04. 2022	Change of a pacemaker, ICD or any other cardiac device	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10049434	Cardiac pacemaker replacement
69	46	E	ASA	84	f	01059	20.07. 2020	23.07. 2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10059862	Cardiac resynchronisation therapy
243	49	E	no ASA	89	f	01648	08.03. 2022	09.03. 2022	Change of a pacemaker, ICD or any other cardiac device	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10049434	Cardiac pacemaker replacement
272	49	E	no ASA	72	f	00127	15.04. 2018	17.04. 2018	Minor Bleeding	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	y	y	r/r			Hospitalisa tion	10018836, 10038078	Haematochezia, Rectal prolapse repair
321	53	E	no ASA	82	f	00216	05.07. 2018	11.07. 2018	Non-cardiovascular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10008629, 10014802	Cholelithiasis, Endoscopic retrograde cholangiopancreatography
321	53	E	no ASA	83	f	00289	29.10. 2018	12.11. 2018	Non-cardiovascular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10069951, 10008611	Bile duct stent removal, Cholecystectomy
723	57	P	ASA	83	m	01218	08.05. 2021	12.05. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10061256, 10062362	Ischaemic stroke, Viral test negative
1300	57	P	ASA	76	m	01082	25.01. 2021	26.01. 2021	Hospitalisation due to AF	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10003658, 10062362	Atrial fibrillation, Viral test negative
1300	57	P	ASA	76	m	01314	24.02. 2021	26.02. 2021	Hospitalisation due to AF	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658, 10007661, 10062362	Atrial fibrillation, Cardioversion, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1568	57	P	ASA	81	m	00721	09.04. 2020	22.04. 2020	Worsening of heart failure	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10007554, 10062362	Cardiac failure, Viral test negative
1928	57	P	ASA	81	f	01188	26.04. 2021	06.05. 2021	Pulmonary embolism	Sever e	Life threatening event	Permanently discontinued due to this event	n	n	r/r			Main reason for hospital admission	10037377, 10062362	Pulmonary embolism, Viral test negative
593	57	E	ASA	82	m	00552	14.10. 2019	22.10. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10058467	Lung neoplasm malignant
593	57	E	ASA	82	m	00601	26.11. 2019	27.11. 2019	Non-cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10062501	Non-cardiac chest pain
593	57	E	ASA	83	m	01084	25.11. 2020	28.11. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10004146, 10059443	Basal cell carcinoma, Skin neoplasm excision
593	57	E	ASA	82	m	01085	16.03. 2020	20.03. 2020	Non-cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r with sequel ae			Hospitalisa tion	10058467, 10035617, 10053975	Lung neoplasm malignant, Pleurectomy, Thoracic cavity drainage
966	57	E	ASA	79	f	00592	26.08. 2019	29.08. 2019	Minor Bleeding	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	y	y	r/r			Hospitalisa tion	10017955, 10014819, 10061816	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Diagnostic procedure
1629	57	E	ASA	82	f	01088	12.02. 2021	14.02. 2021	Minor Bleeding	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10016173, 10018852, 10061225, 10062362	Fall, Haematoma, Limb injury, Viral test negative
1755	57	E	ASA	81	m	01203	15.04. 2021	28.04. 2021	Syncope	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r with sequel ae			Hospitalisa tion	10062362, 10042772	Viral test negative, Syncope
1755	57	E	ASA	81	m	01276	13.06. 2021		Non-cardiovasc ular event	Very severe	Hospitalisa tion	Permanently discontinued due to this event	n	n	Death	6.17.2021	No cardiovascul ar cause	Hospitalisa tion	10011906, 10016454, 10038695	Death, Femur fracture, Respiratory failure
1837	57	E	ASA	82	m	01626	31.01. 2022	08.02. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10062501, 10062362	Non-cardiac chest pain, Viral test negative
19	59	P	ASA	83	f	00427	12.11. 2018	14.11. 2018	Non-cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r with sequel ae			Hospitalisa tion	10006187, 10061816	Breast cancer, Diagnostic procedure
19	59	P	ASA	83	f	00428	16.11. 2018	26.11. 2018	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10076783	Breast conserving surgery

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
19	59	P	ASA	84	f	00622	07.01.2020	11.01.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10013968, 10030124	Cardiac failure, Dyspnoea, Oedema peripheral
24	59	P	ASA	69	m	00232-1	19.11.2018	21.11.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10069339, 10064848, 10038695, 10066152, 10061816, 10014819, 10017955	Cardiac failure, Acute kidney injury, Chronic kidney disease, Respiratory failure, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Gastrointestinal haemorrhage
24	59	P	ASA	69	m	00232-2	19.11.2018		Worsening of heart failure	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	Death	12.9.2018	Death due to heart failure (HF)	Reason for prolongation of existing hospital stay	10049993, 10007554	Cardiac death, Cardiac failure
24	59	P	ASA	69	m	00243	27.09.2018	10.10.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10017955, 10055798, 10015090, 10013839, 10066152, 10014819, 10061816	Anaemia, Gastrointestinal haemorrhage, Haemorrhage, Epistaxis, Duodenal ulcer haemorrhage, Transfusion, Endoscopy upper gastrointestinal tract, Diagnostic procedure
24	59	P	ASA	68	m	00242	11.07.2018	19.07.2018	Pulmonary embolism	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10037377	Pulmonary embolism
24	59	P	ASA	68	m	00256	02.07.2018	05.07.2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049548, 10024612	Knee operation, Lipoma
67	59	P	ASA	78	m	00087	26.12.2017	11.01.2018	Worsening of heart failure	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
67	59	P	ASA	79	m	00111	14.02.2018	16.03.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10004302, 10052693	Benign neoplasm of bladder, Transurethral bladder resection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
466	59	P	ASA	79	m	01536	23.11. 2021	03.12. 2021	Any type of cardiovascular surgery	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007692, 10003194, 10007687	Carotid endarterectomy, Arteriogram carotid, Carotid artery stenosis
466	59	P	ASA	79	m	01537	14.12. 2021	17.12. 2021	Myocardial Infarction	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608	Acute myocardial infarction, Percutaneous coronary intervention
466	59	P	ASA	79	m	01664	13.02. 2022	23.02. 2022	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007686, 10003144, 10062362, 10066152	Carotid artery aneurysm, Arterial aneurysm repair, Viral test negative, Transfusion
679	59	P	ASA	77	m	00474	08.08. 2019	09.08. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038435	Renal failure
679	59	P	ASA	78	m	00475	20.08. 2019	23.08. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10010774	Constipation
679	59	P	ASA	79	m	01374	15.08. 2021	18.08. 2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1451	59	P	ASA	81	m	00790	20.04. 2020	28.04. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10035664, 10007661, 10062362	Atrial fibrillation, Pneumonia, Cardioversion, Viral test negative
2211	59	P	ASA	83	m	01870	10.01. 2022	17.01. 2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10057525, 10072562, 10057518	Peripheral artery occlusion, Peripheral artery stent insertion, Peripheral artery angioplasty
2211	59	P	ASA	83	m	01871	16.05. 2022	27.05. 2022	Myocardial Infarction	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
2211	59	P	ASA	83	m	01872	30.06. 2022	05.07. 2022	Percutaneous coronary	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									intervention (e.g. PCI), cerebrovascular or peripheral procedure			(no intake of study drug)								Coronary arterial stent insertion
2211	59	P	ASA	83	m	01887	02.08.2022	04.08.2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
463	59	P	no ASA	79	f	00176	30.05.2018	31.05.2018	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10040752	Sinus tachycardia
463	59	P	no ASA	81	f	00902	05.06.2020	11.06.2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10046571	Atrial fibrillation, Urinary tract infection
463	59	P	no ASA	82	f	01359	31.08.2021	01.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571, 10011781	Urinary tract infection, Cystitis
467	59	P	no ASA	78	f	00875	26.06.2020	09.07.2020	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10018250	Giant cell arteritis
615	59	P	no ASA	81	f	00241	17.11.2018	21.11.2018	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
615	59	P	no ASA	81	f	00424	30.01.2019	02.02.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
615	59	P	no ASA	82	f	00627	27.11.2019	28.11.2019	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10013968, 10020772	Dyspnoea, Hypertension
615	59	P	no ASA	82	f	00628	10.10.2019	15.10.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
615	59	P	no ASA	83	f	01034	28.12. 2020	05.01. 2021	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10062362, 10007554, 10003658	Viral test negative, Cardiac failure, Atrial fibrillation
615	59	P	no ASA	83	f	01180	16.02. 2021	17.02. 2021	Hospitalisa tion due to AF	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658, 10062362	Atrial fibrillation, Viral test negative
615	59	P	no ASA	84	f	01372	23.08. 2021	25.08. 2021	Hospitalisa tion due to AF	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658	Atrial fibrillation
615	59	P	no ASA	84	f	01373	02.08. 2021	13.08. 2021	Peripheral (limb) embolism	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10061340, 10043530	Peripheral embolism, Thrombectomy
615	59	P	no ASA	84	f	01538	15.11. 2021	19.11. 2021	Hospitalisa tion due to AF	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658, 10007554, 10007661	Atrial fibrillation, Cardiac failure, Cardioversion
615	59	P	no ASA	84	f	01583	15.01. 2022	20.01. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10017955, 10061816, 10014819, 10010007, 10051348, 10013554, 10019022	Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Gastric ulcer helicobacter, Diverticulum, Haemorrhoids
826	59	P	no ASA	83	f	00903	27.02. 2020	17.03. 2020	Non-cardiovascular event	Mild	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10003988, 10061246, 10043882	Back pain, Intervertebral disc degeneration, Tinnitus
1191	59	P	no ASA	69	m	01885	11.01. 2022	16.01. 2022	Non-cardiovascular event	Sever e	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10060862, 10061916	Prostate cancer, Prostatectomy
1230	59	P	no ASA	79	m	01181	30.03. 2021	01.04. 2021	Worsening of heart failure	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10052086, 10065608	Cardiac failure, Coronary arterial stent insertion, Percutaneous coronary intervention
1230	59	P	no ASA	79	m	01182	11.04. 2021	12.04. 2021	Non-cardiovascular event	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10037660, 10062362	Pyrexia, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1230	59	P	no ASA	79	m	01305	10.05. 2021	12.05. 2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052086, 10065608, 10062362	Coronary arterial stent insertion, Percutaneous coronary intervention, Viral test negative
1422	59	P	no ASA	84	m	01454	13.09. 2021	17.09. 2021	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10003658, 10062362	Cardiac failure, Atrial fibrillation, Viral test negative
98	59	E	ASA	73	m	00009	20.02. 2017		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.20.2017	Sudden cardiac death		10049418	Sudden cardiac death
186	59	E	ASA	65	m	00081	21.12. 2017	22.12. 2017	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10052086, 10011078	Coronary arterial stent insertion, Coronary artery disease
380	59	E	ASA	77	m	00158	04.03. 2018	11.03. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10025005, 10041563	Lumbar spinal stenosis, Spinal decompression
380	59	E	ASA	79	m	00612	13.01. 2020	17.01. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10050329, 10052086, 10011078	Coronary angioplasty, Coronary arterial stent insertion, Coronary artery disease
380	59	E	ASA	79	m	00679	03.02. 2020	05.02. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062501	Non-cardiac chest pain

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
380	59	E	ASA	80	m	01179	01.03.2021	02.03.2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608	Percutaneous coronary intervention
380	59	E	ASA	80	m	01371	25.03.2021	30.03.2021	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10077015	Transcatheter aortic valve implantation
416	59	E	ASA	89	f	00279	18.01.2019	25.01.2019	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
416	59	E	ASA	90	f	00426	29.05.2019	04.06.2019	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013968, 10030124	Dyspnoea, Oedema peripheral
416	59	E	ASA	90	f	00440	03.08.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.3.2019	Sudden cardiac death		10049418	Sudden cardiac death
493	59	E	ASA	77	m	01140	07.12.2020	09.12.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10060862, 10044445	Prostate cancer, Transurethral prostatectomy
493	59	E	ASA	78	m	01403	02.06.2021	04.06.2021	Minor Bleeding	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020802, 10015090	Hypertensive crisis, Epistaxis
493	59	E	ASA	79	m	01795	10.05.2022	14.05.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10011078, 10065608, 10052086	Coronary artery disease, Percutaneous coronary intervention, Coronary arterial stent insertion
528	59	E	ASA	83	f	01665-1	22.02.2022	07.03.2022	Any type of cardiovasc	Severe	Hospitalisation	Permanently discontinued	n	n	r/r			Hospitalisation	10057525, 10072561, 10014648	Peripheral artery occlusion, Peripheral artery

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									ular surgery			due to this event								bypass, Endarterectomy
528	59	E	ASA	83	f	01665-2	26.02.2022	07.03.2022	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	y	y	r/r			Hospitalisation	10066152, 10002034, 10051077	Transfusion, Anaemia, Post procedural haemorrhage
528	59	E	ASA	84	f	01812	26.04.2022	28.04.2022	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10057525, 10002475	Peripheral artery occlusion, Angioplasty
528	59	E	ASA	84	f	01884-1	06.07.2022	07.07.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062585, 10002475, 10072561, 10048671	Peripheral arterial occlusive disease, Angioplasty, Peripheral artery bypass, Venous stenosis
528	59	E	ASA	84	f	01884-2	08.07.2022	01.08.2022	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10066152, 10051077, 10048975, 10066050	Anaemia, Transfusion, Post procedural haemorrhage, Vascular pseudoaneurysm, Aneurysm repair
655	59	E	ASA	88	f	01035	15.10.2020	26.10.2020	Minor Bleeding	Moderate	Hospitalisation	None, i.e. still ongoing	y	y	r/r			Hospitalisation	10017955, 10014819, 10010007, 10066152	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Transfusion
655	59	E	ASA	88	f	01036	15.11.2020	23.11.2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10046571, 10070863	Urinary tract infection, Toxicity to various agents
655	59	E	ASA	88	f	01037	15.12.2020	05.01.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10019027, 10035664	Haemothorax, Pneumonia
1105	59	E	ASA	70	f	00623	18.11.2019	25.11.2019	Worsening of heart failure	Severe	Hospitalisation	Permanently discontinued	n	n	r/r			Hospitalisation	10007554, 10003658	Cardiac failure, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event								
1195	59	E	ASA	65	f	00625	27.11.2019	29.11.2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10033557	Palpitations
1245	59	E	ASA	88	m	00626	05.01.2020	08.01.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10018829, 10031161	Haemarthrosis, Osteoarthritis
1245	59	E	ASA	90	m	01681	01.02.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.1.2022	Sudden cardiac death		10049418	Sudden cardiac death
1579	59	E	ASA	67	f	02033	23.09.2022	24.09.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062168	Varicose vein operation
58	59	E	no ASA	79	m	01039-1	21.10.2020	26.10.2020	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r		No cardiovascular cause	Hospitalisation	10061902, 10014802, 10011906	Pancreatic neoplasm, Endoscopic retrograde cholangiopancreatography, Death
58	59	E	no ASA	79	m	01039-2	26.10.2020		Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	Death	11.6.2020		Hospitalisation	10017955, 10066152	Gastrointestinal haemorrhage, Transfusion
149	59	E	no ASA	80	m	01178-1	15.04.2021	25.04.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016454	Femur fracture
149	59	E	no ASA	80	m	01178-2	25.04.2021		Non-cardiovascular event	Very severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	Death	5.22.2021	No cardiovascular cause	Hospitalisation	10011906, 10022694	Death, Intestinal perforation
541	59	E	no ASA	75	m	00425	25.06.2019	27.06.2019	Percutaneous coronary intervention (e.g.	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10002383	Percutaneous coronary intervention, Angina pectoris

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									PCI), cerebrovascular or peripheral procedure											
541	59	E	no ASA	77	m	01526	06.10.2021	09.10.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10000614, 10074431, 10006059	Actinic keratosis, Cancer surgery, Bowen's disease
1140	59	E	no ASA	82	f	00624	18.11.2019	20.11.2019	Hospitalisation due to AF	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003662, 10007661	Atrial flutter, Cardioversion
1140	59	E	no ASA	82	f	00913	18.03.2020	19.03.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1140	59	E	no ASA	82	f	00914	12.04.2020	15.04.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
1140	59	E	no ASA	82	f	00915	19.05.2020	21.05.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
1140	59	E	no ASA	83	f	00916	24.08.2020	26.08.2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017853, 10014819	Gastritis, Endoscopy upper gastrointestinal tract
1140	59	E	no ASA	82	f	00937	28.04.2020	30.04.2020	TIA	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10044390, 10062362	Transient ischaemic attack, Viral test negative
1140	59	E	no ASA	84	f	01375	09.09.2021	11.09.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1140	59	E	no ASA	84	f	01539	17.11.2021	18.11.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003662, 10007661, 10007554, 10053057	Atrial flutter, Cardioversion, Cardiac failure, Oesophagogastroduodenoscopy
1634	59	E	no ASA	85	f	00917	15.09.2020	17.09.2020	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10036653, 10020772, 10019211	Presyncope, Hypertension, Headache
1634	59	E	no ASA	86	f	01376	12.07.2021	15.07.2021	Major Bleeding in non-surgical patients (according	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009944	Colon cancer

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									ISTH, including haemorrhagic stroke)											
1634	59	E	no ASA	86	f	01377	22.07.2021	06.08.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061778, 10048991, 10009944	Colectomy, Ovarian adenoma, Colon cancer
1920	59	E	no ASA	86	f	01183	12.03.2021	13.03.2021	Minor Bleeding	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10017955, 10062362	Gastrointestinal haemorrhage, Viral test negative
1920	59	E	no ASA	86	f	01361	19.05.2021	24.05.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062127	Thyroidectomy
1920	59	E	no ASA	86	f	01569	12.12.2021	23.12.2021	Minor Bleeding	Moderate	Hospitalisation	None, i.e. still ongoing	n	y	r/r			Hospitalisation	10031161, 10003517, 10018829	Osteoarthritis, Aspiration joint, Haemarthrosis
511	70	P	ASA	82	m	00758	28.02.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.28.2020	Sudden cardiac death		10049418	Sudden cardiac death
644	70	P	ASA	79	f	01118	02.03.2021	05.03.2021	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
644	70	P	ASA	80	f	01825	26.11.2021	07.12.2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10035598, 10080743	Cardiac failure, Pleural effusion, Angiocardiogram
765	70	P	ASA	82	m	00573	13.07.2019	29.07.2019	Non-cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10016450	Femoral neck fracture
765	70	P	ASA	85	m	02123	05.05.2022	07.05.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065064, 10049434	Device lead issue, Cardiac pacemaker replacement
1148	70	P	ASA	82	m	00506	10.09.2019	18.09.2019	Major Bleeding in non-surgical patients	Moderate	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10042361, 10055798	Subdural haematoma, Haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									(according ISTH, including haemorrhagic stroke)											
1485	70	P	ASA	81	f	01956	10.03.2022	11.03.2022	Pulmonary embolism	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10037377	Pulmonary embolism
1751	70	P	ASA	82	m	01447	12.03.2021	15.03.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
1751	70	P	ASA	82	m	01448	10.05.2021	18.05.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10003662, 10059864	Atrial fibrillation, Atrial flutter, Cardiac ablation
1950	70	P	ASA	76	m	01826	03.02.2022		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	2.8.2022	No cardiovascular cause	Hospitalisation	10011906, 10040047, 10040070, 10027070, 10010007, 10000279	Death, Sepsis, Septic shock, Mediastinal abscess, Colonoscopy, Abscess drainage
2554	70	P	ASA	71	m	01986	19.08.2022	20.08.2022	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10080743, 10007554	Angiocardiogram, Cardiac failure
1114	70	P	no ASA	76	m	01637	15.01.2021	18.01.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
1114	70	P	no ASA	78	m	02121	12.09.2022	13.09.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10013968, 10070255	Dyspnoea, Coronavirus test positive
1304	70	P	no ASA	76	m	01155	12.01.2021	14.01.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
662	70	E	ASA	81	m	00330	20.08.2018	23.08.2018	Other cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10043570, 10043530	Thrombophlebitis, Thrombectomy
662	70	E	ASA	84	m	02122	24.05.2022	27.05.2022	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
881	70	E	ASA	85	m	00433	19.03.2019	24.03.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008611	Cholecystectomy
1808	70	E	ASA	77	m	01451	01.09.2021	02.09.2021	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061739, 10047302, 10007661	Cardiac electrophysiologic study, Ventricular tachycardia, Cardioversion
2068	70	E	ASA	74	m	01636	27.09.2021	23.10.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10043827, 10016173, 10002034, 10022576, 10055798, 10062362	Tibia fracture, Fall, Anaemia, Internal fixation of fracture, Haemorrhage, Viral test negative
2068	70	E	ASA	74	m	01846	08.02.2022	10.02.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038338, 10062362, 10022576	Removal of internal fixation, Viral test negative, Internal fixation of fracture
2068	70	E	ASA	75	m	02115	18.08.2022	19.08.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10075685, 10002034	Cardiac pacemaker adjustment, Anaemia
16	70	E	no ASA	77	m	00868	27.05.2020	02.06.2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	y	r/r			Hospitalisation	10018867, 10060862	Haematuria, Prostate cancer
253	70	E	no ASA	69	m	00568	27.03.2019	29.03.2019	Hospitalisation due to AF	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1569	70	E	no ASA	80	m	01175	19.02.2021	25.02.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10060734, 10067806, 10012680	Diabetic foot, Debridement, Diabetic neuropathy
1569	70	E	no ASA	82	m	02119	20.09.2022	24.09.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10035759	Cardiac pacemaker replacement, Pneumothorax

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1741	70	E	no ASA	89	m	01639	06.01. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.6.2022	Death of unknown cause		10011906	Death
404	86	P	ASA	74	f	01318	01.07. 2021	02.07. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
554	86	P	no ASA	71	f	01676	05.07. 2021	09.07. 2021	ACS	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10080743, 10051592, 10049434, 10027452, 10062362, 10006187	Angiocardiogram, Acute coronary syndrome, Cardiac pacemaker replacement, Metastases to bone, Viral test negative, Breast cancer
554	86	P	no ASA	71	f	01814	17.06. 2021	23.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
338	86	E	ASA	77	m	00284	20.11. 2018	22.11. 2018	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10075322	Atrial fibrillation, Device inappropriate shock delivery
338	86	E	ASA	79	m	01398	17.06. 2021	18.06. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
338	86	E	ASA	80	m	01677	17.02. 2022	22.02. 2022	Myocardial Infarction	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10000891, 10007554, 10052086	Percutaneous coronary intervention, Acute myocardial infarction, Cardiac failure, Coronary arterial stent insertion
338	86	E	ASA	80	m	01678	22.02. 2022	23.02. 2022	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10031127, 10003658	Orthostatic hypotension, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
338	86	E	ASA	80	m	01679	06.03.2022	15.03.2022	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
352	86	E	ASA	82	m	00150	06.04.2018	13.04.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10035664	Pneumonia
352	86	E	ASA	86	m	01811	04.06.2022		Non-cardiovascular event		Death	Not applicable (no intake of study drug)	n	n	Death	6.4.2022	No cardiovascular cause	No hospital stay	10011906, 10035664	Death, Pneumonia
352	86	E	ASA	85	m	01933	04.02.2021	18.02.2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1263	86	E	ASA	80	m	01256	17.03.2021	18.03.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1428	86	E	ASA	84	m	01739	28.04.2022	03.05.2022	Myocardial Infarction	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
1428	86	E	ASA	84	m	01934-1	15.08.2022	24.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10066152	Anaemia, Transfusion
1428	86	E	ASA	84	m	01934-2	15.08.2022	24.08.2022	Non-cardiovascular event	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10036909, 10061816	Prostate cancer metastatic, Diagnostic procedure
1428	86	E	ASA	84	m	02120	27.11.2022	29.11.2022	Major Bleeding in non-surgical patients (according ISTH, including	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10060862, 10027452, 10049710, 10046528, 10011814, 10005028	Haematuria, Prostate cancer, Metastases to bone, Urethral haemorrhage, Urinary bladder haemorrhage, Cystoscopy,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									haemorrhagic stroke)											Bladder catheterisation
1189	86	E	no ASA	80	f	00473	05.08.2019	12.08.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	r/r			Hospitalisation	10066152, 10017955, 10010007, 10053757, 10061636	Transfusion, Gastrointestinal haemorrhage, Colonoscopy, Therapeutic procedure, Angiodysplasia
1189	86	E	no ASA	80	f	00482	05.09.2019	07.09.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10010007, 10053757, 10061636	Colonoscopy, Therapeutic procedure, Angiodysplasia
1189	86	E	no ASA	80	f	00584	12.12.2019	16.12.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034	Anaemia
1189	86	E	no ASA	80	f	00802	21.05.2020	28.05.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
1189	86	E	no ASA	80	f	00812	15.06.2020	25.06.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
1189	86	E	no ASA	81	f	00901	23.09.2020	01.10.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10052693, 10005003, 10055798, 10066152	Haematuria, Transurethral bladder resection, Bladder cancer, Haemorrhage, Transfusion
1189	86	E	no ASA	81	f	01001	31.10.2020	05.11.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10005003	Bladder cancer
1189	86	E	no ASA	81	f	01012-1	16.11.2020	02.12.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10044412, 10046537	Transitional cell carcinoma, Urinary cystectomy
1189	86	E	no ASA	81	f	01012-2	02.12.2020	05.12.2020	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10025282	Lymphoedema

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1189	86	E	no ASA	81	f	01013	15.12. 2020	24.12. 2020	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10044412	Transitional cell carcinoma
1189	86	E	no ASA	81	f	01083	26.12. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.26.2020	No cardiovascular cause		10011906, 10044412	Death, Transitional cell carcinoma
18	95	P	ASA	78	f	00071	13.09. 2016	16.09. 2016	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10058179	Hypertensive emergency
28	95	P	ASA	73	f	00019	07.10. 2016		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.9.2016	No cardiovascular cause	Hospitalisation	10011906, 10038695	Death, Respiratory failure
22	95	P	no ASA	73	m	00140	08.05. 2018	09.05. 2018	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661	Cardioversion
26	95	P	no ASA	74	f	01970	15.08. 2022	29.08. 2022	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10038695	Cardiac failure, Respiratory failure
30	95	P	no ASA	82	m	00401	23.06. 2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	6.23.2019	No cardiovascular cause		10011906, 10035664	Death, Pneumonia
534	95	P	no ASA	65	m	00154	15.06. 2018	19.06. 2018	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256, 10003658	Ischaemic stroke, Atrial fibrillation
534	95	P	no ASA	66	m	00561	12.11. 2019	22.11. 2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020635	Hyperglycaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1066	95	P	no ASA	75	m	00652	09.06. 2019	12.06. 2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10018867	Haematuria
1066	95	P	no ASA	75	m	00676	01.06. 2019	03.06. 2019	Minor Bleeding	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10018867	Haematuria
1066	95	P	no ASA	75	m	00696	25.02. 2020	05.03. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
1066	95	P	no ASA	75	m	00697	08.03. 2020	12.03. 2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10066152, 10002034	Transfusion, Anaemia
1368	95	P	no ASA	79	f	01040 -1	01.01. 2021		ACS	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Event ongoing		Death due to acute myocardial infarction (MI)	Hospitalisation	10049993, 10000891, 10070255, 10065608, 10051592	Cardiac death, Acute myocardial infarction, Coronavirus test positive, Percutaneous coronary intervention, Acute coronary syndrome
1368	95	P	no ASA	79	f	01040 -2	02.01. 2021		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Other medically important event	Not applicable (no intake of study drug)	n	n	Death	1.2.2021		No prolongation of existing hospital stay	10051101, 10070255, 10066152, 10038749	Puncture site haemorrhage, Coronavirus test positive, Transfusion, Resuscitation
10	95	E	ASA	93	m	01818	19.06. 2022		Non-cardiovascular event				n	n	Death	6.19.2022	No cardiovascular cause		10011906, 10033609	Death, Pancreatic carcinoma
10	95	E	ASA	93	m	01822	06.06. 2022	10.06. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10033610, 10017885, 10014819	Pancreatic carcinoma metastatic, Gastrooesophageal reflux disease, Endoscopy upper gastrointestinal tract
14	95	E	ASA	72	m	01300	12.07. 2021		Death as primary event, e.g. sudden death, not				n	n	Death	7.12.2021	No cardiovascular cause		10011906, 10009944	Death, Colon cancer

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death as outcome of another event											
14	95	E	ASA	70	m	01348	13.11. 2018	29.11. 2018	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061778, 10009944	Colectomy, Colon cancer
53	95	E	ASA	82	m	00024	01.05. 2017	04.05. 2017	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10017866, 10013864	Gastritis haemorrhagic, Duodenitis
53	95	E	ASA	82	m	00026	29.05. 2017	02.06. 2017	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke
53	95	E	ASA	87	m	01786	27.04. 2022	03.05. 2022	Non-cardiovascular event	Mild	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			Main reason for hospital admission	10052693, 10060862	Transurethral bladder resection, Prostate cancer
117	95	E	no ASA	75	m	00050	03.07. 2017	02.08. 2017	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10054221	Enterococcal sepsis
117	95	E	no ASA	77	m	00527	16.09. 2019	18.09. 2019	Stable AP (no ACS)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10002383, 10065608, 10052086	Angina pectoris, Percutaneous coronary intervention, Coronary arterial stent insertion
117	95	E	no ASA	79	m	01746	09.03. 2022	16.03. 2022	Stable AP (no ACS)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007815, 10011078, 10002383	Catheterisation cardiac, Coronary artery disease, Angina pectoris
533	95	E	no ASA	81	f	00715	07.02. 2020	28.02. 2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10033371, 10019974	Pain, Herpes zoster
4	100	P	ASA	81	f	01602	07.06. 2021	09.06. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
846	100	P	ASA	73	m	00460	29.08. 2019	12.09. 2019	Stroke, unknown cause	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
846	100	P	ASA	75	m	01770	21.10.2021	03.11.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10048709, 10062362	Urosepsis, Viral test negative
846	100	P	ASA	76	m	02104	17.08.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.17.2022	No cardiovascular cause		10011906, 10003549	Death, Asthenia
848	100	P	ASA	71	f	01991	19.09.2022	20.09.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
124	100	E	ASA	78	m	00924	22.05.2020	03.06.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	NA, 10052086, 10065608	NA, Coronary arterial stent insertion, Percutaneous coronary intervention
124	100	E	ASA	78	m	01201	16.02.2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.24.2021	No cardiovascular cause	Hospitalisation	10011906, 10062362, 10035664	Death, Viral test negative, Pneumonia
527	100	E	ASA	66	f	00200	19.09.2018	11.10.2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10006586	Bunion operation
527	100	E	ASA	66	f	00332	03.12.2018	06.12.2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10010214, 10041569, 10061161	Compression fracture, Spinal fracture, Pelvic fracture
527	100	E	ASA	66	f	00354	28.01.2019	02.02.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10041563, 10025005	Spinal decompression, Lumbar spinal stenosis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
527	100	E	ASA	67	f	00699	09.01.2020	13.01.2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062262	Spinal operation
527	100	E	ASA	68	f	00923	17.08.2020	18.08.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10003246	Arthritis
537	100	E	ASA	94	m	00524	12.09.2019	27.09.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10006811	Bursitis
933	100	E	ASA	81	m	00711	15.04.2020	29.04.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10060734, 10057518	Diabetic foot, Peripheral artery angioplasty
933	100	E	ASA	81	m	00817	10.06.2020	22.06.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10031252, 10012601, 10071564	Osteomyelitis, Diabetes mellitus, Limb amputation
933	100	E	ASA	81	m	01038	18.12.2020	13.01.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10060734, 10016960	Diabetic foot, Foot amputation
933	100	E	ASA	82	m	01100	18.01.2021	04.02.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061627, 10060734, 10009657, 10012735	Amputation, Diabetic foot, Clostridium difficile colitis, Diarrhoea
933	100	E	ASA	83	m	01876	28.06.2022	07.07.2022	Non-cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10040943, 10062585, 10002475	Skin ulcer, Peripheral arterial occlusive disease, Angioplasty
1327	100	E	ASA	77	f	01320	09.06.2021	14.06.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
201	109	P	ASA	86	f	01146	25.02.2021	01.03.2021	Hospitalisation due to AF	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
39	113	P	ASA	85	m	00090	18.01.2018	25.01.2018	Ischemic stroke (including	Mild	Hospitalisation	Permanently discontinued	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									transient events with matching lesion on cerebral imaging)			due to this event								
60	113	P	ASA	88	m	00066	25.10. 2017	02.07. 2018	Non-cardiovascular event	Very severe	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10029547, 10047249	Non-Hodgkin's lymphoma, Venous thrombosis
60	113	P	ASA	88	m	00089	28.11. 2017	22.12. 2017	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10029547, 10057647	Non-Hodgkin's lymphoma, Cytoreductive surgery
40	113	E	no ASA	81	m	00131	16.02. 2018	20.02. 2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015037	Epilepsy
40	113	E	no ASA	81	m	00134	16.03. 2018	19.03. 2018	Minor Bleeding	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015090	Epistaxis
17	117	P	ASA	67	f	00171	08.12. 2017	14.12. 2017	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
17	117	P	ASA	68	f	00193	28.09. 2018	06.10. 2018	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10067251	Lead dislodgement
17	117	P	ASA	69	f	00785	18.06. 2020	08.07. 2020	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10061637	Cardiac failure, Angiogram
17	117	P	ASA	71	f	01736	26.04. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	4.26.2022	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1155	117	P	no ASA	85	m	00572	10.12.2019	13.12.2019	Hospitalisation due to AF	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
1155	117	P	no ASA	86	m	00896	22.09.2020	24.09.2020	Hospitalisation due to AF	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1155	117	P	no ASA	86	m	00930	12.10.2020	14.10.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
1155	117	P	no ASA	86	m	00964	10.11.2020	13.11.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1155	117	P	no ASA	86	m	01041	01.12.2020	07.12.2020	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007601	Cardiac pacemaker removal
1155	117	P	no ASA	86	m	01042	11.01.2021	12.01.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
264	117	E	ASA	80	m	00334	05.04.2019	09.04.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10050296	Intervertebral disc protrusion
264	117	E	ASA	83	m	01684	28.03.2022	01.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062501, 10080743	Non-cardiac chest pain, Angiocardiogram
320	117	E	ASA	83	m	00156	29.06.2018	05.07.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10017955	Gastrointestinal haemorrhage
320	117	E	ASA	84	m	00237	04.12.2018	11.12.2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10014819, 10022970,	Anaemia, Endoscopy upper gastrointestinal tract, Iron

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																			10010007, 10061816	deficiency, Colonoscopy, Diagnostic procedure
320	117	E	ASA	84	m	00274	28.01.2019	30.01.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061637, 10062585, 10002475	Angiogram, Peripheral arterial occlusive disease, Angioplasty
320	117	E	ASA	84	m	00348	25.04.2019	02.05.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10002034, 10080561, 10066152, 10014819, 10010007, 10053757, 10017955	Cardiac failure, Anaemia, Gastrointestinal vascular malformation haemorrhagic, Transfusion, Endoscopy upper gastrointestinal tract, Colonoscopy, Therapeutic procedure, Gastrointestinal haemorrhage
320	117	E	ASA	84	m	00418-1	15.07.2019	25.07.2019	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10047302, 10079735	Cardioversion, Ventricular tachycardia, Atrial appendage closure
320	117	E	ASA	84	m	00418-2	17.07.2019	30.07.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10055798, 10018852, 10017955, 10066152, 10014819, 10010007, 10061816	Haemorrhage, Haematoma, Gastrointestinal haemorrhage, Transfusion, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure
320	117	E	ASA	84	m	00439	04.08.2019	10.08.2019	Major Bleeding in non-surgical patients (according ISTH, including	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10055798, 10018867, 10046528, 10011814, 10066152	Haemorrhage, Haematuria, Urinary bladder haemorrhage, Cystoscopy, Transfusion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									haemorrhagic stroke)											
320	117	E	ASA	84	m	00452-1	24.08.2019	08.10.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10055798	Haematuria, Haemorrhage
320	117	E	ASA	84	m	00452-2	11.09.2019	16.09.2019	Worsening of heart failure	Severe	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10007554	Cardiac failure
320	117	E	ASA	84	m	00476	15.08.2019	22.08.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10066152	Haematuria, Transfusion
320	117	E	ASA	84	m	00503	10.10.2019	23.10.2019	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10003658, 10002034	Cardiac failure, Atrial fibrillation, Anaemia
320	117	E	ASA	85	m	00523	02.11.2019	16.11.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021789, 10049438	Infection, General physical health deterioration
320	117	E	ASA	85	m	00551	24.11.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.24.2019	Death of unknown cause		10011906	Death
663	117	E	ASA	79	m	00657-1	19.02.2020	20.02.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
663	117	E	ASA	79	m	00657-2	19.02.2020	21.02.2020	Worsening of heart failure	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
943	117	E	ASA	82	m	00608-1	16.01.2020	06.02.2020	Worsening of heart failure	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10014819, 10010007, 10061816	Cardiac failure, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure
943	117	E	ASA	83	m	00608-2	31.01.2020	06.02.2020	Other cardiovascular event	Severe	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10043570	Thrombophlebitis
943	117	E	ASA	82	m	00609	21.07.2019	29.07.2019	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10019974	Herpes zoster
943	117	E	ASA	83	m	00833	08.03.2020		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	3.10.2020	No cardiovascular cause	Hospitalisation	10011906, 10040070, 10023696, 10074984	Death, Septic shock, Laparotomy, Abdominal incarcerated hernia
56	121	P	ASA	89	m	00029	03.05.2017	05.05.2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10022016, 10062003	Inguinal hernia, Hernia repair
56	121	P	ASA	93	m	01473	10.09.2021	17.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10033645, 10008629	Pancreatitis, Cholelithiasis
56	121	P	ASA	93	m	01474	25.08.2021	26.08.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10074431, 10007390	Cancer surgery, Carcinoma in situ of skin
56	121	P	ASA	94	m	01661	22.03.2022	24.03.2022	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
103	121	P	ASA	90	f	00463-1	25.06.2019	04.07.2019	Minor Bleeding	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10055798, 10017955	Haemorrhage, Gastrointestinal haemorrhage
103	121	P	ASA	90	f	00463-3	25.06.2019		Non-cardiovascular event	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	Death	7.4.2019	No cardiovascular cause	Reason for prolongation of existing	10011906, 10048709	Death, Urosepsis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																		hospital stay		
103	121	P	ASA	90	f	00513	15.03.2019	28.03.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10043554, 10016454, 10022576, 10022116, 10066152	Thrombocytopenia, Femur fracture, Internal fixation of fracture, Injury, Transfusion
355	121	P	ASA	83	m	00357	10.05.2019	15.05.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10013968, 10061637	Dyspnoea, Angiogram
355	121	P	ASA	84	m	00746	07.01.2020	10.01.2020	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10002034, 10022970	Anaemia, Iron deficiency
355	121	P	ASA	84	m	00747	21.01.2020	29.01.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061778	Colectomy
355	121	P	ASA	85	m	01581	06.09.2021	08.09.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10061816, 10010007, 10014819, 10066152, 10013554, 10002034	Gastrointestinal haemorrhage, Diagnostic procedure, Colonoscopy, Endoscopy upper gastrointestinal tract, Transfusion, Diverticulum, Anaemia
130	121	P	no ASA	82	f	00028	03.06.2017	12.06.2017	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10021097	Hypotension
130	121	P	no ASA	82	f	00079	12.12.2017	19.12.2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012174	Dehydration
130	121	P	no ASA	82	f	00103	03.03.2018	16.03.2018	Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10040047, 10062190	Sepsis, Metabolic encephalopathy
130	121	P	no ASA	83	f	00220-1	14.10.2018	25.10.2018	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
130	121	P	no ASA	83	f	00220-2	14.10.2018	25.10.2018	Non-cardiovascular event	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10023204	Joint dislocation
130	121	P	no ASA	83	f	00276	16.01.2019	21.01.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10014866	Enteritis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
130	121	P	no ASA	83	f	00281	29.09. 2018	02.10. 2018	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
130	121	P	no ASA	84	f	00629	16.08. 2019	17.08. 2019	Hospitalisa tion due to AF	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007661, 10003658	Cardioversion, Atrial fibrillation
130	121	P	no ASA	84	f	00630	30.12. 2019	07.01. 2020	Non-cardiovasc ular event	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10006451	Bronchitis
130	121	P	no ASA	85	f	00874	06.06. 2020	23.06. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10016173	Fall
130	121	P	no ASA	86	f	01291	13.07. 2021	17.07. 2021	Hospitalisa tion due to AF	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658	Atrial fibrillation
130	121	P	no ASA	86	f	01562	14.12. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.14.2021	Sudden cardiac death		10049418	Sudden cardiac death
41	121	E	ASA	72	f	00003	11.12. 2016	16.12. 2016	TIA	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10044390, 10001903	Transient ischaemic attack, Amaurosis fugax
41	121	E	ASA	73	f	00122	17.04. 2018	19.04. 2018	Change of a pacemaker , ICD or any other cardiac device	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10067251	Lead dislodgement
41	121	E	ASA	73	f	00209	24.10. 2018	26.10. 2018	Stable AP (no ACS)	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10002383	Angina pectoris
109	121	E	ASA	76	m	00040	11.08. 2017	17.08. 2017	Major Bleeding in non-surgical patients (according	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	y	r/r			Hospitalisa tion	10002034, 10051589, 10010007, 10053308, 10053757	Anaemia, Large intestine polyp, Colonoscopy, Polypectomy, Therapeutic procedure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									ISTH, including haemorrhagic stroke)											
109	121	E	ASA	76	m	00049	29.08.2017	06.10.2017	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020903, 10031161	Hyperuricaemia, Osteoarthritis
109	121	E	ASA	76	m	00095	20.11.2017	01.12.2017	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018627	Gout
109	121	E	ASA	76	m	00096	30.01.2018	01.02.2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10034878, 10009199	Phimosis, Circumcision
109	121	E	ASA	76	m	00097	04.02.2018		Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.16.2018	Death due to stroke	Hospitalisation	10061256, 10011906	Ischaemic stroke, Death
111	121	E	no ASA	79	m	00221	06.11.2018	07.11.2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10040979	Sleep apnoea syndrome
111	121	E	no ASA	80	m	00521-1	29.10.2019	05.11.2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
111	121	E	no ASA	80	m	00521-2	29.10.2019	05.11.2019	Hospitalisation due to AF	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
111	121	E	no ASA	80	m	00521-3	29.10.2019	05.11.2019	Other cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10047281	Ventricular arrhythmia
111	121	E	no ASA	80	m	00538	06.11.2019	07.11.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10040979	Sleep apnoea syndrome

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
229	132	P	ASA	84	m	01873	01.03.2022	03.03.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059443	Skin neoplasm excision
1612	132	P	ASA	73	m	01237-1	03.03.2021	08.03.2021	Any type of cardiovascular surgery	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049071, 10014648, 10062362	Vascular operation, Endarterectomy, Viral test negative
1612	132	P	ASA	73	m	01237-2	08.03.2021	10.03.2021	Minor Bleeding	Mild	Prolongation of existing hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062362, 10018852, 10016173	Viral test negative, Haematoma, Fall
1612	132	P	ASA	74	m	01404	13.09.2021	15.09.2021	Myocardial Infarction	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10000891	Acute myocardial infarction
1612	132	P	ASA	74	m	01407	15.09.2021	22.09.2021	Myocardial Infarction	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10052086, 10065608, 10000891	Coronary arterial stent insertion, Percutaneous coronary intervention, Acute myocardial infarction
1612	132	P	ASA	74	m	01481	08.11.2021	09.11.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
8	132	P	no ASA	77	m	00011-1	23.02.2017	19.03.2017	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10027727, 10062202	Mitral valve incompetence, Mitral valve repair
8	132	P	no ASA	77	m	00011-2	06.03.2017	19.03.2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10063188	Post procedural haematoma
8	132	P	no ASA	79	m	00500-1	03.06.2019	04.06.2019	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
8	132	P	no ASA	79	m	00500-2	04.06.2019	06.08.2019	Other cardiovascular event	Very severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007625	Cardiogenic shock
73	132	P	no ASA	71	m	01068	12.01.2021	18.01.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10070255, 10009033	Coronavirus test positive, Chronic obstructive pulmonary disease
73	132	P	no ASA	72	m	01298	19.04.2021	20.04.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10009033, 10062362	Chronic obstructive pulmonary disease, Viral test negative
266	132	P	no ASA	78	m	00311	25.02.2019		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.27.2019	No cardiovascular cause	Hospitalisation	10011906, 10070976, 10069689, 10042361, 10000370, 10042364	Death, Craniocerebral injury, Spinal column injury, Subdural haematoma, Accident at home, Subdural haemorrhage
1436	132	P	no ASA	65	f	00844	14.07.2020	15.07.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
295	132	E	ASA	85	f	00547	26.10.2019	06.11.2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016173, 10021036, 10017577	Fall, Hyponatraemia, Gait disturbance
295	132	E	ASA	85	f	00687	07.02.2020	19.02.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
51	132	E	no ASA	80	f	00533	04.11.2019	02.01.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10012267	Dementia
70	132	E	no ASA	78	m	00160	27.03.2018	29.03.2018	Pulmonary embolism	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10037377, 10051055	Pulmonary embolism, Deep vein thrombosis
188	133	E	ASA	78	m	01967	20.05.2022	25.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021036, 10002034, 10062362, 10014418	Hyponatraemia, Anaemia, Viral test negative, Electrolyte imbalance
376	135	P	no ASA	81	m	00132	23.04.2018	28.04.2018	Myocardial Infarction	Severe	Life threatening event	None, i.e. still ongoing	n	n	r/r			Main reason for	10028596, 10065608	Myocardial infarction, Percutaneous

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																		hospital admission		coronary intervention
7	136	P	ASA	72	m	00001-1	18.07.2016	16.08.2016	Other cardiovascular event	Very severe	Life threatening event	Permanently discontinued due to this event	n	n	r/r with sequel ae			Main reason for hospital admission	10047290, 10038749	Ventricular fibrillation, Resuscitation
7	136	P	ASA	72	m	00001-2	26.07.2016	28.07.2016	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Reason for prolongation of existing hospital stay	10061256	Ischaemic stroke
7	136	P	ASA	72	m	00001-3	29.07.2016		Non-cardiovascular event	Very severe	Other medically important event	Not applicable (no intake of study drug)	n	n	Event ongoing			Reason for prolongation of existing hospital stay	10035664, 10003504	Pneumonia, Aspiration
7	136	P	ASA	72	m	00001-4	16.08.2016		Other cardiovascular event	Severe	Life threatening event	Not applicable (no intake of study drug)	n	n	Death	8.16.2016	Death due to other cardiovascular causes	No prolongation of existing hospital stay	10011906, 10007649, 10047290, 10038695, 10040047	Death, Cardiovascular disorder, Ventricular fibrillation, Respiratory failure, Sepsis
114	140	P	ASA	86	f	01671	22.01.2022	31.01.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
114	140	P	ASA	86	f	01688	01.11.2021	16.11.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10004797, 10006187, 10066152, 10055798	Biopsy lymph gland, Breast cancer, Transfusion, Haemorrhage
114	140	P	ASA	87	f	01958	23.07.2022		Non-cardiovascular event				n	n	Death	7.23.2022	No cardiovascular cause		10033609, 10011906, 10027457	Pancreatic carcinoma, Death, Metastases to liver
171	140	P	ASA	83	m	00459	15.07.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	7.15.2019	Sudden cardiac death		10049418	Sudden cardiac death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
257	140	P	ASA	83	f	00575	03.12.2019	11.12.2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10077015	Transcatheter aortic valve implantation
482	140	P	ASA	83	m	00605	01.05.2019	11.05.2019	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
551	140	P	ASA	81	m	01489	29.10.2021	15.11.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10067268, 10060733, 10066152, 10037660	Post procedural infection, Haematoma evacuation, Transfusion, Pyrexia
551	140	P	ASA	81	m	01502	16.09.2021	26.09.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10056519, 10050307, 10062362, 10010774, 10000081	Abdominal infection, Ureteral stent insertion, Viral test negative, Constipation, Abdominal pain
551	140	P	ASA	81	m	01503	11.10.2021	26.10.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10029116, 10052275, 10037596	Nephrectomy, Ureteral stent removal, Pyelonephritis
551	140	P	ASA	82	m	01984	06.09.2022	16.09.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10030155, 10061965	Oesophageal carcinoma, Gastrectomy
565	140	P	ASA	72	m	01258	02.06.2021	18.06.2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
565	140	P	ASA	72	m	01345	14.08.2021	20.08.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10062362, 10030095	Viral test negative, Oedema
565	140	P	ASA	72	m	01745	24.03.2022	29.03.2022	Any type of cardiovascular surgery	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10066916, 10003190, 10066050	Arteriovenous fistula aneurysm, Arteriovenous fistula operation, Aneurysm repair
565	140	P	ASA	73	m	01959	31.08.2022	01.09.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003190, 10030095	Arteriovenous fistula operation, Oedema
1094	140	P	ASA	82	m	00777	12.03.2020	18.03.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10030194, 10057305	Oesophageal stenosis,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								Oesophageal dilation procedure
1438	140	P	ASA	76	f	01261	22.03.2021	26.05.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10042464	Suicide attempt
1438	140	P	ASA	77	f	01776	12.04.2022	16.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10070255, 10012174	Coronavirus test positive, Dehydration
68	140	P	no ASA	77	f	00957	27.10.2020	30.10.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
432	140	P	no ASA	77	f	00283	08.01.2019	22.01.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007821, 10062262	Cauda equina syndrome, Spinal operation
432	140	P	no ASA	80	f	01393	07.09.2021	17.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062262	Spinal operation
1101	140	P	no ASA	81	f	00536	17.08.2019	20.08.2019	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1101	140	P	no ASA	81	f	00784	07.04.2020	08.04.2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10018627, 10061683	Gout, Arthrodesis
1496	140	P	no ASA	82	m	01301	19.05.2021	20.05.2021	Any type of cardiovascular surgery	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10059862	Viral test negative, Cardiac resynchronisation therapy
1826	140	P	no ASA	82	m	02019	02.10.2022	04.10.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1926	140	P	no ASA	70	f	01174	11.04.2021		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	4.15.2021	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10040070	Death, Coronavirus test positive, Septic shock
254	140	E	ASA	83	f	00109	20.11.2017	01.12.2017	Any type of cardiovascular surgery	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10060734, 10062585, 10049071	Diabetic foot, Peripheral arterial occlusive disease, Vascular operation
254	140	E	ASA	83	f	00165	26.12.2017	29.12.2017	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10007882, 10045285	Cellulitis, Ulcer
254	140	E	ASA	83	f	00177	24.07.2018	25.07.2018	Percutaneous coronary	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10057525, 10072562, 10057518	Peripheral artery occlusion, Peripheral artery

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									intervention (e.g. PCI), cerebrovascular or peripheral procedure											stent insertion, Peripheral artery angioplasty
254	140	E	ASA	87	f	01743	18.01.2022		Non-cardiovascular event				n	n	Death	1.18.2022	No cardiovascular cause		10011906, 10070255	Death, Coronavirus test positive
407	140	E	ASA	78	m	01295	17.06.2021	23.06.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571, 10062362	Urinary tract infection, Viral test negative
407	140	E	ASA	78	m	01296	19.05.2021	20.05.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10050307	Viral test negative, Ureteral stent insertion
436	140	E	ASA	77	f	00172	06.07.2018	07.07.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10005025	Bladder catheter removal
436	140	E	ASA	78	f	00602	28.10.2019	23.12.2019	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10029116, 10061778	Nephrectomy, Colectomy
622	140	E	ASA	83	f	00170	03.08.2018	04.08.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10005025	Bladder catheter removal
622	140	E	ASA	83	f	00260	28.11.2018	12.12.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061611, 10008611	Abdominal wall operation, Cholecystectomy
841	140	E	ASA	85	m	00557	30.08.2019	17.09.2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke
841	140	E	ASA	88	m	02041	24.10.2022	28.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10060925, 10014819, 10010007, 10061816	Abdominal neoplasm, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1394	140	E	ASA	85	f	00692	12.03.2020	13.03.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020751	Hypersensitivity
1394	140	E	ASA	86	f	01152	17.03.2021	27.03.2021	Worsening of heart failure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10020802	Atrial fibrillation, Hypertensive crisis
1394	140	E	ASA	87	f	01691	02.02.2022	07.02.2022	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10020802	Cardiac failure, Hypertensive crisis
1577	140	E	ASA	80	m	01689	06.02.2022	12.02.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10023469, 10062362	Knee arthroplasty, Viral test negative
1578	140	E	ASA	87	m	01747	01.05.2022	03.05.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012174, 10062362	Dehydration, Viral test negative
2357	140	E	ASA	74	m	01767	13.05.2022	21.06.2022	Any type of cardiovascular surgery	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10073742, 10007601, 10007598	Streptococcal endocarditis, Cardiac pacemaker removal, Cardiac pacemaker insertion
212	140	E	no ASA	88	m	00595	14.11.2019	22.11.2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10009033	Chronic obstructive pulmonary disease
212	140	E	no ASA	88	m	00596	12.12.2019	24.12.2019	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
212	140	E	no ASA	88	m	00637	26.01.2020		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.28.2020	No cardiovascular cause	Hospitalisation	10011906, 10038435, 10038695	Death, Renal failure, Respiratory failure
251	140	E	no ASA	81	m	00047	04.09.2017	09.09.2017	Minor Bleeding	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10034544	Periorbital haematoma
251	140	E	no ASA	83	m	00727	12.10.2019		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	10.14.2019	No cardiovascular cause	Hospitalisation	10011906, 10041569, 10038695	Death, Spinal fracture, Respiratory failure
818	140	E	no ASA	89	f	01778	19.04.2022	09.05.2022	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10007554, 10037400, 10066152, 10002034	Cardiac failure, Pulmonary hypertension, Transfusion, Anaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
919	140	E	no ASA	75	m	00837	12.03.2020	13.03.2020	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062168	Varicose vein operation
1929	140	E	no ASA	83	m	02125	06.12.2021	20.12.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10035664, 10066972	Coronavirus test positive, Pneumonia, Superinfection bacterial
319	153	P	ASA	75	m	00076	07.12.2017	13.12.2017	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
319	153	P	ASA	75	m	00084-1	09.01.2018	12.02.2018	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10007554	Cardiac failure
319	153	P	ASA	75	m	00084-2	15.01.2018	12.02.2018	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Prolongation of existing hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
319	153	P	ASA	75	m	00084-3	23.01.2018		Worsening of heart failure	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.12.2018	Death due to heart failure (HF)	Hospitalisation	10064848, 10049993, 10007554	Chronic kidney disease, Cardiac death, Cardiac failure
319	153	P	ASA	75	m	00085	14.12.2017	18.12.2017	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
106	153	E	ASA	79	m	00025	18.05.2017	23.05.2017	Worsening of heart failure	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
106	153	E	ASA	81	m	00487	16.05.2019	20.05.2019	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
106	153	E	ASA	81	m	00507	07.10.2019	10.10.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
106	153	E	ASA	80	m	01499	28.05.2018	31.05.2018	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
106	153	E	ASA	84	m	01756	29.03.2022	30.04.2022	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10004779, 10004842, 10007554, 10062362	Atrial fibrillation, Biopsy heart, Biopsy pericardium, Cardiac failure, Viral test negative
106	153	E	ASA	84	m	01954	14.06.2022	21.06.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
35	153	E	no ASA	84	m	00004-1	15.12.2016	27.12.2016	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
35	153	E	no ASA	84	m	00004-2	15.12.2016	27.12.2016	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10048709	Urosepsis
35	153	E	no ASA	84	m	00006	23.01.2017		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.23.2017	No cardiovascular cause	Hospitalisation	10011906, 10051379, 10069339, 10064848	Death, Systemic inflammatory response syndrome, Acute kidney injury, Chronic kidney disease
110	154	P	ASA	78	m	00105	04.01.2018	18.01.2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10039674, 10041576	Sciatica, Spinal laminectomy
110	154	P	ASA	78	m	00108	13.03.2018	14.03.2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10065064	Device lead issue
110	154	P	ASA	79	m	00184	23.04.2018	11.05.2018	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10060968, 10014568	Arthritis infective, Empyema
110	154	P	ASA	79	m	00304	13.01.2019	17.01.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016454	Femur fracture
110	154	P	ASA	81	m	00885	19.06.2020	22.06.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016173, 10070976	Fall, Craniocerebral injury
110	154	P	ASA	83	m	01996	04.09.2022	13.09.2022	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
110	154	P	ASA	83	m	01997	25.09.2022	27.09.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014819, 10010007, 10061816,	Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																			10017853, 10013554	procedure, Gastritis, Diverticulum
110	154	P	ASA	83	m	02112	28.09. 2022	04.10. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007882, 10067806, 10020649	Cellulitis, Debridement, Hyperkeratosis
181	154	E	ASA	81	m	01801	31.05. 2022	09.06. 2022	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
688	154	E	ASA	87	m	00212	25.10. 2018	31.10. 2018	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
688	154	E	ASA	87	m	00461	15.07. 2019	16.07. 2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10013538, 10017853	Diverticulitis, Gastritis
688	154	E	ASA	88	m	00722	28.04. 2020	30.04. 2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
688	154	E	ASA	89	m	01107	30.01. 2021	08.02. 2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
688	154	E	ASA	90	m	01638	14.02. 2022	22.02. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10039674	Sciatica
688	154	E	ASA	90	m	01733	08.03. 2022	15.03. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10018836, 10018830, 10066152, 10061816, 10014819, 10010007, 10017955, 10030201	Anaemia, Haematochezia, Haematemesis, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Gastrointestinal haemorrhage, Oesophageal ulcer
688	154	E	ASA	90	m	01734	31.03. 2022	05.04. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
688	154	E	ASA	90	m	01735	28.04. 2022	02.05. 2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10070255, 10035664	Cardiac failure, Coronavirus test positive, Pneumonia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
688	154	E	ASA	90	m	01940	19.08.2022	23.08.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021328	Ileus
294	161	P	ASA	71	m	01405	28.09.2021	01.10.2021	Hospitalisation due to AF	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequel ae			Hospitalisation	10007554, 10003658, 10062362, 10080743	Cardiac failure, Atrial fibrillation, Viral test negative, Angiocardiogram
294	161	P	ASA	71	m	02008	26.08.2022	08.09.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003997, 10062362	Bacteraemia, Viral test negative
395	161	P	ASA	68	m	01576	19.10.2021	20.10.2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
230	161	E	ASA	84	m	00210	25.10.2018	29.10.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10042316, 10022116	Subarachnoid haemorrhage, Injury
230	161	E	ASA	84	m	00782	27.05.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	5.27.2019	No cardiovascular cause		10011906, 10010144	Death, Completed suicide
230	161	E	ASA	84	m	00783-1	12.05.2019	15.05.2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisation	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
230	161	E	ASA	84	m	00783 -2	13.05. 2019	15.05. 2019	Myocardial Infarction	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10000891	Acute myocardial infarction
302	161	E	ASA	80	f	00786	23.04. 2020	05.05. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10004637, 10014802, 10040047	Bile duct stone, Endoscopic retrograde cholangiopancreat ography, Sepsis
302	161	E	ASA	80	f	00962	09.09. 2020	11.09. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10004637, 10014802	Bile duct stone, Endoscopic retrograde cholangiopancreat ography
302	161	E	ASA	81	f	01193	12.11. 2020	20.11. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrha gic stroke)	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10055890, 10010007	Haematoma muscle, Colonoscopy
459	161	E	ASA	86	m	01331	15.05. 2021		Non-cardiovasc ular event	Very severe	Hospitalisa tion	None, i.e. still ongoing	n	n	Death	5.19.2021	No cardiovascul ar cause	Hospitalisa tion	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
2304	171	E	ASA	76	m	01979	16.07. 2022	17.07. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10062501	Non-cardiac chest pain
2709	171	E	no ASA	85	m	01930	01.09. 2022	02.09. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10031127, 10013573	Orthostatic hypotension, Dizziness
2709	171	E	no ASA	85	m	01989	27.09. 2022	28.09. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10046571, 10005027, 10000081, 10046555	Urinary tract infection, Bladder catheter temporary, Abdominal pain, Urinary retention
2042	173	P	ASA	85	f	01429	01.07. 2021	15.07. 2021	Non-cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10037660, 10021789, 10062362	Pyrexia, Infection, Viral test negative
2042	173	P	ASA	85	f	01728	26.11. 2021	02.12. 2021	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10061161, 10066152, 10062362, 10046571, 10016173,	Pelvic fracture, Transfusion, Viral test negative, Urinary tract infection, Fall,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																			10042772, 10076776	Syncope, Pelvic operation
176	173	P	no ASA	76	m	00069	23.08. 2017	29.08. 2017	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10031161, 10023469	Osteoarthritis, Knee arthroplasty
1319	173	P	no ASA	85	m	01395	19.07. 2021		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	7.21.2021	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
242	173	E	ASA	73	m	00282 -1	05.02. 2019	05.02. 2019	Any type of cardiovascular surgery	Severe	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			Main reason for hospital admission	10059864	Cardiac ablation
242	173	E	ASA	73	m	00282 -2	05.02. 2019	18.02. 2019	TIA	Severe	Prolongation of existing hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10044390	Transient ischaemic attack
242	173	E	ASA	73	m	00413 -1	18.06. 2019	31.07. 2019	Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
242	173	E	ASA	73	m	00413 -2	18.06. 2019	31.07. 2019	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10044002, 10061482	Tonsil cancer, Renal neoplasm
242	173	E	ASA	74	m	00464	21.08. 2019		Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	8.23.2019	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
1712	173	E	ASA	66	m	01693	06.01. 2022	13.01. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10007554, 10035664, 10069339	Coronavirus test positive, Cardiac failure, Pneumonia, Acute kidney injury
1758	173	E	ASA	71	m	01257	13.06. 2021	29.06. 2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10040070	Septic shock
1758	173	E	ASA	71	m	01332	08.07. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	7.8.2021	No cardiovascular cause		10011906, 10058467, 10062194	Death, Lung neoplasm malignant, Metastasis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
314	173	E	no ASA	73	f	01248	17.12. 2020	13.01. 2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10046571, 10070255	Urinary tract infection, Coronavirus test positive
314	173	E	no ASA	74	f	01867	08.07. 2022	09.07. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003549, 10066152, 10002034, 10017955	Asthenia, Transfusion, Anaemia, Gastrointestinal haemorrhage
314	173	E	no ASA	74	f	01952	28.07. 2022	29.07. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10017955, 10002034, 10066152	Gastrointestinal haemorrhage, Anaemia, Transfusion
322	173	E	no ASA	92	m	00133	10.01. 2018	17.01. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10012671, 10049434	Diabetic ketoacidosis, Cardiac pacemaker replacement
322	173	E	no ASA	92	m	00135	03.03. 2018	12.03. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10012671, 10036978	Diabetic ketoacidosis, Prostatitis
894	173	E	no ASA	69	m	00412	27.06. 2019	02.07. 2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10078811, 10014561	Cystic lung disease, Emphysema
975	173	E	no ASA	86	m	00339	29.03. 2019	01.04. 2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10041823, 10004797, 10059443	Squamous cell carcinoma, Biopsy lymph gland, Skin neoplasm excision
1716	173	E	no ASA	84	m	01859	08.04. 2022	26.05. 2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10054112, 10061108, 10001488, 10001497	Hospitalisation, Disturbance in social behaviour, Aggression, Agitation
1716	173	E	no ASA	84	m	01860	20.06. 2022	23.06. 2022	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10024968, 10062362	Lower respiratory tract infection, Viral test negative
1716	173	E	no ASA	84	m	01861	12.07. 2022	15.07. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10017888, 10062362	Gastroenteritis, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1008	174	P	ASA	72	f	00649	01.01. 2020	03.01. 2020	Worsening of heart failure	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10007554, 10002034, 10038435	Cardiac failure, Anaemia, Renal failure
1008	174	P	ASA	73	f	00683	09.03. 2020		Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	Death	3.31.2020	No cardiovascul ar cause	Hospitalisa tion	10070255, 10011906, 10035664, 10009657, 10048709	Coronavirus test positive, Death, Pneumonia, Clostridium difficile colitis, Urosepsis
1008	174	P	ASA	72	f	01282	09.07. 2019	10.07. 2019	Worsening of heart failure	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10007554, 10046571	Cardiac failure, Urinary tract infection
1008	174	P	ASA	72	f	01283	10.10. 2019	13.10. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10038435, 10002034	Renal failure, Anaemia
1008	174	P	ASA	72	f	01284	24.01. 2020	10.02. 2020	Worsening of heart failure	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
306	174	E	ASA	84	m	00080	19.12. 2017	23.12. 2017	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10062352	Cardiac failure, Respiratory tract infection
306	174	E	ASA	84	m	00094	05.02. 2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.5.2018	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
613	174	E	ASA	65	m	00205	08.10. 2018	11.10. 2018	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10064272	Bladder neoplasm surgery
613	174	E	ASA	67	m	01049	24.08. 2020	29.08. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10046571	Urinary tract infection
613	174	E	ASA	66	m	01050	10.06. 2020	18.06. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10069339	Acute kidney injury
613	174	E	ASA	66	m	01091 -1	08.08. 2019	11.08. 2019	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10018383, 10048956, 10066152, 10043966	Glossectomy, Lymphadenectomy , Transfusion, Tongue neoplasm malignant stage unspecified
613	174	E	ASA	66	m	01091 -2	12.08. 2019	08.10. 2019	Non-cardiovasc ular event	Moder ate	Prolongatio n of existing	Not applicable	n	n	r/r			Hospitalisa tion	10003504, 10035664, 10020635	Aspiration, Pneumonia, Hyperglycaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
											hospitalisation	(no intake of study drug)								
613	174	E	ASA	67	m	01285	24.06.2021	27.06.2021	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10004720, 10018867	Biopsy, Haematuria
613	174	E	ASA	68	m	01572	09.07.2021	11.07.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
613	174	E	ASA	68	m	01573	06.08.2021	07.08.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
613	174	E	ASA	68	m	01574	02.11.2021	12.11.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10035664	Viral test negative, Pneumonia
613	174	E	ASA	68	m	01809	31.01.2022	10.02.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
613	174	E	ASA	68	m	01850	08.03.2022	09.03.2022	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10011814, 10004730, 10018867, 10002034, 10066152, 10062362, 10055798	Cystoscopy, Biopsy bladder, Haematuria, Anaemia, Transfusion, Viral test negative, Haemorrhage
613	174	E	ASA	68	m	01851	23.03.2022	06.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10023872, 10062362, 10023825	Laryngectomy, Viral test negative, Laryngeal cancer
613	174	E	ASA	68	m	01852	16.04.2022	25.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10072831, 10062362	Pharyngeal fistula repair, Viral test negative
613	174	E	ASA	68	m	01854	05.05.2022	30.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10072831, 10062076	Pharyngeal fistula repair, Pharyngeal operation
613	174	E	ASA	67	m	01858	07.07.2020	09.07.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10052693, 10049173	Transurethral bladder resection, Urethrotomy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
613	174	E	ASA	68	m	01862	10.03.2022	13.03.2022	Minor Bleeding	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10052693	Haematuria, Transurethral bladder resection
172	174	E	no ASA	79	f	00233	17.11.2018	21.11.2018	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035728	Pneumonia pneumococcal
1672	174	E	no ASA	76	f	01586	12.01.2022	01.02.2022	Worsening of heart failure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10002918, 10064687, 10003997, 10077015, 10046571, 10080743	Cardiac failure, Aortic valve stenosis, Device related infection, Bacteraemia, Transcatheter aortic valve implantation, Urinary tract infection, Angiocardiogram
2460	175	P	ASA	79	m	01853	12.07.2022	13.07.2022	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059650	Implant site infection
2460	175	P	ASA	79	m	01868	17.07.2022	19.07.2022	Other cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007601	Cardiac pacemaker removal
515	175	P	no ASA	81	f	00121	16.04.2018	17.04.2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10064848	Chronic kidney disease
515	175	P	no ASA	81	f	00335	26.01.2019	05.02.2019	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10046571	Cardiac failure, Urinary tract infection
487	175	E	no ASA	75	f	00724	16.02.2020	20.02.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10006451	Bronchitis
487	175	E	no ASA	76	f	00803	29.05.2020	01.06.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10031161, 10049548	Osteoarthritis, Knee operation
1035	175	E	no ASA	86	m	01009	01.12.2020	02.12.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
128	179	P	ASA	68	f	00052	11.09.2017	20.09.2017	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10031252, 10012601, 10071564, 10049071	Osteomyelitis, Diabetes mellitus, Limb amputation, Vascular operation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
128	179	P	ASA	68	f	00053	18.06.2017	25.06.2017	Other cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10016960, 10012601, 10049071	Foot amputation, Diabetes mellitus, Vascular operation
510	179	P	ASA	88	m	01683	08.03.2022	11.03.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013968, 10062362, 10035664	Dyspnoea, Viral test negative, Pneumonia
1868	179	P	no ASA	72	m	01225	06.05.2021	01.06.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10070255, 10050269	Pneumonia, Coronavirus test positive, Groin abscess
1132	179	E	no ASA	80	f	01530	27.07.2021	29.07.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10073538	Viral test negative, Urinary incontinence surgery
412	195	P	ASA	81	m	01490	07.10.2021	11.10.2021	Worsening of heart failure	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
412	195	P	ASA	81	m	01535-1	13.12.2021	16.12.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10003658	Cardiac pacemaker replacement, Atrial fibrillation
412	195	P	ASA	81	m	01535-2	17.12.2021	23.12.2021	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038435, 10080743	Renal failure, Angiocardiogram
412	195	P	ASA	82	m	01669	14.03.2022	26.03.2022	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10002918, 10077015	Cardiac failure, Aortic valve stenosis, Transcatheter aortic valve implantation
633	195	P	ASA	85	f	00734	12.05.2020	20.05.2020	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1004	195	P	ASA	72	m	01577	17.11.2021	22.11.2021	Any type of cardiovascular surgery	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10072561, 10057518, 10072562, 10072563	Peripheral artery bypass, Peripheral artery angioplasty, Peripheral artery stent insertion, Peripheral artery stenosis
1004	195	P	ASA	73	m	01722	23.03.2022	29.03.2022	Ischemic stroke (including transient	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061256, 10038827, 10007687	Ischaemic stroke, Retinal artery occlusion, Carotid artery stenosis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									events with matching lesion on cerebral imaging)											
396	195	P	no ASA	71	m	00162	29.03. 2018	30.03. 2018	TIA	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10044390, 10003658	Transient ischaemic attack, Atrial fibrillation
396	195	P	no ASA	72	m	00294	15.01. 2019	19.06. 2019	No SAE	Moder ate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			No hospital stay	10020631	Hypergammaglobu linaemia benign monoclonal
396	195	P	no ASA	72	m	00300	03.03. 2019	05.03. 2019	Change of a pacemaker , ICD or any other cardiac device	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10059862	Cardiac resynchronisation therapy
396	195	P	no ASA	75	m	01998	06.04. 2022	09.04. 2022	Minor Bleeding	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10018867, 10046528	Haematuria, Urinary bladder haemorrhage
1233	195	P	no ASA	82	m	00598	18.11. 2019	02.12. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10035664	Pneumonia
398	195	E	ASA	71	m	00255	16.10. 2018	18.10. 2018	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10022020	Inguinal hernia repair
398	195	E	ASA	74	m	01384	24.08. 2021	27.08. 2021	Non-cardiovasc ular event	Very severe	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10059443	Skin neoplasm excision
398	195	E	ASA	74	m	01385	30.08. 2021	06.09. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrha gic stroke)	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10018830, 10017955, 10056091, 10066152, 10061816, 10014819	Haematemesis, Gastrointestinal haemorrhage, Varices oesophageal, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract
398	195	E	ASA	74	m	01394	07.09. 2021	08.09. 2021	Major Bleeding in surgical patients	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10051077	Post procedural haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									(according ISTH, including haemorrhagic stroke)											
398	195	E	ASA	75	m	01618	22.01.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.22.2022	Death of unknown cause		10011906	Death
519	195	E	ASA	83	m	00567	01.12.2019	03.12.2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434, 10059862	Cardiac pacemaker replacement, Cardiac resynchronisation therapy
519	195	E	ASA	84	m	01002	16.10.2020	10.11.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10056325, 10010774, 10002160	Faecaloma, Constipation, Anal lesion excision
617	195	E	ASA	70	m	00400	30.06.2019	02.07.2019	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
617	195	E	ASA	71	m	00488	16.09.2019	12.10.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
617	195	E	ASA	72	m	01047	21.12.2020	23.12.2020	Hospitalisation due to AF	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003662, 10062362, 10059864	Atrial flutter, Viral test negative, Cardiac ablation
1411	195	E	ASA	73	m	02031	17.07.2022	21.07.2022	Any type of cardiovascular surgery	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002882, 10002885	Aortic aneurysm, Aortic aneurysm repair
283	195	E	no ASA	82	m	00317	28.08.2018	24.01.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10063583	Bladder polypectomy
283	195	E	no ASA	83	m	00323	24.01.2019	15.02.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10058467, 10060862, 10066152, 10055101, 10002034	Lung neoplasm malignant, Prostate cancer, Transfusion, Bone cancer metastatic, Anaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
283	195	E	no ASA	83	m	00419	25.04. 2019		Non-cardiovascular event				n	n	Death	4.25.2019	No cardiovascular cause		10011906, 10058467	Death, Lung neoplasm malignant
144	198	P	no ASA	73	f	00173	07.08. 2018	08.08. 2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012735	Diarrhoea
419	202	E	no ASA	71	f	01369	24.02. 2020	27.02. 2020	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10042464, 10022523	Suicide attempt, Intentional overdose
366	205	P	ASA	98	f	00086	10.01. 2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.10.2018	Death of unknown cause		10011906	Death
748	205	P	ASA	88	f	01075	04.02. 2021	05.02. 2021	Non-cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10062501	Non-cardiac chest pain
748	205	P	ASA	88	f	01117	17.02. 2021	26.02. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014802, 10008604	Endoscopic retrograde cholangiopancreatography, Cholangitis
207	205	P	no ASA	81	m	00395	31.05. 2019	03.06. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10024968	Lower respiratory tract infection
207	205	P	no ASA	82	m	00808	26.06. 2020	01.07. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	y	r/r			Hospitalisation	10002034, 10064848	Anaemia, Chronic kidney disease
207	205	P	no ASA	83	m	01169	28.02. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.28.2021	Death of unknown cause		10011906	Death
80	205	E	ASA	88	f	00123	18.04. 2018	16.05. 2018	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
80	205	E	ASA	88	f	00164	13.07. 2018		Death as primary event, e.g.				n	n	Death	7.13.2018	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									sudden death, not death as outcome of another event											
80	205	E	ASA	88	f	00372	17.02.2018	18.02.2018	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisation	10035664, 10007554	Pneumonia, Cardiac failure
336	205	E	ASA	81	m	01994	22.08.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.22.2022	Death due to other cardiovascular causes		10011906, 10007649, 10028600	Death, Cardiovascular disorder, Myocardial ischaemia
516	208	P	no ASA	83	m	01051	15.12.2020	07.01.2021	Pulmonary embolism	Severe	Other medically important event	Permanently discontinued due to this event	n	n	r/r with sequel ae			No hospital stay	10037377, 10011906, 10035603	Pulmonary embolism, Death, Pleural mesothelioma
516	208	P	no ASA	83	m	01079	03.02.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.3.2021	No cardiovascular cause		10028997, 10011906	Neoplasm malignant, Death
524	208	P	no ASA	81	m	00554	13.11.2019	20.11.2019	No SAE	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10046571, 10069339	Urinary tract infection, Acute kidney injury
1036	208	E	ASA	72	m	00366	24.05.2019	24.05.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10002034, 10066152, 10017940, 10017955	Anaemia, Transfusion, Gastrointestinal carcinoma, Gastrointestinal haemorrhage
1362	208	E	ASA	72	m	00847	20.07.2020	21.07.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013573	Dizziness

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1306	208	E	no ASA	83	m	01136	22.11. 2020		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.23.2020	No cardiovascular cause	Hospitalisation	10070255, 10011906	Coronavirus test positive, Death
79	209	P	ASA	83	m	00246	14.09. 2018	15.09. 2018	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10021097	Hypotension
79	209	P	ASA	87	m	02103	30.11. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.30.2022	Death of unknown cause		10011906	Death
143	211	P	ASA	81	m	00566	28.11. 2019		No SAE	Severe	Other medically important event	Permanently discontinued due to this event	n	n	Event ongoing			No hospital stay	10038086	Rectosigmoid cancer
143	211	P	ASA	82	m	00918	17.09. 2020	20.09. 2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10051055, 10007882	Viral test negative, Deep vein thrombosis, Cellulitis
143	211	P	ASA	82	m	00972	29.10. 2020	10.11. 2020	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke
143	211	P	ASA	82	m	01018	14.12. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.14.2020	No cardiovascular cause		10011906, 10028997	Death, Neoplasm malignant
250	211	P	ASA	83	m	00286	21.01. 2019	08.02. 2019	Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10007559, 10040047	Cardiac failure congestive, Sepsis
250	211	P	ASA	83	m	00312	14.02. 2019		Death as primary event, e.g. sudden death, not				n	n	Death	2.14.2019	No cardiovascular cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death as outcome of another event											
356	211	E	ASA	87	m	00182	22.08. 2018	27.08. 2018	Worsening of heart failure	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
356	211	E	ASA	87	m	00199	10.10. 2018	15.10. 2018	Worsening of heart failure	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
356	211	E	ASA	88	m	00376	26.05. 2019		Non-cardiovasc ular event	Very severe	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	Death	6.8.2019	No cardiovascul ar cause	Hospitalisa tion	10007554, 10050017, 10011906	Cardiac failure, Lung cancer metastatic, Death
293	226	P	ASA	78	m	00841	15.07. 2020	18.07. 2020	Other cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10080743, 10002383	Angiocardiogram, Angina pectoris
293	226	P	ASA	79	m	01311	24.07. 2021	19.08. 2021	Other cardiovasc ular event	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10014665, 10007661, 10002916	Endocarditis, Cardioversion, Aortic valve replacement
1434	226	P	ASA	87	f	01006	11.11. 2020	11.11. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrha gic stroke)	Sever e	Persistent / significant disability or incapacity	None, i.e. still ongoing	y	y	r/r with sequel ae			No hospital stay	10038867, 10047555	Retinal haemorrhage, Visual field defect
1434	226	P	ASA	89	f	01787	29.03. 2022	02.04. 2022	Hospitalisa tion due to AF	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10003658, 10007554	Atrial fibrillation, Cardiac failure
413	226	E	ASA	85	m	00929	07.10. 2020	09.10. 2020	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10014418, 10035598	Cardiac failure, Electrolyte imbalance, Pleural effusion
413	226	E	ASA	85	m	00931	11.10. 2020	14.10. 2020	Worsening of heart failure	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10062362	Cardiac failure, Viral test negative
413	226	E	ASA	85	m	01023	15.12. 2020	18.12. 2020	Worsening of heart failure	Very severe	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10014418, 10062362	Cardiac failure, Electrolyte imbalance, Viral test negative
1670	226	E	ASA	90	m	00999	25.11. 2020	26.11. 2020	Non-cardiovasc ular event	Sever e	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10062362, 10006451, 10003553	Viral test negative, Bronchitis, Asthma

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1670	226	E	ASA	90	m	01017	10.12.2020	24.12.2020	Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10007554	Coronavirus test positive, Cardiac failure
1670	226	E	ASA	90	m	01048	28.12.2020	12.01.2021	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
1670	226	E	ASA	91	m	01382	01.08.2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	8.20.2021	No cardiovascular cause	Hospitalisation	10011906, 10058467, 10062362	Death, Lung neoplasm malignant, Viral test negative
1164	226	E	no ASA	72	f	01381	05.06.2021		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	6.13.2021	No cardiovascular cause	Hospitalisation	10033609, 10011906, 10002034, 10066152, 10055798	Pancreatic carcinoma, Death, Anaemia, Transfusion, Haemorrhage
749	232	E	no ASA	73	m	01153	07.01.2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.2.2021	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1544	264	P	no ASA	81	m	01460	20.10.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.20.2021	No cardiovascular cause		10011906, 10028997	Death, Neoplasm malignant
583	264	E	ASA	77	m	00202	15.10.2018	16.10.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10025005	Lumbar spinal stenosis
583	264	E	ASA	80	m	01660	17.03.2022	22.03.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1330	264	E	ASA	66	f	01219	21.05.2021	22.05.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10052693	Transurethral bladder resection
1330	264	E	ASA	67	f	01834	21.06.2022		Death as primary event, e.g. sudden				n	n	Death	6.21.2022	Death due to acute myocardial		10049993, 10000891	Cardiac death, Acute myocardial infarction

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death, not death as outcome of another event								infarction (MI)			
381	264	E	no ASA	78	m	00591	30.12. 2019	04.01. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
381	264	E	no ASA	78	m	00688	20.03. 2020	21.03. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10049071	Cardiac failure, Vascular operation
1219	267	P	ASA	66	m	01409	07.02. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.7.2021	No cardiovascular cause		10011906, 10023825	Death, Laryngeal cancer
1219	267	P	ASA	66	m	01410	10.07. 2020	14.08. 2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10023825, 10023872, 10048956	Laryngeal cancer, Laryngectomy, Lymphadenectomy
1219	267	P	ASA	66	m	01411	03.09. 2020	16.09. 2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10062034	Laryngeal operation
215	308	P	ASA	83	m	02061	25.11. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.25.2021	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
267	308	P	no ASA	78	m	00045	10.09. 2017	13.09. 2017	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10008479, 10018627	Chest pain, Gout
267	308	P	no ASA	82	m	01945	25.08. 2022	29.08. 2022	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10002906, 10077015	Aortic stenosis, Transcatheter aortic valve implantation
267	308	P	no ASA	82	m	01946	09.05. 2022	11.05. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059624, 10062362, 10019022, 10019023	Haemorrhoid operation, Viral test negative, Haemorrhoids, Haemorrhoids thrombosed
267	308	P	no ASA	82	m	01947	21.07. 2022	27.07. 2022	Worsening of heart failure	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10002918	Cardiac failure, Aortic valve stenosis
217	308	E	no ASA	72	m	00146	05.04. 2018	26.04. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10035664, 10006417	Pneumonia, Bronchial carcinoma
217	308	E	no ASA	72	m	00152	16.05. 2018	22.05. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10027083, 10006417, 10027459	Mediastinoscopy, Bronchial carcinoma, Metastases to lymph nodes
217	308	E	no ASA	72	m	00163	12.06. 2018	23.06. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10024741, 10006417	Lung lobectomy, Bronchial carcinoma
217	308	E	no ASA	73	m	00214	04.10. 2018	09.10. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009033	Chronic obstructive pulmonary disease
72	377	P	ASA	84	m	00442	05.03. 2019	07.03. 2019	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002906, 10080743	Aortic stenosis, Angiocardiogram
72	377	P	ASA	86	m	01302	14.07. 2021		Non-cardiovascular event	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	Death	7.14.2021	No cardiovascular cause	Main reason for hospital admission	10018001, 10011906, 10038749	Gastrointestinal perforation, Death, Resuscitation
175	377	P	ASA	89	f	01964	11.07. 2022	18.07. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017913, 10062362	Gastroenteritis rotavirus, Viral test negative
83	377	P	no ASA	85	m	00124	01.02. 2018	19.02. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016450, 10020096	Femoral neck fracture, Hip arthroplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
163	406	P	ASA	85	f	00065	26.09.2017	06.10.2017	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10031161, 10023469	Osteoarthritis, Knee arthroplasty
163	406	P	ASA	85	f	00070	29.11.2017	01.12.2017	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
163	406	P	ASA	85	f	00138	18.04.2018	19.04.2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10064687	Device related infection
163	406	P	ASA	86	f	00215	27.08.2018	31.08.2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
433	414	P	ASA	79	m	01468	04.11.2021	07.11.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003662, 10059864	Atrial flutter, Cardiac ablation
433	414	P	ASA	79	m	01482	03.10.2021	06.10.2021	Worsening of heart failure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10003658	Cardiac failure, Atrial fibrillation
704	414	P	ASA	85	f	00564	25.11.2019	27.11.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
704	414	P	ASA	85	f	00796	02.03.2020	18.03.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10006417, 10035598, 10053975	Bronchial carcinoma, Pleural effusion, Thoracic cavity drainage
704	414	P	ASA	85	f	00806	14.04.2020	23.04.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035598, 10058467	Pleural effusion, Lung neoplasm malignant
704	414	P	ASA	85	f	00821	19.05.2020	28.05.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10006417, 10035598, 10053975	Bronchial carcinoma, Pleural effusion, Thoracic cavity drainage
704	414	P	ASA	85	f	00948	21.08.2020	01.09.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10058467	Lung neoplasm malignant

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
704	414	P	ASA	86	f	01446	10.09.2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	9.10.2021	No cardiovascular cause	Hospitalisation	10011906, 10006417	Death, Bronchial carcinoma
1541	414	P	ASA	77	m	00949	26.08.2020	08.09.2020	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10007554, 10007661	Viral test negative, Cardiac failure, Cardioversion
1541	414	P	ASA	77	m	00950	18.10.2020	21.10.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052086, 10065608, 10007554	Coronary arterial stent insertion, Percutaneous coronary intervention, Cardiac failure
1541	414	P	ASA	77	m	00987	08.10.2020	11.10.2020	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10080743, 10007554	Angiocardiogram, Cardiac failure
1654	414	P	ASA	85	m	01241	26.01.2021		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	1.27.2021	No cardiovascular cause	Hospitalisation	10011906, 10017982, 10061778	Death, Gastrointestinal necrosis, Colectomy
1792	414	P	ASA	88	m	01645	16.11.2021	21.11.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10072804, 10062024	Eventration repair, Intestinal operation
1845	414	P	ASA	81	m	01080	03.02.2021	06.02.2021	Stable AP (no ACS)	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10080743, 10002383	Angiocardiogram, Angina pectoris
1845	414	P	ASA	82	m	02015	03.10.2022	07.10.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1626	414	P	no ASA	88	f	01579	27.05.2021	11.06.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10031161, 10062362, 10023215, 10003239	Osteoarthritis, Viral test negative, Joint effusion, Arthralgia
1686	414	P	no ASA	67	m	01976	25.09.2021	05.10.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061978, 10061331, 10052979	Genital lesion, Papilloma viral infection, Lesion excision
2424	414	P	no ASA	92	m	01837	25.06.2022	04.07.2022	Worsening of heart failure	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10007661, 10003658	Cardiac failure, Cardioversion, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
268	414	E	ASA	82	m	01545	07.06. 2021	11.06. 2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10064979, 10003662	Atrial fibrillation, High frequency ablation, Atrial flutter
970	414	E	ASA	95	m	01505	11.11. 2021	17.11. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	y	y	r/r			Hospitalisation	10017955, 10066152, 10002034	Gastrointestinal haemorrhage, Transfusion, Anaemia
1783	414	E	ASA	89	m	01143	30.03. 2021	03.04. 2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
1783	414	E	ASA	89	m	01278	25.06. 2021		Worsening of heart failure				n	n	Death	6.25.2021	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
1783	414	E	ASA	89	m	01280	21.05. 2021	26.05. 2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1783	414	E	ASA	89	m	01290	11.06. 2021	21.06. 2021	Other cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012174	Dehydration
1943	414	E	ASA	88	m	01357	21.08. 2021	05.10. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke
246	414	E	no ASA	102	f	01347	21.08. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.21.2021	Death of unknown cause		10009944, 10011906	Colon cancer, Death
2183	414	E	no ASA	72	m	01613	30.01. 2022	10.02. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	y	r/r			Hospitalisation	10016173, 10019196, 10008111, 10062362	Fall, Head injury, Cerebral haemorrhage, Viral test negative
2183	414	E	no ASA	73	m	02083	08.11. 2022		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable	n	n	Death	11.27.2022	No cardiovascular cause	Hospitalisation	10011906, 10061536, 10035664,	Death, Parkinson's disease, Pneumonia,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)							10003504, 10038695	Aspiration, Respiratory failure
2570	414	E	no ASA	75	m	01972	29.07. 2022	01.08. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10069339	Acute kidney injury
2570	414	E	no ASA	75	m	01973	26.08. 2022	31.08. 2022	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10010185, 10004782	Complications of transplanted kidney, Biopsy kidney
86	416	P	no ASA	85	f	00297	15.12. 2018	24.12. 2018	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
86	416	P	no ASA	86	f	00663	10.01. 2020	20.01. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009033	Chronic obstructive pulmonary disease
125	416	P	no ASA	79	f	01141	04.12. 2020	11.12. 2020	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10043568, 10061256	Thrombolysis, Ischaemic stroke
125	416	P	no ASA	80	f	01412	01.08. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.1.2021	Death of unknown cause		10011906	Death
445	416	P	no ASA	78	f	00179	08.05. 2018	11.05. 2018	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
547	416	P	no ASA	85	f	01441	19.10. 2021	21.10. 2021	Myocardial Infarction	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10028596, 10065608, 10052086	Myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
84	416	E	no ASA	80	f	00017	17.03. 2017		Death as primary event, e.g. sudden death, not death as				n	n	Death	3.17.2017	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									outcome of another event											
1001	416	E	no ASA	84	f	01651	14.02.2022	18.02.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10041857, 10037794, 10004720	Squamous cell carcinoma of the oral cavity, Radiotherapy, Biopsy
494	419	P	ASA	78	f	01255	25.04.2021	29.04.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434, 10067251	Cardiac pacemaker replacement, Lead dislodgement
244	419	P	no ASA	68	m	00180	17.10.2017	19.10.2017	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
244	419	P	no ASA	68	m	00181	22.05.2018	25.05.2018	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
244	419	P	no ASA	71	m	01319	21.10.2020	28.10.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
464	419	P	no ASA	71	m	01144	30.03.2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	5.21.2021	No cardiovascular cause	Hospitalisation	10070255, 10035664, 10011906	Coronavirus test positive, Pneumonia, Death
690	419	P	no ASA	66	m	00467	08.08.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.8.2019	Sudden cardiac death		10049418	Sudden cardiac death
1137	419	P	no ASA	92	f	02116	17.10.2022		Non-cardiovascular event				n	n	Death	10.17.2022	No cardiovascular cause		10011906, 10048709	Death, Urosepsis
247	419	E	ASA	75	f	00659	18.02.2020	19.02.2020	Change of a pacemaker, ICD or any other	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
211	419	E	no ASA	65	m	00178	07.06. 2018	22.06. 2018	Any type of cardiovascular surgery	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10011077	Coronary artery bypass
323	419	E	no ASA	79	f	00437	09.07. 2019	10.07. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
323	419	E	no ASA	81	f	01642	09.10. 2021	19.10. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke
116	421	P	ASA	67	m	00020	03.05. 2017	18.05. 2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10061365, 10042316, 10042364	Skull fracture, Subarachnoid haemorrhage, Subdural haemorrhage
116	421	P	ASA	67	m	00130	05.02. 2018	07.02. 2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10028762	Nasal septum deviation
116	421	P	ASA	68	m	00278	27.12. 2018	29.12. 2018	Stable AP (no ACS)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10050329, 10052086, 10002383	Coronary angioplasty, Coronary arterial stent insertion, Angina pectoris
116	421	P	ASA	69	m	00677	13.11. 2019	15.11. 2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10067251	Cardiac pacemaker replacement, Lead dislodgement
116	421	P	ASA	69	m	00678	02.02. 2020	04.02. 2020	Change of a pacemaker	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10065064, 10049434	Device lead issue, Cardiac

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									, ICD or any other cardiac device			(no intake of study drug)								pacemaker replacement
126	421	P	ASA	80	f	00952	26.10. 2020	28.10. 2020	Change of a pacemaker , ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
157	421	P	ASA	83	m	00062	04.06. 2017		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	6.4.2017	Sudden cardiac death		10049418	Sudden cardiac death
161	421	P	ASA	82	f	01672	29.10. 2020		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	11.7.2020	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
828	421	P	ASA	82	m	00320	18.03. 2019	22.03. 2019	Stable AP (no ACS)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10011078, 10080743	Coronary artery disease, Angiocardiogram
828	421	P	ASA	82	m	00352	12.04. 2019	09.05. 2019	Any type of cardiovascular surgery	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10011077, 10049434	Coronary artery bypass, Cardiac pacemaker replacement
1000	421	P	ASA	78	m	00445	07.08. 2019	10.08. 2019	Worsening of heart failure	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1000	421	P	ASA	78	m	00665	20.10. 2019	25.10. 2019	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10007554, 10035664	Cardiac failure, Pneumonia
1000	421	P	ASA	78	m	00666	28.10. 2019	15.11. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10035664	Pneumonia
1000	421	P	ASA	78	m	00667	09.12. 2019	12.12. 2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014418, 10064848, 10047340	Electrolyte imbalance, Chronic kidney disease, Vertigo
1000	421	P	ASA	78	m	00668	10.01. 2020	15.01. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021015	Hypokalaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1000	421	P	ASA	80	m	01634	17.02.2022	27.02.2022	Minor Bleeding	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10014819, 10010007, 10013839, 10061816, 10053757, 10062362, 10018836, 10027141	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Duodenal ulcer haemorrhage, Diagnostic procedure, Therapeutic procedure, Viral test negative, Haematochezia, Melaena
1000	421	P	ASA	81	m	01914	21.05.2022	01.06.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10062585, 10002475, 10072562	Peripheral arterial occlusive disease, Angioplasty, Peripheral artery stent insertion
1000	421	P	ASA	81	m	01915	11.07.2022	17.07.2022	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10040943, 10043913, 10062585	Skin ulcer, Toe amputation, Peripheral arterial occlusive disease
1418	421	P	ASA	80	f	00750	10.02.2020	11.02.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10063797	Cataract operation
1841	421	P	ASA	84	m	00975	13.11.2020	16.12.2020	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10070255, 10028524, 10033892, 10041569, 10035742	Coronavirus test positive, Myelitis, Paraplegia, Spinal fracture, Pneumonitis
1841	421	P	ASA	84	m	01165	08.02.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.8.2021	Death of unknown cause		10011906	Death
1884	421	P	ASA	86	m	01109	07.12.2020	15.12.2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10016173, 10017308	Fall, Fractured sacrum

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1884	421	P	ASA	86	m	01110	27.02.2021	09.03.2021	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10046571, 10062362	Cardiac failure, Urinary tract infection, Viral test negative
1884	421	P	ASA	86	m	01510	18.10.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.18.2021	No cardiovascular cause		10011906, 10009944	Death, Colon cancer
2414	421	P	ASA	92	f	01835	21.03.2022	28.03.2022	Worsening of heart failure	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
2702	421	P	ASA	87	m	01987	17.09.2022	22.09.2022	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10035598, 10062362	Cardiac failure, Pleural effusion, Viral test negative
55	421	P	no ASA	77	m	00088	17.01.2018	19.01.2018	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
55	421	P	no ASA	78	m	00250	29.12.2018	13.01.2019	Pulmonary embolism	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10037377, 10035664	Pulmonary embolism, Pneumonia
55	421	P	no ASA	81	m	01762	30.03.2022	14.04.2022	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362, 10002034	Pneumonia, Viral test negative, Anaemia
55	421	P	no ASA	81	m	01763	10.12.2021	10.01.2022	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10049946, 10066152, 10062262, 10002034, 10062362	Cervical vertebral fracture, Transfusion, Spinal operation, Anaemia, Viral test negative
55	421	P	no ASA	81	m	01790	22.03.2022	29.03.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035226, 10021097	Plasma cell myeloma, Hypotension
55	421	P	no ASA	81	m	02079	22.07.2022	29.07.2022	Syncope	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10046571, 10002034,	Urinary tract infection, Anaemia,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)							10066152, 10042772	Transfusion, Syncope
55	421	P	no ASA	81	m	02080	06.09. 2022	07.09. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10066152, 10002034, 10035226, 10062362	Transfusion, Anaemia, Plasma cell myeloma, Viral test negative
55	421	P	no ASA	81	m	02081	18.10. 2022	19.10. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10066152, 10035226, 10070255	Anaemia, Transfusion, Plasma cell myeloma, Coronavirus test positive
55	421	P	no ASA	81	m	02082	08.11. 2022	11.11. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10066152, 10062362, 10035226	Anaemia, Transfusion, Viral test negative, Plasma cell myeloma
544	421	P	no ASA	79	m	00351	11.03. 2019	16.03. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020096, 10031161	Hip arthroplasty, Osteoarthritis
768	421	P	no ASA	88	m	01172	13.11. 2020	23.11. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
768	421	P	no ASA	88	m	01435	18.10. 2021	27.10. 2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009033, 10062362	Chronic obstructive pulmonary disease, Viral test negative
768	421	P	no ASA	89	m	01566	04.01. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.4.2022	Sudden cardiac death		10049418	Sudden cardiac death
1216	421	P	no ASA	83	m	01829	14.02. 2022		Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	2.28.2022	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10002034, 10066152, 10077361	Death, Coronavirus test positive, Anaemia, Transfusion, Multiple organ dysfunction syndrome
1357	421	P	no ASA	71	m	01189	04.02. 2021	06.02. 2021	Change of a pacemaker, ICD or any other	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
1357	421	P	no ASA	71	m	01449	23.05. 2021	29.05. 2021	Myocardial Infarction	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10028596, 10065608	Myocardial infarction, Percutaneous coronary intervention
1505	421	P	no ASA	76	m	01074	24.11. 2020	28.11. 2020	Non-cardiovasc ular event	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10059443	Skin neoplasm excision
1806	421	P	no ASA	67	f	01534	13.12. 2021	13.12. 2021	Other cardiovasc ular event	Moder ate	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10086210	Superficial vein thrombosis
2109	421	P	no ASA	76	m	01761	09.05. 2022	13.05. 2022	Non-cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10050296, 10008334	Intervertebral disc protrusion, Cervicobrachial syndrome
2232	421	P	no ASA	73	m	01337	17.08. 2021	15.09. 2021	Non-cardiovasc ular event	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10035664, 10062362, 10001052, 10069339, 10003517	Pneumonia, Viral test negative, Acute respiratory distress syndrome, Acute kidney injury, Aspiration joint
2232	421	P	no ASA	73	m	01841	06.10. 2021	19.10. 2021	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10070255, 10035664	Coronavirus test positive, Pneumonia
2264	421	P	no ASA	69	f	01963	22.06. 2022	30.06. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10020096, 10031161	Hip arthroplasty, Osteoarthritis
2283	421	P	no ASA	88	m	01690	07.03. 2022		Non-cardiovasc ular event	Very severe	Hospitalisa tion	Permanently discontinued due to this event	n	n	Death	3.11.2022	No cardiovascul ar cause	Hospitalisa tion	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
77	421	E	ASA	66	m	00117	09.04. 2018	23.04. 2018	Change of a pacemaker , ICD or any other cardiac device	Sever e	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10049434	Cardiac pacemaker replacement
77	421	E	ASA	66	m	00269	12.01. 2019	22.01. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10023469	Knee arthroplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
77	421	E	ASA	67	m	00472	28.08.2019	03.09.2019	Myocardial Infarction	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
77	421	E	ASA	67	m	00489	29.09.2019	02.10.2019	Myocardial Infarction	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10052086, 10065608	Acute myocardial infarction, Coronary arterial stent insertion, Percutaneous coronary intervention
77	421	E	ASA	67	m	00654	07.01.2020	13.01.2020	ACS	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052086, 10065608, 10000891	Coronary arterial stent insertion, Percutaneous coronary intervention, Acute myocardial infarction
77	421	E	ASA	67	m	00655	16.01.2020	20.01.2020	ACS	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
77	421	E	ASA	68	m	00829	25.03.2020	27.03.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002475, 10012601, 10060734	Angioplasty, Diabetes mellitus, Diabetic foot
77	421	E	ASA	68	m	00830	02.05.2020	09.05.2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021789, 10037660, 10012601, 10007554, 10062362	Infection, Pyrexia, Diabetes mellitus, Cardiac failure, Viral test negative
77	421	E	ASA	68	m	00831	13.07.2020	18.07.2020	ACS	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10035664	Acute myocardial infarction, Pneumonia
77	421	E	ASA	68	m	01053	25.09.2020	09.10.2020	Myocardial Infarction	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10000891, 10062362	Percutaneous coronary intervention, Acute myocardial

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																				infarction, Viral test negative
77	421	E	ASA	68	m	01054	06.12.2020	10.12.2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10025197	Lymphadenopathy
77	421	E	ASA	69	m	01293	19.02.2021	27.02.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10050269, 10062362	Groin abscess, Viral test negative
77	421	E	ASA	69	m	01294	15.06.2021	19.06.2021	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002906, 10037423	Aortic stenosis, Pulmonary oedema
77	421	E	ASA	69	m	01520	08.11.2021	13.11.2021	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
77	421	E	ASA	69	m	01521	25.11.2021	06.12.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002918, 10077015, 10053377	Aortic valve stenosis, Transcatheter aortic valve implantation, Central venous catheterisation
77	421	E	ASA	69	m	01591	19.01.2022	26.01.2022	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10080743, 10031127	Viral test negative, Angiocardiogram, Orthostatic hypotension
77	421	E	ASA	69	m	01592	30.08.2021	13.09.2021	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10080743, 10062362	Cardiac failure, Angiocardiogram, Viral test negative
77	421	E	ASA	70	m	01695	30.03.2022	06.04.2022	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
77	421	E	ASA	70	m	01863	22.05.2022	30.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015145	Erysipelas
77	421	E	ASA	70	m	01864	05.07.2022	16.07.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015145, 10012735, 10047700	Erysipelas, Diarrhoea, Vomiting
77	421	E	ASA	70	m	02007	16.08.2022	23.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015145	Erysipelas

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
279	421	E	ASA	77	m	00115	03.03.2018	08.03.2018	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
353	421	E	ASA	78	m	00549	23.11.2019	03.02.2020	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10034474, 10049434	Pericardial effusion, Cardiac pacemaker replacement
353	421	E	ASA	79	m	00791	19.02.2020		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.23.2020	No cardiovascular cause	Hospitalisation	10011906, 10063914	Death, Multimorbidity
503	421	E	ASA	76	m	00347	25.04.2019	04.05.2019	Minor Bleeding	Mild	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10018836, 10013554, 10017955, 10010007, 10014819, 10061816	Haematochezia, Diverticulum, Gastrointestinal haemorrhage, Colonoscopy, Endoscopy upper gastrointestinal tract, Diagnostic procedure
503	421	E	ASA	76	m	00493	15.05.2019	23.05.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10027141, 10061816, 10066152, 10014819, 10010007	Melaena, Diagnostic procedure, Transfusion, Endoscopy upper gastrointestinal tract, Colonoscopy
503	421	E	ASA	76	m	00494	28.05.2019	29.05.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061816, 10071360	Diagnostic procedure, Capsule endoscopy
1046	421	E	ASA	73	m	00710	15.04.2020	22.04.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10066152, 10014819, 10061816, 10053757	Gastrointestinal haemorrhage, Transfusion, Endoscopy upper gastrointestinal tract, Diagnostic procedure, Therapeutic procedure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1225	421	E	ASA	86	m	00832	09.03. 2020	12.03. 2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059443	Skin neoplasm excision
1225	421	E	ASA	87	m	00878	31.08. 2020	07.09. 2020	Non-cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10052693	Transurethral bladder resection
1225	421	E	ASA	87	m	01081	31.01. 2021	15.02. 2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1225	421	E	ASA	87	m	01111	20.02. 2021	01.03. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10044412, 10052693	Transitional cell carcinoma, Transurethral bladder resection
1225	421	E	ASA	87	m	01119	03.03. 2021	10.03. 2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571, 10062362	Urinary tract infection, Viral test negative
1307	421	E	ASA	83	m	01325	06.08. 2021	14.08. 2021	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10080743	Cardiac failure, Angiocardiogram
1307	421	E	ASA	84	m	01519	16.11. 2021	02.12. 2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10002918, 10077015	Aortic valve stenosis, Transcatheter aortic valve implantation
1307	421	E	ASA	84	m	01714	13.04. 2022	21.04. 2022	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10003658, 10062362	Cardiac failure, Atrial fibrillation, Viral test negative
1590	421	E	ASA	90	m	01981 -1	05.09. 2022		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	9.9.2022	No cardiovascular cause	Hospitalisation	10011906, 10016173, 10022116, 10077361	Death, Fall, Injury, Multiple organ dysfunction syndrome
1590	421	E	ASA	90	m	01981 -2	05.09. 2022	09.09. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Other medically important event	Permanently discontinued due to this event	n	n	r/r with sequelae			No prolongation of existing hospital stay	10060964, 10022116	Arterial haemorrhage, Injury
1602	421	E	ASA	72	m	00895	17.09. 2020	08.10. 2020	Ischemic stroke (including transient	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									events with matching lesion on cerebral imaging)											
1602	421	E	ASA	74	m	02034	28.10.2022	06.11.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
1883	421	E	ASA	73	m	01363	09.09.2021	10.09.2021	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002882	Aortic aneurysm
1883	421	E	ASA	73	m	01440-1	05.10.2021	08.10.2021	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002882, 10002885, 10071256, 10062362	Aortic aneurysm, Aortic aneurysm repair, Aortic stent insertion, Viral test negative
1883	421	E	ASA	73	m	01440-2	08.10.2021	22.10.2021	Non-cardiovascular event	Mild	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
1899	421	E	ASA	92	m	01797	15.06.2022	17.06.2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1899	421	E	ASA	92	m	01903	15.08.2022	17.08.2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065064, 10049434	Device lead issue, Cardiac pacemaker replacement
1940	421	E	ASA	88	f	01594	22.08.2021		Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	9.10.2021	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554, 10046571	Cardiac death, Cardiac failure, Urinary tract infection
2033	421	E	ASA	81	m	01313	26.07.2021	16.08.2021	Ischemic stroke (including transient	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									events with matching lesion on cerebral imaging)											
2033	421	E	ASA	82	m	02040	30.06. 2022	07.07. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10047340, 10036105	Vertigo, Polyneuropathy
2034	421	E	ASA	93	m	01421	07.05. 2021	17.05. 2021	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10080743, 10002918	Angiocardiogram, Aortic valve stenosis
2034	421	E	ASA	93	m	01422	06.10. 2021	12.10. 2021	Worsening of heart failure	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10002918	Cardiac failure, Aortic valve stenosis
2034	421	E	ASA	93	m	01711	04.01. 2022	08.01. 2022	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
2034	421	E	ASA	93	m	01712	16.01. 2022	08.02. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10060738, 10003988	Intervertebral discitis, Back pain
2034	421	E	ASA	94	m	02003	16.04. 2022	22.04. 2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10013968	Cardiac failure, Dyspnoea
2034	421	E	ASA	94	m	02004	26.04. 2022	05.05. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021789, 10003988	Infection, Back pain
2228	421	E	ASA	69	m	01905	09.05. 2022	16.05. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10004637, 10008629, 10014819, 10014802	Bile duct stone, Cholelithiasis, Endoscopy upper gastrointestinal tract, Endoscopic retrograde cholangiopancreatography
2228	421	E	ASA	69	m	01908	05.05. 2022	06.05. 2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10029983, 10053319	Obstructive sleep apnoea syndrome, Sleep study
2228	421	E	ASA	69	m	01909	05.07. 2022	06.07. 2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10086397, 10029983	Positive airway pressure therapy, Obstructive sleep apnoea syndrome
2228	421	E	ASA	69	m	01910	28.07. 2022		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	8.22.2022	No cardiovascular cause	Hospitalisation	10011906, 10040070, 10038435, 10007554	Death, Septic shock, Renal failure, Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2544	421	E	ASA	80	m	01965	20.06.2022	27.06.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061497, 10004720, 10042609	Salivary gland neoplasm, Biopsy, Surgery
2544	421	E	ASA	80	m	01968	13.07.2022	14.07.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061497, 10077345	Salivary gland neoplasm, Immunochemotherapy
155	421	E	no ASA	82	f	00732	11.08.2019	22.08.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10025005	Lumbar spinal stenosis
155	421	E	no ASA	84	f	01830	27.08.2021	11.09.2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10080743, 10062362	Cardiac failure, Angiocardiogram, Viral test negative
155	421	E	no ASA	84	f	01982	11.01.2022	12.01.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061816, 10010007, 10000081	Diagnostic procedure, Colonoscopy, Abdominal pain
155	421	E	no ASA	84	f	01983	30.04.2022	10.05.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
500	421	E	no ASA	86	m	01402	25.09.2021	08.10.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10039117, 10016173, 10019027, 10049947	Rib fracture, Fall, Haemothorax, Lumbar vertebral fracture
500	421	E	no ASA	86	m	01492	12.10.2021	27.11.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035598, 10053975, 10024741, 10062362, 10019027	Pleural effusion, Thoracic cavity drainage, Lung lobectomy, Viral test negative, Haemothorax
854	421	E	no ASA	78	m	01010	10.08.2020	12.08.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1584	421	E	no ASA	82	f	00985	15.11.2020	20.11.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10016173, 10039117, 10042015	Viral test negative, Fall, Rib fracture, Sternal fracture

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1584	421	E	no ASA	84	f	02059	14.10. 2022	15.10. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10039674, 10034584	Sciatica, Peripheral nerve destruction
1668	421	E	no ASA	71	m	01216	14.04. 2021	06.05. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008611, 10008629	Cholecystectomy, Cholelithiasis
1668	421	E	no ASA	72	m	01322	04.08. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.4.2021	Death of unknown cause		10011906	Death
1933	421	E	no ASA	75	f	01254	15.06. 2021	22.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10009033, 10069339	Chronic obstructive pulmonary disease, Acute kidney injury
1991	421	E	no ASA	80	f	01354	25.04. 2021	27.04. 2021	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10036653, 10070255	Presyncope, Coronavirus test positive
1991	421	E	no ASA	80	f	01356	19.04. 2021	24.04. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10070255, 10042772	Coronavirus test positive, Syncope
2508	421	E	no ASA	80	m	01919	21.03. 2022	23.03. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10047644, 10071181	Vitrectomy, Vitreoretinal traction syndrome
2508	421	E	no ASA	80	m	01920	25.04. 2022	27.04. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10071181, 10047644	Vitreoretinal traction syndrome, Vitrectomy
1642	426	P	ASA	75	f	01899	24.06. 2022	02.07. 2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
569	426	P	no ASA	80	m	02131	05.11. 2020	09.11. 2020	Minor Bleeding	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10052693, 10055798	Transurethral bladder resection, Haemorrhage
569	426	P	no ASA	80	m	02146	15.04. 2021	19.04. 2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10052693	Transurethral bladder resection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
930	426	E	no ASA	72	m	02145	13.09.2021	20.09.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10046571, 10069339	Urinary tract infection, Acute kidney injury
1796	426	E	no ASA	81	m	01504-1	29.09.2021	29.09.2021	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10023696, 10061974, 10077252	Laparotomy, Gastrointestinal obstruction, Proctectomy
1796	426	E	no ASA	81	m	01504-2	30.09.2021	19.10.2021	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10050001, 10020524, 10051985, 10038435, 10018875	Nephrostomy, Hydronephrosis, Renal pelvis fistula, Renal failure, Haemodialysis
1796	426	E	no ASA	81	m	01504-3	20.10.2021		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	Death	10.24.2021	Death due to cardiovascular haemorrhage	Hospitalisation	10011906, 10007649, 10055798, 10017955, 10061816, 10014819, 10066152	Death, Cardiovascular disorder, Haemorrhage, Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Transfusion
508	427	P	ASA	86	m	00116	06.04.2018	07.04.2018	Minor Bleeding	Moderate	Other medically important event	Permanently discontinued due to this event	n	y	r/r with sequelae			No hospital stay	10038063, 10013538, 10010007, 10061816	Rectal haemorrhage, Diverticulitis, Colonoscopy, Diagnostic procedure
1089	427	E	ASA	89	m	01098	10.02.2021	12.02.2021	Minor Bleeding	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10014819, 10061816, 10027141	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Diagnostic procedure, Melaena
652	445	P	ASA	94	f	01358	30.07.2021	03.08.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10010007, 10066152, 10062362, 10053757	Gastrointestinal haemorrhage, Colonoscopy, Transfusion, Viral test negative, Therapeutic procedure
785	445	P	ASA	83	m	00633	24.01.2020		Major Bleeding in non-	Very severe	Hospitalisation	Not applicable	n	n	Death	1.24.2020	Death due to cardiovascul	Hospitalisation	10011906, 10007649,	Death, Cardiovascular disorder,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									surgical patients (according ISTH, including haemorrhagic stroke)			(no intake of study drug)					ar haemorrhage		10055798, 10017955	Haemorrhage, Gastrointestinal haemorrhage
650	445	E	ASA	80	f	00886	08.05. 2020	15.05. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020096, 10031161	Hip arthroplasty, Osteoarthritis
650	445	E	ASA	79	f	00965	02.03. 2019	03.03. 2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052086, 10065608	Coronary arterial stent insertion, Percutaneous coronary intervention
650	445	E	ASA	81	f	01205	05.03. 2021	06.03. 2021	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10080743	Angiocardiogram
650	445	E	ASA	81	f	01224	07.04. 2021	13.04. 2021	Any type of cardiovascular surgery	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10002916	Viral test negative, Aortic valve replacement
651	445	E	ASA	94	m	00318	14.03. 2019	18.03. 2019	Minor Bleeding	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10027141	Melaena
651	445	E	ASA	95	m	00588	09.12. 2019	13.12. 2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
651	445	E	ASA	97	m	02130	15.09. 2021	07.01. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10017955, 10002034, 10061816, 10014819, 10010007	Gastrointestinal haemorrhage, Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy
1506	445	E	ASA	80	m	02036	10.12. 2021	14.12. 2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10017853, 10014819, 10010007,	Gastritis, Endoscopy upper gastrointestinal tract, Colonoscopy,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																			10074625, 10004137	Large intestinal polypectomy, Barrett's oesophagus
1506	445	E	ASA	81	m	02035	12.02. 2022	14.02. 2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10052086, 10050329, 10011078	Percutaneous coronary intervention, Coronary arterial stent insertion, Coronary angioplasty, Coronary artery disease
1574	445	E	ASA	83	f	02011	14.11. 2021	01.12. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096, 10062362	Hip arthroplasty, Viral test negative
1574	445	E	ASA	83	f	02012	16.03. 2022	16.03. 2022	Other cardiovascular event	Moderate	Other medically important event	None, i.e. still ongoing	n	n	r/r			No hospital stay	10038908	Retinal vein thrombosis
784	445	E	no ASA	85	f	00861	11.08. 2020	19.08. 2020	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10063712, 10061902	Duodenal sphincterotomy, Pancreatic neoplasm
159	459	P	ASA	65	m	00042	23.08. 2017	29.08. 2017	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10021036	Cardiac failure, Hyponatraemia
159	459	P	ASA	65	m	00046	11.09. 2017	13.09. 2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10008479	Chest pain
159	459	P	ASA	65	m	00051	25.09. 2017	27.09. 2017	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
159	459	P	ASA	66	m	00203	17.10. 2018	18.10. 2018	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
529	470	E	ASA	81	m	00723	05.05. 2020	06.05. 2020	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10007554, 10080743	Cardiac failure, Angiocardiogram

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
529	470	E	ASA	82	m	01616	18.02.2022	16.03.2022	ACS	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10011077, 10080743, 10002916, 10062362	Acute myocardial infarction, Coronary artery bypass, Angiocardiogram, Aortic valve replacement, Viral test negative
76	479	P	ASA	70	f	00856	07.08.2020	11.08.2020	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
76	479	P	ASA	70	f	00869	20.08.2020	25.08.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003662, 10007661, 10080743	Atrial flutter, Cardioversion, Angiocardiogram
76	479	P	ASA	70	f	01060	24.11.2020	25.11.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10052086, 10002383	Percutaneous coronary intervention, Coronary arterial stent insertion, Angina pectoris
107	479	P	no ASA	75	f	00021	09.05.2017	17.05.2017	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
107	479	P	no ASA	76	f	00106	12.03.2018	14.03.2018	Worsening of heart failure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
107	479	P	no ASA	77	f	00402	25.06.2019	03.07.2019	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
535	479	P	no ASA	91	m	00190	19.09.2018	28.09.2018	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10027727, 10035598	Cardiac failure, Mitral valve incompetence, Pleural effusion
535	479	P	no ASA	91	m	00196	08.10.2018	12.10.2018	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10027727, 10062202	Mitral valve incompetence, Mitral valve repair
535	479	P	no ASA	91	m	00229	21.11.2018	22.11.2018	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
535	479	P	no ASA	92	m	00479	19.07. 2019		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	7.27.2019	Death due to heart failure (HF)	Hospitalisation	10049993, 10035664, 10007554	Cardiac death, Pneumonia, Cardiac failure
1246	487	P	ASA	81	m	00798	02.07. 2020	09.07. 2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty
1652	487	P	no ASA	86	m	01259	20.04. 2021	22.04. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046414	Ureteroscopy abnormal
1652	487	P	no ASA	86	m	01260	21.03. 2021	30.03. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10007554	Pneumonia, Cardiac failure
1652	487	P	no ASA	87	m	01792	08.04. 2022	14.04. 2022	Worsening of heart failure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10002034, 10066152, 10007554	Anaemia, Transfusion, Cardiac failure
405	487	E	no ASA	80	m	00161	26.06. 2018	29.06. 2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10074431	Cancer surgery
2	488	P	ASA	81	m	00099	02.03. 2018	08.03. 2018	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10002034	Cardiac failure, Anaemia
2	488	P	ASA	81	m	00151	30.05. 2018	01.06. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10022016	Inguinal hernia
2	488	P	ASA	85	m	01443	10.10. 2021	20.10. 2021	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
2	488	P	ASA	85	m	01720	24.02. 2022		Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.4.2022	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554, 10016173	Cardiac death, Cardiac failure, Fall
45	488	P	ASA	87	m	00005	19.12. 2016	23.12. 2016	ACS	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10028596, 10065608, 10052086	Myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
45	488	P	ASA	87	m	00022	11.03.2017	13.03.2017	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10037660, 10021789, 10020646, 10012174	Pyrexia, Infection, Hyperkalaemia, Dehydration
45	488	P	ASA	88	m	00148	18.03.2018	10.04.2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
45	488	P	ASA	88	m	00149	12.04.2018	16.04.2018	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009192, 10021097, 10012174, 10021789	Circulatory collapse, Hypotension, Dehydration, Infection
45	488	P	ASA	88	m	00239	04.10.2018	11.10.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10035664, 10002034, 10066152, 10014819, 10061816	Gastrointestinal haemorrhage, Pneumonia, Anaemia, Transfusion, Endoscopy upper gastrointestinal tract, Diagnostic procedure
45	488	P	ASA	89	m	00329	09.02.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.9.2019	Death of unknown cause		10011906	Death
189	488	P	ASA	83	f	00371-1	25.05.2019	26.05.2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10010254, 10016173, 10019196	Concussion, Fall, Head injury
189	488	P	ASA	83	f	00371-2	25.05.2019		Non-cardiovascular event	Very severe	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	Death	6.1.2019	No cardiovascular cause	Hospitalisation	10011906, 10035664	Death, Pneumonia
206	488	P	ASA	83	f	01015	08.09.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	9.8.2020	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
218	488	P	ASA	81	f	00414	02.02. 2019	11.02. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061161, 10000397	Pelvic fracture, Acetabulum fracture
218	488	P	ASA	81	f	00415	18.02. 2019	04.03. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061161, 10033371	Pelvic fracture, Pain
218	488	P	ASA	85	f	01980	23.08. 2022	06.09. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096, 10016454	Hip arthroplasty, Femur fracture
370	488	P	ASA	78	m	00752	28.02. 2020	05.03. 2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10069339, 10047461, 10012174	Acute kidney injury, Viral infection, Dehydration
370	488	P	ASA	78	m	00753	11.03. 2020	19.03. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10012267, 10019211	Dementia, Headache
370	488	P	ASA	78	m	00884	06.09. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	9.6.2020	Death of unknown cause		10011906	Death
474	488	P	ASA	79	m	00183	12.06. 2018	14.06. 2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10000081	Abdominal pain
474	488	P	ASA	79	m	00301	30.10. 2018	06.11. 2018	Stable AP (no ACS)	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10011078	Coronary artery disease
474	488	P	ASA	80	m	00682	03.03. 2020	06.03. 2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062501	Non-cardiac chest pain
474	488	P	ASA	81	m	00887	26.08. 2020	28.08. 2020	Stable AP (no ACS)	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002383	Angina pectoris
1099	488	P	ASA	87	f	00719	20.12. 2019	07.01. 2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10002918	Cardiac failure, Aortic valve stenosis
1099	488	P	ASA	88	f	01105	17.11. 2020		Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	11.22.2020	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
1532	488	P	ASA	84	f	01113	30.09. 2020	07.10. 2020	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062585, 10061637	Peripheral arterial occlusive disease, Angiogram
1532	488	P	ASA	84	f	01115	01.12. 2020	17.12. 2020	Percutaneous coronary	Severe	Hospitalisation	Temporarily discontinued	n	n	r/r			Hospitalisation	10002475, 10057617	Angioplasty, Aortic bypass

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									intervention (e.g. PCI), cerebrovascular or peripheral procedure			due to this event								
5	488	P	no ASA	69	f	00408	27.04.2019	15.05.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061284	Mental disorder
5	488	P	no ASA	70	f	00819	25.02.2020	03.03.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10044002, 10057647	Tonsil cancer, Cytoreductive surgery
5	488	P	no ASA	70	f	00820	26.06.2020	20.07.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10003504, 10035664, 10044002, 10040047, 10066152	Aspiration, Pneumonia, Tonsil cancer, Sepsis, Transfusion
5	488	P	no ASA	70	f	00888	09.03.2020	19.03.2020	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10044320, 10044002	Tracheostomy, Tonsil cancer
5	488	P	no ASA	70	f	00889	19.06.2020	23.06.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10048978, 10044002	Gastrostomy, Tonsil cancer
5	488	P	no ASA	72	f	01570-1	06.01.2022		Minor Bleeding	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Event ongoing			Hospitalisation	10034811, 10049750	Pharyngeal cancer, Tumour haemorrhage
5	488	P	no ASA	72	f	01570-2	09.01.2022		Pulmonary embolism	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	Death	1.9.2022	Death due to other cardiovascular causes	No prolongation of existing hospital stay	10037377, 10011906, 10007649	Pulmonary embolism, Death, Cardiovascular disorder
90	488	P	no ASA	83	m	01974	30.08.2022	16.09.2022	Myocardial Infarction	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10028596, 10011077, 10080743, 10035598, 10003522	Myocardial infarction, Coronary artery bypass, Angiocardiogram, Pleural effusion, Aspiration pleural cavity
134	488	P	no ASA	87	m	01112	30.10.2020	06.11.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008611, 10008614	Cholecystectomy, Cholecystitis acute

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
134	488	P	no ASA	89	m	01765	22.05. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	5.22.2022	No cardiovascular cause		10011906, 10003549	Death, Asthenia
357	488	P	no ASA	82	m	01515	22.11. 2021	26.11. 2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10030137	Oesophageal adenocarcinoma
357	488	P	no ASA	83	m	01874	15.06. 2022	08.08. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10067098, 10053377, 10014819, 10078775, 10021789	Central venous catheter removal, Central venous catheterisation, Endoscopy upper gastrointestinal tract, Oesophageal prosthesis insertion, Infection
357	488	P	no ASA	83	m	01960	13.08. 2022		Non-cardiovascular event				n	n	Death	8.13.2022	No cardiovascular cause		10011906, 10030137	Death, Oesophageal adenocarcinoma
20	488	E	ASA	79	m	00010 -1	01.03. 2017	10.03. 2017	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
20	488	E	ASA	79	m	00010 -2	05.03. 2017	10.03. 2017	Non-cardiovascular event	Mild	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10058818	Skin laceration
20	488	E	ASA	79	m	00010 -3	01.03. 2017	10.03. 2017	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10069339, 10064848	Acute kidney injury, Chronic kidney disease
20	488	E	ASA	79	m	00013	09.04. 2017	18.04. 2017	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10021015, 10021036	Hypokalaemia, Hyponatraemia
20	488	E	ASA	80	m	00058	26.10. 2017	01.12. 2017	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10003658, 10007661	Cardiac failure, Atrial fibrillation, Cardioversion
20	488	E	ASA	80	m	00082	23.12. 2017		Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.2.2018	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
27	488	E	ASA	82	m	00961	18.10. 2020	04.11. 2020	Worsening of heart failure	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10062362, 10007554	Viral test negative, Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
31	488	E	ASA	88	m	00349	23.04. 2019	26.04. 2019	Minor Bleeding	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10048616, 10017955, 10013554, 10074625	Intestinal polyp, Gastrointestinal haemorrhage, Diverticulum, Large intestinal polypectomy
31	488	E	ASA	89	m	00509	15.10. 2019	23.10. 2019	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10031127, 10042772	Orthostatic hypotension, Syncope
31	488	E	ASA	89	m	00736	14.05. 2020	20.05. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10014819, 10061816, 10066152	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Diagnostic procedure, Transfusion
50	488	E	ASA	74	m	00101	05.03. 2018	08.03. 2018	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10007815	Cardiac failure, Catheterisation cardiac
213	488	E	ASA	87	f	00261	25.07. 2018	04.08. 2018	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke
213	488	E	ASA	90	f	01620	14.02. 2022	17.02. 2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10027727, 10007554, 10013968	Mitral valve incompetence, Cardiac failure, Dyspnoea
261	488	E	ASA	68	m	00126	27.03. 2018	28.03. 2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10006580, 10008479, 10011224	Bundle branch block left, Chest pain, Cough
261	488	E	ASA	70	m	00520	18.10. 2019	01.11. 2019	Myocardial Infarction	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10011077	Acute myocardial infarction, Coronary artery bypass
261	488	E	ASA	71	m	01093	06.12. 2020	11.12. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052936	Corpora cavernosa surgery

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
261	488	E	ASA	71	m	01094	20.12.2020	29.12.2020	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10059862	Cardiac failure, Cardiac resynchronisation therapy
280	488	E	ASA	79	m	00083	16.12.2017		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.16.2017	Sudden cardiac death		10049418	Sudden cardiac death
318	488	E	ASA	93	f	01455	16.08.2021	18.08.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012735, 10012174, 10021015	Diarrhoea, Dehydration, Hypokalaemia
318	488	E	ASA	94	f	01563	09.12.2021	16.12.2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
318	488	E	ASA	94	f	01564	25.12.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.25.2021	Death of unknown cause		10011906	Death
343	488	E	ASA	79	f	01071	30.01.2021	05.02.2021	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10058468, 10021328	Laparoscopic surgery, Ileus
810	488	E	ASA	93	f	01211	23.04.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	4.23.2021	Death of unknown cause		10011906	Death
1244	488	E	ASA	77	m	01310	27.06.2021	01.07.2021	Minor Bleeding	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10062362, 10014819	Gastrointestinal haemorrhage, Viral test negative, Endoscopy upper gastrointestinal tract
1244	488	E	ASA	78	m	01779	28.05.2022	30.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038077, 10062362, 10038078	Rectal prolapse, Viral test negative, Rectal prolapse repair

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1244	488	E	ASA	78	m	01780	11.05. 2022	20.05. 2022	Minor Bleeding	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	y	r/r			Hospitalisa tion	10017955, 10017885, 10014819	Gastrointestinal haemorrhage, Gastrooesophagea l reflux disease, Endoscopy upper gastrointestinal tract
25	488	E	no ASA	73	m	00002	14.10. 2016	18.10. 2016	Non-cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10033557	Palpitations
25	488	E	no ASA	73	m	00031	25.06. 2017	30.06. 2017	Other cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10008479, 10013968	Chest pain, Dyspnoea
25	488	E	no ASA	75	m	00470	25.06. 2019	28.06. 2019	Other cardiovasc ular event	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10021097	Hypotension
25	488	E	no ASA	77	m	01366	05.07. 2021	08.07. 2021	Non-cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10012174, 10021097, 10062362	Dehydration, Hypotension, Viral test negative
25	488	E	no ASA	77	m	01367	25.08. 2021	27.08. 2021	Non-cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10017853, 10014819	Gastritis, Endoscopy upper gastrointestinal tract
25	488	E	no ASA	78	m	01595	04.01. 2022	07.01. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10013968, 10062362, 10000081	Dyspnoea, Viral test negative, Abdominal pain
25	488	E	no ASA	78	m	01629	22.02. 2022	25.02. 2022	Hospitalisa tion due to AF	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10003658, 10007554, 10007661	Atrial fibrillation, Cardiac failure, Cardioversion
25	488	E	no ASA	78	m	01715	10.03. 2022	16.03. 2022	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
25	488	E	no ASA	78	m	01717	02.04. 2022	06.04. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10012174, 10021097, 10047340	Dehydration, Hypotension, Vertigo
25	488	E	no ASA	78	m	01719	17.03. 2022	23.03. 2022	Other cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10047340, 10021097	Vertigo, Hypotension
42	488	E	no ASA	66	m	00128	20.02. 2018	23.02. 2018	Change of a pacemaker , ICD or any other cardiac device	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10059862	Cardiac resynchronisation therapy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
42	488	E	no ASA	66	m	00129	19.04.2018	30.04.2018	Other cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10047302	Ventricular tachycardia
42	488	E	no ASA	66	m	00155	14.06.2018		Non-cardiovascular event	Very severe	Hospitalisation	None, i.e. still ongoing	n	n	Death	6.20.2018	No cardiovascular cause	Hospitalisation	10035664, 10040070, 10011906	Pneumonia, Septic shock, Death
121	488	E	no ASA	90	m	00337	25.03.2019	30.03.2019	Non-cardiovascular event	Severe	Life threatening event	Permanently discontinued due to this event	n	y	r/r			Main reason for hospital admission	10002034, 10066152, 10061816, 10014819, 10010007	Anaemia, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy
334	502	P	ASA	69	m	00510-1	01.12.2018	06.03.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10066152, 10017955, 10061816, 10010007, 10014819, 10053757, 10058360, 10061992	Transfusion, Gastrointestinal haemorrhage, Diagnostic procedure, Colonoscopy, Endoscopy upper gastrointestinal tract, Therapeutic procedure, Retroperitoneal haematoma, Haemophilia
334	502	P	ASA	69	m	00510-2	30.01.2019	06.03.2019	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10008611, 10008614	Cholecystectomy, Cholecystitis acute
334	502	P	ASA	69	m	00511	29.04.2019	17.05.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
334	502	P	ASA	69	m	00512	25.07.2019	30.07.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10069951, 10014802	Bile duct stent removal, Endoscopic retrograde cholangiopancreatography
334	502	P	ASA	71	m	01524	04.06.2021	06.06.2021	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10047302, 10007661	Viral test negative, Ventricular tachycardia, Cardioversion
334	502	P	ASA	72	m	01758	31.01.2022	01.02.2022	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
334	502	P	ASA	72	m	01777	01.06.2022	02.06.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
835	502	P	ASA	88	f	00450	05.08.2019	09.08.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10022000	Influenza
1282	502	P	ASA	69	m	01442	21.10.2021	22.10.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864, 10062362	Atrial fibrillation, Cardiac ablation, Viral test negative
1282	502	P	ASA	69	m	01729	10.02.2022	11.02.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10052693, 10062362	Haematuria, Transurethral bladder resection, Viral test negative
1535	502	P	ASA	83	m	01323	16.03.2021	17.03.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
270	502	P	no ASA	92	m	00104	05.03.2018	19.03.2018	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10002918, 10002916, 10077015	Aortic valve stenosis, Aortic valve replacement, Transcatheter aortic valve implantation
602	502	P	no ASA	75	m	00231	25.11.2018	29.11.2018	Myocardial Infarction	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10050329, 10052086	Acute myocardial infarction, Coronary angioplasty, Coronary arterial stent insertion
602	502	P	no ASA	75	m	00258	07.01.2019	08.01.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10011078, 10050329	Coronary artery disease, Coronary angioplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
602	502	P	no ASA	75	m	00288	12.02. 2019	14.02. 2019	Change of a pacemaker , ICD or any other cardiac device	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10059862	Cardiac resynchronisation therapy
602	502	P	no ASA	75	m	00422	23.05. 2019	29.05. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10024670	Liver disorder
602	502	P	no ASA	76	m	00618	29.09. 2019	02.10. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10022020	Inguinal hernia repair
602	502	P	no ASA	76	m	00619	05.10. 2019	09.10. 2019	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10024670	Liver disorder
166	502	E	ASA	87	m	00043	24.07. 2017	29.07. 2017	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10053160	Cardiac failure, Bronchitis viral
166	502	E	ASA	87	m	00044	06.08. 2017		Non-cardiovasc ular event	Very severe	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	Death	8.7.2017	No cardiovascul ar cause	Hospitalisa tion	10011906, 10035664	Death, Pneumonia
1200	502	E	ASA	79	m	01287	06.07. 2021	07.07. 2021	Other cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10080743, 10062362	Angiocardiogram, Viral test negative
1440	502	E	ASA	71	m	01321	28.07. 2021	05.08. 2021	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10020096	Hip arthroplasty
102	502	E	no ASA	75	m	00014	12.04. 2017	14.04. 2017	Other cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10020772, 10007554	Hypertension, Cardiac failure
102	502	E	no ASA	76	m	00273	21.10. 2018	29.10. 2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrha gic stroke)	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	y	r/r			Hospitalisa tion	10018985	Haemorrhage intracranial
102	502	E	no ASA	77	m	00410	09.07. 2019		Death as primary event, e.g. sudden				n	n	Death	7.9.2019	Sudden cardiac death		10049418	Sudden cardiac death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death, not death as outcome of another event											
227	502	E	no ASA	84	m	00635	11.01.2020	17.01.2020	Syncope	Moderate	Hospitalisation	None, i.e. still ongoing	n	y	r/r			Hospitalisation	10042772, 10002034	Syncope, Anaemia
227	502	E	no ASA	85	m	01065	09.11.2020	13.11.2020	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	y	r/r			Hospitalisation	10002034, 10061964, 10061636, 10066152	Anaemia, Gammopathy, Angiodysplasia, Transfusion
227	502	E	no ASA	86	m	01387	16.09.2021	22.09.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10009944, 10017955, 10014819, 10010007, 10061816, 10066152	Colon cancer, Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Transfusion
227	502	E	no ASA	86	m	01423	03.10.2021	18.10.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061778, 10001167	Colectomy, Adenocarcinoma of colon
227	502	E	no ASA	86	m	01578	09.11.2021	02.12.2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061256, 10014498, 10043530, 10046571, 10005028, 10062362	Ischaemic stroke, Embolic stroke, Thrombectomy, Urinary tract infection, Bladder catheterisation, Viral test negative
227	502	E	no ASA	86	m	01604	31.01.2022	02.02.2022	Syncope	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10042772, 10003658, 10062362	Syncope, Atrial fibrillation, Viral test negative
164	514	P	no ASA	68	m	00226	05.11.2018	08.11.2018	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
164	514	P	no ASA	68	m	00385	29.04.2019	02.05.2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061373	Sudden hearing loss
164	514	P	no ASA	71	m	01774	05.01.2022	06.01.2022	Percutaneous coronary	Moderate	Hospitalisation	Temporarily discontinued	n	n	r/r			Hospitalisation	10057525, 10072562,	Peripheral artery occlusion, Peripheral artery

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									intervention (e.g. PCI), cerebrovascular or peripheral procedure			due to this event							10002475, 10062585	stent insertion, Angioplasty, Peripheral arterial occlusive disease
164	514	P	no ASA	71	m	02139	12.07. 2021	16.07. 2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10009033	Chronic obstructive pulmonary disease
456	514	E	ASA	71	m	00691	28.10. 2019	05.11. 2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty
2577	519	E	ASA	75	f	01869	27.07. 2022	09.08. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10015145	Erysipelas
2577	519	E	ASA	75	f	01985	26.09. 2022	10.10. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10061816, 10014819, 10010007, 10002034, 10066152, 10062362, 10013538	Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Anaemia, Transfusion, Viral test negative, Diverticulitis
2400	519	E	no ASA	76	m	01656	18.03. 2022	19.03. 2022	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10014368, 10047289	Electrocardiogram ambulatory, Ventricular extrasystoles
2400	519	E	no ASA	76	m	01742	03.05. 2022	10.05. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10050584, 10054112, 10062362, 10039203	Contusion, Hospitalisation, Viral test negative, Road traffic accident
255	529	P	ASA	80	m	00197	08.10. 2018	15.10. 2018	Peripheral (limb) embolism	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10043607, 10066152, 10043530, 10061340	Thrombosis, Transfusion, Thrombectomy, Peripheral embolism
1399	529	P	ASA	85	m	00969	29.09. 2020		Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	10.1.2020	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1852	529	P	ASA	85	m	01244	07.06. 2021	11.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10009033, 10062362	Chronic obstructive pulmonary disease, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1924	529	P	ASA	83	m	01055	14.01. 2021	21.01. 2021	Myocardial Infarction	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10062362, 10000891, 10052086	Viral test negative, Acute myocardial infarction, Coronary arterial stent insertion
1068	529	P	no ASA	83	m	01192	07.01. 2020	10.01. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10000087	Abdominal pain upper
1068	529	P	no ASA	83	m	01199	12.12. 2019	20.12. 2019	ACS	Very severe	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10051592	Acute coronary syndrome
1068	529	P	no ASA	85	m	02144	11.04. 2021	21.04. 2021	Non-cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10023469	Knee arthroplasty
1848	529	P	no ASA	78	m	01516	26.11. 2021	07.12. 2021	Stable AP (no ACS)	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10002383, 10008479, 10065608, 10052086	Angina pectoris, Chest pain, Percutaneous coronary intervention, Coronary arterial stent insertion
703	529	E	ASA	86	m	01704	07.04. 2022	03.05. 2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10061256, 10014498	Ischaemic stroke, Embolic stroke
703	529	E	ASA	86	m	01708	03.10. 2021	13.10. 2021	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10038695, 10038661	Respiratory failure, Respiratory acidosis
703	529	E	ASA	86	m	01709	07.01. 2022	09.01. 2022	Worsening of heart failure	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10007554, 10062352, 10062362	Cardiac failure, Respiratory tract infection, Viral test negative
703	529	E	ASA	86	m	02105	09.08. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.9.2022	Death of unknown cause		10011906, 10003549	Death, Asthenia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1201	529	E	ASA	69	f	00518	28.06.2019	05.07.2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256, 10070878	Ischaemic stroke, Cerebral small vessel ischaemic disease
926	529	E	no ASA	79	m	02013	09.09.2021	17.09.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061778	Colectomy
1593	529	E	no ASA	84	f	01540	11.01.2021	16.01.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10070255, 10035664, 10046571	Coronavirus test positive, Pneumonia, Urinary tract infection
1593	529	E	no ASA	85	f	01627	26.02.2022	04.03.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10046571, 10035664, 10040047	Urinary tract infection, Pneumonia, Sepsis
1593	529	E	no ASA	86	f	01827	01.07.2022		Non-cardiovascular event				n	n	Death	7.1.2022	No cardiovascular cause		10011906, 10035664	Death, Pneumonia
1823	529	E	no ASA	73	m	01194	07.11.2020	13.11.2020	Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062352	Respiratory tract infection
1823	529	E	no ASA	73	m	01195	06.12.2020	08.12.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062362, 10040979	Viral test negative, Sleep apnoea syndrome
1823	529	E	no ASA	73	m	01196	03.01.2021	14.01.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664	Pneumonia
1823	529	E	no ASA	73	m	01197	01.03.2021	15.03.2021	Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664, 10062352	Pneumonia, Respiratory tract infection
1823	529	E	no ASA	73	m	01198	13.04.2021	14.04.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10002034, 10066152, 10055798	Anaemia, Transfusion, Haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1846	529	E	no ASA	76	m	01125	09.03. 2021	17.03. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10009944, 10062362, 10002034, 10066152, 10061816, 10014819, 10010007, 10017955	Colon cancer, Viral test negative, Anaemia, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Gastrointestinal haemorrhage
2328	529	E	no ASA	79	m	01828	11.04. 2022		Non-cardiovascular event	Severe	Other medically important event	Not applicable (no intake of study drug)	n	n	Event ongoing			No hospital stay	10001150, 10014819	Adenocarcinoma gastric, Endoscopy upper gastrointestinal tract
315	530	P	ASA	69	f	00712	09.12. 2019	15.01. 2020	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014665, 10007601	Endocarditis, Cardiac pacemaker removal
315	530	P	ASA	69	f	01601	01.10. 2020		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	11.11.2020	No cardiovascular cause	Hospitalisation	10070255, 10023804, 10061778, 10010041, 10021321, 10009895, 10017955, 10066152, 10036410, 10011906	Coronavirus test positive, Large intestine perforation, Colectomy, Colostomy, Ileostomy, Colitis ischaemic, Gastrointestinal haemorrhage, Transfusion, Postoperative wound infection, Death
2106	530	P	ASA	77	m	02065	12.11. 2022	22.11. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018964, 10013968, 10009944, 10035598, 10027458, 10027469, 10027463	Haemoptysis, Dyspnoea, Colon cancer, Pleural effusion, Metastases to lung, Metastases to the mediastinum, Metastases to pleura
429	530	P	no ASA	75	f	00206	30.03. 2018	03.04. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
429	530	P	no ASA	75	f	00207	16.07. 2018	17.07. 2018	Non-cardiovascular event	Moderate	Other medically	Not applicable	n	n	r/r			Main reason for	10038528	Renal stone removal

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
											important event	(no intake of study drug)						hospital admission		
271	530	E	ASA	76	m	00578	14.12. 2019	24.12. 2019	Other cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10047302, 10007661	Ventricular tachycardia, Cardioversion
1059	530	E	ASA	77	m	01417	14.07. 2021	29.07. 2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10033609, 10014802, 10082920, 10062362	Pancreatic carcinoma, Endoscopic retrograde cholangiopancreatography, Biliary catheter insertion, Viral test negative
1059	530	E	ASA	77	m	01418 -1	12.08. 2021	15.08. 2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10033644, 10033609	Pancreaticoduodenectomy, Pancreatic carcinoma
1059	530	E	ASA	77	m	01418 -2	16.08. 2021	23.08. 2021	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10067268	Post procedural infection
1513	530	E	ASA	81	m	00779	15.03. 2020		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	3.29.2020	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1521	530	E	no ASA	83	f	00859	13.07. 2020	31.07. 2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038019, 10065100, 10066152	Rectal adenocarcinoma, Gastrointestinal endoscopic therapy, Transfusion
1521	530	E	no ASA	83	f	00860	02.08. 2020	11.08. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10066152, 10053757, 10014819, 10017955, 10013839	Transfusion, Therapeutic procedure, Endoscopy upper gastrointestinal tract, Gastrointestinal haemorrhage, Duodenal ulcer haemorrhage
311	532	P	ASA	76	m	00759	02.01. 2020		Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	1.11.2020	No cardiovascular cause	Hospitalisation	10011906, 10040070, 10038749	Death, Septic shock, Resuscitation
563	535	P	no ASA	84	f	00270	27.12. 2018	02.01. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10042609, 10044412	Surgery, Transitional cell carcinoma

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
605	535	P	no ASA	73	m	01804	16.06. 2022	21.06. 2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10046571, 10018867	Viral test negative, Urinary tract infection, Haematuria
1393	535	P	no ASA	90	f	01764	26.11. 2021	30.11. 2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10048709, 10062362	Urosepsis, Viral test negative
538	535	E	ASA	85	f	00497 -1	29.09. 2019	10.10. 2019	Myocardial Infarction	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10052086, 10065608	Acute myocardial infarction, Coronary arterial stent insertion, Percutaneous coronary intervention
538	535	E	ASA	85	f	00497 -2	03.10. 2019	10.10. 2019	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10069339	Acute kidney injury
538	535	E	ASA	87	f	01943	13.04. 2022		Worsening of heart failure				n	n	Death	4.13.2022	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
538	535	E	ASA	87	f	01944	09.10. 2021	20.10. 2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1693	535	E	ASA	81	m	01844	15.03. 2022	21.03. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	None, i.e. still ongoing	y	y	r/r			Hospitalisation	10002034, 10017955, 10053757, 10010007, 10014819, 10061636, 10066152, 10062362	Anaemia, Gastrointestinal haemorrhage, Therapeutic procedure, Colonoscopy, Endoscopy upper gastrointestinal tract, Angiodysplasia, Transfusion, Viral test negative
756	535	E	no ASA	81	f	00299	23.02. 2019		Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.12.2019	No cardiovascular cause	Hospitalisation	10035598, 10011906	Pleural effusion, Death
1589	535	E	no ASA	82	f	01666	13.03. 2022	13.03. 2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Other medically important event	Temporarily discontinued due to this event	n	n	r/r with sequelae			No hospital stay	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1589	535	E	no ASA	83	f	02017	21.10. 2022	25.10. 2022	Change of a pacemaker , ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10065064, 10049434	Device lead issue, Cardiac pacemaker replacement
1769	535	E	no ASA	78	m	01775 -1	24.05. 2022	31.05. 2022	Myocardial Infarction	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10028596, 10065608, 10052086, 10062362	Myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion, Viral test negative
1769	535	E	no ASA	78	m	01775 -2	27.05. 2022	31.05. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10002034, 10018964, 10017955, 10062362	Anaemia, Haemoptysis, Gastrointestinal haemorrhage, Viral test negative
1328	536	P	ASA	85	m	00528	07.11. 2019	13.11. 2019	Other cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10051055	Deep vein thrombosis
991	536	P	no ASA	92	f	02132	09.11. 2021	12.11. 2021	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10003662, 10062362, 10059864	Atrial flutter, Viral test negative, Cardiac ablation
276	536	E	ASA	77	m	00064	16.11. 2017	21.11. 2017	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Life threatening event	Permanently discontinued due to this event	n	n	r/r with sequelae			Main reason for hospital admission	10061256	Ischaemic stroke
276	536	E	ASA	79	m	00742	20.03. 2020		Non-cardiovascular event				n	n	Death	3.20.2020	No cardiovascular cause		10011906, 10048709	Death, Urosepsis
276	536	E	ASA	79	m	00748	10.03. 2020	19.03. 2020	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10068822	Emphysematous pyelonephritis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
855	541	E	ASA	88	f	00971	04.07. 2020	06.07. 2020	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
855	541	E	ASA	90	f	01751	04.04. 2022	08.04. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10008593, 10027458	Viral test negative, Cholangiocarcinoma, Metastases to lung
855	541	E	ASA	90	f	01796	06.06. 2022		Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	Death	6.9.2022	No cardiovascular cause	Hospitalisation	10011906, 10008593	Death, Cholangiocarcinoma
470	541	E	no ASA	78	f	00271	24.07. 2018	03.08. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10023129, 10004637, 10014802, 10052925	Jaundice cholestatic, Bile duct stone, Endoscopic retrograde cholangiopancreatography, Cholelithotomy
470	541	E	no ASA	80	f	01653	24.09. 2020	06.10. 2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
177	544	P	ASA	70	f	00370	27.05. 2019	27.05. 2019	Other cardiovascular event	Moderate	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10048620, 10008479	Intracardiac thrombus, Chest pain
177	544	P	ASA	70	f	00397	08.03. 2019	09.03. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
177	544	P	ASA	71	f	00728	08.05. 2020	05.06. 2020	Other cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10059864, 10047302, 10080743	Cardioversion, Cardiac ablation, Ventricular tachycardia, Angiocardiogram
1336	544	P	ASA	87	f	00799	29.06. 2020	30.06. 2020	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003662	Atrial flutter
1336	544	P	ASA	88	f	01185	20.02. 2021	04.03. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020028, 10017955, 10014819	Hiatus hernia, Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1336	544	P	ASA	88	f	01433	19.09.2021	29.09.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10003658	Cardiac failure, Atrial fibrillation
1336	544	P	ASA	89	f	02005-1	29.05.2022	07.06.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070863	Toxicity to various agents
1336	544	P	ASA	89	f	02005-2	31.05.2022	07.06.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10002034, 10014819, 10061816, 10066152, 10017955, 10038435	Anaemia, Endoscopy upper gastrointestinal tract, Diagnostic procedure, Transfusion, Gastrointestinal haemorrhage, Renal failure
1476	544	P	ASA	83	f	00776	12.06.2020	13.06.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
1482	544	P	ASA	75	m	00997-1	01.12.2020	02.12.2020	Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10003011, 10003010	Appendicitis, Appendicectomy
1482	544	P	ASA	75	m	00997-2	02.12.2020	13.12.2020	Non-cardiovascular event	Very severe	Prolongation of existing hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10040070	Septic shock
1482	544	P	ASA	77	m	01918	07.06.2022	20.07.2022	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434, 10022020, 10070255, 10035664, 10066152, 10035598	Cardiac pacemaker replacement, Inguinal hernia repair, Coronavirus test positive, Pneumonia, Transfusion, Pleural effusion
1508	544	P	ASA	73	m	00851	15.03.2020	20.03.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1508	544	P	ASA	73	m	00852	07.04.2020	05.05.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
1508	544	P	ASA	73	m	00853	10.06.2020	07.07.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1508	544	P	ASA	73	m	00854	08.07.2020		Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	Death	8.9.2020	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554, 10062362	Cardiac death, Cardiac failure, Viral test negative
137	544	P	no ASA	85	f	00055	13.05.2017	16.05.2017	Syncope	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10042772	Syncope
137	544	P	no ASA	85	f	00137	08.11.2017	13.11.2017	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10023469	Knee arthroplasty
137	544	P	no ASA	88	f	00762	06.05.2020		Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	5.29.2020	No cardiovascular cause	Hospitalisation	10011906, 10008614	Death, Cholecystitis acute
156	544	P	no ASA	93	m	00491	30.09.2019	01.10.2019	Other cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10086210	Superficial vein thrombosis
367	544	P	no ASA	82	m	00293-1	20.02.2019	21.02.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
367	544	P	no ASA	82	m	00293-2	22.02.2019	28.02.2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10067251	Lead dislodgement
367	544	P	no ASA	85	m	01803	30.03.2022	05.04.2022	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062352	Cardiac failure, Respiratory tract infection
575	544	P	no ASA	91	m	00441	09.01.2019	16.01.2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10024968	Lower respiratory tract infection
178	544	E	ASA	88	f	00185	05.09.2018	17.09.2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10037660	Pneumonia, Pyrexia
178	544	E	ASA	91	f	01798	19.04.2022	20.04.2022	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
178	544	E	ASA	91	f	01799	27.04.2022	11.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
178	544	E	ASA	91	f	01802	23.05.2022	31.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
486	544	E	ASA	87	f	01362	08.05.2021	11.05.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571, 10062362	Urinary tract infection, Viral test negative
958	544	E	ASA	77	f	01316	07.02.2021	09.02.2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059864	Cardiac ablation
1190	544	E	ASA	71	m	00590	23.12.2019	30.12.2019	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1190	544	E	ASA	71	m	00770	03.02.2020	05.02.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1190	544	E	ASA	71	m	00772	21.02.2020	23.02.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035664, 10024968	Pneumonia, Lower respiratory tract infection
1190	544	E	ASA	71	m	00773	17.03.2020	19.03.2020	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1190	544	E	ASA	73	m	01525	10.11.2021		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.23.2021	No cardiovascular cause	Hospitalisation	10011906, 10038695, 10035664, 10062362	Death, Respiratory failure, Pneumonia, Viral test negative
1683	544	E	ASA	85	f	01288	20.01.2021	22.01.2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1683	544	E	ASA	85	f	01289	06.03.2021	10.03.2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1683	544	E	ASA	86	f	01582	12.01.2022	20.01.2022	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10062362, 10007554, 10024968, 10070345, 10070249	Viral test negative, Cardiac failure, Lower respiratory tract infection, Pneumovirus test positive, Human

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																				rhinovirus test positive
773	544	E	no ASA	77	f	01170	16.11. 2020	27.11. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10023469	Knee arthroplasty
773	544	E	no ASA	78	f	01917	17.08. 2022	26.08. 2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
839	544	E	no ASA	69	f	01014	22.11. 2020	25.11. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10006187, 10054831, 10068647	Breast cancer, Breast prosthesis removal, Mammoplasty
1345	544	E	no ASA	79	m	00823	07.07. 2020	15.07. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10014819, 10010007, 10002034	Endoscopy upper gastrointestinal tract, Colonoscopy, Anaemia
1345	544	E	no ASA	80	m	01022	21.11. 2020		Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.29.2020	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1367	544	E	no ASA	75	m	00735	08.03. 2020	14.03. 2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061778, 10009944	Colectomy, Colon cancer
1367	544	E	no ASA	75	m	00876	28.08. 2020	04.09. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	r/r with sequelae			Hospitalisation	10038063, 10066152	Rectal haemorrhage, Transfusion
1367	544	E	no ASA	75	m	00958	26.10. 2020	02.11. 2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061778, 10009944	Colectomy, Colon cancer
275	547	P	ASA	88	f	01392	02.05. 2021	10.05. 2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
1088	547	P	ASA	76	m	01184	08.04. 2021	09.04. 2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10022020	Inguinal hernia repair
1088	547	P	ASA	77	m	01464	16.10. 2021	17.10. 2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012267, 10012218	Dementia, Delirium

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1517	547	P	ASA	88	f	01527	28.11. 2021		Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	12.5.2021	Death due to stroke	Hospitalisation	10011906, 10061256, 10014498, 10043568	Death, Ischaemic stroke, Embolic stroke, Thrombolysis
1922	547	P	ASA	73	m	01281	17.02. 2021	18.02. 2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012735, 10062362, 10007554	Diarrhoea, Viral test negative, Cardiac failure
1922	547	P	ASA	74	m	02032	06.07. 2022	08.07. 2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10051055	Deep vein thrombosis
1939	547	P	ASA	83	m	01614	19.08. 2021	20.08. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
273	547	P	no ASA	84	m	00462	17.05. 2019	20.05. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
454	547	P	no ASA	81	m	00188	14.05. 2018	17.05. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10023469	Knee arthroplasty
454	547	P	no ASA	84	m	01631	20.09. 2021	21.09. 2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013496, 10003246, 10003239, 10062362	Disturbance in attention, Arthritis, Arthralgia, Viral test negative
454	547	P	no ASA	84	m	01632	28.10. 2021	12.11. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10003246, 10003239, 10062362	Arthritis, Arthralgia, Viral test negative
454	547	P	no ASA	84	m	01633	25.11. 2021	14.01. 2022	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10021789, 10062362, 10049434	Infection, Viral test negative, Cardiac pacemaker replacement
918	547	P	no ASA	84	m	00574	25.10. 2019	26.10. 2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10022020	Inguinal hernia repair
918	547	P	no ASA	85	m	00988	15.11. 2020		Ischemic stroke	Very severe	Other medically	Not applicable	n	n	Death	11.15.2020	Death due to stroke	No hospital stay	10011906, 10008190,	Death, Cerebrovascular

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									(including transient events with matching lesion on cerebral imaging)		important event	(no intake of study drug)							10061256, 10014498, 10062362, 10043530	accident, Ischaemic stroke, Embolic stroke, Viral test negative, Thrombectomy
922	547	P	no ASA	84	m	01931	06.08. 2022		Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	8.13.2022	Death due to stroke	Hospitalisation	10061256, 10062362, 10011906, 10014498	Ischaemic stroke, Viral test negative, Death, Embolic stroke
2053	547	P	no ASA	82	f	01223	24.04. 2021	24.04. 2021	Stroke, unknown cause	Moderate	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10013573	Dizziness
392	547	E	ASA	83	m	00765	30.03. 2020		Non-cardiovascular event	Very severe	Hospitalisation	None, i.e. still ongoing	n	n	Death	3.31.2020	No cardiovascular cause	Hospitalisation	10070255, 10011906, 10035664	Coronavirus test positive, Death, Pneumonia
1369	547	E	ASA	86	m	01186	05.03. 2021	15.03. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r with sequelae			Hospitalisation	10017955	Gastrointestinal haemorrhage
1369	547	E	ASA	86	m	01465	22.07. 2021	29.07. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10062362, 10017955, 10061816, 10014819, 10010007, 10066152	Viral test negative, Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Transfusion
1369	547	E	ASA	86	m	01466	10.09. 2021	21.09. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016454, 10051060, 10066152, 10062362	Femur fracture, Hip surgery, Transfusion, Viral test negative
1369	547	E	ASA	86	m	01467	29.09. 2021	14.10. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10036978	Prostatitis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1369	547	E	ASA	87	m	01491	13.11. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	Death	11.13.2021	No cardiovascular cause	Main reason for hospital admission	10011906, 10040047	Death, Sepsis
2055	547	E	ASA	84	m	01897	24.06. 2022		Minor Bleeding	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	7.1.2022	No cardiovascular cause	Hospitalisation	10011906, 10036909, 10018867, 10066152	Death, Prostate cancer metastatic, Haematuria, Transfusion
2055	547	E	ASA	84	m	01898	23.05. 2022	24.05. 2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10002034, 10062362, 10066152	Cardiac failure, Anaemia, Viral test negative, Transfusion
2214	547	E	ASA	67	m	02101	29.01. 2022	14.02. 2022	Myocardial Infarction	Severe	Life threatening event	Not applicable (no intake of study drug)	n	n	r/r			Main reason for hospital admission	10000891, 10050329, 10052086	Acute myocardial infarction, Coronary angioplasty, Coronary arterial stent insertion
2214	547	E	ASA	67	m	02102	05.04. 2022	21.04. 2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10027452, 10062362, 10046571, 10058467	Metastases to bone, Viral test negative, Urinary tract infection, Lung neoplasm malignant
2214	547	E	ASA	67	m	02106	25.05. 2022	26.08. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10008614, 10008611, 10062362, 10014802	Cholecystitis acute, Cholecystectomy, Viral test negative, Endoscopic retrograde cholangiopancreatography
2214	547	E	ASA	68	m	02107	31.08. 2022	06.09. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10058305	Clostridium colitis
2214	547	E	ASA	68	m	02108	21.09. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	9.27.2022	No cardiovascular cause	Hospitalisation	10011906, 10040070, 10008604, 10014802, 10028997	Death, Septic shock, Cholangitis, Endoscopic retrograde cholangiopancreatography, Neoplasm malignant

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2605	547	E	ASA	79	m	02002	01.10.2022	04.10.2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256, 10062362	Ischaemic stroke, Viral test negative
499	547	E	no ASA	76	f	01971	17.03.2022	18.03.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
864	547	E	no ASA	77	m	01517	21.07.2021	22.07.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10000081, 10010774, 10000060	Abdominal pain, Constipation, Abdominal distension
1160	547	E	no ASA	72	m	00495	30.09.2019	02.10.2019	Minor Bleeding	Moderate	Hospitalisation	None, i.e. still ongoing	n	y	r/r			Hospitalisation	10017955, 10010007, 10061816, 10018836	Gastrointestinal haemorrhage, Colonoscopy, Diagnostic procedure, Haematochezia
1160	547	E	no ASA	72	m	01414	18.09.2019	19.09.2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10050584, 10016173, 10055082, 10078651	Contusion, Fall, Lip injury, Nasal injury
2495	547	E	no ASA	79	f	01926	22.08.2022	28.08.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013538	Diverticulitis
667	557	P	ASA	88	m	01420	18.08.2021	29.08.2021	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10077015, 10002918	Transcatheter aortic valve implantation, Aortic valve stenosis
667	557	P	ASA	88	m	01424	16.08.2021	17.08.2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608	Percutaneous coronary intervention

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
502	557	E	ASA	84	f	00485	13.07.2019	14.07.2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035664	Pneumonia
714	557	E	ASA	75	m	00328	29.03.2019	08.04.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10013839, 10066152, 10017955, 10055798, 10014819, 10061816	Duodenal ulcer haemorrhage, Transfusion, Gastrointestinal haemorrhage, Haemorrhage, Endoscopy upper gastrointestinal tract, Diagnostic procedure
714	557	E	ASA	75	m	00430	12.07.2019	24.07.2019	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10013968	Cardiac failure, Dyspnoea
714	557	E	ASA	76	m	00490	01.10.2019		Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	10.13.2019	Death due to heart failure (HF)	Hospitalisation	10007554, 10049993	Cardiac failure, Cardiac death
462	564	P	ASA	89	f	00102	02.03.2018	18.03.2018	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10035664	Pneumonia
462	564	P	ASA	90	f	00446	20.03.2019	17.04.2019	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10040047, 10040070	Sepsis, Septic shock
462	564	P	ASA	90	f	00447	20.04.2019		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	5.2.2019	Sudden cardiac death	Hospitalisation	10049418	Sudden cardiac death
1110	564	P	ASA	84	m	00671	20.01.2020	31.01.2020	Non-cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10016173	Fall
1110	564	P	ASA	85	m	01213	01.02.2021	06.02.2021	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
1110	564	P	ASA	86	m	01584	12.09.2021	14.09.2021	Change of a pacemaker, ICD or any other	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
1110	564	P	ASA	86	m	01725	22.07. 2021	02.08. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016173, 10039020, 10038435, 10012378, 10021789	Fall, Rhabdomyolysis, Renal failure, Depression, Infection
1110	564	P	ASA	87	m	01806	04.06. 2022		Non-cardiovascular event		Death	Not applicable (no intake of study drug)	n	n	Death	6.4.2022	No cardiovascular cause	No hospital stay	10011906, 10028200, 10022116	Death, Multiple fractures, Injury
389	564	P	no ASA	84	f	00107	09.03. 2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	3.9.2018	Death of unknown cause		10011906	Death
490	564	E	ASA	72	m	01723	12.12. 2021	17.12. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062352	Respiratory tract infection
548	564	E	ASA	81	f	00362	23.02. 2019	27.02. 2019	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10022000	Influenza
548	564	E	ASA	84	f	02109	06.05. 2022	20.06. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10023469	Knee arthroplasty
974	564	E	ASA	82	f	01061	25.11. 2020	27.11. 2020	Stable AP (no ACS)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002383, 10052086, 10065608	Angina pectoris, Coronary arterial stent insertion, Percutaneous coronary intervention
974	564	E	ASA	82	f	01062	11.11. 2020	12.11. 2020	Stable AP (no ACS)	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10002383, 10080743	Angina pectoris, Angiocardiogram
974	564	E	ASA	83	f	01596	08.01. 2022	10.01. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003553, 10062362	Asthma, Viral test negative
779	564	E	no ASA	69	m	00251	01.01. 2019	04.01. 2019	ACS	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10028596, 10065608, 10052086	Myocardial infarction, Percutaneous coronary intervention,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																				Coronary arterial stent insertion
165	566	E	ASA	78	m	00039	16.06. 2017	20.06. 2017	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10003246, 10039073	Arthritis, Rheumatoid arthritis
165	566	E	ASA	80	m	02136	03.09. 2019	10.09. 2019	Peripheral (limb) embolism	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061340, 10014648, 10057518, 10072562	Peripheral embolism, Endarterectomy, Peripheral artery angioplasty, Peripheral artery stent insertion
165	566	E	ASA	83	m	02137	17.10. 2022	04.11. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035759, 10056342, 10004794	Pneumothorax, Pulmonary mass, Biopsy lung
377	605	P	ASA	67	m	00469	18.07. 2019	18.07. 2019	Other cardiovascular event	Severe	Life threatening event	None, i.e. still ongoing	n	n	r/r			No hospital stay	10047302, 10007661	Ventricular tachycardia, Cardioversion
377	605	P	ASA	69	m	01134	27.03. 2021	31.03. 2021	Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10047302, 10007554	Ventricular tachycardia, Cardiac failure
298	605	E	ASA	81	m	00912	25.09. 2020	05.10. 2020	Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
816	608	P	ASA	78	m	00501	28.05. 2019	30.05. 2019	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10003662, 10059864	Atrial flutter, Cardiac ablation
903	608	P	no ASA	76	f	00386	15.05. 2019	16.05. 2019	Syncope	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10042772	Syncope
903	608	P	no ASA	77	f	00794	17.06. 2020	25.06. 2020	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10052086, 10065608	Cardiac failure, Coronary arterial stent insertion, Percutaneous coronary intervention
1091	608	P	no ASA	93	f	00980	02.10. 2020	20.10. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10004637, 10062362	Bile duct stone, Viral test negative
1450	608	P	no ASA	75	f	01104	20.10. 2020	24.10. 2020	Myocardial Infarction	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10040979	Sleep apnoea syndrome
1450	608	P	no ASA	77	f	01610	07.02. 2022	10.02. 2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2402	608	P	no ASA	82	m	01935	08.08. 2022	14.11. 2022	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10016173, 10035664, 10062362, 10061536	Fall, Pneumonia, Viral test negative, Parkinson's disease
1471	608	E	no ASA	86	m	01108	11.07. 2020	22.07. 2020	Minor Bleeding	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	y	r/r			Hospitalisation	10018867	Haematuria
601	619	E	no ASA	87	f	00213	23.10. 2018	29.10. 2018	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10048617, 10020096	Pseudarthrosis, Hip arthroplasty
601	619	E	no ASA	87	f	00236	29.11. 2018	03.12. 2018	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10033645	Pancreatitis
601	619	E	no ASA	87	f	00390	26.04. 2019	10.05. 2019	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016454, 10022576, 10066152	Femur fracture, Internal fixation of fracture, Transfusion
601	619	E	no ASA	89	f	01229	19.05. 2021	08.06. 2021	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10033645	Pancreatitis
601	619	E	no ASA	89	f	01299	19.06. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	6.19.2021	Death of unknown cause		10011906	Death
581	641	P	ASA	90	m	01439	31.03. 2021	02.04. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
643	641	P	ASA	89	f	00277	10.01. 2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.10.2019	Sudden cardiac death		10049418	Sudden cardiac death
422	641	P	no ASA	85	m	00240	04.11. 2018	06.11. 2018	Change of a pacemaker	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									, ICD or any other cardiac device											
478	641	P	no ASA	82	f	00125	19.04. 2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	4.19.2018	Death due to other cardiovascular causes		10011906, 10007649	Death, Cardiovascular disorder
632	641	P	no ASA	78	m	00375	07.05. 2019		Worsening of heart failure	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	5.15.2019	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
238	641	E	ASA	76	m	00093	15.01. 2018	19.01. 2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10060862, 10050307	Prostate cancer, Ureteral stent insertion
262	641	E	no ASA	70	m	00067	26.08. 2017	04.09. 2017	Worsening of heart failure	Mild	Prolongation of existing hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10037423	Cardiac failure, Pulmonary oedema
262	641	E	no ASA	73	m	01142	02.04. 2021	15.04. 2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10051592, 10052086, 10065608	Acute coronary syndrome, Coronary arterial stent insertion, Percutaneous coronary intervention
292	641	E	no ASA	81	f	01304	04.05. 2021	06.05. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
588	641	E	no ASA	72	m	00516	23.09. 2019	25.09. 2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1015	641	E	no ASA	78	m	00333	25.03. 2019		Death as primary event, e.g. sudden death, not death as outcome of another event		Death	Permanently discontinued due to this event	n	y	Death	3.25.2019	Death of unknown cause	No hospital stay	10012601, 10014561, 10058467, 10011906, 10055798, 10059175	Diabetes mellitus, Emphysema, Lung neoplasm malignant, Death, Haemorrhage, Intestinal haemorrhage
1280	641	E	no ASA	85	f	01232	15.03. 2021	26.03. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10033647, 10004637	Pancreatitis acute, Bile duct stone
379	655	E	ASA	84	m	00871	01.07. 2018	30.07. 2018	Minor Bleeding	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10018852, 10047115	Haematoma, Vasculitis
549	655	E	ASA	77	m	01027	03.11. 2020		Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	11.12.2020	No cardiovascular cause	Hospitalisation	10011906, 10035664, 10070255	Death, Pneumonia, Coronavirus test positive
559	655	E	ASA	80	m	01769	14.05. 2022	26.05. 2022	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10062362, 10035598	Cardiac failure, Viral test negative, Pleural effusion
461	655	E	no ASA	78	f	00660	01.02. 2019	22.02. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664	Pneumonia
461	655	E	no ASA	80	f	00909	23.09. 2020	22.12. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Permanently discontinued due to this event	n	y	r/r			No hospital stay	10017955, 10066152, 10061816, 10014819, 10010007	Gastrointestinal haemorrhage, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy
579	663	P	no ASA	74	f	00268	15.01. 2019	17.01. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10075685, 10065064	Cardiac pacemaker adjustment, Device lead issue
223	663	E	no ASA	75	m	00336	09.02. 2019		Worsening of heart failure	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	3.22.2019	Death due to heart failure (HF)	Hospitalisation	10007554, 10049993	Cardiac failure, Cardiac death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
259	669	P	ASA	70	m	00840	23.03.2020	03.04.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10039674	Sciatica
1220	669	P	no ASA	83	m	00766	10.12.2019	16.12.2019	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1723	669	E	no ASA	78	f	00946	21.10.2020	30.10.2020	Other cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10034474, 10034484, 10033128	Pericardial effusion, Pericarditis, Ovarian cancer
269	673	P	ASA	92	m	01265	23.07.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	7.23.2020	Sudden cardiac death		10049418	Sudden cardiac death
1097	673	P	ASA	71	m	01070	24.01.2021	29.01.2021	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434, 10007554	Cardiac pacemaker replacement, Cardiac failure
87	673	P	no ASA	82	f	00169	29.06.2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	6.29.2018	Sudden cardiac death		10049418	Sudden cardiac death
194	673	P	no ASA	84	m	00585	08.11.2019	15.11.2019	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062352	Respiratory tract infection
194	673	P	no ASA	84	m	00586	02.12.2019	17.12.2019	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10007554, 10024968	Cardiac failure, Lower respiratory tract infection
194	673	P	no ASA	84	m	00809	12.02.2020	20.02.2020	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
194	673	P	no ASA	84	m	00811	19.03. 2020	23.03. 2020	Worsening of heart failure	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10007554, 10062362	Cardiac failure, Viral test negative
194	673	P	no ASA	84	m	00813	16.04. 2020		Worsening of heart failure				n	n	Death	4.16.2020	Death due to heart failure (HF)		10049993, 10007554, 10062362	Cardiac death, Cardiac failure, Viral test negative
821	673	P	no ASA	82	f	00973	29.07. 2020	09.08. 2020	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10058468, 10038019, 10017955, 10003010	Laparoscopic surgery, Rectal adenocarcinoma, Gastrointestinal haemorrhage, Appendicectomy
1150	673	P	no ASA	82	m	00763	30.11. 2019	10.12. 2019	Non-cardiovasc ular event	Sever e	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10009033, 10038695	Chronic obstructive pulmonary disease, Respiratory failure
1150	673	P	no ASA	82	m	00764	11.01. 2020	17.01. 2020	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10009033	Chronic obstructive pulmonary disease
1150	673	P	no ASA	83	m	01025	02.10. 2020		Non-cardiovasc ular event	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	n	Death	10.10.2020	No cardiovascul ar cause	Hospitalisa tion	10011906, 10036909, 10035664, 10062362	Death, Prostate cancer metastatic, Pneumonia, Viral test negative
1567	673	P	no ASA	84	f	00826	12.07. 2020	14.07. 2020	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10061256, 10076994	Ischaemic stroke, Lacunar stroke
1875	673	P	no ASA	85	f	01497	20.09. 2021	27.10. 2021	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10062362, 10069339, 10018875	Viral test negative, Acute kidney injury, Haemodialysis
2086	673	P	no ASA	92	m	01789	08.02. 2022	14.02. 2022	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10035664, 10062362	Pneumonia, Viral test negative
948	673	E	ASA	85	m	01072	26.07. 2020	07.08. 2020	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10046571, 10012735, 10007554, 10046555	Urinary tract infection, Diarrhoea, Cardiac failure, Urinary retention
948	673	E	ASA	85	m	01073	30.08. 2020		Death as primary event, e.g. sudden death, not				n	n	Death	8.30.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death as outcome of another event											
1372	673	E	ASA	81	m	00725	01.12.2019	05.12.2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10046571	Cardiac failure, Urinary tract infection
1713	673	E	ASA	85	m	01855	15.02.2022	03.03.2022	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10062362, 10035664, 10002034, 10066152, 10061905	Cardiac failure, Viral test negative, Pneumonia, Anaemia, Transfusion, Paracentesis
1713	673	E	ASA	85	m	01856	21.03.2022		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	4.12.2022	No cardiovascular cause	Hospitalisation	10011906, 10028537	Death, Myelofibrosis
91	673	E	no ASA	82	m	00008-1	14.02.2017	24.02.2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	r/r			Hospitalisation	10017955, 10002034	Gastrointestinal haemorrhage, Anaemia
91	673	E	no ASA	82	m	00008-2	14.02.2017	24.02.2017	Worsening of heart failure	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
91	673	E	no ASA	82	m	00008-3	14.02.2017	24.02.2017	Non-cardiovascular event	Mild	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062352, 10038695	Respiratory tract infection, Respiratory failure
337	673	E	no ASA	79	m	00986	05.06.2020	06.06.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10004637, 10014802	Bile duct stone, Endoscopic retrograde cholangiopancreatography
427	673	E	no ASA	90	m	00120	13.02.2018	14.03.2018	Hospitalisation due to AF	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10069339, 10007556, 10003658	Acute kidney injury, Cardiac failure acute, Atrial fibrillation
427	673	E	no ASA	90	m	00235	09.05.2018	22.05.2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10046571, 10012735, 10010305	Urinary tract infection, Diarrhoea, Confusional state

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
427	673	E	no ASA	93	m	01475	11.08. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.11.2021	Death of unknown cause		10011906	Death
707	673	E	no ASA	91	f	00910	18.06. 2020		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	6.28.2020	Death due to heart failure (HF)	Hospitalisation	10049993, 10013663, 10007554, 10013654	Cardiac death, Drug dependence, Cardiac failure, Drug abuse
1136	673	E	no ASA	90	f	00767	09.12. 2019	12.12. 2019	TIA	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10044390, 10001903, 10018250	Transient ischaemic attack, Amaurosis fugax, Giant cell arteritis
1136	673	E	no ASA	90	f	00768	28.12. 2019	23.01. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10014819, 10061816, 10066152, 10013839	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Diagnostic procedure, Transfusion, Duodenal ulcer haemorrhage
1168	673	E	no ASA	77	m	01005	28.09. 2020	03.10. 2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10044445, 10004446	Transurethral prostatectomy, Benign prostatic hyperplasia
1866	673	E	no ASA	73	f	01612	01.01. 2022	10.02. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	r/r			Hospitalisation	10017955, 10002034, 10066152, 10053757, 10014819, 10062362, 10072612	Gastrointestinal haemorrhage, Anaemia, Transfusion, Therapeutic procedure, Endoscopy upper gastrointestinal tract, Viral test negative, Electrocoagulation
2263	673	E	no ASA	90	m	01953	20.08. 2022	26.08. 2022	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10009033, 10035664	Chronic obstructive pulmonary disease, Pneumonia
1448	674	P	ASA	78	m	01880	29.07. 2022	05.08. 2022	Stable AP (no ACS)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002383, 10080743	Angina pectoris, Angiocardiogram

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
888	674	P	no ASA	82	f	01351	31.08.2021	03.09.2021	Minor Bleeding	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	y	r/r			Hospitalisation	10020802, 10015090	Hypertensive crisis, Epistaxis
307	675	P	no ASA	74	m	00174-1	06.08.2018	09.08.2018	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Persistent / significant disability or incapacity	Permanently discontinued due to this event	n	n	r/r with sequelae			Main reason for hospital admission	10061256	Ischaemic stroke
307	675	P	no ASA	74	m	00174-2	06.08.2018	09.08.2018	Minor Bleeding	Severe	Persistent / significant disability or incapacity	Permanently discontinued due to this event	n	y	r/r			Reason for prolongation of existing hospital stay	10055677, 10055798, 10019016	Haemorrhagic transformation stroke, Haemorrhage, Haemorrhagic stroke
307	675	P	no ASA	75	m	00343	06.01.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.6.2019	No cardiovascular cause		10011906, 10012271	Death, Dementia Alzheimer's type
233	675	E	no ASA	77	m	02088	28.10.2022	14.12.2022	Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10027191, 10006105, 10052937	Meningioma, Brain abscess, Craniectomy
233	675	E	no ASA	76	m	02128	02.07.2022	20.07.2022	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10027191, 10053765	Meningioma, Meningioma surgery
240	675	E	no ASA	75	m	00341	21.03.2019	25.03.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10077252, 10009944	Proctectomy, Colon cancer
240	675	E	no ASA	75	m	00342	30.03.2019	30.04.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10023696, 10048038	Laparotomy, Wound infection
240	675	E	no ASA	75	m	00344	23.11.2018	22.03.2019	Major Bleeding in non-surgical patients (according ISTH,	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	y	r/r			No hospital stay	10017955	Gastrointestinal haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									including haemorrhagic stroke)											
240	675	E	no ASA	75	m	01206	27.07.2019	31.07.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10008614	Cholecystitis acute
240	675	E	no ASA	78	m	02140	18.01.2022	19.01.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061161	Pelvic fracture
240	675	E	no ASA	78	m	02141	22.07.2022	29.07.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10039203, 10050584	Road traffic accident, Contusion
384	675	E	no ASA	76	f	00112	18.01.2018	24.01.2018	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10004637, 10014802	Bile duct stone, Endoscopic retrograde cholangiopancreatography
384	675	E	no ASA	79	f	01207	06.02.2021	11.02.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
507	675	E	no ASA	82	m	00435	16.10.2018	30.10.2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061902	Pancreatic neoplasm
507	675	E	no ASA	84	m	01208	27.12.2020		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.9.2021	No cardiovascular cause	Hospitalisation	10011906, 10033609	Death, Pancreatic carcinoma
942	675	E	no ASA	87	m	02099	27.01.2022		Other cardiovascular event	Very severe	Hospitalisation	None, i.e. still ongoing	n	n	Death	2.2.2022	Death due to other cardiovascular causes	Hospitalisation	10011906, 10007649, 10062585, 10034576	Death, Cardiovascular disorder, Peripheral arterial occlusive disease, Peripheral ischaemia
711	680	P	ASA	83	m	01388	21.05.2021	29.05.2021	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10033645, 10004637, 10014802, 10062362	Pancreatitis, Bile duct stone, Endoscopic retrograde cholangiopancreatography, Viral test negative
711	680	P	ASA	84	m	01493	03.11.2021	05.11.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10049434, 10007661, 10003658	Viral test negative, Cardiac pacemaker replacement,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																				Cardioversion, Atrial fibrillation
711	680	P	ASA	84	m	01494	26.09. 2021	29.09. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10008629, 10008604, 10051773	Cholelithiasis, Cholangitis, Bile duct stent insertion
772	680	P	ASA	70	m	00249	23.12. 2018	31.12. 2018	Syncope	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10047302, 10042772	Ventricular tachycardia, Syncope
772	680	P	ASA	70	m	00290	07.02. 2019	08.02. 2019	Hospitalisation due to AF	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
772	680	P	ASA	71	m	00716	09.03. 2020	11.03. 2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
772	680	P	ASA	72	m	01158	17.11. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.17.2020	Death of unknown cause		10011906	Death
783	680	P	ASA	73	m	00827	02.07. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	7.2.2020	Sudden cardiac death		10049418	Sudden cardiac death
836	680	P	ASA	81	m	00361	18.04. 2019	23.04. 2019	ACS	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002388, 10036653, 10065608, 10003658	Angina unstable, Presyncope, Percutaneous coronary intervention, Atrial fibrillation
902	680	P	ASA	78	f	00589	02.11. 2019		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.2.2019	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554, 10061161, 10016454	Cardiac death, Cardiac failure, Pelvic fracture, Femur fracture
904	680	P	ASA	82	m	01126	16.03. 2021	17.03. 2021	Change of a pacemaker, ICD or any other	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
981	680	P	ASA	80	m	00438	23.04. 2019	24.04. 2019	Stable AP (no ACS)	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10011078, 10002383, 10080743	Coronary artery disease, Angina pectoris, Angiocardiogram
1037	680	P	ASA	76	m	01662	10.01. 2022	12.01. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10012174, 10012735, 10013968, 10003549	Dehydration, Diarrhoea, Dyspnoea, Asthenia
1037	680	P	ASA	77	m	01975	22.06. 2022	23.06. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10054112, 10061816, 10031161	Hospitalisation, Diagnostic procedure, Osteoarthritis
1044	680	P	ASA	67	m	01623	24.02. 2022	25.02. 2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1064	680	P	ASA	70	m	01099	22.02. 2021	23.02. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1210	680	P	ASA	66	m	00849	06.06. 2020	12.06. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10065608, 10000891	Percutaneous coronary intervention, Acute myocardial infarction
1210	680	P	ASA	67	m	01097	10.02. 2021	15.02. 2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
1339	680	P	ASA	88	f	00529	01.11. 2019	08.11. 2019	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1339	680	P	ASA	88	f	00741	27.02.2020	06.03.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
1347	680	P	ASA	71	m	00617	30.12.2019	31.12.2019	ACS	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10000891	Acute myocardial infarction
1347	680	P	ASA	72	m	01200	01.01.2021		Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.20.2021	No cardiovascular cause	Hospitalisation	10061256, 10011906, 10070255	Ischaemic stroke, Death, Coronavirus test positive
1609	680	P	ASA	76	m	01235	31.05.2021		Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	7.23.2021	No cardiovascular cause	Hospitalisation	10011906, 10064687, 10049071	Death, Device related infection, Vascular operation
1799	680	P	ASA	90	m	01389	16.09.2021	17.09.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1815	680	P	ASA	85	f	01705	15.02.2022	17.02.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10013554, 10010007	Diverticulum, Colonoscopy
771	680	P	no ASA	89	f	00708	16.12.2019	20.12.2019	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020772	Hypertension
771	680	P	no ASA	90	f	01160	08.03.2021	24.03.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10070255, 10039361	Coronavirus test positive, Sacroiliitis
771	680	P	no ASA	90	f	01430	15.07.2021	21.07.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10039361	Sacroiliitis
838	680	P	no ASA	69	m	00761	28.02.2020	03.03.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061018, 10060862	Brachytherapy, Prostate cancer
838	680	P	no ASA	69	m	00771	13.03.2020	17.03.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10060862, 10061018	Prostate cancer, Brachytherapy
1135	680	P	no ASA	74	f	01680	24.03.2022	25.03.2022	Change of a	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									pacemaker, ICD or any other cardiac device											replacement, Viral test negative
1474	680	P	no ASA	75	f	01286	14.06.2021	07.07.2021	Other cardiovascular event	Severe	Persistent / significant disability or incapacity	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			No hospital stay	10038907	Retinal vein occlusion
1474	680	P	no ASA	75	f	01588	18.08.2021	20.08.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
1955	680	P	no ASA	76	m	01383	14.09.2021	21.09.2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequel ae			Hospitalisation	10007554	Cardiac failure
1955	680	P	no ASA	76	m	01397	21.09.2021	24.09.2021	Myocardial Infarction	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10052086, 10000891	Coronary arterial stent insertion, Acute myocardial infarction
1955	680	P	no ASA	77	m	01643	03.03.2022	07.03.2022	Myocardial Infarction	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
2031	680	P	no ASA	76	m	01700	17.03.2022		ACS	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	3.19.2022	Death due to acute myocardial infarction (MI)	Hospitalisation	10049993, 10000891, 10062362, 10051592	Cardiac death, Acute myocardial infarction, Viral test negative, Acute coronary syndrome
698	680	E	ASA	88	f	00465	04.09.2019	09.09.2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
698	680	E	ASA	89	f	00690	31.01.2020		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	2.2.2020	Death due to heart failure (HF)	Hospitalisation	10049993, 10061008, 10007554	Cardiac death, Biliary tract disorder, Cardiac failure
763	680	E	ASA	77	m	01378	16.08.2021	28.08.2021	Any type of cardiovascular surgery	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10002882, 10002885	Aortic aneurysm, Aortic aneurysm repair
763	680	E	ASA	77	m	01379	01.09.2021	10.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10054236, 10009887	Clostridium difficile infection, Colitis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
763	680	E	ASA	78	m	01568	10.01.2022	11.01.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
763	680	E	ASA	78	m	01658	17.03.2022	21.03.2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007598, 10062362	Cardiac pacemaker insertion, Viral test negative
815	680	E	ASA	67	m	00359	22.03.2019	27.03.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10025310	Lymphoma
815	680	E	ASA	67	m	00378	01.04.2019	03.04.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10004794	Biopsy lung
815	680	E	ASA	68	m	00974	07.10.2020	10.10.2020	Worsening of heart failure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10027727	Cardiac failure, Mitral valve incompetence
887	680	E	ASA	83	m	00436	08.06.2019	10.06.2019	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10013968, 10007554	Dyspnoea, Cardiac failure
934	680	E	ASA	80	m	01058	05.10.2020	16.10.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10052693	Transurethral bladder resection
934	680	E	ASA	81	m	01341	17.06.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	6.17.2021	No cardiovascular cause		10011906, 10005003	Death, Bladder cancer
955	680	E	ASA	86	f	01045	06.10.2020	09.10.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013554	Diverticulum
955	680	E	ASA	86	f	01046	12.01.2021	14.01.2021	Change of a pacemaker, ICD or any other	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
993	680	E	ASA	70	m	01028	28.12.2020	31.12.2020	Myocardial Infarction	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10052086, 10000891	Coronary arterial stent insertion, Acute myocardial infarction
998	680	E	ASA	86	f	00353	05.03.2019	13.03.2019	Minor Bleeding	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061045, 10038038, 10055798	Colon neoplasm, Rectal cancer, Haemorrhage
998	680	E	ASA	86	f	00455	04.04.2019	07.04.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10062099, 10004720, 10010007, 10061816	Rectal neoplasm, Biopsy, Colonoscopy, Diagnostic procedure
998	680	E	ASA	86	f	00456	15.05.2019	21.05.2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10062099, 10076445	Rectal neoplasm, Radiotherapy to rectum
998	680	E	ASA	86	f	00457	28.05.2019	06.06.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10010041, 10061778, 10062099	Colostomy, Colectomy, Rectal neoplasm
998	680	E	ASA	86	f	00458	18.06.2019	22.07.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10000081	Abdominal pain
1054	680	E	ASA	69	m	01555	20.12.2021	21.12.2021	Stable AP (no ACS)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086, 10002383	Percutaneous coronary intervention, Coronary arterial stent insertion, Angina pectoris
1065	680	E	ASA	80	f	00892	09.07.2020	18.07.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10028533, 10002034	Myelodysplastic syndrome, Anaemia
1065	680	E	ASA	80	f	00921	04.10.2020		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Permanently discontinued due to this event	y	y	Death	10.10.2020	No cardiovascular cause	Hospitalisation	10011906, 10053942, 10008111, 10028533, 10066152, 10016173	Death, Cerebral haematoma, Cerebral haemorrhage, Myelodysplastic syndrome, Transfusion, Fall
1087	680	E	ASA	70	m	00843	22.07.2020	24.07.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10003658, 10007554	Atrial fibrillation, Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1087	680	E	ASA	70	m	00925	29.08.2020	03.09.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10003658, 10003662, 10059864	Atrial fibrillation, Atrial flutter, Cardiac ablation
1153	680	E	ASA	70	m	00563	04.11.2019	13.11.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10002882, 10002885	Aortic aneurysm, Aortic aneurysm repair
1292	680	E	ASA	73	m	00882	20.08.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.20.2020	Sudden cardiac death		10049418, 10038749	Sudden cardiac death, Resuscitation
1316	680	E	ASA	66	m	00650	17.01.2020	28.01.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008614, 10008611	Cholecystitis acute, Cholecystectomy
1316	680	E	ASA	66	m	00881	24.08.2020	29.08.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10038389	Renal cancer
1316	680	E	ASA	66	m	00906	15.09.2020	23.09.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10033969, 10061392	Paratracheal lymphadenopathy, Tumour excision
1340	680	E	ASA	88	f	00740	28.01.2020		Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	Event ongoing			Hospitalisation	10061018, 10046885	Brachytherapy, Vaginal cancer
1530	680	E	ASA	82	f	01458-1	31.10.2021	03.11.2021	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10012271, 10013395, 10041466, 10062362	Dementia Alzheimer's type, Disorientation, Speech disorder, Viral test negative
1530	680	E	ASA	82	f	01458-2	03.11.2021	30.11.2021	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10012271, 10001497, 10022437, 10070255	Dementia Alzheimer's type, Agitation, Insomnia, Coronavirus test positive

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1530	680	E	ASA	82	f	01458-3	30.11.2021	15.12.2021	Non-cardiovascular event	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10070255, 10035664, 10062362	Coronavirus test positive, Pneumonia, Viral test negative
1530	680	E	ASA	82	f	01458-4	15.12.2021	31.12.2021	Non-cardiovascular event	Mild	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10038695	Respiratory failure
1530	680	E	ASA	82	f	01597	29.01.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.29.2022	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
1645	680	E	ASA	85	f	01805	20.04.2022	21.04.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1664	680	E	ASA	69	m	01552	01.03.2021	02.03.2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061256, 10070255, 10070878	Ischaemic stroke, Coronavirus test positive, Cerebral small vessel ischaemic disease
1664	680	E	ASA	70	m	01553	26.08.2021	27.08.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1664	680	E	ASA	70	m	01554	13.11.2021	15.11.2021	Stable AP (no ACS)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065608, 10052086, 10002383	Percutaneous coronary intervention, Coronary arterial stent insertion, Angina pectoris
1664	680	E	ASA	70	m	01819	23.03.2022	13.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10008614, 10008629	Cholecystitis acute, Cholelithiasis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
1664	680	E	ASA	70	m	01820	15.05. 2022	18.05. 2022	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
1887	680	E	ASA	88	m	01406	25.09. 2021	07.10. 2021	Worsening of heart failure	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10007554, 10062362, 10013968, 10030124, 10021789	Cardiac failure, Viral test negative, Dyspnoea, Oedema peripheral, Infection
1887	680	E	ASA	88	m	01518 -1	10.11. 2021	17.11. 2021	Worsening of heart failure	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10070255, 10007554	Coronavirus test positive, Cardiac failure
1887	680	E	ASA	88	m	01518 -2	17.11. 2021	01.12. 2021	Non-cardiovasc ular event	Sever e	Prolongatio n of existing hospitalisat ion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10070255, 10035664	Coronavirus test positive, Pneumonia
1887	680	E	ASA	89	m	01532	06.12. 2021	16.12. 2021	Non-cardiovasc ular event	Very severe	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10035664, 10046571, 10007554	Pneumonia, Urinary tract infection, Cardiac failure
1887	680	E	ASA	89	m	01558	18.12. 2021		Non-cardiovasc ular event				n	n	Death	12.18.2021	No cardiovascul ar cause		10011906, 10070255, 10022611	Death, Coronavirus test positive, Interstitial lung disease
668	680	E	no ASA	82	f	01624	21.02. 2022	01.03. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10020096	Hip arthroplasty
1071	680	E	no ASA	70	m	01445	23.08. 2021	25.08. 2021	Hospitalisa tion due to AF	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658, 10007661, 10059864	Atrial fibrillation, Cardioversion, Cardiac ablation
1349	680	E	no ASA	88	m	01177	20.12. 2020	23.12. 2020	Myocardial Infarction	Sever e	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r			Hospitalisa tion	10028596, 10052086, 10065608	Myocardial infarction, Coronary arterial stent insertion, Percutaneous coronary intervention
2091	680	E	no ASA	73	f	01477	10.07. 2021	26.07. 2021	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r with sequel ae			Hospitalisa tion	10015145, 10017866, 10062362, 10014819	Erysipelas, Gastritis haemorrhagic, Viral test negative, Endoscopy upper gastrointestinal tract

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2094	680	E	no ASA	77	f	01744	05.05. 2022	07.05. 2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
1419	685	P	no ASA	76	m	00911	21.09. 2020	21.09. 2020	TIA	Moderate	Other medically important event	None, i.e. still ongoing	n	n	r/r			No hospital stay	10044390	Transient ischaemic attack
1419	685	P	no ASA	77	m	01252	15.06. 2021	15.06. 2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			No hospital stay	10065608	Percutaneous coronary intervention
1419	685	P	no ASA	77	m	01425	22.06. 2021	24.06. 2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
403	685	E	no ASA	86	f	00662	16.09. 2019	24.09. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10034122	Patella fracture
123	688	P	ASA	78	m	00041	24.07. 2017	28.07. 2017	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664	Pneumonia
123	688	P	ASA	80	m	00468	16.07. 2019	31.07. 2019	Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10058467, 10030155	Lung neoplasm malignant, Oesophageal carcinoma
123	688	P	ASA	80	m	00499	19.08. 2019		Death as primary event, e.g. sudden death, not death as outcome of				n	n	Death	8.19.2019	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									another event											
728	688	P	ASA	73	m	00755	15.04. 2020	25.04. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061637, 10004720, 10025197	Angiogram, Biopsy, Lymphadenopathy
728	688	P	ASA	73	m	01164	02.06. 2020	04.06. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10025205	Lymphadenopathy mediastinal
728	688	P	ASA	74	m	01457	03.08. 2021	06.08. 2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10037400	Cardiac failure, Pulmonary hypertension
1209	688	P	ASA	66	m	00992	19.07. 2020	20.07. 2020	Hospitalisation due to AF	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10017533	Atrial fibrillation, Fungal infection
1209	688	P	ASA	66	m	00993	11.08. 2020	14.08. 2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
1209	688	P	ASA	66	m	00994	14.09. 2020	21.09. 2020	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062202, 10027727	Mitral valve repair, Mitral valve incompetence
1209	688	P	ASA	66	m	00995	11.11. 2020	17.11. 2020	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021015, 10047290	Hypokalaemia, Ventricular fibrillation
1209	688	P	ASA	66	m	01338	29.01. 2021	04.02. 2021	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10070255	Cardiac failure, Coronavirus test positive
1209	688	P	ASA	67	m	01507	19.08. 2021	20.08. 2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1447	688	P	ASA	77	f	01333	11.08. 2021	17.08. 2021	Ischemic stroke (including transient events with matching lesion on	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cerebral imaging)											
1601	688	P	ASA	79	f	01187	07.12. 2020	12.12. 2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10039117	Rib fracture
2252	688	P	ASA	77	m	01630	22.12. 2021	24.12. 2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10011078, 10080743	Coronary artery disease, Angiocardiogram
2281	688	P	ASA	80	f	01611	10.02. 2022	14.02. 2022	Stable AP (no ACS)	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002383, 10080743	Angina pectoris, Angiocardiogram
2281	688	P	ASA	80	f	01617	01.02. 2022	04.02. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10037802, 10016173	Radius fracture, Fall
2281	688	P	ASA	80	f	01923	23.06. 2022	14.07. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10016173, 10042316, 10061365, 10022116	Fall, Subarachnoid haemorrhage, Skull fracture, Injury
127	688	P	no ASA	83	f	00600	03.04. 2019	05.04. 2019	Stable AP (no ACS)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10080743, 10002383	Angiocardiogram, Angina pectoris
127	688	P	no ASA	85	f	01431	09.08. 2021	24.08. 2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10075425, 10014819, 10010007, 10051589	Reactive gastropathy, Endoscopy upper gastrointestinal tract, Colonoscopy, Large intestine polyp
127	688	P	no ASA	85	f	01432	02.06. 2021	22.06. 2021	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10044640	Cardiac failure, Tricuspid valve incompetence
628	688	P	no ASA	76	m	00272	13.09. 2018	24.09. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008614, 10008629, 10008611	Cholecystitis acute, Cholelithiasis, Cholecystectomy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
640	688	P	no ASA	77	f	00275	15.12. 2018	18.12. 2018	Other cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020802	Hypertensive crisis
640	688	P	no ASA	77	f	00421	15.04. 2019	22.04. 2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10006187, 10076783	Breast cancer, Breast conserving surgery
640	688	P	no ASA	79	f	01166	23.02. 2021	25.02. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10037802, 10022576	Radius fracture, Internal fixation of fracture
842	688	P	no ASA	83	m	00756	20.02. 2020	25.02. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052086, 10065608	Coronary arterial stent insertion, Percutaneous coronary intervention
112	688	E	ASA	73	m	00030	21.06. 2017	23.06. 2017	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10027727, 10007636, 10062202	Mitral valve incompetence, Cardiomyopathy, Mitral valve repair
112	688	E	ASA	74	m	00195	02.10. 2018	05.10. 2018	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
112	688	E	ASA	75	m	00360	02.05. 2019	14.05. 2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10066152, 10002034, 10038063, 10013538, 10061816, 10010007, 10014819	Transfusion, Anaemia, Rectal haemorrhage, Diverticulitis, Diagnostic procedure, Colonoscopy, Endoscopy upper gastrointestinal tract
112	688	E	ASA	75	m	00389	06.06. 2019	08.06. 2019	Major Bleeding in non-surgical patients (according ISTH, including	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10055798, 10017955, 10066152	Haemorrhage, Gastrointestinal haemorrhage, Transfusion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									haemorrhagic stroke)											
112	688	E	ASA	75	m	00729	03.12.2019	06.12.2019	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10079735, 10049812	Atrial appendage closure, Medical device implantation
112	688	E	ASA	75	m	00730	03.02.2020	06.02.2020	Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10027727	Mitral valve incompetence
112	688	E	ASA	75	m	00731	11.02.2020	14.02.2020	Change of a pacemaker, ICD or any other cardiac device	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062202	Mitral valve repair
112	688	E	ASA	76	m	01156	24.11.2020	25.11.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
112	688	E	ASA	76	m	01157	19.01.2021	27.01.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10031161, 10020096	Osteoarthritis, Hip arthroplasty
865	688	E	ASA	69	m	00738	11.02.2020	14.02.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10025005, 10041563	Lumbar spinal stenosis, Spinal decompression
1373	688	E	ASA	83	m	00787	16.06.2020	23.06.2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10001903	Amaurosis fugax
1373	688	E	ASA	84	m	01353	11.07.2021	13.07.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
1373	688	E	ASA	85	m	01924	25.04.2022		Death as primary event, e.g. sudden death, not				n	n	Death	4.25.2022	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death as outcome of another event											
2179	688	E	ASA	80	m	01995	21.09. 2022	23.09. 2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10009033, 10061816	Chronic obstructive pulmonary disease, Diagnostic procedure
2677	688	E	ASA	80	m	01990	25.08. 2022	30.08. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10054112, 10018829, 10066994	Hospitalisation, Haemarthrosis, Joint fluid drainage
2677	688	E	ASA	80	m	01993	09.08. 2022	20.08. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10031161, 10023469	Osteoarthritis, Knee arthroplasty
183	688	E	no ASA	77	m	00416	16.10. 2018	24.10. 2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty
183	688	E	no ASA	78	m	00594	09.10. 2019	21.10. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty
231	688	E	no ASA	86	m	01698	04.10. 2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	10.13.2021	No cardiovascular cause	Hospitalisation	10011906, 10009033	Death, Chronic obstructive pulmonary disease
550	688	E	no ASA	78	m	00417	27.08. 2018	30.08. 2018	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062168	Varicose vein operation
1877	688	E	no ASA	73	m	01210	24.02. 2021	26.02. 2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059624	Haemorrhoid operation
906	689	P	ASA	79	m	00291	19.02. 2019	26.02. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10013864, 10014819, 10010007	Duodenitis, Endoscopy upper gastrointestinal tract, Colonoscopy
906	689	P	ASA	79	m	00411	03.05. 2019	08.05. 2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10074625	Large intestinal polypectomy
232	690	P	no ASA	81	m	00818	20.02. 2020	21.02. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10025005, 10062262	Lumbar spinal stenosis, Spinal operation
1229	692	E	ASA	67	m	00471	10.09. 2019	12.09. 2019	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event								
1229	692	E	ASA	68	m	01306	24.03.2021	17.04.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061008, 10014802, 10023129, 10051773	Biliary tract disorder, Endoscopic retrograde cholangiopancreatography, Jaundice cholestatic, Bile duct stent insertion
1229	692	E	ASA	68	m	01308	26.06.2021		Other cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	6.29.2021	No cardiovascular cause	Hospitalisation	10040070, 10007515, 10011906, 10062194	Septic shock, Cardiac arrest, Death, Metastasis
621	698	P	ASA	80	m	00593	05.12.2019	08.12.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062003	Hernia repair
1123	698	P	ASA	65	m	00380	27.05.2019	30.05.2019	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1123	698	P	ASA	66	m	01204	17.03.2021	23.03.2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10007554, 10052086	Percutaneous coronary intervention, Cardiac failure, Coronary arterial stent insertion
1123	698	P	ASA	68	m	02071	27.09.2022	04.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10019768, 10062362	Hepatitis E, Viral test negative
162	698	P	no ASA	75	m	00295	04.02.2019	09.02.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664	Pneumonia
162	698	P	no ASA	75	m	00296	20.02.2019	22.02.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10059862, 10007598	Cardiac resynchronisation therapy, Cardiac pacemaker insertion
162	698	P	no ASA	75	m	00381	09.05.2019	12.05.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061497, 10034036	Salivary gland neoplasm, Parotidectomy
162	698	P	no ASA	76	m	00713	08.01.2020	15.01.2020	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10059862, 10080743	Cardiac failure, Cardiac resynchronisation therapy, Angiocardiogram

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
162	698	P	no ASA	77	m	00939	14.09.2020	19.09.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052985	Laryngeal prosthesis placement
162	698	P	no ASA	78	m	01230-1	21.05.2021	25.05.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10010007, 10053757, 10066152	Gastrointestinal haemorrhage, Colonoscopy, Therapeutic procedure, Transfusion
162	698	P	no ASA	78	m	01230-2	25.05.2021	01.06.2021	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10040047	Sepsis
162	698	P	no ASA	78	m	01485	07.10.2021	08.10.2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10079735	Atrial appendage closure
162	698	P	no ASA	78	m	01486	27.09.2021	30.09.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10053757, 10010007, 10066152, 10013554	Gastrointestinal haemorrhage, Therapeutic procedure, Colonoscopy, Transfusion, Diverticulum
162	698	P	no ASA	78	m	01587	27.12.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.27.2021	Death of unknown cause		10011906	Death
219	698	E	ASA	85	f	00072	02.12.2017		Death as primary event, e.g. sudden death, not death as				y	y	Death	12.2.2017	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									outcome of another event											
219	698	E	ASA	85	f	00077	20.11. 2017	28.11. 2017	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r with sequelae			Hospitalisation	10008030	Cerebellar haemorrhage
226	698	E	ASA	73	m	00059	25.10. 2017	29.10. 2017	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10066750, 10064272	Bladder transitional cell carcinoma recurrent, Bladder neoplasm surgery
226	698	E	ASA	73	m	00078	01.12. 2017	13.12. 2017	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10046555, 10005028	Urinary retention, Bladder catheterisation
226	698	E	ASA	73	m	00100	13.02. 2018	02.03. 2018	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061011, 10046537	Bladder disorder, Urinary cystectomy
226	698	E	ASA	76	m	01303	14.06. 2021	16.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10074566	Stoma complication
226	698	E	ASA	77	m	01580	19.01. 2022	22.01. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	None, i.e. still ongoing	y	y	r/r			Hospitalisation	10017955, 10002034, 10061816, 10014819, 10010007, 10066152	Gastrointestinal haemorrhage, Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Transfusion
226	698	E	ASA	77	m	01782	28.04. 2022	06.05. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10008604, 10014802, 10063712, 10033645, 10008635	Cholangitis, Endoscopic retrograde cholangiopancreatography, Duodenal sphincterotomy, Pancreatitis, Cholestasis
226	698	E	ASA	77	m	01838	06.07. 2022		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	7.7.2022	No cardiovascular cause	Hospitalisation	10011906, 10057847, 10014802	Death, Biliary sepsis, Endoscopic retrograde

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																				cholangiopancreatography
303	698	E	ASA	76	m	00899	15.09.2020	18.09.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10039906	Seizure
303	698	E	ASA	76	m	00933	24.06.2020	25.06.2020	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862	Cardiac resynchronisation therapy
193	698	E	no ASA	80	f	00689	20.03.2020	21.03.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
193	698	E	no ASA	81	f	00983	15.11.2020	19.11.2020	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10021097, 10013573	Hypotension, Dizziness
1310	700	P	ASA	75	m	01150	08.04.2021	13.04.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008604, 10014802	Cholangitis, Endoscopic retrograde cholangiopancreatography
2483	700	P	ASA	72	m	01823	07.06.2022	20.06.2022	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10051705, 10011737	Hepatic cyst infection, Cyst drainage
158	702	E	no ASA	84	m	00147	05.03.2018	21.03.2018	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554, 10006451	Cardiac failure, Bronchitis
635	704	P	ASA	92	f	01781	19.05.2022	24.05.2022	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10016454, 10022576	Femur fracture, Internal fixation of fracture
761	704	P	ASA	79	m	00374	26.04.2019	06.05.2019	Hospitalisation due to AF	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10003658, 10007554	Atrial fibrillation, Cardiac failure
612	704	E	ASA	74	m	00266	23.12.2018	07.01.2019	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10007554	Cardiac failure
612	704	E	ASA	74	m	00432	30.05.2019	07.06.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10069339	Acute kidney injury

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1682	705	P	ASA	83	m	01020	30.09.2020	03.10.2020	Other cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10080743, 10011078	Angiocardiogram, Coronary artery disease
1682	705	P	ASA	83	m	01021	23.10.2020	27.10.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
1773	705	P	ASA	75	m	01137	24.02.2021	01.03.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062362, 10035664	Viral test negative, Pneumonia
1773	705	P	ASA	76	m	01654	02.11.2021	03.11.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10039674, 10021945	Sciatica, Infiltration anaesthesia
1881	705	P	ASA	79	m	02142	20.07.2022	04.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
2437	705	P	ASA	88	f	02001-1	29.09.2022	17.10.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10042316, 10016173, 10061365, 10008111, 10062362	Subarachnoid haemorrhage, Fall, Skull fracture, Cerebral haemorrhage, Viral test negative
2437	705	P	ASA	88	f	02001-2	02.10.2022	17.10.2022	Hospitalisation due to AF	Moderate	Other medically important event	Permanently discontinued due to this event	n	n	r/r			Reason for prolongation of existing hospital stay	10003662, 10062362	Atrial flutter, Viral test negative
1748	705	P	no ASA	76	m	01625	17.02.2022	25.02.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10002034, 10061816, 10014819, 10010007, 10066152, 10027141	Gastrointestinal haemorrhage, Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Transfusion, Melaena

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1416	705	E	ASA	79	m	00571	06.12.2019	10.12.2019	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10028411	Myalgia
1416	705	E	ASA	79	m	01238	07.09.2020	09.09.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10065064, 10049434	Device lead issue, Cardiac pacemaker replacement
1416	705	E	ASA	79	m	01346	29.09.2020	06.10.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10044445	Transurethral prostatectomy
2272	705	E	ASA	70	m	01929	15.03.2022	04.04.2022	Any type of cardiovascular surgery	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10011077, 10062202, 10059864, 10079735, 10066152, 10002034, 10003658	Coronary artery bypass, Mitral valve repair, Cardiac ablation, Atrial appendage closure, Transfusion, Anaemia, Atrial fibrillation
2740	705	E	ASA	78	m	01939	29.08.2022	30.08.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10018867, 10077989, 10050307	Haematuria, Ureterolithiasis, Ureteral stent insertion
2153	705	E	no ASA	66	f	01343	20.07.2021	07.08.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Other medically important event	Temporarily discontinued due to this event	n	y	r/r			No hospital stay	10017955, 10018836, 10018830, 10015090, 10046910, 10002034	Gastrointestinal haemorrhage, Haematochezia, Haematemesis, Epistaxis, Vaginal haemorrhage, Anaemia
2153	705	E	no ASA	66	f	01523	27.11.2021		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	12.11.2021	Death due to cardiovascular haemorrhage	Hospitalisation	10011906, 10007649, 10055798, 10066152, 10053757, 10014819, 10017955	Death, Cardiovascular disorder, Haemorrhage, Transfusion, Therapeutic procedure, Endoscopy upper gastrointestinal tract, Gastrointestinal haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
282	706	P	no ASA	96	m	01312	05.09.2020	11.09.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020096, 10016173, 10016450	Hip arthroplasty, Fall, Femoral neck fracture
282	706	P	no ASA	97	m	01326	28.11.2020	29.11.2020	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10007554	Cardiac failure
282	706	P	no ASA	97	m	01327	03.12.2020	05.12.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10035664	Pneumonia
282	706	P	no ASA	97	m	01328	16.12.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.16.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
278	706	E	ASA	85	f	00313	22.02.2019	22.02.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Other medically important event	None, i.e. still ongoing	n	n	r/r			No hospital stay	10072562, 10057518	Peripheral artery stent insertion, Peripheral artery angioplasty
208	706	E	no ASA	73	m	00615	19.12.2019	20.12.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10038389, 10064979	Renal cancer, High frequency ablation
248	706	E	no ASA	78	m	00114	06.03.2018	08.03.2018	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10035742	Pneumonitis
480	707	P	ASA	81	m	00606	24.12.2019	31.12.2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256, 10043568	Ischaemic stroke, Thrombolysis
437	707	E	ASA	75	m	00647	05.12.2019	11.12.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	y	y	r/r			Hospitalisation	10052693	Transurethral bladder resection

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
437	707	E	ASA	78	m	01941	04.08. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	8.19.2022	No cardiovascular cause	Hospitalisation	10011906, 10050017, 10035598, 10035664	Death, Lung cancer metastatic, Pleural effusion, Pneumonia
1226	707	E	ASA	79	m	00607	06.01. 2020	14.01. 2020	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	y	y	r/r with sequelae			Hospitalisation	10007554, 10080743, 10002034	Cardiac failure, Angiocardiogram, Anaemia
1226	707	E	ASA	79	m	01335	16.07. 2020	17.07. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009944	Colon cancer
1226	707	E	ASA	81	m	01942	03.03. 2022		Worsening of heart failure	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.16.2022	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554, 10035664	Cardiac death, Cardiac failure, Pneumonia
1873	707	E	no ASA	73	m	01437	26.08. 2021	30.08. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10042316, 10042364, 10061365, 10016173	Subarachnoid haemorrhage, Subdural haemorrhage, Skull fracture, Fall
374	708	E	no ASA	95	f	01513	27.08. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.27.2021	Sudden cardiac death		10049418	Sudden cardiac death
360	711	P	ASA	79	f	00308	09.03. 2019	18.03. 2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
873	711	P	ASA	84	m	00769	02.05.2020	08.05.2020	Worsening of heart failure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1253	711	P	no ASA	78	m	01937	19.04.2022	19.04.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			Main reason for hospital admission	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
518	711	E	no ASA	86	m	00345	28.09.2018	30.11.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Permanently discontinued due to this event	n	y	r/r			No hospital stay	10055798, 10002034	Haemorrhage, Anaemia
518	711	E	no ASA	89	m	01427	19.08.2021	25.08.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
518	711	E	no ASA	89	m	01428	27.09.2021	04.10.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10058467	Lung neoplasm malignant
518	711	E	no ASA	89	m	02124	13.01.2022	04.02.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10058467	Lung neoplasm malignant
611	711	E	no ASA	86	m	01033	02.10.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.2.2020	Death of unknown cause		10011906, 10028980	Death, Neoplasm
796	725	P	ASA	88	m	01992	27.09.2022	03.10.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012218	Delirium
1042	725	P	ASA	81	m	02068	06.10.2022	21.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10033645, 10004637,	Pancreatitis, Bile duct stone, Cholecystectomy,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)							10008611, 10014802	Endoscopic retrograde cholangiopancreatography
1392	725	P	ASA	90	m	01478	19.10. 2021	16.11. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062352, 10062362, 10061543	Respiratory tract infection, Viral test negative, Radiotherapy to lung
1392	725	P	ASA	90	m	01479	07.09. 2021	09.09. 2021	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1392	725	P	ASA	90	m	01480	27.07. 2021	05.08. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
1392	725	P	ASA	91	m	01716	26.11. 2021		Non-cardiovascular event				n	n	Death	11.26.2021	No cardiovascular cause		10011906, 10058467	Death, Lung neoplasm malignant
1631	725	P	ASA	77	m	02009	10.10. 2022	13.10. 2022	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059864, 10003658	Cardiac ablation, Atrial fibrillation
1947	725	P	ASA	84	m	01400	23.09. 2021	04.10. 2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10016173, 10008111, 10022116, 10008030, 10062362	Fall, Cerebral haemorrhage, Injury, Cerebellar haemorrhage, Viral test negative
1947	725	P	ASA	85	m	02075	15.11. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.15.2022	Death of unknown cause		10011906	Death
2041	725	P	ASA	82	m	01279	05.06. 2021	09.06. 2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2041	725	P	ASA	82	m	01315	20.07.2021	31.07.2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
2041	725	P	ASA	82	m	01452	19.08.2021	26.08.2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
2041	725	P	ASA	82	m	01453	10.09.2021	25.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
2041	725	P	ASA	82	m	01710	01.02.2022	16.02.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10007554	Coronavirus test positive, Cardiac failure
2197	725	P	ASA	95	m	01608	04.02.2022	10.02.2022	Myocardial Infarction	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10070255	Acute myocardial infarction, Coronavirus test positive
2197	725	P	ASA	95	m	01813-1	11.06.2022	11.06.2022	Non-cardiovascular event	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10022116, 10019196	Injury, Head injury
2197	725	P	ASA	95	m	01813-2	12.06.2022		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)		Death	Not applicable (no intake of study drug)	n	n	Death	6.13.2022	Death due to cardiovascular haemorrhage	No hospital stay	10011906, 10007649, 10055798, 10042361	Death, Cardiovascular disorder, Haemorrhage, Subdural haematoma
2474	725	P	ASA	77	m	02100	13.10.2022	26.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10023469, 10070255	Knee arthroplasty, Coronavirus test positive
1154	725	P	no ASA	82	m	02024	27.07.2022	09.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10036978	Prostatitis
1442	725	P	no ASA	76	m	01487	15.11.2021	09.12.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10070255, 10035664, 10077989	Coronavirus test positive, Pneumonia, Ureterolithiasis
1442	725	P	no ASA	77	m	01785	28.04.2022	04.05.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062039, 10029148	Lithotripsy, Nephrolithiasis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
782	725	E	ASA	87	m	01171	18.04. 2021	29.04. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10008614	Cholecystitis acute
782	725	E	ASA	88	m	01999	15.07. 2022	23.07. 2022	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007625, 10049447	Cardiogenic shock, Tachyarrhythmia
822	725	E	ASA	70	m	01461	02.11. 2021	06.11. 2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1470	725	E	ASA	76	m	00804	26.04. 2020	01.07. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10061778, 10009944, 10066152, 10062362	Colectomy, Colon cancer, Transfusion, Viral test negative
1470	725	E	ASA	76	m	00805	10.04. 2020	11.04. 2020	Stable AP (no ACS)	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10080743, 10002383	Angiocardiogram, Angina pectoris
1470	725	E	ASA	76	m	00807	26.06. 2020	26.06. 2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10002383, 10065608, 10052086	Angina pectoris, Percutaneous coronary intervention, Coronary arterial stent insertion
1470	725	E	ASA	76	m	01064	09.12. 2020	23.12. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061998, 10074766, 10062362	Hepatic lesion, Liver ablation, Viral test negative
1470	725	E	ASA	77	m	01386	15.06. 2021	18.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10074766, 10009944	Liver ablation, Colon cancer
1470	725	E	ASA	78	m	01847	08.06. 2022	18.06. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10033609, 10074766	Pancreatic carcinoma, Liver ablation
1470	725	E	ASA	78	m	02025	17.10. 2022	03.11. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000279, 10062194, 10033609	Abscess drainage, Metastasis, Pancreatic carcinoma
1619	725	E	ASA	72	m	01000	22.09. 2020	07.10. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10014568, 10062362	Empyema, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2105	725	E	ASA	69	m	01718	23.02.2022		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.15.2022	No cardiovascular cause	Hospitalisation	10011906, 10058467	Death, Lung neoplasm malignant
2494	725	E	ASA	70	m	01628-1	27.02.2022	28.02.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10053757, 10010007, 10066152, 10002034	Gastrointestinal haemorrhage, Therapeutic procedure, Colonoscopy, Transfusion, Anaemia
2494	725	E	ASA	70	m	01628-2	01.03.2022	12.03.2022	Myocardial Infarction	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608	Acute myocardial infarction, Percutaneous coronary intervention
2494	725	E	ASA	70	m	01807	02.06.2022	10.06.2022	Myocardial Infarction	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
2494	725	E	ASA	70	m	01932	28.08.2022	06.09.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10053757, 10010007, 10080561	Gastrointestinal haemorrhage, Therapeutic procedure, Colonoscopy, Gastrointestinal vascular malformation haemorrhagic
2494	725	E	ASA	70	m	02074	06.10.2022	27.10.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10022970, 10066152, 10017955, 10061816, 10014819, 10010007, 10080743	Anaemia, Iron deficiency, Transfusion, Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Angiocardiogram
1620	725	E	no ASA	73	m	01003	03.12.2020	09.12.2020	Change of a pacemaker, ICD or	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10007601, 10063829	Cardiac pacemaker removal, Device malfunction

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									any other cardiac device											
1839	725	E	no ASA	77	m	01159	15.12. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.15.2020	Sudden cardiac death		10049418	Sudden cardiac death
577	728	E	ASA	85	m	00245	01.07. 2018	02.07. 2018	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10004446, 10029446, 10013990	Benign prostatic hyperplasia, Nocturia, Dysuria
387	728	E	no ASA	81	m	00157	28.06. 2018	29.06. 2018	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10058818, 10016173	Skin laceration, Fall
387	728	E	no ASA	81	m	00234	29.11. 2018	30.11. 2018	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10019196, 10016173	Head injury, Fall
387	728	E	no ASA	82	m	00307	07.02. 2019	08.02. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10048959	Peripheral swelling
883	728	E	no ASA	72	f	00306	04.01. 2019	06.01. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062501, 10080743	Non-cardiac chest pain, Angiocardiogram
1560	730	P	no ASA	90	f	01236	04.06. 2021	05.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016667	Fibula fracture
1560	730	P	no ASA	90	f	01380	22.08. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.22.2021	Death of unknown cause		10011906	Death
799	735	P	ASA	72	m	00327	22.03. 2019	26.03. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10024968	Lower respiratory tract infection
799	735	P	ASA	74	m	01024	19.12. 2020		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	12.29.2020	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
925	740	P	ASA	89	m	01879	30.07. 2022	31.07. 2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10037844, 10061623	Rash, Adverse drug reaction

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
925	740	P	ASA	88	m	02014	23.03.2021	24.03.2021	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007882	Cellulitis
1886	740	P	ASA	78	f	01415	04.10.2021	09.10.2021	Myocardial Infarction	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10000891	Acute myocardial infarction
1222	740	P	no ASA	69	f	01390	21.08.2021	22.08.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096, 10031161	Hip arthroplasty, Osteoarthritis
1058	740	E	ASA	79	f	00519	02.10.2019	19.10.2019	Stable AP (no ACS)	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10002383	Angina pectoris
753	740	E	no ASA	79	m	00754	22.05.2020	02.06.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10020096, 10016450	Hip arthroplasty, Femoral neck fracture
866	740	E	no ASA	82	f	01749	21.03.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	3.21.2022	No cardiovascular cause		10011906, 10003549	Death, Asthenia
483	741	P	no ASA	79	m	01560	13.03.2021	17.03.2021	ACS	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10028596, 10051592, 10080743, 10003662	Myocardial infarction, Acute coronary syndrome, Angiocardiogram, Atrial flutter
483	741	P	no ASA	80	m	01561	22.12.2021	23.12.2021	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10035664	Cardiac failure, Pneumonia
1825	741	P	no ASA	80	m	01133	22.02.2021	23.02.2021	Worsening of heart failure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1850	741	P	no ASA	85	m	02023	25.09.2022	29.09.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664, 10062362, 10013538	Pneumonia, Viral test negative, Diverticulitis
2015	741	P	no ASA	71	f	01883	29.07.2022	30.07.2022	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013968, 10024855, 10054112	Dyspnoea, Loss of consciousness, Hospitalisation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1865	741	E	ASA	67	m	02058	03.10.2022	04.10.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062352, 10062362	Respiratory tract infection, Viral test negative
1118	741	E	no ASA	83	m	01476	10.11.2021	22.11.2021	Non-cardiovascular event	Moderate	Other medically important event	None, i.e. still ongoing	n	n	r/r			No hospital stay	10070255	Coronavirus test positive
1118	741	E	no ASA	84	m	02026	28.07.2022	02.08.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10020646, 10012174, 10069339, 10029155	Hyperkalaemia, Dehydration, Acute kidney injury, Nephropathy toxic
1356	741	E	no ASA	78	m	01132	18.03.2021	19.03.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020096, 10064684	Hip arthroplasty, Device dislocation
1356	741	E	no ASA	80	m	02097	01.11.2022	02.11.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10023204	Joint dislocation
1408	741	E	no ASA	80	m	02110	25.11.2022	30.11.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571, 10070255, 10048709	Urinary tract infection, Coronavirus test positive, Urosepsis
1408	741	E	no ASA	79	m	02126	25.09.2022	27.09.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10037596	Pyelonephritis
1408	741	E	no ASA	79	m	02127	15.10.2022	16.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10004446, 10046571, 10061916	Benign prostatic hyperplasia, Urinary tract infection, Prostatectomy
1909	741	E	no ASA	79	m	01032	04.01.2021	07.01.2021	Myocardial Infarction	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10000891, 10080743	Acute myocardial infarction, Angiocardiogram
1909	741	E	no ASA	79	m	01056	10.01.2021	13.01.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
1909	741	E	no ASA	79	m	01057	16.01.2021	19.01.2021	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10070255, 10042772	Coronavirus test positive, Syncope
1909	741	E	no ASA	79	m	01069	29.01.2021		Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	Death	2.3.2021	Death due to stroke	Main reason for hospital admission	10061256, 10011906	Ischaemic stroke, Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
173	748	P	ASA	68	f	00038	22.07.2017	27.07.2017	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012378	Depression
173	748	P	ASA	70	f	00396	20.06.2019	21.06.2019	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10053441	Cardiac pacemaker evaluation
332	748	P	ASA	76	m	01721	19.04.2022	21.04.2022	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
558	748	P	ASA	74	f	01506	23.11.2021	25.11.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
604	748	P	ASA	82	f	00322	25.03.2019	28.03.2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061161	Pelvic fracture
604	748	P	ASA	82	f	00350	05.05.2019	10.05.2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Life threatening event	Permanently discontinued due to this event	n	n	r/r			Main reason for hospital admission	10061256, 10043530	Ischaemic stroke, Thrombectomy
604	748	P	ASA	83	f	00778	15.06.2020	16.06.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation
604	748	P	ASA	84	f	01151	12.04.2021	20.04.2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061256, 10014498, 10062362	Ischaemic stroke, Embolic stroke, Viral test negative
684	748	P	ASA	88	f	00569	05.12.2019	11.12.2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062501	Non-cardiac chest pain
957	748	P	ASA	88	m	00926	07.09.2020		Myocardial Infarction	Very severe	Life threatening event	Permanently discontinued	n	n	Death	9.7.2020	Death due to acute myocardial	Main reason for	10049993, 10000891	Cardiac death, Acute myocardial infarction

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event					infarction (MI)	hospital admission		
1056	748	P	ASA	90	f	00870	19.08. 2020	04.09. 2020	Other cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10047340, 10031127	Vertigo, Orthostatic hypotension
1056	748	P	ASA	90	f	00936	13.10. 2020	15.10. 2020	Minor Bleeding	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018852, 10061225, 10060820, 10018999, 10016173	Haematoma, Limb injury, Joint injury, Haemorrhage subcutaneous, Fall
1056	748	P	ASA	90	f	01131	26.10. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.26.2020	Death of unknown cause		10011906	Death
1139	748	P	ASA	90	m	00534	26.07. 2019	06.08. 2019	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10031161, 10049548	Osteoarthritis, Knee operation
1251	748	P	ASA	95	m	01927	30.08. 2022		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	9.4.2022	No cardiovascular cause	Hospitalisation	10069339, 10012174, 10011906, 10027457, 10038394	Acute kidney injury, Dehydration, Death, Metastases to liver, Renal cancer stage IV
1272	748	P	ASA	85	f	00539	13.11. 2019	21.11. 2019	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10007554	Cardiac failure
1272	748	P	ASA	85	f	00706	14.04. 2020	27.04. 2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012735, 10069339	Diarrhoea, Acute kidney injury
1272	748	P	ASA	85	f	00814	01.07. 2020		Worsening of heart failure				n	n	Death	7.1.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
1285	748	P	ASA	90	m	01808	16.06. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	6.16.2022	Sudden cardiac death		10049418	Sudden cardiac death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1659	748	P	ASA	81	f	00897	21.09.2020	23.09.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10019211	Headache
1659	748	P	ASA	82	f	01500	19.11.2021	20.11.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10047340, 10019211	Vertigo, Headache
1659	748	P	ASA	83	f	01911	30.07.2022	04.08.2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke
1674	748	P	ASA	89	f	00828	10.07.2020	13.07.2020	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020772, 10062501	Hypertension, Non-cardiac chest pain
1674	748	P	ASA	91	f	01878	30.07.2022		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	8.8.2022	No cardiovascular cause	Hospitalisation	10035664, 10070255, 10011906	Pneumonia, Coronavirus test positive, Death
1731	748	P	ASA	84	m	00883	07.09.2020	09.09.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016173, 10077603	Fall, Craniofacial fracture
1731	748	P	ASA	84	m	01268	30.06.2021	13.07.2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke
1731	748	P	ASA	85	m	01768	25.05.2022	30.05.2022	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10058920	Restless legs syndrome
1757	748	P	ASA	87	m	00905	29.09.2020	02.10.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1757	748	P	ASA	87	m	00940	19.10.2020	21.10.2020	Syncope	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10042772, 10020993, 10012601	Syncope, Hypoglycaemia, Diabetes mellitus

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1757	748	P	ASA	87	m	01095-1	19.02.2021	02.03.2021	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10065608, 10052086, 10062362	Percutaneous coronary intervention, Coronary arterial stent insertion, Viral test negative
1757	748	P	ASA	87	m	01095-2	03.03.2021	12.03.2021	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10048709	Urosepsis
1757	748	P	ASA	87	m	01096	26.11.2020	04.12.2020	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10003553	Viral test negative, Asthma
2384	748	P	ASA	87	m	01755	12.05.2022	16.05.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002080	Anaemia vitamin B12 deficiency
2384	748	P	ASA	87	m	01773	29.05.2022	16.06.2022	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10002080, 10066152	Cardiac failure, Anaemia vitamin B12 deficiency, Transfusion
2384	748	P	ASA	87	m	01817	26.06.2022	07.07.2022	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10014819, 10080743	Cardiac failure, Endoscopy upper gastrointestinal tract, Angiocardiogram
2384	748	P	ASA	87	m	01848	15.07.2022		Worsening of heart failure				n	n	Death	7.15.2022	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
564	748	P	no ASA	83	f	00979	23.11.2020	25.11.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
999	748	P	no ASA	81	m	00867	19.05.2020	24.05.2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10063797	Cataract operation
1921	748	P	no ASA	82	f	01173	30.03.2021	31.03.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10037275	Ptosis repair
281	748	E	ASA	76	m	01849	16.07.2022		Non-cardiovascular event	Very severe	Hospitalisation	Temporarily discontinued	n	n	Death	7.18.2022	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event								positive, Pneumonia
532	748	E	ASA	82	f	00664	21.02.2020	26.02.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10014819, 10010007, 10061816, 10066152	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Transfusion
532	748	E	ASA	84	f	01408	24.06.2021	19.07.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014802, 10022576, 10041569	Endoscopic retrograde cholangiopancreatography, Internal fixation of fracture, Spinal fracture
532	748	E	ASA	85	f	02067	08.10.2022	27.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10070255, 10014819	Pneumonia, Coronavirus test positive, Endoscopy upper gastrointestinal tract
532	748	E	ASA	85	f	02070	18.08.2022	22.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049947, 10062362	Lumbar vertebral fracture, Viral test negative
555	748	E	ASA	69	m	00189	12.09.2018	18.09.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Life threatening event	Permanently discontinued due to this event	y	y	r/r			Main reason for hospital admission	10017955, 10014819, 10053757, 10013839, 10066152	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Therapeutic procedure, Duodenal ulcer haemorrhage, Transfusion
555	748	E	ASA	69	m	00201	22.09.2018	09.10.2018	Major Bleeding in surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Life threatening event	Not applicable (no intake of study drug)	y	y	r/r			Main reason for hospital admission	10056743, 10028596, 10065608, 10023696, 10013863, 10008611, 10053757	Gastrointestinal ulcer haemorrhage, Myocardial infarction, Percutaneous coronary intervention, Laparotomy, Duodenectomy, Cholecystectomy, Therapeutic procedure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
555	748	E	ASA	69	m	00244	12.12. 2018	14.12. 2018	Worsening of heart failure	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
555	748	E	ASA	69	m	00285	09.02. 2019	14.02. 2019	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10035664, 10000486	Cardiac failure, Pneumonia, Acidosis
555	748	E	ASA	69	m	00356	15.04. 2019	18.04. 2019	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554	Cardiac failure
555	748	E	ASA	70	m	00393	17.06. 2019	21.06. 2019	Stable AP (no ACS)	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10080743	Angiocardiogram
555	748	E	ASA	71	m	00760	27.05. 2020	31.05. 2020	Change of a pacemaker , ICD or any other cardiac device	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10059862	Cardiac resynchronisation therapy
555	748	E	ASA	72	m	01740	04.05. 2022	10.05. 2022	Worsening of heart failure	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007554, 10003658, 10020635	Cardiac failure, Atrial fibrillation, Hyperglycaemia
610	748	E	ASA	83	m	00168	01.08. 2018	02.08. 2018	Change of a pacemaker , ICD or any other cardiac device	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10059862	Cardiac resynchronisation therapy
610	748	E	ASA	84	m	00540	28.10. 2019	04.11. 2019	Hospitalisa tion due to AF	Moder ate	Hospitalisa tion	Permanently discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10007661, 10003662	Cardioversion, Atrial flutter
610	748	E	ASA	84	m	00751	24.05. 2020	30.05. 2020	Non-cardiovasc ular event	Mild	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10020096, 10031161	Hip arthroplasty, Osteoarthritis
610	748	E	ASA	85	m	00801	29.06. 2020	09.07. 2020	Percutane ous coronary interventio n (e.g. PCI), cerebrovas cular or	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10007661, 10065608, 10052086, 10003658	Cardioversion, Percutaneous coronary intervention, Coronary arterial stent insertion, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									peripheral procedure											
610	748	E	ASA	85	m	00857	04.08.2020	31.08.2020	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10077015, 10002906, 10062362	Transcatheter aortic valve implantation, Aortic stenosis, Viral test negative
610	748	E	ASA	85	m	00858	29.07.2020	30.07.2020	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
610	748	E	ASA	85	m	00900	24.09.2020	29.09.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864, 10007661	Atrial fibrillation, Cardiac ablation, Cardioversion
610	748	E	ASA	86	m	01309	22.07.2021	23.07.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862, 10047208	Cardiac resynchronisation therapy, Venogram
687	748	E	ASA	80	m	00208-1	21.10.2018	30.10.2018	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10035664, 10035598	Pneumonia, Pleural effusion
687	748	E	ASA	80	m	00208-2	30.10.2018	22.11.2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046274, 10017822, 10014819, 10053757	Upper gastrointestinal haemorrhage, Gastric ulcer, Endoscopy upper gastrointestinal tract, Therapeutic procedure
687	748	E	ASA	80	m	00451	18.08.2019	26.08.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10004663, 10008611, 10014819, 10061816	Biliary colic, Cholecystectomy, Endoscopy upper gastrointestinal tract, Diagnostic procedure
928	748	E	ASA	84	f	00403	02.07.2019	09.07.2019	Major Bleeding in non-surgical patients (according ISTH,	Moderate	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10055798, 10017853, 10066152, 10002034, 10017955, 10014819,	Haemorrhage, Gastritis, Transfusion, Anaemia, Gastrointestinal haemorrhage, Endoscopy upper

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									including haemorrhagic stroke)										10010007, 10061816	gastrointestinal tract, Colonoscopy, Diagnostic procedure
928	748	E	ASA	84	f	00409	06.06. 2019	08.06. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	y	y	r/r			Hospitalisation	10046411	Ureteric stenosis
928	748	E	ASA	85	f	00822	07.07. 2020	11.07. 2020	Non-cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
928	748	E	ASA	87	f	01622	23.02. 2022	25.02. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10061816, 10014819, 10066152, 10062362, 10017822	Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Transfusion, Viral test negative, Gastric ulcer
928	748	E	ASA	87	f	01635	02.03. 2022	07.03. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10066152, 10061816, 10014819, 10010007, 10062362, 10017955	Anaemia, Transfusion, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Colonoscopy, Viral test negative, Gastrointestinal haemorrhage
928	748	E	ASA	87	f	01659	19.03. 2022	28.03. 2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10017955, 10061816, 10014816, 10066152	Anaemia, Gastrointestinal haemorrhage, Diagnostic procedure, Endoscopy small intestine, Transfusion
928	748	E	ASA	87	f	01875 -1	29.07. 2022	02.09. 2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10065666, 10023696, 10041105, 10021328	Volvulus of small bowel, Laparotomy, Small intestinal resection, Ileus
928	748	E	ASA	87	f	01875 -2	30.07. 2022	02.09. 2022	Major Bleeding in surgical patients (according	Severe	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing	10066152, 10017955, 10002034, 10053757	Transfusion, Gastrointestinal haemorrhage, Anaemia,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									ISTH, including haemorrhagic stroke)									hospital stay		Therapeutic procedure
992	748	E	ASA	80	m	02006	07.10.2022	08.10.2022	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864, 10062362	Atrial fibrillation, Cardiac ablation, Viral test negative
1096	748	E	ASA	89	f	00862	22.12.2019	03.01.2020	Other cardiovascular event	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10012174	Dehydration
1130	748	E	ASA	76	m	00387	12.06.2019	13.06.2019	Stable AP (no ACS)	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10011078	Coronary artery disease
1415	748	E	ASA	87	f	02020	06.06.2022	21.06.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10016450, 10020096	Femoral neck fracture, Hip arthroplasty
1591	748	E	ASA	81	f	02028	22.04.2022	09.06.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10023825, 10077452	Laryngeal cancer, Vocal cord operation
1591	748	E	ASA	82	f	02029	08.08.2022	10.08.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10067352, 10023825, 10062362, 10062034	Osteoradionecrosis, Laryngeal cancer, Viral test negative, Laryngeal operation
1591	748	E	ASA	82	f	02030	15.08.2022	18.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10067352, 10042566, 10023825	Osteoradionecrosis, Superinfection, Laryngeal cancer
1591	748	E	ASA	81	f	02037-1	25.02.2022	21.03.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10023825, 10023872	Laryngeal cancer, Laryngectomy
1591	748	E	ASA	81	f	02037-2	22.03.2022	31.03.2022	Non-cardiovascular event	Severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10009944, 10077252, 10010007, 10062362	Colon cancer, Proctectomy, Colonoscopy, Viral test negative
1646	748	E	ASA	84	m	01120	08.03.2021	09.03.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1646	748	E	ASA	84	m	01253	15.06.2021	16.06.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								
1885	748	E	ASA	78	f	01031	01.01. 2021	03.01. 2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10017964	Gastrointestinal infection
2049	748	E	ASA	73	m	01264	26.06. 2021	30.06. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10047513, 10027175	Vision blurred, Memory impairment
2203	748	E	ASA	86	m	01450	27.10. 2021	28.10. 2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10087276, 10013554, 10074625, 10062362	Colorectal adenoma, Diverticulum, Large intestinal polypectomy, Viral test negative
2249	748	E	ASA	86	f	01702	06.04. 2022	07.04. 2022	Other cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10058179, 10062362	Hypertensive emergency, Viral test negative
596	748	E	no ASA	74	m	00398	24.06. 2019	27.06. 2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10059862, 10049434	Cardiac resynchronisation therapy, Cardiac pacemaker replacement
641	748	E	no ASA	89	m	00466	04.09. 2019	09.09. 2019	Syncope	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10042772	Syncope
1249	748	E	no ASA	77	f	00477	13.09. 2019	14.09. 2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10014733	Endometrial cancer
1249	748	E	no ASA	77	f	00504	09.10. 2019	10.10. 2019	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10050307	Ureteral stent insertion
1249	748	E	no ASA	77	f	00611	17.01. 2020	29.01. 2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10015037	Epilepsy
1249	748	E	no ASA	77	f	00709	07.04. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	4.7.2020	No cardiovascular cause		10011906, 10062194, 10014733	Death, Metastasis, Endometrial cancer
1301	748	E	no ASA	96	f	00553	26.11. 2019	29.11. 2019	Change of a pacemaker, ICD or any other	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cardiac device											
1301	748	E	no ASA	98	f	01471	30.10. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.30.2021	Death of unknown cause		10011906	Death
1301	748	E	no ASA	98	f	01472 -1	23.09. 2021	05.10. 2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10016450, 10020096, 10035664	Femoral neck fracture, Hip arthroplasty, Pneumonia
1301	748	E	no ASA	98	f	01472 -2	29.09. 2021	05.10. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Very severe	Persistent / significant disability or incapacity	Not applicable (no intake of study drug)	n	n	r/r with sequelae			No prolongation of existing hospital stay	10061256	Ischaemic stroke
1546	748	E	no ASA	81	f	00904	28.09. 2020	29.09. 2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
2222	748	E	no ASA	67	f	01350	31.08. 2021	06.09. 2021	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10062362, 10007554	Viral test negative, Cardiac failure
2358	748	E	no ASA	81	f	01921	09.07. 2022	18.07. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10034010	Parkinsonism
2358	748	E	no ASA	81	f	01936	20.06. 2022	28.06. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty
316	752	P	no ASA	86	f	00544	20.11. 2019	28.11. 2019	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
657	752	P	no ASA	84	m	00399	25.06. 2019	12.07. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10058467	Lung neoplasm malignant

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
570	752	E	ASA	86	f	00159	07.07. 2018	17.07. 2018	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10046571, 10012735	Urinary tract infection, Diarrhoea
862	752	E	ASA	89	f	00377	26.05. 2019	30.05. 2019	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10024968, 10007559, 10007554	Lower respiratory tract infection, Cardiac failure congestive, Cardiac failure
862	752	E	ASA	89	f	00548	10.09. 2019	13.09. 2019	Worsening of heart failure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
862	752	E	ASA	90	f	00733	08.05. 2020	12.05. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10012735, 10017964	Diarrhoea, Gastrointestinal infection
862	752	E	ASA	90	f	00977	21.07. 2020	27.07. 2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
862	752	E	ASA	90	f	00978	15.11. 2020	19.11. 2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
458	752	E	no ASA	81	m	00383	03.06. 2019	04.08. 2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Permanently discontinued due to this event	n	y	r/r			No hospital stay	10055798, 10017955, 10017758, 10014819, 10061816	Haemorrhage, Gastrointestinal haemorrhage, Gastric cancer, Endoscopy upper gastrointestinal tract, Diagnostic procedure
540	756	P	ASA	74	f	00211	25.10. 2018	26.10. 2018	Other cardiovascular event	Moderate	Other medically important event	None, i.e. still ongoing	n	n	r/r with sequelae			No hospital stay	10038908	Retinal vein thrombosis
540	756	P	ASA	75	f	01436	07.01. 2020	24.02. 2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10003997, 10040047	Bacteraemia, Sepsis
448	756	P	no ASA	78	m	00587	27.11. 2019	01.12. 2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10062744, 10039117, 10053975, 10053757	Thoracic haemorrhage, Rib fracture, Thoracic cavity drainage, Therapeutic procedure
509	756	P	no ASA	72	m	00316	12.03. 2019	13.03. 2019	TIA	Moderate	Hospitalisation	Permanently discontinued	n	n	r/r			Hospitalisation	10044390	Transient ischaemic attack

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event								
495	756	E	ASA	74	m	00191	22.06. 2018	27.06. 2018	Stable AP (no ACS)	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10002383, 10011078, 10008479	Angina pectoris, Coronary artery disease, Chest pain
1341	768	P	no ASA	89	f	01621	17.01. 2022		Non-cardiovasc ular event	Sever e	Hospitalisa tion	None, i.e. still ongoing	n	n	Death	1.22.2022	Death of unknown cause	Hospitalisa tion	10011906, 10003988	Death, Back pain
740	768	E	no ASA	75	f	00810	02.07. 2020	03.07. 2020	Change of a pacemaker , ICD or any other cardiac device	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10049434	Cardiac pacemaker replacement
312	774	P	no ASA	76	m	01459	02.02. 2021	09.02. 2021	Worsening of heart failure	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10007554, 10062237	Cardiac failure, Renal impairment
312	774	P	no ASA	75	m	01469	16.08. 2020	07.09. 2020	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10069339	Acute kidney injury
312	774	P	no ASA	77	m	02062	02.02. 2022	09.02. 2022	Worsening of heart failure	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10007554	Cardiac failure
312	774	P	no ASA	77	m	02063	24.02. 2022	02.03. 2022	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10020646	Hyperkalaemia
312	774	P	no ASA	77	m	02064	05.03. 2022	10.03. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10020993	Hypoglycaemia
497	774	E	ASA	70	m	01149	07.04. 2021	08.04. 2021	Worsening of heart failure	Sever e	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10007554, 10062362	Cardiac failure, Viral test negative
497	774	E	ASA	70	m	01154	10.04. 2021	16.04. 2021	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r with sequel ae			Hospitalisa tion	10046555	Urinary retention
497	774	E	ASA	70	m	01212	07.05. 2021	09.05. 2021	Hospitalisa tion due to AF	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10003658	Atrial fibrillation
497	774	E	ASA	70	m	01215	10.05. 2021	12.05. 2021	Other cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10021097	Hypotension

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
497	774	E	ASA	71	m	01783	01.06.2022	08.06.2022	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
660	775	P	ASA	72	f	00522	19.02.2019	27.02.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10006417	Bronchial carcinoma
660	775	P	ASA	74	f	01004	21.09.2020		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	10.10.2020	No cardiovascular cause	Hospitalisation	10011906, 10058467, 10062194, 10023696	Death, Lung neoplasm malignant, Metastasis, Laparotomy
1555	775	P	ASA	77	m	00998	15.12.2020	25.12.2020	Worsening of heart failure	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10049434, 10007554, 10062362	Cardiac pacemaker replacement, Cardiac failure, Viral test negative
1555	775	P	ASA	77	m	01043	30.12.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.30.2020	Death of unknown cause		10011906, 10007554	Death, Cardiac failure
1555	775	P	ASA	77	m	01086	18.11.2020	15.12.2020	Non-cardiovascular event	Mild	Other medically important event	None, i.e. still ongoing	n	n	r/r			No prolongation of existing hospital stay	10025005, 10062262, 10039674	Lumbar spinal stenosis, Spinal operation, Sciatica
603	775	E	ASA	79	m	00257	08.01.2019	16.01.2019	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015037, 10039203	Epilepsy, Road traffic accident
1562	775	E	ASA	67	m	01114	21.10.2020	02.11.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062585, 10014648, 10061657	Peripheral arterial occlusive disease, Endarterectomy, Arterial stent insertion
1562	775	E	ASA	68	m	01176	17.04.2021	24.04.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10050269	Groin abscess

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2173	776	P	ASA	74	m	01508	23.11.2021	23.11.2021	Stable AP (no ACS)	Severe	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			No prolongation of existing hospital stay	10002383, 10011078, 10065608, 10062362	Angina pectoris, Coronary artery disease, Percutaneous coronary intervention, Viral test negative
299	776	E	ASA	85	m	00054	19.10.2017	21.11.2017	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10035664, 10069339, 10027417, 10040070	Pneumonia, Acute kidney injury, Metabolic acidosis, Septic shock
299	776	E	ASA	85	m	01396	01.07.2018		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	7.17.2018	No cardiovascular cause	Hospitalisation	10011906, 10035664	Death, Pneumonia
614	776	E	no ASA	79	f	00198	25.09.2018	28.09.2018	Non-cardiovascular event	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10008479	Chest pain
614	776	E	no ASA	81	f	00919	03.09.2020	10.09.2020	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10062362, 10035664, 10037660, 10015037	Viral test negative, Pneumonia, Pyrexia, Epilepsy
313	780	E	ASA	73	m	00153	15.06.2018	20.06.2018	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10018767	Guillain-Barre syndrome
313	780	E	ASA	76	m	01066	05.02.2021	07.02.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10059862, 10062362	Cardiac resynchronisation therapy, Viral test negative
781	780	E	ASA	69	m	02143	22.11.2022	25.11.2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061256	Ischaemic stroke
354	780	E	no ASA	75	m	00247	04.06.2018	05.06.2018	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10048632	Atrial thrombosis
354	780	E	no ASA	75	m	00248	05.07.2018	06.07.2018	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007661, 10003658	Cardioversion, Atrial fibrillation

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
354	780	E	no ASA	76	m	00394	08.03. 2019	01.07. 2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10055798, 10015090, 10014009, 10018836	Haemorrhage, Epistaxis, Ear haemorrhage, Haematochezia
354	780	E	no ASA	77	m	00954	12.11. 2020	14.11. 2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434, 10062362	Cardiac pacemaker replacement, Viral test negative
625	780	E	no ASA	79	m	00224	28.08. 2018	07.09. 2018	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10017758, 10066152, 10002034, 10017955, 10014819, 10061816	Gastric cancer, Transfusion, Anaemia, Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Diagnostic procedure
625	780	E	no ASA	79	m	00228	16.10. 2018	30.10. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049438, 10061965, 10017758	General physical health deterioration, Gastrectomy, Gastric cancer
625	780	E	no ASA	79	m	00230	10.09. 2018	16.10. 2018	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061965, 10017758	Gastrectomy, Gastric cancer
625	780	E	no ASA	79	m	00319	07.03. 2019	14.03. 2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10049438, 10012735, 10047895, 10017758	General physical health deterioration, Diarrhoea, Weight decreased, Gastric cancer
625	780	E	no ASA	79	m	00364	11.04. 2019		Major Bleeding in non-surgical patients (according ISTH, including	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	4.12.2019	No cardiovascular cause	Hospitalisation	10017955, 10061968, 10011906	Gastrointestinal haemorrhage, Gastric neoplasm, Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									haemorrhagic stroke)											
1376	784	E	ASA	77	m	00963	07.11.2020	20.11.2020	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
1827	788	P	ASA	77	m	01191	08.11.2020		Worsening of heart failure				n	n	Death	11.8.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
1163	799	P	no ASA	76	m	00577	29.11.2019	09.12.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10000891, 10065608	Acute myocardial infarction, Percutaneous coronary intervention
1291	799	E	no ASA	70	m	02094	18.05.2022	28.05.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10008611, 10008614	Cholecystectomy, Cholecystitis acute
1401	800	P	ASA	82	m	01766	10.02.2022	22.02.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10021789, 10030124, 10015150	Infection, Oedema peripheral, Erythema
1421	800	P	ASA	76	m	01202	25.02.2021		Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.28.2021	No cardiovascular cause	Hospitalisation	10035664, 10070255, 10011906	Pneumonia, Coronavirus test positive, Death
1527	800	P	ASA	84	f	00749	23.05.2020	29.05.2020	Myocardial Infarction	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10000891, 10065608	Acute myocardial infarction, Percutaneous coronary intervention
571	800	P	no ASA	70	m	00558	13.11.2019	14.11.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10019646	Hepatic cyst
571	800	P	no ASA	71	m	00984	13.08.2020	18.08.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10019646, 10062040	Hepatic cyst, Liver operation
1667	800	P	no ASA	81	m	01262	14.04.2021		Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	4.20.2021	Death due to stroke	Hospitalisation	10014498, 10061256, 10062362	Embolic stroke, Ischaemic stroke, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
420	800	E	ASA	88	m	00092	10.02.2018	21.02.2018	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
420	800	E	ASA	89	m	00454	26.08.2019	30.08.2019	Myocardial Infarction	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10051592, 10028596	Acute coronary syndrome, Myocardial infarction
420	800	E	ASA	90	m	00726	09.05.2020	15.05.2020	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
420	800	E	ASA	90	m	00873	24.08.2020	04.09.2020	Worsening of heart failure	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
420	800	E	ASA	90	m	01044	28.12.2020		Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.2.2021	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
653	800	E	ASA	68	m	00648	22.01.2020	31.01.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
653	800	E	ASA	69	m	01214	11.05.2021	12.05.2021	Stable AP (no ACS)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002383, 10052086, 10065608	Angina pectoris, Coronary arterial stent insertion, Percutaneous coronary intervention
1128	800	E	ASA	77	m	00603	24.12.2019		Death as primary event, e.g. sudden death, not death as outcome of another event		Death	Permanently discontinued due to this event	n	n	Death	12.24.2019	Sudden cardiac death	No hospital stay	10049418	Sudden cardiac death
1603	800	E	ASA	86	m	00920-1	24.09.2020	07.10.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1603	800	E	ASA	86	m	00920-2	02.10.2020	07.10.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Prolongation of existing hospitalisation	Permanently discontinued due to this event	y	y	r/r with sequelae			Hospitalisation	10042361, 10055798	Subdural haematoma, Haemorrhage

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1603	800	E	ASA	86	m	01030	04.01.2021		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	1.8.2021	No cardiovascular cause	Hospitalisation	10011906, 10033645	Death, Pancreatitis
1332	800	E	no ASA	80	m	00555	27.11.2019	06.12.2019	Minor Bleeding	Moderate	Hospitalisation	Permanently discontinued due to this event	y	y	r/r			Hospitalisation	10018852, 10058818, 10061225	Haematoma, Skin laceration, Limb injury
620	801	P	ASA	67	m	00684	12.03.2020	13.03.2020	Worsening of heart failure	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002034, 10066152, 10014819, 10007554	Anaemia, Transfusion, Endoscopy upper gastrointestinal tract, Cardiac failure
620	801	P	ASA	70	m	01877	21.07.2022	29.07.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10002034, 10014819, 10017822, 10017865, 10066152, 10017955, 10061816	Anaemia, Endoscopy upper gastrointestinal tract, Gastric ulcer, Gastritis erosive, Transfusion, Gastrointestinal haemorrhage, Diagnostic procedure
620	801	P	ASA	70	m	02066	13.09.2022		Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	10.13.2022	No cardiovascular cause	Hospitalisation	10002034, 10061816, 10014819, 10017865, 10017955, 10066152, 10035664, 10069339, 10011906	Anaemia, Diagnostic procedure, Endoscopy upper gastrointestinal tract, Gastritis erosive, Gastrointestinal haemorrhage, Transfusion, Pneumonia, Acute kidney injury, Death
693	801	P	ASA	65	m	00204	18.10.2018		Myocardial Infarction	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	10.27.2018	Death due to cardiovascular procedures	Hospitalisation	10065608, 10011077, 10011906, 10057461, 10000891	Percutaneous coronary intervention, Coronary artery bypass, Death, Cardiac procedure complication, Acute myocardial infarction
1183	801	P	ASA	67	m	01247	24.02.2021	05.03.2021	Ischemic stroke (including transient events with	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									matching lesion on cerebral imaging)											
1183	801	P	ASA	69	m	01824	28.06.2022	29.06.2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1187	801	P	ASA	78	f	00634	26.01.2020	30.01.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020646, 10039906	Hyperkalaemia, Seizure
599	801	P	no ASA	74	m	00420	06.07.2019	09.07.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Persistent / significant disability or incapacity	Permanently discontinued due to this event	y	y	r/r with sequelae			Main reason for hospital admission	10038867	Retinal haemorrhage
599	801	P	no ASA	75	m	01234	03.06.2021	04.06.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10003658, 10059864	Atrial fibrillation, Cardiac ablation
793	801	P	no ASA	76	f	00865	07.06.2020	10.06.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
793	801	P	no ASA	76	f	00866	27.07.2020	05.08.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10002034, 10010007, 10014819, 10035664	Anaemia, Colonoscopy, Endoscopy upper gastrointestinal tract, Pneumonia
969	801	P	no ASA	81	m	02084	23.09.2022	30.09.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10012174, 10003239, 10031161	Dehydration, Arthralgia, Osteoarthritis
543	801	E	ASA	74	f	00367	14.05.2019		No SAE	Moderate	Other medically important event	None, i.e. still ongoing	n	n	Event ongoing			No hospital stay	10020993, 10012601	Hypoglycaemia, Diabetes mellitus
543	801	E	ASA	76	f	01647	08.03.2022	18.03.2022	Other cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10034474, 10034471, 10004724	Pericardial effusion, Pericardial drainage, Biopsy adrenal gland

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1184	801	E	ASA	79	m	00483	23.07.2019	25.07.2019	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10027407	Mesothelioma malignant
1184	801	E	ASA	79	m	00775	06.03.2020		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	3.10.2020	No cardiovascular cause	Hospitalisation	10011906, 10059518	Death, Pleural mesothelioma malignant
2273	801	E	ASA	82	m	01692	01.03.2022	09.03.2022	Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10038435, 10046571, 10007027	Renal failure, Urinary tract infection, Calculus urinary
2273	801	E	ASA	82	m	01732	27.04.2022	30.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10060862, 10004857	Prostate cancer, Biopsy prostate
639	801	E	no ASA	78	m	00175	13.08.2018	16.08.2018	Minor Bleeding	Moderate	Life threatening event	Permanently discontinued due to this event	n	y	r/r			No hospital stay	10018964	Haemoptysis
741	801	E	no ASA	83	m	01696	29.03.2022		Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	Death	5.29.2022	No cardiovascular cause	Hospitalisation	10011906, 10014819, 10010007, 10070255, 10035664, 10002034, 10077361, 10038695	Death, Endoscopy upper gastrointestinal tract, Colonoscopy, Coronavirus test positive, Pneumonia, Anaemia, Multiple organ dysfunction syndrome, Respiratory failure
1334	801	E	no ASA	81	m	00714	24.04.2020	28.04.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	y	r/r with sequelae			Hospitalisation	10017955	Gastrointestinal haemorrhage
1772	801	E	no ASA	78	f	00945-1	26.10.2020	02.11.2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	r/r with sequelae			Hospitalisation	10017955, 10014819, 10010007, 10061816, 10066152	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Transfusion

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1772	801	E	no ASA	78	f	00945-2	30.10.2020	30.10.2020	Non-cardiovascular event	Very severe	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisation	10029202	Nervous system disorder
1772	801	E	no ASA	78	f	00945-3	30.10.2020	30.10.2020	Non-cardiovascular event	Very severe	Life threatening event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10021036	Hyponatraemia
1772	801	E	no ASA	79	f	02089	29.08.2022	02.09.2022	Change of a pacemaker, ICD or any other cardiac device	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10077015, 10002906	Transcatheter aortic valve implantation, Aortic stenosis
349	802	P	ASA	83	m	00119	21.03.2018		Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	4.17.2018	Death due to heart failure (HF)	Hospitalisation	10023126, 10018867, 10049993, 10007554, 10014802	Jaundice, Haematuria, Cardiac death, Cardiac failure, Endoscopic retrograde cholangiopancreatography
629	802	P	no ASA	82	f	00632	15.10.2019	30.07.2020	Other cardiovascular event	Moderate	Other medically important event	Permanently discontinued due to this event	n	y	r/r with sequel ae			No hospital stay	10038867	Retinal haemorrhage
1082	802	E	ASA	83	m	00702	04.03.2020	07.03.2020	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisation	10018867, 10066152, 10044445	Haematuria, Transfusion, Transurethral prostatectomy
1082	802	E	ASA	84	m	00825	25.06.2020		Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	7.10.2020	No cardiovascular cause	Hospitalisation	10011906, 10005003, 10062194, 10066152	Death, Bladder cancer, Metastasis, Transfusion
705	802	E	no ASA	66	f	00324	25.03.2019	28.03.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10028836, 10003239, 10014020	Neck pain, Arthralgia, Ear pain
705	802	E	no ASA	68	f	00991	28.11.2020	29.11.2020	Other cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10043071	Tachycardia
705	802	E	no ASA	68	f	01606-1	10.03.2021	17.03.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10024741, 10041826	Lung lobectomy, Squamous cell carcinoma of lung

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
705	802	E	no ASA	68	f	01606-2	17.03.2021	17.03.2021	Pulmonary embolism	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No prolongation of existing hospital stay	10037377	Pulmonary embolism
2070	813	P	ASA	78	m	01511	16.11.2021	23.11.2021	Myocardial Infarction	Moderate	Life threatening event	Permanently discontinued due to this event	n	n	r/r with sequel ae			Main reason for hospital admission	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous coronary intervention, Coronary arterial stent insertion
2074	813	P	ASA	83	f	01731	07.04.2022	12.04.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10003553, 10070255	Asthma, Coronavirus test positive
1387	815	P	ASA	82	m	01138	25.02.2021	01.03.2021	Peripheral (limb) embolism	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10014513	Embolism arterial
1904	815	P	ASA	87	m	01130	23.03.2021	25.03.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10017955, 10066152, 10010007, 10061816	Gastrointestinal haemorrhage, Transfusion, Colonoscopy, Diagnostic procedure
947	815	P	no ASA	78	f	01089	26.07.2020	29.07.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
947	815	P	no ASA	80	f	01902	18.07.2022	29.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10061284	Mental disorder
1551	815	P	no ASA	89	f	01706	01.02.2022	09.02.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequel ae			Hospitalisation	10035664, 10070255	Pneumonia, Coronavirus test positive
1812	815	P	no ASA	87	f	01217	12.02.2021	18.02.2021	Worsening of heart failure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1812	815	P	no ASA	88	f	01522	14.10. 2021		Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	11.2.2021	No cardiovascular cause	Hospitalisation	10070255, 10011906, 10035664	Coronavirus test positive, Death, Pneumonia
1812	815	P	no ASA	87	f	01707	13.06. 2021	15.06. 2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1896	815	E	ASA	78	m	02138	06.09. 2022	16.09. 2022	Hospitalisation due to AF	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10003658	Atrial fibrillation
2200	815	E	no ASA	84	m	01600	23.11. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.23.2021	No cardiovascular cause		10011906, 10039203	Death, Road traffic accident
1473	824	P	no ASA	89	m	01121	09.02. 2021	11.02. 2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571	Urinary tract infection
892	826	P	no ASA	71	m	01250	22.12. 2020	24.12. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10062362, 10061916, 10048956	Viral test negative, Prostatectomy, Lymphadenectomy
1425	826	P	no ASA	91	f	01529	29.06. 2021	06.07. 2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049548	Knee operation
476	826	E	ASA	81	m	00597	08.01. 2020	10.01. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Severe	Hospitalisation	Permanently discontinued due to this event	n	y	r/r with sequelae			Hospitalisation	10017955, 10001150, 10066152, 10014819, 10061816	Gastrointestinal haemorrhage, Adenocarcinoma gastric, Transfusion, Endoscopy upper gastrointestinal tract, Diagnostic procedure
724	827	P	ASA	79	f	01329	24.08. 2020	31.08. 2020	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10031161, 10049548	Osteoarthritis, Knee operation
764	827	E	ASA	80	f	00907	23.05. 2020	28.05. 2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10036105, 10047340, 10029864	Polyneuropathy, Vertigo, Nystagmus
764	827	E	ASA	81	f	01016	14.12. 2020	23.12. 2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued	n	n	r/r			Hospitalisation	10016454, 10022576,	Femur fracture, Internal fixation of fracture, Radius

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												due to this event							10037802, 10066152	fracture, Transfusion
764	827	E	ASA	81	f	01330	31.12. 2020	20.01. 2021	ACS	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10051592, 10080743	Acute coronary syndrome, Angiocardiogram
764	827	E	ASA	82	f	01949	21.08. 2022	02.09. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r with sequel ae			Hospitalisa tion	10017577, 10016173, 10036105	Gait disturbance, Fall, Polyneuropathy
764	827	E	ASA	82	f	01950	28.03. 2022	23.04. 2022	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10002034, 10079735, 10014819, 10010007, 10061816, 10066152	Anaemia, Atrial appendage closure, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Transfusion
1011	828	P	ASA	81	m	01542	03.12. 2021	03.12. 2021	TIA	Mild	Other medically important event	Permanently discontinued due to this event	n	n	r/r			No hospital stay	10044390	Transient ischaemic attack
987	833	P	ASA	76	m	00656 -1	02.02. 2020	17.03. 2020	Non-cardiovasc ular event	Sever e	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10035664	Pneumonia
987	833	P	ASA	77	m	00656 -2	14.02. 2020	16.02. 2020	Major Bleeding in non-surgical patients (according ISTH, including haemorrha gic stroke)	Moder ate	Other medically important event	Not applicable (no intake of study drug)	y	y	r/r			No prolongatio n of existing hospital stay	10017955, 10014819, 10010007, 10061816, 10066152	Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Colonoscopy, Diagnostic procedure, Transfusion
987	833	P	ASA	77	m	00846	11.06. 2020		Non-cardiovasc ular event	Very severe	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	Death	6.12.2020	No cardiovascul ar cause	Hospitalisa tion	10011906, 10037383	Death, Pulmonary fibrosis
1224	833	P	ASA	74	m	00443	15.08. 2019	20.08. 2019	Non-cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10072627	Orthopaedic procedure
1224	833	P	ASA	75	m	00956	03.11. 2020	04.11. 2020	Percutane ous coronary interventio n (e.g. PCI),	Moder ate	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10052086, 10065608	Coronary arterial stent insertion, Percutaneous coronary intervention

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cerebrovascular or peripheral procedure											
976	833	E	ASA	84	m	01128	16.02.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.16.2021	No cardiovascular cause		10011906, 10051905	Death, Coronavirus infection
1277	833	E	ASA	85	m	00894	21.09.2020	22.09.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10052086, 10065608	Coronary arterial stent insertion, Percutaneous coronary intervention
1277	833	E	ASA	85	m	01352	01.11.2020	05.11.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1277	833	E	ASA	85	m	01416	18.07.2021	22.07.2021	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10014819	Cardiac failure, Endoscopy upper gastrointestinal tract
1277	833	E	ASA	86	m	01686	20.03.2022	23.03.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10062362	Cardiac failure, Viral test negative
1277	833	E	ASA	86	m	01687	23.01.2022	25.01.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1277	833	E	ASA	86	m	01951	19.06.2022	20.06.2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554	Cardiac failure
1637	833	E	ASA	78	m	00835	20.07.2020	22.07.2020	TIA	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10044390, 10001903	Transient ischaemic attack, Amaurosis fugax
1923	833	E	ASA	77	m	01292	13.01.2021	15.01.2021	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10044380	Transient global amnesia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
795	836	P	no ASA	82	m	01741	07.11. 2021		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	11.25.2021	No cardiovascular cause	Hospitalisation	10011906, 10035664, 10062362	Death, Pneumonia, Viral test negative
849	836	E	no ASA	80	f	00891	29.05. 2020		Non-cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	Death	5.31.2020	No cardiovascular cause	Hospitalisation	10008958, 10011906, 10040070	Chronic lymphocytic leukaemia, Death, Septic shock
849	836	E	no ASA	80	f	00893	07.05. 2020	13.05. 2020	Non-cardiovascular event	Very severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10008958, 10037660	Chronic lymphocytic leukaemia, Pyrexia
2001	836	E	no ASA	81	m	01456	11.06. 2021	16.06. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10062362, 10061256	Viral test negative, Ischaemic stroke
2364	836	E	no ASA	73	m	01759	11.04. 2022	26.04. 2022	Other cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10062585, 10072563, 10051055, 10034576	Peripheral arterial occlusive disease, Peripheral artery stenosis, Deep vein thrombosis, Peripheral ischaemia
1853	857	P	no ASA	92	f	02039	01.10. 2022	08.10. 2022	Worsening of heart failure	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10007554, 10035598	Cardiac failure, Pleural effusion
965	868	P	ASA	75	f	00526	04.11. 2019	15.11. 2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035664	Pneumonia
965	868	P	ASA	77	f	01498	15.11. 2021	01.12. 2021	ACS	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10051592, 10065608	Acute coronary syndrome, Percutaneous coronary intervention
899	868	P	no ASA	70	m	00789	23.06. 2020	07.07. 2020	Other cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10043570, 10049071	Thrombophlebitis, Vascular operation
924	868	P	no ASA	79	f	00653	12.01. 2020	17.01. 2020	Ischemic stroke (including transient events with matching lesion on	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256, 10070878	Ischaemic stroke, Cerebral small vessel ischaemic disease

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cerebral imaging)											
754	868	E	ASA	74	m	00525	01.11.2019	06.11.2019	Other cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020772	Hypertension
850	870	P	ASA	80	f	00321	09.12.2018		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.9.2018	Death of unknown cause		10011906	Death
1028	870	P	ASA	73	f	00707	03.04.2020	23.04.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10016454	Femur fracture
1030	870	P	ASA	68	f	01147	01.10.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.1.2020	Death of unknown cause		10011906	Death
1684	870	E	ASA	80	m	01615	06.12.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.6.2021	Death of unknown cause		10011906	Death
1973	870	E	ASA	71	m	01419	05.05.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	5.5.2021	Sudden cardiac death		10049418	Sudden cardiac death
762	871	E	ASA	66	m	00570	29.08.2019	11.09.2019	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016454	Femur fracture

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
808	871	E	ASA	77	m	00407	19.04.2019	25.04.2019	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10052693	Transurethral bladder resection
776	872	P	no ASA	83	m	01101	06.08.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.6.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
891	872	P	no ASA	80	m	00879	02.08.2020		Worsening of heart failure				n	n	Death	8.2.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
1143	872	P	no ASA	79	f	01836	07.12.2019	16.12.2019	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
994	874	P	ASA	78	m	01988	21.01.2021	22.02.2021	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10067434	Intraocular lens implant
792	874	P	no ASA	94	f	00556	19.10.2019		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	10.19.2019	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
716	874	E	ASA	71	m	00373	27.05.2019	07.06.2019	Stable AP (no ACS)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10002383	Angina pectoris
858	874	E	ASA	73	m	01228	07.05.2021		Non-cardiovascular event		Death	Permanently discontinued due to this event	n	n	Death	5.7.2021	No cardiovascular cause	Main reason for hospital admission	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
932	874	E	ASA	89	f	01724	10.08.2021		Death as primary event, e.g. sudden death, not				n	n	Death	8.10.2021	No cardiovascular cause		10011906, 10008958	Death, Chronic lymphocytic leukaemia

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death as outcome of another event											
1469	874	E	ASA	83	f	01087	02.11. 2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	11.2.2020	Death due to heart failure (HF)		10007554, 10049993	Cardiac failure, Cardiac death
1726	874	E	ASA	71	f	01106	31.01. 2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.31.2021	Sudden cardiac death		10049418	Sudden cardiac death
646	875	P	ASA	69	m	01772	13.05. 2022		Non-cardiovascular event				n	n	Death	5.13.2022	No cardiovascular cause		10011906, 10038086	Death, Rectosigmoid cancer
1027	875	E	ASA	78	m	02111	17.02. 2022		Non-cardiovascular event	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	2.17.2022	No cardiovascular cause	Hospitalisation	10070255, 10035664, 10011906	Coronavirus test positive, Pneumonia, Death
2167	875	E	ASA	77	m	01462	16.07. 2021	19.07. 2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256, 10014498	Ischaemic stroke, Embolic stroke
2167	875	E	ASA	77	m	01463	21.08. 2021		Myocardial Infarction	Very severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	Death	8.22.2021	Death due to acute myocardial infarction (MI)	Hospitalisation	10049993, 10000891	Cardiac death, Acute myocardial infarction
636	875	E	no ASA	82	f	01895	12.06. 2022	18.06. 2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008614, 10008611, 10008629	Cholecystitis acute, Cholecystectomy, Cholelithiasis
744	876	P	ASA	75	m	00502	07.10. 2019	11.10. 2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008611	Cholecystectomy

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
736	876	P	no ASA	79	m	00864-1	13.08.2020	11.09.2020	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
736	876	P	no ASA	79	m	00864-2	01.09.2020	11.09.2020	Pulmonary embolism	Moderate	Prolongation of existing hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10037377	Pulmonary embolism
915	877	P	no ASA	69	f	01605	23.04.2021	05.05.2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
1141	877	P	no ASA	70	m	00583	20.12.2019	23.12.2019	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
706	877	E	ASA	85	m	01444	05.04.2021		Non-cardiovascular event				n	n	Death	4.5.2021	No cardiovascular cause		10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
853	877	E	ASA	69	m	01019	04.12.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.4.2020	Death due to heart failure (HF)		10049993, 10007554	Cardiac death, Cardiac failure
876	877	E	ASA	71	f	00836	11.01.2020	29.01.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10003011, 10003010	Appendicitis, Appendicectomy
876	877	E	ASA	71	f	00815	29.04.2020	11.05.2020	Non-cardiovascular event	Moderate	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			Main reason for hospital admission	10014802, 10008611, 10008614	Endoscopic retrograde cholangiopancreatography,

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
																				Cholecystectomy, Cholecystitis acute
876	877	E	ASA	71	f	00816	09.06.2020	17.06.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10057229	Post cholecystectomy syndrome
876	877	E	ASA	71	f	01026	01.08.2020	14.08.2020	Other cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020802	Hypertensive crisis
735	877	E	no ASA	81	f	00314	12.03.2019	13.03.2019	Syncope	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10042772, 10003658	Syncope, Atrial fibrillation
890	877	E	no ASA	79	f	00303	14.02.2019	17.02.2019	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Other medically important event	Temporarily discontinued due to this event	n	y	r/r			No hospital stay	10038063	Rectal haemorrhage
890	877	E	no ASA	79	f	00545	11.03.2019	18.03.2019	Non-cardiovascular event	Mild	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			Main reason for hospital admission	10053757, 10059624, 10051589	Therapeutic procedure, Haemorrhoid operation, Large intestine polyp
890	877	E	no ASA	79	f	00546	02.04.2019	02.04.2019	Non-cardiovascular event	Mild	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			No hospital stay	10053308, 10010007, 10053757	Polypectomy, Colonoscopy, Therapeutic procedure
1084	877	E	no ASA	95	m	01557	29.12.2021	30.12.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1084	877	E	no ASA	95	m	02085	24.02.2022		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	2.24.2022	Death of unknown cause		10011906	Death
1679	877	E	no ASA	70	f	02076	13.05.2022		Death as primary event, e.g.				n	n	Death	5.13.2022	Death of unknown cause		10011906	Death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									sudden death, not death as outcome of another event											
1495	884	P	ASA	66	m	01426	05.10.2021	15.10.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10012735, 10009887	Diarrhoea, Colitis
1377	884	E	no ASA	90	f	02016	05.10.2022	09.10.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096	Hip arthroplasty
984	901	P	ASA	75	m	00379	08.05.2019	11.05.2019	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r			Hospitalisation	10052693, 10018867	Transurethral bladder resection, Haematuria
1549	901	P	ASA	65	m	01076	05.02.2021	08.02.2021	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1549	901	P	ASA	67	m	01922	04.07.2022	26.07.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10061536	Parkinson's disease
1564	901	P	ASA	70	m	01788	27.05.2022	03.06.2022	Other cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10062585, 10060734, 10062362	Peripheral arterial occlusive disease, Diabetic foot, Viral test negative
1859	901	P	ASA	78	m	01334	17.08.2021	21.08.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007697	Carpal tunnel syndrome
1566	901	P	no ASA	83	m	01565	22.11.2021	25.11.2021	Hospitalisation due to AF	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10080743, 10003662, 10062362	Angiocardiogram, Atrial flutter, Viral test negative
1566	901	P	no ASA	84	m	01948	14.08.2022	17.08.2022	ACS	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10002388, 10051592	Angina unstable, Acute coronary syndrome
882	901	E	ASA	88	f	00486	04.09.2019	05.09.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10002475	Angioplasty

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									peripheral procedure											
882	901	E	ASA	88	f	00530	28.10.2019	01.11.2019	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10035664	Pneumonia
882	901	E	ASA	89	f	00580	20.12.2019	21.12.2019	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10002475	Angioplasty
882	901	E	ASA	91	f	01794	30.03.2022	05.04.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10037802, 10022576	Radius fracture, Internal fixation of fracture
1038	901	E	ASA	72	m	00951	28.10.2020	28.10.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Other medically important event	Temporarily discontinued due to this event	n	n	r/r			No hospital stay	10052086, 10049434	Coronary arterial stent insertion, Cardiac pacemaker replacement
1138	901	E	ASA	77	m	00674	03.03.2020	05.03.2020	TIA	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10044390, 10003658	Transient ischaemic attack, Atrial fibrillation
1138	901	E	ASA	78	m	00976	11.09.2020	11.09.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Moderate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10065608, 10052086	Percutaneous coronary intervention, Coronary arterial stent insertion
1138	901	E	ASA	78	m	01220	20.04.2021	23.04.2021	Ischemic stroke (including transient events with matching lesion on	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10014498, 10061256	Embolic stroke, Ischaemic stroke

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									cerebral imaging)											
1138	901	E	ASA	79	m	01509	10.10. 2021	10.10. 2021	TIA	Moder ate	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r			No hospital stay	10044390	Transient ischaemic attack
1138	901	E	ASA	79	m	01575	05.01. 2022	07.01. 2022	Minor Bleeding	Moder ate	Hospitalisa tion	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisa tion	10014819, 10017885, 10030172	Endoscopy upper gastrointestinal tract, Gastrooesophagea l reflux disease, Oesophageal haemorrhage
2427	901	E	ASA	81	m	01609	10.02. 2022	16.02. 2022	ACS	Mild	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10002388, 10065608	Angina unstable, Percutaneous coronary intervention
1057	901	E	no ASA	72	f	00369	29.05. 2019	03.06. 2019	Non-cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	y	r/r			Hospitalisa tion	10066152, 10014819, 10010007, 10002034	Transfusion, Endoscopy upper gastrointestinal tract, Colonoscopy, Anaemia
2435	901	E	no ASA	83	m	01904	18.04. 2022	19.04. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10019196, 10016173	Head injury, Fall
2550	965	P	no ASA	86	m	01831	21.06. 2022	28.06. 2022	Non-cardiovasc ular event	Moder ate	Hospitalisa tion	None, i.e. still ongoing	n	n	r/r			Hospitalisa tion	10069339, 10062362, 10014819, 10050307	Acute kidney injury, Viral test negative, Endoscopy upper gastrointestinal tract, Ureteral stent insertion
2550	965	P	no ASA	86	m	01955	16.08. 2022		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Hospitalisa tion	Permanently discontinued due to this event	n	n	Death	8.26.2022	No cardiovascul ar cause	Hospitalisa tion	10011906, 10001150, 10062194	Death, Adenocarcinoma gastric, Metastasis
2321	965	E	ASA	79	f	01752	09.05. 2022	13.05. 2022	Other cardiovasc ular event	Mild	Hospitalisa tion	Temporarily discontinued due to this event	n	n	r/r			Hospitalisa tion	10014802, 10033610, 10033645	Endoscopic retrograde cholangiopancreat ography, Pancreatic carcinoma metastatic, Pancreatitis

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
2321	965	E	ASA	79	f	01771	02.03.2022	07.03.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10033645, 10070255, 10061902	Pancreatitis, Coronavirus test positive, Pancreatic neoplasm
2321	965	E	ASA	79	f	01800	15.06.2022	28.06.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10048984, 10049721, 10014819	Pancreatic abscess, Metastases to pancreas, Endoscopy upper gastrointestinal tract
2321	965	E	ASA	79	f	01865	12.07.2022	29.07.2022	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10057007, 10042343	Jejunectomy, Subcutaneous abscess
2321	965	E	ASA	79	f	01893	01.08.2022	04.08.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10008604, 10064685	Cholangitis, Device occlusion
2420	965	E	ASA	83	f	01703	27.02.2022	10.03.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10038077, 10046940, 10046814, 10077252, 10046815, 10070519	Rectal prolapse, Vaginal prolapse, Uterine prolapse, Proctectomy, Uterine prolapse repair, Vaginal prolapse repair
1342	1028	P	no ASA	83	f	01675	14.03.2022	19.03.2022	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10063554, 10062362	Hyperglycaemic hyperosmolar nonketotic syndrome, Viral test negative
1561	1028	P	no ASA	73	m	01124	23.12.2020	25.12.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10044445, 10062362	Transurethral prostatectomy, Viral test negative
1561	1028	P	no ASA	74	m	01667	13.12.2021	15.12.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10044445, 10062362, 10004730	Transurethral prostatectomy, Viral test negative, Biopsy bladder
1561	1028	P	no ASA	74	m	01668	14.01.2022	16.01.2022	Minor Bleeding	Moderate	Hospitalisation	Temporarily discontinued due to this event	y	y	r/r with sequelae			Hospitalisation	10018867, 10005027	Haematuria, Bladder catheter temporary
1314	1028	E	no ASA	82	m	01640	28.02.2022	08.03.2022	Non-cardiovascular event	Severe	Hospitalisation	None, i.e. still ongoing	n	n	r/r with sequelae			Hospitalisation	10060121, 10062362	Squamous cell carcinoma of head and neck, Viral test negative
1314	1028	E	no ASA	82	m	01737	31.03.2022		Non-cardiovascular event				n	n	Death	3.31.2022	No cardiovascular cause		10011906, 10041823	Death, Squamous cell carcinoma

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
949	1029	P	ASA	83	m	00675	25.01.2020		Death as primary event, e.g. sudden death, not death as outcome of another event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	2.10.2020	Death due to acute myocardial infarction (MI)	Hospitalisation	10049993, 10000891	Cardiac death, Acute myocardial infarction
1243	1029	E	ASA	89	m	01543	01.09.2021	07.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r with sequelae			Hospitalisation	10061536	Parkinson's disease
1256	1029	E	ASA	70	m	01730	16.03.2022	28.03.2022	Non-cardiovascular event	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10000880, 10066152, 10061758	Acute myeloid leukaemia, Transfusion, Chemotherapy
2090	1029	E	ASA	87	f	01368	12.09.2021	23.09.2021	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
1459	1039	P	ASA	86	m	00780	09.04.2020	16.04.2020	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664, 10062362	Pneumonia, Viral test negative
1459	1039	P	ASA	87	m	01364	10.09.2021	17.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571, 10062362	Urinary tract infection, Viral test negative
1227	1039	E	ASA	80	m	00614	21.01.2020	23.01.2020	Hospitalisation due to AF	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10003662, 10059864	Atrial flutter, Cardiac ablation
1467	1039	E	ASA	80	m	00800	30.03.2020	03.04.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10048667, 10013968, 10038695	Restrictive pulmonary disease, Dyspnoea, Respiratory failure
1467	1039	E	ASA	80	m	00947	19.10.2020	26.10.2020	Worsening of heart failure	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10007554, 10035598	Cardiac failure, Pleural effusion
1467	1039	E	ASA	80	m	01008	12.11.2020	11.12.2020	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10035664, 10062362, 10007554	Pneumonia, Viral test negative, Cardiac failure

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1467	1039	E	ASA	80	m	01052	18.12.2020	23.12.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10012607	Diabetes mellitus inadequate control
1467	1039	E	ASA	81	m	01496	17.11.2021	22.11.2021	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10062362, 10007554, 10042772, 10016173	Viral test negative, Cardiac failure, Syncope, Fall
1467	1039	E	ASA	81	m	01550	14.12.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.14.2021	Sudden cardiac death		10049418	Sudden cardiac death
1534	1039	E	ASA	80	m	01784	05.06.2022	22.06.2022	Worsening of heart failure	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10007554	Cardiac failure
2225	1048	P	ASA	88	f	01839	27.06.2022	08.07.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10020802, 10021036, 10046571, 10062362	Hypertensive crisis, Hyponatraemia, Urinary tract infection, Viral test negative
2225	1048	P	ASA	88	f	01840	10.07.2022	13.07.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10014418, 10021036, 10046571	Electrolyte imbalance, Hyponatraemia, Urinary tract infection
2335	1049	P	ASA	80	f	01652	25.02.2022	03.03.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10027141, 10017955, 10014819, 10053757, 10010007, 10053308	Melaena, Gastrointestinal haemorrhage, Endoscopy upper gastrointestinal tract, Therapeutic procedure, Colonoscopy, Polypectomy
1240	1071	P	ASA	79	m	02147	08.12.2021	21.12.2021	Non-cardiovascular event	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10009033	Chronic obstructive pulmonary disease
1337	1074	P	no ASA	87	f	00745	10.05.2020	12.05.2020	Syncope	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10042772, 10031127	Syncope, Orthostatic hypotension
1337	1074	P	no ASA	87	f	00838	18.07.2020	28.07.2020	Non-cardiovascular event	Moderate	Other medically	Temporarily discontinued	n	n	r/r			Main reason for	10043827	Tibia fracture

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
											important event	due to this event						hospital admission		
1337	1074	P	no ASA	89	f	01913	18.08.2022	20.08.2022	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016997, 10016173, 10022576	Forearm fracture, Fall, Internal fixation of fracture
1548	1074	P	no ASA	85	f	02072	31.07.2022	12.08.2022	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10014418, 10020772	Electrolyte imbalance, Hypertension
1607	1074	P	no ASA	83	m	01590	01.11.2021	23.11.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
1697	1074	P	no ASA	77	m	00863	04.08.2020	06.08.2020	Change of a pacemaker, ICD or any other cardiac device	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10049434	Cardiac pacemaker replacement
1420	1074	E	ASA	68	m	00990	22.06.2020	26.06.2020	Non-cardiovascular event	Mild	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10069339, 10012735	Acute kidney injury, Diarrhoea
1842	1074	E	ASA	68	m	01092	27.01.2021		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	2.5.2021	No cardiovascular cause	Hospitalisation	10011906, 10007554, 10070255	Death, Cardiac failure, Coronavirus test positive
1446	1074	E	no ASA	80	f	01815	21.10.2021	23.10.2021	Non-cardiovascular event	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10037802, 10022576	Radius fracture, Internal fixation of fracture
1708	1074	E	no ASA	92	f	01589	13.09.2021	17.09.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10061161, 10002034, 10066152	Pelvic fracture, Anaemia, Transfusion
1968	1074	E	no ASA	84	f	01434	20.07.2021		Other cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	7.23.2021	Death due to other cardiovascular causes	Hospitalisation	10011906, 10007649, 10071564, 10040943	Death, Cardiovascular disorder, Limb amputation, Skin ulcer
2561	1074	E	no ASA	68	m	01713	10.04.2022		Death as primary event, e.g. sudden death, not				n	n	Death	4.10.2022	Sudden cardiac death		10049418	Sudden cardiac death

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
									death as outcome of another event											
2078	1080	P	ASA	84	f	01585	10.12.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	12.10.2021	Sudden cardiac death		10049418	Sudden cardiac death
1688	1080	P	no ASA	73	m	01077	20.01.2021		Non-cardiovascular event	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	1.29.2021	No cardiovascular cause	Hospitalisation	10011906, 10070255	Death, Coronavirus test positive
1778	1080	E	ASA	83	m	01127	27.01.2021		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.27.2021	Sudden cardiac death		10049418	Sudden cardiac death
1462	1080	E	no ASA	81	f	01029	28.12.2020		Non-cardiovascular event	Very severe	Hospitalisation	None, i.e. still ongoing	n	n	Death	1.3.2021	No cardiovascular cause	Hospitalisation	10011906, 10070255, 10035664	Death, Coronavirus test positive, Pneumonia
1615	1080	E	no ASA	72	f	01275	01.06.2021	16.06.2021	Other cardiovascular event	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10051055	Deep vein thrombosis
1822	1080	E	no ASA	78	f	01233	10.05.2021	14.05.2021	Any type of cardiovascular surgery	Mild	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10062202, 10027733	Mitral valve repair, Mitral valve stenosis
1353	1085	P	ASA	82	m	00850	24.07.2020	31.07.2020	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10062585, 10057518	Peripheral arterial occlusive disease, Peripheral artery angioplasty
1353	1085	P	ASA	84	m	01900	01.08.2022	09.08.2022	Myocardial Infarction	Moderate	Hospitalisation	Not applicable	n	n	r/r			Hospitalisation	10000891, 10065608, 10052086	Acute myocardial infarction, Percutaneous

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
												(no intake of study drug)								coronary intervention, Coronary arterial stent insertion
1537	1085	E	ASA	79	m	01401	23.05.2021	24.05.2021	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Mild	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10015926	Eye haemorrhage
1771	1085	E	no ASA	84	f	01297	12.07.2021	27.07.2021	Hospitalisation due to AF	Moderate	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10003658, 10007661	Atrial fibrillation, Cardioversion
1771	1085	E	no ASA	85	f	01514	28.09.2021	07.10.2021	Minor Bleeding	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10017955, 10013538, 10061816, 10010007, 10002034, 10066152, 10019022	Gastrointestinal haemorrhage, Diverticulitis, Diagnostic procedure, Colonoscopy, Anaemia, Transfusion, Haemorrhoids
1358	1089	P	no ASA	82	m	00681	28.01.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	1.28.2020	Sudden cardiac death		10049418	Sudden cardiac death
1358	1089	P	no ASA	82	m	02018	14.01.2020	19.01.2020	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10046571, 10016173	Urinary tract infection, Fall
1492	1089	P	no ASA	74	f	01063	22.01.2021	02.02.2021	Non-cardiovascular event	Severe	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10070255, 10035664	Coronavirus test positive, Pneumonia
1502	1089	P	no ASA	75	m	00935	10.10.2020	14.10.2020	Minor Bleeding	Moderate	Hospitalisation	None, i.e. still ongoing	n	y	r/r			Hospitalisation	10062362, 10060862, 10018867	Viral test negative, Prostate cancer, Haematuria
1502	1089	P	no ASA	75	m	01167	11.01.2021	12.01.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10013538, 10062362	Diverticulitis, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
1502	1089	P	no ASA	76	m	01168	09.02.2021	11.02.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10005028, 10062362	Bladder catheterisation, Viral test negative
1502	1089	P	no ASA	77	m	01738	02.05.2022	04.05.2022	Major Bleeding in non-surgical patients (according ISTH, including haemorrhagic stroke)	Moderate	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10018867, 10002034, 10046528	Haematuria, Anaemia, Urinary bladder haemorrhage
1522	1089	P	no ASA	85	m	00898	22.08.2020		Death as primary event, e.g. sudden death, not death as outcome of another event				n	n	Death	8.22.2020	Sudden cardiac death		10049418, 10038749	Sudden cardiac death, Resuscitation
1333	1089	E	no ASA	73	m	01239	04.06.2021	08.06.2021	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10020096, 10062362	Hip arthroplasty, Viral test negative
1333	1089	E	no ASA	74	m	01701	05.04.2022	13.04.2022	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10016173, 10062362, 10077603, 10023149, 10015090, 10010254	Fall, Viral test negative, Craniofacial fracture, Jaw fracture, Epistaxis, Concussion
1427	1089	E	no ASA	84	m	01891	19.07.2022	10.08.2022	Non-cardiovascular event	Severe	Other medically important event	Not applicable (no intake of study drug)	n	n	r/r with sequelae			No hospital stay	10060862, 10061816	Prostate cancer, Diagnostic procedure
1504	1089	E	no ASA	71	m	01246	12.05.2021	13.05.2021	Minor Bleeding	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10005144	Bleeding varicose vein
1504	1089	E	no ASA	72	m	01750	20.05.2022	21.05.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10052693, 10011814, 10062362	Transurethral bladder resection, Cystoscopy, Viral test negative
1504	1089	E	no ASA	72	m	02022	03.09.2022	04.09.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10064272	Bladder neoplasm surgery
2344	1097	P	ASA	81	f	01512	25.11.2021	04.12.2021	Pulmonary embolism	Mild	Prolongation of existing	Permanently discontinued	n	n	r/r			Hospitalisation	10037377, 10062362	Pulmonary embolism, Viral test negative

Patient-ID	Centre-ID	Random group[1]	Random stratum (indication)[2]	Age at event	Sex	SAE number	Onset date	Stop date	SAE type (adjudicated by ERC)	Intensity	Criterion for seriousness	Action regarding study drug	Causal relationship to blinded study drug ASA	Causal relationship to blinded study drug edoxaban	Outcome[3]	Death date	Death type (adjudicated by ERC)	Relation to hospital stay	Preferred term (code)	Preferred term (name)
											hospitalisation	due to this event								
2344	1097	P	ASA	81	f	01760	18.05.2022	23.05.2022	Non-cardiovascular event	Severe	Hospitalisation	Not applicable (no intake of study drug)	n	n	r/r			Hospitalisation	10020646, 10072370, 10062362	Hyperkalaemia, Prerenal failure, Viral test negative
1705	1097	E	ASA	74	m	00967	11.11.2020	12.11.2020	Stable AP (no ACS)	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10002383, 10062362, 10080743	Angina pectoris, Viral test negative, Angiocardiogram
1705	1097	E	ASA	75	m	01360	08.09.2021	10.09.2021	Non-cardiovascular event	Moderate	Hospitalisation	None, i.e. still ongoing	n	n	r/r			Hospitalisation	10069339	Acute kidney injury
2401	1097	E	ASA	68	m	01845	13.07.2022	14.07.2022	Percutaneous coronary intervention (e.g. PCI), cerebrovascular or peripheral procedure	Mild	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10080743	Angiocardiogram
2678	1118	P	ASA	83	f	02038	02.11.2022	05.11.2022	TIA	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r			Hospitalisation	10044390	Transient ischaemic attack
2377	1121	E	no ASA	91	m	01559	27.12.2021		Worsening of heart failure	Very severe	Hospitalisation	Permanently discontinued due to this event	n	n	Death	12.28.2021	Death due to heart failure (HF)	Hospitalisation	10049993, 10007554	Cardiac death, Cardiac failure
2444	1121	E	no ASA	81	m	01962	19.09.2022	22.09.2022	Ischemic stroke (including transient events with matching lesion on cerebral imaging)	Severe	Hospitalisation	Permanently discontinued due to this event	n	n	r/r with sequelae			Hospitalisation	10061256	Ischaemic stroke
2519	1146	P	no ASA	87	f	01907	10.07.2022	14.07.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10016454, 10062362, 10020096	Femur fracture, Viral test negative, Hip arthroplasty
2525	1147	E	no ASA	69	f	01928	29.07.2022	30.07.2022	Non-cardiovascular event	Moderate	Hospitalisation	Temporarily discontinued due to this event	n	n	r/r			Hospitalisation	10023469	Knee arthroplasty

[1] P = Placebo; E = Edoxaban


[2] ASA = Acetylsalicylic acid

[3] r/r = recovered/resolved

16.3 Other

Information on the intake of medication

- Please take **both** pills inside of a marked rectangle once daily. Please follow the continuous numbering of the daily doses (1, 2, 3, and so on).



- Take the tablets every morning before breakfast. Do not chew them and swallow them together with a sufficient amount of water
- In case you forget to take your medication on one day, please leave that day's tablets in the package. Continue on the next day with the tablets following the ones you forgot. Do **not** take the double amount of medication the next day. Boxes and packages will be collected by your study centre during your next follow-up visit.
- Please save **all** boxes and packages (**even empty** boxes and packages) and bring these with you for your next follow-up visit at your study centre

Information on the intake of medication, Version 160215,15.02.2016
NOAH - AFNET 6, EudraCT Nr. 2015-003997-33 Page 1 of 1